<SEC-DOCUMENT>0001104659-21-038205.txt : 20210318
<SEC-HEADER>0001104659-21-038205.hdr.sgml : 20210318
<ACCEPTANCE-DATETIME>20210318112909
ACCESSION NUMBER:		0001104659-21-038205
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210318
DATE AS OF CHANGE:		20210318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galmed Pharmaceuticals Ltd.
		CENTRAL INDEX KEY:			0001595353
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				981147233
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36345
		FILM NUMBER:		21753555

	BUSINESS ADDRESS:	
		STREET 1:		16 ZE'EV TYOMKIN ST. (4TH FL.)
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6578317
		BUSINESS PHONE:		97236938448

	MAIL ADDRESS:	
		STREET 1:		16 ZE'EV TYOMKIN ST. (4TH FL.)
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6578317
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>tmb-20201231x20f.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7713.40453 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/18/2021 12:41:50 PM -->
      <!-- iXBRL Library version: 1.0.7713.40461 -->
      <!-- iXBRL Service Job ID: b8aa5fe2-c47a-4fa2-ba10-ddbdf4ce82e7 -->

  <html xmlns:glmd="http://www.galmedpharma.com/20201231" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:EntityCentralIndexKey" id="Tc_88xMTCKqV0-DL8eKUpUG2Q_2_1">0001595353</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:CurrentFiscalYearEndDate" id="Tc_FKxSc8zSFk65kCZiStZlcA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:DocumentFiscalYearFocus" id="Tc_99NkqaqvK0a51GF-y8ONyw_4_1">2020</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:DocumentFiscalPeriodFocus" id="Tc_Bfssm8Zwlk-qkIaAEgDTQA_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:AmendmentFlag" id="Tc_MIey8b95SE6DCdj4mawFlA_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:EntityRegistrantName" id="Hidden_aJ2eNBx_p0eGsv2Yn-BpKg">Galmed Pharmaceuticals Ltd.</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="0" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_MtEzE_Q_dkGNkQI2tGys-g">21325975</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="0" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_rsIlGj2fQ0e_29EHelK7pw">21139385</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yZ1T_sP4_EeOFyO2pue5nQ" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Hidden_eLB7w3VWGEaH55k7AS_AdA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Hidden_oULiP01GyEGoRJwxs7pREQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Hidden_7Wb5Jl6MQU2V63DK4FHwEA">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Hidden_PATlNkw1P0qJ2UewZ8KyFQ">true</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="Hidden_rtPFgq4moU2FnXiiUj0HYA">us-gaap:OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_d2nXIm0PHEKT0HYx5C-QMw" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Hidden_Ccc8RhKJjU6tsVCv0GLiEA">true</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4sF-RiihZ0aMqyVdvdrAXQ" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Hidden_iAeXAqUqkkCSijJ30lE5Og">P2Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tmb-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u4zLwxUaOkSym-aIgXnS5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LVnGSo3_1kWLy8HaZIELzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zF1M1CcFtEuu9rKrGf7EhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Gpq4ytPIkUGTYbUPOM83dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9wQFUwfTykW9qsgqMTxpsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LfEbrk5LkkeSaN-Ppx6W5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lpsu-F7wy0awRiq6md5Tpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iVc9WKPPG0SD2INXCz2fdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2O8hljvvqEmHT8dL4lkKJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hXRilr6SHE66NPYzTTJsLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBQIyJO6Bky2LRwuu2f8fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IfcP6tZx7UKE8vBKiQjAlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember_rI1zXGeK8EmUIgiB1WtYEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glmd:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_qalgby9MtkGBayyVeht6lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_EBlJedVOS0a8vpK59r2GmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_NopUScY-L0CezNXhkry3hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y0ei-czCk0Sc-jHLUaPa8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__8e7PIYNIkuDeGtL1vwa3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LVpIBdN-a02_xjlF3wujBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_r7Ms1ZL-BEiOxWAAdEMExA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GEzGoXG5Ok-EayrH7ZBK0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NyHUYA8FSUyuZNantnazBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_5ym3QBU5HUSdGhzhJHMUXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_glmd_EmployeeStockOptionAndRestrictedStockUnitsMember_1uQb0r1NiEeEwnFMdNS4OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glmd:EmployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2020_To_8_31_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_-BwgIJ4swUqIbUQSXGQ7Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2020_To_8_31_2020_qLCEtGphHkma-pZvOcz6CA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2020_To_3_31_2020_MPCna657d0q_4brWdj6Npg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_12_31_2016_sn54mW8hE0KEfttuS1LktQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_I_8qF4py_U-hFUr5wnrNSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_W0hOEi39s0i4CgIp_7LThA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hf5IyP78Okm12S_Q5Zkpgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_wpVjGpd6BEGCzRJ_fPNzXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nqOXypy73EqMu8z3nQc_ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_srAD6naErEOb_wZF3whfdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WPJh0pmyREubwtCYaYFNjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glmd:AtthemarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DIoFCIoieUy02nLWRrmjlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glmd:AtthemarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_GuaranteeOfIndebtednessOfOthersMember_o_oLvoDldEabEXMAdTrcLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:GuaranteeOfIndebtednessOfOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4sF-RiihZ0aMqyVdvdrAXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4fndOwz4MES4TiHYJ6gb3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QjPdXPDPS0KeLH50EvKEiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KeNcj4ynQEmMLA9cFanIvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_FOpb3JVogkOpHOfrV1dInw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:MalteseSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2019_To_2_7_2019_srt_RangeAxis_srt_MinimumMember_wTFaM2m8mEeYWNwxhsduUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2019_To_2_7_2019_srt_RangeAxis_srt_MaximumMember_G54FxZmw_0-M5Erc8SbIag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_DSjIA39FDUaJmBOrv2YWwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_JOb54R0hTEydao88CStcSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_U--doeSff0eYGwC7nwkM-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_1_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_bgXq7TSYz0qDPCPOCoHLlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_ScwAFiM_R02IVHmPu8-uGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_OfficersAndDirectorsMember_7_l-on5bd0-NL_4bzPYr0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:OfficersAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_OfficersAndDirectorsMember_mrVIWXqvQEmQsa2JBPQ6-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:OfficersAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_ABpxUYDxU0CDiyikjLs1sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:MalteseSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_grcOKAlDuECUUH45djx3zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:MalteseSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_mGyra1etzUCzEOs-2C5hCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_ZJtJgHpgokiYVRcA7a4M5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iP_trPoSQEGHbtnlJrlRyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glmd:AtthemarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_glmd_IncentiveShareOptionPlan2013Member_jMEQ59S6skeyqHQJq4F4Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glmd:IncentiveShareOptionPlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_lcF12gSU0kKvwhOz65xKKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_CuoWWqHob0izym5D8TCYyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dgZLZWqczUq8SCUOT_5URw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hfA5x-MOn0W8xR-xu1Qj7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fI3z7-XQOUCnOyty6hbt5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hEwZ6hKhQ0uK4n7L4nWHsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rvQiaUGGXU66VG6jGIelKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_MutualFundMember_RQBP2VCs0UObKkcYTcqmbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_xfK4x71C_U2XYg59WBWoBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_3UXPMCMApUyirH3ER8JOrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_y1QksogbbUycmgdaOBlLFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_MutualFundMember_bnGgvdd-EU-eaV6XNt9n5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_zok_q8J8GUSWmJBnBBWX4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_ZVJnKS1DoUGuAK-FW8B_lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_QVoQ0VMjTE-tSI7ooqfneQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iGwyJcYXY0S44sJU3W54uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Klh4zVXBdku_FCneIROOiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DsQQrozwdkKxtuirepkykw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2oKKrX6nA0y6X8VJqCajsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yZ1T_sP4_EeOFyO2pue5nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VS3dcnkwpEuaFwkYh1LQkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IsoQh3ECGUWn_hEoSfchBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2016_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_DeA8R8quM027wniT31ykmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">glmd:SamilPharmCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glmd:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2018_To_9_30_2018_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_pXFd672UHU-v_1dF3cq4Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">glmd:SamilPharmCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_T34JgVPuFkWxKLRq7oMiFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">glmd:SamilPharmCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_28_2016_To_7_28_2016_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_YaFu1dKFek-a9yFU3cmXPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">glmd:SamilPharmCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-28</xbrli:startDate><xbrli:endDate>2016-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vDGTRGTNSU-DSOCOXQYOmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_z4Neu-Y5NUaQZ1wt2pNyGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glmd:ComputerSoftwareElectronicAndMedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_gMEa3bvWxUaKSc4FnbNujg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_LCBCJM_bu0mrU9wCYDXIHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glmd:ComputerSoftwareElectronicAndMedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_u4oEdDXj2kiEqeMFb0tldw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_15_2020_oxvKTuBAOkK40v6EQV3YEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2017_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_OSe9LSeVd0mkEr3CGmm7tA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glmd:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_FacilityLeasesMember_xPSqGfctvE-Yl4rAyJNzSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">glmd:FacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_CarLeasesMember_q_0odO7w6EWS9ILHFJbIjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">glmd:CarLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_d2nXIm0PHEKT0HYx5C-QMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_ILS_80PDI-Ft8k2W61vPNXVwKw"><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Options_1PhyUiqh7EyGeetW5z7dOA"><xbrli:measure>glmd:Options</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_dThMR2ywAUCT7W6wxsLiYA"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_ILS_shares_E36EhjGGZkK6K8BwwH-6kA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_LrQLFEabLEqzt_sj9HemMg"><xbrli:measure>glmd:segment</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Dsf4U8uej0-EcPAM2_HySw_28_9" toRefs="_42e2ff89_d58a_4126_9816_39de91f5f9c8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_GoeIdt4KN0u0T0yl9u7wUA_28_6" toRefs="_42e2ff89_d58a_4126_9816_39de91f5f9c8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_xt9it0WKS0itVI7bY09UyA_28_3" toRefs="_42e2ff89_d58a_4126_9816_39de91f5f9c8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_oULiP01GyEGoRJwxs7pREQ" toRefs="_afc9692e_a9e1_46f7_9c18_b560baccbcf1" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;min-height:5.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a6a8a203_be2e_4115_bd42_a56eb80b9a63"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Form&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:DocumentType" id="Narr_hj5kjr1BmUC7HXLAVYkqzw"><b style="font-size:9pt;font-weight:bold;">20-F</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:DocumentRegistrationStatement" id="Narr_BCvAIMp9NE6px3UIXeASNA"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;</span><b style="font-size:9pt;font-weight:bold;">REGISTRATION STATEMENT PURSUANT TO SECTION&#160;12(b)&#160;OR (g)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:DocumentAnnualReport" id="Narr_gXDoswXQb0WkTByuvuyZsQ"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9745;</b></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;</span><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:0pt;margin:0pt;"><span style="font-size:11pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:14.4pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:DocumentPeriodEndDate" id="Narr_vwTYAi-poE-BFib-1Zh4YQ"><b style="font-size:9pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">December&#160;31, 2020</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:DocumentTransitionReport" id="Narr_hiwcl4OMG06t_TSMl9JDjA"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;</span><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:DocumentShellCompanyReport" id="Narr_rdfmjUHt6UK-ZQxDriqv4A"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;SHELL COMPANY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;">Date of event requiring this shell company report ________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from _______________________________</b> to <b style="font-weight:bold;">_______________________________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Commission File No.&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:EntityFileNumber" id="Narr_GPla02HyUEa19vRLmZrgdg"><b style="font-size:9pt;font-weight:bold;">001-36345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_aJ2eNBx_p0eGsv2Yn-BpKg;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:17pt;font-style:normal;font-weight:bold;text-align:center;">GALMED PHARMACEUTICALS&#160;LTD.</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">(Exact name of Registrant as specified in its charter)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 14pt 0pt;"><i style="font-style:italic;">(Translation of the Registrant&#8217;s name into English)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">State of </b><ix:nonNumeric format="ixt-sec:edgarprovcountryen" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:EntityIncorporationStateCountryCode" id="Narr_atqGguAIYk6xrYujjSUKVA"><b style="font-size:9pt;font-weight:bold;">Israel</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">(Jurisdiction of incorporation or organization)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:EntityAddressAddressLine1" id="Narr_982l5Z5dckqEuWdjRdocpQ"><b style="font-size:9pt;font-weight:bold;">16 Tiomkin Street</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:EntityAddressCityOrTown" id="Narr_Y70nTN1U8kWJI_LxDfhcsw"><b style="font-size:9pt;font-weight:bold;">Tel Aviv</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:EntityAddressCountry" id="Narr_UZslERMdIESeV7J6zJ7-cQ"><b style="font-size:9pt;font-weight:bold;">Israel</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:EntityAddressPostalZipCode" id="Narr_vr28e5ZzSEet457q134_nw"><b style="font-size:9pt;font-weight:bold;">6578317</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">(Address of principal executive offices)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A" name="dei:ContactPersonnelName" id="Narr_jnYuBVk_i0a4iRiitQ6YSQ"><b style="font-size:9pt;font-weight:bold;">Allen Baharaff</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">President and Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A" name="dei:EntityAddressAddressLine1" id="Narr_rFrPEtxg50ewmJhvjeET1Q"><b style="font-size:9pt;font-weight:bold;">16 Tiomkin Street</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A" name="dei:EntityAddressCityOrTown" id="Narr_6EL0yKmMIkKpm-62omsL3A"><b style="font-size:9pt;font-weight:bold;">Tel Aviv</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A" name="dei:EntityAddressCountry" id="Narr_byGUWOD5Z0iTxOV3UTUcaw"><b style="font-size:9pt;font-weight:bold;">Israel</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A" name="dei:EntityAddressPostalZipCode" id="Narr_nrHwoZIDfUCz_rdamlbupQ"><b style="font-size:9pt;font-weight:bold;">6578317</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">E-mail: </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A" name="dei:ContactPersonnelEmailAddress" id="Narr_Sa-1OgwZ4kiFZQW0sQxlsg"><b style="font-size:9pt;font-weight:bold;">ab@galmedpharma.com</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Tel: </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A" name="dei:CityAreaCode" id="Narr_BDWiQ6WmDUufM7ycAYExqQ"><b style="font-size:9pt;font-weight:bold;">+972.3</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">.</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A" name="dei:LocalPhoneNumber" id="Narr_7vbcRB0UVUGHLsHA5ClvfQ"><b style="font-size:9pt;font-weight:bold;">693.8448</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Fax: +972.3.693.8447</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Securities registered or to be registered pursuant to Section&#160;12(b)&#160;of the Act.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d475d3a8_f23e_43ad_a910_a7977c1f2335"></a><a id="Tc_c5NvEWNymkCBhkN379FQPg_1_1"></a><a id="Tc_efFVE_FYKk68OIpLaFEsfw_1_3"></a><a id="Tc_5DFfbN0KckCDZVsQC6ajEw_1_5"></a><a id="Tc_pF7EXyH0Pkqt4BmdzJ-1bQ_2_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:36.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td colspan="3" style="vertical-align:top;width:19.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:36.33%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Title of each class</i></p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Trading Symbol(s)</i></p></td><td style="vertical-align:top;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:0pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:38.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Name of each exchange on which registered</i></p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:2.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:36.33%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:Security12bTitle" id="Tc_62NpR8z6Z02qXHS28ISf0w_2_1"><b style="font-size:9pt;font-weight:bold;">Ordinary shares, par value NIS 0.01 per share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:TradingSymbol" id="Tc_q4bv3dxMpUqZduc92-lkXw_2_3"><b style="font-size:9pt;font-weight:bold;">GLMD</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:0pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:38.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:SecurityExchangeName" id="Narr_ZUNHCFSSSkG9oYNydH_IoA"><b style="font-size:9pt;font-weight:bold;">Nasdaq</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> Capital Market</b></p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-indent:0pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Securities registered or to be registered pursuant to Section&#160;12(g)&#160;of the Act.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Title of each class</i></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">N/A</b></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Securities registered or to be registered pursuant to Section&#160;15(d)&#160;of the Act.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Title of each class</i></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">N/A</b></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report (December&#160;31, 2020): </b><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="0" name="dei:EntityCommonStockSharesOutstanding" id="Narr_yt-oriw8l02XMU7obgkljA">21,325,975</ix:nonFraction></b><b style="font-weight:bold;"> ordinary shares are outstanding</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </b><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span><span style="font-size:9pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_f1DcwU4ybUaeB9PBX0ACAA"><b style="font-size:9pt;font-weight:bold;">No</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;min-height:5.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934. Yes </b><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span><span style="font-size:9pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:EntityVoluntaryFilers" id="Narr_zwbE4jQseUqj60vn9MuwMA"><b style="font-size:9pt;font-weight:bold;">No</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Note&#160;&#8211; Checking the box above will not relieve any registrant required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 from their obligations under those Sections.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such a shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:EntityCurrentReportingStatus" id="Narr_ooOw-TLmpEufagr-HRrTrg"><b style="font-size:9pt;font-weight:bold;">Yes</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span><span style="font-size:9pt;"> </span><b style="font-size:9pt;font-weight:bold;">No </b><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files). </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:EntityInteractiveDataCurrent" id="Narr_zxPv0fdPikWJUWz6CGdELg"><b style="font-size:9pt;font-weight:bold;">Yes</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span><span style="font-size:9pt;"> </span><b style="font-size:9pt;font-weight:bold;">No </b><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Large accelerated filer </b><span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="Narr_5NsQNLQ7EU-BcLWcaLy_hg"><b style="font-size:9pt;font-weight:bold;">Accelerated filer</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Non-accelerated filer </b><span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-indent:18pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;white-space:pre-wrap;">Emerging growth company  </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_ZMk9ep5I4EGcTEAqttwTSw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> </span></p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act.&#160;</b><span style="font-family:'Times New Roman';">&#9723;</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Indicate by check mark whether the registrant has filed a report on and attestation to its management</b><b style="font-family:'Wingdings';font-size:9pt;font-weight:bold;">&#8217;</b><b style="font-size:9pt;font-weight:bold;">s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" format="ixt:booleantrue" name="dei:IcfrAuditorAttestationFlag" id="Narr_a9icZODTPEKsvXWLWsT3Qw"><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:20.06%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="dei:DocumentAccountingStandard" id="Narr_6l6ZiqlQV0aWXRktJ3DP3Q"><b style="font-size:9pt;font-weight:bold;">U.S. GAAP</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> &#61560;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:59.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">International Financial Reporting Standards</b></p></td><td style="vertical-align:top;white-space:nowrap;width:20.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Other </b><b style="font-family:'Times New Roman';font-weight:bold;">&#9723;</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:20.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:59.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:center;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">as issued by the International Accounting Standards Board&#160;</b><b style="font-family:'Times New Roman';font-weight:bold;">&#9723;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:20.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">If &#8220;Other&#8221; has been checked in response to the previous question indicate by check mark which financial statement item the Registrant has elected to follow: Item&#160;17 </b><span style="font-family:'Times New Roman';">&#9723;</span> <b style="font-weight:bold;">Item&#160;18 </b><span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="Narr_iKZKzLvcnEG3ilifCFVRTg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> </span><b style="font-size:9pt;font-weight:bold;">No </b><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE&#160;YEARS)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d)&#160;of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes </b><span style="font-family:'Times New Roman';">&#9723;</span> <b style="font-weight:bold;">No </b><span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;text-indent:18pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_74e8fbb3_c582_452c_b745_b748c81fd141"></a></div><div style="clear:both;margin-bottom:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#PARTI_856151"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">PART&#160;I</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM1IdentityofDirectorsSeniorManagement"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;1. Identity of Directors, Senior Management and Advisers.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM2OfferStatisticsandExpectedTimetable"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;2. Offer Statistics and Expected Timetable.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM3KeyInformation_909206"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;3. Key Information.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM4InformationontheCompany_490867"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;4. Information on the Company.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM4AUnresolvedStaffComments_630300"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;4A. Unresolved Staff Comments.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM5OperatingandFinancialReviewandProsp"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;5. Operating and Financial Review and Prospects.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM6DirectorsSeniorManagementandEmploye"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;6. Directors, Senior Management and Employees.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">105</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM7MajorShareholdersandRelatedPartyTra"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;7. Major Shareholders and Related Party Transactions.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">130</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM8FinancialInformation_119041"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;8. Financial Information.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">131</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM9TheOfferandListing_475955"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;9. The Offer and Listing.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">132</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM10AdditionalInformation_98709"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;10. Additional Information.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">132</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM11QuantitativeandQualitativeDisclosu"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;11. Quantitative and Qualitative Disclosures About Market Risk</span></a>.</p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">154</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM12DescriptionofSecuritiesOtherThanEq"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;12. Description of Securities Other Than Equity Securities</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">156</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM12DescriptionofSecuritiesOtherThanEq"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">PART&#160;II</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">156</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM13DefaultsDividendArrearagesandDelin"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;13. Defaults, Dividend Arrearages and Delinquencies.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">157</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM14MaterialModificationstotheRightsof"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;14. Material Modifications to the Rights of Security Holders and Use of Proceeds.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">157</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM15ControlsandProcedures_799339"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;15. Controls and Procedures.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">157</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM16RESERVED_241701"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;16. [RESERVED]</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">158</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM16AAuditCommitteeFinancialExpert_149"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;16A. Audit Committee Financial Expert.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">158</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM16BCodeofEthics_218288"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;16B. Code of Ethics.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">158</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM16CPrincipalAccountantFeesandService"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;16C. Principal Accountant Fees and Services.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">158</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM16DExemptionsfromtheListingStandards"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;16D. Exemptions from the Listing Standards for Audit Committees.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">159</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM16EPurchasesofEquitySecuritiesbytheI"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">159</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM16FChangeinRegistrantsCertifyingAcco"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;16F. Change in Registrant&#8217;s Certifying Accountant.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">159</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM16GCorporateGovernance_519265"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;16G. Corporate Governance.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">159</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM16HMineSafetyDisclosure_291077"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;16H. Mine Safety Disclosure.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">161</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#PARTIII_556100"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">PART&#160;III</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">162</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM17FinancialStatements_41502"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;17. Financial Statements.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">162</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM18FinancialStatements_850188"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;18. Financial Statements.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">162</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:89.99%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM19Exhibits_725828"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ITEM&#160;19. Exhibits</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">163</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_63837643_b451_498f_8b49_80097acc7543"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ABOUT THIS ANNUAL REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221; and &#8220;our Company&#8221;, in this Annual Report on Form&#160;20-F, or our annual report, are to Galmed Pharmaceuticals&#160;Ltd. and its subsidiaries, unless the context otherwise requires. All references to Aramchol mean Aramchol acid or Aramchol meglumine (salt), unless the context otherwise requires. All references to &#8220;shares&#8221; or &#8220;ordinary shares&#8221; are to our ordinary shares, NIS 0.01 nominal par value per share. All references to &#8220;Israel&#8221; are to the State of Israel. &#8220;U.S. GAAP&#8221; means the generally accepted accounting principles of the United States. Unless otherwise stated, all of our financial information presented in this annual report has been prepared in accordance with U.S. GAAP. Any discrepancies in any table between totals and sums of the amounts listed are due to rounding. Unless otherwise indicated, or the context otherwise requires, references in this annual report to financial and operational data for a particular&#160;year refer to the fiscal&#160;year of our company ended December&#160;31 of that&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our reporting currency and financial currency is the U.S. dollar. In this annual report, &#8220;NIS&#8221; means New Israeli Shekel, and &#8220;$,&#8221; &#8220;US$&#8221; and &#8220;U.S. dollars&#8221; mean United States dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CAUTIONARY NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This annual report contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;continue&#8221; or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements may be included in, among other things, various filings made by us with the U.S. Securities and Exchange Commission, or the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors summarized below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the timing and cost of our pivotal Phase 3 ARMOR trial, or the ARMOR Study, for our lead product candidate, Aramchol, or for any other pre-clinical or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">completion and receiving favorable results of the ARMOR Study for Aramchol or any other pre-clinical or clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the impact of the COVID-19 pandemic on our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the commercial launch and future sales of Aramchol or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to comply with all applicable post-market regulatory requirements for Aramchol or any other product candidate in the countries in which we seek to market the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to achieve favorable pricing for Aramchol or any other product or any other product candidate;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our expectations regarding the commercial market for non-alcoholic steato-hepatitis, or NASH, in patients or any other targeted indicated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">third-party payor reimbursement for Aramchol or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our estimates regarding anticipated capital requirements and our needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">market adoption of Aramchol or any other product candidate by physicians and patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to obtain and maintain adequate protection of our intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the possibility that we may face third-party claims of intellectual property infringement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to manufacture Aramchol or any other product candidate in commercial quantities, at an adequate quality or at an acceptable cost;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to establish adequate sales, marketing and distribution channels;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the development and approval of the use of Aramchol or any other product candidate for additional indications or in combination therapy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our expectations regarding licensing, acquisitions and strategic operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in this annual report in greater detail under the heading &#8220;Risk Factors&#8221; and elsewhere in this annual report. Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this annual report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.</p><a id="_74823e5c_c5f4_412e_be52_dd46f50e4d3b"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXPLANATORY NOTE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Market data and certain industry data and forecasts used throughout this annual report were obtained from internal company surveys, market research, consultant surveys commissioned by the Company, publicly available information, reports of governmental agencies and industry publications and surveys. Industry surveys, publications, consultant surveys commissioned by the Company and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable. However, this information may prove to be inaccurate because of the method by which some of the data for the estimates is obtained or because this information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties. As a result, the market and industry data and forecasts included or incorporated by reference in this annual report, and estimates and beliefs based on that data, may not be reliable. We have relied on certain data from third-party sources, including internal surveys, industry forecasts and market research, which we believe to be reliable based on our management&#8217;s knowledge of the industry. However, we have not ascertained the underlying economic assumptions relied upon therein. Forecasts are particularly likely to be inaccurate, especially over long periods of time. In addition, we do not necessarily know what assumptions regarding general economic growth were used in preparing the forecasts we cite. Statements as to our market position are based to the best of our knowledge on the most currently available data. While we are not aware of any misstatements regarding the industry data presented in this annual report, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; in this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2260352c_afc2_4d02_be5e_18c2bafe7e39"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTI_856151"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;I</b></p><a id="ITEM1IdentityofDirectorsSeniorManagement"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;1. Identity of Directors, Senior Management and Advisers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b6762e0d_a0d0_4dc2_ba77_a038be2fdf9d"></a><a id="ITEM2OfferStatisticsandExpectedTimetable"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;2. Offer Statistics and Expected Timetable.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f882b00a_fe30_4fc3_8809_c6c5f6b3b8ae"></a><a id="_contentSection_d2133a01_679e_4e7e_8516_"></a><a id="ITEM3KeyInformation_909206"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;3. Key Information.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A. Selected Financial Data.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth our selected consolidated financial data for the periods ended and as of the dates indicated, which reflects the financial data of the Company and the financial data of Galmed Holdings&#160;Inc., a holdings company incorporated in the British Virgin Islands, or GHI, our predecessor, prior to the Reorganization (as described below). The following selected consolidated financial data for our Company should be read in conjunction with the financial information, &#8220;Item&#160;5. Operating and Financial Review and Prospects&#8221; and other information provided elsewhere in this annual report and our consolidated financial statements and related notes. The selected consolidated financial data in this section is not intended to replace the consolidated financial statements and is qualified in its entirety thereby. In the opinion of our management, our unaudited consolidated financial statements contain all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of our financial position, results of operations and cash flows as of and for the periods indicated therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The selected consolidated statement of operations data for the&#160;years ended December&#160;31, 2018, 2019 and 2020, and the selected consolidated balance sheet data as of December&#160;31, 2019 and 2020, have been derived from our audited consolidated financial statements set forth elsewhere in this annual report. The selected consolidated balance sheet data as of December&#160;31, 2016 and 2017 have been derived from our audited consolidated financial statements not included in this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statement of Operations Data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:65.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2016</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="16" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 467</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,085</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,038</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,271</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,650</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,313</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,180</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,082</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,078</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,799</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,440</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,196</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,128</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,882</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,715</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,376</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,210</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Financial expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 372</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 232</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 42</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 144</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Financial Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (407)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (297)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (976)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,059)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,589)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Taxes on income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 106</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 16,953</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 12,299</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 9,856</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,461</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,771</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Comprehensive loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,832</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,221</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,860</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,415</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,534</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Diluted net loss per ordinary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1.49</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 0.98</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 0.54</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.97</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1.35</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted number of ordinary shares used in computing loss per ordinary shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,374,653</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,487,349</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,137,689</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,114,399</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,280,787</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheet data:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:65.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2016</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="16" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents and restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,097</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,021</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,159</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,043</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,060</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Short-term deposits and marketable securities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,351</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,976</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66,029</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,560</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43,939</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other receivables</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 284</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 155</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 218</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 827</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 812</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 718</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 491</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 194</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 709</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 570</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,450</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,643</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 90,600</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 77,139</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 52,381</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,375</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,848</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,706</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,286</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,228</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total shareholders&#8217; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,075</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,795</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 87,894</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 69,853</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 44,153</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Number of ordinary shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,149,226</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,435,161</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,018,919</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,139,385</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,325,975</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">ASU 2016-02 was adopted as of January&#160;1, 2019, using the modified retrospective method; previous periods were therefore not adjusted and might not be directly comparable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">B. Capitalization and Indebtedness.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">C. Reasons for the Offer and Use of Proceeds.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">D. Risk Factors.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An investment in our ordinary shares is subject to a number of risks. The following summarizes some, but not all, of these risks. Please carefully consider all of the information discussed in &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; in this annual report for a more thorough description of these and other risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Our Financial Position and Capital Requirements</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We are a clinical-stage biopharmaceutical company with a history of operating losses. We expect to incur significant additional losses in the future and may never be profitable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We have not yet commercialized any products and we may never be able to do so, and even if we do, the products may not gain market acceptance.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We will need substantial, additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We are unable to estimate our long-term capital requirements due to uncertainties associated with the development and commercialization of Aramchol.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Our Business, Industry and Regulatory Requirements</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our business is subject to risks arising from epidemic diseases, such as the recent COVID-19 pandemic, which has impacted and could continue to impact our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The clinical trial process is complex and expensive, and commencement and completion of clinical trials can be delayed or prevented for a number of reasons, including as a result of the COVID-19 pandemic.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">There is significant uncertainty regarding the regulatory approval process for any investigational new drug, substantial further testing and validation may be required, and regulatory approval may be conditioned, delayed, or denied, any of which could delay or prevent us from successfully receiving marketing approval and substantially harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Failure to obtain, or any delay in obtaining, FDA or any foreign regulatory approval regarding any potential switch of Aramchol free acid to Aramchol meglumine (salt) in our ongoing ARMOR Study may have a material adverse effect on our business, operating results, financial condition and prospects. Furthermore, although we have submitted patent applications for our Aramchol salts in development, there is no assurance that we will receive any patents for them and even if granted or with respect to granted patents, they are still subject to challenge.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Commencement of our ARMOR Study in jurisdictions outside the United States is subject to acceptance of the foreign equivalent of our IND by regulatory authorities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We may be forced to abandon development of Aramchol or any other product candidate which would have a material adverse effect on our business and may force us to cease operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We recently started developing Aramchol in combination with other therapies, which exposes us to additional risks.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The lack of a reliable non-invasive method for the diagnosis of NASH is likely to present a major challenge to Aramchol&#8217;s market penetration, if ever commercialized.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our Amilo-5Mer program is being conducted under a research and option agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, or Yissum. If we decide to further develop Amilo-5Mer beyond our planned first-in-human Phase I study, we plan to exercise our option to negotiate and enter into a definitive license agreement with Yissum. If we are unable to enter into a definitive license agreement, we would not have the ability to continue the development and potential commercialization of Amilo-5Mer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">If we acquire or in-license additional technologies or product candidates, we may incur significant, incremental expenses, may have integration difficulties and may experience other risks that could harm our business and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The lack of a reliable non-invasive method for the diagnosis of NASH is likely to present a major challenge to Aramchol&#8217;s market penetration, if ever commercialized.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We manage our business through a small number of senior executive officers. We depend on them even more than similarly- situated companies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Our Reliance on Third Parties</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We</span><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"> </b><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">have no manufacturing capacity and anticipate reliance on third-party manufacturers for Aramchol or any other product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our current and potential future product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We depend on third parties to conduct our clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Our Intellectual Property</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The failure to obtain or maintain patents, licensing agreements and other intellectual property rights that are sufficiently broad and protective could impact our ability to compete effectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our potential development of Aramchol meglumine may not result in improved bioavailability compared to the existing form of Aramchol. Furthermore, although we have pending patent applications and granted patent covering Aramchol meglumine in development, there is no assurance that we will receive any patents for them, and even if we receive one or more patents for our Aramchol meglumine in development, they may be of little or no commercial value.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Ownership of Our Ordinary Shares</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The market price of our ordinary shares is volatile and you may sustain a complete loss of your investment.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our President and Chief Executive Officer, along with our principal shareholders, beneficially own approximately 18% of our outstanding ordinary shares, as of February 28, 2020. Therefore, our principal shareholders will be able to exert significant control over matters submitted to our shareholders for approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our U.S. shareholders may suffer adverse tax consequences due to our classification as a passive foreign investment company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Israeli Law and Our Operations in Israel</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our headquarters and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Provisions of Israeli law and our articles of association, or Articles, may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Your rights, liabilities and responsibilities as a shareholder will be governed by Israeli law and differ in some material respects from those under U.S. law.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An investment in our ordinary shares involves a high degree of risk. Prior to making a decision about investing in our ordinary shares, you should carefully consider the risks, uncertainties and assumptions set forth below. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business. If any of these risks occur, our business, financial condition and operating results could be harmed, the trading price of our ordinary shares could decline and you could lose part or all of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Capital Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are a clinical-stage biopharmaceutical company with a history of operating losses. We expect to incur significant additional losses in the future and may never be profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company with an operating history limited to pre-clinical and clinical drug development and no approved products. In addition, we have limited operating experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the pharmaceutical industry. We have funded our research and development programs and operations to date primarily through proceeds from private placements and public offerings. We currently have no products approved for marketing in the United States or any other jurisdiction and have not generated any revenue from product sales to date, although we have generated revenue from our licensing agreement with Samil Pharm. Co.,&#160;Ltd., or Samil. We have incurred operating losses in each&#160;year since the inception of our predecessor in 2000. Our loss attributable to holders of our ordinary shares for the&#160;years ended December&#160;31, 2018, 2019, and 2020 was approximately $9.9 million, $20.5 million and $28.8 million, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $135.7 million. Substantially all of our operating losses resulted from costs incurred in connection with our development program and from general and administrative costs associated with our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our ability to become profitable depends upon our ability to generate revenue in excess of our expenses. To date, we have not generated any revenue, excluding the licensing revenue we recorded in connection with that certain Samil Agreement (as defined below), as our lead product candidate, Aramchol is still in clinical development and has not been approved by the FDA, nor has any other product candidate. We do not know when, or if, we will generate any revenue from sales of Aramchol, Amilo-5MER and/or any other product candidate. We do not expect to generate revenue other than subsequent royalties and/or milestones that can be earned in connection with the Samil Agreement or other potential license agreements, unless and until we, or an ultimate third-party licensor or acquirer, obtain regulatory and marketing approval of, and commercialize, Aramchol or any other product candidate. We will continue to incur significant research </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and development and general and administrative expenses related to our operations. We expect to continue to incur losses for the foreseeable future, which may be significant, and these losses will likely increase as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">manage our ongoing ARMOR Study and any additional clinical trials for Aramchol or any other product candidate and initiate additional research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">seek regulatory approvals for Aramchol or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">implement internal systems and infrastructures, including, without limitation, hiring of additional personnel as needed and developing sales and marketing functions if and when Aramchol or any other product candidate receives applicable regulatory approval and we opt to commercialize it ourselves;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">seek to in-license additional products or technologies to develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">hire additional management and other personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">move towards commercialization of Aramchol or any other product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may out-license Aramchol or any other product candidate including through a territorial license, a worldwide license, or a license for a particular indication, before it is approved by any applicable regulatory agency, commercialized and/or generates revenue, depending on a number of factors, including, but not limited to, our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">demonstrate a compelling and/or novel, pre-clinical, unique mechanism of action of Aramchol, Amilo-5Mer or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">obtain adequate clinical results from and progress from the clinical development of Aramchol or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">develop and obtain regulatory approvals in the countries and for the uses we intend to pursue for Aramchol or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">contract for the manufacture of commercial quantities of Aramchol or any other product candidate by a current good manufacturing practice, or cGMP, compliant manufacturing facility at acceptable cost levels if marketing approval is received; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">establish external, and potentially in the future, internal, sales and marketing capabilities to effectively market and sell Aramchol or any other product candidate in the United States and other countries.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if Aramchol or any other product candidate is approved for commercial sale, it may not gain market acceptance or achieve commercial success. In addition, we anticipate incurring significant costs associated with seeking regulatory approval and commercialization. We may not achieve profitability soon after generating product revenue, if ever. If we are unable to generate product revenue, we will not become profitable and would be unable to continue operations without additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our research and development expenses to significantly increase in connection with our ARMOR Study and initiation of any other pre-clinical or clinical trials. In addition, if we obtain marketing approval for Aramchol , Amilo-5Mer or any other product candidate and opt to commercialize it ourselves, we will likely initially incur significant expenses associated with outsourcing sales, marketing and manufacturing functions to third parties, as well as continued research and development expenses. Furthermore, we expect to incur additional costs associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our limited operating history makes it difficult to evaluate our business and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operating history is limited to pre-clinical and clinical development of one product, and our operations to date have been limited primarily to research and development, raising capital and recruiting scientific and management personnel and third-party partners. Therefore, it may be difficult to evaluate our business and prospects. We have not yet demonstrated an ability to commercialize or obtain regulatory approval for any product candidate. Consequently, any predictions about our future performance may not be accurate, and you may not be able to fully assess our ability to complete development and/or commercialize our product candidates, obtain regulatory approvals or achieve market acceptance or favorable pricing for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have not yet commercialized any products and we may never be able to do so, and even if we do, the products may not gain market acceptance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not yet commercialized any products and we may never be able to do so. We do not know when or if we will complete development of Aramchol or any other product candidate, obtain regulatory approval, or successfully commercialize any approved products. Even if we are successful in developing products that are approved for marketing, we will not be successful unless these products gain market acceptance for appropriate indications at favorable reimbursement rates. The degree of market acceptance for these products will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the timing and scope of regulatory approvals in the countries we intend to pursue with respect to the commercialization of Aramchol or any other product candidate, including the indications for which they are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the competitive environment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the ability for Aramchol, Amilo-5MER or any other product candidate to be manufactured, whether by us or third parties, in compliance with applicable regulatory requirements, including cGMP;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">our ability to effectively promote Aramchol or any other product candidate, whether directly or using third parties, consistent with the approved indications and labeling in the countries in which we intend to pursue approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the acceptance by the medical community of the safety and clinical efficacy of Aramchol or any other product candidate and their potential advantages over other therapeutic products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the development of a non-invasive method for diagnosing NASH as an alternative to the current gold standard of liver biopsy, which we view as a rate-limiting factor to complete market uptake because of its expense and its risks and discomfort to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the adequacy and success of distribution, sales and marketing efforts, including through strategic agreements with pharmaceutical and biotechnology companies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the pricing and reimbursement policies of government and third-party payors, such as insurance companies, health maintenance organizations and other plan administrators.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Physicians, patients, third-party payors or the medical community in general may be unwilling to accept, utilize or recommend, and in the case of third-party payors, reimburse any of our planned future products. As a result, we are unable to predict the extent of future losses or the time required to achieve profitability, if at all. Even if we successfully develop one or more products, we may not become profitable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need substantial, additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, we had a net working capital of $44.0 million, cash and cash equivalents of $6.9 million, restricted cash of $0.1 million, short-term deposits of $3.8 million and marketable debt securities of $40.1 million. Based on our current operating plan, we currently estimate that our cash position will support our current clinical trials and operations as currently conducted for more than 12 months from the date of issuance of this annual report. We will need to raise substantial, additional capital to fund our operations and to develop Aramchol and Amilo-5MER for, and beyond their current development stage, and ultimately commercialize them, if we opt to do so ourselves. In addition, we may choose to expand our current research and development focus, or other clinical operations as well as the development of Aramchol or any other product candidate for other indications or development of other molecules and/or combination of Aramchol with other molecules for NASH or other liver and inflammatory diseases as well as non-invasive biomarkers, which may also require additional capital. Our future capital requirements may be substantial and will depend on many factors including :</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the acceptance of any amendments to our Investigational New Drug application, or IND, or foreign equivalent for the ARMOR Study by the FDA and any other foreign regulatory authority and the acceptance of any other IND or foreign equivalent for any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">adhering to patient recruitment in our clinical trials and sponsored trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">our clinical trials and sponsored trials results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">developing Aramchol and combination of it for the treatment of other conditions or indications beyond NASH, or possible label expansion of Aramchol once its approved, if at all, for the treatment of other conditions or indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the cost of filing and prosecuting patent applications and the cost of defending our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the cost of prosecuting infringement actions against third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the cost, timing and outcomes of seeking marketing approval of Aramchol or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs associated with commercializing Aramchol or any other product candidate if we receive marketing approval, and choose to commercialize our product candidates ourselves, including the cost and timing of establishing external, and potentially in the future, internal, sales and marketing capabilities to market and sell our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs associated with any product liability or other lawsuits related to Aramchol or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs associated with post-market compliance with regulatory requirements, and of addressing any allegations of non-compliance by regulatory authorities in countries where we plan to market and sell Aramchol or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the demand for Aramchol or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs associated with developing and/or in-licensing other research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the expenses needed to attract and retain skilled personnel; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs associated with being a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changing circumstances may cause us to consume capital significantly faster than we currently anticipate, such as losing our Small and Medium Enterprise status at the EMA, which entitles us to significant fee reductions. Because there are numerous risks and uncertainties associated with the development and commercialization of Aramchol or any other product candidate, we are unable to estimate the amount of increased capital outlays and operating expenditures associated with our anticipated clinical trials. We have no committed external sources of funds. Additional financing may not be available when we need it or may not be available on terms that are favorable to us and additional financing may cause significant dilution to our existing shareholders. If adequate funds are not available to us on a timely basis, or at all, we may be required to terminate or delay planned or ongoing clinical trials or other development activities for Aramchol or any other product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may be costly or difficult to obtain and will dilute current shareholders&#8217; ownership interests, potentially substantially.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any debt, equity or structured financing that we may need or desire may not be available on terms favorable to us, or at all. If we obtain funding through a strategic collaboration or licensing arrangement, we may be required to relinquish our rights to certain of our technologies, products or marketing territories. If we are unable to obtain required additional capital, we may have to curtail our growth plans or cut back on existing business, and we may not be able to continue operating if we do not generate sufficient revenues from operations needed to stay in business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely impact our capital structure, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any additional capital raised through the sale of equity or equity-linked securities will dilute our current shareholders&#8217; ownership in us, potentially substantially, and could also result in a decrease in the market price of our ordinary shares. The terms and conditions of those securities issued by us in future capital transactions may be more favorable to new investors and may include the issuance of warrants or other derivative securities, which may have a further dilutive effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are unable to estimate our long-term capital requirements due to uncertainties associated with the development and commercialization of Aramchol or any other product candidate. If we fail to obtain necessary funds for our operations, we will be unable to develop and commercialize Aramchol or any other product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our long-term capital requirements are expected to depend on many potential factors, including, among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the number of product candidates in development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the size, duration and scope of existing and future clinical trials and pre-clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the regulatory path of Aramchol or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the results of our clinical trials, which are unpredictable in product candidate development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">our ability to successfully commercialize Aramchol or any other product candidate, including securing commercialization and out-licensing agreements with third parties and favorable pricing and market share;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the progress, success and cost of our clinical trials and research and development programs, including those associated with milestones and royalties;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs, timing and outcome of regulatory review and obtaining regulatory approval of Aramchol or any other product candidate and addressing regulatory and other issues that may arise post-approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the breadth of the labeling, assuming that Aramchol or any other product candidate are approved for commercialization by a relevant regulatory authority, which may not occur;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">our need, or decision, to acquire or in-license complementary technologies or new platform technologies or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs of enforcing our issued patents and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs of investigating patents that might block us from developing potential product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs of recruiting and retaining qualified personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs associated with contracting with third parties to manufacture the product and to perform other necessary services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">our revenue, if any; and</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our consumption of available resources more rapidly than currently anticipated, resulting in the need for additional funding sooner than anticipated.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain the funds necessary for our operations, we will be unable to develop and commercialize Aramchol or any other product candidate which would materially and adversely affect our business, liquidity and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Business,&#160;Industry and Regulatory Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business is subject to risks arising from epidemic diseases, such as the recent COVID-19 pandemic, which has impacted and could continue to impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In late 2019, a novel strain of COVID-19, also known as coronavirus, was reported in Wuhan, China. Initially the outbreak was largely concentrated in China, but it rapidly spread to countries across the globe, including in Israel and the United States. Many countries around the world, including in Israel and the United States, implemented significant governmental measures to control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and the movement of people, and other material limitations on the conduct of business. In response, we have implemented remote working and workplace protocols for our employees in accordance with Israeli Ministry of Health requirements to ensure employee safety. Many of our trial sites in our ARMOR Study are based in areas currently affected by COVID-19 and there is a general unease of conducting scheduled or elective procedures in medical centers. Given the significant strains on the healthcare system across the globe, during 2020 we temporarily halted the screening of new patients for the ARMOR Study and temporarily suspended the opening of new trial sites. Although we subsequently resumed screening activities and recruitment, in December 2020 we announced the addition of an open label part to the ARMOR Study and temporarily suspended randomization of new patients into the double-blind, placebo-controlled histology-based registrational phase of the ARMOR Study as currently enrolled patients are transitioned to the open label part. The open label part is being conducted in a smaller subset of the ARMOR study which have been less affected by the COVID-19 pandemic. We continue to closely monitor the local situation in the U.S. and other countries around the world. To help mitigate cost overrun, we have taken several cost reduction measures including minimizing clinical related expenses, making certain adjustments to clinical staff and pay according to the current and predicted level of activity, and we downsized our in-house clinical force and we reduced directors&#39; cash fees by 50% for the first half of 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the rapid development and fluidity of the COVID-19 pandemic precludes any firm estimates as to the ultimate effect this disease will have on our clinical trials, our operations and our business and it is not possible to predict the impact of the second and any further wave of COVID-19. As a result, any current assessment of the effects of the COVID-19 pandemic, including the impact of this disease on the ARMOR Study and any other pre-clinical or clinical studies, is difficult to predict and subject to change and we may experience further disruptions that could severely impact our business, clinical trials, and supply chains, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff for the ARMOR Study or any other clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays or difficulties in enrolling patients for the ARMOR Study or any other clinical trial especially if sites do not reopen to screen and enroll patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals and other medical centers serving as our clinical trial sites and hospital and other staff supporting the conduct of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">interruption of, or delays in receiving, supplies of Aramchol or any other product candidate from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays in clinical sites receiving the supplies and materials needed to conduct the ARMOR Study or any other clinical trial and interruption in global shipping that may affect the transport of clinical trial materials;</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">limitations on employee resources that would otherwise be focused on the conduct of the ARMOR Study or any other clinical trial, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">interruptions or delays in the operations of the FDA, EMA or other regulatory authorities, including in receiving feedback or approvals from the FDA, EMA or other regulatory authorities with respect to regulatory submissions;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">changes in local regulations as part of a response to COVID-19 which may require us to change the ways in which the ARMOR Study or any other clinical trial is being conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">refusal of the FDA, EMA or other regulatory authorities to accept data from clinical trials in affected geographies; and</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">impacts from prolonged remote work arrangements, such as increased cybersecurity risks and strains on our business continuity plans.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the spread of COVID-19 has had and may continue to severely impact the trading price of shares of our ordinary shares and could impact our ability to raise additional capital on a timely basis or at all. The COVID-19 pandemic continues to rapidly evolve. The extent to which the COVID-19 pandemic may continue to impact our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the geographic spread of the disease, the duration of the pandemic, travel restrictions, quarantines, shelter-in-place orders and social distancing, business closures or business disruptions and the effectiveness of actions taken to contain and treat the disease. The impact of the COVID-19 pandemic may also have the effect of heightening many of the other risks described in the &quot;Risk Factors&quot; section of this Annual Report on Form 20-F.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The clinical trial process is complex and expensive, and commencement and completion of clinical trials can be delayed or prevented for a number of reasons, including as a result of the COVID-19 pandemic.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to complete or commence the clinical trials that would support our submission of an NDA to the FDA, a Marketing Authorization Application or MAA, to the EMA or any similar submission to regulatory authorities in other countries. Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical trials. The fact that the FDA, EMA or other regulatory authorities permit a company to conduct human clinical trials is no assurance or guarantee that the trials will be successful. On the contrary, most candidate drugs that begin clinical trials do not prove to be successful and do not result in the filing of an NDA, MAA or similar filing. Drug candidates that successfully complete one phase of clinical trials may prove unsuccessful at a subsequent phase. Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements and in part because the results of clinical trials are inherently uncertain and unpredictable. Regulatory authorities, such as the FDA, may decline to permit a clinical trial to proceed or may suspend a clinical trial that it has previously permitted to proceed. Additionally, the clinical trial process is time-consuming, and failure can occur at any stage of the trials. We may encounter problems that cause us to abandon or repeat clinical trials. The commencement and completion of clinical trials may be delayed by several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">difficulties obtaining regulatory authorization to commence a clinical trial or complying with regulatory requirements for clinical trials or with the conditions imposed by a regulatory authority regarding the scope or duration of a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays in reaching or failing to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">insufficient or inadequate supply or quality of a product candidate or other materials necessary to conduct our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">difficulties in obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">challenges in recruiting and enrolling patients to participate in clinical trials for a variety of reasons, including size and nature of patient population, proximity of patients to clinical sites, eligibility and exclusion criteria for the trial, nature of trial protocol, the availability of approved effective treatments for the relevant disease and competition from other clinical trial programs for similar indications; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">inadequate funding.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even though we initiated the Phase 3 ARMOR Study, the ARMOR Study may still be terminated as a result of, but not limited to, safety signals. In addition, the ARMOR Study or other clinical trials may be suspended or terminated by us, the FDA or other regulatory authorities, the principal investigator at a site, the IRBs at the sites where such boards are overseeing a trial or the data safety monitoring board, or the DSMB, that is overseeing the clinical trial at issue, or other regulatory authorities due to a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">irregularities in conducting a clinical trial, including by way of example, failure to conduct the clinical trial in accordance with regulatory requirements, in particular good clinical practice requirements, or GCP, or the FDA-authorized clinical protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">negative findings upon inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">safety issues or lack of clinical drug activity or effectiveness; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">lack of adequate funding to continue the clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have already experienced material delays in both the ARMOR Study largely related to significantly slower than expected recruitment and the ARREST Study largely related to significantly slower than expected recruitment and the length of time required to obtain regulatory authorizations to proceed with clinical trials. We may experience further delays in any or all of our clinical trials, in particular as a result of the COVID-19 pandemic, and there can be no assurance that we will not experience such risks in the future as we progress with our planned clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, positive results in previous clinical studies of our product candidates may not be predictive of similar results in future clinical trials. Also, interim results, if at all, during a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in early- and mid-stage development. Accordingly, the results from the completed pre-clinical studies and clinical trials for our product candidates may not be predictive of the results we may obtain in later stage trials. Our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and/or pre-clinical trials, or to even terminate the development program entirely. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in pre-clinical and clinical studies have nonetheless failed to obtain FDA or EMA, or other regulatory agency, approval for their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we or regulatory authorities may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if the regulatory authorities find deficiencies in our regulatory submissions or the conduct of such trials. Any suspension of clinical trials will delay possible regulatory approval, if any, and adversely impact our ability to develop products and generate revenue.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">There is significant uncertainty regarding the regulatory approval process for any investigational new drug, substantial further testing and validation may be required, and regulatory approval may be conditioned, delayed, or denied, any of which could delay or prevent us from successfully receiving marketing approval and substantially harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical products generally are subject to rigorous nonclinical testing and clinical studies and other approval procedures mandated by the FDA and foreign regulatory authorities. Various federal and foreign statutes and regulations also govern or materially influence the manufacturing, safety, labeling, storage, record keeping, and marketing of pharmaceutical products. The process of obtaining these approvals and the subsequent compliance with appropriate U.S. and foreign statutes and regulations is time-consuming and requires the expenditure of substantial resources. With respect to Aramchol, to date, there are no approved therapies for NASH. The regulatory approval process for product candidates such as ours can be more expensive and take longer than other, better known or extensively studied pharmaceutical or other product candidates. There is not a tested and successful approval path for NASH drugs that we can use as an example and we expect that such a path for regulatory approval for NASH treatments may continue to evolve in the near term as we and other companies refine our regulatory approval strategies and interact with regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2019, we initiated the ARMOR Study. As part of our ongoing review process, we received certain comments from the FDA in the form of guidance regarding our ARMOR Study trial design and statistical analysis plan in which, among other things, the FDA recommended that we should consider that the duration of the first phase of the study (histology based) be extended to longer than 52 weeks and that the study safety database be increased. We are in an ongoing dialogue with the FDA with respect to the comments and have made certain amendments to the ARMOR Study including the addition of an open label part and an extension of the histology-based phase to 72 weeks while reducing the number of patients in the histology-based phase from 1200 to 1000. There can be no assurance that the FDA will accept these changes. As a result of the changes to the ARMOR Study design, this has resulted in extending the duration of the ARMOR Study and has made the clinical trial process more expensive. We plan to transition from Aramchol free acid to Aramchol meglumine (salt), and this may further result in additional delays in the completion of the ARMOR Study and may result in further clinical trial expenses. In addition, our primary use patent for Aramchol for the treatment of fatty liver is expected to expire prior to submission of a new drug application, or NDA, precluding any patent restoration term for the primary use patent (See &quot;<i style="font-style:italic;">Failure to obtain, or any delay in obtaining, FDA or any foreign regulatory approval regarding any potential transition from Aramchol free acid to Aramchol meglumine (salt) in our ongoing ARMOR Study may have a material adverse effect on our business, operating results, financial condition and prospects. Furthermore, although we have submitted patent applications for our Aramchol salts in development, there is no assurance that we will receive any patents for them</i>&quot;). Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements, which may require us to complete additional preclinical studies or clinical trials or impose stricter approval conditions than we currently expect. In addition, the FDA has indicated that the results of the ARMOR Study must be unequivocal and highly persuasive for a single Phase 3 study to support approval of an NDA. Therefore, even if the ARMOR Study meets all of its statistical goals and protocol endpoints, the FDA may not view the results as sufficient to support an NDA. Any additional delays in the completion of the ARMOR Study or any additional preclinical studies or clinical trials would require us to expend substantial additional resources and could significantly extend the timeline for clinical development prior to market approval. As a result of the foregoing, the research and development, preclinical studies and clinical testing of Aramchol and any other product candidate is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the development process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are currently planning to transition from Aramchol free acid to Aramchol meglumine (salt) in our randomized, double-blind, placebo-controlled part of the ARMOR Study. As part of our research and development studies, we have confirmed that several Aramchol salts have improved solubility as compared to the existing form of Aramchol free acid. We have a pending patent application and have been granted a composition of matter patent application for Aramchol meglumine as well as a wide range of other salts, and a method for treating hepatic fibrosis and fibrosis in non-alcoholic fatty acid liver disease. In addition, we have since submitted additional patent applications for Aramchol meglumine, including a low dose composition for Aramchol meglumine. We have since been granted a composition of matter patent for Aramchol salts which includes claims for the treatment of fatty liver in Europe and certain other countries while the patent application is still pending in the U.S. and certain other countries.We have been granted a low dose composition of matter patent for Aramchol meglumine in the U.S. Our composition of matter claims covering Aramchol meglumine patents that have been granted expire in 2034, subject to appropriate maintenance, renewal, annuity or other governmental fees being paid, and our pending application directed to use of Aramchol meglumine for treating hepatic fibrosis and fibrosis in non-alcoholic fatty acid liver disease will expire if and when issued in 2037. There can be no assurance that the U.S. Patent and Trademark Office, or the USPTO, or any other foreign equivalent will issue any additional patents based on the patent applications that we submitted to protect our Aramchol salts, nor, should the USPTO or foreign equivalent issue any patents to us with respect to the Aramchol salts, that we will be provided with adequate protection against potentially competitive products. Furthermore, if the USPTO or foreign equivalent issues us one or more patents for the Aramchol salts or with respect to already issued patents for the Aramchol salts, there can be no assurance that the issued patents will be of any commercial value, or that private parties or competitors will not successfully challenge these patents or circumvent these patents in the United States or their counterparts abroad. In the absence of adequate patent protection, our business may be adversely affected by competitors who develop comparable technology or products and our commercial prospects may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Results from a recent cross over PK study in dogs testing single and multiple oral administration doses of Aramchol free acid and Aramchol meglumine demonstrated bioequivalence with reduced variability. We plan to submit these results along with other supportive data to the FDA and discuss with the FDA, as soon as practical, a plan to appropriately transition from Aramchol free acid to the Aramchol meglumine in the ongoing ARMOR Study. Based on our regulatory and scientific review of relevant FDA guidance and precedents, we expect that we will be required to demonstrate to the FDA that the Aramchol meglumine is bioequivalent to Aramchol free acid in humans and that a number of other data considerations are addressed. Demonstrating bioequivalence requires evidence that there is no significant difference in the rate and extent to which the active ingredient is absorbed and becomes available at the site of action compared to the product with which it is considered interchangeable. However, the FDA or any foreign regulatory authority may determine that our data are not sufficient to support a transition to Aramchol meglumine in the ARMOR trial. If this is the case, the FDA or any foreign regulatory authority may require that we provide additional bioequivalence data, preclinical or clinical data or other data to provide evidence to support the transition to Aramchol meglumine. The size, scope, length and costs of any new or supplemental testing or clinical trials that may be required by the FDA or any foreign regulatory authority to provide such data are not known at this time. Failure or delay in obtaining FDA or foreign regulatory authority approval of the transition to Aramchol meglumine or the FDA or any foreign regulatory authority requiring us to provide additional clinical data may result in delays to our current projected timelines for the ARMOR Study and could have a material adverse effect on our business, operating results, financial condition and prospects. In addition, even if we receive FDA or foreign regulatory authority to transition to Aramchol meglumine, we may experience delays or other disruptions in manufacturing and supplying clinical trial materials for use in the ARMOR Study or any other clinical trial which could have a material adverse effect on our business, operating results, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, success in our earlier pre-formulation studies of Aramchol meglumine does not ensure that later studies will be successful, and the results of later studies may not replicate the results of our prior pre-formation studies. Furthermore, either or both of any future PK and formulation development studies may fail to demonstrate that the Aramchol meglumine result in an improvement in solubility and bioavailability. If any such studies do not support our claims, the completion of development of Aramchol meglumine may be significantly delayed or abandoned and may cause us to abandon development of Aramchol free acid, which would have a material adverse effect on our business, operating results, financial condition and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend largely on the success of our lead product candidate, Aramchol, and we may not obtain regulatory approval of Aramchol.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have invested almost all of our efforts and financial resources in the research and development (clinical and pre-clinical) of our lead product candidate, Aramchol. As a result, our business is largely dependent on the success of the ARMOR Study and our ability to complete the development of, obtain regulatory approval for and successfully commercialize Aramchol in a timely manner. The process to develop, obtain regulatory approval for and commercialize Aramchol is long, complex, costly and uncertain as to its outcome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The research, development, testing, clinical trials, manufacturing, labeling, approval, sale, marketing and distribution of drugs are subject to extensive regulation by the FDA and other regulatory agencies in other countries. These regulations differ from jurisdiction to jurisdiction. We have not received marketing approval for Aramchol in any jurisdiction. We are not permitted to market Aramchol, or any other product candidate, in the United States until we receive approval of a New Drug Application, or NDA, from the FDA, or in any foreign countries until we receive the requisite approval from the respective regulatory agencies in such countries. The results of clinical trials may be unsatisfactory, and even if we believe those clinical trials to be successful, the FDA, or other regulatory authorities, may not grant marketing authorization should we be in a position to request it.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The requirements and length of time for approval vary in different jurisdictions and could involve additional studies of Aramchol beyond those we currently anticipate, including potentially post-approval studies. The time required to obtain approval in other countries might differ from that required to obtain FDA approval in the United States. The marketing approval process in other countries may include all of the risks detailed above regarding FDA approval as well as other risks. In particular, in many countries outside the United States, it is required that a product receive pricing and reimbursement approval before the product can be commercialized. This can result in substantial delays in such countries. In other countries, product approval depends on showing superiority to an approved therapy. This can result in significant expense to conduct complex clinical trials. Finally, we do not have any products approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of Aramchol or any other product candidate will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketing approval in one jurisdiction does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the regulatory process in others. Failure to obtain marketing approval in other countries or any delay or setback in obtaining such approval would impair our ability to develop foreign markets for Aramchol. This would reduce our target market and limit the full commercial potential of Aramchol.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Commencement of our ARMOR Study in jurisdictions outside the United States is subject to acceptance of the foreign equivalent of our IND by regulatory authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2019, we initiated the ARMOR Study and recently we added an open label part to the study. In the event that the FDA or any other regulatory authority requires us to complete additional preclinical and/or clinical studies or we are required to satisfy other FDA or other regulatory requests, the start of the ARMOR Study in the applicable jurisdiction or any of our other programs may be delayed or not started at all. For example, certain regulatory agencies in Europe are requiring that we conduct additional clinical studies prior to initiating ARMOR in those jurisdictions. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence our clinical trial or change their position on the acceptability of our planned trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials or impose stricter approval conditions than we currently expect. As a result of the foregoing, the research and development, preclinical studies and clinical testing of any product candidate is expensive and can take many&#160;years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the development process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be forced to abandon development of Aramchol &#160;or any other product candidate which would have a material adverse effect on our business and may force us to cease operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon the completion of any clinical or pre-clinical trial and/or tests, the results might not support the desired indications for use. Further, success in earlier clinical trials does not ensure that later clinical trials will be successful, and the results of later clinical trials may not replicate the results of prior clinical trials or pre-clinical testing. The clinical trial process may fail to demonstrate that Aramchol or any other product candidate is safe and/or effective for the indications we seek. Any such failure may cause us to abandon Aramchol or any other product candidate and may delay development of other potential product candidates. Any delay in, or termination or suspension of, our clinical trials may delay the requisite filings with the FDA or other regulatory agencies and, ultimately, our ability to commercialize Aramchol or any other product candidate and generate product revenues. In September&#160;2019, we initiated the ARMOR Study. If the results of the ARMOR Study or any other study, including in any interim readout, are not compelling, then the completion of development of our product candidates may be significantly delayed or abandoned which would have material adverse effect on our business, liquidity, operating results and financial condition and may force us to cease operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We recently started developing Aramchol in combination with other therapies, which exposes us to additional risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recently started developing Aramchol in combination with investigational therapies. For example, we recently entered into a research agreement aiming at combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH and we recently entered into a research collaboration with MyBiotics Pharma Ltd., or MyBiotics to investigate the combination of MyBiotics&#39; microbiome therapeutic platform and Aramchol. We will not be able to market and sell Aramchol or any product candidate we develop in combination with an unapproved therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product candidate. In addition, unapproved therapies face the same risks described with respect to Aramchol or any other product candidate currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA or EMA approval. If the FDA, EMA or comparable foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with the product candidates we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain approval of or market such combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The lack of a reliable non-invasive method for the diagnosis of NASH is likely to present a major challenge to Aramchol&#8217;s market penetration, if ever commercialized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Liver biopsy is the standard approach for the diagnosis of inflammation and fibrosis associated with NASH. However, the procedure-related morbidity and, in rare cases, mortality, sample errors, costs, patient discomfort and thus lack of patient interest in undergoing the procedure limit its use. As such, only patients with a high risk of NASH, which includes patients with metabolic syndrome and an indication of Non-Alcoholic Fatty Liver Disease, or NAFLD, are generally sent for liver biopsy. Because NASH tends to be asymptomatic until the disease progresses, many individuals with NASH remain undiagnosed until the disease has reached its late stages, if at all. The lack of a reliable non-invasive method for the diagnosis of NASH is likely to present a major challenge to Aramchol&#8217;s market penetration, as many practitioners and patients may not be aware that a patient suffers from NASH and requires treatment. As such, use of Aramchol might not be as wide-spread as our actual target market and this may limit the commercial potential of Aramchol.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A further challenge to Aramchol&#8217;s market penetration is that currently a liver biopsy is the standard approach for measuring improvement in NASH patients. Because it would be impractical to subject all patients that take Aramchol, when and if it approved, to regular and repeated liver biopsies, it will be difficult to demonstrate Aramchol&#8217;s effectiveness to practitioners and patients unless and until a reliable non-invasive method for the diagnosis and monitoring of NASH becomes available, as to which there can be no assurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we, and other companies in the industry are currently working on advancing non-invasive diagnostic approaches, none of these has been clinically validated, and the timetable for commercial validation, if at all, is uncertain. Moreover, such diagnostics may also be subject to regulation by FDA or other regulatory authorities as medical devices and may require premarket clearance or approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Amilo-5Mer program is being conducted under a research and option agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, or Yissum. If we decide to further develop Amilo-5Mer beyond our planned first-in-human Phase I study, we would need to exercise our option to negotiate and enter into a definitive license agreement with Yissum. If we are unable to enter into a definitive license agreement, we would not have the ability to continue the development and potential commercialization of Amilo-5Mer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are party to a research and option agreement with Yissum with respect to our Amilo-5Mer program. Under this agreement, we are able to research and initially develop Amilo-5Mer, are required to fund the initial research and have been granted an exclusive option to negotiate and enter into a definitive license agreement with Yissum for Amilo-5Mer upon certain pre-agreed upon terms and such other terms to be agreed upon. If we elect to continue development of Amilo-5Mer beyond the currently contemplated first-in-human Phase I study, we would need to exercise our option to negotiate and enter into a definitive license agreement. If we exercise our option to enter into any definitive license agreement with Yissum, there can be no assurance that we will agree upon terms with Yissum or that it will be on terms favorable to us. If we do not enter into a definitive license agreement, then we will not have the ability to continue the development and potential commercialization of Amilo-5Mer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we enter into a definitive license agreement, we will be subject to various additional obligations, including obligations with respect to funding, development and commercialization activities, and payment obligations upon entering into the definitive license agreement and achievement of certain milestones and royalties on product sales. Furthermore, if the definitive license agreement is terminated or breached, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">lose our rights to research, develop or commercialize Amilo-5Mer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">not be able to secure patent or trade secret protection for Amilo-5Mer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">experience significant delays in the development or commercialization of Amilo-5Mer or may have to cease development entirely;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">incur liability for damages.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, even if not terminated or breached, our intellectual property licenses may be subject to disagreements over contract interpretation which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations. If we experience any of the foregoing, it could have a materially adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, due to its early stage of development, Amilo-5Mer will require significant additional research, development, manufacturing, preclinical and clinical testing, marketing authorization, and commitment of significant additional resources prior to any commercialization. These activities will require significant cash for which we will need to raise additional capital. In addition, Amilo-5Mer is prone to the risks of failure inherent in pharmaceutical product development, including the possibility that Amilo-5Mer will not be shown to be sufficiently safe and effective for approval by regulatory authorities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we acquire or in-license additional technologies or product candidates, we may incur significant, incremental expenses, may have integration difficulties and may experience other risks that could harm our business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are currently evaluating the acquisition or in-licensing of additional product candidates and technologies. Any product candidate or technologies we in-license or acquire will likely require additional development efforts prior to commercial sale, including extensive pre-clinical or clinical testing, or both, and approval by the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks of failure inherent in pharmaceutical product development, including the possibility that the product candidate, or product developed based on in-licensed technology, will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure that any product candidate that we develop based on acquired or in-licensed technology that is granted regulatory approval will be manufactured or produced economically, successfully commercialized or widely accepted or competitive in the marketplace. Moreover, integrating any newly acquired or in-licensed product candidates could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may not succeed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining approval of an NDA, or other regulatory approval, even after clinical trials that are believed to be successful, is an uncertain process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we complete our planned clinical trials and believe that the clinical data confirms that Aramchol , Amilo-5Mer or any other product candidate is both safe and effective for its intended use or uses, obtaining approval of an NDA, or other regulatory approval, is an extensive, lengthy, expensive and uncertain process, and the FDA and other regulatory agencies may delay, limit or deny approval of such product candidate for many reasons, including, without limitation, the fact that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">we may not be able to demonstrate to the satisfaction of the applicable regulatory agencies that the product candidate is safe and effective for treatment of the targeted indication in patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the results of clinical trials may not meet the level of statistical significance or clinical significance required by the applicable regulatory agencies for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the applicable regulatory agencies may disagree with the number, design, size, conduct or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the applicable regulatory agencies may not find the data from pre-clinical studies and clinical trials sufficient to demonstrate the clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the applicable regulatory agencies may disagree with our interpretation of data from pre-clinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the applicable regulatory agencies may not accept data generated at our clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the data collected from pre-clinical studies and clinical trials may not be sufficient to support the submission of an NDA or similar regulatory application;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the applicable regulatory agencies may not schedule an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the applicable regulatory agencies require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the applicable regulatory agencies may require development of a risk evaluation and mitigation strategy, or REMS, as a condition of approval;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the applicable regulatory agencies may require simultaneous approval for both adults and children, which would delay required approvals, or we may have successful clinical trial results for adults, but not children, or vice versa;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the applicable regulatory agencies may change their approval policies or adopt new regulations that may impede consideration or approval of our NDA, or similar regulatory application;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the applicable regulatory agencies may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers, or suppliers of active pharmaceutical ingredients, or APIs, with which we enter into agreements for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the applicable regulatory agencies may require post-marketing approval studies, such as Phase 4 clinical trials, in connection with Aramchol or any other product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before we can submit an NDA to the FDA or a similar approval application to other regulatory authorities, as applicable, we (or our commercialization partner, as the case may be) must conduct one or more clinical trials that will be substantially broader than our prior completed trials. We will also need to agree on a protocol with the FDA or any other regulatory authorities for any clinical trial(s)&#160;before commencing any such trial. Clinical trials frequently produce unsatisfactory results even though prior clinical trials were successful. Therefore, the results of any prior trial or any future clinical trials that we may conduct may or may not be successful. The applicable regulatory agencies may suspend all clinical trials or require that we conduct additional clinical, pre-clinical, manufacturing, validation or drug product quality studies and submit data from these additional studies before considering or reconsidering the NDA or similar regulatory application. Depending on the extent of these, or any other studies, approval of any applications that we submit may be delayed by several&#160;years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the applicable regulatory agencies to provide regulatory approval. If any of these outcomes occur, we would not receive approval for Aramchol or any other product candidate and may be forced to cease operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for Aramchol or any other product candidate, the approval might contain significant limitations related to the indications for use for which the drug is approved, use restrictions including, without limitation, for certain labeled populations, age groups, warnings, precautions or contraindications, or may be subject to significant post-marketing studies or risk mitigation requirements. If we are unable to successfully commercialize Aramchol or any other product candidate, we may be forced to cease operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates may produce undesirable side effects or have other properties that could delay or prevent its regulatory approval or result in significant negative consequences following marketing approval, if any, which could substantially increase commercialization costs or even force us to cease operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Undesirable side effects caused by Aramchol or any other product candidate could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or applicable foreign regulatory authorities. To date, we have completed seven clinical trials of Aramchol, and additionally one proof of concept study in patient with gallstones, and a Phase 2a, investigator initiated clinical trial were completed. Although we have not seen any evidence of reactions causing a safety concern in our completed clinical trials, it is possible that the FDA may ask for additional data regarding any adverse events seen in our trials. Results of our future trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or applicable foreign regulatory authorities could order us to cease further development of or deny approval for Aramchol or any other product candidate for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete future trials or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if Aramchol or any other product candidate receives marketing approval, we or others may later identify undesirable side effects caused by the product. In such an event, regulatory authorities may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">suspend or withdraw their approval of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">require the addition of labeling statements, such as warnings, so-called &#8220;black box warnings,&#8221; contraindications or restrictions on the product&#8217;s intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">require us to issue specific communications to healthcare professionals, such as &#8220;Dear Doctor&#8221; letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">issue negative publicity regarding the affected product, including safety communications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">impose a risk evaluation and mitigation strategy (REMS), in the case of FDA, or similar risk management strategies in the case of foreign regulators;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to these potentially significant negative consequences, we could be required to change the way the product is administered, conduct additional pre-clinical studies or clinical trials or restrict or cease the distribution or use of the product, and/or be sued and held liable for harm caused to patients. The foregoing or other events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase commercialization costs or even force us to cease operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, patient willingness to undergo a liver biopsy in our NASH trials, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and disadvantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating, and actual or threatened public health emergencies and outbreaks of disease (including, for example, the COVID-19 pandemic). Potential patients for Aramchol or any other product candidate may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for our studies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will be required to identify and enroll a sufficient number of patients in the U.S. with NASH for each of our planned clinical trials of Aramchol in this indication. We also may encounter difficulties in identifying and enrolling U.S. NASH patients who meet the eligibility criteria for our planned clinical trials. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or other foreign regulatory agencies. In addition, the process of finding and diagnosing patients may prove costly. To date, we have already experienced significant delays in our clinical trials largely related to significantly slower than expected recruitment and the length of time required to obtain regulatory authorizations to proceed with clinical trials. Our inability to enroll a sufficient number of patients for any of our clinical trials could result in further significant delays, additional expenses, or may require us to abandon one or more clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, which may result in necessary changes to clinical trial protocols, which could result in increased costs to us, delay our development timeline or reduce the likelihood of successful completion of our clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in regulatory requirements or guidance or unanticipated events during our clinical trials may result in the need for us to amend clinical trial protocols. In December 2020, we announced the addition of an open label part to our ARMOR Study that involved a significant amendment to the clinical trial protocol. Amendments may require review and approval by regulators and/or IRBs, and re-consent subjects, which may adversely affect the cost, timing or successful completion of a clinical trial. If we experience delays in the completion of, or if we terminate, any of our clinical trials, the commercial prospects for Aramchol or any other product candidate would be harmed and our ability to generate product revenue would be delayed, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if Aramchol or any other product candidate that we develop, receives marketing approval, we will continue to face extensive regulatory oversight and requirements, and any such product may still face future regulatory risks or new requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we receive regulatory approval to market a particular product candidate, any such product will remain subject to extensive regulatory requirements, including requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping. Even if regulatory approval of a product is granted, the approval may be subject to limitations on the uses for which the product may be marketed or the conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product, which could negatively affect us by reducing revenues or increasing expenses, and cause the approved product candidate not to be commercially viable. In addition, as clinical experience with a drug expands after approval, typically because it is used by a greater number and more diverse group of patients after approval than during clinical trials, side effects and other problems may be observed over time after approval that were not seen or anticipated during pre-approval studies. Any adverse effects observed after the approval and marketing of a product candidate could result in limitations on the use of the approved product, withdrawal of FDA approval of the previously approved product, or voluntary withdrawal from the marketplace of the approved product. Absence of long-term safety data may also limit the approved uses of Aramchol or any other product candidate, if any. If we fail to comply with the regulatory requirements of the FDA, and other applicable U.S. and foreign regulatory authorities, or previously unknown problems with any approved commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions or other setbacks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">suspension or imposition of restrictions on operations, including costly new manufacturing requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">refusal to approve pending applications or supplements to applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">suspension of any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">suspension or withdrawal of marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">an injunction or imposition of civil or criminal penalties or monetary fines;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">seizure or detainment of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">banning or restriction of imports and exports;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">issuance of warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">refusal to approve pending applications or supplements to applications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, various aspects of our operations are subject to federal, state or local laws, rules&#160;and regulations, any of which may change from time to time. Costs arising out of any regulatory developments could be time-consuming and expensive and could divert management resources and attention and, consequently, could adversely affect our business operations and financial performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Delays in regulatory approval, limitations in regulatory approval and withdrawals of regulatory approval may have a material adverse effect on the Company. If we experience significant delays in testing or receiving approvals or sign-offs to conduct clinical trials, Aramchol or any other product candidate development costs will increase and our ability to out-license our product candidates may be impeded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we obtain approval to commercialize any product candidate outside of the United States or out-license a product candidate to additional territories outside the United States, a variety of risks associated with international operations could materially adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any product candidate is approved for commercialization outside the United States or we out-license a product candidate to additional territories outside the United States, we will likely enter into agreements with third parties to commercialize a product candidate outside the United States. We expect that we will be subject to additional risks related to entering into or maintaining international business relationships, including, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">different regulatory requirements for drug approvals in foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">differing U.S. and foreign drug import and export rules;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">reduced protection for intellectual property rights in foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">different reimbursement systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">potential liability resulting from development work conducted by these distributors;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters, emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an emergency, including for example, the COVID-19 pandemic); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks associated with clinical co-development agreements in other jurisdictions prior to or post-regulatory approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A failure to timely and effectively address the additional risks related to entering into or maintaining international business relationships could have a material adverse effect on our business, liquidity, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we receive marketing approval for a product candidate, sales will be limited unless the product achieves broad market acceptance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The commercial success of a product candidate for which we obtain marketing approval from the FDA, or other regulatory authorities, will depend on the breadth of its approved labeling and upon the acceptance of the product by the medical community, including physicians, patients and healthcare payors. The degree of market acceptance of any approved product will depend on a number of factors, including, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">demonstration of clinical safety and efficacy compared to other products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ability of physicians to accurately diagnose NASH in its early stages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the prevalence and severity of any adverse side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">limitations, warnings or contraindications contained in the product&#8217;s approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">distribution and use restrictions imposed by the FDA, or other regulatory agencies, or agreed to by us as part of a mandatory or voluntary REMS;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">availability of alternative treatments, including, any competitive products already approved or expected to be commercially launched in the near future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">pricing and cost effectiveness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the effectiveness of our, or any future collaborators&#8217;, sales and marketing strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to obtain sufficient third-party coverage or reimbursement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the willingness of patients to pay for drugs out of pocket in the absence of third-party coverage.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a product candidate is approved, but does not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from the product, and we may not become profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of the product may require significant resources and may never be successful.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have improperly promoted off-label uses, we may become subject to significant liability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are inconsistent with the FDA-approved indications and other conditions or restrictions contained in the approved labeling, including the prescribing information, for the product. In particular, any labeling approved by FDA or other foreign regulatory agencies for a product candidate necessarily limits its use for certain conditions in certain patient populations. Also, regulatory agencies may impose further requirements or restrictions on the distribution or use of Aramchol or any other product candidate as part of a mandatory plan, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe the product candidate to their patients in a manner that is inconsistent with the approved labeling, which is commonly known as &#8220;off label&#8221; use. If we are found to have promoted any product candidate for such &#8220;off label&#8221; uses, we may become subject to significant liability under a variety of statutory theories typically alleged by U.S. regulatory authorities. In particular, the U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion, has enjoined several companies from engaging in off-label promotion, and has requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations may be materially adversely affected in the event of computer system failures or security breaches.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Despite the implementation of security measures, our internal computer systems, and those of our CROs and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyber-attacks, natural disasters, fire, terrorism, war, and telecommunication and electrical failures. If such an event were to occur and interrupt our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade secrets or inappropriate disclosure of confidential or proprietary information, including protected health information or personal data of employees or former employees, access to our clinical data, or disruption of the manufacturing process, we could incur liability and the further development of our drug candidates could be delayed. We may also be vulnerable to cyber-attacks by hackers or other malfeasance. This type of breach of our cybersecurity may compromise our confidential information and/or our financial information and adversely affect our business or result in legal proceedings. Further, these cybersecurity breaches may inflict reputational harm upon us that may result in decreased market value and erode public trust.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to extensive environmental, health and safety, and other laws and regulations in multiple jurisdictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business involves the controlled use, through our service providers, of hazardous materials, various biological compounds and chemicals, and as such, we, our agents and our service providers may be subject to various environmental, health and safety laws and regulations, including those governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal of hazardous, radioactive and biological materials and wastes and the cleanup of contaminated sites. The risk of accidental contamination or injury from these materials cannot be eliminated. If an accident, spill or release of any regulated chemicals or substances occurs, we could be held liable for resulting damages, including for investigation, remediation and monitoring of the contamination, including natural resource damages, the costs of which could be substantial. We may incur substantial capital costs and operating expenses and may be required to obtain consents to comply with any environmental and health laws or regulations and the terms and conditions of any permits required pursuant to such laws and regulations, including costs incurred by us to install new or updated pollution control equipment for our service providers, modify our operations or perform other corrective actions at our facilities or the facilities of our service providers. In addition, fines and penalties may be imposed on us, our agents and/or our service providers for noncompliance with environmental, health and safety and other laws and regulations or for the failure to have, or comply with the terms and conditions of, required environmental or other permits or consents.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect the healthcare industry to face increased limitations on reimbursement, rebates and other payments as a result of healthcare reform, which could adversely affect third-party coverage of Aramchol or any other product candidate and how much or under what circumstances healthcare providers will prescribe or administer Aramchol or any other product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In both the United States and other countries, sales of Aramchol or any other product candidate will depend in part upon the availability of reimbursement from third-party payors, which include governmental authorities, managed care organizations and other private health insurers. Third-party payors are increasingly challenging the price and examining the cost effectiveness of medical products and services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Increasing expenditures for healthcare have been the subject of considerable public attention in the United States. Both private and government entities are seeking ways to reduce or contain healthcare costs. Numerous proposals that would effect changes in the U.S. healthcare system have been introduced or proposed in the U.S. Congress, or Congress, and in some state legislatures, including reducing reimbursement for prescription products and reducing the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the Medicare Prescription Drug,&#160;Improvement, and Modernization Act of 2003, or the Modernization Act, changed the way Medicare covers and pays for most pharmaceutical products in a number of ways. Medicare is the single largest third-party payment program and is administered by the Centers for Medicare&#160;&amp; Medicaid Services, or the CMS.&#160;Medicare traditionally covered prescription drugs administered by physicians. The Modernization Act introduced a new reimbursement methodology based on average sales prices for many of these drugs. The Modernization Act also established a new competitive acquisition program for the purchase of Part&#160;B drugs. This program, when fully implemented, will likely reduce the prices of these drugs. While the Medicare provisions of the Modernization Act apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Most notably, the Modernization Act also expanded coverage through a new Part&#160;D to include ordinary self-administered outpatient drugs. Medicare part D though operates through private insurers, and these insurers negotiate prices with pharmacies and with manufacturers. Intense negotiations can result in reduced revenues to manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Increasing expenditures for healthcare have been the subject of considerable public attention in the United States. Both private and government entities are seeking ways to reduce or contain healthcare costs. Numerous proposals that would effect changes in the U.S. healthcare system have been introduced or proposed in U.S. Congress, and in some state legislatures, including reducing reimbursement for prescription products and reducing the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2010, President Barack Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010, or the Affordable Care Act, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers and impose additional health policy reforms. The Affordable Care Act expanded manufacturers&#8217; Medicaid rebate liability to include covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations, increased the minimum rebate due for innovator drugs from 15.1% of average manufacturer price, or the AMP, to 23.1% of AMP. The rebate on innovator drugs is the greater of 23.1% of the AMP per unit or the difference between the AMP and the best price per unit and adjusted by the Consumer Price Index-Urban (CPI-U) based on a launch date and current quarter AMP. The total rebate amount for innovator drugs is capped at 100.0% of AMP. The Affordable Care Act and subsequent legislation also narrowed the definition of AMP. Furthermore, the Affordable Care Act imposes a significant annual, nondeductible fee on companies that manufacture or import certain branded prescription drug products. The Affordable Care Act &#160;appears likely to continue to put pressure on pharmaceutical pricing, especially under the Medicare and Medicaid programs, and may also increase our regulatory burdens and operating costs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been judicial and congressional challenges to the Affordable Care Act. If a law is enacted, many if not all of the provisions of the PPACA may no longer apply to prescription drugs. While we are unable to predict what changes may ultimately be enacted, to the extent that future changes affect how any future products are paid for and reimbursed by government and private payers our business could be adversely impacted. On December&#160;14, 2018, a federal district court in Texas ruled that the PPACA is unconstitutional as a result of the Tax Cuts and Jobs Act, the federal income tax reform legislation previously passed by Congress and signed by President Trump on December&#160;22, 2017, that eliminated the individual mandate portion of the PPACA. The case, Texas, et al, v. United States of America, et al., (N.D. Texas), is an outlier, and the ruling has been stayed by the ruling judge, but in 2019, the Fifth Circuit Court of Appeals subsequently upheld the lower court decision which was then appealed to the United States Supreme Court. The U.S. Supreme Court declined to hear the appeal on an expedited basis and so no decision is expected until sometime in 2021 before the end of the next Supreme Court&#8217;s current term in early 2021. We are not able to state with any certainty what will be the impact of this court decision on our business pending further court action and possible appeals. In November 2020, Joseph Biden was elected President and, in January 2021, the Democratic Party obtained control of the Senate. As a result of these electoral developments, it is unlikely that continued legislative efforts will be pursued to repeal PPACA. Instead, it is possible that executive and regulatory initiatives, as well as legislation will be pursued to enhance or reform PPACA. We are not able to state with certainty what the impact of potential legislation will be on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August&#160;2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of an amount greater than $1.2 trillion for the&#160;years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal&#160;year, starting in 2013. These reductions will stay in effect through 2030 unless additional congressional action is taken. However, COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2021. In January&#160;2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. If we ever obtain regulatory approval and commercialization of Aramchol or any other product candidate, these laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of Aramchol or any other product candidate may be. Further, the Deficit Reduction Act of 2010, directed CMS to contract a vendor to determine &#8220;retail survey prices for covered outpatient drugs that represent a nationwide average of consumer purchase prices for such drugs, net of all discounts and rebates (to the extent any information with respect to such discounts and rebates is available).&#8221; This survey information can be used to determine the National Average Drug Acquisition Cost, NADAC. Some states have indicated that they will reimburse based on the NADAC and this can result in further reductions in the prices paid for various outpatient drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Various states, such as California, have also taken steps to consider and enact laws or regulations that are intended to increase the visibility of the pricing of pharmaceutical products with the goal of reducing the prices at which pharmaceutical products are sold. Because these various actual and proposed legislative changes are intended to operate on a state-by-state level rather than a national one, we cannot predict what the full effect of these legislative activities may be on our business in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we cannot predict the full effect on our business of the implementation of existing legislation or the enactment of additional legislation pursuant to healthcare and other legislative reform, we believe that legislation or regulations that would reduce reimbursement for, or restrict coverage of, Aramchol or any other product candidate, could adversely affect how much or under what circumstances healthcare providers will prescribe or administer our products. This could materially and adversely affect our business by reducing our ability to generate revenue, raise capital, obtain additional collaborators and market Aramchol or any other product candidate. In addition, we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact any other product sales.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">It will be difficult for us to profitably sell any product candidate if reimbursement for the product is limited by government authorities and third-party payor policies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to any healthcare reform measures that may affect reimbursement, the market acceptance and sales of any product candidate will depend on the reimbursement policies of government authorities and third-party payors. It will be difficult for us to profitably sell a product candidate if reimbursement for the product is limited by government authorities or third-party payors. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage or reimbursement will be available for any product candidate and, if coverage and reimbursement are available, of the extent of coverage and the level of reimbursement. Reimbursement may affect the demand for, or the price of, any product for which we obtain marketing approval. In addition, third-party payors are likely to impose strict requirements for reimbursement in order to limit off-label use of a higher priced drug. Reimbursement by a third-party payor may depend upon a number of factors including the third-party payor&#8217;s determination that use of a product is:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a covered benefit under its health plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">safe, effective and medically necessary;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">appropriate for the specific patient;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">cost-effective; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">neither experimental nor investigational.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of a product candidate to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for any product candidates. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, any product candidates. If reimbursement is not available, or is available only to limited levels, we may not be able to commercialize any product candidates, profitably, or at all, even if approved. In addition, if physicians, government agencies and other third-party payors do not accept the use or efficacy of any product candidates, we will not be able to generate significant revenue, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In some countries, particularly the countries of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of Aramchol or any other product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we or any of our independent contractors, consultants, collaborators, manufacturers, or service providers fail to comply with healthcare and data privacy laws and regulations, we or they could be subject to enforcement actions, which could result in penalties and affect our ability to develop, market and sell Aramchol or any other product candidate and may harm our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are or may in the future be subject to federal, state, and foreign healthcare and data privacy laws and regulations pertaining to, among other things, fraud and abuse of patients&#8217; rights. These laws and regulations include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully soliciting, offering, receiving, or paying any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, ordering or arranging for or recommending the purchase or order of any item or service for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. Liability may be established without a person or entity having actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it. This statute has been interpreted to apply broadly to arrangements between pharmaceutical manufacturers on the one hand and prescribers, patients, purchasers and formulary managers on the other. In addition, the Affordable Care Act amended the Social Security Act to provide that the U.S. government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. A conviction for violation of the Anti-kickback Statute requires mandatory exclusion from participation in federal health care programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and those activities may be subject to scrutiny or penalty if they do not qualify for an exemption or safe harbor.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The federal civil False Claims Act, or FCA, prohibits, among other things, knowingly presenting, or causing to be presented claims for payment of government funds that are false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to such a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. This statute also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. The FCA prohibits anyone from knowingly presenting, conspiring to present, making a false statement in order to present, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. This law also prohibits anyone from knowingly underpaying an obligation owed to a federal program. Increasingly, U.S. federal agencies are requiring nonmonetary remedial measures, such as corporate integrity agreements in FCA settlements. The U.S. Department of Justice announced in 2016 its intent to follow the &#8220;Yates Memo,&#8221; taking a far more aggressive approach in pursuing individuals as FCA defendants in addition to the corporations. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties assessed on a per false claim or statement basis. Government enforcement agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for a variety of alleged promotional and marketing activities, such as providing free product to customers with the expectation that the customers would bill federal programs for the product; providing consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion for &#8220;off-label&#8221; uses; and submitting inflated best price information to the Medicaid Rebate Program.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The federal False Statements Statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry, in connection with the delivery of or payment for healthcare benefits, items, or services.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The federal Civil Monetary Penalties Law authorizes the imposition of substantial civil monetary penalties against an entity, such as a pharmaceutical manufacturer, that engages in activities including, among others (1)&#160;knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2)&#160;arranging for or contracting with an individual or entity that is excluded from participation in federal healthcare programs to provide items or services reimbursable by a federal healthcare program; (3)&#160;violations of the federal Anti-Kickback Statute; or (4)&#160;failing to report and return a known overpayment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), which imposes requirements on certain types of people and entities relating to the privacy, security, and transmission of individually identifiable health information, requires notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, to report annually to the Centers for Medicare &amp; Medicaid Services (CMS) information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members, which is published in a searchable form on an annual basis. Effective January 1, 2022, covered manufacturers will also be required to report on payments and other transfers of value to physician assistants, nurse practitioners or clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, and certified nurse-midwives during the previous year; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">State laws comparable to each of the above federal laws, such as, for example, anti-kickback and false claims laws that may be broader in scope and also apply to commercial insurers and other&#160;non-federal;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Payors requirements for mandatory corporate regulatory compliance programs, and laws relating to patient data privacy and security. Other state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">In the European Union, the General Data Protection Regulation, or GDPR,&#8212;Regulation EU 2016/679&#8212;was adopted in May&#160;2016 and became applicable on May&#160;25, 2018, or GDPR. The&#160;GDPR&#160;further harmonizes data protection requirements across the European Union member states by establishing new and expanded operational requirements for entities that collect, process or use personal data generated in the European Union, including consent requirements for disclosing the way personal information will be used, information retention requirements, and notification requirements in the event of a data breach;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The California Consumer Privacy Act of 2018, or CCPA, effective as of January&#160;1, 2020, gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches, that is expected to increase data breach litigation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">In addition, failure to comply with the Israeli Privacy Protection Law of 1981, and its regulations, as well as the guidelines of the Israeli Privacy Protection Authority, may expose us to administrative fines, civil claims (including class actions) and in certain cases criminal liability. Current pending legislation may result in a change of the current enforcement measures and sanctions.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any such health care laws and regulations, we may be subject to penalties, including significant administrative, civil and criminal penalties, monetary damages, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA or foreign regulatory authorities, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely our financial results. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, principal investigators, consultants, commercial partners or vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are also exposed to the risk of employees, independent contractors, principal investigators, consultants, commercial partners or vendors engaging in fraud or other misconduct. Misconduct by employees, independent contractors, principal investigators, consultants, commercial partners and vendors could include intentional failures to comply with EU regulations, to provide accurate information to the EMA or EU Member States authorities or to comply with manufacturing or quality standards we have or will have established. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices such as promotion of products by medical practitioners. The EU Member States in which we operate have different statutory provisions regulating the cooperation of pharmaceutical companies with healthcare professionals. In addition to these statutory provisions, codes of conduct issued by business associations or other non-statutory standards may be applicable to our activities. Both statutory provisions and non-statutory codes or standards restrict payments or other benefits provided to healthcare professionals, and in case of non-compliance, may result in severe sanctions such as bans, administrative fines, criminal fines or even imprisonment. The advertising of medicinal products for human use in the EU is regulated by Title VIII of European Directive 2001/83/EC. These provisions have been implemented into the law of the EU member States. Such laws inter alia restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and serious and irreparable harm to our reputation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This could also apply with respect to data privacy. In the EU, the EU Directive 95/46/EEC was replaced by the GDPR on May&#160;25, 2018. The GDPR as an EU regulation does not have to be implemented into Member States&#8217; national law, but applies directly in all Member States since May&#160;25, 2018. It applies to companies with an establishment in the European Economic Area (EEA) and to certain other companies not in the EEA that offer or provide goods or services to individuals located in the EEA or monitor individuals located in the EEA. The GDPR implements more stringent operational requirements for controllers of personal data, including, for example, expanded disclosures about how personal information is to be used, limitations on retention of information, increased requirements pertaining to health data and pseudonymized (i.e., key-coded) data, increased cyber security requirements, mandatory data breach notification requirements and higher standards for controllers to demonstrate that they have obtained a valid legal basis for certain data processing activities. The GDPR provides that EU Member States may continue to make their own further laws and regulations in relation to the processing of genetic, biometric or health data, which could result in continued or new differences between Member States, limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial condition. We are also subject to evolving and strict rules&#160;on the transfer of personal data out of the European Union to the United States. Further prospective revision of the Directive on privacy and electronic communications (Directive 2002/58/EC), or ePrivacy Directive, may affect our marketing communications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have implemented procedures to ensure compliance with the GDPR and its requirements. Our actual or alleged failure to comply with this regulation, or to protect personal data, could result in enforcement actions and significant penalties against us, which could result in negative publicity, increase our operating costs, subject us to claims or other remedies and have a material adverse effect on our business, financial condition, and results of operations. It is not always possible to identify and deter misconduct by employees or other parties. The precautions we take to detect and prevent such activity may not protect us from legal or regulatory action resulting from a failure to comply with applicable laws or regulations. Misconduct by our employees, principal investigators, consultants, commercial partners or vendors could result in significant financial penalties, criminal sanctions, civil law claims and/or negative media coverage, and thus have a material adverse effect on our business, including through the imposition of significant fines or other sanctions, and our reputation. In particular, failure to comply with EU laws, including failure under the GDPR, ePrivacy Directive and other laws relating to the security of personal data may result in fines up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial&#160;year, if greater, and other administrative penalties including criminal liability, which may be onerous and adversely affect our business, financial condition, results of operations and prospects. Failure to comply with the GDPR and related laws may also give risk to increase risk of private actions, including a new form of class action that is available under the GDPR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we or our manufacturers fail to comply with manufacturing regulations, our financial results and financial condition could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before an NDA is approved, and before we begin the commercial manufacture of &#160;any product candidate, contract manufacturers must register with FDA or foreign regulators undergo regulatory inspection of their manufacturing facilities, processes and quality systems. In addition, pharmaceutical manufacturing facilities are subject to periodic inspection by the FDA and foreign regulatory authorities after product approval. Due to the complexity of the processes used to manufacture pharmaceutical products and product candidates, any potential third-party manufacturer may be unable to meet local, federal, or international regulatory requirements either at the outset or on an ongoing basis, in a cost effective manner, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not intend to engage in the manufacture of Aramchol or any other product candidate other than for pre-clinical and clinical studies, but we or our materials suppliers may face manufacturing or quality control problems causing product production and shipment delays or a situation where we or the supplier may not be able to maintain compliance with the FDA&#8217;s or foreign regulators&#8217; requirements necessary to continue manufacturing Aramchol or any other product candidate. Drug manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding foreign regulators to ensure continuing compliance with applicable requirements. Any failure to comply with FDA or foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop and market Aramchol or any other product candidate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a third-party manufacturer with whom we contract is unable to comply with manufacturing requirements, we may be subject to fines, unanticipated compliance expenses, recall or seizure of Aramchol or any other product candidate, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions could adversely affect our financial results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our market is subject to intense competition. If we are unable to compete effectively, Aramchol, Amilo-5MER or any other product candidate that we develop may be rendered suboptimal, noncompetitive or obsolete.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are a number of products in development for our target indications, many of which are being developed by pharmaceutical companies that are far larger than us, with significantly greater resources and more experience than us in all aspects of drug development and commercialization. Further, our industry is highly competitive and subject to rapid and significant technological change. Our potential competitors include large, fully-integrated pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. All of these competitors currently engage in, have engaged in or may engage in the future in the development, manufacturing, marketing and commercialization of new pharmaceuticals, some of which may compete with Aramchol, Amilo-5MER or other product candidates. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These companies may have products in development that are superior to any Aramchol or any other product candidate. Key competitive factors affecting the commercial success of Aramchol or any other product candidate that we develop are likely to be efficacy, time of onset, safety and tolerability profile, reliability, convenience of dosing, price and reimbursement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of our potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of drug candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those products. Accordingly, our competitors may be more successful than us in obtaining FDA and other marketing approvals for drugs and achieving widespread market acceptance. Our competitors&#8217; drugs may be more effective, or more effectively marketed and sold, than any drug we may commercialize and may render the product candidates that we develop suboptimal, obsolete or non-competitive before we can recover the expenses of developing and commercializing the product. We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available. Finally, the development of new treatment methods for the diseases we are targeting could render Aramchol or any other product candidate that we develop, non-competitive or obsolete. If we cannot successfully compete with new or existing products, our marketing and sales will suffer and we may never be profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our competitors currently include companies with marketed products and/or advanced clinical programs. Our main competitors of Aramchol include, but are not limited to, Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., AbbVie, Inc. (Abbot through an acquisition of Allergan, Plc.), Madrigal Pharmaceuticals Inc., Novartis, Novo Nordisk and Viking Therapeutics among others. &#160;See also &#8220;Item 4. Information on the Company&#8212;Competition.&#8221; Moreover, several additional companies have reported the commencement of research projects and proof-of-concept trials related to our target indications, including those mentioned in the preceding sentence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face potential product and other liability exposure, and, if claims are brought against us, we may incur substantial liability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates could cause adverse events. These adverse events may not be observed in clinical trials, but may nonetheless occur in the future. If any of these adverse events occur, they may render Aramchol or any other product candidate ineffective or harmful in some patients, and our sales would suffer, materially adversely affecting our business, financial conditions and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, potential adverse events caused by Aramchol or any other product candidate, could lead to product liability claims. Product liability claims might be brought against us by consumers, healthcare providers or others coming into contact with Aramchol or any other product candidate. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">decreased demand for our product candidate for which we obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">impairment of our business reputation and exposure to adverse publicity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">increased warnings on product labels or other regulatory actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">costs of related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">distraction of management&#8217;s attention from our primary business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">substantial monetary awards to patients or other claimants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">loss of revenue; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the inability to successfully commercialize any product candidates, for which we obtain marketing approval.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain adequate insurance with respect to our clinical trials against and from any losses or claims from third parties, our financial condition could be adversely affected in the event of uninsured or inadequately insured loss or damage. We may not be able to obtain insurance policies on terms affordable to us that would adequately cover loss or claims by third parties. To the extent our business suffers any losses or claims by third parties, which are not covered, or adequately covered, by insurance, our financial condition may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If product liability lawsuits are successfully brought against us, our insurance may be inadequate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have obtained insurance coverage for our clinical trials in accordance with market standards and in compliance with applicable Israeli law. However, our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for any product candidate, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain this product liability insurance on commercially reasonable terms. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in our favor, could be substantial. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The product liability insurance we will need to obtain in connection with the commercial sales of any product candidate, if and when they receive regulatory approval, may be unavailable in meaningful amounts or at a reasonable cost. If we are the subject of a successful product liability claim that exceeds the limits of any insurance coverage we obtain, we would incur substantial charges that would adversely affect our earnings and require the commitment of capital resources that might otherwise be available for the development and commercial launch of any product candidate&#39;s programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We manage our business through a small number of senior executive officers. We depend on them even more than similarly- situated companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to recruit, attract, retain, manage and motivate qualified senior executive officers with adequate operational, scientific and technical experience. The loss of the services of our senior executive officers, including our President, Chief Executive Officer, and our Chief Scientific Officer, or the inability to hire or retain experienced management personnel, could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our senior executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not currently carry &#8220;key person&#8221; insurance on the lives of members of senior management. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense competition, we may be unable to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. Additionally, our ability to effectively recruit and retain qualified officers and directors could also be adversely affected if we experience difficulty in obtaining adequate directors&#8217; and officers&#8217; liability insurance. We may be unable to maintain sufficient insurance as a public company to cover liability claims made against our officers and directors. If we are unable to adequately insure our officers and directors, we may not be able to retain or recruit qualified officers and directors to manage the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-style:italic;font-weight:bold;">Failure to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial reporting and internal control requirements for publicly traded companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a public company, we operate in an increasingly challenging regulatory environment which requires us to comply with the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the related rules and regulations of the SEC and securities exchanges, expanded disclosures, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Section 404 of the Sarbanes-Oxley Act requires our management to report on, and our independent registered public accounting firm to attest to, the effectiveness of our internal control structure and procedures for financial reporting. We have an ongoing program to perform the system and process evaluation and testing necessary to continue to comply with these requirements. &#160;During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To build our finance infrastructure, we may need to improve our accounting systems, disclosure policies, procedures and controls. If we are unsuccessful in building an appropriate accounting infrastructure, we may not be able to prepare and disclose, in a timely manner, our financial statements and other required disclosures, or comply with existing or new reporting requirements. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Capital Market or other adverse consequences that would materially harm our business. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed and investors could lose confidence in our reported financial information.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need to significantly increase the size of our organization, and we may experience difficulties in managing growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may experience rapid and substantial growth in order to achieve our operating plans, which will place a strain on our human and capital resources. Successful implementation of our business plan will require management of growth, which will result in an increase in the level of responsibility for management personnel. Any future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. To that end, we must be able to, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">manage our clinical trials and the regulatory process effectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">develop our administrative, accounting and management information systems and controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">hire and train additional qualified personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">integrate current and additional management, administrative, financial and sales and marketing personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If we are unable to establish, scale-up and implement improvements to our control systems in an efficient or timely manner, or if we encounter deficiencies in existing systems and controls, investors may choose not to invest in us, which could cause our share price to decline and negatively impact our ability to successfully commercialize Aramchol or any other product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Failure to attract and retain sufficient numbers of talented employees will further strain our human resources and could impede our growth or result in ineffective growth. If we are unable to manage our growth effectively, our losses could materially increase and it will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our business, including our ability to raise capital, may be affected by macroeconomic conditions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A deterioration in global economic conditions and uncertainties may have an adverse effect on our business. For instance, interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the value of our investments, if any, and our ability to liquidate such investments in order to fund our operations. Interest rates and the ability to access credit markets could also adversely affect the ability of patients and distributors to purchase, pay for and effectively distribute Aramchol or any other product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, we rely and intend to rely on third-parties, including our clinical research organizations, third-party manufacturers and second source suppliers, and certain other important vendors and consultants. As a result of volatile and unpredictable global economic situations, there may be a disruption or delay in the performance of our third-party contractors and suppliers. If such third-parties are unable to satisfy their contractual commitments to us, our business could be severely adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Additional clinical trials may divert a significant amount of our resources and may ultimately be unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are seeking to expand our clinical operations for Aramchol to multiple other indications in order to expand our pipeline, commercial potential and ultimately de-risk the Company for the success of any one given trial. If we initiate additional clinical trials, this may divert a significant amount of Company resources and may be unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Reliance on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have no manufacturing capacity and anticipate reliance on third-party manufacturers for Aramchol or any other product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We do not currently operate manufacturing facilities for the production of Aramchol, Amilo-5MER or their API. We still have not, and may never, develop facilities for the manufacture of product candidates or products for clinical trials or commercial purposes. We rely, and for the foreseeable future, will continue to rely, on third-party manufacturers to produce bulk drug products required for our clinical trials. We plan to initially rely upon contract manufacturers and, potentially, collaboration partners, to manufacture commercial quantities of Aramchol or any other product candidate, if and when approved for marketing by the applicable regulatory authorities. Our contract manufacturers have not completed commercial process validation of Aramchol API and drug product manufacturing processes. If our contract manufacturers and their facilities, as applicable, are not approved by the FDA, or other applicable regulatory authorities, our commercial supply of the drug substance will be significantly delayed and may result in significant additional costs. We purchase finished Aramchol from a third-party under a clinical supply agreement. If we will be required to change the finished product manufacturer, we may encounter significant delay and likely significant additional cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A failure by our contract manufacturer to achieve and maintain high manufacturing standards, in accordance with applicable good manufacturing practices and other applicable regulatory requirements could result in patient injury or death, product shortages, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could seriously harm our business. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our existing manufacturers and any future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business. In the event of a natural disaster, business failure, strike or other difficulty, we may be unable to replace a third-party manufacturer in a timely manner and the production of our product candidates would be interrupted, resulting in delays and additional costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We intend to rely primarily on third parties to market and sell Aramchol or any other product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have no sales or distribution capabilities. To the extent we rely on third parties to commercialize Aramchol or any other product candidate, if marketing approval is obtained, we may receive less revenue than if we commercialize them ourselves. In addition, we would have less control over the sales efforts of any third parties involved in our commercialization efforts. In the event we are unable to collaborate with a third-party marketing and sales organization to commercialize Aramchol or any other product candidate, particularly for broader patient populations, our ability to generate revenue will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Although we may ultimately develop a marketing and sales force with technical expertise and supporting distribution capabilities in the longer term, we do not currently intend to do so and, as such, we will be unable to market our product candidates directly in the near future. To promote any of our potential products through third parties, we will have to locate acceptable third parties for these functions and enter into agreements with them on acceptable terms, and we may not be able to do so. Any third-party arrangements we are able to enter into may result in lower revenues than we could achieve by directly marketing and selling our potential products. In addition, to the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, as well as the terms of our agreements with such third parties, which cannot be predicted in most cases at this time. As a result, we might not be able to market and sell our product candidates in the United States or overseas, which would have a material adverse effect on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our current and potential other product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We intend to seek collaboration arrangements with pharmaceutical or biotechnology companies for the continued development and commercialization of our current and potential other product candidates. We will face, to the extent that we decide to enter into collaboration agreements, significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements. The terms of any collaborations or other arrangements that we may establish may not be favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision making authority. Moreover, collaborations with pharmaceutical or biotechnology companies and other third parties are often terminated or allowed to expire by the other party. Any lack of effort or ability by our collaborators or any such disagreement, termination or expiration could adversely affect us financially and could harm our business reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We depend on third parties to conduct our clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to oversee most of the operations of our clinical trials and to perform data collection and analysis. As a result, we may face additional delays outside of our control if these parties do not perform their obligations in a timely fashion or in accordance with regulatory requirements. If these third parties do not successfully carry out their contractual duties or obligations and meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our financial results and the commercial prospects for Aramchol or any other product candidate could be harmed, our costs could increase and our ability to obtain regulatory approval and commence product sales could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> &#160;<span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The failure to obtain or maintain patents, licensing agreements and other intellectual property rights that are sufficiently broad and protective could impact our ability to compete effectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To compete effectively, we must develop and maintain a proprietary position with regard to our own technologies, intellectual property, licensing agreements, product candidates and business. Legal standards relating to the validity and scope of claims in the biotechnology and biopharmaceutical fields are still evolving. We cannot predict the scope and extent of patent protection for Aramchol or any other product candidate because the patent positions of pharmaceutical products are complex and uncertain. Therefore, the degree of future protection for our proprietary rights in our core technologies and any product candidates or products that might be developed using these technologies is also uncertain. The risks and uncertainties that we face with respect to our patents and other proprietary rights include, but are not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">while the patents we own have been issued, pending patent applications we have filed may not result in issued patents or may take longer than we expect to result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">we may be subject to interference, reexamination, </span><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:justify;">inter pares</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;"> review, or post-grant review proceedings in the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">we may be subject to opposition proceedings in certain foreign countries;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">any patents that are issued may not provide meaningful protection for any significant period of time, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">any issued patents may not be broad or strong enough to prevent competition from other products including identical or similar products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">we may not be able to develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">there may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">there may be other patents or pending patent applications existing in the patent landscape that will affect our freedom to operate for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">other companies may challenge and invalidate patents licensed or issued to us or our customers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a court could determine that a competitor&#8217;s technology or product does not infringe our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">other companies may independently develop similar or alternative technologies, or duplicate our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">other companies may design around technologies we have licensed or developed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">if we are not awarded patents or if issued patents expire or are declared invalid or not infringed, there may be no protections against competitors making generic equivalents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">enforcement of patents is complex, uncertain and expensive, and our patents may be found invalid or enforceable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">our patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations, or could be subject to compulsory licensing; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">if we encounter delays in our development or clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot be certain that patents will be issued as a result of any of our pending applications, and we cannot be certain that any of our issued patents, whether issued pursuant to our pending applications or licensed from third parties, will give us adequate protection from competing products. For example, issued patents may be circumvented or challenged, declared invalid or unenforceable, or narrowed in scope. In addition, because publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain that we were the first to make our inventions or to file patent applications covering those inventions. If any of our composition of matter patents, or pending applications, was subject to a successful challenge or failed to issue, our business and competitive advantage could be significantly affected. Our current patents will expire or they may otherwise cease to provide meaningful competitive advantage, and we may be unable to adequately develop new technologies and obtain future patent protection to preserve our competitive advantage or avoid adverse effects on our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are currently planning to transition from Aramchol free acid to Aramchol meglumine (salt) in our double-blind, placebo-controlled histology-based registrational part of the ARMOR Study. We had been working towards submission of a new drug application, or NDA, in the first half of 2023, assuming positive top-line results, however due to delays in enrollment of the ARMOR Study, we will not be able to submit an NDA to the FDA with respect to Aramchol free acid, a new chemical entity, in time to benefit from any potential Hatch-Waxman patent restoration term. As part of our research and development studies, we have confirmed that several Aramchol salts have improved solubility as compared to the existing form of Aramchol free acid. We have a pending patent application and have been granted patents directed to composition of matter patent application for Aramchol meglumine as well as a wide range of other salts, and a method for treating hepatic fibrosis and fibrosis in non-alcoholic fatty acid liver disease. In addition, we have since submitted additional patent applications for Aramchol meglumine, including a low dose composition for Aramchol meglumine. We have since been granted a composition of matter patent for Aramchol salts which includes claims for the treatment of fatty liver in Europe and certain other countries while the patent application is still pending in the U.S. and certain other countries and we have been granted a low dose composition of matter patent for Aramchol meglumine in the U.S. Our composition of matter claims covering Aramchol meglumine patents that have been granted expire in 2034 and 2035, subject to appropriate maintenance, renewal, annuity or other governmental fees being paid, and our pending application directed to use of Aramchol meglumine for treating hepatic fibrosis and fibrosis in non-alcoholic fatty acid liver disease will expire if and when issued in 2037. There can be no assurance that the U.S. Patent and Trademark Office, or the USPTO, or any other foreign equivalent will issue any additional patents based on the patent applications that we submitted to protect our Aramchol salts, nor, should the USPTO or foreign equivalent issue any patents to us with respect to the Aramchol salts, that we will be provided with adequate protection against potentially competitive products. Furthermore, if the USPTO or foreign equivalent issues us one or more patents for the Aramchol salts or with respect to already issued patents for the Aramchol salts, there can be no assurance that the issued patents will be of any commercial value, or that private parties or competitors will not successfully challenge these patents or circumvent these patents in the United States or their counterparts abroad. In the absence of adequate patent protection, our business may be adversely affected by competitors who develop comparable technology or products and our commercial prospects may be materially adversely affected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Others may obtain issued patents that could prevent us from commercializing our product candidates or require us to obtain licenses requiring the payment of significant fees or royalties in order to enable us to conduct our business. As to those patents that we have licensed, our rights depend on maintaining our obligations to the licensor under the applicable license agreement, and we may be unable to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to patents and patent applications, we depend upon trade secrets and proprietary know-how to protect our proprietary technology. We require our employees, consultants, advisors and collaborators to enter into confidentiality agreements that prohibit the disclosure of confidential information to any other parties. We also require our employees and consultants to disclose and assign to us their ideas, developments, discoveries and inventions. These agreements may not, however, provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to enforce our intellectual property rights throughout the world. This risk is exacerbated for us because we expect Aramchol or Aramchol meglumine will be manufactured and used in a number of foreign countries.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. This risk is exacerbated for us because we expect Aramchol will be manufactured and used in a number of foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our other intellectual property rights. For example, several foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, some countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although most jurisdictions in which the Company has applied for, intends to apply for, or has been issued patents have patent protection laws similar to those of the United States, some of them do not. For example, the Company expects to do business in South America, Eurasia, China and Indochina in the future and the countries in these regions may not provide the same or similar protection as that provided in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may rely on third party patents</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not have rights under some patents or patent applications related to products we may commercialize in the future. Third parties may own or control these patents and patent applications in the United States and abroad. Therefore, in some cases, to manufacture, sell or import some of our future products, we or our collaborators may choose to seek, or be required to seek, licenses under third party patents issued in the United States and abroad or under patents that might be issued from United States and foreign patent applications. In instances in which we must obtain a license for third party patents, we may be required to pay license fees or royalties or both to the licensor. If licenses are not available to us on acceptable terms, we or our collaborators may not be able to develop, manufacture, sell or import these products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to protect the intellectual property rights of third parties from whom we may license certain of our intellectual property or with whom we have entered into other strategic relationships, which could have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of our intellectual property rights may be licensed from third parties, including universities and strategic partners. Such third parties may determine not to or fail to protect the intellectual property rights that we license from them and we may be unable to defend such intellectual property rights on our own or we may have to undertake costly litigation to defend the intellectual property rights of such third parties. There can be no assurances that we will continue to have proprietary rights to any of the intellectual property that we license from such third parties or otherwise have the right to use through similar strategic relationships. Any loss or limitations on use with respect to such intellectual property licensed from third parties or otherwise obtained from third parties with whom we have entered into strategic relationships could have a material adverse effect on our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be party to license agreements with third parties and may need to obtain additional licenses from others to advance our research and development activities or allow the commercialization product candidates we may identify and pursue. License agreements may impose various development, diligence, commercialization, and other obligations on us. For example, we may be required to use commercially reasonable efforts to engage in various development and commercialization activities with respect to licensed products, and satisfy specified milestone and royalty payment obligations. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of product candidates that we may identify. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the priority of invention of patented technology. In addition, the agreements under which we currently or in the future license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing, or increase the costs of commercializing, Aramchol or Aramchol meglumine or any other product candidate.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends significantly on our ability to operate without infringing the patents and other intellectual property rights of third parties. For example, there could be issued patents of which we are not aware that our product candidate infringes. There also could be patents that we believe we do not infringe, but that we may ultimately be found to infringe. Moreover, patent applications are in some cases maintained in secrecy until patents are issued. The publication of discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the underlying discoveries were made and patent applications were filed. Because patents can take many years to issue, there may be currently pending applications of which we are unaware that may later result in issued patents that our product candidates infringe. For example, pending applications may exist that provide support or can be amended to provide support for a claim that results in an issued patent that our product candidates infringes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third parties may assert that we are employing their proprietary technology without authorization. If a court held that any third-party patents are valid, enforceable and cover any of our product candidates or their use, the holders of any of these patents may be able to block our ability to commercialize any such product candidate unless we obtained a license under the applicable patents, or until the patents expire. In addition to litigation proceedings which may be filed against us, we may not be able to enter into licensing arrangements or make other arrangements at a reasonable cost or on reasonable terms. Any inability to secure licenses or alternative technology could result in delays in the introduction of our product candidates or lead to prohibition of the manufacture or sale of products by us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents or other intellectual property. Although we are not currently involved in any litigation, if we were to initiate legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"> <b style="font-weight:bold;">We may be unable to adequately prevent disclosure and unauthorized use of trade secrets and other proprietary information by third parties.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to obtain and maintain patent protection and trade secret protection for our intellectual property and proprietary technologies, our product candidates and their uses is important to our commercial success. We rely on a combination of patent, copyright, trademark and trade secret laws, non-disclosure and confidentiality agreements, licenses, assignment of inventions agreements and other restrictions on disclosure and use to protect our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also rely on trade secrets to protect our proprietary know-how and technological advances, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights. Failure to obtain or maintain trade secret protection could enable competitors to use our proprietary information to develop products that compete with our product candidates or cause additional material adverse effects upon our competitive business position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot be certain that the steps that we have taken will prevent the misappropriation or other violation of our confidential information and other intellectual property, particularly in foreign countries in which laws may not protect our proprietary rights as fully as in the United States and other developed economies. Moreover, if we lose any key personnel, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by those former employees. If we are unable to maintain the security of our proprietary technology, this could materially adversely affect our competitive advantage, business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;"> </span><span style="font-style:italic;font-weight:bold;">Under applicable U.S. and Israeli law, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions irrespective of their agreements with us, which in turn could impact our future profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We generally enter into non-competition agreements with our employees and certain key consultants, or our employment and consulting agreements contain non-competition provisions. These agreements, to the extent they are in place and in effect, prohibit our employees and certain key consultants, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period of time. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants developed while working for us. For example, Israeli courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy of a company&#8217;s confidential commercial information or the protection of its intellectual property. If we cannot demonstrate that such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees or consultants and our ability to remain competitive may be diminished.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee in the course and as a result of or arising from his or her employment with a company are regarded as &#8220;service inventions,&#8221; which belong to the employer, absent a specific agreement between the employee and employer giving the employee service invention rights. The Patent Law also provides that if there is no such agreement between an employer and an employee, the Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, shall determine whether the employee is entitled to remuneration for his or her inventions. Case law clarifies that the right to receive consideration for &#8220;service inventions&#8221; can be waived by the employee and that in certain circumstances, such waiver does not necessarily have to be explicit. The Committee will examine, on a case-by-case basis, the general contractual framework between the parties, using interpretation rules of the general Israeli contract laws. Further, the Committee has not yet determined one specific formula for calculating this remuneration, but rather uses the criteria specified in the Patent Law. Although we generally enter into assignment-of-invention agreements with our employees pursuant to which such individuals assign to us all rights to any inventions created in the scope of their employment or engagement with us, we may face claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any lawsuits relating to infringement of intellectual property rights necessary to defend ourselves or enforce our rights will be costly and time consuming.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be required to initiate litigation to enforce our rights or defend our activities in response to alleged infringement of a third-party. In addition, we may be sued by others who hold intellectual property rights and who claim that their rights are infringed by our product candidates. These lawsuits can be very time consuming and costly. There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries generally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A third-party may claim that we are using inventions claimed by their patents and may go to court to stop us from engaging in our normal operations and activities, such as research, development, and the sale of any future products. Such lawsuits are expensive and would consume time and other resources. There is a risk that such court will decide that we are infringing the third-party&#8217;s patents and will order us to stop the activities claimed by the patents, redesign our products or processes to avoid infringement or obtain licenses, which may not be available on commercially reasonable terms. In addition, there is a risk that a court will order us to pay the other party damages for infringement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, there is no guarantee that any prevailing patent owner would offer us a license so that we could continue to engage in activities claimed by the patent, or that such a license, if made available to us, could be acquired on commercially acceptable terms. In addition, third parties may, in the future, assert other intellectual property infringement claims against us with respect to other product candidates, technologies or other matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our patents and patent applications could face challenges. Any of these challenges, if successful, could result in the invalidation of, or in a narrowing of the scope of, any of our patents and patent applications subject to challenge. Any of these challenges, regardless of their success, would likely be time consuming and expensive to defend and resolve and would divert our management&#8217;s time and attention.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect Aramchol or any other product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity. Therefore, obtaining and enforcing pharmaceutical patents is costly, time-consuming, and inherently uncertain. In particular, the United States has recently enacted, and is currently implementing, wide-ranging patent reform legislation. The United States Supreme Court has ruled on several patent cases in recent years, and could do so again in the future, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty regarding our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by applicable courts and legislatures in the countries in which we may pursue patent protection, including those of the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents and the interpretations of such laws could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"> <span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Ownership of Our Ordinary Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price of our ordinary shares is volatile and you may sustain a complete loss of your investment</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our initial public offering, the trading price of our ordinary shares has been volatile and is likely to continue to be volatile. In addition, the trading volume is and has been volatile and oftentimes relatively illiquid. The following factors, some of which are beyond our control, in addition to other risk factors described in this section, may have a significant impact on the market price and trading volume of our ordinary shares:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">delays in existing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">inability to obtain the approvals necessary to commence further clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">unsatisfactory or inconclusive results of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">termination of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">adverse events in our ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">announcements of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">announcements of therapeutic innovations or new products by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">changes or developments in laws or regulations applicable to our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">any adverse changes to our relationship with manufacturers or suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">any product liability actions or intellectual property infringement actions in which we may become involved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">announcements concerning our competitors or the pharmaceutical industry in general;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">achievement of expected product sales and profitability or our failure to meet expectations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">our commencement of, or involvement in, litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">any major changes in our board of directors, management or other key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">legislation in the United States, Europe and other foreign countries relating to the sale or pricing of pharmaceuticals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">announcements by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">expiration or terminations of licenses, research contracts or other collaboration agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">public concern as to the safety of drugs we, our licensees or others develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">success of research and development projects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">variations in our and our competitors&#8217; results of operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">changes in earnings estimates, cash flow guidance, or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">developments by our licensees, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">future issuances of ordinary shares or other securities; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">natural disasters and political and economic instability, including wars, terrorism, political unrest, results of certain elections and votes, emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an emergency, including for example, the COVID-19 pandemic), boycotts, adoption or expansion of government trade restrictions, and other business restrictions.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These factors and any corresponding price fluctuations may materially and adversely affect the market price and trading volume of our ordinary shares and result in substantial losses by our investors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock market in general, and the Nasdaq Capital Market and the market for biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of our Company and that of small companies. Broad market and industry factors may negatively affect the market price of our ordinary shares, regardless of our actual operating performance. Further, a systemic decline in the financial markets and related factors beyond our control may cause our share price to decline rapidly and unexpectedly. Price volatility of our ordinary shares might be worse if the trading volume of our ordinary shares is low. Following periods of market volatility or a material decrease in the value of our ordinary shares, shareholders may institute securities class action litigation. If we were involved in securities litigation, it could have a substantial cost and divert resources and attention of management from our business, even if we are successful. Future sales of our ordinary shares could also reduce the market price of such stock. Any adverse determination in litigation could also subject us to significant liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, the liquidity of our ordinary shares has been limited, not only in terms of the number of shares that can be bought and sold at a given price, but by delays in the timing of transactions and reduction in security analysts&#8217; and the media&#8217;s coverage of us, if any. These factors may result in lower prices for our ordinary shares than might otherwise be obtained and could also result in a larger spread between the bid and ask prices for our ordinary shares. In addition, without a large float, our ordinary shares are less liquid than the stock of companies with broader public ownership and, as a result, the trading prices of our ordinary shares are more volatile. In the absence of an active public trading market, an investor may be unable to liquidate its investment in our ordinary shares. Trading of a relatively small volume of our ordinary shares may have a greater impact on the trading price of our stock than would be the case if our public float were larger. We cannot predict the prices at which our ordinary shares will trade in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ordinary shares are listed on the Nasdaq Capital Market. As such, we must meet the Nasdaq Capital Market&#8217;s continued listing requirements and other Nasdaq rules, or we may risk delisting. Delisting could negatively affect the price of our ordinary shares, which could make it more difficult for us to sell securities in a financing and for you to sell your ordinary shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ordinary shares are listed on the Nasdaq Capital Market. As such, we are required to meet the continued listing requirements of the Nasdaq Capital Market and other Nasdaq rules, including those regarding director independence and independent committee requirements, minimum shareholders&#8217; equity, minimum share price and certain other corporate governance requirements. In particular, we are required to maintain a minimum bid price for our listed ordinary shares of $1.00 per share. If we do not meet these continued listing requirements, our ordinary shares could be delisted. Delisting of our ordinary shares from the Nasdaq Capital Market would cause us to pursue eligibility for trading on other markets or exchanges, or on the pink sheets. In such case, our shareholders&#8217; ability to trade, or obtain quotations of the market value of, our ordinary shares would be severely limited because of lower trading volumes and transaction delays. These factors could contribute to lower prices and larger spreads in the bid and ask prices for our securities. There can be no assurance that our ordinary shares, if delisted from the Nasdaq Capital Market in the future, would be listed on a national securities exchange, a national quotation service, the Over-The-Counter Markets or the pink sheets. Delisting from the Nasdaq Capital Market, or even the issuance of a notice of potential delisting, would also result in negative publicity, make it more difficult for us to raise additional capital, adversely affect the market liquidity of our ordinary shares, reduce security analysts&#8217; coverage of us and diminish investor, supplier and employee confidence. Additionally, the threat of delisting or a delisting of our ordinary shares from the Nasdaq Capital Market, could reduce the number of investors willing to hold or acquire our ordinary shares, thereby further restricting our ability to obtain equity financing, and it could reduce our ability to retain, attract and motivate our directors, officers and employees. In addition, as a consequence of any such delisting, our share price could be negatively affected and our shareholders would likely find it more difficult to sell, or to obtain accurate quotations as to the prices of, our ordinary shares.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our President and Chief Executive Officer beneficially owns approximately 16.4% of our outstanding ordinary shares, as of February 28, 2021. Therefore, our principal shareholders will be able to exert significant control over matters submitted to our shareholders for approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our President and Chief Executive Officer currently beneficially owns approximately 16.4% of our outstanding ordinary shares as of February 28, 2021. Therefore, our President and Chief Executive Officer will be able to exert significant control over matters submitted to our shareholders for approval. As our President and Chief Executive Officer could significantly influence or even unilaterally approve matters requiring approval by our shareholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of our President and Chief Executive Officer may not always coincide with our interests or the interests of other shareholders. This significant concentration of share ownership may adversely affect the trading price for our ordinary shares because investors often perceive disadvantages in owning stock in companies with controlling shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sales of a substantial number of our ordinary shares in the public market could cause our share price to fall.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of our ordinary shares in the public market, or the perception that these sales might occur, could depress the market price of our ordinary shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our ordinary shares. To date, the lock-up period has expired and substantially all of our outstanding shares are eligible for unrestricted sale. Sales of shares by these shareholders would likely result in the supply of our ordinary shares far exceeding the demand for our ordinary shares and could have a material adverse effect on the trading price of our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital would cause dilution to our existing shareholders, and may restrict our operations or require us to relinquish rights.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may seek additional capital through a combination of private and public equity offerings, &#8220;at-the-market&#8221; issuances, equity-linked and structured transactions, debt (straight, convertible, or otherwise) financings, collaborations and licensing arrangements. Under our existing &#8220;at the market&#8221; equity offering program, or the ATM Offering, as of February 28, 2021, we may sell, from time to time, up to approximately $22.7 million of additional ordinary shares. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through collaboration, strategic alliance and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms that are not favorable to us. Depending upon market liquidity at the time, additional sales of shares registered at any given time could cause the trading price of our ordinary shares to decline.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our U.S. shareholders may suffer adverse tax consequences due to our expected classification as a passive foreign investment company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, if for any taxable year 75% or more of our gross income is passive income, or at least 50% of the average value of our assets is attributable to assets that are held for the production of, or produce, passive income, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. Based upon our review of our financial data, we believe that we were a PFIC for our 2020 taxable year and expect to be a PFIC for the 2021 taxable year. Because PFIC status is determined annually and is based on our income, assets and activities for the entire taxable year, it is not possible to determine with certainty whether we will be characterized as a PFIC for the 2021 taxable year until after the close of the year, and there can be no assurance that we will not be classified as a PFIC in any future year. If we were to be characterized as a PFIC for U.S. federal income tax purposes in any taxable year during which a U.S. Holder (as defined below) owns ordinary shares, such U.S. Holder could face adverse U.S. federal income tax consequences. For example, such U.S. Holder could be subject to additional taxes and interest charges upon certain distributions by us and any gain recognized on a sale, exchange or other disposition of our shares, whether or not we continue to be characterized as a PFIC. Certain adverse consequences of PFIC status can be mitigated if a U.S. Holder makes a &#8220;mark to market&#8221; election or an election to treat us as a qualified electing fund, or QEF. Upon request, we expect to provide the information necessary for U.S. Holders to make &#8220;qualified electing fund elections&#8221; if we are classified as a PFIC. Each investor is urged to consult its tax advisor with respect to the application of the PFIC rules. See also &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212; Certain U.S. Federal Income Tax Considerations.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the securities analysts that currently cover our stock, or will do so in the future, or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations or publish negative reports regarding our business or our shares, our share price and trading volume could be negatively impacted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading market for our ordinary shares is influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover us or provide favorable coverage. If any of the analysts who do cover, or may cover us in the future, adversely change their recommendation regarding our shares, or provide more favorable relative recommendations about our competitors, our share price would likely decline. If any analyst who cover us cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could negatively impact our share price or trading volume.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because we do not intend to declare cash dividends on our ordinary shares in the foreseeable future, shareholders must rely on appreciation of the value of our ordinary shares for any return on their investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid cash dividends on our ordinary shares. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. Moreover, the Israeli Companies Law, 5759-1999, or the Companies Law, imposes certain restrictions on our ability to declare and pay dividends. See &#8220;Item 8. Financial Information&#8212;Consolidated Financial Statements and Other Financial Information&#8212;Dividend Policy&#8221; for additional information.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The requirements associated with being a public company require significant company resources and management attention.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, the Sarbanes-Oxley Act, the listing requirements of the Nasdaq Capital Market, on which our ordinary shares are traded, and other applicable securities rules and regulations. The Exchange Act requires that we file periodic reports with respect to our business and financial condition and maintain effective disclosure controls and procedures and internal control over financial reporting. In addition, subsequent rules implemented by the SEC and the Nasdaq Capital Market may also impose various additional requirements on public companies. As a result, we incurred and will continue to incur additional legal, accounting and other expenses that we did not incur as a privately-held company, particularly since, as of December 31, 2020, we are no longer considered an &#8220;emerging growth company&#8221; as defined in the JOBS Act. Further, the need to establish the corporate infrastructure demanded of a public company may divert management&#8217;s attention from implementing our development plans. We have made and will continue to make changes to our corporate governance standards, compensation policy, disclosure controls and financial reporting and accounting systems to meet our reporting obligations and applicable law. The measures we take, however, may not be sufficient to satisfy our obligations as a public company, which could subject us to delisting of our ordinary shares, fines, sanctions and other regulatory action and potentially civil litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">As a &#8220;foreign private issuer,&#8221; we are permitted to and currently do follow certain home country corporate governance practices instead of otherwise applicable SEC and Nasdaq Capital Market requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a &#8220;foreign private issuer,&#8221; we are permitted to, and currently do, follow certain home country corporate governance practices instead of those otherwise required under the Listing Rules of the Nasdaq Capital Market, or the Nasdaq Listing Rules, for domestic U.S. issuers. For instance, we currently follow home country practice in Israel with regard to, among other things, director nomination procedure and approval of compensation of officers. In addition, we may follow our home country law instead of the Nasdaq Listing Rules that require that we obtain shareholder approval for certain dilutive events, such as the establishment or amendment of certain equity based compensation plans, an issuance that will result in a change of control of the company, certain transactions other than a public offering involving issuances of a 20% or greater interest in the company, and certain acquisitions of the stock or assets of another company. Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the Nasdaq Capital Market may provide less protection to you than what is accorded to investors under the Nasdaq Listing Rules applicable to domestic U.S. issuers. See &#8220;Item 16G. Corporate Governance.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, as a &#8220;foreign private issuer,&#8221; we are exempt from the rules and regulations under the Exchange Act related to the furnishing and content of proxy statements and certain individual executive compensation information, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. Furthermore, foreign private issuers are not required to file their annual report on Form 20-F until 120 days after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form 10-K within 75 days after the end of each fiscal year and U.S. domestic issuers that are large accelerated filers are required to file their annual report on Form 10-K within 60 days after the end of each fiscal year. Additionally, as a &#8220;foreign private issuer,&#8221; we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These exemptions and leniencies reduce the frequency and scope of information and protections to which you are entitled as an investor.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our ordinary shares become a &#8220;penny stock,&#8221; it may be more difficult for investors to sell their ordinary shares, and the market price of our ordinary shares may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ordinary shares could become a &#8220;penny stock&#8221; if, among other things, the share price is below $5.00 per share, we are not listed on a national securities exchange or we have not met certain net tangible asset or average revenue requirements. Broker-dealers who sell penny stocks must provide purchasers of these stocks with a standardized risk-disclosure document prepared by the SEC. This document provides information about penny stocks and the nature and level of risks involved in investing in the penny-stock market. A broker must also give a purchaser, orally or in writing, bid and offer quotations and information regarding broker and salesperson compensation, make a written determination that the penny stock is a suitable investment for the purchaser, and obtain the purchaser&#8217;s written agreement to the purchase. Broker-dealers must also provide customers that hold penny stock in their accounts with such broker-dealer a monthly statement containing price and market information relating to the penny stock. If a penny stock is sold to an investor in violation of the penny stock rules, the investor may be able to cancel its purchase and get its money back.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If applicable, the penny stock rules may make it difficult for investors to sell their ordinary shares. Because of the rules and restrictions applicable to a penny stock, there is less trading in penny stocks and the market price of our ordinary shares may be adversely affected. Also, many brokers choose not to participate in penny stock transactions. Accordingly, investors may not always be able to resell their ordinary shares publicly at times and prices that they feel are appropriate and the market price of our ordinary shares may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Israeli Law and Our Operations in Israel</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our headquarters and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our executive offices are located in Tel Aviv, Israel. In addition, the majority of our officers and directors are residents of Israel. Accordingly, political, economic and military conditions in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations. In recent years, these have included hostilities between Israel and Hezbollah in Lebanon and Hamas in the Gaza strip, both of which resulted in rockets being fired into Israel, causing casualties and disruption of economic activities. In addition, Israel faces threats from more distant neighbors, in particular, Iran.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since February 2011, riots and uprisings in several countries in the Middle East and neighboring regions have led to severe political instability in several neighboring states and to a decline in the regional security situation. Such instability may affect the local and global economy, could negatively affect business conditions and, therefore, could adversely affect our operations. To date, these matters have not had any material effect on our business and results of operations; however, the regional security situation and worldwide perceptions of it are outside our control, and there can be no assurance that these matters will not negatively affect us in the future. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained, or if maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions generally and could harm our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, in the past, the State of Israel and Israeli companies have been subjects of economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial condition or the expansion of our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The legislative power of the State resides in the Knesset, a unicameral parliament that consists of 120 members elected by nationwide voting under a system of proportional representation. Israel&#8217;s most recent general elections were held on April 9, 2019, September 17, 2019 and March 2, 2020. The uncertainty surrounding the results of the recent elections may continue. Actual or perceived political instability in Israel or any negative changes in the political environment, may individually or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our operations may be disrupted as a result of the obligation of Israeli citizens to perform military service.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many Israeli citizens are obligated to perform several days, and in some cases more, of annual military reserve duty until they reach the age of 40 (or older, for reservists who are officers or who have certain occupations) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted by such call- ups, which may include the call-up of our employees or the employees of our Israeli business partners. Such disruption could materially adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exchange rate fluctuations between the U.S. dollar and the New Israeli Shekel currencies may negatively affect our earnings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our functional currency is the U.S. dollar. We incur expenses in U.S. dollars and New Israeli Shekels, or NIS. As a result, we are exposed to the risks that the NIS may appreciate relative to the U.S. dollar, or, if either the NIS devalues relative to the U.S. dollar, that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the U.S. dollar cost of our operations in Israel would increase and our U.S. dollar-denominated results of operations would be adversely affected. The average exchange rate for the year ended December 31, 2020 was $1.00 = NIS 3.215. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation, if any, of the NIS against the U.S. dollar. As of the date hereof, neither the inflation rate in Israel has exceeded the rate of devaluation of the NIS, respectively, during the calendar years 2018, 2019 or 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Provisions of Israeli law and our articles of association, or Articles, may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Companies Law regulates, among others, mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. See &#8220;Item 10. Additional Information&#8212;B. &#8212;Mergers and Acquisitions under Israeli Law&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. See &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;Certain Israeli Tax Considerations&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, the classification of our Board into three classes with terms of approximately three years each, per our Articles, the requirement of affirmative vote of at least 75% of the voting rights of the Company represented personally or by proxy and voting thereon at a general meeting in order to amend or replace our Articles, together with the other provisions of the Articles and Israeli law, could deter or delay potential future merger, acquisition, tender or takeover offers, proxy contests or changes in control or management of the Company.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">It may be difficult to enforce a judgment of a United States court against us, our officers, directors and the Israeli experts named in this annual report in Israel or the United States, to assert United States securities laws claims in Israel or to serve process on our officers, directors and these experts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were and continue to be organized in Israel. Most of our executive officers and directors reside outside of the United States, and all of our assets and most of the assets of these persons are located outside of the United States. Therefore, a judgment obtained against us, or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not necessarily be enforced by an Israeli court. It also may be difficult to effect service of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally, it may be difficult for an investor, or any other person or entity, to initiate an action with respect to United States securities laws in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of United States securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not United States law is applicable to the claim. If United States law is found to be applicable, the content of applicable United States law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, our shareholders may not be able to collect any damages awarded by either a United States or foreign court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Your rights, liabilities and responsibilities as a shareholder will be governed by Israeli law and differ in some material respects from those under U.S. law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we are an Israeli company, the rights and responsibilities of our shareholders are governed by our Articles and Israeli law. These rights, liabilities and responsibilities differ in some material respects from the rights, liabilities and responsibilities of shareholders in a U.S. corporation. In particular, a shareholder of an Israeli company has a duty to act in good faith towards the company and other shareholders and to refrain from abusing his, her or its power in the company, including, among other things, when voting at the general meeting of shareholders on certain matters. Israeli law provides that these duties are applicable to shareholder votes on, among other things, amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers and interested party transactions requiring shareholder approval. In addition, a controlling shareholder, a shareholder who knows that it possesses the power to determine the outcome of a shareholders&#8217; vote or a shareholder who has the power to appoint or prevent the appointment of a director or executive officer in the company, has a duty of fairness towards the company. However, Israeli law does not define the substance of this duty of fairness. There is little case law available to assist in understanding the implications of these provisions that govern shareholder behavior. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. corporations. See &#8220;Item 10. Additional Information&#8212;B Memorandum and Articles of Association&#8212;Shareholder Duties&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Any of the risk factors referred to above could significantly and negatively affect our business, results of operations or financial condition, which may reduce our ability to pay dividends and lower the trading price of our ordinary shares. The risks referred to above are not the only ones that may exist. Additional risks not currently known by us or that we deem immaterial may also impair our business operation</span><b style="font-weight:bold;">s.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dde82198_9b0b_40b9_b9d0_b7d0aa7c3798"></a><a id="_contentSection_acaaa285_e8c8_4a33_b0eb_"></a><a id="ITEM4InformationontheCompany_490867"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;4. Information on the Company.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">A.</b></span><b style="font-weight:bold;">Historical Background and Corporate Structure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Company, Galmed Pharmaceuticals&#160;Ltd., was incorporated in Israel on July&#160;31, 2013 as a privately held company and is governed by the Companies Law. However, our business has been operating since 2000 under a different group of companies established in the same&#160;year, or the Group. Originally, we operated under the parent company, GHI. GHI held all of the equity rights in and to GTTI. GTTI held all of the equity rights in and to GIL (other than 0.1% of the share capital held by GHI). GIL held all of the equity rights in and to GMR.&#160;Our intellectual property was held by GIL. The research and development was conducted by GMR as a service to GIL on a cost plus basis. GIL was responsible for all product development.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:156pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February&#160;2, 2014, we underwent the Reorganization, pursuant to which all of our intangible assets (including our intellectual property) were transferred from GIL to GRD. The Reorganization was effectuated by share transfers and asset transfers, resulting in the Company as the parent company and 100% equity-owner of the following companies: (1)&#160;GRD, which holds all the Group&#8217;s intellectual property, including the Company&#8217;s patent portfolio; (2)&#160;GIL, which is an inactive company; and (3)&#160;GTTI, which was liquidated in 2017. GIL held GMR, which became an inactive company in 2015 and was liquidated in February&#160;2019. The Reorganization was conducted in order to simplify our capital structure, reduce our operating cost and to improve our ability to raise funds. Immediately prior to the Reorganization, all our shareholders collectively held 9,739 ordinary shares of GHI. In connection with the Reorganization, and in accordance with the Tax Pre-Ruling, we issued to all such shareholders ordinary shares of the Company, such that upon the Reorganization all our shareholders collectively held 7,099,731 ordinary shares of the Company, in the same proportion among all shareholders, which reflected a ratio of 729 ordinary shares of the Company for each ordinary share of GHI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a diagram of our corporate structure (following GTTI&#39;s liquidation):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20201231x20f002.jpg" alt="Graphic" style="display:inline-block;height:155.6pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March&#160;18, 2014, we completed our initial public offering and since then have been listed on the Nasdaq Capital Market under the symbol &#8220;GLMD&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our principal executive offices and registered office in Israel are located at 16 Tiomkin Street, Tel Aviv,&#160;Israel, 6578317 and our telephone number is +972-3-693-8448. Our website address is http://www.galmedpharma.com. The information contained on, or that can be accessed through, our website is neither a part of nor incorporated into this annual report. We have included our website address in this annual report solely as an inactive textual reference. Puglisi&#160;&amp; Associates, or Puglisi, serves as our authorized representative in the United States for certain limited matters. Puglisi&#8217;s address is 850 Library Avenue, Newark, Delaware 19711.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The SEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at http://sec.gov. We use our website (<span style="text-decoration:underline;text-decoration-color:#000000;">http://www.galmedpharma.com</span>) as a channel of distribution of Company information. The information we post through this channel may be deemed material. Accordingly, investors should monitor our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. The contents of our website are not, however, a part of this annual report.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:233pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other than as described in &#8220;Item&#160;5. Operating and Financial Review and Prospects&#8212;Contractual Obligations&#8221;, we have not had any material commitments for capital expenditures, including any anticipated material acquisition of plant and equipment or interests in other companies, since January&#160;1, 2014. Additionally, we have not had any material capital divestitures since January&#160;1, 2014.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">B.</b></span><b style="font-weight:bold;">Business Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted stearoyl-coenzyme A desaturase-1, or SCD1, modulator, first in class, novel, oral therapy for the treatment of NASH for various populations. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that our lead product candidate, Aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that constitutes a large unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The conjugated molecule acts upon important metabolic pathways, reducing fat accumulation in the liver, improving fatty acid oxidation and regulating the transport of cholesterol. The ability of Aramchol to decrease liver fat content may also reduce the inflammation and fibrosis in the liver and the risk of cardiovascular complications associated with NASH. Pre-clinical studies suggest Aramchol&#8217;s effect on fibrosis is also direct via collagen production from human hepatic stellate cells. We believe that Aramchol&#8217;s ability to reduce liver fat and liver fibrosis and the safety profile observed to date will enable it to be a treatment for all stages of NASH in patients who are overweight or obese and have pre diabetes or type II diabetes mellitus and prevent the hepatic complications associated therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of our pipeline of programs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20201231x20f003.jpg" alt="Graphic" style="display:inline-block;height:233pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2019, we completed our End-of-Phase 2 meeting with the FDA and reached general agreement on key aspects of the Phase 3 development and registration plan for Aramchol and on the pivotal registration ARMOR study. In September 2019, we initiated our Phase 3 ARMOR Study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis. The ARMOR Study was originally comprised of two parts, a randomized, double-blind, placebo-controlled histology-based registrational part and a clinically based part where subjects will continue with the same treatment for approximately five years. In December 2020, we announced the addition of an open label part to the ARMOR Study and temporarily suspended randomization of new patients into the double-blind, placebo-controlled histology-based registrational part of ARMOR as currently enrolled patients are transitioned to the open label part. We are seeking to introduce Aramchol meglumine into the randomized double-blind, placebo-controlled part of ARMOR and are planning to hold a Type C meeting with the FDA in the second quarter of 2021 to discuss the plan for transition with a view to initiating the double-blind, placebo-controlled histology-based registrational part by the end of the first quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2020, we announced that we entered into a research agreement with Gannex Pharma Co. Ltd, or Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX:1672), or Ascletis, aiming at combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment NASH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, we announced that we entered into a research and development collaboration agreement with MyBiotics to identify and optimize the selected microbiome repertoire associated with the response to Aramchol. The research will also focus on development of a standalone microbiome-based treatment for NASH and fibrosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2021, we announced the treatment of the first subject in the first in human Phase I clinical trial evaluating Amilo-5MER for the treatment of chronic inflammatory diseases. Additional subject enrollment to the study is ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Non-Alcoholic Fatty Liver Disease (NAFLD) / Non-Alcoholic Steato-Hepatitis (NASH)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is estimated that the global prevalence of NAFLD, the precondition to NASH, is approximately 25% in the general population and much higher in certain high risk groups. This disease is also now recognized as one of the most common liver disorders, and a significant growing public health problem. In the US alone, 80 - 100 million people are said to be affected by NAFLD, and its prevalence is rapidly growing in parallel with metabolic syndromes, particularly obesity and diabetes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NAFLD is characterized by the accumulation of fat of 5% or greater in the liver of people who drink alcohol only in moderation, or not at all. There may be numerous causes of NAFLD, however, the disease is mostly associated with a high fat, fructose-rich diet. Although NAFLD is generally asymptomatic, it is a major risk factor for liver inflammation (NASH) and scarring (fibrosis and cirrhosis). In addition, NAFLD is also associated with metabolic syndrome and cardiovascular disease. Currently, NAFLD can only be managed through lifestyle improvements, such as weight reduction and physical activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally, and is associated with increased risk of liver cirrhosis, liver failure, hepatocellular cancer, as well as metabolic and cardiovascular diseases. The major characteristics of NASH are elevated liver fat, inflammation, ballooning and fibrosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">However, despite the growing need, there are currently no approved therapeutic treatments for NASH. Modification of risk factors, such as obesity and hyperlipidemia, and proper diabetic control is generally recommended for the treatment of NASH, and the standard of care includes lifestyle changes to promote weight loss, including low-calorie, low-fat diets and physical activity. Although weight loss can be potentially significant in delaying the progression of NASH, studies have shown that, for most individuals, it is generally very difficult to maintain over the long-term, even following bariatric surgery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are currently no drugs approved by regulatory authorities for the treatment of NASH. Even though certain drugs, such as insulin sensitizers and antihyperlipidemic agents, are prescribed for some NASH patients, they are not approved for the treatment of NASH and their efficacy has not been proven in adequate and well-controlled clinical studies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Currently, it is impossible to predict which of the NAFLD patients will deteriorate to NASH as it is unclear what causes NASH to develop. Researchers are now focusing on several factors that may contribute to the development of NASH. Therefore, lifestyle changes are recommended for all patients with NAFLD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is an exceptionally wide range of estimates regarding the potential commercial market for NASH. This uncertainty stems from (i) the overall size of the patient population, (ii) the percentage of the addressable market that will be diagnosed and, subsequently, seek treatment, (iii) the ultimate cost of the therapies, (iv) the number of approved drugs for NASH and their profile, and (v) uncertainty regarding the regulatory approval process. Some of these factors cannot be known until NASH drugs begin to hit the market or biomarkers replacing the biopsy diagnosis are validated. Independent estimates generally estimate a commercial multi billion market in developed countries, though we do not endorse any estimates, which are based on a number of different underlying assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Aramchol for NASH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidate, Aramchol, is a first-in-class synthetic fatty acid-bile acid conjugate molecule, or FABAC, molecule that we are developing for oral treatment for NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Early in its development, Aramchol&#8217;s ability to modulate hepatic lipid metabolism was observed and validated in numerous pre-clinical trials with different animal species. Mice fed a high fat diet and treated with Aramchol did not develop fatty liver as compared to non-treated mice. In these early studies, we also observed that the mechanism of this effect was not a result of malabsorption of fat in the intestines because the FABAC-treated mice gained weight throughout the test periods to a similar degree to the control mice. This led us to conclude that FABAC therapy triggers a beneficial modulation of intra-hepatic lipid metabolism and reduces liver fat content.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In <i style="font-style:italic;">in-vitro</i> and in vivo studies, Aramchol down regulates the SCD1 enzyme, an enzyme recognized as playing an important role in the metabolism of fatty acids. The SCD1 enzyme is essentially the gateway that regulates the use and storage of fat in the body by converting saturated fatty acids to monounsaturated fatty acids. Experimental animal studies showed that complete inhibition of the SCD1 enzyme protects against diet-induced obesity, hepatic steatosis, or fatty liver, and insulin resistance by instructing the body to use, rather than store, all fatty acids. However, various animal studies have indicated that such complete SCD1 enzyme inhibition has mechanism based serious side effects, such as atherosclerosis, and eye and skin disorders. As observed by us in our pre-clinical and clinical&#160;studies performed to date, and subsequently published in the European Journal of Gastroenterology and Hepatology and Archives of Medical Research in 2008 and 2010 respectively, one of Aramchol&#8217;s unique characteristics is that it down regulates the SCD1 enzyme but does not inhibit it completely&#160;&#8211; a partial effect. To date, side effects that have been observed in animals with knock out of SCD1 have not been observed in our toxicology and clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To better understand the role of Aramchol in NASH, we analyzed the effect of Aramchol in MCD diet model. The aim of this study was to investigate Aramchol&#8217;s mechanism of action and its effect on fibrosis using the methionine- and choline-deficient (MCD) diet model of NASH. We collected liver and serum from mice fed a MCD diet containing 0.1% methionine (0.1MCD) for four weeks, which developed steatohepatitis and fibrosis, as well as mice receiving a control diet; the metabolomes and proteomes were determined. 0.1MCD fed mice were given Aramchol (5mg/kg/day for the last 2 weeks); liver samples were analyzed histologically. Aramchol administration was found to reduce features of steatohepatitis and fibrosis in 0.1MCD fed mice. Aramchol downregulated the SCD1 enzyme, a key enzyme involved in triglyceride biosynthesis whose loss enhances fatty acid &#946;-oxidation. In addition, Aramchol increased the flux through the transsulfuration pathway, leading to a rise in glutathione (GSH) and GSH/GSSG ratio, the main cellular antioxidant that maintains intracellular redox status. Comparison of the serum metabolomic pattern between 0.1MCD-fed mice and patients with NAFLD showed a substantial overlap. These findings were published in Hepatology Communications, Vol. 1, No.&#160;9, 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As the effect of Aramchol on fibrosis was first reported we further analyzed the direct effect of Aramchol on collagen production and reported down regulation of collagen production from the hepatic stellate cells (HSCs) by </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Aramchol. With that we could conclude that Aramchol has potential direct effect on collagen production and therefore reduces fibrosis indirectly by down regulation of steatosis by reducing the sequence of events but also directly affecting collagen producing cells. These findings were published in Hepatology Communications, Vol. 1, No.&#160;9, 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These findings led us to further analyze the effect of Aramchol using the Thiocatemide (TAA) rat model. TAA is the most commonly used toxic agents to induce liver fibrosis. Repeated IP injections of TAA leads to sever fibrosis / cirrhosis. Among all models for fibrosis, the TAA model share multiple characteristics with human liver fibrosis and is considered to best predict efficacy in humans. Results demonstrated that treatment with Aramchol 5mg/kg, significantly prevented TAA induced fibrosis in a dose dependent manner. These findings were presented at EASL, Amsterdam in April&#160;2017 (The anti Fibrotic effect of Aramchol on liver Fibrosis in TAA animal model).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers (NCT00776841)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Aramchol was evaluated in two Phase 1 clinical trials (under a single protocol) to study its safety, tolerability and PK profile in healthy volunteers, in both single and multiple dose administrations. The first Phase 1 clinical trial was an escalating single-dose trial conducted in 17 healthy subjects testing Aramchol doses ranging from 30 mg to 900 mg, performed in one center in Israel. The subsequent Phase 1 clinical trial was a repeated-dose trial conducted over four&#160;days in 25 healthy subjects testing repeated daily doses of Aramchol of 30 mg and 300 mg, performed in one center in Israel. The profiles for the groups were similar and the maximal plasma concentration of Aramchol increased with the higher doses. The PK profile demonstrated that Aramchol is suitable at each dose for once-daily administration and there were neither significant adverse events observed in either Phase 1 trial nor any notable changes in biochemical, hematologic, cardiovascular or other safety parameters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 2a Trial: Aramchol Treatment in NAFLD or NASH Patients (NCT01094158)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2012, we completed a 60 patient multi-center, randomized, double-blind, placebo-controlled Phase 2a clinical trial of Aramchol in patients with NAFLD or NASH between the ages of 18 and 75 in 12 centers in Israel. The Phase 2a study results were published in July&#160;2014 in the peer-reviewed Clinical Gastroenterology and Hepatology Journal. The trial was performed in patients with either NAFLD or NASH, which design was deemed acceptable by the FDA in 2007 at a pre-IND scientific advisory meeting. The trial&#8217;s primary efficacy endpoint was a reduction in liver fat content, and did not consider inflammation or fibrosis, which can be diagnosed only by liver biopsy. We believe that the short study duration of three&#160;months of treatment followed by a one-month follow-up period did not warrant repeated biopsies. The trial evaluated the effects on liver fat content of 100 mg and 300 mg once-daily doses of Aramchol compared to a placebo. At the end of the three&#160;month treatment period, statistically significant reductions in liver fat concentration as measured by MRS were observed in the 300 mg patient group. Specifically, a 12.57% mean liver fat content reduction was observed in the 300 mg group, as compared to a mean reduction of 2.89% in the 100 mg group and a mean increase of 6.39% in the placebo-treated patients. These results indicate that the effects of Aramchol are dose-dependent, as demonstrated in the graph below, which presents the results with respect to the 57 patients who successfully completed the entire treatment period (three patients were excluded from data analysis because of one protocol violation and two withdrawal consents).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:271.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Relative Change in MRS from Baseline after Three&#160;Months of Treatment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20201231x20f004.jpg" alt="Graphic" style="display:inline-block;height:271.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:449.19pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The table above shows that the primary endpoint of the study was attained. The study demonstrated a statistically significant, dose dependent reduction in fat content in the livers of patients treated with Aramchol, with a 19% difference between the 300 mg dose group and the placebo group, while the difference between the 100 mg dose group and the placebo group was not statistically significant. Notably, the minimal effective dose of Aramchol for fat reduction has been defined.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There were no statistically significant differences among the three treatment groups for any of the secondary end points. There was a non-statistically significant trend of mild weight reduction (P=.1) in the high dose Aramchol group. Serum adiponectin levels increased (0.2 &#177; 1.7 &#956;g/mL) in the high-dose Aramchol group but decreased in the low-dose (-0.3 &#177; 1.5 &#956;g/mL) and placebo groups (-0.7 &#177;_1.3 &#956;gg/mL) (P= 0.88 for trend of dose-response relationship by linear regression). FMD increased non-statistically significantly by 1.28% &#177; 2.92% in the high-dose group, by 0.34% &#177;3.54% in the low-dose group, and by 0.46% &#177; 2.28% in the placebo group.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The frequency of adverse events was similar in all treatment groups, and none of them were considered to be related to the treatment. All adverse events in the active treatment arms were mild or moderate and none were serious. None of the patients withdrew as a result of adverse events. The following table shows the most frequent adverse events (occurring in <span style="font-family:'Symbol';">&#179;</span><span style="font-family:'Symbol';"> </span>2 patients in any group) in the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:28.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Placebo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aramchol 100mg/d</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aramchol 300mg/d</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:28.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(N=20)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(N=20)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(N=20)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:28.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">MedDRA preferred term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Events</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Subjects</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Events</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Subjects</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Events</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Subjects</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Abdominal pain</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.19%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.19%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.19%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:28.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Abdominal pain upper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Constipation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Asthenia</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Back pain</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Musculoskeletal pain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upper respiratory tract infection</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of our Phase 2a clinical trial of Aramchol in the peer-reviewed Clinical Gastroenterology and Hepatology Journal were published in December&#160;2014. The trial manuscript, entitled &#8220;The Fatty Acid-Bile Acid Conjugate Aramchol Reduced Liver Fat Content in Patients with Nonalcoholic Fatty Liver Disease,&#8221; provides the full report of the Phase 2a trial, which was completed in January&#160;2012 and presented at the 47<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Annual Meeting of the European Association for the Study of the Liver in 2012. Based on this Phase 2a proof-of-concept results, we established a development plan that we believe may confirm: (i)&#160;the good safety profile of Aramchol, (ii)&#160;the optimal dose of Aramchol, and (iii)&#160;efficacy on steatosis as well as fibrosis in patients with NASH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers (NCT02374437)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April&#160;28, 2014, we commenced PK and food effect studies of Aramchol. In written correspondence from December&#160;2013 regarding a requested pre-IND meeting, the FDA recommended that we conduct such studies prior to commencing our Phase 2b ARREST Study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We conducted the food effect and PK study at the Sourasky Medical Center in Tel Aviv,&#160;Israel involving 66 healthy volunteers to evaluate the PK of Aramchol following single and multiple escalating doses (200 mg, 400 mg and 600 mg), as well as to evaluate the effect of a high-fat, high-calorie meal on the PK of Aramchol following a single dose in healthy volunteers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results showed dose-related, but less than dose-proportional, increases in the mean Aramchol plasma concentrations, or Cmax, area under the curve, or AUC, (0-t), and AUC (inf) of 200 mg, 400 mg and 600 mg doses administered under fasting conditions or following a light meal, both at single and repeated dose administration. Cmax and AUC are metrics used to indicate the significance of a drug&#8217;s exposure. Steady-state was achieved by 144 hours (day seven). Administration of Aramchol after a high-fat, high-calorie meal afforded a 2.6 fold increase in exposure, as measured by Cmax, AUC(0-t), and AUC(inf) compared to the fasting group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No serious adverse events or deaths occurred during the study. Adverse events were equally distributed between placebo and Aramchol doses, were mild (with only one moderate adverse event) and the majority defined unrelated to Aramchol. The PK study provides additional safety data to further support existing safety data from our pre-clinical studies and our Phase 1 and Phase 2a clinical trials of Aramchol.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered under Fed Conditions in Healthy Chinese Volunteers (NCT 02803996)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In 2016, we performed the Chinese PK Study involving Chinese patients who are domiciled in the United States. We enrolled 66 patients in this study, consisting of two parts. In part A, 32 subjects received a single escalating dose; Part&#160;B enrolled 34 subjects which received a multiple escalating dose. Dr.&#160;Evelyn Darius served as the Study Investigator. No safety signal was identified in this study and we deemed no changes were required in the enrollment of Chinese patients into the ARREST Study. Moreover, having this Chinese PK Study data may give us a head start in future licensing discussions with potential Chinese partners for the development of Aramchol in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 2b ARREST Study for Aramchol (NCT 02279524)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2014, the FDA granted Fast Track designation status to Aramchol for the treatment of NASH. Fast Track designation may accelerate the development process and may expedite the review of drugs that show promise in treating serious, life-threatening medical conditions for which no other drug either exists or is as effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February&#160;1, 2015, we began our ARREST Study. The ARREST Study was a Phase 2b, multicenter, global, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety and of two doses of Aramchol for the treatment of NASH in patients who are overweight or obese and have pre diabetes or type II diabetes mellitus. In order to be eligible to participate in the ARREST Study, patients had to be affected by NASH, as diagnosed by a biopsy centrally read (steatosis &#8805;1 + inflammation &#8805;1 + ballooning &#8805;1, total activity NAS score of 4 or more), have a fibrosis stage of 1-3, be overweight or obese as measured by a Body Mass Index between 25 and 40 or waist circumference between 88cm to 200cm for women, and between 102cm to 200cm for men, and who are pre diabetic or type II diabetic. We targeted this specific population as it is at the greatest risk of developing NASH and its complications. We have generated data from animal models that lead us to believe that Aramchol targets all three main pathologies of the disease: steatosis, inflammation and fibrosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A total of 247 patients (approximately one third in the US, one third in Latin America and one third in Europe and Israel) with liver biopsy-proven NASH who were overweight or obese and had pre-diabetes or type II diabetes mellitus were randomized. Patients were randomized in a ratio of 2:2:1 (600mg, 400mg and placebo) taking once-daily oral Aramchol (in the Aramchol treatment arms) or a placebo (in the placebo arm). The treatment part of the trial was 12&#160;months in duration and patients completing this phase were observed for a three&#160;month follow-up period. In February&#160;2017, we completed randomization of the ARREST Study. Baseline histology of patients enrolled into the ARREST study demonstrated a population with advanced disease, with 60% having stage 2 and 3 fibrosis and 70% have NAS<span style="text-decoration:underline;text-decoration-color:#000000;">&gt;</span>5 at baseline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The primary endpoint of the study was the change from baseline to end of study in liver triglycerides ratio as measured by magnetic resonance spectroscopy, or MRS (Aramchol 600mg vs. placebo). Secondary endpoints, demonstrated through biopsy, included fibrosis improvement by at least one stage or more without worsening of NASH (defined by an increase of inflammation and or ballooning) and NASH resolution (defined by ballooning score 0 and inflammation score 0-1 at termination) without worsening of fibrosis. Other secondary endpoints included improvement (2 points or more) in NASH activity index, as measured by NAS or SAF, without worsening fibrosis and change in baseline to week 52/termination in ALT (U/L).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June&#160;12, 2018, we announced top-line results of the ARREST Study and on November&#160;13, 2018 an oral abstract presentation of one-year results of the ARREST Study was presented during a Late Breaking Abstract Oral Session at The Liver Meeting&#174; 2018 during the American Association for the Study of Liver Diseases 2018 Annual Meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Of the 247 patients, 48 patients were in the placebo arm, 101 patients in the Aramchol 400mg arm and 98 in the Aramchol 600mg treatment arm. The majority of subjects completed 52 weeks of treatment and 13 weeks of follow up (89.1%, 89.8%, 85.4% in the 400 mg, 600 mg and placebo arms, respectively). The leading cause of discontinuation was consent withdrawal and early termination due to adverse events; the incidence of early termination due to AEs was very low and similar across study arms.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patients in the ARREST study were planned to undergo MRS, and a liver biopsy at baseline and week 52, which were centrally read, blinded to treatment allocation. The statistical analysis plan included pre-defined analysis sets: (i) a full analysis set for MRI (FAS -&#8212; &#160;MRI): all intent to treat, or ITT, patients with baseline and at least one second MRS. 214 patients were included in this analysis set (41 in placebo; 90 in Aramchol 400mg; and 83 in Aramchol 600mg); and (ii) a full analysis set for liver biopsy (FAS -&#8212; biopsy): all ITT patients with baseline and a second biopsy. 198 patients were included in this analysis set (40 in placebo; 80 in Aramchol 400mg; and 78 in Aramchol 600mg).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Results from the study showed a statistically significant reduction in liver fat by MRS with Aramchol 400mg vs. placebo (p=0.0450) and not with 600mg (p=0.0655) and thus did not reach the primary endpoint of the study. In a post-hoc analysis, a cutoff of 5% absolute reduction in liver fat was used as a surrogate for potentially clinically meaningful MRI reduction. In this responder&#8217;s analysis, a dose-response could be observed; the responder rate was 47.0%, 36.7% and 24.2%, in the Aramchol 600mg, 400mg and placebo arms, respectively. The proportion of the Aramchol 600mg arm compared to placebo was statistically-significant (p=0.0279).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Results for the two biopsy endpoints, which may currently constitute a primary endpoint for a Phase 3 trial to support an FDA marketing application, demonstrated the following: (i)&#160;significantly more patients treated with Aramchol 600mg vs. placebo achieved NASH resolution without worsening of fibrosis (16.7% vs. 5.0%; p=0.0514); and (ii)&#160;a higher proportion of patients showed at least one-point improvement in fibrosis score without worsening of NASH in Aramchol 600mg vs. placebo (29.5% vs. 17.5%; p=0.2110).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Statistically significant reductions in live enzymes alanine transaminase (ALT) and aspartate transaminase (AST) were demonstrated in both Aramchol arms vs. placebo (p&#8804;0.0002) and (p&lt;0.0001), respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Secondary endpoints based on NAS and SAF activity score, &#8805;2 points improvement, showed a higher proportion of patients with improvement in the Aramchol arms (600mg&gt;400mg&gt;placebo; P&gt;0.05).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Exploratory endpoints of glycemic parameters showed statistically significant reductions in HbA1c with both Aramchol arms vs. placebo (p&lt;0.007) implying a potential effect on glycemic control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At 52 weeks of treatment, Aramchol continued to show a favorable safety and tolerability profile. Serious adverse events were reported in 12.5%, 8.9% and 9.2% of patients in placebo, Aramchol 400mg and 600mg arms, respectively. No clustering of event type or atypical events for the studied population was reported in either Aramchol arms. Severe adverse events were reported in 10.4%, 6.9%, and 6.1% of patients in placebo, Aramchol 400mg, and 600mg arms, respectively. Early terminations due to adverse events occurred in 4.2%, 3.0% and 4.1% in placebo, Aramchol 400mg and 600mg arms, respectively.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:225.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the most frequent adverse events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20201231x20f005.jpg" alt="Graphic" style="display:inline-block;height:225.4pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the ARREST results:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aramchol</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aramchol</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Placebo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">400mg</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">600mg</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MRS- &#8211;Absolute change from baseline in mean liver fat (1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.09)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3.41)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3.18)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.0450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.0655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MRS responders- Reduction of&#8201; &#8805;5% in absolute change from baseline (1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24.4</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36.7</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47.0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.0878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.0279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NASH resolution without worsening of fibrosis (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16.7</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.4955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.0514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NASH resolution (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19.2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.2237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.0462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fibrosis improvement (&#8805;1 stage) without worsening of&#160;NASH (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21.3</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.8425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.2110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Progression to Cirrhosis (Post-Hoc Analysis) worsening of NASH&#160;(2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1.3</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.5693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.1008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ALT (U/L) Change from baseline (3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">+11.82</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">-12.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(17.3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P=0.0002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">P&lt;0.0001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AST (U/L) Change from baseline (3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">+6.67</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(7.20)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(10.83)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">p=0.0011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">p&lt;.0001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HbA1C Change from baseline (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">+0.32</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.04)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.13)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">p=0.0061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">p=0.0008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Placebo N=41; 400mg N=90, 600mg N=83; Mixed Effect Model Repeat Measurement (MMRM) adjusted mean changes from baseline; p-values for comparison of active treatment arm vs. placebo.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Placebo N=40, 400mg N=80, 600mg N=78; Baseline adjusted logistic regression; p-values for comparison of active treatment arm vs. placebo.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Placebo N=47, 400mg N=100, 600mg N=98; MMRM adjusted mean changes from baseline; p-values for comparison of active treatment arm vs. placebo.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:178.5pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Placebo N=47, 400mg N=98, 600mg N=96; MMRM adjusted mean changes from baseline; p-values for comparison of active treatment arm vs. placebo.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dose Splitting Pharmcokinetic Study (NCT03774173)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the dose response pattern observed in the ARREST Study, we recently conducted a Phase I, open-label, crossover PK study to assess whether dose splitting of Aramchol 600mg to twice daily 300mg will significantly increase plasma levels. 16 healthy subjects took part in two study periods. Eight subjects received each regimen in the first period and the alternate regimen in the second period. A PK profile was obtained over the dosing interval at steady state on day ten of each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Results of the study showed that the administration of Aramchol 300 mg twice daily resulted in 24-hour plasma concentrations significantly greater than those observed with the administration of Aramchol 600 mg once daily. (P&lt;0.0001). The average plasma levels (exposure) were 53% higher and exposure was greater in all 16 subjects with the twice daily dosing. The treatment in both dosing regimens were similar in terms of safety and were well tolerated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">First in Human Aramchol Meglumine Pharmcokinetic Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2020, we announced new data from a Phase 1, first in human study that compared Aramchol meglumine to Aramchol acid. Armachol acid and Aramchol megluine was administered twice daily to 12 subjects. Below is a summary of the results:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20201231x20f007.jpg" alt="Graphic" style="display:inline-block;height:177.85pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These initial results demonstrated that the new salt form of Aramchol meglumine has a plasma PK profile that is very similar to Aramchol acid. It also showed that the administration of both forms resulted in the same form of Aramchol in the blood, regardless of which drug product is administered and that less Aramchol meglumine is needed for the same exposure of Aramchol acid in the blood.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 3 ARMOR Study for Aramchol</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2019, we initiated the ARMOR Study, a Phase 3 pivotal study of Aramchol for the treatment of NASH, following a successful End-of-Phase 2 meeting with the FDA in April 2019 in which we reached general agreement on key aspects of the Phase 3 development and registration plan for Aramchol. The ARMOR Study was originally comprised of two parts, a randomized, double-blind, placebo-controlled histology -based registrational part where 1200 subjects will be treated with Aramchol or matching placebo for 52 weeks and a clinically based part where subjects will continue with the same treatment for approximately five years, taking into consideration draft guidance issued by the FDA in December 2018 entitled &#8220;Noncirrhotic Nonalcoholic Steatohepatitis with Liver Fibrosis: Developing Drugs for Treatment&#8221;, or the &#8220;December Guidance&#8221;. &#160;The histology-based data is intended to serve as the basis for the submission of a marketing authorization application under regulatory provisions of Sub-part H accelerated/conditional approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In light of the rapid development of the Aramchol meglumine program and due to the delays resulting from the COVID-19 pandemic, in December 2020, we announced the addition of an open label part to the ARMOR Study and temporarily suspended randomization of new patients into the double-blind, placebo-controlled histology-based registrational phase of ARMOR as currently enrolled patients are transitioned to the open label part. We are seeking to introduce Aramchol meglumine into the randomized double-blind, placebo-controlled part of ARMOR and are planning to hold a Type C meeting with the FDA in the second quarter of 2021 to discuss the plan for transition with a view to initiating the double-blind, placebo-controlled histology-based registrational part by the end of the first quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of our planned clinical trial design, which is subject to change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Phase 3 study is a two-part study, an open-label part and a randomized, double-controlled, placebo part, designed to evaluate the safety and efficiacy of Aramchol and is expected to be conducted in approximately 200 sites in the U.S., Europe and Latin America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Part One: Open Label Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The first part, an open-label study, is designed to evaluate treatment response kinetics, pharmacokinetics and safety of twice daily administration of Aramchol 300mg in approximately 150 subjects with NASH and liver fibrosis stage 1-3 (F1 capped at 30 subjects), subjects with NASH who may or may not be overweight, and subjects with NASH who may or may not have type 2 diabetes &#160;or be pre-diabetic. The 150 patients are expected to be comprised of both current ARMOR patients as well as new patients. Patients will be randomized (1:1:1) into three groups with post-baseline liver biopsy being performed at 24 weeks, 48 weeks, or 72 weeks, respectively. A second post-baseline liver biopsy will be conducted after one year for subjects whose post-baseline liver biopsy at week 24, 48 or 72 does not show at least one stage improvement in fibrosis. &#160;The open label part also aims to explore the kinetics of histological outcome measures and the utility of state-of-the-art non-invasive tests (including ProC3 and ELF) and imaging that may be able to provide early predictions for histology responses to Aramchol and long-term safety data to support the planned histology-based Sub-part H submission to the FDA for regulatory approval. The open label part is being conducted at approximately 50 selected sites in the U.S., and around the world which have been less affected by the COVID-19 pandemic. The first data milestone is expected when approximately one-third of the study population (~ 50 subjects) has completed 24 weeks of treatment, which is expected in the fourth quarter of 2021, followed by a second and third data milestone after the relevant patient group has completed the post-baseline liver biopsy.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:225.1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a depiction of the open label part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20201231x20f008.jpg" alt="Graphic" style="display:inline-block;height:225.1pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Part Two: Histology-Based and Clinically-Based Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The second part of the ARMOR Study is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Aramchol 300 mg BID to support regulatory approval, with both a histology-based phase and a clinically-based phase. As currently designed, a total of 2000 subjects with NASH and liver fibrosis stage 2 and 3 who are overweight and are either pre-diabetic or have type 2 diabetes are expected to be randomized 2:1 to receive Aramchol 300mg BID or matching placebo. In the histology-based phase, we intend to treat 1000 subjects with Aramchol or matching placebo for 72 weeks until the second biopsy. The histology-based data is intended to serve as the basis for the submission of a Sub-part H marketing authorization application under regulatory provisions of accelerated/conditional approval. The primary histology-based endpoint is NASH resolution without worsening of fibrosis or fibrosis improvement without NASH worsening. In the clinically-based phase, all subjects will continue with the same treatment assignment for up to seven years until study completion to confirm clinical efficacy. We may announce end-of-study at the time when a total of 380 subjects have experienced at least one pre-specified clinical event or at five years from last subject randomization, whichever comes first. The primary clinically-based endpoint is expected to be based on clinical events including all-cause mortality, histological progression to cirrhosis, MELD score &gt;15, and hepatic decompensation events (e.g., hepatic encephalopathy, variceal bleeding, ascites). If the clinical trial results in the histology-based phase are positive, we plan to submit an NDA for Sub-part H accelerated/conditional approval to the FDA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:249.45pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a depiction of part two of the ARMOR Study:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20201231x20f009.jpg" alt="Graphic" style="display:inline-block;height:249.45pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Amilo-5MER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2020, we announced significant progress in the development of Amilo-5MER, a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine). The 5 amino acids sequence of Amilo-5MER is homologue to a specific MTADV sequence in the human CD44 variant found in synovial fluid cells from joints of rheumatoid arthritis, or RA patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amilo-5MER is being developed through a research collaboration between us and the Hebrew University of Jerusalem. The molecule originated in the laboratory of Prof. David Naor, from the Lautenberg Center for Immunology and Cancer Research, Faculty of Medicine, The Hebrew University. Prof. Naor and his team were the first to publish this specific sequence in the prestigious scientific communication Journal of Clinical Investigation 1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amilo-5MER binds to three pro-inflammatory amyloid proteins, Serum Amyloid A, or SAA, Transthyretin and Apolipoprotein B with high affinity. &#160;The first two are known to be active only in their aggregated forms. By binding to SAA, Amilo-5MER interferes with SAA aggregation and therefor inhibits the destructive autocrine, self-amplifying cytokine loop that causes additional inflammatory reaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">SAA constitutes acute phase reactants, whose concentration in serum rise rapidly in response to acute stimuli such as infection and trauma. An elevated concentration of SAA was identified in sera of patients with multiple autoimmune diseases and more recently, an outstanding increase of SAA was also detected in COVID-19 infected patients2-3. SAA in its aggregated form, is a potent and rapid inducer of cytokine secretion (particularly Interleukin 6 (IL-6). IL-6 plays an important role in chronic inflammation and is implicated in the pathogenesis of many autoimmune diseases, such as Multiple Sclerosis, or MS, RA, Inflammatory Bowel Disease, or IBD and acute COVID 19. Interference with SAA polymerization and aggregation is a valid target to prevent chronic inflammatory conditions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amilo-5MER has been shown to significantly reduce chronic inflammation in animal models of RA, IBD and MS (research work supported by a grant to Prof. Naor from the National Multiple Sclerosis Society (NMSS) of the USA). Amilo-5MER provides a unique mechanism of action to interfere with this vicious cycle, enabling a specific treatment for chronic inflammatory diseases. Data generated from multiple in-vitro, in-vivo and human ex-vivo models have shown that Amilo-5MER significantly improves clinical symptoms. Histological improvements and reduction of pro-inflammatory cytokine secretion were also observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amilo-5MER is considered a New Chemical Entity. As such, it is eligible for NCE patent protection until July 2034. Patents have been granted and maintained in the US (US 1061181937), Europe (EP 3169343) and Australia (AU 2015291151) and have been allowed in Japan (JP 6671363).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Recent research and development of Amilo-5MER is being conducted under a research and option agreement between us and Yissum, the tech transfer company of the Hebrew University. We have completed all IND-enabling studies for Amilo-5MER, including API manufacturing, toxicology, and other supporting data. We recently initiated a first in human Phase I trial of Amilo-5MER for the treatment of chronic inflammatory diseases and in March 2021 dosed the first subject. The trial is a three-part, single center, double-blind, randomized, placebo-controlled first in human study of single ascending doses (Part 1) and multiple doses (Part 2) of Amilo-5MER in young healthy male subjects and a single dose cohort in healthy elderly male and female subjects (Part 3). The study plans to enroll up to 64 healthy male and female subjects (56 young male and 8 elderly male and female). The primary objectives of the trial are to evaluate the safety, tolerability, and pharmacokinetics of Amilo-5MER. Topline data is expected in the second half of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the Phase 1 study is successful, we plan to exercise the option to receive an exclusive license to the Amilo-5MER technology and enter into a definitive license agreement with Yissum, although we may exercise the option earlier. Subsequently, we plan to hold a pre-IND meeting with the FDA in the third quarter of 2021 with the aim of initiating a 6-week open label Phase 1b proof of concept trial in the fourth quarter of 2021 to study the safety and efficacy of Amilo-5MER in 20 active ulcerative colitis patients (10 mild to moderate and 10 moderate to severe). The primary endpoint is expected to be reduction from baseline in the Mayo score at week 6 and key secondary endpoints are expected to be clinical remission at week 6, endoscopic improvement at week 6, SAA, C-reactive protein and fecal calprotectin levels at week 6, and improvement in histologic score. If the Phase 1b study is successful, we presently expect progressing to a 24 months Phase 2 randomized, double blind, placebo controlled, multi-center trial in 220-250 patients, and based on the results of the Phase 2 study, we currently envisage two Phase 3 with an overall study duration of 24 months in a yet to be determined sample size.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Additional Pre-clinical and Clinical Studies Required for Regulatory Submissions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Toxicology Studies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since the completion of the Phase 2a study, pre-clinical toxicology studies have been conducted to support our ongoing clinical programs and regulatory submissions. These studies were performed in compliance with the EMA&#8217;s ICH M3 (R2) guidelines. The toxicity program for Aramchol included repeat dose studies of up to six&#160;months in rats and up to nine&#160;months in dogs by oral administration, the intended route of administration in the clinical trials and beyond. The dose level of 1000 mg/kg/day in rats and 1500 mg/kg/day in dogs, which is the maximal feasible dose in both species showed no side effect and therefore the highest dose of the study was selected as the no-observed-adverse-effect-level, or NOAEL. There were no observations noted in the rat study. The findings in the dog study were limited to changes in plasma lipids, including decreases in total blood cholesterol levels, LDL, HDL and phospholipids, and a slight increase in the size of the adrenal glands, which were&#160;considered to be an extension of the primary pharmacology of Aramchol and non-toxic effects, and skin scales from week 13 onwards in all Aramchol-treated groups, with a dose-related incidence. After six&#160;months this was not accompanied by any microscopic alteration of the skin and therefore considered not toxicologically relevant. Results from the study show that after nine&#160;months the presence of scales in all Aramchol-treated groups was accompanied by minor test item-related microscopic findings in the skin: Hyperkeratosis of the epidermis, correlating to the scales, and keratin plugs in the hair follicles (in males at 750/500 and 1500 mg/kg). After a 12-week treatment-free recovery period, fewer scales were noted and microscopically there was partial recovery. As these findings were minor and no clinical symptoms like scratching were noted, these findings were considered not adverse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Aramchol was non-mutagenic in vitro in the Ames test and chromosomal aberrations test, each of which is a test to determine whether the subject chemical can cause mutations in the DNA of an organism. In addition, in bone marrow micronucleus test in male rats at a 2000 mg/kg oral dose (the maximum recommended dose in accordance with ICH S2 (R1)), Aramchol was not clastogenic, meaning it did not give rise to or induce disruption or breakages of chromosomes, nor was it aneugenic, meaning it did not cause the number of chromosomes in the nucleus of a cell to not be an exact multiple of the monoploid number of a particular species.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Embryo-fetal development toxicity was assessed in rats and rabbits. No maternal or fetal development toxicity was observed in either species. The NOAEL for maternal and development toxicity was at least 1000 mg/kg in rats and 750 mg/kg in rabbits (the maximum feasible dose in both species).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No maximum tolerated doses were reached in the studies. Over 50-fold safety margin exposure was achieved in dogs but not in rats. However, for rats, at least three of the four ICH M3(R2) safety margin criteria were met, and for dogs all four criteria were met. Blood tests revealed a decrease in total blood cholesterol levels, including LDL, HDL and phospholipids, and there was a slight increase in the size of the adrenal glands of the dogs, which WIL Research assessed as a physiologic compensatory response to the decrease in blood cholesterol levels. WIL Research did not consider the decrease in blood cholesterol levels or the physiologic response of the adrenal glands as a toxic effect, but rather as a pharmacodynamic effect, which is a biochemical and physiological effect of the drug on the body. Based on the above, it was concluded that the overall safety data for Aramchol is sufficient to support the proposed Phase 2b clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To support any potential future NDA, we have commenced or are planning to commence several safety studies. Additionally, we plan in the future to conduct a study of Aramchol in the pediatric population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we are conducting carcinogenicity studies to identify whether Aramchol has any tumorigenic potential upon long-term administration in support of any future NDAs or MAAs. Under FDA guidance, we are required to perform two studies, one in rats and the other in mice. The carcinogenicity study in rats is a two&#160;year study which was initiated in February&#160;2020. A transgenic mice study is planned to be initiated in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Aramchol for the Treatment of Other Indications</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On February&#160;14, 2018, we announced topline results from the investigator initiated ARRIVE Study for HIV associated lipodystrophy and NAFLD patients. HIV patients have advanced liver disease which is a major cause for morbidity and mortality. ARRIVE, a Phase 2a, investigator initiated clinical trial conducted at the University of California </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">San Diego by Professor Rohit Loomba was a randomized, double-blinded, placebo-controlled, 12 weeks, proof-of-concept study that evaluated the safety and efficacy of Aramchol at 600mg/day versus placebo in 50 patients with HIV-associated lipodystrophy and NAFLD. The primary end point of successful therapy was improvement in hepatic steatosis at 12 weeks, as measured by MRI-PDFF. Secondary endpoints were improvement in total body fat, metabolic profile, and liver biochemistry. Liver biopsies were not included as part of the evaluation in this pilot trial. The trial showed no difference between HIV patients receiving Aramchol for 12 weeks when compared with HIV patients in the placebo arm. Aramchol showed a favorable safety and tolerability profile. Although the pathology (fatty liver) is similar to &#8220;garden variety&#8221; NASH, the pathogenesis involved in the HIV lipodystrophy and NAFLD is different and multi factorial including the effect of the virus itself and the anti-HIV medications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November&#160;13, 2014, we announced the first administration of Aramchol in a proof-of-concept Phase 2a clinical trial for the treatment of newly formed cholesterol gallstones following bariatric surgery. The primary end-point was to prove that Aramchol dissolves newly formed gallbladder gallstones following bariatric surgery. Patients were to be assigned to one of three treatment arms; 400mg tablets, 600mg tablets and placebo. Only 9 patients were enrolled, and 7 patients completed the study. Due to poor patient recruitment and change in Company focus, we decided to terminate the study on October&#160;1, 2015. We currently believe that it is unlikely that we will revive another study in cholesterol gallstones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Topical Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We selected to test Steamchol, in proof of concept studies through a cosmeceutical route of development. Accordingly, on October&#160;13, 2015, Steamchol received a CAS (Chemical Abstracts Service Registry) name and number to allow its cosmeceutical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October&#160;6, 2016, we initiated a proof-of-concept 20-week, double blind, controlled study to evaluate the efficacy and tolerance of Steamchol (a synthetic FABAC, a conjugate of stearic acid (C18:0) and colic acid with similar properties of Aramchol formulated as topical cream), in subjects with Acne Vulgaris. The study was conducted at the IRSI Institute (International Research Services&#160;Inc.) in Port Chester, New York, US. A total of 68 subjects participated in the study. On July&#160;2017, top line data was received which was determined to be inconclusive. Due to poor data collection and higher-priority clinical programs, we decided not to pursue this indication. At present, we believe that it is unlikely that we will revive another study in Acne Vulgaris.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Competitive Strengths</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe our key competitive strengths include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;text-align:justify;">A drug that targets the main NASH pathologies; steatosis, inflammation and fibrosis</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">. We have generated data from animal models that lead us to believe that Aramchol targets all three main pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol on fibrosis has shown to be indirect via reduction of steatosis and ballooning, and direct via reduction of collagen production from human hepatic stellate cells, the principle fibrogenic cell in hepatic fibrosis, and therefore has a potential to show significant results in NASH resolution without fibrosis worsening and/or fibrosis improvement without worsening of NASH.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;text-align:justify;">600mg dose of Aramchol in ARREST Study demonstrated a significant effect on an endpoint that may currently constitute a primary endpoint for a Phase 3 trial to support an FDA marketing application. </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">In our Phase 2b ARREST Study, significantly more patients treated with Aramchol 600mg vs. placebo achieved NASH resolution without worsening of fibrosis (16.7% vs. 5.0%; p=0.0514). Under current FDA guidance, resolution of NASH and no worsening of liver fibrosis on NASH may currently constitute one of two endpoints that support an FDA marketing application. We believe that if we observe a similar effect on patients in our ARMOR Study, then we believe Aramchol is well positioned to be approved by the FDA. Moreover, in a dose splitting study of 300mg administered twice daily, we observed significantly higher exposure which suggests a potential for even higher efficacy with higher exposure of Aramchol. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;text-align:justify;">An orally delivered drug with a good safety profile. </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">In its current formulation, Aramchol is administered orally as a tablet. Simple and convenient oral delivery is expected to lead to increased patient compliance. Together with Aramchol&#8217;s good safety profile, we believe that Aramchol is well positioned against the competition in the treatment of NASH, where some treatments under development may require intravenous delivery or may cause adverse events, such as itching or an increase in LDL, which can be highly inconvenient for patients with chronic diseases, such as NASH, and may result in low patient compliance. If approved, Aramchol may enable physicians to treat NASH patients with moderate to severe fibrosis in all stages of NASH for long periods of time.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;text-align:justify;">Experienced team with extensive knowledge and expertise in drug development. </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The Galmed team is highly skilled, experienced, and professional, which enables product development in an efficient, cost effective manner to enable timely regulatory approval. We believe our management team, scientific advisors and personnel have extensive knowledge and experience in the treatment of liver diseases, developing FABACs, such as Aramchol, for the treatment of liver diseases and working with lipid molecules, which due to their special physiochemical characteristics, are difficult to synthesize, develop and work with. We believe that such knowledge and expertise makes us competitive in the fields of metabolic and liver diseases.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our strategy is to build a specialized biopharmaceutical company that develops, in a cost-effective manner, novel molecules from clinical stage to market readiness. We seek to create global partnerships with academic institutions and biotechnology or pharmaceutical companies to effectively collaborate in developing a portfolio and ultimately out-license Aramchol. Through this approach, we have successfully advanced Aramchol into various stages of clinical development. Key elements of our strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;line-height:1.27;text-align:justify;">Continue advancing Aramchol through development as a first-in-class treatment for NASH and fibrosis</b><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">. Following the completion of our Phase 2b ARREST Study, we are advancing Aramchol into a Phase 3 ARMOR Study with the goal of offering a first-in-class treatment for NASH. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;line-height:1.27;text-align:justify;">Explore strategic partnerships for Aramchol in different geographies.</b><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;"> We intend to strategically partner with pharmaceutical and healthcare companies that possess experience, resources and infrastructure to execute clinical trial(s), regulatory approval and/or market launch. As part of this strategy, in July&#160;28, 2016, we signed a license agreement with Samil for the commercialization of Aramchol in Korea. See &#8220;Item&#160;4. Information on the Company&#8212;Business Overview&#8212;Strategic Collaborations, Research Arrangements and Other Material Agreements&#8212;Samil Pharm. Co.,&#160;Ltd.&#8221; for more information regarding the Samil Agreement. In addition, we are actively exploring strategic partnership opportunities in other regions. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;line-height:1.27;text-align:justify;">Investigate possible therapeutic combinations of Aramchol with drugs manufactured by others. </b><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">We are seeking to co-develop Aramchol as a best in class drug with drugs manufactured by others in order to increase the commercial opportunities of Aramchol. In September 2020, we announced that we entered into a research agreement with Gannex, a wholly owned company of Ascletis which is developing its ASC41 molecule (THR-beta agonist) for NASH. The research agreement is aimed at combination therapy of ASC41 and Aramchol for the treatment of NASH and fibrosis. In November 2020, we announced that we entered into a research and development collaboration agreement with MyBiotics, to develop innovative treatments based on microbiome for NASH and fibrosis.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;line-height:1.27;text-align:justify;">In-license, develop or acquire additional drug candidates</b><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">. To diversify and expand our product pipeline, we are currently evaluating the acquisition or in-licensing of additional product candidates and technologies. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Strategic Collaborations, Research Arrangements and other Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Samil Pharma. Co.,&#160;Ltd.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July&#160;28, 2016, we entered into a license agreement, referred to herein as the Samil Agreement, with Samil for the commercialization of Aramchol (with the option to manufacture) in the Republic of Korea, or the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Samil Agreement, the Company has granted Samil an exclusive licence, or the Samil License, for fatty liver indications including NASH, or the Field of Use, in the Republic of Korea, or the Territory to such information concerning Aramchol as may be required to support Samil&#39;s applications for regulatory approvals, or the Licensed Information, and the patents for the import, marketing, use, sale, offer for sale, commercialisation and distribution (and, if the option is exercised, manufacture) of Aramchol in tablet form, or any other physical form as may be produced or manufactured by or on behalf of Galmed or by a third party for Galmed and, if the option set out below is exercised, any products within the Field of Use, the development, manufacture or sale of which is based, in whole or in part, on, or involves the use of, the Licensed Information or covered under any patent, or the Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Samil License shall remain in force with respect to each Product (if the Samil Agreement is not early terminated) until the later of: (i)&#160;the date of expiry in the Territory of the last of any patent covering such Product or any formulation, dosing or administration form thereof; and (ii)&#160;the date of expiry of a period of 20&#160;years commencing on the date of first commercial sale by Samil or a sublicensee of such Product in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon the signing of the Samil Agreement, Samil paid the Company a gross upfront fee of approximately $2.1 million and in September&#160;2018, we received a milestone payment of $1.5 million. Samil has also agreed to pay additional clinical and regulatory-based milestone payments, which may aggregate to an additional $4.5 million, as well as tiered, double-digit royalties payable on sales (lower if sales of a generic equivalent commence in the Territory).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Samil Agreement, following the first achievement of US$25 million of net sales in any calendar&#160;year following the first commercial sale of the Product in the Territory, Samil shall have the option to request that the Licensed Information include methods for the formulation of Aramchol from its API, to allow for the manufacture of Aramchol by Samil; provided, however, that we shall have the option, to widen the definition of the Licensed Information as aforesaid at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We shall be entitled, at our option: (i)&#160;to modify the Samil License with respect to any Product so that it is non-exclusive only; or (ii)&#160;to terminate the Samil License hereunder, with respect to any Product if: (a)&#160;a first purchasing order from Samil for at least one Product shall not have been placed by 6&#160;months following the grant of the Korean Ministry of Food and Drug Safety new drug approval; or (b)&#160;commercial sale of such Product having commenced and either (i)&#160;there shall be a period of 1&#160;year during which no sales of any Product shall take place, or (ii)&#160;within 1&#160;year of such commencement, aggregate sales of Products shall not have reached a reasonable level, as determined by the joint development committee, in each case, except as a result of force majeure or other factors beyond the control of Samil. Further, we shall be entitled to terminate the Samil Agreement if Samil challenges the validity of any of the patents. If any such challenge is unsuccessful, Samil shall (in addition to our right to terminate) pay us liquidated damages in the amounts of US&#160;$8,000,000. Either party may terminate the Samil Agreement (i)&#160;upon the other party&#8217;s material breach if such party fails to cure such breach within 30&#160;days, or, in the case of failure by Samil to pay any amount due from Samil to us pursuant to or in connection with the Samil Agreement 14&#160;days after receiving written notice thereof, or (ii)&#160;upon customary events such as the granting of a winding-up order if such order or act is not cancelled within 60&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the event that we do not achieve the primary endpoint as defined in the study protocol, or Successful Completion, of the ARREST Study, we shall as soon as practicable notify Samil of the non-achievement of such Successful Completion, and within 60&#160;days thereof, notify Samil in writing either: (i)&#160;that we have decided not to develop the Licensed Information further for the Field of Use, or the Cessation Notice, or (ii)&#160;that we intend to continue with such development notwithstanding the non-achievement of such Successful Completion, or the Licensor Continuation Notice. Also, in the event that we do not achieve the Successful Completion of the potential Phase 3 Study, we shall, as soon as practicable, notify Samil accordingly, or the Notice of Non-Success. Samil shall thereafter have the option, by notice in writing served to us within 45&#160;days of Samil&#39;s receipt of either a Cessation Notice, a Licensor Continuation Notice or a Notice of Non-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Success, as applicable, to indicate its intention either: (i)&#160;to terminate the Samil License, or (ii)&#160;to continue research and development of the Licensed Information in the Field of Use in the Territory, or the Licensee Continuation Notice. In the event Samil shall serve a Licensee Continuation Notice following the service of a Cessation Notice or a Notice of Non-Success, any such continuation by Samil shall be subject to the entry by Samil into a written agreement with us as to the terms and conditions which would govern such continued research and development, which would be carried out according to Samil&#39;s own development plan and at its sole expense. In the event Samil serves a Licensee Continuation Notice following the service of a Licensor Continuation Notice, or Agreed Continuation, the Samil Agreement shall continue in accordance with its terms. In August&#160;2018, Samil sent a Licensee Continuation Notice to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, following the Successful Completion of the ARREST Study or Agreed Continuation following non-achievement of Successful Completion of the ARREST Study, Samil shall, for a period of 90&#160;days following the date of written notification to it by us of such Successful Completion or following the date of Agreed Continuation following non-achievement of Successful Completion, have the option to require that the Territory be extended to include Vietnam, or the Extension Option. In the event that Samil exercises its Extension Option, the parties shall conduct negotiations in good faith for up to 30&#160;days thereafter in order to agree on milestone payments which would replace those set out in the Samil Agreement. In the event that agreement is not reached in such regard within such period, the Extension Option shall terminate. Discussions for the extension of the Samil License to Vietnam are ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amilo 5-MER </span><span style="font-style:italic;font-weight:bold;">Research and Option Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into a research and option agreement with Yissum, the tech transfer company of the Hebrew University with respect to our Amilo-5MER, a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine). Under this agreement, we are able to research and initially develop Amilo-5Mer, are required to fund the initial research and have been granted an exclusive option to negotiate and enter into a definitive license agreement with Yissum for Amilo-5Mer upon certain pre-agreed upon terms and such other terms to be agreed upon. If we elect to continue development of Amilo-5Mer beyond the currently contemplated first-in-human Phase I study, we plan to exercise our option to negotiate and enter into a definitive license agreement. If we exercise our option to enter into any definitive license agreement with Yissum, there can be no assurance that we will agree upon terms with Yissum or that it will be on terms favorable to us. If we do not enter into a definitive license agreement, then then we will not have the ability to continue the development and potential commercialization of Amilo-5Mer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ascletis Pharma</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2020, we announced that we entered into a research agreement with Gannex, a wholly owned company of Ascletis aiming at combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment NASH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC41 is an oral thyroid hormone receptor beta (THR-beta) agonist which recently received IND approval from China&#8217;s National Medical Products Administration (NMPA) to conduct clinical trials for Non-alcoholic Steatohepatitis (NASH) indication. In a Phase 1 study in 65 subjects with elevated low-density lipoprotein cholesterol (LDL-C) (&gt; 110 mg/dL), a population characteristic of NAFLD, Ascletis reported that preliminary data suggested that ASC41 was safe and well tolerated up to a dose of 20 mg and in the multiple-ascending dose portion of the study, preliminary data suggest that after 14 days of once daily oral dosing, subjects demonstrate clinically meaningful and statistically significant reduction in LDL-C and triglycerides compared to placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MyBiotics</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, we announced that we entered into a research and development collaboration agreement with MyBiotics Pharma Ltd., or MyBiotics, to identify and optimize the selected microbiome repertoire associated with the response to Aramchol. The research will also focus on development of a standalone microbiome-based treatment for NASH and fibrosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the collaboration agreement, MyBiotics will employ its proprietary SuperDonor technology in combination with its MyLiveIn computational AI and screening platforms to identify and optimize consortia of bacteria </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to reconstitute a NASH patient&#8217;s gut flora in order to enhance Aramchol&#8217;s clinical efficacy and response rate. The collaboration also aims to identify specific microbial biomarkers for Aramchol based on macrobiome data collected from Galmed&#39;s clinical studies that could serve as a biomarker for Aramchol at early stage of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">MyBiotics&#39; microbiome therapeutic technology enables the design of bespoke microbial consortia profiles based on MyBiotics&#8217; unique culturing and fermentation capabilities. The microbiome therapeutic technology is a nature-derived culturing and fermentation technology which can be leveraged for single strains, consortia of strains and whole microbiome solutions, integrated with a computational AI platform. It increases the bacterial diversity which can be leveraged for product candidates, and at the same time produces bacteria which are more resistant to gastrointestinal conditions, increasing bioavailability and colonization. The microbiome therapeutic technology was validated in multiple in-vitro and in-vivo models. MyBiotics&#8217; lead product candidate for treatment of recurring clostridium difficile infection (CDI), MBX-SD-202, is expected to enter Phase I clinical trials in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unipharm</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October&#160;7, 2000, in connection with a certain share subscription agreement, we sent a letter to Unipharm&#160;Ltd., or Unipharm, pursuant to which we agreed to negotiate the grant of an exclusive license to Unipharm with respect to the use of patents within our first patent family covering the composition of matter of Aramchol within Israel on to-be-agreed upon terms and conditions. The letter stated that, if granted, such license would at all times be subject to our best interests, as determined in our sole discretion, and all approvals and proceedings required by agreement or by law. As of the date hereof, no such definitive agreement has been executed with regard to this matter and at this stage, we have no intention to pursue such an agreement. The letter is silent as to term, termination and whether or not it is binding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The pharmaceutical industry is characterized by rapidly evolving technology, intense competition and a highly risky, costly and lengthy research and development process. Adequate protection of intellectual property, successful product development, adequate funding and retention of skilled, experienced and professional personnel are among the many factors critical to success in the pharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other companies, including, Intercept Pharmaceuticals, Inc., Madrigal, Inventiva, have molecules currently in Phase 3 or 4 clinical development; Eli Lilly, Pfizer, Novartis, Bristol Myers, Novo Nordisk, Merck, Viking, Enanta, Metacrine, Terns, Poxel, Hepion, Cytodyn, Can-Fite, 89Bio, and Sagimet Biosciences, NGM Bio and others have molecules in Phase 2 clinical development for the treatment of NASH and the fibrosis associated therewith. There are a host of other potential competitors in earlier stages of clinical development relative to us for the treatment of NASH including, but not limited to, Terns. Allergan and AstraZeneca.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2019, Intercept Pharmaceuticals announced its Phase 3 results of their OCA drug for the treatment of liver fibrosis due to NASH and Intercept reported that it submitted an NDA to the FDA seeking accelerated approval of OCA for NASH and an MAA to the EMA. In June 2020, the FDA issued a complete response letter, or the CRL, regarding the NDA of OCA for the treatment of NASH. Recently, Intercept reported that it is in discussions with the FDA with respect to the potential resubmission of its NDA. If approved, OCA will become the first approved NASH drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, see &#8220;Item&#160;3. Key Information&#8212;Risk Factors&#8212;Risks Related to Our Business,&#160;Industry and Regulatory Requirements&#8212;Our market is subject to intense competition. If we are unable to compete effectively, Aramchol or any other product candidate that we develop may be rendered noncompetitive or obsolete.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property and Patent Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The proprietary nature of, and protection for, Aramchol or Aramchol meglumine or any other product candidate and our discovery programs for new indications, processes and know-how are important to our business. We own patent rights to Aramchol and Aramchol meglumine in various jurisdictions worldwide, including within and outside of Israel. We have sought patent protection in the United States and internationally for Aramchol and our discovery programs, and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">any other inventions to which we have rights, where available and when appropriate. The term of U.S. Patent No. 7,501,403, covering the use of Aramchol for the treatment of fatty liver, has been extended due to patent term adjustments of 567 days, resulting in an effective expiration date of November 3, 2023. We have pending patent applications and granted patents directed to composition of matter for Aramc hol meglumine and low dose Aramchol meglumine as well as a wide range of other salts, and methods for treating hepatic fibrosis and fibrosis in non-alcoholic fatty acid liver disease. We have been granted a composition of matter patent for Aramchol meglumine and low dose meglumine which includes claims for the treatment of fatty liver in Europe and certain other countries. Our composition of matter claims covering low dose Aramchol meglumine patents that have been granted expire in 2034, subject to appropriate maintenance, renewal, annuity or other governmental fees being paid, and our pending application directed to use of Aramchol meglumine for treating hepatic fibrosis and fibrosis in non- alcoholic fatty acid liver disease willexpire if and when issued in 2037.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our policy is to pursue, maintain and defend patent rights, whether developed internally or licensed from third parties, and to protect the technology, inventions and improvements that are commercially important to the development of our business. We also rely on trade secrets that may be important to the development of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent Portfolio for Aramchol </span><span style="font-style:italic;font-weight:bold;">and Aramchol Meglumine</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent portfolio for Aramchol contains seven patent families including pending patent applications and granted patents directed to composition of matter, manufacturing methods and methods of use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The first patent family discloses and claims additional FABACs with different conjugation moieties, as well as the use of these and the compounds disclosed in the first patent family above, including Aramchol, in the treatment of fatty liver, reduction of serum cholesterol and treatment of hyperglycemia and diabetes. This patent family includes a U.S. patent directed to the treatment of fatty liver a U.S. patent directed to reduction of serum cholesterol by administering additional forms of FABACs, and a U.S. patent (Continuation-in-Part) directed to the treatment of hyperglycemia and diabetes. This patent family also includes two European patents, one patent which was validated in Austria, Belgium, Cyprus, Denmark, Finland, France, Germany Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey and the United Kingdom, and the second patent which was granted in Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey and the United Kingdom. The family also includes patents in Australia, Canada, China, Czech Republic, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Russian Federation, Indonesia, Japan, Korea, Israel, Mexico, New Zealand, Norway, Poland, Hungary and the Ukraine. A foreign patent application is granted in the Czech Republic. If the appropriate maintenance, renewal, annuity or other governmental fees are paid, the non-extended patent term for this patent family is due to expire on April 15, 2022, with the exception of the Israeli patent, which is due to expire on April 17, 2021. The terms of the U.S. patents in this family have been extended due to patent term adjustments of 567 days for U.S. Patent 7,501,403, which is directed to the treatment of fatty liver, and 24 days for U.S. Patent 8,110,564, which is directed to reduction of serum cholesterol, and 356 days for U.S. Patent 8,975,246, which is directed to disorders associated with altered glucose metabolism or insulin action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A second patent family directed to topical uses of FABAC compounds (anti-acne) was granted in Europe and maintained in Germany, France, Italy, the Netherlands and the United Kingdom. If appropriate and the appropriate maintenance, renewal, annuity or other governmental fees are paid, the non-extended term for this patent family is due to expire about August 2033, not including any patent term extension.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A third patent family discloses and claims second generation FABAC salt compounds include Aramchol meglumine. This patent family includes a pending U.S. application and granted in Europe (maintained in Albania, Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Greece, Hungary, Iceland, Italy, Latvia, Lithuania, Macedonia, Malta, Norway, Poland, Portugal, Romania, San Marino, Serbia, Slovakia, Slovenia, &#160;Spain, Sweden, The Netherlands, Turkey, Belgium, France, Germany, Ireland, Luxembourg, Malta, Monaco, Switzerland and United Kingdom), China, Hong Kong, Macau, Canada, Israel and in Japan, as well as in Australia and pending in India and Korea. If granted and the appropriate maintenance, renewal, annuity or other governmental fees are paid, the non-extended term for this patent family is due to expire about December 4, 2034, not including any patent term extention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A fourth patent family having one U.S. patent application, discloses and claims compositions comprising low doses of the second generation FABAC compounds Aramchol meglumine which was granted by the USPTO. When the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">appropriate maintenance, renewal, annuity or other governmental fees are paid, the non-extended term for this patent family is due to expire about April 2034, not including any patent term extension.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A fifth family is directed to treatment for modulating gut microbiota using Aramchol. This patent family includes a granted patent in Israel and a pending U.S. application as well as foreign patent applications in Brazil, Canada, China, Europe, Israel, Japan and Mexico. When the appropriate maintenance, renewal, annuity or other governmental fees are paid, the non-extended term for this patent family is due to expire about January &#160;2036, not including any patent term extension.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A sixth patent family and eighth family, both having PCT international applications filed in 2017 and two pending US applications, are directed to uses of Aramchol and Aramchol meglumine for treating and inhibiting fibrosis. The two PCT applications entered National Phase in Australia, Brazil, Canada, China, Europe, Hong-Kong, Israel, Japan, Korea and Mexico. If granted and the appropriate maintenance, renewal, annuity or other governmental fees are paid, the non-extended term of this patent family is due to expire about November 2037, not including any patent term extension. In addition, a US Continuation-in-part claiming priority to all of the above applications was filed in November 2018 and claims the treatment and inhibition of fibrosis by a regimen of 300 mg of Aramchol twice daily. The improved bio-availability of Aramchol is supported by the pharmacological model based on the preclinical and the ARREST data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A seventh patent family is directed to a combination therapy for treating fatty liver disease is covered by a provisional US application directed to combination of FABAC and at least one thyroid hormone receptor agonist or thyroid hormone mimetic. The PCT application is expected to enter National Phase by March 6, 2021. The patent term for this patent family is due to expire about on September 3, 2038, not including any patent term extension.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our current and other product candidates and the methods used to develop and manufacture them, as well as successfully defending these patents against third-party challenges. Our ability to stop third parties from making, using, selling, offering to sell or importing our products depends on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We believe that our patents provide broad and comprehensive coverage for the use of Aramchol for the treatment of certain liver diseases and other metabolic diseases. However, the patent positions of biopharmaceutical companies, such as ourselves, are generally uncertain and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary position for the technology will depend on our success in obtaining effective claims and enforcing those claims once granted. There is no certainty that any of the Company&#8217;s pending patent applications will result in the issuance of any patents. The issued patents and those that may be issued in the future, may be challenged, narrowed, circumvented or found to be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products or the length of term of patent protection that we may have for our products. In addition, our competitors may independently develop similar technologies or duplicate any technology developed by us, and the rights granted under any issued or future patents may not provide us with any meaningful competitive advantages against these competitors. Furthermore, because of the extensive time required for development, testing and regulatory review of a potential product, before any of our products can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of such patent. For more risks associated with the protection of our licensed intellectual property, see &#8220;Item&#160;3. Key Information&#8212;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Trade Secrets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. Trade secrets and know-how can be difficult to protect. We seek to protect our proprietary processes, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial partners. These agreements are designed to protect our proprietary information. We also seek to preserve the integrity and confidentiality of our data, trade secrets and know-how by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, such agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors or others.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Seasonality</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business and operations are generally not affected by seasonal fluctuations or factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Raw Materials and Suppliers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that the raw materials that we require to manufacture Aramchol are readily available commodities commonly used in the pharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not own or operate manufacturing facilities for the production of Aramchol or any other product candidate, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on third-party contract manufacturers for all of our required raw materials, API and finished product for our non-clinical research and clinical trials. We do not have long term agreements with any of these third parties. We also do not have any current contractual relationships for the manufacture of commercial supplies of Aramchol if it is approved. If Aramchol or any other product candidate are approved by any regulatory agency, we intend to enter into agreements with a third-party contract manufacturer or collaboration partner and one or more back-up manufacturers for the commercial production of those products. Development and commercial quantities of any products that we develop will need to be manufactured in facilities, and by processes, that comply with the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval. We currently employ internal resources to manage our manufacturing contractors. The relevant manufacturers of our drug substance and drug products for our current pre-clinical and clinical trials have advised us that they are compliant with both cGMP and, cGLP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that Aramchol, if approved, can be manufactured in sufficient commercial quantities, in compliance with regulatory requirements and at an acceptable cost. We and our contract manufacturers are, and will be, subject to extensive governmental regulation in connection with the manufacture of any pharmaceutical products or medical devices. We and our contract manufacturers must ensure that all of the processes, methods and equipment are compliant with cGMP and cGLP for drugs on an ongoing basis, as mandated by the FDA and other regulatory authorities, and conduct extensive audits of vendors, contract laboratories and suppliers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Contract Research Organizations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We outsource certain clinical trial activities to CROs. Our clinical CROs comply with guidelines from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, which attempt to harmonize the FDA, the EMA, and the Pharmaceuticals and Medical Devices Agency of Japan regulations and guidelines. We create and implement the drug development plans and manage the CROs according to the specific requirements of the drug candidate under development. To the extent clinical research is overseen by the CROs (or directly by us), compliance with certain federal regulations, including but not limited to 21 C.F.R. parts 50, 54, 56, 58 and 312, which pertain to, among other things,&#160;IRBs, informed consent, financial conflicts of interest by investigators, correct administration of treatment, follow up of adverse events, good laboratory practices and submitting IND applications, may be required.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Marketing, Sales and Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Given our stage of development, we do not have any internal sales, marketing or distribution infrastructure or capabilities. In the event we receive regulatory approval for any product candidate we intend, where appropriate, to pursue commercialization relationships, including strategic alliances and licensing, with pharmaceutical companies and other strategic partners, which are equipped to market and/or sell our product candidates through their well-developed sales, marketing and distribution organizations in order to gain access to global markets. In addition, we may out-license some or all of our worldwide patent rights to more than one party to achieve the fullest development, marketing and distribution of any products we develop. Over the longer term, we may consider ultimately building an internal marketing, sales and commercial infrastructure. See &#8220;Item 4. Information on the Company&#8212;Business Overview&#8212;Strategic Collaborations, Research Arrangements and other Material Agreements&#8212;Samil Pharm Co.&#8221; for information regarding the license agreement we entered with Samil for the commercialization of Aramchol (with an option to manufacture) for the treatment of fatty liver indications including NASH, in the Republic of Korea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Environmental Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We, our agents and our service providers, including our manufacturers, may be subject to various environmental, health and safety laws and regulations, including those governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal of hazardous, radioactive and biological materials and wastes and the cleanup of contaminated sites. We believe that our business, operations and facilities, including, to our knowledge, those of our agents and service providers, are being operated in compliance in all material respects with applicable environmental and health and safety laws and regulations. All information with respect to any chemical substance is filed and stored as a Material Safety Data Sheet, as required by applicable environmental regulations. Based on information currently available to us, we do not expect environmental costs and contingencies to have a material adverse effect on us. However, significant expenditures could be required in the future if we, our agents or our service providers are required to comply with new or more stringent environmental or health and safety laws, regulations or requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation and Product Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Governmental authorities in the United States and in other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those we are developing. Aramchol or any other product candidate must be approved by the FDA through the NDA process before they may be legally marketed in the United States and by the Committee on Human Medicinal Products, or CHMP, via the EMA and European Commission through the MAA process before they may be legally marketed in Europe. Aramchol or any other product candidate will be subject to similar requirements in other countries prior to marketing in those countries. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">United States Government Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">NDA Approval Processes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and implementing regulations and guidance documents. Failure to comply with the applicable U.S. requirements at any time during the product development process or approval process, or after approval, may subject an applicant to administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product seizures, total or partial suspension of production or distribution, injunctions, fines, disgorgement, and civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">completion of pre-clinical laboratory tests, animal studies and formulation studies conducted according to GLPs, or other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">submission to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">performance of adequate and well-controlled human clinical trials according to GCPs, to establish the safety and efficacy of the proposed drug for its intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">submission to the FDA of an NDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMPs to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">satisfactory completion of FDA inspections of clinical sites and GLP toxicology studies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">FDA review and approval of the NDA.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for Aramchol or any other product candidate will be granted on a timely basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once a product candidate is identified for development, it enters the pre-clinical testing stage. Pre-clinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the pre-clinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some pre-clinical testing may continue after the IND is submitted. In addition to including the results of the pre-clinical studies, the IND will also include a clinical trial protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and, depending on the phase of the study, the effectiveness criteria to be evaluated. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND, due to safety concerns or non-compliance, and may affect one or more specific studies or all studies conducted under the IND.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with the FDA&#8217;s GCP regulations. These regulations include the requirement that all research subjects provide informed consent. Further, an IRB must review and approve the plan for any clinical trial, including the informed consent document, before it commences at any institution. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the investigator brochure and other information about the trial distributed by the sponsor and the consent form that must be provided to each trial subject or his or her legal representative and must monitor the study until completed. All clinical trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, research subject inclusion and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors must also report within set timeframes to FDA serious and unexpected adverse reactions, any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigation brochure, or any findings from other studies or animal or in-vitro testing that suggest a significant risk in humans exposed to the drug. Sponsors must also report to FDA certain amendments to the protocol and other essential information concerning the IND that does not fall within the scope of other required reports.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:justify;">Phase 1.</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;"> The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and elimination. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:justify;">Phase 2</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">. Clinical trials are performed on a limited patient population intended to identify possible adverse effects and risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:justify;">Phase 3</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. Phase 3 clinical trials are conducted to provide sufficient data for the statistically valid evidence of safety and efficacy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:justify;">Phase 4</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">. The FDA may require that the sponsor conduct additional clinical trials following new drug approval. The purpose of these trials, known as&#160;Phase 4&#160;studies, is to monitor long-term risks and benefits, study different dosage levels or evaluate safety and effectiveness. In recent&#160;years, the FDA has increased its reliance on these trials.&#160;Phase 4&#160;studies usually involve thousands of participants.&#160;Phase 4&#160;studies also may be initiated by the company sponsoring the new drug to gain broader market value for an approved drug.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are inherently uncertain and Phase 1, Phase 2, Phase 3 and Phase 4 testing may not be successfully completed. The FDA or the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points are typically prior to the submission of an IND, at the end of Phase 2 and before an NDA is submitted. Meetings at other times may also be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of development. Sponsors typically use the meeting at the end of Phase 2 to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical trial that they believe will support the approval of the NDA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, sponsors usually complete any remaining animal safety studies and also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing commercial quantities of the product in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug and the manufacturer must develop methods for testing the quality, purity and potency of the drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its proposed shelf-life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of product development, pre-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests and other control mechanisms, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product for one or more specified indications. The submission of an NDA is subject to the payment of an application fee, but a waiver of such fees may be obtained under specified circumstances. We will seek a waiver of these fees as a small business submitting its first human drug application to the FDA. If the waiver is granted it would not extend to establishment or product fees. The FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. It may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA may refuse to approve an NDA if the applicable statutory and regulatory criteria are not satisfied or may require additional clinical or other data. Even if such data are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant. The FDA may refer the NDA to an advisory committee for review and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured and tested. The FDA will also inspect selected clinical sites that participated in the clinical studies and may inspect the testing facilities that performed the GLP toxicology studies cited in the NDA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Expedited Review and Approval</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has various specific programs, including Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval, which, in different ways, are each intended to expedite the process for reviewing and approving drugs. Even if a drug qualifies for one or more of these programs, the FDA may later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review or approval will be shortened. Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious or life-threatening diseases or conditions and fill unmet medical needs, and Breakthrough Therapy designation is designed to expedite the development and review of drugs that are intended to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). Priority review is designed to give drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists an initial review within six&#160;months as compared to a standard review time of ten&#160;months. Although Fast Track, Breakthrough Therapy designation and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track or Breakthrough Therapy designated drug and expedite review of the application for a drug designated for priority review. The FDA will also provide Breakthrough Therapy designated drugs intensive guidance on an efficient drug development program and provide these drug developers with an organizational commitment from the FDA involving senior managers. Since sponsors can design clinical trials in a number of ways, in providing its guidance for drugs designated as breakthrough therapies, the FDA will seek to ensure that the sponsor of the product designated as a breakthrough therapy receives timely advice and interactive communications in order to help the sponsor design and conduct a development program as efficiently as possible. During these interactions, the FDA may suggest, or a sponsor can propose, alternative clinical trial designs (e.g., adaptive designs, an enrichment strategy, use of historical controls) that may result in smaller trials or more efficient trials that require less time to complete. Such trial designs could also help minimize the number of patients exposed to a potentially less efficacious treatment (i.e., the control group treated with available therapy). On September&#160;23, 2014, the FDA granted Fast Track designation status to Aramchol for the treatment of patients who are overweight or obese and have pre diabetes or type II diabetes mellitus with NASH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accelerated Approval, which is described in 21 C.F.R. &#167; 314.500 <i style="font-style:italic;">et seq</i>., provides for approval of a new drug that is intended to treat a serious or life-threatening disease or condition and that fills an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a laboratory measurement or physical sign used as an indirect or substitute measurement representing a clinically meaningful outcome. To be used in accelerated approval, a surrogate endpoint must be &#8220;reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence to predict benefit on irreversible morbidity or mortality.&#8221; The term &#8220;reasonably likely&#8221; implies that some uncertainty remains about the relationship of the surrogate to the clinical benefit to the patient. Therefore, accelerated approval is typically contingent on a sponsor&#8217;s agreement to conduct additional post-approval studies to verify and describe the drug&#8217;s clinical benefit. Accelerated Approval does not change the standards for approval, but by allowing a demonstration of efficacy based on a surrogate endpoint may expedite the approval process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">FDA Guidance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2018, the FDA issued &#8220;Noncirrhotic Nonalcoholic Steatohepatitis with Liver Fibrosis: Developing Drugs for Treatment&#8221;, or &#8220;the December Guidance&#8221;. The December Guidance, though nonbinding on the FDA or us, is intended to assist sponsors in the clinical development of drugs for the treatment of noncirrhotic NASH with liver fibrosis, describes the FDA&#8217;s current thinking regarding the necessary components of a drug development program for noncirrhotic NASH with liver fibrosis and identifies knowledge gaps that represent important challenges in the development of drugs for the indication. According to the FDA, the ultimate goal of NASH treatment is to slow the progress of, halt, or reverse disease progression and improve clinical outcomes (i.e., prevent progression to cirrhosis and cirrhosis complications, reduce the need for liver transplantation, and improve survival). Because of the slow progression of NASH and the time required to conduct a trial that would evaluate clinical endpoints such as progression to cirrhosis or survival, the FDA recommends sponsors consider the following liver histological improvements as endpoints reasonably likely to predict clinical benefit to support accelerated approval under the regulations:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Resolution of steatohepatitis on overall histopathological reading and no worsening of liver fibrosis on NASH CRN fibrosis score. Resolution of steatohepatitis is defined as absent fatty liver disease or isolated or simple steatosis without steatohepatitis and a NAS score of 0&#8211;1 for inflammation, 0 for ballooning, and any value for steatosis; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Improvement in liver fibrosis greater than or equal to one stage (NASH CRN fibrosis score) and no worsening of steatohepatitis (defined as no increase in NAS for ballooning, inflammation, or steatosis)</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, according to the FDA, for NASH drugs approved on the basis of liver histology under the accelerated approval pathway, randomized, double-blind, placebo-controlled clinical trials designed to describe and verify the drug&#8217;s clinical benefit should be underway at the time of submission of the marketing application. Clinical benefit can be verified by demonstrating superiority to placebo in delaying disease progression measured by a composite endpoint.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The EMA also issued a reflection paper to provide guidance on drug development in the field of NASH. However, the EMA indicated, among other things, that both resolution of NASH without worsening of fibrosis and improvement in fibrosis without worsening of NASH would both be required as intermediate endpoints for demonstrating statistical significance for stage 2 and 3 fibrosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Patent Term Restoration and Marketing Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of FDA approval of the use of Aramchol or any other product candidate, U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND, and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an approved NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Post-approval Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once an approval is granted, the FDA, European authorities and other regulatory authorities may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further regulatory authority review and approval. Some of these modifications, especially adding indications, would likely require additional clinical studies. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any drug product manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things record-keeping requirements; cGMPs; reporting of adverse experiences with the drug; providing the FDA with updated safety and efficacy information; drug sampling and distribution requirements; notifying the FDA and gaining its approval of specified manufacturing or labeling changes; and complying with FDA promotion and advertising requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMP and other laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of Aramchol. Future FDA and state inspections may identify compliance issues at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be. In particular, it is unknown whether any of the provisions of the 2016 21<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> Century Cures Act that are intended to accelerate drug approval will result in any change in the current approval pathway for Aramchol.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Affordable Care Act (discussed in greater detail below), the Centers for Medicare&#160;&amp; Medicaid Services (CMS) is required to collect and publish information reported by applicable manufacturers about payments and other transfers of value manufacturers have made to physicians and teaching hospitals. Such a law, when applicable to our products, could increase the company&#8217;s regulatory liability through the imposition of additional reporting and regulatory requirements. There are also an increasing number of state laws that require manufacturers to make similar reports to states on pricing and marketing information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face uncertainties over the pricing of pharmaceutical products. Sales of Aramchol or any other product candidate will depend, in part, on the extent to which the costs of Aramchol or any other product candidate will be covered by third-party payors, such as federal health programs, commercial insurance and managed care organizations. These third-party payors are increasingly challenging the prices charged for medical products and services. Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures, foreign governments and third party payors have shown significant interest in implementing cost-containment programs, including price controls, pricing transparency disclosure obligations, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. If these third-party payors do not consider Aramchol or any other product candidate to be cost-effective compared to other therapies, they may not cover Aramchol or any other product candidate after approved as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell Aramchol or any other product candidate on a profitable basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Medicare Modernization Act imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries under Part&#160;D. Under Part&#160;D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Part&#160;D prescription drug plan sponsors are not required to pay for all covered Part&#160;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part&#160;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&#160;D drugs, though not necessarily all the drugs in each category or class. The Centers for Medicare&#160;&amp; Medicaid Services published a final rule&#160;in 2014 implementing the Medicare Modernization Act. Contrary to the proposed rule, which would have enabled Part&#160;D plans to offer fewer drugs, the final rule&#160;maintained the existing six protected classes of drug categories, but stated that some of the proposals not included in the final rule&#160;could still be finalized in the future, which would impact payor formulary and coverage decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. A plan for the research will be developed by the Department of Health and Human Services, the Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of any product, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#8217;s product could adversely affect the sales of Aramchol or any other product candidate. If third-party payors do not consider Aramchol or any other product candidate to be cost-effective compared to other available therapies, they may not cover Aramchol or any other product candidate as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell Aramchol or any other product candidate on a profitable basis.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Affordable Care Act, enacted in March&#160;2010, has had a significant impact on the health care industry. Some of the key changes made to date pursuant to the Affordable Care Act include an expansion of coverage for the uninsured, the creation of insurance marketplaces and increased protection of insureds with new benefits, rights and protections. With regard to pharmaceutical products, among other things, the Affordable Care Act made major changes to the Medicare prescription drug program, which helped reduce drug costs for seniors and increased rebates and other costs for the pharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been judicial and congressional challenges to the Affordable Care Act. In December 2017, Congress passed and then the President Trump signed into law tax reform legislation that made significant changes to the Affordable Care Act including the repeal of the &#8220;individual mandate&#8221; that was in place to strongly encourage broad participation in the health insurance markets. . On December 14, 2018, a federal district court in Texas ruled that the PPACA is unconstitutional as a result of the Tax Cuts and Jobs Act, the federal income tax reform legislation previously passed by Congress and signed by President Trump on December 22, 2017, that eliminated the individual mandate portion of the PPACA. The case, Texas, et al, v. United States of America, et al., (N.D. Texas), is an outlier, but in 2019, the Fifth Circuit Court of Appeals subsequently upheld the lower court decision which was then appealed to the United States Supreme Court. The U.S. Supreme Court declined to hear the appeal on an expedited basis and so no decision is expected until sometime in 2021 before the end of the Supreme Court&#8217;s current term. We are not able to state with any certainty what will be impact of this court decision on our business pending further court action and possible appeals. Given these changes and other statements of political leaders, we cannot predict the ultimate impact on the Affordable Care Act and the subsequent effect on the pharmaceutical industry at this time. In November 2020, Joseph Biden was elected President and, in January 2021, the Democratic Party obtained control of the Senate. As a result of these electoral developments, it is unlikely that continued legislative efforts will be pursued to repeal PPACA. Instead, it is possible that executive and regulatory initiatives, as well as legislation, will be pursued to enhance or reform PPACA. We are not able to state with certainty what the impact of potential legislation will be on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for Aramchol or any other product candidate. Historically, products launched in the EU do not follow price structures of the United States and generally tend to be significantly lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Healthcare Fraud and Abuse Laws</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the U.S., the research, development, testing, manufacturing, handling, storage, distribution, sale and promotion of drug products and medical devices are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare&#160;&amp; Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, state Attorneys General, and other state and local government agencies. For example, sales, marketing and scientific/educational grant programs must comply with the fraud and abuse provisions applicable to pharmaceutical manufacturers, including the federal &#8220;Anti-Kickback Statute&#8221;, the Civil Monetary Penalty Statute, the Stark Law, the federal False Claims Act, as amended, state and federal &#8220;Physician Payment Sunshine Act&#8221; laws and regulations, the privacy regulations promulgated under the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws. Pricing and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws. Some of these health care laws include:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Anti- Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal False Claims Act prohibits anyone from knowingly presenting, conspiring to present, making a false statement in order to present, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. This law also prohibits anyone from knowingly underpaying an obligation owed to a federal program. Increasingly, U.S. federal agencies are requiring nonmonetary remedial measures, such as corporate integrity agreements in False Claims Act settlements. The U.S. Department of Justice announced in 2016 its intent to follow the &#8220;Yates Memo,&#8221; taking a far more aggressive approach in pursuing individuals as False Claims Act defendants in addition to the corporations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Physician Payment Sunshine Act, enacted in 2010 as part of the Affordable Care Act, requires certain manufacturers of pharmaceuticals and medical devices to annually report certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as investment interests held by physicians and their immediate family members. Effective January 1, 2022, covered manufacturers will also be required to report on payments and other transfers of value to physician assistants, nurse practitioners or clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, and certified nurse-midwives during the previous year. In recent years, several states in the United States have also enacted legislation requiring pharmaceutical companies to file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as establish marketing compliance programs. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. Failure to meet these requirements, to the extent they are applicable to our activities, could also result in a variety of governmental sanctions that could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of the foregoing or other applicable health care laws and regulations, we may be subject to penalties, including significant administrative, civil and criminal penalties, monetary damages, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">European Economic Area</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to approval in the United States, we currently intend to seek regulatory approval of Aramchol in the EU. As such, a summary of the EU regulatory processes follows below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A medicinal product may only be placed on the market in the European Economic Area, or the EEA, composed of the 27 EU member states of the EU, plus Norway, Iceland and Lichtenstein, when a marketing authorization has been issued by the competent authority of the respective member state pursuant to member states&#8217; law based on Directive 2001/83/EC, or an authorization has been granted under the centralized procedure in accordance with Regulation (EC) No. 726/2004 or its predecessor, Regulation 2309/93. There are essentially three community procedures created under prevailing European pharmaceutical legislation that, if successfully completed, allow an applicant to place a medicinal product on the market in the respective EU or EEA member states.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The withdrawal of the United Kingdom (UK) from the EU took effect on January 1, 2021, and there are 27 member states remaining in the EU. As of January 1, 2021, the UK is a &#8220;third country&#8221; with regard to the EU (subject to the terms of the EU UK Trade Agreement) and EU law ceased to apply directly in the UK. However, the UK has retained the EU regulatory regime with certain modifications as standalone UK legislation. Therefore, the UK regulatory regime is currently similar to EU regulations, but under proposed legislation, the Medicines and Medical Devices Bill, the UK may adopt changed regulations that may diverge from the EU legislative regime for medicines and their research, development and commercialization. For a two-year period starting January 1, 2021, the UK has adopted transitional provisions, which inter alia apply to the importation of medicines into the UK and rely on certain EMA marketing authorization application procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Centralized Procedure</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Regulation 726/2004/EC governs the centralized procedure when a marketing authorization is granted by the European Commission, acting in its capacity as the European Licensing Authority on the advice of the EMA. That authorization is valid throughout the entire community and directly or (as to Norway,&#160;Iceland and Liechtenstein) indirectly allows the applicant to place the product on the market in all member states of the EEA. The EMA is the administrative body responsible for coordinating the existing scientific resources available in the member states for evaluation, supervision and pharmacovigilance of medicinal products. Certain medicinal products, as described in the Annex to Regulation 726/2004, must be authorized centrally. These are products that are developed by means of certain biotechnological processes in accordance with Paragraph 1 to the Annex to the Regulation. Medicinal products for human use containing a new active substance for which the therapeutic indication is the treatment of acquired immune deficiency syndrome, or AIDS, cancer, neurodegenerative disorder or diabetes, autoimmune diseases and other immune dysfunctions and viral diseases must also be authorized centrally. Finally, all medicinal products that are designated as orphan medicinal products pursuant to Regulation 141/2000 and Advanced Therapy Medicinal Products (ATMP) according to Reg. (EC) No.&#160;1394/2007 and medicinal products for veterinary use that are used primarily as performance enhancers must be authorized under the centralized procedure. An applicant may also opt for assessment through the centralized procedure if the medicinal product contains a new active substance which was not authorized in the EU when Reg. (EC) No.&#160;726/2004 entered into force, or if the applicant can show that the medicinal product constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorization centrally is in the interests of patients or animal health at the community level. For each application submitted to the EMA for scientific assessment, the EMA is required to ensure that the opinion of the Committee for Medicinal Products for Human Use, or CHMP, is given within 210&#160;days after receipt of a valid application. This 210&#160;days period does not include the time that the applicant needs to answer any questions raised during the application procedure, the so-called &#8216;clock stop&#8217; period. If the opinion is positive, the EMA is required to send the opinion to the European Commission, which is responsible for preparing the draft decision granting a marketing authorization. This draft decision may differ from the CHMP opinion, stating reasons for diverging from the CHMP opinion. The draft decision is sent to the applicant and the member states, after which the European Commission takes a final decision. If the initial opinion of the CHMP is negative, the applicant is afforded an opportunity to seek a re-examination of the opinion. The CHMP is required to re-examine its opinion within 60&#160;days following receipt of the request by the applicant. All CHMP refusals and the reasons for refusal are made public on the EMA website. Without a centralized marketing authorization it is prohibited to place a medicinal product that must be authorized centrally on the market in the EU. Once a centralized marketing authorization has been granted by the European Commission, it is valid in all EEA States for 5&#160;years on a renewable basis.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Mutual Recognition and Decentralized Procedures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With the exception of products that are authorized centrally, the competent authorities of the member states are responsible for granting marketing authorizations for medicinal products placed on their national markets. If the applicant for a marketing authorization intends to market the same medicinal product in more than one member state, the applicant may seek an authorization progressively in the community under the mutual recognition or decentralized procedure. Mutual recognition procedure, or MRP is used if the medicinal product has already been authorized in a member state. In this case, the holder of this marketing authorization requests the member state where the authorization has been granted to act as reference member state by preparing an updated assessment report that is then used to facilitate mutual recognition of the existing authorization in the other member states in which approval is sought (the so-called concerned member state(s)). The reference member state must prepare an updated assessment report within 90&#160;days of receipt of a valid application. This report together with the approved Summary of Product Characteristics, the SmPC (which sets out the conditions of use of the product), and a labeling and package leaflet are sent to the concerned member states for their consideration. The concerned member states are required to approve the assessment report, the SmPC and the labeling and package leaflet within 90&#160;days of receipt of these documents. The total procedural time of the MRP is 180&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The decentralized procedure, or DCP, is used in cases where the medicinal product has not received a marketing authorization in the EU at the time of application. The applicant requests a member state of its choice to act as reference member state to prepare an assessment report that is then used to facilitate agreement with the concerned member states and the grant of a national marketing authorization in all of these member states. In this procedure, the reference member state must prepare, for consideration by the concerned member states, the draft assessment report, a draft SmPC and a draft of the labeling and package leaflet within 120&#160;days after receipt of a valid application. As in the case of mutual recognition, the concerned member states are required to approve these documents within 90&#160;days of their receipt, i.e. the total time of the DCP is 210&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For both MRP and DCP, if a concerned member state objects to the grant of a marketing authorization on the grounds of a potential serious risk to public health, it may raise a reasoned objection with the reference member state. The points of disagreement are in the first instance referred to the Co-ordination Group on MRP and DCP to reach an agreement within 60&#160;days of the communication of the points of disagreement. If member states fail to reach an agreement, then the matter is referred to the EMA and CHMP for arbitration. The CHMP is required to deliver a reasoned opinion within 60&#160;days of the date on which the matter is referred. The scientific opinion adopted by the CHMP forms the basis for a binding European Commission decision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Irrespective of whether the medicinal product is assessed centrally, de-centrally or through a process of mutual recognition, the medicinal product must be manufactured in accordance with the principles of GMP as set out in Directive2001/83/EC and Directive 2003/94/EC, or, Directive 2017/1572/EU that will replace Directive 2003/94/EC when the notice according Art. 82(3)&#160;Regulation 536/2014 will have been filed, which has been postponed several times and it is currently unclear when it will occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Directive 2003/94/EC and Volume 4 of the rules governing medicinal products govern GMP in the European community. Moreover, community law requires the clinical results in support of clinical safety and efficacy based upon clinical trials conducted in the European community to be in compliance with the requirements of Directive 2001/20/EC, which implements good clinical practice in the conduct of clinical trials on medicinal products for human use. Clinical trials conducted outside the European community and used to support applications for marketing within the EU must have been conducted in a way consistent with the principles set out in Directive 2001/20/EC. The conduct of a clinical trial in the EU requires, pursuant to Directive 2001/20/EC, authorization by the relevant national competent authority where a trial takes place, and an ethics committee to have issued a favorable opinion in relation to the arrangements for the trial. It also requires that the sponsor of the trial, or a person authorized to act on his behalf in relation to the trial, be established in the community. Directive 2001/20/EC will be replaced by Regulation (EU) No. 536/2014 on Clinical Trials in the near future. Although the Regulation entered into force on 16 June 2014, the timing of its application depends on the development of a fully functional EU clinical trials portal and database, which has been postponed several times. Once the new Regulation becomes applicable, clinical trials law in the EU will be further harmonized.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">National Procedure</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This procedure is available for medicinal products that do not fall within the scope of mandatory centralized authorization. Specific procedures and timelines differ between member states, but the duration of the procedure without clock-stop time is generally 210&#160;days and based on a risk/efficacy assessment by the competent authority of the member state concerned, followed by determination of SmPC, package leaflet and label text/layout and subsequently grant of the marketing authorization. Marketing authorizations granted on this basis are not mutually recognized by other member states, but the national marketing authorization can later be used in an MRP to obtain marketing authorizations in other member states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are various types of applications for marketing authorizations:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:justify;">Full Applications</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">. A full application is one that is made under any of the community procedures described above and that &#8220;stands alone&#8221; in the sense that it contains all of the particulars and information required by Article&#160;8(3)&#160;of Directive 2001/83 (as amended) to allow the competent authority to assess the quality, safety and efficacy of the product and in particular the balance between benefit and risk. Article&#160;8(3)(l)&#160;in particular refers to the need to present the results of the applicant&#8217;s research on (i)&#160;pharmaceutical (physical-chemical, biological or microbiological) tests, (ii)&#160;pre-clinical (toxicological and pharmacological) studies and (iii)&#160;clinical trials in humans. The nature of these tests, studies and trials is explained in more detail in Annex I to Directive 2001/83/EC. Full applications would be required for products containing new active substances not previously approved by the competent authority, but may also be made for other products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:justify;">Abridged Applications</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">. Article&#160;10 of Directive 2001/83/EC contains exemptions from the requirement that the applicant has to provide the results of its own pre-clinical and clinical research. There are three regulatory routes for an applicant to seek an exemption from providing such results, namely (i)&#160;cross-referral to an innovator&#8217;s results without consent of the innovator, (ii)&#160;well established use according to published literature and (iii)&#160;consent to refer to an existing dossier of research results filed by a previous applicant.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Cross-referral to Innovator&#8217;s Data</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Articles 10(1)&#160;and 10(2)(b)&#160;of Directive 2001/83/EC provide the legal basis for an applicant to seek a marketing authorization on the basis that its product is a generic medicinal product (a copy) of a reference medicinal product that has already been authorized, in accordance with community provisions. A reference product is, in principle, an original product granted an authorization on the basis of a full dossier of particulars and information. This is the main exemption used by generic manufacturers for obtaining a marketing authorization for a copy product. The generic applicant is not required to provide the results of pre-clinical studies and of clinical trials if its product meets the definition of a generic medicinal product and the applicable regulatory results protection period for the results submitted by the innovator has expired. A generic medicinal product is defined as a medicinal product:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">having the same qualitative and quantitative composition in active substance as the reference medicinal product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">having the same pharmaceutical form as the reference medicinal product; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">whose bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Applications in respect of a generic medicinal product cannot be made before the expiry of the protection period. Where the reference product was granted a national marketing authorization pursuant to an application made before October&#160;30, 2005, the protection period is either six&#160;years or 10&#160;years, depending upon the election of the particular member state concerned. Where the reference product was granted a marketing authorization centrally, pursuant to an application made before November&#160;20, 2005, the protection period is 10&#160;years. For applications made after these dates, Regulation 726/2004 and amendments to Directive 2001/83/EC provide for a harmonized protection period regardless of the approval route utilized. The harmonized protection period is in total 10&#160;years, including eight&#160;years of research data protection and two&#160;years of marketing protection. The effect is that the originator&#8217;s results can be the subject of a cross-referral application after eight&#160;years, but any resulting authorization cannot be exploited for a further two&#160;years. The rationale of this procedure is that the relevant particulars can, if the research data protection period has expired, be found on the originator&#8217;s file and used for assessment of the generic medicinal product. The 10-year protection period can be extended to 11&#160;years where, in the first eight&#160;years post-authorization, the holder of the authorization obtains approval for a new indication assessed as offering a significant clinical benefit in comparison with existing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the copy product does not meet the definition of a generic medicinal product or if bioequivalence could not be demonstrated through bioavailability studies or in case of certain types of changes in the active substance(s)&#160;or in the therapeutic indications, strength, pharmaceutical form or route of administration in relation to the reference medicinal product, Article&#160;10(3)&#160;of Directive 2001/83/EC provides that the results of the appropriate pre-clinical studies or clinical trials must be provided by the applicant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Well-established Medicinal Use</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under Article&#160;10a of Directive 2001/83/EC, an applicant may, in substitution for the results of its own pre-clinical and clinical research, present detailed references to published literature demonstrating that the active substance(s)&#160;of a product have a well- established medicinal use within the community for at least ten&#160;years with recognized efficacy and an acceptable level of safety in terms of the conditions set out in Annex I of Directive 2001/83/EC. In that event, the test and trial results shall be replaced by appropriate scientific literature. The applicant is entitled to refer to a variety of different types of literature, including reports of clinical trials with the same active substance(s)&#160;and epidemiological studies that indicate that the constituent or constituents of the product have an acceptable safety/efficacy profile for a particular indication. However, use of the published literature exemption is restricted by stating that in no circumstances active substances be treated as having a well- established use if they have been used for less than 10&#160;years from the first systematic and documented use of the substance as a medicinal product in the EU. Even after 10&#160;years&#8217; systematic use, the threshold for well-established medicinal use might not be met. European pharmaceutical law requires the competent authorities to consider among other factors the period over which a substance has been used, the amount of patient use of the substance, the degree of scientific interest in the use of the substance (as reflected in the scientific literature) and the coherence (consistency) of all the scientific assessments made in the literature. For this reason, different substances may reach the threshold for well-established use after different periods, but the minimum period is 10&#160;years. If the applicant seeks approval of an entirely new therapeutic use compared with that to which the published literature refers, additional pre-clinical and/or clinical results would have to be provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Authorization Holder&#8217;s Consent</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under Article&#160;10c of Directive 2001/83/EC, following the grant of a marketing authorization the holder of such authorization may consent to a competent authority utilizing the pharmaceutical, pre-clinical and clinical documentation that it submitted to obtain approval for a medicinal product to assess a subsequent application relating to a medicinal product possessing the same qualitative and quantitative composition with respect to the active substances and the same pharmaceutical form.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Law Relating to Pediatric Research</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Regulation (EC) 1901/2006 (as amended by Regulation (EC) 1902/2006) was adopted on December&#160;12, 2006. This Regulation governs the development of medicinal products for human use in order to meet the specific therapeutic needs of the pediatric population. It requires any application for marketing authorization made after July&#160;26, 2008 in respect of a product not authorized in the European Community on January&#160;26, 2007 (the time the Regulation entered into force), to include the results of all studies performed and details of all information collected in compliance with a pediatric investigation plan agreed by the Pediatric Committee of the EMA, unless the product is subject to an agreed waiver or deferral or unless the product is excluded from the scope of Regulation 1901/2006 (generics, hybrid medicinal products, biosimilars, homeopathic and traditional (herbal) medicinal products and medicinal products containing one or more active substances of well-established medicinal use) according to its Art. 9. Waivers can be granted in certain circumstances where pediatric studies are not required or desirable. Deferrals can be granted in certain circumstances where the initiation or completion of pediatric studies should be deferred until appropriate studies in adults have been performed. The EMA does not evaluate an application for market authorization that is not exempt from Regulation (EC) 1901/2006 if there is no agreed PIP, deferral or waiver. Moreover, this regulation imposes the same obligation from January&#160;26, 2009 on an applicant seeking approval of a new indication, pharmaceutical form or route of administration for a product already authorized and still protected by a supplementary protection certificate granted under Regulation EC 469/2009 and its precursor Regulation (EEC) 1768/92 or by a patent that qualifies for the granting of such a supplementary protection certificate. The pediatric Regulation (EC) 1901/2006 also provides, subject to certain conditions, a reward for performing such pediatric studies, regardless of whether the pediatric results provided resulted in the grant of a pediatric indication. This reward comes in the form of an extension of six&#160;months to the supplementary protection certificate granted in respect of the product, unless the product is subject to orphan drug designation, in which case the 10-year market exclusivity period for such an orphan product is extended to 12&#160;years. If any of the non-centralized procedures for marketing authorization have been used, the six-month extension of the supplementary protection certificate is only granted if the medicinal product is authorized in all member states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Post-authorization Obligations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the pre-authorization phase, the applicant must provide a detailed pharmacovigilance plan that it intends to implement post- authorization. An authorization to market a medicinal product in the EU carries with it an obligation to comply with many post- authorization organizational and behavioral regulations relating to the marketing and other activities of authorization holders. These include requirements relating to post-authorization efficacy studies, post-authorization safety studies, adverse event reporting and other pharmacovigilance requirements, advertising, packaging and labeling, patient package leaflets, distribution and wholesale dealing. The regulations frequently operate within a criminal law framework and failure to comply with the requirements may not only affect the authorization, but also can lead to financial and other sanctions levied on the company in question and responsible officers. EU pharmacovigilance legislation has been significantly modified by the Pharmacovigilance Directive, Dir. 2010/84/EU which amended the legal framework of pharmacovigilance for medicines marketed within the EU provided in Regulation (EC) No 726/2004 with respect to EU authorized medicinal products and in Directive 2001/83/EC with respect to nationally authorized medicinal products (including those authorized through the mutual recognition and decentralized systems). In addition, Commission Implementing Regulation (EU) No 520/2012 outlines the practical details to be respected by marketing authorization holders, national competent authorities and the EMA, and Commission Delegated Regulation (EU) No 357/2014 on post-authorization efficacy studies specifies the situations in which such studies may be required. Furthermore, EU good pharmacovigilance practice (GPC) rules&#160;apply. With the amended pharmacovigilance requirements, the financial and organizational burden on market authorization holders increased significantly, such as the obligation to maintain a pharmacovigilance system master file that applies to all holders of marketing authorizations granted in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004. Marketing authorization holders must furthermore collect data on adverse events associated with use of the authorized product outside the scope of the authorization. Pharmacovigilance for biological products and medicines with a new active substance is strengthened by subjecting their authorization to additional monitoring activities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any authorization granted by member state authorities, which within three&#160;years of its granting is not followed by the actual placing on the market of the authorized product in the authorizing member state, ceases to be valid (Art. 24 (4)&#160;and (5)&#160;Directive 2001/83/EC). When an authorized product previously placed on the market in the authorizing member state is no longer actually present on the market for a period of three consecutive&#160;years, the authorization for that product shall cease to be valid. The same two three-year periods apply to authorizations granted by the European Commission based on the centralized procedure (Art. 14 (4)&#160;and (5)&#160;Regulation (EC) 726/2004).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Countries</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to regulations in the United States, the EU and Israel, we are subject to a variety of other regulations governing clinical trials and commercial sales and distribution of drugs in other countries. Whether or not Aramchol or any other product candidate receive approval from the FDA, approval of such product candidates must be obtained by the comparable regulatory authorities of countries other than the United States before we can commence clinical trials or marketing of the product in those countries. The approval process varies from jurisdiction to jurisdiction, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials and product licensing vary greatly from country to country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The requirements that we and our collaborators must satisfy to obtain regulatory approval by government agencies in other countries prior to commercialization of Aramchol or any other product candidate in such countries can be rigorous, costly and uncertain. In the European countries, Canada and Australia, regulatory requirements and approval processes are similar in principle to those in the United States. Additionally, depending on the type of drug for which approval is sought, there are currently two potential tracks for marketing approval in the European countries: mutual recognition and the centralized procedure. These review mechanisms may ultimately lead to approval in all EU countries, but each method grants all participating countries some decision-making authority in product approval. Foreign governments also have stringent post-approval requirements including those relating to manufacture, labeling, reporting, record keeping and marketing. Failure to substantially comply with these on-going requirements could lead to government action against the product, us and/or our representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted, introduced and passed in governmental bodies that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA or EMA and other applicable regulatory bodies to which we are subject. In addition, regulations and guidance are often revised or reinterpreted by the national agency in ways that may significantly affect our business and our therapeutic candidates. It is impossible to predict whether such legislative changes will be enacted, whether FDA or EMA regulations, guidance or interpretations will change, or what the impact of such changes, if any, may be. We may need to adapt our business and therapeutic candidates and products to changes that occur in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">C.</b></span><b style="font-weight:bold;">Organizational Structure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item&#160;4. Information on the Company&#8212;Historical Background and Corporate Structure&#8221; above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">D.</b></span><b style="font-weight:bold;">Description of Property and Facilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our corporate headquarters are located at 16 Tiomkin Street, Tel Aviv, pursuant to a lease to occupy approximately 590 square meters of space. On March 22, 2015, GRD entered into the lease agreement with Mintz K. Construction Company for the corporate headquarters. The term of the lease was originally for four years with an option, at the election of GRD, for two additional years. We have since exercised the option and extended the lease, most recently in March 2021 for an additional two years, until March 22, 2023 with an option for another year. According to the updated lease, the aggregate quarterly rental payment, together with adjustments and the maintenance fees, is approximately NIS 133,497 plus VAT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_21319a43_96db_4710_8621_4c44aa0138b5"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM4AUnresolvedStaffComments_630300"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;4A. Unresolved Staff Comments.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_6b71666c_40a8_4b5a_a4d0_5b9b3889b5de"></a><a id="ITEM5OperatingandFinancialReviewandProsp"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;5. Operating and Financial Review and Prospects.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with &#8220;Item&#160;3. Key Information&#8212;Selected Financial Data&#8221; above and our financial statements and related notes that appear elsewhere in this annual report. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in the sections titled &#8220;Risk Factors&#8221; and &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted stearoyl-coenzyme A desaturase-1, or SCD1, modulator, first in class, novel, oral therapy for the treatment of NASH for variable populations. In September 2019, we initiated our Phase 3 pivotal ARMOR Study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and plan to initiate a first in human study by the first quarter of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have not generated revenue from the sale of any product, excluding the licensing revenue we recorded in connection with the Samil Agreement, and we do not expect to generate any significant revenue other than the amortization of the upfront payments under the license agreement with Samil and of the subsequent royalties and/or milestones that may be earned in connection with the Samil Agreement or potential other license Agreements, unless and until we commercialize Aramchol, or license the product to additional third parties. As of December&#160;31, 2020, the Company had an accumulated deficit of approximately $135.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our financing activities are described below under &#8220;Liquidity and Capital Resources.&#8221; Obtaining approval of an NDA, MMA, or other similar application is an extensive, lengthy, expensive and uncertain process, and the FDA, EMA and other regulatory agencies may delay, limit or deny approval of Aramchol, Amilo-5MER or any other product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financial Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have funded our operations primarily through proceeds from private placements and public offerings. At December 31, 2020, we had current assets of $51.8 million, which is mainly comprised of cash and cash equivalents of $6.9 million, restricted cash of $0.1 million, short-term deposits of $3.8 million and short-term investment securities of $40.1 million. This compares with current assets of $76.4 million at December 31, 2019, which is mainly comprised of cash and cash equivalents of $15.9 million, restricted cash of $0.1 million, short-term deposits of $27.9 million and short-term investment securities of $31.6 million. We believe that such existing funds will be sufficient to continue our business and operations as currently conducted for more than 12 months from the date of issuance of this annual report. However, we will continue to incur operating losses, which may be substantial over the next several years, and we will need to obtain additional funds to further develop our research and development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenues</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into the Samil Agreement for the commercialization of Aramchol in Korea. Under the terms of the Samil Agreement, we have received upfront and milestone payments of $3.6 million, and may be eligible to receive up to approximately $4.5 million in additional payments for development and regulatory milestones for Aramchol in the licensed territories.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 606, we determined that the Samil Agreement included a combined performance obligation representing the delivery of the exclusive license and completion of the ARREST study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We determined that the transaction price at contract inception was $2.1 million consisting of the upfront, non-refundable payment. None of the clinical or regulatory milestones were included in the transaction price upon inception, as all milestone amounts were fully constrained. Management assessed that the likelihood of occurrence of the other performance obligations in the Samil Agreement was remote upon contract inception. As such, the standalone value of such performance obligations was deemed de minimis and none of the transaction price was allocated to those obligations. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, and therefore have also been excluded from the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During 2018, when we determined that the achievement of its first milestone was probable, it included the variable consideration of $1.5 million as a part of the transaction price allocated to the combined performance obligation including the delivery of the license and completion of the ARREST study. We will re-evaluate the transaction price in each reporting period when events whose outcomes are resolved or other changes in circumstances occur that would indicate it is appropriate to recognize variable consideration as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue allocated to the combined performance obligation of the license and associated ARREST study was recognized ratably, based on the input method, from contract inception through conclusion of the ARREST study in June&#160;2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Costs and Operating Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our current costs and operating expenses consist of two components: (i)&#160;research and development expenses; and (ii)&#160;general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses consist primarily of outsourced development expenses, salaries and related personnel expenses and fees paid to external service providers, patent-related legal fees, costs of pre-clinical studies and clinical trials and drug and laboratory supplies. We account for all research and development expenses as they are incurred. We expect our research and development expense to remain our primary expense in the near future as we continue to develop Aramchol and Amilo-5MER. Increases or decreases in research and development expenditures are primarily attributable to the number and/or duration of the pre-clinical and clinical studies that we conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that a substantial amount of our research and development expense in the future will be incurred in support of our current and anticipated pre-clinical and clinical development projects. Due to the inherently unpredictable nature of pre-clinical and clinical development studies, we are unable to estimate with any certainty the costs we will incur in the continued development of Aramchol, Amilo-5MER and any other potential product candidate. Clinical development timelines, the probability of success and development costs can differ materially from expectations. We currently expect to continue testing Aramchol and Amilo-5mer in pre-clinical studies for toxicology, safety and efficacy, and to conduct additional clinical trials for Aramchol and to initiate a first-in-human clinical study for Amilo-5MER.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we are currently focused on advancing Aramchol&#39;s and Amilo-5Mer&#8217;s development, our future research and development expenses will depend largely on the duration of the ARMOR study, the number of enrolled patients, the clinical success of Aramchol, as well as ongoing assessments of the Aramchol&#8217;s commercial potential. As we obtain results from clinical trials, we may elect to discontinue or delay clinical trials for our product candidate in certain indications in order to focus our resources on more promising indications for such product candidate. Completion of clinical trials may take several years or more, but the length of time generally varies according to the type, complexity, novelty and intended use of a product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our research and development expenses to increase in the future from current levels as we continue to advance our clinical product development into a pivotal stage trial and, potentially, the in-licensing of additional product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The lengthy process of completing clinical trials and seeking regulatory approval for Aramchol and Amilo-5MER or any other product candidate requires the expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations. Because of the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of compensation for employees in executive and operational roles, including finance/accounting, legal and other operating positions in connection with our activities. Our other significant general and administrative expenses include non-cash stock-based compensation costs and facilities costs (including the rental expense for our offices in Tel Aviv,&#160;Israel), professional fees for outside accounting and legal services, travel costs, investors relations, insurance premiums and depreciation. At this time, we do not anticipate that the effects of the COVID-19 pandemic will materially affect our general and administrative expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial Income, Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our financial income consists mainly of interest income from marketable debt securities and short-term deposits, as well as gains from realization of marketable debt securities and foreign currency gains. Our financial expense consists of fees associated with banking activities and losses from realization of marketable debt securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Estimate</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We prepare our financial statements in accordance with U.S. GAAP. In doing so, we must make estimates and assumptions that affect our reported amounts of assets, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. Changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. Significant estimates include, but are not limited to, those related to deferred revenue, revenue recognition, stock-based compensation and fair value of marketable debt securities. For further significant accounting policies please see Note 2 to our audited consolidated financial statements of this annual report. We believe that our accounting policies contained therein are critical in fully understanding and evaluating our financial condition and operating results.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">A.</b></span><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The table below provides our results of operations for the&#160;year ended December&#160;31, 2020 as compared to the&#160;years ended December&#160;31, 2019 and 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,038</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,313</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,180</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,082</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,440</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,196</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,128</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,715</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,376</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,210</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial income, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (934)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,915)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,439)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,781</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,461</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,771</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,856</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,461</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,771</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,860</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,415</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,534</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.54</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.97</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1.35</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2019 and December 31, 2020, we had no licensing revenue compared to $2.0 million of revenue for the year ended December 31, 2018. The revenue for the year ended December 31, 2018 resulted from the amortization of the upfront payment and a $1.5 million milestone payment received under the Samil Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses amounted to approximately $26.1 million during the year ended December 31, 2020, representing an increase of approximately $7.9 million, or approximately 43%, compared to approximately $18.2 million for the year ended December 31, 2019. &#160;The increase primarily resulted from an increase in clinical studies in the amount of approximately $4.9 million and an increase in drug development expenses in the amount of approximately $2.4 million. The increase in clinical trial expenses is in connection with our ongoing ARMOR Study while the increase in drug development expenses are in connection with the manufacturing of Aramchol API to support the ARMOR Study and the development of Aramchol Meglumine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses amounted to approximately $18.2 million during the year ended December 31, 2019, representing an increase of approximately $9.9 million, or approximately 119%, compared to approximately $8.3 million for the year ended December 31, 2018. The increase primarily resulted from an increase in clinical studies in the amount of approximately $4.8 million and an increase in drug development expenses in the amount of approximately $2.5 million, related to continuing preparations and commencement of the ARMOR trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our general and administrative expenses amounted to approximately $4.1 million for the&#160;year ended December&#160;31, 2020, representing a decrease of approximately $0.1 million, or 2%, compared to approximately $4.2 million for the&#160;year ended December&#160;31, 2019. The decrease primarily resulted from a decrease in stock-based compensation expenses and professional services, partially offset by an increase in the cost of our D&amp;O insurance policy premium.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our general and administrative expenses amounted to approximately $4.2 million for the year ended December 31, 2019, representing a decrease of approximately $0.2 million, or 5%, compared to approximately $4.4 million for the year ended December 31, 2018. The decrease primarily resulted from a decrease in salaries and benefits expenses of approximately $0.5 million due to lower year-end bonuses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the foregoing research and development and general and administrative expenses, as well as our failure to generate substantial operating revenues, our operating loss for the year ended December 31, 2020 was approximately $30.2 million, representing an increase in our operating loss of approximately $7.8 million, or approximately 35%, compared to approximately $22.4 million for the year ended December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operating loss for the year ended December 31, 2019 was approximately $22.4 million, representing an increase in our operating loss of approximately $11.7 million, or approximately 109%, compared to approximately $10.7 million for the year ended December 31, 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial Income, Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our financial income, net, for the&#160;year ended December&#160;31, 2020 was approximately $1.4 million, representing a decrease of approximately $0.5 million, or approximately 26%, compared to approximately $1.9 million for the&#160;year ended December&#160;31, 2019. The decrease primarily resulted from a decrease in interest income from marketable debt securities and short-term deposits, as compared to such income for the comparable period in 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our financial income, net, for the&#160;year ended December&#160;31, 2019 was approximately $1.9 million, representing an increase of approximately $1.0 million, or approximately 111%, compared to approximately $0.9 million for the&#160;year ended December&#160;31, 2018. The increase primarily resulted from an increase in interest income from marketable debt securities and short-term deposits, as compared to such income for the comparable period in 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our net loss for the&#160;year ended December&#160;31, 2020 was approximately $28.8 million, representing an increase of approximately $8.3 million, or approximately 40%, compared to approximately $20.5 million for the&#160;year ended December&#160;31, 2019. The increase primarily resulted from the above-mentioned increase in research development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our net loss for the&#160;year ended December&#160;31, 2019 was approximately $20.5 million, representing an increase of approximately $10.7 million, or approximately 107%, compared to approximately $9.9 million for the&#160;year ended December&#160;31, 2018. The increase primarily resulted from the above-mentioned increase in research development expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">B.</b></span><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have funded our operations primarily through proceeds from private placements and public offerings.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred substantial losses since our inception. As of December&#160;31, 2020, we had an accumulated deficit of approximately $135.7 million and working capital (current assets less current liabilities) of approximately $43.8 million. Due to our expectation that we will continue to not generate substantial revenues for the foreseeable future, we expect that losses will continue for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, we had cash and cash equivalents of approximately $6.9 million, restricted cash of $0.1 million, short-term deposits of approximately $3.8 million and marketable debt securities of approximately $40.1 million invested in accordance with our investment policy, totaling approximately $51.0 in highly-liquid assets, as compared to cash and cash equivalents of approximately $15.9 million, restricted cash of $0.1 million, short-term deposits of approximately $27.9 million and marketable debt securities of approximately $31.6 million invested in accordance with our investment policy, totaling approximately $75.6 million in highly-liquid assets as of December 31, 2019. The decrease is mainly attributable to our $26.3 &#160;million negative cash flow from operating expenses during the year ended December 31, 2020. In February 2021, we sold approximately $8.4 million in ordinary shares under our ATM Offering and we raised gross proceeds of $10 million in an underwritten public offering of our ordinary shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2019, we had cash and cash equivalents of approximately $15.9 million, restricted cash of $0.1 million, short-term deposits of approximately $27.9 million and marketable debt securities of approximately $31.6 million invested in accordance with our investment policy, totaling approximately $75.6 in highly-liquid assets, as compared to cash and cash equivalents of approximately $24.2 million, short-term deposits of approximately $6.0 million and marketable debt securities of approximately $60.0 million invested in accordance with our investment policy, totaling approximately $90.2 in highly-liquid assets as of December 31, 2018. The decrease is mainly attributable to our $14.9 million negative cash flow from operating expenses during the year ended December 31, 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flow from Operating Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had negative cash flow from operating activities of approximately $26.3 million for the&#160;year ended December&#160;31, 2020 as compared to a negative cash flow from operating activities of approximately $14.9 million for the&#160;year ended December&#160;31, 2019. The negative cash flow from operating activities for the year ended December 31, 2020 was mainly attributable to our net loss of approximately $28.8 million, partially offset by our $2.1 million of non-cash stock-based compensation expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had negative cash flow from operating activities of approximately $14.9 million for the year ended December 31, 2019 as compared to a negative cash flow from operating activities of approximately $9.0 million for the year ended December 31, 2018. The negative cash flow from operating activities for the year ended December 31, 2019 was mainly attributable to our net loss of approximately $20.5 million, partially offset by an increase in trade payables of approximately $4.2 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flow from Investing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had positive cash flow from investing activities of approximately $16.5 million for the year ended December 31, 2020 as compared to a negative cash flow from investing activities of approximately $6.7 million for the year ended December 31, 2019. The positive cash flow from investing activities for the year ended December 31, 2020 was primarily due to the net maturity of short-term deposits in the amount of approximately $24.4 million, partially offset by the net purchase of marketable debt securities in the amount of approximately $7.8 million. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had positive cash flow from investing activities of approximately $6.7 million for the year ended December 31, 2019 as compared to a negative cash flow from investing activities of approximately $60.0 million for the year ended December 31, 2018. The positive cash flow from investing activities for the year ended December 31, 2019 was primarily due to the net sale of marketable securities in the amount of approximately $28.5 million, partially offset by the net investment in short-term deposits in the amount of approximately $21.8 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flow from Financing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had positive cash flow from financing activities of approximately $0.8 million for the year ended December 31, 2020 as compared to a positive cash flow from financing activities of $0.1 million for the year ended December 31, 2019. The positive cash flow from financing activity for the year ended December 31, 2020 was mainly due to proceeds from our ATM Offering. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had positive cash flow from financing activities of approximately $0.1 million for the year ended December 31, 2019 as compared to a positive cash flow from financing activities of $80.2 million for the year ended December 31, 2018. The positive cash flow from financing activity for the year ended December 31, 2019 was mainly due to the net proceeds from exercise of options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 15, 2020, we amended and restated the Sales Agreement dated December 22, 2017 between us and Stifel, Nicolaus &amp; Company, Incorporated to include Cantor Fitzgerald &amp; Co. as an additional sales agent for our &#8220;at the market offering&#8221; program, or the ATM Offering. Pursuant to a prospectus supplement filed with the SEC on May 15, 2020, we may offer and sell up to $31.9 million of our ordinary shares. During July 2020 , we sold 136,300 ordinary shares under the ATM Offering for total net proceeds of approximately $0.8 million and during February 2021, we sold an additional 1,541,400 ordinary shares under the ATM Offering for total net proceeds of approximately $8.2 million. As a result, we had approximately $22.7 million remaining available for future sales under the ATM Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Current Outlook</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we provide no assurance, we believe that our existing funds will be sufficient to continue our business and operations as currently conducted for more than 12 months from the date of issuance of this Annual Report on Form 20-F. However, additional funding will be necessary to fund our ARMOR Study, our Amilo-5MER program and ongoing research and development work and to advance our product candidates through regulatory approval and into commercialization, if approved. We intend to obtain additional funding through debt or equity financings, governmental grants or through entering into collaborations, strategic alliances or license agreements to increase the funds available to support our operating and capital needs. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining additional financing on terms acceptable to us. Specifically, the COVID-19 pandemic has significantly disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our liquidity. If funds are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or commercialization efforts with respect to Aramchol, Amilo-5MER and/or our other pre-clinical and clinical programs. This may raise substantial doubts about our ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">The extent of our future capital requirements will depend on many other factors, including: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the progress and costs of our pre-clinical studies, clinical trials and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the impact of the COVID-19 pandemic on our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;white-space:pre-wrap;"> </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the scope, prioritization and number of our clinical trials and other collaboration, research and development programs; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the amount of revenues and contributions we receive under future licensing, development and commercialization arrangements with respect to Aramchol, Amilo-5MER or any other product candidate;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs of the development and expansion of our operational infrastructure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs and timing of obtaining regulatory approval for Aramchol, Amilo-5MER or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under our potential future licensing agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs and timing of securing manufacturing arrangements for clinical or commercial production;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs of contracting with third parties to provide sales and marketing capabilities for us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or platforms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the magnitude of our general and administrative expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">any cost that we may incur under future in- and out-licensing arrangements relating to Aramchol, Amilo-5MER or any other product candidate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">market conditions.&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">&#160;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">C.</b></span><b style="font-weight:bold;">Research and Development, Patents and Licenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For information concerning our research and development policies and a description of the amount spent during each of the last three fiscal&#160;years on company-sponsored research and development activities, see &#8220;Item&#160;5. Operating and Financial Review and Prospects&#8212;Results of Operations.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">D.</b></span><b style="font-weight:bold;">Trend Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a development stage company and it is not possible for us to predict with any degree of accuracy the outcome of our research, development or commercialization efforts. As such, it is not possible for us to predict with any degree of accuracy any known trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net sales or revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause reported financial information to not necessarily be indicative of future operating results or financial conditions. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are in this &#8220;Operating and Financial Review and Prospects.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">E.</b></span><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company currently does not have any off-balance sheet arrangements that have had, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">F.</b></span><b style="font-weight:bold;">Contractual Obligations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes our significant contractual obligations at December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More than 5</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 &#8211; 3 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3 &#8211; 5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">years</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="16" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:44.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facility leases (1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 403</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 193</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 210</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Car leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 433</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 206</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 227</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Subsequent to the balance sheet date we have extended our facility lease. For a more detailed description of the facility leases, see &#8220;Description of Property and Facilities&#8221; above.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the ordinary course of business with CROs for clinical trials and clinical supply manufacturing and with vendors for pre-clinical research studies and other services and products for operating purposes, which generally provide for termination within 30 to 90&#160;days of notice, and therefore are cancelable contracts and not included in the Contractual Obligations table above. We have included as purchase obligations our commitments under agreements to the extent they are quantifiable and are not cancelable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other than as described above, we did not have any material commitments for capital expenditures, including any anticipated material acquisition of plant and equipment or interests in other companies, as of December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e8fc55e8_897c_469f_bb59_fe03b6679d2e"></a><a id="ITEM6DirectorsSeniorManagementandEmploye"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;6. Directors, Senior Management and Employees.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">A.</b></span><b style="font-weight:bold;">Directors and Senior Management.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Set forth below is information concerning the directors, senior management and executive officers of the Company as of February&#160;28, 2021, the latest practicable date for inclusion in this annual report. The business address for each of our directors, senior management and corporate officers is c/o Galmed Pharmaceuticals&#160;Ltd., 16 Tiomkin St., Tel Aviv 6578317,&#160;Israel.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.97%;"><tr><td style="vertical-align:top;width:39.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:18.68%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:37.86%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td></tr><tr><td style="vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Allen Baharaff</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">56</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">President and Chief Executive Officer, Class&#160;II Director</p></td></tr><tr><td style="vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Dr.&#160;Liat Hayardeny</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">54</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Chief Scientist Officer</p></td></tr><tr><td style="vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Yohai Stenzler</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">38</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Chief Financial Officer </p></td></tr><tr><td style="vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Guy Nehemya</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">36</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Chief Operating Officer</p></td></tr><tr><td style="vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">David Sidransky, M.D.<sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)(2)(3)(4)(5)</sup></p></td><td style="background-color:#cceeff;vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">60</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Lead Independent Director and Chairman of the R&amp;D Committee, Chairman of our Nomination Committee, Chairman of our Remuneration Committee, and Class&#160;III director</p></td></tr><tr><td style="vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Shmuel Nir<sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(2)(3)(4)(5)</sup></p></td><td style="background-color:#cceeff;vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">59</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Class&#160;I Director</p></td></tr><tr><td style="vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Amir Poshinski<sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(2)(3)(4)(5)</sup></p></td><td style="background-color:#cceeff;vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">60</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Chairman of our Audit Committee, Class&#160;III director</p></td></tr><tr><td style="vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Carol L. Brosgart, M.D. <sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1) (2)</sup></p></td><td style="background-color:#cceeff;vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">69</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Class&#160;I Director</p></td></tr><tr><td style="vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Marshall Heinberg </p></td><td style="background-color:#cceeff;vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">63</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:top;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Class&#160;II Director</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">A member of our research&#160;&amp; development committee.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Independent director under applicable Nasdaq Capital Market and SEC rules, as affirmatively determined by our Board.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">A member of our audit committee.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">A member of our remuneration committee.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">A member of our nomination committee.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Allen Baharaff</i>, our President and Chief Executive Officer of our Board, co-founded the Group in 2000, served as the Chief Financial Officer of GHI from 2000 until January&#160;2015, and has served as our Chief Executive Officer since January&#160;2012 and as our President since March&#160;2015. Previously, he held a senior executive position at Isramex Projects&#160;Ltd., an energy project financing company, and Managing Director of T+M Trusteeship&#160;&amp; Management Services (Israel)&#160;Ltd., a subsidiary of a Swiss company providing trust and similar services. Since 2005, Mr.&#160;Baharaff serves as a Director of the Rubin Museum. Mr.&#160;Baharaff holds a Bachelor of Science degree in economics from the London School of Economics, University of London and LLB and MA degrees from Cambridge University. Since 1993, Mr.&#160;Baharaff has been a member of the Israel Bar Association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dr.&#160;Liat Hayardeny</i>, our Chief Scientific Officer joined the Company in September&#160;2016 bringing more than 17&#160;years of experience in drug development at all stages as part of Teva Pharmaceuticals&#8217; global Research and Development Division. Prior to joining Galmed, Dr.&#160;Hayardeny served as Teva&#8217;s Senior Director and Head of Research Scientific Affairs. In that capacity, Dr.&#160;Hayardeny established the scientific positioning of Teva&#8217;s innovative compounds. Additionally, Dr.&#160;Hayardeny was responsible for Teva&#8217;s relationship with institutions of higher education; managing Teva&#8217;s global research collaborations and publications. Dr.&#160;Hayardeny holds a Ph.D. from Sackler School of Medicine and an MBA from Recanati Business School at Tel Aviv University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Yohai Stenzler</i>, our Chief Financial Officer, has served in such capacity since February&#160;1, 2017. Mr.&#160;Stenzler joined the Company in June&#160;2014 as the Company&#8217;s corporate controller, and later on served as the Company&#8217;s Director of Finance. Mr.&#160;Stenzler has six&#160;years of financial management experience as an accountant at the real estate department at Ernst&#160;&amp; Young LLP, where he was involved in financing, taxes, auditing, advising and accounting of public and private companies, both domestic and international. Mr.&#160;Stenzler is a certified CPA and holds a MBA in Finance from Recanati Business School at Tel Aviv University, and a BA in Economics and Accounting from Ben-Gurion University of the Negev.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Guy Nehemya</i>, our Chief Operating Officer, has served in such capacity since January&#160;1, 2019 and prior to that as Vice President, Operations since March&#160;2017. Mr.&#160;Nehemya joined the Company in October&#160;2013 as the Company&#8217;s Director of Operations, after completing his internship at Agmon, Rosenberg, HaCohen&#160;&amp; Co. Law Offices. Mr.&#160;Nehemya was a key member of management during the Company&#8217;s initial public offering and execution thereof. Mr.&#160;Nehemya holds a LL.B. from the College of Management and is currently completing his MBA degree at the IDC Herzliya. Mr.&#160;Nehemya has been a member of the Israeli Bar Association since 2012.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">David Sidransky, M.D.</i>, the chairman of our Nomination , Remuneration and R&amp;D Committees, joined our Board in June&#160;2014, originally as an external director. Dr.&#160;Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. He serves as the Director of the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is a Professor of Oncology, Otolaryngology, Cellular&#160;&amp; Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. Dr.&#160;Sidransky has written over 600 peer-reviewed publications and has contributed to more than 60 cancer reviews and chapters. Dr.&#160;Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has been the recipient of many awards and honors, including the 1997&#160;Sarstedt International prize from the German Society of Clinical Chemistry, 1998 Alton&#160;Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004&#160;Hinda Rosenthal Award and 2017 Team Award&#160;presented by the American Association of Cancer Research. Dr.&#160;Sidransky has served as Vice Chairman of the Board of Directors of ImClone. He is Chairman of the Board of Advaxis&#160;Inc . (Nasdaq: ADXS), and is a lead director at Champions Oncology and on the board of&#160;directors of Orgenesis (Nasdaq: ORGS), Ayala Pharma (Nasdaq: AYLA) and Biond Bio.&#160;He is serving and has served on scientific advisory boards of corporations and institutions, including Amgen, MedImmune, Roche and Veridex, LLC (a Johnson&#160;&amp; Johnson diagnostic company), among others. In addition, Dr.&#160;Sidransky served as Director of American Association for Cancer Research from 2005 to 2008. Dr.&#160;Sidransky received his B.A. from Brandeis University and his M.D.&#160;from the Baylor College of Medicine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Shmuel Nir</i>, a director of the Company since 2007, serves as President and Chief Executive Officer of Tushia Consulting Engineers&#160;Ltd., an investment and management services company. From January&#160;2001 to January&#160;2016, Mr.&#160;Nir served as Chairman of the board of directors of Matan Digital Printers&#160;Ltd. From March&#160;1998 to January&#160;2008, he served as President and Chief Executive Officer of Macpell Industries&#160;Ltd., a leading industrial group. Between January&#160;1991 and March&#160;1998, Mr.&#160;Nir was an Executive Vice President of Operations at Macpell Industries&#160;Ltd. and President and Chief Executive Officer of two of its subsidiaries, New Net Industries&#160;Ltd. and New Net Assets&#160;Ltd. Prior to January&#160;1991, Mr.&#160;Nir had held various positions with Intel Corporation in Jerusalem,&#160;Israel and Tefen Management Consulting. Between 1999 and 2006, Mr.&#160;Nir served as managing partner at Spring Venture Capital Fund. Mr.&#160;Nir holds a B.Sc. in Industrial Engineering and Management from the Technion&#160;- Israel Institute of Technology in Haifa, which was awarded in 1989.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amir Poshinski</i>, joined our Board in June 2020. Mr. Poshinski is an entrepreneur with over 20 years&#39; management and leadership experience across multiple industries, including technology, biotechnology, banking and real estate. Mr. Poshinski is the owner of DAP Holdings, through which he has acted since 2010 as a management consultant and strategic advisor to global companies. Mr. Poshinski currently serves as a member of the advisory board of Benson Oak Ventures, a venture focused fund, as well as several other private companies. Prior to 2010, Mr. Poshinski served as Deputy CEO of Primsa Investment House, which at the time was Israel&#39;s largest investment house, Deputy CEO of Discount Mortgage Bank, the real estate lending arm of one of Israel&#39;s largest banks, VP of Marketing at Comverse, a telecommunications software company that was listed on Nasdaq, VP Marketing, Sales and Advertising of Mifal Hapayis, Israel&#39;s national lottery, and VP and Deputy CEO of the Economic Company of the Israeli Local Authorities Association. Mr. Poshinski previously served on the board of directors of each of TAS-AGT (a TATA joint venture), Excellence Nessuah Mutual Funds, and Therapix Biosciences (Nasdaq: TRPX) as well as several other private companies. Mr. Poshinski holds a B.A. in Business Administration and Marketing from the New York Institute of Technology.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Carol L. Brosgart, M.D.</i> joined our Board on June&#160;7, 2017. Dr.&#160;Brosgart served as a member of Tobira Therapeutics&#8217;s Board of Directors from 2009 until it was acquired by Allergan in 2016 and on the Board of Juvaris, a vaccine company. Since January&#160;2018, she serves on the Board of Directors of Abivax, a biotechnology company, headquartered in Paris, working on HIV Cure and inflammatory diseases. Dr.&#160;Brosgart serves as a consultant to Dynavax, Allergan and a number of biotechnology companies in the areas of liver diseases and infectious diseases and on the Board of Enochian, focusing on HIV Cure. Dr.&#160;Brosgart currently serves on the Steering Committee of the National Viral Hepatitis Roundtable, the Executive Committee of the Forum for Collaborative Research, the Steering Committee of the HBV Cure Group at the Forum, and is on the Board of Directors of the Hepatitis B Foundation and the Northern California American Liver Foundation and the Board of Berkeley Community Scholars. She is active in the public policy arena for AASLD and IDSA/HIVMA. Dr.&#160;Brosgart served as Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC and to the Viral Hepatitis Action Coalition at the CDC Foundation from 2011 to 2013. Dr.&#160;Brosgart has also served as a member of the clinical faculty of the School of Medicine at the University of California, San Francisco for the past four decades, where she is a Clinical Professor of Medicine, Biostatistics and Epidemiology in the Division of Global Health and Infectious Diseases. In 2011, Dr.&#160;Brosgart served as Chief Medical Officer at biotechnology company Alios BioPharma,&#160;Inc. Prior to Alios, Dr.&#160;Brosgart served as Senior Vice President and Chief Medical Officer of Children&#8217;s Hospital&#160;&amp; Research Center in Oakland, California, from 2009 until February&#160;2011. Previously, she served for eleven&#160;years, from 1998 until 2009, at the biopharmaceutical company Gilead Sciences,&#160;Inc., where she held a number of senior management roles, most recently as Vice President, Public Health and Policy and earlier as Vice President, Clinical Research and Vice President, Medical Affairs. Prior to Gilead, Dr.&#160;Brosgart was the Medical Director of the East Bay AIDS Center in Berkeley, California (1987-1998) and the Medical Director of the Central Health Center for the Alameda County Public Health Department (1978-1987). Dr.&#160;Brosgart received a B.S. in Community Medicine from the University of California, Berkeley and received an M.D. from the University of California, San Francisco. Her residency training was in pediatrics, public health and preventive medicine at UCSF and UC Berkeley School of Public Health. She has published extensively in the areas of HIV, HBV, CMV, and liver disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Marshall Heinberg</i> joined our Board on October 14, 2018. Mr. Heinberg has extensive experience relevant to us and insight into the global capital markets and has worked with several life science and technology companies. Mr. Heinberg serves as a Chairman of the Board of PAE Inc (Nasdaq: PAE) and is the founder and Managing Director of MAH Associates, LLC, which provides strategic advisory and consulting services to various companies, including for the Company from 2013 until September 2018. Mr. Heinberg also serves on the Board of Union Carbide Corporation and of ChannelAdvisor (NYSE: ECOM), since July 2019 and December 2019, respectively. From April 2017 to December 2019, Mr. Heinberg served on the board of directors of Ecology and Environment (Nasdaq: EEI) and was its Executive Chairman of the Board of Directors until the time that EEI was acquired by WSP. Between January 2010 and March 2021, Mr.&#160;Heinberg served on the board of directors of Universal Biosensors (UBI.AX). Mr. Heinberg was a Senior Advisor to Burford Capital (NYSE;BUR) until July 2020. Mr. Heinberg began his investment banking career in 1987 in the Corporate Finance Division of Oppenheimer &amp; Co, Inc., which was acquired by Canadian Imperial Bank of Commerce (CIBC) in 1997. Mr. Heinberg served as Head of the Investment Banking Department and as a Senior Managing Director of Oppenheimer &amp; Co. Inc. from 2008 until 2012, and as the U.S. Head of Investment Banking at CIBC World Markets from 2001 until 2008. Prior to joining Oppenheimer, Mr. Heinberg practiced corporate law for approximately four years. Mr. Heinberg has a B.S. in economics from the Wharton School at the University of Pennsylvania and a J.D. from Fordham Law School.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are no family relationships between any director or executive officer. There are no arrangements or understandings with major shareholders, customers, suppliers or others, pursuant to which any director or executive officer was selected as a director or member of senior management, as the case may be.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Scientific Advisory Board</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We seek advice from our Scientific Advisory Board generally on scientific and medical matters. Our Scientific Advisory Board includes the following: Professor Vlad Ratziu from the University Pierre et Marie Curie in Paris, France and coordinator of the EU FP7 FLIP consortium; Professor Scott Friedman from the Icahn School of Medicine at Mount Sinai in New York, United States; Professor Arun Sanyal, from the Virginia Commonwealth University in Richmond, Virginia; Professor Jose Mato, from CIC bioGUNE Spain; Professor Shomron Ben-Horin, Chief of the Gastroenterology Department at Sheba Medical Center, Dr. Jean-Frederic Colombel, from Icahn School of Medicine at Mount Sinai, and Prof. Stephen B. Hanauer from Northwestern Feinberg School of Medicine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">B.</b></span><b style="font-weight:bold;">Compensation.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain Approvals Required for Office Holders&#8217; Compensation of the Companies Law</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Companies Law, the Company is required to adopt a compensation policy regarding the terms of office and employment of its Office Holders (as such terms are defined below), which includes exemption and release of the Office Holders from liability for breach of his or her duty of care to the Company, an undertaking to indemnify the Office Holder, post factum indemnification or insurance; any grant, payment, remuneration, compensation, or other benefit provided in connection with termination of service; and any benefit, other payment or undertaking to provide any payment as aforesaid, or the Terms of Office and Employment. The Company&#8217;s current compensation policy with respect to the Terms of Office and Employment of the Company&#8217;s Office Holders, or the Compensation Policy, was last approved by the Board in June 22, 2020 after considering the recommendations of the remuneration committee and was adopted by the Company&#8217;s shareholders in August 2020. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The term &#8216;Office Holder&#8217; as defined in the Companies Law includes a general manager, chief business manager, deputy general manager, vice general manager, any other person fulfilling or assuming the responsibilities of any of the foregoing positions without regard to such person&#8217;s title, as well as a director, or a manager directly subordinate to the general manager or the chief executive officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Companies Law, arrangements between the Company and its Office Holders must generally be approved by the remuneration committee and the Board and be consistent with the Compensation Policy. However, under certain circumstances, the Company may approve an arrangement that is not consistent with the Compensation Policy, if such arrangement is approved by a majority of the Company&#8217;s shareholders, provided that (i)&#160;such majority includes a majority of the votes cast by shareholders who are not controlling shareholders and who do not have a personal interest in the matter, present and voting (abstentions are disregarded), or (ii)&#160;the votes cast by shareholders who are not controlling shareholders and who do not have a personal interest in the matter who were present and voted against the arrangement constitute two&#160;percent or less of the voting power of the company, or the Special Majority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The terms of office and employment of directors (including an officer who is a director but is not a controlling shareholder) further require the approval of the shareholders by a simple majority in addition to the approval of the Compensation Committee and the Board, in that order, and under certain circumstances, a Special Majority; with respect to a chief executive officer or an officer who is a controlling shareholder, the approval of the shareholders must be made by the Special Majority. In addition, under certain circumstances, a company may be exempt from receiving the shareholders&#8217; approval with respect to the Terms of Office and Employment of a non-affiliated candidate for chief executive officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under certain circumstances, if the terms of office and employment of Office Holders (who are not directors or controlling shareholders) are not approved by the shareholders, where such approval is required, the remuneration committee and the Board may subsequently override the resolution of the shareholders following a new discussion of the matter and for specified reasons. In addition, amendment of terms of office and employment of Office Holders (who are not directors or controlling shareholders) requires the approval of the remuneration committee only, if the remuneration committee determines that the amendment is not material.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aggregate Executive Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate compensation, including share-based compensation, paid by us to all of our Office Holders as a group, with respect to the&#160;year ended December&#160;31, 2020, was approximately $3.5 million. This amount includes approximately $0.3 million set aside or accrued to provide pension, severance, retirement, vacation or similar benefits or expenses, but does not include business travel, relocation, professional and business association dues and expenses reimbursed to Office Holders, and other benefits commonly reimbursed or paid by companies in our industry. In addition to the six current members of the Board (including the Company&#8217;s President and Chief Executive Officer), the Company considers seven other individuals, namely three former directors, the former Chief Medical Officer, Chief Scientist Officer, Chief Financial Officer and the Chief Operating Officer, to have been Office Holders in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, options to purchase 1,891,603 of our ordinary shares granted to our Office Holders as a group were outstanding, of which options to purchase 1,292,853 of our ordinary shares have vested, with a weighted average exercise price of $5.3 per ordinary share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For outstanding equity-based awards granted to our Office Holders, see below under &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;E. Share Ownership&#8212;Certain Information Concerning Equity Awards to Office Holders.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Individual Compensation of Covered Executives</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table sets forth the compensation granted to the five most highly compensated Office Holders during or with respect to the&#160;year ended December&#160;31, 2020. All amounts reported in the table reflect the cost to the Company, as recognized in its financial statements for the&#160;year ended December&#160;31, 2020. The five individuals for whom disclosure is provided are referred to herein as &#8220;Covered Executives.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Information Regarding the Covered Executives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation&#160;for&#160;Services</b><sup style="font-size:6.75pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Benefits&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity-Based&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Base</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Perquisites&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Bonus&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Compensation&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name and Principal Position</b><sup style="font-size:6.75pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Salary&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6.75pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6.75pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6.75pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;($)</b><sup style="font-size:6.75pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;($)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Allen Baharaff (President and Chief Executive Officer)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 503,283</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 169,282</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 64,018</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 682,359</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,449,589</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dr. Liat Hayardeny (Chief Scientific Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150,593</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43,301</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,555</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 185,159</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 400,608</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dr. Tali Gorfine (6) (former Chief Medical Officer)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150,593</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 42,932</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,238</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 179,746</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 382,509</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Yohai Stenzler (Chief Financial Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 116,082</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,752</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,431</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 166,220</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 333,485</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:38.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Guy Nehemya (Chief Operating Officer)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 116,082</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,032</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,431</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 138,066</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 305,551</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The above-mentioned executives are all full-time employee of the Company. Cash compensation amounts denominated in currencies other than the Dollar were converted into Dollars at an exchange rate of NIS 3. 44 = $1.00, which reflects the average conversion rate for fiscal&#160;year ended December&#160;31, 2020.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Amounts reported in this column include benefits and perquisites, including those mandated by applicable law. Such benefits and perquisites may include, to the extent applicable to the Covered Executives, payments, contributions and/or allocations for savings funds, pension, severance, vacation, car allowance, risk insurance (e.g., life, disability, accident), telephone, convalescence pay, payments for social security and other benefits and perquisites consistent with the Company&#8217;s policies.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Amounts reported in this column refer to the cash bonuses provided by the Company with respect to 2020, which have been provided for in the Company&#8217;s financial statements for the&#160;year ended December&#160;31, 2020 (including if such bonuses were paid in 2021). They exclude bonuses paid in 2020 which were provided for in the Company&#8217;s financial statements for previous&#160;years. Cash bonuses are paid in accordance with the Company&#8217;s 2020 Annual Cash Bonus Plan and are intended to promote the Company&#8217;s work plan and business strategy by rewarding officers for achievement of the Company&#8217;s business and financial goals through teamwork and collaboration. Key performance indicators which are factored into cash bonus determinations are based both on personal </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">evaluation and as well, individual specific and may include: (i)&#160;major progress in research and development stages, (ii)&#160;the execution of in/out-license transactions, (iii)&#160;the execution of strategic collaboration agreements, and (iv)&#160;raising funds throughout public offering or a private placement.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Amounts reported in this column represent the expense recorded in the Company&#8217;s financial statements for the&#160;year ended December&#160;31, 2020 with respect to equity-based compensation. Assumptions and key variables used in the calculation of such amounts are discussed in Note&#160;10 to the Financial Statements. For outstanding equity-based awards granted to Covered Executives see below under &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;E. Share Ownership&#8212;Certain Information Concerning Equity Awards to Office Holders.&#8221;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Amounts reported in this column include payments made with respect to the&#160;year 2020 and recorded in the financial statements for the&#160;year ended December&#160;31, 2020 relating to directors&#8217; fees.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Dr. Gorfine ceased acting as our Chief Medical Officer as of June 30, 2020 and from July 1, 2020, Dr. Gorfine serves as a medical consultant.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compensation of Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As approved by our shareholders at our 2020 annual meeting of shareholders, in connection with their services as directors of the Company, each of our directors from time to time, is entitled to an annual payment of $40,000, plus value-added tax, or VAT, if applicable, and with respect to an expert external director (if applicable), $50,000 plus VAT, payable quarterly at the end of each quarter, and, upon first becoming a member of the Board, each of our non-management directors will receive a grant of options to purchase 30,000 ordinary shares, or the Director Options. The Director Options would be granted under the 2013 Plan, at an exercise price equal to the average price of our ordinary shares on the Nasdaq market in the 30 trading days prior to the appointment by the Board or election by the shareholders (as applicable), and would vest over a period of three years, such that the Director Options will vest with respect to 1/3 of the underlying Ordinary Shares on the first anniversary of the grant (i.e., the date of appointment by the Board or election by the shareholders, as applicable), and thereafter, the Director Options will vest with respect to the additional 2/3 of the underlying ordinary shares on an equally quarterly basis, provided that each non-management director remains continuously a director or its affiliates throughout each such vesting date. The grant is subject to the execution by each director of an option agreement with us confirming the terms and conditions applying to the grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board has determined that each of Mr. Nir, Mr. Poshinski, Mr. Heinberg and Dr. Sidransky are entitled to receive compensation as an &#8216;expert external director&#8217;. The compensation of external directors is also subject to the provisions of the Israeli regulations promulgated pursuant to the Companies Law governing the terms of compensation payable to external directors. See also &#8220;Item 6. Directors, Senior Management and Employees&#8212;C. Board Practices&#8212;External Directors&#8221; and &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;C. Related Party Transactions&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the outstanding equity-based awards granted to our directors, see below under &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;E. Share Ownership&#8212;Certain Information Concerning Equity Awards to Office Holders.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employment Agreements and Arrangements with Directors and Related Parties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We entered into written employment agreements with each of our executive officers. These agreements provide for notice periods of varying duration for termination of the agreement by us or by the relevant executive officer, during which time the executive officer will continue to receive base salary and benefits. These agreements also contain customary provisions regarding non-competition, confidentiality of information and assignment of inventions. However, the enforceability of the non-competition and assignment of inventions provisions may be limited under applicable law. See &#8220;Item&#160;3. Key Information&#8212;Risk Factors&#8212;Risks Related to Our Business,&#160;Industry and Regulatory Requirements.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employment Agreement with Our President and Chief Executive Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;30, 2013, we entered into a personal employment agreement with our controlling shareholder, Mr.&#160;Allen Baharaff who serves as our president and chief executive officer and as the chairman of our Board, as amended on March&#160;15, 2016, July&#160;20, 2017 and August&#160;1, 2019, which provides that Mr.&#160;Baharaff&#8217;s terms of office and employment are for an undefined term, subject to&#160;re-approval under the Companies Law and termination in accordance with the terms of the employment agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of his employment agreement, Mr.&#160;Baharaff is entitled to a gross&#160;monthly salary which is currently NIS 144,375. Commencing January 1, 2021, Mr. Baharaff&#39;s gross monthly salary will increase to NIS 170,000, upon shareholder approval. In addition, Mr.&#160;Baharaff will be entitled to the following cash bonuses based on achievement of qualitative and quantitative performance goals and objectives: (i)&#160;an annual cash bonus in an amount of up to nine times his&#160;monthly base salary, to be determined based on the achievement of certain qualitative and quantitative performance goals and objectives set by our Board and approved by our shareholders; (ii)&#160;upon execution of a Strategic Agreement (as defined below), Mr.&#160;Baharaff will be entitled to receive, subject to the discretion of the Board, a cash bonus in an amount of up to twelve times his&#160;monthly base salary. A &#8220;Strategic Agreement&#8221; means: a license agreement or any other strategic agreement (i.e. research and development, manufacture, distribution,&#160;etc.) for the U.S., Europe, Japan or China; (iii)&#160;upon consummation of a fund raising (excluding funds received from a Strategic Agreement), Mr.&#160;Baharaff will be entitled to receive, subject to the discretion of the Board, a cash bonus in an amount of up to ten times his&#160;monthly base salary if the funds received by the Company are between $8 Million to $10 million and up to twelve times his&#160;monthly base salary if the funds received by the Company are $10 million or more; (iv)&#160;upon a Change of Control Event (as defined below), Mr.&#160;Baharaff will be entitled to receive, subject to the discretion of the Board, a cash bonus in an amount of up to twelve times his&#160;monthly base salary. A &#8220;Change of Control Event&#8221; means: (a)&#160;the acquisition of the Company by another entity or individual or group of individuals by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger, share purchase or consolidation), unless the Company&#8217;s shareholders of record as constituted immediately prior to any such transaction will, immediately after such transaction (by virtue of securities issued as consideration for the Company&#8217;s share capital, assets or otherwise) hold more than 50% of the voting power of the surviving or acquiring entity; or (b)&#160;a sale of all or substantially all of the assets of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Baharaff will also be entitled to the following equity based compensation: (i)&#160;in the event that our options are cashed-out upon a Change of Control Event, all unvested options granted to Mr.&#160;Baharaff will vest immediately prior to the consummation of the Change of Control Event; (ii)&#160;if upon a Change of Control Event (a)&#160;Mr.&#160;Baharaff&#8217;s employment as chief executive officer of the Company or the surviving entity is terminated within twelve&#160;months as of the Change of Control Event, and (b)&#160;unvested options are replaced for new options of the surviving entity as part of the Change of Control Event with a vesting schedule and terms identical to the replaced options, or the Replacement Options, then (x)&#160;all unvested Replacement Options granted to Mr.&#160;Baharaff will vest immediately prior to the termination of Mr.&#160;Baharaff&#8217;s employment, and (y)&#160;Mr.&#160;Baharaff&#8217;s Replacement Options will be exercisable until the earlier of (a)&#160;two&#160;years from termination, and (b)&#160;expiration of the Replacement Options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Baharaff will also receive other benefits required under Israeli law or that are customary for senior executives in Israel such as confidentiality, reimbursement of expenses, payment for absence&#160;days, sick leave, pension and/or a manager&#8217;s insurance policy and study fund.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Baharaff&#8217;s employment agreement is terminable by either party upon six&#160;months prior written notice, or Prior Notice Period, and contains customary provisions regarding noncompetition, confidentiality of information and assignment of inventions. Upon termination, provided such termination was not for cause, Mr.&#160;Baharaff shall be entitled, in addition to the Prior Notice Period, to a payment in an amount of up to twelve times his&#160;monthly base salary, to be paid in twelve equal&#160;monthly installments, in exchange for Mr.&#160;Baharaff&#8217;s undertaking not to compete with the Company for a period of twelve&#160;months, or Non-Compete Grant. Other than in case of resignation by Mr.&#160;Baharaff, excluding resignation for a Good Reason Event (as defined below), or termination for cause: (i)&#160;all Mr.&#160;Baharaff&#8217;s unvested options will vest upon termination; and (ii)&#160;unexercised options granted to Mr.&#160;Baharaff may be exercised until the earlier of (a)&#160;two&#160;years from his termination, and (b)&#160;expiration of his options. A &#8220;Good Reason Event&#8221; means: any of the following events, provided that the event is effected by the Company without the written consent of Mr.&#160;Baharaff: (i)&#160;a material reduction or adverse change in Mr.&#160;Baharaff&#8217;s authority, duties or responsibilities; (ii)&#160;a reduction in Mr.&#160;Baharaff&#8217;s&#160;monthly base salary, other than a reduction of no more than 10% of his then current&#160;monthly base salary as part of an across the board reduction in all salaries for employees of the Company; (iii)&#160;a material breach by the Company of Mr.&#160;Baharaff&#8217;s employment agreement or any other agreements pertaining directly to Mr.&#160;Baharaff&#8217;s compensation or employment or (iv)&#160;death, disability or severe illness. Upon termination for cause by the Company, Mr.&#160;Baharaff shall not be entitled to any Prior Notice Period, Non-Compete Grant or any other payment, and any unvested outstanding equity awards shall terminate immediately upon the date of such termination for cause.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For cash bonuses granted to Mr.&#160;Baharaff see &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212; B. Compensation&#8212;Individual Compensation of Covered Executives.&#8221; For outstanding equity-based awards granted to Mr.&#160;Baharaff see below under &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;E. Share Ownership&#8212;Certain Information Concerning Equity Awards to Office Holders.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">C.</b></span><b style="font-weight:bold;">Board Practices.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are incorporated in Israel, and, therefore, we are subject to various corporate governance practices under Israeli law relating to such matters as external directors (if required), independent directors, audit committees, remuneration committees and internal auditors. These Israeli law requirements are in addition to the requirements of the Nasdaq Listing Rules&#160;and other relevant provisions of U.S. securities laws. Under such Nasdaq Listing Rules, a foreign private issuer may generally follow its home country practices for corporate governance in lieu of such comparable listing rules&#8217; requirements, except for certain matters such as composition and responsibilities of the audit committee and the SEC-mandated standards for the independence of its members. See below under &#8220;Item&#160;16G. Corporate Governance&#8221; for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Membership of the Board</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Articles provide that the minimum number of members of the Board is three and the maximum number of members is eleven. The Board is presently comprised of six members. Under the Regulation, companies with no controlling shareholder whose shares are listed for trading on specified exchanges outside of Israel, including the Nasdaq Capital Market, may adopt exemptions from various corporate governance requirements of the Companies Law so long as the company satisfies the applicable foreign country laws and regulations, including applicable stock exchange rules, that apply to companies organized in that country relating to the appointment of independent directors and the composition of audit and compensation committees. Such exemptions include an exemption from the requirement to appoint external directors and the requirement that an external director be a member of certain committees.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2020, our Board adopted the exemption under the Regulation, and our directors then in office who were elected and classified as external director, Tali Yaron-Eldar and Dr. David Sidransky, were no longer classified as such under the Companies Law. The transition rules set forth under the Regulation provide that such former external directors have the right to remain in office as company directors at their option after the exemption under the Regulation is adopted until the earlier of such director&#8217;s original end of term of office or the second annual meeting of shareholders after the adoption of the exemption under the Regulation. Ms. Yaron-Eldar&#8217;s and Dr. Sidransky&#8217;s term of office expired on June 12, 2020. On May 12, 2020, our Board extended Dr. Sidransky&#8217;s term as director as of June 12, 2020 through the end of the annual meeting of our shareholders which was held on August 13, 2020, and at our annual meeting of our shareholders, Dr. Sidransky&#8217;s term was further extended until the annual general meeting to be held in 2023, as a Class III director. Ms. Yaron-Eldar&#8217;s term was not extended. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 16, 2020, our Board appointed Mr. Amir Poshinski as a Class III director, and at our annual meeting of our shareholders held on August 13, 2020, Mr. Poshinski was elected to serve as a Class III director until the annual general meeting to be held in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The minimum and maximum number of directors may be changed, at any time and from time to time, by a majority vote of our directors then in office, provided that no decrease in the number of directors shall shorten the term of any incumbent director. Under our Articles, the Board consists of three classes of directors which are appointed for fixed terms of office in accordance with the Companies Law and our Articles, with one class being elected each year for a term of approximately three years by our shareholders at our annual general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Directors so elected cannot be removed from office by the shareholders until the expiration of their term of office. The directors do not receive any benefits upon the expiration of their term of office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The three classes of directors are Class I Directors, Class II Directors and Class III Directors. Shmuel Nir and Dr. Carol Brosgart serve as our Class I Directors until the close of the annual general meeting to be held in 2021; Allen Baharaff and Marshall Heinberg serves as our Class II Directors until the close of the annual general meeting to be held in 2022; and Dr. David Sidransky and Amir Poshinski serve as our Class III Directors until the close of the annual general meeting to be held in 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with the Articles, any vacancies on the Board of, including unfilled positions, may be filled by a vote of a majority of the directors then in office, and each director chosen in this manner would hold office until the next annual general meeting of the Company (or until the earlier termination of his or her appointment as provided for in the Companies Law or the Articles).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any amendment of our Articles regarding the election of directors, as described above, require the affirmative vote of at least 75% of the voting rights in the Company, represented personally or by proxy and voting thereon at a general meeting. See &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;C. Board Practices&#8212;External Directors&#8221; for a description of the procedure for the election of external directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A nominee for service as a director in a public company may not be elected without submitting a declaration to the company, prior to election, specifying that he or she has the requisite qualifications to serve as a director, independent director or external director (if required), as applicable, and the ability to devote the appropriate time to performing his or her duties as such.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A director, who ceases to meet the statutory requirements to serve as a director, external director or independent director, as applicable, must notify the company to that effect immediately and his or her service as a director will expire upon submission of such notice.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alternate Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Articles provide, as allowed by the Companies Law, that any director may, subject to the conditions set thereto, appoint a person as an alternate to act in his place, to remove the alternate and appoint another in his place and to appoint an alternate in place of an alternate whose office is vacated for any reason whatsoever. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who is already serving as a director or a person who is already serving as an alternate director for another director, may not be appointed as an alternate director. Nevertheless, a director who is already serving as a director may be appointed as an alternate director for a member of a committee of the board of directors so long as he or she is not already serving as a member of such committee. A person who is not qualified to be appointed as an independent director, pursuant to the Companies Law, may not be appointed as an alternate director of an independent director qualified as such under the Companies Law. Unless the appointing director limits the time or scope of the appointment, the appointment is effective for all purposes until the appointing director ceases to be a director or terminates the appointment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">External Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, unless a regulatory relief is available, under the Companies Law and the regulations promulgated pursuant thereto,&#160;Israeli companies whose shares have been offered to the public, or that are publicly traded outside of Israel, which we refer to as a public company, are required to appoint at least two natural persons as &#8220;external directors.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No person may be appointed as an external director if such person is a relative of a controlling shareholder or if such person, a relative, partner or employer of such person, or anyone to whom such person is directly or indirectly subordinate, or any entity under such person&#8217;s control, has or had, on or within the two&#160;years preceding the date of such person&#8217;s appointment to serve as an external director, any affiliation with the company to whose board of directors the external director is proposed to be appointed, with any controlling shareholder of the company, with a relative of such controlling shareholder, or with any entity controlled, on the date of such appointment or within the preceding two&#160;years, by the company or by a controlling shareholder of the company. If the company has no controlling shareholder or a shareholder holding 25% or more of the company&#8217;s voting rights, a person may not serve as an external director if the person has any affiliation, at the time of the appointment, to the chairman of the board of directors, the chief executive officer or the most senior financial officer of the company, or to a shareholder holding 5% or more of the outstanding shares or voting rights of the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;controlling shareholder&#8221; means a shareholder with the ability to direct the activities of the company, other than by virtue of being an office holder. A shareholder is presumed to have &#8220;control&#8221; of the company and thus to be a controlling shareholder of the company if the shareholder holds 50% or more of the &#8220;means of control&#8221; of the company. &#8220;Means of control&#8221; is defined as (1)&#160;the right to vote at a general meeting of a company or a corresponding body of another corporation; or (2)&#160;the right to appoint directors of the corporation or its general manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;affiliation&#8221; includes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">an employment relationship;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a business or professional relationship maintained on a regular basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">or control; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">service as an office holder, excluding service as a director in a private company prior to the first offering of its shares to the public if such director was appointed as a director of the private company in order to serve as an external director following the initial public offering.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;relative&#8221; is defined as a spouse, sibling, parent, grandparent, descendant, spouse&#8217;s descendant, sibling and parent and the spouse of each of the foregoing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, no person may serve as an external director if: (i)&#160;the person&#8217;s other positions or other business activities create, or may create, a conflict of interest with the person&#8217;s service as an external director or interfere with the person&#8217;s ability to serve as an external director; (ii)&#160;at the time such person serves as a non-external director of another company on whose board of directors a director of the reciprocal company serves as an external director; (iii)&#160;the person is an employee of the Israel Securities Authority or of an Israeli stock exchange; (iv)&#160;such person or such person&#8217;s relative, partner, employer or anyone to whom such person is directly or indirectly subordinate, or any entity under such person&#8217;s control, has business or professional relations with any person or entity he or she should not be affiliated with, as described above, unless such relations are negligible; or (v)&#160;such person received compensation, directly or indirectly, in connection with such person&#8217;s services as an external director, other than as permitted under the Companies Law and the regulations promulgated thereunder. If, at the time of election of an external director, all other directors who are not controlling shareholders of such company or their relatives, are of the same gender, then the designated external director must be of the other gender.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Companies Law, an external director is required to have either financial and accounting expertise or professional qualifications according to criteria set forth in regulations promulgated under the Companies Law, provided that at least one of the external directors has financial and accounting expertise. However, if at least one of the other directors (1)&#160;meets the independence requirements of the Exchange Act, (2)&#160;meets the Nasdaq requirements for membership on the audit committee and (3)&#160;has financial and accounting expertise as defined in the Companies Law and applicable regulations, then neither of our external directors is required to possess financial and accounting expertise as long as both possess other requisite professional qualifications as required under the Companies Law and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2020, our Board adopted the exemption under the Regulation and opted-out from the requirement to have external directors serving on our Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board has determined that the minimum number of directors with financial and accounting expertise, in addition to the external director or directors who have such expertise, will be one, and that Mr. Poshinski qualifies as such. In addition, our Board has determined that Mr. Poshinski qualifies as an audit committee financial expert pursuant to the applicable SEC rules, and accordingly as having the necessary financial sophistication as required by the Nasdaq Capital Market rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Director Independence</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following our &#8220;opt-out&#8221; of the requirement to have external directors serving on our Board, we comply with the director independence requirements and the audit committee and the compensation committee composition requirements under U.S. laws (including applicable Nasdaq Capital Market rules) applicable to U.S. domestic issuers. Our Board has undertaken a review of the independence of each director. Based on information provided by each director concerning their background, employment and affiliations, our Board has determined that Mr.&#160;Nir, Mr.&#160;Poshinski, Dr.&#160;Sidransky and Dr.&#160;Brosgart do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term is defined under the listing standards of the Nasdaq. In making these determinations, our Board considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our Board deemed relevant in determining their independence, including the beneficial ownership of our capital shares by each non-employee director.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Committees of the Board</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Articles also provide that the Board may delegate any, or all, of its powers to one or more committees of the Board, and may entrust to and confer upon a &#8220;managing director&#8221; such of its powers as it deems appropriate. However, the Companies Law provides that certain powers and authorities (for example, the power to approve the financial statements) may not be delegated and may be exercised only by the Board. Notwithstanding the foregoing, we currently do, and intend to continue to, comply with the corporate governance requirements of the Nasdaq Capital Market, except to the extent indicated elsewhere in this annual report, including as set forth under &#8220;Item&#160;16G. Corporate Governance&#8221; below. The Companies Law requires public companies such as the Company to appoint an audit committee and a remuneration committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Audit Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Companies Law requires public companies to appoint an audit committee comprised of at least three directors, including all of the external directors, the majority of whom must be independent directors under the Companies Law. The Companies Law further stipulates that the following may not be members of the audit committee: (i)&#160;the chairman of the board of directors; (ii)&#160;any director employed by or providing services on an ongoing basis to the company, to a controlling shareholder of the company or an entity controlled by a controlling shareholder of the company; (iii)&#160;a director whose livelihood mainly depends on a controlling shareholder; and (iv)&#160;a controlling shareholder or any relative of a controlling shareholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Companies Law further requires that: (i)&#160;the chairperson of the audit committee must be an external director; (ii)&#160;generally, any person who is not entitled to be a member of the audit committee may not attend the audit committee&#8217;s meetings and voting sessions, unless such person was invited by the chairperson of the committee for the purpose of presenting a specific subject matter thereof; and (iii)&#160;the quorum required for the convening of meetings of the audit committee and for adopting resolutions by the audit committee is a majority of the members of the audit committee, provided that the majority of the members present are independent directors and at least one of them is an external director. As noted, under the Regulation, companies with no controlling shareholder whose shares are listed for trading on specified exchanges outside of Israel, including the Nasdaq Capital Market, may adopt exemptions from various corporate governance requirements of the Companies Law so long as the company satisfies the applicable foreign country laws and regulations, including applicable stock exchange rules, that apply to companies organized in that country relating to the appointment of independent directors and the composition of audit and compensation committees. Such exemptions include an exemption from the requirement to appoint external directors and the requirement that an external director be a member of certain committees. In accordance with these Regulations, we elected to &quot;opt out&quot; from such requirements of the Companies Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The responsibilities of the audit committee under the Companies Law include: (i)&#160;identifying flaws in the management of a company&#8217;s business and making recommendations to the board of directors as to how to correct them; (ii)&#160;with respect to certain actions involving conflicts of interest and with respect to certain related party transactions, deciding whether such actions are material actions and whether such transactions are extraordinary transactions, respectively, all for the purpose of approving such actions or transactions; (iii)&#160;reviewing and deciding whether to approve certain related party transactions and certain actions involving conflicts of interest; (iv)&#160;reviewing the internal auditor&#8217;s work program; (v)&#160;examining the company&#8217;s internal control structure and processes, the performance of the internal auditor and whether the internal auditor has at his or her disposal the tools and resources required to perform his or her duties, considering, inter alia, the special needs of the company and its size; (vi)&#160;examining the independent auditor&#8217;s scope of work as well as the independent auditor&#8217;s fees and providing its recommendations to the appropriate corporate organ; (vii)&#160;providing for arrangements as to the manner in which the company will deal with employee complaints with respect to deficiencies in the management of the company&#8217;s business and the protection to be provided to such employees; and (viii)&#160;with respect to related party transactions with a controlling shareholder, regardless of whether such transactions are extraordinary transactions, that prior to entering into such transaction, to establish the requirement of having a competitive process under the supervision of the audit committee or any individual, committee or body on its behalf and according to criteria established by the audit committee and to determine procedures for approving certain related party transactions with a controlling shareholder, which were determined by the audit committee to be non-extraordinary transactions, but which are not negligible transactions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board has adopted an audit committee charter setting forth the responsibilities of the audit committee consistent with the rules&#160;of the SEC and the Nasdaq Listing Rules, as well as the requirements for such committee under the Companies Law, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our audit committee oversees the accounting and financial reporting processes of the Company. It also provides assistance to the Board in fulfilling its legal and fiduciary obligations with respect to matters involving the accounting, auditing, financial reporting and internal control functions of the Company. In carrying out its duties, our audit committee meets with management at least once a quarter, at which time, among other things, it reviews, and either approves or disapproves, the financial results of the Company for the immediately preceding calendar quarter and conveys its conclusions in this regard to the Board. Our audit committee also monitors generally the services provided by the Company&#8217;s independent auditors to ensure their independence and reviews all audit and non-audit services provided by them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board has resolved to delegate to the audit committee the power to pre-approve non-auditing services rendered by the Company&#8217;s independent auditors without the need for further approval by our Board. As such, on March&#160;8, 2020, our audit committee approved the adoption of a pre-approval policy, such that the Chairman of the audit committee is authorized to pre-approve any engagement of our independent auditors during a period of twelve&#160;months from the date of such approval, for the provision of non-auditing services, for fees not to exceed $20,000, and any such engagement which exceeds $20,000 shall require a pre-approval by the entire audit committee. Once services have been pre-approved, our management must then report to the audit committee on a periodic basis regarding the extent of services actually provided in accordance with the pre-approval policy, and regarding the fees for the services performed. Such fees for 2017 were pre-approved by the audit committee in accordance with the pre-approval policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s independent and internal auditors also report regularly to our audit committee, and our audit committee discusses with the Company&#8217;s independent auditors the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments and the clarity of disclosures in the Company&#8217;s financial statements, as and when it deems it appropriate to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the provisions of the Sarbanes-Oxley Act, the audit committee is directly responsible for the appointment, compensation and oversight of the work of the company&#8217;s independent auditors. However, under Israeli law, the appointment of independent auditors and their compensation require the approval of the shareholders of a public company. Pursuant to Israeli law, the shareholders may delegate the authority to determine the compensation of the independent auditors to the board of directors. In addition, pursuant to the Companies Law, the audit committee is required to examine the independent auditors&#8217; fees and to provide its recommendations with respect thereto to the appropriate corporate body. Accordingly, the appointment of our independent auditors is required to be approved and recommended to the shareholders by our audit committee and Board and approved by the shareholders. The compensation of the independent auditors for audit services is required to be approved and recommended to the Board by our audit committee and approved by the Board. The Board has delegated its authority to approve the compensation of independent auditors for non-auditing services to the audit committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Nir, Mr.&#160;Poshinski and Dr.&#160;Sidransky are the current members of our audit committee, with Mr. Poshinski serving as chairperson. Each of our audit committee members are &#8220;independent directors&#8221; in accordance with the Nasdaq Capital Market corporate governance requirements, as affirmatively determined by our Board. In addition, our Board has affirmatively determined that Mr. Poshinski also qualifies as an audit committee financial expert pursuant to the applicable SEC rules, and accordingly has the necessary financial sophistication as required by the Nasdaq Capital Market rules.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Remuneration Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Companies Law requires public companies to appoint a remuneration committee comprised of at least three directors, including all of the external directors, who must generally also constitute a majority of the members. All other members of the committee, who are not external directors, must be directors who receive compensation consistent with that of external directors and that is in compliance with the Compensation Regulations. In addition, the chairperson of the remuneration committee must be an external director.&#160;As noted, under the Regulation, we elected to &quot;opt out&quot; from such requirements of the Companies Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Companies Law further stipulates that directors who are not qualified to serve on the audit committee, as described above, may not serve on the remuneration committee either and that similar to the audit committee, generally, any person who is not entitled to be a member of the remuneration committee may not attend the remuneration committee&#8217;s meetings. Our Board has adopted a remuneration committee charter setting forth the responsibilities of our remuneration committee, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The responsibilities of the remuneration committee under the Companies Law include: (i)&#160;making recommendations to the board of directors with respect to the approval of the compensation policy and any extensions thereto; (ii)&#160;periodically reviewing the implementation of the compensation policy and providing the board of directors with recommendations with respect to any amendments or updates thereto; (iii)&#160;reviewing and resolving whether or not to approve transactions with respect to the terms of office and employment of Office Holders; and (iv)&#160;resolving, under certain circumstances prescribed under the Companies Law, whether or not to exempt a transaction with a candidate for chief executive officer who meets non-affiliation criteria from shareholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our remuneration committee also oversees the administration of the Company&#8217;s various compensation plans and arrangements, in particular, the incentive compensation, deferred compensation and equity based plans of the Company (and to the extent appropriate, of the subsidiaries of the Company) and assists the Board in fulfilling its responsibilities relating to the compensation of directors, the Chief Executive Officer and other Office Holders of the Company. In carrying out these duties, our remuneration committee meets on an ad hoc basis. Under the Companies Law, our remuneration committee may need to seek the approval of the Board and the shareholders for certain compensation decisions as described above. Each member of our remuneration committee is an &#8220;independent director&#8221; in accordance with the Nasdaq Capital Market corporate governance requirements, as affirmatively determined by our Board. Mr.&#160;Nir, Mr. Poshinksi and Dr.&#160;Sidransky are the current members of our remuneration committee, with Dr. Sidransky serving as chairperson.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Compensation Policy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As approved by our shareholders, and as required by the Companies Law, we have adopted a Compensation Policy regarding the terms of office and employment of our &#8220;office holders&#8221; (as defined under the Companies Law, which includes directors, the CEO, other executive officers and any other managers directly subordinate to the CEO), including cash compensation, equity-based awards, releases from liability, indemnification and insurance, severance and other benefits. Each of the named executive officers is an &#8220;office holder&#8221; within the meaning of the Companies Law. The Compensation Policy is reviewed from time to time by our remuneration committee and our Board to ensure its appropriateness, and is required to be brought at least once every three years to our shareholders for approval. See &#8220;Item 6. Directors, Senior Management and Employees &#8212; B. Compensation &#8212; Certain Approvals Required for Office Holders&#8217; Compensation of the Companies Law&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our most recent Compensation Policy was last approved at our annual general meeting of shareholders that was held on August 13, 2020. &#160;The Compensation Policy links pay to performance and aligns our executive officers&#8217; interests with those of the Company and of our shareholders. It allows us to provide meaningful incentives that reflect both our short and long-term goals and performance, as well as the executive officers&#8217; individual performance and impact on shareholder value, while providing compensation that is competitive in the global marketplace in which we recruit talent and is designed to reduce incentives for our executive officers to take excessive risks.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Compensation Policy emphasizes each executive officer&#8217;s individual characteristics (such as his or her respective position, education, scope of responsibilities and contribution to the attainment of our goals) as the basis for compensation variation among executive officers, taking into account the internal ratios between compensation of our executive officers and directors and other employees of the Company. Pursuant to the Compensation Policy, the compensation that may be granted to an executive officer may include: base salary and benefits, annual cash bonuses and other cash bonuses (such as retention and special bonuses), as well as equity-based compensation, retirement and termination of employment benefits and other benefits. The cash bonuses that may be granted under the Compensation Policy are limited to a maximum amount linked to the executive officer&#8217;s base salary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Compensation Policy, an annual cash bonus that will be awarded to executive officers (other than the CEO) will be based on performance objectives and a discretionary evaluation of the executive officer&#39;s overall performance by the CEO and may be subject to minimum thresholds. The remuneration committee and the Board will determine any applicable minimum thresholds that must be met for entitlement to the annual cash bonus (all or any portion thereof) and the formula for calculating any annual cash bonus payout on the basis of, but not limited to, company and individual objectives. Notwithstanding the above, we may determine that, with respect to any executive officer subordinated to the CEO, which does not serve as a director, a portion or all of his or her annual cash bonus will be based on the evaluation of the CEO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Compensation Policy provides that the annual bonus awarded to the Company&#8217;s CEO will be mainly based on measurable objectives of the Company, subject to a minimum threshold on the basis of, but not limited to, company and personal objectives. 25% or less of the annual cash bonus granted to the Company&#8217;s CEO may be based on a discretionary evaluation of the CEO&#8217;s overall performance by the remuneration committee and the Board. The measurable objectives will be determined annually by the remuneration committee and the Board at the commencement of each fiscal year, or upon engagement, in case of newly hired CEO, or in other special circumstances as set forth in the Compensation Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The equity-based compensation under the Compensation Policy for our executive officers is designed in a manner intended to attract and retain officers and align their interests with shareholders&#8217; interests to maximize creation of long-term economic value for the Company, and to strengthen the retention and the motivation of executive officers in the long term. Equity-based awards may be granted from time to time in the form of options and/or other equity- based awards, such as RSUs in accordance with our 2013 Plan as may be updated from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Compensation Policy contains compensation recovery provisions in the event of accounting restatement, which would allow us, under certain conditions, to recover bonuses or performance-based equity paid in excess of what would have been paid under the financial statements, as restated. The Compensation Policy also contains provisions that allow us to exculpate, indemnify and insure our executive officers and directors subject to certain updated limitations set forth in the Compensation Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on information provided to us by our insurance brokers (and which has been supported by our independent insurance consultants), there has recently been a significant increase in the cost of D&amp;O liability insurance for non US companies listed in the US, and especially in the &#160;life sciences sector. The increases have been tied to extensive losses suffered by the D&amp;O insurers as a result, among other things, of significant increases in the number of class actions filed against Nasdaq listed companies. For example, the year 2018 set a 20-year record high for securities class actions filed against issuers of common or preferred stock listed in the US. Due to the above mentioned market environment, insurers adopted a very defensive and selective approach and some of the insurers are no longer providing US traded companies with new offers and those that are still active in the market have been increasing their level of compensation (in the form of premiums), which they believe have not been commensurate with the risk being taken by them. In parallel, there has been an increase in the amounts of the deductibles payable by public companies in situations in which an insurable event occurs. As a result, our most recent Compensation Policy reflects an increase of the premiums payable in order to maintain the coverage levels under our renewed D&amp;O insurance policy.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Compensation Policy also governs the compensation of our board members and provides that our directors will be entitled to an annual cash fee retainer (which shall not exceed 20% of the annual base salary paid to our CEO during the year 2019 plus VAT) and may be paid through the grant of equity awards up to the limits set forth in the Compensation Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nominating Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Nasdaq Capital Market corporate governance requires each company adopting a nominating committee to certify that it has adopted a formal written charter or board resolution, as applicable, addressing the nominations process and such related matters as may be required under U.S. federal securities laws. Although not required as a foreign private issuer to adopt a nominating committee, we have decided to follow such requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board has adopted a nominating committee charter setting forth the responsibilities of the nominating committee consistent with the Nasdaq Listing Rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The nominating committee is responsible for identifying individuals qualified to be appointed as board members, and recommending to the Board appropriate director nominees for election at the general meeting of shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Independent director oversight of nominations enhances investor confidence in the selection of well-qualified director nominees, as well as independent nominees as required by the rules. The Nasdaq Capital Market listing rule&#160;is also intended to provide flexibility for a company to choose an appropriate board structure and reduce resource burdens, while ensuring that independent directors approve all nominations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Mr. Nir, Mr. Poshinski, and Dr. Sidransky are the current members of our nominating committee, with Dr.&#160;Sidransky serving as chairperson. Nasdaq Capital Market Listing Rule&#160;5605(e)&#160;requires that our nominating committee be comprised solely of independent directors unless the nominating committee is comprised of at least three members and the Board determines that such non-independent director&#8217;s membership, which shall not be longer than two&#160;years, is required by the best interests of the Company and our shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">R&amp;D Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our R&amp;D Committee, which was established by the Board on May&#160;2014, advises and assists the Board in its oversight of our research and development programs, including the rationale and timeline of clinical trials and other studies, as well as market surveys in connection therewith. The R&amp;D Committee operates in accordance with the purposes and objectives determined by the Board from time to time. Dr.&#160;Sidransky, Dr.&#160;Brosgart and Mr. Baharaff are the current members of our R&amp;D Committee, with Dr.&#160;Sidransky serving as chairperson.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Internal Auditor</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the audit committee and nominated by the board of directors. The role of the internal auditor is to examine, among other things, our compliance with applicable law and orderly business procedures. An internal auditor should comply with the requirements of the Companies Law and the Internal Audit Law, 5752-1992, and may not be:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a person (or a relative of a person) who holds more than 5% of the Company&#8217;s outstanding shares or voting rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a person (or a relative of a person) who has the power to appoint a director or the general manager of the Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">an Office Holder, including a director, of the Company (or a relative thereof); or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a member of the Company&#8217;s independent accounting firm, or anyone on his or her behalf.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Israeli law, an internal auditor&#8217;s tenure cannot be terminated without his or her consent, nor can he or she be suspended from such position unless the board of directors of the company has so resolved following the recommendations of the company&#8217;s audit committee and, after providing the internal auditor with the opportunity to present his or her position to the board of directors of the company and to the audit committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 12, 2021, our Board appointed Zach Refaeli, CPA, from Ernst &amp; Young Israel - Kost Forer Gabbay &amp; Kasierer, Tel Aviv, Israel, as the Company&#8217;s internal auditor for a period of three years, effective as of January 12, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exculpation and Indemnification of Directors and Officers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, a company may not exculpate an Office Holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an Office Holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of the duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our Articles include such a provision. The Company may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, and the Securities Law, 5738&#8212;1968, or the Securities Law, a company may indemnify, or undertake in advance to indemnify, an Office Holder for the following liabilities and expenses, imposed on Office Holder or incurred by Office Holder due to acts performed by him or her as an Office Holder, provided its articles of association include a provision authorizing such indemnification:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a monetary liability incurred by or imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an Office Holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the Office Holder as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i)&#160;no indictment was filed against such Office Holder as a result of such investigation or proceeding; and (ii)&#160;no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent or as a monetary sanction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a monetary liability imposed on him or her in favor of an injured party at an Administrative Procedure (as defined below) pursuant to Section&#160;52(54)(a)(1)(a)&#160;of the Securities Law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">expenses incurred by an office holder or certain compensation payments made to an injured party that were instituted against an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the Office Holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third-party, or in connection with criminal proceedings in which the Office Holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">An &#8220;Administrative Procedure&#8221; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law and the Securities Law, a company may insure an Office Holder against the following liabilities incurred for acts performed by him or her as an Office Holder if and to the extent provided in the company&#8217;s articles of association:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a breach of the duty of loyalty to the company, provided that the Office Holder acted in good faith and had a reasonable basis to believe that such act would not prejudice the company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a breach of the duty of care to the company or to a third-party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a monetary liability imposed on the Office Holder in favor of a third-party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section&#160;52(54)(a)(1)(a)&#160;of the Securities Law; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">expenses incurred by an office holder in connection with an Administrative Procedure instituted against him or her, including reasonable litigation expenses and reasonable attorneys&#8217; fees.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nevertheless, under the Companies Law, a company may not indemnify, exculpate or insure an Office Holder against any of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company in the event Office Holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the Office Holder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">an act or omission committed with intent to derive unlawful personal benefit; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">a fine, monetary sanction, penalty or forfeit levied against the Office Holder.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, exculpation, indemnification and insurance of Office Holders require the approval of the remuneration committee, board of directors and, in certain circumstances, the shareholders, as described above under &#8220;Item&#160;6<b style="font-weight:bold;">&#8212;</b>Directors, Senior Management and Employees&#8212;B. Compensation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Articles permit us to exculpate, indemnify and insure our Office Holders to the fullest extent permitted by the Companies Law. Each of our Office Holders have entered into an indemnification agreement with us, exculpating them, to the fullest extent permitted by Israeli law, from liability to us for damages caused to us as a result of a breach of the duty of care and undertaking to indemnify them to the fullest extent permitted by Israeli law, including with respect to liabilities resulting from certain acts performed by such Office Holders in their capacity as an Office Holder of the Company, our subsidiaries or our affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the opinion of the SEC, indemnification of directors and Office Holders for liabilities arising under the Securities Act, however, is against public policy and therefore unenforceable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agreements with Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other than a written agreement with our President, Chief Executive Officer and Chairman, as detailed in &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;B. Compensation&#8212;Employment Agreements and Arrangements with Directors and Related Parties&#8212;Employment Agreement with Our President, Chief Executive Officer and Chairman of the Board,&#8221; we do not have written agreements with any director providing for benefits upon the termination of his or her services with our Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">D.</b></span><b style="font-weight:bold;">Employees.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, we had 24 employees, of which 18 were full-time employees and 6 were part-time employees. 18 of the Company&#8217;s employees were involved in our clinical and product development operations and 6 served in general and administrative capacities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While none of our employees are party to any collective bargaining agreements or represented by any labor unions, certain provisions of the Israeli labor laws and certain collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau of Economic Organizations (including the Industrialists&#8217; Associations) are applicable to our employees by order of the Israel Ministry of Economics. These provisions primarily concern the length of the workday, minimum daily wages for professional workers, pension fund benefits for all employees, insurance for work-related accidents, procedures for dismissing employees, determination of severance pay and other conditions of employment. We generally provide our employees with benefits and working conditions beyond the required minimums. We have never experienced any employment-related work stoppages&#160;and believe our relationship with our employees is favorable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">E.</b></span><b style="font-weight:bold;">Share Ownership.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information regarding beneficial ownership of our ordinary shares as of February&#160;28, 2021, the latest practicable date for inclusion in this annual report, held by our directors and executive officers, individually and as a group and beneficial owners of more than 5% of our outstanding shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Beneficial ownership is determined in accordance with the rules&#160;of the SEC and includes voting or investment power with respect to ordinary shares. Ordinary shares issuable under share options, warrants or other conversion rights currently exercisable or that are exercisable within 60&#160;days after February&#160;28, 2021 are deemed outstanding for the purpose of computing the&#160;percentage ownership of the person holding the options, or other conversion rights, but are not deemed outstanding for the purpose of computing the&#160;percentage ownership of any other person.&#160;Percentage of shares beneficially owned is based on 25,083,914 ordinary shares outstanding on February&#160;28, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power and the right to receive the economic benefit of ownership with respect to all ordinary shares held by that person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Unless otherwise stated, the address for our directors and senior management is c/o Galmed Pharmaceuticals Ltd., 16 Ze&#8217;ev Tiomkin St. Tel Aviv, Israel 6578317.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;ordinary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;ordinary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares&#160;beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares&#160;beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">owned</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">More than 5% Holders</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">BVF Inc.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,799,694</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Nantahala Capital Management, LLC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,926,899</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7.7</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Ibex Investors LLC <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,525,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Directors and Executive Officers</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Allen Baharaff<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,256,870</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Shmuel Nir<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 118,146</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amir Poshinski</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dr. David Sidransky<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 68,125</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dr. Carol L. Brosgart<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,625</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Marshall Heinberg<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41,404</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dr. Liat Hayardeny<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(10)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Yohai Stenzler<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(11)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91,625</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Guy Nehemya<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(12)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 79,125</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">All directors and executive officers as a group (9 persons)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,795,920</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18.6</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">*</span></span>Less than 1%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>All options included are either currently exercisable or will be exercisable within 60&#160;days of February&#160;28, 2021.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(2)</span>Based upon information contained in a Statement on Schedule 13G/A filed by the shareholder on February&#160;12, 2021. Shares beneficially owned consist of (i)&#160;923,424 ordinary shares held directly by Biotechnology Value Fund,&#160;L.P., or BVF, (ii)&#160;710,895 ordinary shares held directly by Biotechnology Value Fund II,&#160;L.P., or BVF2, and (iii)&#160;135,355 ordinary shares held directly by Biotechnology Value Trading Fund OS LP, or Trading Fund OS. BVF I GP LLC, or BVF GP, as the general partner of BVF, may be deemed to beneficially own the 923,424 ordinary shares beneficially owned by BVF. BVF II GP LLC, or BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 710,895 ordinary shares beneficially owned by BVF2. BVF Partners OS&#160;Ltd. or Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 135,355 ordinary shares beneficially owned by Trading Fund OS. BVF GP Holdings LLC, or BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 1,634,319 ordinary shares beneficially owned in the aggregate by BVF and BVF2. BVF Partners&#160;L.P., or Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 1,799,694 ordinary shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and a certain Partners managed account, or the Partners Managed Account, including 30,020 ordinary shares held in the Partners Managed Account. BVF&#160;Inc., as the general partner of Partners, may be deemed to beneficially own the 1,799,694 ordinary shares owned by Partners. Mark N. Lampert, as a director and officer of BVF&#160;Inc., may be deemed to beneficially own the 1,799,694 ordinary shares beneficially owned by BVF&#160;Inc. BVF GP disclaims beneficial ownership of the ordinary shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the ordinary shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the ordinary shares beneficially owned by BVF and BVF2. Each of Partners, BVF&#160;Inc. and Mr.&#160;Lampert disclaims beneficial ownership of the ordinary shares beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Account.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(3)</span>Based upon information contained in a Statement on Schedule 13G filed by Nantahala Capital Management, LLC, or Nantahala, and Wilmot B. Harkey and Daniel Mack on February 16, 2021. Nantahala may be deemed to be the beneficial owner of 1,926,899 ordinary shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those shares. The address of Nantahala and Messrs. Harkey and Mack is130 Main St. 2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">nd</sup> Floor New Canaan, CT 06840.</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(4)</span>Based upon information contained in a Statement on Schedule 13G/A filed on January 15, 2021 by Justin B. Borus; Ibex Investors LLC, or the Ibex Investment Manager; Ibex Israel Fund LLLP, or the Ibex Fund; Ibex GP LLC, or the Ibex General Partner; (5) Ibex Investment Holdings LLC, or IM Holdings; and Ibex Investment Holdings II LLC, or Ibex GP Holdings (all of the foregoing, collectively, the &#8220;Ibex Reporting Persons&#8221;). The Ibex Fund is a private investment vehicle. The Ibex Fund directly beneficially owns our ordinary shares reported in the Statement. The Ibex &#160;Investment Manager is the investment manager of the Ibex Fund. IM Holdings is the sole member of the Ibex Investment Manager. The Ibex General Partner is the general partner of the Ibex Fund. Ibex GP Holdings is the sole member of the Ibex General Partner. Justin B. Borus is the manager of the Ibex Investment Manager, IM Holdings, the Ibex General Partner and Ibex GP Holdings. Justin B. Borus, the Ibex Investment Manager, IM Holdings, the Ibex General Partner and Ibex GP Holdings may be deemed to beneficially own the ordinary shares directly beneficially owned by the Ibex Fund. Each Ibex Reporting Person disclaims beneficial ownership with respect to any shares other than the shares directly beneficially owned by such Ibex Reporting Person. The address of Ibex Reporting Persons is c/o Ibex Investors LLC, 260 N. Josephine Street, Suite 300, Denver, CO 80206.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(5)</span>Consists of (i) 3,420,822 ordinary shares, of which 3,416,822 are held through G. Yarom Medical Research Ltd., a company incorporated under the laws of the State of Israel, of which Mr. Baharaff is the controlling shareholder and the chairman of its board of directors and 4,000 ordinary shares held by Mr. Baharaff, which were purchased in the open market; and (ii) options to purchase 836,048 ordinary shares that are currently exercisable within 60 days as of February 28, 2021. Of the 4,256,870 ordinary shares, Mr. Baharaff exercises sole voting and dispositive power over 840,048 shares beneficially owned and shared voting and dispositive power with G. Yarom Medical Research Ltd. over 3,416,822 shares. Does not include options to purchase 220,000 ordinary shares under our 2013 Plan, which were approved by our remuneration committee and Board and subject to shareholder approval.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(6)</span>Consists of (i) 48,938 ordinary shares, of which 41,438 ordinary shares are held through Tushia Consulting Engineers Ltd., of which Shmuel Nir is its controlling shareholder and 7,500 ordinary shares held by Mr. Nir; and (ii) 69,208 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days as of February 28, 2021.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(7)</span>Consists of (i) 7,500 ordinary shares held by Dr. Sidransky; and (ii) 60,625 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days as of February 28, 2021.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(8)</span>Consists of 40,625 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days as of February 28, 2021.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(9)</span>Consists of (i) 24,529 ordinary shares held by Mr. Heinberg; and (ii) 16,875 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days as of February 28, 2021.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(10)</span>Consists of 100,000 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days as of February 28, 2021.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(11)</span>Consists of (i) 5,625 ordinary shares held by Mr. Stenzler; and (ii) 86,000 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days as of February 28, 2021.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(12)</span>Consists of (i) 5,625 ordinary shares held by Mr. Nehemya; and (ii) 73,500 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days as of February 28, 2021.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Change in Control</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To our knowledge, (i) we are not directly or indirectly owned or controlled by another corporation, by any foreign government or by any other natural or legal person severally or jointly, except as disclosed in the above table regarding our major shareholders, and (ii) there are no arrangements which would result in our change in control at a subsequent date.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Significant Changes in the Ownership of Major Shareholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.35pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To our knowledge, other than as disclosed in the table above, our other filings with the SEC and this annual report, there has been no significant change in the percentage ownership held by any major shareholder since January 1, 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Major Shareholders Voting Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">&#160;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our major shareholders do not have different voting rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Record Holders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To our knowledge, as of February 28, 2021, we had one holder of record of our ordinary shares with a U.S. address, Cede &amp; Co., the nominee of The Depository Trust Company. This holder held in the aggregate 21,641,740 ordinary shares, or 86% of our outstanding ordinary shares as of February 28, 2021. The number of record holders in the United States is not representative of the number of beneficial holders of our ordinary shares nor is it representative of where such beneficial holders are resident since many of these ordinary shares were held by brokers or other nominees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2013 Incentive Share Option Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We maintain one equity-based incentive plan, our 2013 Incentive Share Option Plan, or the 2013 Plan. As of February&#160;28, 2021, the latest practicable date for inclusion in this annual report, a total of 4,340,492 shares were reserved for issuance under our 2013 Plan, of which (1)&#160;options to purchase 2,645,888 ordinary were issued and outstanding thereunder (i.e., were granted but not canceled, expired or exercised); (2)&#160;options to purchase 1, 091,183 ordinary shares were exercised and 59,528 ordinary shares were issued upon vesting of RSUs; (3)&#160;options to purchase 220,000 ordinary shares which have been approved for issuance to our CEO&#160;&amp; President, Mr.&#160;Allen Baharaff, are subject to shareholders approval; and (4)&#160;323,893 shares remain unallocated for future equity awards pursuant to our 2013 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our 2013 Plan, which was adopted by our Board on September&#160;2, 2013, and approved by our shareholders in December&#160;30, 2013 (as was amended by the Board and our shareholders on March&#160;30, 2015, May&#160;11, 2015, and August&#160;30, 2018), provides for the grant of options to purchase our ordinary shares and the issuance of RSUs to our officers, directors, employees, service providers and consultants. Our 2013 Plan provides for such equity-based compensation under various and different tax regimes, including those detailed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2013 Plan is administered by our Board, which, on its own or upon the recommendation of our remuneration committee or any other similar committee of the Board, shall determine, subject to applicable law, the identity of grantees of awards and various terms of the grant. Consistent with our Compensation Policy, the 2013 Plan provides for granting options to purchase our ordinary shares pursuant to Section&#160;102 of the Israeli Income Tax Ordinance, or the Ordinance, under the capital gains route, to directors, officers and employees who are Israeli residents holding (or have a right to hold or to purchase) less than 10% of our total share capital and do not have a right to receive 10% or more of the Company&#8217;s profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Section&#160;102 of the Ordinance allows Israeli employees, directors and officers, who are not controlling shareholders to receive favorable tax treatment for compensation in the form of shares or options. However, under this route we are not allowed to deduct any expense with respect to the issuance of the options or shares. Israeli non-employee service providers, consultants and shareholders who hold 10% or more of our total share capital or are otherwise controlling shareholders, may be granted options pursuant to Section&#160;3(i)&#160;of the Ordinance, which does not provide for similar tax benefits. In order to comply with the terms of the capital gains route pursuant to Section&#160;102 of the Ordinance, the granted options as well as the ordinary shares issued upon exercise of these options and other shares received subsequently following any realization of rights with respect to such options (such as share dividends and share splits), must be granted to a trustee for the benefit of the relevant grantee and should be held by the trustee for at least two&#160;years after the date of the grant. If such options or shares are sold by the trustee or are transferred to the grantee before the end of the two-year period, then the grantee would be taxed at top marginal rates upon selling the shares.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For residents, or deemed residents, of the United States, the 2013 Plan provides grants, which are pursuant to Section&#160;422 of the Internal Revenue Code of 1986, as amended, or the Code, as incentive stock options, or ISOs, and any other participants which do not qualify for ISOs, as non-statutory stock options, or NSOs, pursuant to the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Section&#160;422 of the Code allows employees, directors and officers, who are non-controlling shareholders (e.g., less than 10% shareholders) and are considered residents of the United States or those who are deemed to be residents of the United States for purposes of the payment of tax, or are otherwise subject to taxation in the United States with respect to the grant of awards, to receive favorable tax treatment for compensation in the form of shares or ISOs. 10% shareholders or persons which are not service providers will receive NSOs, which do not entitle them to receive similar tax benefits. Section&#160;422(b)&#160;of the Code provides for the ISO track such that the individual does not have to pay ordinary income tax (nor employment taxes) on the difference between the exercise price and the fair market value of the shares issued (however, the holder may have to pay U.S. alternative minimum tax instead). However, if the shares are held for one&#160;year from the date of exercise and two&#160;years from the date of grant, then the profit (if any) made on sale of the shares is taxed as long-term capital gain. Section&#160;422 of the Code requires that any grant of awards shall not be made at a price which is less than 100% of the fair market value of such awards on the date of the grant, all pursuant to the terms of Section&#160;409A of the Code. However, under this ISO track, we are not allowed to deduct any expense with respect to the issuance of the options or shares. In order to comply with the terms of the ISO track, the option granted thereunder must meet the requirements of Section&#160;422 of the Code when granted and at all times until the exercise thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Options and RSUs granted under the 2013 Plan will vest in accordance with the vesting dates as determined by the Board following the recommendation of the remuneration committee or any other similar committee of the Board with respect to each grant. Generally, options that are not exercised within ten&#160;years from the grant date expire, unless otherwise determined by the Board and the remuneration committee, as applicable, provided, however, that, pursuant to our Compensation Policy, any equity-based awards to Office Holders must include both a gradual vesting period of at least three&#160;years from the date of grant, and an exercise period of no more than ten&#160;years from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon such date or dates designated in the applicable award agreement, unless earlier forfeited, subject to the receipt of any approvals required from any relevant tax authority, we shall settle each RSU upon vesting by delivering one ordinary share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In case of termination for reasons of disability or death, the grantee or his legal successor may exercise options that have vested prior to termination within a period of twelve&#160;months from the date of disability or death. If we terminate a grantee&#8217;s employment or service for cause, all of the grantee&#8217;s vested and unvested unexercised options will expire and terminate on the date of termination. If a grantee&#8217;s employment or service is terminated for any other reason, the grantee may exercise his or her vested options within 90&#160;days of the date of termination or within a longer period under specified circumstances determined by our Board. Any expired or unvested options shall return to the option pool reserved under the 2013 Plan for reissuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of grantee&#8217;s termination prior to a vesting date by reason of such grantee&#8217;s death or disability, all of such grantee&#8217;s RSUs shall immediately become vested as of the date of such termination. In the event of a grantee&#8217;s termination for cause prior to settlement, all of such grantee&#8217;s RSUs shall immediately be forfeited for no consideration as of the date of such termination. If a grantee&#8217;s employment or service is terminated for any other reason, (1)&#160;all vesting with respect to such grantee&#8217;s RSUs shall cease, (2)&#160;all of such grantee&#8217;s unvested RSUs shall immediately be forfeited for no consideration as of the date of such termination, and (3)&#160;to the extent not already settled, all of such grantee&#8217;s vested RSUs shall be settled in accordance with the settlement schedule set forth in the applicable award agreement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of a merger or consolidation of our company subsequent to which we would no longer exist as a legal entity, or a sale of all, or substantially all, of our ordinary shares or assets or other transaction having a similar effect on us, or a Transaction, any unexercised options then outstanding will be cancelled. Notwithstanding the foregoing, the Board, or the relevant committee of the Board, may determine that the options will not be cancelled but will be assumed or substituted for an appropriate number of the same type of shares or other securities of the successor company as were distributed to the Company or the shareholders in connection with the Transaction. In addition, the Board, or the relevant committee of the Board, may determine to include in certain option agreements either a clause that provides for acceleration of vesting of all or part of the unvested options in the event of a Transaction or the occurrence of another event or a clause which provides that if the optionee&#8217;s employment with the successor company is terminated by the successor company without cause within a certain period, not to exceed two&#160;years from the closing of such Transaction, all or part of the unvested options shall be accelerated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain Information Concerning Equity Awards to Office Holders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables set forth information, as of February&#160;28, 2021 concerning all outstanding equity awards to Office Holders as of such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Schedule</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Office</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price&#160;per</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;subject</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">vested&#160;and</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">date&#160;of</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Holder</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date&#160;of&#160;grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">to&#160;the&#160;option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unexercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unvested</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">expiration</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Allen Baharaff(1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">December&#160;30,&#160;2013</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">NIS0.01</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 83,770</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 83,770</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Sep-2-2023</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">December&#160;30,&#160;2013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">NIS0.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 241,014</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 241,014</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Sep-2-2023</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">February&#160;4,&#160;2016</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.49</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 140,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 140,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Feb-04-2026</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">February&#160;4,&#160;2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.94</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 170,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 170,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Feb-04-2026</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">July&#160;10,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11.56</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 220,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 151,250</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 68,750</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Jul-10-2028</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">December&#160;17,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 220,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 687,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 68,750</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Dec-17-2029</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Shmuel Nir</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">February 21, 2014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3.57</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,583</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,583</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Sep-02-2023</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">May 11, 2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.49</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">May-11-2025</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">February&#160;4,&#160;2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.94</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Feb-04-2026</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">July 10, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11.56</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,625</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,375</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Jul-10-2028</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Amir Poshinski</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">August&#160;13,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">August 13, 2030</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">David Sidransky</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">May 11, 2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.49</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">May-11-2025</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">February&#160;4,&#160;2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.94</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Feb-04-2026</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">July 10, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11.56</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,625</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,375</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Jul-10-2028</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Dr. Liat Hayardeny</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">September 6, 2016</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4.05</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32,500</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,500</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Sep-06-2026</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 31, 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3.84</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Jan-31-2026</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">July 10, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11.56</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Jul-10-2028</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">December 17, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Dec-17-2029</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">November 10, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3.33</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Nov-10-2030</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Yohai Stenzler</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">December 30, 2014</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.49</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,500</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,500</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Dec-30-2024</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 3, 2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7.61</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Jan-03-2026</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">November 7, 2017</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7.48</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,888</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,112</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Nov-07-2020</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">July 10, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11.56</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Jul-10-2028</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">December 17, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.12</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,500</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,500</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Dec-17-2029</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">November 10, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3.33</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Nov-10-2030</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Guy Nehemya</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">December 30, 2014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.49</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Dec-30-2024</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 3, 2016</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7.61</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,500</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,500</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Jan-03-2026</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">July 10, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11.56</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Jul-10-2028</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">December 17, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.12</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,500</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,500</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Dec-17-2029</p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">November 10, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3.33</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Nov-10-2030</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Carol L. Brosgart</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">April 25, 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4.87</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Apr-25-2027</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">July 10, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11.56</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 206,225</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,375</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Jul-10-2028</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">On November 10, 2020, our remuneration committee and Board approved the grant to &#160;Allen Baharaff options to purchase 220,000 ordinary shares under our 2013 Plan, subject to shareholder approval. The options have an exercise price of $3.33 per share, shall vest over a period of four&#160;years, with one quarter vesting on the first anniversary of the date of grant and the remainder vesting on an equal quarterly basis and have a term of ten&#160;years.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">RSUs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Office</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">subject&#160;to</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Holder</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date&#160;of&#160;grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">the&#160;RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">vested</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unvested</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shmuel Nir</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Feb-04-2016</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,500</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,500</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Sidransky</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Feb-04-2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Yohai Stenzler</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Jan-03-2016</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,625</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,625</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Guy Nehemya</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Jan-03-2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,625</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,625</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2a6b5f46_de28_450b_a809_a1d8e9f3d522"></a><a id="ITEM7MajorShareholdersandRelatedPartyTra"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;7. Major Shareholders and Related Party Transactions.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">A.</b></span><b style="font-weight:bold;">Major Shareholders.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except as set forth in &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;E. Share Ownership,&#8221; to the best of our knowledge, no other person who we know beneficially owns 5% or more of the Company&#8217;s ordinary shares outstanding as of February&#160;28, 2021, the latest practicable date for inclusion in this annual report. None of our shareholders has different voting rights from other shareholders. Other than as described herein, to the best of our knowledge, we are not owned or controlled, directly or indirectly, by another corporation, by any foreign government or by any natural person or legal persons, severally or jointly, and we are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">B.</b></span><b style="font-weight:bold;">Related Party Transactions.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a summary description of the material terms of those transactions with related parties to which we, or our subsidiaries, are party and which were in effect since January&#160;1, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financing Agreement with GRD</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have provided financing to GRD from time to time, pursuant to which the Company and GRD have executed several capital notes for an aggregate outstanding principal amount of $131.8 million. The par value of such notes is in NIS, and they bear no interest nor repayment date; provided, however, that no repayment shall be made before the fifth anniversary from the issuance date of each note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agreements with Directors and Officers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Employment and Consulting Agreements</i>. We have entered into written employment or consulting agreements with certain of our Office Holders. These agreements provide for notice periods of varying duration for termination of the agreement by us or by the relevant Office Holder, during which time the Office Holder will continue to receive base salary and benefits. We have also entered into customary non-competition, confidentiality of information and ownership of inventions arrangements with these Office Holders. However, the enforceability of the noncompetition provisions may be limited under applicable law.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Options. </i>Since our inception, we have granted options to purchase our ordinary shares to certain of our Office Holders. Such option agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. See also &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;E. Share Ownership&#8221;. We describe our 2013 Plan under &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;B. Compensation&#8212;2013 Incentive Share Option Plan.&#8221; If the relationship between us and an Office Holder is terminated except for &#8220;cause&#8221; (as defined in the 2013 Plan and/or the applicable option award agreement), options that are vested will generally remain exercisable for 90&#160;days after such termination; provided, however, that prior to the date of such termination, our remuneration committee may authorize an extension of the terms of all or part of the vested options beyond the date of such termination for a period not to exceed the period during which the options by their terms would otherwise have been exercisable, and provided further that the vested options may lose their status as incentive stock options and/or approved 102 options if such extension extends beyond the maximum extension authorized by the Ordinance or the Code, as applicable<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RSUs.</i> We have granted RSUs to certain of our Office Holders. Such award agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. See also &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;E. Share Ownership.&#8221; We describe our 2013 Plan under &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;B. Compensation&#8212;2013 Incentive Share Option Plan.&#8221; If the relationship between us and an Office Holder is terminated, RSUs that are vested shall be settled in accordance with the settlement schedule set forth in the applicable award agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">C.</b></span><b style="font-weight:bold;">Interests of Experts and Counsel.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1b50a8d7_2f14_45e7_9221_8122950a4995"></a><a id="ITEM8FinancialInformation_119041"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;8. Financial Information.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">A.</b></span><b style="font-weight:bold;">Consolidated Financial Statements and Other Financial Information.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item&#160;18. Financial Statements&#8221; for a list of all financial statements filed as part of this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are neither party to any legal or arbitration proceedings, including those relating to bankruptcy, receivership or similar proceedings and those involving any third-party, nor any governmental proceedings pending or known to be contemplated, which may have, or have had in the recent past, significant effects on the Company&#8217;s financial position or profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividend Policy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our ordinary shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our Board and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our Board may deem relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payment of dividends may also be subject to Israeli withholding taxes. See &#8220;Item&#160;10. Additional Information&#8212;E. Taxation&#8212;Certain Israeli Tax Considerations&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">B.</b></span><b style="font-weight:bold;">Significant Changes.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">No significant changes with respect to our consolidated financial statements have occurred since December&#160;31, 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c86297ce_4cda_49c4_9bc7_f11111093d5a"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM9TheOfferandListing_475955"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;9. The Offer and Listing.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">A.4</b></span><b style="font-weight:bold;">Offer and Listing Details</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ordinary shares have been listed on the Nasdaq Capital Market under the symbol &#8220;GLMD&#8221; since March&#160;13, 2014. Prior to that date, there was no public trading market for our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">B.</b></span><b style="font-weight:bold;">Plan of Distribution</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">C.</b></span><b style="font-weight:bold;">Market for Ordinary Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ordinary shares have been quoted on the NASDAQ Capital Market since March&#160;18, 2014 under the symbol &#8220;GLMD.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">D.</b></span><b style="font-weight:bold;">Selling Shareholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">E.</b></span><b style="font-weight:bold;">Dilution</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">F.</b></span><b style="font-weight:bold;">Expenses of the issue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f0611004_2523_4eba_a8eb_bd8c536260af"></a><a id="ITEM10AdditionalInformation_98709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;10. Additional Information.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">A.</b></span><b style="font-weight:bold;">Share Capital.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">B.</b></span><b style="font-weight:bold;">Memorandum and Articles of Association.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our registration number is 51-495351-2. At the 2014 annual general meeting of shareholders, our shareholders adopted our Articles, which became effective on the consummation of our initial public offering in the United States in March&#160;2014. Under Section&#160;2 of our Articles, the purpose of the Company is to engage in any lawful activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following description of our share capital and provisions of our Articles are summaries and do not purport to be complete and are qualified in their entirety by the complete text of the Articles, which are filed as exhibits to this annual report and incorporated by reference herein, and by Israeli law.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Election of Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board consists of three classes of directors, with one class being elected each&#160;year by shareholders at the Company&#8217;s annual general meeting for a term of approximately three&#160;years. In accordance with our Articles, directors so elected cannot be removed from office by the shareholders until the expiration of their term of office. Ordinary shares do not have cumulative voting rights. As a result, the holders of ordinary shares that represent a simple majority of the voting power represented at a shareholders&#8217; meeting and voting at the meeting have the power to elect all of the directors put forward for election. For further information as to these appointments, see &#8220;Item&#160;6<b style="font-weight:bold;">&#8212;</b>Directors, Senior Management and Employees&#8212;C. Board Practices.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under our Articles, a director shall vacate his or her office if that director dies; is declared bankrupt; is declared to be legally incompetent; resigns such office by notice in writing given to the Company; is not re-elected by the shareholders upon expiration of his or her term at the relevant annual general meeting of shareholders; or otherwise as provided in the Companies Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Articles provide that a director may, by written notice to the Company, appoint another person to serve as an alternate director provided that such appointment is approved by a majority of the directors then in office, and that such appointing director may remove such alternate director. Any alternate director shall be entitled to notice of meetings of the Board and of relevant committees and to attend and vote accordingly, except that the alternate has no standing at any meeting at which the appointing director is present or at which the appointing director is not entitled to participate as provided in the Companies Law. A person who is not qualified to be appointed as a director, or a person who already serves as a director or an alternate director, may not be appointed as an alternate director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless the appointing director limits the time or scope of the appointment, the appointment is effective for all purposes until the earlier of (i)&#160;the appointing director ceasing to be a director; (ii)&#160;the appointing director terminating the appointment; or (iii)&#160;the occurrence, with respect to the alternate, of any of the circumstances under which a director shall vacate his or her office. The appointment of an alternate director does not in itself diminish the responsibility of the appointing director as a director. An alternate director is solely responsible for his or her actions and omissions and is not deemed an agent of the appointing director. See &#8220;Item&#160;6<b style="font-weight:bold;">&#8212;</b>Directors, Senior Management and Employees&#8212;C. Board Practices.&#8221; At present, there are no effective appointments of alternate directors for our Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Borrowing Powers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board may from time to time, and at its reasonable discretion, borrow or secure the payment of any sum or sums of money for reasonable Company purposes. The directors may raise or secure the repayment of such sum or sums in such manner, at such times and upon such terms and conditions in all respects as they see fit and, in particular, by issuing bonds, perpetual or redeemable debentures, debenture stock or any mortgages, charges or other securities on the undertaking of the whole or any part of the property of the Company, both present and future, including current uncalled capital and called but unpaid capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For discussions relating to certain compensation-related requirements of the Companies Law, external directors and financial experts, committees of the Board, and exculpation and indemnification of directors and officers, see &#8220;Item&#160;6&#160;- Directors, Senior Management and Employees.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fiduciary Duties of Directors and Executive Officers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Companies Law codifies the fiduciary duties that Office Holders owe to a company. Each person listed in the table under &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;A. Directors and Senior Management&#8221; is an Office Holder under the Companies Law.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An Office Holder&#8217;s fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an Office Holder to act with the level of care with which a reasonable Office Holder in the same position would have acted under the same circumstances. The duty of loyalty requires that an Office Holder act in good faith and in the best interests of a company. The duty of care includes a duty to use reasonable means to obtain:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">all other important information pertaining to these actions.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The duty of loyalty requires an Office Holder to act in good faith and for the benefit of a company, and includes a duty to:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">refrain from any activity that is competitive with the company;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">disclose to the company any information or documents relating to the company<span style="font-family:'Symbol';">&#8217;</span>s affairs which the Office Holder received as a result of his or her position as an Office Holder.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disclosure of Personal Interests of an Office Holder</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Companies Law requires that an Office Holder promptly disclose to the board of directors any personal interest that he or she may have concerning any existing or proposed transaction with a company, as well as any substantial information or document with respect thereof. An interested Office Holder&#8217;s disclosure must be made promptly and, in any event, no later than the first meeting of the board of directors at which the transaction is considered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, a &#8220;personal interest&#8221; &#160;includes an interest of any person in an action or transaction of a company, including a personal interest of one&#8217;s relative or of a corporate body in which such person or a relative of such person is a 5% or greater shareholder, director or general manager or in which he or she has the right to appoint at least one director or the general manager, but excluding a personal interest stemming from one&#8217;s ownership of shares in a company. A personal interest furthermore includes the personal interest of a person for whom the Office Holder holds a voting proxy or the interest of the Office Holder with respect to his or her vote on behalf of the shareholder for whom he or she holds a proxy, even if such shareholder itself has no personal interest in the approval of the matter. An Office Holder is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of a relative of such Office Holder in a transaction that is not considered an extraordinary transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, an extraordinary transaction is defined as any of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a transaction other than in the ordinary course of business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a transaction that is not on market terms; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a transaction that may have a material impact on a company&#8217;s profitability, assets or liabilities.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Approval Procedure</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If an Office Holder has a personal interest in a transaction, approval by the board of directors is required for the transaction, unless the articles of association of a company provide for a different method of approval. Our Articles do not provide for any such different method of approval. Further, so long as an Office Holder has disclosed his or her personal interest in a transaction, the board of directors may approve an action by the Office Holder that would otherwise be deemed a breach of the duty of loyalty. However, a company may not approve a transaction or action that is adverse to such company&#8217;s interest or that is not performed by the Office Holder in good faith. Approval first by a company&#8217;s audit committee and subsequently by the board of directors is required for an extraordinary transaction in which an Office Holder has a personal interest. Arrangements regarding the Office Holders&#8217; terms of office and employment (which includes compensation, indemnification or insurance) generally require the approval of the remuneration committee, board of directors and, in certain circumstances, the shareholders, in that order, and must generally be consistent with the Company&#8217;s Compensation Policy, as described under see &#8220;Item&#160;6<b style="font-weight:bold;">&#8212;</b>Directors, Senior Management and Employees&#8212;B. Compensation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, a person who has a personal interest in a matter which is considered at a meeting of the board of directors or the audit committee may not be present at such a meeting or vote on that matter unless a majority of the directors or members of the audit committee have a personal interest in the matter, or unless the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present in order to present the transaction that is subject to approval. Generally, if a majority of the members of the audit committee and the board of directors (as applicable) has a personal interest in the approval of a transaction, then all directors may participate in discussions of the audit committee and/or the board of directors on such transaction and the voting on approval thereof, but shareholder approval is also required for such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transactions with Controlling Shareholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Israeli law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling shareholder of a public company. In the context of a transaction involving a controlling shareholder or an officer who is a controlling shareholder of a company, a controlling shareholder also includes any shareholder who holds 25% or more of the voting rights if no other shareholder holds more than 50% of the voting rights. Two or more shareholders with a personal interest in the approval of the same transaction are deemed to be a single shareholder and may be deemed a controlling shareholder for the purpose of approving such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Extraordinary Transactions, including private placement transactions, with a controlling shareholder or in which a controlling shareholder has a personal interest, and engagements with a controlling shareholder or his or her relative, directly or indirectly, including through a corporation under his or her control, regarding the company&#8217;s receipt of services from the controlling shareholder, and if such controlling shareholder is also an office holder or an employee of the company, regarding his or her terms of service or employment, require the approval of the audit committee or remuneration committee, the board of directors and the shareholders of a company by a Special Majority, in that order.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Arrangements regarding the terms of office and employment of a controlling shareholder who is an Office Holder, and the terms of employment of a controlling shareholder who is an employee of a company, require the approval of the remuneration committee, board of directors and the shareholders by a Special Majority, in that order, as further described above under &#8220;Item&#160;6<b style="font-weight:bold;">&#8212;</b>Directors, Senior Management and Employees&#8212;B. Compensation&#8221; with respect to Office Holders&#8217; compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent that any such transaction with a controlling shareholder is for a period extending beyond three&#160;years, approval is required once every three&#160;years, unless, with respect to extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, the audit committee determines that the duration of the transaction is reasonable given the circumstances related thereto.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividends and Dividend Policy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Dividends may be distributed only out of profits available for dividends as determined by the Companies Law, provided that there is no reasonable concern that the distribution will prevent the Company from being able to meet its existing and anticipated obligations when they become due. Under the Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over the two most recent&#160;years legally available for distribution. In the event that we do not have retained earnings or earnings generated over the two most recent&#160;years legally available for distribution, we may seek the approval of the court in order to distribute a dividend. The court may approve our request if it is convinced that there is no reasonable concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, under the Companies Law, the decision to distribute dividends and the amount to be distributed is made by a company&#8217;s board of directors. The Articles provide that the Board may from time to time declare, and cause the Company to pay, such dividends as may appear to it to be justified by the profits of the Company and that the Board has the authority to determine the time for payment of such dividends and the record date for determining the shareholders entitled to receive such dividends, provided the date is not before the date of the resolution to distribute the dividend. Declaration of dividends does not require shareholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to our Articles, subject to the rights of holders of shares with limited or preferred rights, ordinary shares shall confer upon the holders thereof equal rights to receive dividends and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our ordinary shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our Board and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our Board may deem relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payment of dividends may also be subject to Israeli withholding taxes. See &#8220;Taxation&#160;&#8212;&#160;Israeli Tax Considerations&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transfer of Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Ordinary shares which have been fully paid-up are transferable by submission of a proper instrument of transfer to the Company or its transfer agent together with the certificate of the shares to be transferred and such other evidence, if any, as the directors may require to prove the rights of the intending transferor in the transferred shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ordinary shares that are fully paid for are issued in registered form and may be freely transferred under our Articles, unless the transfer is restricted or prohibited by applicable law or the rules&#160;of a stock exchange on which the shares are traded. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our Articles or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, declared as enemies of Israel.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shareholder Meetings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Articles provide that an annual general meeting must be held at least once in every calendar&#160;year, not later than 15&#160;months after the last preceding annual general meeting, at such time and place as may be determined by the Board. The Board may, in its discretion, convene additional shareholder meetings and, pursuant to the Companies Law, must convene a meeting upon the demand of two directors or one quarter of the directors then in office or upon the demand of the holder or holders of 5% of the Company&#8217;s issued share capital and 1% of its voting rights or upon the demand of the holder or holders of 5% of its voting rights. All demands for shareholder meetings must set forth the items to be considered at that meeting. Pursuant to the Companies Law, the holder or holders of 1% of the Company&#8217;s voting rights may request the inclusion of an item on the agenda of a future shareholder meeting, provided the item is appropriate for discussion at a shareholder meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The agenda for a shareholder meeting is determined by the Board and must include matters in respect of which the convening of a shareholder meeting was demanded and any matter requested to be included by holder(s)&#160;of 1% of the Company&#8217;s voting rights. According to regulations promulgated pursuant to the Companies Law and governing the terms of notice and publication of shareholder meetings of public companies, or the General Meeting Regulations, holder(s)&#160;of one&#160;percent or more of the Company&#8217;s voting rights may propose any matter appropriate for deliberation at a shareholder meeting to be included on the agenda of a shareholder meeting, generally by submitting a proposal within seven&#160;days of publicizing the convening of a shareholder meeting, or, if the Company publishes a preliminary notice at least 21&#160;days prior to publicizing the convening of a meeting (stating its intention to convene such meeting and the agenda thereof), within 14&#160;days of such preliminary notice. Any such proposal must further comply with the information requirements under applicable law and the Articles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Companies Law and regulations promulgated thereunder with respect to the convening of general meetings in a public company, shareholder meetings generally require prior notice of not less than 21&#160;days, and for certain matters specified in the Companies Law, not less than 35&#160;days. The function of the annual general meeting is to elect directors in accordance with the Articles, receive and consider the profit and loss account, the balance sheet and the ordinary reports and accounts of the directors and auditors, appoint auditors and fix their remuneration and transact any other business which under the Articles or applicable law may be transacted by the shareholders of a company in general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Articles determine that the quorum required for either an annual (regular) or an extraordinary (special) general meeting of shareholders consists of at least two shareholders present in person or by proxy holding shares comprising in the aggregate more than 33.33% of the voting rights of the Company. If a meeting is convened by the Board upon the demand of shareholders or upon the demand of less than 50% of the directors then in office or directly by such shareholders or directors and no quorum is present within half an hour from the time appointed, it shall be cancelled. If a meeting is otherwise called and no quorum is present within such time, the meeting is adjourned to the same day one week later at the same time and place or at such other time and place as the Board may determine and specify in the notice of the general meeting and it shall not be necessary to give notice of such adjournment. If a quorum is not present within half an hour from the time stated for such adjourned meeting, any two shareholders present in person or by proxy at such meeting shall constitute a quorum even if, between them, they represent shares conferring 33.33% or less of the voting rights of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, under the Companies Law and the Articles, shareholder resolutions are deemed adopted if approved by the holders of a simple majority of the voting rights represented at a meeting and voting unless a different majority is required by law or pursuant to the Articles. The Companies Law provides that resolutions on certain matters, such as amending a company&#8217;s articles of association, assuming the authority of the board of directors in certain circumstances, appointing auditors, appointing external directors (if applicable), approving certain transactions, increasing or decreasing the registered share capital and approving most mergers must be made by the shareholders at a general meeting. A company may determine in its articles of association certain additional matters in respect of which resolutions by the shareholders in a general meeting will be required.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Access to Corporate Records</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, all shareholders generally have the right to review minutes of our general meetings, our shareholder register and register of significant shareholders (as defined in the Companies Law), our articles of association, our financial statements, other documents as provided in the Companies Law, and any document we are required by law to file publicly with the Israeli Companies Registrar. Any shareholder who specifies the purpose of its request may request to review any document in our possession that relates to: (i)&#160;any action or transaction with a related party which requires shareholder approval under the Companies Law; or (ii)&#160;the approval, by the board of directors, of an action in which an office holder has a personal interest. We may deny a request to review a document if we determine that the request was not made in good faith, or if such denial is necessary to protect our interest or protect a trade secret or patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shareholder Duties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward a company and other shareholders and to refrain from abusing his or her power in the company, including, among other things, in voting at the general meeting of shareholders and at class shareholder meetings with respect to the following matters:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">an amendment to the company&#8217;s articles of association;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">an increase of the company&#8217;s authorized share capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a merger; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">approval of interested party transactions and acts of Office Holders that require shareholder approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, a shareholder also has a general duty to refrain from discriminating against other shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain shareholders have a further duty of fairness toward a company. These shareholders include any controlling shareholder, any shareholder who knows that it has the power to determine the outcome of a shareholder vote or a shareholder class vote and any shareholder who has the power to appoint or to prevent the appointment of an Office Holder of the company or other power towards the company. The Companies Law does not define the substance of this duty of fairness, except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mergers and Acquisitions under Israeli Law</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">(i)&#160;Merger</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Companies Law permits merger transactions if approved by each party&#8217;s board of directors, and, unless certain requirements described under the Companies Law are met, a majority of each party&#8217;s shareholders, by a majority of each party&#8217;s shares that are voted on the proposed merger at a shareholders&#8217; meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The board of directors of a merging company is required pursuant to the Companies Law to discuss and determine whether in its opinion there exists a reasonable concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors, taking into account the financial condition of the merging companies. If the board of directors has determined that such a concern exists, it may not approve a proposed merger. Following the approval of the board of directors of each of the merging companies, the boards of directors must jointly prepare a merger proposal for submission to the Israeli Registrar of Companies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For purposes of the shareholder vote, unless a court rules&#160;otherwise, the merger will not be deemed approved if a majority of the shares voting at the shareholders meeting (excluding abstentions) that are held by parties other than the other party to the merger, any person who holds 25% or more of the means of control of the other party to the merger or any one on their behalf including their relatives or corporations controlled by any of them, vote against the merger. In addition, if the non-surviving entity of the merger has more than one class of shares, the merger must be approved by each class of shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the transaction would have been approved but for the separate approval of each class of shares or the exclusion of the votes of certain shareholders as provided above, a court may still rule&#160;that the company has approved the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the appraisal of the merging companies&#8217; value and the consideration offered to the shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, each merging company must send a copy of the proposed merger plan to its secured creditors. Unsecured creditors are entitled to receive notice of the merger, as provided by the regulations promulgated under the Companies Law. Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the target company. The court may also give instructions in order to secure the rights of creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, a merger may not be completed unless at least 50&#160;days have passed from the date that a proposal for approval of the merger was filed with the Israeli Registrar of Companies and 30&#160;days from the date that shareholder approval of both merging companies was obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">(ii)&#160;Special Tender Offer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This rule&#160;does not apply if there is already another holder of 25% or more of the voting rights in the company. Similarly, the Companies Law provides that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These requirements do not apply if the acquisition (i)&#160;occurs in the context of a private offering, on the condition that the shareholders&#8217; meeting approved the acquisition as a private offering whose purpose is to give the acquirer at least 25% of the voting rights in the company if there is no person who holds at least 25% of the voting rights in the company, or as a private offering whose purpose is to give the acquirer 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company; (ii)&#160;was from a shareholder holding at least 25% of the voting rights in the company and resulted in the acquirer becoming a holder of at least 25% of the voting rights in the company; or (iii)&#160;was from a holder of more than 45% of the voting rights in the company and resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The special tender offer may be consummated only if (i)&#160;at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired by the offeror and (ii)&#160;the special tender offer is accepted by a majority of the votes of those offerees who gave notice of their position in respect of the offer; in counting the votes of offerees, the votes of a holder of control in the offeror, a person who has personal interest in acceptance of the special tender offer, a holder of at least 25% of the voting rights in the company, or any person acting on their or on the offeror&#8217;s behalf, including their relatives or companies under their control, are not taken into account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that a special tender offer is made, a company&#8217;s board of directors is required to express its opinion on the advisability of the offer or shall abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. In addition, the board of directors must disclose any personal interest each of member of the board of directors have in the offer or stems therefrom.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An office holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing or foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential purchaser and shareholders for damages resulting from his acts, unless such office holder acted in good faith and had reasonable grounds to believe he or she was acting for the benefit of the company. However, office holders of the target company may negotiate with the potential purchaser in order to improve the terms of the special tender offer, and may further negotiate with third parties in order to obtain a competing offer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a special tender offer was accepted by a majority of the shareholders who announced their stand on such offer, then shareholders who did not respond to the special offer or had objected to the special tender offer may accept the offer within four&#160;days of the last day set for the acceptance of the offer. In the event that a special tender offer is accepted, then the purchaser or any person or entity controlling it and any corporation controlled by them shall refrain from making a subsequent tender offer for the purchase of shares of the target company and may not execute a merger with the target company for a period of one&#160;year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">(iii)&#160;Full Tender Offer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, a person may not acquire shares in a public company if, after the acquisition, he will hold more than 90% of the shares or more than 90% of any class of shares of that company, unless a tender offer is made to purchase all of the shares or all of the shares of the particular class. The Companies Law also provides, subject to certain exceptions, that as long as a shareholder in a public company holds more than 90% of the company&#8217;s shares or of a class of shares, that shareholder shall be precluded from purchasing any additional shares unless tendering an offer to purchase all of the outstanding shares of the company or the applicable class of the shares. If the shareholders who do not respond to or accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class of the shares, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will be accepted if the shareholders who do not accept it hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of the shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, has the right, within six&#160;months from the date of acceptance of the tender offer, to petition the court to determine that the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the purchaser may provide in its offer that an offeree who accepted the tender offer will not be entitled to such rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the conditions set forth above are not met, the purchaser may not acquire additional shares of the company from shareholders who accepted the tender offer to the extent that following such acquisition, the purchaser would own more than 90% of the company&#8217;s issued and outstanding share capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-Takeover Measures under Israeli Law</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights, distributions or other matters and shares having preemptive rights. As of the date hereof, no preferred shares are authorized under our Articles. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our Articles, which requires the affirmative vote of at least 75% of the voting rights of the Company represented personally or by proxy and voting thereon at a general meeting at which a quorum is present. The convening of the general meeting, the shareholders entitled to participate and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Articles and the Companies Law as described above in &#8220;&#8212; Shareholder Meetings.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, certain provisions of the Articles may have the effect of rendering more difficult or discouraging an acquisition of the Company deemed undesirable by the Board. The classification of the Board into three classes with terms of approximately three&#160;years each, may make it more difficult for shareholders who oppose the policies of the Board to remove a majority of the then current directors from office quickly. It may also, in some circumstances, together with the other provisions of the Articles and Israeli law, deter or delay potential future merger, acquisition, tender or takeover offers, proxy contests or changes in control or management of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in Capital</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The registered share capital of the Company is NIS 500,000 divided into 50,000,000 ordinary shares, NIS 0.01 par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Articles enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a resolution duly passed by our shareholders at a general meeting by voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits and an issuance of shares for less than their nominal value (under certain circumstances), require the approval of both our Board and an Israeli court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in Shareholder Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to our Articles, if at any time the share capital is divided into different classes of shares, the Company may by shareholder resolution, unless otherwise provided by the terms of issue of the shares of that class, modify, convert, broaden, add or otherwise alter the rights, privileges, advantages, restrictions and provisions related or unrelated at that time to the shares of any class with the sanction of a resolution passed by a simple majority of those present, personally or by proxy, and voting thereon at a separate general meeting of the holders of the shares of that class. Such majority approval is consistent with Israeli law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">C.</b></span><b style="font-weight:bold;">Material Contracts</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For a description of our material agreements relating to our strategic collaborations and research arrangements and other material agreements, please refer to &#8220;Item&#160;4.B. Information on the Company&#8212;Business Overview&#8212;Strategic Collaborations, Research Arrangements and other Material Agreements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;B. Compensation&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">D.</b></span><b style="font-weight:bold;">Exchange Controls.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are no Israeli government laws, decrees, regulations or other legislation that restrict or that affect our export or import of capital, including the availability of cash and cash equivalents for use by us and our wholly-owned subsidiaries, or the remittance of dividends, interest or other payments to non-resident holders of our securities, except for ownership by nationals of certain countries that are, or have been, declared as enemies of Israel or otherwise as set forth under &#8220;Item&#160;10. Additional Information&#8212;E. Taxation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">E.</b></span><b style="font-weight:bold;">Taxation.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition of our ordinary shares. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign, including Israel, or other taxing jurisdiction.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain Israeli Tax Considerations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a brief summary of the material Israeli income tax laws applicable to us. This section also contains a discussion of material Israeli tax consequences concerning the ownership and disposition of our ordinary shares. This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of this kind of investor include residents of Israel or investors in securities who are subject to special tax regimes not covered in this discussion. To the extent that the discussion is based on new tax legislation that has not yet been subject to judicial or administrative interpretation, we cannot assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion. This summary is based on laws and regulations in effect as of the date hereof and does not take into account possible future amendments which may be under consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General Corporate Tax Structure in Israel</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Israeli resident companies (as defined below), such as the Company, are generally subject to corporate tax at the rate of 23% on their taxable income, as of January&#160;1, 2020 (23% in 2019). However, the effective tax rate payable by a company that derives income from a Preferred Enterprise or a Technology Enterprise, as discussed below, may be considerably less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capital gains derived by an Israeli resident company are generally subject to tax at the same rate as the corporate tax rate. Under Israeli tax legislation, a corporation will be considered an &#8220;Israeli resident&#8221; if it meets one of the following: (i)&#160;it was incorporated in Israel; or (ii)&#160;the control and management of its business are exercised in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Law for the Encouragement of Industry (Taxes), 5729-1969</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Law for the Encouragement of Industry (Taxes), 5729-1969, which we refer to as the Industry Encouragement Law, provides several tax benefits for &#8220;Industrial Companies,&#8221; which are defined as Israeli resident-companies which were incorporated in Israel, of which 90% or more of their income in any tax&#160;year, other than income from certain government loans, is derived from an &#8220;Industrial Enterprise&#8221; that it owns and located in Israel or in the &quot;Area&quot;, in accordance with the definition under Section 3A of the Israeli Tax Ordinance. An &#8220;Industrial Enterprise&#8221; is defined as an enterprise whose principal activity in a given tax&#160;year is industrial production. Eligibility for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tax benefits, among others, are available to Industrial Companies:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">amortization over an eight&#160;year period of the cost of purchasing a patent, rights to use a patent and rights to know-how, which are used for the development or advancement of the company, commencing in the&#160;year in which such rights were first exercised;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">under limited conditions, an election to file consolidated tax returns with related Industrial Companies controlled by it; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">deductions of expenses related to a public offering in equal amounts over a three&#160;year period commencing on the&#160;year of the offering.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that we qualify as an &#8220;Industrial Company&#8221; within the meaning of the Industry Encouragement Law. There can be no assurance that we will continue to qualify as an Industrial Company in the future or that the benefits described above will be available to us at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Law for the Encouragement of Capital Investments, 5719-1959</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Law for the Encouragement of Capital Investments, 5719-1959, which we refer to as the Investment Law, provides certain incentives for capital investments in production facilities (or other eligible assets) by &quot;Industrial Enterprises&#8221; (as defined under the Investment Law). Generally, an investment program that is implemented in accordance with the provisions of the Investment Law, is entitled to benefits. These benefits may include cash grants from the Israeli government and tax benefits, based upon, among other things, the geographic location in Israel of the facility in which the investment is made. In order to qualify for these incentives, an Approved Enterprise, a Beneficiary Enterprise or a Preferred Enterprise is required to comply with the requirements of the Investment Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Investment Law was significantly amended effective April&#160;1, 2005, further amended as of January&#160;1, 2011, or the 2011 Amendment, and as of January&#160;1, 2017, or the 2017 Amendment. The 2011 Amendment introduced new benefits to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment. However, companies entitled to benefits under the Investment Law as in effect up to January&#160;1, 2011 were entitled to choose to continue to enjoy such benefits, provided that certain conditions are met, or elect instead, irrevocably, to forego such benefits and elect the benefits of the 2011 Amendment. The 2017 Amendment introduces new benefits for Technological Enterprises, alongside the existing tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following discussion is a summary of the Investment Law following its most recent amendments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Tax Benefits Under the 2011 Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2011 Amendment canceled the availability of the benefits granted to Industrial Companies under the Investment Law prior to 2011 and, instead, introduced new benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221; (as such terms are defined in the Investment Law) as of January&#160;1, 2011.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The definition of a Preferred Company includes a company incorporated in Israel that is not fully owned by a governmental entity, and that has, among other things, a Preferred Enterprise and is controlled and managed from Israel. Pursuant to the 2011 Amendment, beginning in 2014 and in each&#160;year thereafter until 2016, a Preferred Company may only be entitled to a reduced corporate tax rate of 16% with respect to its preferred income derived by its Preferred Enterprise, unless the Preferred Enterprise is located in a specified development zone, in which case the rate will be 9%. Pursuant to the 2017 Amendment, in 2017 and thereafter, the corporate tax rate for Preferred Enterprise which is located in a specified development zone was reduced to 7.5%, while the reduced corporate tax rate for other development zones remains 16%. Income derived by a Preferred Company from a &#8220;Special Preferred Enterprise&#8221; (as such term is defined in the Investment Law) would be entitled, during a benefit period of ten&#160;years, to further reduced tax rates of 8%, or 5% if the Special Preferred Enterprise is located in a certain development zone.&#160;As of January&#160;1, 2017, the definition for &#8216;Special Preferred Enterprise&#8217; includes less stringent conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of January&#160;1, 2014, dividends paid out of income attributed to a Preferred Enterprise or to a Special Preferred Enterprise are generally subject to withholding tax at source at the rate of 20% unless a lower tax rate is provided under an applicable tax treaty (subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for a reduced tax rate). However, if such dividends are paid to an Israeli company, no tax is required to be withheld (although, if such dividends are subsequently distributed to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower rate as may be provided in an applicable tax treaty will apply).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">New Tax benefits under the 2017 Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2017 Amendment was enacted as part of the Economic Efficiency Law that was published on December&#160;29, 2016, and is effective as of January&#160;1, 2017. The 2017 Amendment provides new tax benefits for two types of &#8220;Technology Enterprises&#8221;, as described below, and is in addition to the other existing tax beneficial programs under the Investment Law.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2017 Amendment provides that a technology company satisfying certain conditions will qualify as a &#8220;Preferred Technology Enterprise&#8221; and will thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as &#8220;Preferred Technology Income&#8221;, as defined in the Investment Law. The tax rate is further reduced to 7.5% for a Preferred Technology Enterprise located in development zone A. In addition, a Preferred Technology Company will enjoy a reduced corporate tax rate of 12% on capital gain derived from the sale of certain &#8220;Benefitted Intangible Assets&#8221; (as defined in the Investment Law) to a related foreign company if the Benefitted Intangible Assets were acquired from a foreign company on or after January 1, 2017 for at least NIS 200 million (approximately $56 million), and the sale receives prior approval from the National Authority for Technological Innovation &#160;(previously known as the Israeli Office of the Chief Scientist), to which we refer as IIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2017 Amendment further provides that a technology company satisfying certain conditions will qualify as a &#8220;Special Preferred Technology Enterprise&#8221; and will thereby enjoy a reduced corporate tax rate of 6% on &#8220;Preferred Technology Income&#8221; regardless of the company&#8217;s geographic location within Israel. In addition, a Special Preferred Technology Enterprise will enjoy a reduced corporate tax rate of 6% on capital gain derived from the sale of certain &#8220;Benefitted Intangible Assets&#8221; to a related foreign company if the Benefitted Intangible Assets were either developed by the Special Preferred Technology Enterprise or acquired from a foreign company on or after January 1, 2017, and the sale received prior approval from IIA. A Special Preferred Technology Enterprise that acquires Benefitted Intangible Assets from a foreign company for more than NIS 500 million will be eligible for these benefits for at least ten years, subject to certain approvals as specified in the Investment Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Dividends distributed by a Preferred Technology Enterprise or a Special Preferred Technology Enterprise, paid out of Preferred Technology Income, are subject to withholding tax at source at the rate of 20%, or such lower rate as may be provided in an applicable tax treaty (subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for a reduced tax rate). However, if such dividends are paid to an Israeli company, no tax is required to be withheld. If such dividends are distributed to a foreign parent company holding , alone or together with other foreign companies, at least 90% of the shares of the distributing company and other conditions are met, the withholding tax rate will be 4% (or a lower rate under a tax treaty, if applicable, subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After examining the impact of the 2017 Amendment, we submitted a request to receive a tax ruling from the Israel Tax Authority to be recognized as a Preferred Technology Enterprise and we received a tax ruling from the Israel Tax Authority granting GRD a Preferred Technology Enterprise status, subject to terms and conditions determined in the tax ruling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Taxation of Our Israeli Individual Shareholders on Receipt of Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Israeli residents who are individuals are generally subject to Israeli income tax for dividends paid on our ordinary shares (other than bonus shares or share dividends) at a rate of 25%, or 30% if the recipient of such dividend is a Substantial Shareholder (as defined below) at the time of distribution or at any time during the preceding 12 month period. However, dividends distributed from taxable income accrued from Preferred Enterprise or Preferred Technology Enterprise to Israeli individuals are subject to withholding tax at the rate of 20%. However, if such dividends are distributed to an Israeli company, no tax is imposed (although, if such dividends are subsequently distributed to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower rate as may be provided in an applicable tax treaty (subject to the receipt in advance of a valid certificate from the Israel Tax Authority (&quot;ITA&quot;) allowing for a reduced tax rate will apply). An average rate will be set in case the dividend is distributed from mixed types of income (regular and preferred income).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A &#8220;Substantial Shareholder&#8221; is generally a person who alone, or together with his or her relative or another person who collaborates with him or her on a regular basis, holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; of a corporation. &#8220;Means of control&#8221; generally include the right to vote, receive profits, nominate a director or an officer, receive assets upon liquidation or instruct someone who holds any of the aforesaid rights regarding the manner in which he or she is to exercise such right(s), all regardless of the source of such right.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With respect to individuals, the term &#8220;Israeli resident&#8221; is generally defined under Israeli tax legislation as a person whose center of life is in Israel. The Israeli Tax Ordinance (as amended by Amendment Law No.&#160;132 of 2002), states that in order to determine the center of life of an individual, consideration will be given to the individual&#8217;s family, economic and social connections, including: (i)&#160;place of permanent residence; (ii)&#160;place of residential dwelling of the individual and the individual&#8217;s immediate family; (iii)&#160;place of the individual&#8217;s regular or permanent occupation or the place of his or her permanent employment; (iv)&#160;place of the individual&#8217;s active and substantial economic interests; (v)&#160;place of the individual&#8217;s activities in organizations, associations and other institutions. The center of life of an individual will be presumed to be in Israel if: (i)&#160;the individual was present in Israel for 183&#160;days or more in the tax&#160;year; or (ii)&#160;the individual was present in Israel for 30&#160;days or more in the tax&#160;year, and the total period of the individual&#8217;s presence in Israel in that tax&#160;year and the two previous tax&#160;years is 425&#160;days or more. Such presumption may be rebutted either by the individual or by the assessing officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payers of dividends on our ordinary shares, including the Israeli stockbroker effectuating the transaction, or the financial institution through which the securities are held, are generally required, subject to any of the foregoing exemptions, reduced tax rates and the demonstration of a shareholder regarding his, her or its foreign residency, to withhold tax upon the distribution of dividend at the rate of 25% (whether the recipient is a Substantial Shareholder or not), so long as the shares are registered with a nominee company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Taxation of Israeli Resident Corporations on Payment of Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Israeli resident corporations are generally exempt from Israeli corporate income tax with respect to dividends paid on ordinary shares of Israeli resident corporations as long as the profits out of which the dividends were paid were derived in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Capital Gains Taxes Applicable to Israeli Resident Shareholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The income tax rate applicable to real capital gains derived by an Israeli individual resident from the sale of shares that were purchased after January&#160;1, 2012, whether listed on a stock exchange or not, is 25%. However, if such shareholder is considered a Substantial Shareholder at the time of sale or at any time during the preceding 12&#160;month period and/or claims a deduction for interest and linkage differences expenses in connection with the purchase and holding of such shares, such gain will be taxed at the rate of 30%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, capital gains derived by an individual shareholder who is a dealer or trader in securities, or to whom such income is otherwise taxable as ordinary business income, are taxed in Israel at their marginal rates applicable to business income (up to 50% in 2019 and 2020, including Excess Tax as detailed below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the sale of securities traded on a stock exchange, a detailed return, including a computation of the tax due, must be filed and an advanced payment must be paid on January&#160;31 and July&#160;31 of every tax&#160;year in respect of sales of securities made within the previous six&#160;months. However, if all tax due was withheld at source according to applicable provisions of the Israeli Tax Ordinance and regulations promulgated thereunder, the aforementioned return is not required to be filed and no advance payment must be paid. Capital gain is also reportable on the annual income tax return.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Taxation of Non-Israeli Shareholders on Receipt of Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Non-Israeli residents are generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25% (or 30% for individuals, if such person is a Substantial Shareholder at the time he or she receives the dividend or on any date in the 12&#160;months preceding such date), or 20% if the dividend is distributed from income attributed to Preferred Enterprise unless a lower rate is provided under an applicable tax treaty between Israel and the shareholder&#8217;s country of residence and provided that a certificate from the Israel Tax Authority allowing for a reduced withholding tax rate is obtained in advance.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A non-Israeli resident who has dividend income derived from or accrued in Israel, from which the full amount of tax was withheld at source, is generally exempt from the duty to file tax returns in Israel in respect of such income; provided that (i)&#160;such income was not derived from a business conducted in Israel by the taxpayer, (ii)&#160;the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed, and (iii)&#160;the taxpayer is not obligated to pay excess tax (as further explained below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For example, under the Convention Between the Government of the United States of America and the Government of Israel with Respect to Taxes on Income, as amended, or the U.S.-Israel Tax Treaty,&#160;Israeli withholding tax on dividends paid to a U.S. resident for treaty purposes may not, in general, exceed 25%, subject to certain conditions. Where the recipient is a U.S. corporation owning 10% or more of the voting shares of the paying corporation during the part of the paying corporation&#8217;s taxable&#160;year which precedes the date of payment of the dividend and during the entirety of its prior taxable&#160;year (if any), the Israeli tax withheld may not exceed 12.5%, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payers of dividends on our ordinary shares, including the Israeli stockbroker effectuating the transaction, or the financial institution through which the securities are held, are generally required, subject to any of the foregoing exemptions, reduced tax rates and the demonstration of a shareholder regarding his, her or its foreign residency, to withhold tax upon the distribution of dividend at the rate of 25% (whether the recipient is a Substantial Shareholder or not), so long as the shares are registered with a nominee company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Capital Gains Income Taxes Applicable to Non-Israeli Shareholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Non-Israeli resident shareholders are generally exempt from Israeli capital gains tax on any gains derived from the sale, exchange or disposition of our ordinary shares, provided that such shareholders did not acquire their shares prior to January&#160;1, 2009 or acquired their shares after the Company was listed for trading on NASDAQ and such gains were not derived from a permanent business or business activity of such shareholders in Israel. These provisions dealing with capital gain are not applicable to a person whose gains from selling or otherwise disposing of the shares are deemed to be business income. However, non-Israeli corporations will not be entitled to the foregoing exemptions if an Israeli resident (i)&#160;has a controlling interest of more than 25% in such non-Israeli corporation or (ii)&#160;is the beneficiary of or is entitled to 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example, under the U.S.-Israel Tax Treaty, the sale, exchange or disposition of our ordinary shares by a shareholder who is a U.S. resident (for purposes of the U.S.-Israel Tax Treaty) holding the ordinary shares as a capital asset and is entitled to claim the benefits afforded to such a resident by the U.S.-Israel Tax Treaty, or a Treaty U.S. Resident, is generally exempt from Israeli capital gains tax unless: (i)&#160;such Treaty U.S. Resident is an individual and was present in Israel for 183&#160;days or more in the aggregate during the relevant taxable&#160;year; (ii)&#160;such Treaty U.S. Resident holds, directly or indirectly, shares representing 10% or more of our voting power of the Company during any part of the 12&#160;month period preceding such sale, exchange or disposition, subject to certain conditions; (iii)&#160;the capital gains arising from such sale, exchange or disposition are attributable to a permanent establishment of the Treaty U.S. Resident maintained in Israel, subject to certain conditions; (iv)&#160;the capital gains arising from such sale, exchange or disposition is attributed to real estate located in Israel; or (v)&#160;the capital gains arising from such sale, exchange or disposition is attributed to royalties. In any such case, the sale, exchange or disposition of our ordinary shares would be subject to Israeli tax, to the extent applicable. However, under the U.S.-Israel Tax Treaty, such Treaty U.S. Resident would be permitted to claim a credit for such taxes against U.S. federal income tax imposed on any gain from such sale, exchange or disposition, under the circumstances and subject to the limitations specified in the U.S.-Israel Income Tax Treaty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Regardless of whether shareholders may be liable for Israeli income tax on the sale of our ordinary shares, the payment of the consideration may be subject to withholding of Israeli tax at the source. Accordingly, shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale. Specifically, in transactions involving a sale of all of the shares of an Israeli resident company, in the form of a merger or otherwise, the Israel Tax Authority may require from shareholders who are not liable for Israeli tax to sign declarations in forms specified by this authority or obtain a specific exemption from the Israel Tax Authority to confirm their status as non-Israeli resident, and, in the absence of such declarations or exemptions, may require the purchaser of the shares to withhold taxes at source.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Excess Tax</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Individuals who are subject to tax in Israel are also subject to an additional tax at a rate of 3% on annual income exceeding a certain threshold (NIS 651,600 for 2020, which amount is linked to the annual change in the Israeli consumer price index), including, but not limited to, dividends, interest and capital gains.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Estate and Gift Tax</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Israeli law presently does not impose estate or gift taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pre-Ruling Regarding a Reorganization of Our Corporate Structure</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Reorganization, as detailed under &#8220;Item&#160;4. Information on the Company&#8212;Historical Background and Corporate Structure&#8221; above, we obtained a pre-ruling from the Israel Tax Authority. The Tax Pre-Ruling confirms that the transfer of shares and assets resulting in the Company as the parent company and 100% equity-owner of GRD, which holds all the Group&#8217;s intellectual property, including the Company&#8217;s patent portfolio and GIL, is not taxable pursuant to the provisions of the Israeli Tax Ordinance as long as certain requirements are met. Pursuant to the Tax Pre-Ruling, certain restrictions under the Israeli tax laws were applied to the Company and its subsidiaries, as well as to those shareholders and option holders and other holders of rights in the share capital of the Company (on a diluted basis), who participated in the Reorganization and held such rights immediately after the consummation of the Reorganization, or the Rights Holders. In this section, each of the terms &#8220;Rights&#8221; and/or &#8220;share capital (on a diluted basis)&#8221; includes shares, options to purchase shares and any other &#8220;right&#8221; in &#8220;a body of persons&#8221; as such term is defined in the Israeli Tax Ordinance. These restrictions generally restrict these entities and Rights Holders from making any disposition of their Rights in the transferred assets and shares for a two-year period following the consummation of the Reorganization, which ended in February&#160;2016, or the Restriction Period. During the Restriction Period, these restrictions included the following:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Sale or otherwise disposition of our intellectual property, other than out-licensing in the ordinary course of business, was not permitted;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the Rights Holders immediately following the Reorganization must not have changed. Notwithstanding this restriction, so long as the aggregate holdings of the Rights Holders, collectively, was 51% or more of the total share capital of the Company at any time during the Restriction Period, certain changes in the holding<span style="font-family:'Symbol';">&#160;</span>percentages of the Rights Holders might have been permitted during the Restriction Period under the Israeli Tax Ordinance and guidelines issued by the Israel Tax Authorities;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the Rights Holders may not have sold or otherwise transfer or dispose of more than 10% of their respective Rights, subject to the exemptions and relief detailed below;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Sale or otherwise transfer or disposition of any of our shares in GHI or GIL, was not permitted; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">during the two tax<span style="font-family:'Symbol';">&#160;</span>years following the end of the<span style="font-family:'Symbol';">&#160;</span>year in which the Reorganization was completed we may not have offset losses (whether business or capital losses) incurred in the<span style="font-family:'Symbol';">&#160;</span>year in which the Reorganization was completed or in the<span style="font-family:'Symbol';">&#160;</span>years preceded that<span style="font-family:'Symbol';">&#160;</span>year up to the fair market value of the transferred asset.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, no deduction for tax purposes is allowed in relation to the Reorganization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If during the Restriction Period, we or the Rights Holders committed a violation, the transfer of shares or other rights and/or assets in connection with the Reorganization will become subject to taxation based on the greater of the transferred assets&#8217; fair market value on the day of such violation or taxes that, but for the Tax Pre-Ruling, would be payable in connection with the transfer of such assets and shares at the time of the Reorganization, linked to the Israeli consumer price index linkage differentials and interest from the day of the actual transfer of such assets and shares until the day of payment of such taxes, unless the Israel Tax Authority is satisfied that such violation was a result of special circumstances beyond our control. The Restriction Period ended on February&#160;2016, and to our knowledge, neither we nor any of the Right Holders has committed a violation during the Restriction Period pursuant to the terms and conditions of the Tax Pre Ruling.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain U.S. Federal Income Tax Considerations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a general summary of certain material U.S. federal income tax consequences relating to the purchase, ownership and disposition of our ordinary shares by U.S. Holders (as defined below). This summary is based on the Code, the regulations of the U.S. Department of the Treasury issued pursuant to the Code, or the Treasury Regulations, the income tax treaty between the United States and Israel, or the U.S.-Israel Tax Treaty, and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect, or to different interpretation. No ruling has been sought from the IRS with respect to any U.S. federal income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position. This summary is no substitute for consultation by prospective investors with their own tax advisors and does not constitute tax advice. This summary applies only to U.S. Holders that hold our ordinary shares as capital assets for U.S. federal income tax purposes (generally, property held for investment) and does not address all of the tax considerations that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax law (including, without limitation, banks, insurance companies, tax-exempt entities, retirement plans, regulated investment companies, partnerships, dealers in securities, brokers, real estate investment trusts, certain former citizens or residents of the United States, persons who acquire our ordinary shares as part of a straddle, hedge, conversion transaction or other integrated investment, persons who acquire our ordinary shares through the exercise or cancellation of employee stock options or otherwise as compensation for their services, persons that have a &#8220;functional currency&#8221; other than the U.S. dollar, persons that own (or are deemed to own, indirectly, or by attribution) 10% or more of our shares (by vote or value), or persons that mark their securities to market for U.S. federal income tax purposes). This summary does not address any U.S. state or local or non-U.S. tax considerations, any U.S. federal estate, gift or alternative minimum tax considerations, or any U.S. federal tax consequences other than U.S. federal income tax consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As used in this summary, the term &#8220;U.S. Holder&#8221; means a beneficial owner of our ordinary shares that is, for U.S. federal income tax purposes, (i)&#160;an individual citizen or resident of the United States, (ii)&#160;a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (iii)&#160;an estate the income of which is subject to U.S. federal income tax regardless of its source, or (iv)&#160;a trust with respect to which a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of its substantial decisions, or that has a valid election in effect under applicable Treasury Regulations to be treated as a &#8220;United States person.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our ordinary shares, the tax treatment of such entity or arrangement treated as a partnership and each person treated as a partner thereof generally will depend upon the status and activities of the entity and such person. A holder that is treated as a partnership for U.S. federal income tax purposes should consult its own tax advisor regarding the U.S. federal income tax considerations applicable to it and its partners of the purchase, ownership and disposition of our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prospective investors should be aware that this summary does not address the tax consequences to investors who are not U.S. Holders. Prospective investors should consult their own tax advisors as to the particular tax considerations applicable to them relating to the purchase, ownership and disposition of our ordinary shares, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Taxation of U.S. Holders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Distributions</i>. Subject to the discussion below under &#8220;Passive Foreign Investment Company,&#8221; a U.S. Holder that receives a distribution with respect to an ordinary share generally will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Israeli tax withheld from such distribution) when actually or constructively received to the extent of the U.S. Holder&#8217;s pro rata share of our current and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). Any distributions in excess of our earnings and profits will be applied against and will reduce (but not below zero) the U.S. Holder&#8217;s tax basis in its ordinary shares, and, to the extent they exceed that tax basis, will be treated as gain from the sale or exchange of our ordinary shares. We do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect that a distribution will be treated as a dividend even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules&#160;described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As noted above, we do not anticipate paying any cash dividends in the foreseeable future. If we were to pay dividends, we expect to pay such dividends in NIS. A dividend paid in NIS, including the amount of any Israeli taxes withheld, will be includible in a U.S. Holder&#8217;s income at a U.S. dollar amount calculated by reference to the exchange rate in effect on the date such dividend is received, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted to U.S. dollars on the date of receipt, a U.S. Holder generally will not recognize a foreign currency gain or loss. However, if the U.S. Holder converts the NIS into U.S. dollars on a later date, the U.S. Holder must include, in computing its income, any gain or loss resulting from any exchange rate fluctuations. The gain or loss will be equal to the difference between (i)&#160;the U.S. dollar value of the amount included in income when the dividend was received and (ii)&#160;the amount received on the conversion of the NIS into U.S. dollars. Such gain or loss generally will be ordinary income or loss and will be U.S. source income or loss for U.S. foreign tax credit purposes. U.S. Holders should consult their own tax advisors regarding the tax consequences to them if we pay dividends in NIS or any other non-U.S. currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to certain significant conditions and limitations, any Israeli taxes paid on or withheld from distributions from us and not refundable to a U.S. Holder may be credited against the U.S. Holder&#8217;s U.S. federal income tax liability or, alternatively, may be deducted from the U.S. Holder&#8217;s taxable income. The election to deduct, rather than credit, foreign taxes, is made on a&#160;year-by-year basis and applies to all foreign taxes paid by a U.S. Holder or withheld from a U.S. Holder that&#160;year. Dividends paid on our ordinary shares generally will constitute income from sources outside the United States and be categorized as &#8220;passive category income&#8221; or, in the case of some U.S. Holders, as &#8220;general category income&#8221; for U.S. foreign tax credit purposes. Because the rules&#160;governing foreign tax credits are complex, U.S. Holders should consult their own tax advisors regarding the availability of foreign tax credits in their particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Dividends paid on our ordinary shares will not be eligible for the &#8220;dividends-received&#8221; deduction generally allowed to corporate U.S. Holders with respect to dividends received from U.S. corporations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain distributions treated as dividends that are received by an individual U.S. Holder from a &#8220;qualified foreign corporation&#8221; may be classified as &#8220;qualified dividend income,&#8221;&#8201;&#8212;&#8201;which is generally taxed at the lower applicable long term capital gains rates provided certain holding period and other requirements are satisfied. A non-U.S. corporation (other than a PFIC for the taxable&#160;year in which the dividend is paid or the preceding taxable&#160;year) generally will be considered to be a qualified foreign corporation (i)&#160;if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information program, or (ii)&#160;with respect to any dividend it pays on stock which is readily tradable on an established securities market in the United States. As discussed below under &#8220;Passive Foreign Investment Company,&#8221; we believe that we were a PFIC for our 2020 taxable&#160;year and expect to be a PFIC for the 2021 taxable&#160;year. Because the PFIC determination is highly fact intensive, there can be no assurance that we will be a PFIC in 2021 or for any other taxable&#160;year. Our ordinary shares will generally be considered to be readily tradable on an established securities market in the United States if they are listed on the Nasdaq Capital Market, as we intend our ordinary shares will be. U.S. Holders should consult their own tax advisors regarding the availability of the lower rate for dividends paid with respect to our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The additional 3.8% &#8220;net investment income tax&#8221; (described below) may apply to dividends received by certain U.S. Holders who meet certain modified adjusted gross income thresholds.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sale, Exchange or Other Taxable Disposition of Ordinary Shares</i>. Subject to the discussion under &#8220;Passive Foreign Investment Company&#8221; below, a U.S. Holder generally will recognize capital gain or loss upon the sale, exchange, or other taxable disposition of our ordinary shares in an amount equal to the difference between the amount realized on the sale, exchange, or other taxable disposition and the U.S. Holder&#8217;s adjusted tax basis (determined under U.S. federal income tax rules) in such ordinary shares. This capital gain or loss will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period in our ordinary shares exceeds one&#160;year. Preferential tax rates for long-term capital gain (currently, with a maximum rate of 20%) will apply to individual U.S. Holders. The deductibility of capital losses is subject to limitations. The gain or loss generally will be income or loss from sources within the United States for U.S. foreign tax credit purposes, subject to certain possible exceptions under the U.S.-Israel Tax Treaty. The additional 3.8% &#8220;net investment income tax&#8221; (described below) may apply to gains recognized upon the sale, exchange, or other taxable disposition of our ordinary shares by certain U.S. Holders who meet certain modified adjusted gross income thresholds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of receiving currency other than U.S. dollars upon the disposition of their ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Passive Foreign Investment Company. </i>In general, a non-U.S. corporation will be treated as a PFIC for U.S. federal income tax purposes in any taxable&#160;year in which either (i)&#160;at least 75% of its gross income is &#8220;passive income,&#8221; or (ii)&#160;on average at least 50% of its assets by value produce passive income or are held for the production of passive income. Passive income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary investment of funds, including those raised in a public offering. Assets that produce or are held for the production of passive income may include cash, even if held as working capital or raised in a public offering, as well as marketable debt securities and other assets that may produce passive income. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A foreign corporation&#8217;s PFIC status is an annual determination that is based on tests that are factual in nature, and our status for any&#160;year will depend on our income, assets, and activities for such&#160;year. Based upon our review of our financial data, we believe that we were a PFIC for our 2020 taxable&#160;year and expect to be a PFIC for the 2021 taxable&#160;year. Because PFIC status is determined annually and is based on our income, assets and activities for the entire taxable&#160;year, it is not possible to determine with certainty whether we will be characterized as a PFIC for the 2021 taxable&#160;year until after the close of the&#160;year, and there can be no assurance that we will not be classified as a PFIC in any future&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Default PFIC Rules</i>. If we are a PFIC for any tax&#160;year, a U.S. Holder who does not make a timely &#8220;qualified electing fund&#8221; election, or &#8220;QEF election&#8221; or a mark-to-market election (as described below), referred to in this summary as a &#8220;Non-Electing U.S. Holder,&#8221; will be subject to special rules&#160;with respect to (i)&#160;any &#8220;excess distribution&#8221; (generally, the portion of any distributions received by the Non-Electing U.S. Holder on the ordinary shares in a taxable&#160;year in excess of 125% of the average annual distributions received by the Non-Electing U.S. Holder in the three preceding taxable&#160;years, or, if shorter, the Non-Electing U.S. Holder&#8217;s holding period for the ordinary shares), and (ii)&#160;any gain realized on the sale or other disposition of such ordinary shares. Under these rules:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the excess distribution or gain would be allocated ratably over the Non-Electing U.S. Holder<span style="font-family:'Symbol';">&#8217;</span>s holding period for such ordinary shares;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the amount allocated to the current taxable<span style="font-family:'Symbol';">&#160;</span>year and any<span style="font-family:'Symbol';">&#160;</span>year prior to us becoming a PFIC would be taxed as ordinary income; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the amount allocated to each of the other taxable<span style="font-family:'Symbol';">&#160;</span>years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that<span style="font-family:'Symbol';">&#160;</span>year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable<span style="font-family:'Symbol';">&#160;</span>year.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a Non-Electing U.S. Holder who is an individual dies while owning our ordinary shares, the Non-Electing U.S. Holder&#8217;s successor would be ineligible to receive a step-up in tax basis of such ordinary shares. Non-Electing U.S. Holders should consult their tax advisors regarding the application of the &#8220;net investment income tax&#8221; (described below) to their specific situation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent a distribution on our ordinary shares does not constitute an excess distribution to a Non-Electing U.S. Holder, such Non-Electing U.S. Holder generally will be required to include the amount of such distribution in gross income as a dividend to the extent of our current and/or accumulated earnings and profits (as determined for U.S. federal income tax purposes) that are not allocated to excess distributions. The tax consequences of such distributions are discussed above under &#8220;Taxation of U.S. Holders&#8212;Distributions.&#8221; Each U.S. Holder is encouraged to consult its own tax advisor with respect to the appropriate U.S. federal income tax treatment of any distribution on our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are treated as a PFIC for any taxable&#160;year during the holding period of a Non-Electing U.S. Holder, we will continue to be treated as a PFIC for all succeeding&#160;years during which the Non-Electing U.S. Holder is treated as a direct or indirect Non-Electing U.S. Holder even if we are not a PFIC for such&#160;years. A U.S. Holder is encouraged to consult its tax advisor with respect to any available elections that may be applicable in such a situation, including the &#8220;deemed sale&#8221; election of Code Section&#160;1298(b)(1)&#160;(which will be taxed under the adverse tax rules&#160;described above).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may invest in the equity of foreign corporations that are PFICs or may own subsidiaries that own PFICs. If we are classified as a PFIC, under attribution rules, U.S. Holders will be subject to the PFIC rules&#160;with respect to their indirect ownership interests in such PFICs, such that a disposition of the ordinary shares of the PFIC or receipt by us of a distribution from the PFIC generally will be treated as a deemed disposition of such ordinary shares or the deemed receipt of such distribution by the U.S. Holder, subject to taxation under the PFIC rules. There can be no assurance that a U.S. Holder will be able to make a QEF election or a mark-to-market election with respect to PFICs in which we invest. Each U.S. Holder is encouraged to consult its own tax advisor with respect to tax consequences of an investment by us in a corporation that is a PFIC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">QEF Election</i>. &#160;Certain adverse consequences of PFIC status can be mitigated for holders of our ordinary shares if a U.S. Holder makes a QEF election. A U.S. Holder who makes a timely QEF election, referred to in this disclosure as an &#8220;Electing U.S. Holder,&#8221; with respect to us must report for U.S. federal income tax purposes its pro rata share of our ordinary earnings and net capital gain, if any, for our taxable&#160;year that ends with or within the taxable&#160;year of the Electing U.S. Holder. The &#8220;net capital gain&#8221; of a PFIC is the excess, if any, of the PFIC&#8217;s net long-term capital gains over its net short-term capital losses. The amount so included in income generally will be treated as ordinary income to the extent of such Electing U.S. Holder&#8217;s allocable share of the PFIC&#8217;s ordinary earnings and as long-term capital gain to the extent of such Electing U.S. Holder&#8217;s allocable share of the PFIC&#8217;s net capital gains. Such Electing U.S. Holder generally will be required to translate such income into U.S. dollars based on the average exchange rate for the PFIC&#8217;s taxable&#160;year with respect to the PFIC&#8217;s functional currency. Such income generally will be treated as income from sources outside the United States for U.S. foreign tax credit purposes. Amounts previously included in income by such Electing U.S. Holder under the QEF rules&#160;generally will not be subject to tax when they are distributed to such Electing U.S. Holder. The Electing U.S. Holder&#8217;s tax basis in our ordinary shares generally will increase by any amounts so included under the QEF rules&#160;and decrease by any amounts not included in income when distributed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An Electing U.S. Holder will be subject to U.S. federal income tax on such amounts for each taxable&#160;year in which we are a PFIC, regardless of whether such amounts are actually distributed to such Electing U.S. Holder. However, an Electing U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If an Electing U.S. Holder is an individual, any such interest will be treated as non-deductible &#8220;personal interest.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any net operating losses or net capital losses of a PFIC will not pass through to the Electing U.S. Holder and will not offset any ordinary earnings or net capital gain of a PFIC recognized by Electing U.S. Holder in subsequent&#160;years.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">So long as an Electing U.S. Holder&#8217;s QEF election with respect to us is in effect with respect to the entire holding period for our ordinary shares, any gain or loss recognized by such Electing U.S. Holder on the sale, exchange or other disposition of such shares generally will be long-term capital gain or loss if such Electing U.S. Holder has held such shares for more than one&#160;year at the time of such sale, exchange or other disposition. Preferential tax rates for long-term capital gain (currently, a maximum rate of 20%) will apply to individual U.S. Holders. The deductibility of capital losses is subject to limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In general, a U.S. Holder must make a QEF election on or before the due date for filing its income tax return for the first&#160;year to which the QEF election is to apply. A U.S. Holder makes a QEF election by completing the relevant portions of and filing IRS Form&#160;8621 in accordance with the instructions thereto. Upon request, we expect to provide U.S. Holders with the information needed to complete IRS Form&#160;8621 (which form would be required to be filed with the IRS on an annual basis by the U.S. Holder) and to make and maintain a valid QEF election for any&#160;year in which we or any of our subsidiaries that we control is a PFIC. There is no assurance, however, that we will have timely knowledge of our status as a PFIC, or that the information that we provide will be adequate to allow U.S. Holders to make a QEF election. A QEF election will not apply to any taxable&#160;year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable&#160;year in which we become a PFIC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each U.S. Holder should consult its own tax advisor with respect to the advisability of, the tax consequences of, and the procedures for making a QEF election with respect to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Mark-to-Market Election</i>. Alternatively, if our ordinary shares are treated as &#8220;marketable stock,&#8221; a U.S. Holder would be allowed to make a &#8220;mark-to-market&#8221; election with respect to our ordinary shares, provided the U.S. Holder completes and files IRS Form&#160;8621 in accordance with the relevant instructions and related Treasury Regulations. If that election is made, the U.S. Holder generally would include as ordinary income in each taxable&#160;year the excess, if any, of the fair market value of our ordinary shares at the end of the taxable&#160;year over such holder&#8217;s adjusted tax basis in such ordinary shares. The U.S. Holder would also be permitted an ordinary loss in respect of the excess, if any, of the U.S. Holder&#8217;s adjusted tax basis in our ordinary shares over their fair market value at the end of the taxable&#160;year, but only to the extent of the net amount previously included in income as a result of the mark-to- market election. A U.S. Holder&#8217;s tax basis in our ordinary shares would be adjusted to reflect any such income or loss amount. Gain realized on the sale, exchange or other disposition of our ordinary shares would be treated as ordinary income, and any loss realized on the sale, exchange or other disposition of our ordinary shares would be treated as ordinary loss to the extent that such loss does not exceed the net mark-to-market gains previously included in income by the U.S. Holder, and any loss in excess of such amount will be treated as capital loss. Amounts treated as ordinary income will not be eligible for the favorable tax rates applicable to qualified dividend income or long-term capital gains.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, stock will be considered marketable stock if it is &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221; within the meaning of applicable Treasury Regulations. A class of stock is regularly traded on an exchange during any calendar&#160;year during which such class of stock is traded, other than in de minimis quantities, on at least 15&#160;days during each calendar quarter. To be marketable stock, our ordinary shares must be regularly traded on a qualifying exchange (i)&#160;in the United States that is registered with the SEC or a national market system established pursuant to the Exchange Act or (ii)&#160;outside the United States that is properly regulated and meets certain trading, listing, financial disclosure and other requirements. Our ordinary shares are expected to constitute &#8220;marketable stock&#8221; as long as they remain listed on the Nasdaq Capital Market and are regularly traded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A mark-to-market election will not apply to our ordinary shares held by a U.S. Holder for any taxable&#160;year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable&#160;year in which we become a PFIC. Such election will not apply to any PFIC subsidiary that we own. Each U.S. Holder is encouraged to consult its own tax advisor with respect to the availability and tax consequences of a mark-to-market election with respect to our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each U.S. Holder should consult its own tax adviser with respect to the applicability of the &#8220;net investment income tax&#8221; (discussed below) where a mark-to-market election is in effect.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, U.S. Holders should consult their tax advisors regarding the IRS information reporting and filing obligations that may arise as a result of the ownership of ordinary shares in a PFIC, including IRS Form&#160;8621,&#160;Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The U.S. federal income tax rules&#160;relating to PFICs, QEF elections, and mark-to market elections are complex. U.S. Holders are urged to consult their own tax advisors with respect to the purchase, ownership and disposition of our ordinary shares, any elections available with respect to such ordinary shares and the IRS information reporting obligations with respect to the purchase, ownership and disposition of our ordinary shares.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain Reporting Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain U.S. Holders may be required to file IRS Form&#160;926, Return by U.S. Transferor of Property to a Foreign Corporation and IRS Form&#160;5471,&#160;Information Return of U.S. Persons With Respect to Certain Foreign Corporations, reporting transfers of cash or other property to us and information relating to the U.S. Holder and us. Substantial penalties may be imposed upon a U.S. Holder that fails to comply. See also the discussion regarding Form&#160;8621,&#160;Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund, above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, certain U.S. Holders must report information on IRS Form&#160;8938, Statement of Specified Foreign Financial Assets, with respect to their investments in certain &#8220;specified foreign financial assets,&#8221; which would include an investment in our ordinary shares, if the aggregate value of all of those assets exceeds $50,000 on the last day of the taxable&#160;year (and in some circumstances, a higher threshold). This reporting requirement applies to individuals and certain U.S. entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">U.S. Holders who fail to report required information could become subject to substantial penalties. U.S. Holders should consult their tax advisors regarding the possible implications of these reporting requirements arising from their investment in our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Backup Withholding Tax and Information Reporting Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, information reporting requirements will apply to distributions on our ordinary shares or proceeds on the disposition of our ordinary shares paid within the United States (and, in certain cases, outside the United States) to U.S. Holders other than certain exempt recipients, such as corporations. Furthermore, backup withholding (currently at 24%) may apply to such amounts if the U.S. Holder fails to (i)&#160;provide a correct taxpayer identification number, (ii)&#160;report interest and dividends required to be shown on its U.S. federal income tax return, or (iii)&#160;make other appropriate certifications in the required manner. U.S. Holders who are required to establish their exempt status generally must provide such certification on IRS Form&#160;W-9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Backup withholding is not an additional tax. Amounts withheld as backup withholding from a payment may be credited against a U.S. Holder&#8217;s U.S. federal income tax liability and such U.S. Holder may obtain a refund of any excess amounts withheld by filing the appropriate claim for refund with the IRS and furnishing any required information in a timely manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Medicare Tax on Investment Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain U.S. persons, including individuals, estates and trusts, will be subject to an additional 3.8% Medicare tax, or &#8220;net investment income tax,&#8221; on unearned income. For individuals, the additional net investment income tax applies to the lesser of (i)&#160;&#8220;net investment income&#8221; or (ii)&#160;the excess of &#8220;modified adjusted gross income&#8221; over $200,000 ($250,000 if married and filing jointly or $125,000 if married and filing separately). &#8220;Net investment income&#8221; generally equals the taxpayer&#8217;s gross investment income reduced by the deductions that are allocable to such income. Investment income generally includes, among other things, passive income such as interest, dividends, annuities, royalties, rents, and capital gains. U.S. Holders are urged to consult their own tax advisors regarding the implications of the additional net investment income tax resulting from their ownership and disposition of our ordinary shares.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY&#160;BE OF IMPORTANCE TO A PROSPECTIVE INVESTOR. EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES RELATING TO THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES IN LIGHT OF THE INVESTOR&#8217;S OWN CIRCUMSTANCES,&#160;INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">F.</b></span><b style="font-weight:bold;">Dividends and Paying Agents.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">G.</b></span><b style="font-weight:bold;">Statements by Experts.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">H.</b></span><b style="font-weight:bold;">Documents on Display.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC. You may read and copy this annual report, including the related exhibits and schedules, and any document we file with the SEC at <span style="text-decoration:underline;text-decoration-color:#000000;">http://www.sec.gov.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a &#8220;foreign private issuer,&#8221; we are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements file reports with the SEC. Those other reports or other information may be inspected without charge at the locations described above. As a &#8220;foreign private issuer,&#8221; we are exempt from the rules&#160;under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions contained in Section&#160;16 of the Exchange Act with respect to their purchases and sales of ordinary shares. Furthermore, as a &#8220;foreign private issuer,&#8221; we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We maintain a corporate website at http://www.galmedpharma.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this annual report and does not constitute a part of this annual report. We have included our website address in this annual report solely as an inactive textual reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">I.</b></span><b style="font-weight:bold;">Subsidiary Information.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_bd860062_152c_4e72_b28c_aa6c24d2b1b4"></a><a id="ITEM11QuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;11. Quantitative and Qualitative Disclosures About Market Risk.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Quantitative and Qualitative Disclosure About Market Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position, results of operations or cash flows due to adverse changes in financial market prices and rates, including interest rates and foreign exchange rates, of financial instruments.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our foreign currency exposures give rise to market risk associated with exchange rate movements of the Euro and NIS mainly against the U.S. dollar because a large portion of our expenses are denominated in Euros and NIS. Our Euro expenses consist principally of payments made to sub-contractors and consultants for pre-clinical studies, clinical trials and other research and development activities. Our NIS expenses consist principally of payments made to employees, subcontractors and consultants for pre-clinical studies, clinical trials, professional services, other research and development activities and general and administrative activities. We anticipate that a large portion of our expenses will continue to be denominated in currencies other than the U.S. dollar. Our financial position, results of operations and cash flow are subject to fluctuations due to changes in foreign currency exchange rates. Our results of operations and cash flow are, therefore, subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. Approximately 25% of our expected expenses are denominated in NIS. Changes of 5% and 10% in the U.S. dollar to NIS exchange rate will increase/decrease our operation expenses by 1.25% and 2.5%, respectively. Approximately 10% of our expected expenses are denominated in Euros, and another 10% are denominated in GBP. Changes of 5% and 10% in the U.S. dollar to Euro exchange rate and in the U.S. dollar to GBP exchange rate, will increase/decrease our operation expenses by 1.0% and 2.0%, respectively. To date, fluctuations in the exchange rates have not materially affected our results of operations or financial condition for the periods under review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have not engaged in hedging our foreign currency exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Rate Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. We currently do not hedge interest rate exposure. Because of the short-term maturities of our cash equivalents and investment securities, we do not believe that an increase in market rates would have any significant impact on the realized value of our investment securities. If a 10% change in interest rates were to have occurred on December&#160;31, 2020, this change would not have had a material effect on the fair value of our investment portfolio as of that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We do not believe that our cash and cash equivalents and available for sale investments have significant risk of default or illiquidity. While we believe our cash, cash equivalents and available for sale investments do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a28915e0_a76e_48fe_ac0c_8eecf9a81704"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM12DescriptionofSecuritiesOtherThanEq"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;12. Description of Securities Other Than Equity Securities.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">A.</b></span><b style="font-weight:bold;">Debt Securities.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">B.</b></span><b style="font-weight:bold;">Warrants and Rights.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">C.</b></span><b style="font-weight:bold;">Other Securities.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">D.</b></span><b style="font-weight:bold;">American Depositary Shares.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c989b57d_790f_4633_a98b_cccbf9f49949"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTII_623688"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;II</b></p><a id="ITEM13DefaultsDividendArrearagesandDelin"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;13. Defaults, Dividend Arrearages and Delinquencies.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ccb98421_201d_4b48_9532_ba14163e4358"></a><a id="ITEM14MaterialModificationstotheRightsof"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;14. Material Modifications to the Rights of Security Holders and Use of Proceeds.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0368e01e_940c_4141_9dff_48dad0cd540e"></a><a id="ITEM15ControlsandProcedures_799339"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;15. Controls and Procedures.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disclosure Controls and Procedures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We performed an evaluation of the effectiveness of our disclosure controls and procedures that are designed to ensure that information required to be disclosed in this annual report and filed with the SEC is recorded, processed, summarized and reported timely within the time period specified in the SEC&#8217;s rules&#160;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act, is accumulated and communicated to the issuer&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. There can be no assurance that our disclosure controls and procedures will detect or uncover all failures of persons within our Company to disclose information otherwise required to be set forth in our reports. Nevertheless, our disclosure controls and procedures are designed to provide reasonable assurance of achieving the desired control objectives. Based on our evaluation, our management, including our President, Chief Executive Officer and Chairman and Chief Financial Officer, have concluded that our disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15(d)-15(e)&#160;of the Exchange Act) as of the end of the period covered by this annual report are effective at such reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rule&#160;13a-15(f)&#160;or 15d-15(f)&#160;promulgated under the Exchange Act as a process designed by, or under the supervision of, the company&#8217;s principal executive and principal financial officers and effected by the company&#8217;s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transaction and dispositions of the assets of the company;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company<span style="font-family:'Symbol';">&#8217;</span>s assets that could have a material effect on the financial statements.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2020. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on that assessment, our management concluded that as of December&#160;31, 2020, our internal control over financial reporting was effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Attestation Report of the Registered Public Accounting Firm</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The effectiveness of our internal control over financial reporting as of December&#160;31, 2020 has been audited by Brightman Almagor Zohar&#160;&amp; Co., Member of Deloitte Touche Tohmatsu Limited, an independent registered public accounting firm, as stated in their report included elsewhere in this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in Internal Controls Over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There were no changes in our internal control over financial reporting that occurred during the&#160;year ended December&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_b14dac91_b873_44ca_974d_ec10e7f8ad8e"></a><a id="ITEM16RESERVED_241701"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;16. [RESERVED]</b></p><a id="_6278964a_c671_4a19_8e69_d320f15d5386"></a><a id="ITEM16AAuditCommitteeFinancialExpert_149"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;16A. Audit Committee Financial Expert.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our Board has determined that [Mr. Poshinski] qualifies as an audit committee financial expert pursuant to the applicable SEC rules and that Mr. Poshinski is &#8220;independent&#8221; in accordance with the Nasdaq Capital Market corporate governance requirements. For information relating to Mr. Poshinski&#8217;s qualifications and experience, see &#8220;Item 6. Directors, Senior Management and Employees&#8212;A. Directors and Senior Management.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_932c5865_41c7_45a9_aaf8_a68ce8566434"></a><a id="ITEM16BCodeofEthics_218288"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;16B. Code of Ethics.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have adopted a Code of Business Conduct and Ethics applicable to all of our directors and employees, including our President, Chief Executive Officer and Chairman, Chief Financial Officer, controller or principal accounting officer or other persons performing similar functions, which is a &#8220;code of ethics&#8221; as defined in Item&#160;16B of Form&#160;20-F promulgated by the SEC and as required by the Nasdaq Listing Rules, which refers to Section&#160;406(c)&#160;of the Sarbanes-Oxley Act. Section&#160;406(c)&#160;of the Sarbanes-Oxley Act provides that a &#8220;code of ethics&#8221; means such standards as are reasonably necessary to promote (i)&#160;honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; (ii)&#160;full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the issuer; and (iii)&#160;compliance with applicable governmental rules&#160;and regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The full text of the Code of Business Conduct and Ethics is posted on our website at www.galmedpharma.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus and is not incorporated by reference herein. We will provide a copy of such code of ethics without charge upon request by mail or by telephone. If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the Code of Business Conduct and Ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules&#160;and regulations of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5979abe8_0e63_4569_9263_d9848e30d2e2"></a><a id="ITEM16CPrincipalAccountantFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;16C. Principal Accountant Fees and Services.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Brightman Almagor Zohar&#160;&amp; Co., a Firm in the Deloitte Global Network, an independent registered public accounting firm, served as our independent public accountants for the fiscal&#160;years ended December&#160;31, 2020 and 2019, for which audited financial statements appear in this annual report.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents the aggregate fees for professional services rendered by such accountants to us during their respective term as our principal accountants in 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(US$ in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(US$ in&#160;thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audit Fees (1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audit-Related fees (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Fees (3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">All other fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 132</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 119</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Includes professional services rendered in connection with the audit of our annual financial statements and the review of our interim financial statements.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Audit related services consist of services that were reasonably related to the performance of the audit or reviews of our financial statements and not included under &#8220;Audit Fees&#8221; above, including, principally, providing consents for registration statement filings.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Tax fees consist of services related to obtaining a tax ruling and applying for a grant.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Audit Committee Pre-Approval Policies and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">One of our audit committee&#8217;s main roles is to assist the board of directors in fulfilling its responsibility for oversight of the quality and integrity of the accounting, auditing and reporting practices of the Company. The audit committee oversees the appointment, compensation, and oversight of the public accounting firm engaged to prepare or issue an audit report on the financial statements of the Company. Our Board has delegated to the audit committee the power to pre-approve non-auditing services rendered by the Company&#8217;s independent auditors without the need for further approval by the board of directors. As such, our audit committee has adopted a pre-approval policy for the engagement of our independent registered public accounting firm to perform certain audit and non-audit services. Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the audit committee pre-approves annually a list of specific audit and non-audit services in the categories of audit services, audit-related services, tax services and other services that may be performed by our independent registered public accounting firm. The last pre-approval policy was adopted by our audit committee on March&#160;8, 2020 for a period of twelve&#160;months. Since its establishment in May&#160;2014, the audit committee has approved all of the audit-related fees, tax fees and all other fees. If a type of service that is to be provided by our auditors has not received such general pre-approval, it will require specific pre-approval by our audit committee. The policy prohibits retention of the independent registered public accounting firm to perform the prohibited non-audit functions defined in applicable SEC rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_0f99d3ab_8b40_4127_9808_d17dea6e8709"></a><a id="ITEM16DExemptionsfromtheListingStandards"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;16D. Exemptions from the Listing Standards for Audit Committees.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5778d021_9794_4260_9c47_76a79df9ecd6"></a><a id="ITEM16EPurchasesofEquitySecuritiesbytheI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_c41de604_7eca_41e0_8691_59e2989b3d36"></a><a id="ITEM16FChangeinRegistrantsCertifyingAcco"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;16F. Change in Registrant&#8217;s Certifying Accountant.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9cd5e2ea_1003_48a4_81fa_05366da89e32"></a><a id="ITEM16GCorporateGovernance_519265"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;16G. Corporate Governance.</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our shares are listed on the Nasdaq Capital Market under the symbol &#8220;GLMD.&#8221; In addition to the corporate governance requirements of the Sarbanes-Oxley Act and the related rules&#160;implemented by the SEC, we must comply with the Nasdaq Listing Rules. Under those Nasdaq Listing Rules, we may elect to follow certain corporate governance practices permitted under the Companies Law in lieu of compliance with corresponding corporate governance requirements otherwise imposed by the Nasdaq Listing Rules&#160;for U.S. domestic issuers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with Israeli law and practice, and subject to the exemption set forth in Rule&#160;5615 of the Nasdaq Listing Rules, we follow the provisions of the Companies Law, rather than the Nasdaq Listing Rules, with respect to the following requirements:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Distribution of certain reports to shareholders</i>. As opposed to the Nasdaq Listing Rules, which require listed issuers to make certain reports, such as annual reports, interim reports and quarterly reports, available to shareholders in one of a number of specific manners,&#160;Israeli law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders, but to make such reports available through a public website. In addition to making such reports available on a public website, we plan to make our audited financial statements available to our shareholders at our offices and will only mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt from the SEC&#8217;s proxy solicitation rules. See &#8220;Item&#160;10. Additional Information&#8212;Documents on Display&#8221; for a description of our Exchange Act reporting obligations.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Quorum</i>. While the Nasdaq Listing Rules&#160;require that the quorum for purposes of any meeting of the holders of a listed company&#8217;s common voting stock be no less than 33.33% of the company&#8217;s outstanding common voting stock, under Israeli law, a company is entitled to determine in its articles of association the number of shareholders and&#160;percentage of holdings required for a quorum at a shareholders meeting. Our articles of association provide that a quorum of two or more shareholders holding at least 33.33% of the voting rights in person or by proxy is required for commencement of business at a general meeting. However, the quorum set forth in our articles of association with respect to an adjourned meeting consists of any two shareholders present in person or by proxy even if, between them, they represent shares conferring 33.33% or less of the voting rights of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Nomination of directors.</i> With the exception of directors elected by our Board due to vacancy, our directors are elected by an annual meeting of our shareholders to hold office until the next annual meeting following three&#160;years from his or her election. See &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;C. Board Practices.&#8221; The nominations for directors, which are presented to our shareholders by our Board, are made by the nominating committee itself, in accordance with the provisions of Nasdaq Capital Market Listing Rule&#160;5605(e), our Articles and the Companies Law. </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Compensation of officers. </i>We follow the provisions of the Companies Law with respect to matters in connection with the composition and responsibilities of our remuneration committee, Office Holder compensation and any required approval by the shareholders of such compensation. Israeli law and our Articles do not require that the independent members of our Board, or a remuneration committee composed solely of independent members of our Board, determine an executive officer&#8217;s compensation, as is generally required under the Nasdaq Listing Rules&#160;with respect to the Chief Executive Officer and all other executive officers of a company. Instead, remuneration of Office Holders is determined and approved by our remuneration committee, and in general, by our Board as well, and in certain circumstances, by our shareholders, as detailed above. The requirements for shareholder approval of any Office Holder compensation, and the relevant majority or Special Majority for such approval, are all as set forth in the Companies Law. Thus, we seek shareholder approval for all corporate actions with respect to Office Holder compensation requiring such approval under the requirements of the Companies Law, including for our Compensation Policy and for certain Office Holder Compensation, rather than seeking approval for such corporate actions in accordance with Nasdaq Listing Rules. All members of our remuneration committee are independent directors under applicable Nasdaq Capital Market and SEC rules, as affirmatively determined by our Board. See &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;B. Compensation.&#8221;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Independent directors.</i> Although Israeli law does not require that a majority of the directors serving on our Board be &#8220;independent,&#8221; as defined under Nasdaq Capital Market Listing Rule 5605(a)(2), but rather requires we have at least two external directors who meet the requirements of the Companies Law, as described above under &#8220;Item 6. Directors, Senior Management and Employees&#8212;C. Board Practices&#8212;External Directors.&#8221;, following our &#8220;opt-out&#8221; of the requirement to appoint external directors, a majority of our Board is independent based on the Nasdaq Capital Market rules. We are required, however, to ensure that all members of our audit committee are &#8220;independent&#8221; under the applicable Nasdaq Capital Market and SEC criteria for independence (as we cannot exempt ourselves from compliance with that SEC independence requirement, despite our status as a foreign private issuer). Our independent directors&#8217; conduct regularly scheduled meetings at which only such independent directors are present, as required by the Nasdaq Listing Rules. Our Board has affirmatively determined that each of Mr. Nir, Mr. Poshinski, Dr. Sidransky and Dr. Brosgart qualifies as &#8220;independent&#8221; under the Nasdaq Capital Market independence standards.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Shareholder approval</i>. We will seek shareholder approval for all corporate actions requiring such approval under requirements of the Companies Law, rather than seeking approval for corporate actions in accordance with Nasdaq Capital Market Listing Rule&#160;5635. In particular, under this Nasdaq Capital Market rule, shareholder approval is generally required for: (i)&#160;an acquisition of shares or assets of another company that involves the issuance of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii)&#160;the issuance of shares leading to a change of control; (iii)&#160;adoption or amendment of equity compensation arrangements; and (iv)&#160;issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (or via sales by directors, officers or 5% shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares. By contrast, under the Companies Law, shareholder approval is required for, among other things: (i)&#160;transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company), for which approvals of the remuneration committee, board of directors and shareholders are all required, (ii)&#160;Extraordinary Transactions with controlling shareholders of publicly held companies, which require the special approval described under &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;C. Board Practices&#8212;Approval of Related Party Transactions under Israeli Law&#8212;Transactions with Controlling Shareholders,&#8221; and (iii)&#160;terms of office and employment or other engagement of the controlling shareholder of the Company or such controlling shareholder&#8217;s relative, which require the special approval described under &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;B. Compensation&#8221; and &#8220;Item&#160;6. Directors, Senior Management and Employees&#8212;C. Board Practices&#8212;Approval of Related Party Transactions under Israeli Law.&#8221; In addition, under the Companies Law, a merger requires approval of the shareholders of each of the merging companies. See also &#8220;Compensation of officers&#8221; above.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_67997425_b07f_45d3_b848_0e829e86e470"></a><a id="ITEM16HMineSafetyDisclosure_291077"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;16H. Mine Safety Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><a id="_contentSection_d1d62607_7d98_4261_939f_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_4d9a61e9_ba39_4ddc_bf9e_8544b290136b"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIII_556100"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;III</b></p><a id="ITEM17FinancialStatements_41502"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;17. Financial Statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have responded to Item&#160;18 in lieu of responding to this item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a249dfc2_952f_447a_8679_e0642066713b"></a><a id="ITEM18FinancialStatements_850188"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;18. Financial Statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Please refer to the financial statements beginning on page&#160;F-1. The following financial statements, financial statement schedules and related notes are filed as part of this annual report, together with the report of the independent registered public accounting firm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:bottom;width:10%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-1</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets_50758"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofOperations_43655"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Statements of Operations</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofComprehensiveLos"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Statements of Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofChangesinStockholdersEquity_"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Statements of Changes in Shareholders&#8217; Equity</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_484762"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-8</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Note1General_156977"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_d85056b4_8e2c_40e4_a6f7_e65d75a0609c"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To the shareholders and the Board of Directors of Galmed Pharmaceuticals Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Galmed Pharmaceuticals Ltd. and subsidiaries (the &quot;Company&quot;) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, shareholders&#39; equity and cash flows, for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the &quot;consolidated financial statements&quot;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#39;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 18, 2021, expressed an unqualified opinion on the Company&#39;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements are the responsibility of the Company&#39;s management. Our responsibility is to express an opinion on the Company&#39;s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Critical Audit Matter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Valuation of Level 2 Marketable Debt Securities Classified as Available-for-Sale&#8211; Refer to Note 3 to the consolidated financial statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Critical Audit Matter Description</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company invests its excess cash primarily in available-for-sale marketable debt securities. Investments in marketable debt securities classified as available-for-sale are reported at fair value in the financial statements. The investments that are categorized as level 2 investments totaled $14.7 million at December 31, 2020 and inherently involve management judgement in determining the fair value.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We identified the valuation of level 2 investments in marketable debt securities classified as available-for-sale as a critical audit matter because of the magnitude of these investments and due to the increased extent of audit effort in relation to our audit as a whole.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">How the Critical Audit Matter Was Addressed in the Audit</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our audit procedures related to the valuation of the fair value of investments in level 2 marketable debt securities classified as available-for-sale included the following, among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We tested the effectiveness of the Company&#8217;s controls over the valuation of investments in marketable debt securities classified as available-for-sale, including an assessment of the relevant controls at each service organization over the determination of fair value.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">With the assistance of our specialists experienced in the valuation of securities, we obtained independent estimates of the fair value of the investments in marketable debt securities classified as available-for-sale held by the Company as of December 31, 2020 and compared our estimates to the Company&#8217;s estimates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We agreed the recorded values of investments in marketable debt securities classified as available-for-sale to the fair values indicated in the service organizations&#39; balance confirmations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ Brightman Almagor Zohar &amp; Co.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Brightman Almagor Zohar&#160;&amp; Co.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Certified Public Accountants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A Firm in the Deloitte Global Network</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tel Aviv, Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">March&#160;18, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2013.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">To the shareholders and the Board of Directors of Galmed Pharmaceuticals&#160;Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Opinion on Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We have audited the internal control over financial reporting of Galmed Pharmaceuticals Ltd. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by COSO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2020, of the Company and our report dated March 18, 2021, expressed an unqualified opinion on those consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#39;s Report on Internal Control over Financing Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Definition and Limitations of Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the consolidated financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ Brightman Almagor Zohar &amp; Co.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Brightman Almagor Zohar&#160;&amp; Co.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Certified Public Accountants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">A Firm in the Deloitte Global Network</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tel Aviv, Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">March&#160;18, 2021</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_9732cbbb_b846_49cb_a57d_0b36a8f40583"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><a id="ConsolidatedBalanceSheets_50758"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-indent:0pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consolidated Balance Sheet</b>s</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">U.S. Dollars in thousands, except share data and per share data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_23015220_61a1_4c77_a2a2_336770e0a296"></a><a id="Tc_eLOT6epZMECqNv0vx5rcgw_1_4"></a><a id="Tc_fMPpu2_9_Eii-AEmRukXQw_2_4"></a><a id="Tc_lzTgPrkYmkKTi1c-fl23bw_2_7"></a><a id="Tc_uMwhkmtIKU6e-NZ2XCzSrA_3_0"></a><a id="Tc_UAUuGZKgSU-iUElNchOdrg_4_0"></a><a id="Tc_681a79TNtkCQVVqvG5w0-w_5_0"></a><a id="Tc_Uxb7iYpO40amVpNsUf4fTA_5_4"></a><a id="Tc_cFy6nERucE2kZ_I-TwOa-Q_5_7"></a><a id="Tc__SZ0ZnZ0H0eJwX9DCVXUUA_6_0"></a><a id="Tc_igg4gngGhkOQRWYe9ldkjg_6_2"></a><a id="Tc_qkkiAvgpBkWyw_7d5I-RtA_7_0"></a><a id="Tc_yc03-1swKU6IjyL4syOTBA_8_0"></a><a id="Tc_OnQMzE_7RUWyv6ZX4WkFrQ_8_2"></a><a id="Tc_ihOOaH87zU-efP2DmZSpGw_9_0"></a><a id="Tc_UCPYp3CD10W0xxOwq53YAA_9_2"></a><a id="Tc_z8EJo7ZEcE6pf99G7X0DGg_10_0"></a><a id="Tc_aobqxTg5ZEeLhAkYEHnzLQ_12_0"></a><a id="Tc_cHVqgONgIUuaMXxI4ImMxA_12_2"></a><a id="Tc_cBD_JfDHkkuDS61N9uoIcw_13_0"></a><a id="Tc_AwvMyL-oU0KOufVmDpzM5w_13_2"></a><a id="Tc_jbri6MNVNUifMuGJPCyF8g_14_0"></a><a id="Tc_zc9qj_WkiUm5h-xqphhfpQ_16_0"></a><a id="Tc_LQpFP3PUtUugbd7ntjwJow_16_4"></a><a id="Tc_UIfua76Zv0-RxaGUuNZ8Rw_16_7"></a><a id="Tc_mh7IuDN7sECA0WcGt8tybw_18_0"></a><a id="Tc_UGcBpuD4fEGjC6CxNq_DBA_20_0"></a><a id="Tc_0RQXnliXTky_92tw_uGAHg_21_0"></a><a id="Tc_MwrJ8u4Ys02yBdhzMVfC8A_21_4"></a><a id="Tc_6__GKainDkyuAAO2z1renw_21_7"></a><a id="Tc_ylw1tl49qkeQTClOwSX5ZA_22_0"></a><a id="Tc_OWxQQ6Ljc0i4lEuBcxKh-A_23_0"></a><a id="Tc_7HzBTqSR20alrNjtAu2GJQ_25_0"></a><a id="Tc_aIatBMu0KUWWrUw7QJE5ng_26_0"></a><a id="Tc_GefFjoUWe0yEwxuXenoqog_26_2"></a><a id="Tc_a26EMzdwMkGqglqMeGthtw_26_4"></a><a id="Tc__mHImV8160OZOi0JsY-4LA_26_7"></a><a id="Tc_YvCzpkp8IEKzDE0c4U9_mw_27_0"></a><a id="Tc_f-l-l-TwGESD-N1D6wl3dg_29_0"></a><a id="Tc_jwXMzUII7UObdDm6fl_PBQ_30_0"></a><a id="Tc_4O3YBUpAH0CGdN1iKuvwHg_31_0"></a><a id="Tc_SI2ohuCD7Em0kaaaIhfSKw_32_0"></a><a id="Tc_yGeBSYneXUeMVuA0kaSfHA_32_2"></a><a id="Tc_uU4HgAWiYkqLzR4quoRq2g_33_0"></a><a id="Tc_wY8PHx2I3ky-Ug9V5216pg_34_0"></a><a id="Tc_wyXoscE7sUe3dZqlwO6beA_35_0"></a><a id="Tc_ICig1YGskEaTcz-Y-jlmbw_36_0"></a><a id="Tc_WFscg1g2AkKbNjJHbwY6VQ_38_0"></a><a id="Tc_0nfbgVPMn0aujKbB35aPNQ_38_4"></a><a id="Tc_d1SotqbbY0C4YGuZJz3PjQ_38_7"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">As of  December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_J3ZBoe_aLUOS3jxMpASwpQ_5_5">6,947</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_F9pHdZeesUmNnm6mUH2w-Q_5_8">15,931</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc__xcTxNHNqU-ebX4_woyMyA_6_5">113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_XG4ofohjlECTere_DwmHLQ_6_8">112</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term deposits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_MAh0HofEak6zdLCKwiG9nQ_7_5">3,807</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_vl4UrMcoSEmqUvTQYdq9MA_7_8">27,938</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="Tc_yZEushpki0y9ymgosW97pA_8_5">40,132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="Tc_cFXyMHrwrU6LZq7vHySyNA_8_8">31,622</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="Tc_4a5gC2ATcU63yjOmVUw_Eg_9_5">812</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="Tc_mYNw0XJNCEGpz7JnDoDoXA_9_8">827</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_IfUM3ZrQjU-SRZVO0MNjdg_10_5">51,811</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_stLqw-OtoE-jEkPqGP6XkA_10_8">76,430</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_EUTJGaZZyESvu1NE-VuyyQ_12_5">394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_jVvhkXbK8E6JDPNf6_zXNg_12_8">538</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_mT4f31fTZEiR_fFFU-d22Q_13_5">176</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc__NfnVRXnMUufuUvxrnZP1A_13_8">171</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_0P2IQDCInk6qHtXrR3jQmg_14_5">570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_pCcM3cmA_UaCZZ1kGjZePQ_14_8">709</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_0_9NtOnm0EiNTt6mg9i3Eg_16_5">52,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_y-U4WDCmikSXUY7EdO4cSA_16_8">77,139</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_cv76LLIhNEmlyn4iYD4L-Q_21_5">7,046</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_td4GTnAqLECKOijRRWUWlQ_21_8">5,999</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_TA52ZINLKkCBS5e0PQTl5A_22_5">966</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_JtLzCgRIGkyVSRPjjlCIpw_22_8">935</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_XOxcI18DkkaOkOBfOPp_rg_23_5">8,012</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_Wz62b2DOjEOdZzuGO1oO5g_23_8">6,934</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_iTyVCmu8oEWjkhWfcSuBLQ_26_5">216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Bg53zFRgVUinMRdshyZ0bQ_26_8">352</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-current liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_hgDzp3KA-ECL2NC5dtshjg_27_5">216</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_6Wp4ddPyl0qAOqJy9Ukhwg_27_8">352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; equity</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ordinary shares, par value NIS <ix:nonFraction unitRef="Unit_Divide_ILS_shares_E36EhjGGZkK6K8BwwH-6kA" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_wQG1TzL070KsPsYmUyCK7g"><ix:nonFraction unitRef="Unit_Divide_ILS_shares_E36EhjGGZkK6K8BwwH-6kA" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Tpas9XLEnEiw7uYHuRuYQA">0.01</ix:nonFraction></ix:nonFraction> per share; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Authorized <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Epk3w1uPHEmwK6j-uRIdvQ"><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_DDSEHOAlnEOiJ2yCStmz2g">50,000,000</ix:nonFraction></ix:nonFraction> shares;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_MtEzE_Q_dkGNkQI2tGys-g;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Issued</span></span> and <span style="-sec-ix-hidden:Hidden_rsIlGj2fQ0e_29EHelK7pw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span>: <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_y3b4f-BUz0OfDi7Mk0P1yg">21,325,975</ix:nonFraction> shares as of December&#160;31,&#160;2020; <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_oHd8Psr3vEuxW6VCNsjsdg">21,139,385</ix:nonFraction> shares as of December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_sRR5dQpek0Cs4R0giSjERA_32_5">58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_OcnMGkrALEq8aBHJ3viM4Q_32_8">58</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional paid-in capital</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_zFW20VZlDkGH1dHUQx5q9A_33_5">179,530</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_WmqGjWNxdESp89l-kRRJ1Q_33_8">176,696</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated other comprehensive income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_i14MOyh8qEmHrY6zKs4oJA_34_5">272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_t6x70ABIjUuoqEXc_DWuuw_34_8">35</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_8LkmO03JfEKOqtlJyRJifQ_35_5">135,707</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_OERtDCJjPkSppdCDT5-NFQ_35_8">106,936</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_meipzxRYgk-OBm78yqVspw_36_5">44,153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3RkhSUEDAEC6Pn6vL7UMKA_36_8">69,853</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_k--SsWYE4EOWTTh6Bjm-Fg_38_5">52,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_cvxRqnVNoEiECwLkaGi7lQ_38_8">77,139</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Accompanying notes are an integral part of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_08291d9a_f519_4666_9412_ddadab3dab90"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_contentSection_7c99a47b_fed0_44b0_898e_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><a id="ConsolidatedStatementsofOperations_43655"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Consolidated Statements of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">U.S. Dollars in thousands, except share data and per share data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_778dfd24_94fa_452f_943f_f2b7b2c6b87c"></a><a id="Tc_-izCQZHKikq-tZTOdPsckA_1_4"></a><a id="Tc_8stlmRcjTEqOGAnzxRyD3Q_2_4"></a><a id="Tc_76ljFRR8r0ajD0PR-9iQIA_2_7"></a><a id="Tc_rCEmeSkUaEyVOBr1XReZtg_2_10"></a><a id="Tc_91qrKKzf4UWsr480jHCWZA_3_0"></a><a id="Tc_e6I8GeZRfEi0Oy84snSWWQ_3_2"></a><a id="Tc_Cu0jnkBvPUqPchUPCksE-g_3_4"></a><a id="Tc_TiOSSoPMoUy59YcOqxiAnQ_3_7"></a><a id="Tc__qTs70UnOUmx8gTYbXxFBA_3_10"></a><a id="Tc_7fJW3IzsmUmEZmFHDI68CQ_4_0"></a><a id="Tc_G2lDw1ceX0ebinv8SJWSIw_4_2"></a><a id="Tc_I_OX6p95KEip3MmEsDOMMA_5_0"></a><a id="Tc_kwfL7QZJjkeWD3XiccJ3-w_5_2"></a><a id="Tc_5uBhQ55oJUG1nukaCWNw7w_6_0"></a><a id="Tc_hM6F2zySakaOWYAal2PvOg_7_0"></a><a id="Tc_eV9djLogDUCqTRAgudJwOQ_7_2"></a><a id="Tc_aOArIDkiiUierk8y1hkXgw_8_0"></a><a id="Tc_z7rD4WFFk0GEehjz-D5MOw_9_0"></a><a id="Tc_GtiwsP-Dm02TcQ1VxPaKqQ_9_2"></a><a id="Tc_19ZmqthpckiqYngcIoRncQ_9_5"></a><a id="Tc_5EnAd0YdBUaitX_8sZrXNg_10_0"></a><a id="Tc_nyQbN7guj0CnywMbu8Dbtw_10_4"></a><a id="Tc_D2eRboCGFUaj-iMQdGvQBw_10_7"></a><a id="Tc_lXHuFKNVQkiXHvEyLp8N5A_10_10"></a><a id="Tc_AisfeKEwj0u5mzchrOT1Zg_12_0"></a><a id="Tc_lJsAW9kp7kyxfmMV_J4Ylg_12_4"></a><a id="Tc_2NngRMJ2d0-yvaAdGFbXgw_12_7"></a><a id="Tc_-MG7xNBMuUmlrFdUILo86w_12_10"></a><a id="Tc_0B6mvUBwNkeyg_CBlSivZQ_13_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="Tc_WdSZ94J5r0qbrO0d4aa6jA_3_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="Tc_B2CiRGghFEmYZGs7ZpUJ4Q_3_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_dNs8xQw0zEiEdL-4Y1yNtg_3_11">2,038</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_rhymIJ3CSkuzHFPt1uJ3TQ_4_5">26,082</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_UUIOLhQYpU-XuMcSggiy6w_4_8">18,180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_fXRcX1CJ9UK8g7XHAP6ckw_4_11">8,313</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_TllmsX4tG0-ic8A3d5o25g_5_5">4,128</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_jycHzRetX0ysBR_iViDppQ_5_8">4,196</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_5vYsDkhG1kmDbeopoReoIw_5_11">4,440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_kE2mXzDpgkqoKIUmGIUG8Q_6_5">30,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_yfz42jImMEemoM3kaMmCEA_6_8">22,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_UhKeTO-Dak6O2K_8h7RmPQ_6_11">10,715</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial income, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_3dK9cLx2i0SDu3C91F9m2Q_7_5">1,439</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_A--kVyLwQke1bVlaIletsw_7_8">1,915</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_vOM-Qt4x4E2I4ROwmDUp5w_7_11">934</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Loss before income taxes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_zQamIZ_5BkiP9zA0bZfjGQ_8_5">28,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_fqvpl9lah0W8lvoamYZgOQ_8_8">20,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_D-TSn__MmUWqNWjvfkiKGQ_8_11">9,781</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_4ikRECncWEaipV0Ug55arg_9_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_ScnW1DJPSkqBx-6mvqVofA_9_11">75</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_vb31lPPjpkyLk_pY6SnEZA_10_5">28,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_8a3FWEOD-UacIiyeWjonsA_10_8">20,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_pANKiftpb0q4wcGgNIBGDw_10_11">9,856</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="Tc_x8VDYROB7kqKZgBDSajXtw_12_5">1.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="Tc_JV0-8znpYUSq4mbTxZ6oCQ_12_8">0.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="Tc_DTrole_yjEG1v_Gx3LVytA_12_11">0.54</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average number of shares outstanding used in computing basic and diluted net loss per share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_fPDTsXGceUOZNLoFzg2bLA_13_5">21,280,787</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_KkXEetWXl0OzOJtR7Nfa3A_13_8">21,114,399</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_sEqVXekn8U6vrhMNTOml4A_13_11">18,137,689</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Accompanying notes are an integral part of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_a93ae809_1988_4965_98e4_192346acb4b5"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_contentSection_c2e8c688_2664_4a87_9b38_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><a id="ConsolidatedStatementsofComprehensiveLos"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Consolidated Statements of Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">U.S. Dollars in thousands, except share data and per share data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dd0ca3fd_a146_48bd_84d2_cd61916c06ff"></a><a id="Tc_8hFyIvzDXUO8tgcWmdikYQ_1_2"></a><a id="Tc_ORGeIb1fYEuKzj3hY3HPpQ_2_2"></a><a id="Tc_QyT2YLdFxUCzBVAf1qP92A_2_5"></a><a id="Tc_nQatgZYJ-kq2JW4yFbjbwg_2_8"></a><a id="Tc_haqLwqfJ-UK15-yBenypDA_3_0"></a><a id="Tc_VB5NsoOtpES9QBUMDwHFuQ_3_2"></a><a id="Tc_BHhaRMXPXUWrT1_7SIUcNQ_3_5"></a><a id="Tc_8jVqE2M4k0Wmyr3U2hylmQ_3_8"></a><a id="Tc_F9mSPhN3yUGLm9q1ZxDcGg_4_0"></a><a id="Tc_43QMBiBAX0aqBChz587pGw_5_0"></a><a id="Tc_UCOHq8PS20yGbcSjJTTclQ_6_0"></a><a id="Tc_0fABGIkuO0unBdS1UiutCQ_6_2"></a><a id="Tc_m9P3AbdeM0KBzC-UYCJtIQ_6_5"></a><a id="Tc_E8RDVk2rkEO_HnrvjblyKA_6_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_ntxV3p8P5U6aJqxZu6E1BQ_3_3">28,771</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_0BPtWol0REKICGKB99bzrw_3_6">20,461</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_dmY5g2jEikCSLpEwOlaxMw_3_9">9,856</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other comprehensive loss (income):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net unrealized loss (gain) on available for sale securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_Cek2vqyVdUqb9G_X5DcKvQ_5_3">237</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_wbkhbVYPE02nL8HrA7XFsg_5_6">46</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" sign="-" scale="3" id="Tc_99WWyHjvYUKFSjiClLN-Bg_5_9">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Comprehensive loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc__eEjBRPdUUSJN5jv1JalZQ_6_3">28,534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_xgvw-BlcnUioNvGTN70cJQ_6_6">20,415</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_KJbFAJMlWkG2lE3ArDKrlA_6_9">9,860</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Accompanying notes are an integral part of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_4ab7b8d0_aba4_45ca_9246_a686ffa0bf67"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><a id="StatementsofChangesinStockholdersEquity_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Statements of Changes in Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">U.S. Dollars in thousands, except share data and per share data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_805d1647_fa53_40aa_9276_96a740ae737d"></a><a id="Tc_cxFyXW_rl0-_sosOy7yBDQ_1_10"></a><a id="Tc_3AV4aC8U3kqneUqOOi9eAg_2_7"></a><a id="Tc_L5xqoQ1CHEaVC9swMEYBDw_2_10"></a><a id="Tc_sqNJhJ6amEiUSc-ofZfeJA_3_2"></a><a id="Tc_bYNlt0Bg5UyeGjKRJUZDDQ_3_7"></a><a id="Tc_HitJ3OQlAEGw836Qb1akQg_3_10"></a><a id="Tc_czuaWeFQy0qWTPTSFEGeYg_3_13"></a><a id="Tc_TpBCM_SF10Gv9llUUEctaQ_4_2"></a><a id="Tc_ivHtRYP2QUiMUjyZP94-LA_4_4"></a><a id="Tc_5yC8h_OYS0WX2sarvs_uKA_4_7"></a><a id="Tc_1qi1CYMVEU-0Yozy05fryg_4_10"></a><a id="Tc_sVvJP85be0qlpmL-7pez0g_4_13"></a><a id="Tc_7SzaeRneh0OP2RFEv31_Xw_4_16"></a><a id="Tc_x2RVHcWXPkqD49xkAOn19Q_6_0"></a><a id="Tc_XS5M9RG81k2DaJyv6FUz2g_6_4"></a><a id="Tc_Eete7_nftEG9LgMjQUUwIA_6_7"></a><a id="Tc_Y1H7Wb6mLkOTTgY4ix8XKg_6_10"></a><a id="Tc_6uh_OC_3Hkimwr4niAgDBw_6_13"></a><a id="Tc_ezIUYlk_Hk27F9AfNT9qQg_6_16"></a><a id="Tc_yzBXZZB-Tka-arokvqibFg_8_0"></a><a id="Tc_pZ1Ey-rUCEa6ahB8NxSyqw_8_2"></a><a id="Tc_lo4JlLpBaUGrZzNJkO_1yA_10_0"></a><a id="Tc_QnSZMhYnmkCsFCAroeY75Q_12_0"></a><a id="Tc_3pmLhkJPSUSQLoD8sv0Guw_12_2"></a><a id="Tc_BcL9AvyTzkK3_YWjL7RFDA_14_0"></a><a id="Tc_Djb9YBGB8UyBcXZljVm-xA_14_2"></a><a id="Tc_8-2HfD8OW0CqLkum_ur0ug_16_0"></a><a id="Tc_HcL8s_ZEFkqCLQXlV1zcCg_16_4"></a><a id="Tc_cBhi-KLvIk-iK1XrJ37GjQ_16_7"></a><a id="Tc_fSuZt_VTa0i3V6PpQmDsOg_16_10"></a><a id="Tc__gzjO5ZMMkG5ecn81Wfd4Q_16_13"></a><a id="Tc_yI0LkaB51kS6hxKVIw4Qyg_16_16"></a><a id="Tc_wTec1I6JWkSzfVK1VLG1nQ_18_0"></a><a id="Tc_2x0smvDLLUy90SWt4GkhQg_18_2"></a><a id="Tc_BFaUMt-rg02u2lF7Wj4SGg_20_0"></a><a id="Tc_aLkJ_cj4jUi_17OoRjbHFA_22_0"></a><a id="Tc_QuUUOKLQlEOxFIYBwFB0PQ_24_0"></a><a id="Tc_z05aIg145k2DdLDGfI00zQ_24_2"></a><a id="Tc_f6kBvjhlREeUVmbUrXs2Lw_26_0"></a><a id="Tc_hZ1krQ2YhUacW1Cfumf3cA_26_2"></a><a id="Tc_EH2qh0K2_ESlOHvS3rCUOA_28_0"></a><a id="Tc_PAPfde5-Jk6lKNJpk7nmPA_28_4"></a><a id="Tc_2-unKHZeukWYnAqdr9SHAg_28_7"></a><a id="Tc_vul0q23690GXHpcy72oHhw_28_10"></a><a id="Tc_0tbCCshAWkuX-d69lGkecA_28_13"></a><a id="Tc_dyJAUbkGb0yU8RZYkmznVg_28_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance - January 1, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IfcP6tZx7UKE8vBKiQjAlQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_FgV8t_RojkCi5QvYsZ79XA_6_2">21,018,919</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IfcP6tZx7UKE8vBKiQjAlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7m4yN5ALLUS2apJuXeC7DQ_6_5">58</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iVc9WKPPG0SD2INXCz2fdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_igAopGoAWkiEFY4psiagCw_6_8">174,322</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2O8hljvvqEmHT8dL4lkKJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_FfA0z97Z10C35FSm5Rh2uQ_6_11">11</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lpsu-F7wy0awRiq6md5Tpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_CIEkBaXpfEStxnMT-wi0Mw_6_14">86,475</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2018_lcF12gSU0kKvwhOz65xKKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_uis2YGG2oEeeKIiBNiL8Rw_6_17">87,894</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yZ1T_sP4_EeOFyO2pue5nQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="Tc_kr2B0B-tZ0iUlCIvrS7Q5Q_8_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VS3dcnkwpEuaFwkYh1LQkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="Tc_wpK3Vn1w0EOBV-UDxIf98w_8_8">2,231</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IsoQh3ECGUWn_hEoSfchBw" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="Tc_iNwrNK3Yh0KdHOkR_McymQ_8_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2oKKrX6nA0y6X8VJqCajsA" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="Tc_6FrO9moo0kKQM0zoKun-aQ_8_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="Tc_nANofCO_ZEi3IRFdIK9jxA_8_17">2,231</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of options and restricted stock units</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yZ1T_sP4_EeOFyO2pue5nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_AGbooUsRFkGgfYzq-yjbnA_10_2">120,466</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_eLB7w3VWGEaH55k7AS_AdA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;">(*)</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VS3dcnkwpEuaFwkYh1LQkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_3y-9Xb0YsUWGzdendcFBWg_10_8">143</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IsoQh3ECGUWn_hEoSfchBw" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_lrC4DCnh60Sp70xzEnOLgw_10_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2oKKrX6nA0y6X8VJqCajsA" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_dtelva1NmEO_j48CGa2FAw_10_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_iAku22sAhk6wNFgGbQrEow_10_17">143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unrealized loss on marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yZ1T_sP4_EeOFyO2pue5nQ" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_auXi_42NskmXCEpDRKi-1w_12_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VS3dcnkwpEuaFwkYh1LQkA" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_WiZ7euRe70WeP3rmaVScZQ_12_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IsoQh3ECGUWn_hEoSfchBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_CZVH-JzCUUmENmPfHj5vMA_12_11">46</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2oKKrX6nA0y6X8VJqCajsA" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_NsZOYGdXcES60Fdj1LWv_w_12_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_wa-uMaLc5U-To_kv3Y1Z6Q_12_17">46</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yZ1T_sP4_EeOFyO2pue5nQ" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="Tc_3s6BKObhP0WkO4q8Dgtvaw_14_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VS3dcnkwpEuaFwkYh1LQkA" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="Tc_BvMdY4KjYkO0HXkQR8OV_Q_14_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IsoQh3ECGUWn_hEoSfchBw" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="Tc_Z8xh4NUKZkS0Jsnsz3jY9A_14_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2oKKrX6nA0y6X8VJqCajsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_MImAmjib2Ey-aN1jgKj3lw_14_14">20,461</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_BisnzQuOK0SOLVnaeh9fZw_14_17">20,461</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBQIyJO6Bky2LRwuu2f8fg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_xHG1kENxf02M_Ljeg0gKtA_16_2">21,139,385</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBQIyJO6Bky2LRwuu2f8fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_orx-9KBq2Uu0--FiCFLlIg_16_5">58</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9wQFUwfTykW9qsgqMTxpsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xTwjleqP4EaNhz6fkWCNoA_16_8">176,696</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LfEbrk5LkkeSaN-Ppx6W5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yvEHqwPRg0KGHhuT7_A0cQ_16_11">35</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Gpq4ytPIkUGTYbUPOM83dQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_kudb7zk1PEqKI_Q9NykcEA_16_14">106,936</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_K1T49t-KB0yZIcLBr9zwWw_16_17">69,853</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="Tc_8nygfTuftEmPdxDMsGUsOg_18_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Klh4zVXBdku_FCneIROOiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="Tc_7jWKBPYHokWM_maiKR8oeQ_18_8">2,066</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DsQQrozwdkKxtuirepkykw" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="Tc_c_eYZ4qBZkS283FNlk_dlA_18_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iGwyJcYXY0S44sJU3W54uQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="Tc_dvVipI1i0EyGIW30C1T-ww_18_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="Tc_BYn0Ld8FMUG5puu1EBrUOA_18_17">2,066</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of options and restricted stock units</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_VYpho-RDJk24dvCiLB3ozQ_20_2">50,290</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_oULiP01GyEGoRJwxs7pREQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;">(*)</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Klh4zVXBdku_FCneIROOiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_XXM8MVb2OEqylpcjnXG30w_20_8">61</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DsQQrozwdkKxtuirepkykw" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_l19Hc7898k-Wpc2jnWXN_A_20_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iGwyJcYXY0S44sJU3W54uQ" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_3GE7AJxzKUSWAleg8DjHrA_20_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_mWzCgOL3zUy8-GxFkUjuRA_20_17">61</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of Ordinary Shares (**)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_HwjJH-IniUmiz8lzfUGfiA_22_2">136,300</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_7Wb5Jl6MQU2V63DK4FHwEA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;">(*)</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Klh4zVXBdku_FCneIROOiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_l7RpjOKadkSOO-YEzA996A_22_8">707</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DsQQrozwdkKxtuirepkykw" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_iZsgwj1sHkKX-H0NgHwHFQ_22_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iGwyJcYXY0S44sJU3W54uQ" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_L2DmWJ9FpkuUQwvW9WMvgQ_22_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_A0jqDMsM0UK0ebNhU3FjJA_22_17">707</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unrealized gain on marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_z_KeuY09-EqSbl4SLV_yHA_24_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Klh4zVXBdku_FCneIROOiQ" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_3qQ8SnOVHkuyWcnxnnuGlQ_24_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DsQQrozwdkKxtuirepkykw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_HMj0_KX2CE6JGlPE5MHNkQ_24_11">237</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iGwyJcYXY0S44sJU3W54uQ" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_FuB5VG5y1kiD1mRF32kPtA_24_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_vCcSB4J5REuOgmjV5DIaTw_24_17">237</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="Tc_K7PIR-2yGkKdl4QMHG7vOw_26_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Klh4zVXBdku_FCneIROOiQ" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="Tc_DwsxRqPXLUmPBJggsLyPAg_26_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DsQQrozwdkKxtuirepkykw" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="Tc_ZlgXbp4oC0-IPxKtZ-8Smw_26_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iGwyJcYXY0S44sJU3W54uQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_a6RL2mFDeEaGg-V9GVKl9w_26_14">28,771</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_7Du_LmEpxUi377ZUxHp2Kw_26_17">28,771</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hXRilr6SHE66NPYzTTJsLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_0k6VirPc1UCwYCWrsKhgKw_28_2">21,325,975</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hXRilr6SHE66NPYzTTJsLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7qbx2TqR90yAcNvGmD8WsQ_28_5">58</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LVnGSo3_1kWLy8HaZIELzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_GYYB5tI2QUOvT34WAcSsvA_28_8">179,530</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zF1M1CcFtEuu9rKrGf7EhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Va4A3h9THEmxiI6ks5PCyQ_28_11">272</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u4zLwxUaOkSym-aIgXnS5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_62FxSWhmTEeCl6BwBtU7hQ_28_14">135,707</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bN_rhdvMJEOVvT8renlb1Q_28_17">44,153</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(*)&#160;<ix:footnote xml:lang="en-US" id="_afc9692e_a9e1_46f7_9c18_b560baccbcf1">Represents amount less than $1</ix:footnote></p><a id="_3192127c_c765_4f48_81a8_3ee23ac622f8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(**) See also Note 10</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accompanying notes are an integral part of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_056d994c_f2e1_4196_a2e9_d8092d8000d3"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_contentSection_b19da25e_822d_4db7_a66b_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><a id="ConsolidatedStatementsofCashFlows_484762"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Consolidated Statements of Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">U.S. Dollars in thousands, except share data and per share data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_356716fc_bc75_4987_aa63_edd84c8f59b7"></a><a id="Tc_uSBP2yhszUCe5I697gyL2w_1_2"></a><a id="Tc_2hk8JWjqtkCiFx61c9tgWA_2_2"></a><a id="Tc_zXhtv2zsi0-lOJSOA6A28Q_2_5"></a><a id="Tc_9KQj0ny23UqfnH0V8Ey0Rg_2_8"></a><a id="Tc_ARNDp1hoFU2jb5VnxyLGnA_3_0"></a><a id="Tc_hoO2H-wkNk2W8U1UX41RQg_5_0"></a><a id="Tc_fXOi7yR_3USgXjubMYag4A_5_2"></a><a id="Tc_nucD-AgmIkGhYv2Cxb0nfA_5_5"></a><a id="Tc_Y-TC5Zatvk2wVAcNm0JIUQ_5_8"></a><a id="Tc_hJh_XQntKEu89W-gjrlTog_6_0"></a><a id="Tc_uaNRGEFjUU-2pcB39nsa1A_7_0"></a><a id="Tc_Y6HRIF665k2-vAz4df8L8g_8_0"></a><a id="Tc_QZahzPCZpUabMSWU7cNygA_9_0"></a><a id="Tc_sNFe-_HXnkamDkYUqyPRDg_10_0"></a><a id="Tc_q5Ky--_A2Ei1Hb_ejuFP2g_12_0"></a><a id="Tc_aHmWZeDBPkiL07oNkWSVCw_13_0"></a><a id="Tc_mEjMls7BX02V_RZcdvFXLQ_14_0"></a><a id="Tc_4tZNzRHXJ0WvgpzsmycjzQ_15_0"></a><a id="Tc_cH0DSxR44kecehWEFkxL3g_16_0"></a><a id="Tc_D9zWfgsdYku-c33ZkPdw1g_17_0"></a><a id="Tc_Pd90z9GF_USrnv_IKB6PaQ_18_0"></a><a id="Tc_xk2Ll3qROEej2fGxMsV5kQ_20_0"></a><a id="Tc_658c4CxswEehDZR0kLL2-g_21_0"></a><a id="Tc_TAA4bblrQkObsqJzNuM_xA_22_0"></a><a id="Tc_Nzwx4KBH4Uu7pjklmypjtA_23_0"></a><a id="Tc_0Zq36_lHCEO1DcZKq6Fgig_24_0"></a><a id="Tc_MUO9rNQvPUKG-jbpPvjReQ_25_0"></a><a id="Tc_NulcxcEkhUmyy_BpWlPvLw_27_0"></a><a id="Tc_SpFe_lnTM0mZ7Gv55GPAbA_28_0"></a><a id="Tc_Aq_kKBraL0-FBu2WSAgzBQ_29_0"></a><a id="Tc_D1vGdCu97kilDPQ3gV8wnA_30_0"></a><a id="Tc__dDTlUdSVEeNvgEcpg9WvQ_31_0"></a><a id="Tc_BirAJ1ICJEqwN80afxDh1A_32_0"></a><a id="Tc_Hvxzpun6XUSWlkrrGGGlUQ_33_0"></a><a id="Tc_Y-3ui0BL5UKte2s32jtaQQ_33_2"></a><a id="Tc_vcGETlyIcUuUxgHgn84tMA_33_5"></a><a id="Tc_4pjw4IpKkU2rgZJ-JCVGgQ_33_8"></a><a id="Tc_mUS0dgLwuEWI_eoahndlaA_35_0"></a><a id="Tc_J-sR9h5f4ky_AvT_Q3ArHQ_36_0"></a><a id="Tc_U4yfYtfwyEyK6h3MByvO3g_36_2"></a><a id="Tc_m_gNZdhQF0OHpsTslSgfqQ_36_5"></a><a id="Tc_R0-bHEAoaEid9dJ2UhBlwA_36_8"></a><a id="Tc_hjcBBD-3sUiP17MyvHpirw_37_0"></a><a id="Tc_o9Tp0Ngn6kmU2-h2bADuPw_37_2"></a><a id="Tc_EzKtYYNvxE29T6UW5lNKBQ_37_5"></a><a id="Tc_qmNSssBKFkCoqkmdfe8G3Q_37_8"></a><a id="Tc_kkpZ0Q8pY0q8OIZFXJU9ow_39_0"></a><a id="Tc_YxWPuGd9FEuc6o4KkBf03Q_40_0"></a><a id="Tc_FCKwFEMYv0yc5yF2B-wYkA_40_2"></a><a id="Tc_l44mO7gaLkSQ2JLVIIAnew_40_5"></a><a id="Tc_PZCIkQGVaE2tcLitrmGNyQ_40_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:101.53%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flow from operating activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss for the&#160;year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_9nsRK-1yzkWZTEnH4tufsQ_5_3">28,771</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_yeegJr1neEaWUghcPshZ-w_5_6">20,461</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_DGIVPRctt025XdUDE4nslQ_5_9">9,856</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Adjustments required to reconcile net loss to net cash used in operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_NI3XaL1Z7kWlEBvkzaytUw_7_3">39</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_gmI2jLt2wUKT2mfGLk1iUw_7_6">35</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_jHxhxn9Pd060q_fB2pk0sg_7_9">387</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of discount/premium on marketable debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_FKBvCm6pdk2v0rGkOwyjmw_8_3">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" sign="-" scale="3" id="Tc_iGttQMzBlkSvNpACgmzHiA_8_6">105</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" sign="-" scale="3" id="Tc_iwLmQBarDUG7OwuYC3fu1g_8_9">144</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss (gain) on sale of marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" scale="3" id="Tc_eWZquPBdzk2ge3PBBoBSfQ_9_3">527</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" scale="3" id="Tc_F-ot4YG5_kmbKOEMwIwHYw_9_6">9</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" sign="-" scale="3" id="Tc__MEX8PK7kkiYaCcWXz214w_9_9">12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income from short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="glmd:InterestsIncomeOnShortTermDeposits" scale="3" id="Tc_01O-Gp82qUK4ILSquri6yg_10_3">285</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="glmd:InterestsIncomeOnShortTermDeposits" scale="3" id="Tc_hsmcX_MgSEKLSZGh6VtESw_10_6">63</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:zerodash" name="glmd:InterestsIncomeOnShortTermDeposits" scale="3" id="Tc_SdvRHR2V5kSWUzUgtJcNIA_10_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_PrZZMTGqHk-Wlr_LkXCtIg_12_3">2,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_iDdbb0N6NEaB7SkhWMwfBw_12_6">2,231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_4DHp1XUbtEOVfydJtFxbfg_12_9">1,783</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Changes in operating assets and liabilities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decrease in deferred revenue from collaboration agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_WcWZ8vOTUkSQ9ev7XgyFvg_14_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_2Kv5Je2xxESvtu9SrxnM8w_14_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_--We3xDUyki0rgO4wmv2Jg_14_9">538</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decrease (increase) in other accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" sign="-" scale="3" id="Tc_33Mk3QUgzk-cizYwtxGaXg_15_3">15</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" id="Tc_ZbxmHP10Hkaf_w_E20QZfw_15_6">609</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" id="Tc_ZVCj21uixkmgwAnY4RH-Tw_15_9">63</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase (decrease) in trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_1cvgYMsuAEGh7lMZOg_rmQ_16_3">1,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_S88_THzmxUq9zhYkgEKZ8g_16_6">4,185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" sign="-" scale="3" id="Tc_xTCgZvj_hkSHJOWdfmFYIw_16_9">462</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase (decrease)&#160;&#160;in other accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="Tc_QshrIXEHC0KxhdxYdM5KVQ_17_3">39</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" sign="-" scale="3" id="Tc_DBmrteKe4UarUNfyrcAqzw_17_6">141</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" sign="-" scale="3" id="Tc_BLgiHznJcEGB88BsSXP8vg_17_9">142</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_PxrTclpwqk6t1emZY63wUw_18_3">26,287</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_UA0gxzcIBk2KKnFbMZfaaA_18_6">14,937</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_B_K5-u6Rl0mR9D74VGnYtw_18_9">9,023</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flow from investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_AxVwzPgbIUSX7uN3PCxSaQ_21_3">44</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_nsTRYkl1L0uC1rVl3IlJWw_21_6">12</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_lbo8OPG2VUyiarvhKuHcug_21_9">90</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment in securities, available for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_QntyYLQVx0CbUXpTgljYPw_22_3">55,034</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_1VCyj4Rcik2xn7lZ14Sh1A_22_6">72,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_UtX28fKJj0CFX6ZwTorhYg_22_9">92,279</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from sale of securities, available for sale</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="Tc_1ZPKlWMdjkSaLpjdNLxrmQ_23_3">47,198</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="Tc_l1xh1sRxMEiem2DZsqQx1g_23_6">101,098</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="Tc_OERVdBgfF0CBFsrb8hTqKA_23_9">38,421</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds (investment) in short-term deposits, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" sign="-" scale="3" id="Tc_98Exu4wiIkWrQEwAtobpzQ_24_3">24,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" scale="3" id="Tc_-b1zeEC93UWApNGigKIAig_24_6">21,808</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" scale="3" id="Tc_FNg9sc3nbU6Cwoa6hHxOgQ_24_9">6,067</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net cash provided by (used in) investing activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_lsyDVYE-okibWamSEjq0dw_25_3">16,536</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_JhIXg59RlU2mpXelnB3m5A_25_6">6,678</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_kWhtgebhxUuAv5x_ak3ifQ_25_9">60,015</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flow from financing activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of ordinary shares and warrants, net of issuance costs (*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="Tc_xt9it0WKS0itVI7bY09UyA_28_3">707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="Tc_GoeIdt4KN0u0T0yl9u7wUA_28_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="Tc_Dsf4U8uej0-EcPAM2_HySw_28_9">79,149</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from exercise of options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_e5CKCptN9EGC9e2e0YZkyA_29_3">61</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_BdW4BSs07UidWThxsCQCfg_29_6">143</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_VSJAeZZzRke0cWIAYyg9tA_29_9">1,027</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_GJTFxW-sRUyGF6z33_HASw_30_3">768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_-CHMrqEt1kOuPhf6r50IZg_30_6">143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_ky44GJzPE0aaksgQTcuYwg_30_9">80,176</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Increase (decrease) in cash and cash equivalents and restricted cash</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_-H8ra9gOu0mZJerBU3fPiA_31_3">8,983</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_WLUZKVt1QEqfHo4GS-6vyQ_31_6">8,116</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_Dwvg0vyowUShJfu4vHmpUw_31_9">11,138</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents and restricted cash at the beginning of the&#160;year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_xZhVK3wZ0k6xjRySKSAnnw_32_3">16,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2018_lcF12gSU0kKvwhOz65xKKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Zol38P49xkWSkf21cXDpYQ_32_6">24,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2017_CuoWWqHob0izym5D8TCYyw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_gWwtY-NUV0qaLluG-ERoFA_32_9">13,021</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents and restricted cash at the end of the&#160;year</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_9F7_t4Ia20CoMohxUWLOtw_33_3">7,060</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_hqmA_yy-8UmJ9lQD2oPzrw_33_6">16,043</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2018_lcF12gSU0kKvwhOz65xKKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_KjQnaFPouU-MmHSvS9otDw_33_9">24,159</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash received from interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromInterestReceived" scale="3" id="Tc_PuiujTgUyUG5zzn4g-QdBA_36_3">1,192</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromInterestReceived" scale="3" id="Tc_dRfqOIhtgk-PkaqnUQ9NYw_36_6">1,953</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromInterestReceived" scale="3" id="Tc_lxzHDX8lXE-xlLRf6zBqXA_36_9">865</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_WYR0tY6w2kSIEiuQtImR0g_37_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_opC7Y6SGDEOczsOUAKqcDA_37_6">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_ctM9qu2SbUy5wTVQUgpXPw_37_9">75</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-cash transactions:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recognition of right-of-use asset and lease liabilities from adoption of ASU 2016-02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_viivQqH6qEqlkH7YaroN1g_40_3">35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_LEA3gH8NkU2WibpGLjFxpg_40_6">653</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_UrygM1VnfUOsnxiFlbff8w_40_9">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(*) <ix:footnote xml:lang="en-US" id="_42e2ff89_d58a_4126_9816_39de91f5f9c8">See also Note 10.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Note1General_156977"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_rOqitYCXm0m8O9RRRC_zIw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;1&#160;&#8211; General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Galmed Pharmaceuticals&#160;Ltd. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company primarily focused on the development of therapeutics for the treatment of liver diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company was incorporated in <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="glmd:EntityIncorporationPlace" id="Narr_fsXmaf49uUWyzTka5VjHYQ">Israel</ix:nonNumeric> on <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" format="ixt:datemonthdayyearen" name="glmd:EntityIncorporationDate" id="Narr_10dPIfRHrke_CNGTAPgeCg">July&#160;31, 2013</ix:nonNumeric> and commenced operations on <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" format="ixt:datemonthdayyearen" name="us-gaap:OperationsCommencedDate1" id="Narr_z77MFU2ZGkeyYg3xxUvMEw">February&#160;2, 2014</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company holds a wholly-owned subsidiary, Galmed International&#160;Ltd., which was incorporated in Malta. Galmed International&#160;Ltd. previously held a wholly-owned subsidiary, Galmed Medical Research&#160;Ltd., which was incorporated in Israel, and had been an inactive company since 2015 and was liquidated in February&#160;2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company also holds two additional wholly-owned subsidiaries, Galmed Research and Development&#160;Ltd and Galtopa Therapeutics Ltd., both are incorporated in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company is a clinical-stage biopharmaceutical company with an operating history limited to pre-clinical and clinical drug development and has no approved products. To date, the Company has focused almost exclusively on developing its product candidate, Aramchol. The Company funded its research and development programs and operations to date primarily through proceeds from private placements and public offerings. The Company currently has no products approved for marketing and has not generated any revenue from product sales to date. As of December&#160;31, 2020, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_5KScjuvq6UOvUi9H2XMR1Q">6.9</ix:nonFraction> million, restricted cash of $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="Narr_WmNrhwxFn0Cow33nRiNXiA">0.1</ix:nonFraction> million, short-term deposits of $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="6" id="Narr_0zzf7uWe80-4z2l4dp_wDw">3.8</ix:nonFraction> million and marketable debt securities of $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="Narr_FephRuRF4U2PD89kcWUtHw">40.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company has incurred operating losses in each&#160;year since inception. The Company&#8217;s loss attributable to holders of its ordinary shares for the&#160;years ended December&#160;31, 2018, 2019, and 2020 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="6" id="Narr_PIUiE8nX0U-LOhwSZX6zLA">9.9</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="6" id="Narr_fxl9JwmbXk-__UhztLaOtQ">20.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="6" id="Narr_ikxfYDkEMUK4PfyFHBGGDQ">28.8</ix:nonFraction> million, respectively. As of December&#160;31, 2020, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_-Xjvd6YNe0uYnAD1q01ROg">135.7</ix:nonFraction> million. Substantially all of its operating losses resulted from costs incurred in connection with the Company&#8217;s development program and from general and administrative costs associated with its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company will need to raise substantial, additional capital to fund its operations and to develop Aramchol for, and beyond its current development stage and any future commercialization, as well as any additional indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;">Based on the Company&#8217;s current operating plan, the Company&#8217;s management currently estimates that its cash position will support its current clinical trials and operations as currently conducted for more than 12&#160;months from the date of issuance of these financial statements.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Note2SignificantAccountingPolicies_49755"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_luzKAOnKs02_jCc6H9uUlA" continuedAt="Tb_luzKAOnKs02_jCc6H9uUlA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Note 2 &#8211; Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_jVu1sMUdwkeCQWsNn-CgZQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (&quot;U.S. GAAP&quot;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:UseOfEstimates" id="Tb_BEdgjdy7EEejZ0Z_mVnAVA" continuedAt="Tb_BEdgjdy7EEejZ0Z_mVnAVA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Use of estimates</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_luzKAOnKs02_jCc6H9uUlA_cont1" continuedAt="Tb_luzKAOnKs02_jCc6H9uUlA_cont2"><ix:continuation id="Tb_BEdgjdy7EEejZ0Z_mVnAVA_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Note 2 &#8211; Significant Accounting Policies (Cont.)</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="glmd:PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock" id="Tb_Bz6b9GzWDUW2lsXHuCE7XA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Financial statement in U.S. dollars</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The functional currency of the Company and its subsidiaries is in U.S dollar (the &#8220;dollar&#8221;), because the dollar is the currency of the primary economic environment in which the Company and its subsidiaries operate, and expect to continue operating in the foreseeable future. Transactions and balances denominated in dollars are presented in their original amounts. Non-dollar denominated transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10, &#8220;Foreign Currency Translation.&#8221; All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_bFH5f7SIXkahIMfD51XRZg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Principles of consolidation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Galmed Research and Development Ltd., Galmed International Ltd. and Galtopa Therapeutics Ltd. All intercompany balances and transactions have been eliminated upon consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_z8d3JiguY0O-HQl73v4TMw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">E.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Cash and cash equivalents</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with maturities of three&#160;months or less as of the date acquired.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_rXw15JjaBkeMZ-bXzBb4kA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">F.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Restricted Cash</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 54pt;"><span style="font-weight:normal;">Cash that is held for a specific purpose and is not available for immediate or general business use due to external restrictions is classified in our consolidated balance sheets as restricted cash.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:MarketableSecuritiesPolicy" id="Tb__x9R7b_nAUupoh-2P83N9w" continuedAt="Tb__x9R7b_nAUupoh-2P83N9w_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">G.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Marketable debt securities</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company invests most of its excess cash primarily in debt securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Marketable debt securities are considered to be available for sale and are carried at fair value. Unrealized gains and losses net of tax, if any, are reported as a separate component of stockholders&#8217; equity. The cost of marketable debt securities classified as available for sale is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Realized gains and losses and declines in value judged to be other than temporary, if any, are also included in other income, net. Interest on securities classified as available for sale is included in interest income. The cost of securities sold is based on the specific identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">For all investments in marketable debt securities, the Company assesses whether the impairment is other-than-temporary. If the fair value of a security is less than its amortized cost basis, an impairment is considered other-than-temporary if (i)&#160;the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its entire amortized cost basis, or (ii)&#160;the Company does not expect to recover the entire amortized cost of the security. If an impairment is considered other-than-temporary based on condition (i), the entire difference between the amortized cost and the fair value of the security is recognized in earnings. If an impairment is considered other-than-temporary based on condition (ii), the amount representing credit losses, defined as the difference between the present value of the cash flows expected to be collected and the amortized cost basis of the security, will be recognized in earnings, and the amount relating to all other factors will be recognized in other comprehensive income. The Company evaluates both qualitative and quantitative factors such as duration and severity of the unrealized </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_484eacfe_bd33_41c8_a2bc_33fb1ede8895"></a><a id="Tc_IpUG13QnFkCUL17GIE9s2A_1_2"></a><a id="Tc_G5K2BjlPsEeBdnp4-Rjs4w_3_0"></a><a id="Tc_nLDtgXaVc0iuA4EPobQ5Cg_3_2"></a><a id="Tc_KNO1GjSsz0CrZ3DDjMONeA_4_0"></a><a id="Tc_4jvGrCErlEiqsB71wHxGqQ_4_2"></a><a id="Tc_a2UzT7zAxkaiP51kJKUU_g_5_0"></a><ix:continuation id="Tb_luzKAOnKs02_jCc6H9uUlA_cont2" continuedAt="Tb_luzKAOnKs02_jCc6H9uUlA_cont3"><ix:continuation id="Tb__x9R7b_nAUupoh-2P83N9w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 2 &#8211; Significant Accounting Policies (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">G.</b></span><b style="font-weight:bold;">Marketable debt securities (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">losses, credit ratings, default and loss rates of the underlying collateral, structure and credit enhancements to determine if a credit loss may exist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">During the&#160;years ended December&#160;31, 2020 and 2019 no other-than-temporarily impaired losses were realized.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_TOMbX5xzoEC2zFJqXyaC3A" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">H.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Concentrations of credit risk</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, marketable securities and short-term deposits. We hold these investments in highly-rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_iigR426Ys0C5LajJC8XMxA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Property and equipment</p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="glmd:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" id="Tb_4IFiMnleXkCXsBGjzsG2gw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The annual depreciation rates are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:12pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office furniture and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vDGTRGTNSU-DSOCOXQYOmw" decimals="2" format="ixt:numdotdecimal" name="glmd:PropertyPlantAndEquipmentDepreciationPercentage" scale="-2" id="Narr_wvwpewzxDUehn7JniCRujw">7</ix:nonFraction>&#8211;<ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_gMEa3bvWxUaKSc4FnbNujg" decimals="2" format="ixt:numdotdecimal" name="glmd:PropertyPlantAndEquipmentDepreciationPercentage" scale="-2" id="Narr_ICTwXJ9XlkKRhYY2W1Tkmw">16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer software and electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_z4Neu-Y5NUaQZ1wt2pNyGA" decimals="2" format="ixt:numdotdecimal" name="glmd:PropertyPlantAndEquipmentDepreciationPercentage" scale="-2" id="Narr_A4UUrVc-806hyv_p59GZog">15</ix:nonFraction>&#8211;<ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_LCBCJM_bu0mrU9wCYDXIHQ" decimals="2" format="ixt:numdotdecimal" name="glmd:PropertyPlantAndEquipmentDepreciationPercentage" scale="-2" id="Narr_KDKqxmZP6ki-qgQ9Ks6vDQ">33</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_u4oEdDXj2kiEqeMFb0tldw" decimals="2" format="ixt:numdotdecimal" name="glmd:PropertyPlantAndEquipmentDepreciationPercentage" scale="-2" id="Tc_JH-TBQVmlkq0m8qRxvZAyw_5_2">10</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_tKW9NTMxgU6nZtgPgTCEgw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">J.&#160;&#160;&#160;Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company&#8217;s and its subsidiaries&#8217; long-lived assets are reviewed for impairment in accordance with ASC 360-10, &#8220;Accounting for the Impairment or Disposal of Long-Lived Assets,&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds their fair value. During 2020 and 2019, no impairment losses were identified.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_AEbpaoiDwUCs0dck2-UJjQ" continuedAt="Tb_AEbpaoiDwUCs0dck2-UJjQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">K.&#160;&#160;&#160;&#160;&#160;Severance pay</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company employees are included under section 14 of the Severance Compensation Act, 1963 (&#8220;Section&#160;14&#8221;) for a portion of their salaries. According to Section&#160;14, these employees are entitled to&#160;monthly deposits at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="4" format="ixt:numdotdecimal" name="glmd:MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" scale="-2" id="Narr_nSgpM3eGy025omkJGTPr8w">8.33</ix:nonFraction>% of their&#160;monthly salary, made in their name with such insurance companies. Under the Severance Compensation Act, 1963, payments in accordance with Section&#160;14 release the Company from any future severance payments to those employees. The aforementioned deposits are not recorded as an asset in the Company&#8217;s balance sheet.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_luzKAOnKs02_jCc6H9uUlA_cont3" continuedAt="Tb_luzKAOnKs02_jCc6H9uUlA_cont4"><ix:continuation id="Tb_AEbpaoiDwUCs0dck2-UJjQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Note 2 &#8211; Significant Accounting Policies (Cont.)</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_S7JVd3C5NEaa1HU_PcdsWA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">L.&#160;&#160;&#160;&#160;Fair value of financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies. Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company could realize in a current market exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The carrying amounts of cash and cash equivalents, short-term bank deposits, other accounts receivables, trade payables and other trade payables approximate their fair value due to the short-term maturity of such instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Fair value is an exit price representing the amount that would be received upon selling an asset or that would be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions used by market participants in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">A three-tier fair-value hierarchy was established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 1&#160;- Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 2&#160;- Other inputs that are directly or indirectly observable in the marketplace; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 3&#160;- Unobservable inputs that are supported by little or no market activity</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_12qEUwlNrEqlSujDv-L_CA" continuedAt="Tb_12qEUwlNrEqlSujDv-L_CA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;">M.&#160;&#160;&#160;Accounting for stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The Company applies ASC 718-10, &#8220;Share-Based Payment,&#8221; which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors, including employee stock options under the Company&#8217;s stock plans, based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#8217;s consolidated statement of operations.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_luzKAOnKs02_jCc6H9uUlA_cont4" continuedAt="Tb_luzKAOnKs02_jCc6H9uUlA_cont5"><ix:continuation id="Tb_12qEUwlNrEqlSujDv-L_CA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 2 &#8211; Significant Accounting Policies (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">M. &#160; Accounting for stock-based compensation (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">In June&#160;2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-07, &#8220;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#8221;, which simplifies the accounting for non-employee share-based payment transactions by aligning the measurement and classification guidance, with certain exceptions, to that for share-based payment awards to employees. The amendments expand the scope of the accounting standard for share-based payment awards to include share-based payment awards granted to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance related to equity-based payments to non-employees. The Company elected to early adopt these amendments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">on June&#160;1, 2018. The adoption of these amendments did not have a significant impact on the Company&#39;s consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company estimates the fair value of restricted shares based on the market price of the shares at the grant date, and estimates the fair value of stock options granted using a <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_NopUScY-L0CezNXhkry3hg" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" id="Narr_mrit9gN63UO6cZgv5-IL-Q">Black-Scholes option-pricing model</ix:nonNumeric>. The option-pricing model requires a number of assumptions, the most significant of which are the expected stock-price volatility and the expected option term (the time from the grant date until the options are exercised or expire).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company&#8217;s calculations of the expected volatility were based upon actual historical stock-price movements over the period, which was equal to the expected option term. The expected option term was calculated for options granted to employees and directors in accordance with ASC-718-10-S99, using the &#8220;simplified&#8221; method, and grants to non-employees were based on the contractual term. Historically, the Company has not paid dividends, and has no foreseeable plans to do so. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_RYKSF5CZ-Ea6ZCtIHXUbOg" continuedAt="Tb_RYKSF5CZ-Ea6ZCtIHXUbOg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">N.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Revenue Recognition</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company only has one license agreement for which is has recognized revenues to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">On January&#160;1, 2018, the Company adopted ASC 606 with full retrospective application. The adoption of did not have an effect on either revenue recognized in prior periods, nor to accumulated deficit as of January&#160;1, 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The new revenue standard amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The new revenue standard provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of the new revenue standard, we perform the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the performance obligations are satisfied.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_luzKAOnKs02_jCc6H9uUlA_cont5" continuedAt="Tb_luzKAOnKs02_jCc6H9uUlA_cont6"><ix:continuation id="Tb_RYKSF5CZ-Ea6ZCtIHXUbOg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 2 &#8211; Significant Accounting Policies (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">N.</b></span><b style="font-weight:bold;">Revenue Recognition (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company only applies the five-step model to contracts when collectability of the consideration to which the Company is entitled in exchange for the goods or services transferred to the customer is determined to be probable. At contract inception, once the contract is determined to be within the scope of the new revenue standard, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. The Company then allocates the transaction price (the amount of consideration the Company expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which we expect to be entitled.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_6y3jYUdCmUKZaEjV707bcg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">O.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Research and development expenses</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Research and development expenses are charged to the statement of operations as incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_YVJdibS6VUGNsXbXPw9iRw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">P.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Income taxes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company accounts for income taxes utilizing the asset and liability method in accordance with ASC 740, &#8220;Income Taxes.&#8221; Current tax liabilities are recognized for the estimated taxes payable on tax returns for the current year. Deferred tax liabilities or assets are recognized for the estimated future tax effects attributable to temporary differences between the income-tax bases of assets and liabilities and their reported amounts in the financial statements and for tax loss carry forwards. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax laws, and deferred tax assets are reduced, if necessary, by the amount of tax benefits, the realization of which is not considered more likely than not based on available evidence. As of December 31, 2020, and 2019, the Company had a full valuation allowance against deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">ASC 740-10 requires a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company has not recorded any liability for uncertain tax positions for the years ended December 31, 2020 and 2019.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_oTHWQjIbVkWez5IZPw65ig" continuedAt="Tb_oTHWQjIbVkWez5IZPw65ig_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Q.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Basic and diluted net loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Basic net loss per share is computed based on the weighted-average number of shares outstanding during each&#160;year. Diluted net loss per share is computed based on the weighted-average number of shares outstanding during each&#160;year, plus the dilutive potential of the ordinary shares considered outstanding during the&#160;year, in accordance with ASC 260-10, &#8220;Earnings Per Share.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">All outstanding stock options and warrants were excluded from the calculation of the diluted loss per share for the&#160;years ended December&#160;31, 2020, 2019 and 2018, because all such securities have an anti-dilutive effect.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_luzKAOnKs02_jCc6H9uUlA_cont6" continuedAt="Tb_luzKAOnKs02_jCc6H9uUlA_cont7"><ix:continuation id="Tb_oTHWQjIbVkWez5IZPw65ig_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Note 2 &#8211; Significant Accounting Policies (Cont.)</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_SE9P7YuMDkunIugVtuJvpA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">R.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Segment Reporting</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. Accordingly, management has determined that the Company operates in <ix:nonFraction unitRef="Unit_Standard_segment_LrQLFEabLEqzt_sj9HemMg" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_V795-4j5PUyxXrj3Rb73wg">one</ix:nonFraction> reportable segment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_jzXrbPXTjkKVDnxmMONaKg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">S.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Comprehensive Loss</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The purpose of reporting comprehensive income is to report a measure of all changes in equity of an entity that result from recognized transactions and other economic events of the period resulting from transactions from non-owner sources.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_Jjr7r1x2d0-OxQR5YXOKsA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">T.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Leases</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">ASU 2016-02, &#8220;Leases (Topic 842)&#8221; was issued by the FASB in February 2016. The Company adopted this ASU 2016-02 effective January 1, 2019 using the modified retrospective application, applying the new standard to leases in place as of the adoption date. Prior periods have not been adjusted. Leases existing for the reporting period beginning January 1, 2019 are presented under ASU 2016-02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Arrangements that are determined to be leases at inception are recognized as right of use assets and lease liabilities in the consolidated balance sheet at lease commencement. Operating lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. As the Company&#8217;s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at the commencement date in determining the present value of future lease payments. Lease terms include options to extend the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company elected to adopt a package of practical expedients offered by the FASB which removes the requirement to reassess whether expired or existing contracts contain leases and removes the requirement to reassess the lease classification for any existing leases prior to the adoption date of January 1, 2019. The Company has also elected the practical expedient to include both lease and non-lease components as a single component and account for it as a lease. Additionally, the Company has made a policy election not to capitalize leases with a term of 12 months or less. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an impairment loss would be recognized for the difference between the carrying amount of the asset and its fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_aq-97aPkPEO5jMWvkXZJug" continuedAt="Tb_aq-97aPkPEO5jMWvkXZJug_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">U.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Recently adopted accounting pronouncements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">From time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_luzKAOnKs02_jCc6H9uUlA_cont7"><ix:continuation id="Tb_aq-97aPkPEO5jMWvkXZJug_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 2 &#8211; Significant Accounting Policies (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">U.</b></span><b style="font-weight:bold;">Recently adopted accounting pronouncements (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In June 2016, FASB issued ASU No. 2016-13, &#8220;Financial Instruments &#8211; Credit Losses &#8211; Measurement of Credit Losses on Financial Instruments&#8221;, which introduces a model based on expected losses to estimate credit losses for most financial assets and certain other instruments. In addition, for available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. The ASU is effective for the Company in the first quarter of 2020, with early adoption permitted. The Company adopted ASU 2016-13 in 2020. The adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In August&#160;2018, the FASB issued ASU 2018-13,&#160;&#8220;Changes to Disclosure Requirements for Fair Value Measurements&#8221;, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for the Company beginning on January&#160;1, 2020. The Company adopted ASU 2016-13 in 2020. The adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">V.</b></span><b style="font-weight:bold;">Recently issued accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 54pt;">In December 2019, the FASB issued ASU 2019-12, &quot;Simplifying the Accounting for Income Taxes&quot;, which will simplify the accounting for income taxes to improve consistency of accounting methods and remove certain exceptions. The amendment is effective for the Company beginning January 1, 2021 and is not expected to have a material impact on the Company&#39;s consolidated financial statements and disclosures.</p></ix:continuation></ix:continuation><a id="Note3Marketabledebtsecurities_345053"></a><a id="_f427e75b_43ad_4426_81cd_76fb8b736c3d"></a><a id="Tc_faGkEOrJAUO8QinAckfOdw_1_2"></a><a id="Tc_9Q3PBrPD30u70UBYyhQXag_2_9"></a><a id="Tc_EzDTBpxyV06aZQCDsr0Eog_3_2"></a><a id="Tc_5YicLQy210Ch3JK5o-_eBg_3_5"></a><a id="Tc_P-hn6CPD40CM2WhX_FzO5g_3_7"></a><a id="Tc_vhOudJdi3ES-1rg9KiFHKQ_3_9"></a><a id="Tc_O2ceRQ2dEEuOsDsUH1W1hw_5_0"></a><a id="Tc_O9gAIu1Nf0iLvQqEDnzrpQ_5_2"></a><a id="Tc_nLz1hRB6I0CiRPgTvCA1cQ_5_7"></a><a id="_62cd7eee_aec1_4b12_a8da_f745828607f8"></a><a id="Tc_gmLxSOh_G0aWA9QQNBoYOQ_1_2"></a><a id="Tc_9AV8ySz1EUSeA3VKc5-ApA_2_9"></a><a id="Tc_50x3YWIymEu9l37mWM6BQA_3_2"></a><a id="Tc_Nhtk86SLmEqKmCIAOcZuAg_3_5"></a><a id="Tc_5iorZRAQ5k2ZwzcCiyzzPA_3_7"></a><a id="Tc_xOivDAfDQkOjCVJQpLjIZA_3_9"></a><a id="Tc_KML8R0Qfjk-hDwU8iJfeXg_5_0"></a><a id="Tc_ttiZJwC4c0mSwN4r5_B1yA_5_2"></a><a id="Tc_dF3YJUNcpkCjtox9jEr-QA_5_3"></a><a id="Tc_kNSR4LV0WU26za-MmHDCUQ_5_7"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="Tb_hmELG3J9Wkes1NwL_2qGQQ" continuedAt="Tb_hmELG3J9Wkes1NwL_2qGQQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;3&#160;&#8211; Marketable debt securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company&#39;s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. Other than the marketable debt securities, which includes corporate bonds and mutual funds as of December 31, 2020, the Company doesn&#39;t have any other financial assets or financial liabilities marked to market at fair value.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:MarketableSecuritiesTextBlock" id="Group_XTfWCJW4eUeiMPyI_ZBXVQ" continuedAt="Group_XTfWCJW4eUeiMPyI_ZBXVQ_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The fair value of the Company&#39;s Marketable debt securities measured at fair value on a recurring basis by level within the fair value hierarchy are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hfA5x-MOn0W8xR-xu1Qj7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_6-DN4AD1X0efUO3gxR0QMw_5_3">25,449</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dgZLZWqczUq8SCUOT_5URw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_tWITVOsUHkam1RNR1jNUfg_5_5">14,683</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fI3z7-XQOUCnOyty6hbt5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_qn-Rsl8WYECf_ig6e1o-WQ_5_9">40,132</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hEwZ6hKhQ0uK4n7L4nWHsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_GPZhnwjttU2RHq9P-0nUwA_5_5">31,622</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rvQiaUGGXU66VG6jGIelKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_j1lY3sbwrEeNn_bpjvzALA_5_9">31,622</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fd9d96e4_01cc_4c76_ac04_a2aeeb56107d"></a><a id="Tc_2cFtar1Q0ESKpSemN82zJQ_1_2"></a><a id="Tc_HmDDoY4u7Uil2_7bWRKP-Q_2_5"></a><a id="Tc_Dhq_09zAQkO_cVtjrnGDZg_2_8"></a><a id="Tc_iG78sOxwM0ukquJg6wEvUw_3_2"></a><a id="Tc__JN3YqUrhk2ggVWrMdQCKQ_3_5"></a><a id="Tc_Hs24GadCS0WdWIO90ue24Q_3_8"></a><a id="Tc_1YQuGMPywkWkUc2jkFhF1A_3_11"></a><a id="Tc_t8to4tozjEado9IMzk3X6w_4_2"></a><a id="Tc_1O7tSBMGck6b60Rv6aO4pg_4_5"></a><a id="Tc_SxnWnv9QPUyKqHAi0jrYhw_4_8"></a><a id="Tc_6UX-sgt8zEOp4FPZiFDA5g_4_11"></a><a id="Tc_U9L-J0ko7kGQ0I7o-AwTsg_5_2"></a><a id="Tc_UYSHgq56SUyOAbsquI-iXQ_6_0"></a><a id="Tc_ANsLteOvNEiTNFTtQSSe2Q_6_2"></a><a id="Tc_rBc0KK9vO0mE4nXJW4dBwg_6_5"></a><a id="Tc_YTnojZw_M0uvsnzDZsszKw_6_8"></a><a id="Tc_lznVruffnEuE2u8WkiIkkA_6_11"></a><a id="Tc_mpAfp50L5k-0hp_EWOFrZg_7_0"></a><a id="Tc_Doan8MIJXEmsZZSA49hkLg_8_0"></a><a id="Tc_GRhlgTzRPEGGNoj-g3y_6Q_8_2"></a><a id="Tc_6c9snxexAU2FPKg_GHizRw_8_5"></a><a id="Tc_7A9YBU0FKk6xteUblvNGzg_8_8"></a><a id="Tc_vHEJJpcymUC6G0iZ0XCN7w_8_11"></a><a id="_eadec28f_8604_4d9a_aea5_20cdcebbd49f"></a><a id="Tc_mS0frki7REmj-MDNh3K9WA_1_2"></a><a id="Tc_fyxRWOnNnESskPKLyXm5Sw_2_5"></a><a id="Tc_X0Qtl05Jm023euqZUHT-1A_2_8"></a><a id="Tc_kgzytKcPqUyhJfI6vfQsnw_3_2"></a><a id="Tc_wE_JkMP9-0elOqeJU6oBiA_3_5"></a><a id="Tc_uPy5v0rbU06TR8ioJHB5Rw_3_8"></a><a id="Tc_HAx8_HcHSEmRnuHD4uYwWw_3_11"></a><a id="Tc_cnVS_YUPbEeEjbotqzltbg_4_2"></a><a id="Tc_qvAQ8dDREUmDLqtyujDZDQ_4_5"></a><a id="Tc_Bn3o6WmA5UebEX0yPC5k3Q_4_8"></a><a id="Tc_0QN2eN6TD0OZZZkRH7HwBQ_4_11"></a><a id="Tc_BEOa2hdKs0me7_xaljnHmA_5_2"></a><a id="Tc_IcdXrcZl8k2CDR86mDQtwA_6_0"></a><a id="Tc_mXyL6o0YjECYCHGUdc2Eaw_6_2"></a><a id="Tc__HLVI3kBuU69ZhLDDVyuvg_6_5"></a><a id="Tc_chcemC2IU0S_B0MLQy1gbg_6_8"></a><a id="Tc_O7qyNXwb2UOX7ToGutliRw_6_11"></a><a id="Tc_zNnBKVAuAEyrPZzHiGMgCw_7_0"></a><a id="Tc_O4I7ZQp3gEaUuz9xj8o6_A_7_5"></a><a id="Tc_nGfUWGb2OEanjMma2c6l3g_7_8"></a><a id="Tc_Bw5p4qAUTkeCqsnT7rpjkg_7_11"></a><a id="Tc_DpiIFt7_d0OqMyhSXiav1A_8_0"></a><a id="Tc_S1LsfZkxrUKFovg6G1z0gg_8_2"></a><a id="Tc_BZR8zVjVxUGX5ehYLllfRQ_8_5"></a><a id="Tc_N3yc4HpADEWQQG29fMsAqg_8_8"></a><a id="Tc_q1pFJQvfI0mVdeSbnqB45Q_8_11"></a><ix:continuation id="Tb_hmELG3J9Wkes1NwL_2qGQQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3 &#8211; Marketable debt securities (Cont.)</b></p><ix:continuation id="Group_XTfWCJW4eUeiMPyI_ZBXVQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s marketable debt securities as of December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:12pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_zok_q8J8GUSWmJBnBBWX4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_vm1Yx46lR0u_OWSYyCd1VA_6_3">14,575</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_xfK4x71C_U2XYg59WBWoBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="Tc_fNyKyErRd0KCYhKFy2fAeQ_6_6">124</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_xfK4x71C_U2XYg59WBWoBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_VSSKaTATNU-nreWcOAFSmg_6_9">16</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_zok_q8J8GUSWmJBnBBWX4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_LCQU275TS0CnifcSHQ66Nw_6_12">14,683</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mutual funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_MutualFundMember_bnGgvdd-EU-eaV6XNt9n5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_F3A8yzEWXUiMfroxOmyVrA_7_3">25,285</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_MutualFundMember_RQBP2VCs0UObKkcYTcqmbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="Tc_R-Oa87XYJUqOrJIgLUMkwQ_7_6">181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_MutualFundMember_RQBP2VCs0UObKkcYTcqmbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_BIekXUQPA0yXrlqXJ1dsGw_7_9">17</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_MutualFundMember_bnGgvdd-EU-eaV6XNt9n5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_LFB4pMu6DkKLKCP5-Wlr3g_7_12">25,449</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total short-term investments</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_RrWmR3xH0EqjNUh3HtqSFw_8_3">39,860</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="Tc_TI0DTjyda0ObenlAqGS1eA_8_6">305</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_lk0cqHqoNUSldEcCUVrnkw_8_9">33</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_QaH2KbhqlESdDJx3Wx5NaQ_8_12">40,132</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_ZVJnKS1DoUGuAK-FW8B_lw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_TulPGSmGs0Krcn9TFIuOyQ_6_3">19,893</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_3UXPMCMApUyirH3ER8JOrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="Tc_6QJpY5vgz0eF0ftQ1pN3kg_6_6">49</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_3UXPMCMApUyirH3ER8JOrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_l43Nd7KpLUKDInnVIrvM3w_6_9">37</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_ZVJnKS1DoUGuAK-FW8B_lw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc__PnLWHEf7Uy4mrs8mwXTtQ_6_12">19,905</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial papers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_QVoQ0VMjTE-tSI7ooqfneQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_ZUbeQpuJQk2vAc6sO9v97Q_7_3">11,694</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_y1QksogbbUycmgdaOBlLFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="Tc_KoJDCK0di0yNd25Y2MVhsw_7_6">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_y1QksogbbUycmgdaOBlLFg" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_kgVPY4CMCkGlkik-asVgPw_7_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_QVoQ0VMjTE-tSI7ooqfneQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_LQxQDujZmEqQsab9cRMbkg_7_12">11,717</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total short-term investments</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_Im_pKKgPSUynxam6HbumWQ_8_3">31,587</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="Tc_yare6_TObkmTHKCjy6vW6w_8_6">72</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_S-AvMFeXeU2MbgwUBz_WqA_8_9">37</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_EVWs3pEWF0Ov30qHhkhemQ_8_12">31,622</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The contractual maturity of the aforementioned marketable securities varies between less than one&#160;year to two&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;">The Company reviews the individual securities in its portfolio to determine whether a decline in a security&#8217;s fair value below the amortized cost basis is other-than-temporary. The Company determined that as of&#160;December&#160;31, 2020 and 2019&#160;there were&#160;no&#160;investments in its portfolio that were other-than-temporarily impaired.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Note4OtherAccountsReceivable_69633"></a><a id="Tc_l7eSdxI4dkqyzPKxwrcKRQ_1_2"></a><a id="Tc_OzO1DNYuI06GywISHdbSDg_2_2"></a><a id="Tc_B7d492uytEaGO2ojYvqCJQ_2_5"></a><a id="Tc_gm7JyS7_HkGqmMj3Q-t77w_3_2"></a><a id="Tc_FQM0qybOW06BPXLHhH2tpw_4_0"></a><a id="Tc_4tmSLRBnMEa04z9R9YW6kw_4_2"></a><a id="Tc_RRxBg6GQkkOQka4VSKsoDA_4_5"></a><a id="Tc_i-02bpHvwUeaU6Lk5QmvbQ_5_0"></a><a id="Tc_Nf1wykQ0k0enIzkuBvjlZA_6_0"></a><a id="Tc_2Ki8sa8Df02FCiKySy2SPA_7_2"></a><a id="Tc_kKzI6ZTap02oXzS7lHtTng_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Tb_Vk9PNZY73ECTtL3N8NlXgg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;4&#160;&#8211; Other Accounts Receivable</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="Tb_02QEQ_B1t0mZimbTYmeRsA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government institutions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="glmd:ReceivablesFromGovernmentInstitutions" scale="3" id="Tc_EyCgs3PAb06DPRRlA0tR8Q_4_3">66</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="glmd:ReceivablesFromGovernmentInstitutions" scale="3" id="Tc_ymKaOwEgvU-Ni6jfSkh2Cw_4_6">178</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_4q-sudrS1kqANz8_KiKj-w_5_3">746</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_1lj8kzGrI0ujDiBKeGhxrQ_5_6">601</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_MyAAvFQAWU-tmbkbmWRDsA_6_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_WOyHRSjYUkCoMjb_A9Jehw_6_6">48</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_QCCUCT3loUa5wdDWSvOGyw_7_3">812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_VHxhF1Ohk0CBgzivj8K24Q_7_6">827</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Note5Leases_448001"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_9c2gqAghyEmFfdV0QynPMw" continuedAt="Tb_9c2gqAghyEmFfdV0QynPMw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;5&#160;&#8211; Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">On January 1, 2019, the Company adopted ASU 2016-02, using the modified retrospective approach for all lease arrangements at the beginning period of adoption. Leases existing for the reporting period beginning January 1, 2019 are presented under ASU 2016-02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company leases, approximately <ix:nonFraction unitRef="Unit_Standard_sqft_dThMR2ywAUCT7W6wxsLiYA" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_5CvHpFWS10meXBrr3sFMbg">590</ix:nonFraction> square meters at a facility located in Tel-Aviv, Israel under an operating lease agreement expiring on March 22, 2021 with additional <ix:nonFraction unitRef="Unit_Standard_Options_1PhyUiqh7EyGeetW5z7dOA" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="INF" format="ixt-sec:numwordsen" name="glmd:LesseeOperatingLeaseNumberOfOptionToExtend" scale="0" id="Narr_dzITegwi0kCtdBbWWXLisg">two</ix:nonFraction> options to <span style="-sec-ix-hidden:Hidden_PATlNkw1P0qJ2UewZ8KyFQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">extend</span></span> until March 22, 2023. During February 2021, the Company extended its lease for an additional <ix:nonNumeric contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_6PgI_qQz0kWY83r2dQAasA">two years</ix:nonNumeric>, through March 22, 2023, with an option for another year. To secure the lease payments, the Company provided a bank guarantee of $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseDepositLiability" scale="3" id="Narr_EDN93oPN5UiZYkPH4k1QPQ">50</ix:nonFraction> thousand. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">In addition, the Company leases vehicles under various operating lease agreements. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_59bcd481_1f05_472e_bc25_5d0fb667b87e"></a><a id="Tc_MDqGew0MqU-3xMWeKZgwhQ_1_2"></a><a id="Tc_sQtJXlUwdkSMhLrHTGE6lQ_2_2"></a><a id="Tc_c-hLuSOaPEOYcxf8NOv4qg_2_5"></a><a id="Tc_uj8UVxbEM0KmZWDZak1S5w_2_8"></a><a id="Tc_uHmum5Csd0uFgkO6dtBZqA_3_2"></a><a id="Tc_QmGOLJPCM06dKOQgWaKjGA_4_0"></a><a id="Tc_U6EoI2GCL0yvp7nMP1BtzQ_4_2"></a><a id="Tc_8vzljScURkGSZRY5Oi3cxA_4_5"></a><a id="Tc_bhAOSGspTEmjVrZnPNyLew_4_8"></a><a id="Tc_8pDzSdBL1Ueujs401hkq0g_5_0"></a><a id="Tc_JDH7pO24Fk6X41bYeDOPVA_6_0"></a><a id="Tc_RTDmzg7QbU6xc_l9uQE-yA_6_2"></a><a id="Tc_gNDg8T_FnE6a9yI0KZcohg_6_5"></a><a id="Tc_5kYoE7BUbEugJxUNyeYtpw_6_8"></a><ix:continuation id="Tb_9c2gqAghyEmFfdV0QynPMw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 5 &#8211; Leases (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">At December 31, 2020, the Company&#8217;s operating lease assets and lease <span style="-sec-ix-hidden:Hidden_rtPFgq4moU2FnXiiUj0HYA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">liabilities</span></span> (both the current and non-current portion) for operating leases totaled $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Narr_eG7eqL4T90y2EBJi9HEMKA">394</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Narr_V21Kd3vB2E6PykO5yCYLkA">419</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company uses its incremental borrowing rate as the discount rate for its leases, as the implicit rate in the lease is not readily determinable. As of December 31, 2020, the Company&#39;s operating leases had a weighted average remaining lease term of <ix:nonNumeric contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr__9TBihrcukanB4bERrMGTA">2.25</ix:nonNumeric> years and a weighted average borrowing rate of <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_21wJoVRyZkK1hOPsPrKpcA">2.75</ix:nonFraction>%. Upon adoption of ASC 842, discount rates for existing operating leases were established as of January 1, 2019.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="Tb_ay62K8tnj0Wsr_k7zFd_cQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s significant contractual lease obligations at December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">3&#160;years</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facility leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_FacilityLeasesMember_xPSqGfctvE-Yl4rAyJNzSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="Tc_J9mHVV7V4U2D_j3O5PpQrA_4_3">403</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_FacilityLeasesMember_xPSqGfctvE-Yl4rAyJNzSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="3" id="Tc_vSkyrjsEX0KSkLdGKA6UbA_4_6">193</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_FacilityLeasesMember_xPSqGfctvE-Yl4rAyJNzSw" decimals="-3" format="ixt:numdotdecimal" name="glmd:ContractualObligationDueInFirstToThirdYear" scale="3" id="Tc_JT650tyktUyiCdc0pqqbxw_4_9">210</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Car leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_CarLeasesMember_q_0odO7w6EWS9ILHFJbIjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="Tc_Mu-UvFf8v0OtDeBRBNJW3A_5_3">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_CarLeasesMember_q_0odO7w6EWS9ILHFJbIjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="3" id="Tc_TPx10CsrHEisV2ptJONBCA_5_6">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_CarLeasesMember_q_0odO7w6EWS9ILHFJbIjw" decimals="-3" format="ixt:numdotdecimal" name="glmd:ContractualObligationDueInFirstToThirdYear" scale="3" id="Tc_7g1AUrsIg0OIekt4V47NoA_5_9">17</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="Tc_R0aHtsY6kUieMrhF48TGyQ_6_3">433</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="3" id="Tc_KhvU1DlC8U-hLf5kphw9cQ_6_6">206</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="glmd:ContractualObligationDueInFirstToThirdYear" scale="3" id="Tc_mSek8DpWDEeW8meSj2KIQg_6_9">227</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Note6Propertyandequipmentnet_134735"></a><a id="Tc_IxR6tnuY50-F0kEgELvkGg_1_2"></a><a id="Tc_8Sw_r4X7U0KB_cmmMyZl2A_2_2"></a><a id="Tc_bU8d_RgqW02IDE8439vAaQ_2_5"></a><a id="Tc_k3PZp9cEqEyOqOpi8yegYw_3_2"></a><a id="Tc_pbtoeibnZ0WYXWzggKq_dQ_4_0"></a><a id="Tc_y7e0pTVIE0qchc4U9FjA4g_4_2"></a><a id="Tc_nhBTdwr63U2eO08sgBtb6g_4_5"></a><a id="Tc_zrRtvrU7fkCD0qOkdYYOow_5_0"></a><a id="Tc_-KzBBbstJ0G22teW-vpVZQ_6_0"></a><a id="Tc_IxKhNRvNn0uabZ3s7KzGMA_7_0"></a><a id="Tc_VbSunOreUUS_EwgKqOCQWg_9_0"></a><a id="Tc_UUm_4cb12UygD-mggSTysg_10_0"></a><a id="Tc_mzWlZxnmz0-SJ-8WGzUL9Q_10_2"></a><a id="Tc_xqj5Ne5vIECYzAhHDFo7Xw_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_hfqIxsv0Q0GSdUJv83iETA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;6&#160;&#8211; Property and equipment, net</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_LcIsthrA8EOi_liW1eR50A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Medical equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="glmd:MedicalEquipmentGross" scale="3" id="Tc_DNiubzFGyU2txMs4JIFE5w_4_3">737</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="glmd:MedicalEquipmentGross" scale="3" id="Tc_LSo3BIsys0qk2Tlje8nE1w_4_6">737</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FurnitureAndFixturesGross" scale="3" id="Tc_SyB6AOZkU0WUr2M03T00lQ_5_3">56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FurnitureAndFixturesGross" scale="3" id="Tc_MEfdTk2EOE--ZyBUw73leQ_5_6">55</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer software and electronic equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareGross" scale="3" id="Tc_6zgVbo5Qukyga6eQVvtYkQ_6_3">78</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareGross" scale="3" id="Tc_pwpeXVuH30yQCF6YM1nGHg_6_6">88</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseholdImprovementsGross" scale="3" id="Tc_4H1xg6oE5ES_BGQ7UKJXuA_7_3">221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseholdImprovementsGross" scale="3" id="Tc_ntaVzkAMjkeXBTt24sM2BQ_7_6">198</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_2NP-9RSZ402mmpaHJ5kiCw_8_3">1,092</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_MJeBIvFaV0el-uhaxFQCLw_8_6">1,078</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Less&#160;- Accumulated depreciation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_afW36F4yg0i15IreWDXaHw_9_3">916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_YTKlwVlz4Eio7UZGbod2Qg_9_6">907</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net book value</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_xUO5JJkOi0OuyIOj_q4g-g_10_3">176</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_ea1G8bMhK0q-3nra7uU8nQ_10_6">171</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Note7Revenue_543542"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="glmd:RevenueTextBlock" id="Tb_U8ih100SiUGg0toV5OyhaA" continuedAt="Tb_U8ih100SiUGg0toV5OyhaA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;7&#160;&#8211; Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 54pt;">Samil Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">On July&#160;28, 2016, the Company entered into a license agreement (&quot;Samil Agreement&quot;) with Samil Pharm. Co.,&#160;Ltd. (the &#8220;Samil&#8221;), for an exclusive, royalty-bearing license for the commercialization of Aramchol (with an option to manufacture) for the treatment of fatty liver indications including NASH in the Republic of Korea. Additionally, following the ARREST Study, Samil has an option to extend the License to Vietnam, which, if exercised, would increase the clinical- and regulatory-based milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Under the terms of the Samil Agreement, the Company received an up-front payment of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_7_28_2016_To_7_28_2016_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_YaFu1dKFek-a9yFU3cmXPA" decimals="-5" format="ixt:numdotdecimal" name="glmd:RevenueRecognitionMilestoneMethodRevenuesRecognized" scale="6" id="Narr_KvQgaUNDHEOq9KVHutbu8A">2.1</ix:nonFraction> million. Samil has also agreed to pay additional clinical and regulatory-based milestone payments, which may aggregate up to $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_7_28_2016_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_DeA8R8quM027wniT31ykmw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="Narr_558vLn-VmUmVCkdcGzejTw">6.0</ix:nonFraction> million, as well as tiered, double-digit royalties payable on sales (under certain limitations). In September 2018, the Company received a milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_9_1_2018_To_9_30_2018_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_pXFd672UHU-v_1dF3cq4Bg" decimals="-5" format="ixt:numdotdecimal" name="glmd:RevenueRecognitionMilestoneMethodRevenuesRecognized" scale="6" id="Narr_u90CqyGvcUWkTLVA5bLFpA">1.5</ix:nonFraction> million from Samil in connection with the completion of its ARREST study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In accordance with ASC 606 the Company determined that the Agreement included a combined performance obligation representing the delivery of the exclusive license and completion of the ARREST study.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_U8ih100SiUGg0toV5OyhaA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 7 &#8211; Revenue (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company determined that the transaction price at contract inception was $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_7_28_2016_To_7_28_2016_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_YaFu1dKFek-a9yFU3cmXPA" decimals="-5" format="ixt:numdotdecimal" name="glmd:RevenueRecognitionNonRefundableUpfrontPayment" scale="6" id="Narr_tBUJBAS5qEGqCFP0uo9hLg">2.1</ix:nonFraction> million consisting of the upfront, non-refundable payment. None of the clinical or regulatory milestones were included in the transaction price upon inception, as all milestone amounts were fully constrained. Management assessed that the likelihood of occurrence of the other performance obligations in the Agreement was remote upon contract inception. As such, the stand-alone value of such performance obligations was deemed de minimis and none of the transaction price was allocated to those obligations. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, and therefore have also been excluded from the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">During 2018, when the Company determined that the achievement of its first milestone was probable, it included the variable consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_T34JgVPuFkWxKLRq7oMiFQ" decimals="-5" format="ixt:numdotdecimal" name="glmd:RevenueRecognitionMilestoneMethodRevenuesRecognized" scale="6" id="Narr_S6MRgUmS0kWaR73d5zNYzQ">1.5</ix:nonFraction> million as a part of the transaction price allocated to the combined performance obligation including the delivery of the license and completion of the ARREST study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">As of December 31, 2020, management evaluated the remaining clinical and regulatory milestones and determined that the variable consideration should not be recorded as revenue for the period ended December 31, 2020. The Company will re-evaluate the transaction price in each reporting period when events whose outcomes are resolved or other changes in circumstances occur that would indicate it is appropriate to recognize variable consideration as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">Revenue allocated to the combined performance obligation of the license and associated ARREST study was recognized ratably, based on the input method, from contract inception through conclusion of the ARREST study in June&#160;2018.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Note8RelatedParties_716917"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_vcj_pJzme0eHRHtzKDZJIg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;8&#160;&#8211; Related Parties</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">As of December 31, 2020, and 2019, the Company had an accrual in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_OfficersAndDirectorsMember_7_l-on5bd0-NL_4bzPYr0g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="Narr_JEMM4u_bfkiSYbNP_gkdSg">0.5</ix:nonFraction> </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">million and $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_OfficersAndDirectorsMember_mrVIWXqvQEmQsa2JBPQ6-w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="Narr_lg7O2WvrwU67_SXtp7-2dg">0.6</ix:nonFraction> million, respectively, pursuant to an employment agreement with its officers and directors&#8217; fee.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During 2020, 2019 and 2018, the Company recorded salary expenses, stock-based compensation expenses and directors&#8217; fee to its related parties in the amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_wpVjGpd6BEGCzRJ_fPNzXQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="Narr_hY_nmg1Ajk28hL90hbL4xg">3.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million, </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nqOXypy73EqMu8z3nQc_ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="Narr_50Fp66AkLkSpbqop1FR3nw">3.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_srAD6naErEOb_wZF3whfdA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="Narr_b2nLOuxTB0KOmv6eO1C3fQ">3.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million respectively.</span></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Note9CommitmentsandContingencies_472596"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_EMJCG9r3EEq1fFap6G8_iA" continuedAt="Tb_EMJCG9r3EEq1fFap6G8_iA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;9&#160;&#8211; Commitments and Contingencies</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">As of December 31, 2020, the Company recorded a pledge on its short-term deposit in favor of its bank in the amount of approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="glmd:BankLienOnMarketableSecurities" scale="3" id="Narr_HdOst_KJH0Gqsu9-4tPQWQ">113</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> thousand to secure the Company&#8217;s commitments to the bank, including a bank guarantee in favor Mintz K. Construction Company, the lessor of the Company&#39;s headquarters, totaling </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_GuaranteeOfIndebtednessOfOthersMember_o_oLvoDldEabEXMAdTrcLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualProvision" scale="3" id="Narr_k5WfQoy8uE-sc4GpY-b9RA">54</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> thousands as of December 31, 2020.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The Company enters into contracts in the ordinary course of business with Contract Research Organizations for clinical trials and clinical supply manufacturing and with vendors for non-clinical research studies and other services and products for operating purposes, which generally provide for termination upon 30 to 90 days&#8217; notice or less, and therefore are cancelable contracts and not considered as commitment or purchase obligations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">For information regarding the Company&#39;s leases commitments, see note 5.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_EMJCG9r3EEq1fFap6G8_iA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 9 &#8211; Commitments and Contingencies (Cont.)</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Other than as described above, the Company did not have any material commitments, including any anticipated material acquisition of plant and equipment or interests in other companies, as of December 31, 2020 and 2019.</span></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Note10ShareholdersEquity_721276"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="Tb_ptyR90ztskG0RBc2PibItA" continuedAt="Tb_ptyR90ztskG0RBc2PibItA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;10&#8211; Shareholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">A.&#160;&#160;&#160;Ordinary shares</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Ordinary shares confer upon the holders the right to receive notice to participate and vote in general meetings of the Company and the right to receive dividends, if declared.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">On December&#160;22, 2017, the Company entered into an At-the-Market Equity Offering Sales Agreement (the &quot;Stifel Sales Agreement&quot;) with Stifel, Nicolaus&#160;&amp; Company, Incorporated, as the Company&#8217;s sales agent (&#8220;Stifel&#8221;). Pursuant to the prospectus relating to the Company&#8217;s shelf registration statement on Form&#160;F-3 filed with the SEC on March&#160;26, 2018 (File No.&#160;333-223923) the Company may offer and sell, from time to time through Stifel, its ordinary shares having an aggregate offering price of up to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_22_2017_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_OSe9LSeVd0mkEr3CGmm7tA" decimals="-6" format="ixt:numdotdecimal" name="glmd:MaximumAmountOfSharesToBeIssued" scale="6" id="Narr_qqQvxpGGekWwtiu62m8kYQ">35</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. On May 15, 2020, the Company amended and restated the Sales Agreement dated December 22, 2017 between the Company and Stifel, Nicolaus &amp; Company, Incorporated to include Cantor Fitzgerald &amp; Co. as an additional sales agent for the Company&#39;s &quot;at the market offering&quot; program (the &quot;ATM Program&quot;). Pursuant to a prospectus supplement filed with the SEC on May 15, 2020, the Company may offer and sell up to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_5_15_2020_oxvKTuBAOkK40v6EQV3YEw" decimals="-5" format="ixt:numdotdecimal" name="glmd:MaximumAmountOfSharesToBeIssuedOffering" scale="6" id="Narr_CdZLwlkJB0GqdeoJ25RPxA">31.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million of its ordinary shares. As of December 31,2020 the Company sold </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DIoFCIoieUy02nLWRrmjlA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_kG7fqZ54iE2gdQ00Y3rj0Q">136,300</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares under the ATM Program for total net proceeds of approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DIoFCIoieUy02nLWRrmjlA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_m-xH4mbNLESPuaQxSP7dPQ">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During February 2021, subsequent to the balance sheet date, the Company sold an additional </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WPJh0pmyREubwtCYaYFNjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Narr_f_UEeRZU5k2n6tVkaFY0oA">1,541,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;ordinary shares under the ATM Program for total net proceeds of approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WPJh0pmyREubwtCYaYFNjA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_HT2bkDuWU0Kf2sTiOo8LmA">8.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. As a result, the Company has approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iP_trPoSQEGHbtnlJrlRyg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="Narr_xskCIU8aH0Oc4Ot8lk1Bag">22.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million remaining available for future sales under the ATM Program as of February 28, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During February 2021, subsequent to the balance sheet date, the Company entered into an underwriting agreement (the &quot;Underwriting Agreement&quot;) with Cantor Fitzgerald &amp; Co. (the &quot;Underwriter&quot;) in connection with an underwritten public offering &#160;(the &quot;Underwritten Public Offering&quot;) of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_cXtjJGuvVky0ockafD5Z4Q">2,197,803</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares (the &quot;Firm Shares&quot;) of the Company (the &quot;Ordinary Shares&quot;). The Underwriter agreed to purchase the Firm Shares from the Company at a price of&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember_rI1zXGeK8EmUIgiB1WtYEA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_tn32DpD-pkyp-gVOQ9nuaQ">4.3258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;per share. The net proceeds to the Company were approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_Qeh1BoZF4ES8LVe0Y7CtXQ">9.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for <ix:nonNumeric contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA" format="ixt-sec:durwordsen" name="glmd:UnderwritersOptionExercisableTerm" id="Narr_9CE3tDu820S_E3zlARJwBQ">30 days</ix:nonNumeric>, to purchase up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA" decimals="0" format="ixt:numdotdecimal" name="glmd:UnderwritersOptionToPurchaseAdditionalShares" scale="0" id="Narr_5OnRJzNSbkmvF80CLDCXtg">329,670</ix:nonFraction> ordinary shares (the &quot;Option Shares&quot; and together with the Firm Shares, the &quot;Shares&quot;) at the same price per share as the Firm Shares.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ptyR90ztskG0RBc2PibItA_cont1" continuedAt="Tb_ptyR90ztskG0RBc2PibItA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 10&#8211; Shareholders&#8217; Equity (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">B.&#160;&#160;&#160;Stock-based compensation</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The Company has an equity-based incentive plan, the 2013 Incentive Share Option Plan (the &#8220;2013 Plan&#8221;). As of December 31, 2020, a total of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glmd_IncentiveShareOptionPlan2013Member_jMEQ59S6skeyqHQJq4F4Nw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_MhLeO99bMkCZhTJ2Bm68NQ">687,973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> shares were reserved for issuance under the 2013 Plan. The 2013 Plan, which was adopted by the Board on September&#160;2, 2013, and approved by the Company&#8217;s shareholders on December&#160;30, 2013 (as was amended by the Board and the Company&#8217;s shareholders on March&#160;30, 2015, May&#160;11, 2015, and August&#160;30, 2018 respectively), provides for the grant of options to purchase the ordinary shares and the issuance of restricted stock units (&#8220;RSUs&#8221;) to the Company&#8217;s officers, directors, employees, service providers and consultants. The 2013 Plan provides for such equity-based compensation under various and different tax regimes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During the year ended December 31, 2020, certain current and former office holders exercised options into </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_yhIRHNgegUGWEm-H4V1pOg">47,509</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company, NIS </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Divide_ILS_shares_E36EhjGGZkK6K8BwwH-6kA" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_8krM9d7E_EWV9AZ_Sd9g5A">0.01</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> par value per share, for total consideration of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Narr_1C2TwSfK0EODo7tPp2zzpw">61</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> thousand.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During the year ended December 31, 2020, restricted stock units held by certain officers, employees and former employees vested resulting in the issuance of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_ahzgQjcAikSYCwVq_uBGCg">2,781</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company, NIS </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Divide_ILS_shares_E36EhjGGZkK6K8BwwH-6kA" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_pXcRG826lUy-cH2v3G7XOw">0.01</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> par value per share.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In March 2020, the Company granted options to purchase </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_3_1_2020_To_3_31_2020_MPCna657d0q_4brWdj6Npg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_4QChMSIq8kmGNOJm8ZpK2A">67,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company to several employees. The options are exercisable at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_3_1_2020_To_3_31_2020_MPCna657d0q_4brWdj6Npg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_UWwYDo9WoES1kiRwPubRuw">4.21</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share, have a </span><ix:nonNumeric contextRef="Duration_3_1_2020_To_3_31_2020_MPCna657d0q_4brWdj6Npg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_GoB15M2w7kaJ32mRLTZcPA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> term and vest over a period of </span><ix:nonNumeric contextRef="Duration_3_1_2020_To_3_31_2020_MPCna657d0q_4brWdj6Npg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_c5GaRpV-PUK6Svh75oqvkQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four years</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. The aggregate grant date fair value of such options was approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_3_1_2020_To_3_31_2020_MPCna657d0q_4brWdj6Npg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="Narr_-6zyELfj7kylL5lDM-VNBA">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In August 2020, the Company granted options to purchase </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_8_1_2020_To_8_31_2020_qLCEtGphHkma-pZvOcz6CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_U1VfqVwiYU2n2Sih36S9WA">30,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company to a director. The options are exercisable at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_8_1_2020_To_8_31_2020_qLCEtGphHkma-pZvOcz6CA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_usn2s-NJQ0iG_-byq3Z7eA">4.77</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share, have a </span><ix:nonNumeric contextRef="Duration_8_1_2020_To_8_31_2020_qLCEtGphHkma-pZvOcz6CA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_UZ3h5KMM4EKMuXumpKFVPA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> term and vest over a period of </span><ix:nonNumeric contextRef="Duration_8_1_2020_To_8_31_2020_qLCEtGphHkma-pZvOcz6CA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_os7RpoksF02KLqgClTAUFg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four years</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. The aggregate grant date fair value of such options was approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_8_1_2020_To_8_31_2020_qLCEtGphHkma-pZvOcz6CA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="Narr_bgmMpW_iiESr_hgGb3JieA">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. In addition, the Company granted options to purchase </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_8_1_2020_To_8_31_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_-BwgIJ4swUqIbUQSXGQ7Ug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_nEfQ57LUP0mg7gkeKE-Nbg">220,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company to the Company&#39;s chief executive officer (after shareholders&#39; approval). The options are exercisable at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_8_1_2020_To_8_31_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_-BwgIJ4swUqIbUQSXGQ7Ug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_ws_OzRmGWU23oyl2nri4hg">5.12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share, have a </span><ix:nonNumeric contextRef="Duration_8_1_2020_To_8_31_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_-BwgIJ4swUqIbUQSXGQ7Ug" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_fb8EkpY6Y0u_xK7cCbdlDw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> term and vest over a period of </span><ix:nonNumeric contextRef="Duration_8_1_2020_To_8_31_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_-BwgIJ4swUqIbUQSXGQ7Ug" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_VtgS_2JdJ0WVZLmmHNJAEw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four years</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. The aggregate grant date fair value of such options was approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_8_1_2020_To_8_31_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_-BwgIJ4swUqIbUQSXGQ7Ug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="Narr_gUxGUDpZYUim1sdjkKM7Ag">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In November 2020, the Company granted options to purchase </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_F1EeknIQ00ap2MncTfUtcQ">267,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company to several employees. The options are exercisable at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_0dlYL4k6MEKTXEDuXXKzeA">3.33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share, have a </span><ix:nonNumeric contextRef="Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_6PH7He41akKVjoyjNoUrjg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> term and vest over a period of </span><ix:nonNumeric contextRef="Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_31exTaTF60ikkTmgGPLL2w"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four years</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. The aggregate grant date fair value of such options was approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="Narr__DEejOtscEGU6xx3fErxOQ">0.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. In addition, the Company&#39;s Board approved to grant options to purchase </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"><ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_11_1_2020_To_11_30_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_5ym3QBU5HUSdGhzhJHMUXg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_tkoz2cU1j0SevZUdGCyPuw">220,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company to Company&#39;s chief executive officer subject to shareholders&#39; approval (as of December 31, 2020 shareholders&#8217; approval was still pending). The options are exercisable at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_11_1_2020_To_11_30_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_5ym3QBU5HUSdGhzhJHMUXg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_aOhONHfJO06fvo8fT-UFLQ">3.33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share, have a </span><ix:nonNumeric contextRef="Duration_11_1_2020_To_11_30_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_5ym3QBU5HUSdGhzhJHMUXg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_u_Gm620j8ku_3JsLq3Dr8w"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> term and vest over a period of </span><ix:nonNumeric contextRef="Duration_11_1_2020_To_11_30_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_5ym3QBU5HUSdGhzhJHMUXg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_ruOhqAK7t0SJ8bzO9wRb4Q"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four years</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_N9xgxbsY1ky3lNREpYfyFw_1_2"></a><a id="Tc_IF85tfunBkSMwR66GZ-VPQ_1_7"></a><a id="Tc_lIDQXFJgfUqCuAqPhZ2JdA_2_4"></a><a id="Tc_9h7q49tWfUmyEwe0BQuGvw_2_9"></a><a id="Tc_9h825Sq78UOakcgUkWI9yA_3_4"></a><a id="Tc_2V4pxAWXGkqr0eJgDrcNqA_3_7"></a><a id="Tc_XLgDTrbjjUigbOv9YNhOqw_3_9"></a><a id="Tc_mibTiF3EoUmRjFyHEiPUSQ_4_2"></a><a id="Tc_WdJIu4g6zkO5-AZnNKBGig_4_4"></a><a id="Tc_RV7byVc-JkWGS1HRWcKG9A_4_7"></a><a id="Tc_bCVmX_tsJ0CocWDxSPJGrw_4_9"></a><a id="Tc_gtRWiZWRqE-Oa5t_T70pmw_5_2"></a><a id="Tc_Fw2O13tmqEaKVsRpkAWGKQ_5_4"></a><a id="Tc_kPjPnRs58UGPGsrvhE7PTw_5_7"></a><a id="Tc_gMp-ZelMg0eVUd41-wusxQ_5_9"></a><a id="Tc_V3HZtWqks06ZlP_EnjNf6A_6_0"></a><a id="Tc_f9wVxqvV7UyFtpAXq_IsLw_6_4"></a><a id="Tc_zxkHfS_WDEiVkB0r31CJjw_6_9"></a><a id="Tc_6mui_0jWaEyTdcFBDvCanA_7_0"></a><a id="Tc_FWekPtj8_0aOC95SyfxUHg_7_4"></a><a id="Tc_Gnb-K0YIWEOjzAvswQzJxg_7_9"></a><a id="Tc_VoT_BO1iPk-QJW-pHVBdbQ_8_0"></a><a id="Tc_SK3pjlcPu02Jqo_zHQID3A_8_4"></a><a id="Tc_GMf33YD39kSDaW3Ba8fqzA_8_9"></a><a id="Tc_AjqJc4jmQkKVjQkgKGIE7g_9_0"></a><a id="Tc__ir_caFFYUSFQXbaIT27hw_9_4"></a><a id="Tc_bXYPaGzKhkKZK40fCn7B4w_9_9"></a><a id="Tc_wHPjnW3VgEeX6b2rbQ3yJA_10_0"></a><a id="Tc_I-IjqGQLeUuRV5-ZQeCYwA_10_4"></a><a id="Tc_bSj2aIMVZUepHzLsorPlGQ_10_9"></a><a id="Tc_eZDEMytjbUuooCEVRNUvGg_11_0"></a><a id="Tc_RD_bBgujzki8aL6HejCtcA_11_4"></a><a id="Tc_QMrqcgWy5EaNqt2I_NxrFg_11_9"></a><ix:continuation id="Tb_ptyR90ztskG0RBc2PibItA_cont2" continuedAt="Tb_ptyR90ztskG0RBc2PibItA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 10&#8211; Shareholders&#8217; Equity (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">B. &#160; Stock-based compensation (Cont.)</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">A summary of the status of the Company&#8217;s option plans as of December&#160;31, 2020 and 2019 and changes during the&#160;years then ended are presented below:</span></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_zPo_guEl2EmGCb_2oVS2oA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Options outstanding at beginning of&#160;&#160;year</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_3zXuPmBqWE6hZHyZBTf1wA_6_2">2,393,715</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_-wqRQgbDgEe6lE7ikuQGnA_6_5">6.12</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2018_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_qalgby9MtkGBayyVeht6lA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_qShw_l9vgk6i-qtlCzRS-A_6_7">2,349,054</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="As_Of_12_31_2018_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_qalgby9MtkGBayyVeht6lA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_jvndHV7910egaXGFS-2_Rg_6_10">5.92</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_3RVDP0piUkuM-pOcAj9GDg_7_2">585,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_xFpMQoNj2UWrYmUa3IEw4A_7_5">4.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_oes0FsH0M0WVSaerXQ1muA_7_7">282,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Ya4Zk0GtMUOPpsjMSMUpKw_7_10">5.07</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Forfeited</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_yh0pdZeZ10yAAzYYUIPMYA_8_2">208,195</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_RiXQiQRmB0GBCltOTotQYA_8_5">7.49</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_lxJFM9uACkCFWkzFwxyXWA_8_7">121,250</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Me5J5m5DSkC4Le9kX6wmwg_8_10">6.37</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_zFPvPV8LX0C0vYUAcPxonw_9_2">47,509</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_CoY8qp4X0UCh65Z6V3_Uxw_9_5">1.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_J6tZ_wlpkUO-F3vs8ws7EA_9_7">116,589</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_CS9mra9Tn0O54QbMyX3L7w_9_10">1.23</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at end of&#160;year</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_EBlJedVOS0a8vpK59r2GmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_qQDFDIK1LkWgSrgYX0b96g_10_2">2,723,011</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_EBlJedVOS0a8vpK59r2GmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_JTClcy_pgU-2viWXM0HHbg_10_5">5.70</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_aQLTMjGT3UWcVMzYNInxQg_10_7">2,393,715</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_QUrSnWAdDE2Kip-Ty9pKEg_10_10">6.12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Options exercisable at&#160;year end</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_EBlJedVOS0a8vpK59r2GmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_NlY9nljr0kmYUBza_HUakQ_11_2">1,754,261</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_EBlJedVOS0a8vpK59r2GmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_zApWywxt_EC_wKnMYZ7zBw_11_5">5.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_Q11FYJEy6k-SJo9L9l8pAA_11_7">1,647,048</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_O1K7JdpZs02RXQVdeYtp2A_11_10">5.02</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The following assumptions were used for the fiscal year 2020, 2019 and 2018 grants:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_par6JoGtyEia2JkNVcELdA"><ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_LZp8xJ7D_Uis9uxuaSWaCQ"><ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_qTuvVaTMfE6ybJ6FQ84cng">0.00</ix:nonFraction></ix:nonFraction></ix:nonFraction>% for all periods.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">risk-free interest rate between <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_-5jLu8n7y0SLst89FxrSYg">2.67</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_Ay8-66Tad0Gz93yaN9DTlA">3.01</ix:nonFraction>% for the fiscal year 2018, <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_DwKwY9haUkOiuk0TxXk6Rw">1.61</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_L1FZNgP9pkmBLEQryMoy0g">2.43</ix:nonFraction>% for the fiscal year 2019 and <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_wb4EvBS9ekKTBJ6_WI-5bA">0.42</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_O2azoLzBKE6tf1inYRf0qw">0.74</ix:nonFraction>% for the fiscal year 2020.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">an expected life between <ix:nonNumeric contextRef="Duration_1_1_2017_To_12_31_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GEzGoXG5Ok-EayrH7ZBK0Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_BDEnfxwIPEm9vOec1M0gZw"><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LVpIBdN-a02_xjlF3wujBg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_leSrHGpuLE-poVLvEKdiyQ"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y0ei-czCk0Sc-jHLUaPa8w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_8T0yZIFgYUmQjnoTNJxj_w">5</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> and <ix:nonNumeric contextRef="Duration_1_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NyHUYA8FSUyuZNantnazBQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr__EYENh9aCUmdrgkSIbV8VQ"><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_r7Ms1ZL-BEiOxWAAdEMExA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_fKz2IUo9C02-W15JXjlzlg"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__8e7PIYNIkuDeGtL1vwa3A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_VTYmqIsvAEGOkRpK2lO1SQ">6.25</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> years for all periods.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">and a volatility rate ranging between <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_mki33hQldkutBxsStxU-2A">78</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_JO-L3wc0fkyUY3jMyT3QIA">92</ix:nonFraction>% for the fiscal year 2018; and <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_s8VL84_ceEGSC3fEaCLJJw">87</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_mbJ5fy8Wfk-a9yPcrNKDww">95</ix:nonFraction>% for the fiscal year 2019 and <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_OH4eqPqy3Eu25jQco3hKCQ">83</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_xAVhXhOyZkSvFSlue_d1gw">88</ix:nonFraction>% for the fiscal year 2020.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">As of December&#160;31, 2020, and 2019, the weighted-average remaining contractual term of the outstanding options, excluding the <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_ZfyaDg63V0iSHGKb0HKQCw">38,637</ix:nonFraction> options granted in 2002 that have no expiration date, is <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_9bVO9FEEO0OFs_EwcmxV9Q">6.60</ix:nonNumeric> and <ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Narr_jaiDD-insEu8CtP9Oxq2bA">6.36</ix:nonNumeric>&#160;years, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The weighted average grant date fair value of the options granted during the&#160;years ended December&#160;31, 2020, 2019 and 2018 is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_DnN4eWWdz0amUQDx9EYpiA">2.76</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_IVKmGE4KvkCAL_nNKg4_iw">4.85</ix:nonFraction>, and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_KW04TY5vo0GtxJwPsBj-0w">8.19</ix:nonFraction> respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">As of December&#160;31, 2020, a total of the <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4fndOwz4MES4TiHYJ6gb3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Narr_acffK-aHeEOlADgTFV8DaA">390,905</ix:nonFraction> outstanding and exercisable options are &#8220;in the money&#8221; with aggregate intrinsic value of $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4fndOwz4MES4TiHYJ6gb3Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="Narr_6J0_5NtGO0ihcXSdBrnHGw">1.1</ix:nonFraction> million; while as of December&#160;31, 2019 a total of <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QjPdXPDPS0KeLH50EvKEiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Narr_CGT1GDIDeUqHVr8PqV1cvw">1,179,398</ix:nonFraction> outstanding and exercisable options were &#8220;in the money&#8221; with aggregate intrinsic value of $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QjPdXPDPS0KeLH50EvKEiw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="Narr_a6_qfxQHWUaeHVsCjGjl5Q">3.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The unrecognized compensation expense calculated under the fair-value method for stock options expected to vest as of December&#160;31, 2020, 2019 and 2018 is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4fndOwz4MES4TiHYJ6gb3Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_A26r1f94xkm76uXwlfks0w">4.0</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QjPdXPDPS0KeLH50EvKEiw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_Q-iNYjGoKkW3I3g18OIxoA">5.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KeNcj4ynQEmMLA9cFanIvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_5FgIy9jlskGcbdD0v7jQ-Q">6.5</ix:nonFraction> million, respectively, and is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_HDa8U_YR3E-Z1U9Z27SGLw">2.41</ix:nonNumeric>&#160;years, <ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_ngZKp3SXBESkUA9BJfXnjA">2.9</ix:nonNumeric>&#160;years and <ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_lG6fbY-D0UeDjz6Ykptk5A">3.1</ix:nonNumeric> years, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">For the&#160;years ended 2020, 2019 and 2018, the Company recorded a total of $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_sDxGcKRdpECFFxfORK0PJw">2.1</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_Zgy3WOB5q0CAZqLdzfVPaA">2.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_nidZekHOTkCMJYzEaB_Mog">1.8</ix:nonFraction> million of stock-based compensation expenses, in connection with the above-mentioned options.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Narr_qx3SZXAbYkmX84RoDVqaAA"></a><ix:continuation id="Tb_ptyR90ztskG0RBc2PibItA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 10&#8211; Shareholders&#8217; Equity (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">B. &#160; Stock-based compensation (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">During 2016, the Company issued a total of <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2016_To_12_31_2016_sn54mW8hE0KEfttuS1LktQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_RRxAenBrWUCTqWxITyldhQ">78,750</ix:nonFraction> restricted stock units (&quot;RSU&quot;). Upon vesting, each RSU will settle by the issuance of one ordinary share. The RSUs vest over <ix:nonNumeric contextRef="Duration_1_1_2016_To_12_31_2016_sn54mW8hE0KEfttuS1LktQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_2INhQnom6kScobTawWM1BA">four years</ix:nonNumeric>. As of December&#160;31, 2020, a total of <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_NTKVw5Kv-0yU4awrEO5YIA">59,528</ix:nonFraction> ordinary shares were issued upon vesting of <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_larseCB5IkKcZBkUASDzkg">2,781</ix:nonFraction> RSUs and there are no outstanding RSUs, while as of December&#160;31, 2019, a total of <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_IO6mY1IQBEGbskfhruA6IA">56,747</ix:nonFraction> ordinary shares were issued upon vesting of <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_X9nZQvxS30WkKoQwk-Af8w">54,316</ix:nonFraction> RSUs and a total of <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_glmd_EmployeeStockOptionAndRestrictedStockUnitsMember_1uQb0r1NiEeEwnFMdNS4OA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Narr_ZxLLtvbj8Ue72Pz7VM8vhA">2,781</ix:nonFraction> RSUs were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">For the&#160;years 2020, 2019 and 2018, with respect to the above-mentioned RSUs, the Company recorded stock-based compensation expenses in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_I_8qF4py_U-hFUr5wnrNSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Narr_sRuts2Lpk0yO8SuZ3DQW8Q">5</ix:nonFraction> thousand, $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_W0hOEi39s0i4CgIp_7LThA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Narr_7Gy6dS5THkOSBx_GrXvDSQ">70</ix:nonFraction> thousand and $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hf5IyP78Okm12S_Q5Zkpgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Narr_NPj1RTqVWUqnfpXZ0pBEIA">94</ix:nonFraction> thousand, respectively. All of the above-mentioned stock-based compensation expenses are recorded under general and administrative expenses. as of December 31, 2020, there are no unrecognized compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 72pt;">The unrecognized compensation expense calculated under the fair-value method for RSU&#39;s expected to vest as of December&#160;31, 2019 is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Narr_ojo02MwHnUedcWS5Y1tfBQ">5</ix:nonFraction> thousand, and is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_56dVcCPVtEyjU1B1klJ3gA">one year</ix:nonNumeric>. As of December 31, 2020 there are no outstanding RSU&#39;s.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Note11ResearchandDevelopmentExpenses_744"></a><a id="_fab0be32_6cad_4e8b_b993_e1d48f65d191"></a><a id="Tc_yKnYy1DJc0CLfDamqZDEhQ_1_2"></a><a id="Tc_1WUPb3RMU0mXdeLC10i6qg_2_2"></a><a id="Tc_450Ia_bNEkC8Y7uDG-MCoA_2_5"></a><a id="Tc_AZzf-qQpe0WVjOTdVsnLWA_2_8"></a><a id="Tc_hTdmrXGpeE2EaIQ_Wz4V7A_3_2"></a><a id="Tc_B2v08j1Xekq2xZPd6Cdtbg_4_0"></a><a id="Tc_c5AIjPSSZEyeQV8BBmw7Bw_4_2"></a><a id="Tc_a6CfsgaoiUy_8yIzQ1yXOg_4_5"></a><a id="Tc_zyfWeAfq0kS4RdKY8MJrLw_4_8"></a><a id="Tc_1d2oCUhzKUW0xTEGGaatuw_5_0"></a><a id="Tc_EOE3H5NxjkOpg_Iv5F7Avg_6_0"></a><a id="Tc_xQhKGOkI402OJdlAqJ9tVw_7_0"></a><a id="Tc_FdCnplZGkUaICVWzOuihrw_8_0"></a><a id="Tc_qLcZQqijPk69NevGYOc3Tw_9_0"></a><a id="Tc_-eMPupNS6EKUXW86EOZwMg_10_2"></a><a id="Tc_PHWHti1BgEm9CwhRPaJ2CA_10_5"></a><a id="Tc_PbXLU_9mwk-694HA3iOiHQ_10_8"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="Tb_0qRMTve6DEuIxRSHEusd0A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;11&#160;&#8211; Research and Development Expenses</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" id="Tb_5RCGV2TbuUiLkv2vcMmQbQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chemistry and formulation studies</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg" decimals="-3" format="ixt:numdotdecimal" name="glmd:ChemistryAndFormulationStudiesExpenses" scale="3" id="Tc_05Okdxm0_U2Q0tKL-jdFFQ_4_3">5,856</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw" decimals="-3" format="ixt:numdotdecimal" name="glmd:ChemistryAndFormulationStudiesExpenses" scale="3" id="Tc_MhzvwfDikU-HcgUEHwqwGw_4_6">3,439</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g" decimals="-3" format="ixt:numdotdecimal" name="glmd:ChemistryAndFormulationStudiesExpenses" scale="3" id="Tc_xhmg3giXTk-wPAjBrgmLDQ_4_9">968</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salaries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" id="Tc_oIK3iuQFhUuYN09ygxob7Q_5_3">2,570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" id="Tc_j2LbRCYIQ0SxzTbLYayWBQ_5_6">2,283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" id="Tc_qfltuD35hUS0rStV4Z-_Kg_5_9">1,617</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_G6X-g6UiU0C01hr2egLpDQ_6_3">871</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_xYYr4WeU50SGba7dGiGO1Q_6_6">883</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_WIGJTeCQJE6fAjk9A44fZw_6_9">582</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and preclinical studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg" decimals="-3" format="ixt:numdotdecimal" name="glmd:ResearchAndPreclinicalStudiesExpenses" scale="3" id="Tc_txMM_cqkOkilt3QSLQIBUw_7_3">1,873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw" decimals="-3" format="ixt:numdotdecimal" name="glmd:ResearchAndPreclinicalStudiesExpenses" scale="3" id="Tc_Zv2ei5-jcUOLeL-nEi2aHw_7_6">1,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g" decimals="-3" format="ixt:numdotdecimal" name="glmd:ResearchAndPreclinicalStudiesExpenses" scale="3" id="Tc_m9tnwF8JrEKIvFyId6N__w_7_9">963</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical studies</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg" decimals="-3" format="ixt:numdotdecimal" name="glmd:ClinicalStudiesExpenses" scale="3" id="Tc_bxG1TTqzxEuaDINJY7o6dw_8_3">13,225</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw" decimals="-3" format="ixt:numdotdecimal" name="glmd:ClinicalStudiesExpenses" scale="3" id="Tc_yyUCaXF9Skia5p2NfW6yqg_8_6">8,346</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g" decimals="-3" format="ixt:numdotdecimal" name="glmd:ClinicalStudiesExpenses" scale="3" id="Tc_EkYtfA1xaUWc8zA3GUKotw_8_9">3,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulatory and other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg" decimals="-3" format="ixt:numdotdecimal" name="glmd:RegulatoryAndOtherExpenses" scale="3" id="Tc_GmuUth_LmUW7fQG_rupbCQ_9_3">1,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw" decimals="-3" format="ixt:numdotdecimal" name="glmd:RegulatoryAndOtherExpenses" scale="3" id="Tc_dy1pn3JU-kCTgkUWVRDTJw_9_6">1,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g" decimals="-3" format="ixt:numdotdecimal" name="glmd:RegulatoryAndOtherExpenses" scale="3" id="Tc_98qmUSgEikWIxhj9o2IveQ_9_9">608</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_VWvHPkr8Ak6Od7NZFTjwIQ_10_3">26,082</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc__sief6Rp50i6zOYdTHeeEA_10_6">18,180</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_ggXS5yZw2Eak5uWQrzX-JQ_10_9">8,313</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Note12GeneralandAdministrativeExpenses_9"></a><a id="_4027fa00_0775_4af5_abf1_b8060086271c"></a><a id="Tc_tu4D_O_6pUWRsLS9bmCI5g_1_2"></a><a id="Tc_5tR7K1a6yk2mzvcoYfr23A_2_2"></a><a id="Tc_dxKQN-oN-0KfsAPPwm5eRg_2_5"></a><a id="Tc_NgrqGe0VYkSRO_nXNMs_FA_2_8"></a><a id="Tc_6fJkqBvSQkCDTz-dZZVkTA_3_2"></a><a id="Tc_7SPgAFgYIUW7RXfMacZemA_4_0"></a><a id="Tc_BJvSI9GeLUy0Tx9GIFjCkw_4_2"></a><a id="Tc_CvzGhVZWx0SYUAvITXY9wA_4_5"></a><a id="Tc_1T7yYEZCm06Ceis_tVEX8A_4_8"></a><a id="Tc_Bticlt9yBUSqREiMNaeC3A_5_0"></a><a id="Tc_ST3dR70IXkGBIg_Y3ZbtJw_6_0"></a><a id="Tc_-XnrKIHu40eJMFaRCTHraw_7_0"></a><a id="Tc_VovRhwlKB0ao__6QGAsdXA_8_0"></a><a id="Tc_h_a6a9akIkiojwabXrWb7A_9_0"></a><a id="Tc_j44LXyPP_EGtQXiUnX9FHg_10_2"></a><a id="Tc_5XIPnDniq0mYFQR36iJTsA_10_5"></a><a id="Tc_R5TZE1Dd3EeK3zFNgqgEgg_10_8"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="glmd:GeneralAndAdministrativeExpensesDisclosureTextBlock" id="Tb_6SwSPwNxGEKZOmhOa0IpJQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;12&#160;&#8211; General and Administrative Expenses</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="glmd:GeneralAndAdministrativeExpensesTableTextBlock" id="Tb_G6XyJMXa7EqfBNnX67Dwmw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_nRt1JN62bkCWqejgC-vQ1g_4_3">1,194</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_DQHqSikUh0yem4j1GxJzgg_4_6">1,349</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_FkrcklaRRUGXH7Tlz-pJtw_4_9">1,201</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="3" id="Tc_F7yZNc1v2UeBx7NKUvjlfA_5_3">796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="3" id="Tc_DjeA5GMETk6hhjgOLIVhJQ_5_6">877</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="3" id="Tc_eLgwvyqAbku9AcsKZQ2crg_5_9">896</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salaries and benefits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" id="Tc_j5AdiIjN30yow9PZE6Nxbw_6_3">828</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" id="Tc_orKaEORlL0-NK_qh5KdRJw_6_6">856</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" id="Tc_1u2MObROqEO4KB_FU-7v3w_6_9">1,346</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rent and office-maintenance fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Tc_706akkoYI0iyE0vZK_bUrw_7_3">430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Tc_PLcT4MVQxkiyFBvh4ffodQ_7_6">482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Tc_w5j_Nsz3g0iq9hfSO8QvBw_7_9">308</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investor relations and business development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessDevelopment" scale="3" id="Tc_pFGRWNBWQk29FILBsTcn1g_8_3">293</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessDevelopment" scale="3" id="Tc_5di1XzKe5ESZvFJt4D3h0w_8_6">364</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessDevelopment" scale="3" id="Tc_zKRVMJNg0Ey-8F-e6O7iSw_8_9">464</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance and other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="Tc_-TSxAxzdU0i8ID7a2RYsZg_9_3">587</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="Tc_TZTTLjLd4kGN51bHYP-45A_9_6">268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="Tc_I5zmtfXOw0OA8qxPwaSqPg_9_9">225</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_0BF7Tj7isEi5QOAxbEvxiw_10_3">4,128</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_gjN7GZL7wUSzh8Kqt9_JPQ_10_6">4,196</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_SZ9-ZsX3VkO89eMS5FiIvQ_10_9">4,440</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Note13Financialincomenet_45595"></a><a id="_e15e4d25_550f_4d18_a89b_87811c848c3e"></a><a id="Tc_HmMJci-8XEC6AGy_SQbOPw_1_2"></a><a id="Tc_T_sNMVc6hEGEANuFuE-oog_2_2"></a><a id="Tc_6cEWy1me_UiyCyn6tJWkkQ_2_5"></a><a id="Tc_OvCd1OOfr0CBqNBwYRFIlw_2_8"></a><a id="Tc_epq19qzZFUybrPpW4-qKcw_3_2"></a><a id="Tc_5P80vmxuY0yMzn8dkJv3jA_4_0"></a><a id="Tc_5uOlmmtdaESBpqWvYPD9dg_4_2"></a><a id="Tc_6l49x16bVEWaUl2pj4nZgw_4_5"></a><a id="Tc_pcMB31uaU0e-BqjIp3A4Dw_4_8"></a><a id="Tc_ze86oGsye0i4QgZ-YaWOQw_5_0"></a><a id="Tc_0xY5RhDwCkGZcStRI67psw_6_0"></a><a id="Tc_96k05NnIlUCoZFpYuw0SJA_7_0"></a><a id="Tc_s0OT94E36EG4CbX_GxZ2cA_8_2"></a><a id="Tc_XNudwFDpyUKLYxn68tYNyQ_8_5"></a><a id="Tc_1puae4iG60Ooaa-igEL1Ww_8_8"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_MYpb6tNGVUuwy1XtyxtCNA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;13&#160;&#8211; Financial income, net</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" id="Tb_602GfVcVOUKUqpqDg2rZxA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bank fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="glmd:BankFees" scale="3" id="Tc_-_JQXErdVEWLSWgaVt3JsA_4_3">31</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="glmd:BankFees" scale="3" id="Tc__nF2_xchVk6JIRv-AYK6kQ_4_6">33</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="glmd:BankFees" scale="3" id="Tc_0h6lF4NOyE-wkdXhlW_5Kw_4_9">42</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="Tc_fhfRWliqu0uoYcbscco1Nw_5_3">1,192</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="Tc_oPZzS_xCkEKJngT1DVCTfQ_5_6">1,953</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="Tc_kubU_FkETU6Ako-l3kt3dw_5_9">959</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain from sale of marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" scale="3" id="Tc_Wsqrq4730EuD1eiwuYX_Fg_6_3">397</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" scale="3" id="Tc_pV_Dw6MhUkO7e2IrFm7N5g_6_6">106</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" scale="3" id="Tc_k-w5rvxZ7kqsywZjdilYHg_6_9">12</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency (gains) losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="3" id="Tc_NHXY6UfrwkSkIbIgiQEilA_7_3">119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="3" id="Tc_rl6BwwBJk0iRnL0lErzuzg_7_6">111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="Tc_bf0hQ9Z_t02zEnpkdqKj-A_7_9">5</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_hOBv58vDoEKgYhhtBzvo0g_8_3">1,439</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_TUPixhhya06O14t4KWvRrw_8_6">1,915</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_YUgfQzaT7EayI5YrvzGYBg_8_9">934</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Note14IncomeTaxes_413029"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_U76XZB3I7kSy0VK6sC-xNA" continuedAt="Tb_U76XZB3I7kSy0VK6sC-xNA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;14&#160;&#8211; Income Taxes</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company is assessed for tax purposes on an unconsolidated basis. Each of the Company&#8217;s subsidiaries is subject to the tax rules&#160;prevailing in its country of incorporation.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Corporate Taxation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Israeli Companies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In January&#160;2016, the Israeli corporate income tax law was amended and reduced as of January&#160;1, 2016 to <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_bgXq7TSYz0qDPCPOCoHLlA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_0hqa6x3_Hk-sC0BELaslyg">25</ix:nonFraction>% (from <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_ScwAFiM_R02IVHmPu8-uGw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_-TcFsn30rkacAjWhR1DaZw">26.5</ix:nonFraction>%). In December&#160;2016, the Israeli corporate income tax law was further amended and reduced as of January&#160;1, 2017 to <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_U--doeSff0eYGwC7nwkM-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_Ka0_ZIMpTEKwGQ5yhej2uQ">24</ix:nonFraction>% and as of January&#160;1, 2018 and onwards to <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2018_To_12_31_2018_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_JOb54R0hTEydao88CStcSA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_0dK9TbtU9Umm-krHQ7LxzQ"><ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2019_To_12_31_2019_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_DSjIA39FDUaJmBOrv2YWwg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_v6yt7yG5okaNVO521uzYGw">23</ix:nonFraction></ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">On February&#160;7, 2018, the Israeli Tax Authority issued a ruling granting the Company&#8217;s Israeli subsidiary, Galmed Research and Development Ltd, a &#8221;Preferred Technological Enterprise&#8221; status&#160; as defined under the Encouragement of Capital Investment Law&#160;-1959 (the &quot;Approval&quot;). The grant of the status means that the Company&#8217;s Israeli subsidiary will be subject to a reduced Israeli corporate tax rate that will range between <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_2_1_2019_To_2_7_2019_srt_RangeAxis_srt_MinimumMember_wTFaM2m8mEeYWNwxhsduUQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_4Y1gStMyRUuOw-6RP9CbwQ">6</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_2_1_2019_To_2_7_2019_srt_RangeAxis_srt_MaximumMember_G54FxZmw_0-M5Erc8SbIag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_NJa9JAkQj0Gx-XIt2l8sJw">12</ix:nonFraction>% on any future taxable &quot;technological income&quot; which includes sales, licenses and royalties from its IP protected products. The tax ruling applies for five&#160;years until 2022 and may be extended for further periods subject to meeting certain requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Maltese subsidiary:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Taxable income of Maltese companies was subject to tax at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_FOpb3JVogkOpHOfrV1dInw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_SFWKYcY2S0GePhQ-TnDs2g">35</ix:nonFraction>% in 2020.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Net Operating Loss Carry forward</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2020, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_AkDDIVRZ1UepVg7svirkdg">110.9</ix:nonFraction> million net-operating-loss carry forwards, consisting of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_ABpxUYDxU0CDiyikjLs1sg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_6XGNZPAVgkutIXQ6wGAMKA">11.7</ix:nonFraction> million of Maltese net-operating-loss carry forwards and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_mGyra1etzUCzEOs-2C5hCQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_rQSuEcZYu0idn_YFrvPZVQ">99.2</ix:nonFraction> million Israeli net-operating-loss carry forward. Additionally, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="6" id="Narr_wYZcglCXaEeI94rEF0_QAA">2.4</ix:nonFraction> million of capital loss carry forward from the sale of marketable debt securities in Israel. The Maltese and the Israeli loss carry forwards have no expiration date.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ca1cefd0_f500_4895_accb_4435a44bffc9"></a><a id="Tc_T0wYKC05AEGBJt_c5SHYvw_1_2"></a><a id="Tc_XQTKyBKO5EKvdtYWSlP8Tw_2_2"></a><a id="Tc_HMLBKvZdskO8-zgGxYuToQ_2_5"></a><a id="Tc_9rUzgsO7iE6p1_T34OMn8g_3_2"></a><a id="Tc_Q-U7h6tMt0GD4eTXvrZg1w_4_0"></a><a id="Tc_UbRPh2QepUmykGgtij5DGA_5_0"></a><a id="Tc_YtRhEzaLVU2sLzOCkPzCLw_5_2"></a><a id="Tc_j8wcErK4F0CbLokzsWXNZQ_5_5"></a><a id="Tc_0hZvljysFESB56Y0Ug8A9A_6_0"></a><a id="Tc_D4DOwQcHR0K4YPJDkvYnZg_7_0"></a><a id="Tc_bCNbplF34UOT9wjt9B65Cw_8_0"></a><a id="Tc_ZtegOpattU-mdrCUbiNalw_9_0"></a><a id="Tc_r4w0oWsGR0a1hn8FhEGPAw_10_0"></a><a id="Tc_wV-A_A2OH0-Tew9eh_mwdw_11_0"></a><a id="Tc_wZz7P3gDBkqgcvYKuDN0MA_11_2"></a><a id="Tc_mSATsQYwZ0Os0Tg5AMZ8oQ_11_5"></a><a id="_dcc4df07_84b4_4906_a4da_c8b47f54c12f"></a><a id="Tc_oTSVj0xVukeoMA2qfPezAQ_1_2"></a><a id="Tc_6tay-wwB7Ey4mPBywJDusQ_2_2"></a><a id="Tc_CY7eoKKCsEqtbx6g-f6cZQ_2_5"></a><a id="Tc_rVAtbZ34QEeP1meGiG2ovw_2_8"></a><a id="Tc_EpnGmsDMyUO1viJ0Gl_QyA_3_2"></a><a id="Tc_-h8WU2RjPki9EOZtDIcxVg_5_0"></a><a id="Tc_sW0RmEmvPkyJIhak3UeJPg_5_2"></a><a id="Tc_9VHbGTfE1kag8ISci0wAxw_5_5"></a><a id="Tc_rbkuIHZ9-U6Cmh3W55_FYA_5_8"></a><a id="Tc_KO7N7f6mck2hYBYfpntKpA_7_0"></a><a id="Tc_bey5_8Vsmka4H4K0uvAuiA_7_4"></a><a id="Tc_Di2nymEBOUCV9C7KPGwdOw_7_7"></a><a id="Tc_Y0OZNKnZv0CAgM2-WDbGjw_7_10"></a><a id="Tc_1U_hAukR0UilP1DmIgwpYw_9_0"></a><a id="Tc_fLpZIj7fDE-DduVuUj4Z2g_10_0"></a><a id="Tc_0vCl-1JUjk6GesogmZk74g_11_0"></a><a id="Tc_IEIjJAIJg0SmexUPF3qpIw_12_0"></a><a id="Tc_kCHevUpUm0qzj7Pm9Zrg0w_12_2"></a><a id="Tc_SBPkknpRck24EBKjTB15pg_12_5"></a><a id="Tc_zWluJk4rxEuUtkzXtd0CDw_12_8"></a><ix:continuation id="Tb_U76XZB3I7kSy0VK6sC-xNA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Note 14 &#8211; Income Taxes (Cont.)</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Deferred income taxes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Deferred-tax assets for carry forward losses in Malta and Israel are calculated using the applicable tax rate at the time of expected realization of the carry forward losses. The Company has provided full valuation allowances in respect of deferred-tax assets. Management currently believes that it is more likely than not that those deferred taxes will not be realized in the foreseeable future.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_-85BCI2DX0yh7LjUNUipMQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">Significant components of the Company&#8217;s and its subsidiaries&#8217; assets are as follows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Israeli companies net-operating-loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_mGyra1etzUCzEOs-2C5hCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_npz0IGr-DE2qZHF1W8GYYQ_5_3">11,906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_ZJtJgHpgokiYVRcA7a4M5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_YGP6G57csUCmr5scocwT8w_5_6">10,085</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Maltese subsidiary net-operating-loss carry forward</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_ABpxUYDxU0CDiyikjLs1sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_t9cinDHaM0-mZ4pMmW4fEw_6_3">4,090</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_grcOKAlDuECUUH45djx3zQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_JKzFSIhG9kSO5Zm6AyjA4w_6_6">4,081</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Israeli subsidiary capital-loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_mGyra1etzUCzEOs-2C5hCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="3" id="Tc_UyiNnKOaN06JdTRgqJHzrQ_7_3">577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_ZJtJgHpgokiYVRcA7a4M5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="3" id="Tc_E8XklkITakCmn1uWws52Xg_7_6">881</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Other reserves and allowances</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="Tc_PvCpN9j2HU-TSvyRgTrW3A_8_3">27</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="Tc_ECGXo1BRJ0eiPiVGQDPwNA_8_6">21</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total deferred-tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_sf2SYkTnJ0u7y0q9_-m63w_9_3">16,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_-6FmKpkBPECixdxm2c7nTA_9_6">15,068</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_7B6FUMjTuUWTJYeVW7cbMQ_10_3">16,600</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_gm0f-M6P_k-kpyYue3w0Rw_10_6">15,068</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net deferred-tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_CV6zZ3wSaECLQ8t7kbWj9Q_11_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_Mjk1uL5Zw0iPxs1d35EJlQ_11_6">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">E.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Tax assessment</b>s</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Israeli subsidiaries received final tax assessments through the&#160;year ended December&#160;31, 2015.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">F.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Effective tax expense</p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_NEZghb-kU0-pXJAC0IehZA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">A reconciliation of the Company&#8217;s effective tax expense to the Company&#8217;s theoretical statutory tax benefit is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before taxes on income, as reported in the consolidated statements of operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_EGz_nh-D-kuL1G0M9MZI9g_5_3">28,771</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_FPO0BpsRD0u-uECq-cB2jw_5_6">20,461</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_R6DFa9bvEkiIIgBGA55jOw_5_9">9,781</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Statutory tax rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_o8NkXNoheEWRtaPf8qYaxw_7_3">12</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_SOgzfFk9DUeGEIGbyiVm3w_7_6">12</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_33Ipqa5yrU2NPP2K_XZ2Aw_7_9">12</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Theoretical tax benefit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="Tc_ydiaMHE1hEGIpV9TPNZZ-g_9_3">3,453</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="Tc_4-eQyYglKkey-HdkI7vDRg_9_6">2,455</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="Tc_IA40Oty-7UmDvJ1VIwyCAA_9_9">1,174</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="3" id="Tc_CDJWc38BakSZR5ZzrjkF5w_10_3">3,453</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="3" id="Tc_T6q-xUlEH0iaesf0Z2dRug_10_6">2,455</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="3" id="Tc_j_qseif72EiHvgL4LkZ8DA_10_9">1,174</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax withheld from upfront payment from Samil</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="Tc_-q-T9MAmC0-Oyg7n2rwyXg_11_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="Tc_8xx4hb43FEybXcMeY75Y2g_11_6">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="Tc_TAZe8sxUxEu-ITtRmjonkg_11_9">75</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actual tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_dM6uD71HAUW4Tead6za4WQ_12_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_6yTZjkwFH0eFsjAKNdG2Hw_12_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_CfI3hiOuoEWj1Ma0MW1egA_12_9">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GALMED PHARMACEUTICALS&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_bJQHI1efcU6Qa_D8I7Pn3g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 15 - Subsequent events</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">During February 2021, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WPJh0pmyREubwtCYaYFNjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_CDGtPcmzGU6skJq92L96gQ">1,541,400</ix:nonFraction> ordinary shares under its ATM Program for total net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WPJh0pmyREubwtCYaYFNjA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_RQLcGmtAJkud1A2on6Bz0w">8.2</ix:nonFraction> million. See also Note 10A.3</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">During February 2021, the Company entered into an underwriting agreement (the &quot;Underwriting Agreement&quot;) with Cantor Fitzgerald &amp; Co. (the &quot;Underwriter&quot;) in connection with an underwritten public offering (the &quot;Underwritten Public Offering&quot;) of <ix:nonFraction unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Wd5zkrI_zUKorhBrP5Zikg">2,197,803</ix:nonFraction> ordinary shares (the &quot;Firm Shares&quot;) of the Company. The Underwriter purchased the Firm Shares from the Company at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ" contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember_rI1zXGeK8EmUIgiB1WtYEA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_yLZkxwjylEeSQ8mqZd-3BQ">4.3258</ix:nonFraction> per share. The net proceeds to the Company, Were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_T8LN_Nlon0a-U3OyHpP2DQ">9.3</ix:nonFraction> million. See also Note 10A.4.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On March 2021, the Company has signed with with Mintz K. Construction Company a lease <span style="-sec-ix-hidden:Hidden_Ccc8RhKJjU6tsVCv0GLiEA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">extension</span></span> agreement to its corporate headquarters for a period of <span style="-sec-ix-hidden:Hidden_iAeXAqUqkkCSijJ30lE5Og;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">two</span></span> additional years until March 22, 2023 with an option for another year. According to updated lease, the aggregate quarterly rental payment, together with adjustments and the maintenance fees, is approximately NIS <ix:nonFraction unitRef="Unit_Standard_ILS_80PDI-Ft8k2W61vPNXVwKw" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_d2nXIm0PHEKT0HYx5C-QMw" decimals="0" format="ixt:numdotdecimal" name="glmd:AggregateQuarterlyRentalPayment" scale="0" id="Narr_y-3F1W53ckaacN78uC6rsA">133,497</ix:nonFraction> plus VAT.</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_2aa581d8_dd09_4b71_81f9_18f9665fb5c2"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM19Exhibits_725828"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ITEM&#160;19. Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.08%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.06%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.85%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000114420414012612/v367917_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Form&#160;of Amended and Restated Articles of Association of Galmed Pharmaceuticals&#160;Ltd. (English Translation) (1)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000110465920032166/tm206796d1_ex2-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Description of Securities Registered under Section&#160;12 of the Exchange Act (13)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000114420414012612/v367917_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Form&#160;of Indemnification Agreement (1)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000114420415020787/v406342_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Galmed Pharmaceuticals&#160;Ltd. 2013 Incentive Share Option Plan (4)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000114420414006610/v367324_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Registration and Information Rights Agreement, dated December&#160;2013, by and among Galmed Pharmaceuticals&#160;Ltd., Shirat HaChaim&#160;Ltd., David&#160;&amp; Debora Goldfarb, Medgal S.A. and G. Yarom Medical Research&#160;Ltd. (2)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000114420414006610/v367324_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Personal Employment Agreement, dated December&#160;23, 2013, by and between Galmed Medical Research&#160;Ltd. and Allen Baharaff (2)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000114420418014234/tv487506_ex4-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Amendment No.1 to Employment Agreement by and between Galmed Research and Development&#160;Ltd. and Allen Baharaff (10)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/0001595353/000110465920032166/tm206796d1_ex4-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Amendment No.2 to Employment Agreement by and between Galmed Research and Development&#160;Ltd. and Allen Baharaff(13)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000110465920082108/tm2024355d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Compensation Policy of Galmed Pharmaceuticals&#160;Ltd.(5)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.8</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000114420417016148/v462263_ex4-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Lease, dated March&#160;22, 2015, between Galmed Research and Development&#160;Ltd. and Mintz K. Construction Company&#160;Ltd.(8)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.9</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000114420417016148/v462263_ex4-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Addendum to Lease, dated February&#160;27, 2017, between Galmed Research and Development&#160;Ltd. and Mintz K. Construction Company&#160;Ltd.(8)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.10</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/tv515440_ex4-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Addendum to Lease, dated August&#160;8, 2018, between Galmed Research and Development&#160;Ltd. and Mintz K. Construction Company&#160;Ltd.(12)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.11</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20201231xex4d11.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Addendum to Lease, dated March 11, 2021, between Galmed Research and Development Ltd. and Mintz K. Construction Company Ltd.**</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.12</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000114420417065092/tv481920_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Amended and Restated Sales Agreement, dated May 15, 2020, among Galmed Pharmaceuticals&#160;Ltd., Stifel, Nicolaus&#160;&amp; Company,&#160;Incorporated and Cantor Fitzgerald &amp; Co. (9)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.13</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000110465921025064/tm217153d1_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Underwriting Agreement between Galmed Pharmaceuticals&#160;Ltd. and Cantor Fitzgerald &amp;Co., as representative of the several underwriters, dated February&#160;16, 2021 (11)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/0001595353/000110465920032166/tm206796d1_ex8-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">List of subsidiaries of Galmed Pharmaceuticals&#160;Ltd.(13)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1595353/000114420416089349/v434576_ex11-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Code of Business Conduct and Ethics of Galmed Pharmaceuticals&#160;Ltd.(7)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20201231xex12d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Certification of Chief Executive Officer pursuant to Exchange Act Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002**</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12.2</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20201231xex12d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Certification of Chief Financial Officer pursuant to Exchange Act Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002**</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20201231xex13d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Certification of Chief Executive Officer and Chief Financial Officer pursuant to Exchange Act Rules&#160;13a-14(b)&#160;and 15d-14(b)&#160;and 18 U.S.C. Section&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002**</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20201231xex15d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Consent of Brightman Almagor Zohar&#160;&amp; Co. (a Member of Deloitte Touche Tohmatsu Limited)**</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following financial information from Galmed Pharmaceuticals&#160;Ltd.&#8217;s Annual Report on Form&#160;20-F&#160;for the&#160;year ended December&#160;31, 2020, formatted in Extensible Business Reporting Language (XBRL): (i)&#160;Consolidated Balance Sheets, (ii)&#160;Consolidated Statements of Operations, (iii)&#160;Consolidated Statements of Comprehensive Loss, (iii)&#160;Consolidated Statements of Changes in Shareholders&#8217; Equity (iii)&#160;the Consolidated Statements of Cash Flows, and (iv)&#160;Notes&#160;to Consolidated Financial Statements**</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to Amendment No.&#160;1 to the Registration Statement on Form&#160;F-1, filed with the SEC on February&#160;28, 2014.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to the Registration Statement on Form&#160;F-1, filed with the SEC on February&#160;6, 2014.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to the Company&#8217;s Report on Form&#160;6-K filed with the SEC on June&#160;1, 2016.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(4)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to Exhibit&#160;A to the Company&#8217;s Report on Form&#160;6-K filed with the SEC on April&#160;2, 2015.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(5)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to Annex&#160;A to the Company&#8217;s Report on Form&#160;6-K filed with the SEC on July&#160;8, 2020.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(6)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to the Company&#8217;s Annual Report on Form&#160;20-F filed with the SEC on March&#160;31, 2015.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(7)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to the Company&#8217;s Annual Report on Form&#160;20-F filed with the SEC on March&#160;22, 2016.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to the Company&#8217;s Annual Report on Form&#160;20-F filed with the SEC on March&#160;23, 2017.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to Exhibit&#160;1.1 to the Company&#8217;s Report on Form&#160;6-K filed with the SEC on May&#160;15, 2020.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(10)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to the Company&#8217;s Annual Report on Form&#160;20-F filed with the SEC on March&#160;13, 2018.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(11)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to Exhibit&#160;1.1 to the Company&#8217;s Report on Form&#160;6-K filed with the SEC on February&#160;18, 2021.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(12)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to the Company&#8217;s Annual Report on Form&#160;20-F filed with the SEC on March&#160;13, 2019.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(13)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Incorporated herein by reference to the Company&#8217;s Annual Report on Form 20-F filed with the SEC on March 12, 2020.</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Portions of this exhibit were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment under Rule&#160;24b-2 of the Exchange Act.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Filed herewith.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6b184cb3_e619_4968_90d0_4c7cdfc908f3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The registrant hereby certifies that it meets all of the requirements for filing on Form&#160;20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GALMED PHARMACEUTICALS&#160;LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:&#160;&#160;</p></td><td style="vertical-align:top;width:45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Allen Baharaff</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Allen Baharaff</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Chairman</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:&#160;&#160;March&#160;18, 2021</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>2
<FILENAME>tmb-20201231xex4d11.htm
<DESCRIPTION>EXHIBIT 4.11
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/18/2021 12:41:10 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 4.11</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">English summary of Principal Terms of the Fourth Addendum to the Lease Agreement (dated March 22, 2015, as amended by that certain Second Addendum entered on February 27, 2017 and that certain Third Addendum entered on August 8, 2018) entered into on March 11, 2021, by and between Mintz K. Construction Company Ltd. (the &#8220;<b style="font-weight:bold;">Landlord</b>&#8221;), as landlord, and Galmed Research and Development Ltd. (the &#8220;<b style="font-weight:bold;">GRD</b>&#8221;), as tenant (the &#8220;<b style="font-weight:bold;">Addendum</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">The Addendum</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Premises covered by the Addendum</u><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">: Approximately of 590 square meters (the &#8220;</font><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Total Premises</b><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8221;).</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Term of Lease</u><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">: According to the Addendum, the term of the lease of the Total premises shall be from March 22, 2021 until March 21, 2023 (the &#8220;</font><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">New Lease Term</b><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8221;), provided however that GRD shall have an option to extend the New Lease Term in accordance with the terms of the Lease Agreement, from March 22, 2023 until March 21, 2024 (the &#8220;</font><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Option Period</b><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8221;).</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Fees</u><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">: GRD shall pay a monthly rental fee in the amount of NIS 35,000 plus VAT for the Total Premises. In the event that the option is exercised by GRD, GRD shall pay monthly rental fees for the Total Premises in the amount of NIS 38,290 during the Option period.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Security</u><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">: GRD shall provide the Landlord with an autonomous bank guarantee of NIS 172,264.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20201231xex4d11001.jpg" alt="Graphic" style="display:inline-block;height:719.93pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:477.5pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20201231xex4d11002.jpg" alt="Graphic" style="display:inline-block;height:720pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:479.54pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20201231xex4d11003a.jpg" alt="Graphic" style="display:inline-block;height:720pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:478.18pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>tmb-20201231xex12d1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/18/2021 12:41:13 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 12.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Allen Baharaff, certify that:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:24.5pt;text-indent:0pt;white-space:nowrap;">1.</font>I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the &#8220;Company&#8221;);</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:24.5pt;text-indent:0pt;white-space:nowrap;">2.</font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:24.5pt;text-indent:0pt;white-space:nowrap;">3.</font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:24.5pt;text-indent:0pt;white-space:nowrap;">4.</font>The Company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:61.2pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:29.55pt;text-indent:0pt;white-space:nowrap;">(a)</font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:61.2pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:29.55pt;text-indent:0pt;white-space:nowrap;">(b)</font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:61.2pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:29.55pt;text-indent:0pt;white-space:nowrap;">(c)</font>Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:61.2pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:29.55pt;text-indent:0pt;white-space:nowrap;">(d)</font>Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting; and</div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:24.5pt;text-indent:0pt;white-space:nowrap;">5.</font>The Company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions):</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:61.2pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:29.55pt;text-indent:0pt;white-space:nowrap;">(a)</font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:61.2pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:29.55pt;text-indent:0pt;white-space:nowrap;">(b)</font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:46.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.91%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Allen Baharaff</p></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:46.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Allen Baharaff</p></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:46.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;March 18, 2021</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>tmb-20201231xex12d2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/18/2021 12:41:16 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 12.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Yohai Stenzler, certify that:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:24.5pt;text-indent:0pt;white-space:nowrap;">1.</font>I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the &#8220;Company&#8221;);</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:24.5pt;text-indent:0pt;white-space:nowrap;">2.</font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:24.5pt;text-indent:0pt;white-space:nowrap;">3.</font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:24.5pt;text-indent:0pt;white-space:nowrap;">4.</font>The Company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:61.2pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:29.55pt;text-indent:0pt;white-space:nowrap;">(a)</font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:61.2pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:29.55pt;text-indent:0pt;white-space:nowrap;">(b)</font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:61.2pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:29.55pt;text-indent:0pt;white-space:nowrap;">(c)</font>Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:61.2pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:29.55pt;text-indent:0pt;white-space:nowrap;">(d)</font>Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting; and</div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:24.5pt;text-indent:0pt;white-space:nowrap;">5.</font>The Company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions):</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:61.2pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:29.55pt;text-indent:0pt;white-space:nowrap;">(a)</font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:61.2pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:29.55pt;text-indent:0pt;white-space:nowrap;">(b)</font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:&#160;&#160;</p></td><td style="vertical-align:top;width:41.66%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Yohai Stenzler</p></td><td style="vertical-align:top;width:53.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Yohai Stenzler</p></td><td style="vertical-align:top;width:53.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:53.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;March 18, 2021</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>tmb-20201231xex13d1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/18/2021 12:41:19 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 13.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18&#160;U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the annual report of Galmed Pharmaceuticals Ltd. (the &#8220;Company&#8221;) on Form&#160;20-F for the period ending December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify that to the best of our knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:2.25pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:&#160;&#160;</p></td><td style="vertical-align:top;width:41.66%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Allen Baharaff</p></td><td style="vertical-align:top;width:53.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Allen Baharaff</p></td><td style="vertical-align:top;width:53.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:top;width:53.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:&#160;&#160;</p></td><td style="vertical-align:top;width:41.66%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Yohai Stenzler</p></td><td style="vertical-align:top;width:53.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Yohai Stenzler </p></td><td style="vertical-align:top;width:53.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer </p></td><td style="vertical-align:top;width:53.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 18, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The certification set forth above is being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the annual report on Form 20-F for the period ended December 31, 2020, or as a separate disclosure document of the Company or the certifying officers.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>6
<FILENAME>tmb-20201231xex15d1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/18/2021 12:41:22 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 15.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.4pt 0pt;"><b style="font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 5pt;">We consent to the incorporation by reference in the Registration Statements on Form S-8 (Registration No. 333-206292 and 333-227441) and the Company&#8217;s Registration Statement on Form F-3 (Registration No. 333-223923) of our report dated March 18, 2021 relating to the consolidated financial statements of Galmed Pharmaceuticals Ltd., (the &#8220;Company&#8221;), which appear in the Company&#39;s Annual Report on Form 20-F for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:49.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">By:</p></td><td style="vertical-align:top;width:45.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">/s/ Brightman Almagor Zohar &amp; Co.</p></td></tr><tr><td style="vertical-align:top;width:49.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brightman Almagor Zohar &amp; Co. <br>Certified Public Accountants</p></td></tr><tr><td style="vertical-align:top;width:49.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">A Firm in the Deloitte Global Network</p></td></tr><tr><td style="vertical-align:top;width:49.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 18, 2021</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>tmb-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/18/2021 12:42:07 PM-->
<!--Modified on: 3/18/2021 12:42:07 PM-->
<schema xmlns:naics="http://xbrl.sec.gov/naics/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.galmedpharma.com/20201231" elementFormDefault="qualified" xmlns:glmd="http://www.galmedpharma.com/20201231" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>00300 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00500 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails" id="DisclosureOtherAccountsReceivableDetails">
        <link:definition>40401 - Disclosure - Other Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40601 - Disclosure - Property and equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails" id="DisclosureResearchAndDevelopmentExpensesDetails">
        <link:definition>41101 - Disclosure - Research and Development Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails" id="DisclosureGeneralAndAdministrativeExpensesDetails">
        <link:definition>41201 - Disclosure - General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails" id="DisclosureFinancialIncomeNetDetails">
        <link:definition>41301 - Disclosure - Financial income, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails" id="DisclosureIncomeTaxesComponentsOfIncomeTaxDetails">
        <link:definition>41401 - Disclosure - Income Taxes - Components of Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails" id="DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails">
        <link:definition>41402 - Disclosure - Income Taxes - Reconciliation of the Company's Effective Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>00400 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureGeneralDetails" id="DisclosureGeneralDetails">
        <link:definition>40101 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40202 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails" id="DisclosureMarketableDebtSecuritiesDetails">
        <link:definition>40301 - Disclosure - Marketable debt securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails" id="DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails">
        <link:definition>40302 - Disclosure - Marketable debt securities - summarizes the marketable debt securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails" id="DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails">
        <link:definition>40502 - Disclosure - Leases - Company's Significant Contractual Lease Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureRevenueDetails" id="DisclosureRevenueDetails">
        <link:definition>40701 - Disclosure - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails" id="DisclosureRelatedPartiesDetails">
        <link:definition>40801 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>40901 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails" id="DisclosureShareholdersEquityCompanySOptionPlansDetails">
        <link:definition>41001 - Disclosure - Shareholders' Equity - Company's Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" id="DisclosureShareholdersEquityAdditionalInformationDetails">
        <link:definition>41002 - Disclosure - Shareholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>41403 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41501 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureGeneral" id="DisclosureGeneral">
        <link:definition>10101 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecurities" id="DisclosureMarketableDebtSecurities">
        <link:definition>10301 - Disclosure - Marketable debt securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivable" id="DisclosureOtherAccountsReceivable">
        <link:definition>10401 - Disclosure - Other Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10501 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10601 - Disclosure - Property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>10701 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureRelatedParties" id="DisclosureRelatedParties">
        <link:definition>10801 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10901 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureShareholdersEquity" id="DisclosureShareholdersEquity">
        <link:definition>11001 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpenses" id="DisclosureResearchAndDevelopmentExpenses">
        <link:definition>11101 - Disclosure - Research and Development Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpenses" id="DisclosureGeneralAndAdministrativeExpenses">
        <link:definition>11201 - Disclosure - General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureFinancialIncomeNet" id="DisclosureFinancialIncomeNet">
        <link:definition>11301 - Disclosure - Financial income, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11401 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11501 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesTables" id="DisclosureMarketableDebtSecuritiesTables">
        <link:definition>30303 - Disclosure - Marketable debt securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableTables" id="DisclosureOtherAccountsReceivableTables">
        <link:definition>30403 - Disclosure - Other Accounts Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30503 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30603 - Disclosure - Property and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureShareholdersEquityTables" id="DisclosureShareholdersEquityTables">
        <link:definition>31003 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesTables" id="DisclosureResearchAndDevelopmentExpensesTables">
        <link:definition>31103 - Disclosure - Research and Development Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesTables" id="DisclosureGeneralAndAdministrativeExpensesTables">
        <link:definition>31203 - Disclosure - General and Administrative Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetTables" id="DisclosureFinancialIncomeNetTables">
        <link:definition>31303 - Disclosure - Financial income, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31403 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>40501 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <element name="UnderwrittenPublicOfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="glmd_UnderwrittenPublicOfferingMember" substitutionGroup="xbrli:item" />
  <element name="MaximumAmountOfSharesToBeIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="glmd_MaximumAmountOfSharesToBeIssued" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="glmd_MaximumAmountOfSharesToBeIssuedOffering" name="MaximumAmountOfSharesToBeIssuedOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="glmd_RevenueTextBlock" name="RevenueTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock" name="GeneralAndAdministrativeExpensesDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock" name="PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" name="ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glmd_GeneralAndAdministrativeExpensesTableTextBlock" name="GeneralAndAdministrativeExpensesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember" name="ComputerSoftwareElectronicAndMedicalEquipmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_PropertyPlantAndEquipmentDepreciationPercentage" name="PropertyPlantAndEquipmentDepreciationPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" name="MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glmd_ReceivablesFromGovernmentInstitutions" name="ReceivablesFromGovernmentInstitutions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="glmd_MedicalEquipmentGross" name="MedicalEquipmentGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="glmd_SamilPharmCoLtdMember" name="SamilPharmCoLtdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized" name="RevenueRecognitionMilestoneMethodRevenuesRecognized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="glmd_RevenueRecognitionNonRefundableUpfrontPayment" name="RevenueRecognitionNonRefundableUpfrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="glmd_OfficersAndDirectorsMember" name="OfficersAndDirectorsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_FacilityLeasesMember" name="FacilityLeasesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_ContractualObligationDueInFirstToThirdYear" name="ContractualObligationDueInFirstToThirdYear" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="glmd_BankLienOnMarketableSecurities" name="BankLienOnMarketableSecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="glmd_EmployeeStockOptionAndRestrictedStockUnitsMember" name="EmployeeStockOptionAndRestrictedStockUnitsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_AtthemarketOfferingMember" name="AtthemarketOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_IncentiveShareOptionPlan2013Member" name="IncentiveShareOptionPlan2013Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_ResearchAndDevelopmentExpensesTable" name="ResearchAndDevelopmentExpensesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_ResearchAndDevelopmentExpensesLineItems" name="ResearchAndDevelopmentExpensesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_ChemistryAndFormulationStudiesExpenses" name="ChemistryAndFormulationStudiesExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="glmd_ResearchAndPreclinicalStudiesExpenses" name="ResearchAndPreclinicalStudiesExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="glmd_ClinicalStudiesExpenses" name="ClinicalStudiesExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="glmd_RegulatoryAndOtherExpenses" name="RegulatoryAndOtherExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="glmd_GeneralAndAdministrativeExpensesTable" name="GeneralAndAdministrativeExpensesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_GeneralAndAdministrativeExpensesLineItems" name="GeneralAndAdministrativeExpensesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable" name="ComponentsOfDeferredTaxAssetsAndLiabilitiesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_MalteseSubsidiaryMember" name="MalteseSubsidiaryMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems" name="ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_IncomeTaxesTable" name="IncomeTaxesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_IncomeTaxesLineItems" name="IncomeTaxesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_EntityIncorporationDate" name="EntityIncorporationDate" nillable="true" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glmd_EntityIncorporationPlace" name="EntityIncorporationPlace" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glmd_LesseeOperatingLeaseNumberOfOptionToExtend" name="LesseeOperatingLeaseNumberOfOptionToExtend" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glmd_CarLeasesMember" name="CarLeasesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_InterestsIncomeOnShortTermDeposits" name="InterestsIncomeOnShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="glmd_IsraeliSubsidiaryMember" name="IsraeliSubsidiaryMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glmd_BankFees" name="BankFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="glmd_UnderwritersOptionExercisableTerm" name="UnderwritersOptionExercisableTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glmd_UnderwritersOptionToPurchaseAdditionalShares" name="UnderwritersOptionToPurchaseAdditionalShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glmd_AggregateQuarterlyRentalPayment" name="AggregateQuarterlyRentalPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>tmb-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/18/2021 12:42:07 PM-->
<!--Modified on: 3/18/2021 12:42:07 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureOtherAccountsReceivableDetails" roleURI="http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureResearchAndDevelopmentExpensesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureGeneralAndAdministrativeExpensesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureFinancialIncomeNetDetails" roleURI="http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxDetails" roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails" roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails" />
  <calculationLink xlink:role="http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637516681264283244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637516681264283244" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637516681264283244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637516681264283244" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637516681264283244" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637516681264283244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637516681264283244" xlink:to="us-gaap_RestrictedCashCurrent_637516681264283244" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637516681264283244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637516681264283244" xlink:to="us-gaap_ShortTermInvestments_637516681264283244" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities_637516681264283244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637516681264283244" xlink:to="us-gaap_MarketableSecurities_637516681264283244" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_637516681264283244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637516681264283244" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_637516681264283244" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637516681264283244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent_637516681264283244" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637516681264293249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637516681264283244" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637516681264293249" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637516681264293249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637516681264283244" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637516681264293249" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637516681264293249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent_637516681264293249" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637516681264293249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637516681264293249" xlink:to="us-gaap_AccountsPayableTradeCurrent_637516681264293249" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637516681264293249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637516681264293249" xlink:to="us-gaap_AccountsPayableOtherCurrent_637516681264293249" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637516681264293249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent_637516681264293249" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637516681264293249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637516681264293249" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637516681264293249" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637516681264293249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637516681264293249" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637516681264303239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637516681264293249" xlink:to="us-gaap_CommonStockValue_637516681264303239" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637516681264303239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637516681264293249" xlink:to="us-gaap_AdditionalPaidInCapital_637516681264303239" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637516681264303239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637516681264293249" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637516681264303239" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637516681264303239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637516681264293249" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637516681264303239" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637516681264303239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637516681264303239" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637516681264303239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637516681264303239" xlink:to="us-gaap_OperatingIncomeLoss_637516681264303239" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637516681264303239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637516681264303239" xlink:to="us-gaap_Revenues_637516681264303239" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637516681264303239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637516681264303239" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637516681264303239" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637516681264313243" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637516681264303239" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637516681264313243" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637516681264313243" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637516681264303239" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637516681264313243" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637516681264313243" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637516681264313243" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637516681264313243" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ProfitLoss_637516681264313243" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637516681264313243" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637516681264313243" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637063337131183771" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681264313243" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637063337131183771" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681264313243" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637516681264313243" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681264313243" xlink:to="us-gaap_ProfitLoss_637516681264313243" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637516681264313243" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681264313243" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637516681264313243" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637516681264323249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681264313243" xlink:to="us-gaap_ShareBasedCompensation_637516681264323249" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_637516681264323249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681264313243" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_637516681264323249" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_637516681264323249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681264313243" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_637516681264323249" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_InterestsIncomeOnShortTermDeposits" xlink:label="glmd_InterestsIncomeOnShortTermDeposits_637516681264323249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681264313243" xlink:to="glmd_InterestsIncomeOnShortTermDeposits_637516681264323249" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637516681264323249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681264313243" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637516681264323249" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637516681264323249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681264313243" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637516681264323249" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_637516681264323249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681264313243" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_637516681264323249" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_637516681264323249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681264313243" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_637516681264323249" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637516681264323249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637063337131183771" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637516681264323249" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_637516681264333236" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637516681264323249" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_637516681264333236" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637516681264333236" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637516681264323249" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637516681264333236" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637516681264333236" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637063337131183771" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637516681264333236" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637516681264333236" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637516681264333236" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637516681264333236" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_637516681264333236" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637516681264333236" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_637516681264333236" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_637516681264333236" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637516681264333236" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_637516681264333236" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_637516681264333236" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637516681264333236" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_637516681264333236" order="4" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Other Accounts Receivable (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ReceivablesFromGovernmentInstitutions" xlink:label="glmd_ReceivablesFromGovernmentInstitutions_637516681264343241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="glmd_ReceivablesFromGovernmentInstitutions_637516681264343241" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637516681264343241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_637516681264343241" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637516681264343241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_637516681264343241" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and equipment, net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637063079814219093" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637516681264343241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637063079814219093" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637516681264343241" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MedicalEquipmentGross" xlink:label="glmd_MedicalEquipmentGross_637516681264343241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross_637516681264343241" xlink:to="glmd_MedicalEquipmentGross_637516681264343241" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross_637516681264343241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross_637516681264343241" xlink:to="us-gaap_FurnitureAndFixturesGross_637516681264343241" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_637516681264343241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross_637516681264343241" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_637516681264343241" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross_637516681264343241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross_637516681264343241" xlink:to="us-gaap_LeaseholdImprovementsGross_637516681264343241" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637516681264343241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637063079814219093" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637516681264343241" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Research and Development Expenses (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637063079814596551" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ChemistryAndFormulationStudiesExpenses" xlink:label="glmd_ChemistryAndFormulationStudiesExpenses_637516681264353244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_637063079814596551" xlink:to="glmd_ChemistryAndFormulationStudiesExpenses_637516681264353244" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_637516681264353244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_637063079814596551" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_637516681264353244" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637516681264353244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_637063079814596551" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637516681264353244" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ResearchAndPreclinicalStudiesExpenses" xlink:label="glmd_ResearchAndPreclinicalStudiesExpenses_637516681264353244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_637063079814596551" xlink:to="glmd_ResearchAndPreclinicalStudiesExpenses_637516681264353244" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ClinicalStudiesExpenses" xlink:label="glmd_ClinicalStudiesExpenses_637516681264353244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_637063079814596551" xlink:to="glmd_ClinicalStudiesExpenses_637516681264353244" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_RegulatoryAndOtherExpenses" xlink:label="glmd_RegulatoryAndOtherExpenses_637516681264353244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_637063079814596551" xlink:to="glmd_RegulatoryAndOtherExpenses_637516681264353244" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - General and Administrative Expenses (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637063079814596551" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637516681264353244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense_637063079814596551" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637516681264353244" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees_637516681264353244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense_637063079814596551" xlink:to="us-gaap_ProfessionalFees_637516681264353244" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_637516681264353244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense_637063079814596551" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_637516681264353244" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense_637516681264353244" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense_637063079814596551" xlink:to="us-gaap_LeaseAndRentalExpense_637516681264353244" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDevelopment" xlink:label="us-gaap_BusinessDevelopment_637516681264363245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense_637063079814596551" xlink:to="us-gaap_BusinessDevelopment_637516681264363245" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_637516681264363245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense_637063079814596551" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_637516681264363245" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Financial income, net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_BankFees" xlink:label="glmd_BankFees_637516681264363245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="glmd_BankFees_637516681264363245" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther_637516681264363245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeOther_637516681264363245" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_637516681264363245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_637516681264363245" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637516681264363245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637516681264363245" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Income Taxes - Components of Income Tax (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637063079814596551" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637516681264363245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637063079814596551" xlink:to="us-gaap_DeferredTaxAssetsGross_637516681264363245" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637516681264363245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637063079814596551" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637516681264363245" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Income Taxes - Reconciliation of the Company's Effective Tax Expense (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637063079814596551" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637516681264373243" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637063079814596551" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637516681264373243" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_637516681264373243" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637063079814596551" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_637516681264373243" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_637516681264373243" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637063079814596551" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_637516681264373243" order="3" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>tmb-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/18/2021 12:42:07 PM-->
<!--Modified on: 3/18/2021 12:42:07 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureMarketableDebtSecuritiesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails" roleURI="http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureRevenueDetails" roleURI="http://www.galmedpharma.com/role/DisclosureRevenueDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureShareholdersEquityCompanySOptionPlansDetails" roleURI="http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureShareholdersEquityAdditionalInformationDetails" roleURI="http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureResearchAndDevelopmentExpensesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureGeneralAndAdministrativeExpensesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxDetails" roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_637516681264373243" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_637516681264373243" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Changes in Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637516681264443240" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637516681264443240" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Significant Accounting Policies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637516681264476078" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637516681264476078" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember" xlink:label="glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637516681264483249" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637516681264483249" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_PropertyPlantAndEquipmentDepreciationPercentage" xlink:label="glmd_PropertyPlantAndEquipmentDepreciationPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="glmd_PropertyPlantAndEquipmentDepreciationPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Significant Accounting Policies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637516681264483249" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637516681264483249" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" xlink:label="glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Marketable debt securities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637516681264493256" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637516681264493256" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637516681264503253" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637516681264503253" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Marketable debt securities - summarizes the marketable debt securities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_637516681264503253" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_637516681264503253" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember" xlink:label="us-gaap_MutualFundMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MutualFundMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Leases - Company's Significant Contractual Lease Obligations (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_OtherCommitmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_637516681264513255" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_637516681264513255" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_FacilityLeasesMember" xlink:label="glmd_FacilityLeasesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="glmd_FacilityLeasesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_CarLeasesMember" xlink:label="glmd_CarLeasesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="glmd_CarLeasesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ContractualObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ContractualObligationDueInFirstToThirdYear" xlink:label="glmd_ContractualObligationDueInFirstToThirdYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="glmd_ContractualObligationDueInFirstToThirdYear" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Revenue (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637516681264523255" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637516681264523255" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_SamilPharmCoLtdMember" xlink:label="glmd_SamilPharmCoLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="glmd_SamilPharmCoLtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized" xlink:label="glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_RevenueRecognitionNonRefundableUpfrontPayment" xlink:label="glmd_RevenueRecognitionNonRefundableUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="glmd_RevenueRecognitionNonRefundableUpfrontPayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Related Parties (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637516681264533247" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_637516681264533247" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_OfficersAndDirectorsMember" xlink:label="glmd_OfficersAndDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="glmd_OfficersAndDirectorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and Contingencies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_637516681264543258" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_637516681264543258" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteeOfIndebtednessOfOthersMember" xlink:label="us-gaap_GuaranteeOfIndebtednessOfOthersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_GuaranteeOfIndebtednessOfOthersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_BankLienOnMarketableSecurities" xlink:label="glmd_BankLienOnMarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="glmd_BankLienOnMarketableSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="us-gaap_LossContingencyAccrualProvision" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualProvision" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Shareholders' Equity - Company's Option Plans (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637516681264553257" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637516681264553257" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Shareholders' Equity - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637516681264573258" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637516681264573258" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637516681264583257" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637516681264583257" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637516681264583257" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637516681264583257" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_UnderwrittenPublicOfferingMember" xlink:label="glmd_UnderwrittenPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="glmd_UnderwrittenPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_EmployeeStockOptionAndRestrictedStockUnitsMember" xlink:label="glmd_EmployeeStockOptionAndRestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="glmd_EmployeeStockOptionAndRestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637516681264593250" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637516681264593250" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_AtthemarketOfferingMember" xlink:label="glmd_AtthemarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glmd_AtthemarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IncentiveShareOptionPlan2013Member" xlink:label="glmd_IncentiveShareOptionPlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="glmd_IncentiveShareOptionPlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MaximumAmountOfSharesToBeIssued" xlink:label="glmd_MaximumAmountOfSharesToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="glmd_MaximumAmountOfSharesToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MaximumAmountOfSharesToBeIssuedOffering" xlink:label="glmd_MaximumAmountOfSharesToBeIssuedOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="glmd_MaximumAmountOfSharesToBeIssuedOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_UnderwritersOptionExercisableTerm" xlink:label="glmd_UnderwritersOptionExercisableTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="glmd_UnderwritersOptionExercisableTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="glmd_UnderwritersOptionToPurchaseAdditionalShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="glmd_UnderwritersOptionToPurchaseAdditionalShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Research and Development Expenses (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ResearchAndDevelopmentExpensesTable" xlink:label="glmd_ResearchAndDevelopmentExpensesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="glmd_ResearchAndDevelopmentExpensesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637516681264723263" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637516681264723263" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ResearchAndDevelopmentExpensesLineItems" xlink:label="glmd_ResearchAndDevelopmentExpensesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems" xlink:to="glmd_ResearchAndDevelopmentExpensesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ChemistryAndFormulationStudiesExpenses" xlink:label="glmd_ChemistryAndFormulationStudiesExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems" xlink:to="glmd_ChemistryAndFormulationStudiesExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ResearchAndPreclinicalStudiesExpenses" xlink:label="glmd_ResearchAndPreclinicalStudiesExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems" xlink:to="glmd_ResearchAndPreclinicalStudiesExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ClinicalStudiesExpenses" xlink:label="glmd_ClinicalStudiesExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems" xlink:to="glmd_ClinicalStudiesExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_RegulatoryAndOtherExpenses" xlink:label="glmd_RegulatoryAndOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems" xlink:to="glmd_RegulatoryAndOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - General and Administrative Expenses (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_GeneralAndAdministrativeExpensesTable" xlink:label="glmd_GeneralAndAdministrativeExpensesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="glmd_GeneralAndAdministrativeExpensesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_GeneralAndAdministrativeExpensesLineItems" xlink:label="glmd_GeneralAndAdministrativeExpensesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems" xlink:to="glmd_GeneralAndAdministrativeExpensesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_ProfessionalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDevelopment" xlink:label="us-gaap_BusinessDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_BusinessDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Income Taxes - Components of Income Tax (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable" xlink:label="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IsraeliSubsidiaryMember" xlink:label="glmd_IsraeliSubsidiaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="glmd_IsraeliSubsidiaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MalteseSubsidiaryMember" xlink:label="glmd_MalteseSubsidiaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="glmd_MalteseSubsidiaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:label="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:to="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Income Taxes - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IncomeTaxesTable" xlink:label="glmd_IncomeTaxesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="glmd_IncomeTaxesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IsraeliSubsidiaryMember" xlink:label="glmd_IsraeliSubsidiaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="glmd_IsraeliSubsidiaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MalteseSubsidiaryMember" xlink:label="glmd_MalteseSubsidiaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="glmd_MalteseSubsidiaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="glmd_IncomeTaxesTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637516681264853258" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_637516681264853258" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="glmd_IncomeTaxesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IncomeTaxesLineItems" xlink:label="glmd_IncomeTaxesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="glmd_IncomeTaxesLineItems" xlink:to="glmd_IncomeTaxesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="glmd_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="glmd_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="glmd_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Subsequent events (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_AtthemarketOfferingMember" xlink:label="glmd_AtthemarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glmd_AtthemarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_UnderwrittenPublicOfferingMember" xlink:label="glmd_UnderwrittenPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="glmd_UnderwrittenPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_AggregateQuarterlyRentalPayment" xlink:label="glmd_AggregateQuarterlyRentalPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="glmd_AggregateQuarterlyRentalPayment" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>tmb-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/18/2021 12:42:07 PM-->
<!--Modified on: 3/18/2021 12:42:07 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US">Contact Personnel Email Address</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US">Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US">Marketable debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Net book value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease obligation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares par value NIS 0.01 per share; Authorized 50,000,000 shares; Issued and outstanding: 000 shares as of December 31, 2020; 21,139,385 shares as of December 31, 2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, Shares, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, Shares, Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Total operating loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Financial income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Financial income net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss before taxes on income, as reported in the consolidated statements of operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Actual tax expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Loss attributable to holders of its ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted-average number of shares outstanding used in computing basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Consolidated Statements of Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive loss (income):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Net unrealized loss (gain) on available for sale securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized gain (loss) on marketable debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements of Changes in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive income (loss) [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation and Exercise of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Exercise of options and restricted stock units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Exercise of options and restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Total consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon stock option exercises</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Ordinary Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Ordinary Shares (In shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flow from operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of discount/premium on marketable debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US">Marketable Securities, Realized Gain (Loss), Excluding Other than Temporary Impairments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US">Loss (gain) on sale of marketable debt securities</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_InterestsIncomeOnShortTermDeposits" xlink:label="glmd_InterestsIncomeOnShortTermDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_InterestsIncomeOnShortTermDeposits" xlink:to="glmd_InterestsIncomeOnShortTermDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_InterestsIncomeOnShortTermDeposits_lbl" xml:lang="en-US">Represents Interest Income On Short Term Deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_InterestsIncomeOnShortTermDeposits_lbl" xml:lang="en-US">Interests Income on Short Term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="glmd_InterestsIncomeOnShortTermDeposits_lbl" xml:lang="en-US">Interest income from short-term deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Decrease in deferred revenue from collaboration agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Decrease (increase) in other accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Increase (decrease) in trade payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Increase (decrease) in other accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flow from investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Investment in securities, available for sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from sale of securities, available for sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl" xml:lang="en-US">Payments for (Proceeds from) Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl" xml:lang="en-US">Proceeds (investment) in short-term deposits, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flow from financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Issuance of ordinary shares and warrants, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash at the end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash at the beginning of the year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="us-gaap_ProceedsFromInterestReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInterestReceived" xlink:to="us-gaap_ProceedsFromInterestReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Proceeds from Interest Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Cash received from interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash transactions:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Recognition of right-of-use asset and lease liabilities from adoption of ASU 2016-02</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US">Marketable debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Marketable debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Other Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Other Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_RevenueTextBlock" xlink:label="glmd_RevenueTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_RevenueTextBlock" xlink:to="glmd_RevenueTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_RevenueTextBlock_lbl" xml:lang="en-US">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_RevenueTextBlock_lbl" xml:lang="en-US">Revenue [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_RevenueTextBlock_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Parties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Parties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Shareholders' Equity and Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and Administrative Expenses</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:label="glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:to="glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Financial income, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Financial income, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock" xlink:label="glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock" xlink:to="glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Policy disclosure of presentational currency of financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Presentation Currency of Financial Statements Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Financial statement in U.S. dollars</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of credit risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Severance pay</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Accounting for stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted and issued accounting pronouncement</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" xlink:label="glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" xlink:to="glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US">It represents the depreciation rates for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Depreciation Rates for Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of depreciation rates for property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Marketable debt securities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of marketable debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of accounts, notes, loans and financing receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Summary of Company's significant contractual lease obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of status of Company's option plans and its changes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xml:lang="en-US">Schedule of research and development expenses</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_GeneralAndAdministrativeExpensesTableTextBlock" xlink:label="glmd_GeneralAndAdministrativeExpensesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_GeneralAndAdministrativeExpensesTableTextBlock" xlink:to="glmd_GeneralAndAdministrativeExpensesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_GeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_GeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_GeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_lbl" xml:lang="en-US">Schedule of Other Nonoperating Income, by Component [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_lbl" xml:lang="en-US">Schedule of financial income, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of components of income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of effective income tax rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_EntityIncorporationDate" xlink:label="glmd_EntityIncorporationDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_EntityIncorporationDate" xlink:to="glmd_EntityIncorporationDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_EntityIncorporationDate_lbl" xml:lang="en-US">Date of Incorporation of the Entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_EntityIncorporationDate_lbl" xml:lang="en-US">Entity Incorporation Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_EntityIncorporationDate_lbl" xml:lang="en-US">Date Of Incorporation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperationsCommencedDate1" xlink:label="us-gaap_OperationsCommencedDate1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperationsCommencedDate1" xlink:to="us-gaap_OperationsCommencedDate1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperationsCommencedDate1_lbl" xml:lang="en-US">Operations Commenced Date</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_EntityIncorporationPlace" xlink:label="glmd_EntityIncorporationPlace" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_EntityIncorporationPlace" xlink:to="glmd_EntityIncorporationPlace_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_EntityIncorporationPlace_lbl" xml:lang="en-US">Place incorporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_EntityIncorporationPlace_lbl" xml:lang="en-US">Entity Incorporation Place</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">marketable debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_PropertyPlantAndEquipmentDepreciationPercentage" xlink:label="glmd_PropertyPlantAndEquipmentDepreciationPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_PropertyPlantAndEquipmentDepreciationPercentage" xlink:to="glmd_PropertyPlantAndEquipmentDepreciationPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_PropertyPlantAndEquipmentDepreciationPercentage_lbl" xml:lang="en-US">It represents property plant and equipment depreciation percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_PropertyPlantAndEquipmentDepreciationPercentage_lbl" xml:lang="en-US">Property, Plant and Equipment, Depreciation, Percentage</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" xlink:label="glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" xlink:to="glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_lbl" xml:lang="en-US">Collection of monthly deposits from the employees on their monthly salary for severance pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_lbl" xml:lang="en-US">Monthly Deposits of Employees, Percentage on Monthly Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_lbl" xml:lang="en-US">Monthly Deposits of Employees, Percentage on Monthly Salary</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xml:lang="en-US">Marketable Securities [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xml:lang="en-US">Marketable Securities [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Marketable debt securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Estimated Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Available-for-sale Equity Securities, Amortized Cost Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xml:lang="en-US">Available-for-sale Equity Securities, Gross Unrealized Gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xml:lang="en-US">Gross Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Available-for-sale Equity Securities, Gross Unrealized Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ReceivablesFromGovernmentInstitutions" xlink:label="glmd_ReceivablesFromGovernmentInstitutions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_ReceivablesFromGovernmentInstitutions" xlink:to="glmd_ReceivablesFromGovernmentInstitutions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_ReceivablesFromGovernmentInstitutions_lbl" xml:lang="en-US">Amount receivable from government institutions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_ReceivablesFromGovernmentInstitutions_lbl" xml:lang="en-US">Receivables from Government Institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="glmd_ReceivablesFromGovernmentInstitutions_lbl" xml:lang="en-US">Government institutions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Others</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Receivables, Net, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of Land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land under operating lease agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_LesseeOperatingLeaseNumberOfOptionToExtend" xlink:label="glmd_LesseeOperatingLeaseNumberOfOptionToExtend" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_LesseeOperatingLeaseNumberOfOptionToExtend" xlink:to="glmd_LesseeOperatingLeaseNumberOfOptionToExtend_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_LesseeOperatingLeaseNumberOfOptionToExtend_lbl" xml:lang="en-US">Represents the number of options to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_LesseeOperatingLeaseNumberOfOptionToExtend_lbl" xml:lang="en-US">Lessee, Operating Lease, Number of Option to Extend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_LesseeOperatingLeaseNumberOfOptionToExtend_lbl" xml:lang="en-US">Number of additional options to extend</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lease renewal term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseDepositLiability" xlink:label="us-gaap_LeaseDepositLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseDepositLiability" xlink:to="us-gaap_LeaseDepositLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseDepositLiability_lbl" xml:lang="en-US">Lease Deposit Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseDepositLiability_lbl" xml:lang="en-US">Bank guarantee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases, weighted average remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases, weighted average borrowing rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">Contractual Obligation, Due in Next Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">Less than 1 year</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ContractualObligationDueInFirstToThirdYear" xlink:label="glmd_ContractualObligationDueInFirstToThirdYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_ContractualObligationDueInFirstToThirdYear" xlink:to="glmd_ContractualObligationDueInFirstToThirdYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_ContractualObligationDueInFirstToThirdYear_lbl" xml:lang="en-US">Amount of contractual obligation due in the first to third fiscal year following the latest fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_ContractualObligationDueInFirstToThirdYear_lbl" xml:lang="en-US">Contractual Obligation, Due in First To Third Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_ContractualObligationDueInFirstToThirdYear_lbl" xml:lang="en-US">1-3 years</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MedicalEquipmentGross" xlink:label="glmd_MedicalEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_MedicalEquipmentGross" xlink:to="glmd_MedicalEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_MedicalEquipmentGross_lbl" xml:lang="en-US">Amount before accumulated depreciation of tangible personal property used in the normal conduct of business.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_MedicalEquipmentGross_lbl" xml:lang="en-US">Medical Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="glmd_MedicalEquipmentGross_lbl" xml:lang="en-US">Medical equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and Fixtures, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Office furniture and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Capitalized Computer Software, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Computer software and electronic equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold Improvements, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less - Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xml:lang="en-US">Deferred Revenue Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized" xlink:label="glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized" xlink:to="glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized_lbl" xml:lang="en-US">The amount of consideration recognized during the period for the milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized_lbl" xml:lang="en-US">Revenue Recognition Milestone Method Revenues Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized_lbl" xml:lang="en-US">Milestone Method Revenue Payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued Royalties</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_RevenueRecognitionNonRefundableUpfrontPayment" xlink:label="glmd_RevenueRecognitionNonRefundableUpfrontPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_RevenueRecognitionNonRefundableUpfrontPayment" xlink:to="glmd_RevenueRecognitionNonRefundableUpfrontPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_RevenueRecognitionNonRefundableUpfrontPayment_lbl" xml:lang="en-US">The non refundable amount of consideration recognized during the period for the milestone or milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_RevenueRecognitionNonRefundableUpfrontPayment_lbl" xml:lang="en-US">Revenue Recognition Non Refundable Upfront Payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Due to Related Parties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_BankLienOnMarketableSecurities" xlink:label="glmd_BankLienOnMarketableSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_BankLienOnMarketableSecurities" xlink:to="glmd_BankLienOnMarketableSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_BankLienOnMarketableSecurities_lbl" xml:lang="en-US">These lines are represents that lien on marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_BankLienOnMarketableSecurities_lbl" xml:lang="en-US">Bank Lien On Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="us-gaap_LossContingencyAccrualProvision" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualProvision" xlink:to="us-gaap_LossContingencyAccrualProvision_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualProvision_lbl" xml:lang="en-US">Loss Contingency Accrual, Provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualProvision_lbl" xml:lang="en-US">Bank guarantee, commitment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of share options, Outstanding at end of year (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of share options, Outstanding at beginning of year (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of share options, Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of share options, Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of share options, Exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of share options, Options exercisable at year end (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at end of year (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options outstanding at beginning of year (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise Price, Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options exercisable at year end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility rate, minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility rate, maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Vested term period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US">Aggregate grant fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Price per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MaximumAmountOfSharesToBeIssued" xlink:label="glmd_MaximumAmountOfSharesToBeIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_MaximumAmountOfSharesToBeIssued" xlink:to="glmd_MaximumAmountOfSharesToBeIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_MaximumAmountOfSharesToBeIssued_lbl" xml:lang="en-US">The maximum number of shares to be issued in the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_MaximumAmountOfSharesToBeIssued_lbl" xml:lang="en-US">Maximum Amount Of Shares To Be Issued</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MaximumAmountOfSharesToBeIssuedOffering" xlink:label="glmd_MaximumAmountOfSharesToBeIssuedOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_MaximumAmountOfSharesToBeIssuedOffering" xlink:to="glmd_MaximumAmountOfSharesToBeIssuedOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_MaximumAmountOfSharesToBeIssuedOffering_lbl" xml:lang="en-US">The maximum amount of shares to be issued in the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_MaximumAmountOfSharesToBeIssuedOffering_lbl" xml:lang="en-US">Maximum Amount of Shares to be Issued, Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_MaximumAmountOfSharesToBeIssuedOffering_lbl" xml:lang="en-US">Ordinary shares offered</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_UnderwritersOptionExercisableTerm" xlink:label="glmd_UnderwritersOptionExercisableTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_UnderwritersOptionExercisableTerm" xlink:to="glmd_UnderwritersOptionExercisableTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_UnderwritersOptionExercisableTerm_lbl" xml:lang="en-US">Period of option exercisable by underwriters during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_UnderwritersOptionExercisableTerm_lbl" xml:lang="en-US">Underwriters, Option Exercisable Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_UnderwritersOptionExercisableTerm_lbl" xml:lang="en-US">Option exercisable period</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="glmd_UnderwritersOptionToPurchaseAdditionalShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_UnderwritersOptionToPurchaseAdditionalShares" xlink:to="glmd_UnderwritersOptionToPurchaseAdditionalShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_UnderwritersOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of additional shares to be purchased by the underwriters.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_UnderwritersOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Underwriters, Option to Purchase Additional Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_UnderwritersOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Additional shares to purchase</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Total proceeds from sale of ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ResearchAndDevelopmentExpensesTable" xlink:label="glmd_ResearchAndDevelopmentExpensesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_ResearchAndDevelopmentExpensesTable" xlink:to="glmd_ResearchAndDevelopmentExpensesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_ResearchAndDevelopmentExpensesTable_lbl" xml:lang="en-US">Research and Development Expenses [Table]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ResearchAndDevelopmentExpensesLineItems" xlink:label="glmd_ResearchAndDevelopmentExpensesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems" xlink:to="glmd_ResearchAndDevelopmentExpensesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_ResearchAndDevelopmentExpensesLineItems_lbl" xml:lang="en-US">Research and Development Expenses [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ChemistryAndFormulationStudiesExpenses" xlink:label="glmd_ChemistryAndFormulationStudiesExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_ChemistryAndFormulationStudiesExpenses" xlink:to="glmd_ChemistryAndFormulationStudiesExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_ChemistryAndFormulationStudiesExpenses_lbl" xml:lang="en-US">This element represents that, the amount of chemistry and formulation studies expenses under research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_ChemistryAndFormulationStudiesExpenses_lbl" xml:lang="en-US">Chemistry and Formulation Studies, Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="glmd_ChemistryAndFormulationStudiesExpenses_lbl" xml:lang="en-US">Chemistry and formulation studies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Salaries and benefits</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ResearchAndPreclinicalStudiesExpenses" xlink:label="glmd_ResearchAndPreclinicalStudiesExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_ResearchAndPreclinicalStudiesExpenses" xlink:to="glmd_ResearchAndPreclinicalStudiesExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_ResearchAndPreclinicalStudiesExpenses_lbl" xml:lang="en-US">This element represents that, the amount of research and preclinical studies expenses under research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_ResearchAndPreclinicalStudiesExpenses_lbl" xml:lang="en-US">Research and preclinical studies, Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="glmd_ResearchAndPreclinicalStudiesExpenses_lbl" xml:lang="en-US">Research and preclinical studies</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ClinicalStudiesExpenses" xlink:label="glmd_ClinicalStudiesExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_ClinicalStudiesExpenses" xlink:to="glmd_ClinicalStudiesExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_ClinicalStudiesExpenses_lbl" xml:lang="en-US">This element represents that, the amount of clinical studies expenses under research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_ClinicalStudiesExpenses_lbl" xml:lang="en-US">Clinical Studies, Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="glmd_ClinicalStudiesExpenses_lbl" xml:lang="en-US">Clinical studies</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_RegulatoryAndOtherExpenses" xlink:label="glmd_RegulatoryAndOtherExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_RegulatoryAndOtherExpenses" xlink:to="glmd_RegulatoryAndOtherExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_RegulatoryAndOtherExpenses_lbl" xml:lang="en-US">This element represents that, the amount of Regulatory and other expenses under research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_RegulatoryAndOtherExpenses_lbl" xml:lang="en-US">Regulatory and Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_RegulatoryAndOtherExpenses_lbl" xml:lang="en-US">Regulatory and other expenses</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_GeneralAndAdministrativeExpensesTable" xlink:label="glmd_GeneralAndAdministrativeExpensesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_GeneralAndAdministrativeExpensesTable" xlink:to="glmd_GeneralAndAdministrativeExpensesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_GeneralAndAdministrativeExpensesTable_lbl" xml:lang="en-US">General and Administrative Expenses [Table]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_GeneralAndAdministrativeExpensesLineItems" xlink:label="glmd_GeneralAndAdministrativeExpensesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems" xlink:to="glmd_GeneralAndAdministrativeExpensesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_GeneralAndAdministrativeExpensesLineItems_lbl" xml:lang="en-US">General and Administrative Expenses [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent and office-maintenance fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDevelopment" xlink:label="us-gaap_BusinessDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDevelopment" xlink:to="us-gaap_BusinessDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDevelopment_lbl" xml:lang="en-US">Business Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessDevelopment_lbl" xml:lang="en-US">Investor relations and business development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Other General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Insurance and other</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_BankFees" xlink:label="glmd_BankFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_BankFees" xlink:to="glmd_BankFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_BankFees_lbl" xml:lang="en-US">Amount of expense classified as bank fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_BankFees_lbl" xml:lang="en-US">Bank Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_BankFees_lbl" xml:lang="en-US">Bank Fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest Income, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xml:lang="en-US">Gain from sale of marketable debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency (gains) losses</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable" xlink:label="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable" xlink:to="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable_lbl" xml:lang="en-US">Components Of Deferred Tax Assets And Liabilities [Table]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:label="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:to="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems_lbl" xml:lang="en-US">Components Of Deferred Tax Assets And Liabilities [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net-operating-loss carry forward</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Deferred tax assets, capital loss carry forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Capital-loss carry forward</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Other reserves and allowances</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred-tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred-tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective income tax rate reconciliation, at federal statutory income tax rate, percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Theoretical tax benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Tax withheld from upfront payment from Samil</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IncomeTaxesTable" xlink:label="glmd_IncomeTaxesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_IncomeTaxesTable" xlink:to="glmd_IncomeTaxesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_IncomeTaxesTable_lbl" xml:lang="en-US">Income Taxes [Table]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IncomeTaxesLineItems" xlink:label="glmd_IncomeTaxesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_IncomeTaxesLineItems" xlink:to="glmd_IncomeTaxesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_IncomeTaxesLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_AggregateQuarterlyRentalPayment" xlink:label="glmd_AggregateQuarterlyRentalPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_AggregateQuarterlyRentalPayment" xlink:to="glmd_AggregateQuarterlyRentalPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_AggregateQuarterlyRentalPayment_lbl" xml:lang="en-US">The aggregate quarterly rental payment, together with adjustments and the maintenance fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_AggregateQuarterlyRentalPayment_lbl" xml:lang="en-US">Aggregate Quarterly Rental Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_AggregateQuarterlyRentalPayment_lbl" xml:lang="en-US">Aggregate quarterly rental payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember" xlink:label="glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember" xlink:to="glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_lbl" xml:lang="en-US">Computer Software Electronic And Medical Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_lbl" xml:lang="en-US">Computer software, electronic and medical equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Recurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US">Investment Type Categorization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US">Investments [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate bonds [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember" xlink:label="us-gaap_MutualFundMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MutualFundMember" xlink:to="us-gaap_MutualFundMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MutualFundMember_lbl" xml:lang="en-US">Mutual Fund [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MutualFundMember_lbl" xml:lang="en-US">Mutual Fund [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial Paper [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial papers [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US">Other Commitments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US">Other Commitments [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_FacilityLeasesMember" xlink:label="glmd_FacilityLeasesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_FacilityLeasesMember" xlink:to="glmd_FacilityLeasesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_FacilityLeasesMember_lbl" xml:lang="en-US">Facility Leases [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_FacilityLeasesMember_lbl" xml:lang="en-US">Facility Leases [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_CarLeasesMember" xlink:label="glmd_CarLeasesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_CarLeasesMember" xlink:to="glmd_CarLeasesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_CarLeasesMember_lbl" xml:lang="en-US">Represents the information pertaining to car leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_CarLeasesMember_lbl" xml:lang="en-US">Car Leases [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_CarLeasesMember_lbl" xml:lang="en-US">Car Leases [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_SamilPharmCoLtdMember" xlink:label="glmd_SamilPharmCoLtdMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_SamilPharmCoLtdMember" xlink:to="glmd_SamilPharmCoLtdMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_SamilPharmCoLtdMember_lbl" xml:lang="en-US">Samil Pharm Co Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_SamilPharmCoLtdMember_lbl" xml:lang="en-US">Samil Pharm. Co. Ltd [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_OfficersAndDirectorsMember" xlink:label="glmd_OfficersAndDirectorsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_OfficersAndDirectorsMember" xlink:to="glmd_OfficersAndDirectorsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_OfficersAndDirectorsMember_lbl" xml:lang="en-US">Officers And Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_OfficersAndDirectorsMember_lbl" xml:lang="en-US">Officers And Directors [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xml:lang="en-US">Loss Contingency Nature [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteeOfIndebtednessOfOthersMember" xlink:label="us-gaap_GuaranteeOfIndebtednessOfOthersMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeOfIndebtednessOfOthersMember" xlink:to="us-gaap_GuaranteeOfIndebtednessOfOthersMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeOfIndebtednessOfOthersMember_lbl" xml:lang="en-US">Guarantee Of Indebtedness Of Others [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GuaranteeOfIndebtednessOfOthersMember_lbl" xml:lang="en-US">Guarantee of Indebtedness of Others [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed To Issuers Equity Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_UnderwrittenPublicOfferingMember" xlink:label="glmd_UnderwrittenPublicOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_UnderwrittenPublicOfferingMember" xlink:to="glmd_UnderwrittenPublicOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Underwritten Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Underwritten Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Underwritten Public Offering [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_EmployeeStockOptionAndRestrictedStockUnitsMember" xlink:label="glmd_EmployeeStockOptionAndRestrictedStockUnitsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_EmployeeStockOptionAndRestrictedStockUnitsMember" xlink:to="glmd_EmployeeStockOptionAndRestrictedStockUnitsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_EmployeeStockOptionAndRestrictedStockUnitsMember_lbl" xml:lang="en-US">Employee Stock Option And Restricted Stock Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_EmployeeStockOptionAndRestrictedStockUnitsMember_lbl" xml:lang="en-US">Employee Stock Option And Restricted Stock Units [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_AtthemarketOfferingMember" xlink:label="glmd_AtthemarketOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_AtthemarketOfferingMember" xlink:to="glmd_AtthemarketOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_AtthemarketOfferingMember_lbl" xml:lang="en-US">Atthemarket Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_AtthemarketOfferingMember_lbl" xml:lang="en-US">At-The-Market Offering [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IncentiveShareOptionPlan2013Member" xlink:label="glmd_IncentiveShareOptionPlan2013Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_IncentiveShareOptionPlan2013Member" xlink:to="glmd_IncentiveShareOptionPlan2013Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_IncentiveShareOptionPlan2013Member_lbl" xml:lang="en-US">Incentive Share Option Plan2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_IncentiveShareOptionPlan2013Member_lbl" xml:lang="en-US">Incentive Share Option Plan 2013 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IsraeliSubsidiaryMember" xlink:label="glmd_IsraeliSubsidiaryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_IsraeliSubsidiaryMember" xlink:to="glmd_IsraeliSubsidiaryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glmd_IsraeliSubsidiaryMember_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_IsraeliSubsidiaryMember_lbl" xml:lang="en-US">Israeli Subsidiary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_IsraeliSubsidiaryMember_lbl" xml:lang="en-US">Israeli Subsidiary [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MalteseSubsidiaryMember" xlink:label="glmd_MalteseSubsidiaryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glmd_MalteseSubsidiaryMember" xlink:to="glmd_MalteseSubsidiaryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glmd_MalteseSubsidiaryMember_lbl" xml:lang="en-US">Maltese Subsidiary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glmd_MalteseSubsidiaryMember_lbl" xml:lang="en-US">Maltese subsidiary [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US">Scenario Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US">Scenario, Plan [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>tmb-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/18/2021 12:42:07 PM-->
<!--Modified on: 3/18/2021 12:42:07 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureGeneral" roleURI="http://www.galmedpharma.com/role/DisclosureGeneral" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureMarketableDebtSecurities" roleURI="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecurities" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureOtherAccountsReceivable" roleURI="http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivable" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureLeases" roleURI="http://www.galmedpharma.com/role/DisclosureLeases" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNet" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureRevenue" roleURI="http://www.galmedpharma.com/role/DisclosureRevenue" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureRelatedParties" roleURI="http://www.galmedpharma.com/role/DisclosureRelatedParties" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureShareholdersEquity" roleURI="http://www.galmedpharma.com/role/DisclosureShareholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureResearchAndDevelopmentExpenses" roleURI="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpenses" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureGeneralAndAdministrativeExpenses" roleURI="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpenses" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureFinancialIncomeNet" roleURI="http://www.galmedpharma.com/role/DisclosureFinancialIncomeNet" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureIncomeTaxes" roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureSubsequentEvents" roleURI="http://www.galmedpharma.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureMarketableDebtSecuritiesTables" roleURI="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureOtherAccountsReceivableTables" roleURI="http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureLeasesTables" roleURI="http://www.galmedpharma.com/role/DisclosureLeasesTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureShareholdersEquityTables" roleURI="http://www.galmedpharma.com/role/DisclosureShareholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureResearchAndDevelopmentExpensesTables" roleURI="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureGeneralAndAdministrativeExpensesTables" roleURI="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureFinancialIncomeNetTables" roleURI="http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureGeneralDetails" roleURI="http://www.galmedpharma.com/role/DisclosureGeneralDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureMarketableDebtSecuritiesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureOtherAccountsReceivableDetails" roleURI="http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureLeasesAdditionalInformationDetails" roleURI="http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails" roleURI="http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureRevenueDetails" roleURI="http://www.galmedpharma.com/role/DisclosureRevenueDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureShareholdersEquityCompanySOptionPlansDetails" roleURI="http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureShareholdersEquityAdditionalInformationDetails" roleURI="http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureResearchAndDevelopmentExpensesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureGeneralAndAdministrativeExpensesDetails" roleURI="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureFinancialIncomeNetDetails" roleURI="http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxDetails" roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails" roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20201231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_637516681264913275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable_637516681264913275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_637516681264913275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637516681264913275" xlink:to="dei_EntityAddressesAddressTypeAxis_637516681264913275" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_637516681264913275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis_637516681264913275" xlink:to="dei_AddressTypeDomain_637516681264913275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember_637516681264913275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain_637516681264913275" xlink:to="dei_BusinessContactMember_637516681264913275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_637516681264913275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637516681264913275" xlink:to="dei_DocumentInformationLineItems_637516681264913275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_DocumentType_637516681264923283" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_AmendmentFlag_637516681264923283" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_DocumentPeriodEndDate_637516681264923283" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_DocumentFiscalYearFocus_637516681264923283" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_DocumentFiscalPeriodFocus_637516681264923283" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityFileNumber_637516681264923283" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityRegistrantName_637516681264923283" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityAddressAddressLine1_637516681264923283" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityAddressCityOrTown_637516681264923283" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityAddressPostalZipCode_637516681264923283" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityAddressCountry_637516681264923283" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_ContactPersonnelName_637516681264923283" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress_637516681264923283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_ContactPersonnelEmailAddress_637516681264923283" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637516681264933264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_CityAreaCode_637516681264933264" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637516681264933264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_LocalPhoneNumber_637516681264933264" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637516681264933264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityCentralIndexKey_637516681264933264" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637516681264933264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_CurrentFiscalYearEndDate_637516681264933264" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637516681264933264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityWellKnownSeasonedIssuer_637516681264933264" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637516681264933264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityVoluntaryFilers_637516681264933264" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637516681264945287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityCurrentReportingStatus_637516681264945287" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637516681264945287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityIncorporationStateCountryCode_637516681264945287" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement_637516681264945287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_DocumentRegistrationStatement_637516681264945287" order="22" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637516681264945287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_DocumentAnnualReport_637516681264945287" order="23" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637516681264945287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_DocumentTransitionReport_637516681264945287" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_637516681264945287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_DocumentShellCompanyReport_637516681264945287" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637516681264953276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityInteractiveDataCurrent_637516681264953276" order="26" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637516681264953276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityFilerCategory_637516681264953276" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637516681264953276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_Security12bTitle_637516681264953276" order="28" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637516681264953276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_TradingSymbol_637516681264953276" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637516681264953276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_SecurityExchangeName_637516681264953276" order="30" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637516681264953276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityCommonStockSharesOutstanding_637516681264953276" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637516681264953276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityShellCompany_637516681264953276" order="32" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637516681264963268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_EntityEmergingGrowthCompany_637516681264963268" order="33" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard_637516681264963268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_DocumentAccountingStandard_637516681264963268" order="34" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637516681264963268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637516681264913275" xlink:to="dei_IcfrAuditorAttestationFlag_637516681264963268" order="35" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_53" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637516681264963268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_53" xlink:to="us-gaap_AssetsAbstract_637516681264963268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637516681264963268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637516681264963268" xlink:to="us-gaap_AssetsCurrentAbstract_637516681264963268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637516681264963268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637516681264963268" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637516681264963268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637516681264963268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637516681264963268" xlink:to="us-gaap_RestrictedCashCurrent_637516681264963268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637516681264963268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637516681264963268" xlink:to="us-gaap_ShortTermInvestments_637516681264963268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637516681264963268" xlink:to="us-gaap_MarketableSecurities_637516681264973280" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637516681264963268" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_637516681264973280" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637516681264963268" xlink:to="us-gaap_AssetsCurrent_637516681264973280" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637516681264963268" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637516681264973280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637516681264963268" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637516681264973280" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637516681264963268" xlink:to="us-gaap_AssetsNoncurrent_637516681264973280" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637516681264963268" xlink:to="us-gaap_Assets_637516681264973280" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_53" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637516681264973280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637516681264973280" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637516681264973280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637516681264973280" xlink:to="us-gaap_AccountsPayableTradeCurrent_637516681264973280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637516681264973280" xlink:to="us-gaap_AccountsPayableOtherCurrent_637516681264973280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637516681264973280" xlink:to="us-gaap_LiabilitiesCurrent_637516681264973280" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637516681264973280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637516681264973280" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637516681264973280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637516681264983268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637516681264973280" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637516681264983268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637516681264983268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637516681264973280" xlink:to="us-gaap_LiabilitiesNoncurrent_637516681264983268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_637516681264983268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_53" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_637516681264983268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637516681264983268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_637516681264983268" xlink:to="us-gaap_CommonStockValue_637516681264983268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637516681264983268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_637516681264983268" xlink:to="us-gaap_AdditionalPaidInCapital_637516681264983268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637516681264983268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_637516681264983268" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637516681264983268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637516681264983268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_637516681264983268" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637516681264983268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637516681264983268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_637516681264983268" xlink:to="us-gaap_StockholdersEquity_637516681264983268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637516681264983268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_53" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637516681264983268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_84" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637516681264993267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637516681264993267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637516681264993267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84" xlink:to="us-gaap_CommonStockSharesAuthorized_637516681264993267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637516681264993267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84" xlink:to="us-gaap_CommonStockSharesIssued_637516681264993267" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637516681264993267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84" xlink:to="us-gaap_CommonStockSharesOutstanding_637516681264993267" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_94" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637516681264993267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94" xlink:to="us-gaap_Revenues_637516681264993267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637516681264993267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637516681264993267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637516681264993267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637516681264993267" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637516681264993267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94" xlink:to="us-gaap_OperatingIncomeLoss_637516681264993267" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637516681264993267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637516681264993267" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637516681264993267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637516681264993267" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637516681264993267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637516681264993267" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637516681264993267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94" xlink:to="us-gaap_ProfitLoss_637516681264993267" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_637516681265003277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_637516681265003277" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637516681265003277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637516681265003277" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_110" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637516681265003277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_110" xlink:to="us-gaap_ProfitLoss_637516681265003277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637516681265003277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_110" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637516681265003277" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637516681265003277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637516681265003277" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637516681265003277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637516681265003277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_110" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637516681265003277" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Changes in Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_120" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637516681265003277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_120" xlink:to="us-gaap_StatementTable_637516681265003277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637516681265003277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637516681265003277" xlink:to="us-gaap_StatementEquityComponentsAxis_637516681265003277" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637516681265003277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637516681265003277" xlink:to="us-gaap_CommonStockMember_637516681265003277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637516681265003277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637516681265003277" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637516681265003277" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637516681265003277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637516681265003277" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637516681265003277" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637516681265003277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637516681265003277" xlink:to="us-gaap_RetainedEarningsMember_637516681265003277" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637516681265013278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637516681265003277" xlink:to="us-gaap_EquityComponentDomain_637516681265013278" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637516681265013278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637516681265003277" xlink:to="us-gaap_StatementLineItems_637516681265013278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637516681265013278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265013278" xlink:to="us-gaap_StockholdersEquity_637516681265013278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637516681265013278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265013278" xlink:to="us-gaap_SharesOutstanding_637516681265013278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_637516681265013278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265013278" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_637516681265013278" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637516681265013278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265013278" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637516681265013278" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637516681265013278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265013278" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637516681265013278" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637516681265013278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265013278" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637516681265013278" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637516681265013278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265013278" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637516681265013278" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637516681265013278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265013278" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637516681265013278" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637516681265013278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265013278" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637516681265013278" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637516681265013278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265013278" xlink:to="us-gaap_ProfitLoss_637516681265013278" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6375166812650132781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265013278" xlink:to="us-gaap_StockholdersEquity_6375166812650132781" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637516681265023269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265013278" xlink:to="us-gaap_SharesOutstanding_637516681265023269" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_139" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637516681265023269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637516681265023269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637516681265023269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637516681265023269" xlink:to="us-gaap_ProfitLoss_637516681265023269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637516681265023269" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637516681265023269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637516681265023269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_637516681265023269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_637516681265023269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_637516681265023269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_637516681265023269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_InterestsIncomeOnShortTermDeposits" xlink:label="glmd_InterestsIncomeOnShortTermDeposits_637516681265023269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" xlink:to="glmd_InterestsIncomeOnShortTermDeposits_637516681265023269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637516681265023269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" xlink:to="us-gaap_ShareBasedCompensation_637516681265023269" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637516681265023269" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637516681265023269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637516681265023269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_637516681265033279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_637516681265033279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637516681265033279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637516681265033279" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_637516681265033279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_637516681265033279" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681265033279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637516681265023269" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637516681265033279" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637516681265033279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637516681265033279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637516681265033279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637516681265033279" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637516681265033279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_637516681265033279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637516681265033279" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_637516681265033279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_637516681265033279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637516681265033279" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_637516681265033279" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_637516681265033279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637516681265033279" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_637516681265033279" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637516681265033279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637516681265033279" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637516681265033279" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637516681265033279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637516681265033279" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_637516681265043274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637516681265033279" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_637516681265043274" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637516681265043274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637516681265033279" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637516681265043274" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637516681265043274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637516681265033279" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637516681265043274" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637516681265043274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637516681265043274" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637516681265043274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637516681265043274" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6375166812650432741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6375166812650432741" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637516681265043274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637516681265043274" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="us-gaap_ProceedsFromInterestReceived_637516681265043274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637516681265043274" xlink:to="us-gaap_ProceedsFromInterestReceived_637516681265043274" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid_637516681265043274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637516681265043274" xlink:to="us-gaap_IncomeTaxesPaid_637516681265043274" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637516681265053269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637516681265053269" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637516681265053269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637516681265053269" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637516681265053269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureGeneral" xlink:type="extended" xlink:title="10101 - Disclosure - General">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_176" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637516681265053269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_176" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637516681265053269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637516681265053269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637063079814062678" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637516681265053269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecurities" xlink:type="extended" xlink:title="10301 - Disclosure - Marketable debt securities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_637516681265063282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_637063079814062678" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_637516681265063282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivable" xlink:type="extended" xlink:title="10401 - Disclosure - Other Accounts Receivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_637516681265063282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract_637063079814062678" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_637516681265063282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10501 - Disclosure - Leases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_637516681265063282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_637516681265063282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10601 - Disclosure - Property and equipment, net">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637516681265063282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637063079814062678" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637516681265063282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureRevenue" xlink:type="extended" xlink:title="10701 - Disclosure - Revenue">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_RevenueTextBlock" xlink:label="glmd_RevenueTextBlock_637516681265063282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637063079814062678" xlink:to="glmd_RevenueTextBlock_637516681265063282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureRelatedParties" xlink:type="extended" xlink:title="10801 - Disclosure - Related Parties">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637516681265073280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637063079814062678" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637516681265073280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10901 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637516681265073280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637063079814062678" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637516681265073280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureShareholdersEquity" xlink:type="extended" xlink:title="11001 - Disclosure - Shareholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_637516681265073280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637063079814062678" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_637516681265073280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpenses" xlink:type="extended" xlink:title="11101 - Disclosure - Research and Development Expenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_637516681265073280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract_637063079814062678" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_637516681265073280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpenses" xlink:type="extended" xlink:title="11201 - Disclosure - General and Administrative Expenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:label="glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock_637516681265073280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_637063079814062678" xlink:to="glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock_637516681265073280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureFinancialIncomeNet" xlink:type="extended" xlink:title="11301 - Disclosure - Financial income, net">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_637516681265083279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_637063079814062678" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_637516681265083279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11401 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637516681265083279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637063079814062678" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637516681265083279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11501 - Disclosure - Subsequent events">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637516681265083279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637516681265083279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637516681265083279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637516681265083279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637516681265083279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637516681265083279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock" xlink:label="glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock_637516681265093279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock_637516681265093279" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_637516681265093279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_637516681265093279" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637516681265093279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637516681265093279" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637516681265093279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637516681265093279" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_637516681265093279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy_637516681265093279" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637516681265093279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637516681265093279" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637516681265093279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637516681265093279" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637516681265093279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637516681265093279" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_637516681265093279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_637516681265093279" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637516681265093279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637516681265093279" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637516681265093279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637516681265093279" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637516681265093279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637516681265093279" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637516681265103286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637516681265103286" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637516681265103286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637516681265103286" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637516681265103286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637516681265103286" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_637516681265103286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_637516681265103286" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637516681265103286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637516681265103286" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637516681265103286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637516681265103286" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637516681265103286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637516681265103286" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" xlink:label="glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_637516681265113285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637063079814062678" xlink:to="glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_637516681265113285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Marketable debt securities (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock_637516681265113285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_637063079814062678" xlink:to="us-gaap_MarketableSecuritiesTextBlock_637516681265113285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableTables" xlink:type="extended" xlink:title="30403 - Disclosure - Other Accounts Receivable (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_637516681265113285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract_637063079814062678" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_637516681265113285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Leases (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_637516681265113285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_637516681265113285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30603 - Disclosure - Property and equipment, net (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637516681265123288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637063079814062678" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637516681265123288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureShareholdersEquityTables" xlink:type="extended" xlink:title="31003 - Disclosure - Shareholders' Equity (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637516681265123288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637063079814062678" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637516681265123288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesTables" xlink:type="extended" xlink:title="31103 - Disclosure - Research and Development Expenses (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_637516681265123288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract_637063079814062678" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_637516681265123288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesTables" xlink:type="extended" xlink:title="31203 - Disclosure - General and Administrative Expenses (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_GeneralAndAdministrativeExpensesTableTextBlock" xlink:label="glmd_GeneralAndAdministrativeExpensesTableTextBlock_637516681265123288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_637063079814062678" xlink:to="glmd_GeneralAndAdministrativeExpensesTableTextBlock_637516681265123288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetTables" xlink:type="extended" xlink:title="31303 - Disclosure - Financial income, net (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_637516681265133271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_637063079814062678" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_637516681265133271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31403 - Disclosure - Income Taxes (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637516681265133271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637063079814062678" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637516681265133271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637516681265133271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637063079814062678" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637516681265133271" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureGeneralDetails" xlink:type="extended" xlink:title="40101 - Disclosure - General (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_EntityIncorporationDate" xlink:label="glmd_EntityIncorporationDate_637516681265133271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5" xlink:to="glmd_EntityIncorporationDate_637516681265133271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperationsCommencedDate1" xlink:label="us-gaap_OperationsCommencedDate1_637516681265133271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5" xlink:to="us-gaap_OperationsCommencedDate1_637516681265133271" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_EntityIncorporationPlace" xlink:label="glmd_EntityIncorporationPlace_637516681265133271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5" xlink:to="glmd_EntityIncorporationPlace_637516681265133271" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637516681265133271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637516681265133271" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637516681265133271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5" xlink:to="us-gaap_RestrictedCashCurrent_637516681265133271" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637516681265133271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5" xlink:to="us-gaap_ShortTermInvestments_637516681265133271" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637516681265133271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5" xlink:to="us-gaap_MarketableSecuritiesCurrent_637516681265133271" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637516681265143284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5" xlink:to="us-gaap_ProfitLoss_637516681265143284" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637516681265143284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637516681265143284" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Significant Accounting Policies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637063079814062678" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637516681265143284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637063079814062678" xlink:to="us-gaap_StatementTable_637516681265143284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637516681265143284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637516681265143284" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637516681265143284" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637516681265143284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637516681265143284" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637516681265143284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_637516681265143284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637516681265143284" xlink:to="us-gaap_OfficeEquipmentMember_637516681265143284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember" xlink:label="glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_637516681265143284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637516681265143284" xlink:to="glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_637516681265143284" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637516681265143284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637516681265143284" xlink:to="us-gaap_LeaseholdImprovementsMember_637516681265143284" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637516681265143284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637516681265143284" xlink:to="srt_RangeAxis_637516681265143284" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637516681265143284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637516681265143284" xlink:to="srt_RangeMember_637516681265143284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637516681265143284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637516681265143284" xlink:to="srt_MinimumMember_637516681265143284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637516681265143284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637516681265143284" xlink:to="srt_MaximumMember_637516681265143284" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637516681265153281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637516681265143284" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637516681265153281" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_PropertyPlantAndEquipmentDepreciationPercentage" xlink:label="glmd_PropertyPlantAndEquipmentDepreciationPercentage_637516681265153281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637516681265153281" xlink:to="glmd_PropertyPlantAndEquipmentDepreciationPercentage_637516681265153281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Significant Accounting Policies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637063079814219093" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637516681265153281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637063079814219093" xlink:to="us-gaap_StatementTable_637516681265153281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637516681265153281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637516681265153281" xlink:to="us-gaap_AwardTypeAxis_637516681265153281" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637516681265153281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637516681265153281" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637516681265153281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637516681265153281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637516681265153281" xlink:to="us-gaap_RestrictedStockMember_637516681265153281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637516681265153281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637516681265153281" xlink:to="us-gaap_StatementLineItems_637516681265153281" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" xlink:label="glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_637516681265153281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265153281" xlink:to="glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_637516681265153281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_637516681265153281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265153281" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_637516681265153281" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_637516681265153281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637516681265153281" xlink:to="us-gaap_NumberOfReportableSegments_637516681265153281" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Marketable debt securities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable_637516681265163287" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable_637516681265163287" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637516681265163287" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637516681265163287" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637516681265163287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637516681265163287" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637516681265163287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable_637516681265163287" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637516681265163287" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637516681265163287" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637516681265163287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637516681265163287" xlink:to="us-gaap_FairValueInputsLevel1Member_637516681265163287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637516681265163287" xlink:to="us-gaap_FairValueInputsLevel2Member_637516681265163287" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable_637516681265163287" xlink:to="us-gaap_MarketableSecuritiesLineItems_637516681265163287" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems_637516681265163287" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637516681265163287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Marketable debt securities - summarizes the marketable debt securities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract_637063079814219093" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_637063079814219093" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_637516681265163287" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_637516681265163287" xlink:to="us-gaap_InvestmentTypeAxis_637516681265163287" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_637516681265163287" xlink:to="us-gaap_InvestmentTypeCategorizationMember_637516681265163287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_637516681265163287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637516681265163287" xlink:to="us-gaap_CorporateDebtSecuritiesMember_637516681265163287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember" xlink:label="us-gaap_MutualFundMember_637516681265173283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637516681265163287" xlink:to="us-gaap_MutualFundMember_637516681265173283" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637516681265173283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637516681265163287" xlink:to="us-gaap_CommercialPaperMember_637516681265173283" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637516681265173283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_637516681265163287" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637516681265173283" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637516681265173283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637516681265173283" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637516681265173283" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_637516681265173283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637516681265173283" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_637516681265173283" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_637516681265173283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637516681265173283" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_637516681265173283" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637516681265173283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637516681265173283" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637516681265173283" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Other Accounts Receivable (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ReceivablesFromGovernmentInstitutions" xlink:label="glmd_ReceivablesFromGovernmentInstitutions_637516681265173283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="glmd_ReceivablesFromGovernmentInstitutions_637516681265173283" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637516681265173283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent_637516681265173283" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637516681265173283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent_637516681265173283" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_637516681265173283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesNetCurrent_637516681265173283" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Leases - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand_637516681265183285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AreaOfLand_637516681265183285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_637516681265183285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_637516681265183285" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_LesseeOperatingLeaseNumberOfOptionToExtend" xlink:label="glmd_LesseeOperatingLeaseNumberOfOptionToExtend_637516681265183285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="glmd_LesseeOperatingLeaseNumberOfOptionToExtend_637516681265183285" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_637516681265183285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_637516681265183285" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseDepositLiability" xlink:label="us-gaap_LeaseDepositLiability_637516681265183285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseDepositLiability_637516681265183285" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637516681265183285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637516681265183285" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637516681265183285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability_637516681265183285" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_637516681265183285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_637516681265183285" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637516681265183285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637516681265183285" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637516681265183285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637516681265183285" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Leases - Company's Significant Contractual Lease Obligations (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637516681265183285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637516681265183285" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637516681265183285" xlink:to="us-gaap_OtherCommitmentsAxis_637516681265193285" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis_637516681265193285" xlink:to="us-gaap_OtherCommitmentsDomain_637516681265193285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_FacilityLeasesMember" xlink:label="glmd_FacilityLeasesMember_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_637516681265193285" xlink:to="glmd_FacilityLeasesMember_637516681265193285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_CarLeasesMember" xlink:label="glmd_CarLeasesMember_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_637516681265193285" xlink:to="glmd_CarLeasesMember_637516681265193285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637516681265183285" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637516681265193285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637516681265193285" xlink:to="us-gaap_ContractualObligation_637516681265193285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637516681265193285" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_637516681265193285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ContractualObligationDueInFirstToThirdYear" xlink:label="glmd_ContractualObligationDueInFirstToThirdYear_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637516681265193285" xlink:to="glmd_ContractualObligationDueInFirstToThirdYear_637516681265193285" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and equipment, net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637063079814219093" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MedicalEquipmentGross" xlink:label="glmd_MedicalEquipmentGross_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637063079814219093" xlink:to="glmd_MedicalEquipmentGross_637516681265193285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637063079814219093" xlink:to="us-gaap_FurnitureAndFixturesGross_637516681265193285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637063079814219093" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_637516681265193285" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637063079814219093" xlink:to="us-gaap_LeaseholdImprovementsGross_637516681265193285" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637516681265193285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637063079814219093" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637516681265193285" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637516681265203286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637063079814219093" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637516681265203286" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637516681265203286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637063079814219093" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637516681265203286" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Revenue (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637516681265203286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637516681265203286" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637516681265203286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637516681265203286" xlink:to="dei_LegalEntityAxis_637516681265203286" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637516681265203286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637516681265203286" xlink:to="dei_EntityDomain_637516681265203286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_SamilPharmCoLtdMember" xlink:label="glmd_SamilPharmCoLtdMember_637516681265203286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637516681265203286" xlink:to="glmd_SamilPharmCoLtdMember_637516681265203286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637516681265203286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637516681265203286" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637516681265203286" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized" xlink:label="glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized_637516681265203286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637516681265203286" xlink:to="glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized_637516681265203286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_637516681265203286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637516681265203286" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_637516681265203286" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_RevenueRecognitionNonRefundableUpfrontPayment" xlink:label="glmd_RevenueRecognitionNonRefundableUpfrontPayment_637516681265203286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637516681265203286" xlink:to="glmd_RevenueRecognitionNonRefundableUpfrontPayment_637516681265203286" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Related Parties (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637063079814219093" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637063079814219093" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637516681265213285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637516681265213285" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637516681265213285" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637516681265213285" xlink:to="us-gaap_RelatedPartyDomain_637516681265213285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637516681265213285" xlink:to="srt_ChiefExecutiveOfficerMember_637516681265213285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_OfficersAndDirectorsMember" xlink:label="glmd_OfficersAndDirectorsMember_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637516681265213285" xlink:to="glmd_OfficersAndDirectorsMember_637516681265213285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637516681265213285" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637516681265213285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637516681265213285" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_637516681265213285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637516681265213285" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637516681265213285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and Contingencies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable_637516681265213285" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_637516681265213285" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_637516681265213285" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis_637516681265213285" xlink:to="us-gaap_LossContingencyNatureDomain_637516681265213285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteeOfIndebtednessOfOthersMember" xlink:label="us-gaap_GuaranteeOfIndebtednessOfOthersMember_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain_637516681265213285" xlink:to="us-gaap_GuaranteeOfIndebtednessOfOthersMember_637516681265213285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_637516681265213285" xlink:to="us-gaap_LossContingenciesLineItems_637516681265213285" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_BankLienOnMarketableSecurities" xlink:label="glmd_BankLienOnMarketableSecurities_637516681265213285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637516681265213285" xlink:to="glmd_BankLienOnMarketableSecurities_637516681265213285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="us-gaap_LossContingencyAccrualProvision_637516681265223287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637516681265213285" xlink:to="us-gaap_LossContingencyAccrualProvision_637516681265223287" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Shareholders' Equity - Company's Option Plans (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637063079814435276" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265223287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637063079814435276" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265223287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_637516681265223287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265223287" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_637516681265223287" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637516681265223287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis_637516681265223287" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637516681265223287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637516681265223287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637516681265223287" xlink:to="us-gaap_EmployeeStockOptionMember_637516681265223287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265223287" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637516681265223287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637516681265223287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637516681265223287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637516681265223287" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637516681265223287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637516681265223287" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637516681265223287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637516681265223287" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6375166812652232871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6375166812652232871" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637516681265223287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637516681265223287" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637516681265233278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637516681265233278" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637516681265233278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637516681265233278" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637516681265233278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637516681265233278" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637516681265233278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637516681265233278" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6375166812652332781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6375166812652332781" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637516681265233278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265223287" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637516681265233278" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Shareholders' Equity - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_637063079814440293" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265233278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_637063079814440293" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265233278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637516681265233278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265233278" xlink:to="us-gaap_StatementEquityComponentsAxis_637516681265233278" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637516681265233278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637516681265233278" xlink:to="us-gaap_EquityComponentDomain_637516681265233278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637516681265243289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637516681265233278" xlink:to="us-gaap_CommonStockMember_637516681265243289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637516681265243289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265233278" xlink:to="srt_TitleOfIndividualAxis_637516681265243289" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637516681265243289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637516681265243289" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637516681265243289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_637516681265243289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637516681265243289" xlink:to="srt_ChiefExecutiveOfficerMember_637516681265243289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637516681265243289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265233278" xlink:to="us-gaap_SubsequentEventTypeAxis_637516681265243289" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637516681265243289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637516681265243289" xlink:to="us-gaap_SubsequentEventTypeDomain_637516681265243289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637516681265243289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637516681265243289" xlink:to="us-gaap_SubsequentEventMember_637516681265243289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637516681265243289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265233278" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637516681265243289" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637516681265243289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637516681265243289" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637516681265243289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_UnderwrittenPublicOfferingMember" xlink:label="glmd_UnderwrittenPublicOfferingMember_637516681265243289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637516681265243289" xlink:to="glmd_UnderwrittenPublicOfferingMember_637516681265243289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637516681265253311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265233278" xlink:to="us-gaap_AwardTypeAxis_637516681265253311" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637516681265253311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637516681265253311" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637516681265253311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637516681265253311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637516681265253311" xlink:to="us-gaap_EmployeeStockOptionMember_637516681265253311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_EmployeeStockOptionAndRestrictedStockUnitsMember" xlink:label="glmd_EmployeeStockOptionAndRestrictedStockUnitsMember_637516681265253311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637516681265253311" xlink:to="glmd_EmployeeStockOptionAndRestrictedStockUnitsMember_637516681265253311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637516681265253311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637516681265253311" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637516681265253311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637516681265253311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265233278" xlink:to="us-gaap_PlanNameAxis_637516681265253311" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637516681265253311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637516681265253311" xlink:to="us-gaap_PlanNameDomain_637516681265253311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_AtthemarketOfferingMember" xlink:label="glmd_AtthemarketOfferingMember_637516681265253311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637516681265253311" xlink:to="glmd_AtthemarketOfferingMember_637516681265253311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IncentiveShareOptionPlan2013Member" xlink:label="glmd_IncentiveShareOptionPlan2013Member_637516681265253311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637516681265253311" xlink:to="glmd_IncentiveShareOptionPlan2013Member_637516681265253311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637516681265263282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265233278" xlink:to="srt_RangeAxis_637516681265263282" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637516681265263282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637516681265263282" xlink:to="srt_RangeMember_637516681265263282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637516681265263282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637516681265263282" xlink:to="srt_MinimumMember_637516681265263282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637516681265263282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637516681265263282" xlink:to="srt_MaximumMember_637516681265263282" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637516681265233278" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637516681265263282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637516681265263282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637516681265263282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637516681265263282" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637516681265263282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637516681265263282" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637516681265263282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637516681265263282" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637516681265273288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637516681265273288" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637516681265273288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637516681265273288" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637516681265273288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637516681265273288" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637516681265273288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637516681265273288" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637516681265273288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637516681265273288" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637516681265273288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637516681265273288" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637516681265273288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637516681265273288" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637516681265283301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637516681265283301" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_637516681265283301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_637516681265283301" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637516681265283301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637516681265283301" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637516681265283301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensation_637516681265283301" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637516681265283301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_SharesIssuedPricePerShare_637516681265283301" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637516681265293293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637516681265293293" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637516681265293293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637516681265293293" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637516681265293293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637516681265293293" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637516681265293293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637516681265293293" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637516681265293293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637516681265293293" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637516681265293293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637516681265293293" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MaximumAmountOfSharesToBeIssued" xlink:label="glmd_MaximumAmountOfSharesToBeIssued_637516681265303294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="glmd_MaximumAmountOfSharesToBeIssued_637516681265303294" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MaximumAmountOfSharesToBeIssuedOffering" xlink:label="glmd_MaximumAmountOfSharesToBeIssuedOffering_637516681265303294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="glmd_MaximumAmountOfSharesToBeIssuedOffering_637516681265303294" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637516681265303294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637516681265303294" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637516681265303294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637516681265303294" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637516681265303294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637516681265303294" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637516681265313284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637516681265313284" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637516681265313284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637516681265313284" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_UnderwritersOptionExercisableTerm" xlink:label="glmd_UnderwritersOptionExercisableTerm_637516681265313284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="glmd_UnderwritersOptionExercisableTerm_637516681265313284" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="glmd_UnderwritersOptionToPurchaseAdditionalShares_637516681265313284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="glmd_UnderwritersOptionToPurchaseAdditionalShares_637516681265313284" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637516681265313284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637516681265313284" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637516681265323285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637516681265323285" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637516681265323285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637516681265263282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637516681265323285" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Research and Development Expenses (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_637063079814596551" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ResearchAndDevelopmentExpensesTable" xlink:label="glmd_ResearchAndDevelopmentExpensesTable_637516681265383281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract_637063079814596551" xlink:to="glmd_ResearchAndDevelopmentExpensesTable_637516681265383281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637516681265383281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_ResearchAndDevelopmentExpensesTable_637516681265383281" xlink:to="us-gaap_IncomeStatementLocationAxis_637516681265383281" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637516681265383281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637516681265383281" xlink:to="us-gaap_IncomeStatementLocationDomain_637516681265383281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637516681265383281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637516681265383281" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637516681265383281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ResearchAndDevelopmentExpensesLineItems" xlink:label="glmd_ResearchAndDevelopmentExpensesLineItems_637516681265383281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_ResearchAndDevelopmentExpensesTable_637516681265383281" xlink:to="glmd_ResearchAndDevelopmentExpensesLineItems_637516681265383281" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ChemistryAndFormulationStudiesExpenses" xlink:label="glmd_ChemistryAndFormulationStudiesExpenses_637516681265393309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems_637516681265383281" xlink:to="glmd_ChemistryAndFormulationStudiesExpenses_637516681265393309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_637516681265393309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems_637516681265383281" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_637516681265393309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637516681265393309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems_637516681265383281" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637516681265393309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ResearchAndPreclinicalStudiesExpenses" xlink:label="glmd_ResearchAndPreclinicalStudiesExpenses_637516681265393309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems_637516681265383281" xlink:to="glmd_ResearchAndPreclinicalStudiesExpenses_637516681265393309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ClinicalStudiesExpenses" xlink:label="glmd_ClinicalStudiesExpenses_637516681265393309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems_637516681265383281" xlink:to="glmd_ClinicalStudiesExpenses_637516681265393309" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_RegulatoryAndOtherExpenses" xlink:label="glmd_RegulatoryAndOtherExpenses_637516681265393309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems_637516681265383281" xlink:to="glmd_RegulatoryAndOtherExpenses_637516681265393309" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637516681265393309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_ResearchAndDevelopmentExpensesLineItems_637516681265383281" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637516681265393309" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - General and Administrative Expenses (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_637063079814596551" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_GeneralAndAdministrativeExpensesTable" xlink:label="glmd_GeneralAndAdministrativeExpensesTable_637516681265393309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_637063079814596551" xlink:to="glmd_GeneralAndAdministrativeExpensesTable_637516681265393309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637516681265393309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_GeneralAndAdministrativeExpensesTable_637516681265393309" xlink:to="us-gaap_IncomeStatementLocationAxis_637516681265393309" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637516681265393309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637516681265393309" xlink:to="us-gaap_IncomeStatementLocationDomain_637516681265393309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637516681265403300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637516681265393309" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637516681265403300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_GeneralAndAdministrativeExpensesLineItems" xlink:label="glmd_GeneralAndAdministrativeExpensesLineItems_637516681265403300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_GeneralAndAdministrativeExpensesTable_637516681265393309" xlink:to="glmd_GeneralAndAdministrativeExpensesLineItems_637516681265403300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637516681265403300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems_637516681265403300" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637516681265403300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees_637516681265403300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems_637516681265403300" xlink:to="us-gaap_ProfessionalFees_637516681265403300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_637516681265403300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems_637516681265403300" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_637516681265403300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense_637516681265403300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems_637516681265403300" xlink:to="us-gaap_LeaseAndRentalExpense_637516681265403300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDevelopment" xlink:label="us-gaap_BusinessDevelopment_637516681265403300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems_637516681265403300" xlink:to="us-gaap_BusinessDevelopment_637516681265403300" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_637516681265413948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems_637516681265403300" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_637516681265413948" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637516681265413948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_GeneralAndAdministrativeExpensesLineItems_637516681265403300" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637516681265413948" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Financial income, net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_BankFees" xlink:label="glmd_BankFees_637516681265413948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="glmd_BankFees_637516681265413948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther_637516681265413948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_InterestIncomeOther_637516681265413948" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_637516681265413948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_637516681265413948" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637516681265413948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637516681265413948" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637516681265413948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637516681265413948" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Income Taxes - Components of Income Tax (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637063079814596551" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable" xlink:label="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637063079814596551" xlink:to="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable_637516681265423305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable_637516681265423305" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637516681265423305" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637516681265423305" xlink:to="us-gaap_RelatedPartyDomain_637516681265423305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IsraeliSubsidiaryMember" xlink:label="glmd_IsraeliSubsidiaryMember_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637516681265423305" xlink:to="glmd_IsraeliSubsidiaryMember_637516681265423305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MalteseSubsidiaryMember" xlink:label="glmd_MalteseSubsidiaryMember_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637516681265423305" xlink:to="glmd_MalteseSubsidiaryMember_637516681265423305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:label="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable_637516681265423305" xlink:to="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems_637516681265423305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems_637516681265423305" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637516681265423305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637516681265423305" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637516681265423305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637516681265423305" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_637516681265423305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637516681265423305" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_637516681265423305" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637516681265423305" xlink:to="us-gaap_DeferredTaxAssetsGross_637516681265423305" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637516681265423305" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637516681265423305" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637516681265423305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637516681265423305" xlink:to="us-gaap_DeferredTaxAssetsNet_637516681265423305" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Income Taxes - Reconciliation of the Company's Effective Tax Expense (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637063079814596551" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637516681265433296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637063079814596551" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637516681265433296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637516681265433296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637063079814596551" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637516681265433296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637516681265433296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637063079814596551" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637516681265433296" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_637516681265433296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637063079814596551" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_637516681265433296" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_637516681265433296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637063079814596551" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_637516681265433296" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637516681265433296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637063079814596551" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637516681265433296" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Income Taxes - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637063079814596551" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IncomeTaxesTable" xlink:label="glmd_IncomeTaxesTable_637516681265433296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637063079814596551" xlink:to="glmd_IncomeTaxesTable_637516681265433296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637516681265433296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_IncomeTaxesTable_637516681265433296" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637516681265433296" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637516681265433296" xlink:to="us-gaap_RelatedPartyDomain_637516681265443298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IsraeliSubsidiaryMember" xlink:label="glmd_IsraeliSubsidiaryMember_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637516681265443298" xlink:to="glmd_IsraeliSubsidiaryMember_637516681265443298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_MalteseSubsidiaryMember" xlink:label="glmd_MalteseSubsidiaryMember_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637516681265443298" xlink:to="glmd_MalteseSubsidiaryMember_637516681265443298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_IncomeTaxesTable_637516681265433296" xlink:to="srt_StatementScenarioAxis_637516681265443298" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637516681265443298" xlink:to="srt_ScenarioUnspecifiedDomain_637516681265443298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637516681265443298" xlink:to="us-gaap_ScenarioPlanMember_637516681265443298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_IncomeTaxesTable_637516681265433296" xlink:to="srt_RangeAxis_637516681265443298" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637516681265443298" xlink:to="srt_RangeMember_637516681265443298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637516681265443298" xlink:to="srt_MinimumMember_637516681265443298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637516681265443298" xlink:to="srt_MaximumMember_637516681265443298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_IncomeTaxesLineItems" xlink:label="glmd_IncomeTaxesLineItems_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_IncomeTaxesTable_637516681265433296" xlink:to="glmd_IncomeTaxesLineItems_637516681265443298" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_IncomeTaxesLineItems_637516681265443298" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637516681265443298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_IncomeTaxesLineItems_637516681265443298" xlink:to="us-gaap_OperatingLossCarryforwards_637516681265443298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_637516681265443298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glmd_IncomeTaxesLineItems_637516681265443298" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_637516681265443298" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Subsequent events (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637516681265453291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637516681265453291" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637516681265453291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637516681265453291" xlink:to="us-gaap_PlanNameAxis_637516681265453291" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637516681265453291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637516681265453291" xlink:to="us-gaap_PlanNameDomain_637516681265453291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_AtthemarketOfferingMember" xlink:label="glmd_AtthemarketOfferingMember_637516681265453291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637516681265453291" xlink:to="glmd_AtthemarketOfferingMember_637516681265453291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637516681265453291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637516681265453291" xlink:to="us-gaap_StatementEquityComponentsAxis_637516681265453291" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637516681265453291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637516681265453291" xlink:to="us-gaap_EquityComponentDomain_637516681265453291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637516681265453291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637516681265453291" xlink:to="us-gaap_CommonStockMember_637516681265453291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637516681265453291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637516681265453291" xlink:to="us-gaap_SubsequentEventTypeAxis_637516681265453291" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637516681265453291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637516681265453291" xlink:to="us-gaap_SubsequentEventTypeDomain_637516681265453291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637516681265453291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637516681265453291" xlink:to="us-gaap_SubsequentEventMember_637516681265453291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637516681265453291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637516681265453291" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637516681265453291" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637516681265463299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637516681265453291" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637516681265463299" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_UnderwrittenPublicOfferingMember" xlink:label="glmd_UnderwrittenPublicOfferingMember_637516681265463299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637516681265463299" xlink:to="glmd_UnderwrittenPublicOfferingMember_637516681265463299" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637516681265463299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637516681265453291" xlink:to="us-gaap_SubsequentEventLineItems_637516681265463299" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637516681265463299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637516681265463299" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637516681265463299" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637516681265463299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637516681265463299" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637516681265463299" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637516681265463299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637516681265463299" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637516681265463299" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637516681265463299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637516681265463299" xlink:to="us-gaap_SharesIssuedPricePerShare_637516681265463299" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_637516681265463299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637516681265463299" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_637516681265463299" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_637516681265463299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637516681265463299" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_637516681265463299" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20201231.xsd#glmd_AggregateQuarterlyRentalPayment" xlink:label="glmd_AggregateQuarterlyRentalPayment_637516681265463299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637516681265463299" xlink:to="glmd_AggregateQuarterlyRentalPayment_637516681265463299" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tmb-20201231x20f002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20201231x20f002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $X \L# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M +YH_LSS#ZV^Q]!_\)!I7_01MO\ OX*?'K>F32+''?6[NW 42 DU\\_9X?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3?\ KN*RK_PV5#XD?0*]!3J:O04ZOF#UT%%%% PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *\]^*W_(&LO^N_\ 2O0J\]^*W_(&LO\
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MXK*O_#94/B1] KT%.IJ]!3J^8/704444#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KSWXK?\@:R_Z[_P!*]"KSWXK?\@:R_P"N_P#2
MM\-_%B9UO@9YA1117TO4\E!1110,**** "BBB@ HHHH$(>172:VQFL="O1@1
M[ A/H0:YRIS>3FQ6R9LP*V]5]#652#DTUT*B[(Z-KQ)O$UY/::G%;EE4(95W
M1R#'(-3+?Z7#JM\8)(UWV91F085Y/:N.P,8QQ1Q6?U=::E>U;-[P\]FEK=*[
MP1WQQY#W"Y0#O^-;,^NVEOJ^ES&YBF$<)BEDC7 4GOBN(P*,"B6&C*5VQJJT
MK'6:A>30VLB_VO9RPR,!Y<,(5F&>YJ>VGANO&WVN*0-!#!N9ATX6N,P.N*L6
M][/:1S1P/M69=K\=1Z4OJ_+&T0]K=ZD<\@ENI9!T=R:91P!172E96,@HHHIW
M ****!A1110 4444 %7M"_Y&/3?^NXJC5[0O^1CTW_KN*QK?PV5#XD?0*]!3
MJ:O04X5\R>L%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *X7XFV-Y?:1:)9VTEPZS9*H.0,5W5-*BJA-PDI(F4>96/GS^P]<_Z
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M]0M[+;Y\FW<< 8)S0!;I*S?[=L/^>K?]^S1_;UA_SU;_ +]FGRL5T:5%9O\
M;UA_SU;_ +]FC^WK#_GJW_?LT<K"Z-*BLW^WK#_GJW_?LT?V]8?\]6_[]FCE
M871I45F_V]8?\]6_[]FC^WK#_GJW_?LT<K"Z-*BLW^WK#_GJW_?LT?V]8?\
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M +]FCE871I45F_V]8?\ /5O^_9H_MZP_YZM_W[-'*PNC2HK-_MZP_P">K?\
M?LT?V]8?\]6_[]FCE871I45F_P!O6'_/5O\ OV:/[>L/^>K?]^S1RL+HTJ*S
M?[>L/^>K?]^S1_;UA_SU;_OV:.5A=&E16;_;UA_SU;_OV:/[>L/^>K?]^S1R
ML+HTJ*S?[>L/^>K?]^S1_;UA_P ]6_[]FCE871I45F_V]8?\]6_[]FC^WK#_
M )ZM_P!^S1RL+HTJ*S?[>L/^>K?]^S1_;UA_SU;_ +]FCE871I45F_V]8?\
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MHS0 S8OH/RHV+Z#\J?FC- #-B^@_*C8OH/RI^:,T ,V+Z#\J-B^@_*GYHS0
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M!];?8]U_X33P[_T%8/S-'_":>'?^@K!^9KPKR8_^>:_E1Y,?_/-?RH_LR/\
M,'UM]CW7_A-/#O\ T%8/S-'_  FGAW_H*P?F:\*\F/\ YYK^5'DQ_P#/-?RH
M_LQ?S!];?8]U_P"$T\._]!6#\S1_PFGAW_H*P?F:\*\F/_GFOY4>3'_SS7\J
M/[,C_,'UM]CW7_A-/#O_ $%8/S-'_":>'?\ H*P?F:\*\F/_ )YK^5'DQ_\
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M1117*;!1110 4444 %%%% "'I7G?Q7_Y!VG_ /74_P J]$/2O._BO_R#M/\
M^NI_E6^%_C1,JWP,\SHHHKZ4\H**** "M/1=473)Y!-&9+6=-DJ#J1ZBLRBI
MG%25F-.SN=/:W^@Z4ET]G<7<SS1&-8G7 &:73=;T^'3;.&2YN+1[=]SK"/\
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M[3O^NZ_SK.M_#94/B1]"+]T?2G4U?NCZ4ZOESV HHHH **** "BBB@ HHHH
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MM]IT9+1]PQ(BD#'Y5T*PVHN["P&BQ213PAGG"X(R.N:4ZZBM4-4[]3B#@>E
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MF+_?7\Z+H!]%,\Q?[Z_G1YB_WU_.BZ ?13-Z_P!]?SI0Z_WU_.BZ =5O2?\
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M]PY(]CG/^$$\.?\ 0-C_ #-'_"">'/\ H&Q_F:Z.BCVD^X<D>QSG_"">'/\
MH&Q_F:/^$$\.?] V/\S71T4>TGW#DCV.<_X03PY_T#8_S-'_  @GAS_H&Q_F
M:Z.BCVL^X<L>QSG_  @GAS_H&Q_F:/\ A!/#G_0-C_,UT=%'M)]PY(]CG/\
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M V/\S1_P@GAS_H&Q_F:Z.BCVD^X<D>QSG_"">'/^@;'^9H_X03PY_P! V/\
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M[ARQ['.?\()X<_Z!L?YFC_A!/#G_ $#8_P S71T4>TGW#DCV.<_X03PY_P!
MV/\ ,T?\()X<_P"@;'^9KHZ*/:3[AR1['.?\()X<_P"@;'^9H_X03PY_T#8_
MS-='11[2?<.2/8YS_A!/#G_0-C_,T?\ "">'/^@;'^9KHZ*/:3[AR1['.?\
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tmb-20201231x20f003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20201231x20f003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '2 \L# 2(  A$! Q$!_\0
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M_A/M;_O6_P#WZ%'_  GVM_WK?_OT*Z/JDS@_M6D>S[U_O#\Z-Z_WA^=>,?\
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M -^W_P"_5'_"QO$']^W_ ._5'U2H']J4//[CV2BO&_\ A8VO_P!^W_[]4?\
M"QM?_OV__?JCZI4#^U*'G]Q[)17C?_"QM?\ []O_ -^J/^%C:_\ W[?_ +]4
M?5*@?VI0\_N/9**\;_X6-K_]^W_[]4?\+&U_^_;_ /?JCZI4#^U*'G]Q[)17
MC?\ PL;7_P"_;_\ ?JC_ (6-K_\ ?M_^_5'U2H']J4//[CV2BO&_^%C:_P#W
M[?\ []4?\+&U_P#OV_\ WZH^J5 _M2AY_<>R45XW_P +&U_^_;_]^J/^%C:_
M_?M_^_5'U2H']J4//[CV2BO&_P#A8VO_ -^W_P"_5'_"QM?_ +]O_P!^J/JE
M0/[4H>?W'LE%>-_\+&U_^_;_ /?JC_A8VO\ ]^W_ ._5'U2H']J4//[CV2BO
M&_\ A8VO_P!^W_[]4?\ "QM?_OV__?JCZI4#^U*'G]Q[)17C?_"QM?\ []O_
M -^J/^%C:_\ W[?_ +]4?5*@?VI0\_N/9**\;_X6-K_]^W_[]4?\+&U_^_;_
M /?JCZI4#^U*'G]Q[)17C?\ PL;7_P"_;_\ ?JC_ (6-K_\ ?M_^_5'U2H']
MJ4//[CV2BO&_^%C:_P#W[?\ []4?\+&U_P#OV_\ WZH^J5 _M2AY_<>R45XW
M_P +&U_^_;_]^J/^%C>(/[]O_P!^J/JE0/[4H>?W'LE%>-_\+&U_^_;_ /?J
MC_A8VO\ ]^W_ ._5'U2H']J4//[CV3-&1ZUXW_PL;7_[]O\ ]^J3_A8VO_W[
M?_OU1]4J!_:E#S^X]ER/6C(]:\:_X6-K_P#STM_^_5'_  L77_\ GI;_ /?J
MCZI4#^U:'G]Q[+D>M&1ZUXU_PL77_P#GI!_WZH_X6+K_ /ST@_[]4?5*@?VK
M0\_N/9,CU%&1ZBO&_P#A8FO_ -^#_OU1_P +%U_^_!_WZH^J5 _M2AY_<>R9
M'J*,CU%>-_\ "Q=?_OP?]^J/^%B:_P#WX/\ OU1]4J!_:E#S^X]DR/449'J*
M\:_X6)KW]^#_ +]T?\+$U[^_!_W[H^J5 _M2CY_<>RY'J*,CU%>-?\+#U[^_
M!_W[H_X6'KO]^W_[]?\ UZ/JE0/[4H^?W'LN1ZBC(]17C7_"PM=_OV__ 'Z_
M^O1_PL+7?[]O_P!^O_KT?5*@?VI1\_N/9=P]11N'J/SKQK_A86N_W[?_ +\_
M_7I/^%A:[_>M_P#OS_\ 7H^J3#^U*/G]Q[-N7U'YT;E]1^=>,_\ "P==_O6W
M_?JC_A8.N_WK;_OU1]4F+^U:/F>S;E]1^=&Y?4?G7C/_  L'7?[UO_WZH_X6
M#KG]^W_[\_\ UZ?U.8?VK1\SV;<OJ/SHW+ZC\Z\9_P"%@ZY_?M_^_/\ ]>D_
MX6!KO]ZW_P"_5'U.8?VK1\SV?<O]X?G1N7^\/SKQC_A8&N?WK?\ []4?\+ U
MS^];_P#?JE]4F']JT?,]GW+_ 'A^=&Y?[P_.O&/^%@:Y_>M_^_5)_P + US^
M];_]^J/JDP_M6B>T;E_O#\Z-Z_WA^=>,?\+ US^];_\ ?JD_X3_7/[UO_P!^
MJ/JDP_M6B>T;U_O#\Z-Z_P!X?G7B_P#PG^N?WK?_ +]4?\)_KG]ZW_[]4_JD
MQ?VK1/:-Z_WA^=)O7^\/SKQC_A/]<_O6_P#WZH_X3_6_[UO_ -^J/JDP_M6C
MV/:-Z_WA^=&]?[P_.O%_^$_UO^];_P#?JC_A/];_ +UO_P!^J/JDP_M6B>S[
MU_O#\Z-Z_P!X?G7C'_"?:W_>M_\ OU1_PGVM_P!ZW_[]4?5)A_:M$]GWK_>'
MYTN]?[P_.O%_^$^UO^];_P#?H4?\)]K?]ZW_ ._0H^J3#^U:)[1O7^\/SHWK
M_>'YUXO_ ,)]K?\ >M_^_0H_X3[6_P"];_\ ?H4?4YA_:M(]GWK_ 'A^=&]/
M[R_G7C'_  GVM_WK?_OT*])TNXDN]+MKB7'F21AFQTS43P\H;F]#&PK.T3H*
M***YSM"O-_B=_P >UI_UV;^5>D5YO\3O^/:T_P"NS?RKHPW\1'%F'\!GFU%%
M%>H?,!1110 4444!<**** U"BBB@-0HHHH#<**** "BBB@ HHHH$%%;NEZ3;
MW6B/>RJ6=+I8FS*$ 0KDGGOQ4<6A"X>-8;M!YN]U#*>(USEB?H.E0ZD4[&WL
M)-)HQJ*U!HV4$ZW2FTV%S-L/&#C&.O<5)=:0C7:K;2)Y1^S1AL'YFDCW;OIP
M3^-'/&]A>QG:]C'HK5?1E@,8N+N.,R.0JA2=RAMI/\^/:EOM(6+Q$^EVDQD
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M1V>N7MO$,1I,P4>@STK/K2-K71A/FO:3V"BBBF2%%%% !1110 4444 %%%%
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MSUR1VK2M]*M([-HXGCFECN9(Y'FM^FV-NGS<C(XZ?2N9>]N9#EYW)V"/)/\
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M>D?S-H^'1+]HF$X65$>X\KRMJ%%?:<?-G],>]%[I$%YXMO;.-Q:PQJTF4C!
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MO.?]RG_75'%;5_NC\J-J_P!T?E2T5G<^ NQ-J_W1^5&U?[H_*EHHN+43:O\
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M$?D0_P#/)/\ OD4>1#_SR3_OD5)10%D1^1#_ ,\D_P"^11Y$/_/)/^^14E%
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M><7Y"D\F#_GG%^0KPJ2_N?\ GYE_[[-59+^Z_P"?F;_OLUHDV;QSA2^Q^/\
MP#W_ ,JW_P"><7Y"D\JW_P"><?\ WR*^>)-0NO\ GZF_[^&JLFHW>?\ C[G_
M ._AJE3;ZF\<Q4OL'TCY5O\ \\X_^^12>5;Y_P!7'_WR*^99-2O.?]+G_P"_
MA_QJJ^I7IZ7EQ_W\;_&K5%]SHCBD_LGU'Y5O_<B_(4>7;?W(OR%?+7]HWO\
MS^7'_?P_XT?VA>_\_EQ_W]/^-5[!]R_K"['U*(8&Z1QGZ**/(A_YY1_]\BOG
M/PWXQU+P[J0N5EDGA(VR0R.2&']#7T!HVM6.O:<E[82B2)N".ZGN"/6LYP<#
M2$XR+GV>'_GE'_WR*3R(?^>2?]\BI:3%1J:6(O(B_P">4?\ WR*/(B_YY1_]
M\BI<4E K$7D1?\\H_P#OD4?9X?\ GDG_ 'R*DHIZA9$7D0_\\D_[Y%'D1?\
M/)/^^14E%&HK$?V>+_GDG_?(I/(A_P">2?\ ?(J6DHU!I$7D0_\ /)/^^11Y
M$/\ SRC_ .^14E%&HK+L1>1%_P \8_\ OD4>1#_SRC_[Y%244]0LB/[/#_SR
M3_OD4>1#_P \D_[Y%24E,5D1^1#_ ,\D_P"^11]GA_YY)_WR*DHH"R(_L\/_
M #R3_OD4?9X?^>2?]\BI**061%Y$/_/)/^^11Y$/_/)/^^14E%.X61'Y$/\
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MG!.ZW:S%F501A>>_XB@^1P=:%+$593=M'VWOTOU-^"VMX_%ZB"*-&-J3(B\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M H1Z<(@ LAVCH"./_P!=(--(BVF=B<\&K]% A*2EI*8!1110(2BBB@ HHHH
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M2E-)0 4444 %(:6@T )1110!J4445B= 5Y)\:/\ CPT__KX?^5>MUY'\:/\
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MT!2U22262YB;?A6B+%0/<4JW$H,+MM*RMC:!R/QI7&7*6J]F\DMLDDC [QG
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MN<ZA:**6@84M)2BD 4M)2TABTHI*44 %+24M(8M%%% PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!].%-IPI /'2G+31TIRT#'CI3A31TIPI +3Q3*>*
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MK.U33K2&QL[^PDF-O<EEV3 ;E*]>1P1S1J5#!8"I+EC?].O^1WG_  M#3?\
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M'GM+*<-+!&NYMO0$#OBLYJ*M8Z:$JDKN3T]+&U9ZY9WDJQ#S8I'^XLT90O\
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M7DJ589=..&./8<C!I]CHT-E>27AGN+FY>,1>9.P)5 <A1@#C)[\^] ),SO\
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M49+?7I^=59M?N&EO;2&:R>9+:21&ADW^65XP_O6HNCVRZG/?9D+SQ^6R;OD
MX!('4$X'.>U5K+PU:617$]S,%A-NJRN"%C/88 _/K0%F43KUW:6]A!,$DN[B
M R[UB=UV@#J%R<DM4\.N7M]*D%I9B*00">47&5(R2-H]#P>35L:&BPVZK>W0
MFMP5CG&S>%/5?NX(X'49XI;C0;>XECE^T7<<BQ^2[I+AI4SG:QZ_B,$9."*
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M7_XFERLW_MO"^?W'D=%>N?\ "LM#_P">U]_W\7_XFD_X5EH?_/:^_P"_B_\
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M8"4E&:* "DI:2F(0T4&B@04E+24" TE*:2@!****8!24II*!!1110 4&B@T
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M_P#"5:9_STE_[]FE_P"$KTO_ )Z2_P#?LUS4.C))>Z=$&;$\?F2EC]T G/\
M*EBT>&[NHBEQY,%P)'7*[MBJ<8Z\U+PV'6[?]?\ #%K'8R6R7]?\.CI?^$LT
MO^_+_P!^S1_PEFE_\])?^_9KETT0^;"DLY3S&E!Q'G&P YZ\YS5:\L8[>U@N
M89S-#-D LFP@CJ",FG'"X>4N5/\ K[B)9AC(KF:7X'8_\);I?_/27_OV:7_A
M+=+_ .>DO_?LUR"Z)J#R!%A!8KNQO' ]^>*1=&OW,H$',1(<%@",#/XT_JF'
M_F%_:&,_E_ ['_A+M+_OR_\ ?LT?\)=I?]^7_OV:Y:RT-[BSN+B8%0L/F1 ,
M 2>V1Z52N=-NK16:>+:JOL)R.N,T+"8=OE3%+,,7%*3BK';?\)=I?]^7_OBC
M_A+M+_OR_P#?LUY_16G]GTO,R_M:OY?<>@?\)=I?]^7_ +]FC_A+M+_OR_\
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MC2**+.U$Z9/6NR_X0W3/[T__ 'V/\*7_ (0[3/[T_P#WV/\ "B.(PT7>*?\
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MKE**.9A[&)U?_"06/K)_WS1_PD%CZR?]\URE%',P]C$ZO_A(+'UD_P"^:/\
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M&ES7S; MW=2&.#S9'"EBJDDX')--4W3KN3SF7.W(R1GT^M+ZE_>_#_@A]?\
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M[7X(K#_1+2YM/M*&8$[<#YE/N#7JRK1C+E9X\:,I1YD<;1766_@H726C0:K
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M.P?6*G</\\4445L8A1110 4444 %>G_#[CPZ_P#U\/\ R6O,*]/^'W_(NO\
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MP*<.E3"G"D5<B%.J2G4AW(Q2T\4M [C:44M+2&)12TM #:7-+24 %%+BD-,
MHHI*8!1110 444E(04E+24 %)2FDI@)1110 E%%%,0E%%% @I*6DH$%)0:*
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MX]RL8C!MR0^YL<CT]>E+GCW*5*;V1FT5>DTN2&SANI9X4692T:DG)QU[5.=
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MA2&.%.%-%+0,=2TVE!I%#J*2EI#0M+3:6@8M%)10 M%%!H *#24IIC$HHH-
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M\:TJS9O]<_U-7#<SJ;#:*!16AD%%%% !1112 6BDI:!A1110 4M)10 M%%%
M!2TE% QPHI*6D M%)2T %%%% Q:*3I2T#%HHS10 M+30:6D M%%% Q:6FTM(
M!:*2ES0 4M)10 ZBDHH&.HI**0#J*2@4 +2TF:,T#%HI,TM "T4F:*0#J*;2
MYH&+129HW 4 .HINX4;A0 ZBFY%&10 ZBDHS0 M%-R*7- "T4W(%&<T .I*,
MTA- "T4W-+F@ HI**!"FDHS29H 6DHHI@%%)D44 +244E A:2BDI@+2&DHH
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M&2&.1@>G*D_E7175M#>0&&=-\9()&2.AR.E4X]#TZ&9Y8[95=YQ<,P9N9 ,
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M'KUH$9,?B0RZD^V.3]U"8WMN,^?YBIC/U8#-,N_&L=FSP26+F\CR'M_-4'(
MP%/\1.1@"M8:#IHC*"V.&0QDF1MQ!.XDG.<Y&=W7WJC=^%+:4DVYCB)C9"\J
MM,^YOX]Y8-N'8Y-,"U:ZZ+J\2S%LZW"R,DZ;@?*P <D]P05_.M;-9.G:(MAJ
M4MZ9C++);QP%F7YFV#EF.>6/KQTK5H 4FDS110 444E @HHI* "BBBF 4E%)
M0 M)110 4E%%,044E% @HHHH *2EI*!!2444 )1113 ***2@0&BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tmb-20201231x20f004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20201231x20f004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (? X,# 2(  A$! Q$!_\0
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M3_&H-353TL_\2VV'_3)?Y5<H **** "CK110!YG\6QFQL<_\]/3ZUUWA,?\
M%/VPST3UKD?BU_QXV/!'[SO^-=?X5./#]MTY6@#; RH_QIV*1?NBC/.,?C0
MTC''XGCK4<RDQD)]_!Z5*>"0._)J">86]N9>N!W[4 <-XACU"QN%G2Y92>B[
MJ@;5=1U69+6"38^S+ &J][JQU373'-&ZQH?3@U-*LNFZL;R.,B%UVC H V_"
M]]<FXFL[ABS(W!KJG<J,#' SGK7(^%[>::_N+MD98VZ9KJIHFECV_=SP#WH
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M_A++#&-RY''6@^+;#@97IUW5=_X1S3>IMU/%'_".:<1C[.H]: *?_"6Z?_>
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M&! H]: *0\6V!'50<=-U+_PEEA_?YX_BJY_PCFG9'^CJ>U-/A_3 3_HZ^V*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?\ D7[7_=KD/BV0+&QQR/,_QKK_  K_ ,B_:_[M &XOW11CG-"_=%&.<]Z
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M- $^X>HHW#U%0>4W=B.<4>6W)+8Q0!/N'J*-P]14'E,"?F.!WH\ILCYC@]Z
M)]P]11N'J*@\MC@ALYH\INS9YQ0!/N'J*-P]14!B;GYLX["CRF_O<XSB@"?<
M/44;AZBH!$W'S8SV-'E-W8CG% $^X>HHW#UJ#RFY);&*/*8$_,<#O0!/N'J*
M,@D<].:@\ILCYC@]Z7RGS][MF@"3*^A(ZTDF-K<9/OTI@C;& _?'TIDB.(V.
M\CMS0!QFAG'B6?ZG.#BNZ^48'!]2:X#00X\3W1]Z[SRF'?/% $@/RG&!0<>H
M!QUJ)HG(X.,C&*#$^1\V>: )21VP2>*,CCIC^M0>2^W[QXI?*?/WCR* )LYY
MX'8&C<,CYABH?*?U//Z4GDN0W- $^5YSGGM1D YSCCI4/DMG&XX/>@1-@8;.
M: )@><]SQ]*7(SC-0>4W4,3@XXH,+XZT 3;N.<>_/2C@=QQT]JA\E]P&XXH\
MI\'YNE $O'M@<DT<#'0>OTJ+R7X.Z@1-V8^O- $N5 P<8S^5*-O7&.<5"87Z
M Y'O1Y1Y(8GVH FPN,\8H)![X(J'RFY&_DCI2^4YYW'GUH EXQG@GC)HRO(X
MV]ZA\IN"6QS087&/FH F)&3G&1THS@= /7VJ'RG ZGK2>4PP<X^O<T 3Y4'C
MZ<4A*CD'WXJ(PL.YY/6CRFW-\QH FRI/]: PQR?QJ'R7QG<?I1Y+Y!W'F@"8
M<<;O:CD\9#5#Y3\\GKBCRF!X?D<X% $F1C&!GMGO39"&0K@8/O3!&X<$G..W
M>L'7X-4\EC9-RHSB@#H5\N)1M &.O:G @CKDGD&O*](OO$=_J#0LS 1MAJ])
MLXI_LJ^:3OZ&@"Y\I'4C/-+E02<_K41B<MRQ]<T@B?!.3UH GW#U%&Y?45!Y
M3=-_..E'EMQ\V,]J )]P]11N'J*@\MN[8Y H\M@#EL8H GW+ZBC</45#Y39/
MS<=<T@B;(^;@]Z )]P]11N7U%0>6Q PV<T&-N<-GGL* )]P]: P/2H/+8='Y
M&.E*(7P,M_\ 6H F# XQFJ>IG_B7S$$8"FIQ&YP2?K5/44==/F.2?E;KZT <
MOX$R9+O/'SD=?>J7Q-SMM/\ KHO\ZN^ 0P:[SG!D/:J7Q-)V6>3G]XH_6@#O
M-,_Y!MKQTB7!_"K=4],YTVUX/$2_RJY0 4444 %%%% 'F?Q:_P"/&Q_ZZ?XU
MU_A7_D7[7_=_I7(?%O\ X\;' X\S_&NO\*_\B_:_[M &XOW12TB_=%+0 4AZ
M&EHH H3V,,MR)G3+ 8S5:[T6"\(9\GC-:IY;G'IUI H(!SR1CGF@"O:64=G"
M8HU ]_3TJP!AP?08^M*>YX.>.E&/F'T["@#BM;.?%5MG!PH_F:[2,8C7!P<=
M*XK6<#Q9;<\8Y[8ZUVL>?*4X&0.* ).W-%(!\N#^M+0 4444 %%%% !1110
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M3Q1MZ<GBH-DO3CD'OTHVRY!QU.>M $^WCJ>N:"N<\GFH-LN/R'6@I+@_CWH
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MB MH.1F1>OUH [S3,?V;;<\^4O'X5;JIIG_(,MN/^62\_A5N@ HHHH ****
M/,_BZ3]AL>,$R<?K77^%?^0!:_[M<?\ %S)L+#GI+GI]:Z_PJ<^'[7'/R^M
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MVCCCI2T4 )M'I[T;0<\=>M+10 F!GI[4;0,<=.E+10 FT>G?-&T<\=>M+10
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MESBJ/Q-SMM,_\]%_G5[P'@-=C^'>>_O5'XG<"TX/,B_SH [O3.=-M>3Q$O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_K79_\ "1Z;QBX4GU)H UR 3@?4\TH(/2L=?$>F@?\ 'PO3'!H_X233,?\
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M>./K0)&X^4\4 6:*K>8V/ND=_I1YC<_(>3TH LT56\QN3M)X_.CS&&#M/ H
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MAZS$3XD<X7GYJV<]^.:CEVB*09P G- '$>'M$@DU.Y7)V^8,9Z=ZZ8^&[3(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY']3ZFO1EZ+R: #;U X]#3J** "BBB@ HHHR* "BBB@ HHHH **** "BBB@
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MGL<J>>@Y%>7Z/SXP3<./?FO4<X8=<$4 !Y.!Q[TZD'3G'X4M !1110 4444
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M!S@C'< 4 <#J^GVH\6P@1+@C_&NLCT33F1<VZDGVKF]9X\6P=%XKM(2=B_\
MZZ */]@:80/]&3VI?[!TW)_T9.>O%:.!Z4M &:=!T[/_ ![(/PI/[ TWG_1D
MYK3HH S?[!T[_GV3\J/[!T[_ )]D_*M*D)Q0!FG0=-  ^S)Z=*CN-"TT6\C"
MV7E>U:O/7^+TS44XQ;2@9'!H \BMM$L9]=N$:$%0<^U:?_",Z7G)@3'TIMC_
M ,AZYXXZ5L8Y[\&@#*'AK2P?]0N>G2E_X1O2P,"!?R]:U2.<<T=B<]>>O:@#
M+_X1G2\X\A>GZ4#PSIIP?)3UZ5J#D?[.1G-+CJ3\Q]!0!E#POI@_Y8)VI/\
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MA\=#79?:M4 P;//)- &MG.<]#UQ2^OM^M9!N]4'_ "YG&,XH%WJO>R;)_04
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M_.@#NM,YTVUX/$2_RJY5/3.--M>.L2Y/X5<H **** "BBB@#S3XM\6%B./\
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M-0W++]FE'3@T >:V1QKUSDY(SG!K9.1C!XSD5BV6/[<NL'(Y_K6T,=_NXYH
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MXH.!SWZYSQ0 ^BF$@'/ZFC@'CU[F@!Y&1BFGH"0<^@IN1CJ..1S2DKSAO7-
M#N,CUI00>E55NHY)!%&P+CK4P91@[@?6@"2BFY7)Y]J3Y#CGVH ?13"5.!@Y
MQ1P0#UR.QXH ?13"1C/?&<YXH.!SWZYSQ0 ^BF' .?QR3Q0< \>O<T /HIG
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MTN!D8 QUH KF.3;U(]:JZ@L@T^7./NFM+)YX_6J>J*382X_NF@#D/ 0.+K)
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MQFDST.WK1GOM[T +N!/44;@>]'3/R]*._3M0 ;@>XHW#U%(.WRXS1GC[OM0
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MQ@<<=.E&!Z>] %??)TSVXH\R0XYZU8P.>.O6C ]* *_F2<<]^:3S)<'GI5G
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M#1GY<[?PH 7(YYZ49'//2DR"<8SSS02 >1^- "Y'K1D<<]>E)GC.WGTHR,@
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MTI,#Y3@T >?Z@M]I_B(7L=N63-: \4:@>?L3X]JZQ[=94PZ#.<\\TGV2#CY
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M@VL.0NP4 <M_PD]]Q_H<G- \47I.%LG'M74?9(./D/-+]EA.!Y? /6@#EO\
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M&!TH 9Y:9X521UHQ_LGUQBI*3;SD\T , ![C//&*4+@C QZTX>^*;\N1^@H
MX?6<?\)5;],8KMX^$3+=NE<5K)/_  EUN,C)'^-=K&28U(["@"2BBB@ HP/2
MBB@ Q1@#M110 48HHH , =J*** # ]**** "DQSFEHH 3:,GWI<444 %%%%
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M  '2EH *0C-+10 F!G-+110 4FT;<=J6B@ HHHH 3'.:  *6B@ I",C!I:*
M$(!(]J6BB@ I,#GWI:* $  H(R,&EHH **** "@\BBB@!NTX[<=*=_.BB@ H
MHHH ,#THHHH **** "C%%% !1110 8HHHH ,#TJEJF#82Y.#M-7 ,9YJGJ>X
MZ?,,=5/- ')^ SDW9[^8<>G6J/Q-^[:_]=%_F*O> ^MU@<F0]?K5'XF_=M/^
MNB_S% '=Z7G^S;;KCRE_E5RJ>F<Z;:\GB)?Y5<H **** "BBB@#S/XM\V-CG
M_GIZ?6NO\*_\B_:_[M<A\6R!8V/;,G?\:Z_PK_R+]K_NT ;B_=%&><4+]T49
MYQC\: #=SC!_*DRO3'?IBA_KU[4TX/S=CQS0 O0CG)Z4JD8QST[U7^U0LQ7>
M..W>G/,D*[F?Y3WH FR#R!DCI29&\9Z_2HDF5TS&1C/:I,_..OY=: .*UH?\
M5;  .U=JG^J7TQR:XK62#XNM\'&1Q^M=M& (AQGB@!XZ44F1P._I1N''/7I0
M M%)N'KWQ1D$D>E "T444 %%%% !12;@3C- 8'H: %HI 01D&EH ***,T %%
M)N!QSUZ4;AZ^U "T4@(.<=J6@ HI"0!DFC(SU]Z %HI-P..>O2EH **** "B
MBB@ HHI-P]>^* %HI-PYYZ=:,C)&>E "T4F1D#/6C<..>O2@!:*3</7OB@L!
MGGIUH 6BDR,]?>C<#CGKTH 6BDW#U[XHW#GGIUH 6BDR,D9Z49&0,]: #'&#
MS36QCCCGZ4[<..>O2D/3!('- $,UM'<Q[7&1[TY(5C 1 %"]!4G!S@\FE&",
M]?>@"-4&!W)[]<TI4X(R#[#BG]1@'&#1UR!Q[T ,P<,,@ =B* H],?A3^W-+
M0!%M"@X8$]1]:<PZ'O3N,D<4?-@<#WH CP"!M!QGH:=C! _'IQ2@GC.>?TI0
M !Q0 @')XP.@I0,#%+10 444F1G'>@!:*3<, YZT;AZT +12;ASSTZT9&2,]
M* %HI,CCGK1N''/7I0 M%)N'K[4;@,\].M "T4F1GK[T;@<<]>E "T4FX>O?
M%&X<\].M "T4F1G&>E&X<<]: %HI-PXYZT;AZ^U "T4FX#//3K06 ZGWH 6B
MDR,XS[T;AQSUH 6BDW#CGK1N&<9H 6BD# G - ((R* %HI"P!Y-&X#//3K0
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MF"?,3C_:%<__ ,(5%_??_ONE_P"$(@QCS9/^^Z .@_M6U_YZ)_WT*/[5M?\
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M=.U&9-:D\ESY;#C/XU82TEOH+V=G;>I;'- 'I8O;8ML\X9/4YZTK7<48)=E
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M9_LQQSZ4?VIXL)YTQ_R]: -^/0X$NYIQR91BJ.J:%;QZ;<8&=^",=\'-9_\
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M.X@2.60EEZ9-+%X9 LC;/+O4C%9?]J>+&/\ R#&S].:/[5\6<?\ $K8@\=*
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M "9.#\O>@\G'3^M+10 F3Q\M&3C[O>EHH 0C/M0<;O?%+10 T=!CD>M*1@Y
MR32T4 )D\_+_ /7H)/\ =S2T4 )D\\=*"3_=[4M% "9YZ4F3_=IU% "$D?P]
MJ._2EHH ;DX^[2]^G:EHH 3)QG;SZ4$G/W:6B@!IR01M-&#P%X IU% "<CU/
+-+110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tmb-20201231x20f005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20201231x20f005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '# \L# 2(  A$! Q$!_\0
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M[3/[[_\ ?-+VD>XC>HK!_P"$MTS^^_\ WS1_PENF?WW_ .^:/:1[@;U%8/\
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M]GV?_/O'_P!\T?V=9?\ /O'_ -\U9S11SU.X[(K_ -G6?_/O'_WS2?V=9_\
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M)NEI_P!=174)]Q?H*Y?Q-]VT_P"NH_G74)]Q?H*]_ _"93W'T445WDA1110
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M_P _R?\ ?-2L%6[A=&N+:(,&\I01Z"G[ 3DJ,_2L;^SM?_Y_D_[YH_L[7_\
MG^3_ +YJ7@:W<.9&PT8/\(S]*1X5D #H''N*R/[.U_\ Y_D_[YI/[-U__G^3
M_OFA8"LNH<R-E4"+M51CTQ0(P,X49/M6-_9NO_\ /\G_ 'S2_P!G:_\ \_R?
M]\T?V?5O=,;DF;)3=U&1Z4&)"H4H"!ZBL;^SM?\ ^?Y/^^:3^SM?_P"?Y/\
MOFFL!5Z,7,C9$2*<K& 1T(%(UO&S;FB4GUQ6/_9VO_\ /\G_ 'S2C3M?_P"?
MY/\ OFJ^HUUK<.9&UC   Q[5C>(="&M01J&V21L"K4G]G:__ ,_R?]\T?V=K
M_P#S_)_WS2A@JMW*X<R+]M9!+:..=5D91C)%2"SMP<^0F?85E_V;K_\ S_)_
MWS1_9NO_ //\G_?-/ZE6?45XFR8UX)4$CIFG$'&,5B?V=K__ #_)_P!\TO\
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M)H-QK;P(KA8D;+#UK<M+<6MK'"HX08%97]FZ_P#\_P G_?-']FZ__P _R?\
M?-/ZE5<>1O8.9&TT8<;67</>FK!&H $8 ] *R/[-U_\ Y_D_[YI/[-U__G^3
M_OFI6"K1V8^9&SY8S]T<=*4H&7:P!'N*Q?[-U_\ Y_D_[YH_L[7_ /G^3\J7
MU"MO<.9&UY8(P0-OI1Y:[=NT;?2L7^SM?_Y_D_[YH_L[7_\ G^3_ +YH^H5=
M-?,.9#=?T)]9BAA,FV-'!('I6Q;0K;6\<*\!%"BLG^SM>_Y_D_[YH_L[7O\
MG^3_ +YJG@J[2B^HDTC<SFE%87]FZ_\ \_R?]\T?V;K_ /S_ "?]\U*R^MU'
MSHW:,UA?V=K_ /S_ "?]\T?V=K__ #_)_P!\T_J-7L'.C=-)6'_9VO\ _/\
M)_WS1_9NO_\ /\G_ 'S42P%4%)#?$WW;3_KJ*Z=#E%/L*Y1] U:[GC:[O%94
M8$ "NJC7: OH,9KU,+3E3C:1$G<EHHHKL)"BBB@ HHHH *0G S2FHICB)N>U
M #MZY'(Q2[US]X?G6=;V0EBW&5QD^M2_V:O_ #UD_.@"YO7^\/SHWK_>'YU2
M_LY?^>K_ )T?V<O_ #U?\Z +N]?[P_.C<G]X?G5+^SE_YZO^=']G+_SU?\Z
M+A9#W'YTA*9^\/SJI_9R_P#/5_SH_LU/^>K_ )T 7 R=BOYT;U_O+^=4_P"S
M4_YZO^=']FI_SUD_.@"YO7^\OYT;U_O+^=4_[,3_ )ZR?G1_9B?\]9/SH N;
MU_O+^=&]?5?SJG_9J?\ /63\Z/[-3_GI)^= %S>OJOYT;E_O#\ZI_P!FQ_\
M/5_SH_LV/_GJ_P"= %S<O]X?G1N7^\/SJG_9L?\ SU?\Z/[-C_YZO^= %S<O
M]X?G1N7^\/SJG_9J?\])/SH_LU#_ ,M9/SI60%S<O]X?G1N7^\/SJG_9J?\
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M*BF_U3_2@".S_P"/45,7 P"0#[FJ]K_QZBO./&.LZG-K4D6F2D):@&3% 'J
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M +)O/^>1I1I-[_SR-=SP?>EQ0!PITF\Z^2:3^RKS_GB:[IC@9IO7KTH X?\
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M%G,CL%4OU//% 'KNC7R:CI5O=)TD0,:T*YSP1$\/A.P1P0PB'\JZ.@ HHHH
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M=#56S^_+_O5:;I56S^_)_O4 6^]+110 4444 %%%% !1110 4UN!3J8W7^E
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M-J/MS?\ /-J +V:,U1^W-_SS:C[<W_/-J +U%4?MS?\ /-J/MS?\\VH <_\
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MUH G[T4=Z* "BBB@ HHHH **** #M1FBEZ=.: $((Y+9'M0 1SV/;%<;X_\
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MX:\(6ND:+#:72K<R1L"&8?=/M6Z=/M/M0N3;H9E& ^.0* +.,<4444 %%%%
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M2H4MS(A4%1CFH_"/AX>'-'2TW!YB2SM0@9O"BC.<FBA@%%%% !1110 4444
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MU.""2%PWEI@,?4&O?H05C0-U Q0!-1110 4444 %%%% !1110 4444 %%%%
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M*** "BBB@ HHHH 1NA^E5+/[\O\ O5:;H:JV?WY?]Z@"Y1110 4444 %%%%
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M:'2[FV\Q?-WLVT^E+\- 7\7>()H_]5YIP>V<TP/60>*6F]*=0 4444 %%%%
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M<C/-<WXNU6ZT;P?<WMJ?WR*2,U@_\)M,/ARNIFYC_M#RR0-U 'H1R&Q@Y-&
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M@9ZX]J4J2,$$>AJ"Y\X6\@MUQ-M.,GC->0ZSX@\7^'M7M9)[Z*>.>;:8$;)
MS0![)E2=N4S]>:/I7F6NZK=:9XNT>\\UDANP%=.V37IBG<BL.A&10 M%%% !
M1110 4444 % [T4#O0!7N/\ 7V_^\/YUL+]T5CW'^NM_]X?SK87[HH 6BBB@
M [BHI_\ 4O\ 2I>XJ*?_ %+_ $H X'X@(TG@*]6-&9MAX7O7GO\ P@EK_P *
MS74")?M7EY"9.?RKVR.))K;RY5#IGH1FI#;PF,Q>4OE?W<<4 ?/^I6=[%H?A
M^X82QV\> ^%SM]ZZ#0K6WM+C4=6L+E[NY^SG,>W@\5ZX]C;R1>5);H8^P*\4
MRVTRRLU<6]LB[N" N,T ?/%]=7>KG3YFW"83@M$B<+S70M<0Z)XUN)]8M'FA
MF@VQG;D9Q7LD>D6,;%UM(MQY^X*?<:=97;*9[=&9>F5!H \2\.7ESIOA[Q#>
M6U@_SRDHA7H,UF6[W-]XITBX1FDD/WL)@+[5]!BRM1 T26Z"-A@C:.:BBTNQ
M@P8;6(-ZA1Q0!X_X>U6U\.^)-4BUJS9I9G_=NRYS]*N"TBU/XK),]H3:M;9
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M]377$BFL@*%&4%3U!H:T ^>H8X9%T.'1X[A;]''V@8/'->J?$2&9OA]+D;I
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M@M+8R"&WBD5RHZ'!S0@)/!<3Q>%+%7^]Y8S6_BH[:%+:VC@C&$C&T<>E29%
M!12\>M''K0 E%+QZT<>M "44O'K1QZT  ZU6A_X^):L< ]:KPX^T2\T 6**.
M,]:7CUH 2BEX]:./6@!**7CUHX]: $HI>/6CCUH 2BEX]:3Z&@!#TYZ=ZY'X
MAZO!8^&[JVE#-+,F(U49KKB#U S4,]G;W?-Q"CX_O#- 'C?AO[7K7PU71=,+
M1WP4;@XQVK#N-+\1Z?XGT6"6U :)AM*]QWKZ @LK6U.8($0G^ZN*>UM!)*LC
MQKO7H2.133 P?&,<T_@B^7'[SR"<#Z5@>!-3MK'X?I-*QVQ[@P R<UWMQ"ES
M:O#)]UQM(Q7/^&_"T6@P74+MYEO*Y81D9Q2>K'<\[\ Z];P>+-4:2*4"Y?,9
MVGGK53X@76C:E]H:,70U%&&Q,'!.:]I32["%A+':Q!NQ"#(ICZ/ITLOG/:1M
M)ZE!0]1)'#Z%XJNM%\-:5#J%G,TLY"#:OW1[UB^+K/0/[1NKJ*XF@OI$Y1%^
M]7K36D$@4- AV?=!'2JTVDV$T_G2VT;2>I44#/)])TR31?A7J4MRI0W+%D5N
MI[?TKO/AU"T'@NR20$,RYYJWXG\.#Q!IT-FCB*)7W,O3BMBRM([&SBMHN$C0
M+TZT7 GHH&,4<47%8**7CUHX]: $HI>/6CCUH 2BEX]:./6@!*.U+QZT<>M
M"'[M06W5_K4Y(QUJM;'F3/\ >H L]Z*,C-+QZT )12\>M''K0 E%+QZT<>M
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M!S3#( <9&?3- &3_ ,3/&/)4?\"HVZE_SP3_ +ZK84\^M.XH Q"NI8QY"_\
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MD<K#O'(%=!<Z_8>(X=4TN\MI$A@X=B.O7D?E0,XJ/Q5XHTN73-5OKV">RO7
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M,QZHM5[:YF#R81?O4 :]&:H_:I_[BTGVJ?\ N+0!?S1FJ'VJ?^XM'VJ?^XM
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MU>]UK5-"O;QKF%$8"0>N#6Q\,M0F>YU33+AV<V\S;23VS0!Z+T[T?C0!D<T
M4 'XT?C1BC% !^-'XT8HQ0 ?C1^-&*,4 'XT9XHQ1CB@""X/[Z#_ 'JUQTK'
MN/\ 7P?[P_G6POW10 M%%%  :BG_ -2WTJ7O44_^I?Z4 <)X\AEN? MU#"A>
M1E^4 9YKS[Q/X4OO^$.T_4["%UO(H]DB@<D5[5;J'M@K#(R:F:-=NW:"O<4
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M E%+BC% "44N*,4 )1VI<44 (>E06_5_K4YJO;]7^M %CO12=Z6@ HI<48H
M2BEQ1B@!**7%&* $I0.<@Y;L*3'-'KVH X_QU%H\EK&-5MI7YX>/.0?PKBO
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MQ110 8HQ110 8HQ110 8HQ110!0U#[\/_705>'2J-_\ ?A_WQ5X=* %HHHH
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M=S1FL+SM3]5I?.U/U6@#:8!@5.#Z@U&D*1?ZM0H] *R3+J?]Y,4AFU/'WEH
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M1S0![F+^V^T?9O,43_W,\U8.!VKRGQ/-+I?BS0]2+$--A) .A->IQMOB5O4
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M110 4444 %%%% "CK5:'_CXEJR.M5H?^/F6@"Q12FDH **** "BBB@ HHHH
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M67L]7Z* *'V6;^_0;2;N^:OT4 4!:S Y#\T&UEP?GYJ_10!0^RR_WZ/LLO\
M?J_10!0^RR_WZ/LLO]^K]% %#[++_?H^RR_WZOT4 4/LLO\ ?H^RR_WZOT4
M4/LLO]^C[+-_?J_10!0^RR_WZ9'8RQ[L/U.:TJ* *'V67^_1]EE_OU?HH H?
M99?[]'V67^_5^B@"A]EE_OT?99?[]7Z* *'V67^_1]EF_OU?HH H?99O[_Z4
M?99O[]7Z* *'V67&-U'V68='J_10!0^R2]=_-'V27^]^E7Z* *'V67^_1]EE
M_OU?HH H"TE'\=*+:;/+C\JO44 43;3$Y+_I2?99>SU?HH H?99?[]'V67^_
M5^B@"A]EE_OT?99?[]7Z* *'V67^_1]EE_OU?HH H?99?[]'V6;&-]7Z* ,[
M[ [NC,WW36@.E+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tmb-20201231x20f007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20201231x20f007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %D \L# 2(  A$! Q$!_\0
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MY[/1Y+?\]GH EHJ+R6_Y[/1Y+?\ /9Z ):*B\EO^>ST>2W_/9Z ):*B\EO\
MGL]'DM_SV>@"6BHO);_GL]'DM_SV>@"6BHO);_GL]'DM_P ]GH EI*C\EO\
MGL]'DM_SV>@"2BHO);_GL]'DM_SU>F(EI*C\EO\ GL])Y+?\]GH EILCI&I9
MV"J.I)IGE-_SV>J.IV<TJ0L@,XCD#M$Q WB@"QITB2:=;E'5L1J#@YP<5:K-
MLK>5KB>X\IK1'"@1<9)&>3CC_P#55WR7_P">ST"):*A\E_\ GL]'DO\ \]WH
M F-)47DO_P ]WI/)D_Y[O^E B6BHO)D_Y[O^E)Y+_P#/=_TI@345#Y+_ //=
M_P!*3R9/^>[_ *4")Z#4!CD7DS,13O*8_P#+5Z )**C\IO\ GJ]1[)'/RRN
M.YH!EBDJ'R)?^?A_TI/(E_Y^'_(4Q$])4/D2_P#/P_Y"D\B7_GX?\A18">BH
M/(E_Y^'_ "%'DR_\_#_D*+")Z2H/(E_Y^&_*CR)?^?A_R%%@)Z2H/(E_Y^'_
M "%)Y$W_ #\/^0IV$6**K^1-_P _#_D*3[/-_P _+_D*+ 6:2H/L\W_/R_Y"
MD,$O_/P_Y"BPBQ15?[/+_P _#?E1]GE_Y^&_*BP$]%5_(E_Y^&_*D\B8=+AL
M^XHL!9-2V_5JIHK-D&1PPZBK5JA5FRY;CO2>Q4-RS1114&P5'-_JS4E1S?ZL
MTUN*6Q6HHI:LP"@44M !1110,*6BB@ HHHH&%+2"EI7 *6@44 %%%% PI:**
M "EI*6@8444HI %%%% !1110 4HI!2T %+112&%%%% PI:!10 4444AA2T44
MP"BBEI#"BBB@ HHHH **** "BBB@ J*<?NOQ'\Q4M1S_ .J_X$/YB@"2BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO+]?U"]NOB9<Z1
M)XKN=$L(K!)D\IHU#.6P>7![4 >H45YAH/C5])77CJ&K2ZUIU@T:V]V(U$DK
MOQY8VX#'..:Z.Q\<P3W%Q:WNG7=C=16C7BQ2[29(P.<$'K[4 =917GT/CE-;
M?0[F.#5-.MKN\5(2R)MN5*L<-SD+QVYZ5:D^)%G%%+>#2[]M(AG\B2_51Y8.
M[:3C.2H/?% ';T5PWBCQVME!J]KIMC>W4MG:&26ZMU4I 64[3R>2.#Q6MX#O
M[K5/ FBW][,TUS/:H\DC8RQ/<T ='130ZMT(/T-<+\1-8\2:98B32(X;>R1X
M3/=LWSG=(J[$7\>2>U '>4E"?=%+0 E%%%,0E%+24@"BBBF E%%% @HHHH$Q
M**6DIB$HHHH :_W#0F0HSZ4C<L%[=33Z $(X-,C/[L5)48RLA'9N130,?1BF
M2G$3GIA37B=KJL$GARYU*Z\?ZO;ZHC3%+9+A6 96.U=A4YZ 8I#/;J*X*R\<
M7ZV.E64FGM=:U+8I=7*&1850'U+=SZ4DOQ-ADCTI=.TFYN[K43+&L 95:-XS
MAE8]*!6.]HKSRV\:1:=J/B%YUU&>XBN[>WCLG=6 D=>$C]!ZYK3_ .$[BL?[
M3BUO3YK"YL+3[8T>Y9!)%G&5(ZG/&/>@5CL**\[A\6:IJ7B[PW ^GW6G6MVD
MLP5Y 5F3:"N['0CKBO07ECB \QU0'IN.* L.I*JZB+N73)QILD2W31GR7DY4
M,>A-<%$-4T+QKH.F1^(=0U6XNP[:E;W#*\<<87.\8 V?-P/6F%CT>BBBF(**
M**!"4444 %)2TUF"@D]!0(8.;@X[+S5F#J:K1#Y2QZMS5F#J:)#AN3T445F;
MA4<W^K-25'-_JS36XI;%:EH%%68!2TE+0 444HH&%%%% (****"@I:Y;XA^(
MY/"_@R]U"W/^EG$5OW_>,<#\N3^%<_\ #KQ#XA?Q#JOASQ5<)+J-O%%/$0 /
ME902!ZXR/R-)@D>E45P7PU\1:GX@E\2+J,_FBSU)X(?E VH!TK L?B1?:;I'
MB_4=2<W7]GZ@+6SB  Y;A1_7\*0['KE KR?R_BM;Z=!K:7UG?.^R1M)2$*=K
M8^4,>X!KU.TEDGM8998&@D= S1,02A(Y!(XXH%:Q-1110 M%%% PI:2EH **
M** "BBE% !2TE+2&%%%% PHHI: "BBB@84M%% !112TAA1110 4444 %%%%
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M4M( HHHI@%+112&%%%% !1110 4444 %%%% !1110 5'/_JO^!#^8J2HY_\
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M<O\ #C_D2[7_ *Z2_P#H;5+'T.LHHHI@%9&N_P#"0^5%_P (\=,$NX^;]O\
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MH,$60,^:G\ZB&KD?ZW3[V/\ [99_D:R]:\1V\0BB2.1VW!R&4IC!]Q0!TX
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M# @]#Q61!H&FP:@+F"V594.2^3R?\YKGB][G)S[WZD]WHVGZE ([ZSAG[Y=
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M5H[%H@+E5+L 5V[L#N:LFZA=(P;B-@PW%L@9%"$UH6(E^4L?O-R:)6*IQU/
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MU^]EL;JW33=6>%]064'S 8R"-GUP*EN? ^IR^*96CN+<:#<7T>HS1D'S1*H
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M:E&]\H@%K*D6%B$+;DR,\Y.<T_\ X174HBFH0ZC"-8\]Y9)3#^Z8,H4KMSD
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MY>I7BWMKH,?B1_#L\T@:*!(,/EOG"._SJI.:]@T^)8=-M8DB:%$B15B8Y*
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M''<FHHHJ#8*9-_JS3Z9-_JS36XI;%<44"BK,"M?ZA::9:FYO9UAA! W-W)Z
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M^5 YKFM)E^(VE^+M;UY/!L;R:H(]\1N0 FP8&#WKVZ*&.")(HD5(T4*JJ,
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MJ)HV3<!G&1C-9OA/P^OA?PU::,EP9Q;*5\PKMW<YZ4 <7_PEWQ,_Z$2W_P#
MS_ZU9FK_ !.\<Z&]HNH>#+>)KN80PC[7G<Y[=*]BKF/%WA%/%,VDR/=M;_V=
M=K<@!-V_';VH Y?_ (2_XE_]");_ /@9_P#6H_X2_P")?_0B6_\ X&?_ %J]
M. XH/0YH \?L_B;XZO\ 5[S2[?P9;O>684SQ_:_NYZ=JTO\ A+OB9_T(EO\
M^!G_ -:NJT?PHFE^+=8U];MI&U)4!B*8";??O72T >3ZAX^^(>EZ?/?7?@>W
MCMX$+R/]KS@#\*-.\??$/5=/@OK/P1;R6\Z!XV^UXR#^%>B^(-)&NZ#?:6TI
MB%U"T1D SMSWQ2>'M(&@Z!8:4LIE%K"L7F$8W8[T <)_PEWQ,_Z$2W_\#/\
MZU9M_P#$WQUINIV.G7?@NW2ZOF*P)]KSN(Z]J]AKF==\(IK?B31=8:[:)M,=
MG$87._(QUSQ0!RW_  E_Q,_Z$2W_ / S_P"M1_PE_P 2_P#H1+?_ ,#/_K5Z
M=0: /']+^)WCK69[V"Q\%V\LEE+Y,X^UXVMZ=*TO^$N^)G_0B6__ (&?_6KJ
M/"_A)/#6HZS=+=M.=3NOM!4ICR^,8SWKIZ /)-5^(?Q T73)]1O_  3;Q6L"
M[I'^UYP/RJ>U\<?$:]M(KF#P-;O#*@=&^V=0>1VKN_%6@KXF\-7NCM.8%NDV
M&0+G;SZ5=TJR&G:5:V*N7%O$L6XC&[ QF@#SP^+OB7G'_""6_P#X&?\ UJS;
MCXF>.K77+71IO!ENM]=(TD47VO[RCKVKU\=37-ZCX42_\;Z9XD-VR-80O$(0
MF0^[OGM3$<M_PEWQ,_Z$2W_\#/\ ZU(?%WQ+Z_\ ""6__@9_]:O3Z:WW32 \
M?T7XF^.?$$5Q)IO@RWF6WF,,I%WC:XZCI6I_PEWQ+_Z$2W_\#/\ ZU=/X,\)
M)X1M]1A2[:Y^V7;71)3;MW8X_2NFI@>1ZQ\1_'N@Z;)J&H^"K>&VCQN<W><9
M./2KD?C+XDRQI(O@6 JP!!^V=ORKL?&'AQ?%GARXT9[DVXGV_O FXC!STK:@
MC\F".+.=BA<^N!0!YM_PEWQ+_P"A$M__  ,_^M6<WQ*\=KKRZ*W@NW^WM"9Q
M%]KZH#C.<5Z]7.2>%ED\=P^)_M3!H[-K7R-O!!.<YH$<I_PEWQ*_Z$2W_P#
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M/3- $>N^((=%B7,1GE()$:, < >_<]AWKDK'P_)KTZ75S: ^9<.US/-(7\U
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M_P#0VK4O_$>BV3S6UUJEI#.@PT;R@,./2N5\ >)]"M?"%M%<:M9Q2"24E7E
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MPO\ A2_\(UH?_0(LO^_"_P"%:@HHL%S+'AK0_P#H$67_ 'X7_"C_ (1K0_\
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MI*NW&?,0K6!\2G,?PWU]@Q4BS<@@X(H Z5;F%R DT;$]@P-.:14&68*/4FO
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M#>V0:]*\F(OO\M-XZ,5YJ3.!2 \SE\%^)]:UW^U]9O+!9?[/GLUBMU8*I=<
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MU'4KBTM=$8R0&U2[N3(S%&! D?) !/ 'O3#0W;_X@7+>9I-WH&HZ5?7-G--
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MVBC% "44N*,4@$I:,4N* $I:,48H&%%%% !1110 4444 %%%% !44_\ JO\
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M33_(7U-.2,(3C/-)LJ,6F.HHHJ30**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tmb-20201231x20f008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20201231x20f008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '# \L# 2(  A$! Q$!_\0
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MY]KG_OT:5F'.BYFEJE_:"_\ /M<_]^C1_:*_\^]S_P!^C19ASHNT52_M%?\
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M"[L9&[&.-U+K'CDZ5]O"V'G-:-:J 'QO\[./RQ70ZE8V6HZ;/87EH9K9E *
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M=&&593D$4ACJ**6@!>U!Z9X_&@4'[I^E /9F?I4*2:3"DL4)&6^5#N7[QK1
M"@ # JAHHQI, "(O7Y4;('S&M"D]["ALAV*44E+0R@I:2EI#0HI<#THHH 7%
M+24M(8HZ4N***0"XHQ110,,48HHH ,48HHH ,4F*6B@!,48I:* $P*,4M% "
M8%&*6B@!,48I:* #%&*** $Q1M%+10 F!1@4M% "8%&!2T4 )M%&T"EHH 3
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M@23."JW%R\J>ZG&/Y5R@3P^Y\0-JC#[8)7\D.<?3';.:]31%CC"(H5%& H'
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MV"Z\+VD4+[G@79(,$8/6@9TE**2G4@%HHHH&+2TE+2 6D;&PY]*6D;[AY[4
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M9H&.HIN:,T .HINZC- #J*;FC- #J*;FC- #J*;FC- #J*;FC- #J*;FC=0
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M]0U6Z>6V1/L^Z&W1<;G7GCMS0JD1NE+HSS/[7<_\_$O_ 'V:/M=S_P _$O\
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M1Y9)7,S=3^--W3 */M5SA6+#]\W4]>]+2460#<28 ^TW6 V__7MU_.G>9/\
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M*G<\7U;Q7J^M6PM[RX0PAM_EQQ*@+>IV@9J3PC_R&Q_N-7LG_"IO"G_/K/\
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M +\M_P#%4?\ "X_$O_/+3_\ ORW_ ,51["8OK,#WG(HKP?\ X7%XE_YY:?\
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M?IXIUL,GF26;*,[P("-WT^;BE7Q7K0$>Y[,[2=V(3R.V/FXHY&'M$=Z:3K7
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M]2V>NVMI9B(6YW>44)"CD^N>M*[':)F?V3J& WV2;:<<A:9_9M[Y_D?9I/-
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M]_&_^)I?^%/>(?\ GYL/^_C?_$U[C2TO;3*]A \-_P"%.^(?^?FP_P"_C?\
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M9@6'O\O'ZTY_"&N9D*_8CA1LS*W)[@_+QW]:]#Q1BCVC#V://&\(:X"^P61
M4%<RL,MZ?=X'O^E-'A#7MQ!6QVA,@^<WWO3[O3W_ $KT7%&*.=A[-'GH\'ZW
ME?\ CR V'/[UN&[#[O3WIO\ PB&N_)Q8\I\_[YN#Z#Y>?TKT3%&*.=A[-'G<
M?A'7BT?F+8JISOQ,QQZ8^7G]*5?"&N?N]WV(98A\2M\H]1\O)_*O0\48HYV'
MLT>=#PAKYVY6Q!W8/[YN!Z_=_3]:7_A$->P<BQSOP/WS?=]?N]?;]:]$Q1BC
MG8>S1YVWA#70CE!9%M_R@RL,KZ_=_2JTWA/7END18[(D[MA\Y@,>_P O^->F
MU3F/_$QMAEA\K\=CTIJHR94XV.(;PAK8,FS[$0 /+S*PR>^?EX[^M#^$-<!D
MV"R(P"N96&3[_+Q_GBO0ATI<4N=E>S1YT/"&O9.5L<!<C]\W+>GW>GO^E/\
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M]:AMO#%U86NG_9+R-;JTWC<ZDJX8YQC-9VNZ+>6VD;FG\^]NM1CE=TC^5<#
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M Z<$T <_/K]U!X^B?SV.E2'[-U^7?L!_/)K9\)2WEUIEY>74SR">>0Q!CPJ
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MO?OZTE2J?F5[9]4>N266C:A?:YIW]E6<26:0R1/&,,2P!;G/O5+XC:5;:3I
M2VT^!5>Y&)88"OEH!PK,>I)KS:UN9+2ZBN8C\\3!USR,BMW7/&5[KEDUJ]M9
MVT<D@EF^SQ[3*WJW/-#@TU9A[1.+NCT'P=,T7@S1F6U>8+=/YDB2[1 #_$WK
M^-8VD""&XL8XKE9HU\1RE90>&7RU^;Z5YKDCH<4G04_9ZO4/:NR1Z)KJ:E9:
M+XD75YV6*XG3[%%-*&8D2 DJ,Y VYKSNER?6D_&JBN4B<N8****JY%F%%%%%
MPLPHHHHN%F%%%%%PLPHHHHN%F%%%%%PLPKH_!F?[4EY'^JZ>M<Y^-='X.D6/
M49B[JH\ON?>E+8J.Z.ZHIAFB!(\Q..OS#BCSHQG,B# R?F'%8'2/HJ/SXO\
MGJGK]X=*7SH^/WB<C/WATH ?14?G19'[Q.1D?,.:431-C$J'/3##F@!]%,$T
M9 _>)\QP/F'-)Y\7&)4.>GS"@"2BF>=$?^6B=<?>'7TH\Z( DR)@''WAUH ?
M149GA _UL?'7YAQ2F:($YD08Z_,.* 'T4PS1#=F5!MZ_,.*031'/[Q#@9^\.
ME '6Z*L5C:6\DUS'"9W+,C DNF, <?6B>TMK/3I0(H7D-UY:N_93WKDS-&0,
MR+TSRW:@W$1X,RGN/GJ.7S+YO([*^TZV2"%FBBW"XC7*+@%2>?J*<ZV:_:3]
MBM_W5R(EXZJ>]<7YT38Q*AST^8<T":,XQ(GS=,,.:.5]PYO(ZN6TCA:[%E:0
MW$@GP5;!VICM^-3W30SF"VD@C(-D6W]2"!P!7&_:8N")T))P#OZT>=$1_K4/
M;[PZ^E/E#F.MM;6U^S6X$$+VS6Y::=B,J_I[50\0%2NG[2#_ *.!P?<U@^=%
M@_O4QG!^;O2&>(@_OD('!RPXH40YCLXVQH82[S"5="2[AO,Y'2ABT-W=RWK@
MVLDZ&+<P(//4?A7&F:,9S*@ Z_-TH,\8RK2H,=06'%+E#F.WN2I26.Z976:\
M0PJ6SE<CD>V,U4$MKN'^A6X_TKR>1_#ZUR8GB[2IP,_>Z"CSXQ_RU3IG[WZT
M<H<WD=S%IEK'%*\<$; 3R<%-Q91T K*\,N%U6Z++C,383ISGI6?;>)'MK6.V
M'V:3R\F-GY9<]Q6:URDCEO.0LYSG=U]:%%AS+1H[&0JU]:N3LD^S2*T);)7B
MJJQWCVFDO:NRQHI\Q@^ OS=ZY031G!\Q#GI\PYH^T0G $L>#P,,*.4.8O:F\
M<FIW+1$%"YP1T-4R:9YT?:1#S@<CD^E'G1 ?ZU.N/O#K5HS;NQV3Z49/I3//
MBP3YJ<<'YAQ09HAG,B#'7)Z4Q:#N?2C)]*:9XE)!D0$=<L.*3SXCG$J<#)^8
M<"@!V3Z4G/I2>='_ ,]$Z9^\.GK2>?%G'FIZ_>% :#N?2C+>E()8CC$B<]/F
M'-)YT6!^\3GI\PYIAH+D^E)EO2D\^$XQ*ASTPPYH\V+C]XG)P.>I]*!:"Y;T
MH+'^[33/%C_6IUQ]X=:/.BY_>IP<'YAP?2@!<G^[6WX1$IUF:2*+,8BVRL#W
MZ@5AF6/D;TR./O=^PKT'0-)72M-16C5;B3YYBO=J3=D5"+N6;9W^T7G )\T9
M _A^1>#5C>__ #S/YU'!_K[H90XD'W1R/D7K[U8J&7%:%NS),'S#!S5BH+3_
M %/XU/6+W.B.PV3_ %;_ $-8M;4G^K?Z&L6J@14"@44#K5F8M HH% "THZTE
M*.M ![4O3I244#'"E%)0.M(!U%)2T %+@'J!24M Q:.HQ110-"T"BBD,=2T@
MI: "EI*6@!:23_5/P#P>#2BFRC,3CKD'CUI+<4MF9&DZ5I\FD6CR:?:AVB4D
M! >WKS_.KPT?3/\ GPMO^_0I-&C,6CV:&,Q[8E&PG)7CI5ZFV[A%*Q3_ +'T
MS_GPMO\ OT*7^QM,_P"@?;?]^A5VBDV.R*7]C:9_T#[;_OT*<-&TS_H'VW_?
MH5<I:5V-)%,:-IG_ $#[;_OT*/[&TS_H'VW_ 'Z%712T78612_L;3/\ H'VW
M_?H4O]BZ9_T#[;_OT*NTM*X[(I_V+I?_ $#[;_OT*/[%TO\ Z!]M_P!^A5T4
MM%QV12_L72_^@?;?]^A1_8NE_P#0/MO^_0J]12N%D4?[%TO_ *!]M_WZ%']B
MZ7_T#[;_ +]"KU%%PLBC_8NE_P#0/MO^_0H_L72_^@?;?]^A5ZBBX611_L72
M_P#H'VW_ 'Z%']BZ7_T#[;_OT*O447"R*/\ 8NE_] ^V_P"_0H_L72_^@?;?
M]^A5ZBBX611_L72_^@?;?]^A2?V+I?\ T#[;_OT*OT47"R*/]BZ7_P! ^V_[
M]"D_L72_^@?;?]^A5^BBX610_L72_P#H'VW_ 'Z%+_8NE_\ 0/MO^_0J]11<
M+(H_V+I?_0/MO^_0H_L72_\ H'VW_?H5>HHN%D4?[%TO_H'VW_?H4?V+I?\
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MV3IXQ_H4' P/W8Z5<IDDL<,9DED5$'5F. /QH"R*PTJP7;BS@&WIA!Q2C2[
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MV_\ A6O^='YT7#D\V9!_X2''W=-_[Z?_  JNXUTWD1,6GE]K;6WOQT]JWO\
M/-4Y0O\ :EOP<['YS]*:D3*.VK*H_P"$A_NZ=_WT_P#A1_Q4/]W3O^^W_P *
MU\48I7*Y'W9D9\0_W=._[[?_  HSXA_NZ=_WV_\ A6QBC%+F#D\V8^?$/]W3
MO^^W_P *,^(?[NG?]]O_ (5L8HQ3N')YLQ\^(?[NG?\ ?;_X49\0_P!W3O\
MOM_\*O0WD<]W<VR9WVY4/^(R*LBB_D)0OLV9&?$/]W3O^^W_ ,*,^(?[NG?]
M]O\ X5L8HQ1<?)YLQ\^(?[NG?]]O_A1GQ#_=T[_OM_\ "MC%)BE<.3S9D?\
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M6IQZ<_E4UU-:)\3+8I&1BSE29EC."Y*D GH>!75PV%M;W5Q=11A9K@@R-W;
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ML"1@FG0L@)VL;@ D?E6J?PH_*FG8F2;T3L9'VO6B/^09!_X$_P#V-'VO6?\
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MK^&M<L_$YU&VDN;M;NY7;%;*J>5$O(0L3P.W%>@Z=)>2V2-?V\<%P>L<<F\
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M)35]#VIU @-(:4TV@!****8"&D-*:0T )110: $KBO$,=MHGB*WUZXOILO\
MNH;-.LCGC')^E=K7.^(-!M;J674Y8/M+1VSHT#<AQC(V^C9'6@1J:9J(U*V:
M0P2V\J.4DAE&&1A@X]^".1ZU<KAM$\67 EMX[SR&MC:&>8Q*W^C8X"L3U./Q
MKKM/U*TU2V\^TE$B9P>,$'T(/(IH1LVG^I_&IZ@M/]3^-3UF]S5;#9/]4_\
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M M%)D>M+D&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2\.7]J<9>%L?4#(_45Y#'J4P+^.VAE/DS+8+'CYMGDLA_P#'RM>R_P!I6/\
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M 4444 %%%% "444E !244AIB"DHHH$(>E)0:*8!2444" TE%)FG8!#UHHI*
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MC-9/V+6/^@G%_P" X_QH^Q:Q_P!!.+_P''^-%O,.=]C6S1FLG[%K'_03B_\
M <?XT?8M8_Z"<7_@./\ &BWF'.^QK9HS63]BUC_H)Q?^ X_QH^Q:Q_T$XO\
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MW^X^E&[BN,6QCO/$NG?9X;A-/BL)3&K%U4.) %R._<C/:LNQ2_:XTH+%?+K
MOLWTK[MIA!.[)/RX(P!2&=_:7R7=I]H52%RXQ_NL5/\ *G6=XE[:1W,:NJ2#
M(#J5(^H-<&L2":T2TMKU-1%[+YK[7 \O<YYSQM((INEQA=.TI-<M[MX1IXVC
M#D"7<=V['\6-N,T >B;O:C=STKSZ33KJ]F474=TR)H\C(I9A^\#$KG'\0&.O
M-.M;75H+:%K0W0NI]'+R/([,6GP,9W=#UH [_=[49KC/"5A<07_GR:DT@:W
MEMEM7B7?D'<Q9CENHJEXB6_D\1V\MNK1-%?6Z82!V=XRZ[VWYPJXR",&@#N;
M:]M[SS?(E63RG,;[3]UAU!K*E\564.I-9R17*A9A;F?ROW?F'&!G\1^=9?@S
M3H=-U'6HFMFBN&O'=25(#1G&,$UG:C;,]WJ"B:^%Q_:230VJ1YCDP$P3\O3(
M.3GM0!Z"#1FO/[2349O&%O=-";=?M,L<D2PR%C&%.&9R<$$@8 %-0:BEMJ]K
M:"5T8+(MZT3[R"_S*RD_,P'IC(IV [/5-5CTJ.W>5&<3W"0+M[%C@&K4%RMP
MA=%< ,5^88Z5YZVEW,:1&*\:\C.HVCB*.U>*.+!.6&6;\>G2K[Z?/>ZGI,-S
M'.UL9[GS1E@"/X<X[46 [C/6C/3%>71VNKRI8V]W<S0V:?:$!G@>4<2?)G##
M^'H37<Z5>PP"STF2Z>XNQ;"0N8V&Y1@;CGIGT/-(#8S2Y-<'XIM=4O-3FTJP
M-S"EPHN?/CSA2BG"Y]VQQ5?[-J=WH\5]<R26[7]Z\LPEA:01Q8*Q@H"#C@'K
MWIV ]"JN]\B:C%9;3ODC:0'L #BO/+K3]51=+MUU)Y--9YS+*UHYC5N-@*;L
M[?O8R<58U*PU6*#2V@FN+^.")S<%4:-YHMWW!SD<?F!2 ]#W=ZH:WK=GH&F/
M?WK,(E( "#+,3V [_P#UJYFX#1>([&[L4:>&7RH_L[PN&A7'WE;.,<\@CK4W
MC:RU:[MYVM;&WN[:.SE"K)*59)""-RJ%.X[>!TZF@#JK6YCO+."ZBR8YHUD3
M/H1D54N-<LK;6+72W=OM5SDHH7., GD]NE4/#6H%=,TW3+M/*OTLHW>)<L%4
M  9..#[55\1310^)M!D*/^ZF=Y76,G ,; 9('J: -*7Q):P:FEE+!=)OE$*S
M&(B,N>@W>];/:N.N=1.K>*(;.426^G6<RO\ -$V;F7^'G'"J<'/<UTMIJ5O?
M2W,5NY8VS^7(=I W8Z9[T 4;;Q-9SZLFFM#<P3R;C$9HBJR;>NT]ZLV^MV=S
MK5SI,;$W-LBO(,< 'WKEHKBXUK6YK]_W5Q;"2'2[:1& !(P97..IZ8["H/#E
MGK&E^+)6O["".(V0,]RMP7#-N8EN5&23V["@#T'/%8L?BK3)+"]O5E;[/9S&
M&1MOWFX^[ZYW"G:O]LU/P\3I)4R7"*R;V,>4."><$J2/:N0FM=5BT;6[2318
M(H6N( BPR--M&R-2RC:,[0,Y]0: .UTK7+75_.6%9(Y8&VRQ2KM9#U&16CNX
MS7)>$;>:VU#55W2W%L[HT=W<)B24XY!/?'K6([ZG-XJCN(XY(%::>.2)(7SL
M (5F<G!!X(&.,T >C[LUGSZQ%!K5II;1L9;F-Y%8= %QU_.N8L]/N[.TTZ2S
M6=;N>RF69F9B2^T%<[O?.*S_  _;LWB;19A:WJRI9R"[DG5\>:<9Y/&?I3$=
M;K'B2#12YN+.\>)$WM+%%N0#ZYI#XHM%GMXVM[M4F* 3-"1&I?&T$_B*A\0V
ML^J7>GZ:JM]CDD,MVV."B]%/U.*HZIJ)N_$,.DM&\&G6K)+,YC)\]@<HB\=
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M8=I_S?@9?]N1_P#/CJ'_ ("M1_;L0_Y<=1_\!6K4HHNNP6G_ #?@9G]O1?\
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MR?ZI_P#=-857 SJ!2BDHJS,6BBB@ I:2BD,6EI*6@ HHHH 6BDI: %HI*6@
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84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tmb-20201231x20f009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20201231x20f009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'S \L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT?\ "-2_]!W5?_ @T<L>X<\_Y?Q-ZBL'_A&I?^@[JO\ X$&C_A&I?^@[JO\
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M5G\8Q20Z%<:>;>:#4KD0.SN5*\<A?4]:T[SQ1HFGWRV5WJ4$5RV $9O7U]*
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MMQWQ_.G8#N**RKWQ)HVGRB.[U"&)S'YH!/5,@9'KR:;?^*-$TR6..]U*"%Y
M"JL><'I]/QI :]%9>H>)-'TI86O=0AA$XS'DYW#U&.U4SXB;_A+(M+7[,;62
MT^T"4R?/C/ITQ0!T%5-2T^'4[-[>9<YY5NZGL15?3O$.DZM<206%_%/+']Y4
M/2M.FG9W$TFK,Q?#MW<O#-8WQS=6K;"W]Y>Q_*MJL&([/&MP@Z26JL?J#BMZ
MJGO<SI/W;/IH%%%%0:A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8'B/_ (_M"_Z_U_\
M06K?K \1_P#']H7_ %_K_P"@M5T_B,J_P?=^9OT445!J%%%% !1110 4444
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M[F;M%87]H>(O^@'#_P"!:T?VAXB_Z </_@6M'(_Z8>VCV?W,W:*PO[0\1?\
M0#A_\"UH_M#Q%_T X?\ P+6CD?\ 3#VT>S^YF[16%_:'B+_H!P_^!:T?VAXB
M_P"@'#_X%K1R/^F'MH]G]S-VBL+^T/$7_0#A_P# M:/[0\1?] .'_P "UHY'
M_3#VT>S^YF[16%_:'B+_ * </_@6M']H>(O^@'#_ .!:T<C_ *8>VCV?W,W:
M*PO[0\1?] .'_P "UH_M#Q%_T X?_ M:.1_TP]M'L_N9NT5A?VAXB_Z </\
MX%K1_:'B+_H!P_\ @6M'(_Z8>VCV?W,W:*PO[0\1?] .'_P+6C^T/$7_ $ X
M?_ M:.1_TP]M'L_N9NT5A?VAXB_Z </_ (%K1_:'B+_H!P_^!:T<C_IA[:/9
M_<S=HK"_M#Q%_P! .'_P+6C^T/$7_0#A_P# M:.1_P!,/;1[/[F;M%87]H>(
MO^@'#_X%K1_:'B+_ * </_@6M'(_Z8>VCV?W,W:*PO[0\1?] .'_ ,"UH_M#
MQ%_T X?_  +6CD?],/;1[/[F;M%87]H>(O\ H!P_^!:T?VAXB_Z </\ X%K1
MR/\ IA[:/9_<S=HK"_M#Q%_T X?_  +6C^T/$7_0#A_\"UHY'_3#VT>S^YF[
M16%_:'B+_H!P_P#@6M']H>(O^@'#_P"!:T<C_IA[:/9_<S=HK"_M#Q%_T X?
M_ M:/[0\1?\ 0#A_\"UHY'_3#VT>S^YF[16%_:'B+_H!P_\ @6M']H>(O^@'
M#_X%K1R/^F'MH]G]S-VBL+^T/$7_ $ X?_ M:3^T?$(Y.AQX]KI<T<C_ *8>
MVCV?W,WJ*Q[/7UENEL[ZVDLKI_N)+T?Z'H:V*EIK<N,U)704444B@HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P/$?_ !_:%_U_
MK_Z"U;]8'B/_ (_M"_Z_U_\ 06JZ?Q&5?X/N_,WZ***@U"BBB@ HHHH :713
MAF4'W-+O7^\.F>M>2^(WT#_A:=POB,%[06:[%(<C=_P#FMB:2QB\>Z;#9P-Y
M3:6YB;S& "]AM/\ 6G8#OX+B&YC\R"5)$SC<C9&:DKQGPKXHUGP]X>%P=+@?
M1UOFBDF,I\PEFQD#&,"NKC\9ZS>^+KS2+'3K9K:TVO)<2R$80C/0#DT6 [NB
MO-Y/B%K7V>76(=)MFT*.Z^SF0S$2D9P6 QC%7;KQOJ#^+FTC3[2R:*-4<^?.
M4DF#?W!C!Q18#N@020",CK2UYM'KJ:%JWC.^ALWEEMC&Q!E)#DCZ<"NG\'ZW
MJ&NZ:UU?1V0#;3$]G-YBL".0<]"*5@.A# D@$9'44M>7Q:NNE>-_'=W!;9N+
M.T2;+RDJY" @8[5*/'_B8/I+-H-IY>KJ1:#[0<A@!RW' YS3L!Z717GO_">Z
MK:Z7KYU#3[9-0TAT#)$Y9'#=",\TZU\>:M#KMC8ZOI$-K%J,)EM624LRX!.&
M&.O%%@/0**\\TSQ]JUQHE_K=WIMM'IUJ'12LAWR2 X  QTJ2#QEXAMK^PBU;
M2K.*'448V[0S,Q5L9"L"*+ =_17GZ_$&YD\/6=Q':1'4[B[-K]GR< @\GUZ5
M1UCXHW%GJ5W!;1:9Y=D0LJW-ULDE;N$7%%@/3J*\_O?'FIRZOIMAH^G03O?V
MGVA/.D*A#WR<=!6<OQ'\1_V1-JC:%:"ULI_(NF^T'+-G!V#';(ZT6 ]1HK@/
M$WQ#?3-5@TZP&GK(UN+AY;^X\I #T4<<DU7?XDWMQI.AW6G:5%/<:A,\#P&7
M 5E'9L=.]%@/1Z*\OUCQ;XAG\,^)K.2V@LM4TP+YCPS-CRV .Y3C.<8KK?#-
MUK,G@^&YU%(&N_LX>+RW9MXV J6)[GO2L!T=%>:2_%&6'2="N6M8?.OIVBN4
MW'$(5@I(_.M_2?%LVHZ]KEN\,2:?IH&)P3ECCG/Y4[ =''J%G+?2V4=Q&UU$
M TD0;YE!Z9%6:\OT35_[#\,ZGXLN(#+=ZG=G[/&3C>"<(,]AWK;TKQ5KB^(K
M32M>TVUMOML1D@>WE+=.Q!'6BP':%E7J0/J:,@8R1STKSCXLV[7L>BV:RM'Y
M]ULW*<8)'!JF=1FNG\+6UPY-U9W[6T_/)*KP3]118#U,LH(!(&?4T$A1DD >
M]>1>-)9]?UW4I[6:1!X?B62/8>&DR"<_AFM'QE=76JZ)X?U:*UN+_1R!)?06
M[$%ACOCD@'-%@/3-ZXSN&/7-!8#J0,UX_P"(K_0I/AE)/H$LT=NM]"9(9&8M
M VX97!Y%2^+_ !5I>MZEX9ATV\>5TO4+CRW3N/4#-%@/7****0!1110 4444
M 8"_\CR__7F/_0JWZP%_Y'E_^O,?^A5OU<^GH94OM>K"BBBH-0HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %8-]XPT:PBE:6YR\;M&8P/F+#K6]7%_\(MH_B*"
M])CEBF2[D!ER"<]_PK2FHOXMC"O*HE:G:_F7?#_C&UUJ.>64QVJH^$61QDCU
MK:_MC3?^?Z#_ +[%8/ACP?%HT5S%>16UT&?,;M&&./Q%;_\ 9&F?] ZT_P"_
M"_X4Y^SYO=V)H^WY%SVN)_;&F_\ /]!_WV*/[8TW_G^@_P"^Q2_V1IG_ $#K
M3_OPO^%']D:9_P! ZT_[\+_A4>Z:_O/(3^V--_Y_H/\ OL4?VQIO_/\ 0?\
M?8I?[(TS_H'6G_?A?\*/[(TS_H'6G_?A?\*/=#]YY"?VQIO_ #_0?]]BC^V-
M-_Y_H/\ OL4O]D:9_P! ZT_[\+_A1_9&F?\ 0.M/^_"_X4>Z'[SR$_MC3?\
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MSYO=V)H^WY%SVN2_VQIG_01M/^_Z_P"-']L:9_T$;3_O^O\ C47_  CNB?\
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M8DN19G-M#<WRM'#_ +HX_6NF_P"$=T3_ * ^G_\ @,G^%'_".Z)_T!]/_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!3U=_*T:^DV*^VWD;8XR&PIX(]*72W\S2;-]BIN@0[5&
M/E' ]J=J/GC3+O[,2+CR7\O'7=@X_6EL/._LZU^T9\_RD\S/][ S^M5]DS^W
M\BQ1114F@4444 %%%% !1110!CVT)7Q5>3>=&=UN@\L-\PY/)'I6Q6/ +8>+
M+HJTAN3:IN4@;0NXXP>N:V*J1G2V?JPHHHJ30**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QO#LD4D%Z8H%B NY 0
M&)W'/7FMFLK0GNI(;LW2E6%S($RNW*YXJE\+,Y?&OF:M%%%2:!1110 4444
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MB"5EW")ROJ%.*.>7</8T_P"5%_\ X2'5O^?Z;_OJC_A(=6_Y_IO^^JS0"3@
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MD8Y'2J]EXVT:Y\6ZSY[&WT_4(A$)2.A'<U7&IZ#X0\)ZC9:9JJ:C>7OR@QC
M532 T=5U<^"8?#^EV%G:E+B%7N&>,,7R1GG\:=KO@G3=7^(L5HH-M;W-EYY$
M0 ^89_\ K52NKSPUXKM=%O;W6H[*YL8U2:%QRP&.GY5;M?&VDW?Q,^WO=+!I
M\-F8(Y). 3R?ZT#,^R^'F@:O;7L6G:S(UW8,!<NZX0=<D>W!_*LO5_!^CGPH
MVMZ%?RSI#,(I1*N,G.,BK/@K7--T^/Q6+N\CA-W$1!N/WS\_3\Q5?1=4L5^&
MNHZ4UR@OI[I3'!GYF&1THU$:EG\/_#\-SIVF:IJ-P-4O(]X2)?E7C.,UPWB*
MRL=.U^YL]/DE>"%]FZ48.1U_6O=+J6V@ELK1)K*+55@5+<W*EI4)7U'!KPOQ
M)I]YI?B&[MK]U>Y$FYV7HV><_K0F#/<Q:ZN8]%&FQ:>+$PK]I$RKN/TKC--A
MM/\ A<TT<%IY4.&_=LF!G') JUJEYH>LKH]PGBN&R-G$H>-6.21S54>+M'NO
MB=;Z@+A8[.& Q&=Q@.?6A#)O"L@L[[QA=1QQF2#<R;T! (/I4/ACQ OCIKK1
MM;LK9F:%FBFBB"%2/I5?PUK&C_;O$\5WJ<-M'?96*5SP03UIND3^&? \-U?6
M^KIJFH/$4B2(8"YH$><W4/V>[FASGRW*Y^AJ&GS2M//)*WWG8L?J:95""BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ&ZYZICC-=OI4ZW.E6LR0F%7C!$9_AXZ4@+E%%% !1110!A:7_R-&L_]LO\
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M:%XX[J12PGV9.<]#GUHBFTQ5)*,XW\SL:*Y_^U]>_P"@'%_X%K_A1_:^O?\
M0#B_\"U_PHY'_30_;1[/[G_D=!17/_VOKW_0#B_\"U_PH_M?7O\ H!Q?^!:_
MX4<C_IH/;1[/[G_D=!17/_VOKW_0#B_\"U_PH_M?7O\ H!Q?^!:_X4<C_IH/
M;1[/[G_D=!17/_VOKW_0#B_\"U_PH_M?7O\ H!Q?^!:_X4<C_IH/;1[/[G_D
M=!17/_VOKW_0#B_\"U_PH_M?7O\ H!Q?^!:_X4<C_IH/;1[/[G_D=!17/_VO
MKW_0#B_\"U_PH_M?7O\ H!Q?^!:_X4<C_IH/;1[/[G_D=!17/_VOKW_0#B_\
M"U_PH_M?7O\ H!Q?^!:_X4<C_IH/;1[/[G_D=!17/_VOKW_0#B_\"U_PH_M?
M7O\ H!Q?^!:_X4<C_IH/;1[/[G_D=!17/_VOKW_0#B_\"U_PH_M?7O\ H!Q?
M^!:_X4<C_IH/;1[/[G_D=!17/_VOKW_0#B_\"U_PH_M?7O\ H!Q?^!:_X4<C
M_IH/;1[/[G_D=!17/_VOKW_0#B_\"U_PH_M?7O\ H!Q?^!:_X4<C_IH/;1[/
M[G_D=!17/_VOKW_0#B_\"U_PH_M?7O\ H!Q?^!:_X4<C_IH/;1[/[G_D=!17
M/_VOKW_0#B_\"U_PH_M?7O\ H!Q?^!:_X4<C_IH/;1[/[G_D=!17/_VOKW_0
M#B_\"U_PH_M?7O\ H!Q?^!:_X4<C_IH/;1[/[G_D=!17/_VOKW_0#B_\"U_P
MH_M?7O\ H!Q?^!:_X4<C_IH/;1[/[G_D=!17/_VOKW_0#B_\"U_PH_M?7O\
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M,?RG'I]:.20_;0V_1F_17.1>*+B2":0Z#J2&, A&CY?)[5JZ7J(U.T\[[/-
MP.&CF7:P-)P:W'&K&3LBM>&W'B73=XD\\QRA",;<8&<UKUCWTH3Q'ID?DHQ=
M9,2'.5X[5L42V00WEZ_H@HHHJ30**** //I==M-9\3QG4$NH;.QFQ;0FV?,L
MG3>QQC [?G74_:[!?$4D?V"07:VX=KOR?E*?W=W7/M6Q10!Q.BZY:3^-=194
MN0MPB+&S0.H)'7DBKOC:T-Y;:5%Y)F3^T(BZA<C'/7VKJ:* ..\1W<UGK,,
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M#:>*H^%&N6\+V!N]WF^6?O#!VY.W],5I_P N_F8/^.O1_FC9HHHK,W"BBB@
MHHHH *S)%-AK<=\;A4MYAY4J.3][^$C\:TZK7]G%?V4EO,I*,.QP:J+LR)QN
MM-Q]Z;S^VM/\D,;8[_.(4$=.,GM6G7+V]PNJW^E7"ND+6SR1/#*_SD@8X]?6
MNHIS5K(FE+FNU_6B"BBBH-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$GAVWUZ7=IS6(=5G/[N23'\6>#^-0^)$MAXETFPL18R:/L=DAN9V6W9\\@D
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M-6?[!TG_ *!UM_W[%']@Z3_T#K;_ +]BCW/,/WOE^)6_MC3/^@A:_P#?Y?\
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MB_>^7XF/H>M6+Z1"TUY:QR'=E?,5<<GM6C_;&F?]!"U_[_+_ (U6T'0+ :/
M+FRMI)?FW-M!SR>]:7]@Z3_T#K;_ +]BJER<S)I^UY%L5O[8TS_H(6O_ '^7
M_&C^V-,_Z"%K_P!_E_QJS_8.D_\ 0.MO^_8H_L'2?^@=;?\ ?L5/N>9?[WR_
M$K?VQIG_ $$+7_O\O^-']L:9_P!!"U_[_+_C5G^P=)_Z!UM_W[%']@Z3_P!
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M(00?W8Z#DUJ5FZ +E=%MQ=[O/P=V[KU-:55+XF12^!>@4445)84444 %%%%
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MM6U :5I=Q?&"280KN*1C)-<IHWC>^UCQ!'90Z;&UJ8]\DT<X?R\] 2.,^V:
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M''(YHW G&1GTS0 M%)N7^\/SHR,XSTH 6BL>T\4:1?:[-HMM=B6^A4M(BJ<
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M**C%Q";DVPE3SPF\Q[OF"YQG'IF@+DE%%% !7E'B..:Q\97&@P1'[+KDD,Q
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M3L=/AL&N6B+$SRF5LGN:MTY33=[$4Z4XQLY/\/\ (P?[6US_ * !_P# E?\
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MZG^-;E%',NP<DOYG^'^1QGAO5-1AT@)%HTTR^;(=PD4?Q'BM?^V=5_Z $_\
MW]3_ !K5M+."Q@\FW3;'N+8SW)R:GIRFF[V)ITIQBES?E_D8?]LZK_T )_\
MOZG^-']LZK_T )_^_J?XUN44N9=BN27\S_#_ ".*\4:IJ$VB.DNC30IYB'>9
M%/\ $/2MG^V=4[Z!<8]I4_QK4O+*"_MS!<IOC)!(SCD'(JQ3<U9*Q"I34F^;
MMV_R,3^W+W_H WWYI_\ %4?VY>_] &^_-/\ XJMNBES+L7R2_F_(Q/[<O?\
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M[=NYF?VY>_\ 0!OOS3_XJC^W+W_H WWYI_\ %5MT4N9=BN27\WY&)_;E[_T
M;[\T_P#BJ/[<O?\ H WWYI_\56W11S+L')+^;\CB]&U:ZCU36&71[N0O< LJ
ME,I\O0\UL_VY>_\ 0!OOS3_XJM.WLH+::>6)-KSMOD.>IQBK%.4XMWL3"E.,
M;<WY&)_;E[_T ;[\T_\ BJ#K=X1@Z!?$?5/_ (JMNBES+L5R2_F_(Y?5]9NY
M-%OHSHE[&K6\@+,4PHVGG[U1V&NZG%I=E'#X?NI46WC ?S%&?E'/6NHGACN;
M>2"4;HY%*,/4$8-+#"EO!'#&,)&H11Z # I\\;6L0Z4^:_-^7^14CO;E].2X
M-A*LS$ P,PW#GUZ4NH7EU:I&UM8O=%L[@C!=OYU=HJ+J^QMRNUKE2RNKFYMF
MDGLWMY!G$;,"3^(K"\537']DZ?*;;$_VR,^3O'7GC-=144]M#<A!/&L@1@Z[
MAT(Z&JC)*5[$3@Y0Y;E'3[[4;F<I=Z7]E0#(?S@V3]!5V&69YIED@\M$.$;=
MG>/7VJ:BI;OT+C%I:NYCIJ.K->")M&VP[\>;YXZ>N,5@?$FYN;;2K9K?>F)0
M?-5L%37;U6O-/M;]46[@294;<%<9&:N$U&2=C*K2E.FX*6K.!T'5/$VN6<$$
MEHS11RHWVIF*$@')'O7HPZ#-"JJ*%4  < "EI3FI/16'1I.FK.5V%%%%0;!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 57OKR+3[&:[G.(XE+,:L56U&"*XT^>.9
M Z%#E3TIJU]12O9V.8T37+R/5(H-1D5DU%3/;D'[F?X?RKL*X'1((I]?T82H
M&":8&7/8Y'-=]6E9)/0Y\+*3@[A11161TA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/>*M3
M-O#;Z;#-Y5S?N(E?^XIZG^GXUT-<_P"*XT,&GN5&\7T(#8Y'S5=.W,KF->_L
MW8/"VI_:8)]/ED\RXL7,3/\ WP.AKH*PO"\:"SN7"@.;J7+8Y/SFMVBI;F=A
MT+^S5PHHHJ#4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_7!/_015NH>YM'X4%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M -"^G_@8E;U%',NR_'_,?LY?S/\ #_(P?[2\0_\ 0OI_X&)1_:7B'_H7T_\
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MG7%KOV>=&4W8SC(JS10G835U9G.6^C^(+:WC@CUN )&H5<VO8?C4G]G>(_\
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M^A?3_P #$H_M+Q#_ -"^G_@8E;U%',NR_'_,/9R_F?X?Y&#_ &EXA_Z%]/\
MP,2C^TO$/_0OI_X&)6]11S+LOQ_S#V<OYG^'^1@_VEXA_P"A?3_P,2C^TO$/
M_0OI_P"!B5O44<R[+\?\P]G+^9_A_D8/]I>(?^A?3_P,2C^TO$/_ $+Z?^!B
M5O44<R[+\?\ ,/9R_F?X?Y&#_:7B'_H7T_\  Q*/[2\0_P#0OI_X&)6]11S+
MLOQ_S#V<OYG^'^1@/J'B%D9?[ 3D8_X_$JYX>LY[#0;2UN5"31J=R@YQEB>O
MXUIT4G*ZM8<:=I<S;?W?Y!1114F@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tmb-20201231xex4d11001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20201231xex4d11001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6@ [P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** ,N]DVZ]I:87YA-U'/"CI6I67?$C7]*&.HF[?
M[([UJ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!EZA&TFLZ9M^7'F$OW' X_&M2LF_P ?\)%I'!Z3
M<^GRBM:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,F_Q_PD6D<GI-_P"@BM:LN^?_ (GFEQ[%*MYI
M)/484=*U* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!DW^/^$BTCKG$W_H(K6K+O2HU[2@0=Q$V#NQCY1V[U
MJ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*[34M+TVVT'4K72;VS>]U)OWMQ),N1GN>?08K&_L&^M/#_\ PCNEZMX?&E+
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M H0D*LQ8A/E!ZD]?6@"'P]XI\;7&A:_HDUI'<:]IK"-9HS\K[B1QQSC&:TO
M_B_Q/=>(I/#WB6Q2*[BM?.5D_BQCKP/6K&IW>FV_AZ?3O"NN6^FWTDOF-<NC
M,>OS=CSBN9\.:?J=EXLMM9UCQU;W7E_+((HB&F4\A3E.F!VH 63QI\2-%U2.
M[U71 -(GNPK +_JE8A0"<<<\UZ3XWN-6MO"=Z=$MFN+]TV1A205R/O#'I61X
MIU;2/$&EI81:K;1Q--')*SJ^<*X8;<#U'>IO$7B:"]TQH-%UVVM+HN 994<X
M7OCCK0!YS8^-?B<GAZWU?[':W&G@X<J,NH5MA#?+P<BM[6/%7C'7->DMO"#V
MD9L;9)I[>Y WN23E0,'TXJ;1K/1]+\"7>A/K\4MS=$O),5;:"7SD#%9UW;:F
MMZ#I7CN"QM8E$<<:099E7G+DH>>: &^(?B)XMD^&]MKVF:?%:W$5R\5XQ^?R
MS&Q4C:1C!(/TJ%O%WQ*T;6]%37&T\65_((QY2 [LJ3UP,5N6-CHD?P\O?"]Y
MKR32WC3,]P$;[TK%L_=]ZJ>&=,TS3M0M;W7O$ZZH;"/;9JR'$74;ONCG!(H
M9IOBGQAI/CG6/"]S;)=/-'/>6$I;I@$JO3OQQVKE=-\6?%>;1+G4+.:S>UM9
MW29&B#R(=QSG(Z5VNI6VF77C:\\3VOB&&"[>R%K;?(W[HD$%NG7D?E3O"\&F
M:-HNK6NI^((=2N-1;=([QLJG QT"B@#N/".K2:[X2TS5)CF2YA#MQCGZ5M5A
M^#[2WT[PI86%K<+/%;1^6)%!P>_?ZUN4 %%%% !1110 4444 %%%% !1110
M4444 %%%% &7?%1K^E C)(FP=V,?*.W>M2LF_P#^1ATC@'B;GT^45K4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^@9:_\ ?L4?\([HW_0,M?\ OV*TZ* ,O_A'-&R3_9EKD\']V*7_ (1W1O\
MH&VW_?L5IT4 9G_".Z-_T#;;_OV*/^$=T;&/[,M?^_8K3HH S/\ A'=&_P"@
M9;?]^Q1_PCNC?] RV_[]BM.B@"&VM8+.$0VT211CHJ# %3444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% &5?+GQ!I+<<";O_LBM6LF_P#^1ATCD=)N
M/^ BM:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M--=WCGYI3CY57CG^'CFF^&;_ ,77_P 0?[?N/#SVT%]&EN_F-@H$SDXQ_M4
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M=<T=_$%S#IMO<-JUY$%MV<;?+ 8$D_B*K>"_AYK6@6DES?ZD]Q>1*PL;??\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 4--T:RTF2\DM(V5[R8SS%F+;G( SS[ 5?HHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R;__ )&'2.1T
MF_\ 016M63J/RZ[I+ ;F'F@+WY49-:U !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11427$+SO"D
MJM(@RR@\CZT 2T444 %%%% !14,5W;S320QRHTD?#J#ROUJ:@ HHHH ****
M"BC(SCO10 4444 %%%% !1110 4444 9-^?^*BT@9(XFX]?E%:U95_G_ (2'
M2>>,39_[Y%:M !1110 4444 %%%% !1110 444FX!@N1D]!0 M%)N4MMW#=Z
M9YH!!) (R* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>?#Z/Q#:WEI!<V$DJ7<3H-LOEN5)SGCI1:>-O$=[XCTJT>%;5-4T\O#&Z?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ /2N@J"\O+>PM7N;J58H4^\[' '.* .+G\/ZK;>)!=VVI1PW-Y/,Q&W.8P
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MH-Y:65MJ>#-.5)=/4#CK@?K0!CIX\\67GA7Q?+"D<D]A<,BE>/*CRVX@XYP
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MBB@ HHHH **** "BBB@!&!*D X..#7+-HGB9X3#+K5C-&6R5ELRWT_BKJJ*
M.8_L?Q)YL<O]JZ=YD:E4;["<J#U ^:G/I7B9VW-J^GEB-N38GIUQ]ZNEHH Y
MQ]-\42QM&^LV#(P(939'!!_X%35TWQ5'&$CUK3U50 H%B< #_@5=+10!S1TK
MQ,TJRMJ^GF11@-]A.1_X]3GT_P 5O&RC7+%21C(LSD?^/5T=% ')#0/$RNSQ
MZY9H\F/,9;0@O[GYNM6]-TC7[?489K[6X[BVCW9B2$J6)&.3DUT5% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ,EBCGB:*5 Z,,%6&0:<JA%"J  .@%+10 4444 9-^1_
MPD.D=,XF[?[(K6K)O_\ D8=(Y'2;C_@(K6H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ4NJV<.JQ:8\
MP%W*GF+'W*YQG\Z *U__ ,C#I' Z3<_\!%:U95\C-K^DN$)51-ENP^45JT %
M%%% !1110 4444 %%%% !1110 445F66O6.H:M>Z;;.SW%GCSN/E!)(QGUXH
M TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO?3/;V
M$\T8RZ(2![U8J.<RB!S" 9<?*#T)H \F\%^(+_4[JRDU3QD5FFD<FP,0!X+
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M;3:DAMI+\WUY'&A42G& HYX'"G\*E_X5;J,GC ZO/X@,EC]K^T"Q,9VJ V4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW7Y6=C@?E\PXKJM2TSXDQ7-M::%>:9;:7!:QQ 2 .[,$ /5>F0>]*? .H_\
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M!?&>B'Q3-X<:ZV:E$H8HXP#D @ ]S@T6'C/0=3:]2TOXY7LE9YE4@D #).*
M-^BN1A^(VASPZ7(CR'^TYS#;C;R<$ D^@Y%:OA_Q'9^(XKF2S8,MO*8F(.>1
M0!LT5Q^L_$GP]H>L7FE7EVJ75M;^?@G 8X/RY_O<=/>K%EX\T2^;2%BN%9M4
M0M"%.>1@$?@3B@#J**Y'_A8VA?\ $U_>N/[-D$<I*X!R0./7[U6(_'WAU]=M
M]&-\$O+B)9(UD&T$-T&?4^E '34444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4FT%@V!D=#BEHH **** "BBB@ HHHH **** "B
MBB@"*>VAN4"3Q+(H.0&&1FI1P,"BB@ HHHH R;\_\5#I YY$W_H(K6K*OE8Z
M_I+#=M FS@<?='6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***:X8QL$(#XX)'&: /.O$_@Z76/B#IF
MKI:Q06ME^]N+K<0\@'\(Q_GBN<\.'0=4^*WVKPZ!]D>W:*[B ."?F^8^QSBO
M17L_%[JZMJ6DE3G@VK],\?Q>E4[+PWKFG2O+:2Z)#(PQN2T<''_?5 'E%M<Z
M;X<\7W4>NNZQ:5=2R:?:1IEI!*V[/T&T=^]>D_"7PW<Z#X;N9[N-X9=1N&N3
M$_5 2< _A@UH2^'=<N+U+V:717NEQB4VCY&/^!5=-KXNQ\NI:4/^W5__ (J@
M#D_BKX6TA/"NJ:K'IT<FH2E09"2223V_.LCQ58^$[3PAX<L=2F?3+\V:/;7$
M((,3%06)Q[FN\N]*\47T:PW%[H\L.=S(]JYR1R/XO6JEYX;\1Z@8/MEQH4WE
M'"[[-SA?0?-0!Y?H<UMJ/PIU]GA>:^GNEC:X*8\Y\H!M_#%5M?B\/6OARQ\/
M6JS'Q-:S09F.2YDS\R@^Q%>M+X;UZ.-(8YM#6"/YHT%F_P K>OWJK2>%O$[S
M"X^T^'3<!_,$AL9/O>OWZ .ST]773;59<^8(4#9ZYP,U9J. 2K;QB=D:4*-[
M(, GO@5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 95\3_ ,)!I( .")L\
M_P"R*U:R;\?\5#I!P3@3<CH/E%:U !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ."<<<TNMZYXDL=7D@T[0!>621JPFW$%F.<@#VH ZJBO.)OB'K5UH<>K:-H
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M/X>\*6FF/*LL\*,2X& 69BW\S7+:9H_C&PUR>]2+3,7=UON))$)?RR?NJ0W
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M]4!3<0J5  Z8!]JUK\_\5%I')'$W'K\HK6H 9$ACA1"<E5 )]:?110 4444
M%%%% %'6(KZ?2;F+39D@NWC(BD89"G'!KF_!G@5/#<L]]>W<E_J=P/GGD.=H
M/55]LUV5% '-^(/"4&I>&]0TO3EAM)+P[FD*D@MQR>_:N=B^&!D^&A\,ZC=Q
M75Z@8P7C*<1M_#CO@5Z-10!RL7@V/[=HUU<3":32X-D3'KOY&[\B:=I/A)].
ML]<22[\V?5)99"^.%WC KJ** ,S0-)&AZ-!8"3S/+S\WKFM.BB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH Y63Q[ID'C.3PS<1S0W00-'(X^24D [5
M]^?TK,TKXN^&M1A=IWFL9!<"!(YXSE\D $$ C&3W-7M;\-3:[XUTF^EB5+33
M<R"4$;V?LOTP33?'VEV \!WEMY&R!"CA(ACD,",?B* )H/'NF/XLG\/SK);S
MJ%,+NIVS9Z[2/P_.L^U^*_A^47'VEYK9HG*JCPN2V#CL"*Q=>EE1O $\2LDC
M2P(V5.X*VW(-6=%\=065IJT-Q]MN[B*\-O%%'"S_ #%=P P.!0!NO\1='6SL
M;R-99+:[G: 2@8"$8Y;/^]3M)^(FAZQKTVD6\CB9,['=2%EQUVGO7)ZY8&X\
M&Z7IVI6@2ZU.]%[-#U"*A5Y%QZ;13/$NK:-K+^'[/P]%+'?6FH1B#_1V0(H!
MXSV'2@#:/Q?T%'E26WO8VCD*'=">0!UZ=*[#0==L/$>DQ:EITPD@DXS_ '3W
M!]Q7/>$;O4;[PMJ$NJR223$R#]YT V] /2JGPAMWM_!LZ-$T8.H3L@*E<J6&
M"!Z4 ;?C3Q?:^"]$_M*Z@EF4N$5(QDYK(TCXK^'=5OXK-FFM)9CB/ST*ASZ#
MBM#XA75I%X1N[2Z65S=@1QQPJ69FSD=/I7&^.K::[\,>#[O4(9&NH+V$LC*2
MP8NHY/:@#I;?XEZ:[ZU;SVT\5YI8=S;E?FF12?F7]/SJCI'QBT/4I+6&:VN[
M2>X8JJ31D<@$X_2EGL7B^.]C=[%V3:7,-PZ\>6.:M_$9()&T!9$8S?;_ -R0
M,[6VG/Z9H 73/B597]SJ]G+97-K>:?&\HAE S*J@G*X^E1:)\6-#UBYBMFBN
M;2:0X GC*@FK;:!+%XUNO%VHA1':6[1VZ0KN<K@[B<=<C&!6/XBURT\7"QT_
M3M+U&2Y,ZL'N+)XE1<'G<PP* -*\^)%K%IMS=06<I:WU!+%E<CDDK\W!Z?-5
MS6/'VGZ,VL>=;SRC31%GREW&5G!(51Z_+WKAM:T7^RO&]V^IV]W)HD^R[$5I
M:O*7F!X^Z#C&U3FM>[75K;2M;\1VUM+976J&)(HD!,@10P#8'(8@_A0!?T_X
MMZ'?W=K ;>\MQ.XCWS1D*AQGFN_KB?'-K/?>#[2-8)KB<M$2J<.3QDYKM1T%
M '!Z[\3(M"\3W6D2:/>W"VZ(QEA4$$L,@=:FTSXE66K:?J4\&G7B7%BF\VTB
M@.XX (]LFHM6UU?#/CF2>ZL-0FM;J $2VML\P#* ,$*#BH=(UJ+4?&NH>(8;
M#4(K"+3%@)FM'1V<2%N%(R>#0!/H'Q,M]5OK2RO=*O-.DN5&R6< (S_W1@DY
MK._X6Z?M=U!'X7U6Y6"4Q^9 $VDCZM2ZYJ=EX\DTVQTZQU.*ZM[V*X\^YLI(
M-B*V6PS#&<4Z+5Y/!OBC5[(V>H75M=E9;7R;5W56V@$%@,#)R<T 20?%NTN=
M$.H0:%J4DBW#6\EJ-@D0@#DY.,'-3Z/\4K74M<@TN[T34=,>=6:.2Z"[6((&
M/E)YYKF=7T;7K#2;:[\N5-1U76([FZAM\L%7>F0<=A@UU?C0LGB?P],()I%A
ME,KF*(N0H(STH S5^,-O%<11WOAW5+:&2;R?M+A-F<X!ZYKTNO)?'OBRQ\1:
M%]@LM)UB6Y$\90R:9* N'&2"1Z UZM#*L\*2J&"N,@,,'\10!RNK>.%T/Q=9
MZ-?Z?.EO>$+!>#&PMZ'GZUA7GQ<%CX@U#2/^$<U*[DM6RKVX7#1]FY([YJ_\
M3["XO[#2!$&81Z@CE%B+DD!O3H*AT>\EU/XG37=M9WL4$>GI;RR3PM&K88GC
M(YZT (?BI'<Z!#JFFZ#J%T6E:.6%0NZ+:<'//^<4ZR^*EO?VNH*FBW\6HV<8
MD^PR!?,D7(&1@X[]S6IX.M#9ZAK:K"(HGNF< #J222?QK,TRUG3XTZG<-!(L
M+:=@2%"%)WKQGH: *%K\7)[O6[;3%\)ZHDLXX5B@;Z_>Z"M?2O'\MY'K,5WI
M,UMJ%AN:.V/6= >J\_3\ZAU.SN6^+NF:BMO(UK:6<IED$9QRC  'N?:J,>LZ
MEJ7C7^UH]*N+:R@L+A%,D3;Y&#* <8SV.* '0?%F9DB,_A'5U#G!D4Q[!SU^
M]6GK7Q"DTN_MX+7P_J&HQ31+)YEN%Q\W0<D5#HD5Y_PJ:(W$5Q]NDB9G5T._
M=O.,CKTQ4L7BN?0]*TVSDTB_NI_LT9=HX6P#CZ'GVH WO#'B6S\4Z7]MM4DB
M96*2PR#YXV!Q@]NU;5<GX$M;E+"\O[JS^QR7TYD\C&-H&0./<<UI^*?$,?AC
M0WU.6!IU62.,1J<$EV"C^= '/Z[XVUO2-8N+>'PG>WEG#'O^T1LG/'NPXHF\
M=:G=Z3I6HZ#X<NM1CO$,DB*RAHU!*]V SD5V4++?6,;RQ86:,%HVYQD=#7F_
MA#Q!?>'?"%K:7.B7TC)+(J*D;9"[V.>E &A;_$R.339I+C39K2_MKJ.WN;28
MC=&&;:7X/(')_"K.H>/Q8S^(,6OF0:3!'-N7K)N4,/YUA'PQ<^+KW7O$$M@]
MK-<62P6,4C;665 V&.>G+#\JR]&T[5];T:?0GTNYAGOL1:K?W;9RJ?+A<@9Z
M#!YH ZF;Q_?V.N:;!>Z.PTS44'D749S^\Y.T\^F/SIC_ !$U W%U96WAZYNM
M2BF95M8BN?+!^\23CD>]7/&&E3KINC6MA%(ZV\ZD[><*,9S61I.LRZ1J.IZF
M=#U"6:_N7C/R-G;&2%/3H0>* +S?$#4KG1K:[TOP[<7=R9"EU;AT#6Y&>#EA
MSP#WZTNG^/M4.NV.FZUX8N],%Z66&65T()49(X8^U8>E:#J,^J"]GL)8;34=
M96X> GE8Q"5^;C^\!70^-M-N]0\5>$C:VQF2&XF>0D?*@VKR3VZ<4 =Q7G%W
M\0O$</B:ZTBV\'7=PT2>:FUTW-'G&[EL8SD5Z/7#VD6I:G\1SJB6<UI:P6OV
M=W=^)AN)QC'J<T 1?\)_?/X1DUR/19 ]K=M;WEJ[+OC"G#D<XXY[U-+\1+:X
MAT.?2X/M$&IW @:1ND1P3@CKGBN1U+1=>$&I?8M*>6W.M_:C"\@!F429...
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M:9JKO$5X^1&==O3ITH ]KHJO8SBZL()P21)&&Y&.U6* "BBB@ HHHH ****
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M)D,T]Q->^6?-D^9P!M/ )-+K/A?6!X!TC2;>)9;Z&<,^Y]P7YBQY^AQ7I-%
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MKT.B@!B*4B5<[BJ@9]:XS5_#VL>)+E8K^"S@M?,1_,4!Y%"L& !^H_6NVHH
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MXKZ?X=U*VMTL[J[BDA6:1XHVPJL 5YQW!J#4OC#I5I=Z(T%K<2Z=J*AVNMA
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MXGU6'6-,7[+8ZO:%"C,OF)M<$CH>O'K3;#7O$>N^'[2XTNW@2\CG,=V)AE6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH R;\?\5#I'RYXFY]/E%:U9-_C_ (2+2.#TFY_X
M"*UJ "BBB@ HHHH **** "BJ\%];7%S-;Q2JTL./,4=5JQ0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 9\FN:7%J:Z;)?P+?,,B
M O\ .1]*;9:_I.HR7"6>HV\[6XS,(W!V?7TKEOB#HNGN=+U9U$-S;7:GSESD
MK@Y4^U11>'[;_A8B:C;6;6EO;VW[^8MB.;((QUZC.: .O&O:4=-;41J%O]C5
MBIGW_*".HS3[/6=-U!7:TO89U0;F*-G ]:X;P_8:)'XH\4V>;<Z23;2JIE_=
M^8P8M@D]<U,+'08/&DT5DUN8)-&</;QRY5R),]CUXH Z9/%_AV1PB:S9LQ&0
M!*.16RCJZ*ZL"K#(([BO,;?1M$U?X8WNI_V5!;2BTF=!&S?(0A(QDUV?@QIV
M\&Z2;B599#:Q_,H/3:,=: +-OXCT:[O;FSM]2MI+FU&9XE<%H_J.U3:;K.FZ
MPLC:=>PW2QML<Q-NVGT->=>.FTRP\:^']0L71;U;@B[,)SB,J0"_XG%2G6+#
M3/B]%:Z</,6]AVSI#@(K#N>V>3TH Z[Q=KLWA_38KR-8_+\T+,SG 1/7^56+
M7Q3H5X66WU6UE9$+L%D!P ,D_@*MZK'I\NG2C4Q&;3&9/,.!BO/M*TW1-8\?
M/>Z-&(K"RM66:9 0DQ<,I7YO0'.?>@#T$:QIS6UM<B]A,%S(L4#[N)';H!ZD
MU;=UCC9W8*B@EB>@ KQVV:!KJ#P<MPTTUIK45Y&T?S'RF+,3N'RX7('K7L1C
M4Q>6PW*5VD'N* ,BS\6>']1F2&SU>TGDD^XJ2 EOI3G\4Z$FHOI[:K:B\0@-
M"9!N!/3BN2\=^&=(TS0H+^PL8[>ZM[R%XY(R<@[QQUZ'%3:A/X%BLY(]2>R2
MZDC$LH+-NW$9SD<]Z .MEU_28-3BTV74+=+V9-\<!<;V7U _ U!)XHT6**:5
M]0A$4$HAD?<-JN21@GUX->7:SI#?\*M\,7T]NWVZUG@!F)^= 9@,9^AK0\3V
ML-KXMU'3[B[M;'3-06*X8R@Y^0'?MQW.Z@#OKSQ?X?L7N$N-6M4DMXQ+*AD&
M44XP2/3D?G45KXX\+WMPD%MKUC+,YPJ)*"37GMI")X_$'C2"!;>!K5;6!;I>
M) &4;R/PJ[XW@!^%VEWDL,:WINK,M(B!3DRKGI0!ZID8SGCKFL2Y\8^'K.S%
MY=:O:P6QD,2RR2 *S#D@&M6T&ZP@![Q+_*O,-#N=!\,7^M:-K+1%+>[::RCD
M0L=A09P,<\YH Z/4?'FG6NK:-.FIVG]A74<YENRXV!E"[1N_$UKV_C'P[>6+
MWMKJ]I/;HXC,D<@(W'H/K7'>##8:+HVH:IK#1P:??7DDUI;S1Y*(3D87!/0B
MH+;PU-J'@SQ/>F,(=5E$]M$%VM&$P!QVR!G\: .ZO/%>CV)O!-=*/L:!YB/X
M<G 'UK4M+F*]LX;J$YBF19$/J",BO$EG/BG1V2"*.YU?6VCD,,0;;:QJP(+D
M]Q@\9->U:=;/9Z9:VLCAWAB6-F'0D#&: ,"X^(WA"TOIK.ZU^R@GA.'624#!
M]*O/XNT!-&&L?VK;'3BX3[2'&S/UK A_L;5/B3*UM'#<D:7Y<H$8*J?-SDG'
M)[52\-WNB:#H.LKJ[Q16::Y<1H&0LH.Y<# !H Z[3O%6@ZO!+-IVK6MU'",R
M-%(&"CWIP\2:6VGV=\+@>1>'$+?WCTKA=(\0^&7\<ZC=6EU&;22T+2$0LJJ%
MV@\8%84,_AN'Q7I*:%J,M[IANG;^SEC<")RO4%@..AZT >BW'Q%\(V=_/976
MOV4$\!VNLDH&#W'U%;NFZI8:O:BZTZ[BNH#TDB;<#6#IHAOO&&N120PRVT*0
M>6&B4@,0V_G&<YQ65\*B&T6_*A0OVQP-H('4^M &_J'C30M*\00Z)?7J6][,
MH9!(0 <]!GU.*DLO%FDW^NW.C03G[=;KO:,C&5]1ZU@?%:RM)O")GG@5I$N8
M-K@88?..]6HM"DO=<T74!"D5O:VJGS$^\[87"GU'6@"W9^.M%OM'O-3A>;RK
M,D3QE,2)CVS1!X\T"YL]-NX+HR0ZA)Y4+* </Q\K<\'D53%A9Z!J^N>(]7*6
M]FZB  (2ICR#N( /.3BO,X+/3+OPMXBNI;@6EN^HRW&F2%6&XHQ(PN,XZ=J
M/7KWQEHUA/J,$T[>;IZ!YT R0#CIS[BET?QCHFNZ@]CI]XLLZ1B0J,=#G_"N
M'\,75FU]<^,=7MS86?V5+7=.I8W'"Y8*,GJOIFK=IKF@:K\2;&?3YGPD!5=M
MLZ*QP<@Y44 >A:A?0:9I\]]<DB"!"[D#D 5R5M\5_"MS&D@NI(XG./,D0*HY
MQR<UU>I7UGIUA+=7[A+9!ER5+<?0 YKR_2;*.3X1ZHKQK-;@N;9VBVDJ7SZ
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MD>VM)_OJP!*DX..I'Y5'9#4?'$6FZ=<:/-IMEIDL;7,EQM)G9!MPN">#SUH
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M7#S/ ,$29+8#>W(/'H* ,?Q5J7C2RUV2XT[3M.DLK6)I83+<%7=0"7 &T\X
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M2K %2,$'O2T4 126\,UN;>2)6A9=I0C@CTJ0 *H4#  P!2T4 %%%% !1110
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M $WPC<6T%W!<S/,X4^5&Q" _Q$X_3K3M,^(GA[5+A+:.YFBN&0N(YH'3@>Y
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M=:;?7AABMXU;S$CR/F/..A_2@#T:BO,_%5QXUTM[W4TUC3K>T'$%JT;L[_0
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MI5[\1;2]\.6TQTRSBD$]XLA,4K,I "]B0?YBO4+N]M=.M'N;RXC@@C&6DD;
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M)C?:@[DL[$'CIT]L\52M=!\2260\)W.FQ"R6_:9KT2<& LQP!C[P!'>O5Z*
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M\/6-\D1;>]MJ*D@9Z;0O4?TI=6^(=[IUQX?N/[.S8ZJC!0K9;S<'"].!G'-
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M#FO 5B]GX-LO,&R>9/,D [,:R_AN]S:G7M(NHG22VU"68.PP'65V8$?A7=@
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MM<\8Z=JVK6$5C!8PRIM0DEV8KCKVXK"\0>%=3A3QWJ6Q?+OVB-NO=@IBR?\
MQTUZU3)H8YXFBE0/&W!4]#0!YY/:ZIXP?1;?47AM=+<K<A(QEY7C(8 @C &0
M.E:&KS>+-06YTFWTBS6WD4HL\CL%"]LXK=NHT@UW1HH@$15F 0#C&T5LT 8O
MA73[[2O#MK8WZVRS0+M_T<DKC.>X%;5%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!EWQQK^E#9G(F^;T^
M45J5EWK*->TI2JDD38)SD?*.E:E !1110 4444 %%%% !1110 4444 %%%%
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M)(R?0T 7:*BN+B*TMY)YW"11C<S'H!64OBS0WT)M:&H0_P!GKPTV>%YQS^-
M&U16;#K^DW%L;F&_@>$1F4LK9^4#.:CA\3:-<:/+JT>H0FPB!,D^?E7G'- &
MM16%%XT\-S!3'K-JP?[N&ZU9D\1:3"UV);Z)!:*CS$GA0PRI_$"@#4HK'7Q7
MH3Z5-JBZI;FRAP))@W"YQ_B*9!XNT"Y:-8M5MV>0@*N[DD]J -NBCK6?K.MZ
M?H&GM?:E<+!;J0"S>I.* -"BL6W\6Z#<F%8M3MR\V-B[N3GI3;+Q?H=_?7MG
M!?Q&>RYF4GH..?IS0!N45@VOC7PW>L%M]7MG9G\M0&ZMZ4:;XRT+5KR\M;6_
MC::T8B5<],'!_*@#>HK!L?&?A_4)EAM]3@:5CA4SR:9<>-=#MHKB62[79;W*
MVLI'\,A.,?G0!T-%8\_BG1K5KD3WT<:VT0EF9NB*<8)_,5GP_$;P?<2+'%K]
MHS,P0#)Y). .GK0!U%%%9'B'Q-I/A>R2[U>[2WCD?8F[J[>@_"@#7HKEK7XC
M>$[R[CM8=:MS+(55%Y&YB< #CK3[_P"('AC2]3DT^^U6&WGCQN#YP,_A0!TU
M%<WJGCSPYH_V(WFHQ*EX,Q..05]?IQ4.F?$;POJUW):VVJ1>:@+!6R-RCJ1[
M4 =517$+\6?"/V@12:B(_F*EW4A5]S52\^)6GZ7XKN$O;Q3I$EC!-:.BY\QF
M9@Q!^@% 'H5%96@^(]+\2V1N]*NDN(E;:Q7^$^AK3=UCC9V.%4$D^U #J*X)
M?B_X3^USV[W;QM"Y0EEX/N/:M*[^(GAZTAT^Y^U&6SOFVQW,8S&#DCD]N10!
MU=%<U>^.-(L;G4H)&D+:? L\NT#!5B0,?E4$GQ!TJ.>*'R;EGEL#J"!5!S&
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M\6ZU?:3IRVFA6UDUL[ $).^0V<'J,=_:NI^&,:)X+MV@?=:R.7MP%("QD#
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M=VFHZKIZZ=;V0'V.T#!F'^TQ'&?\:M^.=,O-332DLXC(T=VKOS@!00376T4
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M0 >&Y_P- '14R.&*)G:.)$+G<Q50-Q]37'ZG\2M)TN_>TEMKZ1T R8[9V7D
M\$+@]:DF^(VB0^&#KQ,_V83"!D,3!U?(&"",]Z .KD@AE.9(D<XV_,H/'I3P
MH"[0!CIBN!7XN:#E3)!?1(Q'[R2V=5'XE:[U'$B*Z]& (H 2.&.($1QHF>3M
M4#-(((58L(D#$[B0HR3ZUSOBOQ)<:/<:;86$4<M]?3A$$GW0F0&;\,BH+CQ_
MIEI#J+2K(S:?*D,^%(&Y@#Q^= '6,JNNUE##T(S044@ J"%Y''2N-U+XCZ;I
M'C*V\.WUK<0FX \N[8?NRQZ+]<_SJ2'XC:-+XCOM#Q,MY:KN560_O1WV\=J
M.M>-)4*2(KJ>H89%+M!7:0,>E>=:=\7M-U*W@ECTRZ4S7[6(0L,A@FXM],5I
M6WQ&TVYAUV=8Y#'I+%&3'S2,,\#ZXH [0# P.E,>*.3[\:-T^\H/3I7F]O\
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MXWQSX^@\&&SC:SFNI;@_=B4G"\\_I66GQ;T^[\,WFJ6=A<M/;2K$;4J=Y)(
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MQ\2^'O-?^QVMTG$8G^3.[DCL.E>C:SX9T_7KFUFOT=_LQW(H<J,^^#43^#-
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MOS8$B@X/I52UOO#D?CC7M?O8<VZRQP0L8]P9PN&('L01FO5Y88YE"RHK@$,
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M:Y1DF6-BRL,$9=CT_&LOQ1<FU^(GA)P,[END_-4%=N!@8'2J<NEV4^I0:A+
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M?W"12B*2%+23S5/NF,CIZ5V%>3:-K<'ACQ5XRU&]@N&MC/ BK#'DLQ+]!D4
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M=G-874B6<\-Y:.GG6MP"C!&)^8$@<<&L7PG=ZGX/\./:KH=_J$INGS]FBW
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M6?0O$7CW2+K08DE$44@N)4@*+MW+E2"!G/\ 2NF\*6T%MJGB001+&&U#)"C
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M3O+0RB7:-X&T-WQZ4ZB@ (R,&HXH(H 1%&J G)"CJ:DHH *145!A0 /:EHH
M8\,<C*SHK,ARI(Z&E=%==K*"/0TZB@!KQI( '4, 0PSV([T21I+&4D4,AZ@]
M#3J* $V+LV8&W&,5&MM"K!EB4,O0XZ5+10 @4!< <>E"JJ#"@ >@I:* &F-"
M22HR>M.HHH *:(T$AD"C>1@GO3JADNH(IXX9)5663[BD\M0!-17+ZGXKDL/&
M%KHB6@>.6VEGDE)^[M7( ^M<IKWQ3OM)\+V&L_V5CSKMXY(\GA%9ES^. : /
M4515+%5 +')QW-.KRRS^+-\^KV^FW_AZ>RFN(W:+S/XB%) '/<C%&B?%+4-1
MT#63<Z/)%K5B=J6HYW%L[?Y<T >IT5YEX5^)>I:GJD>C:QH<]EJ#P-(H(X8Y
MX[]*?X:^(>J7PUNQU?29;35;")IHX".77!VC\P: /2J0J"02.1TKS#P]\3]4
MN-<T[1]>\/SV$][_ *MST.<;3U]#6<_Q7UE5U&UGTM+;48;]8$@<G(0[>?KR
M: /8:*\ZT;Q]J.I^)/$UH=/+0Z.1&D4/+RMEAW^E9:_$_P 3V&ER7VJ>#[N.
MVC9BT_&U5W8&>?2@#UFBLU]65O#S:K!&\B^09511R>,UY9I?Q=\17.A7&I?\
M(K<7%O#(X,Z?= !/7GJ* /9:*\ZU#X@:K<^'M&U3PYHDVHO=L6EA7^%1N&,^
MN156#XJ7=UX7UBXCT25=:TO_ (^+'^X#GYC[#!_*@#T^BO%[WXO^*]/TJ'4I
M_!K1V4BKBXD<A22/;MUK>\7>-O%6G:O86^@>''U")TW2'. [$?='TX- 'I54
M#HUF=<76"C&\6 P!L\!2<]/J*XCP[\0]8O6U>#7M!&E75C;"=8W8_,,$G/H.
M*DT/QKJNIS>'XI+11)?B22X4?\LXP[*&_0?G0!Z%15:]U"TT]$>[G2%7<(I;
MNQ. /S-8GC/4=9TG2%O]'@2<PR!IXSU,?.<4 =#-$D\$D,@RDBE6'J",&JVE
M:7::-IL-A8Q^7;PKM1?05YVU[XPAU;^W=$TR._MM0M@S0SS,HA;=C  SZ4]O
M''BRXT&&[M](T]+U;Z6TF@>9L$J0!M..<Y- 'IO2FHZR(&1@RGH0>#7F<WB3
MQ=?:DGA[5M'M+ 7\)\NX@F<E3^(J"'6?'?AC2=/2[TK3S9V]PELY\]S)*K,%
MW8([;L_A0!ZK16-XGFUF#1G.@P1RW[,%42'"J#U8_2N)TCQ5XSF\9SZ)?6VF
M 6MJ;B?RI&/RXP,?+UR10!W=Z5&O:4"A+$38;^[\HK4KQRU\7>-;RPB\0_V;
MIEPMOYP^SB9PRX4%NW85T>J^)?$%LND:Y9K;SZ1<(@N+8']XKL 2%XYQSWH
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ME:9X;TVR:=%)N6G.5!+$X'(]15CPAX.O(K77+_7U1=5UDNEPD)^01G. .O\
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MY4J%]#D'\Z]+HH P-9T&74M?TG4$E"I9/O93_%6_110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9-__P C#I'RYXFY]/E%:U95\F?$&DMQ\HF[_P"R
M*U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH R;_/_  D.D<C&)O\ T$5K5E7S$>(-)49P1-GT^Z*U
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMM;O^S_(;J)7\I7VMC)7%P1P>U '<:QX[T+0]4M]/O+A_,FP=R(65 > 6(X
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MEC1R%5@1P#C/1?2H="\)ZK?S:<-:MH;'3=,*O;VMNYS+,O\ RT?@=",]\YH
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M 4  =!110 8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P +BN;&[1=9\-W=G:R3^7'-C(VDX!//K4MW\3=8B\<2Z/:>'KF\MS#YD B
M+2K_ 'ASTZ4 >I45YI;?$G4=:T?7/[.T:6+4]-3<8)1R3D<=^QJ%_BG>ZEX3
MT[4M!T:2]O;B39-"GW8RN"XSGT- 'J-%>>Z7\2Y[CQ+8:)J>@W>G3WJYC,P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ?%SPW<6EKMB%I/YTBQG;]].I'&:U?B;#:S> =26[8I'A/F R0=ZX_7%3_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!EWV?[>TKYP!B;*XZ_**U*RKX@:_I0P
MV2)L$'@?*.M:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!X<CUXWR"PD8*')Z$D#!_,5Y-X;MB_Q%.B>-(GGN#:&WM)RI(G4D$$D=P._
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MMI:17R0)*I("0* JKV Q6E110 4444 0O:6\EPMP\$;3*NU7*\@>F:J?V!I
MG$_]F6OFAMP?RAG/KFM&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV0O-.N!/;EBN\*1R.O45>H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP>?6M&?1+:?Q#9:RQ(GM()($4=-KD$_^@B@#SS0="N];L->L[B^U1='@F/\
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M^-QKI*AMK2VLXO*M;>*"/.=D2!1GZ"IJ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** $"@9P ,]:6BB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K(UGPWIVO36DM[$SO:R>9&0Q&#^!]ZUZ* *=QIEM=7EE=2IF6S+&$_W2PV
MG]*/[,M?[5_M+RQ]IV;-_M5RB@#'U;POH^NW<%SJ5F+B2 8CW,P YST!J;5-
M TW6I;>2_MA,UON\O+$;=PP>A]JTJ* .?M_!'ARUE22'2XE="2I+,<'UY-3Z
MMX5T76[NWN=0L4FE@X1B2,#TX/(K9HH 9##';PK%"BI&@PJJ, "L*V\%:!;3
MV\RV"&2WW&(L20I9BQ.,XSDFN@HH I7VD6.I2PRW=N)'A618VR05#KM;IZCB
MLF'P'X8MXO*CTB$)D-@ECDCOR:Z.B@!%150( -H& /:LRS\.:187<EU;6$,<
MTCM(SXS\QZD9Z?A6I10 $9!!Z&LV+0=,AL[JTCM%6"[9FG0$_.2,$GGTK2HH
M Y\^"/#;)&C:3 RQ*J(&R< # '6K*^%]%1(433XE2%2L8&0%!SG^9K7HH Y)
MO"V@Z?KFG);:7;Q^:LH8@') 7BKC>!?##,6.CVY)R2<'O5N_S_PD.D<G&)N/
M7Y16M0!'!!';0I#"@2-!A5'0"I*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BD9E099@H]2<4M &5?$?\)!I(
M(&2)L<_[(K5K)O\ _D8=(X'2;GT^45K4 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ6#8&X<9I2 >HS110 8&,8I,#T%+10 $ ]11110 F!Z"EQ110 =:,#&,444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<[O';RO%&9)%0E4'\1
MQP*P-274M:\$W\4E@UO?3PNBVY8$Y[<YQ71T4 >9^(O#>K#P?H,]G"W]K:7*
MKA01GD[2/3HQKOKJYN[;26GALFN+E4R+>,@$G'0$\5>HH X7P?IFJPV^OW]]
MISZ?/J,JR):JX)3"[>N2.>M8N[Q/I0TP6O@DWD]E#M6Y:5 023D#YAQ@UZI1
M0!Y?#X7UV_\  VHM=64=MJDUTUW#:@C[P)*@G/?/K6AH5AXFU[5K"^\1V4>G
MV^F_-!;JV2\F"NX\D8P37H%% '$:A9ZG;^/KC5K>R\Y%L-L W@>;( WRCGZ?
MG53PUX5U73_ 6J6EVH^W7\DLWD9!$9=BVW]:ZR_'_%1:1P3Q-SZ?**UJ ,OP
MY:S67AZRMKB/RYHX\,F>AR:U*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+O@IU[2B2VX";&.GW1UK4K
M+OE!U[2FVDD";D'@?**U* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH S+T+_;NEDLX($N !P?E'6M.
MLV\W?VWIF) HQ+E,?>^45I4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!EWK :]I2EB"1-@#H?E%:E
M9MX<:WIHWJ,B7Y2.3\HZ5I4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!F7I4:[I8(7)$N"1R/E'2M
M.LN^YUO2QL8_ZT[@<;?E%:E !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 95_G_ (2'2>.,39/_  $5
MJUDZA@:]I+G^'SN_JHK6ZT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!DWXSXATCY<\3<^GRBM:LR]
MS_;NE_(I&)OF/4?*.E:= !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 9UX2-:TT"+<")<OC[ORC^=:-
M9EZX&NZ6N!EA-@Y/]T5IT %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!EWS8U_2AM0Y$W)ZCY1TK4K*
MU 1G6]+!++-^]V$#(QM&?TK5H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+O@#KVE$R!2!-A<?>^4
M5J5DW_\ R,.D=.DW7K]T5K4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!EWRJ=?TIBR@@38!ZGY1TK
M4K,O=O\ ;NEYC8MB;##HORCK6G0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tmb-20201231xex4d11002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20201231xex4d11002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6@ \ # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** ,F[8#Q-IJ[5),,OS$<CITK6K)NY&7Q-IT8V[
M6BE)R.>,=*UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH R;O;_P )-IN=V[R9<8QCMUK6K(NX\^)]
M-?CY89A][GMVK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#(NT<^)]-88VB&;/Z5KUC7F/\ A*]+
MX/\ J9OI_#6S0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% &1=NP\3Z:@*[3#-G/7M6O6->?\C5IGRC
M_4S<^GW:V: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH R+Q,^*--;CB&;O_N]JUZQKS_D:M,Y'^IFX
M[_PULT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!C7G_(U:9P/]3-SW_AK9K(NY,>)]-3CYH9C]WGM
MWK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BHXIX9PQAE20*<$JV<'TJ2@#'O@5\2Z;(2 @CE4_4XQ6Q
M6-> ?\)7I9P<^3-SZ?=K9H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!9!9S:+TWC!0'_=P: ._!#*&!R",BN:\6>+U\*_9&ETZZN(KB58O,B4$*S$
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MGZ\UNV1F-C";B,1S;!N0'A3Z5S/CO3M6N;:QO=$MA=7MI,&6$N%# D9Y/TH
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M64>-EI"N.F$ Q4T,T=Q"DT3!XW4,K#N#6%9>+].NM>N]&DWV]W;R,BK*,"4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#"/VMM-]E:X\ZX2':K8V[F"Y_#-;59^H:/::I<6<UTK,;5RZ+N(&2.X[T
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MYBNLK&O!_P 55IAVY_<S<^GW:V: "BBB@ HHHH **** "BBB@ HHHH ****
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MV>HYXYXKT.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *0J",$ CT(I:* "BBB@ Z4444 %%%% "$!@00"#U!I0
M   !@#M110 4444 %&!G..:** "BBB@ HHHH **** "BBB@ HHHH **** ,>
M\)_X2G3 !QY,V>?]VMBL:\ _X2O2S@Y\F;GT^[6S0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &->8
M_P"$KTODY\F;CM_#6S6->'_BJM,&['[F;CU^[6S0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7%:U\4/#OA[7I=*U*Y\J2-021SUP<?K7:UXUJT$NL?&;2)=.T63[
M':$Q7T\J H^3G//ITH Z6[^,'AE-%N=1L;@W7V<KYD:]5#,!D^W-6]7^)_A[
M2-'TO4I;I'BOW4(%8$A?XC^&1FN/&@&/Q]XP,>G@6#Z<Q9?+^1V 8C'XXZ5T
MGPPT2.3P#IG]J:7 DR%GC1E)V@X(//K0!<N/BAX=/AJ\UFPNA=I:@%HU/S=0
M,8_&HKWXJ:!9^$;'Q"9P8;N58UB)P_4;N/\ 9!!-<_X-T*=]=\9R6-E#';SR
M^7;_ &I"$)VKG@=NM:"QVGPT\,6&F3Z3+K4\\DDFRWC5@&P-Q&[&!0!MP_$G
MPW>:!>ZM8WJ31VB;WCR-WY51T[XG65^FFDVY0W5DUY)SD1(-V/SVUB^!=/;6
MO%7B+59-#DTZPND2-;>X5<YV#)P"1U%<CI-M=^&]8UO0K/1]1U74=C6-O<.J
MB".(\\=#_$: /11\6-&7P,WB>4,L)F>&&+^*1E./RJUH?Q6\*:]J46G6M]BZ
ME VJX #'&< YY-<U=Z-J'@+X0VNFZ9!'<:H\J@+)'OP[]<<8SGUXJYXPT:YE
MU+P7+;:="KBZ4SM%&%<-Y39SCC% '9>+/%5AX/T5M3U!OW88*%'5B3VKE+7X
MX>#KJ6"%9;P2S$*%,/0GUYK<^(6J6VF^&)X[C39]0-TC0)%"@9@6&,\\#&:X
MB]T*\/PBLX5TX0ZF90(PT:^8HYVY(]L4 ==KGQ.T/0=56RN/.E5=OG2PIN6$
MGH'.>.U&J_$O1]-UK1[-)$GMM1)"W4;953QC\#FN--Y#INL^(9+7PMK&I27J
M&.9\1>4&V#E<D&K \,7$OPKTFS_LQTNOMT4B1D#=&I.>OI0!T7B'XM>'?#?B
M#^R;MIYG$6YS;)O*L>@(SZ'-01_&3PY=Z1JE]:"Y!T]%:1;F/R\EB0H!R>I%
M.U/4IM/\5R6ZZ8ER(-&$P@\M"99/,5<YZ]#CDUFP>'KG1]+UW6=3TM[W4=<_
M=?V=;*N(D.=H&<#(+'G- #[;X]>$)(+=YEU")I0 2;?Y0W<9ST!KNM8\16.C
M^&YM<FD!M8X]X(_BST'YXKR?3?"NI6OP5U#39M&_T^625;>W=5,D8+DCD?XU
MZ0TMSI'@2'[7IK7UQ'"J/;0A3N8G QNX[T </;_&KPS=26>JWD.H0/"CQNJ6
MVY 6QGYLCIBMW7?B]H.AZC:P.D]Q!-!Y[2P)N* ^HKF-$\/:M'X4\166H:(]
MK+J"W,EO&X0LN<X!P3SSQBMJ&]U31]-M])M/!LFIF"U"2S0A/E<C('SL"1@_
MG0!HZM\5M%M/!UOXAL=UU'<2B..$_*Y.1N&.>0#G%-L_BYH6I:!J6HV45TTF
MGQ;Y89(]ISCMSTJS\./#L^F^%WCU>P6*XGNGN3!*JMY>X#@8R.U<KXBT/7VU
MGQ==:#IN^.ZMXH(455&YMF"P!XX([^M '5-\3-)E\*0:W8_Z7YDJ1&&,Y,;%
M@,-Z<'-,U?XF6>E:T+46%W=V<:M]HN+:/?Y3C^$CUZY]*X"3X;ZII]AIGB#2
MM/\ LEU&5^U:3,Q*.<XW<$\]#U[5WUHVOW7Q#BAN;6"'2X;(/<+&@VR3..>O
MH1^M &[X6\7Z7XOLYKG2VFVPOLD69-K*<9Y&:WJXCP'I5UINK^*'GMC!%<7J
M/#P &41@9&/>NWH **** "J.L#43I-R-),8O]O[DR_=W9[U>KF=4UC6I/#^I
M26.@WBWT9*01.R9E_P!H?-T^M &=X+\2:]JNNZMI6LV<*"PPHN86RKOGE>@P
M1Q^==O7%> )+VWLC8W?AS4-/E \R:ZNGC/GR'J?E8\\"NUH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ (R"*Y!?"6KFYE>3Q-
M?F-BQ5%<C;D\=^U=?10!QA\'ZSY8"^*;\/CDER1G\ZL7'A+4&\CR/$>I)M7]
M[NF)W'U'I75T4 <P/"EW^]SX@U0Y8>7^_/RC'(/KSFE'A6Y^S,IU_5/.SP_V
M@X ^E=-10!R@\(7;,"_B/5N!P%N".?>I(_"$RA5;Q#K+)CYO]*.XGV/:NGHH
M Y4>"V";?^$CU[._.?MIZ>G2G_\ "%)G/_"0^(>F/^/\_P"%=/10!RP\$(!C
M_A(_$9^NH'_"F_\ ""Q_]#+XD_\ !B?\*ZNB@#E/^$%C_P"AE\2?^#$_X4?\
M(+'_ -#+XD_\&)_PKJZ* ./C^'=A%=R7:ZQKANY(_*-P;T^8%SG ..F14Y\$
M(0H_X2/Q'Q_U$#S^E=310!S8\'H(GC_M[7CN_B-\<CZ'%1'P0A4#_A(_$?'?
M^T#S^E=310!Q[^'DM]8LK3^V-9?S(Y&WO>DL,8]JT/\ A%$\K9_;>M_[WVPY
M_E5B\(_X2K3!W,,W;_=K8H PO^$87_H,:Q_X%G_"C_A&%_Z#&L?^!9_PK=HH
M P?^$63G_B=:UR<_\?A_PI3X84C']LZS_P"!9_PK=HH R].T1=.NFG&HZC<;
MDV[+FX+J/<#'6M2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *AN[N"QM);JYD$<,2EG8] *FK'\4G3/^$8U#^V%W:>8L3#GD9'ISUQ0
M!B6WQ6\%W-G'<?V[:Q;_ /EG*X5U^HSQ6I%XTT.;Q'%H,=V'OI8!<(!C:4(!
M'/N&!%>.>$_ GAK5/!_B:Z?1?/6V:X-E>N64L%3*@#(Z?3O6U_9N=3^'VH)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% &5J$^H_P!HVUI;V/FV4ZLL\^\#RN#V/)[=/6N)\"Z4OFZ]X8U;2V>V
MM-0-Y#)*IV2;FRI'N-M>ET4 9QL(--CO;O3K!&NY@&95.#*P&%R3[5Q_A3P_
MXENM=;Q!XL>$3JI%M:1?=A)R#SD]C7H-% 'G*Z!XJ\0>-8;[6IOLNB6<_FP6
M4; [W0_([=>O/YUN:II^IP>*KG6M/M4G(TG[-$A8#=+YN[!S[5U5% 'CUOI7
MQ$\5^(-+_P"$ITJPL]/LIO/W0L#E@01QN/<5Z#I6GWD&O^(IY_\ CWNI(C;C
M/81X/ZUT%% '+^!M$O-"TR[MKP8+W+21C(/RD#TK0\4VSW?A;5((8O,EDMG5
M5'5B1TK8HH \VUJ;X@6,5G8^&]'LIK5;8++-<,,EO8;ACBK_ (6\+:C:?#_4
M-+U3;]OOS/)* 00&D7%=U10!X?I?P_\ &6J64&A:M'9Z=HMO/N81<O<*,XR0
M37HWB?P[-J-KI5K8HJI:SJ['@!5&/\*ZJB@#R:31O'ECK>JZ[I]I;2WMY<*D
M2SL#Y<*$@9P1U!''M3;'3OB+INGZCJ$%A9'6-2U!9I8PP$<:",+G[WJ!W[UZ
MW10!Y=X,T+QQ'X^N=;\0_9XH9K589!$>)-N[;W/0FIOB7HGB_P 0W$>G:-'"
M-+DB*SN[#).1[_6O2Z* .#UWPOJ=]XITK4[< QZ?:,  P&Z0HRX^G(KBKGPA
M\1-=M/['U!+2TTFXF5IEB(R@SSCD^M>XT4 >=>/O!NKZC:Z%=>')1'JFF,JK
M*3CY I']:U? _A"?0&O=3U2=+G6=0?=<2H,#'4*/H2?SKL** /)8O#/C+1?#
MEW:Z+&B7EYJ$\\K.ZD+&9&*@<]P0:UT\%ZH- \):='.(_P"SI6>Z).<C!/\
M,UZ'10!P^IZ+)<?%?2-1<X@CM90!GJ<+7<5C7F?^$JTSI_J9OK_#6S0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &/>*3XITQMF0(9LMZ?=K8K(O)&'BC34#D*T,Q*]C]VM>@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS$=P))HF$*$S*&!*C'.17">&)K/5/%-QKXGM+:QAA\NSC615+)CYG89SC&*
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M02Q/&>/O5>UKP.FI>)8-9M;V6TD$92XCCZ3CC;NY[<_G77$@#). *8DT4O\
MJY4?_=8&@#"L?#C:1X0;1-.N?+?:X29TW;2S$G@]>IKG['X<W46FZ?I=QKMQ
M_9MK D;6\(*>8PZY8'H>.*[SSXO,\OS4W_W=PS^5--W;+)Y9N(A)TVEQG\J
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MVF2-DW8SC(QFN+N_A[-<:?96T/B"]M3:ASN@)0.S$') /;TKN:0,&&001[4
M<WX=\(1>']&NK-;V>ZN;O<9KJ=BS,Q&,\GTQQ5";X>PS>!H?#AOY%>*194NT
M3:PD4Y#8SZCUKLPP;[I!^AI00>AS0!S/A[P;;Z'NN9;J:^U)DVM=W!+$#_9!
M)VCIP*-#\&P:;>R:C?W<NI:C(<^=/]V/_<4DA/PKI"Z*P5F4$] 3UI<C.,C/
MI0 M96M:,=2T6\L+.Y;3Y;D#_2(5PRG(YXQS@8K5I P)(!&1U&: .-T+X=6F
MCZM%J5QJ6H:C-"FV(7<[.J$]2 2>3Q],5U=]9Q:A936DX)BE7:V#@XJ<D*,D
M@#WHW*" 6&3TYZT >;CX0VLF(KG7]7GM,\V[7+[2/3[U>@6>GVUC;6UO!$ E
MM&(HB>2J@8QG\*F$L9Z2*><=>]+O3GYEXZ\]* .%E^&Q>TNHX]>OH)KN\^US
MSPN49SMVA>#TQC\JZ#P_X8M=!TU[,R27C.Q:2:Y.]W]B3DD5M"1"0 ZDD9 S
MVI0P)(!!(ZC- '.>)O"$7B3R,W]Y9>0I"?996C_D13]$\'V.C>'Y](+RW,=S
MN,\DS$M(2,$DGOBNAI'=8U+.P51U). * .-\/?#?3- U!+O[5>7A@&VUCN9F
M=8%]%!)'&!S5C5/ \&H/?/%J-[:27EP)Y'@E96X0+M!!X' -=/'<02Q>;'-&
M\?\ ?5@1^=06FIV-\S+:W<4K*<%589'X4 8?A;P39>&+B>[2ZN[R^N(UCEN+
MJ9I"57) &2<=35WQ)X6T[Q1:PPWPE5H9!+%+!(8W1AGHPY[UM9P,FD#*>C Y
M]#0!QND?#71]-O[>_GGO;^[@R5>[N&D7=ZA6)QQ79T50LM8L;^:XA@G4RV[[
M)%/!4_Y% $=UH5I>:Y:ZK,"TUJA6(=@<]?UHUS1+;7[&.TNBPCCN(K@;3CYH
MV##]14PU6T.IMI_F@7"Q^:5/'RYQ5DW$("DS1X<X7YAS]* .5UKX=Z1X@UB7
M4K^YU'S6"A5ANWC5,#' !JU:>!=#L=-M]/@@<6\,OG?,Y+._JQ_B/3K70O-%
M&ZH\J*S= 6 )I7DCC7<[JH]6.* .;\0Z3:ZQXAT2&Z#?N':YC*OC#(01QWKI
MJQK@B7Q-ILD>UT6&8%U.<=*V: "BBB@#&F\+Z9--?RF.17OUVSE'*[A_D5G6
M_P .O#=JA6*S8 V[6Q^<_P"K88(_*NJHH Y,_#?PTSLS6;N6V@AI"00  !^E
M=/;6\5I;1V\*A8HUVJH["I:* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JIJEV]CI=S=1Q/*\<9941<ECV
MXJW535+B>TTRXGM;=[B=$RD2=6- 'A>F?&#QDME>&7P]/=3P2-YVU"#%[%<9
M %=1J7Q#\1WFGZ-;>'[&!M6OX6N'$Q 554@$8]?F%2^!O#OB6WE\3:OKD")/
MJD3;;5?[V#[=\@52LM'\4Z&NEK9Z!!>7MMYKM<SR,H17?<(QCKQ@<^E #;CX
MD^)-1\%7MQ8Z/);:QI\@%W%(#G8",L%QGOC]:FUOXA>(9O"^@:MH.ESW4MRI
M>X6*,L%V[21P.^>*O:!I7B.XLO%&IZOIXMKV_#)%:H<\;0.">3S6%-9ZMX;T
M/P'HYDEBDDO(FN8U^4CE<J<>G- $>D_%;Q=-XCL-/U/09+:.]#;%:(J_ //3
MVK$T?XK?$&\;4+6'3$FN+'+SJ\1#H/0CKV->D:7X>U>_UNX\4:]'F]M@\>GV
MB'A%SP3ZD_UK(\ >&/$B^)/$&MZ_;):MJ,.SRD_C/S9S^= %FP^(.IZKX8\/
MW]OY4=W?ZA]EFC>$G"@D-@9XP16_\/O$>I^)++4;C41#B&[,4!B'!0 ?US5;
MP1X)CTG2H?[2@!O+>YN6A(<D*DDA8<>N,<UUNEZ59:-8)96$"PP)G"CW.>3W
MZT 3W%S!9P-/<S1PQ(,L\C!0/J367K9O-2\.S/H-_#'.Z9BG'SJ<>F#4^OPS
M3Z+<QV]I#=RLIVPS$A7]CBI+"%K?2(HF@B@98N8HONJ<=!0!YJG]M^-H-(UO
M3XK>/5=)FD@NEG&4\S: <#CIG.:UH-<\6R:;X@L[W[%::A8>7LN6(6)4=2=Y
MYQQ@=ZSO"=SK-OH>N1Z):)/=RZS,@:4D+$-J?,:UK[PA?I\.M=T\S&\U?48'
MWN3]YSG 'L,T 0'5O&%@+674VT^ZL)V$;F!1E@1C(.36?-8>+_ NEZQ-I(L7
MTN.>:]5' W!3R1U[ 5T.L:5?0^&-(L;6V>XFA= X7^''4FC5K3Q%XCU633VC
MCL=$C8>9(>7N1GE<$8 /U[T 5+=;F/QQI&L^?,T6IV"K)"<E$<[3D>G2N^KA
M(+A=2^)4-G9I*++2;+9(^/D\S*[5_P"^37='.T[<9QQF@#S;4++5=*\?:/%9
MZ[J-Q]JN&FN+:6<M&L.X9 7MC(IWCR35].\6^&[BVU>XBM+N[,$EK&Q"G",V
M3Z]*JZ<GC*S\4W6H-X?MYFNIS%YTLS?NHE) (XX!&#4_CJP\5:UK>D-IVEV[
M6^FW(GWR2,"[%2I' Z<_I0!Z77E&MW TWXI:/#;:Y?PJ9=UU#-*1 5/\*YX]
M#BO1$EU?^TK9)8+<6K1$RLC$D/CIR.E<3>Z3XG\4ZG'::II6GVEA%<&0W2,3
M,Z D #C@].] 'H5W;B\M)8#))&)%*[XVPPSZ&O+?#TE[H?C;7A:7M[?Z)8VJ
MEC<W&_\ >[>1GZ@_2N[N!KC6FK6ZQ0 >6RV3JYW'(P,\<5S'A+3/$T=O_9.K
M:796]@\+">>.1FDED/<Y'UH Y33KS6+"+PKXI74[^X&JW<D=Y;R3$QA?G ^@
M^5:Z'Q#HT.E>+[2;1-3U#^V+Z\66>W^T9C\K<"^5QP,9Q5#2_!/BB=='T74X
MK6/2=(N7N$EBE;=,#NPI&/5L_A5^RL_&6G^+;_45T/3[E[J?:+J6=PR0Y^50
M,8&,GZT 4O&.IWFKWD\L>JRVNG6LZP_9HY-AF&,L6'H",5ZO;NLEM$R,&4J,
M$'.:\^\6_#>RU.UB>ULW^U2SJ]P5N'  P<XY]:[W3[*+3M/@LX 1%"@506)/
MYF@#D?'.I^);;5]$L?#\]K MW*5FDGCW[>1@XR,]>E9]QJOC;PYKFE#6K[3;
MO2[N0Q2O!;>6T;8)'&XYZ#\ZW/&ND:K>1V6H:)Y3ZA9RAEBF.$=>IYP>>!6$
M]GXR\4:KI<>MZ9865C:3^=(\,K,S_*1C!'J0: +%O<>)(?&&IZ)<:K!,EU;O
M+:NL9!MR0<9YY X]*S-,3Q'XJT^XL+F[@CUC0+^.2&Z*;XY6VMC(SZ'UKKYM
M)G?QS'J(C/D&V,;/T['O^--O=)N]"T*6W\*6T0NYY2Q>=R<%B26).2: ,GPG
MJOB5O&VI:-K][:7(@LDG0VT/E@$N1SR?2NMUE-0DTJ=-+=$O&4B-G' /K6=X
M:\.OI)N+Z]G^TZI=G,\V,?\  1[5T% 'CEZOC71?%/AS1[SQ4LRWLQY2W8'H
MQPQW<CBIM1\4>(]+N?&EA/,T<MNOVBQE(+_NF+8 '; 7\*ZSQ)X<O-4\;>']
M5A \C36:5\G[WRL,#\ZQ;_0M=\:^(8VOK)=)TRWWQR.#^]N5(Q@CIM_'N: *
M4&J^)-*UWPSJ4NI_:='U=88)HY3_ *IR@).<]\$UZQU&:Y/Q+X<>\M/#UE91
MX@L;^%WQ_#&JL,_RKJP,*!Z4 >>^.=+MAJNEG3WECUNYNXWCVGC8I^8D>@R*
MC^*-C:+H$=S)/=?VPQ2*S6%\%GR"1CTQDTV\T#QM_P )A=ZO:?V;LE*Q1/+*
MQ>*,<<+MP"1C/TK1\4Z/XIN]:L+S1UTZ40VVUOM;$!9<_>4!3SCB@#K-*BN(
M=*MHKMR]PL8$C%LDGZUYC\1)ELO'6BW<?]H0+',KW-V$8P1J.Q.,?K7>(GB,
M1:,KR6QD"G^T2#P3@8V\>N?2N>USP_XN\475SIU_<6%KH,WRL("7E*_BO'YT
M =RIBN[,8<212IC<IZ@BO.-+TUM+^(-]/I%P[:58VN+B(ON5I".@]Q@YKJ[?
M3=;MKB_A6[A^P&U\NR0#!C?& 3QTKD_!WA7QQI$RVVJ7FG'3Y'>6Y:$EI)68
MYYRO3KWH YJYBF_X0BS\9K>W0U3[:SNQDR&42,@7Z8Q^5;GQ&TG37U.Q_LM6
M_P"$CN[F%L0M\RQAP78@<@$9Y]JFTOX=Z]:7!TJYU*";PZ+@SK&1^\Y).W&.
MF3GK4]]X:\9Q>.;O6M*;2Q#.JPJ\S$R+&">GRG!Y- "?%JWV^%(Q%IU[?:DL
M?EP26R%C$V/OG /I76>"KVWO_"&FSVUPTZ&( NXPV<\Y!Z&LOQ#:>.Y[RU71
M+S3X;58=LYE^\[G&6 VGWK>\-Z'%X=T&UTR)RXA4[G(P6)))/ZT <O\ $V[U
M."+1H-,U"6R>YOXH6>,D<,P'/M6=K,/BGPK<Z=J,NOM>VOV@)/ 4(RI!]_I7
M2>//#U_XAT6!-)EABU&VN8[B"27[H*G//!KGT\/^/M7U"Q37[O3!803"200$
MLS8!&,%10!*7U?3/B(^E-JCRV.N1S/$G(:U8(3E3GZ5SCZCXCTSP9XHMH-8D
MN)-$E$\=^<AI 0Q*'GG!XS[5Z%?^'[B[\<Z3K*N@@LHY%8'JQ92O%)KGA>*Y
MT7^R[!/)ANKK?=$#)*L26SGKR: .-U!_'$NDVWBJ+4/LL:E';3&SRAP""<X)
MZGI7J&GW?V[3[>[V%/.C#[2<XSVKA-4T+QUJ=O-IYO-/AL6954J<L$!!_N]>
M*[RQM196,%J'+B) FXC!.* ..\1>"]0N]6N=6TO79=->2/\ >+$"-Y ZG!]J
MXR;4/$VI:+X2LFURYMVO)I(I+F$E7E"J"&)SSFO1O$.BZMK6K6T$>H&WT7RC
M]JBC&'E;/ W=0,>AJMJ_A66YUCPU]B6.+3]+>1B,G(!7  _&@#E[&Z\2^'/%
M,GA;4-?^TB_M9);.]N$),3*0 #D\_>]NE49M,\11>$%\2:=XVOKB"-FGVRJW
M[Q02I7&>!D&NQ\3^%+[6/&.DZO;21+'8VLR8?^)V92HZ=.#4Z^%[B#X<_P#"
M.AUDF$10MT!RY8_SH U?"FI2ZQX3TK49O];<VR2M]2,URWC33]:U/Q7I=K8:
MY-I\#1D[8@1EL]20:Z[PYIO]C^'-.T[G_1K=(N?88K*\7>'M3U:2SN]&U 6-
M];M_K"H8;>>,'CKB@#CYH/$'@_Q9HR:CXDN=2L-3:2!H6!RK;."#D]R*=%=:
M_P"%[[Q+9:??MJBQ6S7-NLN7,,F,A#SWST]JU]+\%Z]<ZY9ZAXHUL:@MEE[>
M)(E0!R,$G 'M71:AH<D=EJ#Z(T=KJ-WC=.XW<@'!P<^M 'FNEW>MZ"VC:A!J
MEW=V.O;X6ANL[H),,=PSTY6I_"NB^(M7M-1MCXQNEO;2[EMYR-V.. 0,\'KS
M6Y8>"_$\^J6,NNZ]'<V=G*94@CMT3)P1V QUIEY\/M9'B34;C2==:QTW4B7N
MD1 7+'.<$].OK0!CSV6LZG\/K77/[9G&J:5-*!)N.V4+*5^89ZX[UL>*9M1T
M/Q1HNOVVHS26=T5MI[0$LK9X# ?5OTKI[GPVD7@Z70]/PN8]JLYZMG))^IR:
MRIO"VMWWB.UFO-4C;2+8[H[98E!SC@YQGTH [6O)-,T[7M3\>>)8;?Q)<0-;
MSA0C E=I13P,^IZUZW7!ZUX.UQ?$4^K>&=873WO%_P!*#QJ^YAP",@XX H P
M]#?6=5U+Q5X9U?7',=DB217:YC:/);DDGI\M8<6O:O9Z+H?B&]U":>QLM0>U
MDD3)\^(%QN/TV@5Z%X2\%SZ1)J=[K-[]OU#4@$N'VA5*C.!@?4UJ:[X4L=8\
M*W&@QJMI!*F$:)!^[/7('2@#SE4U7_A'4O(YKA/MVL">W4N8V\H[!CGZ'BK'
MC+PKK&E:;J.IKXHOE%Q/DQ1.455.>,9KJO#?@R[L;J.^US5'U&YB39"A0)'&
M/4 <$_A6SXGT/_A(M&?3C*8@[ E@,G H XO7-)N= .B:_:ZQ=KY*I'-%*Q=)
M%;MCZG-1MX<UG6O$VLRVGBB^L)$G8?9T+!-F?E(Y^M=EXA\-KKFA0Z89FC6,
MH=PZG;C_  JQI.D266H:C>SN&ENICMQVC!^4?7DT <_\,=9U#5= N(M3D::Y
ML[J2 S,>7 8@$_@*ZK5K:&\TB[@G0O$\3!E'?BL?PIX=GT*XU:29HRMY<>:B
MH<A1S_C6MK-K>7NES6]A=FTN'P!,$#;1GG@\=* .*^$-G;#P#/9^3_HPO[F/
MRI.?EWXP:KZ#X>LA\1-3UO2;5(K*S@,(%OA5EEX;\1CCZUIZ!X#O_#-C?QV?
MB&XN9+@2/&)HE54D;DMQ[T>%_ 6H>&[F!U\3W4]NC%I+5H$"N3DD;NO4T 6-
M*UO7_$D4]K=:!)I$4D;*+A[@.1D?W< US]UX<U/PIKWAZZC\1:C<PW&H);2P
M32EE*L"3Q^%>D7\$US83PV]P;>9T(24 ':<=<&N$D^&NIW5Q9SWGC&^F:VF6
M=%-N@ <?_K- 'HE>9>,? UO9PZOXBBUJ_L<1--*D$I ) )Z#K7IB@J@!.2!C
M/K7+W'A2?4_$TM]J=^\VG!5$5D.$)[EO7Z&@#EM+\%W&O^%M(U/5=8U**^AM
M'C>5)2CR1EF8;OPQ6%:Z//<_"6\NS>7;SZ=>33V%SO.[RP%(Y].*],UWPQ)K
M=]:AM0FM]/ACP]M#\OF'/&2.0,5HWVD0S>';O2;9$ACEMG@0 8"[E(_K0!R%
MQX('BZTTC6;K5KZ&Y%A&4,,I7#,BDG\3S7'7D]Y>QS>'=6O+Z[CL=4-K%=17
M'EM(-BG#$@YQG-=Y<>"=6GM+*&'Q5=V:V]ND.R*!"#M4#.3]*GM_ EO:VFF6
MZW#2M:SF>>:0?-.Q&,GWZ?E0!RTGAN;P?XRT".PU?4I+2X+++%-.67(*_P"/
M2O6*Y?7=-?4/%VA$W 2"%996CQR[#:1744 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1139-_E/Y9 ?!VY]: '45YUI^L>+K'QU9Z1J=]97\%Q$SR1Q1A'@(!/..H]
MZS-5\:^*3I^J>)-*:V.E:=<-$]HZ#<ZH2KMOQD<CI[T >L54N=,LKRYM[FXM
MDDFMR3$[#E"?3\JXKQ#K7B&*RMM9TC4[;['*$"6C0*3*6(!PW7C/Z5>\::QJ
M&B^&8M2;6(-*=%_>[H%E#N1PHR1WH [*BN7^'_B&7Q+X2M;^YN8)[HEA*T.
M/O'' Z<8JKX\\6:OX4AM+C3](2^ADF6&0O*4PSD*O8]S0!V5%>?6?C_5[77;
M?3?$F@#3Q<QL\+P2F7)! P<@8ZU6TGXGS2F*[U33XXM*NI?+@N;>3S-C9P%D
M&!M/^(H ]*HKS5O'/BR7Q)JNF:=X=M;Q;.3&6N2C;23M) 4]<5#%X^\5:C%?
M16FA6T6H:=<*+F 3EPT13<2#MZ\B@#T>TL+6Q,YM8$B-Q*9I=H^^YZL??@59
MKA;_ ,<7L>E:+K]G8B31KO!N&)PZ!N!QCL?>NWAE2>".:,Y210RGV(S0 ^BO
M-9?''C%?$][HUOX5@E>*/SXV>Y*;H\[<CY>>:?-X\\02Z'-J-IHL"OI[R#4H
M99R-@3^X=OS=_2@#T8(JDD* 3U('6EKB=1UWQ@;FTN-&T2UNK":V64^;<%#D
M@'KM/K52;Q9XJOM#34-+T>U4VS'[?').<H5Y95&WYN._% 'H-%<=J.N>*I!I
MMYH6C6]U:SVPEECGG,9#, 0,[3TR:SI/'FHM!#+_ &>L#VM^+74HMV[R@4R,
M''J5]* /0J:CI(NY'5EZ94Y%>7S_ ! UNUM]6N_L\4\$>K"PM3C:""^WKCGJ
M*ECU#QGX4\.3.-$L)K2(O,9I+XA\,V?N[??UH ]-HJGI=W)?Z7;74T7E22H&
M9 <[37$GQ%XVN_$6H6NEZ;I$\%I(H9&O=K '.,_+QG'X4 >A45YC_P )SXDU
MS0)+W0["VAN]-NS%J4$LF1M"YPAQSU'I6O<>,=0MDTG69[01Z#=0AYW'+PLP
MXSZ =S0!V]%>=2^/[V3PK>:O:PQ-";CR;6YSF+;S\[''0$8HT_Q7XIE>ZT*Y
ML[/^WQ;K<6[I+F*122,DXXZ'B@#T6BO,8_''B3_A&YI9+&U_M33[I8[N,2?+
M*N3D)QU.*TCX[EU-M+@TF(17TUSY5S:W(VL@V%O\.: .\HKSA]?\>2Z]J=KI
M]GH]S!;/\JM=[61<G&?E//%=/X,\0S^)O#J:A<VJVT_FR1/&K[E#(Q4X.!GI
M0!T%%<;K_BF]T+7O(N5BALIK1VMY&/WYE#$KGZ 55T_Q3KUPNA1RVD33ZE9R
MS'8<@, NSMT^8YH [RBO.K;Q/XHMO#NN0ZM%;QZW8$/$T6&22/<.<8'8XJM/
MXX\6"W3Q);Z+ WALJ&*O+MGV=WV[?3G&>U 'IU%>=2^+/$-EXNTR)X[>XT?6
M%3[)CY9(BR@Y/'(JAI_B?Q_J\VH:=:65DM]IUVT=Q([?NRN 0JG')YH ]4HK
M#\+:Y-KFE-+=0+!=PRM!/$K;@&4X.#Z5M2/Y<3O_ '5)H /,C,AC#KO R5SR
M!]*9<W,-G;27%Q(L<,8W.['  KS2RNM2M-*U?Q1&S_;;_4%AMED.\+"6 4 '
M_>-7/$,/B3Q-9>(-"MOLYC-E'$%D^3$KH#UQTSF@#T#SH_(\\.IBV[MX/&/6
MF6=Y;W]N+BUE62)NC+T->3V.K^,[+5;'P=JME8HMS92('AFW?P-@GY1CD5EZ
M;/\ $+X;:#I^G75KIUQ ]R(4(N-S,7. /N]!0![G17CWA+7_ !TNK:]X;U&&
MWFU*.W-S:,TF$Y8#;NQT&[K[5%_PF7CKP+=:/9>*+2RNH;Z1;6%X9LMOR!DG
M;_M"@#V:BO'XM2^)4WB#64T^71I'WJ?L[W63"H!V_+MXR.:[7X>^)[GQ5X92
M]O(XTN4<QR"-L@D?RH ZNBN(\9KXWDU.S/A>*T\B$%I3/+MWGCC&#67::_XT
M\2^"YAIEK91ZU'.896>;:J@$\CCKP!B@#TNBO--*\1^,;ZYUOP[J5E;P:M;V
M0F@E@?<AW;@.<#'(K!\/^+?$5[]@BCN!)]ABN!J3./E657 4%NPQNH ]IHKP
M%M<\9WWP[37M.N"SVMX9;K+G+H.,*/2MC5/%_C*;7?#5[IT%NUOJNGEK> R8
M E91N9^.BDC% 'LU%>4Z1KWQ!DNM6\/:HMC_ &V+,SV;I@1GY@.3CWH\+Z]X
MSTKQ=I'A;Q'%;&.:!SYT<GF%MJD\G'7B@#U:HTGBD;:DJ,?0,#3I$$D;(20&
M&,@X->-:/I,VG>/9+O0K^^N-*L;>0W\T\C.CR_,<+DD< KQ[4 >R&6-7V&1
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M9_9H"X)V'<IW'CV-85G\,_$FH:[IUYXN\2)JUK82&:&$)M*OQ@\*.X%>J44
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M;&?+0MCUP,U)4-W&TUE/$OWGC91]2* /-]*\?^*]7T)=6M/#4,L#AG7$C?=
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MM;U#7H=8T#5;>PN1&8Y#-&S;ACC&/QJOH7@K7H_%$>M^(]:AOY(8##"D,;*
M"03G/TH K:?J&N2:-KNG7NIA)--E*PZ@B M(5P0I7&.>GXUECQ[KEUH#:7<6
M[VOB%Y(TA7:/WZ.#AA^F?K7:>(O"C7OA>ZTK0I(=.GGD602E20"""2?RJAKO
M@BZUCPA:V+7RKK-HJM#?A<%74=?IF@"MK>L:[X=\3Z)YMVL^FZH_V=H2@#0R
M!"V0<<CCOZUGVP\77'C+5]$;Q*UOY427-OMMD8-OW?*21T&!^=:%YX+U_4O$
M]CJ%]J]M-I]@_FV]J8VSO\O;ECGGDDU>\,^&M?L_$-[K/B#58+N6=%2**WC*
MK$!G/7/K0!5T.?Q'XH\+V=S#K'V*X2:6*>5(58OL=EZ$8'2KO@^\UDZCJVG:
MO>_;3:S%8I_+5"R\=0.,]:R%\'^+[+1[6QT77K2R$<\TTI:)B7WR,P'!Z8-:
MWA/P]X@TK5[^^UK5+2[%RBA4MXF3# \DY)H ;XBDOV\2V=A;^*&TLW49,,"6
MZ2%R, GYA[U'IK:[;>*KKP_>ZTUXKZ=]JBN# B,A\S9T Q6A>^'+B]\>:=KD
MLL)M+*VEB2+:=^YRISGI_#1JNA:E<>(;C5=.NXH)6TS['$SJ3M?S=^XX[8H
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M' 7& *Z*B@#E-6\*RW7P_'AVV>/S D:!I%RO# GC\#5?1O!MSIOC6767N%:
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MK3" "!#-\P/3[M;- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ:;F,11PI(6+8&"2<#TH RW\>^(]9TG1KSP[I<4DTLK)=Q33*GS#<-BY(R>
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M75-066>X,[JDS*#DYQ@'IS5_5OA]9ZIJ9O1?7-N9%"3)&>)5&.#S[#FNPHH
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M?SZC8WEYXRU>Z:RF\Z%)(X0 V".R^A(KK=6L!JFCWNGER@N8'A+#MN!&?UH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU"WOIRC0(A P<GO[U9N_ _B_6O%VHM:^.H8KH*&DCCB?$:D\+0![C2%E!P6
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MZ;:RM/:0RNI1G16*GL2.E $M%%% !1110 4444 %%%% !1110 4444 %%%%
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M5E&[:5P>.F":[2[)_P"$HTT9X,,W'/\ LUKT >;"\U.XUZ/Q#)X4NQ=Q1&)
MS-P,'HN.^:U_^$FU]U!;PO+N!! )/'Z5V5% 'EVM6=_K=S<75WX9N#/- +=6
M61OD7.3CC@GD9]ZS/"?A<>#=2:^TOPM>B9DVDR3,PY[8(KV2B@#SB]EU2_\
M$%EK$OAJZ:XM$V1(9&"#)^\1CKUKT2(NT2F10KD<@'.#3Z* "BBB@ K)OO#F
MG:CK=CJ]PCF\LL^2P<@#/J.]:U% ',1^ /#Z>(I]<>WDFNYI/-99I"\8?U"'
M@&NGHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,X7:#T]*T="\-:1X:LQ;:3916R?Q%% +>Y/<T :U%%% !1110 4444 %%%%
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M>L+XGNKV"&9?/MI2-A5F"\<>K"M7Q%X3UHW6HZU9>*+ZT8QEA%&1LPN2!C%
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M W8XS7F>B^/O%?B/PGJ45M911>(-.D*SAEVJZ@YX';C%>K6,4L-A!%-M\U$
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M4-CFO<='=I-$L'<DLUM&23W.T4 7:*** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(L!/S%1CG]10!SVG?##PKI4LDMIIP221"A;C.#U[5!:_"3P9:7*3II$;,AW
M. 1GZ8KI$\1:1+;WD\=_"\5D_EW# _ZML X/YC\Z99^)=(O[Y+*"]B:Z>%9U
MBS\Q1NAH U$18XU1%"HH 4#H *P)_ _AVYU\ZW/IL,M\<'>Z@\^OUJU!XGT6
MZ17M]0AE5IS;@J?^6@S\OUX--N_%6B:?#<37NH16\=O+Y4C.> W''ZB@#9
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MHVJVVN:/:ZG9DFWN4WH3UQ6)K/CB#0=1BMK[2M1C@DE6);SRU\DLW09SG]*
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M*P_#GBJP\3)<?8UE22W<QRQRC#(P[&K>N:I)H^ERWD=E<7C)_P LH%!;]2*
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M8RC#KZG@_7\J .SHKSYOBA"N@V6NG3+C^S9G:*9@!OBD!P1C/3(-;D_BR/\
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MWB!@FG/&DFW>H;:=PR,X/K0!Y3IFOZ'I?C+Q!KM_#+$DUP+2)TM7<R856W<
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M5_:QR*((&?=,BJ@&0#COUKH/#^C72:%KVI:C&T%QJHEF, P3"I3 7COQ7<$
MXR.E+UH \3UG4V/P_@\*6MA?2:E-%B%_(;"G'RDMC SG\*[GPM)<3>(]1CN#
M<8M88X-LBX0':I.TXYZUV04#H *  ,X'7K0!Y_\ #VWFA\2>+GDBD1'U*0H6
M7 ;YNU=-XHU^'P_IBSSVUQ.DS^3B",N5R#R0 >.*V514SM4#)R<#J:=0!Y+K
M]A>)\&M(T];69[@R0 P["S?ZT'G'2M'7=.NW^('@IDM6"P6\OFD*2J8*<$]*
M])HH XWXG1>;X,GC2 RR&2/8%0L0=Z],>V:O:EX>:_\ %%OJ]\\,ME81%K>
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M!>W$LL1&T F4E3@]\&NTMO#5YX6\4QSV41N-/NXG2,'EK,A2V ?3/ZFO2J*
M/*/#=IJ=AI)^WQ2&\F:_G5'.6<,017?^%[6>S\.VD-S$(I0"60=LDG^M270)
M\1Z>?)+ 12_O/[O3C\:U* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ)):RVPN&E>&W$161 9">1UR>O2I8_%TNGZ%'I3:+JD]PMJ5+K;.%)((ZXH
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M=B=I&<=*Z;1?M8TBV2^M5MKA(PC1K(' QQU% %^BBB@ HHHH **** "BBB@
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M-Q QDUDKXPT)K&TO5OD,%W*(H6P>7) Q[=126OC+0;S69M)AOT-W$I9E((!
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M#L.LK*\L$[>7$B(2[OS\H&,YX-49?B7H4?AN76@TQ2%@DD)C*R*20,8(SWH
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M48YIU8_AKQ'9^*=)_M&Q$@B\QHB)%*D,O4$&L7Q;XEUGP]-Y\%E;S6*X+;I
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MI6 M)/M#NH#9W ]^E8^L:9K>@?$637M$TUM0BO[7;<QF0JJN" #P#V%>D44
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M:T2[BGME5Y([FW:)@&S@X;Z&N*T#Q!!X8MM;U&6RN_(U+4\Z?:JN7?\ =J,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=;4["Q6YV,-Y9L!1SST-7==O_$*Z%:W>@6=K/<.HDE6XFV!5VYXX.3F@#HB
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MC=]:IMX>T=V+-IML6))),8YSUH QOAO<I/X"TQU+[5BP2X(/!K+2[T?5/B;
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MM5U37D\-3::IM1#%8%U+RL&W;CABOMU[5/XKN==O=(T<?\([>72SXDOK6W=
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M=:)9I=Z;>0F01L?FCD7HH.>AR?RJSX9\.W_]G^)I=6L8X7U>X\];53PN(U4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+7<,#R1VEQ/)($'0>2V/UXJMX4N]2UOQ3?ZS)I\NGV4D$:".?EI" >?;']:
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MZ9/<6%@NJZWJ,@DNF$@1%QG ^8^_K0!I:7XPU*_74;.71I(-6MHO-2W)X<9
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M.S3RM6LHOWEM)U#Y'0=P:HZCH&O76L>-9K.U<?;K2.WMV+@>81OS]!\PIS^
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MQ_PDFG_O'!\J7Y0.#TZUJT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>2*UKFYAL[=[BXD6.)!EF8X %8/B*_L;K08BNOP:8ESAX[DS!=R^QS[T 7-
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MHRV8US7&N[:WF68P+"JAG0@HV0,]>U=6][:QR&-[F%7!P5,@!S]*GH X?4O
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M*ZFB@##U31+^ZDMO[-UJ33(H!CRHK='#?G5*Q\$6EII6JVDMS)<2ZH&%S.X
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MJVFGN'N)GC_C+ #&,\#BEA\"6<>DSV#WMT_VB823S!RLD@&<+N!R!@UU8(8
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MTW#3MN[%L<#VXH \Z72YKCQ7JWAB^U.[FT^2T5]PG8.A"COGOFI_#&A7>O\
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MDT^QLHWGCBLYFF3:PRS,".>/]JDC\!:6)XIIY;FY>.191YS@Y93D'IZTV_\
MB#H^F>(%T:[AOHYFD$:RF#]T3C/WLU=U[Q?I7AR]T^SOWD\Z_F$,*QKN^8D#
MGT'- #+'P5H5AJKZHEDLE\S[_/DY9?I70T44 4M4TJUU>V2"[4M&DBR >I'2
MH]7T:VUG29--N"ZP/MSL.#\I!'Z@4[5]5AT;3VO)X9YD4@;((][D^PK/T+Q?
MIWB!+_[-#=PS6#;9X+F'9(#M#?=SZ$4 5;SP!H=];W$,\+,+F<SS-G!D8G/-
M,B^'7AVWTF;3(;4QVT\@DE56^^0,#/YU8T/QMIVO:DVGQ6U_:W(C$H2[@\LL
MISR.>>E=#+*D$3RR,%1!EB>PH YW0_ F@>';]KW3K,13$;<YS@5OW=M'>6DM
MM+_JY5*M]#65X=\1)XCBGN;>!ULPY$,QZ2CU%1^)?%,7AM(FDT^_NMZLY-K
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTLZ&UKK5G&&C@,PD5]V<'< !CBJZ_$#6-/U"RT[7O#K64EYE(KE)Q(A?!('
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MU/2);'^RXW>WA/WI6*D8_6O0** //GO/$/B>;3[*_P##DEE;&X$[R2'[BH>
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MC=+T:XL/%=G=7]R9KN6Q$3,JC#,B@,3Z=:LZ)X7GTWQGKVN2S(8]0=/+1>H
M50<_B*T+S'_"5Z7P<^3-SV_AK9H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)
M\1^(K#PMHLNJZDSK;1LJG8N3EC@<?6N9A^,'@V;9_P 3'8&P"6  4GL>>*V/
M':,_A2XVPF8HZ/L"YS@YZ5Q?BW5M U?P%<Z5IT2OJT]J D,5H58O@<9*XZ^]
M '3:S\3?#VAZU!IMU.Q::'SE>,97'/?/M2Q?$OP_>6-W<:?++=/;(&,4:99@
M<XP,].*YVZM["]G\+6,<1CU/3GW2VYA)(!0@AF(P1SZUM#3H8OBJCQ6<:Q&S
M(9E3 Z<>U %A/B1HDN@PZS$+A[0S"&8K'DP'!Y;G@<5J:KXOTG2+&PO9I7EM
M[Z5(H)(%W@EB /PR17G^MNMA::S"WF?9;G4HT988>&79DC&/4=:FU_18/#^N
M:3JJQSW7AN68-+9H,K#*<;9/7KCCVZ4 >K]JX>;QNVHVVL6&FPR0:O9H72.9
M,;UR,L/7O7;1NLL:R(<JP# ^H-</K:VME\2M)NI7CC\VW:/&TY; 9CTZ\4 1
MZ%\2])ELM,M;\W4=_.(XCYD.W=(W''/K4Y^*.B+-<HUMJ&V%RFX6^0V."1ST
MS5(74WB[Q590V>E&+1;1O/>[>,*)7!!3;W['M3O!$5W/<^+&U"$E/M6+?S(P
M/EV=N/6@"&\^(8BU:PU1$O)M GA^40V^YQ+@Y#<\'IQ74^&/%^F^+$NCIZ7,
M;6K*LJ7$6Q@6!(XS[5RGAC5(O#_@F'[7923W,TSBWMECR9#@=,\#\<5TO@[3
M;RUM;F_U&&.&^OI/,>-!]Q1G8I]P#@T ;M\]W'9R/8PQS7(^Y'(^Q3SW.#BL
M7PWXBN]8O-0L[VRCMI[-]K".7>IY/? ]*T=;U*VTO2IKB[1WAQM94!)(/!Z?
M6N$\,6UIIOB'5=4T*UEAT&*V#$?,?M#X.=N[G(]_6@#JO%OB"Z\/VMDUG;6\
M\UU<B "XG\I1D$YS@^E:6C7-_=Z<DVI6T%O<-_!!-YBX]FP*R?$MSX>N;"TC
MUR(NLN)88RCDAL?[/0\U%\/[22T\/-F"2W@DF9[>*1B62,@8!R3[T :7B3Q#
M!X<T];B2*6>:60106\*[GE<] !^%8UA\0[+4].OFM;*Z;4K% \^GM'B4#('W
M>O>M3Q3X;7Q'8PQI<-:W4$JS07*?>C8=" >/S%8=M!L^*-Y%#&(YSH0!E8#$
MC^;C<<4 /;XF:4VBVFIQPSB*:[6TE$B[3"Q(!W>G6I-5^(5KI=YJD9M)I;?3
MK<32RH,[LX(QZC#=:RKC0;+P_P"!=1L=?N(7O=2>5VEAC<@RL."HQQ@^U4_"
M6D:OJL.I2:II\MM;O:"VA:?:6E 4 -@'_9[T :+_ !;TVUM1=7^C:S;VYC#^
M8;0XY/UZ>]69_BIH]NIF:PU22U\E)EGAM=R[6&>3G@BN9L=3U6[\#6'A:WTB
MY?52HMKF615VQ)GYF)/^R3C%=)?7NGZ?H<WAJUMI'EAMEMTD\KACMQZ>U '7
M:/JUIKNDV^IV+E[:X7=&Q&#C./YBLCQ1XKD\.W%I#%I-Y?M.')^SQEBH4 _U
MJ+X>L4\)6UF=/FLOLI:/RY<9.23D8/3FNI**Q!*@D="1TH XY/'\5_X<OM4T
MK3+R>6R($UM+&4<'&>!S3I/B%IT=AI-Z\,T5MJ*&199EVJ@ )P3Z\=/I4NAV
MGE>)?%IV )++"0H4C_EE^7Y5R#:?+-I^@6MW#,8(9YKAHPGS1HJ95?3DC'XT
M =1I'Q%T_5-573WM+JTEG#-:-<1[5N .ZGOU'YT_P_\ $"PUF:_L9XGLM5L=
MWG6DPPV!R"/4$8KG[[5#XJU/P^EMX=O+2:WOHK@3RA0$B4_,.#WXJAH6A7/B
M/PGJBM83V6O"9W6^GP/-;. 1CMM^7D4 =!;_ !'FU#1K+4=,T*]O$N))$*Q(
M3@* <CUSGBMWPYXRT[Q)<7-K!%<VUY:[1-;W47EN,C/ SR*YCPWXEN-"\+:?
M93^&+I+F%WMGAM]N%* 9;)/0Y_2K/A&SO-2\:ZQXDN+&>P@=4A@AEVY<;1EC
MC/<4 =9KVK-HFDS7RV=Q=F,9\J!-S'_ZU<K_ ,+*%M9V%[J&B7]M:WCJBR^4
M2 6Z9^M=-XGO_P"S_#]W(+::Y=XS&L,.-S$C'&>.]<1+I6H7GPMM+;4K.0W$
M=PDD<3?>11]WIW H Z0>.+.W\5?V%J:"SDG426+NW$Z8'Y'.>.>E4W\<7T\_
MB"/3M+CN/[(E\L[IBI?!._C'8#CUK!CTB\U7QCJMG>Z7<_9YK5([>]^7;%PI
MR.<]0>E7/ -GJNG/K/A;5[0!U!D_M%!_Q\[\@MSWXSTH TSX^:Y\'RZ_I^E3
MRBW;$\,H*$ 9R5ZYP173:+JUMKNC6NJ6A8V]RF]-PP:Y3P[!?#P%J%E=VCI+
M')/&A('[Q=YVG\L5I_#NVFL_A_H]O<1M'*D)#(W4?,: )=<U[5=.OX[>QT2:
M]C*%FE7(4>W2J5CXV9[ZZL=3TV:QN(+8W($@.UTW!>"?<XIFOVNH7'C_ ,/R
M6\-P;6&.4S.K )R5QD9^M0^(XY+?Q?/J+Z9-?VB:(T;0Q$ R,9@=HR1SCF@"
MG<>+]8U'3[C3I]*FTV[O+>46=Q'ET8[#@;L#!/%16GC+6O#VGZ5;ZQH,ZQ$Q
MV\MPTC.Q<CKR.>AJM;ZM<ZE=:-I]OX2U33;.Q!D4SNC*$ ! R&)[5I+;:AXX
MUZVN;^QN=/T?3Y2\<,I7-S(#PW!/'7TZT -/Q&O[O4M1M]*T"6Z@L&*RREBO
M0 ],'GFI8OB5'=VFBWEIITLEM?W0M)W;C[/+D#!_$G\J9X)TR[M_&GBZ[EMF
MCM+BZ_=%NC#:O05A1>&KR[\)>*K8V,S2_P!I37%I&A"EF#,5(YH V;/XFRW4
M=XXTH*(=0%DG[P_/\N=W3VKT/)VY YQ7F^CZ;JVLZCI<4^B-I&E:=ME<2E2U
MQ+MP>A/')Z^E>DT <1+XK\4)>W$">%@Z1N0KB8\KV)^7BJZ_$A[C1+*:UTS.
MJ7<[6Z6DKE%#J-Q!;'' ]*T?!=AJ%I)K4M_%.K3W3&,RL#N4%L8QVQBN6L8=
M2TF&:.;PA>ZJ3>M.AC=%*# &1EAZ4 ;$7CW5+_2M06RT-UUK370W-E,2JE#G
ME6QST/:I[KQMJ$^C:3J.CZ5]H%Y(4DBD<JP(R"HX.3D4OA"+5;SQ5KNM:EHT
M^F1W<4$44,Y4L=F[).TD=Q7'ZGI]]I/ASPFDRR1SIK,Q,0.,@F5A^A% '9Z?
MXQU>37K'3-3T$V?VP2^6_F$Y*+N(Z"J=KXX\1WFIZE8Q>&!OLI51MTQ!*L"5
M8_+P"!FIM$LM;U?Q"?$FMV+VBVD3)8V!8%P2"&8D$C)! Z]J/"MCK%SXNU[7
MM1L)=.CN1'%%;R,"7"*5W<$^GZT 2-XTU.ZTS1[W2M&6Y74 VX/*4V%=W X.
M?NT[3?&NH/XEM-%U?17L'NHV>*3<65MH&1R!ZBN4\-:'XB%UX1:>PN([>PN)
MO.+,N%4A\' /3)%=/K&G:G>_$_1;J&U)L;2"7S)G/R@L!P.^>* .RNY98;26
M2"+S957*IG&X^E<;+XQUW2XK.?6O#Z6\%Q,L+/#,9/+9B ,_*."2*[BN3^(.
MG76I:!;QV<3S2)?VTAC7NHE4D_@!F@"M8^+M43Q9=^']3TZ-+HQ27%F89-PD
MC4CJ<#!^8<5(GB?7K?4]*M=2T6VMTU&9XD9+DLRD*6Y&T>E4]<T_5+;XCP>(
M+'2Y[R*WTN="$90'D)3:@R1R<'K6)=:IXSUO7]%N+GP;<6D6GW+3>8\B$8*%
M3G#$]Z -V3QAK%MI'B1[G3A'?:9ODC7^%HN=K=.>E37GB;Q+:Z6=2BT6SEL4
MMHYC*]V49LJ"?EV^I/>N>O+37?&?B6[DTVS;2[ @6UU/=_\ +S&,@A0,]B>H
M'6K'B/5_%XL+G0]+\&W4MJ(1!%<>9'S@ 9QNZ<>E '<^&]97Q#X<L-76/RA=
MQ"0)G.VJ?B'5M8L+^S@TJTLKGSE;<ES<^4<Y&,<'-5_AU9:CIO@32[#5+4VU
MU;Q"-HR02/KBI-:TJ\O_ !7HT\48%K;!I)92>A!&%_'G\J ,A?&/B"+7%T*^
MT2UAU&>V,\ BNC(A&2.3M&.13K?7O&T&JZ5I^H:)INZXSYLD=Z3PN-S ;??I
M4NH:/>7/Q9T[4DA_T2#3BKR'INWMQ]>:U]4M;V7Q9HES;P!K>%)Q-(3PF5&/
MSYH YZ#QQK-SK6H:)9Z,)]3M)1E9',<0C(R#OP>>1QBF/XXUV;2+J:WT/.H:
M?<>7>6J.6^7C)0X^;@GM4-NGB+0[^^U6U\/27EWJ=Q\X+J#$BY4$_,." #QZ
MU#87/B_3)KS41X7\V:_N7+P*X_=KM&&/S=SQ0!=MO'][K.O);Z+9Q3VBV3RR
MM(^T),,81S@[>X_"FCQ?XQCT;^U6T/1Y[%>6GAU(MD;L' V<UDZ3HGB0>*=4
MUM]&6QLY;-E:RB8;KB4C@CD@8Y[CK6_I>A:E;_":/1WMRE_Y3#RB1D$R%L>G
M0T ==I5^NJ:5:WZ*56XC$@4]1FN3\7>*M:\*ZS9S-9PW&CW4@MQM?$BR$9!Q
MCD<'O72>&[2:Q\-Z=:W";)HH%1U]"!2ZCX?T[5;^UN[V 326IS$&)PK>N/6@
M#SZ\^(>L;KW3X8XTU2#4HX1&$#Y@)3)'KP6K</B/7]5DURVT."T>\LI4CC2:
M3:H!W9).#Z#BJ/B/PWKEMXREUSP_9V4KW%JL!,^[]V^XYDX]B/RKI_"?AUO#
M^G,MS,MQJ$[>9<W '^L8_P!.30!A+XTUW3-7BT_Q!HD$!F@:2&2UN#*&9020
M?E&.AK/TCXBZL\&EZIJ>GV_]CZI(J12P2[WA=R JLN!W(YS6WXGTG4;OQ1I>
MH65LLJ6B,6WG@DAAM_6N?DTWQAKD-AIE_H^FV%C%=0W):V+97RW#8Y)ZXH U
M;7Q!XSEO]5BBTW1[M+9\*J7^&3NH8!."1S6_X2UZ?Q%H,5_=6?V.9B0\.[=M
M/UP*H^%O#D^BWFOW4A);4)Q(H], BI? UAJ&GZ"8M2B\NX,A8@GG'OB@"+QS
MJ7B'1M/35-%CMYK:T!ENX93@N@Y(4X/.,UFWOBK7-/U#3[YK>";1]0*QI&#B
M6-BN<]/FZ$8KJO$>/^$<U'/3R'_E7/\ A;2;;5/#>C:C=6P^UVRN8\DX'S,!
MQF@!UKKFOV7BQ])U6V@>*]\V339(VQP@R4;CL,<^]0W'B+Q5HL4,NK:38M \
MY1I(KH[@"3MPNWGBLZX\.^+KSQ!#KUY?(19RNUK90CHK  @DCN!CK5+71\1M
M;M_LO]DZ=#$LP>.4,V]1SC/..AH ]31MZ*WJ :XOQ%K'BW0HK_55M+*;3;2-
MY?+,N&91SZ5V-L)5M8EFV^:% ;;TS7!^(=+\<:\VJZ="^EPZ9>0M OG;\J",
M;N.YH 9K?C36++1-,\36R6PTV2)?/M)6P[,6Q\IQD_2J>J^/=5TO5]3TV>:&
M.Z)@DL8F0;BDCE<8[MQ73^'O"7V7POINE:\MM>S6)W(\>[;GG!YQV-9OB[P=
MJ&H>*-.U[1OL?VR&-XG%V&V %<*PV\Y!)- #;SQ5K%KJ&IP(D;M:6"SK%(NP
M&0JI.3VY)K/3QGXHTSPO;^)-0L[6YLIB@D1'VM$&?;D8'S5OP^%KVU\,:E#+
M>"]UB]C_ 'ES(, MV P!P.E5-9\*7]U\+T\/1%'NP(P2/N\2!C^E %/Q#KOB
M >,-%ATN2VBL-0MW,3RQ NK87UZ=>E7_  CXFU:]\1:IX?U>.%[BP )N(>C9
M (!&.#@U6E\.ZK-XJT6.\OK(6-E$&A@0/YCLN,G.,8Z=ZU-/\/W5K\0=0UKY
M!:7-N$Q_$7RO/Y"@#JZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K(O- @OO$%EJLYW/9J?)7'W6.03^1K7HH **** $ "@ # %+110 444
M4 %%%% !68FC1KXE?6C(QF:U^RA>P7=N_G6G10 TQHTBR%077.T]QFG444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !5#4]&LM7:T:\B\PVLWG1>S8(S^1-7Z* "BBB@ HHHH ***XC5/$
M/BS3K_4IUT."32K56*/O.]U49+8Q0!V]%>=ZCX\U.#2;'Q1:6 N-"^SE[M$_
MUB-P<X]!SWJSJ/B;Q?%=/<Z?X=CFTQ$#9D<B1AC.5 X[^M '=T5Y\GQ(2>_T
MDK L-E>PS;FF.&65%!V?F<59T?Q5JMYH6C74UN@GO;Z2!P> $!?&/?Y10!W%
M-+H'"%AO(R%SR17G=CXX\0WL=[9VFCQW&J6,Y2X1F(15&.A'>H1KNN^()+#Q
M!H&FP37%J)[2YMKB9D"-N / SGE30!Z917*^#_$6KZU+J-MK.F16=S9RB,F!
MRR'Y0<9/.>:R-:\4>+X/&<VDZ-I%G<P1PK(&FE9<YSZ#VH ]!HKS[3/&/B+4
MY]6T6;2[6TURUA$D*"1C&^<=R,]_2JR^+_%.J:#,VG65M'JFF3,FHQ2L0/E
M)V<'/XXH ]*HK@K/QKJ%SXAT)9[+[-INH6[ D]1-\N!].3BL;_A,O%D]OK-Q
M:PVN-*U+R95E)'[KRP>PZY84 >K45PT_B'QA>)9W.B:+936LMJLS-/*RY8C[
MHP#TK(_X69J$FDZ/J3V,<,<NH&TO41B2I!887/\ NT >H45Y?=^/=770[N\2
M-(V&L):1'&?W1*9^OWC7>Z])JT>F-_8L,$MZS!5$[%54'N2 >E &G17GFE>*
M_%E]XOG\.76GZ5#);VYFEFAG=N.@QE>N2*CTGQ5XFGT36K"6WM9M?TL$,ZL1
M'(.>1QUX/&* /1Z*\M?QYXPL/#46NWNC:7)8JVV8PSN9%QP3C&.OO7H6I-J$
M^BNVE&);UXP8C*<*"?7K0!;N+>&[MY+>XC66&12KHPR&![&G0PQV\*Q0HJ1H
M,*JC  K@8/$?BO0=2TFS\36U@\-Y(+<3VDC,Q<D $@@ ?A1?ZEX_T<W.H3VV
ME3Z=&X;RQ*PD"9 Z;>O.>M 'H-%<'J/B36M+U[3[YO+GT#4&6)$4?O(V8X!Z
M=.1W[5ES^,M76VBL'=/[4_M<6QVCD1,7*G'T H ]0HKRJ_\ %_B3=XD2UO+&
MW2PO5@2:[.U8U(3T!R23CGUJW;:MX[TZXTJ?5I-)FT^ZN$A9X)&+-O/!'RB@
M#TJBN.^)>LZAHGA&6YTR>.&Y+JJE^^2.!Q7/W^I?$G0HTU+4!I4UDLJ"2*%R
M6VD@'&5% 'ID5S!-))'%,CO&0'56!*D^OI4M>:7.D^,K/4[W4?#,FFQ:??)'
M.5NI&WAMO/\ ">Y/>H;3Q7XB:STF_O'5;>]T^7>H4 "=-YSGKT44 =U=E?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!C7F/^$KTOKGR9OI_#6S6->'_BJM+&XC]S-QZ_=K9H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:* .6O?A_H5_>3W-PERTD[%G'GM@D]>*Z&ULK>SMH8((E2.%!&@ Z*!BK%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@?RH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0Y.<]-WK6[;ZOIMW+Y=M?VTS_P!V.4,?TIT&J6%TLK6][;RB+_6%) =OU]*
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M3_"?45'8:78Z8A2RM8X0QR=HY/U/6L&;QGIUGXE?3[V_M+>W:%989))54."
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M 4ZLC1/$VE>(?/&G7(D:!MLB'AE/T_&M9F51EB ,XYH 6BN4UCQ[IVB_VO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH QKS/_"5:9T_U,WU_AK9K)N]G
M_"3:;E6+^5+AAT'3K6M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% &;<EAK]B 'VF*3)!^4=.HK2K)
MN]O_  DNG99PWE2X ^Z>G6M:@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,B[5#XGTUB^'$,VU<=>F
M:UZR;M@/$VG*8\DQ2X?/3I6M0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &3=G_BI=.'E@YBE^?^[T
MK6K)N]__  DVFX+;/)EW #CMC-:U !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9-V/^*ETX[P/W4OR
MY.3T[5K5F7.W_A(+#)?=Y4N .G;K6G0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7=?\ (QZ?\P'[
MJ7C=C/3MWK4K.N%SKMDV\C$<GR\8/3\:T: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J2K"=2MV8)
MYH1]A*\XXS@]JMUEW2L?$6GL(B5$4N7SPO3M6I0 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tmb-20201231xex4d11003a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20201231xex4d11003a.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M_?R@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H X^3Q_I<6LQ^'C<Q_VM)9R7RV@),@M8Y8X6F8 $(ADD5$WE3(1)L#>5+L
M.PH * "@ H * "@ H * "@ H * "@ H X_P'X_TOXGV":IHUS'>6,DD\<=Q$
M28Y&MYGMY"C8 =!)&X61<I( '1F1E8@'84 % !0 4 % !0 4 <?XR\?Z7\/D
MMI-4N8[9;R\MK&V#D[IKJZD$<,,:@%F=F.3@$(BO*Y6*-W4 ["@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H X_P 9>/\ 2_A\EM)J
MES';+>7EM8VP<G=-=74@CAAC4 LSLQR< A$5Y7*Q1NZ@'84 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M''Z5X_TO7=4O=%M;F.74=-CMI+V!"2T"W8D, D(&U7=8G<1YWA-DC*$EB9P#
ML* "@ H * "@ H * "@ H * "@ H * ./UWQ_I?AF_T_2[RYCBOM5DFCL;<D
MF2=H(7N)BJ@$A(XT)>1L(I:-"V^6-7 .PH * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@#C_ ?C_2_B?8)JFC7,=Y8R23QQW$1)CD
M:WF>WD*-@!T$D;A9%RD@ =&9&5B =A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !>_;Q\2_LP?$UM,\;Z='!X*U"-$TZ\M@TS(J'Y[PR!5:5]T@6]M H>W00O
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M(?[-?A#3_"G_  K'Q!?_ &#[3_I/EWL'F>?<RW'^J_LZ7;M\W9]]L[=W&<
M^S_V4?\ @HF_[2>LZOX>N?#5YIFK:59S70M!<QRR2M;RK#-;,+B.R$%P))(T
M192$),GF20>6-X!V'[/G[;W_  NGX:ZSX\?3_+N-&_M9IK(2;4?['$;N&))C
MO8YMW@CDF:-,SB5E@6/8I .?^&/[9MYI7P57XG>(X?MEW_IDCV]L%A5F?5)K
M2UA0G.R),PQM(WFRB)3(PGER' //_P!JO]O+Q#\,O"_A?Q%H.B7$EOJ=OIVK
M:M-Y4TEO9V<Q@D%E]L-L;99;HNUMYS9DA0;Q;B2XMY$ . _X>D^,O[._M?\
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MY97C5V,4UK:.T4:R;Y6@,TJ_(JP.9!@ _7^@ H _(#Q5^WG\0_#7BC5_[/\
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MTU_:6@7FE?V9XQTJW=Y+"9Y8K>=H=D,I,AADEM-MRPCE@D2:6%'0JUTRRK&
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MS\0?\*V^(&G2:;XPM8VC\X &.]E@1Y9"T<:[(':!5G22-GM;D>9)$T*-;PR
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MT'B'PX\DMWKT<(T:[^R2/;HLZ+-Y\ID")&_D%GMXI@7>8+FWDABN?+ /#_\
MAX[\0_\ HDWB#_OJ]_\ E50!ZA^S'_P4CL/C?<>(+/7]+D\.7/AZSEO;F&66
M:ZD^SVK,MZSHMI"T3VS>4K1$-,YD(5,QO0!X!X3_ ."J_BKX@/?77A[X>ZIK
M6DI>/%:7-JUQN6-8XR$N?)L[J+[023,RHX$:2QQ8DV>?, ?3_P"R_P#\% K?
MX[^()_"&N:)>>&O$<4;S)97DBD21JD4@0>:EM/\ :&21IA"("/L\;3>:1D*
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M$FI-]GCDDOT@^RV\45O,75H3"TR,3*@VK$ID /L^@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /@#_@J/_P DA\0_
M]P[_ -.5I0!]_P! 'XX_ C2;?1?VG?&D5K%'#&VAI*4C144R3#2)97(4 %Y)
M'>21NKNS.Q+,20"__P %'?\ DH?PF_[&!O\ TMTJ@#]?Z /S@_;T^&\7[4%Y
MX<^',#_Z1+J"ZUJ3)-$C6ND6:O:SRX;?()9GNUBL\0R1R2I*7*1PR, #Q_\
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MB3>R6\ @VJ,!47<S/*XC5$,LDCA07- '0?\ !4?_ ))#XA_[AW_IRM* /O\
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M_#J61@#/\6>*;SQS\"KO5=0D\Z]OO \US<R[53?--I)DD?:@5%W,Q.U0JC.
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M6K.]TZRB@MU-]JFI7\;0M(L$7S,B-+&F6,C16ZV]OYDTQA24 ^L/V+_@Y>?
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M.!9_)AFF2[E:6]>8CRW)CM@"U@QH _0^@#X _8%_YGW_ +*!K_\ [;T ??\
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M[40$O(\<2NZ@'/\ [&/[/%Q\'+#4-<UR&.'Q5XGO)=1UI(96DMX9))II8K:
M9*JD*SL&(:8F9Y/](FB6$J ?9] &?JVDV^OV\MG>11SVT\;Q30RHKQR1NI5T
M=&!5D92596!# D$$&@#\\/\ @F-IUYX/\+ZWX8N;K[7%X;\4:MI-K+Y2Q9A@
M,4A.U2Q^>66:7#O(R^9LWE%4  \?_P""<7_)0_BS_P!C O\ Z6ZK0 ?\%'?^
M2A_";_L8&_\ 2W2J /U_H _''_@HSI-O#\2_A3>+%&+F77%BDF"*)'CBOM.:
M-&?&YD1I96122%,DA !=L@'U?^V5X3U'X]P67P[L+2X-IJUQ;7&MZB87CM[3
M2[6X2618;M@8CJ$LL<:6\ 2X(3S))HX8BDU 'U_X3\+6?@;3K32M/C\FRL;>
M&VMHMS/LAA01QIN<L[;54#<Q9CC)).30!X!^VMX6L_&'PU\46U]'YL2:/>7*
MKN9<36D374#Y0J?DEBC?:3M;;M8,A92 ?D!\1O@Y>:)^S1X:UN5OL&K^'[B+
M5K.XC"M<"'4-0D\D0W$;A[?>MW:W9*DL'@C1T610T0!^E_PO\%6_Q!\0?\+G
M\0-9VMLVAPQZ)$Q7%EI4B&\:]OIYE"Q7K+-*D@MRL%K;F2(SW0D:4 'A_P"Q
MUHO_  NOXH>+/BSIZW$?AZ^MX=+TN2>#ROMWDI:QW%Q$&<2+$CV05"T8\SSB
MI,<UO-"H!Z!^QO\ '37/C+X^^(MMJL^ZTT;4+73]/MDRL,,,$^HQ%@A)S++Y
M:O/*26=@JC;%'#'& >/_ /!1W_DH?PF_[&!O_2W2J /U_H * /@#]IOX52_M
M:^(])\'W=A<?\(MI%P-4UN\D26V6XF\B2.RLK&X./M&[S9&OS"NV&+8BW<-U
M^[(!T'_!0'P%9_%OPA#X8F&+W6=8TNST^46C73P3-<K)<7"*H^3R;*.]EDD+
MQ+Y"2H95#X(!]?\ A;PM9^"[..PL(_*MXMQ +,[,SL7DDDD<M)++([-)--(S
MRS2N\LCO([,0#\\/V+O!5O\ "CXA_$KPYIC2)I-O>:->6UIE5@MY-1M9KB<0
MQ1JD4:9*1(%4'R8849G\L-0!V'_!4?\ Y)#XA_[AW_IRM* /?_V3O^2>>%/^
MQ?TG_P!(H: /H"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M/A#^R1I?P\U1?$^KW=YXA\5>6Z'5]1D+M"LPS+%8VRX@L[?>TK11QJ7A2>6
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MHQYB%DR\4J#.6C=<J0#];])TFWT"WBL[.*."V@C2*&&)%2..-%"HB(H"JBJ
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MXU.U:\U'6[R-8KS6=3N7O-0N(T;*(\SX5451''MA2,.D,/F!VB5@ ?1] !0
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M58M\# 4 ?9^DZ3;Z!;Q6=G%'!;01I%##$BI''&BA41$4!515 554 *    *
M//\ XW^"KCXE>%=;T.S:-+G4M+OK.%Y2PC62XMY(D+E59@@9@6*JQ SA2>"
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MBJ>XC>/Q%)I(@MT5MT4>G60@+2.< O)(\F$4$*B(WF,TC)$ <?\ M ?LM?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <?\
M$+P5;_$K1M0T.\:1+;4K.XLYGB*B18[B)HG*%E90X5B5+*P!QE2." '@#P!I
M?PLTNVT71;:.STZSC$<$$8.U5R222269V8EY)'+/([-([,[,Q .PH * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /+_C)\(=+^.^B3^'M:61].NI+9YXXW,;2+;W$
M5R(RX^94=H@DA0J^QFV/&^UU /0-)TFWT"WBL[.*."V@C2*&&)%2..-%"HB(
MH"JBJ JJH 4    4 :% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 >/_![XZ:'\>8M0N?#\_VNTT[4)-/>
MY7'DS3110RNT#@GS(AYP02X"R,C,F^(QR. >P4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MCSW'EMY<1,0EED$.Y%<1! V7W$@'@'[?7_,A?]E T#_VXH \O_X*_P#C_5/
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M?#W_ '$?_3E=T ??] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 ?/_ .TI^S7H?[5.A_V!K_VA;=;B.YAFMI!'-%-&&4.A97C.4>2-
MED1UVN2 ) CJ >P>$_"UGX&TZTTK3X_)LK&WAMK:+<S[(84$<:;G+.VU5 W,
M68XR23DT ?GAJW_!)GX9:UX@EUR6VO%@FD>1])BN!#IX9T*D(L4:7$:;SYJQ
MQSJB/A%58 (0 ?H_I.DV^@6\5G9Q1P6T$:10PQ(J1QQHH5$1% 5450%55 "@
M   "@#0H \?^.GP+T/\ :+T.?P_X@@\ZTF^9'7"S6\R@A)X'(.R5,G!P592T
M;J\3R1L > ?LU_\ !/?P-^R]>?VII4%Q>:H/,$5]?RK+-"DJJK)$L:10IPK#
MS!'Y^V66,RF)RE '0?M2_L9Z3^UQ]EBUW5=8M[*SRT=E936\5N9CN!GD62VE
M=Y=K>6I9BL:;A&J&68R 'Q__ ,.5/AY_T$O$'_@39?\ R#0!]@?%C]BCPO\
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M\Q@JAI'VF1G$4(C /K^@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M_:5O?#VE2Z?X8T?4+)]/M&MKVZND:XNH6A0QSSL^KH[2RKB20LJ,78DJIR
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M-NUC;VLMMJ$.5%FLDT;;$NU2*ZDDENG0O'(VV-6D /W^H * "@#\T/VL=?\
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MT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^0'_!:O_DGFF_\
M8P6W_I%?4 ?K_0!^&/\ P3T\%7'AG7OBQH7A5H["2WU2"QT^60M*MG&EUJ<"
M3 2+*9WMXQYL<4O%R\:Q231K(TR 'Z7Z_P#LY16O@:W^'V@R_8-+:WCT^[N0
M(OM L2I^V,B>089+N[&Z*25EB"/<RWHWRQ+#* >O^+/AIIWBOP]=^&-GV33;
MO3YM.\NU5(O)MY83!M@7:8TV(<1C847 &TJ,4 ?CC_P3]\-V_P 5/">FVOBB
M[CTZQ^'.J7EQ<Z3+M@G&H1RRW<&HW\TCI+;6]L)KF%+79&CS6\TLT\J*;:(
M]?\ $<EO^WM\3=!O-!CDD\+^ [R>>[UM)%6"\U FWFBM;+,;B=(Y+>%II00C
MPO(5>,-:2W0!^M] !0!\H?MQ> _$'Q/^'FM:-X72235KR.WBBCCG2W:2,W4/
MVA#)(\:!&@$JR*S 2(6C(;=M(!^('_!0OQ_\9?%7A6T@^(?A_2]*TE=4A>&>
MSE1Y&NA;W(2,A=0NCL,9F8G8HRJ_./NL >@?MJ^)OB;X93P-X_\ B!IFEPMH
M^N2N-/T]RC(RR6UQ%'<3M<W:L]RMG,4,".ENB R.TLPAC /N_P#X*%_%+1_B
MC\')9M#N/[07Q)<:9:Z.+:.25KNX:\BF\A$1"ZRA;>8-'($=98S P$V(R ?&
M'QVDN/V+?B1\,-;U^.-].TWPW9Z-<W,4C&/S+>.>TO9458VG9($O8KA085,X
MQ&N'W^6 ?3__  5)LD^.^@^$O"N@S1W6H^(=<@GTXQB2:"2UCM9EFNS+ DJ_
M9XENH99'&X^26E572-RH!^M] !0 4 >'_'GX\Z7\!M+DN[N2.7498Y!IFF"0
MBZU*Z!1(K6UB1))I'>62&-FCCD$0D$C@(": /$/V;_V,K/X-_#6?P)?3>9+J
MMO>+JUU:EEWS7T1AD:#SMX7RHO+AC8HJR>4)F@5Y'2@#X0_X)^^&[?XJ>$]-
MM?%%W'IUC\.=4O+BYTF7;!.-0CEENX-1OYI'26VM[837,*6NR-'FMYI9IY44
MVT0!Z_XCDM_V]OB;H-YH,<DGA?P'>3SW>MI(JP7FH$V\T5K99C<3I');PM-*
M"$>%Y"KQAK26Z /UOH * "@#\@/^"U?_ "3S3?\ L8+;_P!(KZ@#]7_%GA:S
M\<Z==Z5J$?G65];S6US%N9-\,R&.1-R%77<K$;E*L,Y!!P: /SP_X)D>)W\*
M_#>YTG7(H]-D\)ZIJNG7\DMQ&8U:"0WD\CR#$4:1&X:-B'=,1&7S-K84 \_^
M#<EO^U[\:;SQ]81R1Z)X/LWT:SNED5X]1O&:Z5Y8F2-X7MUBN9FPDWF8>RG.
M%G:) #];Z /@#]@7_F??^R@:_P#^V] 'W_0 4 ?&'_!0CX7V_P 5?AEK]O/Y
M:265G)J4$KPK*T<E@#<'R\E3&\L:26YD4Y1)GX=2R, =!^R%\8K?Q_\ #+0_
M$=[<2)''I:K?7=](H;S+ -;W=Q-*[L-C202R^;(V2A#OM8LH /E_]C;2;?XT
M_$CQA\5[&*\31[^.UTS1[B9%ACO(X(X8KV9(F'G%!+9PB&0^6,/+&Z>>DD<
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M +AW_IRM* /?_P!D[_DGGA3_ +%_2?\ TBAH ^@* "@ H _(#XR?\G0^#/\
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M336\<H\J-EN-US,9 >0GDAHX)A-$ #/\*Z!_PA_[0^K_ &:XN/*UKP?!J-W
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M_P"R=_R3SPI_V+^D_P#I%#0!X!^WU_S(7_90- _]N* /O^@ H * "@#\@/\
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MS]HU]-8GT>STDZE=VB'2-.8-"+>&.>,S[Y;>6ZNXPTL<<\2W(AM]X:0 \_\
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M?LM:I)K6EB\O=1,?EPSZA)#*ULK!A(;<10PJCR*=CR$,X0&-&1))ED /N^@
MH Y_Q9IUYJ^G7=MI]U]AO9K>:.VN_*6;[/,Z%8YO*<A)?+8A_+8A7V[2<$T
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MKPU#X5U.*2UTZUD@DLQ8LMNUJUNICC$*[&A"")GA\MHW14<[55U1T .O\4_
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M0C=7$D$>B:Y::R%C52TTEG',(HBS9"(9)$>0[6+(C1KL9Q+& <A\:_V7K/\
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M-VC:+X>U'5]<BTG0;.WM;6TM[BU2-V@B$*W,X:T<R7'E@)NR$0%_*CC\V7S
M#YO_ .'*GP\_Z"7B#_P)LO\ Y!H _4_P!X TOX6:7;:+HMM'9Z=9QB."",':
MJY))))+,[,2\DCEGD=FD=F=F8@'84 % !0!\X? ;]F?2_@->Z_JEK))/J/B/
M5+C4+V9\JH5YYI8+>.,,55(5G<%^7E=G=BJ&*&( ^CZ /RP\?_\ !)/PA\4]
M4N=:UK6_$EYJ-Y(9)YY+JRW,V   !8!515 2.- J1HJQHJHJJ #L/@7_ ,$M
M? /P&UR#Q!;-J&HW=I\ULFH2P2PPS9!2=4BMX<RQX/E%RZQL?,51*D<B &?'
M^P!>_&&_DU3XI^(KS7HYI([E=!M))[/1[6?R9(F2)!,TLB1!P()D^RS-L9Y_
M.:>44 ?H?X6\)Z=X&LX]/TJTM[&RAW>5;6T*0PIO8NVR.,*B[F9F; &68L>2
M30!T% !0 4 % !0!\8?"K]B71OA3\/KKX?V=Y>)#J4<HU*_B\H7%Q)<(D5RR
M).EQ#"DD2"!45&,<.")#<9N& /D__ARI\//^@EX@_P# FR_^0: /U/\  '@#
M2_A9I=MHNBVT=GIUG&(X((P=JKDDDDDLSLQ+R2.6>1V:1V9V9B >0? ;]F?2
M_@->Z_JEK))/J/B/5+C4+V9\JH5YYI8+>.,,55(5G<%^7E=G=BJ&*&( \O\
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M^+6EZ%HMU926NG>'I";*"TF:%3%(5,\$Q.YG2=D1YY<K=,X,BW"/)*S@'/\
M[3'_  3K\%?M2ZI'K6J"\LM1$?ES3Z?)#$URJA1&;@2PS*[QJ-B2 *Y0B-V=
M(X5C /;_ -GK]F+PO^R_ISZ?X:M/)\[RC=7,CF6XNGB0('FD;_@3".,1P1O)
M(T<4?F," ?0% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ''^+/
M&E^.GL9-3MH[IM-O$OK,2 E8KJ..2..8+G:SHLKF/<&"/ME4"6-'4 ["@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'Q!^V;H/Q*\1V<(\$ZMH^@:?9XO=0U*^N98IO\
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M2_ KQCX$N[>[CM_"]WJC6VJ^9$T=NK2[("]W=^:J;%@GFGMH6\M$FMGN9/M
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METBS^*-[I>LZ%K4BAKVWC"M:QQ-Y=PT7V>VMY2\0FAGE22WF$R!8H)$D:4H
M?3_Q.^.'B7X;_'7P[HE[=QQ^%=9TN>"!)(F@@%TV]BHF,NRXO3-;VL<>1B*&
M\6".W66=IYP#/^&GBG7/%G[1/B:VN9+B;2-%\/PVUJNT_9[5KT:9=%,J @EG
M99GW.3+(D.W)CMU6, X_X8?'_P")OQXUGXDZ+X?N=+CN]'U2#3])-XIBM[&
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M:?I$7B;6%BL[NXOPD5Q8Z;;BRL'5Y_)A/VD075_ 8=XDM;F-A-,BJ5 /G_\
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M"WE)YTMK]GR7W1-+$S(?,B64 _7^@ H \?\ BS\?O"_P*^Q?\)+J=OIW]HW
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M$K6[.VF:7I\T0%S>3W:;EG<K.?GC>9VNF<RM)=;+:Y /T/\ @#\'+/\ 9_\
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M'BSX@>#-?U#0]&L8-<CU/34>XBLU,>J1&40QB9HD*001VB&.) (79UWNAB(
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M^-_A7X:W"V>N:WI>FW+QB5(;R^M[>1HRS*'"2R*Q0LK*& P2K#.0< 'Y@_\
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MDZ?X\T^_LI;@26J7NNVLGV6'8I,,:+.MNNZ=KB=I(88&D\Y4D$AA60@'C_\
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M_P (5_9_B#1[O[)XXT.ZN?(U&VE\FWB\_P R>79(=D29&^1L(N1DC(H ^_\
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M$+1O&/@7P_9Z9J%G>7-AH>DQ7L-O<1326TGV1%V3I&S-$^Z-UVR!3E'&,J<
M'U?0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0!X_P#&'X%Z'\>8M/MO$$'VNTT[4(]02V;'DS31131(LZ$'S(AY
MQ<Q9"R,BJ^^(R1N >P4 >/\ P+^!>A_LZ:'!X?\ #\'DVD/S.[8::XF8 //.
MX WRO@9. JJ%C14B2.-0#U#5M,36K>6UE,BQS1O&YBEDAD"NI4E)8F26-\'Y
M9(V5T.&5E8 @ ^$/^'7'PA_Z%[_RHZE_\ET ?1_P0_9N\)_LX6]Q:^%=-CL(
M[N19+@B26:21D7:@:6=Y)2B@MLCW;$+R,JAI'+ 'B'BS_@G#\+?'.HW>JZAH
M7G7M]<37-S+]OU!-\TSF21]J7*HNYF)VJ%49P !@4 >H?!#]D7P1^SC<7%YX
M7TF.RN;J-8I9C-/<2&-6W;%>XEE:-"V&=8RHD*1EPQC3: =?XY^!>A_$G7-&
M\0:K!]IN]!^U-IZ/@PQS7)@)G*$?-+'Y"^02=L;,T@4RK#)$ <_X_P#V7/"'
MQ0\0V'BO5]/^T:UIGV?['<_:;F/ROLTS7$/[J.5(GVRNS_.C;L[6RH  !] 4
M ?.&N?LF>#M7\,77@Z'3H[+1+Z\2\NK:S_<"61;J.[8%E&Y4=HDA(0J8[<+#
M"T*QQ>6 >_Z3I-OH%O%9V<4<%M!&D4,,2*D<<:*%1$10%5%4!550 H    H
M\O\ A3\"]#^#4NJ7.E0;;O6=0N=0U"Y?#3333RR2A2X Q%%YC)!$ %12S'=+
M)-)( >P4 % &?JVDV^OV\MG>11SVT\;Q30RHKQR1NI5T=&!5D92596!# D$$
M&@#Y0^&G[ _PS^$6HIJND:!;I>Q;3%+/+<7?E,KK(LD2W<LR1RJR*4F0+*G(
M5P&8$ ^K]6TQ-:MY;64R+'-&\;F*62&0*ZE24EB9)8WP?EDC970X965@" #Y
MP^+/[&?@3XX?8EU[2_M$6FVXMK&WCN[NVM[:$8^2&WMIXH4X5%+*@8I'&A)2
M*-5 ./\  '_!/3X8?##5+;6=+T&..^LY!+;R275Y<+'( =KB.XGDB+J3NC8J
M3&X61"KJK  ]_P#C)\(=+^.^B3^'M:61].NI+9YXXW,;2+;W$5R(RX^94=H@
MDA0J^QFV/&^UU .@B\ :7;O8/';1QKI<;1V$2 I!;*T8AS% I$*NL0,,<@3?
M%#)-#&R13S)( ?(&K?\ !,[X4Z_<2WEYHDD]S/(\LTTNJ:F\DDCL6=W=KPLS
MLQ+,S$EB22230![_ /!#]F[PG^SA;W%KX5TV.PCNY%DN"))9I)&1=J!I9WDE
M**"VR/=L0O(RJ&D<L <!\(?V'?AY\"-476O#VBQVNHI&\<<[W%U<-&L@PYC%
MS-*L;E<H9$"OL9X]VR1U8 ]?^,GPATOX[Z)/X>UI9'TZZDMGGCC<QM(MO<17
M(C+CYE1VB"2%"K[&;8\;[74 ] U;2;?7[>6SO(HY[:>-XIH945XY(W4JZ.C
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MK)^_AA<DJA5@#T#PMX3T[P-9QZ?I5I;V-E#N\JVMH4AA3>Q=MD<85%W,S,V
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M%Z'?>+4\;3P>=K4.GII]M+)AEMH5DGD=H5Q\LLGGLDDI);R@(TV*\PE /8*
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MA_!O3DTKP]86^GV2;3Y4"!=[*BQ^9*WWY92J('FE+RR;07=CS0!Y!\:_V,_
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ME,:%W9Y)#\SR22,\LCX"J&D9BJ*D8(1$50#U"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@#/TS2;?14,5K%'#&TDLI2-%13)-(TLKD* "\
MDCO)(W5W9G8EF)(!H4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M+SXE^-/%GAF:Q^Q6_AO^RXXF=U>:X:\CN)6F/EN\:1,B0F"/_6A2S2E)'-O
M ?3] !0!GQZM;S7$EFLL9N8HXY9(0ZF1(Y6D6-V3.Y4=HI51B &,<@!)1L &
MA0!GZ3JUOK]O%>6<L<]M/&DL,T3J\<D;J&1T=259&4AE920P(()!H T* "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M^(/VOOV1-1_:9O-$U#2O$5QX<O=$^W>5<VT+O,WVQ84;9)'<VSQ86)E;!;>L
MA4X (8 _-#]K#]EKXE_LT>$[KQ5!\2M<U*.RDMQ/;O<7UJWESRK &C<7UP&<
M221Y1@@V%V\S<BHX!ZA^T=\6_$?A&U^$/Q$OM4N$TMO[/;7'VP&W6:]M(C//
M]ECB\QY9K634$RBR+ BXMUMY929@#V_XH:9JGB;]I+PLD!DEL=*\-W5]-&90
M(X%G-_9O,L;, 7DD>TB?RP78+&6&R+* &A\-/BKKGB#]HGQ-X?N;^X?2-/\
M#\)M;'>5MXV8:9*9/*7"-*6N)OWSAI=C^7O\M510#]/Z ,_5K)]1MY8(II+:
M22-T2>(1F2)F4@2()4DB+J3N42)(A(&Y&7*D _#'PEK?Q%_X)\>/M!\):KJO
M_"2>%O%&H&.":X^2;[3>3PK=3 NTUQ#+%-,LSQF26VN5GDD!6ZFE>W /0/\
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M]DWPY+XTM/B3K&I_V9<6KRVUP]U&I62=(E(22\NXI\2O&'@F01/$9-S' CD
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MUGX/@>VL8_*B>XNKEEW,V9KNXDNIWRY8_/++(^T':N[:H5 J@ _/#0_!5O\
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MTOH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MQXT>WE\8^(_):[2"*,0Z?;Q*%BL8)%#.VU5C%PXD=)&AA&Z9H?M4X!]OT %
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M"_:V\&?LN:IXWT7QC?R:7J,_C36+Z*"2RO79K6Y$!@F!AMY%V2*I>/)RR%9
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MQ7_V+^K?^D4U '@'_!+C_DD/A[_N(_\ IRNZ /G_ /X)Q?\ )0_BS_V,"_\
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M\\ :7\3[!]+UFVCO+&22"22WE!,<C6\R7$8=<@.@DC0M&V4D *.K(S*0#/\
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MM#\/ZQ>^(+:PMTU?4-HNK[8&N)%6.&(1^:V76(+;P_N4*Q;T\S9YC,[ 'H%
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M!XZ^$_A[XH>3_;VE:?J?V??Y'VVTAN?*\S;O\OSD?9NV)NVXW;5SG P >?\
M_#)WP\_Z%3P__P""FR_^,T >X:3I-OH%O%9V<4<%M!&D4,,2*D<<:*%1$10%
M5%4!550 H    H T* "@#G_%GA:S\<Z==Z5J$?G65];S6US%N9-\,R&.1-R%
M77<K$;E*L,Y!!P: -#2=)M] MXK.SBC@MH(TBAAB14CCC10J(B* JHJ@*JJ
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MPJK.&*B*, @1K@ \O_X9.^'G_0J>'_\ P4V7_P 9H ^@* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MW9,[E1VBE5&( 8QR $E&P <_I7C_ $O7=4O=%M;F.74=-CMI+V!"2T"W8D,
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M"/[%W_!.CPE\=/\ A(M*\2:CJ":_X<UB:PN8M.EC2W\E<QQ2JUQ9N7\R6&Z
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MDBV]Y/;QEVP"[B.- TC9>0@N[,[,Q /L^@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(_)TVS^SVMM9VBPH[;BL<<%K"\D,9\M 7\M6&R"*1@-J$4 ? '_#YGP;K/\
MHVD:)X@O-2F_=V=K]GME\^X?Y88<QW4T@\QRJ92*5QG*QNV%(!]8?L"?L\7'
M[,_@.RT?488X=6GDFO-16.5I5^T3-A 6)*!XX$@AD$/[G?&S*TFXRN ?DA^S
M/^TQIW[!NHZ[X'U?0M0UGQ)8ZA<V.AW4-LBW%S;S.&@LP)"UQ;6EQ,J7D26_
MVI)'O'F6%G :< _2_P#9X^$/B7XM^((?B?\ $%9+.^CCE3P]X?5V$>D6MPA1
MY+@?*9+V>,XE#J"@/[Q%=8;>P /8/B]^UOI?P\U1O#&D6EYXA\5>6CC2-.C+
MM"LPQ%+?7+8@L[?>T2RR2,7A2>*<PM$X8@&A\ _A;J-K>7WC'Q5;V\7B;6-B
M^3%(\XTO3HU00:9%,[LC;65KB[DMUAAGO)9&".D<+T ?3] 'Y(?\$8=)N-.^
M'-W+/%)''<ZY=2P.Z,JRQBVM(B\9( =!)')&67(#QNF=RL  'Q8TFXU']IWP
MG+!%))';>&YY9W1&98HR-6B#R$ A$,DD<89L O(B9W,H(!^A_P 6?@IIWQK^
MQ0:Q)<2Z;:7 N)M,5D%G?.F#"M\AC,DT43@2I!YB022!3-',J(J@'D'[4O[;
M_A+]D?[+%KKW%Q>WF6CLK)(Y;@0C<#/(LDL2)%N7RU+,&D?<(U<13&, _)#]
MH[]O#P+^T3<:?J?A6R\2:=X\TZ15T/4+>RM'DDD=B%L9XTO':>WF9VC\O9(4
M,C[8Y8Y9[>X /U?^/7QTT;X0?#ZSU7XH:='.UY'80WVE16T5Y')J#H)Y($CE
MD> I$\4LJM+*4 A!61Y3&' /S@^(7_!4WX<ZCX%U#P=H>EZY;1R:'<:58++#
M;&.)6M&MH \AOI)2B@J&8^8Y )^9NH!]7_#?X::C\(OV<;S2-53RKU/"^MSR
MQ%75HOM<5W=K%(LBHZ2QK,J3(5^2574%@ Q /F#_ (F/@O\ 9)_Y>+*X>W_V
MX7:WO-<_X"QBGMYO]R:"7^*-^0#]/_AOXX\/?MR^"WNY]+N#H&J^=!]GU!85
M:=(I-C2J+>>8Q[9481.6BG26+S4"XBD8 ^+_ -C"Y\8_LH>)4^$'B&RDU#1G
MCN[S0=;M8,1+;JQFG%SC(1#)( P=FFM[J>.'=/;7-K*@ ?!;2;B;]IGQM>+%
M(;:+0[.*28(QC226#2FC1GQM5W6*5D4D%A'(0"$;  ?\%E=)N-?\"Z19V<4D
M]S/XDLXH88D9Y))'M+U41$4%F=F(554$L2  2: /UOH ^(/VI?V_O"7[).HV
MNE:W%J%S>W5N;D164$;^7"7:-'D:::!/G9) JH78>6Q<(&C+@'0?L#_#34?A
M%\,] TC54\J]2WEGEB*NK1?:[B6[6*19%1TEC694F0K\DJNH+ !B ?$'[%5]
MH?[*?PU\=1>)6^W:1HGBC5K"Z_T8/]L5(K.S$?V=F=/](8K'Y<C&)?,Q)((P
MS@ S_ ?_  5L^%'PPL$TO1M$URSL8Y)Y([>*ULQ'&UQ,]Q($7[>0B&21RL:X
M2,$(BJBJH /;_P#@D9\--1^'?PU6?4$\K^U]0GU&VC*NKBW>*""-G5U7'F?9
MS-&5WH\$D4@8[R% ./\ ^"<VDW$/CKXK7C12"VE\2-%',481O)%=ZBTB*^-K
M.BRQ,Z@DJ)(R0 ZY ,_]E?XU_P#"D-1^+G_"0Q_9=-T7Q!<ZP-R^5<2_V@]Q
ML1/.DCC?STMK;[$OR>:\XQ(ZRQ[0#V#P)X-\0_MAZY9>*_&&GW&A>'=!U"2Y
M\/Z)+YT%]=7$918K_58_,V)Y+1N]K"J*^99%:26UP]Z <?\ MO\ [='AKPJ-
M;^&<=KJE_P"(=1TN:QB2SM5DC6ZU*V9+:$[Y8Y7<B:)SY$<PQ(JJ6E#QJ ?8
M&D_!"XF^&D7@6\N(XKD^&TT::YB5I8TD-B+1Y45O*:1 V74-Y98  ["> #P_
M_@EQ_P DA\/?]Q'_ -.5W0!]_P! !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MF=JJ  %[I-OJ+PRSQ1R26TAE@=T5FBD,;Q%XR02CF.22,LN"4D=,[68$ T*
M"@ H S],TFWT5#%:Q1PQM)+*4C144R32-+*Y"@ O)([R2-U=V9V)9B2 :% !
M0!GZ9I-OHJ&*UBCAC:264I&BHIDFD:65R% !>21WDD;J[LSL2S$D \ ^%_P0
MN/ OC/Q=XJGN(WC\12:2(+=%;=%'IUD("TCG +R2/)A%!"HB-YC-(R1 'T?0
M 4 % &?I.DV^@6\5G9Q1P6T$:10PQ(J1QQHH5$1% 5450%55 "@   "@#0H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0/%/Q5T/P7H<GB:_O[>+18K=;DWH</"T+@&-XV3=YOF;E$*Q[VF9T6,.SJ"
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M\*OB7IWQDT.P\0Z4^^RU"W2>++(S)N'S12>6SHLL3;HID#-Y<J.A.5- '/\
M@;XZ:'\2=<UGP_I4_P!IN]!^RKJ#I@PQS7)G @#@_-+'Y#>> -L;,L98RK-'
M$ >8> _VX_ASX_L$U&+Q%I=I')).B17M[;6MQMAF>$2-!+*LL:2A/-B$BHYA
M=&9$8E  >G^%OVA?!OCF\CT_2O$&CWU[-N\JVMM1MIIGV*7;9''(SMM569L
MX52QX!- &?XD_:7\%>#-4N-%U37]+L=1M8X9)H+J\AMV19PQC&9652Y5=[1@
MET1XI'54FA9P#T#P5\0M&^)5NUYH>H6>I6R2&)YK.XBN(UD"JQ0O$S*'"LK%
M2<@,IQ@C(!V% 'A_QL_:*\-?L]I8/XAO8[5M2O(;2U1F4,S22(DDS;V54MX%
M<2W,[E4B3 R99(HY #0\+?M"^#?'-Y'I^E>(-'OKV;=Y5M;:C;33/L4NVR..
M1G;:JLS8!PJECP": .0^,W[6?@[X ZII>C^(=1CM;O59-L2GE88R&"W%TV<0
M6[2*(5E?@NQ;_4PW,L(![_JVK6^@6\MY>2QP6T$;RS32NJ1QQHI9W=V(5450
M69F("@$D@"@#G]3^(6C:+I8URZU"SATEHXI1?R7$26ICF*B)Q.S"(I(701MN
MPY9=I.X9 #P5\0M&^)5NUYH>H6>I6R2&)YK.XBN(UD"JQ0O$S*'"LK%2<@,I
MQ@C(!Q__  O[PO\ \)1_PA?]IV__  D/V?[1]AR=^S&[;NQY?F[/WWD;O/\
M(_?^7Y/ST >H:MJUOH%O+>7DL<%M!&\LTTKJD<<:*6=W=B%5%4%F9B H!)(
MH \OUSX_>%_#&AV/B74-3M[32-2^Q_8[JX)A67[:%:WP) KKN5O,?>J^3$LD
MLOEQQ2,H!S__  UC\//^AK\/_P#@VLO_ (]0![AI.K6^OV\5Y9RQSVT\:2PS
M1.KQR1NH9'1U)5D92&5E)# @@D&@#0H * "@ H * "@ H * "@ H * "@ H
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M+-)TB>8%XY)-/NVF::V9XV5BA90R'.^$M(8FC,LFX ]0_P"'7'PA_P"A>_\
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M&Y\/WDV@:-9ZC=PVTMLMNH_M&^CCFNF0O>32-;B>.*)_LMI'$6R\R  ^</\
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M]F/0;J:VVZEHN_5H@D*W$S6-]=SNP$D;%H8C;W,-[.?F"K;*)41D+1 'T_\
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MSXZ?:]4\>?:-2U^^\[;<QWLZ)ID+Y\BSL$010M%:@_)+/;EKJ<RW,T0\YH4
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M.X[B71;:WN6TW11/<6T3//>W,_\ :=QY0MY6EDBE6*TCWRP1VNZX1V:^9(
M^#_P._X8;^-MII&C"X?PSXRT^]%M$]QA;6XLE-VZ%=SO<>0J!())EC=8KYE\
MV5XIFE -_P#;M_9)@_:)\6V/_"&G^S?'-I;Q:C=ZB3<6]H+-)##:--<00RD:
M@98C]B*8D-O:W/F-MAM  #D%_:(O_P!HWP'XE^&WCC2I/^$_M(X;!-.CDAAE
MU*[D8-97D$0FB!2"2..\OGB+6:VJ?;%8VLOD1@'I_P"V!\)_AQ\#_ .CWGCV
MRN-?ET+3[31M,C2ZO;1;FX2# Q%!<>3;>:(&DGF8.XBB5-T[QP1, >H:M_P2
ML^$FHV\L$6BR6TDD;HD\6H7QDB9E($B"6XDB+J3N42)(A(&Y&7*D \?_ .",
M.K7&H_#F[BGEDDCMM<NHH$=V98HS;6DI2,$D(ADDDD*K@%Y'?&YF) /UOH *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M+=<M9-:L[C3DN)9+E8X6O(FMQ([2Z=#$J(9-S&22)  2TB+E@ ?K=\)_ O\
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MA$D;H(E+;5FC:@#S_P#X)9Z_XJTOPPGA+7/#5YHUMHD<A2]OA<027DEY=3W
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MENCI%&LVUIVE*LX58U<^<( #]/Z /RP^"W@#5)?VB/&WB$6TG]DQZ79V+79
M$9NI+72IEA4D@NXCC9WV!A&#'O*^;%O #_@K9X U3XI^$-$T71;:2\U&\\26
ML<$$8&YF^Q7Y)))"JBJ"\DCE4C16D=E168 'UA^U+\?M6^ 6G6MSHGAS4/$U
M[<W!C-I91W!\N%49GFDEAM;E$PWEHL;A&DWLR%A%)@ ^7_\ @F[\*M<T:7Q;
MXUU^PN-(N/%>L27,.EW*%9H(8Y;B4.Y;9)\SW4D:K)#"Q6 3 -'.F #R#]@K
MXC^*/@M\+]0TUM)N-9UK1O%%SHMGI$&%V.SV[SQRW<$4T4,44LUU,]W<$P#
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M!\(?\%,=)N-?^%.MV=G%)/<SR:7%##$C/))(^IV:HB(H+,[,0JJH)8D  DT
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M^BWGAN.^L[;3K?3KQ&\R1ECM1+('E2WEV(+2+!, 20W#*LA:WD! .@_X) >
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M%O &J2_M$>-O$(MI/[)CTNSL6NR (S=26NE3+"I)!=Q'&SOL#",&/>5\V+>
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M;/ &J?%/PAHFBZ+;27FHWGB2UC@@C W,WV*_)))(54507DD<JD:*TCLJ*S
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M*7,@!]G_ +&_[,^J?#:XU7QIXODCG\8>)9!->(F)(]/@W%DL+>9VDE**"BR
M2M"!!;PQ[TMEGE /N^@#X@_:E_:N\0_ ;4;73]!\%ZQXF\ZW,\]S:),MO#EV
M1(A)#:W6^7Y&:1&$?EH8F!?S"$ /0/V+_@Y>? +X?Z)X=U!LWMM;O)<KA1Y<
MUU-)=20Y1Y$?R6F,/F*Q639Y@"A@H /B_P#8WMKC]DWP'XT;3M)U35X],\6:
MO#IEI#$SW5_' UM8Q.I2,!T$D;"XFBC81B*=A$S1&*@#T#]E:X\2_'SQU??$
M;7_#]YX7CMM#BT&WL+S<TERS7;7LMP#+%;2HD8\J, PLDAD;;-NBD0 &A\;O
MAIO^.G@'Q#;)<2ROI^N07>U=T,-O:6S^5*VU<Q[I=1,3.[;&9H$4*Y^< _1^
M@#Q_XU_&>S^!^G1WUS::AJ$MQ<+;6MCIMJUW>7,S))*4BB4J/DBBFF=G9%$<
M3\E]J, > >#? GC3XZ:QI^N>/;+3]'TO2;C[;IF@0R1W]Q]N$<ENEQJ%X4,)
M\@-)/9I9A"'GC>5Q+:J' ./_ &R/VM_#7A<7OP[%IJFNZ[K&EWL#:=HT:RW$
M2SVSA5E<[S"[QLTHV0W+Q0KY[VYC:(2@'A_[)_[&OCG4H/#C?$V]VZ;X5Q+H
M^B0W+2O]LCN)6AN=0F1WC?[.GEI9Q0R/&D CC(A47,-T ?K_ $ ?EA_P5L\
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MRR1LKH<,K*P! !]7_P#%+_LM>%_^7?1_#VCV_N$B0'_@4DLLCM_TTGN)Y/\
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MW!2Z;95!BD1V /U/H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@#/O=)M]1>&6>*.22VD,L#NBLT4AC
M>(O&2"4<QR21EEP2DCIG:S @&A0 4 % !0 4 % !0 4 % !0 4 % !0!GV6D
MV^G/-+!%'')<R"6=T15:601I$'D( +N(XXXPS9(2-$SM50 #0H * "@ H *
M"@ H * /'_VA?"UYXY\&^(-*T^/SKV^T?4;:VBW*F^::VDCC3<Y5%W,P&YBJ
MC.20,F@#D/V1?@A<?LX^"-)\+WEQ'=7-E',9I8E98S)<3RW#JF[YF1&E,:NP
M0R!0YCC+;% /?]3TFWUI!%=11S1K)%*$D17420R++$X# @/'(B21MU1U5U(9
M00 :% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MMK/R(EU"[ADBMY;F1@'B(*[XH@KQ/'=RA;:5/-D\Q(5@FN0#T#]HW]M?PO\
MLP:QH^DZ]-Y?]I_:))YES)]CMX8V*32PPK+<-YTP2"$+&$;$\AD'V<HX!X?K
MO_!63X8:=?Z?:VNHR75M=23"\O!:7D<=E''"[HS(]OYTSRR^7"B0HP4-)+))
M&(U64 ] ^(?_  4)\)_"[QCIGA/5DO+./4;..Y.HW=O+:6]NUQM-JDJ7*1RA
M& D6>8J$M)@L4N&6[-H >W_M._M"Z=^R_P"%[OQ+J">=Y.R.VM1*D3W5Q*=L
M<*%S]9)"JR/'!'+*(Y/+*D \ _X>C_"'_H8?_*=J7_R)0![_ / O]J/PA^TI
M]L_X134/M_V#R?M/^C7,'E^?YGE?\?$46[=Y4GW-V-O.,C(!X!\)O^"C_@OX
MG^*+WPG*UQI>H0Z@;&Q%]#)#]M9058890;:7S4>);>Z\N5]T 4?:)7MH0#[_
M * /D#XQ_MW_  _^ FN+X>\0:I]GO?LYGE\N":X6#)3RHIOLZ2.DLJN98TVG
M$2%W,8EM_. ./TG_ (*:?"36KB*UB\11K)-(D:&6SOH8PSL%!>66V2*-,GYI
M)&5$&69E4$@ ]@_:J_:8TO\ 90\-2^(=3CDG8R+;V=K'D-<73J[QQ&3:RQ)M
MC=Y)6!"(C;5DE*12 'C^D_\ !33X2:U<16L7B*-9)I$C0RV=]#&&=@H+RRVR
M11ID_-)(RH@RS,J@D 'T?\=/CIH?[.FAS^(/$$_DVD/RHBX::XF8$I! A(WR
MO@X&0JJ&D=DB2210#D/V?OVL_!W[35N)?#FHQRW(C\R:PE_=7D "QE]\#'<R
M(TJ1M/%YEN9"429R* ./^,?[=_P_^ FN+X>\0:I]GO?LYGE\N":X6#)3RHIO
MLZ2.DLJN98TVG$2%W,8EM_. ./TG_@II\)-:N(K6+Q%&LDTB1H9;.^AC#.P4
M%Y9;9(HTR?FDD94099F502 #[OH ^?\ ]H+]IWPO^S#9VU[XFN_LZWEPD$$:
M(99GRRB641)ES% K>9.X!VKM10\TL,4@!X!_P]'^$/\ T,/_ )3M2_\ D2@#
MZ/U;]H?P_9>#I?'5I-)J.B1V;WBR643SR21IG<%C #*ZL"DHE\L6Q5S<-"L4
MK( <A^RC^U=H?[6NAC5=*/DW<.Q-0T]W#36DS D D ;XGPQ@G "RJ&!5)4FA
MB //]._;V\+S_$6Z^'-VMQ8WL/E16]U=1F&&YO'RS6R"0*Z[E:(VLK 1WC,Z
MQ'!M6NP#T#X^?MC>"_V9[RQL?$U_]GN+_>RI'%).T4*JY\^9(E>1(F=/)C(5
MFDE8[5,<5Q)" >/_ /#T?X0_]##_ .4[4O\ Y$H ^O\ Q3\5=#\%Z')XFO[^
MWBT6*W6Y-Z'#PM"X!C>-DW>;YFY1"L>]IF=%C#LZ@@'G^O\ [4_@OPQX7M_&
MEWJ]NF@77EBWNP)'\UI"5$:1(C3-*I5Q)"$\V'RY?,1/*DV@&A\$/VD?"?[1
M]O<77A74H[^.TD6.X CEADC9UW(6BG2.4(P#;)-NQRDBJQ:-PH![A0!^>&K_
M /!3OX>>%?$NL>'M6O)+)=(DCM_M3VUU*MQ=*TR7<4<<$$C*ENR1H99"HF=W
M\M3%&LLH!]/_  0_:1\)_M'V]Q=>%=2COX[218[@".6&2-G7<A:*=(Y0C -L
MDV['*2*K%HW"@'B'CO\ X*,?#/X::Y>^']5UCR;NP\M9G2VN+B'SF+B2 /;1
MR_O8=J^>" J-(L89I4GCA /?_@Y\?O"_[0%FU]X8U.WU"),>:L9*S0[F=%\Z
M"0)-#O,;F/S43S%4NFY,,0#P#X#_ +>WA?X\>*-5\)0+<6&I6%Q+%:QWL9@>
M^2 8G:.*0+)%+&ZR;K64+.(%68J&%S%; 'M\G[17AI/&,?@07L;:Z]G)=M &
M7"*GEE86)8$W$D;M<) @9Q;Q23N(XS$T@!@:5^TQI>O_ !!N?AY9QR27UAI;
M:A?3G*1PL7M1#;J"N97>.Y$SNI"1CRT!D=I%@ /C_P#X*&?''2_&OP\\8Z;X
M<UF0:CH,FG0:M%:9"[;VZ6W:TFF:,JR,IE6=+>0.KQ&WF8(9H) #U#_AZ/\
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M$IYB@*^W<!@B@#V#]J']LW0_V8=#T[7YX;C4[34[B".V>Q DA:&0"5YA<_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <?XU^'NC?$JW6SUS3[/4
MK9)!*D-Y;Q7$:R!64.$E5E#A690P&0&89P3D _)']@S]FSPSX?UCQMX(U[P[
MI]_+H&L1RVE[J-O9WMQ)8W\;&S1F\DA<16Z3D*P&^Y93#"Z,& ,_]E_P!I?P
MP_:2\8:7HUM'9V,>AB2.WB!$<;7!TFXD"+DA$,DCE8UPD8(1%5%50 >__P#!
M3GP!I?Q:\/Z5X<%M'<>*-5U2"UT%\$R6S,Z/?7,GEDS"RCMT;[6R1S)&6MY'
MCRD<D8!](>#_ -D'P;I&DZ=8ZKHNCZM>V.GV5E+?W.EVSS7'V.WCMED<R+*X
MRL2A5+OL4! Q"B@#\T/BQ\$/"NG?M&^$]#@T32X])N=#GEGL$L;=;6601:L0
M\D C$3N#'&0S*2#&G/RK@ ^G_P#@K)X TOQ-\,-1U2\MHY;[2I+22QN"")(&
MGO+>WF"L""4DC<AXVRC%8W*[XHV0 \O^/?P+L_C+^SQI-RT%NVI:-X7TW4+*
MYEW*T*P6=O+=JCH"Q\VWCD01,#$\HA9MK1I)& ?4'[/WP:^'GQD\):+XA;PO
MX7>74-/MI[C[-I5DT*7#1K]HB3Y'*^5+YD3(S,\;(48[U:@#Y _9$^%NG>%O
MC]XXF\,V]O%H%AI\=JXMI$,,%Y=FSF>!$#DKB6WO T:#R[9HC!B+$<= '7_\
M%&_@-I?[3OB#POX3L(XXO%%S)-//J*QF0V6B0(YF:Z2-PY22=T6Q\U1$]P)H
MEN(#+(7 /UOH _-#XLW7@6S^*F@^!7\'Z'=7VO1WFI:CJ%SIEH[>6(;V1-A,
M9>2XEGMV>:27A4& )'F+P 'G_P#P4J_9H\%>%?AAJVJ:9H&EV%]926,EO<6=
MG#:R*TEY#;N"T"QET,<S@QR;DR5?;O1&4 ^L/@1\)_#WQ0^'G@[^WM*T_4_L
M_A_3/(^VVD-SY7F65OO\OSD?9NV)NVXW;5SG P ?'_\ P4W_ &6_!OA_X9ZA
MJ^E:-I^EWNFW%E/%+865M;-)YEPEHT4K1Q!VB*W#/L#+^]CB8DA2K &!9?$_
MQ'X)USX;^)M5T;4/$.BW'@^PLXKR)()IK76M5-M'+</<7#)LEN/]$M3)=3VZ
M.MQ,8Y687$<@!X__ ,%1OV<-#_9RBT3X@^#;:WT;4H-8AC>.VA A>98O/M9D
MA+&VB\DV9W1I"%G:8O(2RG> ?9_Q9NO MG\5-!\"OX/T.ZOM>CO-2U'4+G3+
M1V\L0WLB;"8R\EQ+/;L\TDO"H, 2/,7@ //_ /@I5^S1X*\*_##5M4TS0-+L
M+ZRDL9+>XL[.&UD5I+R&W<%H%C+H8YG!CDW)DJ^W>B,H!]W_ +)W_)//"G_8
MOZ3_ .D4- 'SA_P44\;>%?@CX:/BC5_#6EZ]JTLD>FZ>U]96\ZI(ZS3)YTDB
MF46\8263RXR"[D(#%YC31@'T!JW['?PYUJWEM9?"NAK'-&\;F+3K:&0*ZE24
MEBC26-\'Y9(V5T.&5E8 @ ^#_P#@BI_R3S4O^Q@N?_2*QH Y#]E_P!I?PP_:
M2\8:7HUM'9V,>AB2.WB!$<;7!TFXD"+DA$,DCE8UPD8(1%5%50 '_!:_P!I<
MOA72O$)MH_[6CU2*Q6[ (D-K);W4S0L00'021JZ;PQC)DV%?-EW@'T?^V-X@
M\&_#WQ#X9LK[PKH^K:UXMUBULFO;S3[:;R[>.:U@GDDD=#+)*(IHX[=2=B_?
M9ML*PS '0?M6_LI> ;;P#XDG@\-Z/;7%MH]_<P3VUA!;31S6T#SQ.DL")(,.
MBEE#;77,;AHV92 >?_L&_#33OC)\!--\/:JF^RU"WU2"7"HS)NU&[VRQ^8KH
MLL3;987*MY<J(X&5% '/_L#_ +(^G:SX$T#4O&EE;ZG+_9\HTVQNXTN+2TL[
MR[EOA,L#O-"UW<B6-Y;@+'(MNEM:^7&\4[S@'/Z5\"[/]D[X\Z+/X;@M[?2/
M&6GZK;S6GS'[--:1B]G-LBA$AB=H[4QH6E5=US&L<,8@" 'Z_P! 'S__ ,,G
M?#S_ *%3P_\ ^"FR_P#C- 'YH_LD>"K?X-_M#>-?#FCM)#I+:7]L%HI5(%DF
M?3[A0L4:I$$@-W/%;#;F*%B@8[G9@#]+O^&3OAY_T*GA_P#\%-E_\9H _+'P
MY\+[?]F/]IFPT[PYY=II?B/2[FXFLHH56.*-H+J1X$W%]J&YL$N5\KR1&&%N
MB+"F' .@_P""A'@#2]"^*_PSUJUMHXM1U+7(([V= 0TZVEYIP@,@!VLZ+*Z"
M3&\ILC9BD42H =_^W+IC_![XF^ ?B1&8TMOM@T/49[J6-+6W@N#($DP6C=7\
MFYOY&E9FAC,$1<*,K* >P?LW_!VXU_XD>*OBC<V]Y8VVJ1P:=I5O=QM;7$EO
M;QV\5S<S6LB":%));2,V8E,4S0^8\EN@>(T > ?\$_? %E\3->^*.HWMM9ZI
MX<U;Q(T<#2""ZM;IK:ZO+DD1DNKHJW-K+'(5V,75HV8HVT ^[_%G[*7PQBTZ
M[;4/#?A^VLA;S&YN/L%K:^5"$/F2?:$2-X-BY;SE=&BQO#J5#  ^7_\ @D9\
M--1^'?PU6?4$\K^U]0GU&VC*NKBW>*""-G5U7'F?9S-&5WH\$D4@8[R% /O_
M ,=?"?P]\4/)_M[2M/U/[/O\C[;:0W/E>9MW^7YR/LW;$W;<;MJYS@8 /S@_
M;)_9^\)?#K4? .JZ)HNGZ;>CQQHML9;*VCM=\,SO(Z2+"J))\T$95G#-'A@A
M422!@#[_ /C-\!_#WQ[TZ73]>L;>YW6]S!!<O!#)<6GVE-CRVLDT<GDRC",K
MJ.'1&(.T"@#\X/\ @FW\"_#/BWP7/IOB;PKH[ZUH&L:CI-[/<V=G=S330R+.
MQ>4Q-GR_M'V=0'E4K"&5]K!5 .0_X)F> -+T7Q5\5/#T5M&VDPZI%8I:2@S1
MFU2XU2$0N)2YD3RQL;S"Q<9W%LG(!^EW_#)WP\_Z%3P__P""FR_^,T ?EC^Q
MC\+[?X+?&GQS\/+?RY_#D^EFX>REA5XVC=K62W@?SC,\B0PZA-;-N<BX!,DB
M$E0@!^G^K?L=_#G6K>6UE\*Z&L<T;QN8M.MH9 KJ5)26*-)8WP?EDC970X96
M5@" #P__ ()<?\DA\/?]Q'_TY7= 'T_\>++P]_PCU]J'B?3;?5=-TJWGU&2V
MGM8;K_CUAD=FBCG_ '?F[-ZH25^\5+*K$T ?*'[)/P]\"_M'^#+#Q5=>#/#=
MI)?R7I%O'I=HZQQPWMQ!$I=H07<1QIYCX0.^YECC4A% /F#]E_P!I?PP_:2\
M8:7HUM'9V,>AB2.WB!$<;7!TFXD"+DA$,DCE8UPD8(1%5%50 =__ ,%&_@-I
M?[3OB#POX3L(XXO%%S)-//J*QF0V6B0(YF:Z2-PY22=T6Q\U1$]P)HEN(#+(
M7 /K#]LG]E[2?VB?"^K1?V;;SZ^=/==.NQ%;K>": FXMX$NID)BBDE'ER#<B
MF.64;DWEP ?/_P"Q?\"_ /Q]^%^B7VH>%='$MSI[V=S+]C@-Q(UJ\EE)<?:D
MBCF268PF;S%82QN_$K.HD(!Y_P#\$5/^2>:E_P!C!<_^D5C0!P'[.OPJT/P?
M^T3XU\/V-A;Q:0_A]@UCL#6Y6[&E2SQ^4^Y/*=I9/W('E*C>6J+&%0 'Z??\
M,G?#S_H5/#__ (*;+_XS0!^</_!%3PGIW_"&ZEJ_V2W_ +2_MBYM?MGDI]H^
MS_9K&3R/.QYGE;_G\O=LW_-C=S0!G_\ !0CP!I>A?%?X9ZU:VT<6HZEKD$=[
M.@(:=;2\TX0&0 [6=%E=!)C>4V1LQ2*)4 /I_P#;C^%.C?M27&E_#YHH_P"V
MYX[C48]3'E/)H]G;M&DD[0>=#-,EW*T5DD(/EN3)<DEK!10!\P?"KXF^)?V.
MKBZ^%/CV"/7M-NK.6+PC<2JPCU9G9+>'1G9HYXHTD,JQ,+HA+ 9C=YK*2T90
M#]+OV6/@I_PSMX+TCPPTGG2V-N?M$@;>IN)I'GN/+;RXB8A++((=R*XB"!LO
MN) /4/&OP]T;XE6ZV>N:?9ZE;)()4AO+>*XC60*RAPDJLH<*S*& R S#."<@
M'Q!^V!^R+X%F^'WB.6ST'2]/N;72[J\ANK+3[2WN$DLT-T@658=RH[1".4+@
MM"[H&4MN  ?\$]]6M]:^"FD2^(98YK%;/4HKM[YU> 6<-W=1%)C,2@MXX$$>
MU_W:0J$P$7  /'_^"<W[+6EVNB>(-;NK&-O#GBZ\2?3-%O[8RM#IMI<7+V+7
M*W!D61W61)(^95V)#.MQ*9?W8!]P:M^QW\.=:MY;67PKH:QS1O&YBTZVAD"N
MI4E)8HTEC?!^62-E=#AE96 ( /S _P"":GPY>6W^)OPPO[R2;2;2\DT_S(HX
MX9"URM[87-PFX2E7DCM82J.TJ1E!@'+EP#R_X/6NN?%3X.:A\'8[/=XDMO$$
MFD^7$I>&PA@O(=1GNM4N4:2*&(2B[AA=,M=-$(K:&X>.9@ ?0'_!4'X;Q:1\
M//!_@+17\^].L:9I^F6\TT2W%PL%E/:(Q)\I#AI8%EEPD2/*F[8'44 >W_MY
M_ 9_'_B#P'KFC1QKXAMO$EI;1S/'&T?V5$FU&1[A=\,LR6PLWECA6>(D27")
M^]F5@ >P:M^P!\/M?\/RZ%>:7'/-/&XFUF54?6)+AW,KW;Z@R&9KAI296+9A
M;)B,)MSY- 'R?^QI9:=X?^%6NZ1XZTW3]6LO >L:Y T0M4NED^P(;N:6-;O"
M-*6N+A(7*P?NBBL$)=F /</V2?A[X%_:/\&6'BJZ\&>&[22_DO2+>/2[1UCC
MAO;B")2[0@NXCC3S'P@=]S+'&I"* ?,'[+_@#2_AA^TEXPTO1K:.SL8]#$D=
MO$"(XVN#I-Q($7)"(9)'*QKA(P0B*J*J@ _:Z@#\8?VL/V;/#/PF^(O@/Q%9
M^'=/DT74-0_L+4;!;>SBL3->;H[.9K80GS)1YUQ,S,KJPM((]T#;'8 \_P#^
M"O7[/WA+X=>#=,U71-%T_3;T:Q';&6RMH[7?#-;7,CI(L*HDGS01E6<,T>&"
M%1)(& /H_P#X*<_!VX>PTKXE:';QS:WX/O(+QT:-G$]G',DI$HB3SI$MY56;
M!EACAMWO9-P9@: /(/\ @JO<V_QO^&GA37-*LI)KG5-4T]M/0P*]YY>HV-Q*
M+=1'YC;Y&6 /%$S!Y(X_OE$- 'Z?:M^S)X%U^XEO+SPUH<]S/(\LTTNF6CR2
M2.Q9W=VB+,[,2S,Q)8DDDDT ?EC\$?A/X>LOVE?$^GQ:5IZ66GZ/:W5E;+:0
MK#:W"II#K/!&$V12AG=A)&%<,[,#EB2 ?1__  5D\ :7XF^&&HZI>6T<M]I4
MEI)8W!!$D#3WEO;S!6!!*21N0\;91BL;E=\4;( >0?&3QMX5^"/P8\*^*-7\
M-:7KVK2Z'HNFZ>U]96\ZI(]@9D\Z213*+>,)+)Y<9!=R$!B\QIHP#[_U;]CO
MX<ZU;RVLOA70UCFC>-S%IUM#(%=2I*2Q1I+&^#\LD;*Z'#*RL 0 ?!__  14
M_P"2>:E_V,%S_P"D5C0!^O\ 0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M7P+USQ?\?M#\600;=%T;P^5N;J3*J\TYU.%((>#YDH\Y99 ,+%$ 796DA24
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M%]HF,O2!F:!//1(0#L/V.?A#JGPH\/W,^OK''KNO:I>ZUJL$+A[>WNKYP3!
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MR?##7'OA>ZC)81V]X\%HTEI>2M=VZ1QD706&W<0H\C2I'%(WG;(UD=(VD\I
M#V#P!_P4+^&'Q/U2VT;2]>CDOKR016\<EK>6ZR2$':@DN((X@[$;8U+ R.5C
M0,[*I #]I_\ ;@\/_LHZIHVG:W!>-'JLC^;=1PN8+6W0;6E+;<3NLC1^9;P%
MIHX6:9EW&VBN0#V_XI?'30_A)X7N/&%]/YVD06\=PLUKB?SUF*+ ("AV/YS2
M1K&Y98OG#M(D>YP ?('A/_@JQ\+=7TZTN=0U?[#>S6\,ES:?8]0F^SS.@:2'
MS4M DOEL2GF* K[=P&"* /J_X(?M(^$_VC[>XNO"NI1W\=I(L=P!'+#)&SKN
M0M%.D<H1@&V2;=CE)%5BT;A0#R#XF_\ !0+X>?!KQ!>>&M?U*2SOK*.W>4FS
MNI8RUPAD$:M!%(2ZQF*1R0$Q-&JN[K,D0!Z_\$/VD?"?[1]O<77A74H[^.TD
M6.X CEADC9UW(6BG2.4(P#;)-NQRDBJQ:-PH![A0!GZMJ::+;RW4HD:.&-Y'
M$44DTA5%+$)%$KRR/@?+'&K.YPJJS$ @'R!^R1^W'X:_:]2[CTP26>HV<DA>
MPN2OGM:^9MANDVDJR,I03*I8V\S>4Q9&@FG .@U/]M/P=HOCP?#JZN9(=9:.
M(B22/9:FXF59(K03,P)N)(W22,;?)<LL*S&Y80D ]_\ '_C_ $OX6:7<ZUK5
MS'9Z=9QF2>>0G:JY    +,[,0D<:!GD=EC16=E4@!\/?&MO\2M&T_7+-9$MM
M2L[>\A24*)%CN(EE0.%9E#A6 8*S '.&(Y(!V% !0!^<'_!1[QE_PKBS\(:O
M<ZA<6>EV_C#2#J44?,,MO$SW9>94C::3R3;!XXT;8S$LT4LJ0-$ =!_P]'^$
M/_0P_P#E.U+_ .1* /#_ -I']IKP_P"'_&?PV\9OKLC>#[F/7)F,:O):B1+(
MV\4YAAA-P;C?=-;R+*&-N0R".!S=&0 ]P_X>C_"'_H8?_*=J7_R)0!T'[1/[
M>WA?]F^\T"'4%N+FRUW]Z-0MHS):0V97BY2504N?F>(M%;EY%MV,Y&6MHKH
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M_M,:7\!KW0-+NHY)]1\1ZI;Z?90IE5"O/#%/<22%2JI"LZ$)R\KLB*%0RS1
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M!M6NP _:U_;MT/\ 8_O-+M-7L=0N_P"T?.=GMHAMBAB4C*/*8XII3*8E:!)
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M H!)( H ^,/@I_P41^'7QVU&32M/U/[->BX:&VBOD^R_; 'CCCDM6<['\YI
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M6+Q%&LDTB1H9;.^AC#.P4%Y9;9(HTR?FDD94099F502 #[OH * /B#X^?\%
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M(K6+Q%&LDTB1H9;.^AC#.P4%Y9;9(HTR?FDD94099F502 #W_P"/O[0_A_\
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M&=E4@!^T_P#MP>'_ -E'5-&T[6X+QH]5D?S;J.%S!:VZ#:TI;;B=UD:/S+>
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MM7PKK]U]FVZ>;NXNU62=89GD18+1HK9)I1+)$9+AC(L2QQ" CS/M V '/_\
M#T?X0_\ 0P_^4[4O_D2@#[?\)^*;/QSIUIJNGR>=97UO#<VTNUDWPS()(WVN
M%==RL#M8*PS@@'(H Z"@#XP_:(_;J\)_LR^(-*\/Z[))')?QR7%Q.(I7CL[4
M),(I6$4<CRO-/$($BB4E1YDTC1JL:S '0?"']N+X>?'?5%T7P]K4=UJ+QO)'
M ]O=6[2+&,N(S<PQ+(X7+F-"S[%>3;LC=E ,_P#:-_;7\+_LP:QH^DZ]-Y?]
MI_:))YES)]CMX8V*32PPK+<-YTP2"$+&$;$\AD'V<HX!Y_\ \/1_A#_T,/\
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MI?[5WA]O$&E1R01I>7-K)!+GS(FB?,>\[0A>2!X)V6)I$C,IA\V1HV:@#/\
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MCP!I>A?%?X9ZU:VT<6HZEKD$=[.@(:=;2\TX0&0 [6=%E=!)C>4V1LQ2*)4
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M5F4,!D!F&<$Y /B#]L#]D7P+-\/O$<MGH.EZ?<VNEW5Y#=66GVEO<))9H;I
MLJP[E1VB$<H7!:%W0,I;< #G_P!@7X>Z-\:OA)X7E\4:?9ZU):QW\5N^HV\5
MXT,:WT\2I&;A9"B".&*,*N $BC0#:B@ !^V_^Q=X*UKX?:W<:9HVEZ3?:;9S
M:C;W=G80P2!K-&F>,F#R2Z2QJ\)$A=$+K-Y;/$F #Y \3>"K_P#:*_9;TR\G
M:2XOM#C>\@"&&)3;Z7<W-D1("JADAL/,8!2LTCQ(=TCEED /?XM)N/V[_$'P
MZ\1"*1++P]9IK&K7T*-#9OJ%PEK+%8V,DHE^TO#<VK+>JA9+:,- ]REY^[
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M&O[0U3^SO]7_ ,?G]F6GV?\ UW[K_6[/];^[_O\ RYH ]O\ V4OAUX:_:?\
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MBKQ1H5GKT>D:Y<FWM[FVMYV\RY@TR!51[A'$*/(T7G.H8A%W".5D5" ?J_\
M!#X">!?B5X5T37+SPEX;2YU+2[&\F2+2+01K)<6\<KA T;,$#,0H9F(&,L3R
M0#XP_P""6WA:S\#>,OB=I6GQ^396.L06UM%N9]D,-SJD<:;G+.VU5 W,68XR
M23DT ?L]0!S_ (I\)Z=XYLY-/U6TM[ZRFV^;;7,*30OL8.N^.0,C;6567(.&
M4,.0#0!^0/P._9L\,^ OC-XM\)ZEX=T^]TW4M/M]=TF2\M[.X6VA$WE3PV\'
MDE88C<7,L4:_NF2*SB!65626@#G_ !%\*M#^$W[3GA6#0+"WTZWN]'N+F:"V
M010F;[)JD!=(EQ''E(8PRQJBLP,A!D=V8 T/^"U_@#2Y?"NE>(3;1_VM'JD5
MBMV 1(;62WNIFA8@@.@DC5TWAC&3)L*^;+O /U>\:_!#PK\2KA;S7-$TO4KE
M(Q$DUY8V]Q(L89F"!Y8V8(&9F"@X!9CC).0#\<?^"M'P'\/?!_P]H?B?PQ8V
M^B:E::PD$<FF00V6[S89)UE=H(TD,L+VB&!PX\O?*0"S J ?K=^TI>^&M.\'
M:Q/XOACN="CLY'O('*@RJO*1Q%WC N&D"+;$/&XN#%Y;K)M8 'R!^P5^QO;_
M  ^^'-OI/C&RL]2DU&\_MEK&]LED6SDGMHHHXGCN4)%Q'&A$I*(8WDEA&Y5\
MR0 ]P^*O[#'@'XD:'?Z1!H.CZ=<7=N\<%[;:;!%-;38S%,C0"&0^6X5VC$B+
M*H,3DQNP(!^:'[%7@J__ &F/V>?$/A5VDFD@O+V'2X8S#$WF0I:ZE;P&1U"E
M)+QV\QI3G9(RB2-50H 'A/2;C]O;X9> ?!L44A-E>1/K-Y;(T=K8Z?I0N+ 1
M/<R"5!J<\$D$D-LJR.2_VF2*"T>-B >__MYZ8_C;XI?"S2]/,<U];ZI/?36X
MEC62.UAGLKAYF5F!">7:W)3/,IAD2,.Z[: .P\/6?P\\5_%6_P#AS;>"O#Z1
M:3HYO;NZDTFRW27$CV311PA8\")8KDF1G&]Y2%58TBW3@'S!_P %>OV?O"7P
MZ\&Z9JNB:+I^FWHUB.V,ME;1VN^&:VN9'21851)/F@C*LX9H\,$*B20, ?N]
M0 4 ?CC_ ,%.?@%H/@NPTKXAV.A6<TFC:Y!=:S!'%:V\>H6MS,AF^VDQ%[AW
MG6&$,1*5%U.[Q2*69 #?_P""E7[-'@KPK\,-6U33- TNPOK*2QDM[BSLX;61
M6DO(;=P6@6,NACF<&.3<F2K[=Z(R@!\7;;Q!/\$?!#:'I,FNP0Q^%;C5M*CB
M29KW3[>"*=H#&T<SLCSQVPD\J.1PFYF1H!,* -#]KCX$^$OVL?AK>_$&/2?[
M,U<Z/)JUI>RQQK>-##$DZ"Y%I<-%-Y]M L41G>9K6.4$(DBO%0!ZA^P[I-O^
MT'\%-%T[Q1%'J-I<V=Q92Q2(JJUO:7<UO;J/+"%7BCAB\N52)E>-9@_G#?0!
M\X?\$??">G>.?ACJVGZK:6]]93>()_-MKF%)H7V6NGNN^.0,C;6567(.&4,.
M0#0!]'_LD_#WP+^T?X,L/%5UX,\-VDE_)>D6\>EVCK''#>W$$2EVA!=Q'&GF
M/A [[F6.-2$4 ^8/VHOV=?#6G_%[X;V7A2RTO2]1>\EO;Z"V5;=6M=-DAO(W
M>W@7:KNL5Y'#*8U,SKY;R[(08@#H/^"G/P"T'P78:5\0['0K.:31M<@NM9@C
MBM;>/4+6YF0S?;28B]P[SK#"&(E*BZG=XI%+,@!O_P#!2K]FCP5X5^&&K:II
MF@:787UE)8R6]Q9V<-K(K27D-NX+0+&70QS.#')N3)5]N]$90#[O_9._Y)YX
M4_[%_2?_ $BAH ^@* /S0_:L^'NC>,_BW\.(M3T^SO([N/Q'%<I<6\4RS1V]
MBLL"2B16$B12.\D2MD1N[.H#,20#Z0\6?L7_  \\5Z==Z?\ \(YH]I]KMYH/
MM-KIME%<0^:A3S8)/(.R5,[HWP=K@-@XQ0!\7_\ !&'5KC4?AS=Q3RR21VVN
M744".[,L49MK24I&"2$0R222%5P"\COC<S$@' >./ &E^!?VI/#4FF6T=JVI
M:7=WUX(P0LMU);:K'),5SM5W6)#)M"AWW2L#+([L =!_P4Y^ 6@^"[#2OB'8
MZ%9S2:-KD%UK,$<5K;QZA:W,R&;[:3$7N'>=880Q$I474[O%(I9D -__ (*5
M?LT>"O"OPPU;5-,T#2["^LI+&2WN+.SAM9%:2\AMW!:!8RZ&.9P8Y-R9*OMW
MHC* ?6'P(^$_A[XH?#SP=_;VE:?J?V?P_IGD?;;2&Y\KS+*WW^7YR/LW;$W;
M<;MJYS@8 /E_]LG]G[PE\.M1\ ZKHFBZ?IMZ/'&BVQELK:.UWPS.\CI(L*HD
MGS01E6<,T>&"%1)(& /U?H * /B#_@HC:Z'J'PZU.VUFS^WW%QLM]'MHU#7+
MZO/F*Q-HFY)'E5W+ND):1[9;A?+EC+QN :'[/_[&^C> ?!&A^%_%5EI>NW.E
M1W)$MQ913QQR7<[W$RP?:$9@@9ECWXC,PB1VC0D(H!X_^V_^Q=X*UKX?:W<:
M9HVEZ3?:;9S:C;W=G80P2!K-&F>,F#R2Z2QJ\)$A=$+K-Y;/$F #U#_@F]XI
MO/&'PH\.7-])YLJ6\]LK;57$-I=3VL"80*/DBBC3<1N;;N8LY9B ?;] 'A^K
M?LR>!=?N);R\\-:'/<SR/+--+IEH\DDCL6=W=HBS.S$LS,26))))- 'Y8W/P
MTT[X%_M.:%:^'4_L^RUC1YI[JSME2WMOEM+Z/RDAA6-/*+64-PR.'S<@RYSL
M" 'O_AZS^'GBOXJW_P .;;P5X?2+2='-[=W4FDV6Z2XD>R:*.$+'@1+%<DR,
MXWO*0JK&D6Z< ^8/^"O7[/WA+X=>#=,U71-%T_3;T:Q';&6RMH[7?#-;7,CI
M(L*HDGS01E6<,T>&"%1)(& /V>\=?"?P]\4/)_M[2M/U/[/O\C[;:0W/E>9M
MW^7YR/LW;$W;<;MJYS@8 /S@_;)_9^\)?#K4? .JZ)HNGZ;>CQQHML9;*VCM
M=\,SO(Z2+"J))\T$95G#-'A@A422!@#ZP_;C\ :7\0?ASXBCU2VCN5L]+O;Z
MV+@[H;JUMI9(9HV!#*ZL,'! =&>)PT4CHP!\W_L&_#33OC)\!--\/:JF^RU"
MWU2"7"HS)NU&[VRQ^8KHLL3;987*MY<J(X&5% '/_L#_ +(^G:SX$T#4O&EE
M;ZG+_9\HTVQNXTN+2TL[R[EOA,L#O-"UW<B6-Y;@+'(MNEM:^7&\4[S@'/Z5
M\"[/]D[X\Z+/X;@M[?2/&6GZK;S6GS'[--:1B]G-LBA$AB=H[4QH6E5=US&L
M<,8@" 'Z_P! &?JVDV^OV\MG>11SVT\;Q30RHKQR1NI5T=&!5D92596!# D$
M$&@#X _9U^'O@7XW/XE,_@SPW;1Z+XDO]&@5-+M&9X[*. &61C" 7DD>1P%5
M0B%(_G9&ED /E#_@IY^R]X2&G>&--\-Z;H^D:_JWB"WT^V,$4=GYD-RCI*TL
M=N@,L4<IM=\ICE:#>%7;YQ60 ]_O_$>I^&_C1JNG^(_#=QJFD>)M/T_2M&U$
M6]J]O%;1P3W%]9S22[$:*5OMMQ<0O(URZ6L86UN(V@V 'RA^TE\!M+_90^,?
M@#6_!T<>F1ZYJGV:XM(HRT:L]U%#=.@E>1(TF@OS L,*1);B(-%M9AL /8/C
M1\%/#7P\^.OA^^OM+T.31_&5G?6MW#?0K*IU*#]\;E(IAY$=Q<.UG C)N:=Y
M+D&/SYO-D /?_P!L#]FCX<^'/A]XCO&T#0["2#2[J2WN8K.VLY$ND0FU"31+
M&X=IQ$BQAL3%A"5=9"C '8?\$WO"UYX/^%'ARVOH_*E>WGN57<K9AN[J>Z@?
M*%A\\4L;[2=R[MK!7#* #[?H \?\4_L]>#?'-Y)J&J^']'OKV;;YMS<Z=;33
M/L4(N^22-G;:JJJY)PJA1P * /R1_;(^#NC? SXK_#35?"]O'H\FHZI%9W$-
MA'%:0-'%>6JL=END9+S1WLL-P6+"6$)&5"AMX!Z?_P % OA5H?@SQIX+\>W=
MAH[VEQK$6D:Z=00-#/#=1[(9YXWQ;G[+"ERPN)2&C9;7<)8H56, ^X/%G[*7
MPQBTZ[;4/#?A^VLA;S&YN/L%K:^5"$/F2?:$2-X-BY;SE=&BQO#J5#  _)#]
MCC3=!^$'P*U'QGXQ\.V>MVT&J7=UIL-S!:W#2+/]BTX;&F63[.C7,)29BN\)
M%Y@BE B5P#]/_@A\!/ OQ*\*Z)KEYX2\-I<ZEI=C>3)%I%H(UDN+>.5P@:-F
M"!F(4,S$#&6)Y(!\8?\ !+;PM9^!O&7Q.TK3X_)LK'6(+:VBW,^R&&YU2.--
MSEG;:J@;F+,<9))R: /V>H Y_P 4^$].\<V<FGZK:6]]93;?-MKF%)H7V,'7
M?'(&1MK*K+D'#*&'(!H _&']C+X;V?P"^/WB_P )Z&]Q%HL6CI<):O,SJ&<Z
M?,@.?O\ D_:IHH'DWRK$[!I'9Y'< [_X'^$_^&.?C;J7ABWM-N@>.+=K[3)(
MX<+!<6:SSR6H91!#'%$'N@(8DG>.*33P67=(2 'P$\)_V7^TKXWGL[3RK)-'
M@\Z2*';"MQ=IIDYWLH""6=EN)CN^>5EFD^8AS0 ? O\ 8HT[_A._'-E+#CP<
MFL:3<+I_R+#=7B6C7_V26.)HT.GVK:@DBVDD!CF9;,&5EMKB.< P/^"B7[+V
MA_!C3-/^)OA#3=/TW4O#&H6%Q+;Q1"WM+F$72>4'M[=$5Y5N'BRZM S6[3*T
MCLENJ 'Z?>*?V>O!OCF\DU#5?#^CWU[-M\VYN=.MIIGV*$7?))&SMM555<DX
M50HX % 'Y@_M+?LO:&?BU\/;;P;INGZ?>PW$FI:K':1"%(['3KBVGBFGAMT*
M1>8PN+>"=T03SLD#2X1?+ /V>H * "@ H * "@ H * /R \%_MQ_#_PEXY\7
M:MXQU#[!K5OJ#Z#8PM:37/DZ7IK$;HIK:R+#[5=O<SS))(Y&V"/!6"-V /$/
M^"0'[1OACP3H,GA"]NY%UW4M<FEM+..TNIVDC>UM4#EX89(D0&&4R-(RB)$:
M1RL8W4 ?O=0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'YP?\%-_@7KG[1?AG1O#_A^#SKN
M;Q!;,[ME8;>%;.]#SSN =D29&3@LS%8T5Y7CC8 _1^@#\X/^"6OP+USX#> 6
MMO$$'V2[U'4)=02V;/G0PRP6\2+.A \N4^27,62T:NJOLE$D: 'W_P"%O">G
M>!K./3]*M+>QLH=WE6UM"D,*;V+MLCC"HNYF9FP!EF+'DDT ?FAX_P#C3^T1
M+JER?#W@G2X])\PBT6^O+62Z,8  :9H=5CB#L07V(I$881^9+M\UP#G_ -GC
MX,_$WQW\2(?'WC;2M+\,R65G+;W TZ0M)K*S1F.**Y6*^NHBEL5242R;7)CM
MX]LJQQO: '8?%7XN?M"6>N7\/AGP?H\NBQ7#QV4US=PO--"AVK,Y&I6VWS<>
M:L9B1HE<1L79"[ ''_ #X(_$CXK_ !-MOB'\2],L]&DT72VL["&QGC9;B24W
M"Y=%GO3L2.YN-Y,D)WFVV*ZK-0!ZA^V1\"]<^,OC[X=7.E0;K31M0NM0U"Y?
M*PPPP3Z=*%+@',LOELD$0!9V#,=L4<TD8!G_ !T\!?$C3?BYIWBCP9IUG/IT
M^AVVC7][>-&\=K&^HR7$\HMA>VD\KQ((Y $)#@L@RYRH!]0?M5?LSZ7^U?X:
ME\/:G)) PD6XL[J/):WND5TCE,>Y5E3;(Z21,0'1VVM'*$EC /G_ ,.^"OB#
M9?!SQ%H?C1H]2UY-+UJSLWM2]Q<7=N+62*U,I"[IKB5LF,A?.DA:#SE^UF<4
M >P?L._"'5/@1\/-%\/:TL::C:QW#SQQN)%C:XNIKD1EQ\K.BRA)"A9-ZML>
M1-KL >'_  C^!>N6/QT\8>-IX/)T6;3[33[:63*M<S-;:;([0KCYHH_(9))2
M0OFD1IO9)A$ ?H_0!Y?\:-=\0>&O#]]=>%=/CU36TC LK.69((WD=U3<[R/&
MNR-6:9DWQF41F)9$9PP /D#]E;X=>//%7BJ^\??$BPL]*U9=+BT6QL[&57C:
MU%PUY-/,!-=#>9#&D16=3A9@\ _=R, =!\8?@O<:W\8/ _BJPL9)%L[/6XM4
MO06\N*W6V\NS1MS; YFO)MBH/.D#2,0T4#&( \O^*OQ<_:$L]<OX?#/@_1Y=
M%BN'CLIKF[A>::%#M69R-2MMOFX\U8S$C1*XC8NR%V ./^ 'P1^)'Q7^)MM\
M0_B7IEGHTFBZ6UG80V,\;+<22FX7+HL]Z=B1W-QO)DA.\VVQ759J /4/VR/@
M7KGQE\??#JYTJ#=::-J%UJ&H7+Y6&&&"?3I0I< YEE\MD@B +.P9CMBCFDC
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M!XDT?1](LM?^P2:K*SK<87383;Q0V,5OJ$CI+*KG?)<%XDPT@#%5MY0#]?Z
M"@#\X/'7P+USQ?\ '[0_%D$&W1=&\/E;FZDRJO-.=3A2"'@^9*/.660#"Q1
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M-5^).C:?HNE^&+B:_CEL;B(O--N@DBBVBZOBV98(2V1"OD"<>:)3$* /L_\
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M#]L_L^:WM&2)W7=-$GFQNS6TI1TD4EXE:@#]3Z "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \O^)?PATOX
MM/I3ZHLCKH^J0:K;(CE%-U;QRI"9,?,R(TOFA05#.B!]T6^-P#U"@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@#R_P"%WPATOX0)J":8L@;5-4O=5O'D<NTEU>R;Y".BJBJ$BC50 $C4MOE+
MR. >H4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % 'E_A'X0Z7X*UO6O$-JLAU'7I+1[V1W)7;96ZVT$<:
M#"JBJ'<G!=GE?<Y01)& >H4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?
M('P\_9:_X13XF>(_B-<W6^75K>VLK2UC'RQV\=O9K+),67)E:6V C5#L2(%F
M:1Y=L !]?T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * ,^/5K>:XDLUEC-S%''+)"'4R)'*TBQNR9W*CM%*J,0 QCD )*
M-@ T* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M?\<Z9H6NZ/<0^&[RW8R:R?GW2LR /;QQE]\5O]V[C;%T?-66.+8D(O@#Q_\
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MY_M$P$AO'=IYK=!$K&.* Q"59/+EG$S1RQ!0#H/@%_P51TGX^^-/^$9L=(U
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M%?\ X<^.M4MM,DCU335NI!&+R^AMH[6)B#M,TD=U*T:%L+YA78A8/(T<0=U
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M?Q#%/<:;9:%Y9U#^T(EC:-)@?)=?)>=)/-9'BBCC9IWE78(LR1>8 ?&'@/\
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M!\8OVI?#7PF\'7'C,7UG>V*QR"Q,-RKQWUTN]8[6"6(3!G>2-D9D600A9)'
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MJ*H+,S$!0"20!0!^,/A/_@M?X5E>^.KZ5JD<?VQQIZVL5O(QLQ'&$:Y:2ZC
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_A8GP_DT&UM/MNM:GJ%A;Z- (?,<W@F$TC(Y!6WVVD5VTD\C11I )0\@5B&
M/K_X3^!?^%7^'M*T'SOM']F:?:67G[/+\W[-"D/F;-S[-VS=MW-MSC<<9(!Z
M!0 4 ?C#_P %%/"UG:?%/X6ZJD>+VYUB"VFEW,=T-KJ%C)"FTG8-K7,YW* S
M;\,6"H% /L_]NWQ);OX.N_#$5I'JFM^)(WT_2-*.TR3W#XW7*AD=42Q4_;7G
MD\N&$Q1[IX6>-Z -#P[^S[>? KX57/@OPS<W%SJ5MH^I165R'6VF>^N4GE5X
MW#*L'^D2YA)?,*[-TS,ID(!Y?_P3FB\->/\ P=I/BVQL+.'7?[+MM$U"XB99
M+C;I?^CQK,P"F-Y8TAG9" YA:U1WEC@MV !X!_P3,TFWT#QU\5+.SBC@MH-<
MBBAAB14CCC2[U141$4!515 554 *    * .?_P""QGAA_"%OX8\?Z9+';:MI
M.J+;12"WC>1V96O+9VD?(9+>2U<I#(DB$W$A^7YQ( ?7_P 4/VF-4T#XP>%O
MAY9QQQV-_9W6H7TYP\DRBVOQ#;J"N(D22V$SNI+R'RT!C19%G .?_P""J>DV
M^H_"36I9XHY)+:33Y8'=%9HI#?6\1>,D$HYCDDC++@E)'3.UF! /H_\ 9._Y
M)YX4_P"Q?TG_ -(H: ,#]M-+.Y^'7B*"\@^T_:=/EMK6 6[7+27USB#3TCB1
M'8RF[>W$+*N4EV297;N4 /V+_@Y>? +X?Z)X=U!LWMM;O)<KA1Y<UU-)=20Y
M1Y$?R6F,/F*Q639Y@"A@H /I^@ H _&'_@MIX6L[OP;HVJO'F]MM8%M#+N8;
M8;JVGDF3:#L.YK: [F!9=F%*AG# '[/4 ?F!_P %<?AIIWC#X9W6KW*?Z;HM
MQ:SVDJJFX?:+B*TEB9F5G\IUE#LB,FZ6&!F)$>T@'J'C_2;C6O@/<Q>(8I)K
MY?!9ENTOD9YQ>0Z:)2\PF!<7$<Z"3<_[Q)E#Y#KD 'S_ /LF?"%/CU^SA;>&
MF6-I+^SU5+<RO)'&ETFHW4EK([19<)'.D4C !@P4J4=248 \0_9_\+7G[>OP
MZ\%^&;R/SM(T'4/,US4)&6)=NG>;#:Z1##"8YY)9;.XMS)=KY<4$6&\ZXN_,
MB4 ]O_;#LD^-OQ>^'OA[19HY]1T"\FU75HP)&6SM4DL;E#.\:.L;RK;E(E<@
M[Y;??Y:7$3L ?0'A']IC5/&/QIU;P"(XX=)T70_M#$8:2YNIFT^1968J#&D4
M=PT21)P29)'9]T20 'S!_P %K])MYO NE7C11FYBUR**.8HID2.6TNFD17QN
M5':*)G4$!C'&2"47 !^QU !0!^6'_!6+P5<)X3T[QMI;1PZMX3U2VO(+ARQ9
M(YI8XB(XBKPR/]H%G(1,N D3@-\S1R 'J'P\^%O_  O;XBP_%>YM_(TNTT>*
MR\.AY-TUXD_F3'52D;@6\3Q7<D$%M<!YV5FFFBM942.@#P_]E:R3XK_'#QOX
M\T::.Z\/)9VVE1WB"3R[BZ$5CY@MY-GE2I$;-_,97QB6WD3S(IE>@#];Z /Q
MA_9U\+6?@_\ ::\:VUC'Y43Z.URR[F;,UVVE74[Y<L?GEED?:#M7=M4*@50
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M#"\C!XF /L_PG\--.\*>'K3PQL^UZ;::?#IWEW2I+YUO%"(-LZ[1&^]!B0;
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MC1YI[JSME2WMOEM+Z/RDAA6-/*+64-PR.'S<@RYSL" '[?4 ?F!_P3=^#/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZ+X=\%QZ?J&J65O9:<;O4FD@LXH;6V*O=2Q0EYG\PPK"D,3%DDN$D9FBBDR
M9_PA_9@?P?JB^)?%&LWGB?Q&D;QPW=TD<%K9+(-DATZPBS#9O-$D4=Q(I=Y2
MC,&033(X!Y_^U)^S/JGQY\:^!=4M9(X-.\.7EUJ%[,^&8LDUA+!;QQA@S/,T
M#@OPD2*[L6<10R@'W?0!^,/@K]@GQ1X4^!>I^!BUN^OZYJ%G>O"9 L-GNN;
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M:=)\?&2.'2=%T/[.H.&DN;J9M0C:)5# QI%'<+*\K\$F.-%?=*\ !Z!^V_\
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MM9=D<\4B,* /N_2=)M] MXK.SBC@MH(TBAAB14CCC10J(B* JHJ@*JJ %
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M (L_M'^SKO\ LC[/_:7V>;[']JW_ &?[1L/D^?Y?[SRM^WS-GS[,[?FQ0!\
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M\:-=D(GN"%+)#'B*&-0J1H"0N]Y'< ]PH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H X_P;X TOX?)<QZ7;1VRWEY<WUR4!W375U(
M9)II&)+,[,<#)(1%2) L4:(H!V% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 <?'X TN+69/$(MH_P"UI+..Q:[()D%K
M'+),L*DDA$,DC.^P*9"(]Y;RHM@!V% !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!Q_CSP5;_$.P?3;QI!;2R0-,B%0)HXIDE>WE#*RO;S
MJA@N8F!$UO)+$<!\@ ["@#YP^ W[,^E_ :]U_5+622?4?$>J7&H7LSY50KSS
M2P6\<88JJ0K.X+\O*[.[%4,4,0!]'T % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 <_XLT#_A*].N]/^T7%I]KMYH/M-K)Y5Q#YJ%/-@DP=DJ9W1O@[7 ;!
MQB@#0TG2;?0+>*SLXHX+:"-(H88D5(XXT4*B(B@*J*H"JJ@!0   !0!H4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!Q_@/Q_I?Q/L$U31KF.\L9))XX[B(DQR-;S/;R%
M&P Z"2-PLBY20 .C,C*Q .PH * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H X_QEX_TOX?);2:I<QVRWEY;6-L')W375U((X
M88U +,[,<G (1%>5RL4;NH!V% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 9^K:M;Z!;RWEY+'!;01O+--*ZI''&BEG=W8A515!9F8@* 22 * ,_P
MGXIL_'.G6FJZ?)YUE?6\-S;2[63?#,@DC?:X5UW*P.U@K#." <B@#H* "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _.#]LO\ :\US
M]E[Q1X8\ZPV>#KJXVZKJG+Y:021>1A(Y7B^SJ5OL!?-O?+\F)D6*YW@'N'[:
M?[1UQ^RQX.N?$5GI\FH7(DCMX5"L;>"2;<$GNV4AEMU8!3M(,LSPP!XS+YJ
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M  ^W_P!CO_@H-_PU)XAU+PQ?:!<:'J6GV[SM')<>?_J9D@GBF5X+>2&5'DC
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M?%MAX3\8>%-0\+W&I[$LY+EY9&:::3RK</!):6TBQ2N'B6==ZK* &41^9+$
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MD^#[NPN/^$6TBX&J:W>2)+;+<3>1)'965C<''VC=YLC7YA7;#%L1;N&Z_=D
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MYU)460W,,8!^[VDZ3;Z!;Q6=G%'!;01I%##$BI''&BA41$4!515 554 *
M * -"@ H * /QQ^+&DV^G?M2>$Y8(HXY+G0YY9W1%5I9!;:M$'D( +N(XXXP
MS9(2-$SM50 #]CJ /R _;O\ A;_PDOQ:^%]YIUOYFI3:@_VA_,VYL]*N+6^/
M#N(QY227<GR@229V?.PC0 'Z_P! !0!\ ?\ !4?_ ))#XA_[AW_IRM* .?\
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MIZ'-'<VGA/0Y(-7F42&.&ZD-_"MH)50Q&XS=*Q0L !%<IN\Z"2( '8?\D?\
MVB?^8@;3QIX?_P"W-M1T\?\  %/DVEI_TVFCDO/X(KCY0#0_X*D^-;=_!D?@
MF!9)M=\67EI9Z3;H%"O)#>VLKF261DBC3)CC!9LEY4.WRUEDC /N_P"$_@7_
M (5?X>TK0?.^T?V9I]I9>?L\OS?LT*0^9LW/LW;-VW<VW.-QQD@'R!^WU_S(
M7_90- _]N* /O^@ H * /G#]L32;?6OASXJBNHHYHUT/490DB*ZB2&VDEB<!
M@0'CD1)(VZHZJZD,H( /#_\ @EQ_R2'P]_W$?_3E=T ?/_\ P3B_Y*'\6?\
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MO@IX*T;X=>&M+TKP\T<FDVUG"MI-&8F6>,J&%P7A58I'G),TDJ "5Y&D_BH
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M >#4^'VEVVEQW-Y>+;1A#<WUS)=74S9):2::0EF=F).!M1 0D:1Q*B* =A0
M4 ?D!_P3B_Y*'\6?^Q@7_P!+=5H _7^@#X0;]C&]'Q/N?B#%XCO(+&\DM9+O
M1+=9[>.X:SLUMK<3SPW:"9$D7S_+DA9&!>!E9'<L ?1_QT^!>A_M%Z'/X?\
M$$'G6DWS(ZX6:WF4$)/ Y!V2IDX."K*6C=7B>2-@ ^ /PF_X45X7TSPU]MN-
M1_LZW$/VJX/SOR6PHR=D29\N"+<_DP)'%O?9N(![!0 4 ?FA_P $_/"?B73M
M9\?:GK5]>7MC=>)+BUL9+QV,DK:=+/;37(01QVX1D%O;!K950&T: 1Q);QH
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MP^7 \DDLS[$*1M#%+)$P!V'[4O[/_BWX]_98-"\7W'ABRM\O(EE:R&XGF.X
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M[/=?9[+PQ<75Z\:#,T]P9+.2UC!*E%B#6[-.QRY4+$B@RF:$ ^OZ "@ H ^
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@#Q_X4_ O0_@U+JESI4&V[UG4+G4-0N7PTTTT\LDH4N ,11>8R01 !44L
MQW2R322 'L% !0 4 % !0 4 <_X3\+6?@;3K32M/C\FRL;>&VMHMS/LAA01Q
MIN<L[;54#<Q9CC)).30!Y_<? O0[[Q:GC:>#SM:AT]-/MI9,,MM"LD\CM"N/
MEED\]DDE)+>4!&FQ7F$H![!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!X_X5^!>A^$/$>K^+((-VM:SY"W-U)AF2&""&%((>!Y<
M1\E99 ,M+*079ECA2( ]@H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H Y_PGX6L_ VG6FE:?'Y-E8V\-M;1;F?9#"@CC3<Y9VVJH&YBS
M'&22<F@#H* "@ H * "@ H * "@ H * /+_C)\(=+^.^B3^'M:61].NI+9YX
MXW,;2+;W$5R(RX^94=H@DA0J^QFV/&^UU /0-)TFWT"WBL[.*."V@C2*&&)%
M2..-%"HB(H"JBJ JJH 4    4 :% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!X_X&^.FA_$G
M7-9\/Z5/]IN]!^RKJ#I@PQS7)G @#@_-+'Y#>> -L;,L98RK-'$ >P4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MUUWX6:-]KUK4?-MYQ+>6.W1YHL+*91/-'YTIR'M$*!7B>.YGC12MM, >/_\
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MI72]:AUK1Y+7Q'X>DV7EG;J(5F:0S^5%%'=S*T%P&@DAECN)%17"N9D$CQP
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M3P(T0:U$B0VZI+^\6 L1NNHP#S#2?BQ^U)IUO%!+X3T.YDCC1'GEGMA)*RJ
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M9&_?+"MT89"L]W$V^V8SK()8UC\IHF#R2JJ ' ?M*?M*?$7]B[XB_P!OZ_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M/V-O@7%^SMX&TG0_(\B]%NEQJ(/E,YOIU#W >2$!)?+8^1&^7(@BB3S'"!B
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M_P#"'V?A/Q_';7%Y+X7\06TSP1G;";>5DF<S.(Y#%NEM+:".4_(K3%2DCO&
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M (L>%KR+P;JNE>&(_LUZ-'N[;2HK5EM?*F%L\=JD# QI!L;8(V!18L @J%R
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^UMIUKI6MWNH6UE:W!N1%9-;IYDP1HT>1IK>=_D5Y JH44^8Q<.5C* 'R?X
M_P""0'PY\"ZI;:G))JFI+:R"06=]-;26LK ':)HX[6)I$#8;RRVQRH219(BZ
M, ?J?0!^:&K?\$F?AEK7B"77);:\6":1Y'TF*X$.GAG0J0BQ1I<1IO/FK''.
MJ(^$55@ A !^C^DZ3;Z!;Q6=G%'!;01I%##$BI''&BA41$4!515 554 *
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M\M0A0-(' /M^@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H Y_P 6>%K/QSIUWI6H1^=97UO-;7,6YDWPS(8Y
M$W(5==RL1N4JPSD$'!H T-)TFWT"WBL[.*."V@C2*&&)%2..-%"HB(H"JBJ
MJJH 4    4 :% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 9^K:FFBV\MU*)&CAC>1Q%%)-(51
M2Q"11*\LCX'RQQJSN<*JLQ (!X_^SE\;[?\ :.\,6GBBSMY+6VO9+L0Q2LK2
M".WNIK=&?;\JNZQ"1D4N(RQ022!=[ 'N% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?/_P"T[^T%9_LP^%[OQ->6UQ>+;[$C@@1COFE.R(2RA62W
MB+$!YY/E7(55EF>*&0 ^@* "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /G_P =
M_M!6?@CQ?X?\&FVN);W7_MCK/L9+>&&TMI9W/FE=DLI9$3R(SNC1_-E:,&!;
M@ ^@* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * ,_5M331;>6ZE$C1PQO(XBBDFD*HI8A(HE>61\#Y8XU9W
M.%568@$ \?\ V<OC?;_M'>&+3Q19V\EK;7LEV(8I65I!';W4UNC/M^57=8A(
MR*7$98H)) N]@#W"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#Y_^&O[05G\4/%'B/PS:6UQ$WAO[ EQ/.C1>=-=B=R(HG57\I%B
M0I.?EN/,+1J81'-, ?0% !0 4 % !0 4 % !0 4 >?\ Q"^*NA_":*VGU^_M
M].M[NX^S0SW+B*$S>5+.$>5L1QY2&0JTC(K,!&"9'16 ,_P5\;_"OQ*N&L]#
MUO2]2N4C,KPV=];W$BQAE4N4BD9@@9E4L1@%E&<D9 /4* "@ H * "@ H *
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MS0[;29-+L7L()8(C)%:M;QF"-R=)D)=8RJL2\A)!^=OO$ ] _9G_ &C?B1X
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MX@7^GZ[I?B6X2RB-LD$2H\D\4+2(\=I;3"6 RQ.RR(T$L4IC5A+F2W /7_\
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MVMM8^./]L>&/&(MX?%GA^X\BYCB$:>?%%B"27:DTBR2I<1R"Y>!([5/.MQ&
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M%ZEX6\9ZUH]A=^%=8U:P$8N0LT\,$GGR2QPNPN+C=-+<)#Y4*M(J)&(C*&W
M'0?LS6LO[77Q*OOBO<V?D:'I%O)H_AB;;*OVU5EN%FO\NT3G"RS1['@\H?:?
M*R;FRD=@#]7Z "@#\@/^"U?_ "3S3?\ L8+;_P!(KZ@ _P""CO\ R4/X3?\
M8P-_Z6Z50!^M^K:3;Z_;RV=Y%'/;3QO%-#*BO')&ZE71T8%61E)5E8$,"000
M: /YT?V3/B7J/PB_9Q\8ZOI3^5>IK$D$4H9U:+[7%IEHTL;1LCI+&LS/"X;Y
M)51B& *D _4_XF_LU?#[]L;P5!H&D7=G-::1&MII.HV%PEZVGR0PQJL7FK(Y
MD3RQ$+B"23,R;'+),L,\8!X?^P#^T%%?ZQK'A7QI;?V=\2WN-^IS3I%&^JK;
MQA8#$8E2+_1[8($@A'E209OX6E\^Z= #[_\ C'\?O"_[/]FM]XGU.WT^)\^4
MLA+33;61&\F",/--L,B&3RD?RU8.^U,L #Q#]F#X3/)JFL_$?6+22TUOQ/(F
MRTN+>.*>PTVV'DV4+@23.EQ/#'!<7R>8%\[RXC#&UO\ , ?9] 'YP?M8>+-.
M\#?%+X::AJMW;V-E#_PD_FW-S,D,*;]/A1=\DA5%W,RJN2,LP4<D"@#Z?_X:
MQ^'G_0U^'_\ P;67_P >H ^$/^",.DW&G?#F[EGBDCCN=<NI8'=&598Q;6D1
M>,D .@DCDC++D!XW3.Y6  ,_X-_\G0^,_P#L7[?_ -%:-0!]P>,/@IJ/Q1\:
M:=K&LR6XT#P]FXTNPC9Y6N]1ECV&[ODEC$,?V09^P+")9EE=[C[3%G[.0#Z?
MH ^?_P!K'_DGGBO_ +%_5O\ TBFH \0_9D_:;\"Z!X%\-6=YXET."Y@T/3(I
MH9=3M$DCD2TB5T=&E#*ZL"K*P!4@@@$4 ?*'B+Q9IWQ;_:5\*ZAX=N[?5K*S
M\/W'VJYL)DNH8/DU1/WLD)=(_FGA7YR/FFB7K(@(!]__ !X^"FH_'O4=*TV\
MDMXO"=G<1:AJ$(9WN-2N+=]UO8S0-']F_L_.)KCS#.\[I'&L4!3SR ;_ .U5
M\+?^%T^!M>T%;?[7<7>GS_9(/,\K?>1+YUG\^]%&+A(F^=A&<8DS&6! /S!_
M8V_:'^'6G>%])\9>,M?MUUS0]/31[?3YGW?V9#"1;"33[!(S<22W<'V=[R\0
M7+']Y$LD%M%);Q@'O_[.G@W4?VG_ !ROQDUK3_[,TV#3S8^&+.7>+R2W9I3_
M &C<A9/+7S$GG2*+#H\<P=<K#!=70!]0>,/@IJ/Q1\::=K&LR6XT#P]FXTNP
MC9Y6N]1ECV&[ODEC$,?V09^P+")9EE=[C[3%G[.0#Y/_ ."K&AW&@>']#\=:
M;:QSZCX4URTO%DE=A'';NZ[@\8DC\Q)+F.Q1@F9E&2K(AE:@ LOVJ_AE^SCI
M<VHZ!J<GBSQ-XCD%RB1.+K5M4NG*):V]SY$*K9)$LR0P6K0P"")9$@M)+@21
MN >X?L2?LZ:C\&;/5]=\1+;IXF\4ZA)J6IQVQ<PVWF,\D=FA:61'\EIIF:1.
MK2F+S)TBCF< [#X\_M5:7\-7D\/:/+'J?C6ZCDCTS18%-Q*UT8T>(W:HZ+:V
MZK(EQ-)<2VX-JDLL;-L. #K_ -F+]GK3OV7_  O:>&M/?SO)WR7-T8DB>ZN)
M3NDF<(/I'&&:1XX(XHC))Y88@'T!0 4 ?D!_P14_Y)YJ7_8P7/\ Z16- !^V
MIK6G?LK?%#PA\2-WD6^H?:-+UU8YTB\VW"(D=P\$2-<W?D"7S93LF3_1+&',
M$A@9@#T#]C'P)>?%3QIXA^,EY97&F6FOV]O::+:3R+YTEC'' K7<\03Y/.^R
MV[VX60C:TW^MB-O<2 'Z?T ?EA_P5*UGPUX_\$7_ (<6\L[OQ1;7FFR:?I,5
MTK:A]JFGBA 2SCD\Z5WM[F7;&8W!202!<A' ![A_P4A\+7GC#X4>([:QC\V5
M+>"Y9=RKB&TNH+J=\N5'R112/M!W-MVJ&<JI /7_ -D[_DGGA3_L7])_](H:
M /@#_@G%_P E#^+/_8P+_P"ENJT ?<&@?!34=;\<W'C3Q%);M]BMY-/T"Q@9
MYHK:WD8-/?2M-&FS4+C_ %+_ &942*U40-+=YWJ >'^#OC+I=U\9?$UEK]_9
MVESI=GHVE:#!->&%IEU%/MEX(K>6;9-<2S?9(W:*/?LAMH^N3( ?('[4WP4L
MOV*-97Q+IVER7WPZUR\MF\5:%%# UO#+:R^992(7!=+<SR&5;7]U:M-$+.65
M;>ZA@C /I_\ X*$>/]+^*?P-U?6M%N8[S3KR/39()XR=K+_:5J""" RNK I)
M&X5XW5HW575E !](>-OVP/"7PW\)6?C#5[K[)::CI\5_96<AC^W7*RQQ2+%#
M;B0^9*/.B638QBB+AY)4B!D !Y?^R?\ ";5)O$'B/XD>(+2.ROO$\ENMA926
MX2\LM-M4\J!;EC)(8KBXC6"2ZMD8JDD*%B'_ '-N ?('_!7;XA:-\2O"NG^'
M-#U"SU+6T\26\3Z;9W$5Q>+(+>\@*&VB9I@XE98BI7(D94QN(! /U>\:_&_P
MK\-;A;/7-;TO3;EXQ*D-Y?6]O(T99E#A)9%8H65E# 8)5AG(. #\\/\ AH7P
M;_PO7^U_^$@T?^S?^$'^R_;/[1MOL_VC^UO,\CSO,\OS=GS^7NW[/FQMYH S
M_A/JUQJ/[3OBR*>622.V\-P10([LRQ1D:3*4C!)"(9)))"JX!>1WQN9B0#/_
M ."U?_)/--_[&"V_](KZ@#]?Z "@#\L/'&L^&OBM\:_ >M>%[RSU:YM[/78]
M4GT^Z6\6WM8K1A:&X$,DB0(9KN5$D8(9'E$99B$50#/_ ."BGA:\N_&7PMU5
M(\V5MXH@MII=RC;-=7-C)"FTG>=RVTYW*"J[,,5+(& /8/\ @J/_ ,DA\0_]
MP[_TY6E 'J'P-DUF+X4>'CX>CLY-6_X1O21:+?22QVHD-G" TS0QR2E%!+[$
M4&0J(_,BW>:@!W_[/'P0M_V??#\.C17$E]<F26YO]0F51<7UY<.9)[F<C+,[
M,=JF1I9%A2.-I9"F\@'YX?!O_DZ'QG_V+]O_ .BM&H _1_Q3^T+X-\#7DFGZ
MKX@T>QO8=OFVUSJ-M#,F]0Z[XY)%==RLK+D#*L&'!!H ^$/V<OC?X5G^+?Q
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M_P#\*6^%GPMU#5[>XC_L;6/"D]Y;>7MN$^QZ?*\T7ER%,2C8R['*8<;6*\D
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MC0/#V;C2["-GE:[U&6/8;N^26,0Q_9!G[ L(EF65WN/M,6?LY /I^@#\@/\
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MH T/&OQO\*_#6X6SUS6]+TVY>,2I#>7UO;R-&690X2616*%E90P&"589R#@
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MXP $/GI)OB586W1*J  ^C])TFWT"WBL[.*."V@C2*&&)%2..-%"HB(H"JBJ
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M+,<9))R: //_  K\"]#\(>(]7\600;M:UGR%N;J3#,D,$$,*00\#RXCY*RR
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MZ\1Z;'-KNA:'I]G&+B0W$=E/#% TC01;Y+5+@2PK_I<*^<1&BB8QJHH ^KZ
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M/X1:BFJZ1H%NE[%M,4L\MQ=^4RNLBR1+=RS)'*K(I29 LJ<A7 9@0#Z_H *
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M  W^%6A_!^S?3_#]A;Z?:2W$UR\-N@16FG;<[D#\$1?NQQ)'"@2*.-% /0*
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!GZGI-OK2"*ZBCFC62*4)(BNHDAD66)P&!
M >.1$DC;JCJKJ0R@@ T* "@ H * "@ H * "@ H * "@ H * "@ H * "@#/
MTS2;?14,5K%'#&TDLI2-%13)-(TLKD* "\DCO)(W5W9G8EF)(!H4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &?9:3;
MZ<\TL$4<<ES()9W1%5I9!&D0>0@ NXCCCC#-DA(T3.U5  -"@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M6*%E90P&"589R#@ ]0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#Y_M_P!H*SOO'S^ 8K:X^UPZ.^JSW4B-%"%\^"&*
M.'>H^T;O-=I)8SY431B$-)+YR6X!] 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?/_ ,-?V@K/
MXH>*/$?AFTMKB)O#?V!+B>=&B\Z:[$[D11.JOY2+$A2<_+<>86C4PB.:8 ^@
M* "@ H * "@ H * "@ H ^?_ (:_M!6?Q0\4>(_#-I;7$3>&_L"7$\Z-%YTU
MV)W(BB=5?RD6)"DY^6X\PM&IA$<TP!] 4 ?/_P"S_P#M!6?[0T6L7-A;7%M;
MZ5K%QI0^THT4TK6T4#R2/ ZK)!\\K(L4@\T*@:18I&:&, ^@* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
MX_QK\0M&^&MNMYKFH6>FVSR"))KRXBMXVD*LP0/*RJ7*JS!0<D*QQ@' !Q^@
M?'/P]\1/M%MX8U?1]7U**WDFCM8-2A?.W"J93!]HDBB+LB/*(I-F\$([$*P!
M^&/PZTG]H'0?'FM^!;+Q)9V^K2QG7KN[NH%DM;L2K:VYDMI9M.DE**#%;K''
M'';Q&VDA0+Y>T@'N%C\<OC1^RYX^\-:)\0+_ $_7=+\2W"641MD@B5'DGBA:
M1'CM+:82P&6)V61&@EBE,:L)<R6X![__ ,%*OAAXTOM.LO&W@_6;BUE\*^;?
M2:>'CCB941C+>(2H$LL<1D22"X,D4MJTL<:J[RPW@!V&A_$CQK^V+\'[75/"
MK6>C>(=9C>&6X:YFBCMEAN9+>YEMV2WN)0\HA81)\KVXFWK<M+ C2 'Q!X\\
M#_M&_LL>#GO8O$NES:3H5G!&EI96D5Q<):P[(05$NE*62&/]Y+)))E88WD9C
MM.0#[OM3>?\ !0WX1V<EIJ=QX?N-9MU6\EMX%96:"5K>]@,1E,AM)7CE"!9X
MY6B,8E9HVGMY #Y__8B^/OQ%TSQ1KWPN\9_9]4U?1-/-U9WDEQLWB,6T<,4U
MQ'#(\D4ZSPSBYEC:\CW2>='-(PCA "Z^"O[33WEY=V_BWP_;K>7#3_9U5I88
M<JJ+% +C2YGCB544! QW-NE<O-++(X!@? /]MSQS\6=#\8^%+^.WM?B!X;T^
MY>U:WM6NFNGLP8+D&WB9K=KM9U5$:-S!)+<QM'920P21R@!-^U#KGB#]FB7Q
M/::ELU^UMX=/N+N"4O<1LNH161:5W>21+N6U=)GE)67?.+B/R]T94 W_ -IG
MXX^*/V3O@?X3GT8_V?J[V^B:=.UQ;AIK;;IS2RJ(9U*+*&MQ$XFC?:K2#:LF
MUT /4/VH/V;_ (F^*O'4'C'X>:OI>E2+H::5,UX"\C*+N6Y<"-K*ZBV$F$AO
ME?*L.%^\ ?$'[1WQ5_:(_8WM]/USQ!K^EZEITUXL+);VUJT9D"F58)P;*TG"
M3)'*-UNV5"/F2%S$6 /Z#J "@#YP^-_[)/@S]H^XM[KQ5827\EI&T=N#>WL,
M<:NVYRL4$\<0=B%WR;=[A(U9BL:!0#X?_P""4_@J_P# 2>+[.U:2;P>NN2KH
M%VYA=;L0R3V]Q<1RQJIF1HX;13*H^SLZN(L.LZ@ \P_9_P#@MX<_X*83^*O'
M7BM+B:*?4&TK1(1+/!+IEI:VZM'(@6XEA,L@N8Y9(G22W6Z260*Z3N@ -#_@
MFMJWB#X&>-?$OP@UB62ZM-*C>]L)'= L48FB^:.-3*42\CNX+HQ>=BW=7!3S
MIIFH ]?_ &Z?V*OAY?\ AKQ/XRU"WD@UL6=Q=KJ,FHW18W2+FWA"7$TD&R1U
MCM8X%C ".L, C81%0#Z@_89TGQ!H'PW\/V?B>*2#5(+/RFAE1$DCMTD=;-'1
M -KK;"!65P)E((E F$E 'Q?_ ,%-/AU\*/[.U+5?$]UY/B^;3R-*Q?74MQOB
M25K5$L@\L45I++$\4DA@C@WR2L98[B3S: /M#]AGP;JG@#X;^'].UBYCN[N.
MSW^;%<BZC\B:1YK:-)U+)(D4#Q1*8F>$! L3O"$<@'U?0!\(?\%$/ /C7XF>
M"KK3?!TL<2F.>;4@))A=75K#"S&PM8H;:9I7N6PK 20%@@MSYD5Q*% /A#X"
M3_M(?M$^'+/Q/I7B[1X;*^\[RH[FUMTF'DSR0-O6/2I4&6B8KAVRI!.#D  ^
MC_V$OVP?$'C'2_%=G\1?+COO!DC'4;Y%3<8P;HS+)#:(8F>W-K(H>V!$R% (
MRZM), <!X@T7XZ^.DTWXG>$M7LY5U*S@G7PINQ:Q6,TD4]O"'N-D-S</$Q>]
MNF-C<(?,AMI3$8HU /7_ -F#]N/6?VL/!6LWVA:79_\ "8:1&B#3Y+B5;6>2
M2',4XD:-1&DLB7 CMC*Q!A5);N%)1<* ?"'['F@?'GXH>$+;4/"'C'1XM-:X
MO-T%WY=Q>17#W,DT_P!J=].NI/-E>0W/[R5W:.:-^%=0 #U ?&;XU_LS?$'P
MIH_CW5;/6-)\07BVJK9QVD<;M*ZVS9D%C!<*]N]Q!<%0JI,-L0EYE\L /VR?
M$'CS]ASQXGQ,L]1DUCPYK$D-E=:?<RJBQJBR21V(1%"JBJ)YK*ZB0O$YF%PL
MIEE:^ /T/_;-_9VUS]H_0X;#0-?N-#N[2X%V@CR(;F:$;[99I(MMQ%Y<RQR1
MRQLZQ,#*;::5(&A /B#]D3X^_%7XO>%_$7@V'^ST\8^&;B'3SJFI7#ML60W,
M3M*(8;E+F[MVMF1)2?*GWI++YK12?;  \+?![]I7[''%8>.?#]Q;V^ZV$AV7
M+;K9C!(DDSZ3)))*CQM',TC-+YJN)"9 U '?_L1?M%_$"^\<Z]\-OB&UO>ZE
MIEN;V.^A$,>$#6RK&%@BCCDBE2XCN(F9(IXLNDJEF"6X!^K] !0!_/C\08OC
MKX,^++:39:U9V-]XPC>:TE*_:]/AM=/%W-%8+/<:;D/;1ERX@@4R/<1SS?/.
MS@ Z#XS?&;X^?L1OI?B'Q?JNEZ]HDUY]GGM;:.WC5V,;.(GD%C:SQNZ+*\,L
M0E1'A_>JRE8I@#ZO_P""E7PP\:7VG67C;P?K-Q:R^%?-OI-/#QQQ,J(QEO$)
M4"66.(R))!<&2*6U:6.-5=Y8;P [#0_B1XU_;%^#]KJGA5K/1O$.LQO#+<-<
MS11VRPW,EO<RV[);W$H>40L(D^5[<3;UN6E@1I #X@\>>!_VC?V6/!SWL7B7
M2YM)T*S@C2TLK2*XN$M8=D(*B72E+)#'^\EDDDRL,;R,QVG(!]WVIO/^"AOP
MCLY+34[CP_<:S;JMY+;P*RLT$K6][ 8C*9#:2O'*$"SQRM$8Q*S1M/;R 'S_
M /L1?'WXBZ9XHU[X7>,_L^J:OHFGFZL[R2XV;Q&+:.&*:XCAD>2*=9X9Q<RQ
MM>1[I/.CFD81P@!=?!7]II[R\N[?Q;X?MUO+AI_LZJTL,.55%B@%QI<SQQ*J
M* @8[FW2N7FEED< [#]AC]LGQ+\<[C7?!/BE+.S\8:'&Z),L+21RM WV6XDN
M(H9%A9X;CRVE$$\"7 GVP)"D324 <?\ LG_M.^*/%?PE\8WNM7>/%GAS^W"Q
ME0"\A<6[W<+W-M+E4V7!G@BC\J.!8[86ZQ8A<4 4/ ?Q>\2_ S]FE/%$32+K
MOESSI/>HTDC-J6LN!=L)>97>.Y^TQ/)O24LDC++&Q5P UOX,?%GXQW'ACXC^
M#-;TNPU&\\%Z79W\]X@\R:29C>SD0BQN8%1W>-@4"%2K*%5/O 'S_P#M'?%7
M]HC]C>WT_7/$&OZ7J6G37BPLEO;6K1F0*95@G!LK2<),D<HW6[94(^9(7,18
M _H.H * /R0\?_#S]H;6_$MS=:9XI\-Z2M]&6M=)69[A8K6U8*6C6YTMV=U:
MY3[5<JJ&1Y8E8)$MM#$ > ?&;XS?'S]B-]+\0^+]5TO7M$FO/L\]K;1V\:NQ
MC9Q$\@L;6>-W197AEB$J(\/[U64K%, ?I?\ MF_L[:Y^T?H<-AH&OW&AW=I<
M"[01Y$-S-"-]LLTD6VXB\N98Y(Y8V=8F!E-M-*D#0@'Q_P#LH_M*?$SXW^%_
M&GAV[^SIXY\,[X+>[,=NWFW,ANE$#Q(T5F)8Y+9X8[@-]F^>*22&58I/M(!Z
M!^PE^U=JWQQ\)7WAVY-O;^/M MY;3[-J#W&Z=H(Q%!=WB./M'^NQ#?A&DE25
M3(WE&XAC !H?\$\?VA]9\9_#*]\4^.)I/+L;S4YCJ$D4NZ:SC NI9PJAA(D4
MCW$$:VR+'&ENMO'&&B((!Y!X@T7XZ^.DTWXG>$M7LY5U*S@G7PINQ:Q6,TD4
M]O"'N-D-S</$Q>]NF-C<(?,AMI3$8HU +_P^^-FH_P#!43X:ZWHNGW7_  CO
MB&V\F&Z6!W>WN4DBR!*[0^9#:7;I<1/%#)+/"D0\Q[B%V@N #T#_ ()H?M"^
M*/BA9ZWX4\8)OU?PG<0V<UVTHDFFW-<1&.=E+))+"ULZ&X5V^T*59MTBO-,
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MZC)K_ASQWJD:))=2J)1+))#;>9L10L%Q:K+!&PAC2UN;411JD)CC2R /W.H
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MMS>QWT(ACP@:V58PL$4<<D4J7$=Q$S)%/%ETE4LP2W /U?H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H \/^-_[.7AC]HZWM[/Q1:27MM:R-
M+%"+NZMXQ(R[=[);S1+(X7*HT@8QAY A42/N ,_X%_LN>$/V:_MG_"*:?]@^
MW^3]I_TFYG\SR/,\K_CXEEV[?-D^YMSNYS@8 /C#QQK/AKXK?&OP'K7A>\L]
M6N;>SUV/5)]/NEO%M[6*T86AN!#)(D"&:[E1)&"&1Y1&68A%4 S_ /@HIX6O
M+OQE\+=52/-E;>*(+::7<HVS75S8R0IM)WG<MM.=R@JNS#%2R!@#[?\ VL?^
M2>>*_P#L7]6_](IJ / /^"7'_)(?#W_<1_\ 3E=T >__ +6/_)//%?\ V+^K
M?^D4U 'SA_P3.DN(?@QHC6<<<MR(]4,,<LC11O(-0O-BO(L<K1H6P&=8Y"H)
M81N1M(!] ?LX_!"X^$MOJ%_K%Q'>^(]=O&O]6NHU;RQ(RA8K.V:7=/\ 8K1!
MY5JDSL5!=@L0D\I "_\ \-8_#S_H:_#_ /X-K+_X]0!\0?LI:=9_%GXT>.O'
MVD77VG2([>RTFWN(XF-O=3&"U^TF&X)"/Y#62J0@=9$N(YE<1M&TH!\P?L_Z
M'X2^'7BCQ5\-/&]];Z+H&E>(&UC3M)N;R.*SU&&8+]GCOYYF<7$4$26%Q#9M
M-&TDCR-<QW7DE( #W_Q_K\'_  4_UBPT+0;?S? .AZA;WVK:S<1W$/VZX2-@
M-.LHR891F*9EN)6V/%O$HV!+<7P!^M^K:M;Z!;RWEY+'!;01O+--*ZI''&BE
MG=W8A515!9F8@* 22 * /SP\87VA_M_ZYIVDZ8WV_P )^&]0.H:K?"V#VEWJ
M5L?*M=,AEF81W$3)+//>M'#<0O;FV1)T-R' !^C] !0!\ ?M?_%_3K_4;?X;
MW.M:?H-OJ^GW%SK5_>RI"\>EEQ;&VLC<+]F:[O2TT0=W8VL$,\WDO(8: /I_
MX:?%CP;XKV:1X8U71[O[);KY=GIUW;2^3;Q;8UVPP.=D291!A0BY51C(% 'X
MP_\ !.+XZ6?[(6L:_P#"[QS/;Z7+#J$EQ;7DVZ&W>98UCF#W$YC"1310P3V+
MO'&LJ,^9-\MO&P!]/_LB:1%\8OBYXX^)>FR[M%'EZ%:N#%(MU-!%9BYFC>*9
M_P!TOV6)X6VE9XKI'#(T<D= '8:M\=?"OQ<\;R_\)!X@T/3]$\&ZH\=GI]W<
M6\5S>ZQ# 8Y;V87BHT=O9-/+!9BW!\V[CDNC/MB@0@'W_P""OB%HWQ*MVO-#
MU"SU*V20Q/-9W$5Q&L@56*%XF90X5E8J3D!E.,$9 /E#XJ_%+X*>(+R_F\57
M'A>[U#1]]K<B_CM+B[C\A?.>"))4>:;89&'EVXD_T@RP ?:%DC4 Y_\ X)M^
M%I?#W@N>YBCN+;1=2UC4;_0+*Y:4S6>D32*+6)UE+[-VQ[A?+>6.19Q.)7:5
MC0!]_P! ''^-?B%HWPUMUO-<U"STVV>01)->7$5O&TA5F"!Y652Y568*#DA6
M., X /A#_@F?X6L_"FA^)HM*CVZ*WC#6#I,BLTD,UC&(((9()F+>?%^Z:,3!
MG#,C N6#4 >/_L9_"W[3XY^,.@Z];YM]1U"'SX/,_P!99ZDVI3)\\+[E\RWG
M1OE99$WX.R12% /8/V6M0^&/[*NG76DZ?X\T^_LI;@26J7NNVLGV6'8I,,:+
M.MNNZ=KB=I(88&D\Y4D$AA60@'C_ /P30_XG/C+XH:O;?OM-O/$'^BWD?SV\
M^VYU&0^3,N8Y,)-"YV,<)+&WW74D T/V2_B%HW[,'BSX@>#-?U#0]&L8-<CU
M/34>XBLU,>J1&40QB9HD*001VB&.) (79UWNAB( ,_PYK\'_  4'^*&FZU86
M_F^"?!&^>TU+R[B/[?JDZ6TJQ?O3;R1_9W2.78(Y0/L_[XF*^A50 _X+5_\
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M@SX4?M)64]]I?BSPWI'BH1RB'5(=5LXFN%E@^S26M^\4N^:WEA_<%CO>%#A
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M(MOK-\MO'IO@O1[R5]0DN618;[5?+#HX"K"GV:QMGEN!-(2L6H6LODJICFH
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MW%<' !Q__!+C_DD/A[_N(_\ IRNZ /@#]G_0_"7PZ\4>*OAIXWOK?1= TKQ
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M 3XA:-\-?AIX2O-<U"STVV?0](B2:\N(K>-I#8QL$#RLJERJLP4')"L<8!P
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MAX7AN;5MRMYD*MIEJ7PI)7$MO,FUPK?)NQL968 _5^@ H * "@ H * "@ H
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M7A?P?X2OO!6C6G]FZ1J%O>03K;N6F/VR-HI93-/YKO+M8*CS>9M5(TQY<:H
M#U#P!X TOX6:7;:+HMM'9Z=9QB."",':JY))))+,[,2\DCEGD=FD=F=F8@''
M^%?@7H?A#Q'J_BR"#=K6L^0MS=289DA@@AA2"'@>7$?)660#+2RD%V98X4B
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M4JB!YI2\LFT%W8\T <?\7?V>/#_QWN-.E\1PR7MMIDCS0V#RN+.2X9HBD]Q
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M_P"5'4O_ )+H ^[])TFWT"WBL[.*."V@C2*&&)%2..-%"HB(H"JBJ JJH 4
M   4 >/_  __ &>/#_PT361IT,D<_B"\N[S4KM97CNI9+J21R%N(3'+$D(E9
M+81,AA&9 WGO+,X!R'Q9_8S\"?'#[$NO:7]HBTVW%M8V\=W=VUO;0C'R0V]M
M/%"G"HI94#%(XT)*11JH!Q_@#_@GI\,/AAJEMK.EZ#''?6<@EMY)+J\N%CD
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MHWB#58/M-WH/VIM/1\&&.:Y,!,Y0CYI8_(7R"3MC9FD"F589(@#S#XO?L0>
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MQ[MDCJP!]/ZMI-OK]O+9WD4<]M/&\4T,J*\<D;J5='1@59&4E65@0P)!!!H
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M &?\:_@)X<_:)TZ/2O$]G]NLH;A;F.+SIX<3(DD:ON@DB<X65QM)*G=DC(!
M!H?"'X+^'_@+I:Z-X:L8["Q61Y3&A=V>20_,\DDC/+(^ JAI&8JBI&"$1%4
M(_A#I:>*I/&)61M6?2X]*5BY\M+5+B2Y8+&, O)(ZEV?<0(HPGEYE\P ]0H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M_#6GZK_8_P!OV1W-T('G<VX.Z2% EQ;;?-P(Y"S2(T#2Q&,^8&0 _$']CO\
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MS":=K:U0L MX\:.MM;HJRC2KM@IA2">W*20V\XN #Z/_ &N?C/%^U-\(TOO
M6L>1)J^H6.G"R+10W-W-=RK!)I$A>5?(E_>K--M9EDMH7^9[*=I2 ?J_0 4
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M)_B-\.O&]YJ>K7=FE[J(D59H]59+:9A+:16Z36\R,CI'IMC)#*D <>5=C;&
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MTGR?B7I.MW$,6C>3:0VMIYEJ]C#=;HIKL7(N\O+-+)%;R""&-F@>)7W) \C
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M^TP0744MK//<PLC17*>5+N+JY9E6)XHY& /Z#J "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /R _X+5_\D\TW_L8+;_TBOJ /U_H _(#_@BI
M_P D\U+_ +&"Y_\ 2*QH Z#XL6LOP!^/WA_Q!8V?VBW\::?-I-ZD"RSW(FMC
M"6NMA98XHHT6P\UU+*MM!=R&$2 2. ?J_0 4 ?*'P1_8^\/_ +/GB76]?T#S
M+:#6H[<'3D9UM;>2-I6E:*)7$120NAC1HR;0B9()$@G," 'Q?\&_^3H?&?\
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MVD/^&SHI/AI\(X/(T@VZVNL:[+9^58V.ER1"/R+.V<([2RKYEM'&Z0%1$_E
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MKQ?J%G8MXSU1[K3Y([24SS:;;P1VVF92+S[F1#:117DC2+$MO-?M"T4$K[&
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M@>:VN8MROLFATDQR)N0LC;64C<I93C()&#0!\O\ [-/_ ":]=?\ 8O\ B?\
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M]0?P,+B.YUC6)HFLK?4X;?+P6.G^=%]IES>(OVR5!:M;I:21K-NN(BP!^C]
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M_P#A2GB7_A-/L_\ PCW]L7?V[[1G9L^R6&W;M_>>;OV>1Y/[_P _R_)_?;*
M/?\ X'?MI? 3]G;1QH?A[6O(LA<7%Q@Z=J+.6GD9\/)]C#R^6I2"-Y2\H@BB
M1Y'*;B > ?L/>%KSP_\ LY^,+FYCV1:A;^(;FU;<K>9"NFK:E\*25Q+;S)M<
M*WR;L;&5F /J_P" G[8/A_X4_!;PUXH\1^99VR6:Z9#%$KW$EQ<6"SVZ(FU%
M57G6R>1?-,<,98(\V!O8 ] _9M^''B#QUXEN?BGXL@DTJ^U'2X=-T[02Z2-8
M:>&CG?[5*(87>XEG5IEC95>V20Q2%GQ%; 'S?_P4=_Y*'\)O^Q@;_P!+=*H
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MO%YBB*UMHI9I5,<4MSY*&:%P ?;] !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0!Q_@7X3^'OA?YW]@Z5I^F?:-GG_ &*TAMO-\O=L\SR43?MWMMW9V[FQC)R
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M\$/"OPUN&O-#T32]-N7C,3S6=C;V\C1EE8H7BC5BA958J3@E5.,@8 .@\>>
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M ()4_!1Q\+;BS\4:7')8ZQJDE]!;7L,<L=Q:F"T$,S0R!AL:2 O%YB@L%29
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MK6?/:VM8\,R0P033//-R/+B/DM%&3EI920BLL<SQ 'H'_"6:=_:/]D?:[?\
MM+[/]J^Q^<GVC[/O\OS_ "<^9Y6_Y/,V[-_RYW<4 &@>+-.\5_:/[/N[>[^R
M7$EK<^1,DODW$6/,@EV$[)4R-\;8=<C(&10!Q_@KXW^%?B5<-9Z'K>EZE<I&
M97AL[ZWN)%C#*I<I%(S! S*I8C +*,Y(R 9_CK]H'PE\,-1ATK7=:T_3;V>W
M>YCBN[F.#,*.L9<M(RHNYFQ&K$-+LE,8<0S% #/TG]IOP+K]Q%9V?B70Y[F>
M1(H88M3M'DDD=@J(B+*69V8A5502Q( !)H ]PH \?^.GQTT/]G30Y_$'B"?R
M;2'Y41<--<3,"4@@0D;Y7P<#(55#2.R1))(H!S__  UC\//^AK\/_P#@VLO_
M (]0!ZAIGQ"T;6M+.N6NH6<VDK'+*;^.XB>U$<)82N9U8Q!(RCB1MV$*MN(V
MG !Q_P #OCIH?[1.CC7/#T_GV1N+BWR<*X:"1DR\>2\7F*$GC24)*8)8G>-"
M^T '/^)/VG?"_A37+WP]<W?^FZ7H]SK.I>6AD6SL[<Q9\[9N?S7642QPHKR&
M)2[*HD@\X Y#2?VX_ASJ.C1:U+XBTNVCDLTNWM9;VV-Y$K1"4PO;12R2FX4'
M8T$8D<R QJ&; (!T'AC]K?P5XI\-2^*H]7LTTZUL[>[O@;B&2>R6X7='#=10
M/*T=P6S$L W/),IBC$CX! .O^!?QTT/]HO0X/$'A^?SK2;Y71L+-;S* 7@G0
M$[)4R,C)5E*R(SQ/'(P!S]U^U;X!T^\O-/N?$FCV]W87#6US#<7\$#),JJSH
M!*Z;]N\([)N5)5DA8B6*1$ .P\%?&_PK\2KAK/0];TO4KE(S*\-G?6]Q(L89
M5+E(I&8(&95+$8!91G)&0#U"@#Y_\=?M0^$OAEXAA\,ZWJ5OI][-I[Z@)+N6
M.VMUA698$4S3.B-+*WF&.)-[;()6?8/+\P Y"3]N/X<IK,>BCQ%I;2/9R7;7
M0O;;[&BI+'$L+7)E$1N)"[.D"%G$<4DCB-3$9 #O_!7[17AKXA^)=5\)Z9>Q
MSZIHT<3WB*R[0SLZ21Q_-ND>W946Z*J4@>:*)G\XO'& :'Q6^.FA_!J72[;5
M9]MWK.H6VGZ?;)AIIIIY8XBP0D8BB\Q7GE)"HI51NEDACD .0\-_M9^#O%GC
M&[\"V>HQR:W9Q[GC_P"6<DB[_/MXI,[9+BW50]Q$O*!F W-!=+  >WZ_XLT[
MPI]G_M"[M[3[7<1VMMY\R1>=<2Y\N"+>1OE?!V1KEVP< X- '/\ CKXL>'OA
M?Y/]O:KI^F?:-_D?;;N&V\WR]N_R_.=-^W>F[;G;N7.,C(!V&DZM;Z_;Q7EG
M+'/;3QI+#-$ZO')&ZAD='4E61E(964D,"""0: .?TSXA:-K6EG7+74+.;25C
MEE-_'<1/:B.$L)7,ZL8@D91Q(V["%6W$;3@ S_ OQ8\/?%#SO[!U73]3^S[/
M/^Q7<-SY7F;MGF>2[[-VQMN[&[:V,X. #T"@#YP\6_M;^"O ?B4^%=4U>SL]
M12S:[F-Q<0P00+NB6.&665T47$JR^;% -S^3&TKA$:$R@%__ (:Q^'G_ $-?
MA_\ \&UE_P#'J .@^.GQTT/]G30Y_$'B"?R;2'Y41<--<3,"4@@0D;Y7P<#(
M55#2.R1))(H!T'PT^*NA_&33DU7P]?V^H63[1YL#AMC,BR>7*OWXI0KH7AE"
M2Q[@'13Q0!T&@>+-.\5_:/[/N[>[^R7$EK<^1,DODW$6/,@EV$[)4R-\;8=<
MC(&10!Q_@KXW^%?B5<-9Z'K>EZE<I&97AL[ZWN)%C#*I<I%(S! S*I8C +*,
MY(R <!\9OVL_!WP!U32]'\0ZC':W>JR;8E/*PQD,%N+ILX@MVD40K*_!=BW^
MIAN980#W_2=6M]?MXKRSECGMIXTEAFB=7CDC=0R.CJ2K(RD,K*2&!!!(- '/
M^/\ Q_I?PLTNYUK6KF.STZSC,D\\A.U5R    69V8A(XT#/([+&BL[*I /C#
M]G7_ (*#Z'^U#XRO/#'AZSN#96>GS7?]I3L(O.:*YB@VQ6VUG\IUE25)97BE
MZH]LA&: /N_5M6M] MY;R\EC@MH(WEFFE=4CCC12SN[L0JHJ@LS,0% )) %
M'Q!\"/V\=+_:'\:W?A/2-.O(K:UTLZ@+^[!MVG4S0+$8;5E+_9YX;B*Y@GD:
M-W1P#;J"&(!]WT ?.'BW]K?P5X#\2GPKJFKV=GJ*6;7<QN+B&""!=T2QPRRR
MNBBXE67S8H!N?R8VE<(C0F4 W])_:;\"Z_<16=GXET.>YGD2*&&+4[1Y))'8
M*B(BREF=F(554$L2  2: ,#PW^UGX.\6>,;OP+9ZC')K=G'N>/\ Y9R2+O\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MV\4 9]K\(=+_ &=?VF=#L?#*R6%CK6EW=W=6<3E;<-)!J&Z%(UP!;^9:Q3K
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M5X#\,>/_  U>Q>,4DDT*TC:]O$2>ZA7R[56E+2"S=)9D0*9!$=X+HCA#(D9
M!\ ?LY?L3_!C]H[PQ:>*+/PM):VU[)=B&*74]0:01V]U-;HS[;O:KNL0D9%+
MB,L4$D@7>P!YA^QE\-[/X!?'[Q?X3T-[B+18M'2X2U>9G4,YT^9 <_?\G[5-
M% \F^58G8-([/([@'W?X_P#^">_PU^*>J7.M:UI$EYJ-Y(9)YY-2U'<S8
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MX@^&-_XO\/Z-<:?*_A]]8L93>W331[;7[9$DD<MQ<0G< (YEP_RL^R17V2*
M?5__  3+U:XUKX2>'9;J62:18[R(/([.PCAOKF*) 6)(2.-$CC7HB*J* J@
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M)%3;!/$APTKG<06.[!.   #\D/\ @HQ_P3]\)_#+1M#G\#:;):ZMJ.N6^E)
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M'['4 ?F!^VQ\./A:?$.A2^+](N-6U_Q+J%GI5BOV_4(DCA\Z&*63]W.L,,4
MG$GE1J&GGESM'F3W$8!Q_P"TO_P35^&'A7P5K^IZ7I,EE?6&EWEY;W$=]>2,
MLEK"TZ@I<331,CF/RY 4)V,VQD?:Z@'L'_!/32;?XI_!C0;/7XH]4MI([J)X
M;U%N8VCMM0G6W1DF#J4B6*)8E(Q&(T"@!%P ?.'[#W[-\'@_XB^.Y/#4]PG@
M:/SM%\L7EQ%,=17[/)/'&4,<P^Q%[B"&[9EF59D,,\[--, #Q_4?V&/ G@+X
MVVOAC4M)N+CPWXAT>6728%DNXX;:^ME#SHUU]J$LV(K:65AO8HU[ AA"!):
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MQX9LO&_P@\2I)>6FCWGE"1YV"SZ?J\$FU(XXW8VJ21QM=%8YBZO>."$F1V<
M\P_8H_8RE\3:'K/A7Q)-<2^$].\4:O&;>,RV@UN:W%O:1S3%-LB6EL]M(\<<
M%Q(LUXQ$I0V"BX #QI^S+9_L)?%#PCXI\(17":!KFH)H=]8?:F"0S7J"&+]Y
M(\DT\3G-WY,BR*D]G_KH_-@6$ _;Z@#\<?'_ .R+X(^)_P >+G3M4TF.2TO/
M"9U>XBCFGMUDU ZD+=KD_9Y8R':,?O "$D<M,ZM,S.0"_P#M5?\ !-#X<>&O
M VO:EH.F?V=J5AI\][!<_:KVXQ]D7[0\?E371C/FI&T.Y@WE^9Y@5F0 @'T!
M^P.D7QI^#F@0>(X+?4[=K>6V>"YMXI(7AL;R6"U1XBGEMY:00A692Q9!(Q,F
M6(!\X?L$? )/AK\3?&M]X6FD'@JTD?24ADGD+-J41MIIHQ$P#.EDS7$$<\V6
M*3*(Y;C?/* #C_V=/V,I=&\7^/O!UM-<6O@XZAI1NFA,L3W=LUM<78T5)F\Q
M_*"WL*WTZ7"W+01)%L"Z@SP '/\ [8'['FC_ +%LNC_%'P%;7%K%H6H6AU/3
MTO) LMN\NTN+B>229/-+K93QJ)TDBG5O*1(Y_- /U/\ VI?@[X.^+/AJ^/C.
MWC:QLK.YF-\(]UU8QHHEEGM9%225' A5V5%83",1R1RH3&P!\W_\$K/AOKGP
MV^&MJNMOE=0N'U#3X?.,OD6-U%"T2XY2+S&$ESY2$@>?N?;,TJ* ?H_0!^./
MP(TFWT7]IWQI%:Q1PQMH:2E(T5%,DPTB65R% !>21WDD;J[LSL2S$D ]_P#V
MG_B5X:\0^-=&\#>*KVSL=$@LWU_45U"58+74&CF^S:?8F1[F))$$WFWL\$T<
MJ2FTMQM93+M /D#X3_&_PKIW[1OBS7)];TN/2;G0X(H+][ZW6UED$6D@I'.9
M!$[@QR JK$@QOQ\K8 /V^TG5K?7[>*\LY8Y[:>-)89HG5XY(W4,CHZDJR,I#
M*RDA@002#0!\@>/_ /@GO\-?BGJESK6M:1)>:C>2&2>>34M1W,V   !=!515
M 2.- J1HJQHJHJJ #\\/^":_P$\.67Q*\=W,=GB7PQK#VVC-YTY^RPRRZG:R
M)@R8ES$BING$K#&X$.2Q -#_ (+&_"'2_"5EI?Q"TQ9++Q&-4MK1[NV<Q-(J
MP3S0S.5PWVB!K=%AG5E<(=C%Q'!Y0!]G_P#!0/\ 9+TS]HGPOJ&H>3<2Z_IN
MGS2:6T;W4V&B(N'AALDF6%I;H1_9S)Y;RG=&<2>3$@ /F#]EC]@KX4?M$_#K
M2-:;1KB&]OM/,-Q=B]NDF%Y#OM;BXCC^T2VXS/%)+"&C:,J4W0@;H@ '_!*#
MPU!\8/A+JN@ZV]Q<::^L7=J8!=7$.VW:WLYG@1X9(Y(XG>21I(T94D\V4.&6
M60, =?\ M+_\$U?AAX5\%:_J>EZ3)97UAI=Y>6]Q'?7DC+):PM.H*7$TT3(Y
MC\N0%"=C-L9'VNH!]W_LG?\ )//"G_8OZ3_Z10T :'[17@/PQX_\-7L7C%))
M-"M(VO;Q$GNH5\NU5I2T@LW269$"F01'>"Z(X0R)&0 ? '[.7[$_P8_:.\,6
MGBBS\+26MM>R78ABEU/4&D$=O=36Z,^V[VJ[K$)&12XC+%!)(%WL >8?L9?#
M>S^ 7Q^\7^$]#>XBT6+1TN$M7F9U#.=/F0'/W_)^U310/)OE6)V#2.SR.X!S
M_P#P5Z^!>A_#C3M,\>Z%!_9>O_VQ'#)<66+?S6D2YNQ<R",*?M:2Q;EN5*RM
MO;S&DVPF( ^O_P!IWX'_  X\?>._#MAXGT2XU35_$OVV&*Y;4;V*&VM],M&N
M&"Q1W*HNYF0+%$B(S2SSNXD!$P!H:M_P2L^$FHV\L$6BR6TDD;HD\6H7QDB9
ME($B"6XDB+J3N42)(A(&Y&7*D \ _P""5GP7M_&?PAO].\1V,=SI.N:I>2I%
M(599K=8[:WWC8V^)TGMI/+;,<T;Q+,A7]VY ,_\ X)2:!_PKOQ#\1O#%M<7$
MNFZ1K$,%K'-)NQLFOX#*54+&)9$MX1*Z(F_RT& J*% /+_VI_P!B[P9\-?B;
MX0O;K3KRZ\.>)+R;3]3@\Z]F9M2N"PM[B:^ENC-OGEN$D=/,1BEG-(HG+2(
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M?"34;>6"+19+:22-T2>+4+XR1,RD"1!+<21%U)W*)$D0D#<C+E2 ?GA^R_\
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MDDDLSLQ+R2.6>1V:1V9V9B =A0!^6'_!(#P!JG@7X<R2:G;26JZEJDU]9B0
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MGPP^&&@Z7K-M)9WT<=U));R@"2-;B\GN(PZY)1S'(A:-L/&24=5=64 'S_\
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M\RYN;P ^[Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,_5M)M
M]?MY;.\BCGMIXWBFAE17CDC=2KHZ,"K(RDJRL"&!(((- &A0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MDTFS3);B>-KJZ6,M'<22V\0=+9$F5XHAY\KRA&D9(5,?F 'T?0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M/,S:K;XBAMW?>-K(@!^E] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'C_Q9^"FG?&O[%!K$
MEQ+IMI<"XFTQ606=\Z8,*WR&,R311.!*D'F)!)(%,T<RHBJ :'Q>^-'A_P"
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MX.DN[BYO-098&FU"98GMH+=+>24.\$D%O<OF784)69$#0K= '['4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * /R _P"%R?M0_P#0F>'_ /P(B_\ ES0!0O?B=^TSJ+PRS^!_#<DEM(98
M'>6!FBD,;Q%XR=8)1S'))&67!*2.F=K," 7_ /A<G[4/_0F>'_\ P(B_^7-
M%"3XG?M,S7$=XW@?PV;F*.2*.8RP&1(Y6C:1%?\ MC<J.T43.H(#&.,D$HN
M"_\ \+D_:A_Z$SP__P"!$7_RYH /^%R?M0_]"9X?_P# B+_Y<T '_"Y/VH?^
MA,\/_P#@1%_\N: /U_H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M2"[B..20JN2$C=\;58@ Y_7?'^E^&;_3]+O+F.*^U62:.QMR29)V@A>XF*J
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MZLH .@LM6M]1>:*"6.22VD$4Z(ZLT4AC24)( 24<QR1R!6P2DB/C:RD@&A0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M^'7A+6M;TK4]8%[INGW-[$+F2VFA?[+&TS1ND=M _P ZHR*P<>6S"0K(%,;
M'/V_A#PS\7/@7X9\2?$OQ!K%MINE6\]M;6%A)9Q+<36US<VMJD<+6K-/=_9X
ME@C9WVQQ)),QB5KN=P#W#5O^"*'@6:WE6SU77(KDQN(9)9;26-)"IV,\:VL3
M2(&P619(RP!42(3N !U__!);QEK'Q+^&-S:7VH7!:QU"YTZQN!Y;S6MNMK;/
M$L9ECD1_):9S")EE1%"1;3"B1@ Y#5O^"*'@6:WE6SU77(KDQN(9)9;26-)"
MIV,\:VL32(&P619(RP!42(3N !]/_P#!,O5KC6OA)X=ENI9)I%CO(@\CL[".
M&^N8HD!8DA(XT2.->B(JHH"J  #[OH \_P#BK\-[/XP:'?\ A_4'N(K34+=[
M>9[:9H)E5Q@E'7_QY'#Q2+F.6.2)WC8 _"']C/\ X)?^#?VB? FE^)]5O=8A
MO;[[7YL=M/;)"/)NYX%V+):2N,K$I;+MEB2,#   >(OV=?\ AW;\6O!$_A6\
MN)M-\07"Z=/'>3;Y7\VXB@NED6WBMHVB"7-O-;AO,Q=0^8ZE8T# 'TA_P5;_
M &9]+.B2_$[3))--\1Z/)9,]Q;91KI3<0V\+.RLK)<0,Z/#<J=X1/)8,! UN
M =_^T1X9T'XZ_!S0O$OQ%U/5(K&TTO3M5O!IJ6JR75]<VL4:':]M( [27#QQ
MK&8+=3.6EPB*\0!Q_P#PY4^'G_02\0?^!-E_\@T >8?L"_!"X_9Q^-/B_P +
MZ?<7EUHEEI<1:5U98S)<-:7%FMQL_<M<)%+<QQN0AD"W#QQQJTB* =!:_#SQ
MC\./CGXHTWP[J<GG>)]#348;NZD^U1V$;WL$+3SV[M"LKVBI=P:9"HG""6TB
MD(MVNWC /+_VKO\ @GS>?LNV9^)?@+6M8FUK2KA[V^>\=;JYD65@);A'BMTW
M[=[O>)<K)%-;-,\CJL;QS@'[G?#WQK;_ !*T;3]<LUD2VU*SM[R%)0HD6.XB
M65 X5F4.%8!@K, <X8CD@'84 ?"'[4'_  3T\*_M9ZS!KFN7>J07,%FEFB6<
MUND9C2664$B6VF;?NF8$A@,!?E!!) /R0_;C_P"">&G?LFZ=HVO>"K_6)M2F
MUB"RA@=DEN#<2I)-;26KVL4$B2J\!5559'=Y$*-&T>) #];_ -IC_@G]H/[5
M^J1ZGXAU?7 L$?EVMG;W%JEK;J0OF&*-[21M\C*&ED=G=R%3<(HXDC /S _:
M%^!=_P#\$L-4T3Q=X)U'5+C0KF\CAU:RN+F%5GDB#R)!+Y<:I(D\!N5B9K:0
MV;QM,LGF21!0#[_^-'_!++PA\>O$%]XEUG5-<:^OY \@BFLHXT5$6..-%^PD
MA(XT2-2Q9V"AG=W+.P!Q_P#P3O\ A-_PSOXO^(/@NVO;B[TW3;C19K43'&W[
M;;3S$E%/E^;L\F*65%3SO(1MB*%C0 _5^@ H _%&;_@FW\-/C/XQ\16$NL>)
M+C6[&2VO-7E,EC'&;C5?.N%"[;!5+E5\UQ&@A02QJK%A(D8!\_\ [;/_  2Z
M\*_L]>"+[Q1H>HZH]S826I>*\>WFCECGGCMRH\J"!HW#2K(')D&$9/+RX= #
MZ_\ C+\64\/>'/AMX0\<7=YIUCXDLXD\1WDUQ)!<,MK80>997DCQF>-+JZGB
MCOIO,A=(5F2214EE>, ^8/VC_P!F._\ V'-+?XD_"+Q!>0:3-);/<V:RPW-K
M]GNC,D%PKR,8KNW0W$,-M'+%=3*93<BX."R@'H'_  4CLG^-'@KP9X\OYM4B
M\.2R:9/JVCV0CF6"#4(1*UVDS)&OVB-6-I$]R#"SSQ!%MS),MP >G_\ #E3X
M>?\ 02\0?^!-E_\ (- &!_P22TZ\^'6H^/?!;W7VFRT+6(HX6\I8]\Q>[M9I
ML LX\U;. ^6SNL>WY3EG9@#]GJ //_BK\/8OBSH=_H$]S<6EOJ-N]M/-;>5Y
MPAE&V5$,\4T8\Q"T;,4+*KDH4D"NH!_/#\#O^"='A+Q;\1?%O@+Q!J.H)<:/
M]GN=+%G+&&FL9OG+W$DMFT9EC2XLED51$#+)+L$D:[E /</@S\&7_8C^/FE>
M$/#VJ7DVB:]I<ES=07'EEG6.WOC&DI151WCFM3+%,D<+HDK0<JTK3 'H'P0\
M%6_[!'QIN/#,;26WA7QC9JVE>85:-;R%MT=O)<SK&V^-FN8(8HWGD<7=B)?,
MED#H :'Q+T#^QOVJ/#,_VBXF^V:/-/Y<TF](-MEJ<'E6ZX'EQ'R?.*<YGEFD
MS\^  >7_ +</['UO\"_$'AWQ'\*/,TWQ5J&J/!;Z5:,I$KE)9Y;J&.5]L-O$
MO[F\B*_8%MY8PZ01"03 'U?_ ,%%?V*/"_Q<\/:SXO\ )^Q>(=.T^6[^W0Y_
MTA+&&23R+B+<(WWH/+$^!/'LA^=X8O(< \ US2=<_:F_9CAU#4-3N)-2L[>Z
MOYII)B@NX=*N[E3%=E49I_\ 1XMZ;\-)>16\TLNX.Y /3_#/[*-_^W)X0T&\
M\>:OJD&F1Z7I;Z=8VLT(EED^Q1BXU'49I5NQ<7%Q(SM;\J8+4J7"W-S=1H 9
M_P#P3QT[7/V;?%OB'X2:Y=7%Y;V=O%JFBS>44MC:/)MN'B,A\Q?,>>'=#&9;
M>.YBO LGF;WF #_ARI\//^@EX@_\";+_ .0: /,/V!?@A<?LX_&GQ?X7T^XO
M+K1++2XBTKJRQF2X:TN+-;C9^Y:X2*6YCC<A#(%N'CCC5I$4 _<Z@ H * "@
M H * /YT?&/[2&I>,_&,_P 5)O#>J>*/#FDR74/ANU%M>1Z?9V]KM\[6FNS9
M^0KN\3LD;QS31/YAFEMCIUD9@#]?_P!D3]KO1OVO]&EU/3(I+2YM)$AO;*9X
MFDBD:)9-Z>6Q9K=F+QPS2)"93#+^Z0H0 #Y?_P""J?P4\-7_ ,/-:\2OI=F-
M;@DT^1-12%4NBQNK>TQ),@5Y4\F1HQ'*70 (P4-'&R@'V?\ LG?\D\\*?]B_
MI/\ Z10T ?0% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_!7;P+\-?"NB:'>:?KCW.FZ78V<SQ6]H8VDM[>.)RA:\5BA925+*I(QE0>
M:'P5^(47[='QMTWQ[X9MKBWT7PSH_P!FU W_ )44QFN5U)(4BCAEGW[O/W;B
M555AEW%6,2R@'T?\:/\ @JMX%^"'B"^\.7EOJEY<V$@BFFLH[2:W\S8K.BNU
MW&V^-F,4JLJE)D=",K0!Y!X0\>V__!2+QYX9\0Z3H]Y#X7\'27=Q<WFH,L#3
M:A,L3VT%NEO)*'>"2"WN7S+L*$K,B!H5N@#V_P#X*%^%KS1/^$7^(-A'J$S>
M$=82YOTL67>-(FV'4'V$H\GRP1Q,H=8Q!+.9AY.^2( ^</&O[1WB#_@I1;KX
M1^'NGZIH^@W4@76O$-XJ1QI;HK?:;$)$9%D=UDMV$<=RDTP9H9(X[1IIJ .@
M_P""M/@!-%^&GAWP]H=M(T<.N:;8V%I$))I"J6-Y#!"@)>61\!47)9W..68\
M@'['4 ?C#_P2@\4V?P;^$NJZ_P"(9/[/TM-8N[G[5.K*CPK;V<.^+C,N94>!
M%B#M).IA0-+\E &__P /J_AY_P! WQ!_X#67_P G4 =!_P $COC#%XO\"6OA
MV#3]07^QOM2W.HR1Q+8O-/=RW"00R><99)1%,KR 1!8@!O9?,A\T _5^@ H
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M'#3* >X?LV?L^R_"#^T]9U>Y^W>)O$-PMWK%RCRFW5DW^1:6:3,SK:6JR-#
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M-?!6W^R^'-+L]-C:.&.0V\*I),L"E8S/+CS9W4,W[R9G<EG8L69B0#U"@ H
M* "@ H * ,_3-)M]%0Q6L4<,;22RE(T5%,DTC2RN0H +R2.\DC=7=F=B68D@
M&A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M\4:7'JEKXLU.UA2ZNH+%1:VT=O!%]FM9IV:*WW1OM7=(2_F,\LLQED8 ^S]
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M#:KNL3N(\[PFR1E"2Q,X!Q_@;XZ:'\2=<UGP_I4_VF[T'[*NH.F##'-<F<"
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M.YR%5%4 -(Y5 [Q1;O-FB1P#C_\ AK'X>?\ 0U^'_P#P;67_ ,>H ^@* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \_\ BQXZ
M_P"%7^'M5U[R?M']F:?=WOD;_+\W[-"\WE[]K[-VS;NVMMSG:<8(!\@?L;?L
MX:&GP>TGP[JEM;W]EK.GI?7RF$1><U^!=*7*L7,L"M%#'<!A*OV>*1#$414
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .?\6:C>:1IUW<Z
M?:_;KV&WFDMK3S5A^T3(A:.'S7!2+S& 3S&!5-VXC - 'QA\,=:\:_M3_"W5
M[?Q1I$>@Z[J=GJFGP12K-!&ZS0/##</!)YMQ;)O<HR2>8["(W" QS1H #/\
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M-0!T'@#P!I?PLTNVT71;:.STZSC$<$$8.U5R222269V8EY)'+/([-([,[,Q
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'C_PF^ /A?X%?;?\ A&M,
MM]._M&X-Q=>2#\[\X4;B=D29;RH(]D$.]_+C3>V0#V"@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#R_X>?"'2_AI<
M:G?6:R27VL7DEW?7D[F6XE8LWDPF0\BWMHR(+6!<)#"N "[2.X!ZA0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!X_\ '3XZ:'^SIH<_B#Q!/Y-I#\J(N&FN)F!*00(2-\KX.!D*
MJAI'9(DDD4 Y_P#X:Q^'G_0U^'__  ;67_QZ@#V#PMXLT[QS9QZAI5W;WUE-
MN\JYMIDFA?8Q1MDD99&VLK*V"<,I4\@B@#R_4_VE/!VB^)1X0NM8LX==:.)Q
M9R2;&)F94BB#MB(W$A=#';;OM#HRR+$8V#$ ]PH ^4/ ?[<?PY\?V":C%XBT
MNTCDDG1(KV]MK6XVPS/")&@EE66-)0GFQ"14<PNC,B,2@ /3_"W[0O@WQS>1
MZ?I7B#1[Z]FW>5;6VHVTTS[%+MLCCD9VVJK,V <*I8\ F@#D/#?[6?@[Q9XQ
MN_ MGJ,<FMV<>YX_^6<DB[_/MXI,[9+BW50]Q$O*!F W-!=+  ;_ ,;/VBO#
M7[/:6#^(;V.U;4KR&TM49E#,TDB)),V]E5+>!7$MS.Y5(DP,F62*.0 S_P#A
MK'X>?]#7X?\ _!M9?_'J /<-)U:WU^WBO+.6.>VGC26&:)U>.2-U#(Z.I*LC
M*0RLI(8$$$@T > :9^V)\.=60R1^*M#"B26,B34;:)MT4C1L0LDBL4+*3'(
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M#'( >X:MJUOH%O+>7DL<%M!&\LTTKJD<<:*6=W=B%5%4%F9B H!)( H \?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MU=7&FV7B#P^M[?ZA;AUFT_[;J,?VF.VED6=#=W;65P8&8P?9EGEGA5C8I%*
M<_\ MK_\$VO#GPX\+S>*_A[!<:1J^@?Z>1#>3OYL,)5Y)!)<W!>&6V56N8I(
M6#-L>/RY)'B:( ]?_; USX<>,/ .C_$GQ[HUQ?RW6GVATS34U"]11<7\'VH6
MX:"2*%.%8SW;1!VB@4;9'2" @'J&K?\ !*SX2:C;RP1:+);221NB3Q:A?&2)
MF4@2();B2(NI.Y1(DB$@;D9<J0#Q_P#X(PZM<:C\.;N*>622.VURZB@1W9EB
MC-M:2E(P20B&2220JN 7D=\;F8D _6^@#\@/^"K7[)>F>.?"]_XVLH;A]?T[
M[-))('NKG?8QDQ2PI 9C#;11B4WDDD<6!Y,KL!YLLM &!\5?V"OA1X@^&-_X
MO\/Z-<:?*_A]]8L93>W331[;7[9$DD<MQ<0G< (YEP_RL^R17V2* >__ +!7
MA:S^-OP0T;2O$D?]I65U;WMM-%<,SYAAO[B.%%8G>GDK'&(&0JT'EQF,H8T*
M@'@'_!*30/\ A7?B'XC>&+:XN)=-TC6(8+6.:3=C9-?P&4JH6,2R);PB5T1-
M_EH,!44* ?5^K?\ !,[X4Z_<2WEYHDD]S/(\LTTNJ:F\DDCL6=W=KPLSLQ+,
MS$EB22230!\8?L-^!?\ AG?XY>-/!&ES?\27^SUO4@V?=_>6DUK'OD:24_9X
MK^6#<9/WW^M==VT( :'QA_95TO2/C=X2/P^BCTK48HQJVNV]NQM+6+3;:>&W
M$D21HJ[[M3/9RP0%ED.UI8HDDGGD /M_Q_\ \$]_AK\4]4N=:UK2)+S4;R0R
M3SR:EJ.YFP   +H*J*H"1QH%2-%6-%5%50 ?FA\2_@=!^P=\9O!NH>#!]ETC
MQ)<1Z=+8O<7$H&^:&VNU.Y@[1%;BWN8!++/B\C9RHCCBCH ]PN-)M_V9?VC7
MU*2*.'2?%NAWDKW3(MI:V<EM$+J]=I2#%,^=/$]RQ,14WPED)QNF /7_ /@G
MG\+[C3KWQEXX?S%L?%NN376EI)"T32Z>D]S+;W@#D2JEP+IO+26.)PD:RC>D
MR$ 'RA_P3K^%N@^+?@IK'_"<6]Q_PCRZQ>:E+^\O+=)K>SM+;=+_ *(\<EQ%
M&\,OR#S$,\/"&:%=H![?^SE^Q/\ !C]H[PQ:>*+/PM):VU[)=B&*74]0:01V
M]U-;HS[;O:KNL0D9%+B,L4$D@7>P!YA^QE\-[/X!?'[Q?X3T-[B+18M'2X2U
M>9G4,YT^9 <_?\G[5-% \F^58G8-([/([@'[?4 ?EA_P4K^"_A_Q]<>"KS4;
M&.6YNO%FDZ1/,"\<DFGW;3--;,\;*Q0LH9#G?"6D,31F63< >H?\.N/A#_T+
MW_E1U+_Y+H ^8/\ @DEIUY\.M1\>^"WNOM-EH6L11PMY2Q[YB]W:S38!9QYJ
MV<!\MG=8]ORG+.S 'U?JW_!,[X4Z_<2WEYHDD]S/(\LTTNJ:F\DDCL6=W=KP
MLSLQ+,S$EB22230!\(?!;X;R_L7?M")X3T-\>'O$VGRW"6KS2RF*%(;B9 <[
M%,L-Q:310/)]H9;.9@TC32R.  \#_L2>$+OXS>)_"GB72+C4K*\T^+7M*N[G
M5+DS*CS+%=*[0RI+-YES/*BO=.9U6U#,9C,9F -#_@H%_P $_?AY\(/AYJ7B
M'P]ILEAJ-A)9O'(EY=3+(LUU%;/'(ES+,NS;,7!0(X=$^?9O1P#L/BG\./AZ
M=.\!2_$;2-0U;QCXEM]#TH+=7^IQ2QMLM8KN2?,ZI#Y#3F22(*)9[J4EE#27
M%Q& =?\ M+_\$U?AAX5\%:_J>EZ3)97UAI=Y>6]Q'?7DC+):PM.H*7$TT3(Y
MC\N0%"=C-L9'VNH!] ?\$R]6N-:^$GAV6ZEDFD6.\B#R.SL(X;ZYBB0%B2$C
MC1(XUZ(BJB@*H  /N^@#\,?^"G/[*_ACP=<:5\1);*\N;8ZY /$\<<EU<R7-
MG,R9;S);G;:I&L/V2!(_(CS<PQ+)$(XE( ?\% O^"?OP\^$'P\U+Q#X>TV2P
MU&PDLWCD2\NIED6:ZBMGCD2YEF79MF+@H$<.B?/LWHX!]?\ BO2?#_Q/^".D
MR^.8KS4X)M#T>4O CW.I2:A<0016[VAP[M>RSS+&C/E)&E9)R8))@0#XP^ .
MM>.?^"96HZ9X9\=-;WO@S6;@0V^H6\[-;Z5>2N<AI;A(/*B;F:>*0+'L,EU
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M.AV/AE9+"QUK2[N[NK.)RMN&D@U#="D:X M_,M8IU@;<D<P!C"(D21@'K_\
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M!XT\(^*M#DNKGP]JD)L[R749UDDT^^21[-72SDAAW^5"L[/C>QN3&T<1BVT
M<_\ \%&/V)O#'[/6C:'KG@"QO+#6WURWLX$M+JZGDEDFBEEA,0DDEF%PDL""
M P,AR[95V\LH ?I?_P %!_@7H?QE\ ZO<ZK!NN]&T^^U#3[E,+-#-! TI4.0
M<Q2^6J3Q$%74*PVRQPR1@'C_ .Q3\,=,_:1^"'A_2O%:W&H61^TAHC>746];
M6_N8[>-V@FC=XHE2,1PN3$GE1$(#%&5 /D#]AW]ACP)XMO/%GA7Q?I-Q?ZUX
M<U@Q"[EDN[)9K&=2MHZ10W2X\S[/+< LK Q3PE9I5/R@'H'[&7PWL_@%\?O%
M_A/0WN(M%BT=+A+5YF=0SG3YD!S]_P G[5-% \F^58G8-([/([@'V?JW_!,[
MX4Z_<2WEYHDD]S/(\LTTNJ:F\DDCL6=W=KPLSLQ+,S$EB22230!Y_P#\$P_!
M5O\ #71O%FAV;2/;:;XTU>SA>4J9&CMXK6)"Y554N54%BJJ"<X4#@ 'Z7T ?
M.'QO_9)\&?M'W%O=>*K"2_DM(VCMP;V]ACC5VW.5B@GCB#L0N^3;O<)&K,5C
M0* ?CA_P4=_9+\.?LA:=H'C3P)#_ &3>V>L1QE=\]UOFV-=6TV;N:9%\AK5A
MY>PK+YWSG$85@#]/_P#@H/\  O0_C+X!U>YU6#==Z-I]]J&GW*86:&:"!I2H
M<@YBE\M4GB(*NH5AMECADC /#_V2?ADG[37[/EAX=UB>1UOK.]MDGD:21H&M
M[^X%DX D1G2V:& QP[U0I$L)Q%\M 'F'[%/[(<'QV^''A]?'<=Q+HMM;W+:;
MHHGN+:)GGO;F?^T[CRA;RM+)%*L5I'OE@CM=UPCLU\R0 !\'_@=_PPW\;;32
M-&%P_AGQEI]Z+:)[C"VMQ9*;MT*[G>X\A4"023+&ZQ7S+YLKQ3-* ;_[=O[)
M,'[1/BVQ_P"$-/\ 9OCFTMXM1N]1)N+>T%FDAAM&FN((92-0,L1^Q%,2&WM;
MGS&VPV@ !R"_M$7_ .T;X#\2_#;QQI4G_"?VD<-@FG1R0PRZE=R,&LKR"(31
M I!)''>7SQ%K-;5/MBL;67R(P#T_]L#X3_#CX'^ ='O/'ME<:_+H6GVFC:9&
MEU>VBW-PD&!B*"X\FV\T0-)/,P=Q%$J;IWC@B8 ]0U;_ ()6?"34;>6"+19+
M:22-T2>+4+XR1,RD"1!+<21%U)W*)$D0D#<C+E2 >/\ _!&'5KC4?AS=Q3RR
M21VVN744".[,L49MK24I&"2$0R222%5P"\COC<S$@'ZWT % !0 4 % &?JVK
M6^@6\MY>2QP6T$;RS32NJ1QQHI9W=V(545069F("@$D@"@#\ ;;4OBIXK\07
MOQG\/^%9-2DO(YTT9-1$)CL]$C3$,EM9"^^W&]N5#,1;^7$1+<-"EXNI+]F
M/T?_ &"_VTD_;'T:[GN+6.RU;3)((KR")Y'C=98LI<H711&DLB7"K!OF>(1#
M?(V]68 ^K_BK\2].^#>AW_B'57V66GV[SRX9%9]H^6*/S&1&EE;;%"A9?,E=
M$!RPH ^8/V-OV:[SX.2^(/$VL?N=:\6Z@^HW>GI(LT-@K2W$T5J)E5?/E3[2
MXGF7$3-M6-=J>;, ?;] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MJ]^SUX6O/ W@WP_I6H1^3>V.CZ=;7,6Y7V30VT<<B;D+(VUE(W*64XR"1@T
M?"'P6\ :I+^T1XV\0BVD_LF/2[.Q:[( C-U):Z5,L*DD%W$<;.^P,(P8]Y7S
M8MX ?L8Z_P"*O"'C7Q?X9NO#5Y;Z3>>)-=UD:W="XMX'CEFCABBME:U,5P[E
M4D4^?&#"9)%W>6%D -#]LW]GKQ1X<UR'XK?#9\>(K"W$.I:8L0*ZK9H<D,B!
M7N)0H5&B=C)+%%!]F>*ZMH%E /T?\)ZC>:OIUI<ZA:_8;V:WADN;3S5F^SS.
M@:2'S4 27RV)3S% 5]NX#!% &?X_\?Z7\+-+N=:UJYCL].LXS)//(3M5<@
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MXDS&6A7RV$A9 #[/H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?.'QF_:S
M\'? '5-+T?Q#J,=K=ZK)MB4\K#&0P6XNFSB"W:11"LK\%V+?ZF&YEA ._P#'
M_P 7M+^'WAJY\5R-)>:7;69O0]BANFF@VAU>'R\JR,I#>:66%$)EDECA5Y%
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M +*^S1BZ$<UTEQ<.)&N84%I%/L^S8BCD,K(YG:6+RU\@LX ?\/1_A#_T,/\
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MA^UUX(_:.N+BS\+ZM'>W-K&LLL)AGMY!&S;=ZI<11-(@;"NT881EXPY4R)N
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ML/A#\:/#_P >M+76?#5]'?V+2/$9$#HR21GYDDCD5)8WP58+(JED9) "CHS
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M2L ?.'@;X.6?[)/[2&E:)X8;[-I&NZ/-)):8:3RX1;W+-#YL[S2MFYT]+GS
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M?\ :7\,/VDO&&EZ-;1V=C'H8DCMX@1'&UP=)N) BY(1#)(Y6-<)&"$15154
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MX0\2#1[C6_#.BZA>7VLV]O#',T#I:E+2\(96=?LJR75PCYC@$L<8DFA<P2*
M?.'_  5#_94\-:GX(NO'UGID>CZ[;R6<]V%15DG6ZG\N6&X6WF-J;CS;H2RW
M2_:'D,/EB5XV5U .@_;@TFW^+_[/VG^*M<BCNM;@TO0[V&]**DD=Q?-91W3+
MY810DJRMOB \DD1ML#11% #O_B%J^C> ?@+HGBC4]"TO7;G2O#>C"RBU*VBG
MCCDNXK.WW?O$9@@9DDD2,QF81!/,0D.H!]G_ /#)WP\_Z%3P_P#^"FR_^,T
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M;X TOXI_"CP]HNM6T=YIUYX;TF.>"0':R_8X2"""&5U8!XY$*O&ZK(C*ZJP
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M)([236(RKKJ6JQQ).D)>VG$MJ^G@P127ACDG+S- (S_9Z*P!S^G^.]4_;?\
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M ((PZM<:C\.;N*>622.VURZB@1W9EBC-M:2E(P20B&2220JN 7D=\;F8D /
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M T/^"@?["?A+Q)X&U#5=!TK3](U31+>:_BEM(([-)885$ES%.L$6)<Q(Q@W
M,DZH!+'$\X< ^T/!7AS1OVFO"OA[7/%6CZ7J%S=:7:7@2XLXKB."2\MX99A
M+@2M&A;:,;B2$3<S%0: /A__ (*0_LT>"M"^'EW)H^@:7::V]YI\.E"QLX;>
MZGNIKJ.,V\*VZH]R[PM.?L^) 0IE$>Z)70 S_P!O;X%V?AOX#6L&KP6]QJ_A
MC3]&M[>[CW'RIA)9V5R87(1VBE7<"CJ%?$<C1B2*,H ??_[)W_)//"G_ &+^
MD_\ I%#0!] 4 ?BC_P %"/ &EZ%\5_AGK5K;1Q:CJ6N01WLZ AIUM+S3A 9
M#M9T65T$F-Y39&S%(HE0 ^C_ /@ISKD7A;POHFHWUC_:&D6?BC2;C5H?L<5U
M_H,1E:08F4I%YC".#>6B$GG?9FD\NX=' /K_ .!WP.T?]GG1QH6A"X6P6XN)
MXXY[B2?RO/D:0Q1&1CLB3.U$7&<&60R7$DTT@![!0 4 % !0 4 % !0 4 %
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M%7BJ^\??$BPL]*U9=+BT6QL[&57C:U%PUY-/,!-=#>9#&D16=3A9@\ _=R,
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MUL'A>&Z\[[6LDDI6[O'7REN'&W,?F-)$P8"&190#]/\ _A$]._M'^U_LEO\
MVE]G^R_;/)3[1]GW^9Y'G8\SRM_S^7NV;_FQNYH Z"@#\X/'7P+USQ?\?M#\
M600;=%T;P^5N;J3*J\TYU.%((>#YDH\Y99 ,+%$ 796DA24 _1^@#\X/'7P+
MUSQ?\?M#\600;=%T;P^5N;J3*J\TYU.%((>#YDH\Y99 ,+%$ 796DA24 [#]
MICXH?&#0-4CL_AYX6L[^QCCS/?:A=6P6:1PI"V\(O[:5$C&5=YAF1R0L:I&L
MDX!\0?$/X9?'7]K>XTS3/%7AW0]!CM;R.XM_$%M-F\TMD97>6V,&J32L[B-5
M$6TH\GE.S0M&EQ" ?5_[9'P+USXR^/OAU<Z5!NM-&U"ZU#4+E\K###!/ITH4
MN <RR^6R01 %G8,QVQ1S21@'U?\ M-Z3<:_X%\2V=G%)/<SZ'J<4,,2,\DDC
MVDJHB(H+,[,0JJH)8D  DT <!^P[\(=4^!'P\T7P]K2QIJ-K'<//'&XD6-KB
MZFN1&7'RLZ+*$D*%DWJVQY$VNP!]7T ?E!\>_"_Q<_:=U:\\$ZAH&GZ=X!O-
M0ACFU,7<3WQL;2XCG,T96XDVRW'D9AC>S81&5(I3A'GH ^T/VP/ "?$_X?>(
M]+:VDO))-+NI+>WB$ADDNK=#<6H18B'=Q/'$5C&1(0$*LK%2 =?^SUX6O/ W
M@WP_I6H1^3>V.CZ=;7,6Y7V30VT<<B;D+(VUE(W*64XR"1@T ?"'_!/3X+^,
M?V>/A;=PRV,::]J5Y->V%G<' @-Q!;6\#7ZEHVC1&C^T7,4;-<);Y14-W_HP
M .@^(<GQ/_9\M],\)_"?PE9WFB:79QPO?:A<6:&YDVJ2Z0Q7MFRN6WO<S2(I
MN+B21EB15$DX!Y_X6\)_&7]I/Q!H4'Q'T32]%T+1-4AUKS[*=#<2W5DD@MH%
M"WE\"C22AI0R1@PH^V=)-BN >X?M*?$OXT>']<^S?#[PSI^H:0EO'ONK^:!6
MDN&+,_E :G;N(E4QI^]B1_-64C='Y;, >/\ @GX:_%S]IW7-)G^)MII_A_1?
M#NH0:M;VVGF*2:_OH"?LX9_M5[Y<4/SF4[HRZR^6$=F6:U /L#]L;]GK_AI_
MP7?^&XGMX;V7RIK*XN(O,6&XAD5U((!>+S%#V[RQAG2*:0A)!F-P#X0U/X4_
M'#]LE!H'C^+2_"_A<R1'48K'RIKJ_C619T6$^=?B-XY($&\R6X43%S'=A#"
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M?'/4/%5K8R1Z=>>$X8KR]);RY=0:]2-$7>W+BVLX]ZPC9&%C:0*\ZF4 \_\
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M:Y<^._'MU;ZMXQN=\4#0!S8Z59Y8);:>DJJZ[E9O,E91(0[IEFDN9[L ^?\
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M/A72])\*Z->>(KFUCM-,LK43PVY,=O;G]]=W<BK# @B@8&39B2X>&%44S J
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#Y _8@_9:_X9'\
M))H4MU]LO;BX>]O9%&(1<2QQ1M' "JOY2+$BAI/GD8-*5B#B&, ^OZ "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * ./^(7@JW^)6C:AH=XTB6VI6=Q9S/$5$BQW
M$31.4+*RAPK$J65@#C*D<$ T/"?A:S\#:=::5I\?DV5C;PVUM%N9]D,*".--
MSEG;:J@;F+,<9))R: .@H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@#Y _9B_9:_X4)JWBK79[K[1>^)]8
MN+UXT&(8+<7%S):Q@E0[2E;AFG8X0,5B12(C-, >W_"[X0Z7\($U!-,60-JF
MJ7NJWCR.7:2ZO9-\A'1515"11JH "1J6WREY' /4* "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M ,_4]6M]%02W4L<,;211!Y'5%,DTBQ1("Q +R2.D<:]7=E1068 @&A0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % &?'JUO-<26:RQFYBCCEDA#J9$CE:18W9,[E1VBE5&( 8QR $E&P
M :% !0 4 9^F:M;ZTAEM98YHUDEB+QNKJ)(9&BE0E20'CD1XY%ZHZLC ,I
M-"@ H * "@ H * "@ H * "@ H S[W5K?3GABGECCDN9#% CNJM+((WE*1@D
M%W$<<DA5<D)&[XVJQ !H4 % !0 4 % !0 4 % !0 4 % !0 4 % &?)JUO#<
M1V;2QBYECDECA+J)'CB:-9'5,[F1&EB5V (4R1@D%UR :% !0 4 9^K:M;Z!
M;RWEY+'!;01O+--*ZI''&BEG=W8A515!9F8@* 22 * -"@#/U/5K?14$MU+'
M#&TD40>1U13)-(L42 L0"\DCI'&O5W944%F (!H4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M>.;WX?6WVA]7T_3UO[I_+"V\:LT($6]F#M*5N(9?D1HMCX\WS%:-0#Z H *
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MI%&N9)9(XD>10#P#]E']M?PO^UI9C^RYOL^KQ6Z37NERY\ZWRQ1BCE52XB#
M8EBSM62'S4@DE$0 /G_XI?\ !1W_ (4#XYN-!\8:!J&F^'F\N'3]6\OS//E5
MD-Q<85C'):!)HVQ;M+=0;,20F:X^SVH!ZA^T_P#\%!O"O[+[Z,+I9-4CUB-[
MD-I\MO*T=F(\Q7(5I5$B3R%$@.Y(Y$6XD64M (I0#G_V>/\ @IIX*_:3\00^
M&M,@U2TOKF.5[<WEO"L<K0H9'C#07$Y5_+5Y 9 B$1LN_>41P#0_;5_;5O/V
M0;S0Y)-#N+W1;VX9=0U!64+&H5@(( &_X^_^7@"X\J*6*)HHV9FFFLP#[/\
M 'C_ $OXIZ7;:UHMS'>:=>1B2">,G:RY((((#*ZL"DD;A7C=6C=5=64 '84
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M:5HD6H6U[:VXN3%>P1IYD(=8W>-H9IT^1GC#*Y1CYBE X60H ?;] !0!\_\
M[3O[05G^S#X7N_$UY;7%XMOL2."!&.^:4[(A+*%9+>(L0'GD^5<A5669XH9
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MEY UAK$UO#<-':W-O# RW,*JO[XI-/!)%N?S D;*6\H1R,4D=X8@#ZP_9?\
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M)"7!DDC=3=>3#* +>-VDEDEM #Z/^!?QTT/]HO0X/$'A^?SK2;Y71L+-;S*
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MP53TQ+_X2:U(YD#02:?(@261%+&^MX\2*C*LJ;9&(CE#H'"2A1+'&Z@'A_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M&+F77%BDF"*)'CBOM.:-&?&YD1I96122%,DA !=L@'['4 % 'P!_P4M\)_\
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M]!^+%[ID-Q>Z;H&L6]EI:7CO]G>X%Y/8O(Q14C>54>SDNEA$3R(L*%HE:)U
M/V^_9Z\4WGCGP;X?U74)/.O;[1].N;F7:J;YIK:.21]J!47<S$[5"J,X  P*
M /S1_P""9FDV^@>.OBI9V<4<%M!KD44,,2*D<<:7>J*B(B@*J*H"JJ@!0
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MG[2NKZC=W.G^*?#]C937$TEM:;$F^SPNY:.'S7T4/+Y:D)YC ,^W<1DF@#Z
M_9:_9DUSX?ZC=>,/'>K?VWXQOK<633Q$I9VMBCJZ6]M$(X$^=D6:5_*C'F$A
M$#&>:Y #Q9\,/B+\=M1NX-3UG_A%?#,=Q-';6^BOG6+R&-RL<T^H.I2SW-%'
M<Q1VJ,S6]Q):W!#J6H ^K_ '@#2_A9I=MHNBVT=GIUG&(X((P=JKDDDDDLSL
MQ+R2.6>1V:1V9V9B =A0 4 ?D!\9/^3H?!G_ &+]Q_Z*UF@#T#X[>!?[/_:
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MS>Q:Z:3R[&\2\$(*^5-)''(L0G1E82)%(Z740^4QW5O;SJP:(9 .PH * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H X_7?'^E^&;_3]+O+F.*^U62:.QMR29)V@A>XF*J 2$CC0EY&P
MBEHT+;Y8U< ["@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#C_&7C_2_A\EM)JES';+>7EM8VP<G
M=-=74@CAAC4 LSLQR< A$5Y7*Q1NZ@'84 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <?XR\?Z7\/DMI-4N8[9;R\M
MK&V#D[IKJZD$<,,:@%F=F.3@$(BO*Y6*-W4 ["@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^'[Q-1T".-TTZW>2^:\:X606L<3P6WG*[RQ/'*?L[) A6=G9/,$0!\X>&O\
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MGN?$_P .=8TC39;B.&2ZGFF3&[+,(A/86\<LH17=(C+'OV$%T4%E /T>\?\
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MM%Z'!X@\/S^=:3?*Z-A9K>90"\$Z G9*F1D9*LI61&>)XY& /8* /Q!\1_\
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MIJ%NYA6V=EGLXI5$UK!,4=/M=PQC@"QQW$D44C2%(I)+5W /'_\ AX[\0_\
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MZ19>"_#^H:U+-<1W.I26UE<S+'9PRH3;)*EO+"LMT!)&SDR26T2E_)WS02H
M?/\ HG_!4[4=%US2M+\:>"M0\,66J7'D+?7UR\:QY*J92MU9VB-%&TD9N'$@
M\F)C)AB%1P#Z _:E_:\\3?!G6+73/#'@W6/$:IF34;B*SO%MPKQMY4-M<1V\
MJ/+N9))9 LD4:*8 &FD=K4 \O^$W_!3A-?\ $MIX5\9^%]4\+:CJ4EO'IXN!
M)*LC3M)&AE62WM9HT>55ABD2.9&=F\QH4C9Z /4/VD/VFO'/[._B&"?_ (1;
M^U_!DWV.V^U6$K2ZBMY<S"/F#'_;*&#R_+FFDMQ_:$<DWV9 #Z?^!?QTT/\
M:+T.#Q!X?G\ZTF^5T;"S6\R@%X)T!.R5,C(R592LB,\3QR, >P4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'XX_\$:M)M]?^&FKV=Y%'/;3ZY>130RHKQR1O8V2NCHP*LC*2K*P(8$@@@T
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MS$R3S;7>0IYLKR2^6'98]^Q3L50 #\X/@W_R=#XS_P"Q?M__ $5HU 'Z_P!
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MAKXD?%J.WDMUU^34=9T>SOH0K-:VJWEY:SS".8MLG:X*^6"A*1"6.62*>.0
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M7JVG:C"EO&&F73K<W2222G+,[,;5 0%=$M$C\QHG,:@'E_\ P4=_Y*'\)O\
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M!V% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M  2G34;B*S\2^+]<UKPO92(]AH<LLD<<2PL%@C>0SR(46 O;L;:&T<ART3P
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ME$%%B9/,VO*L$D !]7_M(_!"W_:/\)ZEX5NKB2TCOXXP+B-5=HY(94GB8HV
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M\/+;P9X1U*--1M8Q%'J=Y )%C:XNC+>7*VZG:SHLL[VD$C,F]88YI)$\R1@
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MA_V5/<W%A=V]Q'>Z;J%L[+-97T 807"!63?MWL&0E258E'BE$<T8!\P? O\
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M^QEH?[3TNG:A/-<:9K6F7$$EMJMB1'=K#'*)'A#_ /?3V\ARUK<$3("IFAG
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M;7>0IYLKR2^6'98]^Q3L50 #V"@ H * "@ H * "@ H * "@ H * "@ H *
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M2%,DA !=L@&A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!X_\ %;XZ:'\&I=+MM5GVW>LZA;:?I]LF&FFFGECB+!"1B*+S%>>4
MD*BE5&Z62&.0 ]@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M ^)<L%O;^$[BXEAUBTM69I9KQ9+NTF!1Y(F:)K>*6YL(M[1Q72G[4\IBMG8
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MK[3"DWE[]J;]N_;NVKNQG:,X !Z!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MGC_5/B#\1OBA)JES)<M9ZI:6-L'(VPVMK<ZI'##&H 5451DX +NSRN6ED=V
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M1+SQ)+9Z>EH5\L1V4MS*#$(U\D6YBO(! 8F((5OE50A8 ^[_ -K'_DGGBO\
M[%_5O_2*:@ _9._Y)YX4_P"Q?TG_ -(H: /H"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MPRO=7# MY8ED1(UV1JQ6*-%1$!9]IEDE>0 ^CZ "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M?^&N/"2:[+:_8[VWN'LKV-3F$W$4<4C20$LS^4ZRHP63YXV+1%I0@FD /?\
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MKCPDFNRVOV.]M[A[*]C4YA-Q%'%(TD!+,_E.LJ,%D^>-BT1:4()I #Z_H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%,DA !=L@'T?_P %1_\ DD/B'_N'?^G*TH ]_P#V3O\ DGGA3_L7])_](H:
M,#]J[PMXC^)VAGPIX=C\G^W-]I?ZL[0&'3K%@/M+&"0F6XEGB+VT$4*@!I&D
M>YMMB.P![?X \ :7\+-+MM%T6VCL].LXQ'!!&#M5<DDDDEF=F)>21RSR.S2.
MS.S,0#X0_9$T#_A!OB9\3](@N+B2R&H:3J*12R;E2XU2WGN[ID4!47<S*@(7
M>8HH5=G,8:@#R_X3Z3<:=^T[XLEGBDCCN?#<$L#NC*LL8&DQ%XR0 Z"2.2,L
MN0'C=,[E8  _4_Q3XLT[P-9R:AJMW;V-E#M\VYN9DAA3>P1=\DA5%W,RJN2,
MLP4<D"@#X@_93^&D'C3Q1X@^+CIL_P"$D\NVTB,K<(ZZ7:A(%N7698?^/_[-
M!=QHT1,, BVS/YT@ !]_T ? '_!+C_DD/A[_ +B/_IRNZ /O^@#\\/\ @EKX
M_3Q_\,+!VN9+N^MKS4H]0DE,C2?:IKR6\)>209E=X[F*5I 7!,A!;>'  //]
M=DL/VWOB;X<U'0XX]1\+^"9+V>]U4231P2ZG(5\BUM2(T%P\$EM;7;2Q/):R
M0R ,^&B2X /T_P!6U:WT"WEO+R6."V@C>6::5U2..-%+.[NQ"JBJ"S,Q 4 D
MD 4 ? 'PR\%6'[1GQ-G^*$#1S:3HEFVAZ+,AF*WEPAD:[U")]L436\9NKC3X
MRANH9W2:99$\N+< >'_\$XO^2A_%G_L8%_\ 2W5: ,#_ (+:>%K.[\&Z-JKQ
MYO;;6!;0R[F&V&ZMIY)DV@[#N:V@.Y@679A2H9PP!^SU 'Y8?&GQ_JDO[1'@
MGP\;F3^R8]+O+Y;0$",W4EKJL+3,  7<1QJB;RPC!DV!?-EW@'J'_!4?_DD/
MB'_N'?\ IRM* /?_ -D[_DGGA3_L7])_](H: /@#_@BI_P D\U+_ +&"Y_\
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MJV<WAW4W\F,00*9&GMVFNI6"1(TTR3/S&Z0V,SJTJF2, 'ZGT <?\0O!5O\
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MV@ETN^F\6Z4EV\\$=O&B_P!G3R"Y:1Q<-/<* L<AF2$HXCB@GF>< _6^@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * /F#_AD/PO_P + _X63Y=Q_;OV
M?R<>>?L^_P G[-]H\O&[S?L_^CXW^1L^?R?/_>T >/\ _#N'PE=^.?\ A/[Z
M\UB^U0:A_:"PW%W&UNLR-N@50D"3>5;D1B"(RE52*.)M\09& /K_ .+'@7_A
M:'A[5=!\[[/_ &GI]W9>?L\SROM,+P^9LW)OV[]VW<N[&-PSD &A\/?!5O\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M1XY%ZHZLC ,I  -"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MH3X':'/+$^L:9HNF6]Q<R1VWB"&.&"&,//,Z0P7W^_(RQJ6=B2 6/(!^E_[
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MC_Q9XJ_:!T:UL;FSN?"Z^&Y[Z$VIB<-IMZJJTTLK@F1Y;^WM/+^RLR_9U@8
M![LL ?*'[:_P"^-_QE^($VN^&[34(=-T[]QHLD>J6%H\*-"L=S+"([Q)$^T/
MYC%WQ.\#1Q2!%188P#G_ -B+XG_%7X0?%>T\"^.;K4)5U6WF::WU*Y>]VK%:
MSW,,]G.994&6B:*0Q.\3?O(Y%,T*&$ \_P#B7^QU\=-(\9>)M5\(0:A8V6K:
MQ?7*RV6M6UG]HA>YFD@>14O(G.%E)59 &3>PPI+"@#H/V!M?^+7B[Q-XMT*3
M6]0.J:;H][:))JEQ<:C8V6J+>01H'!EEA$I$5RL,@\T +)*(KF))(9 #/_X)
MV7OCS]E;XGV_PYUV&2RM-8CGGN+&<K+'NCLYIXKNUDB=HM[& 02O$SHX5XI%
M,T$9@ /Z3J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /@#X^?M[>!O@=XTL?#'B)<M#;O>R:B
ML:W*Z=</&\<$;11"2X266!Y@S(@=(IX!M>&YE>$ ^_Z /PA_:A_;^UC]I&74
MOAM\+M'N-0ENO-LKS4E\N=7MVE>UN&@6,R0I:2AX@-1GE1$BF8^7"_ESJ ?K
M]\ ?@Y9_L_\ A?3/#%BV^+3[<1M+AE\Z9B9)YMKO(4\V5Y)?+#LL>_8IV*H
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M "_(N8KC_5?9(MV[RMGWUQNW<XP0#]K_ /@GOX^N/B/\,M O)[:.UCALX[&
M).TS2QZ>!9&:0&&(1/))!(PB4S!4V'SF9F5 #YO_ ."=?A:\M/&7Q2U5X\65
MSXHGMH9=RG=-:W-]),FT'>-JW,!W, K;\*6*N% / /V0_P!LF\^%GPE\2_$#
MQ"_]KZI-XH8>5/<K;/=S36^G1^7$WEN%\J+?(D,495(("B(D290 ]?\ V*/A
MYXM_:0\40_&;Q[#;VK+I_P!DT"RABDAVPN&!NPID9_*=9;@1"X:=I_M+S+Y4
M,=H7 /,/VZ?^"F]OX5NO$_P[M='CO8WL[C33J<>I+M62ZM-DN8%MG&^WDE>*
M2/S0=\3*QC;(4 Z#2=6\0? #]EF*\LY9-.U06:2PS1.AD2WU/5@R.CJ6V/);
M70964K-"7!!CF3Y0#]/OV9-)N- \"^&K.\BD@N8-#TR*:&5&22.1+2)71T8!
ME=6!5E8 J000"* /SP_X)Q?\E#^+/_8P+_Z6ZK0!^O\ 0!\__M8_\D\\5_\
M8OZM_P"D4U 'SA_P3WU-/A9\%-(U'6A)9VUG9ZE?3M)%)N6U^UW5R)A&%+LC
M0D2Q[%8R(RL@8,N0#\4?B5^V7>>'_B5KVL_"*:X1?$GV>V\K^SU'F7:RQ+Y]
MM:;I4N);AHV>.6X@6X_T^Y0VZ3-YK '[7?\ !//]DC5/V:M+U#4_$=W)=>(_
M$,D-SJ*-()EA:,RLB-,=S3W!:>1KF;<R,Y")O$9GG /+_@EX6O+O]I#QUJJ1
MYLK;1]/MII=RC;-=6^FR0IM)WG<MM.=R@JNS#%2R!@#Y0^'WQ5M_#?B7QI^T
M'K5K'/I(D;3/#">4L#:G)N2TBFM6NG\Z)TM[8+=2)$Q*37VQ/]&FMJ /G#]J
MG]OB\_;ZT[2_!>G^'OL-[-K%K);-_:*S>;,Z36L<.'M[=$WM< ^8SA5V\C!+
M* ?M]^V]^VM9_L9:=I]R]E_:5[J-Q)'#:>>UM^YA3=--YH@G3Y&>!/+8*S^=
MN4D1O@ _"']H_P#X*0_\- ^(?"6O?V%]B_X1?4#>^1]O\[[5F:TF\O?]EC\G
M_CUV[MLOW\[?EPP!^UW_  4QDN)O@QK;7D<<5R8]+,T<4C2QI(=0L]ZI(T<3
M2(&R%=HXRP 8QH3M !]7_L]>%KSP-X-\/Z5J$?DWMCH^G6US%N5]DT-M''(F
MY"R-M92-REE.,@D8- 'YX?\ !9[2;C4?AS:2P1221VVN6LL[HC,L49MKN(/(
M0"$0R21QAFP"\B)G<R@@'RAX3_X+>WFD:=:6VH>&_MU[#;PQW-W_ &FL/VB9
M$"R3>4E@4B\Q@7\M253=M!P!0!ZA_P $ZO'UQ^U'\6?%OQ'6VCL+9]+L[.2S
M,[3R+),+9(RK^3&KIMTZ5G)"%2\:A7&YE /;_B7X6O/$'[37AFYMH]\6G^%Y
MKFZ;<J^7"S:G:A\,06S+<0IM0,WS[L;%9E -#XT^/]4E_:(\$^'C<R?V3'I=
MY?+: @1FZDM=5A:9@ "[B.-43>6$8,FP+YLN\ ^8/BC\;_&/_!277M2^&OA6
MWL[+PI:W@35-95OMBR6]K=2&*=9ALBV7!BBEMK:$&:5XB?M?V7[0R 'W?^W+
MK\'P&^%5QH.AV^9;ZWMO#FCV(CN+EI?M2"V\B/86D:5;59FA:1CNEC0-YCL(
MY #X0L/VNK+_ ()@>']$\ G1X]6UW[&=0ULQ74%H+>ZO',BV\S0I>&:XCCVQ
M,[[ ;>.UD0M'*J1 &A_P3O\ B7>?M/\ QA\4_$!-/^PV4VCV]M-%]H6;R9G-
MG'"FXK$[^8MC/)N6,*FW8QR4+@!XL_X+>V>D:C=VVG^&_MUE#<31VUW_ &FT
M/VB%'*QS>4]@7B\Q0'\MB63=M)R#0!H?\$1_'UQ?Z-KGA];:,6UG>)?279G;
MS#)>Q)#'"MOY.TH%LY7>4S @M&@A8%G4 _<Z@#X0_8N_;(N/VQ+C7;R#2I-.
MT33I+:"QFE+/)<R.UPTQ=P!"KK$+1FMXS(8#(2T\JRQ[0#\H/VE_VAM4_8Y_
M:#U?Q.EE)/;75G;1O;.1 M[:O86T>8YWAEPB7,"L9(E)+V[P%@#(* -#XL?\
M%E/^%H>'M5T'_A%OL_\ :>GW=EY_]J^9Y7VF%X?,V?8DW[=^[;N7=C&X9R #
M];_^">'@JX\ ?"OPU9W31O))9M> QEBOEW\TM[$"653O6.=%D&,!PP5F4!B
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MF]U3X57'QM\8V\,;1VVJ:H]FTI#1R76FMJ-R\;QHZR[%$]N6/R!Q(0C[E;:
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M?+A9M3M0^&(+9EN(4VH&;Y]V-BLR@'ZOT % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MLO\ XS0![AI.DV^@6\5G9Q1P6T$:10PQ(J1QQHH5$1% 5450%55 "@   "@
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M2/'$TC1HSXW,B-+*R*20IDD( +MD T* "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M?_*=J7_R)0 ?\/1_A#_T,/\ Y3M2_P#D2@ _X>C_  A_Z&'_ ,IVI?\ R)0
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MX>C_  A_Z&'_ ,IVI?\ R)0 ?\/1_A#_ -##_P"4[4O_ )$H /\ AZ/\(?\
MH8?_ "G:E_\ (E !_P /1_A#_P!##_Y3M2_^1* #_AZ/\(?^AA_\IVI?_(E
M!_P]'^$/_0P_^4[4O_D2@ _X>C_"'_H8?_*=J7_R)0 ?\/1_A#_T,/\ Y3M2
M_P#D2@ _X>C_  A_Z&'_ ,IVI?\ R)0 ?\/1_A#_ -##_P"4[4O_ )$H /\
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M_P#E.U+_ .1* #_AZ/\ "'_H8?\ RG:E_P#(E !_P]'^$/\ T,/_ )3M2_\
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M^$/_ $,/_E.U+_Y$H /^'H_PA_Z&'_RG:E_\B4 '_#T?X0_]##_Y3M2_^1*
M/O\ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MY2,RO#9WUO<2+&&52Y2*1F"!F52Q& 649R1D ]0H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M6OY)([4W4RPK(T49DD.YR%5%4 -(Y5 [Q1;O-FB1P#C_ /AK'X>?]#7X?_\
M!M9?_'J /H"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M&2"[LD2!I9$1@#]3Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MQ!^(WPOCTNVDN6L]4N[ZY* ;8;6UN=+DFFD8D*J*HP,D%W9(D#2R(C 'V?\
MM8_\D\\5_P#8OZM_Z134 >8?\$]/ &J?##X8:#I>LVTEG?1QW4DEO* )(UN+
MR>XC#KDE',<B%HVP\9)1U5U90 ?9] !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "RU:WU%YHH)8Y)+:013HCJS12&-)0D@!)1S')'(%;!*2(^-K*2 :% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!Y_P#%76=8\/Z'?W/A^R_M#5TMW^PVI:-5DN&&V+S#
M+-;H(E8AYOWJ/Y2N$W2;%8 _E2^)/[/'QP^!7A_5=3UEM4L=$GD:752NMQ/'
M<27KI;R/<0P7CM.\S.D<K,CEP?G)4$@ _3_]GJ'7OV??@!K?B'Q-JEY'<WVE
MR/H\GVZZN&L[6>T2VTB.%%=TM'::4.AMPIC26'SG0P[( #0^ 7@74?V-/V?=
M>O=<FN-+U*^M]0O8TV/%<65Q>P1V-A'F)GD25G2WDW$1/;O-LE6-H7>@#/\
M@7^R;X\\'? 74= TIH[/Q#KTES>36-Y JR"UN(H[=[(.TA2&XG@A5A),@,)F
M:W=+>5?M4(!X_P#\$Q_$GCSPEK/B/X3:C<2:7)9Z7>7%J+B%;B33+XRP1K+
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M_7-&\9:/JOV31;?-G:?9/W,T-S*4N)8KM69OMD5Q]D1PK VVVW\J2W5AYMV
M>W^!O^"AEQ^T)\,M>U'P^]GIOC?1=+FNKFUG#-$(X &FO+13O,B>6'\E) X@
MNC%#<;X626< ^L/V _[8_P"%7^&?[<_X^_[/3R_]7_QY[V^P?ZKY?^/3[/U_
M>?\ /7][OH ^OZ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MOV-O97$]Q<QPFV<F&XABD*"9(V>22'#B2!HY'9F:$S B.5%4 ^OZ "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_!WP!U32]'\0ZC':W>JR;8E/*PQD,%N+ILX@MVD40K*_!=BW^IAN980#V_\
MX2S3O[._M?[7;_V;]G^U?;/.3[/]GV>9Y_G9\ORMGS^9NV;/FSMYH \?\)_M
M6^ ?'/V1=/\ $FCS2WWDBVM_M\"7#M-CRX_L[NLRRL6"^2R+*'.PH'RM 'J'
MC_Q_I?PLTNYUK6KF.STZSC,D\\A.U5R    69V8A(XT#/([+&BL[*I ./^.G
MQTT/]G30Y_$'B"?R;2'Y41<--<3,"4@@0D;Y7P<#(55#2.R1))(H!Z!K_BS3
MO"GV?^T+NWM/M=Q':VWGS)%YUQ+GRX(MY&^5\'9&N7;!P#@T '_"6:=_:/\
M9'VNW_M+[/\ :OL?G)]H^S[_ "_/\G/F>5O^3S-NS?\ +G=Q0!Q^I_&_PKHN
MJ#0[K6]+AU9I(HA827UNET9)@IB00-()2\@=#&NW+AEV@[AD Z#Q_P"/]+^%
MFEW.M:U<QV>G6<9DGGD)VJN0   "S.S$)'&@9Y'98T5G95(!Y?\ \-8_#S_H
M:_#_ /X-K+_X]0![!X6\6:=XYLX]0TJ[M[ZRFW>5<VTR30OL8HVR2,LC;65E
M;!.&4J>010!H:MJUOH%O+>7DL<%M!&\LTTKJD<<:*6=W=B%5%4%F9B H!)(
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M9%B,;!B >P:MJUOH%O+>7DL<%M!&\LTTKJD<<:*6=W=B%5%4%F9B H!)( H
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MYQD9 .PTG5K?7[>*\LY8Y[:>-)89HG5XY(W4,CHZDJR,I#*RDA@002#0!H4
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M =__ ,+^\+_\)1_PA?\ :=O_ ,)#]G^T?8<G?LQNV[L>7YNS]]Y&[S_(_?\
ME^3\] 'J&K:M;Z!;RWEY+'!;01O+--*ZI''&BEG=W8A515!9F8@* 22 * ,_
MPGXIL_'.G6FJZ?)YUE?6\-S;2[63?#,@DC?:X5UW*P.U@K#." <B@#H* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M=0A^PW/[Q,V>H64MPW[IMN/,^SV[_O$$B;-HV;G# '[?4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?.'Q
MO_9)\&?M'W%O=>*K"2_DM(VCMP;V]ACC5VW.5B@GCB#L0N^3;O<)&K,5C0*
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M"A>DW&M?$;X3Q6L4DTBZY/*4C1G81PW.F2RN0H)"1QH\DC=$16=B%4D &?\
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M%"@'/_M._LDZCX]^(%WXG^$9_LSQ)H6R?5Y'+VUO<W]Q#Y\,5FS0M;RW<D+
MZBDKI:.EW:F4EY[PT :'C+XG6_\ P4A\!VWA2\L)++QFFN6UK=V:%=^ER6K
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M"W\"ZKJ.H:SI3>="IN)V@F2Q:3,-D)K0PRF*.(+$^7(E4R1A8[1DM8@#XO\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M6O>3]G_M/3[2]\C?YGE?:84F\O?M3?MW[=VU=V,[1G  /0* "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,_5KU].MY9XH9+F2
M.-W2"(QB25E4D1H97CB#L1M4R/&@)&YU7+  ^$/V5OVS=1_:/\#:IXJ71O\
M3[/4+JSM-.MY7?[2^V&2SC:7RCY.?M,4$]PZ^1%LDO)/(M]R0@'G_C#XZ:U^
MQI9Z=X/\.>$?$'C"6UMS)J6J)#?)#+>7#?:)YA.UO?&>6>62:XG"N8X&D6)9
M'<21P@'F%K\4/&O[;?B#PWI.I^"=4\+6.BZY:Z]<:C>><T973TE*6X2>ULPS
MS22)&#&\CQ@M+Y+I&Y4 _7[3-)M]%0Q6L4<,;22RE(T5%,DTC2RN0H +R2.\
MDC=7=F=B68D@!I.DV^@6\5G9Q1P6T$:10PQ(J1QQHH5$1% 5450%55 "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9]
MEI-OISS2P11QR7,@EG=$56ED$:1!Y" "[B...,,V2$C1,[54  T* "@#P_0O
MA"B>,=0\8WRQM?/9PZ5I[1/)A--39<R":,X4W$EX\Q9AN46\5J$\MS<>8 ?.
M'_# O_4^_$#_ ,'_ /\ <] !_P ,"_\ 4^_$#_P?_P#W/0 ?\,"_]3[\0/\
MP?\ _P!ST '_  P+_P!3[\0/_!__ /<] !_PP+_U/OQ _P#!_P#_ '/0 ?\
M# O_ %/OQ _\'_\ ]ST '_# O_4^_$#_ ,'_ /\ <] !_P ,"_\ 4^_$#_P?
M_P#W/0 ?\,"_]3[\0/\ P?\ _P!ST '_  P+_P!3[\0/_!__ /<] !_PP+_U
M/OQ _P#!_P#_ '/0 ?\ # O_ %/OQ _\'_\ ]ST '_# O_4^_$#_ ,'_ /\
M<] !_P ,"_\ 4^_$#_P?_P#W/0 ?\,"_]3[\0/\ P?\ _P!ST '_  P+_P!3
M[\0/_!__ /<] !_PP+_U/OQ _P#!_P#_ '/0 ?\ # O_ %/OQ _\'_\ ]ST
M'_# O_4^_$#_ ,'_ /\ <] !_P ,"_\ 4^_$#_P?_P#W/0 ?\,"_]3[\0/\
MP?\ _P!ST '_  P+_P!3[\0/_!__ /<] !_PP+_U/OQ _P#!_P#_ '/0 ?\
M# O_ %/OQ _\'_\ ]ST '_# O_4^_$#_ ,'_ /\ <] !_P ,"_\ 4^_$#_P?
M_P#W/0 ?\,"_]3[\0/\ P?\ _P!ST ?3_P %/A#_ ,*6TZ33_P"U]8UGS+AI
M_M.L7GVRX3<D:>4DFQ,1#9N5,'#O(V?FP #/^*GPA3XM:IH3Z@L;Z7H]X=5"
M!Y$G.I6X5+ C;\K6Z++=2S*2K-,EJ/FA\^-P#W"@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .?\ %G]H_P!G7?\
M9'V?^TOL\WV/[5O^S_:-A\GS_+_>>5OV^9L^?9G;\V* ./\ @O\ "'2_@+X?
ML?#6C+(MC81E(S*YDD=G=I))';@%Y)'>1@H5%+%41$"HH!ZA0 4 % !0!GWN
MDV^HO#+/%'));2&6!W16:*0QO$7C)!*.8Y)(RRX)21TSM9@0#0H * /#_C[\
M(4^.^EP^'KU8WT>ZO('U:,O)'+):VY-RD<#Q_==[F*U24DJ?LK7'EO'/Y3J
M9_QT^ 7_  O'['_Q/O$&B?9/._Y NH?8O/\ -\O_ %_[N3S-GE_NNFS?)UW<
M '@'_# O_4^_$#_P?_\ W/0 ?\,"_P#4^_$#_P '_P#]ST '_# O_4^_$#_P
M?_\ W/0 ?\,"_P#4^_$#_P '_P#]ST '_# O_4^_$#_P?_\ W/0 ?\,"_P#4
M^_$#_P '_P#]ST '_# O_4^_$#_P?_\ W/0 ?\,"_P#4^_$#_P '_P#]ST '
M_# O_4^_$#_P?_\ W/0 ?\,"_P#4^_$#_P '_P#]ST '_# O_4^_$#_P?_\
MW/0 ?\,"_P#4^_$#_P '_P#]ST '_# O_4^_$#_P?_\ W/0 ?\,"_P#4^_$#
M_P '_P#]ST '_# O_4^_$#_P?_\ W/0 ?\,"_P#4^_$#_P '_P#]ST '_# O
M_4^_$#_P?_\ W/0 ?\,"_P#4^_$#_P '_P#]ST '_# O_4^_$#_P?_\ W/0
M?\,"_P#4^_$#_P '_P#]ST '_# O_4^_$#_P?_\ W/0 ?\,"_P#4^_$#_P '
M_P#]ST '_# O_4^_$#_P?_\ W/0 ?\,"_P#4^_$#_P '_P#]ST >P?!3]F/_
M (4MJ,FH?\)-XHUGS+=H/LVL:I]LMTW/&_FI'Y28E&S:KY.$>1<?-D 'O_BS
M^T?[.N_[(^S_ -I?9YOL?VK?]G^T;#Y/G^7^\\K?M\S9\^S.WYL4 <?\%_A#
MI?P%\/V/AK1ED6QL(RD9E<R2.SNTDDCMP"\DCO(P4*BEBJ(B!44 ]0H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#Y@^-?[&?@3
M]HG48]5\3Z7]NO8;=;:.7[7=PXA1Y)%3;!/$APTKG<06.[!.   #Q_\ X=<?
M"'_H7O\ RHZE_P#)= !_PZX^$/\ T+W_ )4=2_\ DN@ _P"'7'PA_P"A>_\
M*CJ7_P ET '_  ZX^$/_ $+W_E1U+_Y+H /^'7'PA_Z%[_RHZE_\ET '_#KC
MX0_]"]_Y4=2_^2Z #_AUQ\(?^A>_\J.I?_)= !_PZX^$/_0O?^5'4O\ Y+H
M/^'7'PA_Z%[_ ,J.I?\ R70 ?\.N/A#_ -"]_P"5'4O_ )+H /\ AUQ\(?\
MH7O_ "HZE_\ )= !_P .N/A#_P!"]_Y4=2_^2Z #_AUQ\(?^A>_\J.I?_)=
M!_PZX^$/_0O?^5'4O_DN@ _X=<?"'_H7O_*CJ7_R70 ?\.N/A#_T+W_E1U+_
M .2Z #_AUQ\(?^A>_P#*CJ7_ ,ET '_#KCX0_P#0O?\ E1U+_P"2Z #_ (=<
M?"'_ *%[_P J.I?_ "70 ?\ #KCX0_\ 0O?^5'4O_DN@ _X=<?"'_H7O_*CJ
M7_R70 ?\.N/A#_T+W_E1U+_Y+H /^'7'PA_Z%[_RHZE_\ET '_#KCX0_]"]_
MY4=2_P#DN@ _X=<?"'_H7O\ RHZE_P#)= !_PZX^$/\ T+W_ )4=2_\ DN@
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M\.N/A#_T+W_E1U+_ .2Z #_AUQ\(?^A>_P#*CJ7_ ,ET '_#KCX0_P#0O?\
ME1U+_P"2Z #_ (=<?"'_ *%[_P J.I?_ "70 ?\ #KCX0_\ 0O?^5'4O_DN@
M _X=<?"'_H7O_*CJ7_R70![!\%/V,_ G[.VHR:KX8TO[#>S6[6TDOVN[FS"[
MQR,FV>>5!EHD.X ,-N <$@@'T_0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\ ?\.N/A
M#_T+W_E1U+_Y+H /^'7'PA_Z%[_RHZE_\ET '_#KCX0_]"]_Y4=2_P#DN@ _
MX=<?"'_H7O\ RHZE_P#)= !_PZX^$/\ T+W_ )4=2_\ DN@ _P"'7'PA_P"A
M>_\ *CJ7_P ET '_  ZX^$/_ $+W_E1U+_Y+H /^'7'PA_Z%[_RHZE_\ET '
M_#KCX0_]"]_Y4=2_^2Z #_AUQ\(?^A>_\J.I?_)= !_PZX^$/_0O?^5'4O\
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M]"]_Y4=2_P#DN@ _X=<?"'_H7O\ RHZE_P#)= !_PZX^$/\ T+W_ )4=2_\
MDN@ _P"'7'PA_P"A>_\ *CJ7_P ET '_  ZX^$/_ $+W_E1U+_Y+H ]_^!?[
M+GA#]FO[9_PBFG_8/M_D_:?])N9_,\CS/*_X^)9=NWS9/N;<[N<X& #Z H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H _.#]K7_@HSH?[+/B/2]#E3[=N\Z764ML27-I"8";1$1GBB\V:5DD8
M22AH[9"QA/VB"0 'SAKO_!:_PJ+_ $];#2M4.G&28ZG)/%;BX6,0OY"VL:71
M1G:8H97ED01PHZK'(\@:( ^[_P!J']L33OV4]#T[6M8TW4';4+B"'[+&B,T&
MX"2<33H[VJRQ1[_+B69OM,J%8W\E9KF$ T/CG^UOI?P)\2^&_#%W:7D]SXCO
M$MHYHXRL$"NPA1S*^U)7\Z2%9(8V+Q0LT[[2;>*Y /G_ ,2?\%%+?X8?$VX\
M$^+=-DT727CA6PU6X==LDC%O](E*EHELICB.*56)MWB8W/E[YDL0#T#]I;]M
MJW_9P\8^&O#E_9R1Z=K$A-YJLNU+:&-M\"+'([QIOCF:&:]=VQ;6A!$<KSJ8
M@#V#]JK]IC2_V4/#4OB'4XY)V,BV]G:QY#7%TZN\<1DVLL2;8W>25@0B(VU9
M)2D4@!W_ ,$/&MQ\2O"NB:Y>+&ESJ6EV-Y,D081K)<6\<KA S,P0,Q"AF8@8
MRQ/) /4* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * ,_5M6M] MY;R\EC@MH(WEFFE=4CCC12SN[L0JHJ@LS,0% ))
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0!^0'QD_Y.A\&?\ 8OW'_HK6: /L#]I'X1?\-$:QX=T&[L_-T73=036]3GEX
MB;[/'-#:62I)!)%=?:)9':ZC##R;6!A)L:[M2X >.?A%_P +F^(NC:M?V?\
MQ*_"-O=2P32]+G5+[R"BI#+ 0\5I%$LXNHY !>2PQQMYMI<H@!\8?\%K])MY
MO NE7C11FYBUR**.8HID2.6TNFD17QN5':*)G4$!C'&2"47 !]G_ +=/[.G_
M  T[X&OM&@7=J4&+W3.<9O(%;9'S+%'^^1I+;=*QCB\[SBI:-: /@#X[_M'Q
M?'W]FB;6-0N;<:I<_8;&Y3SHB\E]:ZA 9!L18PDLT4)OOLZH#' ^X!HE$A /
MU>_9Z\+7G@;P;X?TK4(_)O;'1].MKF+<K[)H;:..1-R%D;:RD;E+*<9!(P:
M/8* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@#Y_P#VL?\ DGGBO_L7]6_](IJ / /^"7'_ "2'P]_W$?\
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MO/AMX[\<^(&@M[;3=>N-):R2+:&D:VM&-W.Z(-J^9<3R9+'S9)5FD90K))*
M?7] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!Q\?@JW369-<9I)+EK..SC1RK1P1
MK+)+(8!MW1O<,T0N2&Q,+6TRN8%- '84 >'ZM^S)X%U^XEO+SPUH<]S/(\LT
MTNF6CR22.Q9W=VB+,[,2S,Q)8DDDDT 9_P#PR=\//^A4\/\ _@ILO_C- !_P
MR=\//^A4\/\ _@ILO_C- !_PR=\//^A4\/\ _@ILO_C- !_PR=\//^A4\/\
M_@ILO_C- !_PR=\//^A4\/\ _@ILO_C- !_PR=\//^A4\/\ _@ILO_C- !_P
MR=\//^A4\/\ _@ILO_C- !_PR=\//^A4\/\ _@ILO_C- !_PR=\//^A4\/\
M_@ILO_C- !_PR=\//^A4\/\ _@ILO_C- !_PR=\//^A4\/\ _@ILO_C- '0>
M%OV>O!O@:\CU#2O#^CV-[#N\JYMM.MH9DWJ4;9)'&KKN5F5L$95BIX)% 'L%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 >?_ !8\"_\ "T/#VJZ#YWV?^T]/
MN[+S]GF>5]IA>'S-FY-^W?NV[EW8QN&<@ S_ (+_  ATOX"^'['PUHRR+8V$
M92,RN9)'9W:221VX!>21WD8*%12Q5$1 J* >H4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &?'JUO-<26:RQFYBCCEDA#J9$
MCE:18W9,[E1VBE5&( 8QR $E&P :% !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!Y_\ %7QM+\-]#O\ 5X+.XU&XM+=Y(+*VBEEFN9L8BA18(II!YCE4
M:01NL2DRN!&C$ '\L6I_'3X_?"K3M7N[T>(-.LM2N)+G4KVXTDPXFN4BM=ZW
M<MJ'MOE2&&!8)(5AVQK"(R%H _4_]E'XB^,_A_\  S5_$OB6_DLY+32YD\-B
MYBLH8X;6WLECTZ2-?)5Y'GG(CC%V93<!+=HT*S;YP _9-\0>)?A#\#/$/C'7
M]1D35M1CU'5;&\OY6DN-WV*&ST\RF\4B1Y9+>,VJGS4FADM@N[S!& #C_P!G
M^Q^)VA? C6-9T];C4_$FOW%Q>PR7%S=?VDMC);068N(2RB6:[$5MYMDB2 -"
MT$L3RN$M)0#C_P#@E]^TQXUUI-7^&MU'&^HZ/I=U-I,FI><C6D]O)';+87B*
MOG-;I+*F!\LULB20+N3R4MP#0_X)Q?M%^*/#7Q U_P !_$%KC^VM4N)+U?M
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M/%;W#F9F=WGA2*=I22)C(95PCJ  ?5] !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ? '_!4?\
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M'&(YHYH I$6Y@#ZOH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MB@#H* .?U_Q9IWA3[/\ VA=V]I]KN([6V\^9(O.N)<^7!%O(WRO@[(UR[8.
M<&@#H* ./TKQ_I>NZI>Z+:W,<NHZ;';27L"$EH%NQ(8!(0-JNZQ.XCSO";)&
M4)+$S@'84 >?^,/BKH?P_O-.T_5;^WM+O5[@VVGPRN%:XF"[BB _\!0,<*99
M(803+-"C@'8:MJUOH%O+>7DL<%M!&\LTTKJD<<:*6=W=B%5%4%F9B H!)( H
M S_"?BFS\<Z=::KI\GG65];PW-M+M9-\,R"2-]KA77<K [6"L,X(!R* .@H
M\?\ V@?'6H_##PEK6NZ5#;SWNFZ?<W<4=R[I"?(C:1BYC5G;:JLRQC9YK 1&
M6$.9D #]GKQ3>>.?!OA_5=0D\Z]OM'TZYN9=JIOFFMHY)'VH%1=S,3M4*HS@
M # H [#Q_P"/]+^%FEW.M:U<QV>G6<9DGGD)VJN0   "S.S$)'&@9Y'98T5G
M95(!V% ''^$_'^E^.GOH],N8[IM-O'L;PQDE8KJ...22$MC:SHLJ"3:6"/NB
M8B6-T4 ["@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M4\L<<ES(8H$=U5I9!&\I2,$@NXCCDD*KDA(W?&U6( ,__A+-._M'^R/M=O\
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M_P#$CXJZ'\'[--0\07]OI]I+<0VR37#A%::=MJ("?Q=V^['$DDSE(HY'4 ]
MH \O^&7QK\-?&9)Y/#NJ6>I+:R-'.+:99&B8221@NH.Y4=HI##(1LG1?-B:2
M(JY .P_X2S3O[1_LC[7;_P!I?9_M7V/SD^T?9]_E^?Y.?,\K?\GF;=F_Y<[N
M* .@H S])U:WU^WBO+.6.>VGC26&:)U>.2-U#(Z.I*LC*0RLI(8$$$@T :%
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M=XTB6VI6=Q9S/$5$BQW$31.4+*RAPK$J65@#C*D<$ _+#_ARI\//^@EX@_\
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MTE:W24P[V1'+LOSR2NX!X_\ M%? KQ!\(/B;>^,?@V\E_JUO&U]XETI)$E6
MW9:<1R1O*DMPE^(Y9A91![B!XTFB,?G6(C /8/CU\5K#_@H7\)K-= EO++5-
M3URPTY+ ><8_[04B6X@NWAAD\VRAMC)J)F"J@%O#*P2:-K< '['4 ?F!_P %
M/?V4HOCIX7NO$7VVX2]\.:?<W-G:EHDL]JE)KUWQ;O</+)!#LC7S5B$D<7$8
M:9W /D#X _\ !*[P#^T!X&TSQ%8ZOK"7NH:>&:3= UO#?*IBG7R'M8Y7BBN4
MD3:)5,B)\L^&64@'T?\ \$K-6N/CG\*+_1O$<LE_8QWEYI"1R.P9=/>SMO\
M1A(A678HGD6,[M\2%8T94CC5 #XP^$WB/Q'_ ,$]-1O?$&@BX\1_"*ZU PM>
M1R0/DAS;M<PJDF4EAFC:T-RR0V>H^7& R":RDB /T?\ $&C0?&OXN>"O$^AW
MMQ<V5AX?O-2N(Y%N%M([/48G@T^6%6A")=W;2S&1)'21[>P!9$,*B0 \O_X*
M1_!+P=;W'A_Q5>1R:9K%]XDT;3YM<M;S[%);6^Z1WN9697A+Q11'RYV$<T12
M!C.8(/(D /L#P;\"?$&J^ [GP9XQUZ2_GN([FR;5+2)(KJ33W8QQK,URMRCW
M$D&4GE*;U$A4/)/']MF /S0_:!_X)"^#?AUX2UK6]*U/6!>Z;I]S>Q"YDMIH
M7^RQM,T;I';0/\ZHR*P<>6S"0K(%,; 'ZW?LR:M<:_X%\-7EY+)/<SZ'IDLT
MTKL\DDCVD3.[NQ+,[,2S,Q)8DDDDT '[0_P(LOVD_#\WAK4[N\M+&YDB>X-F
M8%DE6%Q(D9:>"<*GF*DA,81R8U7?L+HX!^"/[%W_  3H\)?'3_A(M*\2:CJ"
M:_X<UB:PN8M.EC2W\E<QQ2JUQ9N7\R6&Z P58)&I:*/<"X!]0?L$^#[S]FSX
MP^*_AM9:C<76@6VGB_CAF"C]\YL&BD(' E6*Y,$LD?EK<;$=HUV1)$ ?7_[=
MOBS_ (32SL?A?I%WY6O^+;B*W813;9K32XV,U_>NF4$D7E02P&W>2$W:O,D9
MD\N2.@#0^/O_  3T\*_M"V^C6%_=ZI9Z=H-F+/3K.SFMQ'%'MC0DO<6T\\CE
M(H4)>5AB)2%#M(S@'Y0?M?\ [(%O_P $Z'\/>/?!-]>226VJ"*9+^=69I#&9
M8D46L-L3;R1Q7,5VK2 NDB1J-K2$ 'V?_P %.WE^$NN>!?B,)[A+31]86VO8
MX+B43/#,5G9((2ZVX\R&WNH;AMT33K)##(9(E'E '8>+O!5Q\0?VDM)U*P:.
M2V\.>&]VIN"S"&2Y.H106[%%94N)%NDG2*4QE[=9)5W  , <_P#"?5KC4?VG
M?%D4\LDD=MX;@B@1W9EBC(TF4I&"2$0R222%5P"\COC<S$@'R!?^ _$'[#/C
M'6_%GPI236O!6G2"'Q!9"='CMY(\27%BWSM/*]FDJ2I>I'(;,220W#2^3?"0
M ^W_ (OZY8?MD7'PQUGPS=7FV37/[6%K(DR6XL],8-?RW:I'(BW%O,D5E;.S
MB-IKQTC>2*;S5 ,__@KQX U'5/!=IXGTV_N+27PWJ$%T8X[AXE;SY$@CG144
MDW<$K1&WDWQ^5%)=$$NRB@#H/C-^P#/^V'YNL>--8U"SO_\ 21I&GVWV?['I
M=N__ ![I<18F^TW9VI)J$D-PB2R?Z/#+]G@@E( ?\$R/%.N:)IVN_#[Q-)<3
M:IX1U!+9'D4^4+&9"+5('D"3219@FEA:5% M9;81GRML<0!^G] 'C_QT^#T7
MQYT.?P_<ZAJ&G6EW\MR^GR11330X(>!GEAFQ%)D>:$"-(H\MF,3R1N ?B#^V
M9_P2_P#!O[.W@35/$^E7NL37MC]D\J.YGMGA/G7<$#;UCM(G.%E8KAUPP!.1
MD$ ^D/ 7P"\-? S]GO6+R*:2*37_  VNI7=S-.L$C75QI\9M[5)H1 [6_GML
MAM9&D$IN)86\U;AT< S_ (R?L[WGPX_9YTWP/<R;M?FN--AM;7[2MMYNI:AJ
M:S&R^6?R;GRA/,OSL\+>1]LVIY2O$ ?7_P 5OV%]#^,O@'2_!>JR;KO1M/MK
M73]62$+-#-!!'"91&7.8I?+4SVQ<JZA<2++'#/& ?GA^R!\*KC]N/X&7WAS6
M[J2>YTO5)XM"FEE9!:R6]E"UHCNJ.SVZM<RQ,KK*4MY"D00Q0>4 ?7__  3V
M\?O\;?AD_A74;F\LM;T6.XT._"&.TO[-5#QVLD2J-\+Q0[88Y98U?[3:S9#M
M&SL >7_\$5/^2>:E_P!C!<_^D5C0!^O] !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '/\ BS0/^$KTZ[T_[1<6GVNW
MF@^TVLGE7$/FH4\V"3!V2IG=&^#M<!L'&* /Q!_8H^ _BCXC^$M9^'.HZK<6
M.@:5X@U>PU:YLY0TUSY<=NBZ?I\DNXV]H93<7-Z9+=//66*% WVB^$0 >&O@
M'>?\$V_BAX?DTB^U"Z\'>*KA=+N(F19'6[=/+MDNF"16YQ/*MQ!,GEW @6\B
M6-E20W(!]/ZA\(/^$[_:)B\0V5QNM_#WA^%]0'G^?LO+T7UM;VOEM-NM=]NY
MN]L:>7\GF,@DO/-< /V;?A!]I^-'CSQI:7'FZ;'Y.D1GS_M/F7CP65S?)YC3
M/)%]E>-(?)*^6GF^1'Y2VIB4 _/#]G;]B^R_;$\:^/(_'&L:I>:CHFJ);&^M
MF@@:Y;SKR!G>.2&X6- MK&(88BJ0)^Z7**@4 [#XP?";_AU%XH\.>)?#5[K%
MWX;O[AH=:M9CO1_*!7#F VEO+*T-Q/)8Q3J/+GMWEWR(76, ^S_V[OV<O OQ
M*UG1[KQMKVN)<ZE>6VEZ-I5I/:"-9+B6**1X87M68(&9)KRXD=B!Y<6XG[);
MD ^</V@?^"0O@WX=>$M:UO2M3U@7NFZ?<WL0N9+::%_LL;3-&Z1VT#_.J,BL
M''ELPD*R!3&P!^A__!/3Q_JGQ/\ AAH.J:S<R7E])'=1R7$I!DD6WO)[>,NV
M 7<1QH&D;+R$%W9G9F(!Z?\ M"_LQ>%_VH-.33_$MIYWD^:;6YC<Q7%J\J%"
M\,B_\!8QR"2"1XXVDBD\M0 #X _X):>!=8TS1_%.@ZI-_:_@R+4)K+19YDC>
MSOHEDNH;^2W0M+NM)L1,5#26K2/,$9Y#<D@'@'QB_9]L_P!AOXM>"-0\#7-Q
MI]EXDU"*PNK#>TJ+"MQ9PW,?F3-(\D4ZSJ_ER[VAGC\Z.0'R5@ /4/V\?V:K
M_4O'FG>)_AG=R+\0FC%Y<Z?'<0HS6=LJVHU M<R)%&F3%926[[H[U&;;$1!>
M&0 Z_5/VJX/VN/A'XJL=0BU#1_$VGVZ:?J.GVL5PLQU&XE\FSMX5$<DIBO;E
M/L<ULX,T:O/;RG9LN9 #]+_@AX*N/AKX5T30[QHWN=-TNQLYGB+&-I+>WCB<
MH656*%E)4LJDC&5!X !ZA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M.2 =A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ _6^@#\D/\ @C#I-QIWPYNY9XI(X[G7+J6!W1E66,6UI$7C) #H)(Y(RRY
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M)7@&#PA9ZA#_ ,(_J$^HW\E]"B(EO%+9SEMUM+<[<_9C"ID\M#/-!'N'F94
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MIO\ \<H /^&>/B]_T4__ ,M;3?\ XY0 ?\,\?%[_ **?_P"6MIO_ ,<H /\
MAGCXO?\ 13__ "UM-_\ CE !_P ,\?%[_HI__EK:;_\ '* #_AGCXO?]%/\
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M%\([/4=3G@\C6O$FH3ZQJD;>4[6\UVQE%@L\0_?16F]HU<LRR2M/.@C6?RD
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M8@'N&IZ3;ZT@BNHHYHUDBE"2(KJ)(9%EB<!@0'CD1)(VZHZJZD,H( -"@ H
M* /+_%GP4\->.K*QTS4]+L[K3M-D22SLI(5-K$T<$EM&!;X\ED2*5UCC961#
MM=5#QHR@'H&DZ3;Z!;Q6=G%'!;01I%##$BI''&BA41$4!515 554 *    *
M-"@#YP_:F^$+_M ^'U\)LLBV.J7ELFH743QK):VML_VPR(LF1(\LEO%:* &,
M1N1<%)$@>-P ^+OPE\3Z_;Z=9^"?$4?A2VL8WB>&+2+6]CDC"Q+;HB3,BP)"
MJ.JK&,,' P BT >'_P##/'Q>_P"BG_\ EK:;_P#'* #_ (9X^+W_ $4__P M
M;3?_ (Y0 ?\ #/'Q>_Z*?_Y:VF__ !R@ _X9X^+W_13_ /RUM-_^.4 '_#/'
MQ>_Z*?\ ^6MIO_QR@ _X9X^+W_13_P#RUM-_^.4 '_#/'Q>_Z*?_ .6MIO\
M\<H /^&>/B]_T4__ ,M;3?\ XY0 ?\,\?%[_ **?_P"6MIO_ ,<H /\ AGCX
MO?\ 13__ "UM-_\ CE !_P ,\?%[_HI__EK:;_\ '* #_AGCXO?]%/\ _+6T
MW_XY0 ?\,\?%[_HI_P#Y:VF__'* #_AGCXO?]%/_ /+6TW_XY0 ?\,\?%[_H
MI_\ Y:VF_P#QR@ _X9X^+W_13_\ RUM-_P#CE !_PSQ\7O\ HI__ ):VF_\
MQR@ _P"&>/B]_P!%/_\ +6TW_P".4 '_  SQ\7O^BG_^6MIO_P <H /^&>/B
M]_T4_P#\M;3?_CE !_PSQ\7O^BG_ /EK:;_\<H /^&>/B]_T4_\ \M;3?_CE
M !_PSQ\7O^BG_P#EK:;_ /'* #_AGCXO?]%/_P#+6TW_ ..4 >P?!3X5>._
MVHR7/B?QC_PD-DUNT<=I_8MII^R8O&RS>; [.VU5=/+(VGS-Q.4% 'O_ (LU
M&\TC3KNYT^U^W7L-O-);6GFK#]HF1"T</FN"D7F, GF,"J;MQ& : /'_ -F+
M]GK3OV7_  O:>&M/?SO)WR7-T8DB>ZN)3NDF<(/I'&&:1XX(XHC))Y88@'T!
M0 4 % !0!GZ9I-OHJ&*UBCAC:264I&BHIDFD:65R% !>21WDD;J[LSL2S$D
M+W2;?47AEGBCDDMI#+ [HK-%(8WB+QD@E',<DD99<$I(Z9VLP( 2:3;S7$=X
MT49N8HY(HYBBF1(Y6C:1%?&Y4=HHF=00&,<9()1< !JVDV^OV\MG>11SVT\;
MQ30RHKQR1NI5T=&!5D92596!# D$$&@#0H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_P#!M9?_ !Z@ _X:Q^'G_0U^'_\ P;67_P >H /^&L?AY_T-?A__ ,&UE_\
M'J #_AK'X>?]#7X?_P#!M9?_ !Z@ _X:Q^'G_0U^'_\ P;67_P >H /^&L?A
MY_T-?A__ ,&UE_\ 'J #_AK'X>?]#7X?_P#!M9?_ !Z@ _X:Q^'G_0U^'_\
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M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\
MQZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@
M_P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&
ML?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY
M_P!#7X?_ /!M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY_P!#
M7X?_ /!M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY_P!#7X?_
M /!M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M
M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\
MQZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@
M_P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&
ML?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY_P!#7X?_ /!M9?\ QZ@ _P"&L?AY
M_P!#7X?_ /!M9?\ QZ@#T#P+\6/#WQ0\[^P=5T_4_L^SS_L5W#<^5YF[9YGD
MN^S=L;;NQNVMC.#@ ] H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \O\:_!#PK
M\2KA;S7-$TO4KE(Q$DUY8V]Q(L89F"!Y8V8(&9F"@X!9CC).0#C_ /AD[X>?
M]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?
M_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?
M]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?
M_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?
M]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?
M_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?
M]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?
M_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?
M]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?
M_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?
M]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?
M_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?
M]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?
M_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?
M]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?
M_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?
M]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?
M_&: #_AD[X>?]"IX?_\ !39?_&: #_AD[X>?]"IX?_\ !39?_&: .P\%?!#P
MK\-;AKS0]$TO3;EXS$\UG8V]O(T996*%XHU8H656*DX)53C(& #U"@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#Y_P#^&3OAY_T*GA__ ,%-E_\ &: #_AD[X>?]"IX?
M_P#!39?_ !F@ _X9.^'G_0J>'_\ P4V7_P 9H /^&3OAY_T*GA__ ,%-E_\
M&: #_AD[X>?]"IX?_P#!39?_ !F@ _X9.^'G_0J>'_\ P4V7_P 9H /^&3OA
MY_T*GA__ ,%-E_\ &: #_AD[X>?]"IX?_P#!39?_ !F@ _X9.^'G_0J>'_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M9X5E>X@ .?\ V/OV\=4\9^(/^%;?$#3I--\86L;1^< #'>RP(\LA:.-=D#M
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M'^%];\,7-U]KB\-^*-6TFUE\I8LPP&*0G:I8_/++-+AWD9?,V;RBJ  >/_\
M!.+_ )*'\6?^Q@7_ -+=5H _7^@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^0/$/[+7_"5_%6P^(U
MS=;(M)T<65I:QCYI+B1[U99)BRX$2Q7($:H=[RDLS1I%MG /K^@ H ^0/VS/
MV6O^&N-)TK0I;K['96^L0WM[(HS,;>*WN8VC@!5D\UVE10TGR1J6E*RE!#(
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M_P#E.U+_ .1* #_AZ/\ "'_H8?\ RG:E_P#(E !_P]'^$/\ T,/_ )3M2_\
MD2@#T#X6_MZ_#CXTZQ;Z#H.L_:]2N_,\B#[%>Q;_ "HWF?YYK=(QA$9OF89Q
M@98@$ ^OZ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M*"%1$;S&:1DB /H^@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Y^V\+6=IJ,^JI'
MB]N;>WMII=S'=#:O/)"FTG8-K7,YW* S;\,6"H% .@H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ./\ B%X*M_B5
MHVH:'>-(EMJ5G<6<SQ%1(L=Q$T3E"RLH<*Q*EE8 XRI'! #P!X TOX6:7;:+
MHMM'9Z=9QB."",':JY))))+,[,2\DCEGD=FD=F=F8@'84 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
>0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>tmb-20201231x20f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:glmd="http://www.galmedpharma.com/20201231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmb-20201231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u4zLwxUaOkSym-aIgXnS5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LVnGSo3_1kWLy8HaZIELzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zF1M1CcFtEuu9rKrGf7EhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Gpq4ytPIkUGTYbUPOM83dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9wQFUwfTykW9qsgqMTxpsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LfEbrk5LkkeSaN-Ppx6W5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lpsu-F7wy0awRiq6md5Tpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iVc9WKPPG0SD2INXCz2fdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2O8hljvvqEmHT8dL4lkKJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hXRilr6SHE66NPYzTTJsLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBQIyJO6Bky2LRwuu2f8fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IfcP6tZx7UKE8vBKiQjAlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember_rI1zXGeK8EmUIgiB1WtYEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glmd:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_qalgby9MtkGBayyVeht6lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_EBlJedVOS0a8vpK59r2GmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_NopUScY-L0CezNXhkry3hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y0ei-czCk0Sc-jHLUaPa8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__8e7PIYNIkuDeGtL1vwa3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LVpIBdN-a02_xjlF3wujBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_r7Ms1ZL-BEiOxWAAdEMExA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GEzGoXG5Ok-EayrH7ZBK0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NyHUYA8FSUyuZNantnazBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_5ym3QBU5HUSdGhzhJHMUXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_glmd_EmployeeStockOptionAndRestrictedStockUnitsMember_1uQb0r1NiEeEwnFMdNS4OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glmd:EmployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2020_To_8_31_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_-BwgIJ4swUqIbUQSXGQ7Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2020_To_8_31_2020_qLCEtGphHkma-pZvOcz6CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2020_To_3_31_2020_MPCna657d0q_4brWdj6Npg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_12_31_2016_sn54mW8hE0KEfttuS1LktQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_I_8qF4py_U-hFUr5wnrNSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_W0hOEi39s0i4CgIp_7LThA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hf5IyP78Okm12S_Q5Zkpgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_wpVjGpd6BEGCzRJ_fPNzXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nqOXypy73EqMu8z3nQc_ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_srAD6naErEOb_wZF3whfdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WPJh0pmyREubwtCYaYFNjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glmd:AtthemarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DIoFCIoieUy02nLWRrmjlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glmd:AtthemarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_GuaranteeOfIndebtednessOfOthersMember_o_oLvoDldEabEXMAdTrcLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:GuaranteeOfIndebtednessOfOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4sF-RiihZ0aMqyVdvdrAXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4fndOwz4MES4TiHYJ6gb3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QjPdXPDPS0KeLH50EvKEiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KeNcj4ynQEmMLA9cFanIvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_FOpb3JVogkOpHOfrV1dInw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:MalteseSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2019_To_2_7_2019_srt_RangeAxis_srt_MinimumMember_wTFaM2m8mEeYWNwxhsduUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-07</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2019_To_2_7_2019_srt_RangeAxis_srt_MaximumMember_G54FxZmw_0-M5Erc8SbIag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-07</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_DSjIA39FDUaJmBOrv2YWwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_JOb54R0hTEydao88CStcSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_U--doeSff0eYGwC7nwkM-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_1_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_bgXq7TSYz0qDPCPOCoHLlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_ScwAFiM_R02IVHmPu8-uGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_OfficersAndDirectorsMember_7_l-on5bd0-NL_4bzPYr0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_OfficersAndDirectorsMember_mrVIWXqvQEmQsa2JBPQ6-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_ABpxUYDxU0CDiyikjLs1sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:MalteseSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_grcOKAlDuECUUH45djx3zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:MalteseSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_mGyra1etzUCzEOs-2C5hCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_ZJtJgHpgokiYVRcA7a4M5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">glmd:IsraeliSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iP_trPoSQEGHbtnlJrlRyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glmd:AtthemarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_glmd_IncentiveShareOptionPlan2013Member_jMEQ59S6skeyqHQJq4F4Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glmd:IncentiveShareOptionPlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_lcF12gSU0kKvwhOz65xKKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_CuoWWqHob0izym5D8TCYyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dgZLZWqczUq8SCUOT_5URw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hfA5x-MOn0W8xR-xu1Qj7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fI3z7-XQOUCnOyty6hbt5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hEwZ6hKhQ0uK4n7L4nWHsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rvQiaUGGXU66VG6jGIelKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_MutualFundMember_RQBP2VCs0UObKkcYTcqmbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_xfK4x71C_U2XYg59WBWoBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_3UXPMCMApUyirH3ER8JOrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_y1QksogbbUycmgdaOBlLFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_MutualFundMember_bnGgvdd-EU-eaV6XNt9n5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_zok_q8J8GUSWmJBnBBWX4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_ZVJnKS1DoUGuAK-FW8B_lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_QVoQ0VMjTE-tSI7ooqfneQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iGwyJcYXY0S44sJU3W54uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Klh4zVXBdku_FCneIROOiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DsQQrozwdkKxtuirepkykw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2oKKrX6nA0y6X8VJqCajsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yZ1T_sP4_EeOFyO2pue5nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VS3dcnkwpEuaFwkYh1LQkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IsoQh3ECGUWn_hEoSfchBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_28_2016_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_DeA8R8quM027wniT31ykmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">glmd:SamilPharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-28</instant>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glmd:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2018_To_9_30_2018_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_pXFd672UHU-v_1dF3cq4Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">glmd:SamilPharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_T34JgVPuFkWxKLRq7oMiFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">glmd:SamilPharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_28_2016_To_7_28_2016_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_YaFu1dKFek-a9yFU3cmXPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">glmd:SamilPharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-28</startDate>
            <endDate>2016-07-28</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vDGTRGTNSU-DSOCOXQYOmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_z4Neu-Y5NUaQZ1wt2pNyGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glmd:ComputerSoftwareElectronicAndMedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_gMEa3bvWxUaKSc4FnbNujg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_LCBCJM_bu0mrU9wCYDXIHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glmd:ComputerSoftwareElectronicAndMedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_u4oEdDXj2kiEqeMFb0tldw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_15_2020_oxvKTuBAOkK40v6EQV3YEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2020-05-15</instant>
        </period>
    </context>
    <context id="As_Of_12_22_2017_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_OSe9LSeVd0mkEr3CGmm7tA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glmd:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-22</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_FacilityLeasesMember_xPSqGfctvE-Yl4rAyJNzSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">glmd:FacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_CarLeasesMember_q_0odO7w6EWS9ILHFJbIjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">glmd:CarLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_d2nXIm0PHEKT0HYx5C-QMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_ILS_80PDI-Ft8k2W61vPNXVwKw">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_Options_1PhyUiqh7EyGeetW5z7dOA">
        <measure>glmd:Options</measure>
    </unit>
    <unit id="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_sqft_dThMR2ywAUCT7W6wxsLiYA">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Divide_ILS_shares_E36EhjGGZkK6K8BwwH-6kA">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_LrQLFEabLEqzt_sj9HemMg">
        <measure>glmd:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tc_88xMTCKqV0-DL8eKUpUG2Q_2_1">0001595353</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tc_FKxSc8zSFk65kCZiStZlcA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tc_99NkqaqvK0a51GF-y8ONyw_4_1">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tc_Bfssm8Zwlk-qkIaAEgDTQA_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tc_MIey8b95SE6DCdj4mawFlA_6_1">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Hidden_aJ2eNBx_p0eGsv2Yn-BpKg">Galmed Pharmaceuticals Ltd.</dei:EntityRegistrantName>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="0"
      id="Hidden_MtEzE_Q_dkGNkQI2tGys-g"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">21325975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="0"
      id="Hidden_rsIlGj2fQ0e_29EHelK7pw"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">21139385</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yZ1T_sP4_EeOFyO2pue5nQ"
      decimals="-3"
      id="Hidden_eLB7w3VWGEaH55k7AS_AdA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA"
      decimals="-3"
      id="Hidden_oULiP01GyEGoRJwxs7pREQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA"
      decimals="-3"
      id="Hidden_7Wb5Jl6MQU2V63DK4FHwEA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Hidden_PATlNkw1P0qJ2UewZ8KyFQ">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      id="Hidden_rtPFgq4moU2FnXiiUj0HYA">us-gaap:OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_d2nXIm0PHEKT0HYx5C-QMw"
      id="Hidden_Ccc8RhKJjU6tsVCv0GLiEA">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4sF-RiihZ0aMqyVdvdrAXQ"
      id="Hidden_iAeXAqUqkkCSijJ30lE5Og">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:DocumentType
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_hj5kjr1BmUC7HXLAVYkqzw">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_BCvAIMp9NE6px3UIXeASNA">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_gXDoswXQb0WkTByuvuyZsQ">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_vwTYAi-poE-BFib-1Zh4YQ">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_hiwcl4OMG06t_TSMl9JDjA">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_rdfmjUHt6UK-ZQxDriqv4A">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_GPla02HyUEa19vRLmZrgdg">001-36345</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_atqGguAIYk6xrYujjSUKVA">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_982l5Z5dckqEuWdjRdocpQ">16 Tiomkin Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_Y70nTN1U8kWJI_LxDfhcsw">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_UZslERMdIESeV7J6zJ7-cQ">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_vr28e5ZzSEet457q134_nw">6578317</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A"
      id="Narr_jnYuBVk_i0a4iRiitQ6YSQ">Allen Baharaff</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A"
      id="Narr_rFrPEtxg50ewmJhvjeET1Q">16 Tiomkin Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A"
      id="Narr_6EL0yKmMIkKpm-62omsL3A">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A"
      id="Narr_byGUWOD5Z0iTxOV3UTUcaw">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A"
      id="Narr_nrHwoZIDfUCz_rdamlbupQ">6578317</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelEmailAddress
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A"
      id="Narr_Sa-1OgwZ4kiFZQW0sQxlsg">ab@galmedpharma.com</dei:ContactPersonnelEmailAddress>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A"
      id="Narr_BDWiQ6WmDUufM7ycAYExqQ">+972.3</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_k_RCIY1Dh0u-H7wg5_KN5A"
      id="Narr_7vbcRB0UVUGHLsHA5ClvfQ">693.8448</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tc_62NpR8z6Z02qXHS28ISf0w_2_1">Ordinary shares, par value NIS 0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tc_q4bv3dxMpUqZduc92-lkXw_2_3">GLMD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_ZUNHCFSSSkG9oYNydH_IoA">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="0"
      id="Narr_yt-oriw8l02XMU7obgkljA"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">21325975</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_f1DcwU4ybUaeB9PBX0ACAA">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_zwbE4jQseUqj60vn9MuwMA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_ooOw-TLmpEufagr-HRrTrg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_zxPv0fdPikWJUWz6CGdELg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_5NsQNLQ7EU-BcLWcaLy_hg">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_ZMk9ep5I4EGcTEAqttwTSw">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_a9icZODTPEKsvXWLWsT3Qw">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_6l6ZiqlQV0aWXRktJ3DP3Q">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_iKZKzLvcnEG3ilifCFVRTg">false</dei:EntityShellCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_J3ZBoe_aLUOS3jxMpASwpQ_5_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">6947000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_F9pHdZeesUmNnm6mUH2w-Q_5_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">15931000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc__xcTxNHNqU-ebX4_woyMyA_6_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">113000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_XG4ofohjlECTere_DwmHLQ_6_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">112000</us-gaap:RestrictedCashCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_MAh0HofEak6zdLCKwiG9nQ_7_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">3807000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_vl4UrMcoSEmqUvTQYdq9MA_7_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">27938000</us-gaap:ShortTermInvestments>
    <us-gaap:MarketableSecurities
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_yZEushpki0y9ymgosW97pA_8_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">40132000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_cFXyMHrwrU6LZq7vHySyNA_8_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">31622000</us-gaap:MarketableSecurities>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_4a5gC2ATcU63yjOmVUw_Eg_9_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">812000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_mYNw0XJNCEGpz7JnDoDoXA_9_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">827000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_IfUM3ZrQjU-SRZVO0MNjdg_10_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">51811000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_stLqw-OtoE-jEkPqGP6XkA_10_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">76430000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_EUTJGaZZyESvu1NE-VuyyQ_12_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">394000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_jVvhkXbK8E6JDPNf6_zXNg_12_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">538000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_mT4f31fTZEiR_fFFU-d22Q_13_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">176000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc__NfnVRXnMUufuUvxrnZP1A_13_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">171000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_0P2IQDCInk6qHtXrR3jQmg_14_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">570000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_pCcM3cmA_UaCZZ1kGjZePQ_14_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">709000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_0_9NtOnm0EiNTt6mg9i3Eg_16_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">52381000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_y-U4WDCmikSXUY7EdO4cSA_16_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">77139000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_cv76LLIhNEmlyn4iYD4L-Q_21_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">7046000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_td4GTnAqLECKOijRRWUWlQ_21_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">5999000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_TA52ZINLKkCBS5e0PQTl5A_22_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">966000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_JtLzCgRIGkyVSRPjjlCIpw_22_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">935000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_XOxcI18DkkaOkOBfOPp_rg_23_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">8012000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_Wz62b2DOjEOdZzuGO1oO5g_23_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">6934000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_iTyVCmu8oEWjkhWfcSuBLQ_26_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">216000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_Bg53zFRgVUinMRdshyZ0bQ_26_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">352000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_hgDzp3KA-ECL2NC5dtshjg_27_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">216000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_6Wp4ddPyl0qAOqJy9Ukhwg_27_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">352000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="2"
      id="Narr_wQG1TzL070KsPsYmUyCK7g"
      unitRef="Unit_Divide_ILS_shares_E36EhjGGZkK6K8BwwH-6kA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="2"
      id="Narr_Tpas9XLEnEiw7uYHuRuYQA"
      unitRef="Unit_Divide_ILS_shares_E36EhjGGZkK6K8BwwH-6kA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="0"
      id="Narr_Epk3w1uPHEmwK6j-uRIdvQ"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="0"
      id="Narr_DDSEHOAlnEOiJ2yCStmz2g"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="0"
      id="Narr_y3b4f-BUz0OfDi7Mk0P1yg"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">21325975</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="0"
      id="Narr_oHd8Psr3vEuxW6VCNsjsdg"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">21139385</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_sRR5dQpek0Cs4R0giSjERA_32_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">58000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_OcnMGkrALEq8aBHJ3viM4Q_32_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">58000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_zFW20VZlDkGH1dHUQx5q9A_33_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">179530000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_WmqGjWNxdESp89l-kRRJ1Q_33_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">176696000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_i14MOyh8qEmHrY6zKs4oJA_34_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">272000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_t6x70ABIjUuoqEXc_DWuuw_34_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">35000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_8LkmO03JfEKOqtlJyRJifQ_35_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-135707000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_OERtDCJjPkSppdCDT5-NFQ_35_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-106936000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_meipzxRYgk-OBm78yqVspw_36_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">44153000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_3RkhSUEDAEC6Pn6vL7UMKA_36_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">69853000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_k--SsWYE4EOWTTh6Bjm-Fg_38_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">52381000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_cvxRqnVNoEiECwLkaGi7lQ_38_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">77139000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_WdSZ94J5r0qbrO0d4aa6jA_3_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_B2CiRGghFEmYZGs7ZpUJ4Q_3_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_dNs8xQw0zEiEdL-4Y1yNtg_3_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2038000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_rhymIJ3CSkuzHFPt1uJ3TQ_4_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">26082000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_UUIOLhQYpU-XuMcSggiy6w_4_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">18180000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_fXRcX1CJ9UK8g7XHAP6ckw_4_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">8313000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_TllmsX4tG0-ic8A3d5o25g_5_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">4128000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_jycHzRetX0ysBR_iViDppQ_5_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">4196000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_5vYsDkhG1kmDbeopoReoIw_5_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">4440000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_kE2mXzDpgkqoKIUmGIUG8Q_6_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-30210000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_yfz42jImMEemoM3kaMmCEA_6_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-22376000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_UhKeTO-Dak6O2K_8h7RmPQ_6_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-10715000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_3dK9cLx2i0SDu3C91F9m2Q_7_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1439000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_A--kVyLwQke1bVlaIletsw_7_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1915000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_vOM-Qt4x4E2I4ROwmDUp5w_7_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">934000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_zQamIZ_5BkiP9zA0bZfjGQ_8_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-28771000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_fqvpl9lah0W8lvoamYZgOQ_8_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-20461000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_D-TSn__MmUWqNWjvfkiKGQ_8_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-9781000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_4ikRECncWEaipV0Ug55arg_9_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_ScnW1DJPSkqBx-6mvqVofA_9_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">75000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_vb31lPPjpkyLk_pY6SnEZA_10_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-28771000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_8a3FWEOD-UacIiyeWjonsA_10_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-20461000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_pANKiftpb0q4wcGgNIBGDw_10_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-9856000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="2"
      id="Tc_x8VDYROB7kqKZgBDSajXtw_12_5"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">1.35</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="2"
      id="Tc_JV0-8znpYUSq4mbTxZ6oCQ_12_8"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">0.97</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="2"
      id="Tc_DTrole_yjEG1v_Gx3LVytA_12_11"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">0.54</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="0"
      id="Tc_fPDTsXGceUOZNLoFzg2bLA_13_5"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">21280787</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="0"
      id="Tc_KkXEetWXl0OzOJtR7Nfa3A_13_8"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">21114399</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="0"
      id="Tc_sEqVXekn8U6vrhMNTOml4A_13_11"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">18137689</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_ntxV3p8P5U6aJqxZu6E1BQ_3_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-28771000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_0BPtWol0REKICGKB99bzrw_3_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-20461000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_dmY5g2jEikCSLpEwOlaxMw_3_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-9856000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_Cek2vqyVdUqb9G_X5DcKvQ_5_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">237000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_wbkhbVYPE02nL8HrA7XFsg_5_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">46000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_99WWyHjvYUKFSjiClLN-Bg_5_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc__eEjBRPdUUSJN5jv1JalZQ_6_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-28534000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_xgvw-BlcnUioNvGTN70cJQ_6_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-20415000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_KJbFAJMlWkG2lE3ArDKrlA_6_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-9860000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IfcP6tZx7UKE8vBKiQjAlQ"
      decimals="0"
      id="Tc_FgV8t_RojkCi5QvYsZ79XA_6_2"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">21018919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IfcP6tZx7UKE8vBKiQjAlQ"
      decimals="-3"
      id="Tc_7m4yN5ALLUS2apJuXeC7DQ_6_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iVc9WKPPG0SD2INXCz2fdg"
      decimals="-3"
      id="Tc_igAopGoAWkiEFY4psiagCw_6_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">174322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2O8hljvvqEmHT8dL4lkKJw"
      decimals="-3"
      id="Tc_FfA0z97Z10C35FSm5Rh2uQ_6_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lpsu-F7wy0awRiq6md5Tpw"
      decimals="-3"
      id="Tc_CIEkBaXpfEStxnMT-wi0Mw_6_14"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-86475000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_lcF12gSU0kKvwhOz65xKKg"
      decimals="-3"
      id="Tc_uis2YGG2oEeeKIiBNiL8Rw_6_17"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">87894000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yZ1T_sP4_EeOFyO2pue5nQ"
      decimals="-3"
      id="Tc_kr2B0B-tZ0iUlCIvrS7Q5Q_8_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VS3dcnkwpEuaFwkYh1LQkA"
      decimals="-3"
      id="Tc_wpK3Vn1w0EOBV-UDxIf98w_8_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2231000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IsoQh3ECGUWn_hEoSfchBw"
      decimals="-3"
      id="Tc_iNwrNK3Yh0KdHOkR_McymQ_8_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2oKKrX6nA0y6X8VJqCajsA"
      decimals="-3"
      id="Tc_6FrO9moo0kKQM0zoKun-aQ_8_14"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_nANofCO_ZEi3IRFdIK9jxA_8_17"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2231000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yZ1T_sP4_EeOFyO2pue5nQ"
      decimals="0"
      id="Tc_AGbooUsRFkGgfYzq-yjbnA_10_2"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">120466</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VS3dcnkwpEuaFwkYh1LQkA"
      decimals="-3"
      id="Tc_3y-9Xb0YsUWGzdendcFBWg_10_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">143000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IsoQh3ECGUWn_hEoSfchBw"
      decimals="-3"
      id="Tc_lrC4DCnh60Sp70xzEnOLgw_10_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2oKKrX6nA0y6X8VJqCajsA"
      decimals="-3"
      id="Tc_dtelva1NmEO_j48CGa2FAw_10_14"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_iAku22sAhk6wNFgGbQrEow_10_17"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">143000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yZ1T_sP4_EeOFyO2pue5nQ"
      decimals="-3"
      id="Tc_auXi_42NskmXCEpDRKi-1w_12_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VS3dcnkwpEuaFwkYh1LQkA"
      decimals="-3"
      id="Tc_WiZ7euRe70WeP3rmaVScZQ_12_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IsoQh3ECGUWn_hEoSfchBw"
      decimals="-3"
      id="Tc_CZVH-JzCUUmENmPfHj5vMA_12_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">46000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2oKKrX6nA0y6X8VJqCajsA"
      decimals="-3"
      id="Tc_NsZOYGdXcES60Fdj1LWv_w_12_14"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_wa-uMaLc5U-To_kv3Y1Z6Q_12_17"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">46000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yZ1T_sP4_EeOFyO2pue5nQ"
      decimals="-3"
      id="Tc_3s6BKObhP0WkO4q8Dgtvaw_14_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VS3dcnkwpEuaFwkYh1LQkA"
      decimals="-3"
      id="Tc_BvMdY4KjYkO0HXkQR8OV_Q_14_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IsoQh3ECGUWn_hEoSfchBw"
      decimals="-3"
      id="Tc_Z8xh4NUKZkS0Jsnsz3jY9A_14_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2oKKrX6nA0y6X8VJqCajsA"
      decimals="-3"
      id="Tc_MImAmjib2Ey-aN1jgKj3lw_14_14"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-20461000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_BisnzQuOK0SOLVnaeh9fZw_14_17"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-20461000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBQIyJO6Bky2LRwuu2f8fg"
      decimals="0"
      id="Tc_xHG1kENxf02M_Ljeg0gKtA_16_2"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">21139385</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBQIyJO6Bky2LRwuu2f8fg"
      decimals="-3"
      id="Tc_orx-9KBq2Uu0--FiCFLlIg_16_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9wQFUwfTykW9qsgqMTxpsQ"
      decimals="-3"
      id="Tc_xTwjleqP4EaNhz6fkWCNoA_16_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">176696000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LfEbrk5LkkeSaN-Ppx6W5g"
      decimals="-3"
      id="Tc_yvEHqwPRg0KGHhuT7_A0cQ_16_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Gpq4ytPIkUGTYbUPOM83dQ"
      decimals="-3"
      id="Tc_kudb7zk1PEqKI_Q9NykcEA_16_14"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-106936000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_K1T49t-KB0yZIcLBr9zwWw_16_17"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">69853000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA"
      decimals="-3"
      id="Tc_8nygfTuftEmPdxDMsGUsOg_18_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Klh4zVXBdku_FCneIROOiQ"
      decimals="-3"
      id="Tc_7jWKBPYHokWM_maiKR8oeQ_18_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2066000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DsQQrozwdkKxtuirepkykw"
      decimals="-3"
      id="Tc_c_eYZ4qBZkS283FNlk_dlA_18_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iGwyJcYXY0S44sJU3W54uQ"
      decimals="-3"
      id="Tc_dvVipI1i0EyGIW30C1T-ww_18_14"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_BYn0Ld8FMUG5puu1EBrUOA_18_17"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2066000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA"
      decimals="0"
      id="Tc_VYpho-RDJk24dvCiLB3ozQ_20_2"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">50290</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Klh4zVXBdku_FCneIROOiQ"
      decimals="-3"
      id="Tc_XXM8MVb2OEqylpcjnXG30w_20_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">61000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DsQQrozwdkKxtuirepkykw"
      decimals="-3"
      id="Tc_l19Hc7898k-Wpc2jnWXN_A_20_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iGwyJcYXY0S44sJU3W54uQ"
      decimals="-3"
      id="Tc_3GE7AJxzKUSWAleg8DjHrA_20_14"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_mWzCgOL3zUy8-GxFkUjuRA_20_17"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">61000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA"
      decimals="0"
      id="Tc_HwjJH-IniUmiz8lzfUGfiA_22_2"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">136300</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Klh4zVXBdku_FCneIROOiQ"
      decimals="-3"
      id="Tc_l7RpjOKadkSOO-YEzA996A_22_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">707000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DsQQrozwdkKxtuirepkykw"
      decimals="-3"
      id="Tc_iZsgwj1sHkKX-H0NgHwHFQ_22_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iGwyJcYXY0S44sJU3W54uQ"
      decimals="-3"
      id="Tc_L2DmWJ9FpkuUQwvW9WMvgQ_22_14"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_A0jqDMsM0UK0ebNhU3FjJA_22_17"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">707000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA"
      decimals="-3"
      id="Tc_z_KeuY09-EqSbl4SLV_yHA_24_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Klh4zVXBdku_FCneIROOiQ"
      decimals="-3"
      id="Tc_3qQ8SnOVHkuyWcnxnnuGlQ_24_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DsQQrozwdkKxtuirepkykw"
      decimals="-3"
      id="Tc_HMj0_KX2CE6JGlPE5MHNkQ_24_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">237000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iGwyJcYXY0S44sJU3W54uQ"
      decimals="-3"
      id="Tc_FuB5VG5y1kiD1mRF32kPtA_24_14"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_vCcSB4J5REuOgmjV5DIaTw_24_17"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">237000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj6uGOrVxkmGhYy0Mo13tA"
      decimals="-3"
      id="Tc_K7PIR-2yGkKdl4QMHG7vOw_26_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Klh4zVXBdku_FCneIROOiQ"
      decimals="-3"
      id="Tc_DwsxRqPXLUmPBJggsLyPAg_26_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DsQQrozwdkKxtuirepkykw"
      decimals="-3"
      id="Tc_ZlgXbp4oC0-IPxKtZ-8Smw_26_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iGwyJcYXY0S44sJU3W54uQ"
      decimals="-3"
      id="Tc_a6RL2mFDeEaGg-V9GVKl9w_26_14"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-28771000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_7Du_LmEpxUi377ZUxHp2Kw_26_17"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-28771000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hXRilr6SHE66NPYzTTJsLA"
      decimals="0"
      id="Tc_0k6VirPc1UCwYCWrsKhgKw_28_2"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">21325975</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hXRilr6SHE66NPYzTTJsLA"
      decimals="-3"
      id="Tc_7qbx2TqR90yAcNvGmD8WsQ_28_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LVnGSo3_1kWLy8HaZIELzQ"
      decimals="-3"
      id="Tc_GYYB5tI2QUOvT34WAcSsvA_28_8"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">179530000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zF1M1CcFtEuu9rKrGf7EhQ"
      decimals="-3"
      id="Tc_Va4A3h9THEmxiI6ks5PCyQ_28_11"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u4zLwxUaOkSym-aIgXnS5A"
      decimals="-3"
      id="Tc_62FxSWhmTEeCl6BwBtU7hQ_28_14"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-135707000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_bN_rhdvMJEOVvT8renlb1Q_28_17"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">44153000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_9nsRK-1yzkWZTEnH4tufsQ_5_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-28771000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_yeegJr1neEaWUghcPshZ-w_5_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-20461000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_DGIVPRctt025XdUDE4nslQ_5_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-9856000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_NI3XaL1Z7kWlEBvkzaytUw_7_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">39000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_gmI2jLt2wUKT2mfGLk1iUw_7_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">35000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_jHxhxn9Pd060q_fB2pk0sg_7_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">387000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_FKBvCm6pdk2v0rGkOwyjmw_8_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">90000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_iGttQMzBlkSvNpACgmzHiA_8_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-105000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_iwLmQBarDUG7OwuYC3fu1g_8_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-144000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_eWZquPBdzk2ge3PBBoBSfQ_9_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">527000</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_F-ot4YG5_kmbKOEMwIwHYw_9_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">9000</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc__MEX8PK7kkiYaCcWXz214w_9_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-12000</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <glmd:InterestsIncomeOnShortTermDeposits
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_01O-Gp82qUK4ILSquri6yg_10_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">285000</glmd:InterestsIncomeOnShortTermDeposits>
    <glmd:InterestsIncomeOnShortTermDeposits
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_hsmcX_MgSEKLSZGh6VtESw_10_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">63000</glmd:InterestsIncomeOnShortTermDeposits>
    <glmd:InterestsIncomeOnShortTermDeposits
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_SdvRHR2V5kSWUzUgtJcNIA_10_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</glmd:InterestsIncomeOnShortTermDeposits>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_PrZZMTGqHk-Wlr_LkXCtIg_12_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2066000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_iDdbb0N6NEaB7SkhWMwfBw_12_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2231000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_4DHp1XUbtEOVfydJtFxbfg_12_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1783000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_WcWZ8vOTUkSQ9ev7XgyFvg_14_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_2Kv5Je2xxESvtu9SrxnM8w_14_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_--We3xDUyki0rgO4wmv2Jg_14_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-538000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_33Mk3QUgzk-cizYwtxGaXg_15_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-15000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_ZbxmHP10Hkaf_w_E20QZfw_15_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">609000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_ZVCj21uixkmgwAnY4RH-Tw_15_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">63000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_1cvgYMsuAEGh7lMZOg_rmQ_16_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1047000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_S88_THzmxUq9zhYkgEKZ8g_16_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">4185000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_xTCgZvj_hkSHJOWdfmFYIw_16_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-462000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_QshrIXEHC0KxhdxYdM5KVQ_17_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">39000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_DBmrteKe4UarUNfyrcAqzw_17_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-141000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_BLgiHznJcEGB88BsSXP8vg_17_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-142000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_PxrTclpwqk6t1emZY63wUw_18_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-26287000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_UA0gxzcIBk2KKnFbMZfaaA_18_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-14937000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_B_K5-u6Rl0mR9D74VGnYtw_18_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-9023000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_AxVwzPgbIUSX7uN3PCxSaQ_21_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">44000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_nsTRYkl1L0uC1rVl3IlJWw_21_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">12000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_lbo8OPG2VUyiarvhKuHcug_21_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">90000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_QntyYLQVx0CbUXpTgljYPw_22_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">55034000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_1VCyj4Rcik2xn7lZ14Sh1A_22_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">72600000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_UtX28fKJj0CFX6ZwTorhYg_22_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">92279000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_1ZPKlWMdjkSaLpjdNLxrmQ_23_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">47198000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_l1xh1sRxMEiem2DZsqQx1g_23_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">101098000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_OERVdBgfF0CBFsrb8hTqKA_23_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">38421000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_98Exu4wiIkWrQEwAtobpzQ_24_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-24416000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_-b1zeEC93UWApNGigKIAig_24_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">21808000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_FNg9sc3nbU6Cwoa6hHxOgQ_24_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">6067000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_lsyDVYE-okibWamSEjq0dw_25_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">16536000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_JhIXg59RlU2mpXelnB3m5A_25_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">6678000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_kWhtgebhxUuAv5x_ak3ifQ_25_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-60015000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_xt9it0WKS0itVI7bY09UyA_28_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">707000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_GoeIdt4KN0u0T0yl9u7wUA_28_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_Dsf4U8uej0-EcPAM2_HySw_28_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">79149000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_e5CKCptN9EGC9e2e0YZkyA_29_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">61000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_BdW4BSs07UidWThxsCQCfg_29_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">143000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_VSJAeZZzRke0cWIAYyg9tA_29_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1027000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_GJTFxW-sRUyGF6z33_HASw_30_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">768000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_-CHMrqEt1kOuPhf6r50IZg_30_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">143000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_ky44GJzPE0aaksgQTcuYwg_30_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">80176000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_-H8ra9gOu0mZJerBU3fPiA_31_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-8983000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_WLUZKVt1QEqfHo4GS-6vyQ_31_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-8116000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_Dwvg0vyowUShJfu4vHmpUw_31_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">11138000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_xZhVK3wZ0k6xjRySKSAnnw_32_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">16043000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_lcF12gSU0kKvwhOz65xKKg"
      decimals="-3"
      id="Tc_Zol38P49xkWSkf21cXDpYQ_32_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">24159000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2017_CuoWWqHob0izym5D8TCYyw"
      decimals="-3"
      id="Tc_gWwtY-NUV0qaLluG-ERoFA_32_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">13021000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_9F7_t4Ia20CoMohxUWLOtw_33_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">7060000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_hqmA_yy-8UmJ9lQD2oPzrw_33_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">16043000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_lcF12gSU0kKvwhOz65xKKg"
      decimals="-3"
      id="Tc_KjQnaFPouU-MmHSvS9otDw_33_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">24159000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_PuiujTgUyUG5zzn4g-QdBA_36_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1192000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_dRfqOIhtgk-PkaqnUQ9NYw_36_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1953000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_lxzHDX8lXE-xlLRf6zBqXA_36_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">865000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_WYR0tY6w2kSIEiuQtImR0g_37_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_opC7Y6SGDEOczsOUAKqcDA_37_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_ctM9qu2SbUy5wTVQUgpXPw_37_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">75000</us-gaap:IncomeTaxesPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_viivQqH6qEqlkH7YaroN1g_40_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">35000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_LEA3gH8NkU2WibpGLjFxpg_40_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">653000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_UrygM1VnfUOsnxiFlbff8w_40_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_rOqitYCXm0m8O9RRRC_zIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;1&#160;&#x2013; General&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Galmed Pharmaceuticals&#160;Ltd. (the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company primarily focused on the development of therapeutics for the treatment of liver diseases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company was incorporated in Israel on July&#160;31, 2013 and commenced operations on February&#160;2, 2014.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company holds a wholly-owned subsidiary, Galmed International&#160;Ltd., which was incorporated in Malta. Galmed International&#160;Ltd. previously held a wholly-owned subsidiary, Galmed Medical Research&#160;Ltd., which was incorporated in Israel, and had been an inactive company since 2015 and was liquidated in February&#160;2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company also holds two additional wholly-owned subsidiaries, Galmed Research and Development&#160;Ltd and Galtopa Therapeutics Ltd., both are incorporated in Israel.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company is a clinical-stage biopharmaceutical company with an operating history limited to pre-clinical and clinical drug development and has no approved products. To date, the Company has focused almost exclusively on developing its product candidate, Aramchol. The Company funded its research and development programs and operations to date primarily through proceeds from private placements and public offerings. The Company currently has no products approved for marketing and has not generated any revenue from product sales to date. As of December&#160;31, 2020, the Company had cash and cash equivalents of $6.9 million, restricted cash of $0.1 million, short-term deposits of $3.8 million and marketable debt securities of $40.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company has incurred operating losses in each&#160;year since inception. The Company&#x2019;s loss attributable to holders of its ordinary shares for the&#160;years ended December&#160;31, 2018, 2019, and 2020 was approximately $9.9 million, $20.5 million, and $28.8 million, respectively. As of December&#160;31, 2020, the Company had an accumulated deficit of $135.7 million. Substantially all of its operating losses resulted from costs incurred in connection with the Company&#x2019;s development program and from general and administrative costs associated with its operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company will need to raise substantial, additional capital to fund its operations and to develop Aramchol for, and beyond its current development stage and any future commercialization, as well as any additional indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"&gt;Based on the Company&#x2019;s current operating plan, the Company&#x2019;s management currently estimates that its cash position will support its current clinical trials and operations as currently conducted for more than 12&#160;months from the date of issuance of these financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <glmd:EntityIncorporationPlace
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_fsXmaf49uUWyzTka5VjHYQ">Israel</glmd:EntityIncorporationPlace>
    <glmd:EntityIncorporationDate
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_10dPIfRHrke_CNGTAPgeCg">2013-07-31</glmd:EntityIncorporationDate>
    <us-gaap:OperationsCommencedDate1
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_z77MFU2ZGkeyYg3xxUvMEw">2014-02-02</us-gaap:OperationsCommencedDate1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-5"
      id="Narr_5KScjuvq6UOvUi9H2XMR1Q"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">6900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-5"
      id="Narr_WmNrhwxFn0Cow33nRiNXiA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">100000</us-gaap:RestrictedCashCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-5"
      id="Narr_0zzf7uWe80-4z2l4dp_wDw"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">3800000</us-gaap:ShortTermInvestments>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-5"
      id="Narr_FephRuRF4U2PD89kcWUtHw"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">40100000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-5"
      id="Narr_PIUiE8nX0U-LOhwSZX6zLA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-9900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-5"
      id="Narr_fxl9JwmbXk-__UhztLaOtQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-20500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-5"
      id="Narr_ikxfYDkEMUK4PfyFHBGGDQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-28800000</us-gaap:ProfitLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-5"
      id="Narr_-Xjvd6YNe0uYnAD1q01ROg"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-135700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_luzKAOnKs02_jCc6H9uUlA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;Note 2 &#x2013; Significant Accounting Policies&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;A.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles ("U.S. GAAP").&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;B.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Use of estimates&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;Note 2 &#x2013; Significant Accounting Policies (Cont.)&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;C.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Financial statement in U.S. dollars&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The functional currency of the Company and its subsidiaries is in U.S dollar (the &#x201c;dollar&#x201d;), because the dollar is the currency of the primary economic environment in which the Company and its subsidiaries operate, and expect to continue operating in the foreseeable future. Transactions and balances denominated in dollars are presented in their original amounts. Non-dollar denominated transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10, &#x201c;Foreign Currency Translation.&#x201d; All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;D.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Principles of consolidation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Galmed Research and Development Ltd., Galmed International Ltd. and Galtopa Therapeutics Ltd. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;E.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with maturities of three&#160;months or less as of the date acquired.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;F.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 54pt;"&gt;&lt;span style="font-weight:normal;"&gt;Cash that is held for a specific purpose and is not available for immediate or general business use due to external restrictions is classified in our consolidated balance sheets as restricted cash.&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;G.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Marketable debt securities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company invests most of its excess cash primarily in debt securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Marketable debt securities are considered to be available for sale and are carried at fair value. Unrealized gains and losses net of tax, if any, are reported as a separate component of stockholders&#x2019; equity. The cost of marketable debt securities classified as available for sale is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Realized gains and losses and declines in value judged to be other than temporary, if any, are also included in other income, net. Interest on securities classified as available for sale is included in interest income. The cost of securities sold is based on the specific identification method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;For all investments in marketable debt securities, the Company assesses whether the impairment is other-than-temporary. If the fair value of a security is less than its amortized cost basis, an impairment is considered other-than-temporary if (i)&#160;the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its entire amortized cost basis, or (ii)&#160;the Company does not expect to recover the entire amortized cost of the security. If an impairment is considered other-than-temporary based on condition (i), the entire difference between the amortized cost and the fair value of the security is recognized in earnings. If an impairment is considered other-than-temporary based on condition (ii), the amount representing credit losses, defined as the difference between the present value of the cash flows expected to be collected and the amortized cost basis of the security, will be recognized in earnings, and the amount relating to all other factors will be recognized in other comprehensive income. The Company evaluates both qualitative and quantitative factors such as duration and severity of the unrealized &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="display:inline-block;text-align:left;width:18pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;G.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Marketable debt securities (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;losses, credit ratings, default and loss rates of the underlying collateral, structure and credit enhancements to determine if a credit loss may exist.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;During the&#160;years ended December&#160;31, 2020 and 2019 no other-than-temporarily impaired losses were realized.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;H.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Concentrations of credit risk&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, marketable securities and short-term deposits. We hold these investments in highly-rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;I.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The annual depreciation rates are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7&#x2013;16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer software and electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;15&#x2013;33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"&gt;J.&#160;&#160;&#160;Impairment of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company&#x2019;s and its subsidiaries&#x2019; long-lived assets are reviewed for impairment in accordance with ASC 360-10, &#x201c;Accounting for the Impairment or Disposal of Long-Lived Assets,&#x201d; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds their fair value. During 2020 and 2019, no impairment losses were identified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"&gt;K.&#160;&#160;&#160;&#160;&#160;Severance pay&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company employees are included under section 14 of the Severance Compensation Act, 1963 (&#x201c;Section&#160;14&#x201d;) for a portion of their salaries. According to Section&#160;14, these employees are entitled to&#160;monthly deposits at a rate of 8.33% of their&#160;monthly salary, made in their name with such insurance companies. Under the Severance Compensation Act, 1963, payments in accordance with Section&#160;14 release the Company from any future severance payments to those employees. The aforementioned deposits are not recorded as an asset in the Company&#x2019;s balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;Note 2 &#x2013; Significant Accounting Policies (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"&gt;L.&#160;&#160;&#160;&#160;Fair value of financial instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies. Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company could realize in a current market exchange.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;The carrying amounts of cash and cash equivalents, short-term bank deposits, other accounts receivables, trade payables and other trade payables approximate their fair value due to the short-term maturity of such instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;Fair value is an exit price representing the amount that would be received upon selling an asset or that would be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions used by market participants in pricing an asset or a liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;A three-tier fair-value hierarchy was established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 1&#160;- Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 2&#160;- Other inputs that are directly or indirectly observable in the marketplace; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 3&#160;- Unobservable inputs that are supported by little or no market activity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;"&gt;M.&#160;&#160;&#160;Accounting for stock-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company applies ASC 718-10, &#x201c;Share-Based Payment,&#x201d; which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors, including employee stock options under the Company&#x2019;s stock plans, based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#x2019;s consolidated statement of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;M. &#160; Accounting for stock-based compensation (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;In June&#160;2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-07, &#x201c;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#x201d;, which simplifies the accounting for non-employee share-based payment transactions by aligning the measurement and classification guidance, with certain exceptions, to that for share-based payment awards to employees. The amendments expand the scope of the accounting standard for share-based payment awards to include share-based payment awards granted to non-employees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and supersedes the guidance related to equity-based payments to non-employees. The Company elected to early adopt these amendments &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;on June&#160;1, 2018. The adoption of these amendments did not have a significant impact on the Company's consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company estimates the fair value of restricted shares based on the market price of the shares at the grant date, and estimates the fair value of stock options granted using a Black-Scholes option-pricing model. The option-pricing model requires a number of assumptions, the most significant of which are the expected stock-price volatility and the expected option term (the time from the grant date until the options are exercised or expire).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company&#x2019;s calculations of the expected volatility were based upon actual historical stock-price movements over the period, which was equal to the expected option term. The expected option term was calculated for options granted to employees and directors in accordance with ASC-718-10-S99, using the &#x201c;simplified&#x201d; method, and grants to non-employees were based on the contractual term. Historically, the Company has not paid dividends, and has no foreseeable plans to do so. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;N.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company only has one license agreement for which is has recognized revenues to date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;On January&#160;1, 2018, the Company adopted ASC 606 with full retrospective application. The adoption of did not have an effect on either revenue recognized in prior periods, nor to accumulated deficit as of January&#160;1, 2017.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The new revenue standard amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The new revenue standard provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of the new revenue standard, we perform the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the performance obligations are satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="display:inline-block;text-align:left;width:18pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;N.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Revenue Recognition (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company only applies the five-step model to contracts when collectability of the consideration to which the Company is entitled in exchange for the goods or services transferred to the customer is determined to be probable. At contract inception, once the contract is determined to be within the scope of the new revenue standard, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. The Company then allocates the transaction price (the amount of consideration the Company expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which we expect to be entitled.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;O.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Research and development expenses are charged to the statement of operations as incurred.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;P.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Income taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company accounts for income taxes utilizing the asset and liability method in accordance with ASC 740, &#x201c;Income Taxes.&#x201d; Current tax liabilities are recognized for the estimated taxes payable on tax returns for the current year. Deferred tax liabilities or assets are recognized for the estimated future tax effects attributable to temporary differences between the income-tax bases of assets and liabilities and their reported amounts in the financial statements and for tax loss carry forwards. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax laws, and deferred tax assets are reduced, if necessary, by the amount of tax benefits, the realization of which is not considered more likely than not based on available evidence. As of December 31, 2020, and 2019, the Company had a full valuation allowance against deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;ASC 740-10 requires a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company has not recorded any liability for uncertain tax positions for the years ended December 31, 2020 and 2019.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Q.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Basic net loss per share is computed based on the weighted-average number of shares outstanding during each&#160;year. Diluted net loss per share is computed based on the weighted-average number of shares outstanding during each&#160;year, plus the dilutive potential of the ordinary shares considered outstanding during the&#160;year, in accordance with ASC 260-10, &#x201c;Earnings Per Share.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;All outstanding stock options and warrants were excluded from the calculation of the diluted loss per share for the&#160;years ended December&#160;31, 2020, 2019 and 2018, because all such securities have an anti-dilutive effect.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;Note 2 &#x2013; Significant Accounting Policies (Cont.)&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;R.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Segment Reporting&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. Accordingly, management has determined that the Company operates in one reportable segment.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;S.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The purpose of reporting comprehensive income is to report a measure of all changes in equity of an entity that result from recognized transactions and other economic events of the period resulting from transactions from non-owner sources.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&lt;b style="font-weight:bold;"&gt;T.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;ASU 2016-02, &#x201c;Leases (Topic 842)&#x201d; was issued by the FASB in February 2016. The Company adopted this ASU 2016-02 effective January 1, 2019 using the modified retrospective application, applying the new standard to leases in place as of the adoption date. Prior periods have not been adjusted. Leases existing for the reporting period beginning January 1, 2019 are presented under ASU 2016-02.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Arrangements that are determined to be leases at inception are recognized as right of use assets and lease liabilities in the consolidated balance sheet at lease commencement. Operating lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. As the Company&#x2019;s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at the commencement date in determining the present value of future lease payments. Lease terms include options to extend the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company elected to adopt a package of practical expedients offered by the FASB which removes the requirement to reassess whether expired or existing contracts contain leases and removes the requirement to reassess the lease classification for any existing leases prior to the adoption date of January 1, 2019. The Company has also elected the practical expedient to include both lease and non-lease components as a single component and account for it as a lease. Additionally, the Company has made a policy election not to capitalize leases with a term of 12 months or less. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;In accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an impairment loss would be recognized for the difference between the carrying amount of the asset and its fair value.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;U.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Recently adopted accounting pronouncements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;From time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="display:inline-block;text-align:left;width:18pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;U.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Recently adopted accounting pronouncements (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;In June 2016, FASB issued ASU No. 2016-13, &#x201c;Financial Instruments &#x2013; Credit Losses &#x2013; Measurement of Credit Losses on Financial Instruments&#x201d;, which introduces a model based on expected losses to estimate credit losses for most financial assets and certain other instruments. In addition, for available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. The ASU is effective for the Company in the first quarter of 2020, with early adoption permitted. The Company adopted ASU 2016-13 in 2020. The adoption did not have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;In August&#160;2018, the FASB issued ASU 2018-13,&#160;&#x201c;Changes to Disclosure Requirements for Fair Value Measurements&#x201d;, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for the Company beginning on January&#160;1, 2020. The Company adopted ASU 2016-13 in 2020. The adoption did not have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;V.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Recently issued accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 54pt;"&gt;In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes", which will simplify the accounting for income taxes to improve consistency of accounting methods and remove certain exceptions. The amendment is effective for the Company beginning January 1, 2021 and is not expected to have a material impact on the Company's consolidated financial statements and disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_jVu1sMUdwkeCQWsNn-CgZQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;A.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles ("U.S. GAAP").&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_BEdgjdy7EEejZ0Z_mVnAVA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;B.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Use of estimates&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <glmd:PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_Bz6b9GzWDUW2lsXHuCE7XA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;C.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Financial statement in U.S. dollars&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The functional currency of the Company and its subsidiaries is in U.S dollar (the &#x201c;dollar&#x201d;), because the dollar is the currency of the primary economic environment in which the Company and its subsidiaries operate, and expect to continue operating in the foreseeable future. Transactions and balances denominated in dollars are presented in their original amounts. Non-dollar denominated transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10, &#x201c;Foreign Currency Translation.&#x201d; All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.&lt;/p&gt;</glmd:PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_bFH5f7SIXkahIMfD51XRZg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;D.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Principles of consolidation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Galmed Research and Development Ltd., Galmed International Ltd. and Galtopa Therapeutics Ltd. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_z8d3JiguY0O-HQl73v4TMw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;E.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with maturities of three&#160;months or less as of the date acquired.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_rXw15JjaBkeMZ-bXzBb4kA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;F.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 54pt;"&gt;&lt;span style="font-weight:normal;"&gt;Cash that is held for a specific purpose and is not available for immediate or general business use due to external restrictions is classified in our consolidated balance sheets as restricted cash.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb__x9R7b_nAUupoh-2P83N9w">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;G.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Marketable debt securities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company invests most of its excess cash primarily in debt securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Marketable debt securities are considered to be available for sale and are carried at fair value. Unrealized gains and losses net of tax, if any, are reported as a separate component of stockholders&#x2019; equity. The cost of marketable debt securities classified as available for sale is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Realized gains and losses and declines in value judged to be other than temporary, if any, are also included in other income, net. Interest on securities classified as available for sale is included in interest income. The cost of securities sold is based on the specific identification method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;For all investments in marketable debt securities, the Company assesses whether the impairment is other-than-temporary. If the fair value of a security is less than its amortized cost basis, an impairment is considered other-than-temporary if (i)&#160;the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its entire amortized cost basis, or (ii)&#160;the Company does not expect to recover the entire amortized cost of the security. If an impairment is considered other-than-temporary based on condition (i), the entire difference between the amortized cost and the fair value of the security is recognized in earnings. If an impairment is considered other-than-temporary based on condition (ii), the amount representing credit losses, defined as the difference between the present value of the cash flows expected to be collected and the amortized cost basis of the security, will be recognized in earnings, and the amount relating to all other factors will be recognized in other comprehensive income. The Company evaluates both qualitative and quantitative factors such as duration and severity of the unrealized &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="display:inline-block;text-align:left;width:18pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;G.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Marketable debt securities (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;losses, credit ratings, default and loss rates of the underlying collateral, structure and credit enhancements to determine if a credit loss may exist.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;During the&#160;years ended December&#160;31, 2020 and 2019 no other-than-temporarily impaired losses were realized.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_TOMbX5xzoEC2zFJqXyaC3A">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;H.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Concentrations of credit risk&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, marketable securities and short-term deposits. We hold these investments in highly-rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_iigR426Ys0C5LajJC8XMxA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;I.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The annual depreciation rates are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7&#x2013;16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer software and electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;15&#x2013;33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <glmd:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_4IFiMnleXkCXsBGjzsG2gw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The annual depreciation rates are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7&#x2013;16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer software and electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;15&#x2013;33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</glmd:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock>
    <glmd:PropertyPlantAndEquipmentDepreciationPercentage
      contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vDGTRGTNSU-DSOCOXQYOmw"
      decimals="2"
      id="Narr_wvwpewzxDUehn7JniCRujw"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.07</glmd:PropertyPlantAndEquipmentDepreciationPercentage>
    <glmd:PropertyPlantAndEquipmentDepreciationPercentage
      contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_gMEa3bvWxUaKSc4FnbNujg"
      decimals="2"
      id="Narr_ICTwXJ9XlkKRhYY2W1Tkmw"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.16</glmd:PropertyPlantAndEquipmentDepreciationPercentage>
    <glmd:PropertyPlantAndEquipmentDepreciationPercentage
      contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_z4Neu-Y5NUaQZ1wt2pNyGA"
      decimals="2"
      id="Narr_A4UUrVc-806hyv_p59GZog"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.15</glmd:PropertyPlantAndEquipmentDepreciationPercentage>
    <glmd:PropertyPlantAndEquipmentDepreciationPercentage
      contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember_LCBCJM_bu0mrU9wCYDXIHQ"
      decimals="2"
      id="Narr_KDKqxmZP6ki-qgQ9Ks6vDQ"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.33</glmd:PropertyPlantAndEquipmentDepreciationPercentage>
    <glmd:PropertyPlantAndEquipmentDepreciationPercentage
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_u4oEdDXj2kiEqeMFb0tldw"
      decimals="2"
      id="Tc_JH-TBQVmlkq0m8qRxvZAyw_5_2"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.10</glmd:PropertyPlantAndEquipmentDepreciationPercentage>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_tKW9NTMxgU6nZtgPgTCEgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"&gt;J.&#160;&#160;&#160;Impairment of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company&#x2019;s and its subsidiaries&#x2019; long-lived assets are reviewed for impairment in accordance with ASC 360-10, &#x201c;Accounting for the Impairment or Disposal of Long-Lived Assets,&#x201d; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds their fair value. During 2020 and 2019, no impairment losses were identified.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_AEbpaoiDwUCs0dck2-UJjQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"&gt;K.&#160;&#160;&#160;&#160;&#160;Severance pay&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company employees are included under section 14 of the Severance Compensation Act, 1963 (&#x201c;Section&#160;14&#x201d;) for a portion of their salaries. According to Section&#160;14, these employees are entitled to&#160;monthly deposits at a rate of 8.33% of their&#160;monthly salary, made in their name with such insurance companies. Under the Severance Compensation Act, 1963, payments in accordance with Section&#160;14 release the Company from any future severance payments to those employees. The aforementioned deposits are not recorded as an asset in the Company&#x2019;s balance sheet.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <glmd:MonthlyDepositsOfEmployeesPercentageOnMonthlySalary
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="4"
      id="Narr_nSgpM3eGy025omkJGTPr8w"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.0833</glmd:MonthlyDepositsOfEmployeesPercentageOnMonthlySalary>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_S7JVd3C5NEaa1HU_PcdsWA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"&gt;L.&#160;&#160;&#160;&#160;Fair value of financial instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies. Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company could realize in a current market exchange.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;The carrying amounts of cash and cash equivalents, short-term bank deposits, other accounts receivables, trade payables and other trade payables approximate their fair value due to the short-term maturity of such instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;Fair value is an exit price representing the amount that would be received upon selling an asset or that would be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions used by market participants in pricing an asset or a liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;A three-tier fair-value hierarchy was established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 1&#160;- Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 2&#160;- Other inputs that are directly or indirectly observable in the marketplace; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 3&#160;- Unobservable inputs that are supported by little or no market activity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_12qEUwlNrEqlSujDv-L_CA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;"&gt;M.&#160;&#160;&#160;Accounting for stock-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company applies ASC 718-10, &#x201c;Share-Based Payment,&#x201d; which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors, including employee stock options under the Company&#x2019;s stock plans, based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#x2019;s consolidated statement of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;M. &#160; Accounting for stock-based compensation (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;In June&#160;2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-07, &#x201c;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#x201d;, which simplifies the accounting for non-employee share-based payment transactions by aligning the measurement and classification guidance, with certain exceptions, to that for share-based payment awards to employees. The amendments expand the scope of the accounting standard for share-based payment awards to include share-based payment awards granted to non-employees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and supersedes the guidance related to equity-based payments to non-employees. The Company elected to early adopt these amendments &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;on June&#160;1, 2018. The adoption of these amendments did not have a significant impact on the Company's consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company estimates the fair value of restricted shares based on the market price of the shares at the grant date, and estimates the fair value of stock options granted using a Black-Scholes option-pricing model. The option-pricing model requires a number of assumptions, the most significant of which are the expected stock-price volatility and the expected option term (the time from the grant date until the options are exercised or expire).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company&#x2019;s calculations of the expected volatility were based upon actual historical stock-price movements over the period, which was equal to the expected option term. The expected option term was calculated for options granted to employees and directors in accordance with ASC-718-10-S99, using the &#x201c;simplified&#x201d; method, and grants to non-employees were based on the contractual term. Historically, the Company has not paid dividends, and has no foreseeable plans to do so. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_NopUScY-L0CezNXhkry3hg"
      id="Narr_mrit9gN63UO6cZgv5-IL-Q">Black-Scholes option-pricing model</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_RYKSF5CZ-Ea6ZCtIHXUbOg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;N.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company only has one license agreement for which is has recognized revenues to date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;On January&#160;1, 2018, the Company adopted ASC 606 with full retrospective application. The adoption of did not have an effect on either revenue recognized in prior periods, nor to accumulated deficit as of January&#160;1, 2017.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The new revenue standard amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The new revenue standard provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of the new revenue standard, we perform the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the performance obligations are satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="display:inline-block;text-align:left;width:18pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;N.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Revenue Recognition (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company only applies the five-step model to contracts when collectability of the consideration to which the Company is entitled in exchange for the goods or services transferred to the customer is determined to be probable. At contract inception, once the contract is determined to be within the scope of the new revenue standard, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. The Company then allocates the transaction price (the amount of consideration the Company expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which we expect to be entitled.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_6y3jYUdCmUKZaEjV707bcg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;O.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Research and development expenses are charged to the statement of operations as incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_YVJdibS6VUGNsXbXPw9iRw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;P.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Income taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company accounts for income taxes utilizing the asset and liability method in accordance with ASC 740, &#x201c;Income Taxes.&#x201d; Current tax liabilities are recognized for the estimated taxes payable on tax returns for the current year. Deferred tax liabilities or assets are recognized for the estimated future tax effects attributable to temporary differences between the income-tax bases of assets and liabilities and their reported amounts in the financial statements and for tax loss carry forwards. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax laws, and deferred tax assets are reduced, if necessary, by the amount of tax benefits, the realization of which is not considered more likely than not based on available evidence. As of December 31, 2020, and 2019, the Company had a full valuation allowance against deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;ASC 740-10 requires a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company has not recorded any liability for uncertain tax positions for the years ended December 31, 2020 and 2019.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_oTHWQjIbVkWez5IZPw65ig">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Q.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Basic net loss per share is computed based on the weighted-average number of shares outstanding during each&#160;year. Diluted net loss per share is computed based on the weighted-average number of shares outstanding during each&#160;year, plus the dilutive potential of the ordinary shares considered outstanding during the&#160;year, in accordance with ASC 260-10, &#x201c;Earnings Per Share.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;All outstanding stock options and warrants were excluded from the calculation of the diluted loss per share for the&#160;years ended December&#160;31, 2020, 2019 and 2018, because all such securities have an anti-dilutive effect.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_SE9P7YuMDkunIugVtuJvpA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;R.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Segment Reporting&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. Accordingly, management has determined that the Company operates in one reportable segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="INF"
      id="Narr_V795-4j5PUyxXrj3Rb73wg"
      unitRef="Unit_Standard_segment_LrQLFEabLEqzt_sj9HemMg">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_jzXrbPXTjkKVDnxmMONaKg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;S.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The purpose of reporting comprehensive income is to report a measure of all changes in equity of an entity that result from recognized transactions and other economic events of the period resulting from transactions from non-owner sources.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_Jjr7r1x2d0-OxQR5YXOKsA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&lt;b style="font-weight:bold;"&gt;T.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;ASU 2016-02, &#x201c;Leases (Topic 842)&#x201d; was issued by the FASB in February 2016. The Company adopted this ASU 2016-02 effective January 1, 2019 using the modified retrospective application, applying the new standard to leases in place as of the adoption date. Prior periods have not been adjusted. Leases existing for the reporting period beginning January 1, 2019 are presented under ASU 2016-02.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Arrangements that are determined to be leases at inception are recognized as right of use assets and lease liabilities in the consolidated balance sheet at lease commencement. Operating lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. As the Company&#x2019;s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at the commencement date in determining the present value of future lease payments. Lease terms include options to extend the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company elected to adopt a package of practical expedients offered by the FASB which removes the requirement to reassess whether expired or existing contracts contain leases and removes the requirement to reassess the lease classification for any existing leases prior to the adoption date of January 1, 2019. The Company has also elected the practical expedient to include both lease and non-lease components as a single component and account for it as a lease. Additionally, the Company has made a policy election not to capitalize leases with a term of 12 months or less. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;In accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an impairment loss would be recognized for the difference between the carrying amount of the asset and its fair value.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_aq-97aPkPEO5jMWvkXZJug">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;U.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Recently adopted accounting pronouncements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;From time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="display:inline-block;text-align:left;width:18pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;U.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Recently adopted accounting pronouncements (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;In June 2016, FASB issued ASU No. 2016-13, &#x201c;Financial Instruments &#x2013; Credit Losses &#x2013; Measurement of Credit Losses on Financial Instruments&#x201d;, which introduces a model based on expected losses to estimate credit losses for most financial assets and certain other instruments. In addition, for available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. The ASU is effective for the Company in the first quarter of 2020, with early adoption permitted. The Company adopted ASU 2016-13 in 2020. The adoption did not have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;In August&#160;2018, the FASB issued ASU 2018-13,&#160;&#x201c;Changes to Disclosure Requirements for Fair Value Measurements&#x201d;, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for the Company beginning on January&#160;1, 2020. The Company adopted ASU 2016-13 in 2020. The adoption did not have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;V.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Recently issued accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 54pt;"&gt;In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes", which will simplify the accounting for income taxes to improve consistency of accounting methods and remove certain exceptions. The amendment is effective for the Company beginning January 1, 2021 and is not expected to have a material impact on the Company's consolidated financial statements and disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_hmELG3J9Wkes1NwL_2qGQQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;3&#160;&#x2013; Marketable debt securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company's financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. Other than the marketable debt securities, which includes corporate bonds and mutual funds as of December 31, 2020, the Company doesn't have any other financial assets or financial liabilities marked to market at fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;The fair value of the Company's Marketable debt securities measured at fair value on a recurring basis by level within the fair value hierarchy are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Marketable debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,449&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,683&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,132&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Marketable debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,622&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,622&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 3 &#x2013; Marketable debt securities (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"&gt;The following table summarizes the Company&#x2019;s marketable debt securities as of December 31, 2020 and 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,575&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,683&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Mutual funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,285&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,449&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total short-term investments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,860&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 305&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,132&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,893&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial papers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,717&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total short-term investments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,587&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,622&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;The contractual maturity of the aforementioned marketable securities varies between less than one&#160;year to two&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"&gt;The Company reviews the individual securities in its portfolio to determine whether a decline in a security&#x2019;s fair value below the amortized cost basis is other-than-temporary. The Company determined that as of&#160;December&#160;31, 2020 and 2019&#160;there were&#160;no&#160;investments in its portfolio that were other-than-temporarily impaired.&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Group_XTfWCJW4eUeiMPyI_ZBXVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;The fair value of the Company's Marketable debt securities measured at fair value on a recurring basis by level within the fair value hierarchy are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Marketable debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,449&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,683&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,132&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Marketable debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,622&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,622&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"&gt;The following table summarizes the Company&#x2019;s marketable debt securities as of December 31, 2020 and 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,575&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,683&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Mutual funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,285&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,449&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total short-term investments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,860&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 305&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,132&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,893&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial papers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,717&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total short-term investments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,587&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,622&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hfA5x-MOn0W8xR-xu1Qj7Q"
      decimals="-3"
      id="Tc_6-DN4AD1X0efUO3gxR0QMw_5_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">25449000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dgZLZWqczUq8SCUOT_5URw"
      decimals="-3"
      id="Tc_tWITVOsUHkam1RNR1jNUfg_5_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">14683000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fI3z7-XQOUCnOyty6hbt5A"
      decimals="-3"
      id="Tc_qn-Rsl8WYECf_ig6e1o-WQ_5_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">40132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hEwZ6hKhQ0uK4n7L4nWHsA"
      decimals="-3"
      id="Tc_GPZhnwjttU2RHq9P-0nUwA_5_5"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">31622000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rvQiaUGGXU66VG6jGIelKw"
      decimals="-3"
      id="Tc_j1lY3sbwrEeNn_bpjvzALA_5_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">31622000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_zok_q8J8GUSWmJBnBBWX4Q"
      decimals="-3"
      id="Tc_vm1Yx46lR0u_OWSYyCd1VA_6_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">14575000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_xfK4x71C_U2XYg59WBWoBw"
      decimals="-3"
      id="Tc_fNyKyErRd0KCYhKFy2fAeQ_6_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">124000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_xfK4x71C_U2XYg59WBWoBw"
      decimals="-3"
      id="Tc_VSSKaTATNU-nreWcOAFSmg_6_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">16000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_zok_q8J8GUSWmJBnBBWX4Q"
      decimals="-3"
      id="Tc_LCQU275TS0CnifcSHQ66Nw_6_12"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">14683000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_MutualFundMember_bnGgvdd-EU-eaV6XNt9n5w"
      decimals="-3"
      id="Tc_F3A8yzEWXUiMfroxOmyVrA_7_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">25285000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_MutualFundMember_RQBP2VCs0UObKkcYTcqmbA"
      decimals="-3"
      id="Tc_R-Oa87XYJUqOrJIgLUMkwQ_7_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">181000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_MutualFundMember_RQBP2VCs0UObKkcYTcqmbA"
      decimals="-3"
      id="Tc_BIekXUQPA0yXrlqXJ1dsGw_7_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">17000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_MutualFundMember_bnGgvdd-EU-eaV6XNt9n5w"
      decimals="-3"
      id="Tc_LFB4pMu6DkKLKCP5-Wlr3g_7_12"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">25449000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_RrWmR3xH0EqjNUh3HtqSFw_8_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">39860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_TI0DTjyda0ObenlAqGS1eA_8_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">305000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_lk0cqHqoNUSldEcCUVrnkw_8_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">33000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_QaH2KbhqlESdDJx3Wx5NaQ_8_12"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">40132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_ZVJnKS1DoUGuAK-FW8B_lw"
      decimals="-3"
      id="Tc_TulPGSmGs0Krcn9TFIuOyQ_6_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">19893000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_3UXPMCMApUyirH3ER8JOrQ"
      decimals="-3"
      id="Tc_6QJpY5vgz0eF0ftQ1pN3kg_6_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">49000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_3UXPMCMApUyirH3ER8JOrQ"
      decimals="-3"
      id="Tc_l43Nd7KpLUKDInnVIrvM3w_6_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">37000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_ZVJnKS1DoUGuAK-FW8B_lw"
      decimals="-3"
      id="Tc__PnLWHEf7Uy4mrs8mwXTtQ_6_12"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">19905000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_QVoQ0VMjTE-tSI7ooqfneQ"
      decimals="-3"
      id="Tc_ZUbeQpuJQk2vAc6sO9v97Q_7_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">11694000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_y1QksogbbUycmgdaOBlLFg"
      decimals="-3"
      id="Tc_KoJDCK0di0yNd25Y2MVhsw_7_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">23000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_y1QksogbbUycmgdaOBlLFg"
      decimals="-3"
      id="Tc_kgVPY4CMCkGlkik-asVgPw_7_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_QVoQ0VMjTE-tSI7ooqfneQ"
      decimals="-3"
      id="Tc_LQxQDujZmEqQsab9cRMbkg_7_12"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">11717000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_Im_pKKgPSUynxam6HbumWQ_8_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">31587000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_yare6_TObkmTHKCjy6vW6w_8_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">72000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_S-AvMFeXeU2MbgwUBz_WqA_8_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">37000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_EVWs3pEWF0Ov30qHhkhemQ_8_12"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">31622000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_Vk9PNZY73ECTtL3N8NlXgg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Note&#160;4&#160;&#x2013; Other Accounts Receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 827&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_02QEQ_B1t0mZimbTYmeRsA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 827&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <glmd:ReceivablesFromGovernmentInstitutions
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_EyCgs3PAb06DPRRlA0tR8Q_4_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">66000</glmd:ReceivablesFromGovernmentInstitutions>
    <glmd:ReceivablesFromGovernmentInstitutions
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_ymKaOwEgvU-Ni6jfSkh2Cw_4_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">178000</glmd:ReceivablesFromGovernmentInstitutions>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_4q-sudrS1kqANz8_KiKj-w_5_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">746000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_1lj8kzGrI0ujDiBKeGhxrQ_5_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">601000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_MyAAvFQAWU-tmbkbmWRDsA_6_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_WOyHRSjYUkCoMjb_A9Jehw_6_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">48000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_QCCUCT3loUa5wdDWSvOGyw_7_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">812000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_VHxhF1Ohk0CBgzivj8K24Q_7_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">827000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_9c2gqAghyEmFfdV0QynPMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;5&#160;&#x2013; Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;On January 1, 2019, the Company adopted ASU 2016-02, using the modified retrospective approach for all lease arrangements at the beginning period of adoption. Leases existing for the reporting period beginning January 1, 2019 are presented under ASU 2016-02.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company leases, approximately 590 square meters at a facility located in Tel-Aviv, Israel under an operating lease agreement expiring on March 22, 2021 with additional two options to &lt;span style="-sec-ix-hidden:Hidden_PATlNkw1P0qJ2UewZ8KyFQ;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;extend&lt;/span&gt;&lt;/span&gt; until March 22, 2023. During February 2021, the Company extended its lease for an additional two years, through March 22, 2023, with an option for another year. To secure the lease payments, the Company provided a bank guarantee of $50 thousand. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;In addition, the Company leases vehicles under various operating lease agreements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 5 &#x2013; Leases (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;At December 31, 2020, the Company&#x2019;s operating lease assets and lease &lt;span style="-sec-ix-hidden:Hidden_rtPFgq4moU2FnXiiUj0HYA;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;liabilities&lt;/span&gt;&lt;/span&gt; (both the current and non-current portion) for operating leases totaled $394 and $419, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company uses its incremental borrowing rate as the discount rate for its leases, as the implicit rate in the lease is not readily determinable. As of December 31, 2020, the Company's operating leases had a weighted average remaining lease term of 2.25 years and a weighted average borrowing rate of 2.75%. Upon adoption of ASC 842, discount rates for existing operating leases were established as of January 1, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;The following table summarizes the Company&#x2019;s significant contractual lease obligations at December 31, 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1&#160;year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;3&#160;years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Facility leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 403&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 193&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Car leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 433&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="INF"
      id="Narr_5CvHpFWS10meXBrr3sFMbg"
      unitRef="Unit_Standard_sqft_dThMR2ywAUCT7W6wxsLiYA">590</us-gaap:AreaOfLand>
    <glmd:LesseeOperatingLeaseNumberOfOptionToExtend
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="INF"
      id="Narr_dzITegwi0kCtdBbWWXLisg"
      unitRef="Unit_Standard_Options_1PhyUiqh7EyGeetW5z7dOA">2</glmd:LesseeOperatingLeaseNumberOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      id="Narr_6PgI_qQz0kWY83r2dQAasA">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseDepositLiability
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Narr_EDN93oPN5UiZYkPH4k1QPQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">50000</us-gaap:LeaseDepositLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Narr_eG7eqL4T90y2EBJi9HEMKA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">394000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Narr_V21Kd3vB2E6PykO5yCYLkA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">419000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      id="Narr__9TBihrcukanB4bERrMGTA">P2Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="4"
      id="Narr_21wJoVRyZkK1hOPsPrKpcA"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.0275</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_ay62K8tnj0Wsr_k7zFd_cQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;The following table summarizes the Company&#x2019;s significant contractual lease obligations at December 31, 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1&#160;year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;3&#160;years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Facility leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 403&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 193&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Car leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 433&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_FacilityLeasesMember_xPSqGfctvE-Yl4rAyJNzSw"
      decimals="-3"
      id="Tc_J9mHVV7V4U2D_j3O5PpQrA_4_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">403000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_FacilityLeasesMember_xPSqGfctvE-Yl4rAyJNzSw"
      decimals="-3"
      id="Tc_vSkyrjsEX0KSkLdGKA6UbA_4_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">193000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <glmd:ContractualObligationDueInFirstToThirdYear
      contextRef="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_FacilityLeasesMember_xPSqGfctvE-Yl4rAyJNzSw"
      decimals="-3"
      id="Tc_JT650tyktUyiCdc0pqqbxw_4_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">210000</glmd:ContractualObligationDueInFirstToThirdYear>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_CarLeasesMember_q_0odO7w6EWS9ILHFJbIjw"
      decimals="-3"
      id="Tc_Mu-UvFf8v0OtDeBRBNJW3A_5_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">30000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_CarLeasesMember_q_0odO7w6EWS9ILHFJbIjw"
      decimals="-3"
      id="Tc_TPx10CsrHEisV2ptJONBCA_5_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">13000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <glmd:ContractualObligationDueInFirstToThirdYear
      contextRef="As_Of_12_31_2020_us-gaap_OtherCommitmentsAxis_glmd_CarLeasesMember_q_0odO7w6EWS9ILHFJbIjw"
      decimals="-3"
      id="Tc_7g1AUrsIg0OIekt4V47NoA_5_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">17000</glmd:ContractualObligationDueInFirstToThirdYear>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_R0aHtsY6kUieMrhF48TGyQ_6_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">433000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_KhvU1DlC8U-hLf5kphw9cQ_6_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">206000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <glmd:ContractualObligationDueInFirstToThirdYear
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_mSek8DpWDEeW8meSj2KIQg_6_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">227000</glmd:ContractualObligationDueInFirstToThirdYear>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_hfqIxsv0Q0GSdUJv83iETA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Note&#160;6&#160;&#x2013; Property and equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Medical equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 737&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 737&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer software and electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,092&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,078&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less&#160;- Accumulated depreciation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 907&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net book value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_LcIsthrA8EOi_liW1eR50A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Medical equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 737&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 737&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer software and electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,092&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,078&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less&#160;- Accumulated depreciation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 907&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net book value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <glmd:MedicalEquipmentGross
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_DNiubzFGyU2txMs4JIFE5w_4_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">737000</glmd:MedicalEquipmentGross>
    <glmd:MedicalEquipmentGross
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_LSo3BIsys0qk2Tlje8nE1w_4_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">737000</glmd:MedicalEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_SyB6AOZkU0WUr2M03T00lQ_5_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">56000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_MEfdTk2EOE--ZyBUw73leQ_5_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">55000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_6zgVbo5Qukyga6eQVvtYkQ_6_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">78000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_pwpeXVuH30yQCF6YM1nGHg_6_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">88000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_4H1xg6oE5ES_BGQ7UKJXuA_7_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">221000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_ntaVzkAMjkeXBTt24sM2BQ_7_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">198000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_2NP-9RSZ402mmpaHJ5kiCw_8_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1092000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_MJeBIvFaV0el-uhaxFQCLw_8_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1078000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_afW36F4yg0i15IreWDXaHw_9_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">916000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_YTKlwVlz4Eio7UZGbod2Qg_9_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">907000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_xUO5JJkOi0OuyIOj_q4g-g_10_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">176000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_ea1G8bMhK0q-3nra7uU8nQ_10_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">171000</us-gaap:PropertyPlantAndEquipmentNet>
    <glmd:RevenueTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_U8ih100SiUGg0toV5OyhaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;7&#160;&#x2013; Revenue&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 54pt;"&gt;Samil Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;On July&#160;28, 2016, the Company entered into a license agreement ("Samil Agreement") with Samil Pharm. Co.,&#160;Ltd. (the &#x201c;Samil&#x201d;), for an exclusive, royalty-bearing license for the commercialization of Aramchol (with an option to manufacture) for the treatment of fatty liver indications including NASH in the Republic of Korea. Additionally, following the ARREST Study, Samil has an option to extend the License to Vietnam, which, if exercised, would increase the clinical- and regulatory-based milestone payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Under the terms of the Samil Agreement, the Company received an up-front payment of approximately $2.1 million. Samil has also agreed to pay additional clinical and regulatory-based milestone payments, which may aggregate up to $6.0 million, as well as tiered, double-digit royalties payable on sales (under certain limitations). In September 2018, the Company received a milestone payment of $1.5 million from Samil in connection with the completion of its ARREST study.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;In accordance with ASC 606 the Company determined that the Agreement included a combined performance obligation representing the delivery of the exclusive license and completion of the ARREST study.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 7 &#x2013; Revenue (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company determined that the transaction price at contract inception was $2.1 million consisting of the upfront, non-refundable payment. None of the clinical or regulatory milestones were included in the transaction price upon inception, as all milestone amounts were fully constrained. Management assessed that the likelihood of occurrence of the other performance obligations in the Agreement was remote upon contract inception. As such, the stand-alone value of such performance obligations was deemed de minimis and none of the transaction price was allocated to those obligations. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, and therefore have also been excluded from the transaction price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;During 2018, when the Company determined that the achievement of its first milestone was probable, it included the variable consideration of $1.5 million as a part of the transaction price allocated to the combined performance obligation including the delivery of the license and completion of the ARREST study.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;As of December 31, 2020, management evaluated the remaining clinical and regulatory milestones and determined that the variable consideration should not be recorded as revenue for the period ended December 31, 2020. The Company will re-evaluate the transaction price in each reporting period when events whose outcomes are resolved or other changes in circumstances occur that would indicate it is appropriate to recognize variable consideration as revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;Revenue allocated to the combined performance obligation of the license and associated ARREST study was recognized ratably, based on the input method, from contract inception through conclusion of the ARREST study in June&#160;2018.&lt;/p&gt;</glmd:RevenueTextBlock>
    <glmd:RevenueRecognitionMilestoneMethodRevenuesRecognized
      contextRef="Duration_7_28_2016_To_7_28_2016_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_YaFu1dKFek-a9yFU3cmXPA"
      decimals="-5"
      id="Narr_KvQgaUNDHEOq9KVHutbu8A"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2100000</glmd:RevenueRecognitionMilestoneMethodRevenuesRecognized>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="As_Of_7_28_2016_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_DeA8R8quM027wniT31ykmw"
      decimals="-5"
      id="Narr_558vLn-VmUmVCkdcGzejTw"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">6000000.0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <glmd:RevenueRecognitionMilestoneMethodRevenuesRecognized
      contextRef="Duration_9_1_2018_To_9_30_2018_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_pXFd672UHU-v_1dF3cq4Bg"
      decimals="-5"
      id="Narr_u90CqyGvcUWkTLVA5bLFpA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1500000</glmd:RevenueRecognitionMilestoneMethodRevenuesRecognized>
    <glmd:RevenueRecognitionNonRefundableUpfrontPayment
      contextRef="Duration_7_28_2016_To_7_28_2016_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_YaFu1dKFek-a9yFU3cmXPA"
      decimals="-5"
      id="Narr_tBUJBAS5qEGqCFP0uo9hLg"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2100000</glmd:RevenueRecognitionNonRefundableUpfrontPayment>
    <glmd:RevenueRecognitionMilestoneMethodRevenuesRecognized
      contextRef="Duration_1_1_2018_To_12_31_2018_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_T34JgVPuFkWxKLRq7oMiFQ"
      decimals="-5"
      id="Narr_S6MRgUmS0kWaR73d5zNYzQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1500000</glmd:RevenueRecognitionMilestoneMethodRevenuesRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_vcj_pJzme0eHRHtzKDZJIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;8&#160;&#x2013; Related Parties&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;As of December 31, 2020, and 2019, the Company had an accrual in the amount of approximately $0.5 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;million and $0.6 million, respectively, pursuant to an employment agreement with its officers and directors&#x2019; fee.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;During 2020, 2019 and 2018, the Company recorded salary expenses, stock-based compensation expenses and directors&#x2019; fee to its related parties in the amount of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$3.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$3.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$3.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_OfficersAndDirectorsMember_7_l-on5bd0-NL_4bzPYr0g"
      decimals="-5"
      id="Narr_JEMM4u_bfkiSYbNP_gkdSg"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">500000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_OfficersAndDirectorsMember_mrVIWXqvQEmQsa2JBPQ6-w"
      decimals="-5"
      id="Narr_lg7O2WvrwU67_SXtp7-2dg"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">600000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_wpVjGpd6BEGCzRJ_fPNzXQ"
      decimals="-5"
      id="Narr_hY_nmg1Ajk28hL90hbL4xg"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">3500000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nqOXypy73EqMu8z3nQc_ow"
      decimals="-5"
      id="Narr_50Fp66AkLkSpbqop1FR3nw"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">3600000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_srAD6naErEOb_wZF3whfdA"
      decimals="-5"
      id="Narr_b2nLOuxTB0KOmv6eO1C3fQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">3700000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_EMJCG9r3EEq1fFap6G8_iA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;9&#160;&#x2013; Commitments and Contingencies&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;As of December 31, 2020, the Company recorded a pledge on its short-term deposit in favor of its bank in the amount of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$113&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; thousand to secure the Company&#x2019;s commitments to the bank, including a bank guarantee in favor Mintz K. Construction Company, the lessor of the Company's headquarters, totaling &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; thousands as of December 31, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;The Company enters into contracts in the ordinary course of business with Contract Research Organizations for clinical trials and clinical supply manufacturing and with vendors for non-clinical research studies and other services and products for operating purposes, which generally provide for termination upon 30 to 90 days&#x2019; notice or less, and therefore are cancelable contracts and not considered as commitment or purchase obligations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;For information regarding the Company's leases commitments, see note 5.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 9 &#x2013; Commitments and Contingencies (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Other than as described above, the Company did not have any material commitments, including any anticipated material acquisition of plant and equipment or interests in other companies, as of December 31, 2020 and 2019.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <glmd:BankLienOnMarketableSecurities
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Narr_HdOst_KJH0Gqsu9-4tPQWQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">113000</glmd:BankLienOnMarketableSecurities>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_GuaranteeOfIndebtednessOfOthersMember_o_oLvoDldEabEXMAdTrcLA"
      decimals="-3"
      id="Narr_k5WfQoy8uE-sc4GpY-b9RA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">54000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_ptyR90ztskG0RBc2PibItA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;10&#x2013; Shareholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"&gt;A.&#160;&#160;&#160;Ordinary shares&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Ordinary shares confer upon the holders the right to receive notice to participate and vote in general meetings of the Company and the right to receive dividends, if declared.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;On December&#160;22, 2017, the Company entered into an At-the-Market Equity Offering Sales Agreement (the "Stifel Sales Agreement") with Stifel, Nicolaus&#160;&amp;amp; Company, Incorporated, as the Company&#x2019;s sales agent (&#x201c;Stifel&#x201d;). Pursuant to the prospectus relating to the Company&#x2019;s shelf registration statement on Form&#160;F-3 filed with the SEC on March&#160;26, 2018 (File No.&#160;333-223923) the Company may offer and sell, from time to time through Stifel, its ordinary shares having an aggregate offering price of up to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million. On May 15, 2020, the Company amended and restated the Sales Agreement dated December 22, 2017 between the Company and Stifel, Nicolaus &amp;amp; Company, Incorporated to include Cantor Fitzgerald &amp;amp; Co. as an additional sales agent for the Company's "at the market offering" program (the "ATM Program"). Pursuant to a prospectus supplement filed with the SEC on May 15, 2020, the Company may offer and sell up to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$31.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million of its ordinary shares. As of December 31,2020 the Company sold &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;136,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; ordinary shares under the ATM Program for total net proceeds of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;During February 2021, subsequent to the balance sheet date, the Company sold an additional &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;1,541,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;&#160;ordinary shares under the ATM Program for total net proceeds of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$8.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million. As a result, the Company has approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$22.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million remaining available for future sales under the ATM Program as of February 28, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;During February 2021, subsequent to the balance sheet date, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Cantor Fitzgerald &amp;amp; Co. (the "Underwriter") in connection with an underwritten public offering &#160;(the "Underwritten Public Offering") of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;2,197,803&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; ordinary shares (the "Firm Shares") of the Company (the "Ordinary Shares"). The Underwriter agreed to purchase the Firm Shares from the Company at a price of&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$4.3258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;&#160;per share. The net proceeds to the Company were approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$9.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for 30 days, to purchase up to an additional 329,670 ordinary shares (the "Option Shares" and together with the Firm Shares, the "Shares") at the same price per share as the Firm Shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 10&#x2013; Shareholders&#x2019; Equity (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;B.&#160;&#160;&#160;Stock-based compensation&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;The Company has an equity-based incentive plan, the 2013 Incentive Share Option Plan (the &#x201c;2013 Plan&#x201d;). As of December 31, 2020, a total of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;687,973&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; shares were reserved for issuance under the 2013 Plan. The 2013 Plan, which was adopted by the Board on September&#160;2, 2013, and approved by the Company&#x2019;s shareholders on December&#160;30, 2013 (as was amended by the Board and the Company&#x2019;s shareholders on March&#160;30, 2015, May&#160;11, 2015, and August&#160;30, 2018 respectively), provides for the grant of options to purchase the ordinary shares and the issuance of restricted stock units (&#x201c;RSUs&#x201d;) to the Company&#x2019;s officers, directors, employees, service providers and consultants. The 2013 Plan provides for such equity-based compensation under various and different tax regimes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;During the year ended December 31, 2020, certain current and former office holders exercised options into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;47,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; ordinary shares of the Company, NIS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; par value per share, for total consideration of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$61&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; thousand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;During the year ended December 31, 2020, restricted stock units held by certain officers, employees and former employees vested resulting in the issuance of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;2,781&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; ordinary shares of the Company, NIS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; par value per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;In March 2020, the Company granted options to purchase &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;67,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; ordinary shares of the Company to several employees. The options are exercisable at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$4.21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; per share, have a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;10-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; term and vest over a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;four years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;. The aggregate grant date fair value of such options was approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;5.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;In August 2020, the Company granted options to purchase &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;30,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; ordinary shares of the Company to a director. The options are exercisable at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$4.77&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; per share, have a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;10-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; term and vest over a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;four years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;. The aggregate grant date fair value of such options was approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million. In addition, the Company granted options to purchase &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;220,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; ordinary shares of the Company to the Company's chief executive officer (after shareholders' approval). The options are exercisable at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$5.12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; per share, have a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;10-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; term and vest over a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;four years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;. The aggregate grant date fair value of such options was approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;6.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;In November 2020, the Company granted options to purchase &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;267,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; ordinary shares of the Company to several employees. The options are exercisable at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$3.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; per share, have a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;10-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; term and vest over a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;four years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;. The aggregate grant date fair value of such options was approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; million. In addition, the Company's Board approved to grant options to purchase &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;220,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; ordinary shares of the Company to Company's chief executive officer subject to shareholders' approval (as of December 31, 2020 shareholders&#x2019; approval was still pending). The options are exercisable at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$3.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; per share, have a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;10-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; term and vest over a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;four years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 10&#x2013; Shareholders&#x2019; Equity (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;B. &#160; Stock-based compensation (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;7.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;A summary of the status of the Company&#x2019;s option plans as of December&#160;31, 2020 and 2019 and changes during the&#160;years then ended are presented below:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options outstanding at beginning of&#160;&#160;year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,393,715&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,349,054&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.92&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Granted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 585,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 282,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Forfeited&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (208,195)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.49&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (121,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercised&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (47,509)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (116,589)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.23&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at end of&#160;year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,723,011&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.70&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,393,715&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options exercisable at&#160;year end&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,754,261&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,647,048&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.02&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;"&gt;The following assumptions were used for the fiscal year 2020, 2019 and 2018 grants:&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;dividend yield of 0.00% for all periods.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;risk-free interest rate between 2.67% and 3.01% for the fiscal year 2018, 1.61% and 2.43% for the fiscal year 2019 and 0.42% and 0.74% for the fiscal year 2020.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;an expected life between 5 and 6.25 years for all periods.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;and a volatility rate ranging between 78% and 92% for the fiscal year 2018; and 87% and 95% for the fiscal year 2019 and 83% and 88% for the fiscal year 2020.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;"&gt;As of December&#160;31, 2020, and 2019, the weighted-average remaining contractual term of the outstanding options, excluding the 38,637 options granted in 2002 that have no expiration date, is 6.60 and 6.36&#160;years, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;"&gt;The weighted average grant date fair value of the options granted during the&#160;years ended December&#160;31, 2020, 2019 and 2018 is $2.76, $4.85, and $8.19 respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;"&gt;As of December&#160;31, 2020, a total of the 390,905 outstanding and exercisable options are &#x201c;in the money&#x201d; with aggregate intrinsic value of $1.1 million; while as of December&#160;31, 2019 a total of 1,179,398 outstanding and exercisable options were &#x201c;in the money&#x201d; with aggregate intrinsic value of $3.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;"&gt;The unrecognized compensation expense calculated under the fair-value method for stock options expected to vest as of December&#160;31, 2020, 2019 and 2018 is approximately $4.0 million, $5.5 million, and $6.5 million, respectively, and is expected to be recognized over a weighted-average period of 2.41&#160;years, 2.9&#160;years and 3.1 years, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;"&gt;For the&#160;years ended 2020, 2019 and 2018, the Company recorded a total of $2.1 million, $2.2 million, and $1.8 million of stock-based compensation expenses, in connection with the above-mentioned options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 10&#x2013; Shareholders&#x2019; Equity (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;B. &#160; Stock-based compensation (Cont.)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;"&gt;During 2016, the Company issued a total of 78,750 restricted stock units ("RSU"). Upon vesting, each RSU will settle by the issuance of one ordinary share. The RSUs vest over four years. As of December&#160;31, 2020, a total of 59,528 ordinary shares were issued upon vesting of 2,781 RSUs and there are no outstanding RSUs, while as of December&#160;31, 2019, a total of 56,747 ordinary shares were issued upon vesting of 54,316 RSUs and a total of 2,781 RSUs were outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;For the&#160;years 2020, 2019 and 2018, with respect to the above-mentioned RSUs, the Company recorded stock-based compensation expenses in the amount of $5 thousand, $70 thousand and $94 thousand, respectively. All of the above-mentioned stock-based compensation expenses are recorded under general and administrative expenses. as of December 31, 2020, there are no unrecognized compensation expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"&gt;The unrecognized compensation expense calculated under the fair-value method for RSU's expected to vest as of December&#160;31, 2019 is approximately $5 thousand, and is expected to be recognized over a weighted-average period of one year. As of December 31, 2020 there are no outstanding RSU's.&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <glmd:MaximumAmountOfSharesToBeIssued
      contextRef="As_Of_12_22_2017_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_OSe9LSeVd0mkEr3CGmm7tA"
      decimals="-6"
      id="Narr_qqQvxpGGekWwtiu62m8kYQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">35000000</glmd:MaximumAmountOfSharesToBeIssued>
    <glmd:MaximumAmountOfSharesToBeIssuedOffering
      contextRef="As_Of_5_15_2020_oxvKTuBAOkK40v6EQV3YEw"
      decimals="-5"
      id="Narr_CdZLwlkJB0GqdeoJ25RPxA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">31900000</glmd:MaximumAmountOfSharesToBeIssuedOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DIoFCIoieUy02nLWRrmjlA"
      decimals="0"
      id="Narr_kG7fqZ54iE2gdQ00Y3rj0Q"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">136300</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DIoFCIoieUy02nLWRrmjlA"
      decimals="-5"
      id="Narr_m-xH4mbNLESPuaQxSP7dPQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WPJh0pmyREubwtCYaYFNjA"
      decimals="0"
      id="Narr_f_UEeRZU5k2n6tVkaFY0oA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1541400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WPJh0pmyREubwtCYaYFNjA"
      decimals="-5"
      id="Narr_HT2bkDuWU0Kf2sTiOo8LmA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">8200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iP_trPoSQEGHbtnlJrlRyg"
      decimals="-5"
      id="Narr_xskCIU8aH0Oc4Ot8lk1Bag"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">22700000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA"
      decimals="0"
      id="Narr_cXtjJGuvVky0ockafD5Z4Q"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">2197803</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember_rI1zXGeK8EmUIgiB1WtYEA"
      decimals="4"
      id="Narr_tn32DpD-pkyp-gVOQ9nuaQ"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">4.3258</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA"
      decimals="-5"
      id="Narr_Qeh1BoZF4ES8LVe0Y7CtXQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">9300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <glmd:UnderwritersOptionExercisableTerm
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA"
      id="Narr_9CE3tDu820S_E3zlARJwBQ">P30D</glmd:UnderwritersOptionExercisableTerm>
    <glmd:UnderwritersOptionToPurchaseAdditionalShares
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA"
      decimals="0"
      id="Narr_5OnRJzNSbkmvF80CLDCXtg"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">329670</glmd:UnderwritersOptionToPurchaseAdditionalShares>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glmd_IncentiveShareOptionPlan2013Member_jMEQ59S6skeyqHQJq4F4Nw"
      decimals="0"
      id="Narr_MhLeO99bMkCZhTJ2Bm68NQ"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">687973</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="0"
      id="Narr_yhIRHNgegUGWEm-H4V1pOg"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">47509</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="2"
      id="Narr_8krM9d7E_EWV9AZ_Sd9g5A"
      unitRef="Unit_Divide_ILS_shares_E36EhjGGZkK6K8BwwH-6kA">0.01</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Narr_1C2TwSfK0EODo7tPp2zzpw"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">61000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="0"
      id="Narr_ahzgQjcAikSYCwVq_uBGCg"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">2781</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="2"
      id="Narr_pXcRG826lUy-cH2v3G7XOw"
      unitRef="Unit_Divide_ILS_shares_E36EhjGGZkK6K8BwwH-6kA">0.01</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_3_1_2020_To_3_31_2020_MPCna657d0q_4brWdj6Npg"
      decimals="0"
      id="Narr_4QChMSIq8kmGNOJm8ZpK2A"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">67500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_3_1_2020_To_3_31_2020_MPCna657d0q_4brWdj6Npg"
      decimals="2"
      id="Narr_UWwYDo9WoES1kiRwPubRuw"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">4.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_3_1_2020_To_3_31_2020_MPCna657d0q_4brWdj6Npg"
      id="Narr_GoB15M2w7kaJ32mRLTZcPA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_3_1_2020_To_3_31_2020_MPCna657d0q_4brWdj6Npg"
      id="Narr_c5GaRpV-PUK6Svh75oqvkQ">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="Duration_3_1_2020_To_3_31_2020_MPCna657d0q_4brWdj6Npg"
      decimals="-5"
      id="Narr_-6zyELfj7kylL5lDM-VNBA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_1_2020_To_8_31_2020_qLCEtGphHkma-pZvOcz6CA"
      decimals="0"
      id="Narr_U1VfqVwiYU2n2Sih36S9WA"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_8_1_2020_To_8_31_2020_qLCEtGphHkma-pZvOcz6CA"
      decimals="2"
      id="Narr_usn2s-NJQ0iG_-byq3Z7eA"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">4.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_8_1_2020_To_8_31_2020_qLCEtGphHkma-pZvOcz6CA"
      id="Narr_UZ3h5KMM4EKMuXumpKFVPA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_8_1_2020_To_8_31_2020_qLCEtGphHkma-pZvOcz6CA"
      id="Narr_os7RpoksF02KLqgClTAUFg">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="Duration_8_1_2020_To_8_31_2020_qLCEtGphHkma-pZvOcz6CA"
      decimals="-5"
      id="Narr_bgmMpW_iiESr_hgGb3JieA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_1_2020_To_8_31_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_-BwgIJ4swUqIbUQSXGQ7Ug"
      decimals="0"
      id="Narr_nEfQ57LUP0mg7gkeKE-Nbg"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_8_1_2020_To_8_31_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_-BwgIJ4swUqIbUQSXGQ7Ug"
      decimals="2"
      id="Narr_ws_OzRmGWU23oyl2nri4hg"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">5.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_8_1_2020_To_8_31_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_-BwgIJ4swUqIbUQSXGQ7Ug"
      id="Narr_fb8EkpY6Y0u_xK7cCbdlDw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_8_1_2020_To_8_31_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_-BwgIJ4swUqIbUQSXGQ7Ug"
      id="Narr_VtgS_2JdJ0WVZLmmHNJAEw">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="Duration_8_1_2020_To_8_31_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_-BwgIJ4swUqIbUQSXGQ7Ug"
      decimals="-5"
      id="Narr_gUxGUDpZYUim1sdjkKM7Ag"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ"
      decimals="0"
      id="Narr_F1EeknIQ00ap2MncTfUtcQ"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">267500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ"
      decimals="2"
      id="Narr_0dlYL4k6MEKTXEDuXXKzeA"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">3.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ"
      id="Narr_6PH7He41akKVjoyjNoUrjg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ"
      id="Narr_31exTaTF60ikkTmgGPLL2w">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ"
      decimals="-5"
      id="Narr__DEejOtscEGU6xx3fErxOQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_5ym3QBU5HUSdGhzhJHMUXg"
      decimals="0"
      id="Narr_tkoz2cU1j0SevZUdGCyPuw"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_5ym3QBU5HUSdGhzhJHMUXg"
      decimals="2"
      id="Narr_aOhONHfJO06fvo8fT-UFLQ"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">3.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_5ym3QBU5HUSdGhzhJHMUXg"
      id="Narr_u_Gm620j8ku_3JsLq3Dr8w">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_5ym3QBU5HUSdGhzhJHMUXg"
      id="Narr_ruOhqAK7t0SJ8bzO9wRb4Q">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_zPo_guEl2EmGCb_2oVS2oA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options outstanding at beginning of&#160;&#160;year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,393,715&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,349,054&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.92&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Granted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 585,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 282,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Forfeited&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (208,195)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.49&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (121,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercised&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (47,509)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (116,589)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.23&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at end of&#160;year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,723,011&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.70&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,393,715&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options exercisable at&#160;year end&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,754,261&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,647,048&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.02&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA"
      decimals="0"
      id="Tc_3zXuPmBqWE6hZHyZBTf1wA_6_2"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">2393715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA"
      decimals="2"
      id="Tc_-wqRQgbDgEe6lE7ikuQGnA_6_5"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2018_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_qalgby9MtkGBayyVeht6lA"
      decimals="0"
      id="Tc_qShw_l9vgk6i-qtlCzRS-A_6_7"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">2349054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2018_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_qalgby9MtkGBayyVeht6lA"
      decimals="2"
      id="Tc_jvndHV7910egaXGFS-2_Rg_6_10"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">5.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw"
      decimals="0"
      id="Tc_3RVDP0piUkuM-pOcAj9GDg_7_2"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">585000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw"
      decimals="2"
      id="Tc_xFpMQoNj2UWrYmUa3IEw4A_7_5"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">4.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw"
      decimals="0"
      id="Tc_oes0FsH0M0WVSaerXQ1muA_7_7"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">282500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw"
      decimals="2"
      id="Tc_Ya4Zk0GtMUOPpsjMSMUpKw_7_10"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">5.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw"
      decimals="0"
      id="Tc_yh0pdZeZ10yAAzYYUIPMYA_8_2"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">208195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw"
      decimals="2"
      id="Tc_RiXQiQRmB0GBCltOTotQYA_8_5"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">7.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw"
      decimals="0"
      id="Tc_lxJFM9uACkCFWkzFwxyXWA_8_7"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">121250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw"
      decimals="2"
      id="Tc_Me5J5m5DSkC4Le9kX6wmwg_8_10"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">6.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw"
      decimals="0"
      id="Tc_zFPvPV8LX0C0vYUAcPxonw_9_2"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">47509</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_9K4RMA5IaUaL0U-wnmvqdw"
      decimals="2"
      id="Tc_CoY8qp4X0UCh65Z6V3_Uxw_9_5"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">1.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw"
      decimals="0"
      id="Tc_J6tZ_wlpkUO-F3vs8ws7EA_9_7"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">116589</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_NjcjidKHKk2-E7Nm1zySNw"
      decimals="2"
      id="Tc_CS9mra9Tn0O54QbMyX3L7w_9_10"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">1.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_EBlJedVOS0a8vpK59r2GmA"
      decimals="0"
      id="Tc_qQDFDIK1LkWgSrgYX0b96g_10_2"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">2723011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_EBlJedVOS0a8vpK59r2GmA"
      decimals="2"
      id="Tc_JTClcy_pgU-2viWXM0HHbg_10_5"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA"
      decimals="0"
      id="Tc_aQLTMjGT3UWcVMzYNInxQg_10_7"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">2393715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA"
      decimals="2"
      id="Tc_QUrSnWAdDE2Kip-Ty9pKEg_10_10"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_EBlJedVOS0a8vpK59r2GmA"
      decimals="0"
      id="Tc_NlY9nljr0kmYUBza_HUakQ_11_2"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">1754261</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_EBlJedVOS0a8vpK59r2GmA"
      decimals="2"
      id="Tc_zApWywxt_EC_wKnMYZ7zBw_11_5"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">5.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA"
      decimals="0"
      id="Tc_Q11FYJEy6k-SJo9L9l8pAA_11_7"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">1647048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_j3wT2sGKC0C6QIkL99hFdA"
      decimals="2"
      id="Tc_O1K7JdpZs02RXQVdeYtp2A_11_10"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw"
      decimals="4"
      id="Narr_par6JoGtyEia2JkNVcELdA"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug"
      decimals="4"
      id="Narr_LZp8xJ7D_Uis9uxuaSWaCQ"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA"
      decimals="4"
      id="Narr_qTuvVaTMfE6ybJ6FQ84cng"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw"
      decimals="4"
      id="Narr_-5jLu8n7y0SLst89FxrSYg"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.0267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw"
      decimals="4"
      id="Narr_Ay8-66Tad0Gz93yaN9DTlA"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.0301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug"
      decimals="4"
      id="Narr_DwKwY9haUkOiuk0TxXk6Rw"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug"
      decimals="4"
      id="Narr_L1FZNgP9pkmBLEQryMoy0g"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.0243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="4"
      id="Narr_wb4EvBS9ekKTBJ6_WI-5bA"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.0042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="4"
      id="Narr_O2azoLzBKE6tf1inYRf0qw"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.0074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2017_To_12_31_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GEzGoXG5Ok-EayrH7ZBK0Q"
      id="Narr_BDEnfxwIPEm9vOec1M0gZw">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LVpIBdN-a02_xjlF3wujBg"
      id="Narr_leSrHGpuLE-poVLvEKdiyQ">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y0ei-czCk0Sc-jHLUaPa8w"
      id="Narr_8T0yZIFgYUmQjnoTNJxj_w">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NyHUYA8FSUyuZNantnazBQ"
      id="Narr__EYENh9aCUmdrgkSIbV8VQ">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_r7Ms1ZL-BEiOxWAAdEMExA"
      id="Narr_fKz2IUo9C02-W15JXjlzlg">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__8e7PIYNIkuDeGtL1vwa3A"
      id="Narr_VTYmqIsvAEGOkRpK2lO1SQ">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw"
      decimals="2"
      id="Narr_mki33hQldkutBxsStxU-2A"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw"
      decimals="2"
      id="Narr_JO-L3wc0fkyUY3jMyT3QIA"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug"
      decimals="2"
      id="Narr_s8VL84_ceEGSC3fEaCLJJw"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug"
      decimals="2"
      id="Narr_mbJ5fy8Wfk-a9yPcrNKDww"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA"
      decimals="2"
      id="Narr_OH4eqPqy3Eu25jQco3hKCQ"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA"
      decimals="2"
      id="Narr_xAVhXhOyZkSvFSlue_d1gw"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA"
      decimals="0"
      id="Narr_ZfyaDg63V0iSHGKb0HKQCw"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">38637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA"
      id="Narr_9bVO9FEEO0OFs_EwcmxV9Q">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug"
      id="Narr_jaiDD-insEu8CtP9Oxq2bA">P6Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA"
      decimals="2"
      id="Narr_DnN4eWWdz0amUQDx9EYpiA"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">2.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug"
      decimals="2"
      id="Narr_IVKmGE4KvkCAL_nNKg4_iw"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">4.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw"
      decimals="2"
      id="Narr_KW04TY5vo0GtxJwPsBj-0w"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">8.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4fndOwz4MES4TiHYJ6gb3Q"
      decimals="0"
      id="Narr_acffK-aHeEOlADgTFV8DaA"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">390905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4fndOwz4MES4TiHYJ6gb3Q"
      decimals="-5"
      id="Narr_6J0_5NtGO0ihcXSdBrnHGw"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QjPdXPDPS0KeLH50EvKEiw"
      decimals="0"
      id="Narr_CGT1GDIDeUqHVr8PqV1cvw"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">1179398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QjPdXPDPS0KeLH50EvKEiw"
      decimals="-5"
      id="Narr_a6_qfxQHWUaeHVsCjGjl5Q"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">3100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4fndOwz4MES4TiHYJ6gb3Q"
      decimals="-5"
      id="Narr_A26r1f94xkm76uXwlfks0w"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">4000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QjPdXPDPS0KeLH50EvKEiw"
      decimals="-5"
      id="Narr_Q-iNYjGoKkW3I3g18OIxoA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">5500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KeNcj4ynQEmMLA9cFanIvg"
      decimals="-5"
      id="Narr_5FgIy9jlskGcbdD0v7jQ-Q"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">6500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA"
      id="Narr_HDa8U_YR3E-Z1U9Z27SGLw">P2Y4M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug"
      id="Narr_ngZKp3SXBESkUA9BJfXnjA">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw"
      id="Narr_lG6fbY-D0UeDjz6Ykptk5A">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA"
      decimals="-5"
      id="Narr_sDxGcKRdpECFFxfORK0PJw"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug"
      decimals="-5"
      id="Narr_Zgy3WOB5q0CAZqLdzfVPaA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_m9G9MKKo1U2b4aV0kcTnBw"
      decimals="-5"
      id="Narr_nidZekHOTkCMJYzEaB_Mog"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2016_To_12_31_2016_sn54mW8hE0KEfttuS1LktQ"
      decimals="0"
      id="Narr_RRxAenBrWUCTqWxITyldhQ"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">78750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2016_To_12_31_2016_sn54mW8hE0KEfttuS1LktQ"
      id="Narr_2INhQnom6kScobTawWM1BA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dL5eSCQ2-UWWlJTgsR5kQA"
      decimals="0"
      id="Narr_NTKVw5Kv-0yU4awrEO5YIA"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">59528</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="0"
      id="Narr_larseCB5IkKcZBkUASDzkg"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">2781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="0"
      id="Narr_IO6mY1IQBEGbskfhruA6IA"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">56747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PX9SGKeWOkOJTjPcJIscug"
      decimals="0"
      id="Narr_X9nZQvxS30WkKoQwk-Af8w"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">54316</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_glmd_EmployeeStockOptionAndRestrictedStockUnitsMember_1uQb0r1NiEeEwnFMdNS4OA"
      decimals="0"
      id="Narr_ZxLLtvbj8Ue72Pz7VM8vhA"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">2781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_I_8qF4py_U-hFUr5wnrNSQ"
      decimals="-3"
      id="Narr_sRuts2Lpk0yO8SuZ3DQW8Q"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">5000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_W0hOEi39s0i4CgIp_7LThA"
      decimals="-3"
      id="Narr_7Gy6dS5THkOSBx_GrXvDSQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">70000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hf5IyP78Okm12S_Q5Zkpgg"
      decimals="-3"
      id="Narr_NPj1RTqVWUqnfpXZ0pBEIA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">94000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Narr_ojo02MwHnUedcWS5Y1tfBQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">5000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Narr_56dVcCPVtEyjU1B1klJ3gA">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_0qRMTve6DEuIxRSHEusd0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Note&#160;11&#160;&#x2013; Research and Development Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Chemistry and formulation studies&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,856&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,439&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 968&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Salaries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,570&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 871&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 883&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 582&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and preclinical studies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Clinical studies&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,225&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,346&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Regulatory and other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 608&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,082&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,180&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,313&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_5RCGV2TbuUiLkv2vcMmQbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Chemistry and formulation studies&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,856&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,439&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 968&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Salaries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,570&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 871&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 883&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 582&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and preclinical studies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Clinical studies&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,225&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,346&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Regulatory and other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 608&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,082&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,180&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,313&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock>
    <glmd:ChemistryAndFormulationStudiesExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg"
      decimals="-3"
      id="Tc_05Okdxm0_U2Q0tKL-jdFFQ_4_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">5856000</glmd:ChemistryAndFormulationStudiesExpenses>
    <glmd:ChemistryAndFormulationStudiesExpenses
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw"
      decimals="-3"
      id="Tc_MhzvwfDikU-HcgUEHwqwGw_4_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">3439000</glmd:ChemistryAndFormulationStudiesExpenses>
    <glmd:ChemistryAndFormulationStudiesExpenses
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g"
      decimals="-3"
      id="Tc_xhmg3giXTk-wPAjBrgmLDQ_4_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">968000</glmd:ChemistryAndFormulationStudiesExpenses>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg"
      decimals="-3"
      id="Tc_oIK3iuQFhUuYN09ygxob7Q_5_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2570000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw"
      decimals="-3"
      id="Tc_j2LbRCYIQ0SxzTbLYayWBQ_5_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2283000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g"
      decimals="-3"
      id="Tc_qfltuD35hUS0rStV4Z-_Kg_5_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1617000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg"
      decimals="-3"
      id="Tc_G6X-g6UiU0C01hr2egLpDQ_6_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">871000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw"
      decimals="-3"
      id="Tc_xYYr4WeU50SGba7dGiGO1Q_6_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">883000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g"
      decimals="-3"
      id="Tc_WIGJTeCQJE6fAjk9A44fZw_6_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">582000</us-gaap:AllocatedShareBasedCompensationExpense>
    <glmd:ResearchAndPreclinicalStudiesExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg"
      decimals="-3"
      id="Tc_txMM_cqkOkilt3QSLQIBUw_7_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1873000</glmd:ResearchAndPreclinicalStudiesExpenses>
    <glmd:ResearchAndPreclinicalStudiesExpenses
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw"
      decimals="-3"
      id="Tc_Zv2ei5-jcUOLeL-nEi2aHw_7_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1962000</glmd:ResearchAndPreclinicalStudiesExpenses>
    <glmd:ResearchAndPreclinicalStudiesExpenses
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g"
      decimals="-3"
      id="Tc_m9tnwF8JrEKIvFyId6N__w_7_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">963000</glmd:ResearchAndPreclinicalStudiesExpenses>
    <glmd:ClinicalStudiesExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg"
      decimals="-3"
      id="Tc_bxG1TTqzxEuaDINJY7o6dw_8_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">13225000</glmd:ClinicalStudiesExpenses>
    <glmd:ClinicalStudiesExpenses
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw"
      decimals="-3"
      id="Tc_yyUCaXF9Skia5p2NfW6yqg_8_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">8346000</glmd:ClinicalStudiesExpenses>
    <glmd:ClinicalStudiesExpenses
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g"
      decimals="-3"
      id="Tc_EkYtfA1xaUWc8zA3GUKotw_8_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">3575000</glmd:ClinicalStudiesExpenses>
    <glmd:RegulatoryAndOtherExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg"
      decimals="-3"
      id="Tc_GmuUth_LmUW7fQG_rupbCQ_9_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1687000</glmd:RegulatoryAndOtherExpenses>
    <glmd:RegulatoryAndOtherExpenses
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw"
      decimals="-3"
      id="Tc_dy1pn3JU-kCTgkUWVRDTJw_9_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1267000</glmd:RegulatoryAndOtherExpenses>
    <glmd:RegulatoryAndOtherExpenses
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g"
      decimals="-3"
      id="Tc_98qmUSgEikWIxhj9o2IveQ_9_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">608000</glmd:RegulatoryAndOtherExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg"
      decimals="-3"
      id="Tc_VWvHPkr8Ak6Od7NZFTjwIQ_10_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">26082000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6oQVpcmKQ02Wtmjcd2dovw"
      decimals="-3"
      id="Tc__sief6Rp50i6zOYdTHeeEA_10_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">18180000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uN1QRRhN9U-goAtBHvRg0g"
      decimals="-3"
      id="Tc_ggXS5yZw2Eak5uWQrzX-JQ_10_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">8313000</us-gaap:ResearchAndDevelopmentExpense>
    <glmd:GeneralAndAdministrativeExpensesDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_6SwSPwNxGEKZOmhOa0IpJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Note&#160;12&#160;&#x2013; General and Administrative Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,194&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,349&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,201&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 896&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Salaries and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 828&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 856&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Rent and office-maintenance fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Investor relations and business development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 293&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 364&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 464&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Insurance and other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 268&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,128&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,196&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</glmd:GeneralAndAdministrativeExpensesDisclosureTextBlock>
    <glmd:GeneralAndAdministrativeExpensesTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_G6XyJMXa7EqfBNnX67Dwmw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,194&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,349&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,201&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 896&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Salaries and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 828&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 856&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Rent and office-maintenance fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Investor relations and business development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 293&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 364&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 464&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Insurance and other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 268&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,128&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,196&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</glmd:GeneralAndAdministrativeExpensesTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g"
      decimals="-3"
      id="Tc_nRt1JN62bkCWqejgC-vQ1g_4_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1194000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg"
      decimals="-3"
      id="Tc_DQHqSikUh0yem4j1GxJzgg_4_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1349000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw"
      decimals="-3"
      id="Tc_FkrcklaRRUGXH7Tlz-pJtw_4_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1201000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g"
      decimals="-3"
      id="Tc_F7yZNc1v2UeBx7NKUvjlfA_5_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">796000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg"
      decimals="-3"
      id="Tc_DjeA5GMETk6hhjgOLIVhJQ_5_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">877000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw"
      decimals="-3"
      id="Tc_eLgwvyqAbku9AcsKZQ2crg_5_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">896000</us-gaap:ProfessionalFees>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g"
      decimals="-3"
      id="Tc_j5AdiIjN30yow9PZE6Nxbw_6_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">828000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg"
      decimals="-3"
      id="Tc_orKaEORlL0-NK_qh5KdRJw_6_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">856000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw"
      decimals="-3"
      id="Tc_1u2MObROqEO4KB_FU-7v3w_6_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1346000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g"
      decimals="-3"
      id="Tc_706akkoYI0iyE0vZK_bUrw_7_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">430000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg"
      decimals="-3"
      id="Tc_PLcT4MVQxkiyFBvh4ffodQ_7_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">482000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw"
      decimals="-3"
      id="Tc_w5j_Nsz3g0iq9hfSO8QvBw_7_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">308000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:BusinessDevelopment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g"
      decimals="-3"
      id="Tc_pFGRWNBWQk29FILBsTcn1g_8_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">293000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg"
      decimals="-3"
      id="Tc_5di1XzKe5ESZvFJt4D3h0w_8_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">364000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw"
      decimals="-3"
      id="Tc_zKRVMJNg0Ey-8F-e6O7iSw_8_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">464000</us-gaap:BusinessDevelopment>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g"
      decimals="-3"
      id="Tc_-TSxAxzdU0i8ID7a2RYsZg_9_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">587000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg"
      decimals="-3"
      id="Tc_TZTTLjLd4kGN51bHYP-45A_9_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">268000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw"
      decimals="-3"
      id="Tc_I5zmtfXOw0OA8qxPwaSqPg_9_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">225000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g"
      decimals="-3"
      id="Tc_0BF7Tj7isEi5QOAxbEvxiw_10_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">4128000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pwupgc1Acki_km96CXmEfg"
      decimals="-3"
      id="Tc_gjN7GZL7wUSzh8Kqt9_JPQ_10_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">4196000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R1vRZ1YhKUeDBJQ9cGfiYw"
      decimals="-3"
      id="Tc_SZ9-ZsX3VkO89eMS5FiIvQ_10_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">4440000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_MYpb6tNGVUuwy1XtyxtCNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Note&#160;13&#160;&#x2013; Financial income, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Bank fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,192)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,953)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (959)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gain from sale of marketable debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (397)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (106)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign currency (gains) losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 119&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,439)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,915)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (934)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_602GfVcVOUKUqpqDg2rZxA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Bank fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,192)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,953)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (959)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gain from sale of marketable debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (397)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (106)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign currency (gains) losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 119&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,439)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,915)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (934)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock>
    <glmd:BankFees
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_-_JQXErdVEWLSWgaVt3JsA_4_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">31000</glmd:BankFees>
    <glmd:BankFees
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc__nF2_xchVk6JIRv-AYK6kQ_4_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">33000</glmd:BankFees>
    <glmd:BankFees
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_0h6lF4NOyE-wkdXhlW_5Kw_4_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">42000</glmd:BankFees>
    <us-gaap:InterestIncomeOther
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_fhfRWliqu0uoYcbscco1Nw_5_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1192000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_oPZzS_xCkEKJngT1DVCTfQ_5_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1953000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_kubU_FkETU6Ako-l3kt3dw_5_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">959000</us-gaap:InterestIncomeOther>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_Wsqrq4730EuD1eiwuYX_Fg_6_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">397000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_pV_Dw6MhUkO7e2IrFm7N5g_6_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">106000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_k-w5rvxZ7kqsywZjdilYHg_6_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">12000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_NHXY6UfrwkSkIbIgiQEilA_7_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-119000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_rl6BwwBJk0iRnL0lErzuzg_7_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-111000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_bf0hQ9Z_t02zEnpkdqKj-A_7_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">5000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_hOBv58vDoEKgYhhtBzvo0g_8_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1439000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_TUPixhhya06O14t4KWvRrw_8_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1915000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_YUgfQzaT7EayI5YrvzGYBg_8_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">934000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_U76XZB3I7kSy0VK6sC-xNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;14&#160;&#x2013; Income Taxes&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;A.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Company is assessed for tax purposes on an unconsolidated basis. Each of the Company&#x2019;s subsidiaries is subject to the tax rules&#160;prevailing in its country of incorporation.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;B.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Corporate Taxation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;Israeli Companies:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;In January&#160;2016, the Israeli corporate income tax law was amended and reduced as of January&#160;1, 2016 to 25% (from 26.5%). In December&#160;2016, the Israeli corporate income tax law was further amended and reduced as of January&#160;1, 2017 to 24% and as of January&#160;1, 2018 and onwards to 23%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;On February&#160;7, 2018, the Israeli Tax Authority issued a ruling granting the Company&#x2019;s Israeli subsidiary, Galmed Research and Development Ltd, a &#x201d;Preferred Technological Enterprise&#x201d; status&#160; as defined under the Encouragement of Capital Investment Law&#160;-1959 (the "Approval"). The grant of the status means that the Company&#x2019;s Israeli subsidiary will be subject to a reduced Israeli corporate tax rate that will range between 6%-12% on any future taxable "technological income" which includes sales, licenses and royalties from its IP protected products. The tax ruling applies for five&#160;years until 2022 and may be extended for further periods subject to meeting certain requirements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;Maltese subsidiary:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;Taxable income of Maltese companies was subject to tax at the rate of 35% in 2020.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;C.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Net Operating Loss Carry forward&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2020, the Company had approximately $110.9 million net-operating-loss carry forwards, consisting of approximately $11.7 million of Maltese net-operating-loss carry forwards and approximately $99.2 million Israeli net-operating-loss carry forward. Additionally, the Company had approximately $2.4 million of capital loss carry forward from the sale of marketable debt securities in Israel. The Maltese and the Israeli loss carry forwards have no expiration date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;Note 14 &#x2013; Income Taxes (Cont.)&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;D.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Deferred income taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;Deferred-tax assets for carry forward losses in Malta and Israel are calculated using the applicable tax rate at the time of expected realization of the carry forward losses. The Company has provided full valuation allowances in respect of deferred-tax assets. Management currently believes that it is more likely than not that those deferred taxes will not be realized in the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;Significant components of the Company&#x2019;s and its subsidiaries&#x2019; assets are as follows&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Israeli companies net-operating-loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Maltese subsidiary net-operating-loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,090&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,081&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Israeli subsidiary capital-loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Other reserves and allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total deferred-tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15,068)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred-tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;E.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Tax assessment&lt;/b&gt;s&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;"&gt;The Israeli subsidiaries received final tax assessments through the&#160;year ended December&#160;31, 2015.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;F.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Effective tax expense&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;A reconciliation of the Company&#x2019;s effective tax expense to the Company&#x2019;s theoretical statutory tax benefit is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="11" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss before taxes on income, as reported in the consolidated statements of operations&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,771&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,461&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,781&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Statutory tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Theoretical tax benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,453&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,455&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,174&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,453)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,455)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,174)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax withheld from upfront payment from Samil&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Actual tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_bgXq7TSYz0qDPCPOCoHLlA"
      decimals="2"
      id="Narr_0hqa6x3_Hk-sC0BELaslyg"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_ScwAFiM_R02IVHmPu8-uGw"
      decimals="3"
      id="Narr_-TcFsn30rkacAjWhR1DaZw"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_U--doeSff0eYGwC7nwkM-g"
      decimals="2"
      id="Narr_Ka0_ZIMpTEKwGQ5yhej2uQ"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.24</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_JOb54R0hTEydao88CStcSA"
      decimals="2"
      id="Narr_0dK9TbtU9Umm-krHQ7LxzQ"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_DSjIA39FDUaJmBOrv2YWwg"
      decimals="2"
      id="Narr_v6yt7yG5okaNVO521uzYGw"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_2_1_2019_To_2_7_2019_srt_RangeAxis_srt_MinimumMember_wTFaM2m8mEeYWNwxhsduUQ"
      decimals="2"
      id="Narr_4Y1gStMyRUuOw-6RP9CbwQ"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_2_1_2019_To_2_7_2019_srt_RangeAxis_srt_MaximumMember_G54FxZmw_0-M5Erc8SbIag"
      decimals="2"
      id="Narr_NJa9JAkQj0Gx-XIt2l8sJw"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.12</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_FOpb3JVogkOpHOfrV1dInw"
      decimals="2"
      id="Narr_SFWKYcY2S0GePhQ-TnDs2g"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-5"
      id="Narr_AkDDIVRZ1UepVg7svirkdg"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">110900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_ABpxUYDxU0CDiyikjLs1sg"
      decimals="-5"
      id="Narr_6XGNZPAVgkutIXQ6wGAMKA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">11700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_mGyra1etzUCzEOs-2C5hCQ"
      decimals="-5"
      id="Narr_rQSuEcZYu0idn_YFrvPZVQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">99200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-5"
      id="Narr_wYZcglCXaEeI94rEF0_QAA"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2400000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_-85BCI2DX0yh7LjUNUipMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;Significant components of the Company&#x2019;s and its subsidiaries&#x2019; assets are as follows&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Israeli companies net-operating-loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Maltese subsidiary net-operating-loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,090&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,081&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Israeli subsidiary capital-loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Other reserves and allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total deferred-tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15,068)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred-tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_mGyra1etzUCzEOs-2C5hCQ"
      decimals="-3"
      id="Tc_npz0IGr-DE2qZHF1W8GYYQ_5_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">11906000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_ZJtJgHpgokiYVRcA7a4M5Q"
      decimals="-3"
      id="Tc_YGP6G57csUCmr5scocwT8w_5_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">10085000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_ABpxUYDxU0CDiyikjLs1sg"
      decimals="-3"
      id="Tc_t9cinDHaM0-mZ4pMmW4fEw_6_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">4090000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_MalteseSubsidiaryMember_grcOKAlDuECUUH45djx3zQ"
      decimals="-3"
      id="Tc_JKzFSIhG9kSO5Zm6AyjA4w_6_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">4081000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_mGyra1etzUCzEOs-2C5hCQ"
      decimals="-3"
      id="Tc_UyiNnKOaN06JdTRgqJHzrQ_7_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">577000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_glmd_IsraeliSubsidiaryMember_ZJtJgHpgokiYVRcA7a4M5Q"
      decimals="-3"
      id="Tc_E8XklkITakCmn1uWws52Xg_7_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">881000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_PvCpN9j2HU-TSvyRgTrW3A_8_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">27000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_ECGXo1BRJ0eiPiVGQDPwNA_8_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">21000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_sf2SYkTnJ0u7y0q9_-m63w_9_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">16600000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_-6FmKpkBPECixdxm2c7nTA_9_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">15068000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_7B6FUMjTuUWTJYeVW7cbMQ_10_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">16600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_gm0f-M6P_k-kpyYue3w0Rw_10_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">15068000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA"
      decimals="-3"
      id="Tc_CV6zZ3wSaECLQ8t7kbWj9Q_11_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2019_kJttlaop7U-EyGC1uCQNPQ"
      decimals="-3"
      id="Tc_Mjk1uL5Zw0iPxs1d35EJlQ_11_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_NEZghb-kU0-pXJAC0IehZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;A reconciliation of the Company&#x2019;s effective tax expense to the Company&#x2019;s theoretical statutory tax benefit is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="11" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss before taxes on income, as reported in the consolidated statements of operations&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,771&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,461&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,781&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Statutory tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Theoretical tax benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,453&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,455&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,174&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,453)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,455)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,174)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax withheld from upfront payment from Samil&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Actual tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_EGz_nh-D-kuL1G0M9MZI9g_5_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-28771000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_FPO0BpsRD0u-uECq-cB2jw_5_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-20461000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_R6DFa9bvEkiIIgBGA55jOw_5_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-9781000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="2"
      id="Tc_o8NkXNoheEWRtaPf8qYaxw_7_3"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.12</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="2"
      id="Tc_SOgzfFk9DUeGEIGbyiVm3w_7_6"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.12</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="2"
      id="Tc_33Ipqa5yrU2NPP2K_XZ2Aw_7_9"
      unitRef="Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA">0.12</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_ydiaMHE1hEGIpV9TPNZZ-g_9_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">3453000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_4-eQyYglKkey-HdkI7vDRg_9_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">2455000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_IA40Oty-7UmDvJ1VIwyCAA_9_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">1174000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_CDJWc38BakSZR5ZzrjkF5w_10_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-3453000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_T6q-xUlEH0iaesf0Z2dRug_10_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-2455000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_j_qseif72EiHvgL4LkZ8DA_10_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">-1174000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_-q-T9MAmC0-Oyg7n2rwyXg_11_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_8xx4hb43FEybXcMeY75Y2g_11_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_TAZe8sxUxEu-ITtRmjonkg_11_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">75000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      decimals="-3"
      id="Tc_dM6uD71HAUW4Tead6za4WQ_12_3"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_0BgdkFcq70GtA_6kroLlDg"
      decimals="-3"
      id="Tc_6yTZjkwFH0eFsjAKNdG2Hw_12_6"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw"
      decimals="-3"
      id="Tc_CfI3hiOuoEWj1Ma0MW1egA_12_9"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">75000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg"
      id="Tb_bJQHI1efcU6Qa_D8I7Pn3g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 15 - Subsequent events&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;During February 2021, the Company sold 1,541,400 ordinary shares under its ATM Program for total net proceeds of approximately $8.2 million. See also Note 10A.3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;During February 2021, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Cantor Fitzgerald &amp;amp; Co. (the "Underwriter") in connection with an underwritten public offering (the "Underwritten Public Offering") of 2,197,803 ordinary shares (the "Firm Shares") of the Company. The Underwriter purchased the Firm Shares from the Company at a price of $4.3258 per share. The net proceeds to the Company, Were approximately $9.3 million. See also Note 10A.4.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;On March 2021, the Company has signed with with Mintz K. Construction Company a lease &lt;span style="-sec-ix-hidden:Hidden_Ccc8RhKJjU6tsVCv0GLiEA;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;extension&lt;/span&gt;&lt;/span&gt; agreement to its corporate headquarters for a period of &lt;span style="-sec-ix-hidden:Hidden_iAeXAqUqkkCSijJ30lE5Og;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;two&lt;/span&gt;&lt;/span&gt; additional years until March 22, 2023 with an option for another year. According to updated lease, the aggregate quarterly rental payment, together with adjustments and the maintenance fees, is approximately NIS 133,497 plus VAT.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WPJh0pmyREubwtCYaYFNjA"
      decimals="0"
      id="Narr_CDGtPcmzGU6skJq92L96gQ"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">1541400</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_PlanNameAxis_glmd_AtthemarketOfferingMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WPJh0pmyREubwtCYaYFNjA"
      decimals="-5"
      id="Narr_RQLcGmtAJkud1A2on6Bz0w"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">8200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA"
      decimals="0"
      id="Narr_Wd5zkrI_zUKorhBrP5Zikg"
      unitRef="Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww">2197803</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember_rI1zXGeK8EmUIgiB1WtYEA"
      decimals="4"
      id="Narr_yLZkxwjylEeSQ8mqZd-3BQ"
      unitRef="Unit_Divide_USD_shares_6jPbDHQUnEux8CGSpu-VXQ">4.3258</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glmd_UnderwrittenPublicOfferingMember__Tq689W8VEmo1Tp5jJhhXA"
      decimals="-5"
      id="Narr_T8LN_Nlon0a-U3OyHpP2DQ"
      unitRef="Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ">9300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <glmd:AggregateQuarterlyRentalPayment
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_d2nXIm0PHEKT0HYx5C-QMw"
      decimals="0"
      id="Narr_y-3F1W53ckaacN78uC6rsA"
      unitRef="Unit_Standard_ILS_80PDI-Ft8k2W61vPNXVwKw">133497</glmd:AggregateQuarterlyRentalPayment>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_Dsf4U8uej0-EcPAM2_HySw_28_9"
          xlink:label="Tc_Dsf4U8uej0-EcPAM2_HySw_28_9"
          xlink:type="locator"/>
        <link:footnote id="_42e2ff89_d58a_4126_9816_39de91f5f9c8" xlink:label="_42e2ff89_d58a_4126_9816_39de91f5f9c8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See also Note 10.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Dsf4U8uej0-EcPAM2_HySw_28_9"
          xlink:to="_42e2ff89_d58a_4126_9816_39de91f5f9c8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_GoeIdt4KN0u0T0yl9u7wUA_28_6"
          xlink:label="Tc_GoeIdt4KN0u0T0yl9u7wUA_28_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_GoeIdt4KN0u0T0yl9u7wUA_28_6"
          xlink:to="_42e2ff89_d58a_4126_9816_39de91f5f9c8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_xt9it0WKS0itVI7bY09UyA_28_3"
          xlink:label="Tc_xt9it0WKS0itVI7bY09UyA_28_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_xt9it0WKS0itVI7bY09UyA_28_3"
          xlink:to="_42e2ff89_d58a_4126_9816_39de91f5f9c8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_oULiP01GyEGoRJwxs7pREQ"
          xlink:label="Hidden_oULiP01GyEGoRJwxs7pREQ"
          xlink:type="locator"/>
        <link:footnote id="_afc9692e_a9e1_46f7_9c18_b560baccbcf1" xlink:label="_afc9692e_a9e1_46f7_9c18_b560baccbcf1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents amount less than $1</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_oULiP01GyEGoRJwxs7pREQ"
          xlink:to="_afc9692e_a9e1_46f7_9c18_b560baccbcf1"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972218857544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Galmed Pharmaceuticals Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16 Tiomkin Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6578317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001595353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par value NIS 0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLMD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">21,325,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16 Tiomkin Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6578317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Allen Baharaff<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">ab@galmedpharma.com<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">693.8448<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number Section<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972215390504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,947<span></span>
</td>
<td class="nump">$ 15,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term deposits</a></td>
<td class="nump">3,807<span></span>
</td>
<td class="nump">27,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable debt securities</a></td>
<td class="nump">40,132<span></span>
</td>
<td class="nump">31,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other accounts receivable</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">51,811<span></span>
</td>
<td class="nump">76,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">52,381<span></span>
</td>
<td class="nump">77,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">7,046<span></span>
</td>
<td class="nump">5,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payable</a></td>
<td class="nump">966<span></span>
</td>
<td class="nump">935<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,012<span></span>
</td>
<td class="nump">6,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligation</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares par value NIS 0.01 per share; Authorized 50,000,000 shares; Issued and outstanding: 000 shares as of December 31, 2020; 21,139,385 shares as of December 31, 2019</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">179,530<span></span>
</td>
<td class="nump">176,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(135,707)<span></span>
</td>
<td class="num">(106,936)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">44,153<span></span>
</td>
<td class="nump">69,853<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 52,381<span></span>
</td>
<td class="nump">$ 77,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972215165256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, Par or Stated Value Per Share</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, Shares Authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, Shares, Issued</a></td>
<td class="nump">21,325,975<span></span>
</td>
<td class="nump">21,139,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, Shares, Outstanding</a></td>
<td class="nump">21,325,975<span></span>
</td>
<td class="nump">21,139,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972299069144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">26,082<span></span>
</td>
<td class="nump">18,180<span></span>
</td>
<td class="nump">8,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,128<span></span>
</td>
<td class="nump">4,196<span></span>
</td>
<td class="nump">4,440<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating loss</a></td>
<td class="nump">30,210<span></span>
</td>
<td class="nump">22,376<span></span>
</td>
<td class="nump">10,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Financial income, net</a></td>
<td class="num">(1,439)<span></span>
</td>
<td class="num">(1,915)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="nump">28,771<span></span>
</td>
<td class="nump">20,461<span></span>
</td>
<td class="nump">9,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 28,771<span></span>
</td>
<td class="nump">$ 20,461<span></span>
</td>
<td class="nump">$ 9,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of shares outstanding used in computing basic and diluted net loss per share</a></td>
<td class="nump">21,280,787<span></span>
</td>
<td class="nump">21,114,399<span></span>
</td>
<td class="nump">18,137,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972298901688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 28,771<span></span>
</td>
<td class="nump">$ 20,461<span></span>
</td>
<td class="nump">$ 9,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss (gain) on available for sale securities</a></td>
<td class="num">(237)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="nump">$ 28,534<span></span>
</td>
<td class="nump">$ 20,415<span></span>
</td>
<td class="nump">$ 9,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972217958824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss) [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 174,322<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">$ (86,475)<span></span>
</td>
<td class="nump">$ 87,894<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">21,018,919<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Exercise of options and restricted stock units</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">143<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Exercise of options and restricted stock units (in shares)</a></td>
<td class="nump">120,466<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,461)<span></span>
</td>
<td class="num">(20,461)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">176,696<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="num">(106,936)<span></span>
</td>
<td class="nump">69,853<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">21,139,385<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,066<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Exercise of options and restricted stock units</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">61<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Exercise of options and restricted stock units (in shares)</a></td>
<td class="nump">50,290<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Ordinary Shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">707<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Ordinary Shares (In shares)</a></td>
<td class="nump">136,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(28,771)<span></span>
</td>
<td class="num">(28,771)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 179,530<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="num">$ (135,707)<span></span>
</td>
<td class="nump">$ 44,153<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">21,325,975<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents amount less than $1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972215483848">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flow from operating activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (28,771)<span></span>
</td>
<td class="num">$ (20,461)<span></span>
</td>
<td class="num">$ (9,856)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of discount/premium on marketable debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Loss (gain) on sale of marketable debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(527)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_InterestsIncomeOnShortTermDeposits', window );">Interest income from short-term deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(285)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,066<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in deferred revenue from collaboration agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(538)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Decrease (increase) in other accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="num">(609)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase (decrease) in trade payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">4,185<span></span>
</td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Increase (decrease) in other accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26,287)<span></span>
</td>
<td class="num">(14,937)<span></span>
</td>
<td class="num">(9,023)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Investment in securities, available for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(55,034)<span></span>
</td>
<td class="num">(72,600)<span></span>
</td>
<td class="num">(92,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale of securities, available for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,198<span></span>
</td>
<td class="nump">101,098<span></span>
</td>
<td class="nump">38,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromShortTermInvestments', window );">Proceeds (investment) in short-term deposits, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,416<span></span>
</td>
<td class="num">(21,808)<span></span>
</td>
<td class="num">(6,067)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,536<span></span>
</td>
<td class="nump">6,678<span></span>
</td>
<td class="num">(60,015)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of ordinary shares and warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">707<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">79,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">768<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">80,176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,983)<span></span>
</td>
<td class="num">(8,116)<span></span>
</td>
<td class="nump">11,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,043<span></span>
</td>
<td class="nump">24,159<span></span>
</td>
<td class="nump">13,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at the end of the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,060<span></span>
</td>
<td class="nump">16,043<span></span>
</td>
<td class="nump">24,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received from interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">1,953<span></span>
</td>
<td class="nump">865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash transactions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Recognition of right-of-use asset and lease liabilities from adoption of ASU 2016-02</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 653<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See also Note 10.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_InterestsIncomeOnShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents Interest Income On Short Term Deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_InterestsIncomeOnShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212772136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">General</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;1&#160;&#8211; General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Galmed Pharmaceuticals&#160;Ltd. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company primarily focused on the development of therapeutics for the treatment of liver diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company was incorporated in Israel on July&#160;31, 2013 and commenced operations on February&#160;2, 2014.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company holds a wholly-owned subsidiary, Galmed International&#160;Ltd., which was incorporated in Malta. Galmed International&#160;Ltd. previously held a wholly-owned subsidiary, Galmed Medical Research&#160;Ltd., which was incorporated in Israel, and had been an inactive company since 2015 and was liquidated in February&#160;2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company also holds two additional wholly-owned subsidiaries, Galmed Research and Development&#160;Ltd and Galtopa Therapeutics Ltd., both are incorporated in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company is a clinical-stage biopharmaceutical company with an operating history limited to pre-clinical and clinical drug development and has no approved products. To date, the Company has focused almost exclusively on developing its product candidate, Aramchol. The Company funded its research and development programs and operations to date primarily through proceeds from private placements and public offerings. The Company currently has no products approved for marketing and has not generated any revenue from product sales to date. As of December&#160;31, 2020, the Company had cash and cash equivalents of $6.9 million, restricted cash of $0.1 million, short-term deposits of $3.8 million and marketable debt securities of $40.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company has incurred operating losses in each&#160;year since inception. The Company&#8217;s loss attributable to holders of its ordinary shares for the&#160;years ended December&#160;31, 2018, 2019, and 2020 was approximately $9.9 million, $20.5 million, and $28.8 million, respectively. As of December&#160;31, 2020, the Company had an accumulated deficit of $135.7 million. Substantially all of its operating losses resulted from costs incurred in connection with the Company&#8217;s development program and from general and administrative costs associated with its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company will need to raise substantial, additional capital to fund its operations and to develop Aramchol for, and beyond its current development stage and any future commercialization, as well as any additional indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;">Based on the Company&#8217;s current operating plan, the Company&#8217;s management currently estimates that its cash position will support its current clinical trials and operations as currently conducted for more than 12&#160;months from the date of issuance of these financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212669224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Note 2 &#8211; Significant Accounting Policies</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles ("U.S. GAAP").</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Use of estimates</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Note 2 &#8211; Significant Accounting Policies (Cont.)</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Financial statement in U.S. dollars</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The functional currency of the Company and its subsidiaries is in U.S dollar (the &#8220;dollar&#8221;), because the dollar is the currency of the primary economic environment in which the Company and its subsidiaries operate, and expect to continue operating in the foreseeable future. Transactions and balances denominated in dollars are presented in their original amounts. Non-dollar denominated transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10, &#8220;Foreign Currency Translation.&#8221; All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Principles of consolidation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Galmed Research and Development Ltd., Galmed International Ltd. and Galtopa Therapeutics Ltd. All intercompany balances and transactions have been eliminated upon consolidation.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">E.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Cash and cash equivalents</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with maturities of three&#160;months or less as of the date acquired.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">F.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Restricted Cash</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 54pt;"><span style="font-weight:normal;">Cash that is held for a specific purpose and is not available for immediate or general business use due to external restrictions is classified in our consolidated balance sheets as restricted cash.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">G.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Marketable debt securities</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company invests most of its excess cash primarily in debt securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Marketable debt securities are considered to be available for sale and are carried at fair value. Unrealized gains and losses net of tax, if any, are reported as a separate component of stockholders&#8217; equity. The cost of marketable debt securities classified as available for sale is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Realized gains and losses and declines in value judged to be other than temporary, if any, are also included in other income, net. Interest on securities classified as available for sale is included in interest income. The cost of securities sold is based on the specific identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">For all investments in marketable debt securities, the Company assesses whether the impairment is other-than-temporary. If the fair value of a security is less than its amortized cost basis, an impairment is considered other-than-temporary if (i)&#160;the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its entire amortized cost basis, or (ii)&#160;the Company does not expect to recover the entire amortized cost of the security. If an impairment is considered other-than-temporary based on condition (i), the entire difference between the amortized cost and the fair value of the security is recognized in earnings. If an impairment is considered other-than-temporary based on condition (ii), the amount representing credit losses, defined as the difference between the present value of the cash flows expected to be collected and the amortized cost basis of the security, will be recognized in earnings, and the amount relating to all other factors will be recognized in other comprehensive income. The Company evaluates both qualitative and quantitative factors such as duration and severity of the unrealized </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 2 &#8211; Significant Accounting Policies (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">G.</b></span><b style="font-weight:bold;">Marketable debt securities (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">losses, credit ratings, default and loss rates of the underlying collateral, structure and credit enhancements to determine if a credit loss may exist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">During the&#160;years ended December&#160;31, 2020 and 2019 no other-than-temporarily impaired losses were realized.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">H.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Concentrations of credit risk</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, marketable securities and short-term deposits. We hold these investments in highly-rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Property and equipment</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The annual depreciation rates are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:12pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office furniture and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7&#8211;16</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer software and electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15&#8211;33</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">J.&#160;&#160;&#160;Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company&#8217;s and its subsidiaries&#8217; long-lived assets are reviewed for impairment in accordance with ASC 360-10, &#8220;Accounting for the Impairment or Disposal of Long-Lived Assets,&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds their fair value. During 2020 and 2019, no impairment losses were identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">K.&#160;&#160;&#160;&#160;&#160;Severance pay</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company employees are included under section 14 of the Severance Compensation Act, 1963 (&#8220;Section&#160;14&#8221;) for a portion of their salaries. According to Section&#160;14, these employees are entitled to&#160;monthly deposits at a rate of 8.33% of their&#160;monthly salary, made in their name with such insurance companies. Under the Severance Compensation Act, 1963, payments in accordance with Section&#160;14 release the Company from any future severance payments to those employees. The aforementioned deposits are not recorded as an asset in the Company&#8217;s balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Note 2 &#8211; Significant Accounting Policies (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">L.&#160;&#160;&#160;&#160;Fair value of financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies. Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company could realize in a current market exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The carrying amounts of cash and cash equivalents, short-term bank deposits, other accounts receivables, trade payables and other trade payables approximate their fair value due to the short-term maturity of such instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Fair value is an exit price representing the amount that would be received upon selling an asset or that would be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions used by market participants in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">A three-tier fair-value hierarchy was established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 1&#160;- Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 2&#160;- Other inputs that are directly or indirectly observable in the marketplace; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 3&#160;- Unobservable inputs that are supported by little or no market activity</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;">M.&#160;&#160;&#160;Accounting for stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The Company applies ASC 718-10, &#8220;Share-Based Payment,&#8221; which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors, including employee stock options under the Company&#8217;s stock plans, based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#8217;s consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 2 &#8211; Significant Accounting Policies (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">M. &#160; Accounting for stock-based compensation (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">In June&#160;2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-07, &#8220;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#8221;, which simplifies the accounting for non-employee share-based payment transactions by aligning the measurement and classification guidance, with certain exceptions, to that for share-based payment awards to employees. The amendments expand the scope of the accounting standard for share-based payment awards to include share-based payment awards granted to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance related to equity-based payments to non-employees. The Company elected to early adopt these amendments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">on June&#160;1, 2018. The adoption of these amendments did not have a significant impact on the Company's consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company estimates the fair value of restricted shares based on the market price of the shares at the grant date, and estimates the fair value of stock options granted using a Black-Scholes option-pricing model. The option-pricing model requires a number of assumptions, the most significant of which are the expected stock-price volatility and the expected option term (the time from the grant date until the options are exercised or expire).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company&#8217;s calculations of the expected volatility were based upon actual historical stock-price movements over the period, which was equal to the expected option term. The expected option term was calculated for options granted to employees and directors in accordance with ASC-718-10-S99, using the &#8220;simplified&#8221; method, and grants to non-employees were based on the contractual term. Historically, the Company has not paid dividends, and has no foreseeable plans to do so. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">N.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Revenue Recognition</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company only has one license agreement for which is has recognized revenues to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">On January&#160;1, 2018, the Company adopted ASC 606 with full retrospective application. The adoption of did not have an effect on either revenue recognized in prior periods, nor to accumulated deficit as of January&#160;1, 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The new revenue standard amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The new revenue standard provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of the new revenue standard, we perform the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the performance obligations are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 2 &#8211; Significant Accounting Policies (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">N.</b></span><b style="font-weight:bold;">Revenue Recognition (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company only applies the five-step model to contracts when collectability of the consideration to which the Company is entitled in exchange for the goods or services transferred to the customer is determined to be probable. At contract inception, once the contract is determined to be within the scope of the new revenue standard, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. The Company then allocates the transaction price (the amount of consideration the Company expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which we expect to be entitled.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">O.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Research and development expenses</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Research and development expenses are charged to the statement of operations as incurred.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">P.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Income taxes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company accounts for income taxes utilizing the asset and liability method in accordance with ASC 740, &#8220;Income Taxes.&#8221; Current tax liabilities are recognized for the estimated taxes payable on tax returns for the current year. Deferred tax liabilities or assets are recognized for the estimated future tax effects attributable to temporary differences between the income-tax bases of assets and liabilities and their reported amounts in the financial statements and for tax loss carry forwards. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax laws, and deferred tax assets are reduced, if necessary, by the amount of tax benefits, the realization of which is not considered more likely than not based on available evidence. As of December 31, 2020, and 2019, the Company had a full valuation allowance against deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">ASC 740-10 requires a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company has not recorded any liability for uncertain tax positions for the years ended December 31, 2020 and 2019.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Q.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Basic and diluted net loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Basic net loss per share is computed based on the weighted-average number of shares outstanding during each&#160;year. Diluted net loss per share is computed based on the weighted-average number of shares outstanding during each&#160;year, plus the dilutive potential of the ordinary shares considered outstanding during the&#160;year, in accordance with ASC 260-10, &#8220;Earnings Per Share.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">All outstanding stock options and warrants were excluded from the calculation of the diluted loss per share for the&#160;years ended December&#160;31, 2020, 2019 and 2018, because all such securities have an anti-dilutive effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Note 2 &#8211; Significant Accounting Policies (Cont.)</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">R.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Segment Reporting</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. Accordingly, management has determined that the Company operates in one reportable segment.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">S.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Comprehensive Loss</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The purpose of reporting comprehensive income is to report a measure of all changes in equity of an entity that result from recognized transactions and other economic events of the period resulting from transactions from non-owner sources.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">T.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Leases</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">ASU 2016-02, &#8220;Leases (Topic 842)&#8221; was issued by the FASB in February 2016. The Company adopted this ASU 2016-02 effective January 1, 2019 using the modified retrospective application, applying the new standard to leases in place as of the adoption date. Prior periods have not been adjusted. Leases existing for the reporting period beginning January 1, 2019 are presented under ASU 2016-02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Arrangements that are determined to be leases at inception are recognized as right of use assets and lease liabilities in the consolidated balance sheet at lease commencement. Operating lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. As the Company&#8217;s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at the commencement date in determining the present value of future lease payments. Lease terms include options to extend the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company elected to adopt a package of practical expedients offered by the FASB which removes the requirement to reassess whether expired or existing contracts contain leases and removes the requirement to reassess the lease classification for any existing leases prior to the adoption date of January 1, 2019. The Company has also elected the practical expedient to include both lease and non-lease components as a single component and account for it as a lease. Additionally, the Company has made a policy election not to capitalize leases with a term of 12 months or less. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an impairment loss would be recognized for the difference between the carrying amount of the asset and its fair value.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">U.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Recently adopted accounting pronouncements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">From time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 2 &#8211; Significant Accounting Policies (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">U.</b></span><b style="font-weight:bold;">Recently adopted accounting pronouncements (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In June 2016, FASB issued ASU No. 2016-13, &#8220;Financial Instruments &#8211; Credit Losses &#8211; Measurement of Credit Losses on Financial Instruments&#8221;, which introduces a model based on expected losses to estimate credit losses for most financial assets and certain other instruments. In addition, for available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. The ASU is effective for the Company in the first quarter of 2020, with early adoption permitted. The Company adopted ASU 2016-13 in 2020. The adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In August&#160;2018, the FASB issued ASU 2018-13,&#160;&#8220;Changes to Disclosure Requirements for Fair Value Measurements&#8221;, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for the Company beginning on January&#160;1, 2020. The Company adopted ASU 2016-13 in 2020. The adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">V.</b></span><b style="font-weight:bold;">Recently issued accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 54pt;">In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes", which will simplify the accounting for income taxes to improve consistency of accounting methods and remove certain exceptions. The amendment is effective for the Company beginning January 1, 2021 and is not expected to have a material impact on the Company's consolidated financial statements and disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972214164536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable debt securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Marketable debt securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;3&#160;&#8211; Marketable debt securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The Company's financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. Other than the marketable debt securities, which includes corporate bonds and mutual funds as of December 31, 2020, the Company doesn't have any other financial assets or financial liabilities marked to market at fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The fair value of the Company's Marketable debt securities measured at fair value on a recurring basis by level within the fair value hierarchy are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,449</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,683</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,132</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,622</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,622</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3 &#8211; Marketable debt securities (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s marketable debt securities as of December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:12pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,575</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,683</p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mutual funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,449</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total short-term investments</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,860</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 305</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,132</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,893</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,905</p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial papers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,717</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total short-term investments</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,587</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,622</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The contractual maturity of the aforementioned marketable securities varies between less than one&#160;year to two&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;">The Company reviews the individual securities in its portfolio to determine whether a decline in a security&#8217;s fair value below the amortized cost basis is other-than-temporary. The Company determined that as of&#160;December&#160;31, 2020 and 2019&#160;there were&#160;no&#160;investments in its portfolio that were other-than-temporarily impaired.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212638840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Other Accounts Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Other Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;4&#160;&#8211; Other Accounts Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government institutions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 601</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 827</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972214157768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;5&#160;&#8211; Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">On January 1, 2019, the Company adopted ASU 2016-02, using the modified retrospective approach for all lease arrangements at the beginning period of adoption. Leases existing for the reporting period beginning January 1, 2019 are presented under ASU 2016-02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company leases, approximately 590 square meters at a facility located in Tel-Aviv, Israel under an operating lease agreement expiring on March 22, 2021 with additional two options to <span style="-sec-ix-hidden:Hidden_PATlNkw1P0qJ2UewZ8KyFQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">extend</span></span> until March 22, 2023. During February 2021, the Company extended its lease for an additional two years, through March 22, 2023, with an option for another year. To secure the lease payments, the Company provided a bank guarantee of $50 thousand. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">In addition, the Company leases vehicles under various operating lease agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 5 &#8211; Leases (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">At December 31, 2020, the Company&#8217;s operating lease assets and lease <span style="-sec-ix-hidden:Hidden_rtPFgq4moU2FnXiiUj0HYA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">liabilities</span></span> (both the current and non-current portion) for operating leases totaled $394 and $419, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company uses its incremental borrowing rate as the discount rate for its leases, as the implicit rate in the lease is not readily determinable. As of December 31, 2020, the Company's operating leases had a weighted average remaining lease term of 2.25 years and a weighted average borrowing rate of 2.75%. Upon adoption of ASC 842, discount rates for existing operating leases were established as of January 1, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s significant contractual lease obligations at December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">3&#160;years</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facility leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 403</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 193</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 210</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Car leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 433</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972308888872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;6&#160;&#8211; Property and equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Medical equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 737</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 737</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer software and electronic equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 198</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,092</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,078</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Less&#160;- Accumulated depreciation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 907</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net book value</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 176</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 171</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212479688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_RevenueTextBlock', window );">Revenue</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;7&#160;&#8211; Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 54pt;">Samil Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">On July&#160;28, 2016, the Company entered into a license agreement ("Samil Agreement") with Samil Pharm. Co.,&#160;Ltd. (the &#8220;Samil&#8221;), for an exclusive, royalty-bearing license for the commercialization of Aramchol (with an option to manufacture) for the treatment of fatty liver indications including NASH in the Republic of Korea. Additionally, following the ARREST Study, Samil has an option to extend the License to Vietnam, which, if exercised, would increase the clinical- and regulatory-based milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Under the terms of the Samil Agreement, the Company received an up-front payment of approximately $2.1 million. Samil has also agreed to pay additional clinical and regulatory-based milestone payments, which may aggregate up to $6.0 million, as well as tiered, double-digit royalties payable on sales (under certain limitations). In September 2018, the Company received a milestone payment of $1.5 million from Samil in connection with the completion of its ARREST study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In accordance with ASC 606 the Company determined that the Agreement included a combined performance obligation representing the delivery of the exclusive license and completion of the ARREST study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 7 &#8211; Revenue (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company determined that the transaction price at contract inception was $2.1 million consisting of the upfront, non-refundable payment. None of the clinical or regulatory milestones were included in the transaction price upon inception, as all milestone amounts were fully constrained. Management assessed that the likelihood of occurrence of the other performance obligations in the Agreement was remote upon contract inception. As such, the stand-alone value of such performance obligations was deemed de minimis and none of the transaction price was allocated to those obligations. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, and therefore have also been excluded from the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">During 2018, when the Company determined that the achievement of its first milestone was probable, it included the variable consideration of $1.5 million as a part of the transaction price allocated to the combined performance obligation including the delivery of the license and completion of the ARREST study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">As of December 31, 2020, management evaluated the remaining clinical and regulatory milestones and determined that the variable consideration should not be recorded as revenue for the period ended December 31, 2020. The Company will re-evaluate the transaction price in each reporting period when events whose outcomes are resolved or other changes in circumstances occur that would indicate it is appropriate to recognize variable consideration as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">Revenue allocated to the combined performance obligation of the license and associated ARREST study was recognized ratably, based on the input method, from contract inception through conclusion of the ARREST study in June&#160;2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_RevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_RevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972327129768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;8&#160;&#8211; Related Parties</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">As of December 31, 2020, and 2019, the Company had an accrual in the amount of approximately $0.5 </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">million and $0.6 million, respectively, pursuant to an employment agreement with its officers and directors&#8217; fee.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During 2020, 2019 and 2018, the Company recorded salary expenses, stock-based compensation expenses and directors&#8217; fee to its related parties in the amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$3.5</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million, </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$3.6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$3.7</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million respectively.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212795768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;9&#160;&#8211; Commitments and Contingencies</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">As of December 31, 2020, the Company recorded a pledge on its short-term deposit in favor of its bank in the amount of approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$113</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> thousand to secure the Company&#8217;s commitments to the bank, including a bank guarantee in favor Mintz K. Construction Company, the lessor of the Company's headquarters, totaling </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$54</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> thousands as of December 31, 2020.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The Company enters into contracts in the ordinary course of business with Contract Research Organizations for clinical trials and clinical supply manufacturing and with vendors for non-clinical research studies and other services and products for operating purposes, which generally provide for termination upon 30 to 90 days&#8217; notice or less, and therefore are cancelable contracts and not considered as commitment or purchase obligations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">For information regarding the Company's leases commitments, see note 5.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 9 &#8211; Commitments and Contingencies (Cont.)</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Other than as described above, the Company did not have any material commitments, including any anticipated material acquisition of plant and equipment or interests in other companies, as of December 31, 2020 and 2019.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212712712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;10&#8211; Shareholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">A.&#160;&#160;&#160;Ordinary shares</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Ordinary shares confer upon the holders the right to receive notice to participate and vote in general meetings of the Company and the right to receive dividends, if declared.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">On December&#160;22, 2017, the Company entered into an At-the-Market Equity Offering Sales Agreement (the "Stifel Sales Agreement") with Stifel, Nicolaus&#160;&amp; Company, Incorporated, as the Company&#8217;s sales agent (&#8220;Stifel&#8221;). Pursuant to the prospectus relating to the Company&#8217;s shelf registration statement on Form&#160;F-3 filed with the SEC on March&#160;26, 2018 (File No.&#160;333-223923) the Company may offer and sell, from time to time through Stifel, its ordinary shares having an aggregate offering price of up to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$35</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. On May 15, 2020, the Company amended and restated the Sales Agreement dated December 22, 2017 between the Company and Stifel, Nicolaus &amp; Company, Incorporated to include Cantor Fitzgerald &amp; Co. as an additional sales agent for the Company's "at the market offering" program (the "ATM Program"). Pursuant to a prospectus supplement filed with the SEC on May 15, 2020, the Company may offer and sell up to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$31.9</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million of its ordinary shares. As of December 31,2020 the Company sold </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">136,300</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares under the ATM Program for total net proceeds of approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.8</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During February 2021, subsequent to the balance sheet date, the Company sold an additional </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">1,541,400</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;ordinary shares under the ATM Program for total net proceeds of approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$8.2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. As a result, the Company has approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$22.7</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million remaining available for future sales under the ATM Program as of February 28, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During February 2021, subsequent to the balance sheet date, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Cantor Fitzgerald &amp; Co. (the "Underwriter") in connection with an underwritten public offering &#160;(the "Underwritten Public Offering") of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2,197,803</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares (the "Firm Shares") of the Company (the "Ordinary Shares"). The Underwriter agreed to purchase the Firm Shares from the Company at a price of&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$4.3258</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;per share. The net proceeds to the Company were approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$9.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for 30 days, to purchase up to an additional 329,670 ordinary shares (the "Option Shares" and together with the Firm Shares, the "Shares") at the same price per share as the Firm Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 10&#8211; Shareholders&#8217; Equity (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">B.&#160;&#160;&#160;Stock-based compensation</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The Company has an equity-based incentive plan, the 2013 Incentive Share Option Plan (the &#8220;2013 Plan&#8221;). As of December 31, 2020, a total of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">687,973</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> shares were reserved for issuance under the 2013 Plan. The 2013 Plan, which was adopted by the Board on September&#160;2, 2013, and approved by the Company&#8217;s shareholders on December&#160;30, 2013 (as was amended by the Board and the Company&#8217;s shareholders on March&#160;30, 2015, May&#160;11, 2015, and August&#160;30, 2018 respectively), provides for the grant of options to purchase the ordinary shares and the issuance of restricted stock units (&#8220;RSUs&#8221;) to the Company&#8217;s officers, directors, employees, service providers and consultants. The 2013 Plan provides for such equity-based compensation under various and different tax regimes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During the year ended December 31, 2020, certain current and former office holders exercised options into </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">47,509</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company, NIS </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">0.01</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> par value per share, for total consideration of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$61</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> thousand.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During the year ended December 31, 2020, restricted stock units held by certain officers, employees and former employees vested resulting in the issuance of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2,781</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company, NIS </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">0.01</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> par value per share.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In March 2020, the Company granted options to purchase </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">67,500</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company to several employees. The options are exercisable at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$4.21</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share, have a </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> term and vest over a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four years</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. The aggregate grant date fair value of such options was approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In August 2020, the Company granted options to purchase </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">30,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company to a director. The options are exercisable at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$4.77</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share, have a </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> term and vest over a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four years</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. The aggregate grant date fair value of such options was approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. In addition, the Company granted options to purchase </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">220,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company to the Company's chief executive officer (after shareholders' approval). The options are exercisable at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$5.12</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share, have a </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> term and vest over a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four years</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. The aggregate grant date fair value of such options was approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.8</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In November 2020, the Company granted options to purchase </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">267,500</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company to several employees. The options are exercisable at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$3.33</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share, have a </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> term and vest over a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four years</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. The aggregate grant date fair value of such options was approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. In addition, the Company's Board approved to grant options to purchase </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">220,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> ordinary shares of the Company to Company's chief executive officer subject to shareholders' approval (as of December 31, 2020 shareholders&#8217; approval was still pending). The options are exercisable at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$3.33</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share, have a </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> term and vest over a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four years</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 10&#8211; Shareholders&#8217; Equity (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">B. &#160; Stock-based compensation (Cont.)</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">A summary of the status of the Company&#8217;s option plans as of December&#160;31, 2020 and 2019 and changes during the&#160;years then ended are presented below:</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Options outstanding at beginning of&#160;&#160;year</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,393,715</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,349,054</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.92</p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 585,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 282,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.07</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Forfeited</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (208,195)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.49</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (121,250)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.37</p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (47,509)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (116,589)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.23</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at end of&#160;year</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,723,011</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.70</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,393,715</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.12</p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Options exercisable at&#160;year end</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,754,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,647,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.02</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The following assumptions were used for the fiscal year 2020, 2019 and 2018 grants:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">dividend yield of 0.00% for all periods.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">risk-free interest rate between 2.67% and 3.01% for the fiscal year 2018, 1.61% and 2.43% for the fiscal year 2019 and 0.42% and 0.74% for the fiscal year 2020.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">an expected life between 5 and 6.25 years for all periods.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">and a volatility rate ranging between 78% and 92% for the fiscal year 2018; and 87% and 95% for the fiscal year 2019 and 83% and 88% for the fiscal year 2020.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">As of December&#160;31, 2020, and 2019, the weighted-average remaining contractual term of the outstanding options, excluding the 38,637 options granted in 2002 that have no expiration date, is 6.60 and 6.36&#160;years, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The weighted average grant date fair value of the options granted during the&#160;years ended December&#160;31, 2020, 2019 and 2018 is $2.76, $4.85, and $8.19 respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">As of December&#160;31, 2020, a total of the 390,905 outstanding and exercisable options are &#8220;in the money&#8221; with aggregate intrinsic value of $1.1 million; while as of December&#160;31, 2019 a total of 1,179,398 outstanding and exercisable options were &#8220;in the money&#8221; with aggregate intrinsic value of $3.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The unrecognized compensation expense calculated under the fair-value method for stock options expected to vest as of December&#160;31, 2020, 2019 and 2018 is approximately $4.0 million, $5.5 million, and $6.5 million, respectively, and is expected to be recognized over a weighted-average period of 2.41&#160;years, 2.9&#160;years and 3.1 years, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">For the&#160;years ended 2020, 2019 and 2018, the Company recorded a total of $2.1 million, $2.2 million, and $1.8 million of stock-based compensation expenses, in connection with the above-mentioned options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 10&#8211; Shareholders&#8217; Equity (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">B. &#160; Stock-based compensation (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">During 2016, the Company issued a total of 78,750 restricted stock units ("RSU"). Upon vesting, each RSU will settle by the issuance of one ordinary share. The RSUs vest over four years. As of December&#160;31, 2020, a total of 59,528 ordinary shares were issued upon vesting of 2,781 RSUs and there are no outstanding RSUs, while as of December&#160;31, 2019, a total of 56,747 ordinary shares were issued upon vesting of 54,316 RSUs and a total of 2,781 RSUs were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">For the&#160;years 2020, 2019 and 2018, with respect to the above-mentioned RSUs, the Company recorded stock-based compensation expenses in the amount of $5 thousand, $70 thousand and $94 thousand, respectively. All of the above-mentioned stock-based compensation expenses are recorded under general and administrative expenses. as of December 31, 2020, there are no unrecognized compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 72pt;">The unrecognized compensation expense calculated under the fair-value method for RSU's expected to vest as of December&#160;31, 2019 is approximately $5 thousand, and is expected to be recognized over a weighted-average period of one year. As of December 31, 2020 there are no outstanding RSU's.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972213865960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;11&#160;&#8211; Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chemistry and formulation studies</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,856</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,439</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 968</p></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salaries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,617</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 871</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 883</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 582</p></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and preclinical studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 963</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical studies</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,346</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,575</p></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulatory and other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 608</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,082</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,180</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,313</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972213865960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;12&#160;&#8211; General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,194</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,349</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,201</p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 896</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salaries and benefits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 828</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 856</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,346</p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rent and office-maintenance fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investor relations and business development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 293</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 364</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 464</p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance and other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,128</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,196</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,440</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972298593160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial income, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Financial income, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Financial income, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;13&#160;&#8211; Financial income, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bank fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,192)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,953)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (959)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain from sale of marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (397)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (106)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12)</p></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency (gains) losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,439)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,915)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (934)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972217896984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;14&#160;&#8211; Income Taxes</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company is assessed for tax purposes on an unconsolidated basis. Each of the Company&#8217;s subsidiaries is subject to the tax rules&#160;prevailing in its country of incorporation.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Corporate Taxation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Israeli Companies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In January&#160;2016, the Israeli corporate income tax law was amended and reduced as of January&#160;1, 2016 to 25% (from 26.5%). In December&#160;2016, the Israeli corporate income tax law was further amended and reduced as of January&#160;1, 2017 to 24% and as of January&#160;1, 2018 and onwards to 23%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">On February&#160;7, 2018, the Israeli Tax Authority issued a ruling granting the Company&#8217;s Israeli subsidiary, Galmed Research and Development Ltd, a &#8221;Preferred Technological Enterprise&#8221; status&#160; as defined under the Encouragement of Capital Investment Law&#160;-1959 (the "Approval"). The grant of the status means that the Company&#8217;s Israeli subsidiary will be subject to a reduced Israeli corporate tax rate that will range between 6%-12% on any future taxable "technological income" which includes sales, licenses and royalties from its IP protected products. The tax ruling applies for five&#160;years until 2022 and may be extended for further periods subject to meeting certain requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Maltese subsidiary:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Taxable income of Maltese companies was subject to tax at the rate of 35% in 2020.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Net Operating Loss Carry forward</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2020, the Company had approximately $110.9 million net-operating-loss carry forwards, consisting of approximately $11.7 million of Maltese net-operating-loss carry forwards and approximately $99.2 million Israeli net-operating-loss carry forward. Additionally, the Company had approximately $2.4 million of capital loss carry forward from the sale of marketable debt securities in Israel. The Maltese and the Israeli loss carry forwards have no expiration date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Note 14 &#8211; Income Taxes (Cont.)</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Deferred income taxes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Deferred-tax assets for carry forward losses in Malta and Israel are calculated using the applicable tax rate at the time of expected realization of the carry forward losses. The Company has provided full valuation allowances in respect of deferred-tax assets. Management currently believes that it is more likely than not that those deferred taxes will not be realized in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">Significant components of the Company&#8217;s and its subsidiaries&#8217; assets are as follows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Israeli companies net-operating-loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,085</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Maltese subsidiary net-operating-loss carry forward</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,090</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,081</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Israeli subsidiary capital-loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 881</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Other reserves and allowances</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total deferred-tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,068</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,600)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,068)</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net deferred-tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">E.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Tax assessment</b>s</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Israeli subsidiaries received final tax assessments through the&#160;year ended December&#160;31, 2015.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">F.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Effective tax expense</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">A reconciliation of the Company&#8217;s effective tax expense to the Company&#8217;s theoretical statutory tax benefit is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before taxes on income, as reported in the consolidated statements of operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,771</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,461</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,781</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Statutory tax rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Theoretical tax benefit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,453</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,455</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,174</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,453)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,455)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,174)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax withheld from upfront payment from Samil</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actual tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212709400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 15 - Subsequent events</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">During February 2021, the Company sold 1,541,400 ordinary shares under its ATM Program for total net proceeds of approximately $8.2 million. See also Note 10A.3</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">During February 2021, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Cantor Fitzgerald &amp; Co. (the "Underwriter") in connection with an underwritten public offering (the "Underwritten Public Offering") of 2,197,803 ordinary shares (the "Firm Shares") of the Company. The Underwriter purchased the Firm Shares from the Company at a price of $4.3258 per share. The net proceeds to the Company, Were approximately $9.3 million. See also Note 10A.4.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On March 2021, the Company has signed with with Mintz K. Construction Company a lease <span style="-sec-ix-hidden:Hidden_Ccc8RhKJjU6tsVCv0GLiEA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">extension</span></span> agreement to its corporate headquarters for a period of <span style="-sec-ix-hidden:Hidden_iAeXAqUqkkCSijJ30lE5Og;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">two</span></span> additional years until March 22, 2023 with an option for another year. According to updated lease, the aggregate quarterly rental payment, together with adjustments and the maintenance fees, is approximately NIS 133,497 plus VAT.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972298955848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles ("U.S. GAAP").</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Use of estimates</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock', window );">Financial statement in U.S. dollars</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Financial statement in U.S. dollars</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The functional currency of the Company and its subsidiaries is in U.S dollar (the &#8220;dollar&#8221;), because the dollar is the currency of the primary economic environment in which the Company and its subsidiaries operate, and expect to continue operating in the foreseeable future. Transactions and balances denominated in dollars are presented in their original amounts. Non-dollar denominated transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10, &#8220;Foreign Currency Translation.&#8221; All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Principles of consolidation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Galmed Research and Development Ltd., Galmed International Ltd. and Galtopa Therapeutics Ltd. All intercompany balances and transactions have been eliminated upon consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">E.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Cash and cash equivalents</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with maturities of three&#160;months or less as of the date acquired.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">F.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Restricted Cash</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 54pt;"><span style="font-weight:normal;">Cash that is held for a specific purpose and is not available for immediate or general business use due to external restrictions is classified in our consolidated balance sheets as restricted cash.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable debt securities</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">G.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Marketable debt securities</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company invests most of its excess cash primarily in debt securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Marketable debt securities are considered to be available for sale and are carried at fair value. Unrealized gains and losses net of tax, if any, are reported as a separate component of stockholders&#8217; equity. The cost of marketable debt securities classified as available for sale is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Realized gains and losses and declines in value judged to be other than temporary, if any, are also included in other income, net. Interest on securities classified as available for sale is included in interest income. The cost of securities sold is based on the specific identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">For all investments in marketable debt securities, the Company assesses whether the impairment is other-than-temporary. If the fair value of a security is less than its amortized cost basis, an impairment is considered other-than-temporary if (i)&#160;the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its entire amortized cost basis, or (ii)&#160;the Company does not expect to recover the entire amortized cost of the security. If an impairment is considered other-than-temporary based on condition (i), the entire difference between the amortized cost and the fair value of the security is recognized in earnings. If an impairment is considered other-than-temporary based on condition (ii), the amount representing credit losses, defined as the difference between the present value of the cash flows expected to be collected and the amortized cost basis of the security, will be recognized in earnings, and the amount relating to all other factors will be recognized in other comprehensive income. The Company evaluates both qualitative and quantitative factors such as duration and severity of the unrealized </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 2 &#8211; Significant Accounting Policies (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">G.</b></span><b style="font-weight:bold;">Marketable debt securities (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">losses, credit ratings, default and loss rates of the underlying collateral, structure and credit enhancements to determine if a credit loss may exist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">During the&#160;years ended December&#160;31, 2020 and 2019 no other-than-temporarily impaired losses were realized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">H.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Concentrations of credit risk</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, marketable securities and short-term deposits. We hold these investments in highly-rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Property and equipment</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The annual depreciation rates are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:12pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office furniture and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7&#8211;16</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer software and electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15&#8211;33</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">J.&#160;&#160;&#160;Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company&#8217;s and its subsidiaries&#8217; long-lived assets are reviewed for impairment in accordance with ASC 360-10, &#8220;Accounting for the Impairment or Disposal of Long-Lived Assets,&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds their fair value. During 2020 and 2019, no impairment losses were identified.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">K.&#160;&#160;&#160;&#160;&#160;Severance pay</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company employees are included under section 14 of the Severance Compensation Act, 1963 (&#8220;Section&#160;14&#8221;) for a portion of their salaries. According to Section&#160;14, these employees are entitled to&#160;monthly deposits at a rate of 8.33% of their&#160;monthly salary, made in their name with such insurance companies. Under the Severance Compensation Act, 1963, payments in accordance with Section&#160;14 release the Company from any future severance payments to those employees. The aforementioned deposits are not recorded as an asset in the Company&#8217;s balance sheet.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">L.&#160;&#160;&#160;&#160;Fair value of financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies. Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company could realize in a current market exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The carrying amounts of cash and cash equivalents, short-term bank deposits, other accounts receivables, trade payables and other trade payables approximate their fair value due to the short-term maturity of such instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Fair value is an exit price representing the amount that would be received upon selling an asset or that would be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions used by market participants in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">A three-tier fair-value hierarchy was established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 1&#160;- Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 2&#160;- Other inputs that are directly or indirectly observable in the marketplace; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 3&#160;- Unobservable inputs that are supported by little or no market activity</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;">M.&#160;&#160;&#160;Accounting for stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">The Company applies ASC 718-10, &#8220;Share-Based Payment,&#8221; which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors, including employee stock options under the Company&#8217;s stock plans, based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#8217;s consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 2 &#8211; Significant Accounting Policies (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">M. &#160; Accounting for stock-based compensation (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">In June&#160;2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-07, &#8220;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#8221;, which simplifies the accounting for non-employee share-based payment transactions by aligning the measurement and classification guidance, with certain exceptions, to that for share-based payment awards to employees. The amendments expand the scope of the accounting standard for share-based payment awards to include share-based payment awards granted to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance related to equity-based payments to non-employees. The Company elected to early adopt these amendments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">on June&#160;1, 2018. The adoption of these amendments did not have a significant impact on the Company's consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company estimates the fair value of restricted shares based on the market price of the shares at the grant date, and estimates the fair value of stock options granted using a Black-Scholes option-pricing model. The option-pricing model requires a number of assumptions, the most significant of which are the expected stock-price volatility and the expected option term (the time from the grant date until the options are exercised or expire).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company&#8217;s calculations of the expected volatility were based upon actual historical stock-price movements over the period, which was equal to the expected option term. The expected option term was calculated for options granted to employees and directors in accordance with ASC-718-10-S99, using the &#8220;simplified&#8221; method, and grants to non-employees were based on the contractual term. Historically, the Company has not paid dividends, and has no foreseeable plans to do so. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">N.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Revenue Recognition</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company only has one license agreement for which is has recognized revenues to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">On January&#160;1, 2018, the Company adopted ASC 606 with full retrospective application. The adoption of did not have an effect on either revenue recognized in prior periods, nor to accumulated deficit as of January&#160;1, 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The new revenue standard amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The new revenue standard provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of the new revenue standard, we perform the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the performance obligations are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 2 &#8211; Significant Accounting Policies (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">N.</b></span><b style="font-weight:bold;">Revenue Recognition (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company only applies the five-step model to contracts when collectability of the consideration to which the Company is entitled in exchange for the goods or services transferred to the customer is determined to be probable. At contract inception, once the contract is determined to be within the scope of the new revenue standard, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. The Company then allocates the transaction price (the amount of consideration the Company expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which we expect to be entitled.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">O.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Research and development expenses</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Research and development expenses are charged to the statement of operations as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">P.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Income taxes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company accounts for income taxes utilizing the asset and liability method in accordance with ASC 740, &#8220;Income Taxes.&#8221; Current tax liabilities are recognized for the estimated taxes payable on tax returns for the current year. Deferred tax liabilities or assets are recognized for the estimated future tax effects attributable to temporary differences between the income-tax bases of assets and liabilities and their reported amounts in the financial statements and for tax loss carry forwards. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax laws, and deferred tax assets are reduced, if necessary, by the amount of tax benefits, the realization of which is not considered more likely than not based on available evidence. As of December 31, 2020, and 2019, the Company had a full valuation allowance against deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">ASC 740-10 requires a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company has not recorded any liability for uncertain tax positions for the years ended December 31, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Q.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Basic and diluted net loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Basic net loss per share is computed based on the weighted-average number of shares outstanding during each&#160;year. Diluted net loss per share is computed based on the weighted-average number of shares outstanding during each&#160;year, plus the dilutive potential of the ordinary shares considered outstanding during the&#160;year, in accordance with ASC 260-10, &#8220;Earnings Per Share.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">All outstanding stock options and warrants were excluded from the calculation of the diluted loss per share for the&#160;years ended December&#160;31, 2020, 2019 and 2018, because all such securities have an anti-dilutive effect.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">R.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Segment Reporting</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. Accordingly, management has determined that the Company operates in one reportable segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">S.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Comprehensive Loss</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The purpose of reporting comprehensive income is to report a measure of all changes in equity of an entity that result from recognized transactions and other economic events of the period resulting from transactions from non-owner sources.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">T.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Leases</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">ASU 2016-02, &#8220;Leases (Topic 842)&#8221; was issued by the FASB in February 2016. The Company adopted this ASU 2016-02 effective January 1, 2019 using the modified retrospective application, applying the new standard to leases in place as of the adoption date. Prior periods have not been adjusted. Leases existing for the reporting period beginning January 1, 2019 are presented under ASU 2016-02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">Arrangements that are determined to be leases at inception are recognized as right of use assets and lease liabilities in the consolidated balance sheet at lease commencement. Operating lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. As the Company&#8217;s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at the commencement date in determining the present value of future lease payments. Lease terms include options to extend the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The Company elected to adopt a package of practical expedients offered by the FASB which removes the requirement to reassess whether expired or existing contracts contain leases and removes the requirement to reassess the lease classification for any existing leases prior to the adoption date of January 1, 2019. The Company has also elected the practical expedient to include both lease and non-lease components as a single component and account for it as a lease. Additionally, the Company has made a policy election not to capitalize leases with a term of 12 months or less. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an impairment loss would be recognized for the difference between the carrying amount of the asset and its fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted and issued accounting pronouncement</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">U.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Recently adopted accounting pronouncements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">From time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 2 &#8211; Significant Accounting Policies (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">U.</b></span><b style="font-weight:bold;">Recently adopted accounting pronouncements (Cont.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In June 2016, FASB issued ASU No. 2016-13, &#8220;Financial Instruments &#8211; Credit Losses &#8211; Measurement of Credit Losses on Financial Instruments&#8221;, which introduces a model based on expected losses to estimate credit losses for most financial assets and certain other instruments. In addition, for available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. The ASU is effective for the Company in the first quarter of 2020, with early adoption permitted. The Company adopted ASU 2016-13 in 2020. The adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">In August&#160;2018, the FASB issued ASU 2018-13,&#160;&#8220;Changes to Disclosure Requirements for Fair Value Measurements&#8221;, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for the Company beginning on January&#160;1, 2020. The Company adopted ASU 2016-13 in 2020. The adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">V.</b></span><b style="font-weight:bold;">Recently issued accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 54pt;">In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes", which will simplify the accounting for income taxes to improve consistency of accounting methods and remove certain exceptions. The amendment is effective for the Company beginning January 1, 2021 and is not expected to have a material impact on the Company's consolidated financial statements and disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Policy disclosure of presentational currency of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212780280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of depreciation rates for property, plant and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The annual depreciation rates are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:12pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office furniture and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7&#8211;16</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer software and electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15&#8211;33</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the depreciation rates for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972214068984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable debt securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of marketable debt securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">The fair value of the Company's Marketable debt securities measured at fair value on a recurring basis by level within the fair value hierarchy are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,449</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,683</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,132</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,622</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,622</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s marketable debt securities as of December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:12pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,575</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,683</p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mutual funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,449</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total short-term investments</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,860</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 305</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,132</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,893</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,905</p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial papers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,717</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total short-term investments</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,587</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,622</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972214114488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Other Accounts Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of accounts, notes, loans and financing receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government institutions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 601</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 827</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972298283480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Summary of Company's significant contractual lease obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s significant contractual lease obligations at December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">3&#160;years</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facility leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 403</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 193</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 210</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Car leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 433</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212714104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Medical equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 737</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 737</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer software and electronic equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 198</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,092</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,078</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Less&#160;- Accumulated depreciation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 907</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net book value</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 176</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 171</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972214054792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of status of Company's option plans and its changes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Options outstanding at beginning of&#160;&#160;year</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,393,715</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,349,054</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.92</p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 585,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 282,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.07</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Forfeited</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (208,195)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.49</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (121,250)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.37</p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (47,509)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (116,589)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.23</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at end of&#160;year</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,723,011</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.70</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,393,715</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.12</p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Options exercisable at&#160;year end</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,754,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,647,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.02</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212747432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock', window );">Schedule of research and development expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chemistry and formulation studies</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,856</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,439</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 968</p></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salaries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,617</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 871</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 883</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 582</p></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and preclinical studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 963</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical studies</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,346</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,575</p></td></tr><tr><td style="vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulatory and other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 608</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,082</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,180</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,313</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972214065768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_GeneralAndAdministrativeExpensesTableTextBlock', window );">Schedule of general and administrative expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,194</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,349</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,201</p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 896</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salaries and benefits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 828</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 856</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,346</p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rent and office-maintenance fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investor relations and business development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 293</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 364</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 464</p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance and other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,128</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,196</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,440</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_GeneralAndAdministrativeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_GeneralAndAdministrativeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212808328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial income, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Financial income, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock', window );">Schedule of financial income, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bank fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,192)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,953)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (959)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain from sale of marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (397)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (106)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12)</p></td></tr><tr><td style="vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency (gains) losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,439)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,915)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (934)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the detailed components of other nonoperating income. May include methodology, assumptions and amounts for: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212690264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense (benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">Significant components of the Company&#8217;s and its subsidiaries&#8217; assets are as follows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Israeli companies net-operating-loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,085</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Maltese subsidiary net-operating-loss carry forward</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,090</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,081</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Israeli subsidiary capital-loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 881</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Other reserves and allowances</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total deferred-tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,068</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,600)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,068)</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net deferred-tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">A reconciliation of the Company&#8217;s effective tax expense to the Company&#8217;s theoretical statutory tax benefit is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before taxes on income, as reported in the consolidated statements of operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,771</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,461</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,781</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Statutory tax rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Theoretical tax benefit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,453</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,455</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,174</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,453)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,455)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,174)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax withheld from upfront payment from Samil</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actual tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972215209896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_EntityIncorporationDate', window );">Date Of Incorporation</a></td>
<td class="text">Jul. 31,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperationsCommencedDate1', window );">Operations Commenced Date</a></td>
<td class="text">Feb.  02,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_EntityIncorporationPlace', window );">Entity Incorporation Place</a></td>
<td class="text">Israel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,947<span></span>
</td>
<td class="nump">$ 15,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term deposits</a></td>
<td class="nump">3,807<span></span>
</td>
<td class="nump">27,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">marketable debt securities</a></td>
<td class="nump">40,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Loss attributable to holders of its ordinary shares</a></td>
<td class="nump">28,771<span></span>
</td>
<td class="nump">20,461<span></span>
</td>
<td class="nump">$ 9,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (135,707)<span></span>
</td>
<td class="num">$ (106,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_EntityIncorporationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date of Incorporation of the Entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_EntityIncorporationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_EntityIncorporationPlace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Place incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_EntityIncorporationPlace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperationsCommencedDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the operations of the entity commenced, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperationsCommencedDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972214571384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_PropertyPlantAndEquipmentDepreciationPercentage', window );">Property, Plant and Equipment, Depreciation, Percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_PropertyPlantAndEquipmentDepreciationPercentage', window );">Property, Plant and Equipment, Depreciation, Percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember', window );">Computer software, electronic and medical equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_PropertyPlantAndEquipmentDepreciationPercentage', window );">Property, Plant and Equipment, Depreciation, Percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember', window );">Computer software, electronic and medical equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_PropertyPlantAndEquipmentDepreciationPercentage', window );">Property, Plant and Equipment, Depreciation, Percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_PropertyPlantAndEquipmentDepreciationPercentage', window );">Property, Plant and Equipment, Depreciation, Percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_PropertyPlantAndEquipmentDepreciationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents property plant and equipment depreciation percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_PropertyPlantAndEquipmentDepreciationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972403382600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary', window );">Monthly Deposits of Employees, Percentage on Monthly Salary</a></td>
<td class="nump">8.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used</a></td>
<td class="text">Black-Scholes option-pricing model<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collection of monthly deposits from the employees on their monthly salary for severance pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of method used to estimate fair value of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972215465256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable debt securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 40,132<span></span>
</td>
<td class="nump">$ 31,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">40,132<span></span>
</td>
<td class="nump">31,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">25,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 14,683<span></span>
</td>
<td class="nump">$ 31,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972298545560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable debt securities - summarizes the marketable debt securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 39,860<span></span>
</td>
<td class="nump">$ 31,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">40,132<span></span>
</td>
<td class="nump">31,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">14,575<span></span>
</td>
<td class="nump">19,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">14,683<span></span>
</td>
<td class="nump">19,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember', window );">Mutual Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">25,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 25,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial papers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972215036360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Other Accounts Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_ReceivablesFromGovernmentInstitutions', window );">Government institutions</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Others</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables, Net, Current</a></td>
<td class="nump">$ 812<span></span>
</td>
<td class="nump">$ 827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_ReceivablesFromGovernmentInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount receivable from government institutions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_ReceivablesFromGovernmentInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972298319048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Options</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land under operating lease agreement | ft&#178;</a></td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_LesseeOperatingLeaseNumberOfOptionToExtend', window );">Number of additional options to extend | Options</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseDepositLiability', window );">Bank guarantee</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Operating Lease, Liability, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, weighted average remaining lease term (in years)</a></td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, weighted average borrowing rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_LesseeOperatingLeaseNumberOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of options to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_LesseeOperatingLeaseNumberOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121604594&amp;loc=SL77919106-209958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972215506552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Company's Significant Contractual Lease Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">$ 433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Less than 1 year</a></td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_ContractualObligationDueInFirstToThirdYear', window );">1-3 years</a></td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=glmd_FacilityLeasesMember', window );">Facility Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Less than 1 year</a></td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_ContractualObligationDueInFirstToThirdYear', window );">1-3 years</a></td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=glmd_CarLeasesMember', window );">Car Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Less than 1 year</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_ContractualObligationDueInFirstToThirdYear', window );">1-3 years</a></td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_ContractualObligationDueInFirstToThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the first to third fiscal year following the latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_ContractualObligationDueInFirstToThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=glmd_FacilityLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=glmd_FacilityLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=glmd_CarLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=glmd_CarLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972218925032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_MedicalEquipmentGross', window );">Medical equipment</a></td>
<td class="nump">$ 737<span></span>
</td>
<td class="nump">$ 737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Office furniture and equipment</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Computer software and electronic equipment</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - Accumulated depreciation</a></td>
<td class="nump">916<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_MedicalEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used in the normal conduct of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_MedicalEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972213964568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - Samil Pharm. Co. Ltd [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 28, 2016</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized', window );">Milestone Method Revenue Payment</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued Royalties</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_RevenueRecognitionNonRefundableUpfrontPayment', window );">Revenue Recognition Non Refundable Upfront Payment</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_RevenueRecognitionNonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The non refundable amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_RevenueRecognitionNonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=glmd_SamilPharmCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=glmd_SamilPharmCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212545064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_OfficersAndDirectorsMember', window );">Officers And Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972298711016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_BankLienOnMarketableSecurities', window );">Bank Lien On Marketable Securities</a></td>
<td class="nump">$ 113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_GuaranteeOfIndebtednessOfOthersMember', window );">Guarantee of Indebtedness of Others [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Bank guarantee, commitment</a></td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_BankLienOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>These lines are represents that lien on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_BankLienOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_GuaranteeOfIndebtednessOfOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_GuaranteeOfIndebtednessOfOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972216723064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Company's Option Plans (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share options, Granted (in shares)</a></td>
<td class="nump">267,500<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of share options, Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised (in dollars per share)</a></td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 4.77<span></span>
</td>
<td class="nump">$ 4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share options, Outstanding at beginning of year (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,393,715<span></span>
</td>
<td class="nump">2,349,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share options, Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">585,000<span></span>
</td>
<td class="nump">282,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of share options, Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(208,195)<span></span>
</td>
<td class="num">(121,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of share options, Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,509)<span></span>
</td>
<td class="num">(116,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share options, Outstanding at end of year (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,723,011<span></span>
</td>
<td class="nump">2,393,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share options, Options exercisable at year end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,754,261<span></span>
</td>
<td class="nump">1,647,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Options outstanding at beginning of year (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="nump">$ 5.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.18<span></span>
</td>
<td class="nump">5.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise Price, Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.49<span></span>
</td>
<td class="nump">6.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.27<span></span>
</td>
<td class="nump">1.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at end of year (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70<span></span>
</td>
<td class="nump">6.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable at year end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.42<span></span>
</td>
<td class="nump">$ 5.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972203374120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>May 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 22, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 707,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,500<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 4.77<span></span>
</td>
<td class="nump">$ 4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Vested term period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate grant fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,066,000<span></span>
</td>
<td class="nump">$ 2,231,000<span></span>
</td>
<td class="nump">$ 1,783,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_MaximumAmountOfSharesToBeIssuedOffering', window );">Ordinary shares offered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
<td class="nump">56,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glmd_AtthemarketOfferingMember', window );">At-The-Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_MaximumAmountOfSharesToBeIssued', window );">Maximum Amount Of Shares To Be Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glmd_IncentiveShareOptionPlan2013Member', window );">Incentive Share Option Plan 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
<td class="nump">2.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.43%<span></span>
</td>
<td class="nump">3.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 28 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="nump">$ 8.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,528<span></span>
</td>
<td class="nump">54,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,905<span></span>
</td>
<td class="nump">1,179,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=glmd_EmployeeStockOptionAndRestrictedStockUnitsMember', window );">Employee Stock Option And Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">$ 94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 5.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Vested term period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate grant fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,290<span></span>
</td>
<td class="nump">120,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member] | At-The-Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Total proceeds from sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member] | Subsequent Event [Member] | At-The-Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="nump">1,541,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 1,541,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance | shares</a></td>
<td class="nump">22,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Total proceeds from sale of ordinary shares</a></td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member] | Subsequent Event [Member] | Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="nump">2,197,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="nump">$ 4.3258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_UnderwritersOptionExercisableTerm', window );">Option exercisable period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_UnderwritersOptionToPurchaseAdditionalShares', window );">Additional shares to purchase | shares</a></td>
<td class="nump">329,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Total proceeds from sale of ordinary shares</a></td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_MaximumAmountOfSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares to be issued in the offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_MaximumAmountOfSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_MaximumAmountOfSharesToBeIssuedOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of shares to be issued in the offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_MaximumAmountOfSharesToBeIssuedOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_UnderwritersOptionExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of option exercisable by underwriters during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_UnderwritersOptionExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_UnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares to be purchased by the underwriters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_UnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glmd_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glmd_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glmd_IncentiveShareOptionPlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glmd_IncentiveShareOptionPlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=glmd_EmployeeStockOptionAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=glmd_EmployeeStockOptionAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=glmd_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=glmd_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972215833096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_ResearchAndDevelopmentExpensesLineItems', window );"><strong>Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense, Total</a></td>
<td class="nump">$ 26,082<span></span>
</td>
<td class="nump">$ 18,180<span></span>
</td>
<td class="nump">$ 8,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_ResearchAndDevelopmentExpensesLineItems', window );"><strong>Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_ChemistryAndFormulationStudiesExpenses', window );">Chemistry and formulation studies</a></td>
<td class="nump">5,856<span></span>
</td>
<td class="nump">3,439<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salaries</a></td>
<td class="nump">2,570<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">871<span></span>
</td>
<td class="nump">883<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_ResearchAndPreclinicalStudiesExpenses', window );">Research and preclinical studies</a></td>
<td class="nump">1,873<span></span>
</td>
<td class="nump">1,962<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_ClinicalStudiesExpenses', window );">Clinical studies</a></td>
<td class="nump">13,225<span></span>
</td>
<td class="nump">8,346<span></span>
</td>
<td class="nump">3,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_RegulatoryAndOtherExpenses', window );">Regulatory and other expenses</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
<td class="nump">608<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense, Total</a></td>
<td class="nump">$ 26,082<span></span>
</td>
<td class="nump">$ 18,180<span></span>
</td>
<td class="nump">$ 8,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_ChemistryAndFormulationStudiesExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents that, the amount of chemistry and formulation studies expenses under research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_ChemistryAndFormulationStudiesExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_ClinicalStudiesExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents that, the amount of clinical studies expenses under research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_ClinicalStudiesExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_RegulatoryAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents that, the amount of Regulatory and other expenses under research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_RegulatoryAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_ResearchAndDevelopmentExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_ResearchAndDevelopmentExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_ResearchAndPreclinicalStudiesExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents that, the amount of research and preclinical studies expenses under research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_ResearchAndPreclinicalStudiesExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972217672808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_GeneralAndAdministrativeExpensesLineItems', window );"><strong>General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expense, Total</a></td>
<td class="nump">$ 4,128<span></span>
</td>
<td class="nump">$ 4,196<span></span>
</td>
<td class="nump">$ 4,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_GeneralAndAdministrativeExpensesLineItems', window );"><strong>General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
<td class="nump">1,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">877<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salaries and benefits</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">856<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent and office-maintenance fees</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDevelopment', window );">Investor relations and business development expenses</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Insurance and other</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expense, Total</a></td>
<td class="nump">$ 4,128<span></span>
</td>
<td class="nump">$ 4,196<span></span>
</td>
<td class="nump">$ 4,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_GeneralAndAdministrativeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_GeneralAndAdministrativeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972212531192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial income, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Financial income, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_BankFees', window );">Bank Fees</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="num">(1,192)<span></span>
</td>
<td class="num">(1,953)<span></span>
</td>
<td class="num">(959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Gain from sale of marketable debt securities</a></td>
<td class="num">(397)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency (gains) losses</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Financial income net</a></td>
<td class="num">$ (1,439)<span></span>
</td>
<td class="num">$ (1,915)<span></span>
</td>
<td class="num">$ (934)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_BankFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as bank fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_BankFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972214695560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital-loss carry forward</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Other reserves and allowances</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred-tax assets</a></td>
<td class="nump">16,600<span></span>
</td>
<td class="nump">15,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(16,600)<span></span>
</td>
<td class="num">(15,068)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred-tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_IsraeliSubsidiaryMember', window );">Israeli Subsidiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net-operating-loss carry forward</a></td>
<td class="nump">11,906<span></span>
</td>
<td class="nump">10,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital-loss carry forward</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_MalteseSubsidiaryMember', window );">Maltese subsidiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net-operating-loss carry forward</a></td>
<td class="nump">$ 4,090<span></span>
</td>
<td class="nump">$ 4,081<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_IsraeliSubsidiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_IsraeliSubsidiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_MalteseSubsidiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_MalteseSubsidiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972217839400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Company's Effective Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before taxes on income, as reported in the consolidated statements of operations</a></td>
<td class="nump">$ 28,771<span></span>
</td>
<td class="nump">$ 20,461<span></span>
</td>
<td class="nump">$ 9,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Theoretical tax benefit</a></td>
<td class="nump">$ 3,453<span></span>
</td>
<td class="nump">$ 2,455<span></span>
</td>
<td class="nump">$ 1,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards</a></td>
<td class="num">(3,453)<span></span>
</td>
<td class="num">(2,455)<span></span>
</td>
<td class="num">(1,174)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Tax withheld from upfront payment from Samil</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Actual tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972215932504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 07, 2019</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at federal statutory income tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred tax assets, capital loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at federal statutory income tax rate, percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at federal statutory income tax rate, percent</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_IsraeliSubsidiaryMember', window );">Israeli Subsidiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at federal statutory income tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred tax assets, capital loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 577<span></span>
</td>
<td class="nump">$ 881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_IsraeliSubsidiaryMember', window );">Israeli Subsidiary [Member] | Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at federal statutory income tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_MalteseSubsidiaryMember', window );">Maltese subsidiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at federal statutory income tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_IsraeliSubsidiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_IsraeliSubsidiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_MalteseSubsidiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=glmd_MalteseSubsidiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139972215974408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 707,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glmd_AggregateQuarterlyRentalPayment', window );">Aggregate quarterly rental payment | &#8362;</a></td>
<td class="nump">&#8362; 133,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Ordinary Shares (In shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member] | Subsequent Event [Member] | Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Ordinary Shares (In shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,197,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.3258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glmd_AtthemarketOfferingMember', window );">At-The-Market Offering [Member] | Ordinary shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Ordinary Shares (In shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glmd_AtthemarketOfferingMember', window );">At-The-Market Offering [Member] | Ordinary shares [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,541,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Ordinary Shares (In shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glmd_AggregateQuarterlyRentalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate quarterly rental payment, together with adjustments and the maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glmd_AggregateQuarterlyRentalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=glmd_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=glmd_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glmd_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glmd_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M >T2;'RE%#YOW+3J7T[Y'U!+ P04    " "@6W)2223-L>0#   Y#0  &
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;*676X^;.!3'OXJ%^M!*G8"!<*F2
M2)W)=K?2=G<TTVZ?G7 24,'.8I-,O_T>&X9)P2$C[4NXY'\NO^/;87$2]0^9
M RCR5)5<+IU<J<,'UY7;'"HF9^( '/_9B;IB"A_KO2L/-;#,&%6EZWM>Y%:L
MX,YJ8=[=UZN%:%19<+BOB6RJBM4_;Z$4IZ5#G><7#\4^5_J%NUH<V!X>07T[
MW-?XY/9>LJ("+@O!20V[I?.1?EC30!L8Q3\%G.39/=$H&R%^Z(?/V=+Q=$90
MPE9I%PPO1[B#LM2>,(]_.Z=.'U,;GM\_>_]DX!%FPR3<B?)[D:E\Z20.R6#'
MFE(]B-,?T '-M;^M**7Y):=.ZSEDVT@EJLX8,Z@*WE[94U>(,P,:73#P.P-_
M:!!>, @Z@^"U!F%G$)K*M"BF#FNFV&I1BQ.IM1J]Z1M33&.-^ 77X_ZH:ORW
M0#NUNA-<BK+(F(*,/"J\X* J2<2._'V FNG!D>2&?'M<D[=OWI$WI.#D:RX:
MR7@F%Z["'+0G=]O%NVWC^1?B49]\$5SEDOS&,\A^=>!B\CV!_TQPZT]Z7,-V
M1@+ZGOB>[UD2NGNU.4TMYNO7FR<3-$$_'H'Q%_R?\9B($_9Q0A,GO!#G 8[
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M,!3]*Q;J0RNMY3.05DFD-MFT2>M6->OV[,!-L IV9INDVZ_?M2$L)23KPU[
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M(33V9;O,<=2"- 'X?2F$WFU,@G9X3_X 4$L#!!0    ( *!;<E*Z'K*&804
M  L8   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULO5C?;]LV$/Y7"*/
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M >#['>?R:: FZ.[_5_\!4$L#!!0    ( *!;<E*6HB*/F@<   L?   8
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M8]@X"#IL(;Y?XE509ET7,&8Q2SOSA^!H- N3-C\$-PM87WHVQH(F'S&[LCR
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MZN2U^F'5SA\M+I6U:NLO-X+G0CL /%\I(%W_<"\XGG_?_1]02P,$%     @
MH%MR4G\D0;[G!0  60X  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6R5
M5]MNW#80_15B:Q0MX.S-=N+$%\!.FC1%701)+\]<:79%A")5DO+:_?J>&4I:
M[<))FY==76;.S!S.'%*76Q\^QXHHJ8?:NG@UJ5)J7LUFL:BHUG'J&W)XL_:A
MU@FW83.+32!=BE-M9\OY_/FLUL9-KB_EV8=P?>G;9(VC#T'%MJYU>+PEZ[=7
MD\6D?_#1;*K$#V;7EXW>T"=*?S0? NYF TII:G+1>*<"K:\F-XM7MZ=L+P9_
M&MK&T;7B2E;>?^:;]^759,X)D:4B,8+&WSV])FL9"&G\W6%.AI#L.+[NT=]*
M[:AEI2.]]O8O4Z;J:G(^426M=6O31[_]F;IZSABO\#;*K]IFV\7)1!5M3+[N
MG)%!;5S^UP\=#R.'\_D7'):=PU+RSH$DRS<ZZ>O+X+<JL#70^$)*%6\D9QPO
MRJ<4\-; +UV_(T=!V\M9 A@_FA6=XVUV7'[!<;%4=]ZE*JJ?7$GE/L ,60RI
M+/M4;I=?17Q#Q52=+([5<KZ<?P7O9"CM1/!.OJ6T/:33 >E4D$Z_G:2O._[F
M$ZF%^OZ[\^5B<:$Z'/5.VYI*]:'2Z*N"VF0*;:/Z-953]4.J2!R6\XO7OFZT
M>Y2[Q<6/RD2E58$@;/\L)DR-6AG?[.&H(GNI)AC,F;&/:NW120B(*6#TDNXQ
MC U&*RF_YD=!-^(=81K$)F'"4V]A,3A!E282^C].U>\PZ')36QV5<84/C0\Z
M(8AQZGT,FBR'^Z5%^+RFBQ.E7<G9 ;;@;!K$Y=&,;/F65J&%+*BE&)_N1ZF\
M+;GX+2[LXS._=0"([2J:TL#IN*?TO4L4G*"""2;T&#ZFJ)[,\T[;I*=?]@6%
M=&]\&U%$1;;\'PG<42F+\)% 5D#<_\HA<W4LW%2Z5"LB:)7#JRQ8PW)&>!)3
M<R:VC&7-WZTI>Z0=@_/%RWWZT%V^XS!MO=)E:;HRGZ['4!PJ&BKAJ&]&K8/*
MY!GLDF\T!]SU42Y[Y1/\ GVAZOTDOZV[MX:A7=]%;J,J [5$^=;4AL,DS^OW
MK$?,W=??E*'=[ U"YC\J!WJ:)OA[(."O;(O$'>\5\WPLLS$TI8[#:($K'Y.B
MA\*V$<N&CD%3=P$X.Y-BCZ<*!#,9[R;HNL :[%.Q;EE3Q2>,Z1\G#+ -G*.\
M&,U2RJF.QC]5P;>;BCT*(O3 .OB:W]^+G06YC)B1FG9E38&I7U- W@?37K0A
MP-0^]ESU%.U(8P5!X,\DB[*C-:F-R!\O#4-AM,BUU">3F8G:TE#"5-U$EA]L
M#%2OH$#]YG"X#%A7'3-#<D$8BWL@<4WP/WH^?8F]TUKP<\R$IF *3D.,V6 ^
M7>P,8N5#>@8MJ,%WXZ/I4$ZFY[V1A,I%ZI5E15TA=P([F"O*YJ<CT ,QRS+
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M96&6VGIP%$S=K8WRC.BGWVPC(*85QLS!RWG@)?%&D6B0?P:Q?IT]!K)!XS.
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M3?9523Q JT+YQ7:M"!0Y0M?3D\DS<"R-62,9=FL2@^2%T6"K',8N:4CV%\6
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ML@%]J.R%0KKA0+0P7$*D^0[Z1&=1GTH:SY8 SSW;!E]B@V7>L2;D?)^BFV+
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MN8)D@W59844-6&$$UU*83,,[D6*Z"Q"08K5VT5:[R^@@XEM,.A"';8BZ4?<
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M#<SN-4.6HK(,]'TFZ;;?+.P&]6\>D[\ 4$L#!!0    ( *!;<E*9;H-"3@(
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M7:/ST44 NFT9K4&J\F6Z5F2+WB]SVV51.X ]WRC[+3K#7=#W[=D_4$L#!!0
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M^8>3+$W/(<+ GQI^%[JA!H 0:WIZ +Y$N#)5+?0CB,+4'@N8W][S[M&')#N
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M:R0[>&O'5T2MJ=# L+"ET6DZ"$"U%M<F1E;>5E;26)/R86G_"J@<P*X7TK[
MF\1MT/UG9G\!4$L#!!0    ( *!;<E(1#TH:8 8  .X/   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;)57[V_;-A#]5PBO&!+ D7^D38,V">"D'=JN
M[8JDW3[3TMDB2I$:2<5Q__J](R793N)T_6)+%._NW?'=(WFVLNZ[+XF"N*NT
M\>>#,H3ZU6CD\Y(JZ3-;D\&7A765#'AURY&O'<DB&E5Z-!V/3T:55&9P<1;'
MOKB+,]L$K0Q]<<(W527=^I*T79T/)H-NX%HMR\ #HXNS6B[IAL*W^HO#VZCW
M4JB*C%?6"$>+\\%L\NKR.<^/$_Y6M/);SX(SF5O[G5_>%^>#,0,B37E@#Q)_
MMW1%6K,CP/BW]3GH0[+A]G/G_8^8.W*92T]75O^CBE">#TX'HJ"%;'2XMJMW
MU.;S@OWE5OOX*U9I[N1X(/+&!UNUQD!0*9/^Y5U;ARV#T_$>@VEK,(VX4Z"(
M\HT,\N+,V95P/!O>^"&F&JT!3AE>E)O@\%7!+EQ<TRV9ALY& <YX:)2WAI?)
M<+K'<#(5GZP)I1=O34'%KH,14/10IAV4R^F3'M]0GHGCR5!,Q]/Q$_Z.^]2.
MH[_C7TEMQ]/SWM/SZ.GYKQ?I:<//-I!X*7[_[70ZF;P6K1]Q(RNEQ6SIB,#O
M(/XRXD.CUV)ZRLE/3H8BE"2N;%5+LQ:808X*H4RP0@JM<O0$"=F;'PSN.1P<
M@D6A;.-\*:6K,KC+AN)C*#)QP-X9TW3\.DZ)SY/7AT.!+A?2"+K+=>/1+D/A
M[%KJL#Z:DW3*+/OP/)/]Y+:JR.5*:O5#QD:S"S%SLLI+D/D@XH!'6\=OR*"2
MIEF@&1M'A[V7 $$),1E8+V0(:P2Z)8>D"Y5'OQ[/0%4PB,^SFW=XC:;75#=S
MH&++/RW\9&)6%(I-I-9KSDE#>MB,I\^NK]_>?!4WH2GP+56HE'X7(]T%,D6<
M_['-%Z.0A&!D-12K4N7E4*@%)G+NG@H,VD;S(N6 P/.Y-N #T.LC>"\@8<M&
MRV =BHD9!=I9$QK<D*CEFI/WF?B&9FI+0J[RG!2_W%O@78(XR@G%*CB'ICY:
M./1EYY(=R+IV]DY!P@@D>S;-)AQ:(]=LNP#:VT2J@I.%O9!]'?M4_F\F;9&P
MVG"SA-<EH@,=NWYVDHT[!$.!T"N(,O\'Q40?BL)B1>FH4$L56@(J\NQ;8EQ@
MC;Q$0''0Q&KEY *V'S"F4B%QY3 3[XVXH3I0-<<4=-7IOJ(]1,]%>S;)7G0@
M!4I:M:5"G-P:TVXJD=YM&]2:.OZKX#NB>29:1"/SW+I"FIR2V>SF2IR,3W90
M%<3+#A5A\LF0&-LW>FJ B!GQYG%:32YNS>S6H@^6J0D=88_V,.IX7U!LJ'7'
MJ+[%-X*"E=U-8ZM?VC3V"-K!%2B7'8JO/TDE.&F\3*6K'>(*?$ Y,9[']"BU
MX IDV.8IS_'*QV1:7$T=>3X4QIHC[.2@0B1'NX0,%0O:3N[9"[G9D'>S\$Q!
M1YOZMM+R$&Y3X[''&<D+D=EBD*QL _HG?XL& A2QPQ-7(A.?I,%9)ZZF])Z\
MWRZ/5M^Q2J6U!0.W>=XX1W%A4QH6/V[/BOL.](8N7$5'E0TM[H>%AE1ZG,=8
MS-C4!W#@2&I.Y%;J)@;FSWMC<HB"PQ7XX_,)6M!')IFM\C^LXRH5SD+:D]R$
MTOH=UX!F4NT4>KPCM>[F1P&XKSXI\D8P5F"/F!/WNET:]0-S5R6E,G6^DI+$
M6@^C.=>8D"Q!%=$=41;G1.VFR.R(:O!H7IEXT\1=,NE-'^RIGI!YJ=!&G>ZP
M="R4\V&+5%PM2/B<"8YM9TL(V,$M-N9(_=UBW=<PKCBZPX7]JW)O1>BG*K/9
MD1^3F%\1EEG<ZG $3'K='0.'?%SH&H:8DPE>7$"^<W#L/7O3?5X\5OP]M?-E
MW,R-#1U]7)1=[J>D>-W!!851:%?B,_!#^-F.(D8Z.CKJ\MBS"NAC BE8PJV+
MDM<&B73B^*POJ5^:@,)R?HYA>JMY1P.TI!1Y*<V2HC+DRN5-Q0V>=W1/5>B.
M+?&819%</IT8@":"M)O^V5>O36&R?D_X93(]PAI(I,U5=+)-EU;9^J8&"H#"
M<2[I@4U-ITS=H(L(TH(S16S:1[::4#K;+$O^%#?$QPG*)?S0H!6YL;/'KA2C
MK3L8#L3+>-/T<(OM(%W'^M'^,CM+=[C-]'03_B3=4D%<-2U@.LY>OA@(EVZ7
MZ278.M[HYC;@?A@?2US(R?$$?%]8:'[[P@'Z*_[%?U!+ P04    " "@6W)2
M-3KT5JT"   ,!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R=5=MR
MVC 0_94=-],GZAN$T 28"4D[[4,Z3#)MGX6]QIKHXDIR"7_?E6P<:)L\Y 6T
MMZ-S%NTRWVGS:&M$!T]2*+N(:N>:RR2Q18V2V5@WJ"A2:2.9(]-L$]L89&4H
MDB+)TW2:2,95M)P'W]HLY[IU@BM<&["ME,SL5RCT;A%ET<%QS[>U\XYD.6_8
M%A_0?6_6AJQD0"FY1&6Y5F"P6D37V>5JXO-#P@^..WMT!J]DH_6C-[Z6BRCU
MA%!@X3P"HZ_?>(-">""B\:O'C(8K?>'Q^8#^.6@G+1MF\4:+G[QT]2*:15!B
MQ5KA[O7N"_9ZSCU>H84-G[#K<K-I!$5KG99],3&07'7?[*GOPU'!+'VA(.\+
M\L"[NRBPO&6.+>=&[\#X;$+SAR U5!,YKOR/\N ,13G5N>4]"N:PA#4SCJ.=
M)XY ?2@I>H!5!Y"_ )#E<*>5JRU\4B66IP )L1DHY0=*J_Q5Q%LL8AAG(\C3
M/'T%;SQ(' >\\5LDGB!.!L1)0)R\O6FO WS3#F$&[]_-\BR[@K_P((OAVH*N
M@%J!<H-F:,<(F"KIE'T<@:L1;K1LF-I#S4J*T!LO3,L$<!6B3.I6.0_$FL;H
M)TZO&,4>SM+XG!Z3$&$N") <TX-C1+-F&PS3(O8C:%IC6T8P3OLK4#9"[VDL
M';"M00RG'7<U<.<Y5[Q 8P-JR0W!:&.#SHLKJ!!CR&.X;0U7VUZ0%W-0-3M5
M1>7:T*,"RP1M#, GVD46[0AH+HK'#WX<2R@HF]PL3/DAY44"7H9G:OJ>-WW/
M_VG9V?BY22-O34];-HXO!L=QQ^+_/;#D:$(EFFW80Y:HTV7=L [>8=5==Q/^
MG-[MR3MFMEQ9$%A1:1I?G$=@NMW3&4XW8=XWVM'V",>:UC4:GT#Q2M/KZPU_
MP? 'L/P#4$L#!!0    ( *!;<E)]/;V9!00   X)   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;*U6VV[C-A#]E8&[Z 7(RK;L=)-=QT"2;=&B2#?(
M]O),2V.+"$4J)&4G^_4]0]F*#&P"%.V#;9&:.7/FS SIQ<[Y^U Q1WJLC0T7
MHRK&YOUX'(J*:Q4RU[#%F[7SM8I8^LTX-)Y5F9QJ,\XGDQ_'M=)VM%RDO5N_
M7+@V&FWYUE-HZUKYIRLV;G<QFHX.&W=Z4T79&"\7C=KP9XY_-K<>JW&/4NJ:
M;=#.DN?UQ>AR^OYJ+O;)X"_-NS!X)LEDY=R]+'XM+T83(<2&BR@("C];OF9C
M! @T'O:8HSZD. Z?#^@_I]R1RTH%OG;F;UW&ZF)T-J*2UZHU\<[M?N%]/J>"
M5S@3TC?M.MO99$1%&Z*K]\Y@4&O;_:K'O0X#A[.7'/*]0YYX=X$2RX\JJN7"
MNQUYL0::/*14DS?(:2M%^1P]WFKXQ>6UJVL=H7(,I&Q)U\Y&;3=L"\UA,8X(
M(8;C8@]WU<'E+\!-<[H!0A7H)UMR>0PP!K>>8'X@>)6_BOB1BXQFTQ/*)_GD
M%;Q9G_ LX<W^>\)'^/,>?Y[PY_^7H*_#_>XBTSE]^\U9/IU^H%?1:9K192"W
M)HC&]8I]+]P)Q8K%NU'V"<-4.(_RD*+&<+EAPGQH0(;*^?@VLJ_1V8T+.I*V
MM%9;YP563%;*WLNFX*G:M3;*&]4TWCUJ3 F;)WHSG<Y@X-H@'*.CP$7K><@A
M)?3N0Z!BD!$LQ41"G"!&8=H2R8%E"KIIE5<V,C]SNM$V?J'?,M$A1-]VD[X/
MT>5L.(2._2#Z=X$JG& /0$2R 98N*B.QWIS.>^:0^.MJ9I1G],= 4+ '#'@A
M@P(E\3ALPD$E2*TM#CR\:7U@05RU 74. <,>JU1$\: [#JQ\4=$GOU%6?U&2
M3B <O52 G2Z4H>BU,EWQ^[W0-@UDKY5MU\!I?5(-%@E^R[9TOH.QSK[MW?PA
M7(@0FCM0!\HXM-EO=;'?0FG+5A(2!%P'7DG/4=-ZM A#O5VE@8(NQ"L#(G#8
MZI*3O303TD^%:1M\S292Y_,)E>HI[-L O"+"0:I4KY,45H@P(-!G^!3*%FS4
MRO! 83&#J^P$!/32TL.6$D#0+"HENJ^,WG22XD3)"*<Z2M3=:]T5LU$^-=QQ
MIQB&]U&CGD ?EL!,IQG]JQ']7I;9#S3/Z%-2.E;*"NF20^'U2C)8N2T?#VRI
MNSPKM84:5DH-7=$(QZP&(P,;S(HN= /+\ME>%0^MQEQ+PFC$QL JT63L-P?-
MM/0SAZZ'NXXH$A4MY7YA*A),/IF>9U\[1L>#.ZIFOTDWL:B*$Z2[KOK=_K*_
M[.ZX9_/NG\*-\AMMI3!KN$ZR=Z<C\MWMVRVB:]*-MW(1]V=ZE'%G+P9XOW8H
MV7XA ?J_0,M_ %!+ P04    " "@6W)2J@N(C:P,  "W*0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-RYX;6S-6MMRVS@2_164UIG$533-BRY4G*3*R22[
M>4CBBB<[SY (2=SPH@%).YZOW],-\*:+[6PR6_-BBP30[#[=?;H!\L5MH;^6
M&Z4J\2U+\_+E:%-5V^?GY^5RHS)9NL56Y1A9%3J3%2[U^KS<:B5C7I2EYX'G
M3<\SF>2C5R_XWI5^]:*HJS3)U94699UE4M^]5FEQ^W+DCYH;GY/UIJ(;YZ]>
M;.5:7:OJR_9*X^J\E1(GF<K+I,B%5JN7HTO_^>LQS><)_T[4;=G[+<B215%\
MI8OW\<N11PJI5"TKDB#Q[T:]46E*@J#&'U;FJ'TD+>S_;J2_8]MART*6ZDV1
M_I[$U>;E*!J)6*UDG5:?B]M_*6O/A.0MB[3DO^+6S WPQ&5=5D5F%^,Z2W+S
M7WZS./061-Z1!8%=$+#>YD&LY:^RDJ]>Z.)6:)H-:?2#3>754"[)R2G7E<9H
M@G75J^N-U&I3I+'2Y5/Q]H\ZJ>Y>G%>03./G2ROEM9$2')'B!^)#D5>;4KS-
M8Q4/!9Q#I5:OH-'K=7"OQ%_5TA6A[XC "[Q[Y(6MG2'+"_]G.P=BQZW8,8L=
M_R!\]TOY6%1*^-XO_X@"W[\0?:%\;W9A18M+5WS2<9(C?T1)TTKA[]]:%OE*
M:5%O$?;51@DKBW]K"E-1%<BHI4)"B+RHDJ6B.UNI\3/92F@C\UC<D%I)+M8J
M5UJF(D.0)?FZ%,6*1;TILJW,[WCN0=%Q<I/$*H]+1R0KY,HRA7JQ*P*HG NX
M6&4+Z!D$Y&9_Y@RDJKQ2F T%(%'FXK(ZP_#9!ZF_@JLL'I]6,!0ZB6N9PO#+
MM58*E%&)9R1J=%TE*Y7N#HY.D6351IA11WQ,D$6R+L4O,MM>- HXXGV^+/2V
MT, C=H0L^^I9OY2B9-G@+WHHW0V\"R.8+_R+4U=<U;JL9<[8D(RM+LHM: F/
MU"J5!&HSM"=^H](59JV3LH(B1&1E!8782%P0-8EW9Z%8)2G 8KM(SO7;-S0,
MM)8;$4P9X$@\>X=9XF.!U K#LR (YT%X.D ]DW=P+T4/>17L"7Q6NLA$!2IF
M)?G_1A?UND,PJ1 4.T&XD3=D%SPGUT!^35%5-.[::HHYQ%&]):$GX03DEJ8P
MCT/C [3P)R;YAU$A83@8AK7#4P@*$WR[ 1#SR%Z,B86J;I7*]P+X>X*!5$[R
M95K'D &_%EJ\2ZH_UY0E<;O0I9 A\^,X(<<A@_K!@H+:5^)I*4:RXCN9"?$&
MK!'%RUK+S ;UY6\?Q)6Y,]H)+MD/K;+>;E,#QK'@.(;R?A2TCO+=>>,J\M\!
MS[OBDBFBQ1XT3H\8/*$$)0D_G#JAY^V%3@T7&W!ZMAK B@HPYD 'ABZ5BOE)
M<HNK;PEJM$KOQ(GG1ETTA:[XM>:8>Z<6NJ:G0!D4EK)>E.J/6G5IN9"IS!&6
MIANB '+V=1XZU'<F8]\9_WP;(C?H; ">DJ(=G<90HPU%V'!A$+BSUD%:45_&
M:7@CDU0ND/VDPJJN:JUL.![65+)6'681QPF*S?CG ;I+\:S)K4Z8$.4.EW_I
M#^YQ^7UIN+->:2Q"64.5S&UOR"+Z"E1@B&V]2)-EQUD[8FC*E9G25"'(!6:!
MX\]G3N2%>S%A)+Q+0-E<XTNSH ^)F=(6]&::*W[#_9X)!AYFHFT-CD=CRG)Z
MPBUO]WFN8H:PU'LR=L-@$HDMI+&"YB&#P!Q6)7$+=^T&W-P-NTC]TL82=,S:
M3N&P[X;!@*C+&S(?& J>V9*7'*&^*;U,RC:,0P]!=8?NHH^"(:IAFH;!W)G.
M]I/4HLWB&ZQ-.U.L%<9TQYD]8(W>H]:%EK9+U":+;@MITS7T5KOB\>W>LS?H
MJMU3\=I%?2J67\]H Q(C<C-LRDK3#OC&;0-*R(5B 78^:A7@IHYLBX0TZJ,8
MAE34[  K(2P25YAEL+$-#4^FNUU/L\_QMHY(2W 8G48S9SX+&[0Y>O!#Z1LH
M10Y,2BI= *SCH/91QJSVTA&WFP2]S"W9%R,B(&)QQTM>%U+'5-"N%6Z;<L_5
M/G38F1RP-]W\_1ZK<P")Z8SRC!CQ# _E!]ON8_#@IOU]2*SIQ:Q,E%TNOWYS
M15(NZS5V?,V4B+"B6@[_I'>G#F4E]=-EVSIPRA#0)D'*/3;8C?=&U1;W8L5=
M%(*6\"PIQN +*NI-+_OY^DO9>/U8DPJ*1-1K)$:<H/<'$>.GRK9I<:<H7<CC
MG!;& &T4 ?]218,)Y8ZOAY:6-6 ;Q/,@_DWHW$B=%+41'"?$QUR'Y#?NG3-*
MNZ M7&3#G9):&&\>"&)84TFJ$;5F02263D PR1C;[JDL)T%,XP2N9N.9,_'F
M>PX8LCVZS??7PG,]G_9>L"&M>]SA]+H%PHJ0,R83>4]]2(+%T*S?Y#QLVA%_
M8Y_!<=U8WOFT=60?A>[F#>2IV+8GI$*2[\58X,PB_X? X+[C?;NAV>M8F^IQ
M*!.FY(M]\M^IO%A1JAO>Z+;&F;AL9!)#]DL0>!\U-/#[+L.N!P-@]S/V E5!
MLY<&2@(DI*D"HUDH8GK^JJ@UNZL4YE'=5LGD-O5,8B63!@^LX71H5+K=;P"]
M?N<X8= LKWP?:F A[U&HR3;K'P/7;/8WANM]US4\'BBPY".1&F[WEIM$K0BA
M9<TEV&8<BLVJ:A!JCY9,#9/IZ<,83UP_^+MAW-N031GFCWBPJ=3?%93!7YG+
MH1N&?S?@I@\')T+)-B)-GP/S;6OP0^'Z<*ABR_<?9#[C?3!<N7,ZU"<.YC==
M;[N*H"@K& Y\<ZBY?D38_T3O_=P&O9DS0]/<O/QHT*8#K'H7^ZZO,NTX->VE
M. 8DV83.:6YZJHW,UW!F/.P&>!.2VYZ P-M2&\Y9MJ#W,L^YT??"B__;?U:]
MNX#ZQV;^SB]6H.FC!YK_DAA@K=KKCS4C!Q2/S3@^LVGSVAMF>_? <!.O=L\]
MN/IDKXJZ0A1PE%,<+]"NYGQD@Z=SY+8H.>$\=&;^I+US C(%UV-@/'>\R;@W
M,''G@?BG9=))-.&4[X;'+K87010PF?97>3,Z4EZIA-8]"[S(\>>3T]Z4F3N>
MBV=^X#O!Q#L=J!+.Q-NV&WYF.N#^#-\-9ECJ3YU)M#L0BD]#'!"K+0)H'X/0
M\7Q_H"KV\T<A:<#=(8FF,Q:^,YN,G6 ZE#@.,#"%XMXX&J(2M)=$0ZLB1=*P
MHFARLX:_:7M;EW9K2ZFW2LHEV,S8P'6N353>WS%)E\_%6?NF1-PEU(?#<#3"
MWA.6))D&B:A0P\Z$3LJO9RNMZ-4,'9^!S>A0NCW8#MSI[ D_(T0O_>2(,G[D
M /:I;V8&[C@\.M,H[ &=)_;7;'QL<N"1BG3^\(UVKL B35:=;A,6,'6#B:6E
M _;QCEW<%/1>)"6.9>N U)H ;R3-(J/,/#ANX07/B"P:\\D#%D:AF1A%]UEW
M_-S#\K"IS;>6G,X:BNF.8K&7J[1<5C4$<U6R[-\G DL5=.1%KQD:+@\C9XHL
M:XBDZ92PXPH\Q&BU08QSW<L+\D!B]XOFY#4I@?S4LRX(I\8%SN"4P9391OF6
M'X\V,%6O*#?:[-6>HUO1839 OY/ G4T=VB9$]DCD)'(Q9ZCB8XZ>&*VYY\R]
MR9!A(;-/"OV.PIYXV/UK5N3JSIY\V /BMJ%#YL'&,EEV2)SXKM_T:A=T5I6J
MPR6;3.[T]!U_-@>+18_2DBGFQ]0,.S6-L^L<F[=BG2=_[C8NE,,Y:AHR8%FG
M_.*K.Z>C.#@S8C-5;0K#>N9$H6C9UY( ^D-NNX[T, <B8:<1'KM>H[5#.YQ)
M=\51,NW?Z4>+&4^&NBPH'5N;;2^XE[%=<PAZ])ML"=RY#6M#L?[A-'IG":2?
M 0=,'>Y\2"G-+5H7($@)OV=ZT&U7K>E^M[GB+<6Q-M1ZD][%[[_[("WD DB<
MT<$\;G?[K[^J';8'5D!A.D2!#HZ&&,PBE&OOZ$GEZ//U%WI%\H6^=Z X@UPP
MI\3>"B,P$ 6F5%6%1+('M_VS*=BZLQ<R>4$'G[W-0K=!>!P!3>;.)(CV=EF<
MP=;"NJ=O=TK&S[4'M?0"03.;]]F!9CCW4\Q0E:DS&\^^2Q4T1Z$_[73I2>MI
MR1)ZFNV&_<& YWBSR=(<BNR&GK'P8&H\&-_-^:/,BMJ<CI],VJ-29-#,:Z],
M LW'O>&=2I.VQ617Q8?UD%IU:AOB;+ZDX6?'&?H!\U7'C6J7N<=)<A 0#]+V
M7\#N<,O3Q[(Z?+Y/XWU'_ 1>IM2E2#N:D??FT-/2/?0%V'GO8[I,Z35_,DC?
M5"&:S'=U[=WVJ\1+\S%>-]U\TOA!:C2MI4C5"DO1-T]&YB.IYJ(JMOQIWJ*H
MJB+CGQLEX02:@/%5 >JU%_2 ]EO-5_\%4$L#!!0    ( *!;<E+['A'TQ (
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MIZ.!1U0SG1O%R(V;B"MI<+XZL< '#90UP/-<XAUK%1N@>R)GOP%02P,$%
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MU0CA!L>YXD?5*ELVS1$QH_;X)$61U3#+OD$2N?BTN%D4/UY?O[]XN)C V9.
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MK0FP)(M*6<\'XE(J\P0V,CNN&?$UW'6R+5@@IPSGX)3SD<UYD5OXCBGA(PD
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M2[O3C[[&[DP)U;/',8HOTW]$P*&/]K7DC6&ZO.7=9H:Y9\,8$>?U24J5W#*
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M@T3)R9@Z20SVK8]A(V@J4^"\!J4QM<5H&T+3'+&61@I6#,D <2&C0;@^!BN
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M)Q<<0?!?.K.G/[@ [D%G=O1QJ\!FM_@"/-\8T-7R!2<(?X+C^_\&4$L#!!0
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M(X_(=OUO+UK4=N5>"HT+O'W,\8L)I&' ]RLA].YB%'3?8(O_ %!+ P04
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M-@#=#(M&L*KR#;I4EMK='PN:KZB= =WGBCY/*[@ W<2>_@%02P,$%     @
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MQ@O,#B"-/T$2)=$.OK0O,?5\Z<X2=Q"->J*1)QJ]07377EQ0!2Q4W3"Y^6C
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ME249\F9)NH_:!=!YH93=.NZ"[D\R_0U02P,$%     @ H%MR4N:#JO+] @
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MD4L(!1;6(3#:?N(%"N& *(T?6\R@#^D<A^<=^@?/G;@LF<$+);[QTM:S8!)
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MMKMR)_Z+3=>:?2=R1\W^RF!K+*/+J:FQ[+J=;J!%X\[_C="FFW"7E>D00=H
M<W\KA'X>V 6&GG/Y/U!+ P04    " "@6W)2Z,U>F;L"   2"P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S-2YX;6R]5EUKVS 4_2O",-@@Q);SU98DT#8;
M*[0LM&Q[&'M0[.M$5!^N)#<M[,?O2DGM#!:GL#4OMB3KGG.NCG6YX[4V]W8%
MX,B3%,I.HI5SY5D<VVP%DMFN+D'AET(;R1Q.S3*VI0&6AR IXC1)AK%D7$73
M<5B;F^E85TYP!7-#;"4E,\\7(/1Z$M'H9>&6+U?.+\33<<F6< ?N:SDW.(MK
ME)Q+4)9K10P4D^B<GEW0H0\(.[YQ6-N=,?&I++2^]Y.K?!(E7A$(R)R'8/AZ
MA$L0PB.ACH<M:%1S^L#=\0OZIY \)K-@%BZU^,YSMYI$)Q')H6"5<+=Z_1FV
M"0T\7J:%#4^RWNY-(I)5UFFY#48%DJO-FSUM#V(G@/;W!*3;@#3HWA %E3/F
MV'1L])H8OQO1_""D&J)1'%?>E3MG\"O'.#>]XTO%"YXQY<AYENE*.:Z69*X%
MSSA8\GX&CG%A/XQCAW0^*,ZVT!<;Z'0/] RR+NG1#DF3-/DS/$:5M=2TEIH&
MO/X>O"\%Z@125$9Q5QD@3.4$'BI>XE_BR(\;D LP/\DO<L,5EY6LEUK(>S5Y
M+Y#W]I#/#5X$XYX[9"[\67GNCPWW-6XG5PZD;2/KUV3]UDQ;R3ID!G@!,\[\
M;XU;P&2XC%?H;Q:U$XVZ2?*N1?"@%CSX7]:PI]=:,ZS)AV]OS:@F&QW+FG8B
M.CS@S4FM^*05Z%++LG* E5@7;LT,=$BHB48KG@7]$G(L .*?[])IK>CT[0VC
M25/ADF-9=H")#@YX1G?*,GU3UUY_S6A3?VEZ!-^:BDM[1_.MG:G7.^1;4[EI
M>T6]!FP15EKDA,O2Z$?P8NVK?&B*+1T<P8>FO-+AT7QH9Z+)/A_BG0['=XLW
MS"RYLD1 @4A)=X0G9C8-V&;B=!F:GH5VV$*%X0J;5C!^ WXOM'8O$]]'U6WP
M]#=02P,$%     @ H%MR4A[7X>"Q @  (@8  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL?57;;AHQ$/V5T4J56BFPL 0:18 $(5'SD H%)7VH^F"\
MPZZ%+UO;A/#W'7MA2RNR+ZPO,V?.&<\,X[VQ6U<B>GA74KM)4GI?W::IXR4J
MYKJF0DTW&V,5\[2U1>HJBRR/3DJF6:\W2A43.IF.X]G23L=FYZ70N+3@=DHQ
M>YBC-/M)TD].!\^B*'TX2*?CBA6X0O]2+2WMT@8E%PJU$T:#Q<TDF?5OYZ-@
M'PU>!>[=V1J"DK4QV[!YS"=)+Q!"B=P'!$:?-[Q#*0,0T?A]Q$R:D,'Q?'U"
M?XC:2<N:.;PS\H?(?3E);A+(<<-VTC^;_3<\ZAD&/&ZDB[^P/]KV$N [YXTZ
M.A,#)73]9>_'/)PY#(8?.&1'ARSRK@-%E@OFV71LS1YLL":TL(A2HS>1$SH\
MRLI;NA7DYZ<K46BQ$9QI#S/.S4Y[H0M8&BFX0 <=F.6Y" ED$AYU704AG9\7
MZ)F0[LLX]<0CH*7\&'->Q\P^B-G/X,EH7SJXUSGF_P*D)*!1D9U4S+-6Q 7R
M+@SZ5Y#ULI[#@JK&M\ .FN0,(NSU!["1I3S  BOCA'=@-G"O*FD.B.X*EF@Y
M!:+:!4K(R7C%)%7WI:RT![OI#@:?6DA?-Z2O6W&^[]0:;:!JB;;U;"T1+N:D
M9E6C#2-::.&W:7^<OET@,&P(#%L)/*/S5G"/.:R\X5OX^82!TJ\6<:,&>]2*
MO2J9Q4YHPQSNC*+1Y.IRG%G+=(%!)*SI$<[LENP0CV=[9O,K>&#"PBN3.X29
MHUE4!7]ZS2?TI<GAQ?U?D76:VGG-)>/;SHJ71E+3F(C9J2@+H9F4R5%>$I^>
M]:U"6\3IY"!V8=W"S6DS &=UW_\UKZ?G$[.%T XD;LBUU_U*;V3KB51OO*GB
M%%@;3S,E+DL:XFB# =UOC/&G30C0_"U,_P!02P,$%     @ H%MR4@_?]1IW
M @  ?0@  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULM59=;]HP%/TK
M5M2'5MI([(04JA!I!4VKU$D(UNUAVH,)%V+5B9EMH)/VXV<[:4A72EL)7A)_
MW'/N/2>);Y*MD/<J!]#HH>"E&GBYUJLKWU=9#@55';&"TNPLA"RH-E.Y]-5*
M IT[4,%]$@2Q7U!6>FGBUL8R3<1:<U;"6"*U+@HJ_UP#%]N!A[W'A0E;YMHN
M^&FRHDN8@KY;C:69^0W+G!50*B9*)&$Q\#[AJR$F%N BOC/8JM8862DS(>[M
MY&8^\ );$7#(M*6@YK:!(7!NF4P=OVM2K\EI@>WQ(_MG)]Z(F5$%0\%_L+G.
M!U[/0W-8T#77$['] K6@KN7+!%?NBK95;$P\E*V5%D4--A44K*SN]*$VH@7
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MS<.25:^K)EJL7+N8"6V:CQOFYO\ I TP^PLA]./$=J#FCR/]!U!+ P04
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M[+Y XV=D^!+!E?TENSHWU!632J'(&[".<U;47[IO]N$(X \O ((&$+P7,&@
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M<;"_ 8*/)[[$OLL\#AHD:Y<.;I4<$_D?:<?[<L<GUCO>%SS^8,67N'I$HJ:
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MJ)T#[:^5LGO#C8KF4S+^!U!+ P04    " "@6W)2^S:H1JL"  "B!P  &0
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MF3<88"32^EU&TG;4N_Q^O?KJH4  K*^[.ZR+C0PF8<>%TD89]%#')=I&"0#
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M:S(X6.4@#L)!PL8@?^8G@WR-04D8V],5]XKB246WM*+\1.#QR!T)HL$>6EE
M)/8'@8]!.,21/?*DCSR9CERR[/Z-+D(YREBM$VY285.2C/S'$1X(L6!&.L:8
MX.#H'<G WG-)\,X_,:J;R!2@S&@UM:<ZDT<K&D>#<%<V5!(.[HK4@DK"$[<
M/BAT>/JHG*,"C^/S"0F&,L:PV)^%0QECE!]$P0D=Y%D'^45V-OJ,L^[,,UD
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M#!)+3H%\P4/&LR*48_G2-(3&4ROD_#I$OT(H3J9WR.DV4_H5I=]*^2 P2Z8
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MHNU@GL^%T \-^QY??*P:_0]02P,$%     @ H%MR4O?;CR."!   QQ,  !D
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M&[/\Z_?6[36M==D<\EGW<<#D$U!+ 0(4 Q0    ( *!;<E('04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ H%MR4ODI9(3O    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ H%MR4IE<G",0!@  G"<  !,
M     ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "@6W)2
M3D+R#2(&  #V&P  &               @($."   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ H%MR4K^)5@<&!0  #Q,  !@
M     ("!9@X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M *!;<E*)&5-X7@(  *@&   8              " @:(3  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " "@6W)2223-L>0#   Y#0  &
M            @($V%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ H%MR4LU'B-#  @  R <  !@              ("!4!H  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( *!;<E*Z'K*&804   L8
M   8              " @48=  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " "@6W)2EJ(BCYH'   +'P  &               @('=(@
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ H%MR4G\D0;[G
M!0  60X  !@              ("!K2H  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( *!;<E(?4;ITB!P  #%9   8              "
M@<HP  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "@6W)2
M?>SSG,H$  #_$   &0              @(&(30  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( *!;<E*9;H-"3@(  ,,%   9
M      " @8E2  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ H%MR4A(@%Q0[!   / H  !D              ("!#E4  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "@6W)2VFP)>)L"  !S!@
M&0              @(& 60  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( *!;<E(1#TH:8 8  .X/   9              " @5)<  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ H%MR4C4Z]%:M
M @  # 8  !D              ("!Z6(  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " "@6W)2?3V]F04$   ."0  &0
M@('-90  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( *!;
M<E*J"XB-K P  +<I   9              " @0EJ  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ H%MR4OL>$?3$ @  &0<  !D
M         ("!['8  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " "@6W)2=O)YI=8"   N!P  &0              @('G>0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( *!;<E*>0[I\E (  &D&
M   9              " @?1\  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ H%MR4LO(%<NL!P  "14  !D              ("!OW\
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "@6W)2_]!7
MW"T#  !'!P  &0              @(&BAP  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( *!;<E(KP?=3!!X  (YC   9
M  " @0:+  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
MH%MR4M^:3?:\ @  %@8  !D              ("!0:D  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " "@6W)2:E8 Y*\#  "/#0  &0
M            @($TK   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( *!;<E+P,)!#:@(  +T%   9              " @1JP  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ H%MR4D6SN9.# @
M+08  !D              ("!N[(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " "@6W)2ER2+Q*,"  !5!@  &0              @(%U
MM0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( *!;<E+F
M@ZKR_0(  (X'   9              " @4^X  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ H%MR4HL7%E_3 @  ] 8  !D
M     ("!@[L  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *!;<E+HS5Z9NP(  !(+   9              "
M@7S,  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ H%MR
M4A[7X>"Q @  (@8  !D              ("!;L\  'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " "@6W)2#]_U&G<"  !]"   &0
M        @(%6T@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( *!;<E*-D/1-]0,  "80   9              " @035  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ H%MR4@0' 015 @  ,P8
M !D              ("!,-D  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " "@6W)2.KW>Y)$#  #3"@  &0              @(&\VP
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( *!;<E*DNDAK
MH@(  *P(   9              " @83?  !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ H%MR4C#% 4K" @  30@  !D
M ("!7>(  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "@
M6W)2N+Q@:XL"  !6!@  &0              @(%6Y0  >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( *!;<E+[-JA&JP(  *('   9
M          " @1CH  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#
M%     @ H%MR4FX 4SUH @  PP4  !D              ("!^NH  'AL+W=O
M<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " "@6W)27PKG?*($  "Y
M$P  &0              @(&9[0  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM
M;%!+ 0(4 Q0    ( *!;<E+1ZR)A6@L  -Y'   9              " @7+R
M  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ H%MR4KQQ
MOV=T P  5 P  !D              ("! _X  'AL+W=O<FMS:&5E=',O<VAE
M970T."YX;6Q02P$"% ,4    " "@6W)2,^+M(8@#  !J#   &0
M    @(&N 0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M *!;<E+[@ /KYP(  +P(   9              " @6T% 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ H%MR4C1[0Z 9 P  60H  !D
M             ("!BP@! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " "@6W)2^D9,%H$#  !U"@  &0              @(';"P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( *!;<E+GQM@QYP,
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( *!;<E(ZF)U$; 0  -@C   /
M      "  >H; 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "@6W)2#Y14
M2-H!  !9(   &@              @ &#( $ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " "@6W)2(5VG)LT!   D(   $P
M    @ &5(@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /@ ^ .D0  "3
%) $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>114</ContextCount>
  <ElementCount>312</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00500 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureGeneral</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Marketable debt securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureMarketableDebtSecurities</Role>
      <ShortName>Marketable debt securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Other Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivable</Role>
      <ShortName>Other Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpenses</Role>
      <ShortName>Research and Development Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpenses</Role>
      <ShortName>General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Financial income, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureFinancialIncomeNet</Role>
      <ShortName>Financial income, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Marketable debt securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesTables</Role>
      <ShortName>Marketable debt securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureMarketableDebtSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Other Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableTables</Role>
      <ShortName>Other Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivable</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureLeases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureShareholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Research and Development Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesTables</Role>
      <ShortName>Research and Development Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31203 - Disclosure - General and Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesTables</Role>
      <ShortName>General and Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Financial income, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetTables</Role>
      <ShortName>Financial income, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureFinancialIncomeNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40101 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureGeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Marketable debt securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails</Role>
      <ShortName>Marketable debt securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Marketable debt securities - summarizes the marketable debt securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails</Role>
      <ShortName>Marketable debt securities - summarizes the marketable debt securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Other Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails</Role>
      <ShortName>Other Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Leases - Company's Significant Contractual Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails</Role>
      <ShortName>Leases - Company's Significant Contractual Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Property and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureRevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureRevenue</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureRelatedParties</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Shareholders' Equity - Company's Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails</Role>
      <ShortName>Shareholders' Equity - Company's Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Shareholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Shareholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41201 - Disclosure - General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails</Role>
      <ShortName>General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Financial income, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails</Role>
      <ShortName>Financial income, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Income Taxes - Components of Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Income Taxes - Reconciliation of the Company's Effective Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Company's Effective Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41403 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tmb-20201231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galmedpharma.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="tmb-20201231x20f.htm">tmb-20201231x20f.htm</File>
    <File>tmb-20201231.xsd</File>
    <File>tmb-20201231_cal.xml</File>
    <File>tmb-20201231_def.xml</File>
    <File>tmb-20201231_lab.xml</File>
    <File>tmb-20201231_pre.xml</File>
    <File>tmb-20201231xex12d1.htm</File>
    <File>tmb-20201231xex12d2.htm</File>
    <File>tmb-20201231xex13d1.htm</File>
    <File>tmb-20201231xex15d1.htm</File>
    <File>tmb-20201231xex4d11.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tmb-20201231x20f002.jpg</File>
    <File>tmb-20201231x20f003.jpg</File>
    <File>tmb-20201231x20f004.jpg</File>
    <File>tmb-20201231x20f005.jpg</File>
    <File>tmb-20201231x20f007.jpg</File>
    <File>tmb-20201231x20f008.jpg</File>
    <File>tmb-20201231x20f009.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tmb-20201231x20f.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "contextCount": 114,
   "dts": {
    "calculationLink": {
     "local": [
      "tmb-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20201231x20f.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "tmb-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 391,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 9,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 15
   },
   "keyCustom": 27,
   "keyStandard": 285,
   "memberCustom": 11,
   "memberStandard": 24,
   "nsprefix": "glmd",
   "nsuri": "http://www.galmedpharma.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document And Entity Information",
     "role": "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Marketable debt securities",
     "role": "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecurities",
     "shortName": "Marketable debt securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Other Accounts Receivable",
     "role": "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivable",
     "shortName": "Other Accounts Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Leases",
     "role": "http://www.galmedpharma.com/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Property and equipment, net",
     "role": "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glmd:RevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Revenue",
     "role": "http://www.galmedpharma.com/role/DisclosureRevenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glmd:RevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Related Parties",
     "role": "http://www.galmedpharma.com/role/DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Commitments and Contingencies",
     "role": "http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Shareholders' Equity",
     "role": "http://www.galmedpharma.com/role/DisclosureShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Research and Development Expenses",
     "role": "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpenses",
     "shortName": "Research and Development Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glmd:GeneralAndAdministrativeExpensesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - General and Administrative Expenses",
     "role": "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpenses",
     "shortName": "General and Administrative Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glmd:GeneralAndAdministrativeExpensesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "role": "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Financial income, net",
     "role": "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNet",
     "shortName": "Financial income, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Income Taxes",
     "role": "http://www.galmedpharma.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Subsequent events",
     "role": "http://www.galmedpharma.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glmd:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glmd:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Marketable debt securities (Tables)",
     "role": "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesTables",
     "shortName": "Marketable debt securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Other Accounts Receivable (Tables)",
     "role": "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableTables",
     "shortName": "Other Accounts Receivable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Leases (Tables)",
     "role": "http://www.galmedpharma.com/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Property and equipment, net (Tables)",
     "role": "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.galmedpharma.com/role/DisclosureShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_ILS_shares_E36EhjGGZkK6K8BwwH-6kA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_ILS_shares_E36EhjGGZkK6K8BwwH-6kA",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Research and Development Expenses (Tables)",
     "role": "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesTables",
     "shortName": "Research and Development Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "glmd:GeneralAndAdministrativeExpensesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glmd:GeneralAndAdministrativeExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - General and Administrative Expenses (Tables)",
     "role": "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesTables",
     "shortName": "General and Administrative Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "glmd:GeneralAndAdministrativeExpensesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glmd:GeneralAndAdministrativeExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - Financial income, net (Tables)",
     "role": "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetTables",
     "shortName": "Financial income, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31403 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.galmedpharma.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glmd:EntityIncorporationDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - General (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureGeneralDetails",
     "shortName": "General (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glmd:EntityIncorporationDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "glmd:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vDGTRGTNSU-DSOCOXQYOmw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "glmd:PropertyPlantAndEquipmentDepreciationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Significant Accounting Policies (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "shortName": "Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "glmd:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vDGTRGTNSU-DSOCOXQYOmw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "glmd:PropertyPlantAndEquipmentDepreciationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationRelatedCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "glmd:MonthlyDepositsOfEmployeesPercentageOnMonthlySalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationRelatedCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "glmd:MonthlyDepositsOfEmployeesPercentageOnMonthlySalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Marketable debt securities (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails",
     "shortName": "Marketable debt securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fI3z7-XQOUCnOyty6hbt5A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Marketable debt securities - summarizes the marketable debt securities (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails",
     "shortName": "Marketable debt securities - summarizes the marketable debt securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "glmd:ReceivablesFromGovernmentInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Other Accounts Receivable (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails",
     "shortName": "Other Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "glmd:ReceivablesFromGovernmentInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements of Operations",
     "role": "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_sqft_dThMR2ywAUCT7W6wxsLiYA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_sqft_dThMR2ywAUCT7W6wxsLiYA",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Leases - Company's Significant Contractual Lease Obligations (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails",
     "shortName": "Leases - Company's Significant Contractual Lease Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "glmd:MedicalEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Property and equipment, net (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "shortName": "Property and equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "glmd:MedicalEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "glmd:RevenueTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_7_28_2016_To_7_28_2016_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_YaFu1dKFek-a9yFU3cmXPA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "glmd:RevenueRecognitionMilestoneMethodRevenuesRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Revenue (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureRevenueDetails",
     "shortName": "Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "glmd:RevenueTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_7_28_2016_To_7_28_2016_dei_LegalEntityAxis_glmd_SamilPharmCoLtdMember_YaFu1dKFek-a9yFU3cmXPA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "glmd:RevenueRecognitionMilestoneMethodRevenuesRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_wpVjGpd6BEGCzRJ_fPNzXQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Related Parties (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails",
     "shortName": "Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_wpVjGpd6BEGCzRJ_fPNzXQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "glmd:BankLienOnMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "glmd:BankLienOnMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_11_1_2020_To_11_30_2020_UyKYU53TnkCIrFxxVf4vHQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Shareholders' Equity - Company's Option Plans (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails",
     "shortName": "Shareholders' Equity - Company's Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_fgIJ67ohKEO6itu-nYJBww",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Shareholders' Equity - Additional Information (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
     "shortName": "Shareholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Research and Development Expenses (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails",
     "shortName": "Research and Development Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_R6DmOF0RC0aqPuXMd5r6Rg",
      "decimals": "-3",
      "lang": null,
      "name": "glmd:ChemistryAndFormulationStudiesExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - General and Administrative Expenses (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails",
     "shortName": "General and Administrative Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "glmd:GeneralAndAdministrativeExpensesTableTextBlock",
       "glmd:GeneralAndAdministrativeExpensesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZBDijHYne0eWl1duaJFl8g",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2018_To_12_31_2018_eF-AacRn-UOPyNZmeqlMaw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "glmd:BankFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Financial income, net (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails",
     "shortName": "Financial income, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "glmd:BankFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Income Taxes - Components of Income Tax (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails",
     "shortName": "Income Taxes - Components of Income Tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41402 - Disclosure - Income Taxes - Reconciliation of the Company's Effective Tax Expense (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails",
     "shortName": "Income Taxes - Reconciliation of the Company's Effective Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_FVi-Zc_wS0WBhSsJZ2YUGA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41403 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2020_wJfr1VV8-Uq9Ph5EwuqhCA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Subsequent events (Details)",
     "role": "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_3_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_d2nXIm0PHEKT0HYx5C-QMw",
      "decimals": "0",
      "lang": null,
      "name": "glmd:AggregateQuarterlyRentalPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_ILS_80PDI-Ft8k2W61vPNXVwKw",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IfcP6tZx7UKE8vBKiQjAlQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "role": "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IfcP6tZx7UKE8vBKiQjAlQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - General",
     "role": "http://www.galmedpharma.com/role/DisclosureGeneral",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Significant Accounting Policies",
     "role": "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20201231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_YvRz7trJQUiWKIIHUhTAEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document And Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "glmd_AggregateQuarterlyRentalPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate quarterly rental payment, together with adjustments and the maintenance fees.",
        "label": "Aggregate Quarterly Rental Payment",
        "terseLabel": "Aggregate quarterly rental payment"
       }
      }
     },
     "localname": "AggregateQuarterlyRentalPayment",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_AtthemarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Atthemarket Offering [Member]",
        "terseLabel": "At-The-Market Offering [Member]"
       }
      }
     },
     "localname": "AtthemarketOfferingMember",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glmd_BankFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as bank fees.",
        "label": "Bank Fees",
        "terseLabel": "Bank Fees"
       }
      }
     },
     "localname": "BankFees",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_BankLienOnMarketableSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "These lines are represents that lien on marketable securities.",
        "label": "Bank Lien On Marketable Securities"
       }
      }
     },
     "localname": "BankLienOnMarketableSecurities",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_CarLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to car leases.",
        "label": "Car Leases [Member]",
        "terseLabel": "Car Leases [Member]"
       }
      }
     },
     "localname": "CarLeasesMember",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glmd_ChemistryAndFormulationStudiesExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that, the amount of chemistry and formulation studies expenses under research and development.",
        "label": "Chemistry and Formulation Studies, Expenses",
        "verboseLabel": "Chemistry and formulation studies"
       }
      }
     },
     "localname": "ChemistryAndFormulationStudiesExpenses",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_ClinicalStudiesExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that, the amount of clinical studies expenses under research and development.",
        "label": "Clinical Studies, Expenses",
        "verboseLabel": "Clinical studies"
       }
      }
     },
     "localname": "ClinicalStudiesExpenses",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets And Liabilities [Line Items]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glmd_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets And Liabilities [Table]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesTable",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glmd_ComputerSoftwareElectronicAndMedicalEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Software Electronic And Medical Equipment [Member]",
        "terseLabel": "Computer software, electronic and medical equipment [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareElectronicAndMedicalEquipmentMember",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glmd_ContractualObligationDueInFirstToThirdYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation due in the first to third fiscal year following the latest fiscal year.",
        "label": "Contractual Obligation, Due in First To Third Year",
        "terseLabel": "1-3 years"
       }
      }
     },
     "localname": "ContractualObligationDueInFirstToThirdYear",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_EmployeeStockOptionAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option And Restricted Stock Units [Member]",
        "terseLabel": "Employee Stock Option And Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionAndRestrictedStockUnitsMember",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glmd_EntityIncorporationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of Incorporation of the Entity.",
        "label": "Entity Incorporation Date",
        "terseLabel": "Date Of Incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDate",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "glmd_EntityIncorporationPlace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Place incorporation.",
        "label": "Entity Incorporation Place"
       }
      }
     },
     "localname": "EntityIncorporationPlace",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glmd_FacilityLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facility Leases [Member]",
        "terseLabel": "Facility Leases [Member]"
       }
      }
     },
     "localname": "FacilityLeasesMember",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glmd_GeneralAndAdministrativeExpensesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for general and administrative expenses.",
        "label": "General and Administrative Expenses Disclosure [Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpensesDisclosureTextBlock",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glmd_GeneralAndAdministrativeExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses [Line Items]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpensesLineItems",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glmd_GeneralAndAdministrativeExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses [Table]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpensesTable",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glmd_GeneralAndAdministrativeExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of general and administrative expenses.",
        "label": "General and Administrative Expenses [Table Text Block]",
        "terseLabel": "Schedule of general and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpensesTableTextBlock",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glmd_IncentiveShareOptionPlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Share Option Plan2013 [Member]",
        "terseLabel": "Incentive Share Option Plan 2013 [Member]"
       }
      }
     },
     "localname": "IncentiveShareOptionPlan2013Member",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glmd_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glmd_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glmd_InterestsIncomeOnShortTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Interest Income On Short Term Deposits.",
        "label": "Interests Income on Short Term Deposits",
        "negatedLabel": "Interest income from short-term deposits"
       }
      }
     },
     "localname": "InterestsIncomeOnShortTermDeposits",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_IsraeliSubsidiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Israeli Subsidiary [Member]",
        "terseLabel": "Israeli Subsidiary [Member]"
       }
      }
     },
     "localname": "IsraeliSubsidiaryMember",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glmd_LesseeOperatingLeaseNumberOfOptionToExtend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of options to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Number of Option to Extend",
        "terseLabel": "Number of additional options to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfOptionToExtend",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "glmd_MalteseSubsidiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maltese Subsidiary [Member]",
        "terseLabel": "Maltese subsidiary [Member]"
       }
      }
     },
     "localname": "MalteseSubsidiaryMember",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glmd_MaximumAmountOfSharesToBeIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares to be issued in the offering.",
        "label": "Maximum Amount Of Shares To Be Issued"
       }
      }
     },
     "localname": "MaximumAmountOfSharesToBeIssued",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_MaximumAmountOfSharesToBeIssuedOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of shares to be issued in the offering.",
        "label": "Maximum Amount of Shares to be Issued, Offering",
        "terseLabel": "Ordinary shares offered"
       }
      }
     },
     "localname": "MaximumAmountOfSharesToBeIssuedOffering",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_MedicalEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used in the normal conduct of business.",
        "label": "Medical Equipment, Gross",
        "verboseLabel": "Medical equipment"
       }
      }
     },
     "localname": "MedicalEquipmentGross",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of monthly deposits from the employees on their monthly salary for severance pay.",
        "label": "Monthly Deposits of Employees, Percentage on Monthly Salary",
        "terseLabel": "Monthly Deposits of Employees, Percentage on Monthly Salary"
       }
      }
     },
     "localname": "MonthlyDepositsOfEmployeesPercentageOnMonthlySalary",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "glmd_OfficersAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers And Directors [Member]",
        "terseLabel": "Officers And Directors [Member]"
       }
      }
     },
     "localname": "OfficersAndDirectorsMember",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glmd_PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Policy disclosure of presentational currency of financial statements.",
        "label": "Presentation Currency of Financial Statements Policy [Policy Text Block]",
        "terseLabel": "Financial statement in U.S. dollars"
       }
      }
     },
     "localname": "PresentationCurrencyOfFinancialStatementsPolicyPolicyTextBlock",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glmd_PropertyPlantAndEquipmentDepreciationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents property plant and equipment depreciation percentage.",
        "label": "Property, Plant and Equipment, Depreciation, Percentage"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDepreciationPercentage",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "glmd_ReceivablesFromGovernmentInstitutions": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount receivable from government institutions.",
        "label": "Receivables from Government Institutions",
        "verboseLabel": "Government institutions"
       }
      }
     },
     "localname": "ReceivablesFromGovernmentInstitutions",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_RegulatoryAndOtherExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that, the amount of Regulatory and other expenses under research and development.",
        "label": "Regulatory and Other Expenses",
        "terseLabel": "Regulatory and other expenses"
       }
      }
     },
     "localname": "RegulatoryAndOtherExpenses",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_ResearchAndDevelopmentExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesLineItems",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glmd_ResearchAndDevelopmentExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses [Table]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesTable",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glmd_ResearchAndPreclinicalStudiesExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that, the amount of research and preclinical studies expenses under research and development.",
        "label": "Research and preclinical studies, Expenses",
        "verboseLabel": "Research and preclinical studies"
       }
      }
     },
     "localname": "ResearchAndPreclinicalStudiesExpenses",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_RevenueRecognitionMilestoneMethodRevenuesRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of consideration recognized during the period for the milestones.",
        "label": "Revenue Recognition Milestone Method Revenues Recognized",
        "verboseLabel": "Milestone Method Revenue Payment"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodRevenuesRecognized",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_RevenueRecognitionNonRefundableUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The non refundable amount of consideration recognized during the period for the milestone or milestones.",
        "label": "Revenue Recognition Non Refundable Upfront Payment"
       }
      }
     },
     "localname": "RevenueRecognitionNonRefundableUpfrontPayment",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glmd_RevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue",
        "label": "Revenue [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueTextBlock",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glmd_SamilPharmCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Samil Pharm Co Ltd [Member]",
        "terseLabel": "Samil Pharm. Co. Ltd [Member]"
       }
      }
     },
     "localname": "SamilPharmCoLtdMember",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glmd_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the depreciation rates for property, plant and equipment.",
        "label": "Schedule of Depreciation Rates for Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of depreciation rates for property, plant and equipment"
       }
      }
     },
     "localname": "ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glmd_UnderwritersOptionExercisableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of option exercisable by underwriters during the period.",
        "label": "Underwriters, Option Exercisable Term",
        "terseLabel": "Option exercisable period"
       }
      }
     },
     "localname": "UnderwritersOptionExercisableTerm",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "glmd_UnderwritersOptionToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares to be purchased by the underwriters.",
        "label": "Underwriters, Option to Purchase Additional Shares",
        "terseLabel": "Additional shares to purchase"
       }
      }
     },
     "localname": "UnderwritersOptionToPurchaseAdditionalShares",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "glmd_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering [Member]"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.galmedpharma.com/20201231",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chief executive officer.",
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails",
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]",
        "verboseLabel": "Summary of Company's significant contractual lease obligations"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r205",
      "r207",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r205",
      "r207",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r195",
      "r205",
      "r207",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r195",
      "r205",
      "r207",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r162",
      "r206",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r136",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Other accounts receivable"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r9",
      "r39"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other accounts payable"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r9",
      "r39"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "verboseLabel": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r367",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r153"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "verboseLabel": "Less - Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r48",
      "r49",
      "r50",
      "r375",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r93",
      "r94",
      "r95",
      "r280",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r28",
      "r239"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r236",
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional paid-in capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation and Exercise of Stock Options",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r209",
      "r232",
      "r241"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      },
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails",
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails",
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r64",
      "r77",
      "r311"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "verboseLabel": "Amortization of discount/premium on marketable debt securities"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Area of land under operating lease agreement"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r87",
      "r117",
      "r126",
      "r131",
      "r146",
      "r275",
      "r281",
      "r298",
      "r361",
      "r374"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r45",
      "r87",
      "r146",
      "r275",
      "r281",
      "r298"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r87",
      "r146",
      "r275",
      "r281",
      "r298"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r141",
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Equity Securities, Amortized Cost Basis",
        "verboseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Equity Securities, Gross Unrealized Gain",
        "verboseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Equity Securities, Gross Unrealized Loss",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r139",
      "r142",
      "r148",
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities",
        "terseLabel": "Marketable debt securities",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails",
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r210",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDevelopment": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.",
        "label": "Business Development",
        "verboseLabel": "Investor relations and business development expenses"
       }
      }
     },
     "localname": "BusinessDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Capitalized Computer Software, Gross",
        "verboseLabel": "Computer software and electronic equipment"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r35",
      "r79"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r81",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r13",
      "r81",
      "r85",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r73",
      "r79",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at the end of the year",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at the beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r73",
      "r303"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash transactions:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial papers [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Ordinary shares, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Ordinary shares, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Ordinary shares, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r26",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Ordinary shares, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Ordinary shares par value NIS 0.01 per share; Authorized 50,000,000 shares; Issued and outstanding: 000 shares as of December 31, 2020; 21,139,385 shares as of December 31, 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Severance pay"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "verboseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r59",
      "r369",
      "r382"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "negatedTotalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r106",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue Disclosure [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, Due in Next Fiscal Year",
        "terseLabel": "Less than 1 year"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r196",
      "r204",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Gain (Loss)",
        "negatedLabel": "Gain from sale of marketable debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r259",
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Deferred tax assets, capital loss carry forwards",
        "verboseLabel": "Capital-loss carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "verboseLabel": "Total deferred-tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred-tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r259",
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net-operating-loss carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r259",
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "verboseLabel": "Other reserves and allowances"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r254"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r77",
      "r115"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r91",
      "r327",
      "r366",
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r249",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Effective income tax rate reconciliation, at federal statutory income tax rate, percent",
        "verboseLabel": "Statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r97",
      "r98",
      "r100",
      "r103",
      "r147",
      "r174",
      "r175",
      "r236",
      "r237",
      "r238",
      "r262",
      "r263",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r291",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r196",
      "r197",
      "r202",
      "r204",
      "r291",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r196",
      "r197",
      "r202",
      "r204",
      "r291",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r85",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Foreign currency (gains) losses"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures, Gross",
        "verboseLabel": "Office furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteeOfIndebtednessOfOthersMember": {
     "auth_ref": [
      "r169",
      "r273",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreements (contracts) that contingently require the guarantor to make payments of principal and interest to a lender on another party's debt if that party fails to comply with the terms of the borrowing arrangement.",
        "label": "Guarantee Of Indebtedness Of Others [Member]",
        "terseLabel": "Guarantee of Indebtedness of Others [Member]"
       }
      }
     },
     "localname": "GuaranteeOfIndebtednessOfOthersMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r151",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r90",
      "r117",
      "r125",
      "r127",
      "r130",
      "r132"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "negatedLabel": "Loss before taxes on income, as reported in the consolidated statements of operations",
        "negatedTotalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.",
        "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share",
        "verboseLabel": "Basic and diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails",
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails",
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r250",
      "r251",
      "r257",
      "r264",
      "r267",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r99",
      "r100",
      "r116",
      "r248",
      "r265",
      "r268",
      "r383"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income taxes",
        "totalLabel": "Actual tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r85",
      "r246",
      "r247",
      "r251",
      "r252",
      "r256",
      "r261",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "verboseLabel": "Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "verboseLabel": "Theoretical tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "verboseLabel": "Tax withheld from upfront payment from Samil"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesReconciliationOfCompanySEffectiveTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r74",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Decrease (increase) in other accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "verboseLabel": "Increase (decrease) in trade payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Decrease in deferred revenue from collaboration agreement"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "verboseLabel": "Increase (decrease) in other accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "verboseLabel": "Rent and office-maintenance fees"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseDepositLiability": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease.",
        "label": "Lease Deposit Liability",
        "terseLabel": "Bank guarantee"
       }
      }
     },
     "localname": "LeaseDepositLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r8",
      "r152"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "verboseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r87",
      "r146",
      "r298",
      "r362",
      "r377"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r87",
      "r146",
      "r276",
      "r281",
      "r282",
      "r298"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r23",
      "r24",
      "r87",
      "r146",
      "r276",
      "r281",
      "r282",
      "r298"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "Other Accounts Receivable"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.",
        "label": "Loss Contingency Accrual, Provision",
        "terseLabel": "Bank guarantee, commitment"
       }
      }
     },
     "localname": "LossContingencyAccrualProvision",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "verboseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r3",
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss), Excluding Other than Temporary Impairments",
        "negatedLabel": "Loss (gain) on sale of marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable debt securities [Table Text Block]",
        "verboseLabel": "Schedule of marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MutualFundMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.",
        "label": "Mutual Fund [Member]",
        "terseLabel": "Mutual Fund [Member]"
       }
      }
     },
     "localname": "MutualFundMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flow from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flow from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r73",
      "r75",
      "r78"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Cash flow from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently adopted and issued accounting pronouncement"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office furniture and equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r117",
      "r125",
      "r127",
      "r130",
      "r132"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTotalLabel": "Total operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets",
        "verboseLabel": "Right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases, weighted average borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases, weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperationsCommencedDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the operations of the entity commenced, in CCYY-MM-DD format.",
        "label": "Operations Commenced Date"
       }
      }
     },
     "localname": "OperationsCommencedDate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "auth_ref": [
      "r173",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of options indexed to an issuer's equity.",
        "label": "Option Indexed to Issuer's Equity [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed To Issuers Equity Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneral"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureLeasesCompanySSignificantContractualLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss (income):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r48"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax",
        "negatedLabel": "Net unrealized loss (gain) on available for sale securities",
        "terseLabel": "Unrealized gain (loss) on marketable debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "verboseLabel": "Insurance and other"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Financial income, net",
        "negatedTotalLabel": "Financial income net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromShortTermInvestments": {
     "auth_ref": [
      "r67",
      "r68",
      "r80"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments for (Proceeds from) Short-term Investments",
        "negatedLabel": "Proceeds (investment) in short-term deposits, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r66",
      "r68",
      "r140"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Available-for-sale Securities",
        "negatedLabel": "Investment in securities, available for sale"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r210",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r149",
      "r150"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "verboseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest received on loans and other debt instruments during the current period.",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Cash received from interest"
       }
      }
     },
     "localname": "ProceedsFromInterestReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Total proceeds from sale of ordinary shares",
        "verboseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "verboseLabel": "Issuance of ordinary shares and warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r66",
      "r67",
      "r140"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Available-for-sale Securities",
        "verboseLabel": "Proceeds from sale of securities, available for sale"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r70",
      "r235"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "verboseLabel": "Professional fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r52",
      "r54",
      "r72",
      "r87",
      "r96",
      "r99",
      "r100",
      "r117",
      "r125",
      "r127",
      "r130",
      "r132",
      "r146",
      "r274",
      "r278",
      "r279",
      "r283",
      "r284",
      "r298",
      "r370"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss",
        "negatedTerseLabel": "Loss attributable to holders of its ordinary shares",
        "negatedTotalLabel": "Net loss",
        "terseLabel": "Net loss for the year",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r38",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r157",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r37",
      "r152"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r154",
      "r379"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Net book value",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r85",
      "r154",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r27",
      "r34",
      "r378",
      "r394"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "totalLabel": "Receivables, Net, Current"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r203",
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails",
      "http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r203",
      "r326",
      "r330",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxDetails",
      "http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r324",
      "r325",
      "r327",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock": {
     "auth_ref": [
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Table Text Block]",
        "terseLabel": "Schedule of research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r243",
      "r416"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r85",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r2",
      "r13",
      "r83"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r175",
      "r239",
      "r376",
      "r389",
      "r391"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r97",
      "r98",
      "r100",
      "r147",
      "r236",
      "r237",
      "r238",
      "r262",
      "r263",
      "r386",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial income, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Financial income, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r58",
      "r87",
      "r113",
      "r114",
      "r124",
      "r128",
      "r129",
      "r133",
      "r134",
      "r135",
      "r146",
      "r298",
      "r370"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r318",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Recognition of right-of-use asset and lease liabilities from adoption of ASU 2016-02"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      },
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "terseLabel": "Salaries",
        "verboseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralAndAdministrativeExpensesDetails",
      "http://www.galmedpharma.com/role/DisclosureResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The scenario under which facts represent plans as distinct from actual.",
        "label": "Scenario Plan [Member]",
        "terseLabel": "Scenario, Plan [Member]"
       }
      }
     },
     "localname": "ScenarioPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of accounts, notes, loans and financing receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureOtherAccountsReceivableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureMarketableDebtSecuritiesSummarizesMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax expense (benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the detailed components of other nonoperating income. May include methodology, assumptions and amounts for: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.",
        "label": "Schedule of Other Nonoperating Income, by Component [Table Text Block]",
        "terseLabel": "Schedule of financial income, net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureFinancialIncomeNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r89",
      "r328",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r210",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r216",
      "r224",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of status of Company's option plans and its changes"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of method used to estimate fair value of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Number of share options, Options exercisable at year end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Options exercisable at year end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of share options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Number of share options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r218",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of share options, Outstanding at end of year (in shares)",
        "periodStartLabel": "Number of share options, Outstanding at beginning of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Outstanding at end of year (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price, Options outstanding at beginning of year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r208",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise Price, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r85",
      "r210",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Accounting for stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "verboseLabel": "Aggregate grant fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Vested term period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r229",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r176",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r22",
      "r363",
      "r364",
      "r373"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "verboseLabel": "Short-term deposits"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureGeneralDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r43",
      "r93",
      "r94",
      "r95",
      "r97",
      "r98",
      "r100",
      "r103",
      "r147",
      "r174",
      "r175",
      "r236",
      "r237",
      "r238",
      "r262",
      "r263",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Comprehensive Loss"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Changes in Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r103",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Ordinary Shares (In shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Exercise of options and restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r26",
      "r174",
      "r175",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of share options, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityCompanySOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r174",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of Ordinary Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r25",
      "r26",
      "r174",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Exercise of options and restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r174",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Total consideration",
        "verboseLabel": "Issuance of common stock upon stock option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r26",
      "r31",
      "r32",
      "r87",
      "r137",
      "r146",
      "r298"
     ],
     "calculation": {
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r310",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r310",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r310",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r310",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r333",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.galmedpharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r104",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Weighted-average number of shares outstanding used in computing basic and diluted net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galmedpharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121548805&loc=d3e10037-110241"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90198-114008"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519491&loc=d3e90476-114009"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121604594&loc=SL77919106-209958"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r418": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r419": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r421": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r422": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r423": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r424": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r425": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r426": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r427": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(6))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3337-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3098-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001104659-21-038205-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-038205-xbrl.zip
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ML+/S4D_VXYWQ;!0?-/SU?U!+ P04    " "@6W)2D 5:Y(T-  "^MP  %
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MBJB.LC1I,0@9NHT0?Y+Q&P39SPA-1.S::6,WX,DWDM]6IQN'<;_$7W\?<+Z
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MQ<C?;]26FPRV)@1JCA0T:0!B=& -M,LI;<W9![ 4%XG2[H++"@(YD-!<956
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M$$DQB:9Y8MK9:]_2W;^Z*BZS338!P8R;M<YW_+3#>WED:/[U_P%02P,$%
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MC5.!Z:/!Z!F_#XJ@W%YK]EER<+BMJX[][IY5!@NR654SHMZEUC@TL!94!R&
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MX:D[G+'F+^9HEAH3/(YI$DH1VE2A048[]3P9 J $F;8:Y^@\'(H( =[>QX.
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M7K]3[-?,F;QY6[J27;P/_UKU@LCY >$V>7@B#O$19WNRKTCSJ.<?K+'<&OU
M8:@E6Z(L8IYANCE2C9"=*P;Q)7GL1%:NG)W**AK5L?8V08P*HF101>?U(DNV
MS/],$ZQ&K,1)I>*X=A+S"%4]9F3QOYPBGQ54JE AE>.77N^ZF>JJVQ0%,.";
M+R7KO8=?/4B8UU\*-N1/P"2/(L R(08QKWBY -^]RC[0/]M5&72H>KS(XZ[
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M6V8>Q(KE%X+ TM+EOGBHY>;CJO\[TZ8KGUX_O$9A&L=!!OJ$12C/;K?GU:-
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MA\Q""2LVPV#@(*]$QS!>]RN!VU]?';,D*HX9/D_"J^@K_93+K-L"'F;W;!1
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M[+92,=9'B/Q+P(;>5$P2K+&=V1^\?$I"G'W)HJ+ R=UQ'4>;V^T6*XOJ6^(
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MSUID#$)Y<>LG1>6.78BT]&,XW.N5_V',2&^D:%''I#:L>[_.%CG\#&=2#ZW
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MX*XF"'X>Z#PDK2@$/AJ/#H_Z"KN0: 7H:F+@FZ#K.O+LQ/,+/WP1O7-X('7
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M!O&51J.VC#,#HFC51[\Z^>T8_SA((^H$'-2'>UY?QZC 7^8,Z\U"6H8OB&,
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M2>4V<\"A$M&CPR!PP02)/*1,&+3BNT*31GI0- OX35@B;!?N?,<5-0RX[*Y
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MMRY7\>/\NW^+*V]TE#Z=%1V4/OX>7)8(2.1+LMB-O"PNP[@TR:C1PS$N*XU
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M1>[PJK,AOA&+'^Q*UG*D@=BJ3IG6KFYM^9J0ZZ:+U$>)'LX [+KKY9>XEC[
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M7[<[R!DES"TJH;H5Y>WO0>7M&4D6!M1UNC277#MMFGD/S(TJX<K&<$'9!*%
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M!$9S!  "KYJ=FV7MUZ -D Y5&9@ZTKM>B $5QI-+Y>'^@:_'X]9E4[I+Q)W
M>J0;IL.O'NLQ&Z0?!,?REHZSQZ13J)BWS_U!H?<PX:\-0;(#ZYN$9;=W#HFL
MJB+R-!+@06I1SX$ALH'FPN-*Z\5?;N_/U+[3RN=T6*Q5*NC0U<;:(8=0>1TJ
MBN(,'+JICI8?)\U,V"-<&$%FW[FP.;=N;DSC9:SVKYYM!YEPV)_T VM]; J;
M38=_S!!ZU;7]D'4B&E=7YGU2S_*3Y'WZ]O(I!QZ#FTD92.LD$$[OQ\"Q;)U,
M_@B-EE6-MV18R4\JXM"!"?W0IY]/LTZ. !+KK9/;NJ0J>G\\E!V0'_<?>D+I
MIG_H:N-+K)-C@,K&UDG1,FYZDIPK-._T5D\VZAVE%]S8R*%8)U^8(Y5B51&$
M9$N%J%6"7:#)M->S7=YU,$!:M0?,0<XHV5YVU#G,IFOI)^>:%U-C'34D8=(?
M! X)>%"G"X-R]W6O'-6>5N>343ZUD[WY&YXJ^#5%*OR_LO(@=:#!2H>^80:G
MIJY"<VPBVX9ZU6EC,B^4VF@UGI+IS%WZ5AX80F.8>+SL]>X/?6H*?OF)K=Z[
MDK^N9+W%X+WY>%]Z^F#&MPB1:4D\^[*E4AW>Y]5D2FQ>-*.CEJ#F)>4I?A:X
M1<LO5*J+*PZ9C5<<<%.)W_^BTY8,;TCQR^YMU<GW[YZO2K6GE'&-\H'ST@+$
M\*];8II92ICC[S:;'D#>$=2K/.Q'06:2;TK*X+X:N,DM* Q?,)S>*!N=VHE&
M7TH^?^MX'\_NJ9H&?HL](=6![*RN$H-@2,9]-EFRH%BAU&D+]TFC\T*C5FB4
MZ\WH>;V2J]S?/%2"9U._^Z"@C2V,#2@YLW)6DG(_AOP>=SCL$F14_1!#U+&A
M63<Z]AB84-:@8IN&CI0LV0:B(@5+]P+^7N)EZ$0?$N4FN/DCC&UQ6)X4 J><
M H(_J@[?0>5C@.;<:5B[TW_=:QE([='=<Q-<U95X7F^7G<? F;_O/E<KU'^?
M [)WZ[]2[BQW>=UJ._S ;&;&N8?S^^)%X*SQ@.#OV^B_]^BW$@06[!F:6AP,
M36/$RFUX4(X;LGI^_RCVD?P$K_-MWM;4P%EY[])%:X9]6&P7,JW^I6UKP!BF
MFE%Y4L@)3NZF7-V[,M@NL+SC_7N)EI!@F#>>1U<-YRQ;Z5_%^5%2OKF5'N1@
M%<DD*1V)J)#8(>M%<?[XL6T*1%?J,%.JPUN5'_1E4\H5!H-4<+,!=U*B^6.+
M(K3&J2CN46%[BWD#1'=H6C,VYH&"--Q)JJ^F)6"J]:="1[%'<O1!BYO9R67Y
MI1Y8O;QJ<"XG5XWNL-3O1DS, 7..?T\MWE KJ7%2OJMGBJ6+_&6[^'B(_%L8
M6-!9M\LMPS5H05)5CQP@1*KF&=346-B\DSP?5/)\+<>#IZIS?ZTFS&0M<%[B
M5IMW-ACVWE;-@IP9N2O()(V;VZ$RN+KAQ3M[\*BHHFJ, JL:@@Z90&0\?623
MX":0<<K"3:W6*V>:T:Z1M<\N1K5N<(_I"SQD K [;$G+\&==M9]7GE)\P<ZV
MDGW3*&GG03@'(?#"!O/1+%!J>K19J4[*?P;P2;L&07 /@X,YR9>A);FVD/#!
M#"M5U.^+ [YZ(5\U^(N'YT0N>G,=V&GLZX_'6<P.DC;/#I+V4X=N?-DQA=O;
M=+3YE*GV$O+8>>KE]AXE"*AC0%(G9)9@H*HFM+#'XWZ8R@-I<N982,<7<_C1
M0/%DH=^JY8H/PGF/=Z(7J7$WT;HJ!Z\Z/4FD6#_$D]^DS<HQ'K/)OP2&AU'M
M)66;ES=-='=5+%XT>XVL'+3)^-,HY^B(D:V)/Y!\7ET%IMJRR!E45JO3+5XF
M4T;O2JXDD>U$]8?+L_%L'ABP$M^_W3[2>[SW>+]YW\F+WGAIL51OI?GJ>3&:
MM]-]\2XIC*KE^]OQU?(;D67$12%UBF_YP N;]?-6^_IZ_!1%9S?RH'8F)[/%
M,P>H-Z^^$-_R@1>R^@A62ZCV)DWTU$O)DP*$]EWB):56LDLO94<=LWL^\-8A
M;M_*WZ+H'Z4UKO-W9[VZ=?E'?&@6EE_I8@9__, +K:>.W5(;O>N:.!EGF[E&
MZBXY?K9*Z&'YA8YMGI+VV[_N'(VPA%'4N'"5I:3<>RP4_O2ODE=IC-2+:-*W
MUTBE-_@?5G8&$&L+PWPGOI;N)Q?/H6X,D+[JL9L*RMPC?L[W?E.Z$'"[=$D^
M5MOG%S=-77:>T[E"?>A$;^]O/D*7-\0@D'29P9--9ZV2>5/*RZ!=DI]>[);U
MF+F @^ON:BET[UF/4O1\:I(#38F\]M"0PSZP:6CS<P9I'S/,[D^1YZ6?;HN?
M'3P71SN&8>N&#4^XCFD,:K!C_7/24%KG5B?>3#OPD8_*2C5[+;8N)O4QR0O-
MG'"VP=JUXB(4.YUTIJ4FTJ 5%\1D*Y,6DBTIH\*,T$ET,DKZA#-,%9K_G AX
MD#\7>KNO[A<,6%3M^%69=_@&/]$R3FK<S)+N)P^A^\]V!MG\W56=1_9M,=5^
MX#/-">V^%/CN7R 5FR MHUE"55XH3.2"4;O$BC@UK,DWOMZ#CI))9D38 ADH
MM.+)3JJ54;#WW4XD^390E+;2$=[H/;MB&8ZI0(M][4&@4M,'2^COO_$?SK(G
M9$ #\!P=(]7NG0H\_^]?0Z"J2.]&-=BQ3^.Q>&IVR43=WO2:8=$]E^Z+1_#7
MR<)3S2[2H[8Q/!6%6')H_\*:(MJ#]!&)6"J!K_C>BF\>>K=VL$T4[9"$X\GI
M?QK8J+:X,AQS-6, ]/]$V!7\KX4MJ<Y_?M'6%GJ!^$'D+?2]I_@C1_Z3W _D
M!8#KF;#SS\F_&I4<_FH-@;Z35[*OY$&GNF$.@,:NC-E8W4O$RHL"#77U4T)9
MW)\&:&N0,SH<,?[)4M#?/TF7,(< _F^X@E.*!H%YVC;LWJ]%IJWB!J#*M@62
M( U$7FJU(<947! 2K;8:%UL@D83M--_.@*1TPMZZ&Q9X<,$=M8W!J>"[1.!
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MFCV!Q=H!-]0P;[%")T%QUA> OSKF^RHM;&?!;*_\]FBW[ !+P0Q&"_[8X_3
MK-DE=HK&9N.=KWHFK:AZMNG1'*^3*P#4VA7KD[L9"Q9C+*838H>X@>>-!^9'
M]2Y'QG]H9.ZYG:DX3'?:;:FE)-)B*YX0E58[%4^0/VDE+714(>Z=QAG6U0AL
M70V!CTF)Q<(:WL6/5-:("V%IC4\HK>$>2DL'2Y[Y.;*RSBYH,$LZS^4JY89<
M;M1W; %_6&IWM43HPI^*$7!LP[O 9(A>^<R*P>G,\98,%M9FQP9U8"L68Y8G
M!D6!L-/Y]7ZV[LUHFA>TJ6*M9FN-8BN=2 H)X2LUK-?-D]^D1\S7*BZIUWF
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M,.\7LN8TNV'AU\CT@-PL.[ZI-CW,.X^!Y%99Y*/Y"#GA@]R_<,P3/877X I
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M$$&:CDB"%((T!&F002JD(T(Z5*4A2@.-4C$9X=/B)O[BD:W+%MPR\K1XH#I
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M[M(145R>P;_+XJS5 R;L&9H*38OH4"'UBU9*MB=AL"<,]AR[[ M"A%_K8X:
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MG7'#& ,"2'JY#3D5F?AYVH13C,$0F 1,L5=$<=<ZD*H,0D-/;ZP[9/LLQN7
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M(Y2IP:Z#VQ'S+?060D'>7) )IMHNIA:"#=2UQF*.:/"U8QH##@Z1"@=((8$
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MW&2FJI/KJKCNR)[BZCR;DY=AMFKSLE,'ALO!A>)BTPXE3[]CNG9<3'8G&S3
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M01,K9V*-:I>##LW544E8CD98#\$&XE*(40E2;, 0JUG&Y4/SQ=&G6IK][&&
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M&@Y3A#U#7YC'\[)Y:R$H!]K(-+ME[+0%2G9R- #0WO4C%$ZH-@E]KG+:)L>
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M+=.)R>/O$'H2N<);OD4J\1AC.;U<Q]VX(IT$&GU<SO7*1/AC6T;=2XXMMXN
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MH]S Q)+3+4P]]9@',J]^!?W0?F07<N*MCWS@^8X3#/3)?2PFD/--_3KD]%=
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MM'M3;2X^S5;?Y]NVO 2\<O)6>?J?@^:C5@G\JPG_$U1MQ\B7_U."*8$<E_R
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M:1?LG7,C3<7M %;.PM]J13;A,P\K#]S)\"A4<K@3DZ!I$P5EV#C"D#5M)8R
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M]H>K]*=<HY'92H6P_+@3F[#DWQMQ$;%9ZM<M'\)6" <3XAC!(#H^NFQS9!'
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M(<:E#%P#+68W.BZ4YWX3'M_LBW:1V$5B/[RO1W'D5A&OM+=#]&MNKES34E'
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MD?TH2>_NDJX"QHV^+#<)^2;8@AXQ\ SZ.<*^NY_^UI3AJU3L0^VE&</.< 9
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MRP"&Y'TE,8@>]>$40,Z/V;2%'0X3E#J+!,\D7KKD=]HMB5:S-5TTM"("RFK
MO&&DF6=#GH!IG3VQ-(I]D- 4?A4P?$1E+&ZML%L5^FY]-I]L,@?,$1AST//\
MZ,XMT>RI"+F&)S1<T1_EZ7"H'8@K7[WGM;\#6;T$1G\[ %B=1*_E)7? S>LB
M$FF4PJG$4\>.LM)F^;E8_16PUG1,!:N>77A>=_HPVJRF1@ON-7:V[P>Z_,\
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MZA9]@+U!N>7%ZFU1<(&2C/[5L=B3;>LJ=E:OXCJ@+NCILY<7JQ_#\72_,8'
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M"$8,AMFV4VV:H+_WK7;YC<[B:)+-L*+Y 25YU$>(E?-DDM5;C9?A;B;P,0N
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M4,4:8KF/C2Y%70HRO@-3V;5<YL-E<]V&:'J!K!)K920.<E2(_C!PMI!)4^.
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M\7E&Z],,TFQ]HF38Y9;:@=7&BU1&BC"9,3.8?=Z4:LYAX"R4U3,Z^D,^E=
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MVZO-9%#A3 8E<Y1#4\[?'LED"=2R"E=%Q8Y2BWW=%PUU@+=VNZ[H@HTY*IX
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M &'PQ@F20T# +7@Z?#Q=%-$<SCY.\]IS"'YXUCX,C \ .%KBN?+" $7G<#C
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MH9W<OTEMMTF<#X"R>N+-07ZHK.2S%'4.W#9H( !3,VZI85FHV.0HA(';T=^
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MA$Y597IP'7H$FS>9U9/Z Z]!BQ9]<,"JI=>9_O?_^BS-+3B6X*U/-#<U[2&
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M[_:[Q%IUDH#U,@)23."=8UUH%ON6O_9:PFW@J#,ZJG!5O$.L!,!WW?'G[OC
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MDV7N&O7 TX6C%?I&2P##%\Y@& K=T"Q]G??03";1*-*CJEJ&?X&-@6EJ*'
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MC9^C\7-\>S_'AO@T C4 DU<H^0<3QM@A6FE,D!G*1U_+'$FOB0".(#'&V$D
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M&G!"EZSP$B/NN+7?<('/!S.7B:#9%?B;J*(]2RK1!.S7HY<\ ,LW$+3U!'2
MO_]M[_@T#TL)V'N[QI^8NYW(H<>AI\X5DLG0SMR1'X__;OG"A98J\<"YQM1
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MF")G@$:C>_=^K+V6/,WLH)PT,)AEL % _V\;B5X6#T3'%E]!^R8XR;\-%WG
MIP.]2:&("%%*V6S5.D0;(!8-_.W**BIJN?0**'G<NQ'*2D\ Q8NZ521KRDG$
M!*,X:>KE"]J !^4M@V-"=0)^LD1@9!!ME9:6;B0J)O)MID-R&2Y:H6'?\"Q2
M?UQ+QA"OI1 :L_A(PSG9GS7URZ96(NI+;0B;/'_X%YN\7"1'$>2ZZ[:=]9ME
M4Z.,RT]/EOBSXDS^\_3H!&J)*S62I<L"&D,&DX$Z5ICPC8)X?L)MMYH@^\^3
MH\=ZK2,9%;4"0V>:'!'FGLVW/K1-U++BB7'(.:S1C0P<![N:7UZB1,(8X[SR
ME_W/1W$P1#I'$'$X/"5LB['V+<K+LILU]39?44HTW(:=^8I64CL[@"QS T/+
M_Z9U2FWGX+<.)V(XU01"O?900EM1>\0S_PYL(B+A_F6_9ID $X1WC/LD]97_
M\N$_3VV:F3FLDWDB("AP\&%V%GGC^("GKCO<P"K8M6.7ZJ)G*TO@I]3YA*]"
MRAQ*!3YYUB@MQ[KHKH W5V_#&;B4(@>(,\I,OWN318(C_5IR5KJOJ35ZH0+W
M8?E=*>&^)HDG'X5N<@-&:3F965 VZOQ,/A;V'!KQ6YB$G#G!!4>_)POQS_J\
M%Q2YE!USIHFD&CVZ/\I(R!4IMY'//#I1\:RZ:MK:$^) !B9ZXG6UVK[ \> .
MI2&-6GHGG&3DD62WWK3$(9S+)57F>].'*#F7@Q).#:VD&&&9U@(LG0V?9@A'
M?]2AHWYE<AJ?)-I+Z9ZB"$27" 4 U>PMG\UTT+Y&?PWL[4OD83]PHTT5WCWE
M9=57Y^FY>* R6Z,=FARD88PL]*[L\I0>91D0[Y0T[M7[ __$68@%2:R+H8?B
MFEE>_W;I*EW^2<@PL_1MBHOK+ZM#UC&RF8N'B-WFG?K)@U>@.ARHX>1MS0!V
MT6E+":*D?_DOU*6?UGC6Z[+K"@[6R/^;Y_"\P]($F1BSRW*3#MP;<AO7^5\*
M<< YRF FS%9$\21 )[HQH@_#NCJ:O8;L,BW7B=TV)@T<N9UR(4#,5\&(7XH'
M'U8&4VK+^U"%-8[8N'^HVLI,ZU>9D<H+!'L##DDM/;N)HC%8 <I1)J-\0*Y#
M#[6JO_:4!0?KRSJ_C-H^^;KN!;#ZRP=^\__Y+#L^/L;_CF:O>#ER* 4'XO89
ML&7;JRM6Q^];L]I:81\7M#S(4\"S2\"6ERN"!,_Q ND/\CE9H _%T5WD6PJ.
M+8C'LJ E$*Z [YI/JSX4?#QZ7FH4<!8E? !4P.ZPYZALCIZ(N=$:3#[SR:,X
M'!%ZBXRU-PV6;H4-4;+()IS[P<:CR9J',Z%FK@IJ?;-."3-/6N0(0R%EL<-^
M([91)Y#_104D"X+FP#03IYY,WQ,W??^Z\XV;+IDRN% B#["YU2+?=R7-%1-*
MXV0XEF0U/$\=B7?7\YHE(#]$ZN5S0XAFNO=&R%#>5J 7JMD?V*!))+C9,%AX
M>TL+D/@*.!P'OAV]@QWWI?Z1\0N(*R*Y!Y(#8>7@C?.!D(2I/%-D7P?D=UI#
MW.GH+-G"F0.6YC+DE^=A_/SQGVC9#I:K#B"B\^8*3F;61$R#M^!A</A#V^65
M0;-^Y?0E*;"ZF0D<VH\2O,QM;<;@B\MJ\DYFFXV_0D'!@Z62[5@K@Q>9)T2B
M_! \7 )(A$F081PEYIU6!=N2D7\;K)I8$[=*A*6#[9BLLT>/W3K30TXRCV2A
M-C3MXG'D$Z\]OW7".560/LU76;5\?%^UO*]:_AM5+7^=@@/;'[)G4H\@,T:0
M."JF%!3 D[6GW3\^D6X- X>GASLN=N*Z;HO5)[+P$]F.M&923!\8B0?B[:_2
M-]WV]4$$V0J],WEH0U,Z92KCQ)OO[V]BSJL%(BJ-*JFH,.;@%%U$EX'*F.IP
M#K!P?<L4Q2Z))1P5'$,HI/"F[L.L7B*7726#(OWSZ;>5)=^](+VK!L+$**S8
M 8B;^Q,()([^E9,J&DE<=[3>6M1& -,/\S_]IO".VG_@)=UVMM$".N,,K/]S
M-AD"\"NR93TA"(LGHFFG1SGK+\.^],EB?21XM[<_$!WQ^Y.72M7MTMF^U<-*
M>/^F)]M=;L)=O//5D\@Y$P; F$9Y[MWQ] &T9.*CN*44;,E =MA_K(R[VWLE
M(=C)Z_XVSYSM2N<"0FCIW%C#NI#^?A%"T)3NG\JBJ_*UF<Y7I@C_\X;)[L8!
M&T^LUDQ)0V3T/54V8?YTVRJ4D:J*RQHT\:KJ3#0V(7P/.P:O*02X88 /1_$2
M>\8>O4WFCO&[P_)'8IV:@C)?X3+$B2?57SD^IMI%!@^<#VN,3FB65@ WH*@+
MSFD-$2R?FE3U]_7X/)J]+-MY3_01,;M>V+>2RH/F6</SR\LC]&1=788P^?*?
MQ$G^J]%#9V$(]>SQX=M7[R>90.YTD??^+)*IM!>W;Q@DI5Z^#=4N.W=P;/^?
MLFW[=2:G=O@HR3P"NN&Z O#''XH0<=QX9;UAQIVX)C'UAX_#S".V>SS+(7+/
M>@=1,V%3A*$$>_#VX]G+/\T.WA9A)8,Z.9R)'X,W+C^>K7+YH67A +I,-OM3
M#B2OD7ERW[W#24G/%36SU.D4L&0$<XQ)BX>,%RG9H2#GLI<TKGPMO5;,_RNV
M*$$513NI%D@X.RHV+/1^M':D**1Q QZ_'NZ[M*&R+.F\:#KBPVZ*0ZGD<D[4
M?"_.V%'LS;\40L_X8<H, ZFVDG=H'L; 5W8W]_EM3WC:%>&XH 2P=2TSIS7G
M-]YP"BWJTW+?(YEU5V+Z!V;,'F;ZJOXZU?;.<Y_Q@:#,7UC-X=<L"Y+(./ !
MX5Z!?X%D9KGL11^^H*.$/Q=UP=CSDL>0A-*='U^X73LA>*7;6)6$$O&B,N9?
M\P!;Q$P]EIF:!AC:4OB=?<3?]$C0OB;&E.Z;_?[7]7GEY9JH!K[0BC71YY5T
M9QU\.'\Y.PGCNBHOX ,^F.C7$M[W/9ER?BYB[V?VQ.YJV]3AG+JJFW5=,;1F
M ]E9>FR;@ <Z ^+UX6-D @V*\^:GE[%7FTI Y\%3RZTX]9-*[+PEW;M5+&V>
MI6BM@Y_>OCM[X*6[TP9Q=M\0Z>>K>7U%S$X?2)6 U0#P?@\PZP\2G1JT*(M1
M/HEJ,T\>#\2$PIEPS:*4]<WA MXA86 W-8H@Q4!D[.#'ES\>GC^8'?S79?=B
M=G)R/(,&YH\/,B+442GQ 3,6=_"]_O%E%M=C<)_KIM,E'\ZV%18HBC,D)B$$
MT/IW?HD0 @(S)9= @"EBY::.3KD96TXAAC_%R!1510 1,/R$..<P;\.+I#P"
M?1;#</ZP'%Z[!B2^.T4-)X]FFA '=I>YKH6ADX!Y69QI1T=O+Q>$Z05\GTM$
M8720=V'ZVD[^F$HVJ(@$\U0>GC-<MRDO5]O@(00WJXW*E:A2BE;>UV.ZK<ER
M#XWV/[_35 ZP&3HA*)!.>U!-Z%X]?NCA2F)*9.U<_VG8;,&)K*D1,(K06AT:
MOGTMX9\GO')I5?9\ "8D"40X-0//,9]152Y?P:;&>PN6\ N$0?_2ZG'L-=CQ
M:C+W6F@BX '76\I10- -$JPP%!_Z,,TOZPHG8J0KH^)_/'(MB?=V"TG<-RPX
MVW=Z6)R]85,P#S<GZ"F<;>2LV]WO'3($,&,Y7L0%&]ZO5 /]R7T%[;Z"]C^U
M@D9YC$1UQG,[1XIN"#2%Q9\GB<NBNJ)@=<3H;<YD(GII1K^A9.''L?DCZ'@Y
ML#O$+ G25S'QP%Z5-;4&-0/>J,B$D-M)Y,49D4& U\P]-5+,<9R2*K=*,0M2
MKE)+(Y(.O6=ZRUQ;-9B1$CZ='CS[$Y'884*/[,_ISI&RN!-$.7\YB(=;2'8>
M+_!3X5Y$/ :$N-VQ4;B;TK*8]57YUQZIG57'B$\ZCXL&<R5.?+[A5 )UN&.!
M?'FHB+-FX:3KFR+$$@W%2;?<PGTSX5T'KK,);W#!C65 O3!768G6U^2XD]]R
M3$!M4&Z4JO1#[*9=<=E$QR<?G[MZTH;0J3,6%YYV/517RD'0W3KB,6= IA5)
M\M$@UPM4N+:FM?'4YJLB1TF45 T$W#N!$EZ"3@S -?#Y5/S&I>J:Z8!)F;NL
M\^L0C6@F2!1I0SC[-XD-[_8V$7 1Y%257#6( E_"=1G&(A%6^,=U+:I_1^.U
M1L($HSGAU(&G>0G&KV]HI<Q7-1H&%V6_%D;EDNZZ% SEP?G+-R'H?/O=_W_X
MX>5A\,JSH1@"Y],T)SD,J,.SA"^=[&MEXY>J)#*Z?0N%ACK-3]$%?7R<32%<
M<\M<MU?$O=1?!*>VW Q]:^#@N%J]*KJ.SS)]_M@-3C&0_CI+ +92E2M<GU/,
M+">0_'$_, <]>MU1J:.SKDGKBI5Z''+.TE_ 77O\0F+S'L<3:W4MB)<[[[A5
M,&78"E=[TS9Y00*577UXL2O/'W<[;V"9+V0-) ZEIE2I4PA#NCXF5RV1O$#>
MA%9-B@3!$PGW%0+9MFN'P'IY;,)3+$I$*!&12IA7;316]OIY>(@P%VTLMZ"I
MUB)>;K)=Y3=$:B@)&+(,$<JJ&%#+A\>OH[^-"C-"J[C0UT=U4WI[9:N3;M:W
M%/[E2-U<U0Z2%'6?&35=^;J#FW1<IJ3F,T'#%%B66GW5CKZ;*Y9:"4^*%#TW
MPUPPZ'H/E)[/HSS+7C&;8YX'9)SABSVUT(0)C-G%O_&2"F=7N2".GWI%8/EX
MAO'!CPW@M6AH-:@ 0U.VG[8LEK#BLQ)M$]W5=G<.A]8VH+9GB["RB5@/R5)3
M?\4]R<?MF4 (Z9=MYDC"I_0;PD;2JZ$DJ0Y3V&6R-N'M3(A%C+0BG 8#E4C7
MM=BC-7402__*'(#?N8I6TL T5[IC[O?'A6;23V-DS2)#0S8C>7OJYWF7/$:+
M/\W#0?(V7X1@')(:8$8,4WN="_ E\MO'BF=9&7 [[.)'DY3M+V:O5N7LQY*0
M2^^6X2&;##E#E+/#;;]#&CP8^[?;\%[H#W7X?TTPH9_":,)@PW_^5'ZBT;^J
M@O'.\>LN1$U<*R\:^'?OZL_H=?JAV)#1/=]V]6*+'_+J\'79A0\^>Q[\+C;'
M'_++,/W=+/R"A#KFF*2?OG^+7T22F';XV/:PIY//^05R/FXI%9DAEVBDPBJK
M77RD&BNMRME5S:WOTMCCJY&T46OF541 5_(Q=PMK_DQ#=T&N[QZI6RH7/;44
MS)#J9[=19AL= *NBN10@X1F"C/];!/<FWY\]\*::O2XNFAZ9Q]/CD^>WK'R7
MK4;F4=>SZD#SR5LVLY_/1=K\%B45>\&BD&)O/]X]K>V4T#2YH,8[PD[\]/),
M72O(H2HE9QXLD!9SK*H6[HHQ)3EC]%.>V25>O3VC2M<?^JJ0[+Q>&15Y:A@4
M7G>7Z.9#/+:IO/\Q&Q#^8I3N[I-+Z6CV7HJ"V6U/SYI;"X?&LLP[ACGE<\;-
M@'<4)J]5S!;>WT]09DVDPC!,P1O,)9[3IG%5=:7YP\O=GQ7\TT0W#WJG"726
M866,Z:4?LCR&@W$+S_/[8$UGK_EL<[]JPSMBM$J86BBF*/>T,$V]4;\"2^M]
M),UYSQZK9Y+^N3<N;GA_T7.>\# 4W %+UU<*^N /%%ZBQ,F\I5PVHVC9&I $
MTF3,0"A?4.-6Y56!T*]Z 5>]*Y3H^E_O<+[Q?M$[\8MHZM]Q%+470COJ@;K2
M#J>TB#U'O"WU]I9H&_7O,,KV%9>K'I'3E]ZLLEC"1-0D9!@^$Z*X-1]C: YW
M;%29>I]"1 FMJ,.K^H;6&G,U:><I(CI9[J3$ Z2\A*M4CFA]Q2\%>L3!!]NE
MPC5_Z8,G$P8B./^Z62U D.#<+PUH^9&Z%O"_8+4XOJ4QL%H.5$8L=':S*0YH
M",B)Q:LSNDT*2JM< >*#M._.">37]556PI[>5\+N*V'_4RMAT5R6'*/5K'AJ
MN3[FA" CI@*RDO(6T=P;X"/)^PE&W$I<2-!0J]?1AR,]<WZJCV9/L\?')]FC
MXX=9FL&3Y-_M[.2.-C#S62GIC!!'68P=C2!?8 I,X.OQDZ<SYB!@EYQ(V%7,
M4938B*J+,TO:]&&HE(=(PYX^C/9U(P@GN6?"#HC)42BS)C47P=71Q/ETTM+L
M[2P]'2A=$@X?PE)-G!Z._2DG-IT9L97&N*_-5YV8Z80*"!.,1V"(V]P%E@XW
M@EFJ$EP<OPL"HB?"AW%N4BSWCL?5I.[T>9X\=/RU$/-Q%PQ*F50]_=*2P3.\
MZN$+<9)7DN:UI#CZJFNH  ?W<WJP<B-;N+>]#WWCY$V.YX-66<'ED8>/,N_E
MNKTT [->N$XNJC?!0T$Z)429/9&3*%4*=_]1N6\%#C3L#%Z6I4B<$GFW+%:W
M2I,%.=R#\6%^_4*9?7FE4""E\[",MD3"29Z:I_L316%=;/!$*@+)^>N,7U(N
MSMBB6()B(?'^,LM/2TQ1F)]%8.)&BP=2J(]DF*46-'$[]MZLLR3F7<UPDP.W
MID!T'5>?B"H)\ARI-N^\#A'KHLB6^+,$46A(L[%"0\L"I224)>0.$B+]JNON
M:450SJIW)EJ9F*:_N_LI\?G?ZL;:M[+C1^,X<JJ=R02@T8%@ % [KY*:'$LL
M:7SRFY^,GJ85%]9#S!]HX</!B.V/R?AHZ:&T>(GX:55K8"G'BB-V9.EED<,Q
M2;@P]W_I+]ENK^L0,+-U<+2/T9$*/[:%)8MI0D,$T]J=#:X]-;S\(A@0'VQ&
MZ><I#>G$+8L :E11BJ9?)[AV!E.[+U]M-T5#V.IUF0N%<7Y1= R%*=O!T.S0
MS]FUE+_ZU7.K#[#[:U\8. JJTDT@8I+Q=3%J%)QS(IG-92]_IP/?,8Q6KG?!
MNC^X?=R_<FK(2-O\=#>U>#NY;E-0;YEGHA[^$'ERABQ=F6>S[XK598EVK?/M
MING#=U\6%;)RV>QU6:V(F/EUPX[)]\'51B#Q!L$,_O FV,%P,OW8?PY^<[#Z
ME]GL;9BI>9V%K8>#$!^C4DO3]50A^A!<E2K\YZ8(^PK_+;N_\<>RV<>^^51L
M;3%+SN*/X24LZG6DTVZ!Z%N,'T\M37@X>Z8O/DOXH2D*_&+X4,D#_-W#YBAI
M\LVI1=27$=Y.3M6G?('_HO4E_.=OZ"U5#O1L=A9N>Y&7?\DK>G,YO;$_;IO+
M[=^0]@T_YW_+/UWQS^^1'\]1UE@4C9 DO*D687&TN-4?\@U]@TG5.:6$0MGG
MDE_@S>S_%CD_XT]U<Y.C%E?SOW_HJ\N\<0_]": Q$#U1PAF(NO&! '?*O20J
M%"2/1TE>ZKC[+5QCN$/L&'?":F41I \=.9P8&R KR(CKBC;F,*35[.0Q18>G
M62P[,-^AZWKAR2R-ZSNJ@NVX)@%_3D]B4&WX#6==I)Y<MCK(&&_\'<$Q/;F/
MVUW,'L=[1X/+V_/TT?25GV4G)\?9XR>/=ESY=IO,UW[X^,FNBS]_^C@[??1D
MQ\7#44AYN';4JQ$B9<KT!R]MSI%G%X[$5=FNF62P[5=$&$(%B+UQ-LX&%M!\
M#?>FZ@W5<_NVB.>5\PX.P%EXF,^KXL'0=+K(6>,=_H,93+6@8B>IN!=MY4X[
MJ/4UV=;ZL=][J_^J/1[>?M\)!PRBTH<9PXS,07*L\G1AHW_8I^6A8>47/5%9
M1T0 SA::%PI22&ZU* W).&'P)==-@P/:KOXD\)%!7'0'Z8H[6UWD%0ZJZ*OT
MJW#LT#'9U.%*>?1:A@>EG?ROP#F"3YH+H">^'&)A)<\'_DS>7>,;/P8CT?,0
MWH*JN)8?5P"4#(_$Z./06\8G/Z"T'L9;A>/T0SBWZ7>K^CK_I#\5]#FNG Y\
MC(_IOE(_PSEL(U?&7)C$(>/AJE_F7!=Z"^DV?6".QP_ ./VQKN@*\[R/GHE@
M*Z455)P(%YUX?X:+>[(*@,L,/_$O1?+XS=+10.RM17@9U@LEAA]EDL>[@UGX
MUYX:9 F6-4A%!\\HY-8($7SDXK9G-FTN7+C._VC*UJ='S67995>B29G(/8X=
M>>&=_N7#NX\_'\W^+"0-7V?Q\=E]\?&^^/@_MOBX?Q:=PZX[V_)]<_&6Y1)$
M;/$1O?.?M(:OZP612(0G0YNC]BAU^:QO?<KO2ZY<FL>=Q1X+SH'M]O2B8[ [
M,T!.PW=-_K=R-<J L&\8\Q/D<-!=.5/A3H8]7&=_R"L"E"JCY,,G7^5Z:\O/
M(S^"-3&",=.%F,U@A-2_>'?^,049#33URI46_TZ>LN]W4\=E]"'Y-'.,#6J8
MB>3[+K!54M%DEY68=O#/J'U.29=P>XPY&64A'!1&/<-0WS1E]X6%"T_ZD#WI
M9 U+YBU9RO\J=Y@<M[NN:4?>\?#IW9<S\>=(,AWT-N$=#Y/E*(6RMTDEI::L
M&R'>0CN4>)=4M4A?$[Q&6U!N>"?/O/^:YJ_\8N#$D]6V2:FP*8#XIS\\/";R
M&[_<NIM2&6IX^4@Y=H%>T<.D6=1_C7"N&\$SBW\KS2$D?8VD#75]QD9C^DA8
M^%Y:K(L\JF@ WRM+092<0ULQ.*+R2=*L9*_Z8HX""<K6Y!3I%9$"E;3HI!9C
M6&:T>UDR3/K7HE+13AHKI:TBNY]^9HV>$.2ML0(&QF.Z?W9@2,)CO*6&J"<^
M__OWI*=Y:]:>#XU03 ^??84'CD!S3*-)NJD(D;\H<$BH,">>N+Y SD@-O.:0
M7%':X6&Y+AF!#8,^,R 7I%4I=O7L5*R_BFIK?2O)9@&3\TBBA%KX[#K)DL36
M-6+57!8&V6\CJ"B_1 V^XXS>(8OP1 4CAC Y=L*V(X$1!RIAG,DZ_R0JL]('
ML%K1#R0U*P3@^"5EO0G;00F"WIZ\E5EOU2!Q@F,7@%#$3JG>*%24I/U$H8T^
M&VWV$<*$]K=6M0'4$[:$/Z/.L1*%$-%6TRN)$-TL6.]\(8V]P1H75UC6UP5?
M$_05BAR[$PA1<6.)"?*"X%HMF-L?C\)9;TIX#F&A.1.03)3UH!G0-=VIKE!X
MN/ ZK@OQ>SB/@G6"EJ/&($BB12OM.)^#+;N4\X%67?B9= .YOWFP5!(L4UM#
M!6NYU5=N*'U#9]@,.2X#MQEK:62.78]Q3T;$I>(?;$'P@D?E1?Y$M&_B &EO
M&[$YZ]O X*]$!5#< 9$(-7:6VP I-&81)),*)%!H1/-2>\U8\0D%HF;;D38]
MQIN@H0S'1CB+'OL]TS_:;@VN5Y4W35@?X:=YV<S[-0[*8L$<Y#UCOW"YBO<-
M2+8KMW&TNL74+=1A1Y,^W/^^VT]VO\A,<TM?L8B[6MXJM^?2A(HS.#:<VBV#
MYZ*MCB7A3<3 OZL%7:E#P?=@_/%ZN!%4364;'F65.XHOV*T:PGG\Y@IZ+V[E
M17 =4;Q'9(!8'_6@H^2RO"+,-+T>>Z,8%4Y'-2$BT4-?<ER"O@\H7URCHQ2M
MD]$\%ZY;*3RMZ=6!<B1#$UD>\3IZX%X+98GU\F-&D_9EIB71KF5KI6J*ZS(<
MQ,01%QO;Y#W@;@BT=8LD5ERX53P]K<IIV]K@-X^)T2)U,Y)^IG=?(0:<M5>0
M3A?._LB0/V+ %3I@-)>CV*N.B,VF$?7S ,(,4O("C"W4=3;%LS<^NPU?N:MA
M_'=I@9OLPMJ?)K&/=,Q^X&-VKW@)WJ12B09?(H'F*11JTI\U<K?D2/.F![M,
M3[%@TW=?3+8&<^/@?(A(7/(^T%;KT;FCHU)[R#)U34D/;%Y72^;ZRIDY2,DO
MM M+,+U8WV$2.3*-GZ&ECELQ0V)1"%M3&&!.,T7-Z"1]@:T$I -_HFN$E4#<
M(76E,;#@3?#YYEFP.4? ;%C%XK8G+>,^B:#A.#T%LXK1V4H449$P*9T*V;((
M8+/;7O/%-O7IK[8M$YJ!W,A=*-QZ7:J+9I\B;P-[LPE1W'ST)?<P_HAIMVTP
M#_ [K\"3I.ZM/H(I8U,N:!&\U$5/A @U6MS%X@F7/%])G;LXW>#ATL&$HZ8-
MQU*K7L.%:%>(.&%AYQ2-PE@MT$Y+G&Y+:8CD[TV<Q.GTXFKDP]Z [5U:G#'?
M)(A"/DAR4$L7(!^X_E#7C).@O+^VHMSS^Z+<?5'NWZ@H]W?Z!Q]8_QE&>:^\
M@Y]=&PG'W1O!$[2#N)@$1"G.9!O5RA/-EJL>7IF$WZ8UO0=44>_SF]E;45OF
MI_O0(U0-QG2O7L(P\4)Q5AC[VL:ND:'I6M5)YBM6:(A],5]0[<A:2^&;U O*
M\O#/""MZU[CP3^!.^CM?X5O?I[)O+TU44.1,YYU3#%IKPD]"1VH)'@D55;+D
M;E0:R# WN*/Z2="I:;U_3HHR-]7@_FX_:_:DAO_(B4(.U<G%C.Q1%A;XC*BX
MNW[9"7>NE(U(@UW#[&3U9K.S=V^DL[$JVZN8';$$!ZIE5GU)&,P&))@T5)EW
MFH85\801!'O@TL?\%2637,8VNM3^2OB\YJ7U<7L:#@M$M%?E)KY$O_V0R?29
M=+(Q:>FT7 JKCG+;4!WRKC0JQ#VEI#@76TDF6+(B.$75G-6+HBIUX;1YAC/S
MY5>+$:74RA+5\"'!_""4.H '!RWV\<*0;BD+BY)ESSF^F-AZ.1#Z<5_\*T@S
M>0MI E&3+4-^&186$D+-B^0MD;&+NY'=_HLDJ)3L> @#MUYH()+J:'8)%$B6
M$!N\!QDFO\J4? 2*U<;[V1211DJHHP;[4!G[I;L5^R+L%1#OLOFGC [Q^_@-
M[P)3U4. 6$HUW+H:&H(Z"S2G'65HJ3,*O[(IUBVJ6P.27DFA=$A3*_%3")21
M'VSM2-MJ\VS8';EJ1Q":8?[]VW<S M7.O__QW?Z4R#[>+J[E.OD\KY5\?KCT
MVIX8@=FZ3*QMX:/EV5'AU"0CZ=:A5%9SDEHM-IT<\RWG4;1)?8?1SI$OI:"7
MV;>2COF8.$T0#C(0H;L9TN9.&$3:IJE;X5/B:Y$7"ANWG*M%OGW8:S0,A+'U
MJNOI\ IN$_M>5DR9F)3QTM-51XN.$\-AX5/Y#;)++",)C$#)G:%A--S9)Y@"
M-0*\T[T9Z,,(&F=E5"$ISFW>+THV)]?!7"<)I9G8W!H,"IS>4*=U#_RQ<QVE
M25#^[-,Q^^:A@<Z);*:5&E-KY>J?6/SG[W]6T@K]&'Z5G F7?;DHH/+8*L%
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M/7O:,%FNN<UV5,K-$#@H)&&BI&N4//.\ DKH(K9O&3-A+%8GFIIW++0K?1T
M*S0DP%RYTP^]G-1;N#\)XY^I,W?B<4H]D9?E%+==V3$8M56"XYBVTQ='8/>C
MV;OAWZ(BD4OP%6&^C>AC&<<#[!GX(C(VL.H,N*Q?0LN:)@B/9F><8&DWX;I
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M!0TQ\^TCH,3'DE"5B-DOF'LO[Z!N3_=PF88R7(AV#/8X:8+*Y5HYUQ%G#F]
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MWW(5_.Y9H7<H]72SCZ@#!!>NTZXK/-);VVZOF!;X.NR7?;.B+TU?HM^(:>P
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M@Y?@+DQ[EU1@D/:."R1]7A5X#RO+F MI3_=6#6V)N0_HOK4)2SE@K/)^V<L
MT%D<1N7V*"H0O2YHY0T>+W.0A&9FSR'/SA>BA[S1;NLPC)R=+/)BY5X94:%4
MVTS20#2IS) 5;A7"WY*>0;UWHURKO,:5OF7YS>GQR9/9Z<G_;OMT ]"2?GKT
M>(C90SY9H7E##%R]"6NX[4)DUV_^>W8>%GP?5M8YY'JI[CM)<A&A/:E.!T]L
MC#)(>997KO842#EJ" @B\V9FZJLL$SV]+Q/=EXGNRT0RZ>]<X(.-?[9<@N@:
M3WX.<P+;<B"2 WP(*N:4);8A#U#?/.  ^)PV'_M ;ZG/NRF8,N"_0G3Q0GY7
M+F8?B@8T%>WLX/SMAP<PK&G&< 4 &A^^/;FQ*<4KQ4=2:(A@AH'+38W&PO+K
M/7!J:ED6G&)G''?Z30JR";V 8XK:R<N\4OG6?(Y ;G95MQMTVK?"Z("6])N,
M)5)3@(4_"C-Q&@Q'R]EEJI$X#1/+=P2G3O+OCO>##]+2 H.8HXB!XX ?=<14
MWK K0.4'ZHVG\5 NQ_@FV.F$7SY+B"T&GB/XFC\5P.!#),84V-'?PC4[8&F:
M<CYV;#R+[M>4>'U?E.N+L&]H/O<MU_IG\OI]\SUY_]>6N.0W :<2(C?AHSWC
M%J.[]B%?I?'(%U!N[$XP4(7)<X+?E$6\2B?E*"YY\I)ONU]_!^*0ORZLR!3"
MKD/<"FB?;=TX\>)EL0!B2V6,(G&="[U*L/"8J"AS!X78C#QD1T!D&CCC^XF_
MI5N'W7_J,50''[-=D!O:7$H=4ODOS*6G^$[LX9""7XI/>(W:I<B/-&?%1,PB
MRQJA'Y R>()7!BQ6)B$&D!Q]1(/HAFC]CS'%"'[B8/;9)2R)6";L; %L =88
M+Y>IL1 G'FXI5>@*D'",;ZL!L\TDW;6]@FOM2<_(GP?9=Q@#]?BLA9P#CW[H
M9V:*E9$>S9A],EO[W-:8-Q3@X&Q;U43(5(>CQFJAP\Q[XS>]V%=703!:<U6V
M"A-*N$%FC)2==;:H-U8J3D8GB8'!4PF47!,S[MM$0&1C!!L.&IPYL33[2P@C
MVX4.GK(M5OU,;ABOS^>2YH4Y2XR3JRHZZD]%TH,?FK+!RC,_O2^$:,V:*N^Z
MR[DF3+,0L92>-DY3J9Y?:VN@!C(.=[Y9[DH@1K$EK0$&CS'9I+K)! \2EDS-
M.Y.$!KGJSUH"B21<)(>JF:!CQA1(;1%,V5T'270=X==A4.1/4#_'_B158 K4
MT9N]K1?(;;#9),>1'!4!DXQV"^6OAX+V_GAJHJ:%Z\VVV_&["J:\(8U%>F/O
MPBIDA_/ET>R7X:^R75\F\I,*162F?AO<6)< D;'2V1.&><T] 9WGOY8F"5J'
MP/Q3SJTSY=S1 QWYT>VX;RKEAM7E7>6-A.0HG>O9Z*])MY$L9JY8&[HL<^*Q
M< SQC-[(3>&3(>6QY8=RG?9\?@L38,=G,N\YLDZ=Y%A*N(\-[PZ'MKG]4?6N
M)AC#9EQI+ 401L_011*D&?I(+E408+[*6ZY?[IX)HUWH#!T ]7+##0G-(=_)
MKH[T-2[.A]^O#W,DBJ'V&M(EFC7]2KX#@J_CDT?I^=;=NK&.*"1M!-@@R2?>
M:KBN@LNXI$E':X&^],&,\*J&525ZT&6!:J%-4S$:J*N.LU\G)TI;?L;].V6:
M1[K4' J=0[+6%]222^G+R!(5TV?A"0BU4=O;M^K(<"R2>^W$+52MI_AY172[
MB9#$'YU1;I7SP2L[%C3&E,/;+QM[MH8C$7;L^T) !1AUB$,(;$1GSQGG-$^/
MCY\[LK>>H>-J;]4EC!Z9DA/F@KY+X##T$HV#.G(/1R%% !O#.V MW3.V+/I'
MDR%5YUVI/BW'_+* VZ">[0_LK./)6+Q5MP\OQS-.2./J/T0?^+W>!%_[_T0^
M2WW;GY1"](U(CDI]AK_/9M'*6QJX2M@BG(6&CG>WH1Q.P74A ,,H":L/J8D#
MK14X MMQ-5VFGK/>Z=0;Z$FLOL_KKL$&UKF#QIP_:MR!L9DSI2\?4QH><0Z;
M7"5DJMA>\VUC_GO\ZLB"Z+1H;$A-%HH'X>]R^.7@*0EV3HZ3'0R# H35NB/!
M$4C?6:L'C)2T @(78'9-GHT_;=,S4FT"H5''4P?PA:5>S %C1DXNO<<R1S(!
M=W3AQ%/^9_O(0R;/?]A;_MK<XZ^M+/'LOBQQ7Y:X+TMXIV=<BLBT% P+_A86
M7AB)CT^.,\J$7>7PL9,<DM1[^?R2C."<4W>+'KJB"7!P]JG86@%:#W,R-IL[
ME$HT:B&\>7@KVNA@)[4Z1WU%^4<%P"*'J*F=F)CD5#GQ#DASN]0-%NIP^Z]
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MW'M3"4Q+6>[-UGO3. !FF"@56YT^6)$J)?N;QH>+XM E\1HK2^5:K;W--DY
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M]X@4%T ' 9P. 7#BO!!P749K.P!U58O8)9E32N0;\VQ=^NW+C9I)RL8R.9E
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MJX=7B$T#C"=*21#S9L@V,Q"-M2>0$1)^=33_VGIW4U N@*:*.DB&$B4^XSI
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M2]TDL7>T 0KJ:9(I\Y8-F'A-!M$-4UHIXE69E@*S:&N.D&K16B*@&[CAJEM
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MLHB+=^&?13@"[9YXS*F8(5WV/LD,-($ _0%KC<18JWY_C19J>;-I;.(R\4:
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MK1/ZZ3JA!ZUSKG5"/WTG=+][T,)YZYQ[^D[H_C*%NH7S%LY;)W0+ZZT3^DD
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M\RPK9K-H[L%VBC'6P4]U7R0:XQJN-4EY&*3+YC/3+2_+BY'NU,?=7^$LKL-
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MH*]"I/EP5X#+B.]Y0IO"E7(W%]\SQV-.QB%..+>:*].-ADKIA3]C\B$LTJS
M.<:3\5B$*2#;&?:K$=@;#20# ,3&266&C#',)NK$,SN0IDVX;'4@9E%A'"?7
MI)L2!4!*#C.>@""!7V"WNL;9;F!S0#EG20PL,>(&.Z5QV08#/P.9XC9[80R
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M7JA<^<Q$R3C2^F(!0PJX;R2>)Q>[)V\O4<Z^/+D\(1*3:_ $8?KUET!BK%*
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M8ODZ\W0)%]#5R/6CG-M3\1_X!5AZ*M'4+U$7"& 3R93^F158\$6F]#U']:!
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M&%/UG&&4!)]+B.DP<56$:/CH]7V(6M4)]DLXHN&_-*D:EDZJ3.=0Z0:%2Y?
M&#XP8=N0:C[KY!2G,LT%YA&A<G$MHLS[))5JASH'F]PI:(V"=KG2A7OLY6AG
M]$J"6K!I;.:C(V/7%NN7<XNQW(0Z 7A;C!(819#MQVQ9.=I2T+U3D]F"E1C)
M'L!".IO0I[,HF4]5N"]:.,H'ZNV@((\9UOPUJAHC.>:"CA+XT3.M=!M>!<K
M=&;,0&C>0TE>74)E=*)+42@8,NE"4<3E<"FT&6"B&%I-"];ZT%Y0/B**^V)5
M)Q>D^,+/>.;3&*Z@/J>/X;XY.MCR8FI>5$%L.%T89P4QQ1>DYES!OT$IF8DY
M:R=N63B_=.B^T9G@9&(XHUR;\\A-#_PS5LEMI(EQ74P#H<J<]T*5XYCK,7P=
MN274+:75S:I)Z"/]%M7A3%*9B7!$Z^+X7G7_Y_;^7YO[)V6R7GV"?>B-T$7;
M4#8Z?2G+YZ@D'IA9RE!A%ES"8O;[^!Q0B#X6LC9<VU2E2I1NWR=KE$FCC]%W
M8!+94XI>E,J!:_SFS47_C 60<,W.6-V&JU93ZF-QA36EV"CF%-K?!()SJ0B"
M1ZL_>%&Z DU&8<L:V8UISJ%+%N>%EGJ5)@]H%I!L--3Q@^;YB$,S:^^3>%U[
M2I&:C !PJ.AJ+Z)Q&$44_H&>OZR8VCM5%7J0F. 2,;W01GHB/EPE%%U?"OA/
MBEP12@1BHG4\E[G7/,PQ\,.)JK3F# )6'?^<JL<8<E(,E3AM"%9E<QK*^:#J
MQIV- 95;>%/)[*1M5R[#(M](G;-,$3>LLC24-8Q>@HT6X?&OH60$SU![5N2U
MF7Z 2)S<H(O(5Q6. R5>!&$:%%.TEJ%?N[1^-$*II5&Q&[M?-ND#FXJ3?-45
M^%XX9BAS!\+0"V?W@@UU3CF79;3&MXR&%K03JAIX-(T9R<'6ZNC728ZY5TA6
M8?82';N9),K F)L*1.1_<E\B @DOCA)Z;R+PJ!0: <131A7'L]-TK/[BLBG=
ME#Z')>"P.V)(9\@Y1RAMA!ECIQP](V3;"?7VOMG*Z8L;-+U6=H#&SBN!B9C*
M'6QO&,%#A43G-XE*MT7? S/U"(FDO0TF4S=.:)"6=A35N "N&U(=;K[)S2$7
MFK,L%S6M@VK'NBK)FZ8,R'#"8<EN/"P,JHE%]_D,^ .%MFD1F:]!J0[Z+$L
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M7D,%UUS8+\/"5]T"_XG#PAK3J8A*Q6W4H]I5-1S[#_^ZG$A/#)-KN3O%/"Z
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MI^&P0#)%$_T$% #H7!((?H04(1/7L&SX-W!R_!KH&OSF>YE$,A('L(IKP1_
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M"<2_'!A:!/KE>VNZCE9*>5PI9>M%% F*0*',*<C&D'-'D4]4'_@OLCL4-J@
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MV#BX!$A+V^IX9Z6_"126!+&2N.(^P/_@2WVT:7)9KLH4!AY*MDY'(M22P5(
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MJ<Y!;HL<X)G1NZ&@X,RF@#F&GAA2G^SQK=YIH7O,1/,TW)_QV.598[LQZ-A
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M<'!2K6>M@)4YF<MUS(PJO^O4[Q>!HVCVD$&'A\6?LSW@SQHX5_W2K\#OVLQ
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M4G,(2J=C%4QE+M?8[SJ33 "ZRK!QHV%71AU9AMM,K0+DT@0B*/,.I($ROQ?
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M"%>Z%/^ ,1SC/0_M&<1)Z*7#_V3(1SC17'N)TA*.,!S+,D8/% TX-=RFMB+
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M00OB]K6R+FA\R2:. 8JA(Y%%$3;B3ZV>83I];A!!R0EXYSWI/3H]A(^$1@)
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M)NQ03*1O03*/#^CC8GV/BWE\P%ZY47<Q*N;AX@XL*N8)?F"A,4_K_8B*>7Q
M[TG845O*XP/N6.3+XP-Z?, ],&X\P-Q.FRJ>?#MM>'A\P/X:$QX?<&_R_W=I
M+WIFEWA\0!_D.<0@C\<'/+ HCR^/.+ HC\<'/+ HC\<'W)](C\<'[*E_H(=+
M]K5/!TEW7_OD.?TPR.YKGPZ3[K[VZ2#)[FN?#I+LOO:I'[5/V2#X-1)%\(M8
MBPR6Z<N?#C0T=B57A5Q.9!:<47BL-5//,X(/CWUKJ^T1?*DG@Z%WI1Y2=&P<
MGOKHV"%%QTY]./2@HF/G_H#O370,--.CX=G=J8L^.K9_2O:.&U5_$PF6007'
MC"MQ[JG:R]B7KW[2BO'@PE<_[:Q9,[Y+ZSD<^NVED7(XY-M%D^-.G(W#(5_?
M+ A0PXZ.1[[X:0_LX5W:B[X9([[XR4=W#C"ZXXN?#BR\<^*+GPXKO#/RX9W#
M"N_X>-X>Q7=\]5-/'00]7'+/3*K7<LHY<Z-S,JLN/5E]@*?/%^?I8#3>(0GD
M SSW,VP.AWX[::;<E79X..3;2:/#AU?[:D* 'G8T.D<3XM('>';;(-ZEO>B9
M-?);>J.L$0KRC(>>$7R0YT""/,>@#WKQ][3B;R]-*,\I/J;T8E^ZZ.P0C^RB
M1>B%R;>X=GIF>X+6S>&KXZ$/7QT83_?.8/1@-WVDNP?O\YQ^&&3WX'V'27</
MWG>09/?@?0=)=@_>UPOPOO])%R(*K@J9_"N6F?<_'&;4S^0@'G-IUXEG!!_U
M.Y"HW^G@Y'(?W*^^LFO+**^']3JH()RG]V$%U#RM]R,FAOF8QU32=>)C8GWB
MS1XNN6?FE('LZT9!]T3=$=/H "R@\\'9:(?DCR_HJI:4^(J@739///GVUMHX
M',KUS79 L+[AL0?KVP-+>)?VHF=FB*GE.N]&#O=\X(,Z>VG2G%SL@_3S09TM
MM>B]J:+P49WM<#".PXL+?\0/)ZQS%HXVP@YY>N^.>8;E3D."VO#E3KWBS1XN
MN6<VU9T Z)ZD.V(>'8 5=!=J>=]XU4=V/%3?'IDHOA?3+AL<OI56;^V';=&^
M?7BG]];P+NU%STR1K8##/2/X^,X>6C9W8)#O#-?[^,ZAH63Y^,[#X)Q[@N^9
MN747,KHG^.X8:-MBJ>^]'=8WWNSADGMF56T%@.[)NB,VT@&80G>@EGM6/4R#
MR--]'\TB3_%#"T/Y@[YWX:MMT;Y]^*KWMOXN[<5> H=[3MG!^-8.[<5>8I#[
M0[.+837/*?O!*7N)<^X990?#>)Y1]H-1]AQ+O6>0Z3^7:WAS(9=KX?TQ^Q#R
MVPK]W)/UFYN-/N2W'61YWUC5EW75JO)VS*/OR[H\^?8FGN8IU\>0V+9@WSXD
MYNWF70J)/3ANN&>#'8QW^7JNNV[E.R#(=X;K?3W7 Z%>>XKOE]7D"=[G0)!O
MP]0;6O?-,ML62GWO#;"^\68/E]PW<\IC]?F83@_XT&/U[;]!LW-E&CZHX['Z
M]L;8\%A]_;4?/%:?C^P<?&3'8_7YV,ZAQG8\5M]AQ78\5M^!Q78\5M^!Q78\
M5M\>!7@\5E]/?00]7'+/K"J/U>>#/'WA18_5Y['Z]B4VU#^Z[Z)9Y"E^:&$H
M?]#W+GSEL?I\^&H?PU<>^F4_.,5C]7FL/G]H>F=%>D[9#T[Q6'V>4?IAKGI&
MV0]&\5A]3QEH>"6R- Y^'00_9FE^+;+">V7V(?#W<I5%,69]8R[EN:>IC_KU
MVBT\N#C?(:>PK^RJ)COMFE/?5W9Y\NU-2,U3KH]1,="_CL:GF#-X[J-BWG3>
MFZC8 ^-+>";8P8"7+^BZZTZ^"ZIB9]C>5W1MF;;J*[IZ'$)Z%*/I+!R/3SW%
M^QD+>@2*7X;'YY[>?0WI/!3DQO>%F,3RK_\YBVZ^7F4<6*7QB+?H!^>7(EWQ
M/^&_%Q(G#+0?7<KEBU6:1T64PC)D+(KH1IJK<?@7W"UG<DT*#>G_O= CXEXW
MAJ-/#\ZD-BC'IP,8>9)F,YD!Y1)IMBX099$&PV"(W_T>/ES]O\Y,IK$4&7+"
MHK;D8UQD=0$/'L&;RJ20F9[U^,126U%\I&OW[.3_U_^SU48ZZU)[.B;^O99'
MDTR*3T=B#I_^0<2W8IVK=9Y?#H[-?@[UM' CP!H:')_^)7#^V^ZL,YVE^'SD
M[)DZ+D>QG!<_J-?T;QD36OW8H/5WM7$-[XU!TE39[V0T.#]])&(Y9Y'.HR-]
M1;#(Y/R_OONWC^]?M=E57_I)_B<.!#R=+47,O]SR8M5/#A/AYL)\/J($"-)Y
M\ J>!K[*C= 7?W5XJ(OUJW1K(P>)&,-WQ"3(<[%8Y?('_1\OOFKI<91(*U3&
MYW=+(9K442S6:5G\,(\^RYG+!IJ5F6!5%Y9Z[(+_5KM!-JZB/NO:K4*D@?EM
MN%<N&E?)L]'S^AQJ=XW+7]6C_OC<UJ!+D_W>)T&C:C,,TC(+,KDL$YD)9*A@
MFBZ745%(&8AD%OR8BFP6B-4J@U=G0;&0P74FDB( X<W7^\LXEDGPHUB(3,SG
M0;K"47+\^ZK,I@N1RV#,D8  :!TEV&4AAX=A#T FPEQP!N/AZ#CX$(LD#/)R
M\@\YI0_08XLTQJ=X"B(>!!]A#OHK"W&#\PSD9YE-(_C4*HNF=,;^'0O^@A6\
M2:.$^#]Q'-S(O A@*3 @_C%*9_CP'.; JUG#@<O#X#8J%@%<5\$_2Y&!%*;W
M@-3P&^W!/,I@')$D</*R')<$H^ ?9J*@S_,FX0[BK[#!(J+%.N/@M&'X6'\C
M7@<3D4<YO<4+"^#G)0TM$V=^ R,X&NK%@U^ _RAAPO/U!A?5EDZIQ_:4T9QG
M<IHR'_] S(7'XD7M+[5K^+N__G[U1]Z/F6ZYE?>0\SP?O(Z5<,![9,KW3_7R
M=Y1G=?,WU:LBTU]UM,#OMDU".@7K['*3LN[<?,[X>%KG<7JKMT3_FPRH'UA5
MNH5-N%-%<>XH\ZB8Y&E<%G5%^.G<NJ-[N'5=+?FK@EKCP7"CZ],3XHD( ?;K
MV<: FZ>$/Q*'18C+P7"CF\H3PI^(PR+$V>#2GX@^$,*?B)X0XGQP[K6F!R3$
M/:M)[C3D'F/5D\J8ROLU2>,9_/$WL42ORW]^/WF(;,6[COE3KXX]/\W_^T#+
MO=,&>>2@2A=7ZP^]@I<F600#_R+C&XE+PX^()#]27WJ2HHT#XXJ[U/"G88I-
M&W!%3F1<[H,E^QX8C>]2+/W!/T"FN$NWVBNFV'7%Y_U\'DWE#NL]#3J[ZWLJ
MV+->JC]/OA&'2?[^ZSDJ(,Y"ODAW7N'Y]C3OA]YS +KMMR=U/[29+R/UERDG
M*A] ^:A&J\]!GL;1+-#Y#OU17GZAS!ZOO'R]\O*M:?XU_/]:%)(Y/YWS_U+N
ME&>+KU9J=IDKBH5B"D[.\KSPE<K.+O,"YDS*F6>"KU:#=ID)RJ2-#1X*^*"J
M.V'J^C=6G*X6RU+&P6]1]ICE4]_@,#Q)39BC$WT;6FY?,?:3G!P-3X[&P]&9
MI_37J#E])_16M:!/U=UO+]FAHNEX=CAT=JCH/'O!#DU6V('XU6MQ SM^%<W
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M)+A=I,&MI"?@E43.HVDDXG@=I+=)'IS^)8"Y+--,:K3&5^D2-GE-TSA_D3<
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M-XH:;2EC"62/ (7\=5S]GU'W(D$O)5W2J):O0'[!15XYK["BZ*^#0)\.JCP
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M2DXY>D=_T(/;B5&B=YFM,).AB@-!>9]8UG8MKJEJF9(LQ.V\C -,KKUYX.2
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M+:SY,<TR]J)]0!6[Q_8C2MX6##]RQA5X)(!3!4AW!I\UQ2N@AM 22:;)::G
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M<:&RE2KO'ZJ%][ 0I<0B)3=A_:#%805XO;[O?;19J[&^.QS *[@Z5M@.MWY
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M"CE%JC/N.:T^:(_,@C-^N+B#'$DZJ[H(8BEP48FLC(M/U\8.*1E&?MZT-W
MEDLJG*$2%F>;*BT,5=T(]Y/6\9Z7+>.ID@SJ2FY(K+P13;*8[%W4+6\7JA-I
M51SA)N+^ZEJ4+/V\U@MVQVJ^6<_\="Y.2JG&\(%<"-1AY_4J 3LCARAJ)C2%
MD,Z\:4GDOJI2.54J=G/AMDF*BE&87L;P  FG1ON6)"V<=E7I!(XMIT<;&=U&
M7)A<A F;683IT"KWTS1\[:!(@\D;44E1.8G:@L;<4"NI5/>K3)C2(^>=71!C
M&Z;/Q2S<[TQ=18J$IG[Y/M[:!U1]<64-W1<G<12+=5H6/\RCSW+FID%HPX85
MI$[3IFG.;)QU?98/8?O\Q[]=GIU?OKC#H'!5O"?#9.C,N*B>%/:HDFJ@1(#A
MKFE:9ER_KXUTJQDW-'C/5IZM.@0P_%,A9E)>,=9&](B/VBQSST9]8B-CJF%Y
M'; 0F59P,4Z)M8SN9Y3$2J,1--!R69"2%4?\8T0@K5T<V%]?Q,YE@9[X+%"?
M!;I'6: /Z<9[J2VM#]BY:59FLF].NK=-/R+9CZU67<T""ZTEJ:K=6_Q+4:[=
M?C;]I#)&Z523.I!@PD*"57PNIDJ< 3=FT9SPBM#552S2F0'?@%D-@DIYN<9A
M<M\G9]YT<<<P/[%O(40LCCA%AT9+T@WNFC:**_D,VVQDQ^91LQZN/7<\4KJ7
M<#7G!V_1>B/EB315DP$*5<(VX)KU>H[Q+]K&MSNMRY/-#*I&A2[9-'J@F&'G
M,_+:TJ;6[VQK[F<5W;&2)]E<626-:1"8,\4>3JK(KW])E+/(J6VG#!-TV@(C
M HWC]3WX=;,]KAUHVYXAF'Z68><8'=2Y%ME,UQ97ZUPTL(GIW*U0*:A8BJI2
MR,_\C"=@7%YN&5?8K*+"[<S+#'-SGE?:FM.26]U#[3W'PW:O/'NF34V9FQ0>
M-@ Q5-,P@1Q!_DI<&_F\[<RXIQWFRQNO>ALJC]O96/5U([>];JNL\]6?&(NE
MUG.Y=T L/^M]#JN !ANO /87*LZOA D8GN?NH(.Z!^K'U,%#,/68&CO#CFJ=
MJ,IRH-FH:V03.@?";5"+)5-_6)^ LD Z/:?\+<)_<*ZMZ4)$F.[6-2H\W;('
MSRI-WY\#IS+6@ Z/6?=OOB"Q[NP*0HQD*M-3_U:/WV@)ZS1YLS>:0W?LW]?8
MM#OV2:B6]ULL:P,GU85-\T[D:N3J?>C"?, @;EEK]VR_UXFO+;RHZZ&=O=/K
M4ZY__$7/4X7R.,3A.M_-$W@38H.]RC52_T1?2_@_VBFJYF:HK6=I&SQ^OS39
M#V66EYB([G0SC-&CSD+ Q%0K)<WV FYPJ(Y2 R^O.>#AEGU*4VJKZY"9Z.9Q
MP8TGU<:YC,+A)\9F-2&MMP;.58-[BIJF85K%=@],VHJ:C\:UN6,>-L3=^1RM
MRXF:5F#R^+:@^-28 Y$4@:O"N#%2'$J:)-6U_,X0_#J]1S[JT^%?6@<8!!]O
M4_.)"K*6"MAO'?*BDK7*B<^,JJQA8A S)J[&YD@_$>N*7MVU;=K8<2!R>1;T
MX".*@Z\[1F\JRJXK#MQH]RJ+;JB9;"RFK/T4E2=- D4GIUK5N?.ICJM#X040
MN#"?XKN_YIACVF.@H^/QFJ>C_U5M]DQ57DZH'GF%-4EG2/7AL*;/UZT2RJM:
M,7*'S&X0)L8&13LFKZHRYMJB:E^AOG+,\0\J(D$JK;26<^G.MX9#ESN3Q-^M
MP1%NM!5:5)\N\Z$SL6?6L!.J#@"R^*Y6DL EWBG%I69*].<\;;#W[K#LU*+;
M*:ZE>\WN#,W^F<'O/Z+++L)EEH>R$9L$WH:F9,]IY$UKUXD)^B:Z(!Z>RK+3
M.4;UU(]VF]XUTOO#JA\YVPX!79)"Y^BMF]KQ'>(VRI5O#B1WE,YX/&+ZB5RG
M1/TJ'&Y8T9V-VHPY>YCKDC4!=+77L FRUNFKV>:6^)H[J4WZU4TZ=KQ54'CK
MZ1U.B;I"&FV PVEL'K)$BG1'P4-.?=C(AXU\V*@C^QLC%,F,+TO]+^76[)O=
M;2>K+2/=NI-D.*K7):D>'+*'-=V(*!8: 7)FUYI;@6E" ;7LN"I4+^,I4A3!
M%9PJV]N1N4XS4;@&$%$TH\1IUY7,JC@CQ-,P<)N@SY'0 $W&."&T)-H!->.,
M2*$NF 7+:]P%N 10UDO=3*5E+8V9B27(._+9:2V'H%39)*4T6Y7C2P"^Z& G
M$'O*:R?MW?PWN\]I?C?JXP68SLLT+\@*090J<YD:0.PZ8>S4C']"[QK&FF0%
M'_YI)Q3BYY'?<BD_M6JDF-A6=91:OJ2X(;,=@\?PPVZT+:7&/_\L;38K.[IO
ML'WG/=G/A8<T'Z[R8:DL050)\_F:G(XP@PK;P1Y(6"Z+0X?M-$:CPW2]$0Z.
MG[D#^TR= ]#\\XC1NATZS2J"D,C,9X1]-*ZDB7*NDFB-!S;-$*9[._1XH9$)
MVV%"-9Y\J- ?$5G(E2,$10T+5H%E1[PI!L-F$_!0I)?!^QI9H:<E9:VKDD$3
MMQ/4Z?JB+!;LP,<-U%*4SQE.&<]/'3BTN;FP-W!:J#DVGS@UD#98*R:;"[VM
M*S>KXU;$M>1A5<AW(N>I,B7I9V-&YBDWY*PQ LM*?61?$P$<7$B]$(-KK&W5
M-@=]?TZ'Z[*N-D-P@C:F&H/XP?&(J-((,FOT14$%3=C!"0TH?BML-.%@&&F$
M<<"XV4KA'>F158 CD/^D3E'\98?&-;9)ZP&9QK6F74,J1:_*T_3YB'QX9",>
ME2L&F,6RK$QS@G/R"6"U7.%*I[#(2$&FFY^YL4II\:&3% &\$38[+@VCZ=;-
M,M:';JFM2%@CUUCA-+1E":\YI3G.%F12J0PT 1WHJ:P_TGUG4#ZQQ8H:$?N"
M*%1 62UR&95+'B9*"&@_SUO7P"&[I$<=U/ZN(J<)6NNVW0;)G&C&H"$B=_<-
MV:*EE;;3+LTJ62BX=.5>;1C%;N[-R."]@^"#E7;5E_3VA>9M>H/O8W3\&YU1
M@3Z3A\X@1PM]=<_D"J]Q/CW)D;FJ+9JRZTG& 2PDKGD&#N>*W&88Y*!"6\+)
M30K$$>=.;<A)VJVN88?=&%9HR^OAT&C<YD2E 05SH<*<%>QKC%Z8)A#]822'
M:+.*64'>[8ETY:*.\>%Y0ME%EY3X_]E[$^;&C6Q+^*\@.MHS4@1*UEZ2W=,1
M*I6JK G7TI+\_+V9F%" )"C!!0)L@)1*_>N_O%OFS42"8FTV93/B+64*2R*7
MN]]S/@+XH$)_O\H^9H[%D&-W]!_R ',)^)98PD FE03S,(SEJ&$+CQIV==.W
M8W(1,%F[<FG:D&.*&Q!!? P 0&@\!\L?Y(91!2A?9_Q->+P'V'W+] "<2D5@
M;ZAKFC5SV3YR4\ 2@U$^T&?R9Z(2F-4W.9X6A\ "I?E8-A7J#++9Y '4<39B
MWB!\1HX;=Y@[0<-&6H#N+N'T.B&7PU?TTF5(D5-Y76W1.?4 :&2K<XS?140[
MA9.!G-(N,)VOAIFX6=\"UVK.51,3G7 =-SERJ:GOGD=HI%1=CEUDC*N2'!4;
MJ49B3&;TL>4J4# @Q4G-O(1@/T@*W&8$4V_T\BWD<Y*Z4GW3HKYHMQJ#E]P+
MU<G:V%J2<53S(=<4X*Z#&&*P=1)0CEO*?@'W?M]GF SSZ$=Y\.8[["Y"HE?W
M/$OB@Y02=H0P@(P$'5F7X$NB(=44:OFP]LF>UM0I>V ;K8P-DZNA/]'0].$Z
M-+T.3:]#TU$#0U6 )6^886SE3(Q^4KFJCU!/D#;0(U18!T3^1UG(858:=9PU
M+E29HF16R!L[!_3'B?F>6T#:F>4BD%LD AKFA(@0'85/V$),TU!@([&C01Z)
MD!,C$.H;:]^G3.SD4== ]-*\3UNT.CQB^>*PB'NJ0A.1F!U.EWV@G44;3!CE
M$V::@S"O5X(+^!'_GF<-![)]PVCF$>AAG6WDD;>ZOD5%1 Z^"\(+KO6 +(PN
MD_<.W@)3Y=>J?=:;.X_92D[04X3[*2L>G7&<S39'E<SVI[%-)F)K^O755/1,
MMQHW=_$Z]0YXIW>J_'D02Y70=1A:P]K>%8[3(F;?P/$@HYR=ZLCG!E%!?(!0
M+$Z;PL8>;5UOA_/5?OW*2)PK]_54^A 9+8$W1$^OZWO@,DLN-&^C(2BN%C-'
MC^W)^.ON,9\&.X]=%&KIP6)Y7E%;[,BOQ5'18S;:36O[+KE7S&87JDB*%]X@
M83"D* "Z:%[>8 )HH63!@=Y CL@&G6TA$U-;HE3$ZED; (X>*L@XZB+;(L=0
M*#Z3TQ*BP9(+-]8T,@&(3@/_-G[FD!DJ=9GKXT>(4:;T&G0V?%X6 RFAZMOR
MX7I%3E[TR*E^&G:@9S-&YL&1F;D UQ?XPR A15\[,F:JF\;B/ZZN\;'-!Q.=
M$D^OICHSCVEO<T*RR2%DC1Z0K*LHW=T=]7HS036U.2P>A,S/1CNC:!K(8O2?
M)88LVHH(TA1;M)I CGUOIC(;._O^5!#X4F?PQ-'*?^3YQ/,LB5S8@F;R;7A!
MHX9Y!>GDT@8>J8Q2C)K5$7P+U0^.NT\,X%0SSV6$*--;WL!,8C@HOX0^C4N!
M;HL;[2C'DXL6'(4,C#[3FR^UF.G2SR9B&89*&;L8N6P:/'/OP#V3#+7QO!IZ
MN9&X45JTCJ5<=2AVN>/UYD@=CBIQ^Z'MH/**^'M90[,494JX%C<K\8'FA.8S
MN^5LG*+)(1]#D66^K^W:;_A7J(*KN:R/L,/X%R:&^P@W%4%E,+Z0:^$(V0@/
MCHUMD^YS260=\0B."YO*\K0>,FZOIAAZ3/W)7YTSYC<QJ]PN9RK^/:^;^<1O
M-\H+G#WG[VS0.6PVI23<JY/<:*GT=O,QHG'IQ:3I$XD--KYWE>I3<S!V@P?&
M4)-H/8>^8 V: AEZI5OCY@:R8T8QNJ:0O;VMO;UX7TB@AK>2<ZT1N&XC[QA=
M$?O>WR!1%\ =:]6FLLB!L5T&@X<.8EOK+I#C4=6RH(H1F[410L:9-]]B-DDZ
M!\A7%/[H%.H*+#7X$(XTT%-V)\5UB3.!Y6-OMXXIR0OUJ&STFQE1Y0J5L+W&
MB#MT]NZA1(=\9-ZQU'WCN[AU8YU?AJOJN,!^788["1A_1XG\(#O(B7>LFPHV
M-29W99:XX;3*(>&*1<,UEMZJ9U '*GTDJ&F>3#=3A"NP[%J!B:+; MWTN3@
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M,7"6/A8Y$\O$NJ&%XLP#IQ>4URS[@*WSWR9M_L7>TNS68[_H,X9:1OE>AH/
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MS1]Z;D@?E<6D .6M&[GA_)2L?J&AL" >@[8NBQ%J>HK8&#>YXK(]J?6+">\
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MU5QL,01VPJ.Z-E2+"U4NH'E"&>B?(W7SK>R?#2XIOCJA?VP^IB:])!+TE6<
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M!W/&$\9'1\^H=$B#31_9%FB>U<B086;:G&5Q! HLC)KHTX(&"<@Z^VH8X8
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M2X<-3#,8M*=&<F&V:V=!,HR4O-WO#G=._-/6[B(<+JL]A\D25*%U]"W_C.-
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M OZ^97;"IP&#+(?&<<*EM%.HT*OGK2LEUAMT\-"_O$KA@CS3D!Y=E*IN D#
ME![$PR2-3TO8^U(Z5 MWFP?AMP0"B_E4*"+.";3AP189ZR/;^ZD(!YS''T!0
M?7$4*?6]JZ-T3ZKX0D=LV3X]4HN+PW, FQ'S' MJ^+URNCX -N^I>+E@8"Z_
M=2S^6=;SH<8_B'81>9A-J+BI9!/()15CI(1ZEIP<[U7=%!1Z(GTC#8.KS(Q
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M011A"SD@J<;<:@-S*)2,N\G*23Z:FNF>9%O#>K+E)9W=:C,I)ZD20A7-D)T
M^_(0<8K:A^0UA<6&DQ$PE35"C0P9J["K'RB.& /,3Z99PX6HX4U;B?EJ1#*P
MO7]Z+-EHU.1M:X%'_1>V=0E)G(S1QI#G%EBV/\[H(A[PVN9[S.8[7]X5<1TL
M:KNMK;[X"?^#W(\E9R1+BM'_^MOU8'1TN+U]N'N]<[ [O-[/G^]>#W:/AM=9
M=CC<W1_M#G8&^W^C,"C=<7YU]F9GYU_4S(CA37/RL;Z/_DOD+]_TS?.JB_8K
MC)6UW,Y6HL>,XDJ-6JF--CD9@#'";7<71?MAE2N&E_RJ[D?]T<<CH@"YKQ(K
M7%TA?&,&:TM&K*D!_7&MA7 8S%LC=Z&O^XV["32%64^T%M!\@-_,#=3"+DT3
MQ62:0>NIQP$O,?R4TV=DYA#"(R;@&BK\'9?U?8L04)"L%FAO-"]PR.Z)_#'&
M\!FR^80]XWZ"G(MS&IL:%WO)@_YM$=[!/9H0.28<KGR*>;K]=9YNG:?[$^7I
MOJ: M]T(#,[M_)=5E.+0+F\93V3$*--1M=Z 5L(N-5^^0]UX/2PRB08$6.<3
MX]#Z 8YY4Z. ?'M^B7X3> )<PF8+*0E,'2JBLSF4IB<EAA<8"4]4!S3R5RUW
M]9M/!')>'(<1W_":5MY#6 #X9GL/@F%@J2%[]"76MG.5'2$=<0WV,X1\RUP4
M@,L_,L&B-KKJV="X#Q"G,RLY'V%AB?UEUA12O2XQEM9L;:A40:#ON[RLIU3W
M#JX05;3CD&&./GG$^61:U@]Y3E#07V7LB$TUSK$!!2[+F[L""_N7_A[\$Q?U
M4(AQ!/ :1OVQ_:.^'.P)8QG!-THP];$=$..4"G8$[VD8BRH>#K8<3?ORU@15
M#;$Y$4;^QN5\R(Q,UM+0%D;WL&E3@8:RY&M3PG4<8]CFJPV!FQN)<8I,)#BM
MV/I.DTKQM1F8J?U/#[_K!&I#/Q83+$Y+=HW>5LLYI-AT_\G&\WS*;S$WFMMA
MF#O;W\F M @Q(Z)#I(62A]#_O47:Q\"?3+(;P^ AV=G:Y=?L;AU\ETIX#1'G
MPN^!@7S*]Z"DDK [[4QX1.3*UR_>?]J7L\33G\Y-.I&+S=/]:]//F:=MF:;M
MSC1=U8BVFOJ;4EBW_(V'H26(1\&D@@C2^Z[N/1>U/KM&'%"1G45^(@CCEB.*
M@%^5WZ].'-'.SWWNOC^O;A!+Q$S3;3ZZ$7[3!0<7O-[D7!]-?"(<8S3G*0Z(
M,2#'&V(?CAV2F51NUHZ&0KMA;H[%/J"0]Q(+RR?#Q=$=^+X3T(BOUR)V%!H?
M"DH5/@/+Z1GFM,1@^0S$W;QU@7?9-M:S([P.!S:FA[JJ=>3GXE5>P,E=59O1
M+.4$&0QD*P3V8>&J<6V5KA$8!>K[AY0;&R%(+.<;L)"=%H'E%,.A!-O"=@/[
M7C?:#:YS9T1YB%M$U_6NM"/=2EZP@<FVJ6)=,AMHWI#E(I2KH&\AC7$'Z%XS
M:1&VA;MM/N0[\+SQ^P=Y6>1W8L545IK"E\DLX<&@SDX\]XAI9%8$FUZ@))CC
M'-)ZPW"!'A)F="!$]H$*@@]A486QBON<E@S?7 ]Q A'/ZF4^S*$7B<)P>SMI
MLKN]NYU20)\?1X/&>8;;;R$3[<X>0S;QN!&'LF_,8->-Z[*H$<V/@4=!&J[J
MV?RY,#O!J)>'/_I(4OPMMMOLIK768KA['?0#\IEF99[H?F5<4[T11?Z/\G&&
M&"5F#<M29L(<0*3A1J M&H<,(?VL]_-'<4Z,^RO8#?V A\R,"FE8I+UNT-8E
MIJY\/D;?4/6W7MM')Q6)"6H45=2QKN7\7B4!]91)FY3@#<37 @X)@DLBU8 ?
M'X1DG-]'X4%G<F\7-DJ 4!L17O\W4FI?EK+(=H^.=P[R[>OL^6%^O7\TSJ^S
MX?;P^BC/A^/C[&CG^;:D+)Y<(/1@'0A=!T)7(A"JLGV[+['^9@K7U.-+:QB\
M S?SR@BVLW^O6+9O=RM18T;L#3OJ!(>=P+B3,V)I=G]<5]8O4S%PLGR5:#Z8
M?</I_;.4"JS+EK]L0[Y8>D/^FC5-)I;C!?QEO2G7F_*;;,K3I3<E::2UF%SO
MR&^[(U\NO2-/)N:M4##Z,D?K$$)SE]\$/?'/LC=7N]IO18;!'OSP^.AX</!\
M=/W\>'M\O7^XMW>='1\-KH?#X6!\/-X_/MX_?JH>_.':@U][\"ODP;\_N;@Z
M/[\^W-T[/#KZJFYZ[[GX5,<=ALC-\>=6NZCXP]Y+BA2WTJ=]TI@3 >P(K;'B
M7^9&$:]8_&$/X@\TYC2142=NV.A]X,"1D.'W,?F>K/(2K3$<'!_M[^Y<[V[O
MC*[W!_M'U\<'>[O7@VQG?^=P+]_?.Y -KC;/_AM.)+U!'"5N*9M!B02Y?_5X
MQ3;//A0Q<_++&[2T0=&X553KP>$+F7WU"Z4BWS/>XGIG/;JSMHULS+=W\NOC
M_>WA];[93M?'H[&Q3(Y&V6A[.#K8W\Z[.^L !'=3ER"$WEOF3&/3'._M':_8
MGCK82F2TA'%AQ[O*O0VJ?:%G]'^TU1]I8ICF#93%$&UC#EF^3(+06,F"Z6RC
MHBM.O4$B4?%0#?6'*D)6F[<;Y9 99#C,BFHE*#VINX,]/$]^O!3;17OW N9D
MZ,XNB'V]05XS' KT#4)EX,3, %8/$/\G/ 1>5B"LH@)LA5^$\MVA5/,?S2LL
M'IQJQ^6VATF[I=M7^J:%&P=3VT/L>,;3WIN^: H!![WBQE4'9$KMSO24&9.K
MULC]#&G4GN[3% M6AL/Y1+&7#>O)9 YELZKYF-YF9\OL8V-%0-[9:Q^9M:HB
M*O]H=(-M"G*_N[2PZTZ& E[&Q.?=B]!_9B:AJF\\KRQ-1>M!<EIR:%[YD5EA
MZC=V> 1V'MT>%ZIK;DC5=->NYF")(X$I]U&.95OF$\PP$041\,@!/!>O@=)F
M_C3>E_!P@:8G^&)<6!_-'0)R]T7;X1=O\QELSMFMH%7SRF\9"6/>;6XKD89U
MR2\(S[.4($!Q3UVA@^"F!I!3A[=%?B<8#' G#$VXQ&NL.C!+;H;S(FNI  <K
M2*T4HI'%]P_\Y;T9%6()I\FI>=78;%?91N]HN^ GG-YFA9FKBO\#+G10]GQA
M2I4?9G#<VOLI2[N1P2D=2\?ZA1,/.WO9LYV#C7S320OSGZ--_6.DH7W3E@1Y
ME+4LFW#C".QD5SPV2FPGPG4:72,L+5O5:J,W=MFM)#FA#R64<D*911KL4A0N
M 8NZQ;5XYJNF>=]Y^YIT5SN%9@>I#++8T8*D(*4V^-]">%_(! SU!/C=@1:0
M8<O-EW=YY%(84;"CO0T]EKW;F/T\TK\\CF) $ NLH9U &3RD)!?EGG8^A9Z+
MELP1PKH=DBBT.^)S- A>D*O"R]B#![71"%CW)5@8J5XPU]="\KK*R_11D>A#
MI#:YPZ/VZHM]  T\]PWAVK)AYBYU,!ZT9S[R\D[G#?2E$EM60(_N4&8!6V&*
MBMQ<,J_PE3QQ92ZUG@1$R^ JT]H<5NEL"<R]'_!P"8LHA0\QU@>APS*;MOD/
M\@\7!#2"8=:8_QW)+10FPM/#H3QQF+Z?C?2%H+^@6X?/()Z]63W]\?ZVF.7/
MS&D?0H#KOLFF.K\1//-K2CV)[*I?(*#8(RL6A?0N'R9&!OY/= )WCGP?,)B%
M%?J>J3#8UER-#K*I$EN 3//6UB:J V)L(N + <N2L)O)PC<Z&[ERB=(<[7-7
MIQ\" 3N086)TX?_B4_VCF[KO8;M]C[OT:TV7'X8^>EPW/,.+ N6 \=_#KJ[D
MJ<>'P]N6C!6LS^%?]APN4D%X_+Q^%^*L(+\9-'.5@UI&VM\:E)MQ")?2/U^@
M:5)6=!FB0>7%E M>L,MJ5,S$-5(G&H<]R.$YV ):5U@,W!E"-C>*RSC_#HD\
M4.(.ZBH0&?#7M=A8BXVUV/ L5R,*[H"\!R1!XR(I,R:*-H=H7LFAP_/^[WDA
M[<38==2$^/WJT"TWIVBA\Z2VHO 9?M+U$_6VY$2$U]8W/>A_EIJ1#N^/:R0K
M4 % F*S2,4W$BUG6XY0N1]YAN%,H6C8I6K56$$__38A<A9_'"US[06MH_*0F
M&&F%C8!58I>/A3#%& _U@&/OGAFM.-P#]]&J2<:VW;8.P(YB7C=-3A<#PV7A
M%!/1TK$W)7QCY$S!B^'+S6 ;VPWVY"I+GJ\K2]:5)2M16;(*LC*(]X'28E3+
MGAS;\G*3(L7QSE5LV)MD'RCF5+3\8HJE^[%UT,XTGF%3H.94Z0,.DIW6$R/:
M9R31+B%<:=2\>?2[YB:KM)$-%U\!2+,YI'07\?ANG+Z[?+<)$C.,W#Z#'VX(
MP?-5DTWR^[KYD&SL;N_L;:K\ .45^S\BB-\OFIOT$^?YWCS,+M6J!LU/S.JT
M,TWF*<MQD=\4[0SS!N_G W-[<N)\L5=%,UDU\^+JVQX-8R:V1IOGQF><$ZF@
MV>0O4+A#JNBDG&0W1B__G_HVXSO_1S:9_FCVZU::O,$'TL/+&HY$<E7/A[#K
MZUMC>+;SY&>P@B#_C WPHQQ<6=BAC5N'*:V#\HG'9ATP;XGVCN2>"TG<.>#9
MO&SS>TQ+1G/DJ[H]3YW)% J -GFWHKD;VHM-3K !E0?W\VG[D7**@C=@K#W.
M!2A&:=@EH[XMB_>C>Q.!B$'+DZ(Y[,$]&%/\0T[\K9T;/E'\_3Z%4)TM\XGP
ML#O[HVQXO',].'J^=[V_/\RNCY_OCZ[SX<YV_GQ\E(V.(I51AQ=GEV<7_W7V
M\GIW?^?Y]LZ*%4,=;B7_5T;X_X*"T^O#W>='QX?[V?7P\/G.]7ZV<WQ]E!\>
M7X_V=K?'.P>C@[VCP\@7GYR S+/JW!XZXFNYWME?M8JPPY.M!,>L;! G*FC8
M?WCI(!AY+S!O>(L% 0"J@AE4/+?_]TUC?-<:$KKMA^+_)< W"15&+8."HQK"
M>AKZ/ ]PR'P>)/5:@,\5GU41)$#]$Q8EN4BJ]S9(YS*FO=)%@F,?B9O"\]]F
M[2C[=W+*!)$,5>NPWF] 5E0<'W)0]\)2JHN32D([,@/WAF6SK3P70P7UAA]=
M "9Z:@S17(9_/LLGR2$46]FT[&5>&4\Y>>,'=L\$$1!?LOOCB;H'+^C<ML7S
ML8(EG\=[N\.#H\.#Z_V=X?/K_8/L^#K+QD?7V>'1,#\Z.#S<WXO@7A^^.*U'
M>3T^,P;"L+W>W3G:_<I%]5_A8+^ 6L\1>A0TSC_V&$=*)"F>.*HI@6%'^X)!
MG,&  =Y7VG7X"0%W"91XV=))O045:N47%3:E_55-K-=+L%8U!)DR.KDNPK&?
M+%==YS"LY&P.>69RG 21+GYM%)Q?N_1PL2,UW]U^]LHCP6"O$ZEW*DQ.V?HV
M_A.+J)^-10VCO" V'QH9<BI@^,]C$-G?/MP8^I57EUDSR,Q2/GOWL<P?D&CC
M,^Z1V@\I?ET\*Y,\,S.,I5G&UJ]&&23'LS8TX/QLG)F;V@A>2]E\6U< :H5;
M"9[. (#S88< 2?YL+-=128L.\*/@,8#5.)UF#;O/8[-Q*8%N0;,&^>P>'"7:
M%XQEZH&CDH0WV^*VF+8_*H[H\;PL4\SEIS;!GTK:P%+WT Q@+8 KMN-B50K:
M&C=)JE:#&D>J!.;]0)6GF+N#0<@HPN"K.IZDQ$#\PV?X=;V-)6SYXP 3V1&&
M>42V$''GEY%"YFQ.:^3@YLI*Q<[R36E9EF!6,=L'<3+G7&?T&)$+.&!%A7AW
M6$AKX:^( DP@#OW#%E(US:=<*HV[^@%J5'#_P^[)RWP*YPGQXQ#9Z@.ATF5F
M<XS0K&"[:YFI-P^]:1 +RSSA/BONL'+9G4GXF3BRC<U'?T\)R3%S1$B?L-8(
MQD45QE(A#'=6&:%_\>RX3S'CH[>&6X._$2K),%CAR]O> V*C?L"MM8(&U,'Q
M\^-LD!]=;^>'QC,\,"[2\:[YU^CX:/\HW]L>[>:[$0/J]+TH3 Z6F25]E6,C
MWR7A0:^:.74*^3%1\F[0"8R:S5["L5XM,VO9P%N&H4K1#3;X]KJL!^9[WQI%
M53<?/B?F!O#>5 !#81%WLW^'Q1"G7')KE*J+WK2+PS<($KR]<YSB \A*D>!C
MM*;&Z"F("2T(\3VYM.#1.BVX3@O^\6E!-=T[.UL'7[/\YO/LNQHZD]!:Q^_V
MF("RFQLHP#%R;@Q2G!@,(M0$1C* -4WJFA2^$EI&L\];%73&K()@E2<( ,S2
MK^,E9ES@YTFQE5+SR]6MJ;?"*O &@,W"!)DB,_& 9_-9+3_0Z<9?/"&@"_GH
MFJZ8G34R,-EQ])F]Q7 DL?DIA[M;^T:*J1D*BL;4"5#/![<&B!)DUN2_GT%)
MW0\D,HVN'#TJJE09F;U4,&>_L8B*IYCPPN4K&I6J>:0&4::]KP)Q=VO[<+T0
M*[ 0.X=;SW?7*[$"*[$^$BNR$.LC\957 NN _=KV+]+2*V(G?=OC_BT^<E'@
M@\,#G?]K0QM?Y5"Q.<E;?&?Z$<B<BU$BKNFWGH]%R%6/S1!8[%]I-M:+__06
M?^?8GXVU5%N1C?TUBIZ^L<7PQ^_?C5\N_YX4G(.%1 [$W=O-)RS/ULO^M98]
M(LFZL>/A,,_'XQ]73<11(1MF9#9V-F.+^JF?LD)[7)3PM_NHWW\+8V1/Q\[W
MO*R&=ZSUL(%G%@?^MW\FQOU9<(K7"_Z76/ G8'^A<'IVD1/$&R8<-G:C0NHI
M;\V_Q [<721QUJNWXJNWE/1X,C;/5?:1+9Z]M<7S%U& NVN#YR^UWL=/TMZ!
MXGPL>P=;YVEJRM\_9O8T=RBW CUIJVB]UE^VUD_:B*IG6;G6IG^)_;NSMS:?
M_EH+WF<_"1J9*K?X_'%ON?58@!"GRV.W=H[S2:0 Q*_J6*:&VQ:>?(P\#E^]
M=9B+?-T]V-JVQ=M57>5V>@'4L4ZV$X0?U(4;GU $^KEKCBR*=F9VGP=3"1T-
M';0]&-6S,GNHY[,?QL7'?!0K$5:S*07KM'5\5;5P\.%@OP;&(B8H%H(6ZKW]
MNU%&\D^=Y8A"&YX+B/4C5=,$Y%8QE*'M@Z?&?&[@Y1Z,>+L&PW4W^5UAOE/#
MU123/N!!/O&=T[[>S-]@,^\^_<U,R<.&X_-V$T.G9='B-K6_8<,F@M:HCF*Y
MDQO]N,=;8+K5?F]X'UO<I=X]SYV;A$Q$^/W<^^PRG;8;?%#?Y:H3,G7=!N5#
MRFV=T*$ 'V2![:F!BQ&([=NA]]=<NMJG**)=G_@AVGOZAPBBT9C:BAT;=4+J
M@67<2&;FGF9>"B\#]) _8/\@--!3M^^"C1AO_D(1:ZV8/[2)-$37>6],TQ-@
M3[HS!_Z]YGW0?&9_,.!.E5N][*/G*/(I(!NH 1JGP!ZHK,4%!T'7Y?@ $V \
M+XU<*86CRO*R$%,'K#942;<P=R(Q$;YF]L",&8!CR*0>*$YMJVE*HY0=Y'#!
MI@V@L0\=RCDS/B'U5 <8"%^?YZV  -7FE02&"#@'>=4R=Q)RE(1#C?>_)GEU
MD]T(JQ. O2-2,\(I.&RBQO+N] $I=\8?0B*5^8W6/N&G$2KN/1# X$">(7_7
M':"N5<_LY$7[W=1K[>+K-EZ\&Y98, &P/S[/D;[-+'J#,>!,=CP_L;M%MI(3
MPNU(8_L./]-AQ;A/ %(6.$0/MGF8IIRZ\<>=KN-'6Y89GA^4=S)DZ@T:#*ED
MGB\[65O)>P\_"L$A8$ *R463>R'X-Q,&8"^A&Z^YL":E;Z:[H*]Q8Q_Z9Q(A
MFF)KK9976IL!$R0I11X3 ]]PX5=))SCPS]W434%'R+^&C]VST&9*4:3;)SE*
M']^ (AQH191HML8GKQ:=Y#)K9]$]<:]V#3^^<^HK0. :WE+XY(A;RDGY,"\8
M'+[[O+QC/,&)D:ZW9MTO"U@3D&664XI(I^")#X*]L[,?7Z9;8='#]GA",K+7
MV3D=YS*?8P$:R+S$"L)J&"7Z,,V5LF4ZF):Q7!C4PY\#.+,P"-AP2 \! \$=
MR?P2WHRF0&B(0!B,7>'VD3?Q\5FF9>)%,5?>&K&/.F FF/?C8+=_XDDE-B=Z
M;JXWM 56TF!),82W)P'$N#T^/A[M98/KH\'^]O7^SN[SZ^.C[:/KT<[S49X=
MYD?/MP5A4,-MO#S[F$^F. V A6(FBY&=+@4B:=7@-EYN)6[,!. "2RR 5';<
M>% #$VO-=;P$;LOSYT>C[=V=Z^/GQ_O7^[N'V]?'P_WGU\\/L^?'H_%Q/AS%
M\"W/C*X;&J&1M_7XS(B!V0-S3QL%,7@P*W2^:AOI#/4SC1FQ\'#4B1NV6"3G
M1.4*$O9D# XPRE^YM_EK;JHO%%?#_9U1?KB]?_T\'V9&7.7;UT>'QSO7!\?Y
M[O'1\6!OM!?;9:\(SKBH+C@\84RC4_"PQ^ 8 OC.JNVR5UL)C1E)'>VHK<'L
M1J^P@_Z2.^H3\3F'HX-\-\^N=[:W]Z[WC[+]ZZ.=<7:]?;!W>#C*CH[SO1B\
MU.M303M[;;%4KP]VCG</#U9MY[P&F$Y!?G6C=7OCR2$1':^1B/(U$E$G@/@7
M)BAI;S.A^08G7!@W^I"@%5,OLG-)T/_USV]>"I8R\(_ MD3GB8,^CR)(6RS!
M+L:J2[&1WZD "0%.$>_WD&,1&'%BYH,8F!XZ\-8>=NQ6\@M_%" H]J#+YA@2
MR$NFCR+H)AN#B7Z="_ 1HZ)/CDQA*[#Q?L[N03.713Z/D4:99U,XDC,DC\ZC
M)88WDU.WBW%S&;#5^"F_;%UN):/:;#8S9L94_:I^YY=MU?,N7/EYVV1Y622E
MF3\"IZ7YIB!HP/65B\.F"&X\CNN#PYT#V8.]>X"7G1UZ NP,XI^\HFEB%ND6
MUSJK%CT4OH0AN62L#A=,+^R::OFOS=7XC\)[.:DT9EWYVS]?@E5?#.82L!+)
M) #*9FNAI+\U5IXYV/_XOO@G!K7K*<D(WGJ+L;4IML9J@D4$\8Q\R,,WI@Q&
M%R!8"CM@,;%#@]/Z[WG6F%\Q5<V797=940J:NAX[4K!0$BA+JKF0\MB0GUF"
M"I!WZ5QK*6$ABN53YCC\D<Q=!'B:4@!$IZ('D5JM%"&\'0AFKX@D!$''@0CH
ML?]:G*J>I4K-XV9VEKTKU101(C.$A2D<R="^6Z$N9EZPGL< QW;P!)1[TS*K
M[!!L"+47P52O7"TVAJP>L.',&P:@I]7'T"VR^2(X\Z+9\."<<0=G(,V--5=!
M4<$=:$;:F3AP,&O< I$2<!$[8RI8+]C(\X\/B/,Q9")+#KTFESX1!3M'V^;E
M/*_FZQ6&-M<@OZR'<U;(56).IYG"![&/*( _RMMA4TSEQ,*DG'TDFB$T>URJ
ML#8+<D.0R]^6M71-3[Q6>:OT/0M5WK_F=3.?D";[];8H\T>L7!'ZEJCUW_@
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M\<[1O9@KV-._'KP_#$Z?@]D[6S?_>%+_2&4:[R+#'B,K2']O_?2MCH$HQ)8
M9&JF9"\CS8/5"[3**W+S\NC(Y_P"?!NHQEHTM4/JMZ<?099^LZO;8.L@S#KE
MF7_P"V[GM&'=L*0*D/[%C/>I<D D@S\_7);DSK(T=@]#-K&O!Q];*%O+6L"<
M@+]6O='[B&2OCXGV2KT$8'EL UX0J2+;U/S1QS?8OTXF76^37B3%=Q<LG$)P
M[(;:&R &HFP56+V=G,7N6=>Q(]AUV 1_!_\VX(SX+_6/(P 26.OE>>W@>J]P
MWGG#G4]?S/Z#&],4S;)TC(B+78SNB;&X0HI=)L:(F,H0K,I0:HS&CMR8SI9
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MEHH*_M!X@).8PD# \'U1_X(JO"AK>$807@+=;4847+18)T4VD+YM#^BON[<
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MC8@],@3:B!!L!/[((&@*QT9@#-J($&P$\XA,1!CV 2 3VHAP; 2.]B$$^P"
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M!5^(^TKV,<HI%7\DWSP9VC%5.^^WP#M[AC5?Z^SZYR@,AG_YOLT<K-.[/D6
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MZJ"0Z+PAT;5;LU[X9KYO7JX]Z;>Q(/+SMA.>7O"P=]W-+Z@G;! @:QEP43,
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MUV,I0Y\_TM-,R90U\(BS]@&<Q\O-[.UE_R.M431G;$A+J/#J/Y^;@P&\G.C
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MIM/1T4C66K/&2%\^[>IF;;A!5.IQ!/7=>A.M9$I1UDPL7F?R?+MXA8X<'D=
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MY+ZE 0,(&, =,H!KJQM790"%L&I$7XJQX6P^JC3RM75Y77I9(P: U)%37V-
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M;%,/U.H@B"0(.?L**D/'4/E9@U!UWB)TP8,9BK%L);LPZJE\,9L2&9%Z&<Q
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M^^CQ[OU)-%/$58&GK-$?\C:LKI$V']+-D2X)$MK10\AB5SB'5L'PX>0]LWI
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M-6*V;%"/2&D]!TN2:PKAKB3-!X,_]&H*$^?P5"A;04):D4H-*<:0).X&/,Z
M=B^ /$+>_@#G]1BRFT-#L.\[@7EQ:^Y#<\V+;D1\!8_< <;./2T!DF.W#X;?
M7#2FJN ?\BH TF"#P%Z70'L_CY.'N140N($/=ST5K;-#<$2_21JQ8NOD@,)P
MIF'G3-$96;$<#AWB,!#[/3AO&^L@&!> <UDX":(%',$(HN\><+;_P=M<_,#K
MQ8!+?TE_6Y[4HZ0TO';LK 9TU"&V'1^EO280JO!+<."U+,U$G ?-*5CZPL*:
M>TH<\3T2[; 9P7O2D0CF>#2(5]&-OG48-4(:0'?/7:.%_"5Y[4)012(*[MT
MUL3XI=Z36CJ>O2)\-N^&JX/\$*).(MX1G!_<KR71,U"% VW:6(-5"=O)#E=C
MQ_$<8L8!R"0=[VJBX*=PPB#)A?G I=MK)VX,X/?$UP%N%,0+T3B+K3W@9"*%
M,!6L*WMOTWK^<$OX'A[+ZEJW3LSAA" IDL\V0+Q0X1@T#RZD\P+0@WLVLB^9
MN(;06W%.#R;B,<<;JJ:?F8R,@:M.$Z>B H4)#EBDC8PB;!6'A.'*$4L3,2F#
MI.G *M!G*$Q#OK#?J./K!\=F[6\?740(C F0[-;<7]AGHZX.PP/N+NZ*IH+
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M'$'X&*JY(B=!P+0 15CR&3!9=5=@F>X0 ^R_T.T@$U'A>,-^F%M;$0T'<Q[
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M/#(7@Z2"@_@TBDA&@H/PQ4$$K,D7!Y%X# C"#^> .%,T. A?' 0=2*]^.(B
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MZA>=HWY12#E57_CT7@?BD"N6C0U0*([!_^GHDA%$U(@-IJ@2S71?L=W'WCR
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M5QT;')SL]IC'0L!WV?SY6YOEY"MU]L3.D!$W8@3QP3#1D!$W8D3RE:1"1CP
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M5O!T:K22YY-$B8PV_,G?"?+#R9Z[<R2V?:R/6H1^XX?\<G]]K P$"UA\-)K
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M+K[,S)W,&32V4M.#1AE8:<<T@><+5G5-]/]QDH&Q6&)>UB*=*3?MI!5)S*W
MI+WX\2_]>GRD\)J!+QCDW *H*OHOO)N)P,9WYB.2/)+M *+A<R#6>&/*(<$M
M>',+^\OQ]%B$_JH \5*5I[+MH^G?KUA!PUK L#T2(3.4>$^=CYF/U/EJ"IST
M7"TB@?0WR5.X_X\OLMQXRTITG.3R7&3.$U*6$F?1U.B^^NLD\?3,S<U%KJNT
MRQTF-BAG#:B_Q.MQ2]V:_1B$T6F@PY"#D& :\,GMF=; ! <I6\06V;;61LY"
M1NYQ; J4-T$486 J:"+P'Y]II3$:I_?D3@+(Y,@: JFQ8/M6>^/[^$Z )Y7P
MO0?>,AB.>8Q$E]4W!]!  39,8 'D3/NV7P*>4^&NK=G&S=GZ6)IT0,X=GV&'
MG(=QCC_(=&<^JZA"?PG%ZN. (IM0'!'I&@-:WYWW1$:WX7;@LV<C1.)P#.O_
M_E][\V6/LA%!WF#GQ8*Q:J270AB!B#^^5AC">_\4U(7@6NMD?')[VM3/3>J!
M\N0#1\>28CM_1Q0Y(B<Z06&':'LG) 0_VS\D8?WA!V-T ][8NO&3)%[1D0U0
M\"+!BT6)UWCL2MSZ*)2AMLR"T>O81 #Y7^U:^E20_EO/X%T(RC)4'W7OJ8*/
M=L0*41L^3]LW,4,,'?OD-ZH$D;;P[VV"/?@0.:9<83-8/<\T*TR:Y=J%-%-N
M!4%..W-)T#MZD+6D;?8D[2_L4IX*GX,*&.@W09)Z/_1J8+*R!B$-1E8P6H$?
M[#0%G46;?4TYI0 'ATZ=ST<$>88[FY#/[+!!2F)Q["#]@/V%Q/1U.\3N$2QA
M^P-S9YN"9@5>E6&BL3/P"\0'Y!T@$PC\4'4!7<(_.HZ"_C9\:&BE$"9QAA=R
MUGT7]:0'9J>X8HIIQ69L;I;.UG%'3X[+H_,1%**.)5N>%Q$X!(Y_IQ<,KH^8
MFP=8>\>O6!7YRL'B35REFSMAU=:G1MZ]";:.39#7.)8!QT"ZNF:^%Q<(,"S8
M.N?"%!IL.[C>T%%AE(V>'5X)B=<K5A$T:*<]-TJP+&!9NS*GR@ITC\:Z+J$'
MUT4_CA$WKZ&C0]??<;6L]4-O_30DFB:8ZG;PW,?2^XHQ%F8Y*)."?FHA084J
MA5[$VR-'-T9?OWM/= L)W0Z5"T(R:#"ZL3P73MLA_S$=%S[A=-%#68BZT(6W
M]BX-'TWS:2=#6%][D^IZO1=;'<;%_IVWL=@"2@\V "B,"F("&"\#GTSK:_E!
MFD?K%^_GB,8 OBR \3IT2[V ?0! D)%#TN&% R??ZW$<?0@A2%G\D'+STN<
M3Q#',O"[=]8QS! =';DCW(AKAJD/D**]P!5;A4$7F NF[*G@/M.N&:82.V'J
M9K?IRW%JFXH61YVZDU6ZRU*Y.8OK%3G;N&^<VJ(KS1$W;>%*5VC&*2FVJO96
MC0_B5*14$ !-^WW%.U Z\&$$M\WXG@K?OAJT/8)J[,_WQR@";0"0^ M*BZ^Q
M&2#X\\GD8<44PC>BP3L)ND,(.J5?[ZB'-?:2UIINKY'*]$)K!-V^][1.T$,&
MR= R  U]?_3XK]BN1^,AGPDBZ_=X1QJ@R0!0[U&8CJK,X L&-_$0 ]T?F3(?
MFAT;,AB]GXD>$[K(*"\%'\TW2N)8T$; ,T*B;(K.%-D2<8VL/A76Z7EO.P%X
M^&'Y&6GX--Y#ZENH?H]>6\+<5Z+PK4"MW=POZ]8))8).@8ZJ .&/=K4GL.4;
M,P:) 6GCOF"^!=1]>)<UPX%X[>',BV^F3GBL]MC4G=$8?>7E7D[K*^)DT=&"
M?44$J]NTRS6.RST?:QY'W/LA\GZ"!VG[9[?+M_O2B:;O$M0A@$+O@8\3=)*(
M7WE[>IW/WKFWV][JJ77N,-2Y..&-XFH*<)!OYNU5*=,O%D:/M!V=.-R.]GVN
M@,)?/=3S]VH7]H1C)^GDJ3]ZB(@JN!#E?@[E)9!.(<).3+].I/G"N5\LZR^C
M:&-[9L'VR[,O<OC@!V5'WB/!1SY3:94XJB4B7@\?X:#6:%>S]O.,-\ULK8E\
MQCXC?$351/M[)&/!V^T4T(:0H*ZC(#\.N_Z6YU'58Z#0_'L*G7)WO]FZIOYL
M6]-B-"DC0Z2';H45^*=Q7HWH6FP@X9%JF8\.5O6>B7]]'V4--1D'M/5]K/OT
M[EF1K52B#C\8*G*K-ZC6^9$BM6#PCI]R2]<P^W 2MO&7H4!=5R"(Y#4$8FIV
M"MVWV1P^1\,2R&*JWJ CO[Z7^CL"H8[B-;([-Q<<'>=;;[81CY"2)Q#'%;;;
M[53H/QIH"VT.D ]C.*;E"%!;4:T-=#MA&*'[6YS;>AMOJPK%I'I %M_/7A/&
MLS#Q?[ A0&YA8-V/ZO=N;FOP/\K4D$]G:C99$F1>D+:N;<SQ/KP?EEF"*L!P
M#RP-Y+%;+_!MH$<6Y*%0  P_]GW[]9)WY11).Q+H=2+*\#7OV( ]+(Q>.:US
MY$G_ I):ILVGQS(8LDL@.@AP E@-D'1A="8Y0Z)3;"Z]:A;Y8;VZ>OMZZN<#
M+YX-9"$+([+=!^Y"4-O]R4F$'?=X;3HBF(E")L;E)#X>E*-+B+#4"9/[L**R
MA?Z'?<1K)RF3>TG*7_(+/I)F;59[<PTW3K&SBI-845I#Y/5?]PNN(<TQ/&O0
M-*.4E98QF.D&D6U2V@))\ZF.G <5%6S7@7S8I[QUUOT* FV93(;6!-9D:P-^
MT<]2B_%0^OK.Y34%>D!JY9JS;*?P4FTZIT&-2%/#!A+H4SVV#RHJ&X'>=<S/
M.-(/WV.2A)[;5/;*V=$!>FDO83D"FH@2>]$X&4O2-TKL[3P(<_ @YW)[;*68
MSB5-BF5GQ# K&'0NP<LG&E-.KWN\QI3D?B9PARH>B.[1)<P+AGG!K^0%3T9J
M F:H0!IYA=@HS++&N@FI!,PI&FR$2K)0I#44YF@+R]_N'@B:\E'^\&$A_-;!
MV'OH]RN'FZ4@X<LRT&I:13 5X&E="SH$IHPBXL.&3L_LYJ6:9?.E8A[/S2PG
M&8G:]487[8\3U!.9W?4!KUY%"WIAL"O,0;+ \AJ\UF@9;"TB67W9V9P7?.D=
M.0)T8&P ML)=D35[A95>O<)&: A\Z0ANX2N/"BS+5X.]NU-)>.\Q$*09O"K4
M' NNUM',>'B_AZ7IO9(29=VR]JQ8RJT*J,.N-MQ^['N]ZY_DULRJ#0N:! ;0
MS]0@)VK#&MI27R=[=5XOS_6,*K'"@'VK,%+;%,N_,6Y[[SE=QM\VJ9LZ\K%T
M[:2R*;'NL*&["8>-6&(T9_0B@V23^?%O+/J$NF:A$H)3AN21$L=_F#/R?)GC
MW6(;K]7#\GN%U_46FSPNY(&LH9RQJ#NFY95$#AQ+1HKN;VJDUQ4:36 !P13'
M6,T<"5K0RFMYY3^;LB/;E*'*^^56Z\\LQS"@9[)MZO7L 5SA77X.-$DW_<N@
M4MG-S\SU[5"YAQPDJOUB'DBLN2P&'T'O1W+0"Z$KH+$+@E\HY)C0BP*;%D2(
M)O K5.^*AH#+4E"WY)5!^1EQKP:5PI$%2^*8)+B;;+BFVZ@:":Y'ENBP#!,5
M'(FH=$9=EP,%%/;+3.U-@9!?-K4UENB"\#'%L7!06OI BOYG[1!13Z?G61TU
MP/O6U4^0C 1S4PZY[RJIJ.M\SUM[@:H$D(P"+'9&ZDYW0WDV8-.)]?SM;LFP
MW2UL=PO;W<)VMVV[V]GLY:6HN:^ZB8^K?2/>HM]I@4MBGTIT'C7&A>['5=V/
MZ-.Y'UXF %7/>X7O$K!$4QX@/W>@H\E >ST]LN\-^UU+&@H(H%E$NKSGD.RD
MC. : 4JC*!N>\F_6"^+,D7TE1J!KH"%K_CF\ZS%KF.<5H1%)EA_I!$T WJ/(
M*"AX)\;>U'!^L+ETC0KS"VXO$7AK#,,2=.@1C/S0]#G;Y>,D0<9OM:UT?']&
MD[P/4Z@6*6C M(XWE@S;;2;QE6TI.;R9$LFZ/"C8)S:63J][O(TE E]#[2Y)
MUI&E3YI;F.8#Z_*A*0DPD7E=;XQM_ZRM4P86>J/OO1T6M-#<W30\WW;8@90@
M!1Y"I/6R+,@N!)K@-["AJP7M56B@T#KCXDV@,M<FP /G.?)?(*('^1QL"@!R
M6*R#W8%UCN;XTM!)E*'L2Y8WG4T"H@H?3WJDG,L?)MK/EURM:1O/(6@_([WR
MW/BY(8T:QD#:C$'$WT,,H!^K#:%6('>GY35Z;[OC_1&,_A1'>%^@'J[8'^;H
M+7G!JC*DD. $\=/_"%/CG^U>6D$3==/03>1.>2[0J<T\O^%<&/E3)(,1D-[5
MUS,@7['Z3D6\U_IIZEY=CA.4"WOY)_WTY<= ':(TE8R&#O@MINM8#NV%9R'=
M_8?/1BAL**M VHZQ:K%IM*:"\L(!Y6F/\@GLKRQ<BE7UP%Y1%!4A22I)4G_O
M\01-HM,1R3V L("J!HV(-I05[YF]_P8MB&NJ>H7]!W@&_5C?2]V9;*>OF>FW
MKT)(\F?=/>RNT]6Z2T@2%=W%-WN):!)R%7J(V_X1QH9\F7JZL-:!8$>QU@+)
M<@MT)'RJL":5SDVG<7M_1Y'^[-9]15C*4V?*>.42M:'G@UEM/04*EN6\T]L^
MFS7F2R.7 TIW8<L.34X32@^5S#UA0?,K5D/ZXF)$[%0Y"B24UZ[MMXM[BB@%
M4SSWT<C/OVSBI37@80-@+\#!] 9TL4,\PLY D==IX$]JP-(056#PEI7MU0C9
M=VGSPU?,'\&Z,XYR%ZK67>C[*6\?(X,.=U_8-DKJ?X>P:V0*TUV\9=H5K.Y_
M'(#L/N0)NX#G;6_Y1'H/K=ZC_C$8_9EX$>.)F!]<ZLMYJ>VDF)I2BN)SFFUT
MJ![[]0KQSZC^&G1.0D!:ZI<7JE),X;F9!/0B&6O6EPR$ .(U^7P@L"X@.S!A
MWG2=@RR(EP39E5$+NNF/*X^?%$?_??GAJ%"DX_JXQ-9HV78B6J^86BQ^K9[F
M*P9M_9M-TMKW_1")=<VKO-TMNT$I65UKH<:M]6S:@IY-%W09<"Y.:N5NTYQ.
MU#V#B'^APL:[LJ\#?G]9W9NIX>L'9)KWU;:J#=\MM,G%A[-^+"JSY$AJX'B/
M,B<XJFJCZ!<*/QY0^[!R<^3-.9MAUCO@[QL55%*&:=!P0- 7 9"LL.KRR;3C
M2TT8]8#+J-L"J0*J[$ U<IO;GC08T\@R'YT.JF6V57>$QK)5CTOU!NHS/G4T
MZX-*R\9I#),A807*9X4FZ%'.@H'I($"%.$"\0*]X8(&9 [8Y@H&@>O.%K#$
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MOGTA4IC,<HTRX)QF)Q;I-T"ZM_"6'M^_-2&%0J73YX"17Y4MW:RKN09:>O0
MH)]A*ZX]&7".KJ?93K/*S7,C%$4</4 SPP]2(V>R4N2$4*;S8)*V108M/7J
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M-]L<S?-^IU%4LH&_H=Z,+,9P@^$&P\TW5/,^"S>RHX,!7Y]RE,X_53K]YBT
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M:WY$+SE%?[)7:]HS[#//A7R7)9GXRRYD__D?6^W5=B I!(^-A86](Q@?1S1
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M <<-WJ[,@T>0=))+$C_1]_[[T;/<?\3IU+9FBA'\!B]DI +[JU^IL,$,B F
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M0I[?^T TKAJ,6V'#Z@T0T,YVWYT'D#;_JO=U2 <-B!>5@?^&9SS=W+Q@[U[
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MPYKZ"7QO P1-882X((3@,4(<#2$0,ASHKH@N3#!? 1/8HW%9*)' *'%:CZ;
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MA4V=@V"D:(/?1(<?R? 4GUR; $^_-1#U3J$^GD\][*/^O>V!^6MOVP-1_PO
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M"B\ MZW93[;.F6W$MHW-=3Z9OU8&6KDYP)C['$@6];IJ'9IJB/8B(R%VI0M
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M[)!H# Z[?H<S?K[S%4_X!E-RP+[,H:@7HG5<[(MXL9+]@1/4*81DDS^< <Z
M@.6^!_\@Y0=.7X6$7#?X'>[*7JBQL!WL:9S]KUT4":Y?65DWG\Z#JM:\6<76
M9L22K3ZI"W=D1I6*J8<>BGI_)X5\:O/WIS*"+4;603]J (F8X2M$YQ\T8.2M
M(C*0^@UQ^.\0B]\<0/@@8DA54_^WJ_%OC7JI1/_5TDVOX_,@Y A@D&IKAP@L
M.<0;L(WV2Z2E*V='9*"9(0>:9]:0'" WQ4A%V;YD+A#B6H/2SDH(0H']U#/\
MCQ9UMGTL3]8FKT17"A0_1_%;*\S\IRZM"(_J\U,>L)TF>  Y9V@V2V4F&LH$
MFET OM6$;ZSA'J].'ZX/O6M9AD'+P=4%8DOYX.ERZ8/]H+-]N],#BP4C)TME
MK>:),>K=T>:M#^FG'K_)=2BIX\DIF/XFX;S1Z (@HH,X3Q#4U"-3T[#[)@+Q
ML>0"D()4J$\?10%;*!,2G,??@ O3():*(4K\+D7L&Q9FK'0Y2-\/4JB_H8D)
M^%]&?YD1^5=&^-:_A;*U:Y$=:(PE\U:]Z5-Z%9\':]H&$U5?1$VHRW$M2*J
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M1E'()$5H.-\@@IU3ZCI(& Y9-AS:>#I;._*$_\I@KP;M<WZDNZRII;<,!1^
M$E1MYX_?7?'9#LIB+'C$1UQNS@VTU5H^@(>ET[H,/*L:S%H1;CONK&+2F;H.
MOR]0S+I0(^]('T</IVEEK\G>?Z'_=OW#<Z 3,=F-J!75J??R3GWH6.[;&]@B
M.8U#/!/,.K;CCI53[]##.!JP3P9+\3QQ/W0MK<H:)N %:L:CAA1MSE:Q5S32
M*VE4)QPX>N60^*;>%HTI!C_)FGJ;T>GNS.,H>TUSC'=@UDK_CL7Z.B]J"+3
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MIF$][Y=I=XQ^G /$@LNL%CA/";(4TD3.SHZ^<>@O*3[YZ)E0[%P(EX._5;D
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MK0S49<RI&E>64]0)^)?U[\I UZ09B14@1B; Z9423NJ,CF>$B;4P3/&=MMH
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MHC%/&Q)LW;$^=!QP+@UOL1;%CEF[:DU 36C/F=R=K-?X XHVM.ZZ B(EJ!]
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MZLO3"_'J>0IXI4IU(O&Z6;I+9'0V(0.$B5_D? $F"5%<9NL<>O2%YM B.Q)
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ML2-2!YD_9/ZC_F7=?U/!N/CP?P!02P,$%     @ H%MR4JA]_$HBH@  L[@
M !<   !T;6(M,C R,#$R,S%X,C!F,# S+FIP9^R\!U143=,NNLG!@,@0)4F0
MG#," R(Y!PE#$,E!,BA!'$D&!,D@&0F207*4H))S5H)(SI(SS)P]B+[O]YWW
MN^>__UGKKG/ONN/J3>_NZJIZJJNKNO?L$?D5^0.XIBBK( N@H0, &O@/0(X#
MT@ N-C8.-A8N#@X.'AXN_F7(E<N7+ETFOTY$ *&BH*&FHJ"DI&7@9**E8Z>G
MI&068F'GYN'GYZ=A$A$7YA7CY./G13%!P\/#NWSI,MF5*V2\-REO\O[?_B ;
M 4)<M &,3@PT.@"=$ V#$ WY!: !]<1"._\ %Q\T= Q,+&P<7#S\2R!!^34
M'0T# QT3 PL+$Q/L]0'[ 4Q"K.LW>:2PB30>X- Y0WA]P]_ATM\I;B+6[-]D
MX#-U\</#)R$E(Z=@O,7$S,+*+R H)"PB*GU71E9.7D%12_N>CJZ>/LS,W,+2
MRMK&UM7-_=%C#T\O_X# YR]>O@J*B(R*CHE]&Q>?EIZ1^3XK.R>WI+2LO**R
MJKKFT^<OS2VM;>T= X-#PR.C7[^-3<_,SLTO+"XMKVQM[^SN[1\<'AVC<*$!
M&&B_/_^(BQ#$A8Z)B8&)@\*%AOX814"(B763!_NZE ;. V<B.EY?7,B=\'?%
M37CT?)J;Q*8N_?@D#/S3C%LH:.?(_FO _/Y;R/X ^PO7&' 9 PV</ Q"  H<
M'*NLB'XX7;9[N55?Z9DFAQEC@:% S^9HN(EE2+NP%IQW3_M=S_YMH]6SZ:.!
MC?L;!#UU]Q%$ZXXG(TC@8$D#">#M5YZMPD]VV=)7(H6AY3;4O1_A=5!1H:*#
M%XO&/'_Z]^1.F<:F#@J0P,8PC?9;N&V_>(H7$O!XZE8[>O)YIX@4"02<&"#V
M&LZ.TQ%$9[_XKX3F*D/+K9/_G27B#\OC?V&YYBV[A]@\7?K>\)TFR:,![%Z\
MZ-Y,64WY7HD$&K1]-!^<Y<D5K]] B4T_5\%]!@G\1=#P=UHSQ'":M\0YTXES
MIJU_9_I!H'?#  E,Y4KD<)\3SO]%V'CH6PCWFD*<@3:ZA&%XCBQS3^'%?@$-
MW[<#+A"*[/S>.4/V*ZZ_T,8B2*Y6_T(V?(MFK.Q)K^5$??I.NLMQ:$^=U7GG
M"?QD!PF,IH,WM>>4:BNN!.LP":M2!]3<A'2N0$6W4@[U1#<."AHVAIE.V:D>
MGXQ,@;PO.%I-B,LMRDZOL+7 IQ_8-7RO0.&$?_HT"O]HCP2>-ASO_C)0U_[#
M4 U9N>PB"B00&%@(=H%0X'M+_WIWG"F%!&PU=DY"+=KV(.9>05M%AWJPC8-U
MT#ZC2, X]%#/Z]<=.$/9-&-13Q"SWUS$9<BIT^KL$"34'\\.H1N3H"'W-C::
M0*[9QYF2B*%WBP?4G>$KS&U[Q+/PS6*!BSY0]*LBL$* L@\KSGXF ;1J7_F7
MEC?^WGG*K@(_V82CID4=6L[L>=9: JIF& I#:1</6OJ70IO%[DC@:!D']+B5
M:(P3S1<I$]Z<<@7DU.6S]__6AR#A;$ "XAQ_0)2)G8.P;ML[-TX(*+97Z=P=
MV>WA"*\+AP E6Z,D]QL+@0YPXS[B[-RU200;4)/X-P2*;"U(8-K,#AQ6^6LR
M6K9P_FXSE#CF<X0H44\O7.HWQS^J,YX;JQP<-X[2 /HWECZ:J7!;=7"6S-/J
M'/]2 :7OR?ZO=:9-L*Y(#7=>B](-00*?6L#):W"\,/H?J7N*OF<YTKT_Q2."
MMAH.]<;^9LD_8O\RN<9_ _@?L7_\H%W&8^IO>OY=ZO^7C"/T$OK? ,XG*U?P
M=ZK(?[ RZ/:\XG8M#>>(=P8N#$1Z'PDDQ_Q!!T.AJZ8N,_<:#8%_:@8!+F;0
MG$NM00*GN_X7^/)0^"+IAS3"5\[GSA1E1/_?'!&G-'\W5AQU6G#H+YR_^WZM
MOA__:O6_ D?\P7F?&_S3E]&&!IRSDU_S%WJ^+K/3Z8=T0>4^7W2!T:/V'"HJ
M'/X#'1C1SBT*1K1_N3D7?!ZQ)L1E;KS(/ET%;0-&PG-G@)YYJ9T',%2 [T4%
M,%0"8CXZ:P7CJ\91?[6/W*(Q'X@(QPBQ5WD^<Z@X['@>L;DNXO"_T_V:X;^"
M=]:>R*\L4,F5#68+,,(7D8.>Y%\(!QWI% GL+4.G3<#0_,L[57]%8Y]., 'W
M5Z/RX!9H1XK_.0?=/T^!.^(I+N=I]3P?U)DA2+!_I12%O](0F*G!*6<J^Y4R
M4)E]-!C^J7$4^A%EHQSH-/2BFGV<\?E$Y]5_SI7P3_!?24[K.*/Y+._N_CFW
M <<+V41G%YDM]%!MK^%OJ3+]ZR_*_O/$O@7_JQL4#H[XN_2UD[])GP4SN1W\
MMW ?T ;G*?8\KQ)].T#M$)3^\"S_Q?/=7UN/OM_0'?^"_AI<TK\9X4.G)7Z+
M#Z31 @TZ\'N;XJBVP?7W#<TNVX!;[2O.W5J[5\X+"F26K<I#:@3,#H[2-_![
M^D7QF=.J>_J*A Z3D #U2,K>MX9H+QG/AB\;A_ME2*"P^S0O_<KI76=+FD:K
M! T9XA4:;HB&#  6-*>T(.8K=X*84P5 'L\FF-."@(N""='Y&9LQ/FD=ZLT:
MXU:CE\ ;@(8_E^R]I='\[M*+D >U4@L;[I>S7HZ*F#[USY3.@:S9KS$,6+>D
ME6.'1!$5#"2H!':-$Y )MX@>$#..A(4\RK.G\Y1;ZW_>=!0O?^!P[*0V*R?F
M^,";?&R?9ZE MS\&@ZRJ]@T??5@N)*GCA@VT-]368/VFZ1;1\J-(<L#E7:(9
M=4/8^RR2J\$Q2^UI-5QK9)P/'W;G;\V]2M9_2]RFF7J9: 4.*Q)Z81YT(PYK
MXOH1Y?K+#7:>Q*T^U^#CH=QP,S>F?K(RG<:^UK'FHG%3(E;2,&)A2=+'L\VL
MRW@"9;QXIF]N$K59C'VITAV/$'\:=9:A'HVWSY-=D%,F7)!_*]X@Y3M[6_BS
MC!<Z=SXO#V34;IZ^>K2\($W43I]/R,P@."4]OO5.^^4D7F:QOXQ=$K[:A_)/
M$[(]%3-SS65^UQ+=]_*#,@:_OKJC@;*Q>2!$0Q+K?UT&G@V!U!CJX"0!OR<*
M_5\*3SSSI7]BIO_W1K__:=BO\D &H@7\XLT":,A L-_)0-0IP)'*Y]Z SYS.
M[W\NN^AA'Q*8P[)  H8Z=:H?2^\@@3#BV#-GV,*7M5 ECL/,);<R#1G/%_U8
M_^)T VS=""9X:WG6V2/'>2,RQQGZU]P(#.&/U-_Q[,OQWONQQ.-&AUL\NM?N
M=-5)SM1[>+R;2,U1<*9GJRZF2H].,J')E.^@1!@G^,<(OAJ#<R>%B'84EA/T
M)4;* DNGN^BGF_IO[])TX8LZ[!7)M!B.*A\M:;]@8@\O=YS.WGB^>GMF*Z,;
MDCDSIHMOX$0^9T(CO:YN]-7 YSD+AR5GCL/ !H\]YY.^M_3BE=Z[N=(Z0VB8
M1L*?2<EF(YN@T=PK0E;YZP>"\$;7Q*=/AK9[JS6C;\4KCB)BM107I2M+%*@7
MCL*P\=^^N/U*<F*G<9%JI3XORP"VPC.FW\D6H]>^HWV9Y)[8-<_5]="GY49[
M2M_$>GGGQ[M$'CYS<0Z=UU!Q%_L9PIX9SXU>O (LG^9&Q'L5*VJOFX?<3!]/
M:']'ZK)>B=,+IWV2X=S:[<?K'7X:J$+SXIU=M7W\X2NQ+4SAUS?;#?U4/:C$
M[?A.5 ]<A<9N<'(C@747 HF/6$S[(=^J=A!]"&LXMX3GE4&HH>9\S@27TA&\
MJ&YR8/>UO);/ET[&+Q6.O)_ZYK7-GSVV*B)?/APJ2).FKKP\&B%'Z3*1[RQ'
MW- V!\BSU<Y3^DX5N+;G&F>8"E2':]^4Q#GP@6HIG15DXV&<%=X9KS1/?D'6
M.Q++L.$=?V*KHR!W?-+)L\Q#=7M=T[!&HE>HDW!/Y2O#]8F4S]1[SG50<P>N
MEPT1; 8VIWX#=VLKS4,W #DJCV,=H?'"^A[[TX7MBK7QY&\]4%'X?N86I\KG
MIYM^1TV3;P+Z9K6J4\1O/&'TG"54W<I_39=WC<J+>^^]9BF):6N$)W]T3N_2
M143C(7K=WOQ:'P<)R-E@9G*+F'!?]=J]E7+UG3MFF *DV1BX:X[6*"Y7);(!
M$Q1U49M>2 2LDH]O6S =8@^T[LQNYTDKEB4HA&++$"HX#4CTZ?NA-2(!,1U.
M9QC?>_Y< 3<DD!>'H_N1\\83#[P/3!$)/(FSEH)[^UFW*I_&$@A'7P[]$&%Z
M![LIL)$> V.@L/G=>%=8C6$UWQ=J9B>,R A<<F'A%F_+C$BYUVLY EWYKZER
M)8:"L3OEV_T1_(GOOMHF.2P8K(R62/:+O8N*<#$S^LS$A$..(1XH:*_ZTWOK
MR79HF7_2BJ^+CRKV%?L)#]/O?7R&QO;!9;YZZ\;$+L+BKH-!/8.F@;OC,18/
MV,2LR<P GM9,"0_8,F;.L.H ?(!.=/+HJUC;)[J2@&NTRH)\T2U7G9=55$SW
M>9@5",7ZI(E?H361T5):R-Z^?&^_[X=.G:-X78+-R$0L:T!QCT%DXVR6E]*5
MZ]^WW5ZL7U4.5V&M 73Q:C&VFJ]JKU%&%T8C@8(@E?PI'LR.!#\(.YVD/+TC
M$[F8UV#^7L)K>64]_6MW^V7)M0,PY^8(=UQ789>F0WG7"P9^S#&PYW_V7X '
MWD-T5NA_HWB$AIDYK%C]"9":]4WV6 \2R?F($5/F;J$[7&1DJ1O%VZ7]P7HH
M.)O6+#06V&\6+\\[X"5)Y'G$KI<6D;$WYAS=6\$Z=TPI&/-^V].<6RB*'C>U
ML@=O4<)7;6@V4]A&_2NL-9>_WAR3_E,^=*1B(TY^_1D4)O*N3SS).+^;(O.'
MK)0@\;L3D1MRQW6+5.+>>[GN[PH-Y*P*C<>_\% H-\FE]BKV%M#;&9&IQ>]'
M?OV_#.<VUIM2?,;\FZW,01-M>6PEA8^9YW)PWHFO"B9'M%]OHW=)D_G:^)@<
MA^8M)*,P/R@@RCQ!R*)_]QL#D9Q7_W@[W=UW]#L\-\D?1,AUB'M"83)]]O?7
M-E]7Z\S/1XA<DA7D['*@791HN&_;YK>_,/SH\VW6GU=\!R4:8'H;/V?H.Y-&
M+]^G/VDEA[YAD]#?M>QPJ_DR9(3=/[#@-HPQ+H7?H4\W<5HQF?G8A/K,9M-&
M4'UB_'E5^+S0*PKL9_P/KPX(76G<%4,8[[UQ+ Q23/;&BKY3!5QII/R!X,_+
M-LIS(*JZ[6\U88:S2Q,MH7] *LXV>7>B=G,!AC!S*FX+Y<M0NCID(=?4HD:C
M3.DUD!FL-LMG3ZG.:C+-$.H"S^N=Q(0?KY+OA<@,1Q?.F8"!9&_"92I.@*RA
MQJ"A_/4+4C(DH">ZV[J=D2Z1GZ.=F1;$7\@/"1+0^QD<RX&O3+]=$<R#0=YK
M&#Y65K";)[\V)IPLDOEF07[.L^#8/J3FR43P&U$?MCCO\;BKQH^93$(9D  N
MK>\Q?M1*Y9S9NJ:9L]E@A"S>:0BG0KE=B'9:TI'2U->8&0\.V%[],*VLQ\CU
M.WF7-UW;,:C]D\MM3D6LL!/<'S/.]>1@NMXQ"_&<&/<DW]N%IBBV4"2M1-%-
M;S_#8J(TR^(ORIV2#Z1>N/,>RN5H7]W#FF@KD<$R8'0)"7Q3[V6-*]2AFL&=
MW?[19FG=M)@LN@U7C#OE_C#>O&B\7AUMQ7;M-=O;5S@<R8>[^6Y#G.E,#S=2
M8A.1@)O)4TF-LW3/EZUCYG3<3;Q>V"=329SZ!U=MH1UZ#8/7>WJ^S]P.%59J
MNLF=^H,2(]GK1,==C6/^RV:^IB),0.325QJ87UF0C:V%$"F7V]^]]0;,(C-Z
M)'XK7T$P;8!FLK9D&EAY2TN4N->K&LWQ_?4#XB\*5).-:J7LVZ5?LLA9L25,
M1"M=6S^:2WL[.R0\B&H16<+V7%44N/0!XKGFE*S7>^!R%<H-9>UN>5QCN>)V
MI!DA2/K96;:2P/U)?^LE[HEP;$RT\,0/32* ^T+N=^N^;S!+I=T3O;OAJ6.B
MW#UHO0SH?(VG-O9[1]=:&;_<F;EK:;9 $[W-LW-9Y\EH)5%KB8(2)_KV[:M^
M4?>45CHBT^U)&GA/19D]:*><=&86;L63?;)0+/2JD,5K6K.U5^TA=]CMO$&+
MH41IMW.7:,%AWI<!(7Y;1W/*B/T.8](GYIMRJ>+.1_$/JI,RW^A$!X<_(ZPM
M%+WGTG'P\(V7C3Y]:J1TQ3;UV*44GK0:\QC+@)OJJ8N4V\)[N009!E61:[%3
MUA9Z7VF#,9[;9PDSH%\57A3)#<V]+S\>/]])PJY&&3DT2-]0\QPN*A+',%[I
M<JR=W5LUL0PM/?-9"!CCOS8NO_$TY]:H=?00&JW6F]H2O*96[**II9@(6W;E
MF6%SCW>OKE/Z+0B("--C,('I=\JN:KNNE.7;\FB]K>.ZP>9)_<!1F[AK&QG.
M-L2EM^IH::R#\:!/\[;UZ\G*,0L%(S-""[F8KJL&XOM;K:/$[$^IRTR:]VYI
MW&BE?%O9<^D-SX[KQN!6_E&Y]ZN'!07^D&OI.2:>/EUZ8)J[!Z\T>M":_.-V
M7J6XXBXT$$_[IX3M)6N$96;K"YT6$97YE;LG&7JR: 0?9B.3>;V<K$.E*]R#
MSTID+?2,W0C-;-N#318C>-D$C62W31$6GZM<]'XN1HZ\Y7*0-+GE1,;ZH5>]
M:OS(Y*GVNE:UV)#C9N3*?IC>RBA)Q09]*Q$QMB3:[#(2&#F^1Q'A_:HPRR8K
MK)W>I<LK_DV9;L5[7IM*$W K>@W<I@+_5M"*,I=?9QM8T'6%]]0_P%SL%(>S
MZR0=O+#GHQ^CE'DLIO&-Q*R1K3IT.DQDK]!E;'^AMTMPL$Y69NP$_M*+XGZE
M472EEO.M\2=O99\NJ*I">VW;P=VDFG2: $OVMP(5/3=<)J=5KTZ["AU/"IJW
M9"UJ'62;<@W3:K'*%0FJ%2F>0;@_K#Q):(T0+J1L87R'(U)#G.U((/0%D,?2
MM#8)%[W;4/-&0":N(G<-7PVP$CY=WN[>([!1L#'S.I *FM6FP]-A%LI_>-?C
MTDFFB7/*S.T&5I^&YU-KL8)I\A3SS54/& R_]-Z:P.ZE=/^Q./9!->>)\K?J
ML*-QI9V#BMW3;,10_11[BFWLDTS8'0)V[3FK)1N7GI&J246.2OON:GXE!?;9
MH+$?HADE1Z5E!@;X(F2]T)2GPV%C3^QSFNVP.CHI:Q7;>%J\_-#$WGAT\Y0;
M+)ITN]^28MH2MVU(X4HLQ:&3:2%SGTDT$ZB]Y9+%ID^!E_45FL0U/G?";Z'K
M5'G462Q\X[$9F8Y(MPT-7BO1RY\"Z!%BW?CV_D["1M^8:-^(-XA^H@CL8[_;
MNM#B03F;*5*NM$A;/I&1%XN9+$WH!V?527'23*MY:K&T:Z>O;WYBEYE3:7-0
M!A7J:)8?P]O=V]"UV SM9M<9_:2?%D%L8;U_6=$I2T1LFQ<*:R2-O403<\LD
MX;)'[V9D!)1/,PF&!'B%QC*Z$H02MQ_Y3'4DY3ZF$;]:?-I-TF>/U7FW)F:+
MHFU@/9@$2QS[I^NX<-JX0MF;F:[R!8LJDRT9COI[D8_Z:Z\T"3/1%%@([ W>
MOJW:'*<8Z;N#,0J%N:R06F?G.369G21)&+LV'?=W2N0;[GK)[0B&OKC;8/U6
ME41;#ERF!=D:]VU:NU,&J7>-EZ\9>U3L]PB1?&@IN*7)+8G_+/%R4!M%?2IQ
ME)%">5BZ=XX(_7*D1L))J=O!?6NXA SK]F/:8)J!B("1M4K-F%><-0G7EOJF
M#,:.M(A?,H1\M&]]^]5$Y,8'K^--<=NE?OYO96WV QL'(3X,/!,^*7%7^Y\Y
M37#ZG.P6/AW5C,"%D4YL18^E4A+/40N+.ZO5C3@X.-PM#G=X31M.'_HLY)D0
MP5,L3EC(3^&AM/1'KTNL*]"5A&/VS2.L*RL.8[%*0_)VKBKLG:Y2+!#9N[/C
M/#)S:>#]L>G]9@@)5!I.2[U-JF[Q;)9A+U%C4V(C>2QB*:Z0%Q0Q^78H6O#C
M\(/H]1K2TV?Y#:M!HZ]T*ZSO;Z.7@"=");V91W(.^EN=?<O6:4$[!&GX._!7
M4UOK-DC *.%(-T,WX505<QQF N^T1-RKOW'X<KH+/CGG60ZI->A#:-L[_DSI
M^&B0PLT(WI]D;:?;P=T0VI<561Y5'JC-RXX@ED^SKT5IKJ/(0@K.!H_4T364
MRAMJX*R"* +)+VFQYR/.^?CBR7">CQB;FH1& __"$KA@$B5WDQRW=8FYJGVF
M/H:-I4"JRT6T#?K-?4GNAWP6W-9XWMEIUF'-+/3C08/$WOWV6(1GP]FV]39X
M2$YV1 )/XG5>&0Y\+:DI/Z[?>LPL#)CLMF)0O]W/[MX;E)N/F[+LJW5M06NC
M21$@C>0ZW8&?S/7/=8(A. 5QQ ^[V<VY,-P0Q#E3=JV-6D=S[48W*]F'UAZ<
M[QA]([QJ#/(Z0JQXF#_VZ-]EG(M30XD3BX,O1B*!J5L1P3J?HQ;9C-84*RN9
M![BC2UDFCN9X]NA'"FR.)[L#$ ]NW?NZ7!QZT(23_'%'&S4L 34L]-;]HP4D
M<-#^+OOCERR&GW'F*Y4+A*1C\U\%?S@@-M0ZRV4/*J_S6$5%/$:7Q7[L?KK"
M!8Z80XU(1X&'@N#+I./5<AX(*,V1&<0!8WG!6X'+1]JSNG#6#A:ZG>MC9GPX
M+D]:F)B@T>I_Z7V?[C>7&/8G.S]%5Q:4.JL=+$4B=#E;)^*?9VPS_D'XZ@)A
MWAVC\5KZM+]UJ?U6)56'7 ;Z6YV_A*!W61 SA7.=;I_;6>G"SE@OEW+^, W]
MK4<JNYR,PA\:S^M(H)<)"=2KH)F*LJK]4;;M0L8EPG[-OVBH[S;L@,%_(U)2
M[TU0Y&^:O_1$_^*FG?R;1NY"H3X2\_]Z*T7X_[/R2/[%SG^L]:R8ZH]!!SQY
M_]C(DO>?U,"Q^HI2+^&B_=;O=BQ+E*E5?IN:"/Z;RW^QF04*(M='6>0W#?7=
MJ0N#_(?FM3;4G#?\GG/'WVYS#G[J-WBA7Y[B1O*/S4ZE**/<^LLH%^Q>!\:A
MK')!]4=3HU]^]N\RTZ;_&2;I)5Z4HSG^=K0+J]7\:OYW_ZO2_S>'F/I?.836
MZ>]($?N'B>T_NSRIE.5_J2-9^<)M9/KT@]-2_@2R^KM_M?^SWZ(Z1BN6?F<(
M8[;?/ 76863TTB68)D=*S:ZFC^2R8K*ZN:0STH+8NB0"V%YLM76IPT=E"V>J
MX)1((-<?45,N4"I6MWC6 1_5=C;0/4G?3K<%STY/M<MT'DN@KZGDG?4?:93#
M:Z"L,.:J<J)???;W?X9VQ 2ASYQ70E TFOV2>.=D@D4'<O-*,L"M8<02F"<:
M)FFB.2"& O\ZDI/BU=^)2:_</2=T1Y"]$02#/XN$S8IXH(O U\/[""D.,,VI
M;1-K>"4G:R%VMBU;(TE/=]1.YC2/>."]X/FT7D9, V9XW'EYVQ2ZW0[=")<+
M_T6@M6Q=2^V/27A!17WW_@ZJ6U-#<8V??*X9M%<DX@B":PK.L0(XQT$^'*0/
MS/G:7B,\F<ZVF;?I?K='!.F:?6C"A)Z/5IJ3N1AX#.,DH?^+ZCX=U]%<RD%;
MUDS,ZS=MH>V_V+ \>=FP& &?HDM1DFDUEYN3OAA<?_<7.[7,#)#)S=],Q%["
MSZDSTL+T"8^N@=-^H3KT0G7)_[_YO]7,[(=R=Y13+%$M7;I9KTPU(X4$T"#3
M$)J='NC)G&[""E^7@-('1B?,WM"WQ_$%^Z^0P&)9RD%_VF*@V#9W0FCI>"\"
M;<64&;J8" =G&3<5G#,-,!K0U>6M$X%B;* ;Z7)CX"I-'H!/R;Y^??*4[;[5
M(1)H%->3QD,",>>T4=(XISNAB"/B>1J;%(0W..<^%&IEO4A / /4,H24YO@S
MS='!^2B[=G^$I]RY9]TB.%JD.=MF:W\Z"#T]B$2<\/ND/8$7HBJ&\%4(?'%J
M%@D >PUTO^A GX.?*UE$3\J7<N3(=+9O?:*,!';&[I^L]3L7TH6>GIS"?U!7
MSS6!WCB+,@]7Y(5><_=1>H$AQB=>XK>P0NC>&^C.QA82>.:U>$$(J5>^,%RX
MSWOXT08HP^9*%RCCN]K)VJ R=$08-$E#*P)M%478 1*J/W@&[Q1NN&E\FW$.
M10?J,FS#Y0!=G %K@[+%,UA<1X_/D1>AD#<?X:NA<)/.L7W*:*A& BEQ\(W2
M>^8--:AJPT8IC.%;G6L@5_'Y$"3040E:WOGIG<A?%92QZSTBU5'4.0T;T[DE
MMD*>X.D29 3>:(^O.%(V*ZW1R!_I@+J@<&AZZAPA 5V4F1?T!=AZX .+2*#A
MQ:EMWHIN5N9\Z]FIXU:>]GW7-.$,1/L>3;3C65O#3;E8>]2?^QQPZ^\@7A05
M=%9N/W#C%&$(GQI$"!@W'7"M7BK>8WZ.O4QIM9062D=S-(^2L0B]<MBJN?DS
M@U-'GRD@I$2:/H(,+GU?TGIL^,W'+,;U@#3Y!+_;.3]Q]_(7<3#D57DY?9)_
M#67Y'2,R,YIEW\?0G4>@<^<*!2,0BH+54%.=C= 3C'O,(-IPN6_3?T4RK\!P
MTG""TVUP)6C\CF3$C!!;-L*SY%_Q*^.O:!03$2*5(?,G9GFB5M,Y2TT-V;22
M-9ES!F:_5QUJDK6CM(;87R)Z?TN0_BV!D>?OJY'&ZL5Y=&159+Y$!RW]?"$
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MF#CS/N+.<67<#M?S)WS>,SXJ]O;:^2:(?5,)O=:&AG*?2ZG6)!*4@YH='=P
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M7R]."/_AQ-!JG1:T(?Q//PW_4SX^GDXY#=H %YW:?UYTMUE1_P'!.^NT&-]
M#D;F#-1#9WG3@2!%<+?#P<AQ\S68&+C_=Q\__W[(OCNMDH4O*>:6Q<$/%@QJ
M4:U L((OR2&FQ3+S[$Z0TZH*9'K$]TT6OKVP.GJ0ACR+S,U0*F;(U2A\ /;+
M4+ZXUJG]RBA\RHJ*]V'2RNAA P,4F(P0#67,#-1.)B(FXJT?>/'%8D0Y#.H!
M!)X,-GBN>QX3UD?[6Q,6&4;0WJ*_[!TY*PDU&=Q" E""T[R1U>ZGS$B@M3SE
M[!%\7A?/I39>X[./;;[U]U$Q/NQ@&L45Y@*)LA/JRN/LAL4-A!(2P)S?]&%N
MVBU,"X+#?/S/M._O'" !\+#MYW(H$65RK*LA0_-_3'OT:L,5Z)SN$R30VXD$
MEM@,[WE!?:%S&$QGCQWG6$1/C_46OVP>?]+:KQ]  ER'3%(R>NFABLEFO<>5
M<5B<K%XLKCC#IVT\BEAJ03QRW(B"!>D@0XKX1!97@I7O%D\HU%F]8"+^*]_-
MR=*R&C,;,[N@>4=A&EH#_5TTNCML_3K,Z6\EBA9TT_(UY+A][G<5R>BEO3$Y
M;H@S#BJ6H6S:@_-^)#8- AD@++Q8FR$H61V[]X*8%PCRCJ*7\B!/(=6_^IZR
M>/!?]+YA;BV_&&JV^;XTC?AJ1V8/A"@XD<CW$!V.CV)FSJ_=MLR*$Q+=MVLA
M@IVD=J&#E_?N>_9B_H+K->2D-\((PU-^*1445'SX1[WW[.&UO.EYO$Z-E.%[
MF2@4=*#R:O^,@EA8.SU36'.!X,'"79:9#,CT;MK,/K49CJ)3%KX36)4PPY)(
M4F2N\KZ9ELCR*2:Z>>U+%KX&V.""I\AB(X,^#W%+U>QCOH0%*5-G ^,=DY?I
MA^=!,-4A7##IF)IX#ZH('[R/O_#DC+0@ZW./ET(]H0"=G9$'=3S!M6%18>3!
M]=*0RF!@C6$"'O,#9<]SD8"M'KQWCN;@:\Y,C,CL];LK2_!7JC**B<9=#M<-
MWH%'6HV;X$)'?YP)B4I[QK^4%O1E"7_G?A!T:]4*"1BE'.EFZL:?:B"!4 /H
M\1H8A=X$_^Q  E,VQPWMR38R$)U'$FN@CNQH,A -$W"5OD9M(_7 59K6".X!
M2,X#0)'\)M/IL_N(VLIMXH6]96I,)!!V"0F,/D+<R;V=;.R(6-^14P.C#XR&
M%?5$#<"'22G)/U"%C+G?!",3!X!JO QC7I>A_7/P_J?2M&64:_Q-WT!>C[VR
M.(?U*[W(DIU7>@QNUK>%EJ+BSX5RLE17@.'^5OW5]^/J0YQ<X5_V=10CWB&$
M+DO2G_V$BAI WA"Z9\H]WK=Q7">!WV8P?6AZ1[RW RZZDCGX,"ON?<P(4WC%
M3TMCU<'HTU#^2E&?I-GTB?%6-MJ;2H5.!#"\>2ON%0ZWVEJL8K\Q#^-O<>\<
M(PS;  >1]J8>SV4#_&VNEZ\-V>7S;!+S(G"Z)\)8YT2- J[5:<"^%-=B6V#D
MD#6=<D-9W7^F8.WRMK+.=H=V/*)2I,Y+\4+ORIRA+5URX(Z@KWM"?<_WP;&V
MR[B<B=OA@]*R2KF:)QD\(0TK#"*4EZE%WWB["61S<" Z8KXK'N$"VO3/<-0Z
MT3,BR.9Y8B5;!"<"D !>$_GI*YH0#)O2Z,W3 Q[I3+2G$=(B$7P/B[/Q@L-<
M1\5,=MYX:^^/PB*7809*3UKLY1[P9EACLFH)JTN12QR1+P$S%06[>9?T3P\Y
MZ-X8VD_D^0>%K]F;EQG(^EZI ?*HA0&W9O1Y*R[.HMS7GL-,G#&QCI2CUW(]
M!V1SK_[ '7-2O8&QK)DP'L<PQ%@2;AZ>5NGN,2,3(T//44F/59R(W5:PS!\B
M8>>1&M%#$L15E>D!>Q)O'Y5'][',7!XB1/5H]S3[JH[V\T.A%_4C![SO<+_%
MZXUZT(:YI(<T;BTG#_>V%MI>%O"V+LS@LN/X$.3]DM@<7;J-%:!Z([QAY%1:
M00(WN\;T;7]M>^M_L/864'$U7;M@$R"$0" A>+ $U^ N(00/D,;=K7'7D$8"
M!'<(3G!W=W<)'MP;=[?N:9*\[_?-?^_,K#7KKL7IYO2I>JIJGWUV/;M.U:YN
M ;HGE1Z\R!'Z%;X?$IU7OER,QXS\3'@TN'G D?R^[X !N2>>>DZO"L\JZ/N4
M\,#S-%KRM#6B8$BE TX$QS,MHSHNAHK<4WR 7#_O,D)JEIEDSJP4-:;U*U08
M8&KC"U0 -%6M/"4U8/GT _[Z/GY?&I8S-?QAH/F'2;9/W:F9_] N*KPXE1C"
MCZ(-UHWD2S4;)GU1"0-<G];#^R%P=VGS:W!O&^:]^UOHUTE2_T8N4/ZVG*N-
M59!'KO"WIRO"@ ,>8F3RV="7:$3LYDK-.1\$R;<[H)K%+<=+QUDP@&]$#G@D
M9AK*!^7HQWRR^%%Q3G.V#S(XVN[WD<]3@AI_N]OLF5P'878\7<9[:@72>(C&
MQ@3&-3>VF5FIFGO<6\[F'+@)0*.6A0%2Z4ONG.] XIU-W."!D*7?B+-71FGU
MGCJ22$$,K#R!/,TNO2')SAA/MJ527M36TU^ ?H1\ /)5==82?/E^#99R"S^*
M=W.KN4R6NV,8XH)^+H8!X)7, ;</CH,W^^%4A1@&(%S']+5R*B1+7T"+)[,;
MPV1\GTMQ-BQP*E=]I'6_E'CAWH#ZP81 K9PT^*Z6Y$S]W9&K8_'&5;+U'</"
MOX@94%RG1!A 4 5\=7@US6*Y<NMZ+H UGQ="Y3]<3UG1'M6PW=JS)FW^ Q0W
M[1396-YAZ5 Q./?D?K; YK%X%J-$[$L$8BT8H  &B.(%7ZG=F-Q=PT_76M;@
MW3V:R$>X*%ZUP$5A'A/4@;OK#,*9B/*BG_>G>=??G:\8''I=N*\@6^G7/0QM
MEPQIZC.:87X57:(MCF0OEB6"[)G'I+ITM@L5=WV DOD'RA1^HWYD@T?^B+6G
M8[E(##1&45O&\$EB;5BH 0G=:BT8DHCGP\'S[-<IHU*15D1$)E_BTU?T/>2/
M4WZ<,]1<MY!>H3S<*?&/_XV9]2_F .@+CAI[8D-#7]'E?=R0'POM$@&UGRX*
MXFEAD5Q'S>Q'+&D'_:=1KN3FI-_7>(CL>+)R11#BAC\'--P<.,, 1Y65(]?'
M#;\U,NQ*7=WD[FKAMTBTE42)>N0NJ/!&#@54H+BQ\7"Y<SW(?0S</C8NM-G]
M][:>U,/[\;V/U*F+;AMQG<E4!R?<)&C?$)-<(Q$J23\3[@$[THS(O%F?")AO
MTAWRXZRQF5"X&6>NS]4,H.=<8?ZXR,YTO;J+?T]TY=Y@U=)[3D>+PEYE,N25
MG>#(/OY<GE!=Y%VPC$;G!:%BLXAURO*9WXNZ%E*IWM2> DO2>,$(5T(30.VC
M^)7JZC#5Z6?C%&Z>R;T@H8:H8),J/8\:E2EK@Y;Z<<.)0C(GB57_#?F.JS)O
M\VSV-7>.,HABB?QTT&03EDI-7O.BH&@-U[/,Q2=B@G:/Z7]$J535C*VV--@B
MV;TIQ9RF,"%5ARR.J!Y+=SW;+[FPB@U&>R^K_=%INV=;X:J^W\B#[H2&Q%V:
MMD,:R;RN^@P)XZH0DEYDD/TU7^I 3D[ZE;+;1O)ZP?-3_0CHZA#!>QC@XWD!
M5!]+D366^!WYFSKW9/U5\/-?E!$:!;0O4MZ51NJVKD'VY#A&MB-'N(+.9GYX
M+8?<;20PAT6<5/-W"\C:F&%$U8]5F7)8\O+]\@KE0;/$>HZ)0CI6'/ \')&6
MPM!>&V20,\#K8K7H0GD"_DRI^9PWI8HX)&:"T,G7$=N^:'I.F\N@X0VS+,+%
M]KLPN<6L"RNM7\-L0R;FO)/5 :85PP27$F5?/YI0U3;0&'J(>.SND*N$[D$/
M\%O1L^ICR5^Q'"IQ?-NH#=U_R[CAH>2(3#<G>3_L,K<?"#C'2 -*M#C(_WS-
M.X6VDY>WP[;](H#\MO\DV"2TMNC0;;WR5CK(&E]3FOUC1(-$_^8/E)2JCI \
M[EHQ/BZ3+2<]VO'(I*Q&I>D\H;O7RCJGQT+;<C$91\GIR""KUQ''5=^NO\3\
MO"Z# 3S O)N?-=#CG&*/YW[$W'6TV\^6=NIMZ^5)%9-P1NY9^W<J=2J%T)TT
MNB5.3:,YFA-M8<S@V8RHQ^:#;"0ML^9$:#HR=9G/.*R:>"UKJ1GW7">Q%,SX
M-.&6N_SA_2;BPV0A6<\2CJL,&("D&GP^ P/$N"FYEG1A7IU7P #%(W>Y6\-[
M%?<7J05W\5TNSA^U%%0D-N TRB5Z2)#WVGSBBX 0X61JA\V.^E ]Z("Q\*!(
M<)P@"C+G=8K9.D457S@/>J$%YPLU+ZZ_F%*P&]3)\TUEU00?+OM1Q.!")&)%
M7W[<&_'')^>@FQ+,;F31'AV.G2J?/K[M/5MZ1E5$-: Q!4Y*$S+1?PS@3PF2
MWUY\X0X#5- V!]):&<9R9]#(?G1=&,G!7B#ONN05C=00-T?WH@0!OY>2183V
MI';_J#P6G<P:BNY#^C#;QQZ(8?,Q?OA+?,9[(R+KIOZS[1J3ZX:7(BL\3)LU
MTNZ_,D/5*(+[2D-\>=>="]2=@K(D?YAC-<U*Z:D&RFV4LF"IO@B]1S91O4H_
MZ.@]60UHS%M/A"!MNK2AS,9:8U6H:LW,;4]5_UR@H__F-=(O.>R>FMB2A2<L
M'\LD%U-CR3%^W=(;*?>T$LV#_7(TJRDMN-(+E;$%O_5.5$.0U'M >')1-VKH
M><!RLOVE1KBMXG175$Q]J#L?:/] GL,E5:CMI[=@#/%((%-QT6&:J;[J@3<3
MMJY8P4^:C'?KW9QU#<5S5"W$/5=VLPB/L_(T\\O5WSG1HWOOMT*K"K)<K.4:
MCC8/?8AE(:A6K\G63-\S"Y$>%]('[2H>=56GF@V:N":8%Q8_%G\JT,US,]&W
MNB!+/P?2C4GW7E!2GB3Z]@TQ7"5'8*N>6%TU,%0^)[LE=@!RSLZ^0#AVVC[D
M:&[ZUBI&9QA(-1V\YHU7FVT6RVOE!3*R%LC0G-><0TW182X>6V 6R$]N"6CN
M'6(LC@?A](F+)CL_^E&WG83%AT7[JG/(U@2)*Q8W3EZC9T.4W:L&N?NQ:UL7
MW@<ZU13WAI/%B^:6E-X@Z5&JA/-G9R_;0(0$V4[!)0?34:$\_%Y74_/UQL$I
MS!65MQ1^4P?<">Q8NGG6ZALKDQROC!>0[R?$7]E%,:^-ETA-P !?\U=EY!>A
M.PM6%#4?5'WZKY1U5G<G+M,A,7GZFM=18T-J?.8_?Q1KB!J5Z,RV-^@'.HD2
M;"$4WC04F"$J3A@UX6XC2CGS9F"AD>2DQ$AE)4_4-26YUI0_/0M[!.Y%@ %V
M&\"OM:VU(Y;EK@$M#_XHW8^Z30@,<+#$KC%EO3E^_H3$R:4RXQ4J58@S=A3Y
MJR8\TB(YI/*EQ?DW"S@UODK"[U@'W_%5; ^IUU>E+-=*5X<0<V*?=" <"$#K
M<(C4]:J2I$$VHSZ$W:/U!PJ5NB3S:X$_KUG1M36U%N=Z7$8'T&VO+;UJ;%$H
MPMIS1_+-V$S='._DQ7$O16OQ^_0UF5#2=LQESOKPY[$;(]"W<@_RN8(?L6*^
MDY4SDSQS6?KH(^<M1X4O]>+D@!J$9)\*')D*W^-243LH9K @BTE7B1N*CUZ^
M!GF+>?0!KR>81VP<+>5?VI*+6P2.>HO+9Y[V5*E5EM42=DWNC_M$J_Y0VL*V
MDZN6O*<S'#?0:!@(WZ_?5E)S1W_$?;>%QH8[U_E6,#7#TK5YU.:HL'.N/J_W
MNK33X#Q[VVVR:^CND^O>>-5Z[F@YCARE?>0K? KB)M1=#?J,SFI>CY+OMQ;J
MG"(+U>CH$Y^V6(310=@G**%;"_3+AEBRXC^]1<DJ&'8B!P@U&"RV(;+/H[LE
MVKA)8X17Y@***S=K$S:HU8Q,@M!10Y[@BPDM$D&*^G+>0=5"<(DC75,;/K':
MB LE"X/2Y]HX!L>14C3\,;HR (^P,5"LDNY-Z8;7BL^IR^LK S4^B]NS^!IB
M8+P"Z44<8$^*'Q-^:#:?8_;LH)B[M*_"P,3?E80!GDS0.^.T?H?0^]4"RX2-
MR8)Q=[VB G_HI2_L2X,RK*E6:;&.)+YQ'@QS,G^2H\ZC\A(T3Z@PSY[%B5T=
MC?)HD/7Y(MDZ/+YE R)5IR*(U0"]%M+GDE)^)[OXU6$YE';_!T,U5*9K(@JY
MAO.X#I&,I-!#([11,<IT5$J2E7LHOI(,['!Y<RSAYIM=1'3Y?O31=0%6GW_X
M8[)B^V#[\^PKIQ.X8DI('G@N&D;887XB]KSS?)0)[5=@+&!O\*U[S)^&SMQ@
M6^NTR9WG,(<\;AE2+Z7]EF4!@2AD4#5L\.?3>^EHH"CR_S;NF*&+W_%>T=Z"
M422'>>V8"&&L?@X/ "!9Y%;D;(1S& &))?E8P+K//8 1?P'Q="?@G)ZV59V?
MEV&W:3=Y@\J!6(%ZP"U@'[P\^;I(9VF'$#VV!$O8H?PZ(EQ"O\DV=-Y6"_DB
M*6Y1FB#+3U6UTJZKAC["I^.1D%0!GG^1KE_7FU@'\S?=M%R/ECCM,(11>,Z&
MD&;B0:LH-:%HIGK6G,K)EZQ]-$KB/:^%^2,%?#5YA\[*.DOG/I1757QLUQWP
M1L7OT;9=FBHDQ9SU0A3EZ&1K/3@>>?6LPW6 Z0F=\!EYZ:&R6"+>=PJ0L2L2
M%=9P:R1J'W5H2Q:"L=',3MR-[Y!O5WU[]32NF#V:8;5='>!LA!O'1&1R2?&E
M:SK^1DAU)>(;B; ,G[L;Q? M&PUA$W0\/):B0FVI&+TX66Z#,+W>MIQ?6S]G
MM"5=3&KKZEPZM0WW4!517HL!UJA;!,\>?1R&V["8E?K 60BRFOI^FF6.K^RC
MFE4U\37%C:FW3&_WD_4E%B6*$Q AG)RO$22UOX:S:7"ED)0WU=751O=3U ;H
M4ZH^^\Z#WFACAR+8GL(N+2P0W=)(-89H31C)K.B)X7*&C1P_@E:D=HZ)'IO
MF>"RJ<_:1N1J[MU11W16=%SPK1+5D6<-!@"^JDB_I$_RNI8729OKL#?@J:V-
M*&QL ]C5*CD^%7_*^IC[L&]],G.\:%HNLBNZSYI,=^?NX%E2V)2GY'?67165
M>JW%K02A!8; 7>R(_0',Z%A$ZI1)AI0WW[4'T'$'MZWI.EM%R..XD<);+8E(
MSG^0!!#.""0N:@T@O/M6SIO**-P+\!J1S:%>3+X/P5H<L$>>G""Q56 '<L^\
MUF:U0T7!1\HC:$UCZ%]3J3/_;AF)/^M4;YI)P/T!&+FDG9JLE*A3"[*V?)W0
M!Y$&48CYR4#5M)FAY[GU N4[]DO&[T][-LJMK@'+6"B?9%%X]I4*&SE ABHO
MYP=Q7UH5T'OCLOW2Q1PI0C &\IXO9#5]?8D4>;"*R'0>L.#DR>O;U\>HT%&L
MO205KJ[V+?,YZ@8>@3RKQ*P )DJ4<K=?T+/ZHOV?"?,XH;85+@J37PZ>+#L2
MK,:N"=?4QO)\&74F"B*-/(A<R?JX:4[2\JV-@/N-9P7UZ$+FS[-+.VF.2L-(
M.\E9WLG9P-D%1D:]ZC!!38FR8K=E]*>QWN$/$],@J<];UG7]H4UQ,,![L\UQ
MA5H9RK.?*GMC4E1ZH<X(H54[ZBV^%AP-5?7UD2N&BB^\7@&8407:SO,15R!A
M,(" M=#A*MSY9"]TGV"Y,AT-IM/>[5VV=&R8X['(\IK4'F3^MK_GMCF5/N'(
M%R*K%+GNK:B+'BDD;SZ*TM'T"NJN#5[J@@%60> 5+=.ET]E3*/0M#/!2-$2H
MDEES_F+ZYPIIITJD5&1T#58^-NN3H\&GV&U"[T&8WTH&W^)N791WYVSLI3HU
M+%VI\'+=733" "U!,$#GN']'"#8,,&"^='O5<B=#&'[\ZUD=&/&K(/5$@@&M
M:1!["?VS)*P.) ]F.@TYO!UEH*OR@#6V1LV>Q!%"MX"'@'DUW(6T3H<!1OXB
MO+VC]\"#5Q8&^%U;TXFXX(&$BK!EF[P2EO$#K$\R?5\U.ON9<=",*LZWE=Y,
M6;_VPX^)LF#AESR!NZ;G)>)P/,O_PB,]*G*0N]Z'TU(P'@P0D &$ 4QUE<[<
MKHE0[BAF(VYQ-T.@W:$15K(_/%$$&Y\6@//G=UZT87NS!\[KLX<XY6^6D%1M
MZQP5L?\7R,.8ATDZ>,3\\$^CO]H3(>FP&Y3\V(R%DD\P6A4SO7'$M F,M/5\
M!\#P)T_+6SFV*D"2(Y1(U(H/%>:/\)DX;3W4.KRC%W@)=5_Z<UL>7&FC'_!Z
MN_\!Q34<((X36+LB<6DF;Y;FL?1N"R"[Y>M5V*3=3G"J*QXH:#- ,*:U?"*O
M4<!EK^T+ SP=$($!4BZ7+H_!5PDZ5\J\I'>7S7_OTJ@Q-X3[29\4;79C&'EZ
MDST4)]0?KE"'+7\4"MQ>_A,&V*RZO+_3@5+%T7-!Y]JO[WLB1K7K_L&=_H,K
M=Z6L3GIW\0_N^ ;>!01OY( _L@FO31 -HVRG/O*QPJD(ZLU1=XT%E,0T5B5"
M$]&>-O@ E3Y/WJ/U47TI2VMVNNM,J%U^Q\S/II0]=9KTPNONSDSV2K_OR*^S
M,M/$.$M6DKG4P)R0-Q4(8:QLE5#!*N>/XS_&*J\*B]I.UHA>3J1 BD:5!F<K
M7BMXQ[&J?S-[Y?5:](6)K5X2D:V"O'R9F&[<IT!J=&\Q=*=P/L/Q*1G1C#Z)
M<>XUE. I7TIFMEC(6;%,\R(".:GS':@;LB7YYCOJISE%K_.>L[N=<^PG0X'F
MRP60GE.3J)K=KD>K5UV-;54^NL'*,92/GF\VP3M0U$\+ZED+A>$2K,6U-^Z3
MSR2K$-PQ9Z2_1>=9 $0^=_ L7USBD.PK61T<:64863/@X(ND,+.,D$"B) M8
MNK>SX\,_8U^O7H;)9-<X>+QF3W22Z=HPB/WLF!NXI,LO!B+A-GXR#D U*"U^
MMU:VKZ1,K#3T(T6MO\<!E2Z-13[S\SQZ<,1LG>ER+C".GSQO4@5/O="5FA'#
M+Q"RS#L/_'57R)F+U9F;+W@\PGW60Z0B05^ZIB>*30AX>+'Y9PTY,MQ[)/W'
M>RP8*_CS-JKH]]LH<3%G(_!AY3U8S#4+&ZCVZ[84[H26PFF#J.?_,OK^9P2^
MB;PU]00!?'.PU*N2.)UQ!3<&G;Y_J+82\<A;+AC Z3HC-SV07F1#].&]&$B4
MDB:3^>$M@-?#-%=1LJ?J4LB(N+&1L>'_KP&O1>R=GZ5G?.RTMOF&(XUK\ MA
M1!_\-"%?1UW:;JH$,;_/FNL[%RU92&&F[5[/<1I!*E7CFZDO@Z,M,]!!8^H^
MNVL4%$^VL/;BYA)#3U*6)/RO2PTAJ4_<7GIUO7.HRYQ8O%&+8K30G<UWV^39
M_1@D55\=@(7VK=QBK5I_RRV-FSSU(@1I(9*I#&_6"JW>(Y9;/X+HD>2BJL/A
MJ W+8A;OT#<3!?J"PB "L1 ?*W(RRVY9LXB?^!I]1,Z(5#0XJ,1K^C."G:LY
M'C22+PO$+08'486XK/QY>OE_TI<;3TR8L6A@QRBM@)SQOQL@8;BL%?$RJ@\;
MX/;A%S8T5I_,F2\;KI3YM%(?Y9>"N%Y0ED9N&#G4N!@R8*BRH(1ELWP<KQ31
M STK,UU7C<[O%;$B>HZI:?+8:R%V;8HANR;09=U),M'"):!\\Y<!54%S'5%<
MM<UL>;TT7P?GQNOP_$U\[K;MJ:3ZCQ$:V_E1U(DFK0PYYNNZDR[L**$W?#6U
M8M$+30.>M2BTE0AGK6E,0[,TZ=[_NY#A**'1Z>'R@0";' 517F_\C")^!11U
MFVR)'>!89+1#FH@OMX(H35K$Q(I,%O83=:"D]#O_O^LX69"IW=1ESYZH2[&)
M/GI*DYDMC2@I!:+UE)<?^[V41)>2DB#=\V$RK/[S4>'TA[>NE(\>DM @_)Y-
M&YT=^6?ZW./ 9X"'&>(/6JX/UW*X(O*QN2.7^\]5*POP'FM[::J$"$UVP !:
MA#4=PK+IP=7,)0$%OOXUZ?LT>ZXU%Z_ (WK7P'N_I=-?7Y0J1-V6@#]^+<,
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MT8DD*)]2Z'K! $TUW"/-/ 4*:AHCCLB#$1!35)9JB6XQS*E"X#O-',>LF<6
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M] IL_"Z/F,61-D^[6(@),@N7,$<81_PKKS>=(M481Y/G"K!X$\;^+G#\.],
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M"#OP6CJTUXBN+/3>&VH8G3J J 7/2;>684;Q25CX3)_E69YMAGU*N'']6CZ
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MXO\D;8MNW\\:P>_)YH'BMB[0P#J$DXQ19K7OL5FNT0-Z&WLBM:)XA&'GYEC
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MLW+@GS<K9H)@=T\'67^02R01_G!VR[+GZOP!<#M&GOJC9!-/""AP0H5(5HU
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MDZ\&5Z/M.*OE.MKL+<NYT^>M%!@8Y55^D"H&(D@A6A]>?OJ^JRW['#$B[U>
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M7/U(]#Z/3P\#DN<:9T!N0+,/=G+>,J8D/[DOA'8JVSA$%IA\L?QGN*XE59L
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M=;]>UW4]K^MY7:_7==^V^'VQ$UAM9G+$!( L P (^ =8; $. BLD)6&2RU?
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M]L\(<3-R4<(AZ"^J@*&\E'5P&;%5&O?6@REX+;(7TJ<&WF8( H,,;7%=AGR
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MBEY(?O-%G'3*^=."^G8GY,5TX>MO^UCPNL**VZPP&[,WO,+7[RC:FWR;]VI
MKWZ<9F_K=C>XM;.R=6-_PN<(&2\=6D[EC'V[:];P[B8EQRN/,U^XQ)V>6F@=
ME2,!S ;,P4MI^9&IQWI\=ITPO><AN_<XC>/KK7_K#NR>VMK#-2\E)8,&\N]]
M*B3<,SQP93)1NF/TX??S@B_]:)[9]7,7:'8$X3<[,%BD3_36;8&$(XO BKZ$
MB("5X&E?$Z3VV;1%@-PQ<HRZ_KO3A4?TX!RB4+[- *KW90*1#JXB6C+G;O+
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M09:=7V'PB$J"W=L)F2_E4RS._69/DD@VCC]<K#]?NWQ3=QM.::LIXI?'A8O
MU9$3K*ZV_9B6Y^KO]<52$\)^23V3QC5XI#B9]-OBG\BW+5_",ZG7[Y\H;5J>
M"Y?)LBQ*_T63'H$8$2HB*,$T X3$2R8S"D,"+RZ)G&B70X N-M\)@7GS1\0Q
MI/S#2S MQ<Q8PI$MMYXW4[4=Q2L*+Q+?IL],VR<$_3!$L(C5_TIV,1!K,36(
M!02JK7AV G-X ]T-]Y,D2\%<8HXQW_,V= <KLW]):D/+\VY1T+NUIGQ5LI<2
M'><OXQT,+OY)$]!.!.NP*-U4OHM<BN).KV3FB+7GEJ[VVX,(2%$1T[TEP^Y?
M?=^V7W&U!EB2#I;G2OA:$5@B8CY$=G"IW7_3P6 W@:?Q0!O\[8E2_)S^_,60
M[2(/C?K)XIJ3#4%QRK7$@5/@W4YBSVX"2Z%Q="IA^MV-4L3A1&GZZ,/3\"Y6
M"4F<9EMCLC*,MY#@-K&/+ZZJSTI8>U1K]I8N$#&F'PYD8LZEA4ZS4E&H9-"R
M0L;5N7()JFW81EA"S[I[7]53MYO_[;F^\GG"1<@K8CCP! PVHD!6WW'$1KG\
MH9FL$A:F&WW&)>;LX_I]3=]9GHFUP\/7\QOU')M#MHC!JYP))*^#E1?ZHW;K
MDP/CLJ]C4V/*I+\/E..$\D,X>,MSAJ7&LEC0X>@=E()J6'FNXNSCX (1>EZ'
M7Z4B?")%7#VJ# \L58^=K/'I.:*X=/U3$N+\D/GVV*5RS)E>R0 ]K[+K5>6F
M"O2(.(%E7G4NE;B.V6F;:A'GWE'?:@CT:Y>K=5?CZ+$RY!RPFICK+@(CBP#G
M=R)9=RC^EV#FX3G< 59?HG]NZ?)9,*-$!!E.6 0P&U@IHNQ,@@[V![DL>P1F
M9[#<5\.B0A'IKM#I)2QZ,<@1%=9;\$ _0+>S_H> 8N*!19-\=<0*<_9"U,$(
M8KLXD=+^J381I>^NE?]D$^0A7*4B#,S4);-%4PW2P.-+ ZE.9$R<J2 P7:GF
M9PU;!$I 4BX9P6"RTZK_/:%^F2YVUT?!%T8Q<O0A;P:W=VZ8)YYI FMJF!/+
M30!SZU@005S P1 L""?!J:Z+0 =8SXK^J0O47_N(U7+<C'FV,.41?>IY";CA
MCNW/Q!>?4X&S L^F#]4_F/'#,U;O)HBKXAY652];Y7&RRBX64YF5E6$OVC;Q
M;?1-6)+?"]*CVQ,3KZ+N'$<=,UD.V+-R4+X:O7O?Q),V<@RW=FY]C-JYQ;Y]
MDM@UIS!O9?!^5O BK>S#6+-\Q.S?C&X-:!%+:^&))]/P&'_F1.'S5.Z\?HL:
M79/\U]G$9>$:XDM.>R:/_NH[F0WV&I'75-:!AYWV ;O;Y24S_-<<Y+M%8./
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MGNAJC'.#8_/C^XK0"#ZECY8$50"R8SN]79BJI+HBRNU,T0/8-G98N5)/Q$;
M5E.'%5:M7.@5D+C\612\[T^C?M%CVU;LH6U=H1_ [1\1?6B_88@S_%BFWJC6
M/X]D_^5:)D^;24($B,B@JJA8XT9[O@BHSN8+UU;;P= OXE+);_NXD:DAZ#V0
MA8&L #G;%+ZN<)A%GW5[%[PY<T;F?-O4.6Y)B6CX@B>VQX%KA&A_3!_\<A4O
M2M\7).>-GEGV%W_W,^ %_2K<16;<I"[XB))6L&,1V+R0-Y]3>=VN]/5K+CI&
MX)XUFB6X-U4RO B8 :T.A9JN&X;#;0&-U$[G+5QDB@0_?I1D!4U/=9)98T*Z
M'&<6HEU<[ +A*E4-M4?X,"R+74/#G"]PL,_;3CN=[PY!93B"%; E C "U0VI
M]<E_X(&Y*L4_EP=-FV&[;M!*5^*QZT.V()8K6!O]CU^;4&KA8'9GM&!U+*Y]
M'.F1GVN@VX;C\TOC5?I"4%^8&V-]-3TWAQ0<;*C%7/"C>/!9%+?<R(WFW8%4
M+2@Q(CIN^(_5G1>W0,$N5.6Z@Q]KD/P</,?-@_6.D8:>SBQK^4B(K0W[T!WF
M*04$'!E>D2AK -Y^3W><ZA>U[>]'D'S>4 /;<<H??SHFE1!N6 T9D.ZZC;&"
M(<#-)J@#]R-!?U*T=1>.H.:1:JWL"U/^WCCO N%QNG/(E87Z\WQ6,4#@ED^'
M=)[9ST;P3"/VX+C5M[O.W6YZ"H1)SZEHZ-5Z']T1RC #NJ]<MR;ZRH>;;U.E
MY ]89/,1Y?&&=B?]D99_M2[05*Y5T 0V%LGHJIM2&)]$V8-@K_2..VBJEF4+
MB]AC#.Y^VS"$Z'/DIBZ,XH,I#,%\RB7?8*UZ2SC 8=X;KD3^,#6,35;9_0X@
M/\VS],]D#/*1G4<#I6T\I3A?#FCQC. $OF\36L^#+ V[E_D WI2'Y8,V/NN<
M)7#A\=93_M0_J&DI@#>T/"]6?=!#+E,SJ9Q](_[,*]CSS47(M^4+9=/=U,T[
MHQR/^G%R ,(B,!IK/WYO6U4GW$?LG='XA0@A.K/8LYLS[4I-05X.^_/B0::Z
M H1!WW NM)K>[RIW;WBVFFY9[/YZ7E<M^;"<Y2')=KA3Q>,?LAI0JC@4.#Z7
M:3]!'WW4UDE^.LFK D&,<G9MA/N4)@W61H^;W) S-H+[";9.^XO><ER9 "T,
MP/T(,LSY'D1;VZC[82IIL,XK=0O82:+XW0-?R8S'#(^^L.[YFD;G/+<!(?-J
MA.)Q/S6%(%I'R&;+@AXK&%(48@XBM8H_$$XA;[0K^_/(SCO(R&L=SO=P!*V)
MH3-Q0P^\774V'TAYY04D2M3FG&CT>%^;&!9_,=>(86-7$N;9FUM_SAZ;%NSE
MGJ+XH8T:K+',3%,R4*B0#5@?4OA_7&&8ON=NH2;T_9FL4T85 2](3W%-K.LE
M'UV@,:.JLR-22I_BN],%%HIG\7,_2FJR_-<JCV@3;V.+3B#O%K2XLA<N+@+Z
MP/!$C6Z+/:DL'WG3[D6<LR#,DT1^81=\XLKO313#%#WW.+T(L/'X#%_AND4@
M.IB]T-QCN"MJIP>A<AQ74;@(2"\"E27NPB'@RIXV!<?XVA(?:PJQ/63UJ#]\
M,OGR]F2*_Y:+\2:$:AA "JR%K2-T*Q>15V=$1 4/4243NA'>PU+=N;F0,_E5
MW2_<.ZE*9Z.>W*HY+-@^<F>7+N]!E6[YMD.?Y6R,E#<BFP4WW1^=O*@3]2W3
M4NH#5 V]+7]D>;771Z?S7T,$*7^_?'RZPAI?8VH+</9%)I4_[-RO3 K>5N1R
M=RSJO@XK(R"G/*757CLR-69'Q.Z@'75J$0\&PKZ3:I?'1W V1W[IWRZW]>,"
M9\%E[,E\*P>5*#4M9VW2!8YJYL^^PCN:/FB]]#HF'*![SX7OE[.V"O#0-G=4
M"#@J-9N/^+$LZ%.#=4'0(>->/=.OA '3APP)/:+1VF&59Y&?&HZKV%SS& ^7
ML6!6QU]3@!CV3BI<47F6N*0FZ?,50X^UWVLEYF^GB]Y#AGV^,A01;]V;MR57
MZU\$+ N^ B-A4BMG\[%+RO))X%3'/Y71H(!J&F%I*H@!NI8X[JSR(,!B89@0
M;R66ZC6Y#O:@]?IW]=?@W"&*:*[#$K)=MXYX7*1JAN+V0XL!/"AR_Y[T])]:
MQKYWWJIQ^4>72 OH T$3X\(_ C1+BFMTPB4L&-414[H0PZ7WDL:]^Z^I_2<(
MCJ'M5,TWAHYA[2'JX#SEVZ"R7-2FMW&8U,$FKL*O]487KP1[<%XE?;XZ0HSH
M_CWUIY8 B[8[O^>ZR6D6;'T=CDF5$#!^0M"6@D_T@<Y5ZT-A>=?3F.U#<4#,
MCA^'!XYLT\M3,ES0_%.O CK-J'^\&15)&3, SRZ7;Q&ZSPC34*C,@5Y%./*8
M>TCM0>K:-B1I!).*& >/EG*?":'&C'08PFW;W<I.CIIB8MDL4B\@4>H(XM61
M[@B*ON-<@XKYT#PCW$%S?)JZ.61;34#G-<G(3VI]BNG7TR8QP@<T\ZC66HE9
M>R(MT#I*EDC1/VYH[JQ,D2-)6(2*W'P^@$EDU#]20U6#WK,JZ^2$R^P!#V)Z
MPVA&"5:CTP_N,Y5^_5&K)"<<D_9AMM!*XEW@>6\+N(R/2HG9O:I@V7X)BR9J
MEBYD]W$9N"/N+XT6MB)WG=3-.6CTB.F#@$UWIQ*E7N4S%1.C CO#;W^^8B(\
MS#/O17,)W,:0K1RE3IJVR^<Q5$O[T[$G?YZ%UUX@4.-"MFUQXBHA-&I@1MB@
M%TC-TGY2?<#1O41J%DCL7F,.KWS3=C2L(_S.QT\%/9-)GSVKQS<"3[;C)Q/W
M,M3YH+$5?L@4%?,>!",.B"54C+BA,4[[#O;B,+3\I,_G_8--40J0;29:H;2F
M$8NH6P?R%0TG/BC?EHCGY)$^L#N_81[J67P&HZ^_;JS;.AM"*7Y>^J=^#\TX
M:T?]GG>FY'3=G5\E/&]E'7D;3GZ3%6<IO!6R^WJRKQJFOM=8'9?QQT7OUM>3
MU:IW1RWQM@#="\PX!S!E+5AD%,_T(9@+X/E1/"K*PY8BQRB-L>_0AQ4:RX*^
MB"EXL%</7\VPJU\!TJAS>JD4]()I]+!,1H]H'%GPR9GV441,%QDYL[ O%^IF
M%7EFFZ[+Y"T"MB';9&2UXM*>TV<>?356E'8C*,>O"<[!6YN>,W2\'WQR8, (
M7A*J[53$1*(10?V/REJ'LA>!S'N"_I&0@Y)%-5Y.V!>/RNJOG>GA3H?C;($1
M7>:L9#._?NL'P?8V&Q::Y>F/^:/D<^;O,R7LL< 6W,.4D7,\T9/I4\)#\P[3
MY!1OY'JP;:]@0*DZ_QSR:B6[%^K,#Y?X'*N%'"9MM-58=F-J[Q?O;3Y?(!'?
MW(O7K_RH-.9?[48[&T_R399> <-$4P(2I:<>6C=]O!AI-#TQ\3=PX<.$XEP]
MC1M&T[>FQ@892 /=.6_IZ\XZPZ1QCS/KM>ZP83#$CO!&+\P93Z8B-U>?[:YR
M/06E! T'8O)TCT'&.H79_WE'^_]R'9./CN@&>S#7#^ 9T"-_11E\(\'A8$T@
MRVD^(T1G6+\6MO(IN$DQO5?4R.UKC^#0<CZXF"\"Z_95$*;?LM>U2PJG)4,0
M_^'$_M^YH(%<[$SY01]R78\ZSB_:QC%TC%+RUZ%K1-=-R+9$V3T?>Q!7IH'S
ME2A&8U%H:>N13.3' F%S,6.:0<[P@Z8:]5RK!@Q_MM[_]9(8B1>N,[=A3OF4
MADU;V)>N,S_.L8PE?HX#>@2P2+8=9/Y3>!)__W SN$,?$OH&EE[?U_0#\ZG"
MC5K64>2^")S;D)>?*#MRE&N1T\-?LPAL+S@A(E0+<1'8^8CZ,:/VO]!HY;_1
MR#UJ)O_(Z]>,I9Y_J7W(FB^I#]DOZA(.@7U_B/2*RG(%E0= /1H(]EFF#W>Z
MIM ^ Z.Z.;P+)%$T($<X3Y5&>*9\V4 ;[T]*6/WZ/[VE$F75;9F"K:^<,PU.
MN2.UGG^H7%<^@#;<&^*-&CB7[*1HJIX"'#D$3?SW=OY_ZI)_32'9;)E_0^JF
M^2-TCEZ_4,6$B^@1X7__AYSMB-0LE>S6I8M!KK5SX@Q,9HZH;R'0>4:R/QNJ
M_^/KQ329/Z#*&/T6GG6-7.<$RVP&NM]M([QL5RE!\R;WM840V/P1._6;.@LY
M?M21Z;FX879)%@GP50B1)9C_QSY'*FJ%2@[>!LWJJUC13#PEQ4 PS=+ 1K+2
MT(,[K$++AE3YRV74>)G&DA..S3R9]B0//%L$M$Y=ATT/E^(J3)&V:7Q4KR=.
M-"HZ 7Y8!-:T.-)GG4H^9WS#[B67Y7[G?S47O.@%%*P/B:\ >GG6S.AKL$K1
MZ+:_60 VD6?5!_44T0M<AYK?AT!>[B]NO&]+[^D<TP#0#)A"H\<.+27 IQP5
M%C9N'<]15*V%H80:H?L(Y_V)+*^4;P)3E?@6[3/4"\T%0\'K'!3+*D/TVCMN
M:ETOF3'KF7?0"K@.'3!"V$>^W/WW6NUX3TQ8M8>:9 4QIII@N-%C@!A+K21!
MZHN4M*,OZSP"6[V%\_09<U7T!\:Q'3EWZ#OE>?7OFG^T+P(?'5<_B:;@]"=T
MUZSK/.]()0%OH_3CK?/2U,-#7B8PH2F[MVZ!RUJ2)A*E<OD-D]7*I+& =+TO
MU#+9['6/8 *79=>)#1/EBKRJ[J<MVP))D\DK]R ,_,#94_.T@J2K]OA]DDV'
M>6RU#,68F%!V8X@ZPQZOZQCE[;;JC<P$!_&C1=U27V4"8M@>3]-H8=BP]\DV
M><O"U-DIVYH(M=<0+LN\"YCJ<5K,X-ATZ2]A0MTB)^95^VS(7CO'F'+E(*9=
M ^02)^V*\('G VHF>,BE7Q6)CZGJ2RPK4(=F92A?4HF'@$<KANJX":AB^ZK[
M$YRG(R9-WG+/)T$;18B6$VDB(PFS_R#J2-6 *O;PK88>88M)]<L?43^5I #X
MO-9?\#^;@H"4+U6A$$'@=&_2N D:!LI^0T%URDYX/$J#BTYS+2S00O]^4E]B
MRV[CTIZYNER[X(,9@.4I= \X?X2U#G+&B^0W8IYK-S4Y8+1V>04:8YU'2<MT
M ^[S)Q +&BV:2#OPN&/8_H[FPE"/J3;.M0,]R,Y0W@(GE(+'Z^O>LG@%3]#Q
MB4U[+-&P$C.]+U&$!FX&:"@HQ65'_%*@*GT3D_-Q8%SI\&E>^#(.G+8=\<8Y
M+\O6Z'YG$ P<OHK V]7E9:G'A7DD!WGKU\MO(ZN@!XS6HV!;6/#5-_@Q0XU)
MAA?G9%VI?=OW'UT$(@%"H2IR-,:.^ $UD3FZQ@ASBNYR:1'HTLQG'N6?JVGR
M#IQ(7"GRJJXC;4'+RO,!GY5% HWSTI\#>?$1M& ITI)-1G/G?1-?OIOX$3@'
M'O9!UR;!8Y@@ X@M[ S5,U[ZUT:,UG*BJ[HCB]&8X\J7&'WZ=2(G?)A<HE=B
M!!=TRQO[>"\82>]S$!H&GG8I@1/E$ (%OTX2C#$8GA8-Y%%9D1?U?](1<B9
M$#A7+PYMK<3WGLF^"&]0.N12*5C/07]]]06%3_3P33J((A.]+?61MGKF+$I8
M,6!I0JSJBP#9 8::;FD\8K*U4LP KWR&>KB>B$O&N5:&L0B7'7NP!M,B(R=%
MH5;?]BLU=L/P-2 7+7_&K66WOBPG8S>H P9C9P 6(H+]9*,^H=8OR>,V LT4
M!8ZKGF+L1W]3*3=-JKOK#^IT4P[I:_LDJ]<Y7A^"1DIK"MGO<$/T*WU%+Z,9
M$E/K/OC;^'\;\3+M0*GWN^>6I<7[PN=KET<FJ=#-M-@QU48G[4 V.N#%Z8C%
M'Q5G>YC'NWA9N2PQ5EC&O[$]",T,?E!TJ;/3%\3TFFECHN_M+Z(6*V/Y)6Y:
ML##[9_JR8WYG#)0'4IHC9GH_210ZXX;IE+)$4>P&C-9,P/=;%KR(BU([^D35
MV95W#+F?'DLXD;.FN\*JJ1?<"QU+[9X\K?!;LX+7^%Q@N0B<<JV Q;WCM&?,
MP':R+U"74\=?.*R]L](%K11-6G"!OOOWI_?D2NT6ZJS3.^&Z?^O9>;@+KSD2
M58R!<^2;Y!X(V)L3%H$-VAX[T;S=I"#P//B<>7N(P/PR8*1\W5<M[$-*Z0>N
MZE1RC<$0;R+]/4N:L[ODJ)5$$WPO(K#VM)<W(?QBOF\ENFI2>'SPS^\?>OP2
M9=RK97=DG-AS=NL#OWV2&5VQ5Y/7_C%XW\?Q[ PL?I*CU/W(%>MM,.H"11ZJ
MVUR?= GF<WNFV-TAI(EYY9"!2R6FYYC\./_#YA!4AIUC>6T0KJ+H].WAAGAG
M^*D-+\F5';#Z(E3(6,.?>(Z1K+*_:J"5%BUX"IU2Q; ,TH B(P%E(P9"WSJ;
M%%A?9R253638ZE'\Q8_8)8E4-ST*BE</'@8MDECO79IE_0<:14_N92:FDEP4
M.6EFMAH0/2J>]&M%'1/A4EI#&!)_7I+J5[U+ 7ABS$20ZD)IM(9LJV6>4+@/
MSZ2.-_)S!7B#B7!U290HK42!X^ RT<L"T4IET3*15:*5XF7B);P.74\XGYT!
M"HY54@<U@NO^MQJ7_]38H2M2+UJJ"*[[K1)05!!/:IUC(3>MJ&(ZXM4VQW(U
M\+UQ0)>/X74+KX!.SKXV#@QP@I1FKCV@.O.LB]C R?!SYE<$H!-AGBH/Q#*A
M2IAQ<]#6^X3&")DPR@.Q+@(K1=DT[3H(8L7Q)<4UV.>@XF9)T*^1H%-%5C2C
M.5FV>[4M]<58&0B-9A0G103"-*WXO^.#&FSZ[Q5PGR27B>F49R%K7<12=>(#
MQ>Z4^<<249#M<Y9_7P1,HK@SI..=/=$\JW-\]\US>S( @KV"4N-57(<PM>CU
M=P[MKX\S>.'!4_211<#F7*V$3"@SU07BI4.;<(SOHQ#K'_CT@8HX%+$'1*^#
M],!>9C()BF;D**$P1//_H#C[O#-*;!Z'DO +Z(E=UN3N<UI5\ZF9T/AO6)L$
M_8MRRA: =[ $;E^'\2/4"]Q:8BX+-UY'3K ?58&>HW:U!\Y_0]YM76DII[UG
M_#\<RIO'Z[=6@EW>OQZ\ZIXHPR?77!.XOQQ]BANEV*X?>+NN2G"VNX(1+QP7
MN&>,/EW5-6!%&JIQ69:;Z6MP]^CZIA,HN.^ZFP%I=DVKV!N&TVII[JG?KES9
M6?50*TIN7X7;QI=^^G%5!&1L?A<>4RN9^1?A^:'-'@^^R!+H9D-U;Q3V<AKS
MLU:=_<JN\+EC>K6)<*YDTW@%MJ@6.I:$13WU5QQJCJ!@>=IR6WQX1M*  O(=
M+D']2_9KA*GN^?4J(5:PM1EP_T)9G?)KKT?#M9KS,UPXY;5K>>=>GI9/GU0
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MCV\96T<XIA#>XR[Z]$CP\\/[OP[%L%/U3R$Y4VUI)CH1X'82LE=W$9!KMK@
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M[JCLJQNV*;]W.>_^H/I31WMZFFOWYPZ7RX[]ED2C#:4GL# HW=8?J@@-OWI
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M*-(T%^B#475M>QG'W6Z/R@:'LIF""0>PI5@A.?#&2W*<D>M&%;U>'1"^)B<
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MYM#ESSSN8CI8C>7X' 1"N/Y$K'*5EB/"/,P*BXRSDFBBQD5HF\%-FM/?FZ3
M*CT)X[LK)O/J=(4>\KC(HY4"$DJ'EGYP^&QY/.D!: >8%3GC<]S^]B]@*BH6
ME".[L?/;2XW)MJ@[!L/6#E3.X_2?]8A;)Y: ZDA!-'-BKJ5>P,K<4/G,>K',
MSUB8FR0G9XF7402"X/30N?K(GV&NV5DZ>[E-<8W.:O+^:8"]LR:#F[6%J)E@
MH5^I2O&U'+(^/+BC(%Y9I9S73=NB=@.#>,J=S.R7\"5^QS_B"G>$V3>Y'.'T
M>&6H33CLB@I\8'\*46*O $Z(+^-<D<-#9E4JJI@L'CQ;?33SAW\/TDJ"-XA0
M0L2:]LM2K"@TT\B47$XK^C+@$A*-=J[:0R_L"'%9 M[?5Z>SY4RNOQ?PUMFC
M>H][?64%7*'$T=S@+JZLZ,847^/!A/^KE__OWQ\P9".\SC<4KVUI<2NS7!,>
M)RNA!:_3Y'$:Z,5XSX84)U&,$?\X0'T;H8SK;;TW%I?^*G0!M)U_?Z+Y__SC
M#*HG4 *RF] ;=T)'"<@4\A(0>^],]+O8X:CJH=B^@!_4M]:^!I]I%7E?+(AL
MJ?_E@ [,>!)O')OU<(WA$ GM^[G;@D+W8#T '7$,9Q2Z2KU<)JP$/LUUO$[J
M(P-V<I>JR^KR9A1&',G))?THH65?<%<!GU "!5QJN55WV[.B;[/HJ%_.T,T-
M7ODY5ZG7[7]O,OWA:WP^)2Y.'$56Z>GO<UO!E_67 )G%Y^3X:(11]8(]MVV[
M_Q* )U2]*EOV$Z7RHARSHCX6J/_LN+]ILUM45W24XZ'0C*Z"L@LE-ZQ77>"1
MC;YXONI^Y.D[5N'A$L?";[M3W!JHO&G7B(N,SU<.!7C=6W_M4>*%1L,_)XI:
M,W]*C1O0;ZU].T/Z=#(R;->EY+K]P;KEVV/&AXGRW8CZR(#A=P _EVP;<N^G
M_.J5N'?C"@D>#J[OGW?4O9AZB+*N037#6OM=$O8$"C,U?!!W.;G^+&3KN6:[
M/V\%56=G!:@S4IO*L@!R6ME"?+T_RU@4V$Y*UW"9&K:WR*LH.07(&D!G+9\Z
MF6:B@$&:1MUZ7&,_+-F,1<W=\E.:=+J1MOY7 @K3(W/^IL>C.6PV_.]D"LG;
MABMUCK.8?FZ ANPT)VN?']E+7_D;I3F3WE:C_"!/;T<6[RE;?N<3PABN2)+?
MJKFV0/[C=\*=LU\D CM8F<+<?(=2<B6@:^[/))N29Y B16<,9T&:+M]'H5A)
MR$E;6OF+%(O,HZ*C*C(144UEBB727&N6&SQYC+;IE)J\Q%%5?&5 2V;$#2/U
M./_8P853HA>?YCXN[@\(REY4WG-NSQ1[6<R^J"C&A]0<03.YSGU/5'UPEAIS
M"0@K8L-;1P$;5+1JT5SC7.(/*03\)> T;R5M\4:^3?33@EBMNJUPM&$)N/JG
MID8\>WE?.%'I9,37^,\=(6[@&+V'3#*QPJJZP5U_8=.8O(U);DG=:FD-&G7B
M[!$%42DL&?9:O+Z N.+O+!AFQ0>^X]TZBS35NT%06^*B01@S.TN8=$S&5H0U
M1Q$H1KUIAI)KF.?M"<SPXST8_!M[LV)*O__><ZH'AL#:Q)DF!,-FUU$IZZQ\
MR<05"09<BP(72L/U.DSMEH&ZG0:@S/Z336-MG;0V7+MW-5@02@XB'#*[;L(J
M\+9-3H0DVYJK$H.DN^_6M:=K=99*:\',JI74TSQXP9;9BNO*9U,[8FM;"J6;
MO&0?OBY6@C]@R^E$](RFDSB1G@VS2OSMGI4:K?GRL2VS7LB\4*7\XXV%ZYO9
M:XQ_5%>S5UZ8B#W\+LX_[6R2Y>GWMN_D[TZR 84J4DNJ.F;$C!E5P9_,E/+%
M3K&E(+1<*/,VYR**LCZ,8WC)1&DHE4@#I')C'$-O1RQR\M\Z1^\D'[JN/ 1:
M/% "$V54P3D*&23E91L"4*80**>'2FIT(MC1J3XQSN)\'_GJ#%M(A8G2)"CE
M1VN62BJ=A-?>633\#_ 6!>=,*620U@+O!OQ*Q=)P'3-4J^Q80K&"_4I;DOEA
MHBG6'JQ-W+PX1<J'= NWSA(_;*^8YK=PX"^1-@-0;339:)8[@Z'1VQ\9L!#'
M*[ZO< G>C"J 5;F_3U?L#/H(8//:D+%]!2.S&\Z-3 3DU?O)5"/:?S&.%9@E
MLBB3<PW7!9PL0$><=\1]9P8> P$E!$'Y9V0.]/;[E_\-4S,%0K,O=:M!$_TP
MH/P[5PR($]?PG(4QA $2[%U+\K96=>CD$SC8^BFQV0]Y\R;>V/;01W>J*VV;
MEP#>6W/&5\)!<*Z5V9LTPF3H33\\K;"WPX/,22LMK7087:W1A9YSH\A3LL9V
MHQRR+86/>CJM$,'B'0XZ+DMTU/NA>_JX[ N^Z*0N^O*_=O4-9XJCSIQ+LAP!
M)Z.6$*N<T<4'\)F0OF+=:[>ISW^\CIRXB[83A&_MG:%T//QJ>@ [2-/Y[C7@
M_NR#NM1;IE- _M8;?<'--P8]+^^7GS;+)[4*!3MV?;G1FX15$LP=O^WQQ-V8
M[NW\:GRFKE$+_KBQ\*2.T1E%"]6#3KRL"QU+@,=*2_FB??;3478?#+_(.?X1
M.:OJ6:]<=M5B[S 1N:[$/J1*OHNO+5J[?.>7F5=F.N7C<2X2X R9NN'(\=TU
MOCWALNBLO0_==K4GK>S4ZT6"5O/;T>J)P+"K9Q ?-/.VY=]QN.<;P_^F?S2@
M5&?EUD[.:BRJ,-2TM2O.Q4\*"+W^:7UBR <"]JH- L5LS=SNI]0J7;SR F/F
M$%N9#R\-2DA^2ET,@"G'VO.#\>ZX'&/O1X <<TQ@*J,*,X0A4K5%.O<8.HYR
M(V>.Z5_4DT8,$5'OX%G \?$!=&5]P\#'IN!22T;JSSC6O=29(K0M<6V<W\1$
MA'OJ)LM-/C==O>S+^?12#Q7ZCL$Y<-D8W.!;5>IK2>YI3>M4GGW-/&84RW^_
M7AU/T#^EKHKAX;\!/V06#+I39 V /3:HV>]RVA8F%R+ 'ILG%*-%K^R1"7O0
M'R[N/# %R-M9Y HQDE:('7T+H5/IPF;GI@=Y]*;;)^;[_45K:V=*1%/U<8SN
M?!^RPX[\A3"MX0)JN@>0.O\NSS24O5A/RN>-'#SPT77!3;-^LF*N'M93MB]V
M7[VO<63 +J(Z=D28>;XN8B5P;B:*T7;5]N*!O+)W6Y> +U:L&(EB^57^[AU[
M7K5Z?DU> M:$^(;)5]$,PXM)*D69JP\2KCVH/%D5JC[*YN4#4X:P4Q]2$8."
M@V<37/ESS3/P9%,#%F*F7E):.U2E]-MX)M*'9T0HAB?6*BDODK* O0-F352@
M8<"LO(=S\(FT?P*A*KG3SW_62HJZ=5_<2U7M\!S+X\.VO7(R@&LL@!SUPPS2
MU,8SO0\%L3FZFE3UM'2X6W458L!TC],JTA;P55;-GN(ZM_%^Y C?B"#I7\'Q
M,,[[0XBM8,M(V@A7UKFMKM;;)^Q[O,J Q6QT7DSD' 1H^]60N[W=] _%2=?M
MMP@23O,5BV9CX-EV0-[9!/C$*/BFNHLE-%G/NHD\FZIJ(4V] QS7K\X8&95S
M&Q^HZNH\&@>[&#(<:U*T(Q;(':AMWEUJ-"P;+0=#"3W9JHPS:8 Z<JS32CJD
MD:VJ9L[*7KOUE*''T2-:DZK?VQ!Y9%;I4(1!C; 2.+;ZPSNI8N19AHZ%Z4CN
MR7ZYT,%D.-*/E N"=(C+%1#I]HSTH6.8.FE\I>:%J.K>\[1MLWZ]X3T';9',
MA<7OX0%O&:.@W^ODG OR]\$_5=#"T#D]XA^;KHP84,:7NI.K>\/JI:@ZCGJ+
MQM8#'Q=%0B<YBJQ<RLW9R&]U(8JPTQ\AR;6D?DS5Y.=4+P$N_BVI:/W>  %Q
M[7N__O EX*"ECKW\[:%C>N0[&>I92D.7T5^)JY0&^/P14JHN-K+4HPJK#E=U
MUT^(M$Z>JY=$V9=U\Q5#_<9BAAH?.V?#NVG8;WK&H&1U["-$!F8#'Z,G @7'
M],<7&YBC6NJ+B5P[(!IJFTW2(7$G'RG-,D AF(O;@D9?^>R;E/M8[.Q\\PS4
M\B'Z@7)P@<H?^%AW.M\.5TPMK=L:[AMIG<X_1&<NAYY7H;,/XHK)T_.?Q0W;
M. \0M*!^ G3S_A=A8X?=^H]4A0ABG_?$P;N3_I#UJEG0@L<T'87B6-SD(ZB4
M'R5@X=)*/V,?E.9-?L+G=EXV7-5-0GZK]8)CSV4);,CLF^L$BZ+M)+XI!N'&
M'6<O%]D7H7<W@@"FIY<9.2.CHF+-08Y:)]@RN.+0CX$"$*;IXDI+NLFW&L$A
MQFWV4 LDPK&_AAH9("8_A1CT#[JQ-1WQP1A"KXBPV[$@U(\_,@'"QXI&Y"KU
M,YWFZJ7(BB7A7=JX'#V3R)*C<0ME(>3FQEX7)]E ]O)!["ZA>LO#[RO4F@;J
M3(9RM[-"%D&3/K/M$.,G:-'C).5TGA%GZ\#U^^@,T^]%NE"\_X3>$>2?9"]"
MSAV%+F*;&%>7FA3 NOZQXQ^FG9>^[<G=LIDW^N^#X:?7+0']H%]%#:V/_!4<
M24"N]\HC]?'7[<+PIT$CWP<*L^!#?RT%D$6;DW]T;XK_>4;7A[6W_S@A,"S[
M4)Y&SOG];[!P3+YST=.7Q832OW9C5??_&1 &3]BQ"?-MUR1;5E?.PSBBZEA+
M@S/G#^F5@6JRL&][IQ]L:AI6.]OP1X[HV\BQ*Q6=H(&KT\G'?]NZ4B5&F#'(
MRRX%MF"K_$B.VKN^_K5,@BEGUG_V-K-(C4PO -W@$S[K.A(YJE3C'[PEX%CI
M;N=8GA$K_)3WLFKX@F=!7&1_>.DK2CU\C'D^3B[B6_FVBYC)++9DNQXB2XD/
MA1UP\A\A*E7)2]P ';^=>AXKF!$W?.[F5%=7D:WL[\[C6*!#%GJ=+O?:?YIF
M5!0,P&Q(+[/\QR/*+%HUR1<<9'J;1W)/KS%P(H6?I>T"N!LM\=_4>A<RC^FU
MZ!ZH>.Y=6HGN6%]Z.!G.V4M4.5$N8*4X)?G*JY(\JD2M):H[T"9]C.%K ^BQ
MP>XOH'&L6Z4T,0P(^/*#V[(+E@#&GR.T;9?'CN4&;F^Y/&R/UD,W'R=Y/G*\
MYL9IZP#D]@/>JVM0"W.#J8@$!+;6>:7C//,+AF-G^[@[.O'\ FB;5QQ35Q*8
MS<"X R=ZVJ?O/+Z-FT0VE;W(I_(K145LJ3'Y=473>3WO]FTPUT1<1W\HX5F]
M*BN-<EZ7Y/1$X)CX]5M_]*&KFY4PJF%CQ V":9)DA+L[4%X%10^(XI;^@L\Y
MF8M**; F+BN HDLH C1R3:VDBY,X,$)2A)MZ'#S63@O(Y*C-V30090")BW(D
ML!C,C&X&18^6E3]H+LLOW0&6 [3=[M%6R3N*+Z@3]:'HP4  FXZ!(I[ISS8Z
MJ[D60C$5X":37DKP)U"@ CAVQ!3@0H5OFP+#IMC:_[SG>-A! :[=RI5_!5RH
MVF--]X?",X#D*J;Z[5"H#/\T/>F((2C(@SZ]V<E5K JR\PT%7O^]< >]V9D)
M]D=*GUO=\V[$\KY)^//J.BWXM29JOVM1#2]XP.$%C%-(-@Y"Q&H*M[PFUX/=
M*W!BV('5Z&&F,I"#XC =DI2&*(ZX"Z!JM^N1Q!$BD&%0$%'PO9ZVG@$4IH&M
MK:0J=:1Y-&#H"E[Q<WO60VJUB3?UTAATYPI6VP); DX<>$A0B!S.7PPX/;AU
M.LI$V +,\U&=G\4A3T%/[3'DP _>)/2=\A#'/YL]^BK[OOS,C?9DAO 0X[_&
MU!-O+B/EH,WEUV_?B;3GG7M\OMHS*N]>^SO2GBUAE-$A%SG")ZKL]8.A4SW(
MRI4KIO?O +:$!6?6R1W ;HKNB6-X>"9<J^$UTB1.)5"<&Q-<=L$T O(B%FP]
M7I4_K>EAI;SB7+G7=%!WASI*GZ@*0VI7\^@%KH/(:);!R5='9\LNO=YH<>E\
M044_/>/%'BO$VL>[%X[>F"TOG^3D!B4ZUZA2CBL\&NOK(%\,&9EI]5P_5ZBI
M 05#E^D-LRY"]<71EWUWAPV-"]E2OX)H]B6_[)K*:!U8 @3U$C]1]^(8ISWP
M+^8;(!(@@>188H/<_9%&VF<:@M:E./J7C]0"Q)8;/TU<;#L,T\^^T+QBJU1%
MMN4SO3)VT $TN(K].#9#*++TUII7?4KXGB)2W<K!#L=*^S=)T+8MTML8PFU<
M=%!"6WM4]!K145=-<)63]H?N#G!+R.Z2_FW#5YP^E)**\LHLG[W<118-R7\P
ML.?0:?-'_Y)?>'%Z<%M^4\4I#26^,EMJ?F4>XF=R1ZSU.:_NS37#L4]"..A%
M#RQ//0W(G]IC[_)G=.?RE=>?EH^WTBE'>)HOI'0C[[RJEW)V]IPN*50&EU@@
MX"O%"OM=;X]-/^^E'0##]9^-?]=LS<7C'V#@]]V 3@39M'=/(VH)T#WHN+C'
M"C@!;[9.9)ZG%\U2&EW?-+70UOO6[=2JKC,P8V7[''3DTU, :<1=11?4I%S&
M0";7,C47T.D-8]CMEK>NU-P['?$ +SHM*@5TOG+58Z%\EU.<4E7R..1GM;;'
MOZ.3#&_Q?DYGX-"IH"_VE7XOOCP854")+Y52/: 29@5+V%-_ EZC>*O.Q+%
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M$;YJW1X0;73(WIN$G?KM\ZI-9Y3MI3??&GE9"@DU%H341HSHW$+I ^#W4&*
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M-;84\-97.-9\.7KK!<NRF7G6O3:K^[[X<[,IQW-(#G.W* _>8-J^1MU,6M!
M3"F[FA[7EE9O'4S>?E*"NB+#V5F(;_58U++NS?IANN6([* ;<5-QL^=M;9WF
M<2*=<&+DD.40>B*>-E,@>X\D<'I HV&!Y*O2Y"Z:BNA+^?:J>-.P%I=[2<Y
MH'#&.BJD$9G!]?'O5>ZA>Y\B#-]*LTU7+!:]J0X7DAX>P5YJQ \ZVLSW"G#I
M?[CP5_V4L8I:@=#E*5EI[ V H4V3>V$0<W'IN\)HR:5[CH/S^CCQT9)S;A^?
M$)CR!8O$MK;/I =LZ?71#L0G4QM"66HVKBFL5P&_U&^=Y27*PMZ\PDG:@;*G
MFD;_BL$E^T0H.OU^-O!5K<R8Q?QGD3^Y_%=-X6$'P-29W+,Z(5.Q2C%6&L+>
MHPHX_U(1>06)N.KZW^[0T/=<G/ \Q=F)'>3?W!.X<5>RQRC((T8"+#4;[U/Y
ME"IZWB2LG&0/A$'1>BET\H_\:UTJB=_,*&\*DESD)CJ2SG7OYD<5]^_+O2H(
MLZ(CYT;S\2?;?"=/EZ\)ZL=3Z!J(%EJ!?/R%QHU<OFE)]L1F#K^9<M]7[V(7
M\T=Q=1W/NL5G/O(*FYE=.=:_5?0M'#CG9Z7(,A>>-U M@7H9-W0)>[N7'VOW
MECQ-Z,#DA] RHS_A[XI7#=_9[;]4(S!O_*SI;%YB1S8/"_7>_ IN0#%Z7*F3
MD)P_D6J[8\-^IU#IVNV3P]9]IT3P.><R^A1>V;5P9#$+#H"G1_EO5AD&LE7/
M]"<#BPT"([0=H8<*:G0OE>[9_[<C0Q9,D/@V6&C$GVL@KZ\T4L>V2G(I*M:A
M<4;J(68^K")HTE >73CZDJ690M>)W7<W$2O-)<]WE:Y>^$CC%J"KX;A.$-U,
M, EO<CXSY].K1WV9^<SB/^,+GJ#_.N]B C!^^U!YT==27YB:H--O^3R@A==]
MM"[SL\IKI3<BS)(++/G:-Y/*=>]:U;]\[X!D&]>'O]VK&6N]"!=F$9G.F4\N
M\V)R$E@X*T>KL+S7Y0J^*_6V!\3/44NS*VB2I:^BWHO+QK?;P:AE]6Z#VP.(
M=_K7)G3M6SUYKB?]R4[&?^FERGCP5#VB7PR-;U/YLD37KWTD.S @.;1K:JT/
MSVWR1GR!G0I3ZU%NC78#)NL6-%[@@DX)_!%;7KW1CN_29O-H5 06,V,<3#3<
ML,3_NSV1A_HAO3WU*J#(*M^PD>ERJ[\[&+#P>%<L^4:$ [CRO.H^&56$WDQ6
MT[D9U&%(7^6=?9R:-66<%J#7$MU)CY'7!A=M;^+1;J>2H&\OH-ZDV>_H.TK=
MF( W_[XU-Q#5AO-D9YOJPY,"S)I+_NE0KU_<[#.?N'SBZ:*K]LCZ>_-G@YS,
MR@>.%;>2$,)2')GOVB;;E+%A/8I,BU#ABF@[6!=\!"FR?Y=X_ 3!5)U9&7DY
M:JYH(07<B[CP!77*KW4O10!+;M#[K8L8_-/]OE5G/8\*AHC^)1>^*5L=1RL,
M7)%E&#J@ H+#5"HC-06[A1%86/+?^3Z5*?;/^^)#2("WH(A[;U3,+5-43QV.
M9N\TUTG0!F?"CE#[4SP:,KCHDGU$09$U:A4AWZ<,S#NXR9@.6+)F_F99M >Y
MA<G#,CSEUQ5'@>;O775FV6]SQE1G@3]M]V XJ$)N25A 7,0;^3Y<$6E+(TV%
MNI\1:'.G&*ZZB,_%#*$YS!==>&.Q3)P%@>( #']<V54N/=M6IA)E\QH_T5R0
MF8!^7N*IMA[FJ<X7'_I.79*:NI<[^55L\U5*?!MP5XWC:<?Q$L[J%MY,?,95
M>\+T$72ABI$ ;==$6/JF!1P#)O!HTQ.[H<+9V0[ [!\KC%O''G/NEQGZ%W$,
M#9L<;?KMP?+<7<Z\S3*/;H&019V][$GJM?VO5FEW0C3XZ2MOT2=)9Y_4?33I
MJNV<K(W@<0S\_LW==+.G[NX!H%$)_\C#:4QZ;&$?[</(X.34_O3[R"N?D=@#
M@.\ONSH%)]Z2JU4/<%)QM-YK/0$F1X)*S=-4.(YD3[Y%=0MCW*X"GFYWPL^V
MU8BXI_1R^%P6*U/0^]:'FB$:[--6+=B";)#K]'*QP339P>O=N"'6X$OEYX\-
MC27VW_=:1Y*NBX6)ZV(*7%$=TJ/%>KF3(V,_CKD//SJ3:;CJK#[%-T "\/;[
M/(^^?+.Q&?MG)JW'WX J0;.YSMYXQ72V!XU+\ZCLT'N9?7O5F;"7W#H&FM#P
MZZ95'7]$H^29*'_+_.%-KQ$AG02-K^[4DH_E <8O@DK%4 R>YWD^Y2]#W\F;
M;<&(@+MW#4]?=Z3/*1;SE-5[[4\GEK_3M.,^/ SVZQ6O747&O=X1@Q<#-ME"
M11';!X"-THF,#$X,]E.<N9GP$]?W37%1-N]GTT1BM&RL':?_ =/W@#OJTT(#
MZQ+Q.\:DC#5BI>ETL.KCYF/+-^1#&M$;A<([.%(]5_)^8D.&PZ@<;%^S$,G(
MX%H6#U1,$OW0TP2FZ3[_N"J2$=6(6=#R7& [<N';7+J@:</0C 4M[0)7NM&J
M?</^5TO_E3-'BB:'N2'+%=&'N\=JPXMNH- GXZ+Q3\'UX7X B).9#2)@KC$Y
MMGWDXY0,K.)^E3)J,:*EO.MM!<VZ5N!T2*/:>GNJ,8F2_KVI+UKU%FB/X]C=
M&QV!H1' X,>5K\J56)588C"OU >1""<YQ\3=/'633_L]JS87/2KF.A"@20;<
M"9H6&-^VJ@?,BU=,^2I9L1=2",T%1\MD#%#QDC/2458%%@> _>;A:JN 9XO2
M$,:DX0/@<_'F0D,&9\RFUL2.0/#)2B^'\IG0C*K;,HUWY1.6[\X8KMJA]K]*
M,06(O\2N;/H#8P>S/,_)]D)0ZC^$J&\.I-XGG(N3PZA6KO4.,+?S^><4.$4E
MO!(A ]J=;1OX0%F8HP:?PXY7F4TUES@9.7WVZ^E9(67IGJ+$Q+H/%D?G3HZR
M4%M@,>2817,^3Q5[>A$/RX#BC=LY2Q<&&.]'E*]$ZE4EW"9;"TA>Z@ARV"R;
M2I6+'G,P7S3GAZYG*2B.[]<_\F3LL43U!WYQ>DKL"5Z\X<HP/S.<_VC7#TY+
M4*Y9]!WY8.0,(I<K=Y+JOI<P[#D9K,QXR(HY6WMFF!*5[#\;UYIS>E3K&^;A
M0II*4:2R[8X\1>UE$,A,F@=EM]X.%HCA8JM-)K2\M 0C#V^=GQ/YB/=XE'=C
MFRW(\F8I&T)N!8GFT*;MWF["VSNVSH5HB$P%BE;3BBSOA-QIG/FS'GZ]RZI[
M_$=I];;0C,'&YRZ1=[&M:3ZLZ:"J&T#_X%ROL:#!OU2'8-LX+]%2ICXJ0'*8
MK5%4D<N-4*@E2(OVM'.:DWSHNNZ@MN;3Y!K4!YQ2UEF#55UY8,V4@.Y*0N<Z
MR?4 &!R5F]M+W)KK],S<,2>!>7JLU<9W&5@5=$[0KGF]4 PT^G3&\<"1)S C
MR%L^3Z%G3 :K0L>UJ% 9TP2X;G9Q\:ER3^\W3,8L!O$]4B!6R*>%@B[WU]T*
MAR[93E(%9Y4[[JX)NG?0;Y$76@Z=>O0OIPU:O=]SN1IPZ!@PJ*37$BOU$D&?
M;@V".S J?5Q@*#E)3J# I$/:0#*<(>^U^0M.P?@90_ ?7(D-,P@X#R>.5(VB
M]GN!X7,Q'*Y^@<G,.5?0.P\/?\:A)1OS,R2(5:Y$_%H!8\\RN-)UNT_=?&KY
MNV\[^WI>I1!O?=N0J0BK)IN1&+,H8B5HTFASCAKKD"8'%QN( A9B95B[?43[
M6^+_Y%?-PQ<=O?J'4?3E]YGEMJE84JIZR1@-C%S9$<R8S80/&'D-(7<? ]5G
MW"CKT_]YIWO63)"U>0A=2XLR,F=F1PH< ,WRI8QIR(@)T"H37Z4&2V-9/[TX
M?LTK-+4^;_T >+SHW'LQT2 RX@NX>FU!QM,UM9E%D0KMB4-^HC(P%ZV5816=
MIR/5-5.]$Y36:-EG$!H8]$+FVLZ#>& ^'FYE0>@&=V]K8_$A0_7GKKJ.@3IG
M$_M.(6-D0+F[$MXI5S> *DWYJ=);<X<QN$4(1Z!HDL1 W'%.N7!&PU0GG!#W
M\TX/4V1/G8D&-/(IV@HJ2^ACY+69FX[I]S40[3\OI:@* K5(W]=\WLB8CC\T
M($YG%-H=A"_5"5UYU#\;E$H0.[2\9-#R(#_7 ?JYP$_!JL[7D+#T*V;>JQAF
MD_T+I:T\G^V(&D\7/JO42ZL,WH[-" I)A3X$[QXQE#+P88 [X&V;H%(Y'_KA
M9=SE+YT0KVJN9:F069C(?,7#=PWZ6EJ<//JPR[%!.<29J*AMJ'CS9E2(!@K-
MA8$::K?0ORULWXI/KX6^]&+%Y 11Y$$3&9:+[AMV( @JMY2.^<\!4*"EI[;L
M!P&":K6PZG)R/$"2^LBRQKP/A"(@#1M3M%ZEF!_V/V^(H<:Z'CW6350!'S[,
M%-JA P:04-]PCX:%94VRA@1$0EJ@67H!F[4?U'$[?F^483VS!%6H@H1L=D7%
MZ$&DS3YT!RGK:(4HT\/R/$Y?8F;?TF ?(P*,K:!MJ%LYE[8DCU41Q,>1'\A&
M-4:6S<^A3=C%]_[E8@8J[Z+^FH;;=\LO$#HRX#TW&'M\K;EY;DX/9"#VA"!E
M :KS J<E:\QS B]\30\IH[3V,3+1K@KM9T#(<E2@(FL0)"E%[J"GY8)(=3F0
M1;T]F85V% )"Z)",IEFO_E@_%-M._:S4&@4+=8'7VU/59X<$?3AF3.UHU"'[
MH!!3]Q>!E+UAJ!*7?7]1$!U0'W3CIY1!'#6H8/6BSY;?_DO6ZSL0U>#@73]U
M)2ZM[LUC/1X _<MZB&)-7]KXJ:^$8*S8^4-=W$Q?VLB41@X=BO!$ZVAH"P6[
M\+^:1N[40]6VDFHT$><-Z,1%5Z=5W,(-+2Z-%JCVUGKMQP&P/BMU 'C_?*3<
M8%<?.6Q8[SMW/7YOT),'>!RWB\E9AF9RUE-;//]3@"UDK[4Y36EU+_!O^Q8V
M)T6+%?[@,S1]5C<,5K'LYZ$/L8.!_P)02P,$%     @ H%MR4D"]%06NE
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MZ:E0FHL*N)597ZN58,N2$J$^/1T6!JA8VI&^DZZB4U"B3>L1ML9QXH-3D!0
M:US(AH3#R4QX3GA7N) 38FT Z2J& %2&!LPVEYF.-W77Y3F<D2?W_CHWSSZ7
M>51OJ7/258AV?"9Y40[0%L:D#V=S=8E.>/OL5VO;-N[?F<J3ZG7X^!)YTHF&
MX/&OEHC#F_@^O8U6 HEV+:7K#O&ND!W1F>-9)U5YN)YL<N9QO#6 =?TL,M8&
M0!^J!D#H$W=Z>_7.IFSZ*B0;'8IWG?A.HW,/4K3TPVD..<8,DEJOV^#6W-W)
M"Z(?4WCA;G<,SQTG6D*^HH#YB$.I]A-?H'_5VMFD*4T:6%R"NTB5:.D@X;U;
MNU41*_F.7AF5X8E7+*X"[#JEN@"^"CNNB4>'K4"H!O1>;"^&& O"''I:/.4E
MFQT=YKL,G35#EP2Y?D,$=()LKJ)U$@F>L(IVKU$04-XEO%*VXQK]W4O/<?R#
M'\R$K&_TC%.(=5PJ_.V@#?Z+EUW;HKPMQV=NZ/C00.*93P!+^G<O_?$?-*K"
M6GNS8WP_Y/ZA5=W0COXI"'86E;@$N^*8^!P1)7N6@ >0RO0:T4/Y92<3PN_F
MZ#2X$KU$!425&D![+FLWND??L*:IXYEI6II QE=PL/29K(!L,YH0ZZ$?_+1[
MA0YYP) ARX^F*;'9'M N>1>5YV)^D2DZ?.;4OP/QQG;'[ RR@; ?=T%M)=4Z
M]9BOG",N1=J"O-L]77'?1/!9/J@M'4KO[\).]BG!CQSD[GO C&EYJA\F"89?
MTV$*X?3K?6RK: 7;\4V 3*.]1O_21D[K9*3DB:C<2#9](:];3.RA51]L#"M1
MV2>R*OPKPZNZ7T!@2XM\9QOD!(W3V Y<?SO#K>]%8"+=0NN0[,(S_9BEY9'=
M)$$A0T_^<>(O%1/1R;[*]-4 WNSE5'-X+2)NVMVN)'-AY\"^4GGNZGJ)@I86
MGUTI84KKCN^/L +=T7IHIPS8*!W5M1/D&FUKTB@JQ'%?TDXL'?G <6E1X!3$
M^R.=?VC9EHU1,5MP0W8*N^?*K2+OMD=)[NDXFFYE&K06:K\*QFSI\.=*(2.%
MNH2#-M4;N*PG\[GGCZP0RG9W18@)QH=V(#_3XT>J0@N-* ++Z5T1'5PKM)2G
MH.]5QW<X^S3=8/I$\JP \LIR6$,L'1A4'N,8%511EVH8DV _O:0+0XGZ)_Y,
MXC\\YN8LS*?>#+_Q<%]TWVZYYD-YF8$,\Z,V7$1EO#X90/YW ?Q H^M.%&K3
M91C;X<H8Z/@SS']DMZV5HOI'9GNYBRQ(W>ANLUNS'PXC1-NR[L(')MA^;_N[
M8>0<:I)C(#B02B8!9H?B[=^]V-#^M.RG$=I+[Q]7([OVX.2&D^%DS7P9[X,,
MRKJ?ZV<TT1'ZWLSTV4KH"L;244I*:1]^Q+WG1VA^&(PX!^N :^0):1H[)[7C
MB/J=E:>ZS= D=M DSJH&H*C%DLT"OA*73?34@';P)7,OVQ.1FSY]_G)"'*9M
M5J_ZENKF?C2=SZ>@=K0XJA154WK23==Q%$ELG3OF'W'^BW _.X<[QC:BZV*'
MZMP(-[3N;)0:'8J?J=;_6DZG IEK[\#\W.!F=:*+5[\<,EJ=X0\>9_$[:]:W
M+"TUJC6Z-'?*T5WDGT'MC^O&%YN-G#T(;<O]:\,U( Y+0#I0<*B! \-^-URY
MGU W.#_>P[4A.L?<&VKKCD[$'\/LW\^&LP0N*K^?Q8MX./B\6_G&Y)$@<K:A
M$:C.NKD?]?RS';=X" 847A=#=+$N^3\]Z](IZ/#^<<@D0LSLFBK6Z=U0(^+.
MET<O3?3?U R_T-T'])*C0X7OG?4G!2%+J@]M\!O:Z5RH"=V_'C^YUG%63[RM
M8VP_;F/F[_@F_J4Y"VIT:94O04]!/X53^G.#"R.]UJ)SN?2;A%?J?JWO/7[2
M]9T0F*_)<*226^-.!M'#>OV!&D3#J&&KN(MK6U:)#MW(;6NUPJXC[^^H?Y_*
MX!J:C,>9WB,/@%3C^YYJOP^L,?9F7J_X9DMM6G0B*/SH.3^.9X-FFF1DHGK!
MY[WGO6.XQ1XIVHZ"1 $F+OI?ZF2-NUZ]: > F\BYK =?.<;Q+F<=N3-3PI("
MY2I_G0)E!_WSE8I(3?T@8%SV2GJ&+1TRJ&$BS_5VG>WHV=;JP0(7+:K/G=Y=
M!$_96!.KF7*3.J0CL)DF-24$9*RI$2,@[T^S:"J;H>];9H94/@7E!'%S#6[6
MYQ$J]<TZ4B_@ZBM"=9B=Z/7\2)R>/.S4.^_QPOTIWN<;1YX>75*13]/T"9G(
MOU S";ZUB(EB(AV'-&CM"(?4-K&,5M&[YM;(MVA,&PG0WS&7:YD0G3=YU7(N
M.]D@W,ZP,SD3W*K2%]M^^_ S1XQ?0:9MS%J?X_AG/7K:;!=>'XFI=WPAU>'#
M':/R3G=+0N?,UI47KHS=?G*YWCQXP"E$XN%3C7"PR$%HE63A:.[[6X&ZTT)\
MP2E(^:>$U0L?7Y-(Q*1/<>3R,6J;2'FL!J#".1/LCE<2,U0F]%/>""@_$\:?
MHYC&YS#!3:M[.E$;I"I?\4;06[Y^7MOO4JN;2P&+XV&<OV[>GK16^$:]_4RI
M1_ M6V[^&/>0R^&^&/#GPF[<HI0O!.&O[M0^9XAO02 \9$8ORM+0X25E;H&/
M[R^091DKE0Y=D/"U Q\J=05<?G6?52;)OMG&5OCZQ\G+#HLEGRPH<Q6HJ483
M4@W@[TR<-?NQ=YW,N#F?+0?'61+T%ZP_S)VL6)D!M5-_DNQPCC&F.I -'];J
M>Q#VE $A.V\T2.NC=T(=IV\H5''Q,GZ]D'.((%)3-C.N,OHEO#=U@.C=R^#
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MR?2&/.$*K-8*A_ ^:#+Q3.FZ$KTU70NQGLZ*3%>N!;T75 /Z94S_KF<9<\:
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MA6^.N;9^E\%Y6X7RQD'9+FJZF>!>H(ZM]=2@?MH0[?!T.8?X3)DARJOYH,G
MB9)VX_7-6V7@G?LU^8Y--NS>(>XV-3S[-CJ"YEXF1&EDB;7J;"U)'KINV$E'
M'2?F^]?H4+I[SI<;]RR2N?\]^4P?(0SB1++')<=B)I"@X7S&:F [^>TC2>V*
MP\%RLV0K-GX0-F) +8+[TW,],LKE_.WXJ*@H(:_:&7HK=4FMIQGMT8*9Z6P/
M_H@6V[K^VTL@_H7CA]+ME4W2$:QH-B&MGSL3_WH9S;&IKP;*>M-G"GJL1T#2
MV3"6!]4(0]235>L:QNH$[M/X>!@MMP[KBMY TH<("*01.JN:G1JT=D6 I_,U
M79- XCH=8'4A=NZ:=O>JE+<,)@[?<6*_;Z\9MA& H6-37MU6U;P> DY9$=!I
M!JI5D@'P1A()5"_D^D'EP^WXR$?;,U/%+/,N4ADI_H;R/#D.POTSM;AV9N$>
MXJ#0/<*[+:CNZ[4;?8=+KK?QNQ,L'C.(,V&LA?U66W3%0<8;C+0%M U.R-H7
M.M2X%9?R][;)Y\5- "&$\BZ3%U!^*3WRSJ6+6C3K5M"3OPS,VE/TK:N27KE!
M;!CQ.[/O(SPQ2=8-215KE\QQU!:E<$*\WDLVU%0U9Z^K8$0FBU7J3W@%T&FC
M6\@E%7^GU'& R^04E)ARZH5G-RLRBO%&?WP_GM]W"7"E/KZV7R)EBA/I:E.?
MH=6:/K?&9FA=&,19LF,9I?R\-H>1SYBDGI.^.XD![[.90^JVH\_.C#KU)I$B
MGQA#U'N6IIJZ21Z>Y>Q%C:?QJ5M$*A4#>CLR;[P7KE6J-RD*7,^86!%N)8\O
M^FCCP@R-?<B<@A%VMTDD0[JX+FE(),*?50R$MI*#>V JN]&<X<;WXDF-"R<\
M>:&Z!EEO^8;/>D^3>=U\W#=$LZ8^9166*/^XW] C7ELOD&K!9WL2W-Z_L)*M
MLS&O*T<GADA*DYG(B?AS7VPM8?<?P0J(/X!= C^(5TS6CQ2M9VPT<4XGW_T6
M:5^?\(QI7X072#N*7P)7.Z@%(4F6+"[WHM-L%F5ODUF-7 +YW/>(Y8?LT5^H
MQF]KUP5GFUOV#;'U#IL ;^N"H[/LKST6#*>2=MSR^Q8L= (,3XM?$+'M+E\L
MV>N,8/OTM:V\R;>9W_L$BP6A956C7$_[+R@?33A?$;!S1KFOZ2(:*,=MT'Y4
MCFJ:%>6[VL8FAPP+F@AI_=^P/DE#Y<L?0.6Y8HTV>!C8UGQ!7;-TY2.N&5X"
M"<^N8K?O&+)7TD>O)#LI10-#5]*%?DH>S0L5K/LIG>:GY%K[7(+-*^E*?2$K
M6?9C6MC!5PDL6PQ)CF.AJ&@4$D$?4LY* ALO@<8>Q\97!LN9E*)W5-%46&:6
MV-$_$5\SK,DQN;9"QQ[S]D5]4#_>< PF0 \-8/06LO&1MF?)(]4=$XPVORK!
ML$OBZ9O_#HK3R-+V&IHWP6K3I08KYZPF0$S!_,RO[!'<___ +-$V/98L?I"+
M)WEURRN#E0@GS80*(][DP6//9X2 SK0([NZ0IWK=X_[ JNCFYNR4Q2/?7#PT
MUC7K?)L>)+^AYT&^1W;1;7@HNW/./XO ,_D/E8"J,H2:#4/R7^C/SY/AV.ZJ
M80ZJH:>O+"99N6_WC98];-(WE3U(N@1:Y4C\/$,\XGG<CE?^=\U_EDS_W$DI
MX<JVHU16?8;G)%H3U61-Y.PV,KTTAT*3(Y9E^RNK,))/QK!Q,G<V[^&9VBX>
M>5T56AG6Q?-84([JPFRZ^D;8E% &ZW?FK_J[09> A#YC3%@.&-"ZZC<TK R[
M_]ON,I!S&GF%DU-XXJ/0ZL5ER-.QXC4&?X:C+DNZ7S[CU4&)JP,3/[0U/FGL
MYQ(Y=<(GWC-LI\##&06["T*#G%*WBUY(F9:54TQ5R:4'AKD_F'EJ<@F0"%X"
M>+O;6$/7I]B_MA&:.;R_$6^<=(&P,5*GT1U?E:-#G,F-F&R;!$'NAF]B[K-6
M'5B^@)G816_N)Y5:)?\0JV2%044F75Q^,,51OC8+95*D"1WV_W[0L.$2Z)D[
M8]'^DB"1\%/',W<Y^C 7!/Z;0--O&0VQB?&^%LBRI, [VV>BA/CF!)'3V9U3
MF7--Q R6+30MB?8^+JLQ/A5VRB(GPY\WMBQPF:(7 R1I!3W'0F5"PSJ;O+M&
MZN(>"8+F*-ZS/]QAS>!OQ']<M'$)K!,%;_IQ;[UUR3W3,*ZX9NKIJ$_I)<V9
MH^I:6:M)HFG+@L_2_!0CJQ9M,U5&8N2 9L?.S:M0-]/FH"+6E%D&NK?U]&TA
M6":1;^+K,Q4ST=37!$'RE<'A9+$8WA@@-.'_P7D"35_(3IW#Z_5I+A3P+[[_
M974$E,7N0 AX7G#MX/D&*">MA/'36%OJFLUW:%);(B&\P?-XG=LB %G:#M&P
M><,.5@L,9HL8(KMMIZ4)L3YC:)F076"<?)O:R^*AVCA]&G4[FA2C"OFRPOSS
MK=A7,<VLC2GHRF:VU8'*BW26FI.06@W9@1M^-[.-B02[!!%L_,@>A2S4''"-
M'PG#B;.*,M_)]#%\@J,9R]3;P,#N*F&;A-&*#$ T#U^'S_2$4)).]]7[[PO;
M=5-DWZS7-R<5>_Z19Y?6JL$R*ILIOB-=)*]>9<QXNE=AB"*M(J<KO>Y5F<-C
MEJ;P.G4!-V4<*M"'H>V>E]YN-[Z;0,#]QZ)U_1]MXB<P3.>)O%>A651CFT=F
MTXW*,M".0,XFIX L@T'YI+X[#+7O3N=C70.9"(;+^IXQ.PS-#R7$ZYF86#TI
M&J?\8[RKSQF"/$ZMF/Q)0GGP3-1,_O9-:+:\A#TY*GKFR;8J+_6,)87E6T.C
M%H9N.S2=JN[6WAP*AVD>FR0E?>BMQ#V&\=8+IJM)Q&(;I^&V+4SP(6GAVE8#
MV/[,S ";;>WMFX*;<@R*CO[/JT99)Q@BXKB1^X@&8F)'&=:V[<ENL-6 T.[
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MB;&NOW!ULL2OC/G7._E<_-OKJLC1GRB>V7=1YF+LY._D@ZS^!G)>])T/PV
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M0>?Z/1GGRE;ZNYTV9&6D@[2<34JX[PNSZ=1^8#X81R]*%+_8Y$T4#8(^YGO
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M81V;5/L:M4?(Y\?M=QZ(]T\=LCTR93V&+AUME_!ATWA6]_1@T2ZPNU.JN-_
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M>@8T>Y>\9N@"2JW\<3GB_P<'R]?^_P902P,$%     @ H%MR4F1PZGI9E0
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MP#T'X''A$'#AH%T !>PYD>#^',#?!QP\ B(2,LH35#1TF$ M#@ /AX  CXB
MA(2("#OK"SL/(.(BX5%Q2B(_53-#>>X"X@J,^_J$6JJJ U]]](2&V_Q-$"H:
MP3-"(F):.GH&1B8>7CY^ 4$AZ1=@&5DY>04-32UM'5T]?0M+JU?6-K9VKF[N
M;ST\O;S??P@."?T8%AZ?D)B4G/+I<VIV3FY>?D%A4?&WZIK:NOJ&QJ8?G5W=
M/;T_^_K'QB<FIZ9G9N=6U]8W-K>V=W;W3L_.+RZOKF]N[Q[U@@,0X/XY_EN]
M<&%ZP2,B(B"B/.H%!^_Q*("+B$3%B8PGJ89BYO+T.5?@$Y!4W->J#E1J;O43
M?/,WHV@$-#RKM*>/JOW1['^G6-#_*\W^0['_U&L.P$" @PT> BX@#ES?,>0K
MR$7&NDA\J;QCRK^&G-[O+$&!)?%T'4;2S2:F_"M8RZY'_77,MBR#:W)A<?/\
M[][SO*5EF 1ISC;+J%;]XSF91[&=3:PW@_@&KOZ>$#<GIV.*H6C5_Q38^B-
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M6F3%[RIN<"#FN87;4$ +"L!3_%)%3%33:UIJ+O#T[C+><_UDRE85\F1(D3P
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MA8F^$)KEQUX@%6R4LW"9=3^$8C8H%$#<3VC^X76%J"QRNMK#K.MLTX,-CH(
MAE"XLR!1 7D2Z3L"%>5$-PJUBY#D<$ !!N-*:1_?,RTKZ(F"@K["(W,Q!84D
MQXX\%_3Z@;T&T:)7"!=/GY,>.1%+O#;]J'M5L*'RF<3OS- ?[<QW4/]]4?$I
M!IV*]L;D1Z'4S_B8?3O9X>^=\Y5@S&@WX1^H]^AR8.,>&,Q*ZTK.<#H8&N+H
MX$ 3Y/.E:"-*I&$BD+C9 6,P$BYC40EP!^E0EWHNUAR#9+/F;#-?-S"4;A^Z
M=->[]  6R:(GC&PB/IAM808O(8,-]G)'>&-&$ERW+K\&8C^X'R'[VC3*FB@P
M<G%/):KCH.E+*OZ90MU_H&5R( R0(8%J AC^8F> /D/>G]<<#O-^-8\5#-B$
M#$#35]"7?O2)_VV)]K\T.:&ZAU&"84@)!%'\4Q8J4TA9T=PNG\S6:;K9T%@?
MB1CW =SZ4L6XR0?Z"A#<)CEABFK(G(^#4&^G?B3RZA)__$5NPRMZ#)'J!.,B
MA[:#T6.P[ P_$VEQVANXBPJ2B;6I6BB ON=]$6^#[N2TS94S#TIDPN,PY.AT
M,:H/N!R8G[$><YJBR^AA4!C DOHF! ^'&$_HL14@+/3/,YZKH/CW69XN_ZY;
MO@,J%"MX3CSNDU7(H$"S Q3(0@,NFOXG[1AR!3MZ]0%]IEQ6-T<]&L]P-N[:
M)R(07L< -";FD*3GK 2_ C._\"0/<O<0.WRFIC85GPJ@*TXP4@0-$,^U?&GB
ML$*XY'4L@=%O"CXH (M,<$+QFG@<OJ(,YE+Q< ('PF.C$OBFS;;Y-H,M1?5%
MKTW]:NU*VL7]Q7]WWFJ% R%>^H0#I>#3/B!0$;TF+L2F_^E,VJ@+%" ?@P)-
MMJ-0H-@D*Y_*)H\G$<8X1A_IW+0 X9%GEA3[K^XV-&T!Q%15#@[&LG,.BK!\
M141$C(S\Y.3X #3[R*++0^7L .)2(DE0'U>NP.'TKH*8/.=LD\;/GQU9!EE[
M#/FR[4S^H>&^G%]A,P,N,!=VBR>/4.;1,F"WZ>!Y[4RC[LO]TF)/\,OFG-BY
M,Y-"F)^7XA4%0[XT.: *[##QWVYH'@CR4I,5RQ^^#%-&Y]?>BN'P#6.2$TJ-
MSGM?5.2#3]97"+,,TW^WC+Q#;=-'LD#0F$FRXZ%_%894&]^[37O8\LMP?5,>
M@=POJ,F. 6%0Q&S%0=%P.K^AMFI<+JU+_>%SLH]O)&IOA3)G>/Q^A_?$=ZK&
M8+%?;O9ERJ+*\I&A@]JJ7,T^&]'?DW8>;/+,RUWU*X(N6I6/?/;#G*9LD>7"
MSUX8(PL *VZ%$-*6F)42<2X]6BO;9^^B]3YB26R<&_&T[9D\C!OV=L;<XAWZ
M[^>VW1%]#94N1?@G<<?*)X]'PTY=3+GWRQEE7;E<HS>#I.U4)@$_..FBKO@X
MK"ZNIL!8,]H+82R6NLC6 HQQ5(S:3K.6E NVTC9%=T.\O-/YO"^&=:H%"<PU
MD"PU0B\,C-\99!)*07D3>'9W@FVVKSSUCG%M?E#E9?*X3K,NJWFT+#87 ==#
M[]S;^P(+SN$W-@P7F9PB'>272S)2V_%B2;1>O[YCGZ+?[&$J\?J,%KSXP871
MUYI#[>I:'[Q0C';=M]5*_">)B<20"S-\]3'U,6*T/RZ),B_+[&\7 -2H_0]A
MZ']F:M,"ZKY(0E4B&F*-#GF];('V9)-C0U]6X^I"8L0YABTDR)WL5YN'04HN
M)0:Z-K&2M)U;<Q:,?=H]1M)(PT2[QGFYN]ISK]E&YCM!XW$TASBKRZ29!7E>
M+S.>-:6NR6_<F-E8)@TT^]M6+LAO7)9#@1_<-^$F->75^>"">1E<5DIYQ&!-
M#-)Z;V#'^&Q)^--AALV4%QPCD5ECP)Y$\<F^MU'WQ%3E\KR\"T"G.R6A!^S'
M'>IZER<\.<W_4MCAZ#=)PRU+<Y_&-IQH73GHHCJWL&A+_"K!P4E@TNVW?7>3
M!9%1<R L>GMPHD0W9&$KAYJ,L;'2-X>JU_KX^%^.L>2\]M>8BVN1SLG/8)]7
MKR6(G'^Q9#.GDN_K6Q+0$,>+;E\RSRP_F%Y#[+U ']MOV,VW"ZAS.7]/K!HF
M]:-2P9$'+<]L062B6I)OY3^R/33\)$*T!L'M5@[C=S'R<+'$"6!$AU(%'F%[
MG\?\Y=3&YJ& !&B0^\5I8L;32B-LK0B%7^/]%@T?!,^6I$8C<7O@=H\U_0CG
M]]ZVX;58855[D"UEE3AM#1,[8)^=]HZ#X/83-5UYPH@X\Z_(G@D,ZGQK2MWU
M:!'3?P.WF+:R%L"F!@;3=JF1RC__*E8 @F,%A7=,<,4^)I\!3269)?F6)"ZG
M"\Y*2))C<<']AUPH4&YQ.UD,<,O8,7^,U]6S-.HDZI8ND"9]^_%G PN7LO<(
M4E..[U.>$_Q438QY.8W \%;-BKQHP3+IIHICX;2W6>@VS9H8"8&1&35'$U-Q
M.%;IFMX)X7E\558$LAGEG3<:6S ?:LY^<Y<)0;@O]EZO&7ZZ,%S<)._42'%C
MH=%@D>=&,8\;77=-#9DE!IK%[\+$%WDD(=GBUV#SO>]4T7-]<P)6;'ZJ9&C1
MOGNLW(:M;=5J#N;$X%N]"#,PX.8>4;3_]JW0!YS^P0;+NM&T5P6_V?*<43*]
MJ2@6ZTWV[/E^=Q*,+TD-BBP+=B8[=%<=V2!X'$X%P#N:(3R<JBF6Z,I$]AP]
M#4Q# <GFVHX&$/0O1V]Q:OA&SS#"+U%BDU)F89!Q=UW5\X_EEFR4I/</+6BO
M[?$I73NNB%^-:&&*@RMK6C+D5DBJ:QRW$<B*?^]>O?']+4>R3\@#9Z ^Z<#Z
M.C=N2QO1 >X)36JF2DO(7;_@RNNOA'?$PQ/WHF:N=O-4<F0R*Z.%%,&&8SP[
M%P-(07RL"8V?KND^/2MBM,6D@EGL2\3\: /18.8T;&^0J2HE/6B"U/'(QD_.
M9"A3\KFZ>@8SN1XO]F%>G4'#!R6B!&32N"!D[J94'4:9K5:0IL[3O!I,EL\S
M+6GP*AL,.+O(.M2%&^I%"UF39.*ZU9-$W275!T/R4B@H*(67)6%GC2;&8+ZR
MG*=*HB_\DSJ]3^P4?DY=ZM4T)$UU;X=]5OW60,@B0>8[:/(M6:],*_]C-[N,
ME"3U*>C@T*5F*N^]O(*W%GCB0-\,;?&'%3T)0N3VKD*'?7)1;N!4NJJ1@:07
M@J0+<1^)N_:.#9[^3"*'*":KZ8URS]0\N#Z#$)<V2=QSY<U"1FVK].@,3?Q;
M:;U19:( L:W(]^.Q/N%;]P;Y,PM0P%I1-!>OWRE+:IB0ILA1=JQ^+7II:-8B
MS"+H20^^)I(6Q=@7?3HLIKYX#D0<&<E]PX>0I(+.-9_KZ"%$F_7@V&*,(N$S
MV3SBE(B+$JO4)VS$6QN,<*R:/R5[Z_'7(22G)A^?]1"<+2[L/</E"5 B1(HH
M'((CG^6=E,46BDO0)^/A.$^SO!*]TYE+<Q=!LQ_ +*7*3Z*6[-DV1;9_WMEU
M)Y/G\DVX-AKF59,U_ X#[X@GFYY<Q1^A#51>;M>Z-C3L#.D0Y!UC&!2R_92C
MCU:;K.-X[:?UJNJ>$X\]M.8:[6OJ%-O[AS@#D$+?+-[D)\W*A_6+PF)=[]30
MRO5&WL>,/:BO;3+5E\OI\E7J@OI,F:*\XM]Q]^\$N845%%"% D>IFQ!2_Y\I
M]E# B!8&X0?=\:! D?^UTALH@"6^H0A#9^7Q4&#'0;UW9/\1*N/'/3IEZ4TP
M%'AR.H[8'/,%QN*Y"0^CTO>-DP,$?KU[";D.%F<.-_RG<E (*A5.<Q2C\_?Y
MD9G437CS^>$8S4\'?W948HB;XJEXZZI*_UHFX4W<5D':$L%9/>9OI)X#CQ[/
MP;=$@*MBV@@\QHIU&2M(]4_J-!C&G3#_@-S'%3E84!MY;/ZSE@#W/Y5_L&L1
MDR 4F/1O#ST'P='R1H^H%/#LV3^,9WS:"A#P%>_*8)RFCC]6_C9J5G-NS&/0
M7(3X@=F"AFG%K7P.@2J(FV^8VV:Y<M,UVN70F(3] XEZ$!3H2GV;9,/3E:SW
M$L_D5X("*+V7\E#=V9EYSBW,[(M,5?*BGJF/YQRO:SRHL%WL)@O]4^X<W!"R
M[80J@E0 9S<),F=@3)Y0./#2O&6Z8_E,3\0#<E@/"6 >VQ\4@>%7VH1>_Z-Y
M_QWX %&6225NB(C.PQ9LA*+XM5-]?+G6#*P6F<HU+7B';GRT)GYQ(5<G;^%X
M,@9(#HNZI +[>]'Y61T$$L.IF4/9Q(T4^VZ_9Z# 8;)_7&FK?=?;TR?9<AMO
M%TA#U#]U7(/@Q@. ]EP:AK[23[S"@U+X/LRB'SO#K$U1-@1YML;RFA .KYW8
M?^/>1T!XX*0HGNJ)?=OQ8,*ME%ODPGR-J=U^T1P!N2N==\*>D2R%A9I;30[U
M-W!E"?:.WAT4#V<,\'E+519.]C3YJX1PH\KRQ?H>'U];?I- _PPR[<%)?F Z
MO$JR];"E4<(KI!8$ ^&ATF.'%[\ES!%KTJK):P H4&_\R\6IX%O,\="\[(9@
MN8_!J+OBP$^K>+E<ZUM &5['5LOQ=&O>?UIE5P*?M4;X10BGB)];<0[+@4%F
M3PUU?3AMETMVS)4,DSZV E#@Y(#H4=WT(KR7B-+THB1)GPAG\1<"HSB[]*&V
M#7SK :ZAOCSIS_)@^0Y0,M_(O+Y,;$]A PKZOOHP)%OE6@G'OS#F850"3\NK
M;7UM>6^YOU1+<+4YWLTS-UB+.^"G/,0-SMDM*TV=[6W4S/ [U7XBA8S0,D 2
MCOP=%#C&WM1FJN$C.%'<DOGD9)A:+8%K" 5Z:]J.,C>58Q[T'Y!DWU2+@)_/
M)B.2S19(T> &,AAUQB2>2N#!<%H7K:Q(%(C]^8NQ;Y$?#*U:&]=RBU.3'KZG
MF(E>+F08M3 WSB.N^"*AZU@BB?+K)&@T)&%ENL!W=2O^U" )=40MLQAK:$/S
M[)6>.*HH<V!_KV#EU6YI1<(EV =XE)6T@6S>9K+<=2=:-W"S^:?;"[U1WZQR
M+:!EUN6]V80,)N^1%*UXMO<FW@S)D4ZEYXJ!FV2W^NA]Q_AT(;R;$*&;+TZ.
M<7H[Q_8^H+[?O;??U9_T,)MT&O-.OY/,!8O6AZ;*$W[[W+(9C?L^.C?>GVE,
MU[LX-4&?6 A?-#5!^-S0:#KJG;C#VE>,N2"6N*Z12LJ3WZ'X;GHW3:?5+D4S
MLS+^(5-XAU# E_]&)]WDGF'BZ%[Y=ZVNR1#=F^/T+D>B(123/"TTMR]^8]HC
MQ3Q%?+>;(U>E0=QJ"X;2]@A*+DQ@O(=MUP#F9!,X QEQCQ*[HHM&\:GJ%OD5
M7ZGMSFGM*Z'O.>[,Y02H6T85P])Q>C*@>>/K%2M"R9K&J#94.SX=[7I<@T4P
M2]"6-5,DZIRE@'B9&QY&P,"DLGV/']G-,[WPNZ.U/:\#2H915-8\HU][-TS>
MIQWEMRWH&&W[M>GZ*F5]%/TU9<II=+?6;_;'"HAJ<L'K3D]MA:Q*M3T\I 27
MY/*TYI0U!6@@22.V3>GE9=987RWH/SMP")L0#F&)YWDY17XGXO0\>ETQ\R*/
M^OGF[$RR*1S*>.HNCTK(NM(857V*=JMB(HJKP2\MU#YJ-+M--+1$!U99 36W
M[(E:X:7)]Z17_B<I2F&4?=61&+C7]?7[6N.=38G.F=4W":I#3] 99"'F+6\[
M.[[3.!%)@ZY27"HROLDS52)9L/FY#%=E1SU1N$X/"B94XA_RV5S*LS(C_UU2
M:*8VT1QH*!MY[X![LMDQ4M!H'SL0MAI65R&^1(T_:KN$,5ISBY&/W)AV9M5D
M0>U7VV :.G 6J78 V1J-Z:]Z7X!*WQKYE<DYWB>#_V2^RX\^5;&!8$E)66#=
MJ&I (,QBN_ G#(_8D3/'OFMB_6#]T#SF'S]9@2$-\D;*H;$IU=ABRK).,.!U
MMY?1<  _+]&.^&+'<!(3AKJFYSYCO+=0\/,K4HXPW<'I$ KOPHWB#T7?U0&B
MVMGC\L6<GW49ZD44]%$Y1/?VUMVIP>EM5^\T#+OBT6<LF7[!H9$D7)0'H68W
M!-.%@./IB;0U8L%&+U_F*7 H=$]T]8U%JE=AE@7G14HQ&]A\C9*!SP[4JUNC
M.27/EZ)[P>'03N;G/6^%\404&S\..3"_HQ#]$VN2E73\K4CF>>IVQ-(VO=CU
MGHI'CNU=(KSPOH#U<8J$G+C^^3'%C;X/V1-_LP4[$I&.+SRQ37##U"+AE\1?
M?5R1:G.GGW'3J,5JZ<W Z<B4?J697C!B&BN@M1CVP]&W4Y7VNQY9H'&DYO@L
MV4'ZL'"U:_Q5%T+84M=X<ADD*?*&1WN4);P45:/&V9?9/-T[.D^6+O1CX9[F
M&S/USHD)+191)=,KSNB-"36P9*4&'130MKWH^V<[#"LMJUY 'VTT#D;\<X3%
M3VB1QG-08/B7^/5,,?%T*,\PSD.BW=L^5_SJSP2,@*6YC"!*F<6>']:)WY<\
M(Q/^X(MZ \]4J>Q9P?8A(75FZ9)HS_R?X9KOW.?:UW++[7]X$T19/+4G5OKP
MEEJ]_D,++H,FR1O)]N-STFE%I4=6RD'"?I<"!=RF.4_6(2^:3>YVV2$A]@4I
M#XI0H,G^TXT+%'AN5/'@!I.1YJ46:F+(_H3$^KC'JB:Q!H,A.\=V56;N+#M3
MQI013EI]-#J/28Z7>=^H)*IN# EE88-XVX''OJA%ME"7_R.O/]T28;KXN\8!
MQ^&3WV@'?I-.4$!T#0I\[S:UO>;P_V%;2B$D0N+CYQ%SM4-4EK];H!PV6E%^
M5$]ZU.C<Y8,!IU-,43L?<^OT[.&*\72 M/%L0Z?7J( '.%4$@_YD?D=4&;)4
M.6V*O?._8B7E+9HLD(*=GLHM2W ;B@?6/ACQ%M4XX;P\4_%YG9J>TV;IWXH#
MTQL*""%[,V0W#+"3YV=-CW?D+::+=0V07HL\W:(_*8Y6]O;CY<M<1R^J]6$F
MDWW14&EPTC,EZ^[0K>."@;(HD(55E]Q )$837.L+YC'H&?O:8.]U]$U,!K,^
M>$_&/]T@HG=T?N\9GW?/%[&TT;G:C=<'I/(X H<CO]6)9D<-67LCCS.&-#-E
M6\:GMN;T6,K?$.(5ZCKV+@ILO*I^1[8^,+ZZ"*]DWK\SOW103YP8B77[1>#G
M?I ,MP3Y9[#+=09?JN Q>:=,X_?*JK>*)84S0&F;)X-(G? D*W_7,^*8;DXG
M)Q^:5,TY&@\7<&9BLFM(;SD#0NL_&ZG^M?QGTD$SZ5_V?A3M:1A+ORZSPE#O
M:T'&ZZM$.G*-_C[YIG#OSBBZJD#>JG">MKOZ;+1-.AH,>!E-ASH=I1[MS5(:
M$2TNZ9I/$5&:)313.P'G<<95^=_$/MN-LM@3!:-]'-+$P#"]QC]?&3?#IM'W
M"'(K.KPO.J+DYU?9DB=UE'89%UM*.K[CB6"+L'C.Q"3:\KJ$\$> IK-H(?SE
M/]F2_Y+YULF;_K?4.."M1E2<:AYHW@"\&QQ_6-=^Q5:50(SBUZ_,K<6ST1C.
MSN29!- $D0CV#0)&W9;V30ZU:](T12EX3"$HI$_'ZIB%M=+Q!&*/%K>831E%
M$ XEGIF%"'NJ,Z384;;#Y^;W/A\@=!/4&*<&[0&%'_QM^W["+%H\W:"XKV!.
MEOU3\BCSMG!0Y&0J$.U%(/ Y/2C2G1X?.9/GC;Y,X5ZW+"7I6MFH!)).QFQ^
M'*&"AME/.,FM4C6))UD!7&]\;2AQ)'=L;;*>X/7/\2_%9K<5&MMY,V0A*^*]
M;#;$$^4.EUN5D\'!$>WCI?UO<OIJ8$Y470CM.,W4!<DB%R,!?P97X"=+C*D.
M :)">BX:EM,N2V>NIP(+?C7C+K9?\\>5R+56*H)/Y^RF=8C3*I<,>K]C,]M2
M<%!GM.E?$(HP9OWPD,W5BRF5@!F)8]35S6:C8LE3^ %NN;(M9O?#;H?  "0G
MXU;Y_K-7M?:::>6S?9[-/_39<O*)MJN5KO80?<14N3HKRQ9)9*M'>78.2JG/
M5@QC&X=I-L;VFM[-134&LK5\FGFW3'=PGJE?ZT!:]:.(Y[M%=.DS1W^TP8F$
MH AOG&UZ))+XM4K+B5*-KJK0EGIM@[=2& $X'EABM6U*[4,N:@1QN+:.^)B+
M[;7U7I]IG'.$+=1_^05H3J@J#7G\J >O- 0>.F;YB^FY\K $E A2(UYWE(>'
M,]9[N/0M+L+F>=C8D;WN:FUUO.M6ST%_.X#?09UP:*!])C*U<_9BE),T!T?N
MOE@=#B4\F@U.^EX$S6&)[VG2F)3%0,HL%$@W Q?-BT=8=<J'ULEIWKZ$<SCL
M<3DV.&/;$-@3!%$CJT[0FT8HK 4.<MFH>Z;R+]9<SG7!["M1G:;(JL# =D][
MEN@9X9QAK#BW=F%VR!%F?4-ON""6,:_%>%RJEFH.&H"0!=I30'(IGU?-5'BM
MH.6UY\43<_[S:>7&1.)(O>6;.A##7B\H'V3Y9(](UIR+\=EV8KU9>Q%CT!$G
M533ENX9)[FF;'MN)FL0 )AA7#<\++<J](O6@RPYGP@SZS']7K?(G6_RXPZQ7
MGP&D]8EHKD6_IFZ/)Z)$T4O::F[OZ?/U&63\[::"C^6.AVP7\VTD-[:(A2,_
M"4;/N#MZCX6F\Y8/($.-7(ZSFWR'Z2[OQY=:?G?4I39[:JA8GDR%L<BP=-/4
MD]"X0?!69#I=".E37^9Z>).BVG_5->CE&B9U?EY:S$$*-Z%U%[W -=]#SA,5
M%)E-6IPIX2QPSQQWFAE-T<FO_3;YSJA[(F$0KV73!4/AZ%DRY%H$S0/QK:8.
M4OF]5*;B-#MKF=O.=M6X,7[;Y[RY?DM*S/>DZY1IXT?OO-RQPS9JC83X1E=:
MHG_85[.1OMS#1H\TM408<E58KUI0A.3!W 7OKW<"4"".;1K2! MX7VL=C>S>
MXJ":)Y\M">(K:^4"T:+,Z*N-F"M?I)Y0]C$B^G^W19$N_;.F.(:F_]>..YVA
MMJ>EU)-^G(K6(M4T)F:R#_.'@MV^^,9PZVVW;%Q08$94/+8H;C R[6MH6O;!
MF+4HC,V+?8$"XOS+U[^A0)GL/>7=*]>KB(.[V^4'N]W"TJ-W3E?1[! _[E0H
M\('D)13(_'+\^P$*3)5OK]"86#>>6C5X6(9L@8P.$P*WM(WL[S&@0&QF)!38
M/V-_*-(B&[:G[9XJ4[?+_2)//J# R C6NZ!UD-H_$'*8G%6"O%!B6U@7EA1X
M8.X_$./:N\O+7IRY>;[GXT'#7#;2T=$!H5 S3EG#OB6H5;F[@(5]"=[53&P1
MR9P93Z:AI6/-ZB K6P]9FOY2;FK<#MXR8I>T,GIS.Z4>?EDC_NXROR54NI1V
M#WM2.[U/BQB (/W1M/O*,EY%Q#M.^S+6JKJGV]?@:X>.7D.T<U;[KCN,.8*O
M(._!B.;YG\4E0O'R&KWZ^V(8_GUL8VTK_G>X!<:)MK7]1Z!BP0(WFYMCI0GW
M?456O*EG?/P)@?Y<=6A2@I0^"8&Z_/Y8U">;1U_*;EXO+YCH&S)X'K%%!GYU
M) 6\7897C<-\?.T+]%LG-[N<)0D'^JB1U&Y2R_+MYY2K$8;SE^<794*Q1AN$
M_;XG#=FYI+*%K6$*M]\]U):^6M;(./-R.)-1J+;$\8:7<<FX3,J],3X4,?EJ
M5[FCGXONQ!Q1$B7S>RBN7J;=S ,W\KI]WSC8;*T,1;/-AX1,>VIM5Y*.80/Q
M=)J\+?B9&./(ZUJJ L.]NM@E<I&"6(2,SKD 04(1X6+V3I]!UC*5>9HV+VV1
M:,T%)Q3([59*-X1@HG89U$O;XAFPBS=_^\M/*[:2DJ*_%80;SH^&[*SSS)AQ
MTFWGXN<%M7F)XZX[SU$IQ08EBREY[GK"B*]=^(V]-@7F/7,^B?9OJZ3#TGK<
MC7?AD8H4[3IY6Y'AP/F^9XOD:K.#@7SUR,8$TF37^-PBS<>J&(YM//@W'"IF
M@[*K,:AVQ,^B#C9L(F8-;#AFB3I6^LOB1>UK)VL/V:7J%:/4KYCETNN8Y9Q1
M+XKO3")X,.W6#^X<2QQ<^+@W<^YG+KN!UZ.ZYYX%TN^5&R9H)[(4%;TBGRJH
MH%(*S/F>@:7-UDTP]U(4':Q*YY2$G:O"@%=W"-,G69A[_XME4<:*'VGNW4(P
M&/+&+M4M^9NAH409%&!EW6#8C_9\'B#BQ\JNT%+WF3<=W3ADB[EQP="V8XJK
MU/GMF7,N7-QEA>6X-FB<57T13:(R*TI%RQ #N[]%N5,E8ZW?WI=?\?1M7D$8
M3<00<="+^*@N4D91YGF>F0\P#JGX5 H/I$9"FO@C&O5(5@&H!5,)$)43]_:J
M.$]?<RGE/R3#<=-^DUNVL9*AQ'O2*T F]"I N)@Y7(QETL$TE61 4;I0KF[0
MINKG/,F0;S@)M3CCD,LTZ'3-5]]V7"%H:OBWH:&(>K6P%U/AUWHL?M<&#%44
M*V/;E>-;E@QA*/#V<7$"?WQWB7OLU<C!)9G,U;R*?4![KTA_@SNM+KQ+&HY]
MW G99MW74_N>:VT/7$.#GW7SM&'OF=]]6@D'+ID>7^5+-/W_$_K]1XE-10)8
M0=J\4.#C\\I6@D$S?^;Z11O3A;(+P?P$'TRZ*SY;3!JGK1<5M2G.0X2F,64T
MI5JH:HT!*]9$N507VDHA>>[N/C1X>BR*1)T"F1X"PR_1IO+7U@YZUJ8B&8J)
MDPZFM ]Y^**<07@=EN@!8K6LP5W3?#_T#J.:G_YXAME;#B9XVZ WMYG*J$2+
M&.4H!ZJ)&!>KF;7$[1F2%#A 5@(8-L,N\HJOIN.4NZGQ+-T7/F!/E8Y0,11N
M9C#X3_TL@IQV"]+(@[@XK$2[ :'XY,];E )LC7<C5$J@FE[W*$7.=E"[.SX&
MO^H"WG/?F?V.HD(<XC"(#O;\UWS#);!]#+\?MKN4[*Z*MMXJ!@*2V;W$^UMB
MN'A-!3XYG:H-]9Y9=6RUCF(G/^+U?H)I>/ VK0SG_G0>IU?*3JXV1E9T2(G)
M@J23-4U",Q-#WYRSRE@ RZAN$WF>O2LZ+G.8#EQ7Q7V)H1+N[G/_9:D &U_>
MCZJZ5Z6M.MK1W=GPFYK-@([C =96Z9="(VKD-3X,?H*?1" JWJ_FM+>*%"T+
MJ;3F1;T:[84FJM5@X?+L1\;D6I=ZF;.W_4XYSDV&-0TWP^58>;7_P)VA&0>-
M;!)YRS1G8I+]\ O%[8'**/:-%JN*46UTWR^7FK(1%"F4J8A09KYXN8VA7NU>
M0]*Q*?:0XZFSP80^W!8)9GP(TQP/:@F2(K:&FF;E)4]&YW_/6ANR \%Z@5]*
M!PO!K[-_=#MVQG\K^+)9J2Y4)/*J0=%!N'-.P$"X) 9G9X=+TU!A#3=#F<8P
MZWY_Q%U4"I.O7SX_X\D7V[/[77CDU\Y<]D,\PF&U@\284OMK@D%>TVZ55(&(
M2HO.7NMY=.JB0B,R+*LX_58QIO-4#O,A0MNM9C?C4DVGR&%(Z3DRWV@/GB90
MM<]%$T($\.M?-;-\51.? R1_+XGY^PD4[2 ,O9->P514FSZVJFJJ5^+7]C11
MU9,\AXL,XO-U9C+(1-A[<Y.O';VV8,/_;'2/6T;R_$4QT'X8),&[PY,=@770
M/G%/MKJHX'7LY.:C=V1)9&OYLJJ]?5#]QB[B6>#!.A@M_"P8H1++ONC?^;+[
M(U^VDX@N#V?(A\$$)%: ;-=6>&R$HP(X7;Y/(?(_(,_\J=,V'>!Y#%&,;+O"
M5ME@HGEC 4,D=MY<,"Y;+?:$V63%Y/[#O344,(GS/U3X6>8?Z'_V]#3SP0\,
M!6J9UAN/3ZY/K7?O,OZ$>+5+:MHPNK"U..F>/:W$"\I+_"'_'RTG@2(WWKV0
MAVDE,!+I\#WS\!/_D5;87?SV/53&2R]*>*HKZQ5]W'Y7]7 @Z>5E8;0Z*8_S
M"E"]U]!-)U ]I:D(&!)R6=XU5O.Y.F36.96VFZK2MZMODB9QJJP_T@<)].UX
M//CH%-^\[YPRIA[O+IMQMS2CX9:9-Z8G(U*QT//F#V1QVW5T="HO=[??_Q35
MO+#T?0N78H4L(,M:O&)F=G>)],1]*A-1S;"W4*\7(ZX00ZN'[(TP;MJDL*BX
MRL1W@IO4?<T@N@QYQR7;=)F3G\J=&3F$A.5?Y&Y\[//VZJ[?['E<5\[AO2YS
MM%PDJZ(F4MM#01!E3,WL=!#6G-A.5=R?.6!+DW<OD&74M7;2)K_9G@K@K6D.
M&PXH/4H?GA.OQI/J+3]F((6X=SPMEUUMP]AG72,9]RKJ0]0(DDW& Q\TK$0+
M7E9H)H_25/E(\,F,?FI7&[$@U>:^49B\4")Y>;Z!NZN$+K-@%6F!P!/B0IQ?
M4GQCK3KE9N^KOK<B/O,NK%S.X\,@-?7* T"]5$?Y7FW$C\JFR73*B>W \;"<
M7*[<D',IRW2;3+ ,^ZFG&1M626'WZ^OJ)8-.!(/0)Q)1 \C2LR$',<[,Z)U^
MI),D/5?>K0NIN95S^@-$*>H,A"D]^%H^&*09%W#BW3&UM\:DOQ&=!SP>"C/4
ME9TC9\1]YJI)('CH_L]L=/R8QVOFF:W2>A&;;!=ZM-7AOTL(>T.2YF^J?X2M
ME1C(13UT)R97AZVG8CABH+1:V[9A3RUKU'^?Y%U4U/%YM8SHX<A'#05\$%H!
MK_M/XMB7[1*4-Z7._OLU[G/WVN,U'2>_U9J3&;XVU&K%SUFJEL<CD[R-&Z:/
MZ2E;N!>J;C@Y^II3]M E[^7G].LG\H9O1Z4X#I.P4RANZZ\W]MY'!6723U$4
M[1O%W5O<S'/*17<02L<VDHWHAN3/MVJ>#&<>XQ.5N,$% #O_]I.3G,P'G?LG
M_ISJFJY0H!@*!&)O,< KV*_;#K]T5<[_SI=V<2Q!S@X:-3#:X]SUS@Q3[Z%)
M/O BX6O @Z-/SK5&H/F]LM;Z7CE9\&)>S_QS?M2:C!Y)21 RZC7ONHX8^?>,
M>?6I"P<5U1B9J+QZ@ET\(@RD<\;(C-G%XVG\ V\=&/W[Q@+IA0+DWZ6\Q(\<
M2/Q?JB+5D\1&?R8LYVQYYNK%)%MDDCN5O,ME\.$#,^3$-%D4"R7O;:(J"H$(
M5:&A)/>2G5KKV4>DTB(" BITQY>1YPEIXU!@%7\BF[%0NO ';XSH9KP&]M$G
MKF#F>D$ $&<ZL,G",I]OGR,:?5US*--# @6JD9_+I]!4D_WR_29?KK@*R;3-
MN]<Y;4V/:C*8EZF;?QYIIL.8P3S)_._K6P1;_M7M8XD>Z/><Y5OBDIH7B^:L
M:HJ=H+WWU._B#A'?O[\+_WGSH=YI)1W\^D7/1O$!SK;_LO&G[7S[P>^$4."'
MEI.7YZE^'\\KSD OZF)KEZ'QGT/V^1EDRA%%/KH[!;*I">E7HIUT14MV5\2N
M3$M&W>C\BU@SPW:=0A7A%N)B@0A08%KXZP/8JZW+B? F?%ZCMHZC+BV;-Z6/
MUH2%<+7Z1DT:G2E>3>44GT6D6#'Q:L8Z>@T_F1XKDHO0C9=*H!SE!X1Y^KA%
MV-J%+M3%BSK_Y3X3@_\[[9S])4JFMS>OU':4?F@J?,AAMKW.-B*B=YK8>:I1
M%:^&9SQ?\V&%,DE^>)S7GO<\.F*M J\MXG X7>1H/-A&#L&S[]8U_$JM_":F
M+<0$"L!KUU9\2*)+FLI/<A[ZHI_.DR"+YA0/!E^: _G=KABW9_G1+]UGVM?/
M*GA.KS]>WKSCIN:+G)+^I6IE+8]B_*FCU"3$F'[JLY,%\;O4(,J7+)+4L],5
M+[>"/R3D[AG!=\J/;S<>NGT(7&K\NF:D& 4AG$ 9'8$"^F?#%#?#ZA%=X>]5
M?G/(3;8T!P^0MSI[:X[^&"IM5"U:W>:W6.*6&ZQ5)#WA;A]TOGL6YCZ0CMPC
M]TZ0I?FKQI97<?B".\)8N:&=&'/JE&H3:XW$U\WR;[+D/ZK=:-*_W*N1]Q58
M6YA/F]0VM_QF<3%F2;\?T,/!+J*&KX43J$AOH;==VQ71LPLR^.W!XJ$HU/S\
MOH D$%*[;[]JY+U:;^Q9=VX+0?=,YKR]+"M9S5&0AYF>B4N>'6[^V!;;3;-A
M[4A-9HVQT>!KHKH<J>:PUZ1HPR?346["BT+R7_11!BB%C2IC4,BJ(Z=T(M\A
MV+OGL#T8GP]&U:.R;7JY=JQ@!>7>^*Q$\2O4I.HIU7UEB2RE\12,B4X;5\LJ
M7*QW*1R[TG'2<+GWS3J>=1"YCMJU=SSSRS)O*>@1QW&?:5%CG\GPT7W>$<ZX
M.K<?UT<YW<K"$!&LI7; J4N<GT [58#Y8_>M1JD7R]BZZX9%!J/9WEB!<,/R
M-(10DTGC0_FZ*UNGX6G45(H]BQ!FB5.PP6#J#N8MF3,*4:&[?(N/6(H;\<#+
ML)=*7>K-XLH+[N5KH%DTMNZ7 %^%Y &C963+Z^)-5$(,H?#A>9JC[(]7Q7=@
M"K$;NN4>M9M\:@P=>TK,AJ72(,JW4.#9=^9)#(BXRJW[:!X4J(L6SW.8L:G6
M,^;MM$O1"-V,EVB@)SQ@UB%=J^TRUY(W27IF@#O,/$O.??K4Y#0I*OC;8B]2
MN-ROO#):UK;HT.=-%1^:DB!%J_+Y$VPT&5I-EMH)A:HE@49OBYQ<7%^=S.>R
M&"DDT+^.KN7]X JV*Q)QH:X@C#R1$9KH;[&234BB=T[2;3),UF$EMMT.=]E5
M(CTW[&5H*$X9%VU-.Y=I3N6AP=;0#FO/YWOA4.M!ZC:L#VSR8+Z]6ENS65HL
M0-E^F '>IRX)!?<^(#B*PW@#L<$38^1$$LN/P@3]<3J_55%8US!?79&X@6L]
M$3+T3OSC2IH<R[Q<"CJI9Y2H<:_' 0H_)5OC^=9?R%35]NY+W!HO2JN**U5E
M*=@5$-4A(XW'^0M^]A#>@85]?O3R%;VLSN"S6>3UX?/RM>J-\5R?4=?M++/V
MAQ$:[#) 9CHUCH(N%>7W6,RNEA/MM/&4)%G+D[=I^.8&)V5+09]VR!3JG'VQ
M&#]N\& ?MBAM!E:+W-[V')R'+PPU/LR+_YKZP'?:D<F"FWD5!GF5E\7F J'T
MM:$Q-B^,$37MVZZS5Q[X[3;;W3)?-']O>G1OK[\VR>9,E@:X!K_6_/@%AVWK
MM8=%@H1AO\VEN_.2>^5BQX_4'^$#>F*4MQNQI)NY*$P$S?1&_6"=\#GX)<<?
M-"CEZQ">KO3T\(A\P3??EA8X]@"'MO[X?=FJW\QAVMJ(O@?5'&5$DH# 7D%F
MG@B.C*P"8<*.J<T<.$C*0^J8BH(_G8CPSE([Y4HI]/Y.]E9KCH'HE[TW;8X\
M;K!EY 8R*@G'?(:2K>XN'_/KT(.=3M)GQG+79:AA E'>]29Y\I$8:+ZHK?T5
M]@YX>'6GVUFW8&L]6\[Y/>3U S/72+*50]$A<:8I^G=??>CI]]753%4,PFJP
M?GQM^:CT>K3FN>J" SU\078 HVWRLF6M[O>A*GRUAO?IO8TEC_NZ/^"SB"J!
MU3LGQGRPA!/4P/C('2^_/.@5C/^A#V7=K.%KX4CXKU XU\MDUA5'P(-UR2EG
M8;&([AC(NEBATP)KY39UR3IW2JV+/4G6H#$V(P(,!T&1-W!EPENH9B)?%$%1
MGP X001JHF-C+R?^CULG<*=PIP'/6%$;M'# FX5[./>-BS.9QA/A^CO>^L79
MP:KPT0!9D7W"24BUOX^'AYD__QPQL[U/8F*6-KSJK,Q\CZ1R RGQ/F,6FIJ\
M H,IE\DE.V2WW&*U]S[L;=OEE,D#9LG_L1;V%[:/RREYS /^M1.<%3Y<&NT$
M&Q9H^UQ2(!V[]\$^#YXHT5!@HV$ "IA>0*3R9>G$'Z8*<FBSPYFY5X)J(<C^
M/S5Z3"YO*2 3I>'3-T10@$J%R']ZP_^W>KEP!A3 ]B?PRRPZJ,F.3]2B4 >I
M@9& O%Q0#08#OC'DBDSHA\]\R#P&;DVT;\"@JQC2J=;TQ[*CM8G5\'FUP,E?
MC'&?+%5/Z["K.JZ1 X3NF/'$G]EP+2@B>J<WMR@,4NGT9YFT)HS@[BH6>%:_
MF'1"RDNZ?Z/<KZ>!I!@X4>X=DP<XC!J>WZQWRCM7UE4X-*;E'RXSF#I+.@9L
MN/&:=W9[T^7QG,SM<=3$LMV"TG/9KQL/C\=B!R/1#-&VQ5=Y1LO7&F-4VL(-
M"E>]J*6>X#D0]6^3A(Y]NR<Z1>LT'G6KGV [_#IQ_/13++[1K3@#?>1O:QZX
M^3%+;58H$%'#RG<R9[3'T<NU[KGQ8?CZ(Z%)3W5*5SW[Z7-V[.SV*?9\] Y*
MQ"KS+F?72%-5%+U4YK#3Y0A>"@SC'9=928S*127ZN99V>=U8^&YG3P'Z,OE3
M]&Z/#**3M25;1B?>@P\U]GP*MS:11PNX]\PQ12"X637#<\]ZQ<K*J@2-YFCF
MB(]X&L1%%C\1TS!B1?<V>\/<?(RX6&4,;OP&.+O4F1W/L;/7B[(P]9GCINX=
MK"E"RYTN%)L-&LN6:-V&#@/G*3@(*2_O2W+?J]9FV):M-T1MUZ-ORY0ED,O(
MR+X.!VK!%BIKK6AS3_(3-.M0.2P(:!#[:E8.R6[7PTN@ .IVR$M4_JL6<@.^
ML3=^TFGO.BG8Q1JRL&)XM*FF+.HGV?TF"V=8$SG E$9=\N0']T,J)"J$][97
M8DS_#VEO'177D[6--A+<W2&XN[L$#\$2W"%8!W<+%B X-,'=(="XNTL(#DUP
M=W>'2S+SFW=FOIG[WF_=/\Y:?5;WJ:K>=:J>O6OO9^]Q%Q:)4A:VM80-!J-
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MO ]=#*89. ETZ,1%'XW<*3/EOA;Y8TH6$0!0H!25?N=C).@;^D^,T)3=S6>
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M&H4UG02[X$$@5[Q6=G98TK"*0=($2*_>3]:D GGY:.=F[?)5MX=1O-S2''V
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M,IP27I1F*$""J?],UJAGIE:[H$&LFW=%2Q_"T-=UV&HC9X*R5Z^66M=P@>%
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M?1F>GZ?:HTC*^-,,_EO*(#F4 WNX=_![5I4ZLSMSWNVF-5HYD3K*C+#[_AF
M8SV?D4*OXAO79?6IW,K&\;)TX7MNC66D!,#':^.O_ -S] W:H 7@7)Y.7VYX
M9*3UF]C900+,42C"A>BI>D/CW:6F5'KFC?A:.6-HKZ(QX9 $1GCD SA/KY21
MFI.?F+;UC9;ESA=&5_:C&&QV>]G-Y04>9 W%M2^V0M7\8F?A,.;4YY&^)90R
M1?^S$\N%-_5+E)/<\SN'K-L< S>W=:"2C-34K-'6M]?XOG,<?0E[-KQX(,?'
M>X#0#(WM7.O"V6W"5:[FF:3!+ST.C(5""4IV>*L]0:)=[A*^2>=P(:90* [9
M8 K0=W@C915XDCN5X OIOK,WD:[&^GM!WA-9&*T.F>\8HU+7A%!UK%[76G#V
M#\JJY44?HUR2K14!4\ 7.<OW6/P\R$8C;*::A!R'PNA2[[G!HD=72KRZP'"O
M5L$Y0T[B60+P3P5^2P7_8-(JN?6B46Z]5%+I]-Z#02I]'820)$EZ;U!K:+&Q
M='V$[*NJ?@+J('$ H8 86"LGO2/ZI^_MEI5P_S,@P^*\V(J^H52V]1FPG?RP
MYV5N;OXCMI?S=X#=4F#85$H8?1$?DMGRWK#H;SM0R9;ADT9^WC^2V/^_)].=
M:_+X/QTGO'G]8_M",Y%2+P938.\S0-'W$:_VH'6_+^O%^.I<>P;D_S;<EE$?
MWEMHWGS:+<H)N[PC\T!=?G ??0;HS=\2A:R(/<3)M>_O&>ZJZS\#^B.> 9?#
M[;%%GV%>##V>\*>V_*?X[?5Z0ZYJ]&H1WG_UE3P#_B4%4+FH+G;T,\"E>&?0
M,B=LX(8"'.V?^3^$?B:R.E$XWP'E/M_+6_RGJ>]1V^W=RSV9A7M>I"PT+)8^
M<C5J?\\J'RY-PP*#U'?*^W7N*OW5]X'0S<5N(3M"%,QNS)NU.BLK*!R-L<Y,
M6OKU4?TP.%_&_.(=(O/*0"_K:(K[JNCXF9WNE(D</ZZCBZ]'-80U<52WCN+&
M2]M. !E.^7TM0=D0GGFOXT-47?7:EI;Z&J NKQP2_0BB!>%&&INRPOY.E@5Q
MB;N%7L85L)7I?6U-PMVL42L;XF?QOHOMP,']PP_'+9C%_=R5EG.EO!!\5P?M
M12EFFE2$9AB&47@[W$55<1*9[)56<3TELLBB3BM3+QO2U@W'+OVHSAI.DA.%
MTQN-PZLO="&R ;,0^IK]HBU Q.8'PA?[-EIC^O_6YR.1T^B+L[PPOSRKTSII
M=?=I)91MDE";D[=0S$WX[/,W*-O)GJO$IH>4]ZJ#9WTCB:A^H'@*SO*RA8A'
MZSG=Y:'B19ZI"MZT 2QZ:+.XA4JQ!*;4ZJI,]78OMP9MU@NA&B^OCG8?_<]F
M]OPC$Q(/J*Y91D[B! DZ/B%?:O;K W_BI3YT8MS6Q?5-WV4$+N5-NMSP)+&J
M3>L0_R+HIZD=P5WWAN8#*,-B.')!&H6:%V6>2(TOD3L_NIA1&Q<,9/524YST
M7!HMY6:#T9$L'8,JIPSX*>J1)KL)OH:&)'%JR!S!.=P@ 68;QH+!.?T6I=Q.
M"_0HYM+SM7>;/AS*4SQ%W&^"%[.:FF)D&Q.6V'\6M>!3444;CV85"TNY^)CF
MZ"U8C7G,T,--PU"CG(D?B0_V>VMB^Q3PYCOD(UP67R*40SY$??")"+%]I[!R
MZT% 54GI)R3EPEK^*F@IVL,6XL@.DG=H]G;?R9W*_)'^&&*9LGS5 JS:C!N*
ML^R(<:5;\)RV0]]%7CU\01QLR;9/8 <*B2KZ,SC)P#&'S)'J2Q:O>W,AH#Z\
MFJY7,0V6-',ENWRLA\V7"/X[(L!X="\OJC>+6=06C@>*RL(@^=%'ATZ5;GX!
M\MZ(JV'MJ(DSK]157VHL;05H*5ML?H/-T/W,=],_I7*7]R S5^%TLY0-B?AU
M9WU:,@]88_5OR=KZEYJ_Z(?AQ_E'I !&QYTMN85D:NM<V?&9PQ8.X.N\HL&6
ML2DZ]#  =[5!%RE7D$(%_GEDEMVB1_OR_/[A9 3DA "G1N65[J/HO'H5:.+H
M-34G"H9ODDATJ_KX!7U--$?;.,_/X[/D0IOA"I_IT2Q<\(L-'UGB[CC_(9T5
MMFI>C^W'I&X=Q'WTO>D"^42=918"&)Q34Q^%@/&B87U0'8-2PT"@B A4E 88
MS=^H]<V_O]<17E)H3\4M> 8LRK[>Z_"Z<\:M=L)6 C(K4LF,Y$N5?QAU4!L7
M)[.%J,WI2&2G\YDWXPS2@"\X0%$PT!/55QT#'T6<^IP,PJA4-J_*SMAU2=;2
M_7<5Q0G(&"99:Y&U:&H?=^N^*4 B[!,!OHC7%]>ERVBW?&U4#5/<BZ)>0G1U
M9T=O*I,@VO4HK]07Q8W><8QZ'CC( 4A? 2@I^_P_2!;M #IP]EYVX@KS4Z4<
M]^!YN2B&CU;4EGEIK%1AXOD!6)Z5@!-!MZ*'#T4&6IVVE"ROTJ+K]DYEUFW;
M&IY:2V@H6AJGZ,;>Y9..QN&X0>IU)4"TJ/W)46A>9)Q066B%0VTV6J(W"9TF
M5.:(;HZ>F>+PVRE@8)[63B+?S,D:00'9IQ_P/Q V:JV+C,*;7U4.DM7V+P[Y
M%@/K$[#WV J$&0T@%%EYNU'ZH7M<G:3%7R$3WHH?2YJ[B13MV+NI-0%,<E\^
M:@&4X<\O<5]/F$U=>-CP5*(,<W$P$=RJ8)_Y>6Z@..D5!G$CVK* :W'O45Q!
M;UD=<"SL/][:1SX#A$<6NW_-V!0-N]@5*/.D07O%1R2MT1%'YP-4,Z[0T;2T
MYW :FI-'XU%4LCCEQ*E/.U:@/7JY[M5LG!2P++G>@ C?.''ON4D$GD.W+Y&R
MNY?)G)$?>HGP7EXVEGG/;P2]H-$':LZTXK/*'U4!CFB.63.ZJXM82H1TYQF\
MG!AP/R]($>E _8U9R/@ZKR(AY3;?<68]X*&EGV@N1&M1EA@J IX4/;!6I+"_
MYC6?/0,<00YG"9<;3A%.,SRRFJ<H?'7@CWG+M_A5 U0!:W));WX2;R%MV)CZ
MR7!IGUBY7=<W!7RYQWW8*?8&]1@LK9A":XV:1O=#_$E5HJ[TU61!<K[5+3'%
M&(3FCAXF/AQ](GLB;-*UX\,=U?JQRG1)I@=YE_WUM?IU(0=7E5(-]0G^CEXK
M[PN2DN(#W5:%D,&*A\D@GIC@QB TK)7H)BVOS[6MT@ *   >\-X-[U1?_.1=
M.+4:@X8&(2Q10ABLJ>43:=WX%NA]@G9:9"RAKD.8Z(!(B4D8/0R;UOCKZ?6(
M9#+DI*@=6TI^]U%O<DFA#^E"[^HF#B 0B$AL,?5=I8C\)2UX0@5*B_-&8T3I
M_6)(+(4;UI!EX;6:G*  66VKO'APU28";)D,IY!FJE)A7:JQ1^ZRCJ*'C_//
M.Y\+JW.EUP* ^A/.2^H5(X==@VB&6]<H<$=A$!( )I_#X*"D4(); Z_$?8AF
M[DT)LY_+)Y0GPN]D=!/;T\[:+(<?$>D_VA,?#4 -RER),)F'0:5II#-[9G[]
M1#M92M:U-JW/0__3"QK%NS)N?,2^(VKA5!\D$QN B>OHZ!IA-DEU2YK;)Q2=
MK_BN(_UW&3-6G&\UW_Y7$L*+UE+]IY8V"T[ [YI[96B&I(9LH1]#F8T$F07]
M)@V<7I][KV6!X)6R8AA0CC[^_3Q[2Y3D&?!/^E,MVX-LSJPP9$8G/X\KJUOF
MS*\[6F'3&VK-!VFF"V]<SQKB($?]+=Y#G(K5DEQJ+,A]BOSWV?=%_3-@'&CP
M3=APM?,9P-&,?O]4NS&V[ZEU4[)6DENDB^SQA4POPVCN)E*B$UPQS%@45G+]
MZ="RM/U&[L+P#DG'=WE<]H':D^WQ%8O8\4ZY;@KOPLJF3_B,[^FZV*.3W88U
MNM\SX$S)Y!E07NR;K]YTBA8!<2J:.I2G_T5F><&#WJF,87EGU_WK\-A%2-<C
MZ.>7/% 0_WJMO:F.C=9^=T%<XP'N"IG0B[JWSO88.'F+="7QLM#0?,=LNY^>
M 6!WWT@>&\'M=>;$&(-.FLK*#^<?.O56'%)6$GK6X]QU0EW-(W$5[PW?/0,R
M?XD=5\I>M:4_ \0J?)=-JD3Q?TT]:5[C TU7+/Z)#+#57GMQ?/L8^'2/6W)B
MH3=1LRC;"_8JTM4MG7&HD9&'/B87HYHI>E'O6F,D58M%/]J(J2_L2AL_ [J,
M5]OOT+1\ER]+>$4IQB^9HJM_[;G68QO5#>2CV NM:(1,ICC7?/M39 S.[W<Y
M!O:_%U$'_%7V[C\69_[/F7+^2J]7[O71IDA''NB&I 0;B!+%B:J5X\>PFZ)?
M%FO)4CI6:@1RXS W\0)YT):I2@/,K07A4DOT)$0VJP:9X3<^Q<;.P)/*>'2N
MU?AU %Y0"4$&R-K=W62>[,MSF%\1Y>$$0NQZL6E)\>GBHFI+I 'JT\Z_7'Q8
MM[I6&L+6N(AQ^"F(-LGE(:Q+_;*-D1I"B!/NM?0GS;D&?O0[V]G]!&5+80!Q
M_K]7O/Y?KR@MD'L&PWMA6Z2JB@&*2[@B*T&T].Q>:D^?JMXM#/TJ15Y!:&5^
M&#\AI(E<;@0F/HVQ YZ:2#L3ELVT7*IOQAD( Q0K40C'.J2>8S*"ZE QG:0M
M#"CTE3UAN)@RT/X= $_U$ <%-&DJ>XF''<R4-O))?&W!BCK#.LSK9I@(6YB"
M X>,AI+SGNKY0>1MLS"5E1A[&7ZJ6+47E9<Z130?+Q,^*.&7H@4QE:ZAO7#1
MN/^MWQ-'!+3@C".^M7_&MSUZ[#^$V]\TW8 P!M0_S@ X4!A#()*"NNK O,IZ
M\8J*(E%[R[?&^Y*.8JNB9A7Z0Z68:O;(=X@;F1(R:SJO-R+&56\9%AU]G.3R
M<@],Y$00"VT[W:9HUM'$0LHG\N I8R("1*QBL:"DIGWCH6=!OZO2_7D-$LA;
M/L?C*L(O_7NVM\O?A<AY&O(K#<+H2]CQ_E0;_EU2V7["'6NW19%FPEH5E4QW
MM6C0TN1GAKT*_Z?'"7&>A7'IX#!\(K)X-R%EAT*=8:;';?=O<3=K.63$8\^
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MU&(2*!E_<<AEWN3=K'7=P-ZVV-%XQ)'Q#6J/>R;65'^D4\8!Y&#P I>(5XW
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M6EC\_"),0[9/%#<IAFC6!O23SOOD!^&RSEH%YN=Z3#9L_02C=@JCU:>11['
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M(+V14?]9OV>=W]&]IP>LR1:-T=#JS0$ C30Y(L]O..R?>4 \0 []]]!-41S
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MI7&I>)CDX\K>2:K>G#0^@MJDV>;6'T%9Q%EWZ^K6HI8FA=HP08^@LS7W1U
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M$4%+BCAYMVS_S8@UJZ5^3HF\AP8-F%*GKQO735K$9A[KQHD/UI=4M*94],E
M#1^MSNO7GV"O/+N#/L9Y]59F50_,]4@;?;H=,7.GG" LNN\<[IU'&^<PKHFO
M)O;5=;8FR<K'(^=DL8Z>L'-*9="&QVX#OY<1OQW+=(NB>I8!\0"Y+2DPLUJJ
MIC(V&26_$TNDZ.L>%;@=#2QZ*.P[I>FY/^_IEXX<B,+1XARR>-?P?CXLYJN
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M2@42+^S4=2HE'#IH)PA@IC1R]2'%CH=N?;&.F?B^;7!85N:3)M?0&C&):G?
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MX0W5%PU2R5F^QL*:@6K')G=//I0[JE'TS99R@D1*\DQ!,\'9NWP]F,U"4_'
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MX48;GS&SG4^,')&K).Q+V9KY>U*Y<1P-6MLG>>,)2B<.6U463@SL.,1WQ'=
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MP*'"@5;2P(KZ30A1PI?R7\MDC$9.S_S3[#HPG;A:G-*0TL"=VWG535%*2@&
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M; _"!E_>R_/M8H^Y.NR82H9EA_6:#PV+\R@@#4K+2AGR[[ -*[Q(C/,J8WM
M:>GSSH7H2$M9LK[T@+IUYQK+?K3VZ#V$_ZP28^*IT!D:EO,QWN:HWZ(5ML:Y
ME]P+F8"A-L<FS>3\\_DPO@"@/GLS1CVK-*%KE6Z06+_L-0$#5L:SHG'6>3B
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M:'4!L=RV&?(SZG%3#K^=IIW*A?0G(,:S@QH\V37WEXPM QYP5/_4[N^-)W;
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MGY)&^/FD_FQYM%OV2N-\4E;6?^VE;=!@"<6+39X"#A/\6#N&*S!HK>D,=IT
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M.'"">=LFO;'M$"SC3\HNF ^<JF-0DDJKY/ZVN;A+)WU16R+IYC!_H#AY3JG
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M/_./+&7SZ"3F?';')MJ9$1H;X>@[H29V3.-#^._ ^Z_?$A5)! >D.(^*21L
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M6[_@0)_(H;-?]?1>(_FRK!WEQ=L+^:YWPT=JI[ UU@0'9T UEI?0??93M?D
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M<905TPDJK+'D;E>]?AL*)4]9@B/@'&"53_^7?3S_/_X(S\?^!U!+ P04
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MKK0S%'8W"( D N 3:K@;P0?WFT@_7P*W1_U<=P9ZK/ZS,\G5TS8>$5Z;*"$
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M'M"%GRIET<;)$<=]Q6^FM#2Q38YYC+^E^/2\BJ:R\ZA18;'>9PTS6KT%<H(
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MFECH?KV5E):99"//CDQ_XA.U7].R<R2N;D">H&RV!5B@4;FT99<R'';]R,_
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M'T\18$.G#5C/C/+$R.;:),-. (:B@ Y[40>J7[)'LC$*9QSI?.U%;#!$#>_
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M]F1MY,/O,/ZDNO*?T'%K)4BVA7X0F_P/8G]Q+DS.G0#AQ_H73'\30^FXA_#
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M:I"B/CGJZG0).#0!);<-:$O>/#?NU%+YR-,;ZX=!HV7]>[:Y8Z0TS$^V_2V
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MQXO3X^G%UR_/;.3])ET,R+&4O"(G%$!)\WQ ,JZMR)?$%M0FSH@>#)[!C !
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M.JGHK'U+J5LRXF4MU9)#[:)0GH'H!O  *#^>#\,VA,]X,[(9C_4]Q,W0X$'
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MOQ:O_<\1F-R-P >3Q"T@/IQ>'HQ'8'@F,^)1;G'&)AKE%A"EM F%4VZR)12
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M1&&P"XO1]G<1+E%&64.->LB8))6$K1C,Q3Q%PSO@&0X$"4)GM"RU!?"K>Z9
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M6J;;7%<U99NMCVO+,UU]2-S[$U!+ P04    " "@6W)2$Y%=D%<&  "#)0
M%P   '1M8BTR,#(P,3(S,7AE>#1D,3$N:'1M[5K[<]I&$/Y7KF2:QPR2D, !
M!&;&]2/-U$X\#FFG/YZD!5U\TJFG$YC\]=T[25A@)TT3-Z$)GC'X7JOO]O'M
MK<[CGRSK-(UI&D)$?IU>G)-(A$4"J2*A!*JP=\E43*8BRVA*+D!*QCGY1;)H
M#H0,[:'MVOV^94W&*.FX6B)2GW0==^!X'<\EKN?W7-_MD,L+\O3M]/B9F7WR
M^GCZY^5I^=#+M[^<OSPF+<MQ_N@>.\[)]*0<Z-D=ETPE37.FF$@I=YS35RW2
MBI7*?,=9+I?VLFL+.7>F5TZL$MYSN! YV)&*6I.Q[L%/H-%DG("B)(RIS$$=
MMMY.SZP!SE!,<9B,G?J[G!N(:#491VQ!<K7B<-A*J)RSU%(B\[N=3(UPI8/#
M6W-NK"6+5(Q[[?P\RF@4L71N<9@I_\ >#&Z[))O'ZSY1;LV7P*EB"]"R&U)#
M#E3Z@5#Q:/L!]ZW,ZG4SD2IK1A/&5_Z3*4L@)Z]@2:Y$0M,G[;('OW.0;/9D
M9&;G[#V@:-R>@AME4<[F*%QC'97[]ZNM!QL/68+93B!XA(.G-S$+F$++N>[8
M"5!/V4.AV@2A!VNQ"Y;C0SE3*S]F400I3GC\:.!UNJ.QHR<^)(R&<MX5N6*S
MU2:RTW3.61Z3O$BP?T7$C%Q*EH8LHYQ,02:Y[E(QD#-12 RN(XTX*A*BA.D^
M!YH#.9I+ !.)3R,351=4AC'QO#;Q.NY!F]"<4!R/<"A8X4**,0M249:2-Q"*
M-+H5C%) FL D9Q#(0L/R^D90GU"<N;%Z&C-Y_^*C8HX[)@.S<O!L/<12A([C
M)437U>,>?B(N+3T M03 89SWGOQFDV.1YDH6H79?;"3(+2MRKB*;/-4*T*;S
M.J./^MDY"N9"1MK'S'QW],SHA%<#;?/H%Y0G"/ *<C#8=-\)+("+S.CVWSWT
MQ=7)G><I2*DVTJ?*J/7:%&1_?U'RZ8PQ1<4UE?(50_5SU*-HP($$Z&$@#UN=
M%H8-YQ6SK]MY1L.Z78DO5UBAX)QF.?CU'Z,'4+.%^4&)Q&_TZ%1E5*#A6IRN
M1*'\&;N!:-3((26H6AM*XF]4 ZZF#:ITIZ+FX$=!;X-<(+&PD/+*%,8JB&^T
MC)D"2^L*_%0L)<U&C8=6.JW /7XT?-X?CK9Q;$X:%^NT*9 #_$<=\_-E*BZ;
M6BR"E GEHZ835UT-3],)OVQ'2,.2FAQ=($]+SE+8'K$VD;8FEQ(2EB/"4"P,
MN1IR;X9(L>FWWWJKK8E/CK),BAN68*+B)N,=##LD_PL3#1 \>(',-PFRBJ?@
MJ^_!<,[='4R%PN1<J]ZPT&ZIN)$I*BK2<>#HB'5,B#\496X<6TT<&C ,_3=5
MOF5Z;CF4U+\U332U5C&1D;1FXWMC8D^]>^K= >K5AW--7N8 OIL\&R)XK?6Z
M5JBS0MNT5+4!_3<W5435*/DMJU-+'E.LX@,@,RF2C<("Z_4B58S7G>51OKO;
M[*W%ET63MN .LW<;32 63)=LL5AB&2++R@OKBLHF,5T %BE$9*8V0BNC,# 5
M&I#-?6+51:CQ!_WZIGQ/4SO!NL3<JB7;]UB\>Y_%>[MM\=>E>BY1HHAVV.#_
MIW3=D.S>)K-U]M[GZ'V.WH$<?0;Z?+Z#J?F6PS.Z(I0DN"S&8DAB(&+NG0%H
MPM:D2A.!C*L9^M7+-Z1[T$;0).-%3GX_FI*9D(V479<D-GE9+L:D@6M-UM#-
M*D^P'/,$R!"GFH(1P;2W$-W%DW_@61_ .6A[6-1%A33'#QRO2#@S)/RMF&[S
M[<Z#U2I[MMNSW0ZPW1L(,=[4:M<9KSS5EB?.ZOU[>2#%HRPME$@%<DE. II>
MDWE!)4T50,TL;M]K>\][_SF#?/&KW_+*K_R,Y3J6:7@]ETB5T9;Y&E=WFP-Q
MJ5H/@6@OL*IV9RN NYVM8UAY8UCU-"\1MZ\G,SH'*Y! KRTZPWK IWQ)5WD5
M4(.![?7J<*]N%#M;UX[?YV5F:"ZLMAR!)7.2R_"PI9+ PM*GXWI=]P9N>I&+
MT%S[739O$<K58>L%DE+,PC6+1RS/D$Q]EAHS!ER$U[5Q^^[0'G:UA4U*N=57
MS<ZV/F3?W79-U:5N>OV^?5!Q[MX!?T@']#[7 ;W.1[SODWQO:!_T]L[W(SM?
MEWX[[QO8Z^/F5_2^+W6UA6#1/WF:4_Y_D?F'I<G?4$L! A0#%     @ H%MR
M4J2+)CB8#0  VI0  !               ( !     '1M8BTR,#(P,3(S,2YX
M<V102P$"% ,4    " "@6W)2D 5:Y(T-  "^MP  %               @ '&
M#0  =&UB+3(P,C Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "@6W)25Q,*V-8B
M  #:+0( %               @ &%&P  =&UB+3(P,C Q,C,Q7V1E9BYX;6Q0
M2P$"% ,4    " "@6W)26L$&PN)6  #)]00 %               @ &-/@
M=&UB+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "@6W)2XG?9G(D^   Z
M8P0 %               @ &AE0  =&UB+3(P,C Q,C,Q7W!R92YX;6Q02P$"
M% ,4    " "@6W)2EXR>-RWC! !7[2L %               @ %<U   =&UB
M+3(P,C Q,C,Q>#(P9BYH=&U02P$"% ,4    " "@6W)2]F]E[AP[  # 6@
M%P              @ &[MP4 =&UB+3(P,C Q,C,Q>#(P9C P,BYJ<&=02P$"
M% ,4    " "@6W)2J'W\2B*B  "SN   %P              @ $,\P4 =&UB
M+3(P,C Q,C,Q>#(P9C P,RYJ<&=02P$"% ,4    " "@6W)2/(W'/,":  #R
MK@  %P              @ %CE08 =&UB+3(P,C Q,C,Q>#(P9C P-"YJ<&=0
M2P$"% ,4    " "@6W)20+T5!:Z4  "1L@  %P              @ %8, <
M=&UB+3(P,C Q,C,Q>#(P9C P-2YJ<&=02P$"% ,4    " "@6W)29'#J>EF5
M  #&GP  %P              @ $[Q0< =&UB+3(P,C Q,C,Q>#(P9C P-RYJ
M<&=02P$"% ,4    " "@6W)2,>X ]5BV  !KR@  %P              @ ')
M6@@ =&UB+3(P,C Q,C,Q>#(P9C P."YJ<&=02P$"% ,4    " "@6W)2"_RT
M3\^-  #KQ0  %P              @ %6$0D =&UB+3(P,C Q,C,Q>#(P9C P
M.2YJ<&=02P$"% ,4    " "@6W)2>?QZ_&,(  !J)@  %P
M@ %:GPD =&UB+3(P,C Q,C,Q>&5X,3)D,2YH=&U02P$"% ,4    " "@6W)2
M0C$"=QT(  ![)0  %P              @ 'RIPD =&UB+3(P,C Q,C,Q>&5X
M,3)D,BYH=&U02P$"% ,4    " "@6W)28#'14AX&   E(0  %P
M    @ %$L D =&UB+3(P,C Q,C,Q>&5X,3-D,2YH=&U02P$"% ,4    " "@
M6W)2#^0,>J $  #W%@  %P              @ &7M@D =&UB+3(P,C Q,C,Q
M>&5X,35D,2YH=&U02P$"% ,4    " "@6W)2$Y%=D%<&  "#)0  %P
M        @ %LNPD =&UB+3(P,C Q,C,Q>&5X-&0Q,2YH=&U02P4&     !(
,$@#$!   ^,$)

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
